{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "qwen3-8b-reasoning",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "sample_size": null,
    "random_seed": null,
    "total_questions_in_experiment": 1000,
    "successful_questions_in_experiment": 1000,
    "failed_questions_in_experiment": 0,
    "questions_evaluated": 1000,
    "completed": true,
    "input_file": "/Users/reeturajharsh/domyn/multihopQA-benchmarking/src/experiments/outputs/experiments/qwen3-8b-reasoning/e2_page_window/qualitative_2hop_cross_year.json",
    "timestamp": "2026-02-04T11:23:36.690812"
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "The gross benefit obligation for LMT's nonqualified defined benefit pension plans decreased from $1.0 billion as of December 31, 2023, to $905 million as of December 31, 2024. Actuarial losses related to these plans also declined, from $347 million in 2023 to $303 million in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the gross benefit obligation decreased from $1.0 billion in 2023 to $905 million in 2024, and actuarial losses declined from $347 million to $303 million. These values exactly match the original answer, with acceptable formatting (e.g., 'as of December 31' adds precision without altering meaning). (2) The answer is complete, addressing both parts of the question—the evolution of the gross benefit obligation and actuarial losses—over the two years. (3) Entity accuracy is correct: LMT (Lockheed Martin) is properly identified, and the financial metrics (gross benefit obligation, actuarial losses) and years (2023 to 2024) are accurate. (4) The reasoning is sound and reflects proper multi-hop synthesis: the model correctly infers a decline in both metrics over time based on data from two consecutive years. (5) The semantic meaning is equivalent to the original answer, with slightly more formal phrasing but no loss or distortion of information. All scoring categories warrant the highest rating.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 321,
        "total_tokens": 1483
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "General Motors' long-term rate of return on U.S. pension plan assets increased from 6.3% in 2023 to 6.5% in 2024, as noted in the 2024 10-K. This upward adjustment reflects strategic shifts toward higher-return asset classes, such as private equity and real estate, within the \"Other\" category of the target allocation (11% equity, 60% debt, 29% other). Despite unchanged target percentages, the increased return suggests a deliberate reallocation to optimize funded status while balancing risk, aligning with the company's goal of improving pension liabilities through higher-yield investments.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 to 2024 increase in the long-term rate of return from 6.3% to 6.5%, which aligns with the ground truth for 2024. However, it omits the 2022 information entirely—specifically, the decrease from 5.6% (2020) to 5.4% (2021) reported in 2022—making the response incomplete regarding the evolution between 2022 and 2024. This is a significant omission because the question explicitly asks about the change *between 2022 and 2024*, requiring both time points. (2) The quantitative accuracy is partially correct: the 6.3% and 6.5% figures for 2023 and 2024 are accurate, but no data is provided for the 2022 reporting period, and there is no mention of the earlier lower assumption (5.4%), so the full trajectory is missing. The allocation breakdown (11% equity, 60% debt, 29% other) is not in the ground truth and cannot be verified, though it may reflect supplementary data; however, its inclusion without confirmation introduces potential inaccuracies. (3) The reasoning correctly infers that an increased return assumption suggests a strategic shift toward higher-return assets and improved funded status, which is consistent with the ground truth’s interpretation. However, the multi-hop synthesis is incomplete because it fails to contrast the conservative 2022 assumption with the more optimistic 2024 one, weakening the analysis of evolution over time. (4) The contextual relevance is high—the answer addresses pension assumptions, return changes, and strategic mix implications—but the failure to cover both ends of the time frame reduces correctness. Scores reflect partial factual accuracy, acceptable reasoning, and strong relevance despite incompleteness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 468,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "Chevron acquired PDC Energy, Inc. (PDC) in 2023, integrating its assets into Chevron's operations. In 2024, PDC's legacy assets contributed to a $2.2 billion increase in U.S. upstream sales volumes, driving a $3.5 billion rise in upstream earnings. This integration enhanced Chevron's production capacity and revenue, with PDC's assets accounting for 19% of net oil-equivalent production growth in 2024. Financially, the acquisition bolstered earnings through higher sales volumes, though no specific operational challenges or costs were detailed in the provided documents.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 acquisition of PDC Energy by Chevron and the 19% increase in net oil-equivalent production in 2024, which matches the ground truth. However, it incorrectly states a '$2.2 billion increase in U.S. upstream sales volumes' leading to a '$3.5 billion rise in upstream earnings', whereas the original answer specifies a '$2.2 billion increase in U.S. upstream earnings' directly attributed to legacy PDC assets. This misrepresents both the metric and the amount, introducing a fabricated $3.5 billion figure not present in the ground truth. (2) The date (2023 acquisition, 2024 impacts) and percentage (19%) are accurate. The $2.2 billion figure is mentioned but misattributed to sales volumes instead of earnings, which is a critical error in financial context. (3) The multi-hop reasoning is partially sound—the model connects the acquisition to operational and financial impacts in 2024—but fails in accurately synthesizing the specific financial outcome, confusing revenue drivers and misstating the nature of the $2.2 billion impact. (4) The correctness score is 5 due to significant quantitative inaccuracies despite correct timeline and partial qualitative alignment. Quantitative accuracy is low (4) due to incorrect figures and misattribution. Qualitative accuracy is moderate (6) as the general narrative of integration and contribution is correct. Contextual relevance is high (8) because the answer addresses the evolution and impacts as asked, albeit with factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 421,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "Southern Company's treatment of energy-related derivatives in 2024 showed changes in the net amounts recognized in the Balance Sheets compared to 2021. In 2024, Southern Company's net amounts for derivatives designated as regulatory hedging instruments increased to $75 million (from $50 million in 2021), while Alabama Power and Mississippi Power saw decreases to $23 million and $17 million, respectively. Unrealized gains and losses were presented as regulatory assets and liabilities, with 2024 data reflecting a shift in the net recognition of these instruments, primarily due to changes in hedging activities and offsetting mechanisms. The presentation included gross amounts offset for collateral, impacting the net amounts reported.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar amounts ($75M, $50M, $23M, $17M) and company-level breakdowns (Alabama Power, Mississippi Power) that are not present in the original answer and cannot be verified against the ground truth. These figures appear fabricated or misattributed, as the original answer does not mention any such numbers or subsidiaries' derivative positions. (2) There is no quantitative support in the original answer for any dollar values or comparisons between 2021 and 2024; thus, the claimed increases or decreases in net amounts are factually unsupported. The original answer references disclosures as of December 31, 2021, and 2020, not 2022 or 2024 balances, and does not provide actual figures. (3) The reasoning is partially sound in identifying a shift in presentation—mentioning regulatory assets/liabilities and net recognition—but incorrectly frames the change around numerical trends not present in the ground truth. The original answer emphasizes a shift from disclosing pre-tax effects of unrealized gains (losses) on regulatory hedging instruments to presenting fair values across various derivative types (energy, interest rate, foreign currency) in balance sheet line items like 'Other' or 'Risk Management Activities'. The LLM fails to mention this broader scope of derivatives or the change in valuation approach, focusing instead on unverified quantitative changes. (4) While the LLM attempts to address the evolution in treatment and presentation, it invents data and misses the core qualitative shift described in the original answer. The contextual relevance is moderate because it discusses related concepts (regulatory hedging, unrealized gains, balance sheet presentation), but the factual inaccuracies and missing key elements (e.g., fair value presentation, expanded derivative categories) severely undermine correctness. Hence, the low scores in quantitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 528,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "Chevron's investment carrying value in Tengizchevroil increased from $23,727 million in 2022 to $27,368 million in 2024, reflecting a rise in its equity interest. Equity earnings from Tengizchevroil fluctuated during this period, reaching a peak of $3,885 million in 2023 before declining to $3,375 million in 2024. By 2024, Chevron's carrying value exceeded its underlying equity in TCO's net assets by approximately $73 million, primarily due to a loan to fund development projects.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in key numbers. According to the ground truth, in 2022, Chevron's carrying value was about $100 million higher than its underlying equity in TCO's net assets, but the LLM incorrectly states a carrying value of $23,727 million in 2022, which is not mentioned in the original answer. The ground truth does not provide Chevron's total carrying value for 2022, only the $100 million excess over equity. The LLM fabricates a specific total investment value for 2022 that is unsupported. The 2024 investment value of $27,368 million is correct, as is the 2023 value of $26,954 million in the original, but the LLM omits the 2023 figure and invents a 2022 figure. (2) Equity earnings are significantly misstated: the LLM claims $3,885 million in 2023 and $3,375 million in 2024, while the ground truth reports $4,386 million in 2022 and $3,033 million in 2024. The LLM invents a 2023 peak not in the original and overstates 2024 earnings. The decline from 2022 to 2024 is understated in magnitude and incorrectly trended due to the fabricated 2023 peak. (3) The multi-hop reasoning is partially sound in that the LLM attempts to track changes over time and links investment value and earnings to TCO, but it fails to accurately synthesize the correct figures across years. The mention of a loan funding development is consistent with the original (FGP/WPMP), but the $73 million excess in 2024 contradicts the original's $100 million excess in 2022 (no 2024 excess amount was given). (4) Scores reflect major quantitative errors (3/10), partial qualitative accuracy in structure and entity identification (5/10), high contextual relevance as it addresses the right companies and metrics (8/10), and an overall correctness score of 4 due to incorrect numbers undermining the answer's reliability despite correct directional trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 511,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "Walmart's ownership stake in Alert Innovation evolved through an acquisition in fiscal 2023, where the company completed a $0.4 billion acquisition, resulting in 100% ownership. There were no changes to this ownership stake between fiscal 2023 and 2024; the entity was subsequently sold and deconsolidated in fiscal 2025.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $0.4 billion acquisition in fiscal 2023 and Walmart achieving 100% ownership, which matches the ground truth. However, it incorrectly states that the sale and deconsolidation occurred in fiscal 2025, while the original answer clearly states this happened in fiscal 2024. This misplacement of the timeline significantly affects the correctness of the evolution of ownership between fiscal 2023 and 2024. (2) Quantitatively, the $0.4 billion figure is accurate, and no other numerical errors are present—hence a high quantitative accuracy score. (3) The reasoning is partially sound: the model captures the acquisition and eventual sale but fails in the multi-hop synthesis of timing, incorrectly extending the ownership beyond fiscal 2024. This breaks the logical chain required to accurately describe the stake evolution within the specified period. (4) Contextually, the answer is relevant and addresses the core question about ownership changes and the transaction type (acquisition and sale), but the erroneous fiscal year for the sale undermines the factual correctness. The answer implies continuity of ownership into 2025, which contradicts the ground truth that Walmart had already exited the entity by fiscal 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 356,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "Starbucks' foreign currency - other derivative asset positions decreased from $73.4 million (as of October 2, 2022) to $54.9 million (as of October 1, 2023), while derivative liabilities dropped from $7.2 million to $2.0 million. This reduction reflects a strategic shift toward managing foreign currency exposure by decreasing hedging activities, likely to mitigate risks associated with currency fluctuations and align with evolving market conditions. The decline in both assets and liabilities suggests a more conservative approach to exposure management, prioritizing cost efficiency and reduced reliance on derivatives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in AOCI, not $73.4 million as stated by the LLM. The LLM claims a decrease to $54.9 million in 2023, but the actual 2023 data shows a much more dramatic reduction: only $1.9 million in current assets and $1.7 million in long-term assets—totaling $3.6 million, not $54.9 million. Similarly, the LLM reports liabilities dropping from $7.2 million to $2.0 million, but the ground truth shows current liabilities of $4.7 million and long-term liabilities of $4.1 million in 2023—totaling $8.8 million, which is higher than the LLM's figure and actually represents an increase, not a decrease. (2) The dates referenced (October 2, 2022, and October 1, 2023) may align with Starbucks' fiscal year-ends, but the numbers associated with those dates are incorrect. There is no mention in the LLM answer of the shift from AOCI to balance sheet asset/liability classifications, which is a key part of the original answer. The LLM also fails to mention that $32.5 million of the 2022 amount was expected to be reclassified into earnings within 12 months—a critical detail for understanding exposure timing. (3) The multi-hop reasoning is flawed. The LLM incorrectly interprets the direction of change in liabilities and misrepresents the scale of asset reductions. It concludes a 'strategic shift toward managing exposure by decreasing hedging activities,' but the actual data suggests a complex rebalancing—moving from large unrealized gains in equity to smaller, more balanced on-balance-sheet positions—rather than a simple reduction in hedging. The LLM’s reasoning is based on false numerical premises. (4) Due to major quantitative errors and incomplete synthesis of the true financial position changes, the correctness score is low at 2. Quantitative accuracy is 2 because nearly all numbers are incorrect. Qualitative accuracy is 3 because while the general idea of reduced exposure is partially valid, the reasoning and entity dynamics are misrepresented. Contextual relevance is 6 because the answer addresses the right topic and attempts to interpret strategy, even if based on wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 611,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "In fiscal year 2022, Medtronic redeemed 1,872 previously outstanding A Preferred Shares for $0.075 million, resulting in no A Preferred Shares being outstanding as of April 29, 2022. This action marked the complete elimination of A Preferred Shares from the company's issued capital, and as of April 26, 2024, no A Preferred Shares remained outstanding.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: Medtronic redeemed 1,872 A Preferred Shares for $0.075 million in fiscal year 2022, with no shares outstanding as of April 29, 2022 (LLM states April 29 in the original timeline but mentions April 26, 2024, which is a minor immaterial variance given that the exact date in 2024 is not critical to the conclusion). (2) Quantitative accuracy is perfect: the number of shares (1,872), dollar amount ($0.075 million), and fiscal year (2022) match the ground truth. The 2024 date is used appropriately to confirm no shares remained outstanding. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes information across fiscal years 2022 and 2024 to conclude that A Preferred Shares were fully eliminated and not reissued. (4) The answer addresses both parts of the question: the specific action in 2022 (redemption) and the evolution through 2024 (continued absence of shares). Wording differs slightly (e.g., 'complete elimination' vs 'discontinuation'), but the meaning is equivalent. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 329,
        "total_tokens": 1528
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "Comcast's equity income from Atairos evolved significantly between 2022 and 2023, driven by fair value adjustments on Atairos' underlying investments. In 2022, Atairos reported a loss of $434 million, contributing to Comcast's equity loss of $537 million. In 2023, Atairos generated income of $1.1 billion from fair value adjustments, leading to Comcast's equity income of $789 million. This marked a reversal from a loss to a substantial gain, reflecting improved performance at Atairos.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key financial figures. While it correctly states that Atairos generated $1.1 billion in income for Comcast in 2023 (matching the ground truth), it incorrectly claims that Atairos reported a loss of $434 million and that this contributed to a Comcast equity loss of $537 million in 2022. The ground truth specifies that Comcast's equity loss from Atairos specifically was $(434) million in 2022 due to fair value adjustments — not $537 million, which is an incorrect figure not mentioned in the original. The LLM introduces a number ($537M) that does not appear in the ground truth and misattributes the $434M loss as Atairos' own loss rather than Comcast's equity loss from Atairos. (2) The 2023 equity income of $789 million for Comcast is also not present in the original answer; the ground truth only states that Atairos generated $1.1 billion in income, without specifying a reduced amount flowing to Comcast. These quantitative discrepancies are significant and suggest incorrect synthesis or data sourcing. (3) The multi-hop reasoning is partially sound — the model correctly identifies the turnaround from loss to gain and attributes it to fair value adjustments on underlying investments, showing understanding of the causal mechanism and timeline. It captures the directional shift and key driver (fair value changes), which supports qualitative and contextual accuracy. (4) Despite correct framing and relevant context, the introduction of unsupported financial figures undermines factual correctness. The answer is semantically close but factually flawed in critical numerical details, warranting a moderate correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 465,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 312 BCF (developed) in 2023 to 296 BCF (developed) in 2024, reflecting downward revisions due to lower prices and development plan changes. However, equity affiliates in the region saw significant growth, with total reserves increasing from 3,697 BCF (2023) to 5,870 BCF (2024). This indicates a strategic focus on partnerships and acquisitions in the region, despite declines in the company's direct reserves, to strengthen its presence and leverage regional opportunities.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the decline in COP's direct natural gas reserves from 312 BCF in 2023 to 296 BCF in 2024, matching the ground truth in magnitude and direction. However, it introduces new information not present in the original answer—specifically, that 'equity affiliates' increased from 3,697 BCF to 5,870 BCF—which is unsupported by the provided ground truth and appears fabricated. This significantly undermines factual accuracy. (2) The core numbers for COP's own reserves (312 BCF and 296 BCF) are quantitatively accurate and correctly attributed to 2023 and 2024. However, the additional figures for equity affiliates are not found in the ground truth and cannot be verified, representing a major quantitative overreach. (3) The reasoning is partially sound in interpreting a decline as potentially indicating strategic shifts, but the model goes beyond the data by attributing the decline to 'lower prices and development plan changes' and asserting a strategic pivot to partnerships—conclusions not supported by the original answer. The multi-hop synthesis fails because it invents data rather than drawing from available facts. (4) While the answer addresses the evolution of reserves and attempts to infer strategic positioning, it adds unverified details that distort the conclusion. The correctness score is 4 due to partial factual accuracy on the main metric but major errors in completeness and reasoning from unsupported data. Quantitative accuracy is 6 because the primary numbers are correct but secondary ones are not. Qualitative accuracy is 4 due to flawed reasoning and unsupported inferences. Contextual relevance is 7 because the response stays on topic and attempts a meaningful interpretation, albeit based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 483,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "ENBREL's revenue in Canada declined from $73 million in 2022 to $47 million in 2023 (a 36% decrease) and further to $28 million in 2024 (a 40% decrease from 2023). This reflects ongoing challenges, including lower net selling prices, inventory reductions, and estimated sales deductions. The trend indicates a negative market trajectory, driven by pricing pressures, competition, and factors like insurance reverification and co-pay expenses, with expectations of continued declines due to regulatory changes (e.g., IRA Medicare Part D pricing) and biosimilar competition.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $47 million revenue in 2023 and $28 million in 2024, which match the ground truth. However, it incorrectly states the 2022 revenue as $73 million instead of the correct $113 million, a significant factual error. This affects the accuracy of the year-over-year decline percentages: while the 40% drop from 2023 to 2024 is approximately correct (47 to 28 is a 40.4% decrease), the 36% decrease from 2022 to 2023 is inaccurate because it is based on the wrong starting value (73 to 47 is ~35.6%, but actual drop from 113 to 47 is ~58.4%). (2) The calculation errors stem directly from the incorrect 2022 revenue figure. The model fails to report the true magnitude of the initial decline, misrepresenting the severity of the revenue drop. (3) The qualitative reasoning about market trajectory—citing pricing pressures, biosimilar competition, insurance reverification, and regulatory changes—is contextually sound and aligns with typical drivers of biologic revenue decline. These explanatory factors, while not in the original answer, are plausible and relevant, enhancing contextual understanding. However, the original answer did not include these details, so their presence is supplementary but not incorrect. (4) Despite strong contextual relevance and reasonable interpretation of trends, the major quantitative inaccuracy in the 2022 revenue figure and resulting flawed percentage change significantly undermines the correctness score. The core downward trend is correctly identified, but the magnitude is misrepresented. Hence, partial credit is given: correctness and quantitative accuracy are penalized, while qualitative reasoning and relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 469,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "Qualcomm's approach to linking human capital advancements with executive compensation in fiscal 2024 maintained the use of non-financial performance modifiers tied to human capital progress, as outlined in the \"Human Capital Advancements Linked to our Executive Compensation\" section. For fiscal 2024, progress toward human capital advancements served as a modifier that adjusted executives' bonus payouts by a range of **0.9 to 1.1**. The document does not explicitly detail changes from fiscal 2023, but the 2024 disclosure confirms the specific modifier range applied.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key factual element—the 0.9 to 1.1 performance modifier range applied in fiscal 2024—which matches the ground truth exactly. This satisfies the quantitative and core factual requirement. However, the LLM fails to fully address the evolution from fiscal 2023 to 2024 as required by the question. The ground truth states that in fiscal 2023, human capital advancements were only 'considered' in determining bonuses, whereas in 2024 they became a formal non-financial performance modifier with a defined multiplier range. The LLM acknowledges that the document does not 'explicitly detail changes' but does not infer or report this evolution, which was part of the original answer and necessary for full completeness. (2) Quantitative accuracy is perfect: the 0.9 to 1.1 range is correctly cited with no calculation involved. (3) The reasoning is sound in identifying the 2024 structure but incomplete in synthesizing the multi-hop evolution between fiscal years. The model should have inferred the shift from general consideration to a quantified modifier based on the disclosed context, even if phrased cautiously. (4) Scores reflect high accuracy on numbers and relevance, with a moderate deduction in qualitative accuracy due to incomplete reasoning synthesis across years, leading to a correctness score of 7 rather than 9–10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 383,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "Between 2022 and 2024, Breyanzi's therapeutic scope expanded from Phase III trials for relapsed/refractory follicular lymphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in 2022 to FDA approvals for these indications in 2024. By 2024, Breyanzi was also approved for relapsed/refractory mantle cell lymphoma (MCL) and high-risk FL, broadening its use across B-cell malignancies. These approvals reflect a progression from investigational status to established treatment options for multiple hematologic cancers.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly notes that Breyanzi progressed from Phase III trials in 2022 for follicular lymphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to FDA approvals in 2024, it incorrectly states that Breyanzi was approved for mantle cell lymphoma (MCL) and high-risk FL in 2024. The ground truth confirms only two approvals: for relapsed/refractory FL (May 2024) and for CLL/SLL (March 2024) — no mention of MCL or high-risk FL. This is a major factual error that misrepresents the therapeutic scope expansion. (2) Regarding quantitative accuracy, the years 2022 and 2024 are correctly referenced, and the timing of approvals (March and May 2024) aligns with the ground truth, though the LLM does not specify exact months. However, the addition of non-existent approvals for MCL and high-risk FL introduces false data, severely impacting this score. (3) The multi-hop reasoning is partially sound — the model correctly infers progression from investigational to approved status across two key indications. However, it fabricates additional approvals not present in the source data, indicating a failure in accurate synthesis or potential hallucination. The model does not reflect the 'accelerated approval' nuance or the specific prior therapy requirements (e.g., BTK and BCL-2 inhibitors) for the CLL/SLL indication, missing key eligibility criteria. (4) Contextual relevance is high because the answer addresses the evolution of therapeutic scope over time and focuses on the correct drug and disease areas. However, due to the inclusion of incorrect indications, the qualitative and correctness scores are significantly reduced. The core progression is captured, but with critical overstatement of the approved indications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 496,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "Disney's Resorts and Vacations segment revenue grew by 5% from $7.95 billion in 2023 to $8.38 billion in 2024, driven by higher cruise ticket prices, increased hotel rates, and occupancy, partially offset by lower Disney Vacation Club sales. The overall Parks & Experiences segment revenue also increased by 5% (from $32.55 billion to $34.15 billion), with growth across theme park admissions (7%), merchandise (4%), and licensing (7%). While both segments showed similar revenue growth rates, the Parks & Experiences segment's broader diversification contributed to slightly higher operating income growth (4%) compared to the Resorts and Vacations segment's performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the revenue figures for Disney's Resorts and Vacations segment as $7.95 billion in 2023 and $8.38 billion in 2024, which are accurate rounded versions of the ground truth values ($7,949 million and $8,375 million). The 5% growth rate is correctly calculated and matches the ground truth. Similarly, the overall Parks & Experiences revenue is accurately reported as growing from $32.55 billion to $34.15 billion (matching $32,549 million to $34,151 million), also representing 5% growth. All numeric values, percentages, and calculations are quantitatively accurate. (2) The LLM adds contextual details not present in the original answer—such as drivers of growth (higher cruise prices, hotel rates, occupancy) and offsets (lower DVC sales), as well as breakdowns of Parks & Experiences subcategories (admissions, merchandise, licensing)—which are plausible and enhance the response without contradicting the ground truth. It also introduces operating income growth (4%) for comparison, which is not mentioned in the original answer and cannot be verified from the provided data. This is a minor overreach but does not undermine the core correctness. (3) The multi-hop reasoning is sound: the model correctly identifies the relationship between the Resorts and Vacations segment and the broader Parks & Experiences segment, compares their growth rates accurately, and draws a reasonable conclusion about relative performance. (4) The answer is semantically equivalent to the ground truth in terms of the core financial evolution and comparative growth, with slight elaboration beyond the original. The only deviation is the unverified claim about operating income growth, which slightly affects qualitative accuracy but does not justify a lower correctness score given the primary focus on revenue. Overall, the answer is factually correct, complete, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 518,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "Between 2023 and 2024, CVS's forward contracts associated with ASR transactions maintained a consistent structure, with forward contracts representing 20% of the notional amount (e.g., $0.4 billion for the $2.0 billion 2023 ASR and $0.4 billion for the $3.0 billion 2024 ASR). However, the **value of these contracts increased** due to the larger notional amount in the 2024 ASR ($3.0 billion vs. $2.0 billion in 2023). The 2024 ASR also extended the timing of the final tranche receipt from February 2023 to March 2024, reflecting adjustments in settlement schedules.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in stating that the value of the forward contracts increased in 2024. According to the ground truth, the forward contract value remained constant at $0.4 billion in both years, despite the increase in total ASR size from $2.0 billion to $3.0 billion. The LLM incorrectly claims the value increased due to the larger notional amount, which contradicts the ground truth. (2) Numeric values for the ASR amounts ($2.0B in 2023, $3.0B in 2024) and forward contract values ($0.4B each year) are correctly stated, as are the final share receipt dates (February 2023, March 2024). However, the claim that the forward contract represented 20% of the notional amount in both years is incorrect: in 2023 it was 20% ($0.4B/$2.0B), but in 2024 it was only ~13.3% ($0.4B/$3.0B). This misrepresents the proportional shift highlighted in the original answer. (3) The multi-hop reasoning is partially sound—correctly identifying the two ASR transactions and their timing—but fails in comparative analysis by asserting an increase in forward contract value when it actually remained flat. The model also misses the key insight that the proportion allocated to the forward contract decreased, which is central to the evolution described in the ground truth. (4) Scores reflect mostly correct entities and context, with high relevance and reasonable qualitative logic, but significant quantitative inaccuracies undermine the correctness, especially the erroneous claim about increasing forward contract value and incorrect percentage calculation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 436,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "Duke Energy's 2024 disclosure on the Master Retirement Trust's pension asset valuation methodology showed enhanced transparency compared to 2023, particularly in clarifying the categorization of fair value measurements. While both years detailed Level 1, Level 2, and Level 3 classifications, the 2024 filing explicitly explained that certain investments (e.g., those using the net asset value per share practical expedient) were excluded from the fair value hierarchy as \"Not Categorized,\" a distinction not as prominently emphasized in 2023. This added specificity improved transparency by explicitly addressing the rationale for non-categorization, aligning with SEC requirements for clearer disclosure of valuation methodologies.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Duke Energy and the relevant years (2023 and 2024), and accurately references the fair value hierarchy and the net asset value per share practical expedient being excluded from categorization. However, it misrepresents the nature of the enhanced transparency in 2024. According to the ground truth, the key new disclosure in 2024 was a reconciliation of beginning and ending balances for Level 3 assets (those using significant unobservable inputs), which the LLM answer omits entirely. Instead, the LLM claims the improvement was 'explicitly explaining' the exclusion of certain investments from the hierarchy as 'Not Categorized,' suggesting a qualitative clarification that was more prominent in 2024 — but the ground truth does not state that this explanation was new or more detailed in 2024, only that it was present. (2) There are no numerical values in the question or answer requiring calculation, so quantitative accuracy is not heavily applicable; however, the absence of specific percentages or dollar amounts from the original answer (e.g., allocation percentages, Level 3 reconciliation details) is not penalized since the LLM correctly notes that allocation percentages were maintained, even if not specified. (3) The multi-hop reasoning is partially sound — the model correctly compares disclosures across two years and identifies a change in transparency — but it synthesizes an incorrect evolution: it focuses on increased explanation of non-categorization, whereas the actual evolution was the addition of a Level 3 balance reconciliation, a significant quantitative disclosure. This represents a failure in accurately capturing the core factual change. (4) The contextual relevance is high because the answer addresses pension asset valuation, fair value categorization, and year-over-year changes. However, the correctness score is moderate (5) due to the central factual inaccuracy about what changed in 2024, undermining the qualitative accuracy despite correct entity and year identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 555,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "Pfizer's financial obligations and revenue recognition related to Paxlovid evolved between 2023 and 2024 due to the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile (SNS). In 2023, a **$3.5 billion non-cash revenue reversal** was recorded in Q4 2023, reflecting expected returns of 6.5 million EUA-labeled Paxlovid treatment courses purchased by the U.S. government. This reversal reduced revenue and deferred liabilities. In 2024, a **$771 million favorable adjustment** was recorded in Q1 2024, reflecting actual returns of 5.1 million courses, reducing the prior-year reversal. Additionally, in Q3 2024, Pfizer recorded **$442 million in revenue** from supplying 1.0 million Paxlovid treatment courses to the U.S. SNS at no cost, with deferred revenues for Paxlovid and Comirnaty totaling **$2.2 billion** as of Dec 31, 2024 (down from $5.1 billion in 2023). The SNS program shifted revenue recognition to future periods as products were delivered, while deferred liabilities decreased due to revenue recognition and adjustments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key financial figures are correct: the $3.5 billion non-cash revenue reversal in 2023, the $771 million favorable adjustment in 2024 based on the actual return of 5.1 million treatment courses (down from the expected 6.5 million), and the $442 million revenue recognized in 2024 for the U.S. Strategic National Stockpile (SNS) delivery of 1.0 million Paxlovid courses. These numbers match the original answer exactly and are presented with appropriate context. (2) The LLM adds incremental but accurate detail not in the original answer—specific quarterly timing (Q4 2023, Q1 2024, Q3 2024) and the deferred revenue balance of $2.2 billion as of Dec 31, 2024 (down from $5.1 billion in 2023). These details are consistent with typical SEC filing disclosures and do not contradict the ground truth; they enhance completeness without introducing error. (3) The multi-hop reasoning is sound: the answer correctly synthesizes the shift from revenue reversal due to inventory return in 2023 to revenue recognition from SNS in 2024, capturing the evolving financial obligations and revenue recognition pattern. (4) The only minor deviation is the mention of Paxlovid being supplied 'at no cost' to the SNS, which could be misleading—while the U.S. government may not pay upfront, the $442 million revenue recognition implies a transaction with value, likely under a deferred revenue or cost-recovery model. However, this does not constitute a factual error given the revenue was recognized, suggesting eventual realization. Overall, the answer is factually correct, comprehensive, and contextually appropriate, warranting a 9 due to slight ambiguity in the 'no cost' phrasing despite accurate financials.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 482,
        "total_tokens": 1956
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "ERLEADA's sales increased by 26.9% from $1.88 billion in 2022 to $2.39 billion in 2023, driven by continued share gains and market growth in Metastatic Castration-Resistant Prostate Cancer. This growth contributed to J&J's Oncology segment achieving a 10.5% sales increase in 2023, highlighting ERLEADA's significance as a key product in the company's oncology portfolio, particularly in prostate cancer treatment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports ERLEADA's sales growth of 26.9% from $1.88 billion in 2022 to $2.39 billion in 2023, which aligns with the ground truth values of $1,881 million and $2,387 million (rounded appropriately). The 10.5% growth in J&J's Oncology segment is also accurately cited. (2) All numeric values and percentages are quantitatively accurate, with acceptable formatting variations (e.g., $1.88 billion = $1,881 million). The 26.9% growth rate is correctly calculated: (2,387 - 1,881) / 1,881 ≈ 26.9%. (3) The reasoning is sound and captures the multi-hop synthesis between ERLEADA's performance and its impact on J&J's oncology portfolio. However, the LLM answer omits the comparative context about the decline in other oncology products like IMBRUVICA and ZYTIGA, which is a key part of the original answer and strengthens the conclusion about ERLEADA's growing strategic importance. This omission slightly reduces completeness and qualitative accuracy. (4) Despite the missing contrast with other products, the LLM answer still correctly identifies ERLEADA as a key contributor to oncology growth and contextualizes its role in prostate cancer, maintaining high contextual relevance and factual correctness. The answer is semantically very close to the ground truth but lacks one layer of comparative analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 375,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "ERLEADA's global sales increased from $1.88 billion in 2022 to $2.39 billion in 2023, representing a 26.9% growth. This significant rise reflects continued market share gains and expansion in the Metastatic Castration-Resistant Prostate Cancer (mCRPC) indication, indicating a strong and positive market trajectory despite competitive pressures in the oncology space.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a major factual error in the 2022 sales figure. The ground truth states ERLEADA's 2022 global sales were $1,291 million ($1.291 billion), but the LLM incorrectly reports $1.88 billion, which is significantly higher. The 2023 sales figure is nearly correct at $2.39 billion (vs. $2,387 million in truth), with minor rounding acceptable. The 26.9% growth rate from 2022 to 2023 is accurate and correctly calculated based on the true values: (2,387 - 1,291) / 1,291 ≈ 84.9%, no — wait, this reveals a critical error: the LLM claims 26.9% growth from $1.88B to $2.39B, but (2.39 - 1.88)/1.88 ≈ 27.1%, which is close, but the real growth from $1.291B to $2.387B is actually (2,387 - 1,291)/1,291 = 84.9%, meaning the reported 26.9% growth in the LLM answer does not match the actual year-over-year increase. However, per the original answer, the 26.9% growth is correct — this implies the original answer may have an internal inconsistency. Rechecking: Original Answer says 2022 sales = $1,291M, 2023 = $2,387M, growth = 26.9%. But (2,387 - 1,291)/1,291 = 1,096/1,291 ≈ 84.9%, not 26.9%. Therefore, either the Original Answer has a calculation error, or the 26.9% refers to something else. However, the LLM repeats 26.9% as the growth from 2022 to 2023, which would only be valid if 2022 sales were ~$1.88B. Thus, the LLM’s 26.9% growth aligns with its own (incorrect) base year number, but contradicts the ground truth’s stated 2022 sales. This suggests the LLM pulled data inconsistent with the provided ground truth. (2) The calculation verification shows a conflict: if 2022 = $1,291M and 2023 = $2,387M, growth is ~84.9%, not 26.9%. Yet the Original Answer claims 26.9%, which is factually incorrect. However, since we must evaluate the LLM against the Original Answer as ground truth, we accept the Original Answer’s numbers and percentages as correct for scoring purposes. Therefore, the LLM contradicts the ground truth by reporting different sales figures and repeating the 26.9% growth despite using a different base, indicating a failure in quantitative accuracy. (3) Multi-hop reasoning: The LLM correctly identifies the trend of growth and infers positive market trajectory, which is consistent with the original answer’s interpretation. It adds context about mCRPC and competitive pressures, which is reasonable but not in the original. However, it fails to mention the prior year’s 70.0% growth or the deceleration in growth rate, missing a key analytical point about maturing growth phase. (4) Justification: Correctness score is 5 due to major error in 2022 sales figure and propagation of inconsistent growth rate. Quantitative accuracy is low (4) because sales numbers are wrong and growth rate doesn’t align with its own inputs. Qualitative accuracy is moderate (6) — reasoning about market trajectory is sound, but misses nuance of slowing growth. Contextual relevance is high (8) — addresses evolution and trajectory, adds relevant clinical context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 790,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "NVIDIA's debt management strategy regarding the 0.584% Notes Due 2024 remained consistent between fiscal years 2023 and 2024. The notes were still outstanding as of January 28, 2024, with a carrying value of $1,250 million, and no changes in their structure or terms were reported. The repayment of these notes occurred in fiscal year 2025, indicating the company maintained the debt until maturity without refinancing or early redemption during the 2023–2024 period.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the $1,250 million carrying value of the 0.584% Notes Due 2024 as of fiscal year 2023 (specifically January 28, 2024), and accurately states that repayment occurred in fiscal year 2025. The interest rate (0.66%) is not mentioned in the LLM answer, which is a minor omission but does not distort the core facts. (2) All numeric values—$1,250 million, fiscal years 2023 and 2024, and repayment in fiscal 2025—are factually correct and match the ground truth. Date alignment is accurate: January 28, 2024, is the correct fiscal year-end for FY2024, consistent with NVDA's reporting. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes that the debt remained outstanding through FY2024 and was repaid in FY2025. However, the conclusion that the strategy 'remained consistent' and that there was 'no change' downplays the strategic significance of retiring the debt at maturity without refinancing, which the ground truth frames as an active debt management decision. The LLM interprets the lack of structural change as continuity, while the ground truth emphasizes the repayment itself as an evolution in strategy. (4) Despite accurate numbers and context, the qualitative interpretation slightly misses the strategic implication emphasized in the original answer—choosing to retire rather than roll over debt represents a meaningful shift. Hence, correctness and qualitative accuracy are reduced slightly, but quantitative and contextual scores remain high due to factual precision and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 429,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "Honeywell's investment in Mortgage/Asset-backed securities decreased from $1,119 million in 2022 to $676 million in 2023, a reduction of $443 million. Non-U.S. plans also saw a decline from $93 million to $10 million, a $83 million decrease. The total reduction across all plans was $526 million.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Honeywell's investment in Mortgage/Asset-backed securities was $982 million in 2022 under U.S. Plans and dropped to $10 million in 2023 under Non-U.S. Plans, a reduction of $972 million. The LLM incorrectly reports $1,119 million in 2022 and $676 million in 2023 for total investments, which does not match the ground truth. It also introduces a 'Non-U.S. plans' decrease from $93M to $10M, which is not supported by the original answer and misrepresents the data. (2) The calculations are therefore incorrect: the claimed total reduction of $526 million is wrong; the actual reduction is $972 million, or over 98%. The LLM's calculation of a $443M drop in total investments and $83M in Non-U.S. plans is unsupported. (3) The multi-hop reasoning is flawed. The original answer indicates a complete strategic shift—moving from U.S. Plans to Non-U.S. Plans with a near-total divestment—while the LLM implies a partial reduction across both plan types without recognizing the shift in plan categorization. It fails to capture the magnitude and strategic implication of the change. (4) Despite incorrect numbers and reasoning, the LLM does address the general topic—change in investment in Mortgage/Asset-backed securities over time—and attempts a quantitative comparison, which provides some contextual relevance. However, due to major factual and quantitative errors, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1160,
        "completion_tokens": 418,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "Capital One's use of securitized debt obligations increased in the funding mix between 2022 and 2023, with the carrying value rising from $16.973 billion in 2022 to $18.043 billion in 2023. These obligations remained classified as Level 3 fair value measurements in both years, reflecting the use of significant unobservable inputs such as prepayment rates and discount rates in their valuation.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. While it correctly states the 2023 carrying value of securitized debt obligations as $18,043 million (or $18.043 billion), it incorrectly claims the 2022 carrying value was $16.973 billion — this figure is not present in the original answer and is unsupported by the provided ground truth. The original answer does not provide a specific carrying value for 2022, only a qualitative description of securitized debt as a 'key component' of funding. Additionally, the LLM incorrectly states that securitized debt obligations remained classified as Level 3 in both years. The ground truth explicitly states that in 2023, all such obligations were classified under Level 2 of the fair value hierarchy, which contradicts the LLM's claim. (2) The quantitative accuracy is partially correct for the 2023 carrying value ($18,043 million) but fails on the 2022 value and misrepresents the fair value classification. The fair value in 2023 was $18,067 million, but the LLM does not mention this at all, omitting a key data point. (3) The multi-hop reasoning is flawed: the question asks about evolution in role and classification, but the LLM invents a comparison in carrying value not supported by the ground truth and mischaracterizes the fair value hierarchy change. The original answer highlights increased transparency and shift toward structured risk management due to Level 2 classification in 2023, which the LLM misses entirely. (4) Contextual relevance is moderate — the answer addresses funding mix and fair value classification, but with incorrect details. Due to major factual inaccuracies in both numbers and classification, the correctness score is low at 3, with corresponding low scores in quantitative and qualitative accuracy. The answer appears plausible but is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 502,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "JPMorgan's CECL-related capital benefit decreased from $1.4 billion in 2023 to $720 million in 2024, reflecting the ongoing phase-in of the CECL capital transition provisions. This reduction of $680 million was part of the transition to fully phase out the benefit by January 1, 2025, as noted in the capital components section of the 2024 filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $1.4 billion in 2023 and $720 million in 2024 are accurately reported. The implied reduction of $680 million ($1.4B - $720M = $680M) is correct and properly contextualized as a phased reduction. The end date of January 1, 2025, for full phase-in is also correctly stated. (2) The answer addresses both parts of the multi-part question: the evolution of JPMorgan's treatment of CECL capital transition provisions (phased reduction) and the quantitative change ($680 million decrease). (3) Entities are accurate: JPMorgan, CECL capital transition provisions, CET1 capital context (implied via 'capital benefit'), and correct years (2023 to 2024). (4) The reasoning is sound and reflects proper multi-hop synthesis: it connects the decreasing benefit to the regulatory phase-in process and correctly infers the trajectory toward full phase-in by 2025. Wording differs slightly from the original (e.g., 'phase out' vs 'phased in'), but 'phase out the benefit' is semantically equivalent to the phase-in of the regulatory treatment reducing the capital benefit. Overall, the answer is factually precise, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 348,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "Salesforce's Revolving Loan Credit Agreement evolved between fiscal 2023 and 2024 by increasing its capacity from $3.0 billion to $5.0 billion and extending its maturity date from December 2025 to October 2029. This change was formalized in October 2024, replacing the prior agreement dated December 2020, as detailed in the 2024 10-K filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurate: the capacity increased from $3.0 billion in fiscal 2023 to $5.0 billion in fiscal 2024, and the maturity date extended from December 2025 to October 2029. (2) Quantitative accuracy is perfect—dollar amounts and dates match exactly, with no calculation errors. The mention of the agreement being formalized in October 2024 aligns with the fiscal 2024 timeline and the 2024 10-K filing, which is contextually appropriate. (3) The reasoning is sound and reflects proper multi-hop synthesis: the model correctly identified the change in terms and capacity by comparing the two fiscal years’ agreements. (4) The answer is contextually relevant, directly addressing the evolution of the Revolving Loan Credit Agreement with precise, concise details. Minor additional context (e.g., reference to the 2024 10-K and the prior agreement date) enhances clarity without introducing error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 284,
        "total_tokens": 1473
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "UPS divested its Coyote subsidiary in the third quarter of 2024, resulting in a pre-tax gain of $156 million ($152 million after tax) during the year. This marked a significant shift from its prior relationship, where Coyote operated as a truckload brokerage subsidiary under the UPS brand. The divestiture contributed positively to UPS's 2024 financial results, with the gain recognized in \"Other expenses\" and excluded from ongoing operations in non-GAAP measures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the pre-tax gain of $156 million and after-tax gain of $152 million match the original answer exactly. The timing (2024) is accurate, and specifying the third quarter adds precision not contradicted by the ground truth. (2) The entity identification is correct—UPS and Coyote are accurately named, and the description of Coyote as a truckload brokerage subsidiary under UPS is factually sound. (3) The reasoning is logically sound: the evolution from an operational subsidiary to a divested asset is correctly synthesized, and the financial impact is accurately tied to the divestiture. (4) The LLM adds contextual detail—mentioning that the gain was recorded in 'Other expenses' and excluded from non-GAAP measures—which is consistent with typical financial reporting practices and enhances the answer without introducing error. The only minor shortcoming is the lack of mention of Coyote’s international operations in Europe and its integration into broader supply chain offerings, which slightly reduces completeness. However, the core facts, financials, and strategic shift are all correctly conveyed, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 353,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "Union Pacific's chassis fleet decreased significantly from 48,340 units in 2023 to 5,553 units in 2024, with both owned (30,635 to 4,356) and leased (17,705 to 1,197) chassis declining sharply. The average age of chassis dropped from 13.2 years in 2023 to 11.6 years in 2024, reflecting a reduction in fleet size and potential replacement of older units.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all quantitative data: total chassis units (48,340 in 2023, 5,553 in 2024), owned units (30,635 to 4,356), and leased units (17,705 to 1,197), matching the ground truth exactly. All numbers are accurate and properly formatted. (2) However, the LLM introduces new information not present in the original answer — specifically, the average age of chassis (13.2 years in 2023, 11.6 years in 2024) — which is not supported by the provided ground truth. This addition, while potentially plausible, is extraneous and not verifiable from the source, slightly undermining qualitative accuracy. (3) The multi-hop reasoning is sound: the model correctly identifies the change in total units and ownership structure across two years and synthesizes the trend of significant reduction. It captures the core transformation in Union Pacific's chassis strategy. (4) Despite the minor overreach with unverified age data, the answer remains highly accurate, complete on the main points, and contextually relevant. The correctness score is reduced slightly due to the unsupported detail, but quantitative accuracy remains perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 329,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "Boeing continued classifying aluminum agreements as derivatives without hedge accounting treatment in both 2022 and 2024, with changes in fair value recorded in earnings. However, in 2024, the disclosure expanded to explicitly state that these agreements hedge forecasted transactions through 2028, providing a clearer time horizon compared to the 2022 disclosure, which focused on long-term strategic sourcing objectives without specifying a timeframe.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the key evolution in Boeing's treatment and disclosure of aluminum agreements between 2022 and 2024. (1) It correctly states that in both years, the agreements were classified as derivatives without hedge accounting, with fair value changes recorded in earnings—this matches the ground truth. (2) The quantitative and temporal details are correct: the 2024 disclosure includes a defined time horizon 'through 2028', which is accurately reported. The absence of a specific timeframe in 2022 is also correctly noted. (3) The multi-hop reasoning is sound—LLM synthesizes changes in disclosure focus from 'strategic sourcing' in 2022 to 'hedging forecasted transactions' in 2024, reflecting a shift in narrative and intent. (4) The only minor shortcoming is that the LLM does not explicitly mention the connection to 'non-U.S. business requirements' from the 2022 disclosure, nor does it frame the 2024 shift as part of a 'broader set of commodity contracts', which slightly reduces completeness. However, the core factual evolution—classification, accounting treatment, and the introduction of a 2028 time horizon in hedging disclosures—is accurately conveyed. Wording differs slightly but maintains semantic equivalence. No calculation errors; all entities (Boeing, aluminum agreements, derivatives, 2022, 2024, 2028) are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 380,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "Procter & Gamble's exposure to currency rate risk remained managed through forward contracts and currency swaps with maturities under 18 months in both fiscal years 2023 and 2024. The company maintained confidence that near-term currency rate changes, at a 95% confidence level based on historical movements, would not materially impact financial statements. No significant evolution in hedging instruments or confidence levels was reported between the periods.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) All key facts are correct: P&G used forward contracts and currency swaps with maturities under 18 months in both fiscal years 2023 and 2024, and maintained a 95% confidence level that near-term currency fluctuations would not materially impact financial statements. (2) There are no numeric values requiring calculation, but the percentage (95%) and time frame (under 18 months) are correctly reported. (3) The multi-hop reasoning is sound—information is synthesized across two fiscal years and confirms no significant change in exposure or hedging strategy. (4) The answer fully addresses the question about evolution (or lack thereof) in exposure, hedging instruments, and confidence level. Wording differs slightly but meaning is preserved. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 261,
        "total_tokens": 1534
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "Adobe's positioning of Frame.io evolved from a standalone collaboration platform in 2022 to a more integrated, AI-enhanced tool within its broader ecosystem by 2024. In 2022, Frame.io was described as a cloud-native platform for real-time creative collaboration, integrated with Adobe apps like Premiere Pro and Photoshop. By 2024, Frame.io was positioned as part of Adobe GenStudio, emphasizing scalable content production and deeper integration with Adobe Express, Firefly Services, and other tools, alongside expanded AI-driven capabilities and enterprise features. Its functional scope broadened to include AI-generated content and seamless workflows across Adobe's product suite.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in its overall narrative and timeline, accurately reflecting that Frame.io evolved from a standalone platform in 2022 to a more deeply integrated component of Adobe's ecosystem by 2024, including its positioning within Adobe GenStudio. The dates (2022 and 2024) are correctly used, and there are no numeric inaccuracies since no specific financials or percentages are involved—thus quantitative accuracy is perfect. Contextual relevance is high, as the response directly addresses the evolution in functional scope and integration. However, there are notable qualitative inaccuracies: the LLM incorrectly states that in 2022, Frame.io was already described as a 'cloud-native platform for real-time creative collaboration' with integration into Premiere Pro and Photoshop. According to the ground truth, in 2022 Frame.io was only listed as a trademark, with no functional description or evidence of integration details. The detailed functional capabilities (real-time upload, frame-accurate commenting, Camera to Cloud) and specific integrations (After Effects, Lightroom, Workfront) are correctly attributed to 2024 in the original answer, but the LLM backdates some integration details to 2022. Additionally, the mention of 'AI-generated content' and 'Firefly Services' integration, while plausible in a broader Adobe context, is not supported in the ground truth provided. This overstates the 2022 integration and introduces unverified AI enhancements. Thus, while the core evolution is correctly captured, the reasoning contains minor factual overreach and lacks precision in the multi-hop synthesis between years and product capabilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 455,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "Between the 2022 and 2023 fiscal years, AMD's investment in the ATMP JV increased in carrying value from **$83 million** (as of December 31, 2022) to **$99 million** (as of December 30, 2023). Financial disclosures for 2023 show higher equity income from the JV, with $16 million recorded in 2023 compared to $14 million in 2022. The JV's operations remained significant, with purchases from the JV at $1.7 billion in both years, though payables to the JV decreased from $463 million (end 2022) to $363 million (end 2023). The disclosures emphasize continued equity method accounting and detailed reporting of transactions under the joint venture.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. The Original Answer states that AMD disclosed carrying values of $69 million (as of Dec 25, 2021) and $63 million (as of Dec 26, 2020) in the 2022 filing, but the LLM claims values of $83 million (Dec 31, 2022) and $99 million (Dec 30, 2023), which are not supported by the ground truth. Additionally, the LLM asserts that equity income was $14M in 2022 and $16M in 2023, and that purchases from the JV were $1.7B in both years—none of which appear in the original answer, and all of which contradict the stated reduction in disclosure. The original explicitly says the 2023 filing omits carrying value and transaction figures, while the LLM claims detailed figures are still reported, which is factually wrong. (2) All numeric values provided by the LLM—$83M, $99M, $16M, $14M, $1.7B, $463M, $363M—are fabricated or misattributed; no such numbers appear in the ground truth for those years. The fiscal dates (Dec 31, 2022; Dec 30, 2023) also do not align with the original’s use of Dec 25, 2021, and Dec 26, 2020. (3) The multi-hop reasoning is fundamentally flawed: the question asks about evolution in disclosure practices and carrying value, and the correct inference is that AMD reduced transparency in 2023. The LLM instead assumes continued detailed reporting and fabricates comparative metrics, failing to recognize the key point—the absence of data in 2023 is itself a change in disclosure. (4) The contextual relevance is low because the answer discusses financial trends that aren't in the source data and misses the core theme: reduced disclosure. The qualitative accuracy is poor due to incorrect entities (wrong amounts, years, metrics), and reasoning failure. Only minimal credit is given for correctly identifying that ATMP is a JV and that equity method accounting is used, which aligns with the original’s mention of structural continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 525,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024, reflecting a decline of approximately 7.3%. However, this decline occurred alongside a significant increase in Commercial Aviation Aftermarket revenue ($6,241 million in 2023 to $7,144 million in 2024). The overall Aerospace segment revenue grew from $13,624 million in 2023 to $15,458 million in 2024, indicating that Honeywell maintained a strong position in the aerospace sector by leveraging its aftermarket services and diversifying into other segments like Industrial Automation and Energy and Sustainability Solutions. This suggests resilience in the aerospace sector, with a strategic shift toward higher-growth areas.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the revenue figures for Commercial Aviation Original Equipment: $2,397 million in 2023 and $2,223 million in 2024, matching the ground truth. The calculated decline of approximately 7.3% is accurate ((2,397 - 2,223) / 2,397 ≈ 0.0726). Additional figures such as Commercial Aviation Aftermarket revenue and total Aerospace segment revenue are quantitatively accurate and consistent with external data, though not part of the original answer. (2) All numeric values and calculations are correct, and formatting is consistent and acceptable. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the decline in Original Equipment revenue but introduces a broader interpretation—about strategic shifts and resilience—based on growth in other segments (Aftermarket, Industrial Automation, etc.) that goes beyond the original answer’s conclusion. While these facts may be true, the original answer attributes the decline to potential demand or supply issues in the OE segment, not a strategic pivot. The LLM overinterprets the data by suggesting a 'strategic shift toward higher-growth areas' and 'resilience,' which are not stated or implied in the ground truth. (4) The correctness score is 7 because core facts and numbers are accurate, but the qualitative interpretation diverges from the original answer’s more cautious and specific implication (weakening demand or supply constraints). The answer is more comprehensive but adds unsupported inference. Quantitative accuracy is perfect. Qualitative accuracy is reduced due to overinterpretation. Contextual relevance remains high as all information is pertinent and enhances understanding, even if extending beyond the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 475,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "The global revenue contribution from Heart Failure Devices increased by **10.2%** from 2023 to 2024. In 2023, the segment's total revenue was $1,161 million, and in 2024, it rose to $1,279 million, reflecting a 10.2% year-over-year growth. This increase was driven by growth in heart assist devices and recovery from pandemic-related staffing challenges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key quantitative facts: 2023 revenue ($1,161 million), 2024 revenue ($1,279 million), and the percentage change (10.2%). These match the ground truth exactly, with acceptable formatting (e.g., $1,161 million vs. $1,161M). The calculation of percentage change is accurate: ((1,279 - 1,161) / 1,161) * 100 ≈ 10.16% → rounded to 10.2%. (2) The question asks for the evolution of global revenue and the percentage change—both are fully addressed. (3) The entities (Heart Failure Devices segment, years 2023 and 2024) are correct. (4) The reasoning is sound and reflects multi-hop synthesis of revenue figures across two years. The only minor discrepancy is in the explanation for growth: the LLM attributes growth to 'heart assist devices and recovery from pandemic-related staffing challenges,' while the ground truth cites 'consistent growth across U.S. and international markets with minimal exchange rate impact.' While the LLM's rationale is plausible and not factually incorrect, it introduces a detail (staffing challenges) not present in the original, slightly reducing qualitative accuracy. However, since the core facts and calculations are fully correct and the answer addresses all required elements, the overall correctness score is 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 364,
        "total_tokens": 1557
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "IBM's treatment of the 0.300% Notes due 2028 remained consistent between the 2022 and 2023 filings. In the 2023 filing, the notes are listed as an actively traded security under Section 12(b) of the Securities Exchange Act, with the New York Stock Exchange as the exchange. The 2022 filing does not mention these notes in the provided sections, but the absence of any changes in the 2023 document suggests no evolution in their treatment, such as restructuring, maturity date adjustments, or disclosure changes. The notes were still outstanding and registered in both periods.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core conclusion. (1) It claims IBM's treatment of the 0.300% Notes due 2028 'remained consistent' between 2022 and 2023, which directly contradicts the ground truth: there was a clear evolution from incorporation by reference in 2022 to explicit listing with a trading symbol (IBM 28B) and formal registration on the NYSE in 2023. (2) The quantitative details (e.g., note name, maturity, interest rate) are accurate, and no numerical calculations are required, so quantitative accuracy is high. (3) However, the multi-hop reasoning fails: the model incorrectly infers that absence of mention in 'provided sections' of the 2022 filing means no evolution occurred, when in fact the 2022 filing did reference the notes via Exhibit 4.1 to the Form 8-K from 2020. The 2023 filing's explicit inclusion in the table of registered securities with a trading symbol represents a material change in disclosure practice, which the LLM overlooks. (4) The answer is partially relevant but fundamentally flawed in reasoning and factual conclusion, hence low correctness and qualitative accuracy scores. Contextual relevance is moderate because it discusses the right instrument and timeframe but mischaracterizes the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 349,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "Apple's Rest of Asia Pacific region saw an increase in net sales from $29.375 billion in 2022 to $29.615 billion in 2023, and operating income rose from $11.569 billion to $12.066 billion, reflecting improved financial performance in the region during this period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: net sales increased from $29.375 billion (equivalent to $29,375 million) in 2022 to $29.615 billion ($29,615 million) in 2023, and operating income rose from $11.569 billion ($11,569 million) to $12.066 billion ($12,066 million). These values match the original answer exactly, with acceptable format variation using billions instead of millions. (2) While the LLM correctly presents the directional change and absolute values, it omits the specific percentage growth (0.8% for net sales, 4.3% for operating income) and the exact dollar differences ($240 million and $497 million). This is a minor omission that reduces completeness but does not affect factual correctness. (3) The multi-hop reasoning is sound—comparing financial performance across two years for a specific geographic segment—and the model correctly synthesizes net sales and operating income trends over time. Entities (Apple, Rest of Asia Pacific, 2022–2023) are accurate. (4) The answer is contextually fully relevant and semantically equivalent in conveying improved financial performance. Quantitative accuracy is perfect. The qualitative score is slightly reduced due to missing explicit growth metrics, but reasoning remains logical. Correctness score is 9 due to high factual accuracy with minor detail omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 385,
        "total_tokens": 1548
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "The vesting period for stock options under the 2007 Omnibus Incentive Plan evolved such that grants made prior to 2022 vested pro rata over a **five-year period**, while grants made after December 31, 2021, vest pro rata over a **four-year period**, as disclosed in the 2022 and 2024 10-K filings. Both vesting schedules terminate ten years from the grant date, but the shortened vesting period for post-2021 grants reflects a plan amendment effective January 1, 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan vested over a five-year period, and those granted after December 31, 2021, vest over a four-year period—this matches the ground truth from both the 2022 and 2024 10-K filings. The key numeric values (5-year vs. 4-year vesting) and the cutoff date (after December 31, 2021) are accurate. (2) All quantitative elements—time periods (five-year, four-year), dates (December 31, 2021, January 1, 2022), and the ten-year termination period—are factually correct and consistent with the original answer. No calculations are required, but the comparison across time periods is accurately represented. (3) The multi-hop reasoning is sound: the model synthesizes information from two different 10-K filings (2022 and 2024) and correctly infers a structural change in the plan effective in 2022. The mention of the plan amendment aligns with the 'amended and restated plan' noted in the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly confirm that the 2024 10-K *reaffirms* the continued application of both vesting schedules (i.e., no further changes), which adds a layer of consistency over time emphasized in the original answer. However, this does not contradict the truth and is implied by stating the current terms. Wording differences are semantically equivalent, and the core facts, entities, and logic are fully accurate. Thus, the answer is highly correct with only a slight omission in contextual reinforcement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 432,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "CVS's approach to validating fair value estimates for Level 2 debt securities remained consistent between 2022 and 2023. The Company continued using matrix pricing models and observable market inputs (e.g., quoted prices for similar assets, interest rates, credit risks) to estimate fair value. Quarterly reviews of selected Level 2 securities against secondary sources and internal independent estimates were conducted, and no price adjustments were made for Level 2 debt securities at December 31, 2023 or 2022. There is no indication of methodological changes or additional price adjustments during this period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: CVS did not adjust any prices for Level 2 debt securities at December 31, 2023 or 2022, used one price per security, and maintained quarterly comparisons to secondary sources. The statement that no price adjustments were made matches the original answer. (2) Quantitative elements—dates (2022, 2023, December 31), and the absence of adjustments—are factually correct. No numerical inaccuracies exist. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the validation approach remained unchanged from 2022 to 2023, including the use of secondary source comparisons and internal reviews. The mention of 'matrix pricing models' and 'observable market inputs' adds detail not contradicted by the ground truth and is consistent with Level 2 valuation practices, though slightly more specific than the original. (4) The only minor gap is that the original emphasizes the 'emphasis on consistent internal validation by the investment team' as a qualitative continuity, which the LLM answer implies but does not explicitly mention. However, this does not detract from factual correctness. Overall, the answer is semantically equivalent, contextually precise, and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 362,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "CVS maintained the same classification and valuation methodology for privately-placed equity securities in 2023 as in 2022. Privately-placed equity securities remained classified in Level 3 of the fair value hierarchy, with fair values determined through internal analysis of financial statements and cash flow projections. Unobservable inputs included earnings/revenue multiples, discount for lack of marketability, and comparability adjustments, as described in both years' disclosures. No changes to the methodology or inputs were noted between 2022 and 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of classification (Level 3), valuation methodology (internal analysis of financial statements and cash flow projections), and the list of unobservable inputs (earnings/revenue multiples, discount for lack of marketability, comparability adjustments) for both 2022 and 2023. All entities, years, and financial terms are correctly identified, and there are no numerical inaccuracies (quantitative accuracy is perfect). However, the LLM incorrectly states that 'no changes to the methodology or inputs were noted between 2022 and 2023,' which contradicts the ground truth. The original answer highlights that while the inputs remained the same, there was an added emphasis in 2023 on the sensitivity of fair value to changes in these inputs—indicating a qualitative evolution in the valuation process, particularly in risk assessment or transparency. This nuance represents a key multi-hop insight (synthesizing disclosures across two years to detect a shift in emphasis), which the LLM failed to capture. Thus, while the factual components are correct, the reasoning and qualitative analysis are incomplete, leading to a partially correct overall response. Contextual relevance is high as the answer directly addresses the question's focus on classification, valuation, and inputs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 367,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an **8.8% decline at actual currency rates**. Internationally, revenue increased slightly from $151 million in 2023 to $153 million in 2024, a **1.5% rise at actual currency rates** (or **7.6% at constant currency rates**), driven by stronger performance in certain regions despite overall market challenges.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total net revenue decline from $272 million in 2023 to $248 million in 2024, and accurately calculates the 8.8% decline. International revenue is correctly stated as increasing from $151 million to $153 million, with a 1.5% growth, matching the ground truth. However, the LLM introduces additional information—'7.6% at constant currency rates'—that is not present in the original answer and cannot be verified from the provided ground truth, which only cites '1.5% growth' without currency adjustments. This addition, while potentially accurate, goes beyond the source data and introduces unverified detail. (2) All numeric values (dollar amounts and percentages) are correct as per the ground truth, and calculations are accurate. The 8.8% decline is correct: (272 - 248)/272 ≈ 0.088. The 1.5% international growth is also correct: (153 - 151)/151 ≈ 0.0132 (rounded to 1.5%). (3) The multi-hop reasoning is sound—revenue trends for both total and international segments across two years are correctly synthesized. The core entities (Alphagan/Combigan, years 2023–2024, revenue metrics) are accurate. (4) The answer is highly relevant and addresses both parts of the question. The only deviation is the inclusion of 'constant currency' data, which, while contextually plausible, is not in the ground truth and slightly undermines qualitative accuracy. Hence, a score of 8 is justified for correctness—core facts are right, but unverified augmentation prevents a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 421,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "Chevron acquired PDC Energy, Inc. (PDC) in 2023, integrating its assets into Chevron's operations. This acquisition contributed to a 7% increase in Chevron's worldwide oil-equivalent production in 2024 compared to 2023, driven by full-year production from PDC's assets, particularly in the Permian Basin, and growth in the DJ Basin. The integration enhanced Chevron's production capacity and reserves, as reflected in the 2024 net production figures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key facts are correct: the 2023 acquisition of PDC Energy by Chevron and the 7% increase in worldwide oil-equivalent production in 2024 are accurately reported, matching the original answer. There are no calculation errors. (2) The LLM correctly identifies the entities (Chevron, PDC Energy), timeframes (2023 acquisition, 2024 production impact), and the operational metric (oil-equivalent production). (3) The reasoning is sound: it correctly infers that the full-year contribution from PDC’s assets (especially in the Permian and DJ Basins) drove part of the production growth, which is consistent with the ground truth’s emphasis on legacy PDC operations contributing to the 7% increase. (4) While the original answer highlights PDC’s exclusion from internal control assessments in 2023 (a detail omitted in the LLM response), this is a secondary compliance point not directly tied to the operational impact on production. The LLM instead adds valuable geographic context (Permian and DJ Basins) not in the original, enhancing clarity. The core multi-hop synthesis—acquisition in 2023 → integration → production impact in 2024—is correctly and coherently presented. The answer is semantically equivalent and contextually complete, warranting a high correctness score with only minor omission of a non-critical detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 391,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "UPS expanded its cold-chain logistics capabilities in 2023 through acquisitions of **Bomi Group** and **MNX Global Logistics**, which enhanced its international cold-chain infrastructure. In 2024, no specific cold-chain-related acquisitions were mentioned in the provided documents. However, the 2024 filing notes a planned acquisition in January 2025 of **Frigo-Trans** and **Biotech & Pharma Logistics** (Germany) to further bolster international complex cold-chain capabilities, though this occurred outside the 2024 timeframe. Thus, the 2023 acquisitions were the primary drivers of growth in this area during the period.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 acquisitions of Bomi Group and MNX Global Logistics, which aligns with the ground truth. However, it incorrectly states that no cold-chain acquisitions occurred in 2024, when in fact the ground truth confirms that UPS acquired Frigo-Trans and Biotech & Pharma Logistics in Germany in 2024 for approximately $440 million. The LLM mischaracterizes the timing of this acquisition, claiming it was 'planned for January 2025' and thus outside the 2024 scope, which contradicts the original answer stating the acquisition occurred in 2024. (2) The $440 million figure is missing from the LLM answer, a key quantitative detail present in the ground truth. While no explicit calculation is required, the omission of the dollar amount reduces quantitative accuracy. (3) The multi-hop reasoning is partially sound—LLM connects 2023 acquisitions to cold-chain expansion and attempts to assess 2024 developments—but fails in synthesizing the correct timing and significance of the German acquisitions. This breaks the chain of accurate inference about UPS’s strategic shift toward high-value international cold-chain investments. (4) Despite the factual error on timing and missing financial figure, the LLM maintains contextual relevance by focusing on the right companies and strategic intent. However, the core claim that no 2024 acquisitions occurred directly contradicts the ground truth, warranting a moderate correctness score due to significant but not total inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 418,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "Linde plc's non-employee director RSU program evolved between 2022 and 2024 through governance enhancements and alignment mechanisms. In 2024, the Board adopted a new **Non-employee Director Deferral Program** (Exhibit 10.16), expanding governance structure by introducing deferral options to align director incentives with long-term performance. The 2021 Long Term Incentive Plan (Exhibit 10.02) already included **performance-based RSUs** tied to Total Shareholder Return (TSR) and Return on Capital metrics, reinforcing long-term alignment. Additionally, the 2023 adoption of an **Executive Clawback Policy** (Exhibit 97.1) further strengthened accountability, ensuring compensation adjustments for non-compliant performance, thereby enhancing shareholder value focus.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution of Linde plc's non-employee director RSU program, noting the introduction of the Non-employee Director Deferral Program in 2024 and its governance implications. It accurately references the 2021 Long Term Incentive Plan as the foundation for performance-based RSUs. However, the original answer does not mention the Executive Clawback Policy adopted in 2023, which is absent from the ground truth; this is an addition not supported by the provided knowledge graph and introduces a factual overreach. (2) Quantitatively, all dates (2021 plan, 2024 deferral program adoption) are correct, and there are no numerical inaccuracies—minor formatting like 'Exhibit 10.16' or 'Exhibit 97.1' may reflect real filing structures but aren't contradicted by the ground truth. (3) The multi-hop reasoning is partially sound: the model correctly links the deferral program to enhanced governance and long-term alignment, and ties performance-based RSUs to shareholder alignment. However, the inclusion of the clawback policy introduces a synthesis not present in the original answer and may reflect confabulation or external knowledge not in the ground truth. (4) The contextual relevance is high as the response directly addresses governance structure and shareholder alignment. The qualitative accuracy is reduced due to the unsupported claim about the 2023 clawback policy, which distracts from the core evolution of the RSU and deferral programs. Overall, the answer captures the key developments but adds unverified elements, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 442,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "Between 2022 and 2024, General Motors' financial relationship with Stellantis primarily involved ongoing indemnification obligations stemming from the 2017 Opel/Vauxhall sale. GM agreed to indemnify Stellantis for certain losses related to inaccuracies in representations and warranties, emissions claims, product liabilities, and recalls, with caps and time limitations on payments. Additionally, in 2021, GM recognized gains related to Stellantis N.V. (Stellantis) warrants, which contributed to non-operating income. By 2024, these indemnification obligations remained in place, though no further specific investment gains related to Stellantis were detailed in the provided documents.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the indemnification obligations from the 2017 Opel/Vauxhall sale, including emissions claims, product liabilities, and recalls, which aligns with the ground truth. It also mentions GM's gains from Stellantis warrants, capturing the financial aspect of the relationship. However, there is a factual error in stating the gain was recognized in 2021, while the ground truth specifies 2022 (a one-year discrepancy). The $0.2 billion gain is not explicitly quantified in the LLM answer, which omits a key numeric detail. (2) Quantitatively, the absence of the $0.2 billion figure reduces precision, though no incorrect numbers are stated. The reference to 2021 instead of 2022 is a clear date inaccuracy. (3) The multi-hop reasoning is partially sound—linking the 2017 sale to ongoing indemnities and connecting warrant gains to the financial relationship—but fails to fully contrast the shift from financial gain in 2022 to legal risk in 2024 due to the incorrect year attribution. (4) Despite the date and magnitude omissions, the answer remains contextually relevant and captures the evolving nature of the relationship, just not with full factual accuracy on timing and scale. Hence, scores reflect minor but notable deficiencies in quantitative and qualitative accuracy, with high contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 377,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "Southern Company's treatment of energy-related derivatives remained consistent in categorizing them as regulatory hedges, cash flow hedges, or non-designated instruments, with financial presentation split into current and non-current assets/liabilities. In 2024, the disclosure expanded to include detailed netting arrangements and cash collateral offsets (e.g., $17 million in broker margin accounts), reflecting more granular presentation of derivative positions. The categorization and hedging accounting methods aligned with prior years, but 2024 introduced specific net amounts recognized in the balance sheets, emphasizing transparency in offsetting derivatives against cash collateral.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. The ground truth indicates a shift from income statement-focused disclosure in 2022 (reporting pre-tax effects on income for prior years) to balance sheet-focused disclosure in 2024 (fair value as assets/liabilities under 'Other' or 'Risk Management Activities'). However, the LLM claims the treatment remained consistent and emphasizes netting arrangements and cash collateral offsets (e.g., $17 million in broker margin accounts), which are not mentioned in the original answer and appear fabricated. (2) The $17 million figure is a specific numeric claim with no support in the ground truth; no dollar amounts were provided in the original answer, making this a clear quantitative inaccuracy. (3) The multi-hop reasoning is flawed: the question asks for evolution in treatment and disclosure from 2022 to 2024, but the LLM fails to identify the key shift from income statement to balance sheet presentation. Instead, it asserts consistency in categorization and introduces new, unsupported details about netting and collateral. (4) While the LLM stays within the domain of derivative disclosures and addresses financial presentation, it misses the core evolution described in the ground truth, leading to a low correctness score. Contextual relevance is moderate because it discusses related concepts but fails on factual accuracy and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 395,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "Between 2023 and 2024, GILD's strategic relationship with Arcus evolved through increased equity ownership and enhanced governance influence. In January 2024, GILD made an additional $320 million equity investment in Arcus, raising its ownership stake from approximately 19.9% (as of December 31, 2023) to 33%. This investment was tied to an amended Collaboration Agreement, which also included paying a $100 million option continuation fee. Governance influence expanded as GILD increased its number of board designees on Arcus' board from two to three, reflecting deeper strategic alignment and control over future collaboration opportunities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: GILD's ownership increased from 19.9% in 2023 to 33% in January 2024 following a $320 million equity investment, and board representation expanded from two to three designees. All numeric values (19.9%, 33%, $320 million, two to three board seats) match the ground truth exactly. (2) Quantitative accuracy is perfect—percentages, dollar amounts, and dates are correct and consistent with the original answer. The mention of a $100 million option continuation fee is not present in the ground truth but does not contradict it; however, its inclusion introduces a minor unverified detail that slightly affects qualitative accuracy. (3) Multi-hop reasoning is sound: the model correctly synthesizes changes in ownership and governance across time (2023 to 2024), linking financial commitment to governance influence. The evolution of the strategic relationship is logically inferred from equity and board changes. (4) The answer is semantically equivalent to the ground truth and fully addresses the question. The only minor issue is the addition of the $100 million fee, which, while plausible in context, is not part of the verified answer and slightly reduces confidence in pure factual replication. Hence, correctness and qualitative accuracy are high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 373,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "The maturity date of the 2021 Multicurrency Credit Facility was extended from **June 30, 2025** (as of December 2022) to **July 1, 2026** in 2023, following amendments on June 29, 2023. The borrowing capacity remained unchanged at **$6.0 billion** throughout this period, with sublimits for multicurrency borrowings and other facilities adjusted but not affecting the total commitment.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the maturity date correctly shifts from June 30, 2025 (as of 2022) to July 1, 2026 (in 2023), and the borrowing capacity remains at $6.0 billion—both matching the original answer. The mention of amendments on June 29, 2023, adds contextual precision without contradicting the ground truth. (2) The answer addresses both parts of the question—evolution of maturity date and borrowing capacity—completely. (3) Entities are correctly identified: the '2021 Multicurrency Credit Facility' is accurately referenced with correct time periods (2022 to 2023). (4) The reasoning is sound: the LLM correctly infers no change in borrowing capacity and a one-year extension in maturity, noting that sublimits were adjusted but the total commitment remained unchanged, which aligns with the strategic intent implied in the original answer. (5) Semantic equivalence is achieved—even though the LLM does not explicitly state 'no increase in total commitment' or 'financial flexibility,' the meaning is preserved through accurate facts and logical synthesis across years. Minor additional detail (amendment date) enhances rather than detracts from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 355,
        "total_tokens": 1555
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "Chevron's utilization of imported crude oil in U.S. refining operations remained approximately **60%** in both 2023 and 2024, as stated in the refining operations sections of both filings. However, **refinery capacity utilization** decreased from **90.8% in 2023** to **86.6% in 2024**, reflecting a decline in operational efficiency or input volumes, while the proportion of imported crude oil remained stable.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Chevron's utilization of imported crude oil remained at approximately 60% in both 2023 and 2024, matching the ground truth. It also accurately reports the refinery capacity utilization figures: 90.8% in 2023 and 86.6% in 2024. All numeric values are correct and properly attributed to the respective years. (2) Quantitative accuracy is perfect—percentages and years are exact, with no calculation errors. The decrease from 90.8% to 86.6% is correctly presented as a decline. (3) The multi-hop reasoning is sound: the model synthesizes data across two years and two metrics (imported crude oil share and capacity utilization), correctly identifying that while the crude oil import dependency remained stable, operational utilization decreased. The only minor shortcoming is the use of 'operational efficiency' in the explanation, which slightly mischaracterizes capacity utilization—it reflects operational intensity or throughput levels, not necessarily efficiency. This does not invalidate the answer but introduces a small conceptual imprecision. (4) The answer is fully relevant, addressing both parts of the question with accurate data and logical synthesis. The core facts and trends are correctly conveyed, warranting a high correctness score despite minor wording nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 371,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "UPS reduced its hedging position in British Pound Sterling (GBP) from $663 million in 2023 to $536 million in 2024, as reflected in the notional amounts of outstanding currency hedges. This decrease suggests a strategic adjustment in currency risk management, potentially aligning hedging activities with reduced exposure or evolving market conditions. The shift indicates UPS's proactive approach to managing foreign exchange risk, prioritizing alignment with forecasted cash flows and operational needs while maintaining flexibility in its hedging program.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the hedging position values for UPS in British Pound Sterling: $663 million in 2023 and $536 million in 2024, matching the ground truth. The reduction of 127 million units (19.15%) is implied by the stated figures, though the percentage decrease is not explicitly mentioned in the LLM response. This omission is minor and does not affect the core accuracy. 2) All numeric values are accurate and correctly formatted; the use of '$' is acceptable as the original answer uses 'units' without specifying currency unit type, but in context, 'million' refers to notional value, so '$' is a reasonable interpretation. The calculation of the difference (663 - 536 = 127) is correct, though not shown. 3) The reasoning is sound: the LLM correctly infers that the reduction indicates a strategic shift in currency risk management, aligning with reduced exposure or changing market conditions. It appropriately links the change to proactive risk management, forecasted cash flows, and operational needs—consistent with the ground truth's interpretation of a more conservative or reassessed strategy. 4) The answer is semantically equivalent and contextually complete. While it doesn't explicitly state the percentage drop (19.15%), it conveys the essential evolution and strategic implication accurately. The multi-hop synthesis—connecting two years of hedging data to infer strategic intent—is correctly executed. Minor deduction in qualitative accuracy due to lack of explicit quantification of the change (e.g., 'reduced by 127 million' or '19%'), but overall reasoning remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 440,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "The fair value of Bank of America's money market investments increased from $1.2 billion in 2023 to $1.3 billion in 2024. This growth indicates a strategic emphasis on maintaining liquidity and managing short-term cash requirements, reflecting a conservative approach to preserve capital and ensure readiness for operational needs. The increase aligns with the company's focus on low-risk, liquid assets to mitigate volatility and support financial flexibility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the fair value of money market investments increased from $1.2 billion in 2023 to $1.3 billion in 2024, matching the ground truth in both values and direction of change. The years are correctly attributed, and the dollar amounts are accurate with acceptable formatting. (2) Quantitatively, both figures are correct, and the implied $0.1 billion increase is accurate. No calculations were required beyond the stated values, and the model reported them precisely. (3) The reasoning is sound and aligns with the ground truth: the increase indicates a shift in short-term investment strategy. While the original answer describes it as 'modest growth' and 'slight expansion,' the LLM interprets this as a 'strategic emphasis on liquidity' and 'conservative approach,' which is a reasonable and plausible interpretation, though slightly more interpretive than the original. It correctly synthesizes the implication of the increase in the context of liquidity and risk management. (4) The answer is fully relevant to the question, addressing both the quantitative evolution and the strategic implication. The only minor difference is in tone and specificity of interpretation, not factual content, justifying a high but not perfect qualitative score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 363,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "The maximum expected volume of natural gas subject to physical supply contracts with sell-back options decreased from **26 million mmBtu** in 2022 to **15 million mmBtu** in 2024. Subsidiary breakdowns showed reductions: Alabama Power (6 → 4 mmBtu), Georgia Power (8 → 6 mmBtu), Mississippi Power (4 → 2 mmBtu), and Southern Power (8 → 3 mmBtu). This reflects a general decline across all subsidiaries.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All numeric values are correct: the total volumes (26 million mmBtu in 2022, 15 million mmBtu in 2024) and subsidiary-specific volumes (Alabama Power: 6→4, Georgia Power: 8→6, Mississippi Power: 4→2, Southern Power: 8→3) match exactly. Minor formatting variation (e.g., 'mmBtu' vs 'million mmBtu') is acceptable and does not affect meaning. (2) Calculations are accurate: the totals are correctly represented, and the directional changes (reductions) are properly noted. (3) Multi-hop reasoning is sound—the model correctly synthesizes data across Southern Company and its four subsidiaries across two years, demonstrating understanding of the hierarchical structure and temporal change. (4) The only minor shortcoming is the use of 'mmBtu' without the 'million' qualifier in the subsidiary list (e.g., '6 → 4 mmBtu' instead of '6 million mmBtu'), which could cause ambiguity, though context makes the scale clear. The conclusion about a 'general decline' is equivalent to the ground truth's 'consistent reduction.' Overall, the answer is factually complete, contextually relevant, and semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 338,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "Adobe's integration of the Firefly Vector Model expanded across its product suite from 2023 to 2024, with enhanced capabilities and broader adoption. In 2023, the model was integrated into Adobe Photoshop, Illustrator, Adobe Express, and Adobe Stock, enabling text-based generation of editable vector graphics. By 2024, the Firefly Vector Model was further embedded into additional products like Adobe Acrobat and Adobe Stock, with expanded AI-powered tools in apps such as Premiere Pro and After Effects. The 2024 filings also highlighted enterprise-focused Firefly Services and Custom Models, allowing businesses to leverage the Vector Model for specialized use cases, while maintaining its core role in creative workflows across Adobe's ecosystem.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 the Firefly Vector Model was integrated into Adobe Express only, enabling text-to-image and text effects in over 100 languages. However, the LLM incorrectly states it was integrated into Photoshop, Illustrator, Adobe Express, and Adobe Stock in 2023, which contradicts the original answer. The expansion in 2024 was specifically into Adobe Illustrator with Generative Recolor, but the LLM claims integration into Acrobat, Premiere Pro, After Effects, and expanded use in Adobe Stock—none of which are supported by the ground truth. The mention of 'enterprise-focused Firefly Services and Custom Models' in 2024 is not present in the original answer and appears fabricated. (2) While there are no explicit numbers (e.g., dollar amounts, percentages) to verify, the temporal claims (2023 vs. 2024 functionality) are factually incorrect, undermining quantitative accuracy related to time-bound developments. (3) The multi-hop reasoning is flawed: the original answer traces a clear evolution from Adobe Express in 2023 to Illustrator in 2024, showing a progression in professional tool integration. The LLM fails this synthesis, instead inventing broader integrations and advanced enterprise features without evidence. (4) Contextual relevance is moderate because the answer discusses the general theme of Firefly’s expansion across Adobe products, which is relevant, but the specific claims are largely incorrect. Due to major factual and entity errors, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 438,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "The commercial significance of Biktarvy for GILD increased from 2023 to 2024, as reflected in the $11,850 million in sales reported for 2023, with continued strong performance in key regions like the U.S. and Europe. This growth underscores Biktarvy's role as a core product in GILD's HIV portfolio, reinforcing the company's strategy to maintain leadership in HIV treatment through sustained demand and market positioning. The consistent revenue contribution highlights its strategic importance in supporting long-term HIV business goals, including maintaining market share and driving innovation in antiretroviral therapies.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 sales figure of $11,850 million for Biktarvy, which matches the ground truth, and correctly identifies Biktarvy as a core product in GILD's HIV portfolio. However, it incorrectly implies continued growth or strong performance in 2024, whereas the original answer states that while Biktarvy remained central, GILD highlighted increased risks due to generic competition and shifting treatment paradigms, indicating a more cautious outlook rather than an improved commercial position. The LLM fails to mention the strategic concern about overreliance on TAF-based products or the need for pipeline diversification, which is a key qualitative shift in 2024. (2) Quantitatively, the $11,850 million figure is accurate and properly attributed to 2023; no other numbers are introduced, so there are no calculation errors. (3) The multi-hop reasoning is partially sound—Biktarvy's importance in 2023 is correctly established—but the synthesis breaks down when projecting into 2024, where the LLM omits critical strategic risks and instead assumes continued strength without evidence. The answer does not reflect the evolving challenge to GILD's HIV business model. (4) The correctness score is 5 due to accurate numbers but significant omission of key strategic implications in 2024. Quantitative accuracy is 10 because all numbers are correct. Qualitative accuracy is 5 due to flawed reasoning about the evolution of commercial significance. Contextual relevance is 8 because the response stays on topic and addresses the HIV business strategy, albeit with incomplete and somewhat misleading analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 451,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "The Series 2018-1A Securities maintained a consistent outstanding principal amount of **$496.1 million (2022)** and **$496.8 million (2023)**, with no significant changes in principal. The **interest rate remained at 3.652%** throughout both years. Key terms, including the maturity date (March 15, 2028) and final legal maturity (March 15, 2048), stayed unchanged. No repayments or adjustments to principal were noted between 2022 and 2023, reflecting stable financial structure and terms.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the principal amounts. According to the ground truth, the outstanding principal in 2022 was $500.0 million, not $496.1 million as stated by the LLM. The 2023 principal is correctly reported as $496.8 million. This misstatement of the 2022 principal by nearly $4 million is a major quantitative error. Additionally, the LLM claims 'no significant changes' and 'no repayments or adjustments', but the ground truth indicates a deliberate reduction from $500.0M to $496.8M, which contradicts the LLM's characterization. (2) The interest rate of 3.652% is correctly reported for both years. The maturity dates (March 15, 2028 and 2048) are contextually relevant but not requested in the question, so their inclusion is neutral. (3) The multi-hop reasoning is partially sound—the model attempts to compare two years and extract financial terms—but fails in data retrieval for 2022 principal. The synthesis is flawed due to incorrect input data. (4) The contextual relevance is high because the answer addresses the evolution of principal and interest rate as asked, and includes relevant security terms. However, the quantitative inaccuracy severely undermines the correctness, warranting a low score. The qualitative accuracy is moderate because the structure and intent are correct, but key facts are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 381,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "UPS's relationship with Coyote evolved from impairment to divestiture between 2023 and 2024. In 2023, UPS recorded a $111 million goodwill impairment charge for the Coyote trade name due to declining market conditions and strategic reevaluation. By 2024, UPS finalized the divestiture of Coyote, resulting in a $156 million gain on the sale. This shift reflected a strategic decision to exit the truckload brokerage business, aligning with broader transformation initiatives to streamline operations and focus on core logistics segments, while reducing exposure to underperforming assets.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $111 million impairment charge in 2023 related to the Coyote trade name and the strategic shift leading to divestiture in 2024, which aligns with the ground truth. However, it introduces a $156 million gain on sale in 2024 that is not present in the original answer or supported by the ground truth, which only mentions the divestiture's impact on revenue due to Coyote's exit, not any gain. This is a significant factual error affecting quantitative accuracy. (2) The $111 million figure is correct and matches the ground truth (impairment charge), but the $156 million gain is incorrect and unsupported. The original answer does not mention any gain from the sale, only the negative revenue impact from Coyote's exit. (3) The reasoning correctly traces a multi-hop evolution from impairment in 2023 to divestiture in 2024 and infers strategic rationale (streamlining, focusing on core logistics), which is plausible and contextually sound. However, the addition of an unsupported financial figure undermines the factual synthesis. (4) The contextual relevance is high as the answer addresses both financial impact and strategic direction. Qualitative accuracy is moderate due to correct reasoning but flawed data. Correctness score is reduced primarily due to the fabricated $156 million gain, which misrepresents the financial impact in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 388,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "Linde plc's Performance Share Unit (PSU) Awards for grants beginning in 2019 utilized **Return on Capital (ROC)** and **Total Shareholder Return (TSR)** as performance metrics, as outlined in the 2021 Long Term Incentive Plan (LTIP) and its amendments. Between 2022 and 2024, the structure remained consistent, with no changes to the performance metrics for these awards, as indicated in the 2024 10-K filing (Exhibit 10.03e). The metrics continued to focus on financial performance and shareholder value creation.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that Linde plc's Performance Share Unit (PSU) Awards for grants beginning in 2019 used Return on Capital (ROC) and Total Shareholder Return (TSR) as performance metrics and that this structure remained unchanged between 2022 and 2024. This aligns with the ground truth, which confirms the dual structure was maintained through 2024 with corresponding exhibits (e.g., 2022: Exhibits 10.11k/l; 2024: Exhibits 10.10l/m). However, the LLM cites the '2021 Long Term Incentive Plan' and refers to Exhibit 10.03e in the 2024 10-K, which diverges from the ground truth specifying the 'Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan' and Exhibits 10.10l and 10.10m. While the core factual claim about metric consistency is correct, the plan name and exhibit reference are inaccurate, indicating a minor sourcing error. The reasoning is logically sound—correctly inferring stability in PSU structure over time—and the answer addresses all key parts of the question. The semantic meaning is equivalent to the original answer, though slightly less precise in documentary references. No calculation errors; dates and entities (Linde plc, 2019 grants, 2022–2024 period) are accurate. Thus, high scores for quantitative and qualitative accuracy, with full marks for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 365,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "Between 2023 and 2024, Trodelvy's regulatory status advanced with the FDA granting it **Breakthrough Therapy designation** for treating **extensive-stage small cell lung cancer (SCLC)** in 2024, marking its second such designation. This indicates accelerated development and regulatory review for a new indication, highlighting its potential to address unmet medical needs in SCLC. Additionally, Trodelvy retained its 2023 approvals for HR+/HER2- breast cancer and urothelial cancer, underscoring its established trajectory as a multi-indication oncology therapy. The Breakthrough Therapy designation for SCLC signals ongoing innovation and regulatory confidence in its efficacy, reflecting a broadening development pipeline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the key regulatory development: the FDA granted Breakthrough Therapy designation to Trodelvy in 2024 for extensive-stage small cell lung cancer (SCLC) in patients who progressed after platinum-based chemotherapy. This matches the original answer's core fact. (2) All dates (2023, 2024) and indications are accurate—LLM correctly notes retained approvals for HR+/HER2- breast cancer and urothelial cancer from 2023, and adds the 2024 SCLC designation. The term 'Breakthrough Therapy designation' is used correctly. (3) The multi-hop reasoning is sound: it synthesizes Trodelvy’s existing indications with the new 2024 designation to infer a broadening development trajectory and regulatory confidence. (4) The only minor shortcoming is that the original answer explicitly mentions 'unresectable locally advanced or metastatic triple-negative breast cancer' as a 2023 indication, which the LLM omits, instead listing only HR+/HER2- breast cancer and urothelial cancer. While not incorrect, this is a partial omission of the full 2023 indication scope. However, the LLM’s conclusion about multi-indication expansion remains valid. Wording differences are semantically equivalent and acceptable. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 381,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "The Vertex AI platform within Google Cloud evolved from 2023 to 2024 by integrating advanced generative AI models like Gemini 2.0, enhancing its capabilities to train, tune, and deploy applications using Gemini, Imagen, and Veo. In 2024, Vertex AI expanded to include pre-packaged AI agents for software development and cybersecurity, alongside Gemini's multimodal capabilities, enabling richer features like AI-driven recommendations and experimental tools (e.g., Project Astra). This integration solidified Vertex AI as a core platform for leveraging Google's cutting-edge AI models across enterprise and developer workflows.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in describing the evolution of Vertex AI from 2023 to 2024 with respect to generative AI integration, and correctly identifies the inclusion of Gemini and other models in 2024. It accurately reflects the platform's expanded capabilities, such as training, tuning, and deploying applications using advanced models. However, the original answer emphasizes specific new services added in 2024—vector search, grounding, and distillation—for improving model cost and quality, which are not mentioned in the LLM response. Instead, the LLM introduces details not present in the ground truth, such as 'Gemini 2.0', 'pre-packaged AI agents for software development and cybersecurity', 'Project Astra', and 'Imagen' and 'Veo' integrations, which are not supported by the provided knowledge graph. While these may be factually accurate in a broader context, they go beyond the verified information and introduce unverified specifics. The timeline (2023 vs 2024) is handled correctly, and the general direction of evolution—toward deeper, optimized generative AI integration—is semantically aligned. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. The reasoning is sound but overextends with unsupported details, slightly reducing qualitative accuracy. Contextual relevance remains high as the response directly addresses the platform’s evolution in capabilities and generative AI integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 401,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "The treatment of weather derivatives in SO's financial disclosures from 2022 to 2024 shows that immaterial amounts associated with weather derivatives were excluded from derivative valuations, as noted in the 2021 report. Specifically, the 2021 document states that \"Net amounts of derivative instruments outstanding exclude immaterial premium and intrinsic value associated with weather derivatives for all periods presented.\" This exclusion remained consistent in subsequent years, as no changes in the treatment or valuation of weather derivatives were explicitly detailed in the provided 2022–2024 pages. Thus, the exclusion of immaterial weather derivatives persisted without modification.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly references the '2021 report' as the source of the disclosure about immaterial weather derivatives, while the question and ground truth focus on 2022–2024. The ground truth states that in 2022, SO disclosed immateriality without specific amounts, and by 2024, added new context with specific cash collateral figures ($17M and $62M). The LLM answer fails to mention these 2023 and 2024 cash collateral amounts entirely, which are key quantitative updates in the disclosure trend. (2) Quantitatively, the LLM omits the $17 million and $62 million cash collateral figures disclosed in 2024 and 2023, respectively—critical data points showing increased disclosure granularity. Instead, it erroneously relies on a 2021 document not in the evaluation scope, undermining numerical accuracy. (3) Regarding reasoning, the LLM incorrectly concludes that 'no changes' occurred in treatment from 2022–2024, when the ground truth indicates an evolution in disclosure practices—specifically, the addition of cash collateral details—even if the treatment of weather derivatives themselves remained immaterial. This reflects a failure in multi-hop reasoning: the model should have recognized that enhanced collateral disclosures represent a change in the overall derivative reporting framework, even if weather derivatives remained excluded. (4) The answer is contextually relevant in addressing the exclusion of weather derivatives and immateriality, but lacks completeness and precision. It captures the consistent exclusion theme but misses the nuanced progression in disclosure depth, resulting in a partially correct but significantly incomplete response. Hence, correctness is scored low due to missing key facts and referencing incorrect years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 494,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "Between 2023 and 2024, **Biktarvy's regulatory and market positioning evolved** through expanded indications and label updates. In 2023, the FDA approved an expanded indication for Biktarvy to treat HIV patients with suppressed viral loads and known/suspected M184V/I resistance, alongside an updated label reinforcing its safety and efficacy for pregnant individuals with HIV-1. In 2024, the FDA further solidified this positioning by approving additional data to reinforce Biktarvy's safety and efficacy profile for pregnant patients, enhancing its market relevance and therapeutic value. Patent expiration dates remained unchanged (U.S. 2033, EU 2033), but the regulatory updates strengthened its competitive standing in HIV treatment.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly swaps the years for key regulatory events. According to the ground truth, in 2023, Biktarvy had a U.S. patent expiration in 2033 (market exclusivity), and in 2024, it received the FDA expanded indication for M184V/I resistance and updated labeling for use in pregnant people. However, the LLM states that these regulatory updates occurred in 2023, with further reinforcement in 2024, which reverses the timeline and misrepresents the evolution. This is a critical factual error. (2) Quantitatively, the patent expiration year (2033) is correctly cited, and no other numbers (e.g., dollar amounts, percentages) are present, so this part is accurate. However, the misplacement of events across years undermines temporal accuracy. (3) The multi-hop reasoning is partially sound—linking patent protection, regulatory approvals, and label updates to market positioning—but the incorrect temporal assignment breaks the logical evolution from 2023 to 2024. The model fails to show the shift from patent-based positioning in 2023 to expanded indication in 2024, instead attributing both to 2023. (4) Contextually, the answer is relevant and uses appropriate terminology, discussing regulatory and market positioning as asked. However, due to the reversal of key events, the core factual narrative is flawed, warranting a low correctness score despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 390,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "Between 2022 and 2023, AMT's utilization of the 2021 Multicurrency Credit Facility involved **$3.0 billion in borrowings** and **$6.1 billion in repayments** during 2023. The facility was amended in June 2023 to extend its maturity to **July 1, 2026**, increase its commitment to **$6.0 billion**, and replace the LIBOR benchmark with SOFR. As of December 31, 2023, the outstanding balance was **$723.4 million**, reflecting active use for debt repayments (e.g., the 2021 USD Delayed Draw Term Loan) and general corporate purposes.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.0 billion in borrowings and $6.1 billion in repayments under the 2021 Multicurrency Credit Facility in 2023, which matches the ground truth. It also accurately reports the June 2023 amendment that extended the maturity to July 1, 2026, and replaced LIBOR with SOFR. However, it incorrectly states that the amendment 'increased' the commitment to $6.0 billion, while the ground truth specifies that the total commitment was 'maintained' at $6.0 billion, implying no increase. This is a factual inaccuracy in characterization. Additionally, the LLM introduces an 'outstanding balance of $723.4 million as of December 31, 2023', which is not present in the original answer and cannot be verified from the provided ground truth, raising concerns about unsupported inference. The 2022 borrowing activity—$850.0 million in net additional borrowings—is completely omitted, which is a significant gap given the question asks about changes between 2022 and 2023. (2) Quantitative accuracy is mostly correct: $3.0 billion, $6.1 billion, July 1, 2026, and SOFR replacement are all accurate. The $723.4 million figure is unverified and potentially misleading. The EUR-to-USD repayment conversion ($919.1 million) is omitted. (3) The reasoning shows partial multi-hop synthesis—correctly linking 2023 activity and amendments—but fails to contrast 2022 and 2023 usage as required by the question. The omission of 2022 data weakens the comparative analysis. (4) Despite missing 2022 details and introducing an unverified balance, the answer remains contextually relevant, focusing on the correct facility, company, and time frame. Scores reflect mostly accurate data with key omissions and one mischaracterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 478,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "Alphabet's advertising revenue recognition strategy, including the role of Google Ad Manager, remained consistent between 2023 and 2024. Google Ad Manager is part of the platforms (e.g., Google Ads, Ad Manager, Display & Video 360) through which customers purchase advertising inventory. Revenue for ads on Google Network properties is recognized on a gross basis, with amounts billed to customers recorded as revenue and payments to partners as cost of revenues. No significant changes in integration with revenue reporting models were noted in the 2024 disclosures compared to 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that there was no change in Google Ad Manager's role between 2023 and 2024. The ground truth confirms a strategic evolution in 2024 where Alphabet shifted from a transactional gross reporting model to a more control-based justification for gross revenue recognition, emphasizing its role as principal, control over inventory, and pricing discretion. The LLM denies this change, stating 'no significant changes,' which contradicts the ground truth. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, the absence of numbers does not impact scoring here, and the response does not introduce any incorrect figures, hence a score of 10. (3) The multi-hop reasoning is flawed: the question requires synthesis of changes in revenue recognition strategy over time, particularly in how Google Ad Manager integrates with reporting models. The LLM fails to recognize the shift in accounting rationale (from transactional to control-based), which is central to the evolution. This represents a failure in qualitative reasoning and entity-function mapping over time. (4) Contextual relevance is moderate—the response discusses Google Ad Manager and revenue recognition in the correct context of Alphabet and gross reporting, but it misses the core analytical point about strategic evolution, making it partially relevant but ultimately misleading. The correctness score is low due to the critical factual inaccuracy regarding the absence of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 427,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "Between 2023 and 2024, UPS recorded a **$56 million goodwill impairment charge for Roadie in 2023**, reflecting the full goodwill amount associated with the 2021 acquisition. In 2024, **no impairment charges were recorded**, but Roadie was identified as one of three reporting units with \"limited excess of fair value\" over carrying amount, indicating heightened impairment risk. The 2024 risk assessment highlighted that factors like increased cost of capital or unmet cash flow forecasts could trigger future impairments, though UPS maintained that Roadie's fair value still exceeded its carrying amount. Strategic monitoring and potential adjustments to intangible asset lives under Efficiency Reimagined initiatives remain key to managing exposure.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the $56 million goodwill impairment charge in 2023 is accurately reported, and the absence of a 2024 impairment is correctly stated. The format '$56 million' matches the ground truth semantically. (2) The answer correctly identifies that in 2024, Roadie was among the reporting units with 'limited excess of fair value over carrying amount,' which aligns with the original answer's 'limited excess of fair value over carrying value'—a synonymous phrasing. (3) The multi-hop reasoning is sound: it connects the 2023 impairment to the 2024 risk assessment, explaining the evolution from active impairment to ongoing monitoring. It also correctly references external risk factors like cost of capital and cash flow forecasts, which are mentioned in the ground truth. (4) The strategic context is well captured, including UPS's Efficiency Reimagined initiatives and the potential for future adjustments to intangible asset lives, which adds relevant depth without introducing inaccuracies. All entities (UPS, Roadie), years (2023, 2024), and financial concepts (goodwill impairment, fair value, carrying value) are correctly used. The answer is complete, factually accurate, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 367,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "Linde's relationship with helium evolved such that the global helium wholesale business, part of the \"Other\" segment, experienced lower sales volumes in 2024 compared to 2023, contributing to a 2% decline in Other segment sales. While helium-related sales decreased, operating profit in the \"Other\" segment increased by $19 million (44%) in 2024, driven by insurance recovery for LAMT, though higher costs due to helium partially offset this gain. The 2022 data provided does not explicitly detail helium's impact, but the 2024 results highlight a shift toward lower helium sales volumes and associated cost pressures.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution of Linde's relationship with helium from 2022 to 2024, noting a shift from neutral/positive to a source of cost pressure and lower volumes. It accurately states the 2% underlying sales decrease in the 'Other' segment due to lower helium volumes and mentions the insurance recovery for LAMT. However, the LLM incorrectly states that operating profit in the 'Other' segment increased by $19 million (44%) in 2024, which contradicts the ground truth that emphasizes increased costs from helium partially offset by insurance recovery—no net increase in profit is implied in the original. This is a significant quantitative inaccuracy. (2) The $19 million and 44% figures are not present in the ground truth and appear to be fabricated or misattributed; the original does not provide a net positive change in operating profit for the segment. All other numbers (2% sales decline) are correct. (3) The multi-hop reasoning is mostly sound: the model connects helium to the 'Other' segment, links lower volumes to sales impact, and recognizes the dual effect of higher costs and insurance recovery. However, the conclusion about operating profit improvement contradicts the original's emphasis on cost pressure outweighing recovery. (4) Scores reflect mostly correct qualitative understanding and contextual relevance, but the incorrect operating profit claim reduces quantitative and overall correctness. Minor omission: the original explicitly notes helium was a 'supply component' in 2022, which the LLM downplays as 'not explicitly detailed,' missing a key baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 443,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "The total value of loans covered under long-term credit protection agreements with FNMA and FHLMC decreased from **$8.7 billion at December 31, 2023** to **$8.0 billion at December 31, 2024**. This reduction indicates a decline in the Corporation's exposure to residential mortgage loans that became severely delinquent, as these agreements provide full credit protection for such loans. Since all covered loans are individually insured, the Corporation does not record an allowance for credit losses related to them. The decrease may reflect improved loan performance, repayments, or portfolio adjustments, but the agreements continue to mitigate credit risk exposure by insuring these loans against severe delinquency.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the loan values of $8.7 billion in 2023 and $8.0 billion in 2024, matching the ground truth exactly. The time reference (December 31) is consistent with standard reporting in SEC filings and adds appropriate precision. (2) Quantitative accuracy is perfect: both dollar amounts are correct, and the implied $0.7 billion decrease is accurate. No calculations were required beyond the stated values, and the LLM presents them correctly. (3) The reasoning is sound and captures the core implication: that a decline in covered loans suggests reduced reliance on full credit protection, which correlates with lower exposure to severely delinquent residential mortgage loans. The LLM correctly notes that no allowance for credit losses is recorded on these loans due to full protection. It adds plausible contributing factors (improved performance, repayments, portfolio adjustments) not in the original but logically consistent and contextually appropriate. (4) The answer is fully relevant, addressing both the quantitative evolution and the implication for credit risk exposure. The only minor shortcoming is that it slightly reframes the implication—while the original emphasizes a potential decrease in high-risk loans, the LLM focuses on reduced exposure and possible portfolio improvements. This is semantically close and not factually incorrect, but slightly less precise in linking the decline directly to a shrinking volume of high-risk loans. Overall, the answer is factually correct, well-reasoned, and comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 431,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024 by emphasizing native integration of generative AI into core products (e.g., Photoshop, Illustrator) and expanding its role in Adobe Experience Cloud to enhance personalization and workflow efficiency. Competitive differentiation centered on AI safety, commercial viability, and seamless ecosystem integration, as highlighted in the 2024 filing. Regulatory risks include evolving AI regulations like the EU AI Act, which may increase compliance costs, governance challenges, and liability exposure, as well as potential conflicts with third-party AI models used in their offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Adobe Firefly's strategic evolution from 2023 to 2024, noting the emphasis on native integration of generative AI into Adobe products (e.g., Photoshop, Illustrator) and expansion into Adobe Experience Cloud—consistent with the competitive differentiation described in the original answer. The mention of AI safety and commercial viability matches the ground truth's focus on 'safe for commercial use.' (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the LLM synthesizes Firefly’s competitive positioning with emerging regulatory risks, particularly the EU AI Act, which is correctly cited as a source of compliance costs and governance challenges. This reflects the shift toward risk-aware positioning noted in the original answer. The only minor gap is that the LLM does not explicitly state that the EU AI Act was 'adopted in 2024,' though it correctly associates it with 2024 developments. (4) The answer adds contextual detail (e.g., workflow efficiency, personalization, third-party AI conflicts) not in the original but plausibly aligned with Adobe’s strategy, enhancing relevance without introducing inaccuracies. Overall, the response is factually correct, comprehensive, and semantically equivalent to the ground truth, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 418,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "Between 2023 and 2024, Trodelvy's financial performance and regulatory trajectory evolved as follows: In 2023, Trodelvy sales surged **56% to $1.1 billion**, driven by expanded demand in new and existing markets, despite the Phase 3 EVOKE-01 trial failing to meet its primary overall survival endpoint. In 2024, the FDA granted **Breakthrough Therapy designation** for Trodelvy in extensive-stage small cell lung cancer, accelerating its development and regulatory review. Additionally, Trodelvy received expanded indications and regulatory approvals, including a Breakthrough Therapy designation for second-line treatment of high-risk follicular lymphoma (FL) and first-line treatment of high-risk large B-cell lymphoma (LBCL), reflecting ongoing clinical and regulatory advancements.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 56% sales growth and approximates the 2023 sales figure as $1.1 billion, which is close to the ground truth of $1,063 million—this minor rounding is acceptable. However, the LLM incorrectly implies that the Breakthrough Therapy designation (BTD) in 2024 was not the second one, omitting that detail explicitly, and falsely states that Trodelvy received BTD for high-risk follicular lymphoma and large B-cell lymphoma, which is not supported by the original answer or ground truth. These are significant factual overstatements. (2) The quantitative accuracy is partially correct: $1.1 billion is a reasonable approximation of $1,063 million, and 56% growth is accurate. However, the additional indications and designations mentioned (FL and LBCL) have no basis in the ground truth and introduce false quantitative and qualitative claims. (3) The multi-hop reasoning is partially sound—linking financial performance in 2023 with regulatory developments in 2024 is appropriate, and the mention of the failed EVOKE-01 trial adds context not in the original but does not contradict it. However, the synthesis fails when it invents additional breakthrough designations, indicating a hallucination or error in entity-event linkage. (4) Correctness is scored 6 due to accurate core financial data but major errors in regulatory claims. Quantitative accuracy is 6 due to acceptable rounding but fabricated metrics. Qualitative accuracy is 6 due to correct reasoning framework but incorrect entity-event mappings. Contextual relevance is 9 because the answer stays focused on Trodelvy’s evolution and addresses both financial and regulatory aspects as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 465,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "Chevron's financial involvement in Angola LNG decreased from 2022 to 2024, as reflected in its equity investments and affiliate transactions. In 2022, Chevron's investment in Angola LNG Limited was $1,857 million, with equity in earnings of $1,857 million. By 2024, the investment value dropped to $1,665 million, and equity in earnings fell to $405 million. This decline suggests reduced profitability or strategic reallocation of resources, though Chevron maintained its 36.4% ownership stake. The decrease aligns with broader trends of lower earnings from equity affiliates and reduced investment activity in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Chevron reported $5,657 million in total income from equity affiliates (which includes Angola LNG among other entities), not $1,857 million specifically from Angola LNG. The LLM incorrectly attributes this $1,857 million figure to Angola LNG with no support in the original answer, and further claims a drop to $405 million in 2024, which is not mentioned or implied in the ground truth. There is no mention of investment values ($1,857M or $1,665M) in the original answer, nor any indication of a decline in financial involvement. (2) The only correct quantitative detail is the 36.4% ownership stake in Angola LNG Limited in 2024, which matches the ground truth. All other numbers are fabricated or misattributed. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a decline in strategic importance due to alleged drops in investment and earnings, while the original answer indicates a continued and more clearly defined strategic emphasis on Angola LNG by 2024. The evolution described in the ground truth is one of increased clarity and stability, not reduction. (4) Contextual relevance is moderate because the answer addresses Chevron, Angola LNG, equity investments, and affiliate transactions over 2022–2024, but the conclusions are based on incorrect data. The qualitative reasoning fails due to incorrect entity-specific financials and misinterpretation of strategic direction. Correctness and quantitative accuracy are low due to invented figures and false trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 439,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "META's Fixed-Rate Senior Unsecured Notes (Notes) increased in value from $18.50 billion as of December 31, 2023, to $29.0 billion as of December 31, 2024. This growth was driven by the issuance of $10.50 billion in August 2024 Notes, which added to the existing debt. The 2023 issuance in May 2023 contributed $8.5 billion, but the 2024 issuance significantly expanded the total outstanding Notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the total value of META's Fixed-Rate Senior Unsecured Notes at the end of 2023 ($18.50 billion) and 2024 ($29.0 billion), as well as the $10.50 billion issuance in August 2024. The 2023 issuance is reported as $8.5 billion in the LLM answer, while the ground truth specifies $8.46 billion. This is a minor rounding discrepancy—$8.5 billion is a reasonable approximation—but not exact, hence a slight deduction in quantitative accuracy. (2) All other numbers and dates are accurate: the May 2023 issuance timing, August 2024 issuance amount, and year-end balances match the ground truth. The increase from $18.50B to $29.0B is correctly attributed to the $10.50B issuance, which aligns with the data. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, two issuance events, and the evolving total value of the notes. It correctly infers that the 2024 total reflects accumulation of prior debt plus new issuance. (4) The answer is contextually complete and relevant, addressing both the value evolution and issuance activity. The only minor flaw is the $8.5B vs $8.46B discrepancy, which does not distort the overall picture but prevents a perfect score. Semantic equivalence is otherwise maintained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 360,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "The provided document pages do not contain any disclosures related to LIN's financial exposure to helium as a raw material, either in 2023 or 2024. The filings focus on financial statements, tax matters, earnings, and liabilities, but no mention of helium or its categorization as a supply or dependency is found. Therefore, no changes in exposure can be determined from the given information.",
      "correctness_score": 0,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 1,
      "detailed_feedback": "The LLM answer is completely incorrect and fails to match the ground truth. (1) The original answer states specific quantitative data: helium costs were 4.2% of total raw material expenses in 2023 and increased to 6.8% in 2024, along with a change in categorization from 'supply' to 'depends_on'. The LLM claims no information was found, which contradicts the availability of this data in the source. (2) There are no numbers or calculations in the LLM response, so quantitative accuracy is absent. (3) The multi-hop reasoning required—comparing LIN's changing relationship to helium across two years using cost percentages and categorization shifts—was not attempted; the model failed to identify or synthesize the relevant entities and disclosures. (4) The response is irrelevant because it denies the existence of key information that was present in the knowledge base, making it factually and contextually invalid. The LLM appears to have defaulted to a 'no information' response despite the data being available in the assumed context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 296,
        "total_tokens": 1513
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "PayPal's utilization of European customer balances for credit activities decreased from $3.8 billion in 2022 to $3.0 billion in 2023, representing a **21.05% reduction**. This reflects a shift in approved amounts for credit activities, with the percentage of European customer balances allocated for such purposes dropping from 37% in 2022 to 39% in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the approved amounts for credit activities in 2022 ($3.8 billion) and 2023 ($3.0 billion), which matches the ground truth. However, it incorrectly states that the percentage of European customer balances allocated for credit activities 'dropped from 37% to 39%', which is factually wrong — 39% is higher than 37%, so the percentage increased, not dropped. This misstatement undermines the reasoning. (2) The percentage change calculation is mathematically correct: (3.8 - 3.0) / 3.8 ≈ 21.05%, so the 21.05% reduction in absolute amount is accurate. However, the interpretation of the percentage of balances (37% to 39%) is reversed, leading to incorrect qualitative inference. (3) The multi-hop reasoning is partially sound — the model connects PayPal, European customer balances, credit activity approvals, and year-over-year change — but fails in synthesizing the correct trend in utilization rate. The ground truth emphasizes that despite a slight increase in percentage utilization (37% to 39%), the absolute amount decreased, indicating a more conservative approach. The LLM incorrectly frames the percentage as decreasing, contradicting the data. (4) Scores reflect that core numbers are correct (justifying a mid-range score), but a critical qualitative error in interpreting the percentage trend reduces overall correctness and quantitative/qualitative accuracy. Contextual relevance is high as the answer addresses the right entities, time frame, and intent of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 422,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "Starbucks' foreign currency - other exposure decreased in fair value from $54.9 million (2023) to $3.6 million (2024), as reflected in derivative assets. The amount reclassified from AOCI to earnings increased from $23.6 million in 2023 to $28.2 million in 2024, indicating a higher impact on earnings from hedging adjustments in 2024 compared to 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect in terms of factual content. (1) Quantitative accuracy fails completely: the reported fair values of $54.9 million (2023) and $3.6 million (2024) are grossly inaccurate compared to the ground truth of $1,164 million (2023) and $920 million (2024). Similarly, the reclassification amounts are wrong—the LLM states $23.6 million (2023) and $28.2 million (2024), while the correct figures are $55.3 million (2023) and $9.5 million (2024). These numbers are not only incorrect but suggest an opposite trend (increasing reclassification impact) versus the actual significant decline. (2) The answer misrepresents the direction and magnitude of change: instead of showing a sharp decrease in both fair value and expected earnings impact, it implies a minimal exposure and increasing earnings effect, which contradicts the ground truth. (3) While the LLM attempts to address the right entities (Starbucks, foreign currency instruments, AOCI reclassification, earnings impact) and time frame (2023–2024), the complete failure in numerical accuracy and resulting flawed conclusion undermines all qualitative reasoning. (4) Contextual relevance is partially maintained as the answer discusses the correct topic areas (fair value, AOCI reclassification, earnings impact), but due to factual inaccuracy, it misinforms rather than informs. The multi-hop synthesis is structurally attempted but based on false data, leading to an invalid conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 405,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "The fair value of energy-related derivatives for Alabama Power decreased from $55 million (2022) to $15 million (2023), while liabilities increased from $11 million to $110 million. For Georgia Power, assets dropped from $75 million (2022) to $13 million (2023), with liabilities remaining stable at $124 million. Thus, Alabama Power's liability position expanded, whereas Georgia Power's liability position remained unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported the asset and liability values for Alabama Power and Georgia Power in both 2022 and 2023, with accurate numbers: Alabama Power assets ($55M to $15M) and liabilities ($11M to $110M); Georgia Power assets ($75M to $13M) and liabilities ($8M to $124M). However, the LLM incorrectly stated that Georgia Power's liabilities remained 'stable at $124 million', when in fact they increased from $8 million in 2022 to $124 million in 2023. This is a significant error in directional change assessment. (2) All provided numbers are quantitatively accurate except for the mischaracterization of Georgia Power's liability trend. The values themselves are correct, but the conclusion about stability is false. (3) The multi-hop reasoning is partially sound—correctly comparing year-over-year changes for each company—but fails in synthesizing the directional shift for Georgia Power. The model should have noted a substantial increase in liabilities, not stability. (4) Scores reflect high factual accuracy in numbers (8 for quantitative), but lower reasoning and qualitative accuracy due to incorrect interpretation of liability movement. Contextual relevance is perfect as all parts of the question are addressed with appropriate entities and timeframes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 360,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "The U.S. Retiree Health Care Plan's asset allocation shifted from 65% fixed income securities and 35% equity securities in 2022 to 80% fixed income securities and 20% equity securities in 2023. This reflects an intentional rebalancing toward a higher proportion of fixed income assets, aligning with updated target ranges (75–85% fixed income, 15–25% equity) to better match liability characteristics and mitigate market volatility.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 65% fixed income and 35% equity in 2022, shifting to 80% fixed income and 20% equity in 2023. These numbers exactly match the original answer. (2) The answer is complete, addressing the evolution of asset allocation between the two years and the shift in distribution between fixed income and equity securities as required by the question. (3) Entity accuracy is correct—'U.S. Retiree Health Care Plan' is properly identified, and the years 2022 and 2023 are correctly referenced. (4) The reasoning is sound and adds contextual insight (e.g., updated target ranges of 75–85% fixed income and 15–25% equity, alignment with liability characteristics, and mitigation of market volatility), which enhances the explanation without contradicting the ground truth. This additional context is consistent with the conclusion that the strategy became more conservative. The multi-hop synthesis—comparing allocations across years and interpreting the strategic shift—is accurate and logically presented. All elements meet or exceed the criteria for correctness, completeness, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 342,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "Between 2022 and 2023, Trodelvy's regulatory approval expanded to include a new indication. In 2023, the FDA approved Trodelvy as a monotherapy for adult patients with unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the advanced setting. This indication was granted under accelerated approval, contingent on confirmatory trials. Additionally, the European Commission approved Trodelvy for this HR+/HER2- breast cancer indication, expanding its use beyond the 2022 approvals for triple-negative breast cancer (TNBC) and urothelial cancer.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) It correctly identifies the 2022 indications for Trodelvy—triple-negative breast cancer (TNBC) and urothelial cancer—and accurately describes the new 2023 approvals for HR+/HER2- breast cancer by both the FDA and European Commission. (2) There are no numerical values requiring calculation, but all dates (2022 to 2023) and regulatory bodies (FDA, EC) are correctly cited. The description of the patient population (adults with unresectable or metastatic HR+/HER2- breast cancer who received endocrine-based therapy and at least two prior systemic therapies) matches the original answer exactly in substance. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 vs 2023), regulatory agencies (FDA and EC), and indications (expansion from TNBC/urothelial to HR+/HER2- breast cancer). (4) The LLM adds minor but relevant context—mentioning that the FDA approval was under accelerated approval with confirmatory trials required—which is consistent with typical regulatory processes and does not contradict the ground truth. All elements of the question are addressed: evolution of approval status and new indications in 2023. Semantic equivalence is maintained with precise, correct terminology. No factual errors, omissions, or inaccuracies present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 378,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "Meta's 2024 disclosure expanded on user perception risks compared to 2023, emphasizing heightened concerns about **privacy, data practices, and user well-being** as critical factors. While 2023 focused on competitive pressures (e.g., TikTok) and global events (e.g., Ukraine war) affecting user engagement, 2024 added specific risks tied to **regulatory changes** (GDPR, CCPA) and **user sentiment shifts** due to questions about data quality, content moderation, and ad transparency. The 2024 risks also highlighted the **impact of user consent mechanisms** (e.g., \"subscription for no ads\" in the EU) on ad targeting effectiveness and revenue, underscoring how evolving perceptions of trust and control could directly affect advertising performance and business operations.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim about the evolution of Meta's risk disclosures. The ground truth states that Meta *reduced* emphasis on user perception risks in 2024, shifting focus to operational and financial risks like acquisition integration and tax liabilities. However, the LLM claims the opposite—that Meta *expanded* on user perception risks in 2024, adding more detail on privacy, data practices, and user consent. This misrepresents the direction of change. While the LLM correctly identifies some risk themes present in the filings (e.g., privacy, regulatory changes like GDPR, ad transparency), it incorrectly synthesizes their evolution over time. There are no numeric values to verify, so quantitative accuracy is not applicable (scored 10 by default for absence of errors). The qualitative accuracy is low because the multi-hop reasoning failed: the model did not correctly identify the shift in emphasis away from user perception in 2024. Contextual relevance is moderate—while the answer discusses relevant topics, it mischaracterizes the trend, undermining the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 316,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "Lockheed Martin's notional amount of variable interest rate swaps increased from $500 million in 2021 to $1.3 billion by 2023, remaining stable at $1.3 billion in 2024. This growth reflects the company's proactive use of swaps to hedge against interest rate fluctuations, converting fixed-rate debt to variable rates (fair value hedges) and vice versa (cash flow hedges). The stabilization in 2023–2024 suggests the company has optimized its hedging strategy to align with borrowing activities and market conditions, demonstrating a balanced approach to managing interest rate risk.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the notional amount of $500 million in 2021 and $1.3 billion in 2024, matching the ground truth. However, it introduces an intermediate data point—$1.3 billion in 2023—with no mention in the original answer, which only specifies 2021 and 2024. While this addition does not contradict the ground truth, it introduces a level of specificity not present in the source and could imply data not confirmed. 2) Quantitatively, the numbers are accurate in magnitude and format ($500 million, $1.3 billion), and the direction of change (increase) is correct. The only minor issue is the unsupported claim about 2023, though the 2024 figure is correct. 3) The reasoning is sound: the LLM correctly infers that increasing variable-rate swaps indicates a strategy of converting fixed-rate debt to variable, aligning with interest rate risk management. It adds context about fair value and cash flow hedges not in the original, which is plausible but not verifiable from the ground truth—this enriches the answer without contradicting it. 4) The answer is contextually relevant, fully addressing both parts of the question: evolution of notional amounts and implications for risk management. The core facts are correct, and the interpretation is logically consistent with the data. The slight over-specification of 2023 data prevents a perfect score, but the overall answer remains highly accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 396,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "PayPal's Seller Protection Programs in 2023 saw a slight decrease in the allowance for transaction losses ($64 million vs. $66 million in 2022), but provisions for transaction losses increased marginally to $1,192 million in 2023 compared to $1,170 million in 2022. This reflects adjustments in estimates and actual losses, with higher realized losses ($1,313 million in 2023 vs. $1,417 million in 2022) offset by recoveries. The programs continued to cover merchant claims for unauthorized transactions or undelivered items, with financial provisions tied to transaction and credit loss provisions as disclosed in the consolidated financial statements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that the allowance for transaction losses decreased from $66 million in 2022 to $64 million in 2023 (matching the ground truth), it introduces incorrect figures for 'provisions for transaction losses' ($1,192M in 2023 vs $1,170M in 2022) and 'realized losses' ($1,313M in 2023 vs $1,417M in 2022), which are not present in the original answer and contradict the focus on seller protection allowances. These numbers appear to conflate broader transaction or credit loss provisions with seller protection-specific data. (2) The ground truth does not mention provisions or realized losses at this scale or context; instead, it emphasizes the shift from qualitative risk disclosure in 2022 to a more structured, quantified allowance in 2023. The LLM invents financial metrics not supported by the source, severely undermining quantitative accuracy. (3) The reasoning fails on multi-hop synthesis: while it identifies the correct direction of change in allowances, it embeds this correct detail within a broader narrative of unrelated or fabricated financial figures, suggesting confusion between seller protection programs and overall transaction/credit loss provisions. (4) Contextual relevance is moderate because the answer addresses PayPal’s Seller Protection Programs and attempts to compare 2022–2023 financial provisions, but the inclusion of incorrect metrics distorts the core evolution described in the ground truth. The qualitative shift from qualitative risk statements to specific allowances is underemphasized and overshadowed by erroneous data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 452,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "Starbucks' derivative asset position related to \"foreign currency - other\" decreased from $54.9 million (as of October 1, 2023) to $3.6 million (as of September 29, 2024), a reduction of $51.3 million. Meanwhile, the derivative liability position increased from $2.0 million (as of October 1, 2023) to $8.8 million (as of September 29, 2024), reflecting an increase of $6.8 million. These changes are reflected in the balance sheet under prepaid expenses, other current assets, and accrued liabilities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported numbers. According to the ground truth, Starbucks' derivative asset for 'foreign currency - other' decreased from $1,164 million in fiscal year 2023 to $1.9 million in 2024, a reduction of approximately $1,162.1 million. However, the LLM reports the 2023 asset as $54.9 million and 2024 as $3.6 million, which is off by over $1.1 billion. Similarly, the liability increased from $2.0 million to $4.7 million in the ground truth, but the LLM reports an increase to $8.8 million — more than double the correct amount. These errors severely undermine the quantitative accuracy. (2) Calculations are internally consistent within the LLM’s incorrect numbers (e.g., $54.9M - $3.6M = $51.3M reduction), but since the base figures are wrong, the derived changes are also incorrect. The actual magnitude of change in assets was over $1.1 billion, not $51.3 million. (3) The qualitative reasoning structure is sound — the model identifies the need to compare asset and liability positions across two fiscal years and discusses balance sheet impact — but it fails at multi-hop synthesis because it uses incorrect source data. The fiscal years are approximately correct (October 1, 2023, and September 29, 2024, align with Starbucks’ fiscal calendar), so entity and time period identification is acceptable. (4) Contextual relevance is high because the answer addresses the right category ('foreign currency - other'), discusses both assets and liabilities, and references the balance sheet appropriately. However, due to massive numerical inaccuracies, the correctness score is low despite reasonable structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 463,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "The financial impact of energy-related derivatives on natural gas cost and revenue hedging positions shifted from a net gain of $37 million in 2022 to a net loss of $44 million in 2023. In 2022, energy-related cash flow hedges contributed a $37 million gain to income, while in 2023, they resulted in a $44 million loss. Additionally, the pre-tax effects on AOCI showed a $3 million gain in 2022 for Southern Company and an $81 million loss in 2023, reflecting a material deterioration in the hedging positions' performance during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude of impacts. According to the ground truth, in 2022, derivatives had a negative impact of $117M on natural gas revenues and $27M on costs (total negative impact of $144M), whereas the LLM claims a $37M gain. In 2023, the ground truth shows a $59M gain on cost and $0 on revenue (net positive $59M), but the LLM reports a $44M loss—completely opposite in sign and magnitude. The LLM introduces 'net gain/loss' figures not supported by the original data. (2) Specific number verification: $117M revenue loss (2022), $27M cost loss (2022), $59M cost gain (2023), and $0 revenue impact (2023) are all misrepresented. The LLM’s figures ($37M gain, $44M loss, $3M AOCI gain, $81M AOCI loss) do not appear in the ground truth and contradict it. Calculations are therefore invalid. (3) Multi-hop reasoning is flawed: the question asks for evolution in hedging impact on cost and revenue separately, but the LLM conflates income effects and AOCI movements, introducing unrelated entities like 'Southern Company' not mentioned in the original answer. It fails to isolate the correct metrics (revenue vs. cost impact) and misrepresents the trend—ground truth shows improvement (from negative to positive), while LLM suggests deterioration. (4) Scores reflect major factual errors in numbers and direction of impact, partial relevance to hedging performance over time, and failure to correctly synthesize the specific financial impacts on cost and revenue. Only the general idea that there was a change over time is contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 440,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "Walmart's Deferred Compensation Matching Plan remained effective as of November 8, 2023, in both the 2023 and 2024 10-K filings. The 2023 filing referenced the plan as amended and restated effective November 8, 2023, while the 2024 filing incorporated the same document as Exhibit 10.1, indicating no change in the plan's terms or effective date. The documentation status was consistent across both filings, with the 2024 filing including the plan as part of its annual report.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the effective date of the Deferred Compensation Matching Plan as November 8, 2023, in both the 2023 and 2024 10-K filings, which matches the ground truth (quantitative accuracy = 10). It also correctly states that there was no change in the plan's terms or effective date, and accurately notes the plan's inclusion as Exhibit 10.1 in the 2024 filing. However, the LLM misses a key qualitative distinction in how the plan was treated across the two filings: in 2023, it was explicitly introduced as 'newly amended and restated,' while in 2024, it was no longer labeled as newly introduced but instead incorporated by reference, signaling its transition to an established, ongoing plan. The LLM incorrectly claims the 'documentation status was consistent,' which contradicts the ground truth—this reflects a failure in multi-hop reasoning and synthesis of the evolving narrative around the plan’s status. While the core facts (dates, exhibit reference) are correct, the answer underrepresents the shift in documentation treatment, which is central to the question. Thus, qualitative accuracy is reduced. Contextual relevance remains high as the response directly addresses the question’s focus on evolution between filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 350,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "The disclosure and treatment of LTIP Units remained consistent between 2023 and 2024. Both years stated that LTIP Units are included in potentially dilutive securities, but no securities had a material dilutive effect during these periods. The accrual policy continued to recognize distributions when declared, with no changes in the methodology or material impact. The terminology shifted from \"dividends\" to \"distributions\" in 2024, reflecting the Operating Partnership's structure, but the core accrual approach and dilution treatment remained unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: LTIP Units are consistently described as potentially dilutive with no material dilutive effect in both 2023 and 2024; the accrual policy of recognizing distributions when declared remained unchanged. (2) There are no numeric values requiring calculation, but the years referenced (2023, 2024, and prior periods) are correctly cited. (3) The multi-hop reasoning is sound—information is synthesized across two reporting years and compared appropriately. The LLM correctly infers stability in treatment despite a minor terminology shift. (4) The only minor gap is that the original answer notes the 2024 disclosure was 'simplified,' while the LLM frames the change as a terminology shift from 'dividends' to 'distributions'—a valid interpretation but slightly less precise in capturing the overall simplification of disclosure. However, this does not affect factual correctness. Semantic equivalence is maintained, and the core conclusion—that there was no significant change in dilutive impact or accrual policy—is fully supported. The answer is contextually complete and directly addresses both parts of the question: dilutive effect and accrual policy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 355,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024 by addressing regulatory challenges and implementing corrective measures. In 2023, Meta faced a €1.2 billion fine from the Irish Data Protection Commission (IDPC) for non-compliance with GDPR and SCCs, leading to appeals and interim stays. The EU-U.S. DPF, adopted in 2023, replaced invalidated frameworks like Privacy Shield, and Meta began steps to align with its adequacy decision. In 2024, Meta further adapted by modifying its advertising practices, such as shifting behavioral advertising from \"legitimate interests\" to \"consent\" in the EU, and introducing a \"subscription for no ads\" option to comply with the Digital Markets Act (DMA) and GDPR. These changes reflect heightened regulatory scrutiny and adjustments to balance data transfer compliance with evolving EU laws.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are accurate: the €1.2 billion fine, the 2023 adoption of the EU-U.S. DPF, and the 2024 regulatory developments are correctly cited. No calculation errors. (2) The LLM correctly identifies key entities: Meta, Irish Data Protection Commission (IDPC), EU-U.S. DPF, GDPR, SCCs, and DMA. The shift in advertising legal basis and the 'subscription for no ads' model introduced in November 2023 (though not dated in the LLM answer) are accurately noted. (3) The reasoning is sound: it captures the evolution from foundational compliance with the EU-U.S. DPF in 2023 to more complex regulatory engagement in 2024, including DMA scrutiny. However, the LLM omits the specific detail that the European Commission opened formal proceedings in July 2024 with preliminary findings of non-compliance — a key development in the original answer. It also does not explicitly mention that the 'subscription for no ads' model was introduced in November 2023, slightly weakening the multi-hop synthesis. (4) Despite these omissions, the core facts, timeline, and regulatory context are correct, and the answer remains semantically close to the ground truth. Hence, a score of 8 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 385,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "Linde's approach to green hydrogen production evolved between 2023 and 2024 by emphasizing renewable energy sources more explicitly. In 2023, the company highlighted green hydrogen production via electrolysis using renewable energy or biomethane. By 2024, Linde further clarified that green hydrogen is produced through electrolysis powered by renewable energy and water, underscoring a stronger focus on renewable energy as the core method for low-carbon hydrogen. The 2024 disclosure also expanded on technologies to recover and purify hydrogen from industrial processes, aligning with broader clean energy goals.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. It accurately captures Linde's shift between 2023 and 2024 toward a more explicit emphasis on renewable energy-powered electrolysis for green hydrogen production. The answer correctly notes that in 2023, Linde included both electrolysis using renewable energy and biomethane reforming as pathways, and that by 2024, the focus narrowed to electrolysis using renewable energy and water, which matches the original answer's description of 'renewable hydrogen.' The dates (2023 vs. 2024) and entities (Linde, green hydrogen, electrolysis, renewable energy) are accurate. However, the LLM answer omits a key element from the original: the increased emphasis on carbon intensity as a differentiating metric in 2024, which is an important part of Linde's refined strategic framing. Additionally, while the LLM mentions hydrogen recovery from industrial processes in 2024, this detail is not present in the original answer and may conflate information from other sources, slightly diluting the precision of the response. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and the reasoning is sound, though not fully complete in capturing all nuances. The answer remains contextually relevant and semantically close to the ground truth, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 384,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "Southern Company sold Sequent to Williams Field Services Group on July 1, 2021, for $159 million, resulting in a pre-tax gain of $121 million ($92 million after tax) and additional tax expense of $85 million due to state apportionment changes. By 2023, Sequent was no longer a reportable segment, and its financial impact was fully reflected in Southern Company's consolidated results, with the sale's proceeds and tax implications accounted for in the 2021 fiscal year.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors, particularly in the timing of the transaction. The original answer states the sale occurred in 2022, but the LLM claims it happened on July 1, 2021—this is a critical error affecting the entire timeline of the relationship evolution between 2022 and 2023. All financial figures ($159 million sale price, $121 million pre-tax gain, $85 million additional tax expense) are correctly reported and match the ground truth, so quantitative elements are accurate except for timing. (2) The numbers themselves—$159M sale, $121M pre-tax gain, $85M tax expense—are all correct and consistent with the original answer. However, the after-tax gain of $92 million is mentioned in the LLM answer but not in the original; while this may be a reasonable derivation ($121M - $85M = $36M after-tax gain, not $92M), it introduces an unsupported and likely incorrect figure, indicating a calculation or interpretation error. (3) The reasoning is partially sound: the LLM correctly identifies the divestiture, the buyer (Williams Field Services Group), and the financial implications. It also correctly notes that by 2023, Sequent was no longer a reportable segment, aligning with the original answer’s claim of full separation. However, the multi-hop reasoning fails on temporal logic—the question asks about the evolution *between 2022 and 2023*, but the LLM places the sale in 2021, making the analysis of changes during the requested period factually invalid. (4) Contextual relevance is high because the answer addresses the nature of the relationship change and financial impact, but correctness is severely undermined by the incorrect year. Thus, while the qualitative understanding of divestiture and financial reporting is present, the core timeline error results in a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 506,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "Walmart's relationship with the Allswell brand remained consistent between 2023 and 2024, as Allswell continued to be listed among Walmart's private brands in both years' 10-K filings. The brand is part of Walmart's strategy to offer high-quality, low-priced private-label products, aligning with its EDLP (Everyday Low Price) and EDLC (Everyday Low Cost) initiatives. There is no indication of significant changes or strategic shifts in Allswell's role during this period, suggesting it maintained its position as a key component of Walmart's private brand portfolio focused on value and customer convenience.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant misrepresentation of the evolution of Walmart's relationship with the Allswell brand. (1) Quantitatively, there are no numeric inaccuracies, as the answer does not include specific numbers, dates, or financial metrics—this is acceptable given the nature of the question. (2) However, the qualitative reasoning is flawed: the original answer states that Allswell was *introduced* in 2023 and then *retained and elevated* alongside mature brands by 2024, indicating growth and integration into the core private brand portfolio. In contrast, the LLM claims the relationship 'remained consistent' with no 'significant changes or strategic shifts,' which contradicts the ground truth that shows a clear evolution from new to established brand. (3) The multi-hop reasoning is weak—the question asks how the relationship *evolved*, requiring a comparison across years to infer strategic progression. The LLM fails to recognize the significance of Allswell’s transition from a newly launched brand to one grouped with mature labels, missing the strategic implication of increased importance. (4) While the LLM correctly identifies Allswell as part of Walmart’s private brand strategy and aligns it with EDLP/EDLC, this contextual framing does not compensate for the incorrect conclusion about lack of change. The answer is relevant and well-structured but factually inaccurate in its core claim about strategic continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 405,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "The strategic importance of Embedded Processing products slightly increased from 2022 to 2023, as revenue grew by 3% ($3,261M to $3,368M), reflecting improved product mix and market demand. However, operating profit declined by 20% ($1,253M to $1,008M) due to higher manufacturing costs, despite revenue growth. While Analog revenue dropped 15%, the company's strategic emphasis on embedded processing persisted, driven by long-term growth opportunities in industrial and automotive markets, aligning with its focus on optimizing performance, power, and cost for specific applications.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific revenue figures for Embedded Processing were disclosed in 2022, but the LLM asserts precise figures ($3,261M and $3,368M) and a 3% growth, which are not supported. Similarly, the claim of a 20% decline in operating profit from $1,253M to $1,008M is fabricated, as no such data appears in the ground truth. The total revenue of $17.52B in 2023 is mentioned in the original answer, but the LLM fails to reference this key aggregate figure. (2) Quantitative accuracy is very low: all specific numbers provided by the LLM are incorrect or unverified, and there is no evidence in the ground truth to support the claimed revenue or profit figures for Embedded Processing. Calculations based on these numbers (3% growth, 20% decline) are therefore invalid. (3) While the LLM correctly identifies that Embedded Processing remained strategically important and partially offset a decline in Analog revenue, it misrepresents the nature of the evidence. The reasoning about strategic emphasis on industrial and automotive markets and optimization of performance, power, and cost is plausible but not present in the ground truth, introducing unsupported details. The core multi-hop insight — that Embedded Processing played a compensatory role in revenue during a downturn — is partially captured, but distorted by false quantitative claims. (4) Contextual relevance is moderate because the answer addresses the evolution of strategic importance and mentions correct segments and market drivers, but correctness and quantitative accuracy are severely compromised by invented data. As a result, the overall correctness score is low despite some alignment in qualitative direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 483,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "Chevron's involvement in Angola LNG, as detailed in its 2024 10-K, shows a 36.4% equity interest in Angola LNG Limited, which processes and liquefies natural gas for international markets. While the 2022 equity earnings were $1,857 million, they decreased to $513 million in 2023 and remained at $513 million in 2024, reflecting potential market or operational challenges. However, Chevron's continued investment underscores its strategic focus on LNG in Africa, aligning with broader efforts to capitalize on global LNG demand and secure long-term energy market positions. The fluctuating equity earnings suggest evolving dynamics but highlight Chevron's sustained commitment to Angola's LNG sector as part of its diversified energy strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces financial data—specifically equity earnings of $1,857 million in 2022, $513 million in 2023, and $513 million in 2024—that are not present in the original ground truth and cannot be verified from the provided context. These figures are factually unsupported in the knowledge base, making them significant inaccuracies. The only confirmed quantitative fact from the ground truth is Chevron’s 36.4% stake in Angola LNG Limited as of 2024, which the LLM correctly reports. However, there is no mention in the ground truth about equity earnings, their values, or trends over time, so including them misrepresents the data. (2) The LLM incorrectly implies a multi-year financial trend that was not part of the source information, introducing false quantitative precision. While the 36.4% figure is accurate, the rest of the numerical content is fabricated or hallucinated. (3) On reasoning, the LLM attempts multi-hop synthesis by connecting Chevron’s stake with broader strategic positioning in LNG, which aligns with the question’s intent. It correctly infers that maintaining a stake reflects strategic commitment to LNG in Africa, which is a reasonable interpretation consistent with the ground truth’s conclusion about a 'strategic shift toward securing a stable position.' However, the reasoning is undermined by anchoring to false financial data. (4) Despite the hallucinated numbers, the LLM captures the directional insight about Chevron’s evolving, sustained involvement and strategic intent, which maintains some qualitative and contextual relevance. Hence, partial credit is given for logical interpretation and relevance, but major deductions apply for factual and quantitative inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 473,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "The CH-53K program's financial contribution and production status within Lockheed Martin's RMS division increased between 2021 and 2024. In 2021, RMS reported higher net sales and operating profit driven by the CH-53K's production volume and risk retirements. By 2024, the program's production volume continued to rise, contributing to RMS's product sales growth, reflecting its sustained importance as a key revenue driver and operational focus within the division. This indicates the CH-53K remains a critical program for RMS, supporting both financial performance and strategic priorities.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increasing financial contribution and production ramp-up of the CH-53K program between 2021 and 2024 and accurately characterizes its growing role within Lockheed Martin's RMS division. However, it omits specific quantitative figures from the ground truth: in 2021, the program contributed to a $540 million increase in net sales and a $140 million increase in operating profit; by 2024, it contributed $1.1 billion to higher product sales. These exact figures are missing, reducing quantitative accuracy. (2) While the LLM correctly references higher net sales and operating profit in 2021 and continued production growth in 2024, it fails to include the precise dollar amounts, which are central to the question’s requirement for financial evolution. The absence of 'risk retirements' as a driver of profit in 2021 and the specific term 'production ramp-up' in 2024 slightly weakens completeness. (3) The multi-hop reasoning is sound—the model correctly infers that increased production volume and financial contribution indicate a transition to a key growth driver—but it does not fully synthesize the magnitude of growth (from $540M to $1.1B+) or explicitly state the program’s evolution from development to mature production. (4) Despite missing key numbers, the LLM captures the correct entities (CH-53K, Lockheed Martin RMS), time periods (2021–2024), and qualitative trajectory, maintaining strong contextual relevance and logical reasoning. The answer is semantically aligned but lacks precision in financial metrics, warranting a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 443,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "PayPal extended the reasonable and supportable forecast period for revolving consumer credit products from approximately 2 years in 2022 to about 5 years in 2023, incorporating more granular macroeconomic factors such as forecasted trends in household disposable income and retail e-commerce sales (and unemployment rates through Q1 2023). While external macroeconomic forecasts remained the primary data source, the 2023 updates to credit loss models did not materially impact the provision for credit losses recorded in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in macroeconomic factors used in PayPal's loss curves between 2022 and 2023, noting the inclusion of household disposable income and retail e-commerce sales, and the use of unemployment rates only through Q1 2023. However, it introduces a specific forecast period extension from 2 to 5 years, which is not mentioned in the ground truth and cannot be verified—this is a significant quantitative addition unsupported by the original answer. (2) The numbers regarding forecast periods (2 years in 2022, 5 years in 2023) are not present in the ground truth and appear to be fabricated or inferred beyond available data, reducing quantitative accuracy. No other numerical claims (dates, percentages, dollar amounts) are made, so the only quantitative issue is this unverified forecast horizon. (3) The multi-hop reasoning is generally sound: the model correctly synthesizes the evolution of macroeconomic inputs and notes the timing of the unemployment rate phase-out. It also correctly states that the 2023 model changes did not materially affect the provision for credit losses, which aligns with typical financial disclosures and adds contextual insight, though this specific point isn't in the ground truth. The core evolution of factors is accurately captured. (4) The answer is contextually relevant and addresses the question about how PayPal's use of macroeconomic factors evolved. While it adds unsupported specifics (forecast period length), the qualitative shift in factors is correctly reported. The answer is mostly accurate but penalized for introducing unverified quantitative details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 452,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "Starbucks' foreign currency debt-related gains/losses in AOCI decreased from a $19.1 million gain in 2023 to a $6.3 million loss in 2024. This shift indicates increased exposure to foreign currency fluctuations, as the loss suggests adverse movements in exchange rates impacted the fair value of foreign currency-denominated debt, reflecting higher risk or less effective hedging during the period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, Starbucks reported a loss of $6.3 million in 2023 and a gain of $135.2 million in 2024. The LLM incorrectly states a $19.1 million gain in 2023 and a $6.3 million loss in 2024—reversing both the direction and magnitude of the actual figures. The correct change is from a loss to a large gain, while the LLM describes a decrease from a gain to a loss, which is the opposite trend. (2) Quantitative accuracy is very low: both years' figures are wrong. The 2023 number is off by over $25 million in direction and amount, and the 2024 number is completely incorrect (reports a loss instead of a substantial gain). No correct calculation or comparison can be derived from these wrong inputs. (3) The multi-hop reasoning is flawed because the model fails to correctly retrieve and synthesize the financial data across years. The conclusion about 'increased exposure' due to adverse movements contradicts the ground truth, which shows a major improvement (large gain in 2024), suggesting reduced adverse exposure or favorable currency movements. The reasoning is internally logical given its incorrect inputs but fails on factual synthesis. (4) Contextual relevance is moderate—the answer addresses the right topic (AOCI, foreign currency debt, exposure implications) and attempts to interpret the trend, so it stays on topic. However, due to severe factual inaccuracies, the conclusion is misleading. Correctness score is low (2) because the core financial data and trend are entirely incorrect, undermining the answer's validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 444,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "The fair value of energy-related derivatives for Alabama Power increased from $13 million in 2022 to $110 million in 2023, while Georgia Power's liability remained at $124 million. Combined, their liabilities rose from $137 million in 2022 to $234 million in 2023, reflecting an overall upward trend.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states Alabama Power's 2022 liability as $13 million, while the ground truth reports a net liability of $144 million in 2022. It also falsely claims Alabama Power's derivatives increased to $110 million in 2023, when $110 million was only the liability portion (with $15 million in assets, resulting in a $95 million net liability). For Georgia Power, the LLM correctly identifies the $124 million liability in 2023 but fails to mention any 2022 data, and incorrectly implies it remained unchanged. (2) Calculations are fundamentally wrong: the LLM claims combined liabilities rose from $137 million in 2022 to $234 million in 2023. The correct 2022 combined net liability is $144M (Alabama) + no Georgia data provided in 2022 = only Alabama’s $144M reported, but Georgia’s 2022 data is missing in both original and LLM. However, in 2023, combined net liability is $95M (Alabama) + $111M (Georgia) = $206M, down from $144M in 2022 (assuming Georgia had no liability in 2022, which is not stated). The LLM incorrectly calculates a rise to $234M, adding Alabama’s $110M and Georgia’s $124M without netting assets, and invents a $137M 2022 total with no basis. (3) Multi-hop reasoning is flawed: the model fails to compute net liabilities by subtracting assets from liabilities, misrepresents year-over-year changes, and does not correctly synthesize data across both companies and years. It omits Alabama’s asset position in 2023 and ignores the concept of net liability. (4) The contextual relevance is moderate because it addresses the right companies and topic (energy-related derivatives), but the quantitative and qualitative inaccuracies severely undermine the answer’s correctness. The conclusion of an 'upward trend' is incorrect—the actual trend shows a reduction in combined net liability from $144M (Alabama only in 2022) to $206M combined in 2023, but since Georgia’s 2022 data is not in the ground truth, a full trend cannot be established; however, Alabama alone saw a decrease from $144M to $95M. Thus, the LLM’s upward trend claim is factually wrong. Scores reflect major errors in numbers, logic, and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 592,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "Walmart acquired Alert Innovation in fiscal 2023, bringing ownership to approximately 100%, and disposed of it in fiscal 2025. Between fiscal 2023 and 2024, there were no acquisition or disposition activities related to Alert Innovation; the entity was held and integrated into Walmart's operations during this period.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. While it correctly states that Walmart acquired Alert Innovation in fiscal 2023 with approximately 100% ownership, it incorrectly claims the disposition occurred in fiscal 2025, whereas the ground truth confirms the sale and deconsolidation occurred in fiscal 2024. This misplacement of the divestiture timeline fundamentally undermines the answer. (2) Quantitative accuracy is partially correct: the $0.4 billion acquisition amount is missing in the LLM response, which fails to mention the financial value of the transaction—a key detail from the original answer. The fiscal years are incorrectly referenced, with 'fiscal 2025' being factually wrong. (3) The multi-hop reasoning is flawed: the question asks about the evolution between fiscal 2023 and 2024, but the LLM asserts no activity occurred in that window, which contradicts the ground truth that the full cycle of acquisition and divestiture happened within that one-year span. The model fails to synthesize the correct sequence and timing of events. (4) Contextual relevance is moderate—the answer addresses the right companies and the general nature of the relationship (acquisition and later disposition), but the incorrect timing and missing financial figure reduce its usefulness. Overall, major factual and temporal inaccuracies result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 388,
        "total_tokens": 1563
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "Between 2022 and 2023, Trodelvy's regulatory approvals expanded from metastatic triple-negative breast cancer (TNBC) to additional indications, including unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. In 2022, the European Commission approved Trodelvy for TNBC, and in 2023, the FDA and EMA granted approvals for HR+/HER2- breast cancer. This evolution reflects Gilead's oncology strategy to broaden Trodelvy's therapeutic applications, solidifying its role in diverse cancer treatments and enhancing the company's position in the oncology market.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the expansion of Trodelvy's regulatory approvals between 2022 and 2023 and links it to Gilead's oncology strategy, which aligns with the ground truth. However, there is a factual inaccuracy regarding the 2022 European Commission approval: the original answer states that no specific regulatory updates for Trodelvy were mentioned in 2022, while the LLM claims the EC approved it for TNBC that year. This is not supported by the ground truth and introduces a significant error. The 2023 approvals by the FDA and EMA (referred to as EC in the original) for HR+/HER2- breast cancer are correctly reported. (2) There are no numeric values requiring calculation, so quantitative accuracy pertains to dates and regulatory bodies. The 2023 approvals are correctly attributed to FDA and EMA/EC, but the 2022 EC approval for TNBC is incorrect per the source, lowering quantitative accuracy. (3) The multi-hop reasoning is generally sound—linking regulatory developments to strategic intent—but hinges on an incorrect premise about 2022 approval. The synthesis across years and agencies is logical but based on a flawed fact. (4) Despite the error, the answer captures the core strategic implication accurately and addresses both parts of the question—regulatory evolution and strategic indication—earning high marks for qualitative accuracy and full contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 392,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "Simon Property Group significantly reduced its financial relationship with ABG between 2023 and 2024 through a series of capital transactions. In Q4 2023, Simon sold a portion of its ABG interest, recognizing a $157.1 million pre-tax gain and diluting its ownership to ~9.6%. This was followed by further deemed disposals in 2023, resulting in additional non-cash gains. In Q4 2024, Simon completed the full sale of its remaining ABG interest for $1.2 billion, generating a $414.8 million pretax gain. These transactions reflect a strategic shift toward divesting ABG, reallocating capital to other ventures like TRG and joint ventures, and focusing on core real estate operations and development projects. The proceeds from ABG's sale were likely reinvested in growth opportunities, aligning with Simon's broader strategy to optimize its portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group (SPG) recognized non-cash pre-tax gains of $36.4 million in Q2 2023 and $145.8 million in Q3 2023 due to dilution from SPARC Group issuing equity, not from a sale in Q4 2023. The LLM incorrectly states a $157.1 million gain in Q4 2023 and a full sale of remaining ABG interest in Q4 2024 for $1.2 billion with a $414.8 million gain—none of which are supported by the original answer. These numbers and events are entirely fabricated or misattributed. (2) Quantitative accuracy is very low: the correct total gains in 2023 were $36.4M + $145.8M = $182.2M from dilution, not $157.1M or $414.8M. There is no mention of a $1.2 billion sale in 2024 in the ground truth. The 9.6% ownership figure is not mentioned in the original and cannot be verified. (3) The multi-hop reasoning is flawed. The original answer indicates a shift from active capital engagement in 2023 (gains from dilution) to no new transactions in 2024, with only historical references. The LLM incorrectly infers a strategic divestment culminating in a full exit in 2024, which contradicts the ground truth that SPG simply stopped reporting new transactions and only referenced past deals. The mention of TRG and other joint ventures is speculative and unsupported. (4) Contextual relevance is moderate because the answer addresses the evolution of the SPG-ABG relationship and attempts to discuss strategic positioning, but the factual foundation is incorrect, undermining the analysis. The conclusion about strategic reallocation is not supported by the provided data. Thus, while the structure and intent align with the question, the factual errors severely limit correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 481,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "Chevron's investment in Chevron Phillips Chemical Company LLC increased from $903 million in 2022 to $8,571 million in 2024, reflecting expanded financial commitments. However, equity earnings from the affiliate declined from $867 million in 2022 to $608 million in 2023, with no change in 2024, indicating lower profitability or operational challenges at the affiliate despite increased investment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Chevron Phillips Chemical Company LLC was a consolidated subsidiary in 2022 (disclosed in Note 8 of the 2022 10-K), not an equity investment of $903 million. The $8,571 million figure for 2024 is correct as the investment value under the equity method, but the 2022 and 2023 investment values are wrong — the ground truth states $7,765 million in 2023, not $903 million in 2022. Additionally, the LLM claims equity earnings declined from $867M in 2022 to $608M in 2023 with no change in 2024, but this data is not present in the ground truth and cannot be verified; more importantly, it distracts from the core issue: the change in accounting method. (2) Quantitative accuracy is very low: the $903M figure for 2022 has no support in the original answer and contradicts the consolidation status, which implies full financial integration rather than a standalone investment value. The earnings figures are unverified and likely fabricated. (3) The multi-hop reasoning is flawed — the key evolution is the shift from consolidation to equity method reporting, indicating a structural ownership change. The LLM fails to identify this critical shift and instead fabricates a narrative of increasing investment and declining earnings without evidence. (4) Contextual relevance is moderate because the answer discusses Chevron’s relationship with Chevron Phillips and uses correct entity names and a plausible time frame, but it misses the central accounting change and introduces incorrect financial data, undermining overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 447,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "Between the end of 2023 and 2024, Meta completed its 2022 Facilities Consolidation Strategy by December 31, 2024, as noted in the 2024 10-K. The financial impact of this strategy in 2024 was minimal, with $31 million in pre-tax charges related to facilities consolidation, compared to $1.495 billion in 2023 (part of the broader 2022 Restructuring). This reflects the completion of the initiative, with costs declining significantly as the company finalized subleases, early terminations, and other consolidation activities.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the financial figures. The claim that Meta incurred $1.495 billion in pre-tax charges in 2023 related to facilities consolidation is incorrect. The ground truth does not specify annual breakdowns of pre-tax charges by year for facilities consolidation, nor does it state that $1.495 billion was incurred in 2023 specifically for this purpose. The $31 million figure for 2024 is not supported by the original answer, which only states that a retrospective summary was provided for 2022–2024 without specifying annual amounts. (2) There is no verification of calculations because the numbers themselves are not present in the ground truth. The LLM fabricates a year-over-year comparison that cannot be substantiated. (3) The reasoning partially captures the evolution of the strategy—from 'substantially completed' in 2023 to 'completed' in 2024—which aligns with the original answer. However, it incorrectly infers financial trends with made-up figures, undermining the multi-hop synthesis. The model conflates the broader 2022 Restructuring charges with facilities consolidation specifically, which is not justified in the source. (4) The contextual relevance is high because the answer addresses the timeline and completion status of the strategy and attempts to quantify financial impact. However, the quantitative accuracy is very low due to unsupported numbers, dragging down the overall correctness. The qualitative accuracy is moderate because the conceptual progression is correct, but entity-level precision (specific charges) is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 447,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "Lockheed Martin's involvement in hypersonics programs has remained a strategic focus from 2022 to 2024, with continued development of hypersonic strike weapons for the U.S. Air Force and Army. In 2022, hypersonics were highlighted as part of Missiles and Fire Control (MFC) programs, emphasizing design, development, and production. By 2024, hypersonics were further integrated into broader initiatives, including the Transport Layer programs under Space, which support proliferated space constellations and early warning communications. The 2024 document also notes advancements in hypersonic capabilities as part of multi-domain solutions and digital innovation, reflecting expanded strategic emphasis on hypersonic technologies alongside other emerging systems.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Lockheed Martin's continued strategic focus on hypersonics from 2022 to 2024 and mentions involvement with the U.S. Air Force and Army, which aligns with the ground truth. However, it misses the key evolution highlighted in the original answer: the shift from a funding-dependent development phase in 2022 to active production in 2024. Instead, the LLM claims hypersonics were already in 'design, development, and production' in 2022, which contradicts the ground truth stating programs were still dependent on future government authorization and funding. Additionally, the LLM introduces new elements not present in the ground truth—such as integration into Transport Layer programs under Space and early warning communications—which are unsupported by the provided truth and represent a factual divergence. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, the absence of incorrect numbers allows a score of 10. (3) The multi-hop reasoning is partially sound—linking hypersonics to strategic focus across years—but fails to accurately synthesize the critical shift in program status (from uncertain development to active production), which is the core of the question. The introduction of unverified space-related programs undermines the reasoning. (4) Contextual relevance is high because the answer addresses strategic focus and program evolution, but correctness suffers due to misrepresentation of the 2022 status and addition of unsupported 2024 initiatives. Thus, while the general direction is relevant, key factual inaccuracies limit the correctness score to 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 457,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "Southern Company's treatment of energy-related derivatives shifted from 2022 to 2023, with a notable move from gains to losses. In 2022, energy-related derivatives designated as regulatory hedging instruments showed a total gain of $9 million, while in 2023, the net impact became a loss of $257 million, reflecting increased unrealized losses in the balance sheets. Financially, 2023 saw a $44 million loss on energy-related cash flow hedges (vs. a $37 million gain in 2022), and OCI gains from derivatives fell to $(81) million in 2023 compared to $3 million in 2022. These changes highlight a deterioration in hedging effectiveness and market conditions, impacting both regulatory assets/liabilities and income.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The original answer states that Southern Company evolved its *disclosure practices* from 2022 to 2023—specifically, expanding in 2023 to include energy-related derivatives not designated as hedging instruments, with retrospective presentation for 2021–2022. The LLM answer instead fabricates specific financial figures (e.g., $9M gain in 2022, $257M loss in 2023, $44M loss on cash flow hedges, OCI of $(81)M) that are not present in the ground truth and misrepresents the nature of the change as a shift in financial performance rather than a change in disclosure scope. (2) There are no verifiable calculations or accurate numbers in the LLM response because all quantitative claims are unsupported by the ground truth. The original answer does not provide any dollar amounts related to gains or losses, so these figures are hallucinated. (3) The multi-hop reasoning is flawed: the question asks about evolution in *treatment and disclosure*, particularly designation and financial impact. The correct answer focuses on a change in reporting scope (from only regulatory hedging instruments to broader derivative disclosures). The LLM incorrectly interprets this as a deterioration in hedging performance and market conditions, introducing entities like OCI and cash flow hedges not mentioned in the ground truth. (4) The contextual relevance is moderate because the answer discusses derivatives and time periods correctly (2022–2023), but it fails on correctness due to fabricated data and mischaracterization of the change. Thus, the correctness score is low (3), quantitative accuracy is very poor (2), qualitative reasoning is partially on track but incorrect in conclusion (4), and relevance is acceptable but not sufficient (6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 496,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "Gilead's intellectual property strategy regarding Truvada evolved between 2022 and 2023 primarily through the continued management of patent expiration and generic competition. By 2022, Truvada's U.S. patents had already expired following the October 2020 loss of exclusivity, leading to significant generic competition. The 2023 filing does not disclose new patent protections for Truvada but highlights ongoing efforts to address the impact of patent expiration, such as focusing on other products like Veklury (which received pediatric exclusivity in 2024). No new patent disclosures specific to Truvada were noted in the 2023 10-K.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the October 2020 loss of exclusivity for Truvada in the U.S., which aligns with the ground truth, and accurately notes that by 2022, the patent had already expired and generic competition was present. This reflects correct factual understanding of the timeline and impact. However, the LLM answer misses the key evolution in Gilead's strategy—shifting from reactive acknowledgment of past exclusivity loss (2022) to proactive, structured disclosure of future patent expiration timelines for key products including Truvada in 2023. Instead, the LLM claims that 'no new patent disclosures specific to Truvada were noted in the 2023 10-K,' which contradicts the ground truth that Gilead did provide structured disclosures about Truvada’s U.S. and EU patent expiration dates in 2023. This omission represents a significant gap in capturing the strategic shift. (2) Quantitatively, all dates (October 2020, 2022, 2023) are accurate, and there are no numerical errors. The mention of pediatric exclusivity for Veklury in 2024 is contextually relevant but not directly related to Truvada, and does not detract from quantitative accuracy. (3) The multi-hop reasoning is partially sound—correctly linking patent expiration to generic competition and revenue impact—but fails to synthesize the evolution in disclosure practices between years, which is the core of the question. The model interprets 'no new patents' as implying no new disclosures, but the ground truth emphasizes transparency in expiration timelines, not new patents. (4) The correctness score is 6 due to accurate facts but major omission of the strategic shift in disclosure practices. Quantitative accuracy is high (9) due to correct dates and no numerical errors. Qualitative accuracy is moderate (6) because while entities and basic logic are correct, the reasoning misses the key conceptual evolution. Contextual relevance is strong (8) as the answer stays on topic and provides related strategic context, even if incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 546,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "Between 2022 and 2024, SPG significantly reduced its reliance on the Supplemental Facility. In 2022, SPG repaid $1.05 billion outstanding under the Supplemental Facility by issuing senior unsecured notes on January 11, 2022. By 2023, further repayments occurred, including the use of €750 million in bonds to settle the facility. By December 31, 2024, the Supplemental Facility had only $323.7 million outstanding, reflecting a substantial reduction in borrowing activity. This shift indicates SPG prioritized repaying the facility through new debt issuances and reduced its dependence on the Supplemental Facility over the period.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, SPG borrowed $1.05 billion in January 2022 under the Supplemental Facility (not repaid it via notes), used it to extinguish $1.16 billion in mortgages, and repaid the borrowing shortly after. The LLM incorrectly states that SPG repaid $1.05 billion by issuing notes, reversing the direction of the transaction. Additionally, in late 2023, SPG borrowed €750 million ($815.4 million) under the Supplemental Facility and repaid it on November 17, 2023—this was a new borrowing, not a repayment as the LLM claims. The LLM incorrectly frames this as a use of bonds to settle the facility, when in fact the facility was used to fund short-term needs. (2) The quantitative inaccuracies are severe: the $323.7 million outstanding at year-end 2024 is not mentioned in the ground truth and appears fabricated. The ground truth states both borrowings were repaid shortly after issuance, implying minimal outstanding balance. The conversion of €750 million to U.S. dollars is omitted in the LLM answer, and the timing (November 2023) is misrepresented as part of a 2023 repayment trend. (3) The multi-hop reasoning is flawed: the LLM infers a reduction in reliance on the Supplemental Facility, while the ground truth shows continued use for short-term financing, indicating reliance persists. The shift in financing strategy noted in the original answer (issuing senior notes to redeem others) is acknowledged in the LLM response but misaligned with the timeline and purpose. (4) The contextual relevance is moderate—the answer addresses SPG’s use of the Supplemental Facility over time and attempts to describe a trend—but the factual foundation is incorrect, undermining the conclusion. Due to major errors in direction of cash flows, amounts, dates, and interpretation, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 513,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "MetLife's cash buffer needs in capital management have remained critical for maintaining liquidity and meeting regulatory requirements, with a focus on preserving financial strength ratings and ensuring flexibility for dividends, debt service, and stress scenarios. In 2022, liquidity was $12.4 billion, supported by $223.0 billion in liquid assets, emphasizing cash buffers to address potential capital demands and regulatory constraints. By 2024, the company continued to prioritize liquidity management, maintaining access to ample short-term funds and adjusting capital allocation to balance growth, risk mitigation, and compliance with evolving market conditions. The role of cash buffers evolved to ensure resilience amid uncertainties, such as interest rate fluctuations and regulatory pressures, while supporting strategic initiatives like dividend distributions and debt obligations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2022 liquidity figures—$12.4 billion in short-term liquidity and $223.0 billion in total liquid assets—matching the ground truth exactly, which satisfies quantitative accuracy. The years (2022 and 2024) and entities (MetLife, capital management, liquidity) are also accurate. (2) All numeric values are correct and properly attributed to 2022; no calculations were required, but the figures align precisely with the original answer. (3) However, the qualitative evolution of cash buffer strategy is not fully captured. While the LLM notes continued prioritization of liquidity in 2024 and mentions balancing growth and risk, it omits the key shift in tone: that increasing cash buffers could actively limit capital for innovation, acquisitions, and shareholder returns. This critical nuance—highlighted in the ground truth as a strategic trade-off—is missing, weakening the multi-hop reasoning that connects liquidity decisions to capital allocation constraints. (4) The answer remains contextually relevant and well-structured, addressing capital management, liquidity, and strategic priorities. Due to the omission of the 2024 cautionary perspective on opportunity costs of high cash buffers, the qualitative accuracy and overall correctness are reduced, but not severely, as core facts and direction of strategy are still present. Hence, correctness and qualitative accuracy score 7, quantitative accuracy is perfect, and relevance remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 414,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "Between 2022 and 2023, Starbucks' exposure to 'Foreign currency - other' derivatives decreased in asset classifications but increased in liability classifications. In 2022, these derivatives were primarily classified as **derivative assets** in **prepaid expenses and other current assets** ($39.9M) and **other long-term assets** ($33.5M). By 2023, derivative assets were reduced to **prepaid expenses and other current assets** ($1.9M) and **other long-term assets** ($1.7M). Meanwhile, liabilities shifted from **accrued liabilities** ($0.3M in 2022) to **accrued liabilities** ($4.7M) and **other long-term liabilities** ($4.1M) in 2023, reflecting a significant increase in liability exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Starbucks had *no derivative asset* for 'Foreign currency - other'—only a $0.3 million liability. However, the LLM claims there were derivative assets of $39.9M and $33.5M in 2022, which is completely incorrect. The only accurate numbers are the 2023 asset ($1.9M) and liability ($4.7M) amounts, though the LLM adds an unsupported $4.1M in 'other long-term liabilities' not mentioned in the ground truth. (2) Quantitative accuracy is very low: the LLM invents large asset values for 2022 that do not exist in the original data, misrepresents the direction of change (claims assets decreased when they actually increased from zero), and introduces a liability category ('other long-term liabilities') with a fabricated amount. (3) The reasoning is flawed: the LLM incorrectly asserts that exposure decreased in assets when in fact it increased from $0 to $1.9M, and it fails to recognize the shift from a pure liability position to a net balanced position. The multi-hop synthesis is unsound because it misrepresents the starting state in 2022. (4) Contextual relevance is moderate—the answer addresses the right topic, time frame, and category of derivatives, and attempts to compare asset and liability classifications across years, but the severe factual errors undermine the analysis. The conclusion about increasing liability exposure is partially correct but overstated due to the invented long-term liability. Overall, the answer is mostly incorrect and misleading despite touching on the right concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 444,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "The Coca-Cola Company's financial stake in Coca-Cola FEMSA remained at 28% as of December 31, 2024, consistent with the 2023 ownership percentage. This equity method investment reflects a strategic partnership, with FEMSA continuing as one of the Company's largest bottling partners. There is no indication of a change in ownership or strategic engagement between 2023 and 2024, as the relationship persists through collaborative operations and shared financial interests.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA as of 2023 and 2024, which aligns with the ground truth. However, it incorrectly claims there was no change in strategic engagement, directly contradicting the ground truth that the relationship evolved significantly in 2024 when Coca-Cola FEMSA transitioned from a key bottler to an equity method investee, indicating a deeper strategic and financial shift. The LLM downplays or misses this evolution entirely. (2) Quantitatively, the 28% stake is accurate for both years, and no other numbers are misstated, so numerical accuracy is strong. However, the answer fails to mention that in 2023, Coca-Cola FEMSA was one of the top five independent bottlers contributing to 42% of global unit case volume — a key contextual fact showing the prior stage of the relationship. (3) The multi-hop reasoning is flawed: the question asks about evolution from 2023 to 2024, requiring synthesis of changes in both strategic engagement and financial stake. The LLM asserts continuity, but the ground truth describes a transformation in the nature of the relationship, moving beyond traditional bottling to a more integrated equity-based partnership. This shift in classification and strategic depth is not reflected. (4) While the answer is relevant and contains correct elements, the failure to identify a major strategic transition results in a low correctness score. The quantitative accuracy is higher due to correct ownership percentage, but qualitative accuracy suffers due to incorrect reasoning and omission of key developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 449,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "Intel's strategic positioning of FPGAs between 2022 and 2024 is not explicitly detailed in the provided documents. However, the 2024 filing notes continued emphasis on external foundry partnerships under the \"Smart Capital\" approach, which may indirectly support FPGA production through third-party manufacturing. Additionally, the 2022 document defines FPGAs as part of adjacent products (e.g., modem, Ethernet, and silicon photonics), suggesting their role in non-platform solutions remained consistent, though no explicit evolution in focus or production strategy is outlined.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content compared to the ground truth. While it correctly notes that in 2022 FPGAs were considered 'adjacent products' (matching the original answer), it fails to identify the key evolution in 2024 where FPGAs were explicitly listed under direct product definitions, indicating a strategic shift to a core product. Instead, the LLM claims no explicit evolution is outlined and speculates about external foundry partnerships under 'Smart Capital' as indirect support—information not relevant to the strategic positioning shift described in the ground truth. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable; the score of 10 reflects no errors in this dimension. (3) The multi-hop reasoning is flawed: the model had access to the necessary information (FPGA classification in 2022 and 2024) but failed to synthesize the correct progression. It missed the critical shift from 'adjacent' to 'core/direct' product status, which is the central point of the original answer. (4) Contextual relevance is moderate—the response addresses Intel and FPGAs over the correct time frame and mentions adjacent products, but introduces irrelevant details about foundry partnerships and concludes there is no explicit evolution, directly contradicting the ground truth. Thus, while some context is correct, the core strategic shift is missed, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 413,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "ConocoPhillips' Lower 48 region experienced a **decrease in sales** from $52.9 billion in 2022 to $38.2 billion in 2023, while **depreciation, depletion, and amortization (DD&A) expenses increased** from $4.85 billion to $5.73 billion. This reflects higher DD&A expenses in 2023, likely driven by increased capital expenditures ($6.49 billion in 2023 vs. $5.63 billion in 2022) and ongoing asset development, though specific asset acquisitions are not detailed in the provided documents.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but introduces significant inaccuracies. While it correctly reports the 2022 DD&A expense as $4.85 billion (matching the ground truth of $4,854 million) and approximates the 2023 figure as $5.73 billion (vs. actual $5,729 million), it incorrectly claims a 'decrease in sales' from $52.9B to $38.2B, which is not supported by the original answer or the knowledge graph—no such sales figures for the Lower 48 region were provided in the ground truth. Additionally, the LLM mentions capital expenditures of $6.49B in 2023 vs. $5.63B in 2022, which are not present in the original answer and cannot be verified from the provided context. (2) The DD&A numbers are acceptably close (rounding differences are minor: $4,854M ≈ $4.85B, $5,729M ≈ $5.73B), and the implied increase of ~$875M is consistent. However, the introduction of unverified sales and CapEx data undermines quantitative accuracy. (3) The reasoning is flawed in attributing higher DD&A to capital expenditures not mentioned in the ground truth. While the original answer links the DD&A increase to continued investment post-Concho acquisition, the LLM fails to mention the Concho acquisition as the key driver in 2022 and instead cites unspecified capital expenditures. This weakens the multi-hop synthesis—missing the link between acquisition and subsequent asset utilization. (4) The answer is contextually relevant, addressing both asset activity and DD&A trends, but fabricates financial data (sales, CapEx) not present in the source, leading to a moderate correctness score. The core DD&A trend is correct, but the supporting narrative is partially invented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 459,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "Emerson's ownership of AspenTech increased from 55% (fully diluted) in 2022 to 100% following its 2024 proposal to acquire the remaining 45% stake. The 2022 acquisition initially benefited gross margins by 0.6 percentage points due to the Heritage AspenTech integration, but the 2024 Test & Measurement acquisition negatively impacted margins by 1.3 percentage points due to inventory step-up amortization. Overall, the strategic relationship evolved from a minority investment to full ownership, with mixed financial impacts on gross margins.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual errors. First, it incorrectly states that Emerson increased ownership from 55% in 2022 to 100% by 2024, while the ground truth confirms Emerson owned 55% *by 2024*, not in 2022, and there is no mention of a full acquisition. Second, it falsely claims a '2024 Test & Measurement acquisition' negatively impacted margins, whereas the ground truth attributes the 1.3 percentage point reduction to acquisition-related inventory step-up amortization from the AspenTech deal itself, not a new acquisition. Third, the answer misrepresents the timeline and ownership evolution, implying a progression that is not supported. (2) Quantitative inaccuracies include: wrong ownership percentages (55% misattributed to 2022 instead of 2024), incorrect attribution of margin impacts (blaming a non-mentioned 'Test & Measurement' acquisition instead of AspenTech inventory amortization), and omission of key figures such as the $6.0 billion cash payment, $87.69 per share, $168 million retained balance, and $231 million amortization cost. The 0.6 and 1.8 percentage point gross margin contributions are partially correct but miscontextualized. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize ownership, financial impact, and timeline across years. It invents a new acquisition and misattributes financial effects, indicating a failure in logical and factual synthesis. (4) Despite these issues, the answer is contextually relevant—it addresses ownership evolution and gross margin impact as asked—hence a moderate relevance score. However, due to major factual and quantitative errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 462,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "Between 2022 and 2024, the availability of shares under the 2015 Director Stock Plan decreased from **34,073,114** to **30,660,961**. This reduction reflects increased share issuance for new awards and imputed reinvested dividends on Deferred Shares (totaling **42,343,146** since 2015) outpacing recovered shares (e.g., forfeitures, cash settlements). The plan’s share recovery mechanics remained consistent, with recovered shares (e.g., from expired or forfeited awards) reintroduced to the pool at a **1.0 ratio** (each share issued under the plan reduces availability by one). Despite this, the maximum performance factor for Performance Shares stayed at 175%, and the plan’s issuance mechanics (using treasury shares or new shares) persisted.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key numbers are correct: the final available shares in 2024 (30,660,961) match the original answer, as do the total shares covered by awards and reinvested dividends (42,343,146) and the recovered shares (37,608,213, though this exact number is not repeated in the LLM answer, it is implied in the context). The starting availability in 2022 is stated as 34,073,114, which is not explicitly in the ground truth but may be a derived value consistent with the timeline; no contradiction is present. (2) The explanation of share recovery mechanics—shares from forfeitures, expirations, or cash settlements being reused at a 1:1 ratio—is correctly described and consistent across years. (3) The reasoning correctly synthesizes multi-hop information: it contrasts ongoing recovery with higher issuance volumes, leading to a net reduction in availability, which reflects the core evolution of the plan. (4) Minor omission: the original answer specifies the initial authorized shares (35,395,894 as of January 1, 2015), which the LLM omits, slightly reducing completeness. However, this does not affect the core conclusion. Wording differences (e.g., 'imputed reinvested dividends', 'maximum performance factor') add detail without distorting facts. Overall, the answer is factually sound, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 399,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "Starbucks' relationship with the Global Coffee Alliance saw continued strategic emphasis in fiscal 2023, with the alliance contributing $216 million in product sales and royalty revenue in fiscal 2022 (SBUX_10k_2022.pdf). While the 2023 document (SBUX_10k_2023.pdf) does not specify exact revenue figures for the alliance, it highlights ongoing collaboration through licensing and digital capabilities, aligning with Starbucks' broader focus on expanding product reach and innovation. The strategic emphasis in 2023 likely maintained its role in supporting revenue growth, though specific evolution details are not explicitly outlined in the provided pages.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the Channel Development segment grew by $250 million in fiscal 2022 due to the Global Coffee Alliance, but the LLM incorrectly reports $216 million in revenue contribution from the alliance itself, which is not supported by the original answer. This misrepresents both the amount and the nature of the financial impact. Additionally, the LLM claims the 2023 report does not specify exact revenue figures — while true — but fails to recognize that the strategic evolution is clearly articulated in the ground truth, which the LLM overlooks. (2) The quantitative inaccuracy is critical: $216M vs. the correct $250M increase (even if attributed differently) is a material discrepancy, and the source of the number is not aligned with the ground truth. No calculation is required, but the number cited does not match the documented revenue growth driver. (3) The multi-hop reasoning is weak: the question asks for evolution in both strategic emphasis and revenue contribution from FY22 to FY23. The LLM acknowledges continued collaboration but misses the key shift identified in the ground truth — that the alliance evolved from a revenue driver to a strategic enabler via the Nestlé licensing relationship, which is explicitly highlighted in FY23. This reflects a failure to synthesize the qualitative strategic shift. (4) Contextual relevance is moderate — the answer discusses the right entities (Global Coffee Alliance, product sales, royalties, licensing) and timeframes, but fails to accurately convey the evolution in strategy or correct financial impact, undermining overall correctness. Minor credit is given for identifying the alliance’s ongoing role in distribution and innovation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 486,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "NEE's financial stake in Mountain Valley Pipeline (MVP) was significantly impacted by impairment charges between 2022 and 2023. In 2022, a $1.2 billion impairment charge was recorded related to NextEra Energy Resources' investment in MVP, reflecting reduced expectations for the project's viability. By 2023, the carrying value of NEE's investment in MVP (part of broader equity method investments) was further adjusted, with approximately $2.4 billion associated with MVP, primarily due to prior impairments. This indicates NEE's strategy involves recognizing financial risks in long-term infrastructure projects while maintaining strategic involvement in key assets. The impairment adjustments suggest a focus on aligning investments with current market conditions and operational realities, even as NEE expands into renewable energy (e.g., RNG acquisition) to diversify its portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that NEE's equity method investments were $6,159 million in 2022 and $6,156 million in 2023, with the Mountain Valley Pipeline (MVP) listed as one of several equity method investees with ownership stakes ranging from 32%–55% in 2022 and 32.8%–52.6% in 2023. However, the LLM claims a $1.2 billion impairment charge in 2022 and a carrying value of $2.4 billion for MVP in 2023—specific figures not present in the original answer and unsupported by the provided truth. There is no mention of impairments or carrying values in the ground truth, nor any indication that MVP accounted for a specific dollar amount within the total equity investments. (2) The quantitative inaccuracies are severe: the $1.2B impairment and $2.4B carrying value are fabricated in context, and no such figures appear in the original. The actual data focuses on total equity investments and ownership percentage ranges, not project-specific valuations or impairments. (3) The multi-hop reasoning is flawed. The LLM incorrectly infers financial performance and strategic implications based on non-existent impairment charges. While it attempts to synthesize investment strategy, it does so using incorrect data. The original answer highlights a narrowing of ownership stake ranges and a change in disclosure context (Nonrecurring Fair Value Measurements), suggesting possible revaluation—not impairment or reduced viability. (4) The contextual relevance is moderate: the answer addresses NEE’s involvement in MVP and attempts to infer strategy, which aligns with the question. However, due to major factual and quantitative errors, the qualitative and correctness scores are low. The answer fabricates financial events (impairments) not present in the truth, leading to a misleading interpretation of NEE’s investment strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 513,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "Between 2022 and 2024, Medtronic's InterStim Therapy product line expanded its neurostimulator offerings, introducing the **InterStim X** and **InterStim II** recharge-free neurostimulators, alongside the **InterStim Micro** rechargeable neurostimulator. These devices continued to target therapeutic indications for **overactive bladder, urinary retention, and fecal incontinence**, with the InterStim Micro also addressing chronic fecal incontinence. In 2024, the line saw further growth through the Western European launch of the **Percept RC** neurostimulator (part of the Percept family for deep brain stimulation) and advancements in spinal cord stimulation (SCS) therapies, though these were distinct from the InterStim platform. The product line maintained its focus on pelvic health while incorporating technological improvements like recharge-free designs and expanded global adoption.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant factual inaccuracies that impact overall correctness. (1) Correct elements include the mention of InterStim II, InterStim X, and InterStim Micro neurostimulators, as well as the therapeutic indications of overactive bladder, urinary retention, and fecal incontinence. The recharge-free designation for InterStim II and X in 2024 aligns with the ground truth. However, the claim that InterStim Micro is rechargeable is not supported in the original answer, which does not specify its charging status. More critically, the LLM incorrectly states that the InterStim Micro 'also addressing chronic fecal incontinence,' implying a new or exclusive indication, whereas the ground truth shows that fecal incontinence (now termed 'chronic fecal incontinence') was an expanded indication for the overall product line by 2024, not limited to InterStim Micro. (2) The introduction of the 'Percept RC' neurostimulator and advancements in spinal cord stimulation (SCS) and deep brain stimulation are factually incorrect in this context—they are unrelated to the InterStim platform and represent a confusion with other Medtronic product lines. This reflects a major error in entity accuracy. (3) The multi-hop reasoning is flawed: while the model attempts to show evolution, it misattributes technological developments and expands the product scope incorrectly. The ground truth emphasizes a refinement in labeling (recharge-free) and a broadening of therapeutic indications across the line, not the introduction of new platforms like Percept RC. (4) Despite these issues, the answer captures the core idea of product evolution and expanded indications, earning partial credit. Wording flexibility is allowed, but the inclusion of unrelated products and incorrect technical details reduces the correctness score significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 510,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "Simon Property Group's financial stake in Authentic Brands Group (ABG) decreased significantly from 2022 to 2024. In 2022, Simon held a 10.4% noncontrolling interest in ABG following a 2021 transaction where it sold part of its stake and acquired additional interests. By 2024, Simon sold its remaining ABG interest for $1.2 billion in Q1 2024, resulting in a $414.8 million pretax gain, effectively ending its financial stake. The strategic relationship shifted from a joint venture partnership to a complete exit, with Simon reallocating capital to other investments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group held a 1.37% interest in ABG in 2022, not 10.4% as claimed. The LLM states Simon sold its 'remaining' stake in Q1 2024 for $1.2 billion, realizing a $414.8 million gain, but the original answer indicates Simon only sold a portion of its stake (not all) and realized a pre-tax gain of $18.8 million, not $414.8 million. Additionally, the LLM claims Simon acquired no new interests, whereas the ground truth states Simon later acquired additional interests in ABG for $100 million in cash in 2024—directly contradicting the 'complete exit' narrative. (2) Quantitative accuracy is very low: the percentage stake (10.4% vs 1.37%), sale proceeds ($1.2B vs partial sale with $18.8M gain), and gain amount ($414.8M vs $18.8M) are all incorrect. The $100 million acquisition in 2024 is entirely omitted. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a full divestiture and strategic exit, while the actual relationship evolved dynamically with both sales and new investments, indicating an ongoing strategic relationship. The mention of SPARC and Forever 21 merger is omitted, weakening the strategic context. (4) Contextual relevance is moderate because the answer addresses the evolution of the financial and strategic relationship, but the incorrect facts and reversed direction of events (exit vs continued involvement) severely undermine correctness. The qualitative score is slightly higher because the structure and intent to trace stake evolution are present, albeit with wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 445,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "ConocoPhillips' Lower 48 segment depreciation, depletion, and amortization (DD&A) expenses increased from $4,067 million in 2021 to $5,729 million in 2023, reflecting growth in capital expenditures, acquisitions (e.g., Shell Permian in 2021), and expanded operations. This trend aligns with higher investment activity and production volumes in the region, as detailed in the 2022 and 2023 10-K filings.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the DD&A expenses for 2021 ($4,067 million) and 2023 ($5,729 million) are accurately reported, with no calculation or formatting errors. (2) The answer addresses the evolution of investment activity by correctly identifying the increase in DD&A as a proxy for growing investment and operational focus in the Lower 48 region. (3) Entity accuracy is strong: ConocoPhillips, the Lower 48 region, and the relevant financial metric (DD&A) are correctly identified, and the time frame (2021 to 2023) is properly observed. (4) The reasoning is sound and enhances the ground truth by adding context—such as referencing the Shell Permian acquisition in 2021 and linking higher DD&A to increased capital expenditures and production volumes—supported in the cited 10-K filings. These additions are factually plausible and contextually appropriate, not speculative. (5) The semantic meaning fully aligns with the original answer, conveying the same core conclusion: rising DD&A reflects heightened investment activity. All evaluation criteria are met with high accuracy and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 330,
        "total_tokens": 1519
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "Verizon's valuation approach for international bonds remained consistent between 2023 and 2024, with both years using **matrix pricing** and **third-party valuation inputs** to determine fair value. The methodology described in the 2023 and 2024 10-K filings explicitly states that international bonds are valued using matrix prices derived from independent third-party sources, with no indication of a methodological change. However, the **amount** of international bonds held in pension plans decreased from $341 million (2023) to $113 million (2024), reflecting strategic reallocations in the overall investment portfolio, though the valuation approach itself did not evolve.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that in 2023, international bonds were included under a general description of fixed income securities valued via matrix pricing with third-party inputs, but were not assigned a specific dollar amount. In 2024, Verizon specifically disclosed international bonds with a total value of $12 million, broken into $10 million (Level 1) and $2 million (Level 2). The LLM incorrectly claims the value was $341 million in 2023 and $113 million in 2024—these figures do not appear in the ground truth and are factually wrong. (2) The quantitative inaccuracies are severe: the LLM invents numbers not present in the original answer and contradicts the disclosed $12 million total for 2024. There is no mention of $341M or $113M in the ground truth, nor any indication of a decrease from 2023 to 2024 in terms of holdings. (3) The reasoning is flawed: the LLM concludes that the valuation approach 'remained consistent' and 'did not evolve', directly contradicting the ground truth, which identifies a clear evolution from a general, non-itemized description in 2023 to a specific, segmented disclosure in 2024. This shift represents a change in transparency and disclosure strategy, which the LLM fails to recognize. (4) The contextual relevance is moderate because the answer addresses Verizon, international bonds, and 10-K disclosures, but the core facts—valuation evolution and amounts—are incorrect. The qualitative accuracy is low due to failure in multi-hop synthesis: the model should have detected the shift from implicit inclusion to explicit itemization, which is a key qualitative change in reporting, regardless of methodology continuity. The correctness score is low because the answer misrepresents both the numbers and the nature of the evolution in treatment and valuation approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 516,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "Emerson's relationship with AspenTech evolved significantly between 2022 and 2024, with Emerson increasing its ownership stake from 55% (post-2022 Heritage AspenTech acquisition) to 57% by 2024, as it proposed acquiring the remaining shares for $240 per share. This move aimed to fully integrate AspenTech into Emerson's operations, leveraging synergies from their combined industrial software and automation capabilities. The 2022 acquisition already established operational integration through the creation of New AspenTech, while the 2024 proposal sought to finalize full ownership, enhancing Emerson's financial stake and strategic alignment with AspenTech.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Emerson did not increase its ownership from 55% to 57% by 2024, nor did it propose acquiring remaining shares at $240 per share. Instead, in 2024, Emerson contributed the AspenTech Industrial Software Business and $6.0 billion in cash to form 'New AspenTech,' retaining a 55% stake. The LLM incorrectly frames the 2024 event as a share acquisition proposal, which contradicts the actual restructuring. Additionally, the claim that Emerson already had a 55% stake post-2022 is false; in 2022, Emerson held a financial stake valued at $8,326 million, not a 55% ownership. (2) Quantitative inaccuracies include the incorrect percentage stakes (55% in 2022 and 57% in 2024), the non-existent $240 per share offer, and the misrepresentation of the $6.0 billion cash contribution as part of a buyout rather than a contribution to a new entity. The only correct number is the $6.0 billion, though it is miscontextualized. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from a financial investment in 2022 to a strategic restructuring in 2024. It invents a share acquisition narrative not present in the ground truth and misattributes the timing and nature of operational integration. (4) Despite these major errors, the answer is contextually relevant—it addresses the evolution of the relationship and mentions operational integration and financial stakes—hence a moderate relevance score. However, due to severe factual and quantitative errors, the correctness, quantitative, and qualitative scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 451,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "Starbucks' interest rate swaps remained classified as designated cash flow hedges in both 2022 and 2023. In 2022, the swaps had a net loss of $5.8 million in AOCI, while in 2023, the net gain was $0.3 million. The associated liabilities increased from $12.0 million in accrued liabilities (2022) to $41.4 million in derivative liabilities (2023), reflecting changes in fair value and hedge effectiveness.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the numbers provided do not match the ground truth: the 2022 liability was $34.0 million (not $12.0 million in accrued liabilities), and in 2023, the total liability was $19.6 million ($0.4M current + $19.2M long-term), not $41.4 million. The AOCI figures ($5.8M loss in 2022, $0.3M gain in 2023) are unrelated to the question about classification and liability amounts and appear to be fabricated or misattributed. (2) The original answer indicates a net decrease in liability from $34.0M to $19.6M, but the LLM claims an increase to $41.4M, which is factually wrong. (3) Qualitatively, the LLM misrepresents the classification evolution: in 2022, the swap was a long-term liability only, but the LLM incorrectly states it was part of accrued liabilities. In 2023, the correct split is between accrued liabilities and long-term liabilities, not a single 'derivative liabilities' category. While the mention of cash flow hedges may be contextually relevant, it does not address the core question about classification changes and liability values. (4) The reasoning fails the multi-hop requirement: the model does not correctly synthesize the shift in classification or compute the net change. The answer introduces irrelevant hedge accounting details (AOCI gains/losses) while missing the actual liability figures and their categorization. (5) Contextual relevance is moderate because it discusses interest rate swaps and liabilities, but the specifics are inaccurate. Overall, major factual and calculation errors lead to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 448,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolved from 2022 to 2023 as follows: In 2022, a $800 million impairment charge was recorded, fully writing off the equity method investment in the pipeline due to prolonged legal/regulatory challenges and low completion probability. However, in 2023, the company still had a $765 million commitment for 2024 capital expenditures related to the pipeline's construction, as noted in the Commitments and Contingencies section. Additionally, a 20-year natural gas transportation agreement with the joint venture remained in place, indicating ongoing financial ties despite the investment write-off.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $800 million (or $0.8 billion) impairment charge in 2022 due to low probability of completion, which matches the ground truth. However, it introduces a new figure—$765 million commitment for 2024 capital expenditures—that is not present in the original answer and contradicts the ground truth, which states that NEER maintained a 32.8% equity investment and committed to a 20-year transportation agreement with ~$70M annual obligation, not a lump-sum capital commitment. This is a significant factual error. (2) The $800 million impairment is accurate and correctly formatted. However, the $765 million figure has no support in the ground truth and appears to be fabricated or misattributed. The correct ongoing financial commitment is the $70 million per year transportation agreement, which the LLM mentions but buries under an incorrect and dominant capital expenditure claim. (3) The reasoning partially captures the paradox of writing off an investment while maintaining contractual obligations, which reflects sound multi-hop logic. However, the synthesis is flawed because it relies on an unsupported number ($765M capex) instead of the correct equity stake (32.8%) and transportation obligation. The model fails to accurately represent the nature of the continued involvement. (4) The contextual relevance is high because the answer addresses the evolution over time and discusses both write-off and continued commitments. However, due to the major quantitative inaccuracy and omission of the correct percentage ownership and annual obligation structure, the overall correctness is significantly reduced. The answer gives a misleading impression of the form and magnitude of the 2023 commitment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 492,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity contracts increased from $1,643 million as of December 31, 2023, to $1,883 million as of December 31, 2024. This reflects a growth of $240 million, indicating an expansion in the captive's solvency capital allocated to these securities.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $1,643 million (2023) and $1,883 million (2024) are accurately reported with correct dates (December 31, 2023 and December 31, 2024), and the implied $240 million increase is correctly calculated ($1,883M - $1,643M = $240M). (2) The answer is complete, addressing the evolution of investments between 2023 and 2024 as required by the question. (3) Entity accuracy is correct: The Coca-Cola Company, its captive insurance company, and the context of reinsuring group annuity insurance contracts are properly referenced. (4) The reasoning is sound and reflects multi-hop synthesis—recognizing that the securities are part of solvency capital funds and that the increase indicates growth in investment. (5) The semantic meaning is equivalent to the original answer, with slightly enhanced detail (explicit mention of $240M growth) that adds clarity without introducing error. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1187,
        "completion_tokens": 292,
        "total_tokens": 1480
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "Intel's approach to the Intel 4 process node evolved from 2022 to 2024, transitioning from initial ramp-up to high-volume manufacturing. In 2022, Intel began shipping the first high-volume client product on Intel 4 (the Core Ultra processor) and shifted production to Ireland in 2024, with Intel 4 representing an increasing share of processor production by 2025. Strategically, Intel positioned Intel 4 as a key node in its IDM 2.0 roadmap, emphasizing performance-per-watt improvements (20% over Intel 7) and enabling products like AI PCs and hybrid architectures. This aligned with broader goals to advance heterogeneous computing and support future nodes (Intel 3, 18A) while addressing supply constraints and competitive pressures.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. Most notably, it incorrectly states that Intel began shipping the first high-volume client product on Intel 4 (Core Ultra) in 2022, while the original answer clarifies that 2022 was marked by higher period charges due to ramp-up challenges—indicating pre-production or early production phase, not high-volume shipping. The correct timeline is that Intel 4 transitioned to high-volume manufacturing by 2024, not 2022. Additionally, the mention of 'increasing share of processor production by 2025' introduces a future date not present in the original answer and adds unverified forward-looking information. The 20% performance-per-watt improvement over Intel 7 and strategic positioning within IDM 2.0 are plausible contextual details but not confirmed in the ground truth, making them potentially speculative. (2) Quantitative accuracy issues include the incorrect timing of high-volume production (2022 vs correct 2024) and the unsupported projection to 2025. The percentage improvement (20%) is not mentioned in the original answer and thus cannot be verified from the provided truth. (3) Multi-hop reasoning is partially sound—the model connects Intel 4 to product roadmap strategy and geographic production shift to Ireland—but incorrectly sequences key milestones. It conflates the start of ramp-up with high-volume production, which undermines the evolution narrative. (4) Despite these errors, the answer captures the general trajectory from development to volume manufacturing and correctly identifies Intel 4’s strategic importance and use in Core Ultra processors. The contextual relevance is high as it addresses both production status and strategic positioning as asked. However, factual correctness is compromised by key date and event misalignments, warranting a moderate correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 513,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "Emerson's strategic relationship with AspenTech evolved significantly between 2022 and 2024, marked by a shift in ownership structure and financial integration. In 2022, Emerson acquired Heritage AspenTech, gaining a 55% ownership stake through the contribution of its industrial software businesses. By 2024, Emerson proposed acquiring the remaining 45% of AspenTech's shares for $240 per share, aiming for full ownership. Financial integration was further advanced through acquisitions like Test &amp; Measurement, which boosted sales, and the consolidation of AspenTech's operations into Emerson's portfolio. The proposed acquisition in 2024 signaled a move toward full integration, enhancing Emerson's control and synergies with AspenTech.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Emerson 'acquired Heritage AspenTech' and gained a 55% stake in 2022, whereas the ground truth indicates that the merger to form 'New AspenTech' with a 55% ownership stake occurred by 2024, not 2022. Additionally, the claim that Emerson 'proposed acquiring the remaining 45% of AspenTech's shares for $240 per share' in 2024 is not supported by the original answer and introduces false information. There is no mention of such a proposal or price in the ground truth. (2) Quantitative inaccuracies include the $240 per share figure, which is entirely fabricated, and misattribution of timing for the 55% ownership stake. The original answer notes financial impacts (0.6 percentage point gross margin improvement in 2023, SG&A influence in 2024), none of which are mentioned in the LLM response. Instead, it references unrelated acquisitions like 'Test & Measurement' that do not appear in the ground truth. (3) The multi-hop reasoning is flawed: the LLM fails to correctly trace the evolution from a strategic partnership in 2022 to partial ownership and financial integration by 2024. It incorrectly frames the relationship as beginning with an acquisition in 2022 and moving toward full acquisition in 2024, reversing the actual sequence and structure (merger forming New AspenTech with 55% ownership). The integration of financials is mentioned vaguely but without the specific, correct impacts noted in the original. (4) While the LLM recognizes that the relationship deepened and that integration occurred, the core facts—timing, ownership evolution, financial effects—are incorrect. The contextual relevance is moderate because it addresses ownership and integration, but the factual foundation is unsound, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 500,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "Intel's approach to the Intel 4 process node evolved significantly from 2022 to 2024, transitioning from development to high-volume manufacturing. By 2024, Intel 4, their first EUV lithography node, achieved manufacturing readiness with high-volume production in Ireland, representing an increasing share of processor output. This node delivered approximately 20% performance-per-watt improvements over Intel 7, enabling products like the Intel Core Ultra Series 1 (launched in 2023) and enhancing efficiency in client and data center applications. The shift to Intel 4 marked a key step in Intel's roadmap to compete with advanced process technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Intel 4 is Intel's first EUV node, achieved high-volume manufacturing by 2024 in Ireland, delivers ~20% performance-per-watt improvement over Intel 7, and was used in the Intel Core Ultra Series 1 launched in 2023. These match the original answer exactly. (2) Quantitative accuracy is perfect: the 20% performance-per-watt gain is correctly cited, and the 2023 product launch date is accurate. No calculations are required, but all numbers and dates are consistent with the ground truth. (3) The multi-hop reasoning is sound—LLM synthesizes information across time (2022 to 2024), technology development (from naming to production), and application (Core Ultra processors). The only minor omission is not explicitly mentioning the 2022 rebranding of the node naming convention, which was part of the original answer. However, the evolution from development to production is clearly conveyed. (4) The answer is contextually excellent, directly addressing both manufacturing readiness and performance improvements as asked. Wording differs slightly but maintains semantic equivalence. The slight deduction in qualitative accuracy is due to the missing detail about the 2022 naming restructure, but the core evolution is accurately captured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 372,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "InterStim Micro has remained a core component of Medtronic's Pelvic Health therapies, positioned alongside InterStim X and InterStim II neurostimulators to address overactive bladder, urinary retention, and fecal incontinence. In 2024, the document highlights continued acceptance and growth of Pelvic Health therapies, emphasizing InterStim Micro's role in the rechargeable neurostimulator portfolio, alongside advancements like the NURO System. This underscores its sustained importance within the division, supported by expanded market adoption and integration into broader therapeutic solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately identifies InterStim Micro as a core component of Medtronic's (MDT) Pelvic Health therapies alongside InterStim X and InterStim II, and correctly notes its use in treating overactive bladder, urinary retention, and fecal incontinence—consistent across both years. The key evolution—InterStim Micro being positioned as the rechargeable option by 2024—is correctly implied by stating its role in the 'rechargeable neurostimulator portfolio,' though the contrast with 'recharge-free' InterStim X and II from the original is not explicitly mentioned, which is a minor omission. (2) There are no numeric values, dates, or calculations in the response or ground truth beyond years (2022, 2024), which are correctly referenced—hence quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model synthesizes the product’s role in the portfolio and its evolving strategic positioning over time. However, it adds a detail—'advancements like the NURO System'—that is not present in the original answer and may introduce extraneous information, slightly affecting qualitative accuracy. (4) Despite minor omissions and the addition of unverified context (NURO), the answer captures the core evolution in positioning and remains contextually relevant and factually accurate in its main claims, warranting a high correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 394,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "The disclosure around the dilutive effect of LTIP Units remained consistent from 2022 to 2024, with no material impact reported across reporting periods. In both the 2022 and 2024 filings, the company noted that LTIP Units were included as potentially dilutive securities in per share/unit calculations but explicitly stated that no securities had a material dilutive effect for the years ended December 31, 2022, 2023, and 2024. This indicates no evolution in materiality or disclosure scope related to LTIP Units during this period.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the disclosure around LTIP Units remained consistent in scope and detail from 2022 to 2024. According to the ground truth, there was a notable reduction in detail: the 2022 filing explicitly mentioned that LTIP units were exchangeable for common stock, while the 2024 filing omitted this conversion feature, even though the conclusion about lack of material dilutive effect remained the same. The LLM answer falsely asserts no evolution in disclosure scope, which contradicts the ground truth. (2) Quantitatively, the years referenced (2022, 2023, 2024) are plausible, but the LLM misattributes the 2022 disclosure content — it incorrectly claims that the 2022 filing already covered the same period (2022–2024), when in fact the 2022 filing discussed 2021, 2020, and 2019. This is a critical error in temporal alignment. The LLM also incorrectly implies that LTIP units were discussed in the context of 2022–2024 in both filings, which misrepresents the reporting lag and content evolution. (3) The multi-hop reasoning is flawed: the model fails to recognize that the change in disclosure detail (removal of exchangeability language) constitutes an evolution in disclosure practice, even if the conclusion about materiality is unchanged. This is a key aspect of the question — how the disclosure *around* the dilutive effect evolved, not just whether materiality changed. The LLM conflates consistency in conclusion with consistency in disclosure richness, missing the nuance. (4) Contextual relevance is high because the answer addresses dilution, LTIP units, and reporting periods, but factual and qualitative inaccuracies significantly reduce correctness. The answer is partially correct in noting no material dilutive effect was reported, but wrong on the evolution of disclosure detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 500,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024 by prioritizing liquidity and regulatory compliance. In 2022, the company had $1.5 billion remaining under its $3.0 billion repurchase authorization, with decisions influenced by cash buffer requirements and legal restrictions. By 2024, the document indicates continued emphasis on liquidity considerations and regulatory constraints, suggesting that repurchase activity remained aligned with maintaining adequate cash reserves, though specific 2024 authorization figures were not detailed. The focus on balancing capital returns with operational needs persisted, reflecting a cautious approach to stock repurchases amid evolving market and regulatory conditions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that in 2022, MetLife had $1.5 billion remaining under its $3.0 billion repurchase authorization, which matches the ground truth exactly. All quantitative figures are accurate and properly contextualized. (2) There are no calculations required beyond correct reporting of dollar amounts and timeframes, and these are presented accurately with acceptable formatting. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 to 2024), identifying a shift from active repurchase capacity to a more cautious, liquidity-focused approach. It captures the core evolution—increased emphasis on cash buffers and regulatory constraints limiting repurchases—though it notes that specific 2024 authorization figures were not detailed, which aligns with the absence of such data in the source. (4) The answer is contextually fully relevant, addressing both remaining repurchase authorization and liquidity considerations as asked. The only minor limitation is that it does not explicitly mention 'innovation' or 'acquisitions' as areas potentially affected by buffer increases (mentioned in the ground truth), slightly reducing completeness in qualitative synthesis. However, the central shift in strategy is accurately conveyed, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 372,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "Starbucks' foreign currency - other derivative positions showed a significant increase in net gains within AOCI from $55.3 million (fiscal 2022) to $103.9 million (fiscal 2023), though balance sheet assets decreased. In 2022, these derivatives were primarily classified as prepaid expenses ($39.9M) and other long-term assets ($33.5M), while in 2023, they were largely reclassified to current assets ($1.9M) and long-term assets ($1.7M), reflecting a reduction in asset balances. Concurrently, derivative liabilities increased from $0.3 million (2022) to $4.7 million (2023) in accrued liabilities, indicating a shift in liability classification and potential settlement or rehedging activities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states that net gains in AOCI increased from $55.3 million in 2022 to $103.9 million in 2023, but the ground truth indicates that $103.9 million was the derivative asset amount in 2022 recognized in OCI before reclassifications, not AOCI balance or net gains. The $22.0 million reclassified from AOCI to earnings in 2022 is omitted entirely. The LLM falsely claims derivative assets in 2022 were $39.9M in prepaid expenses and $33.5M in other long-term assets, which is unsupported by the original answer. These numbers are entirely fabricated. The liability increase from $0.3M in 2022 to $4.7M in 2023 is incorrect—the original answer does not provide 2022 liability amounts, so this comparison is speculative. (2) The only correct numbers are the 2023 balance sheet figures: $1.9M in prepaid expenses, $1.7M in other long-term assets, $4.7M in accrued liabilities, and $4.1M in other long-term liabilities. All other figures are either wrong or misrepresented. (3) The multi-hop reasoning is flawed: the model fails to correctly track the evolution from 2022 to 2023, misrepresents classification shifts by inventing prior-year balances, and draws incorrect conclusions about increases in AOCI and liabilities. It does not acknowledge the significant reduction in asset positions as emphasized in the ground truth. (4) The contextual relevance is moderate because the answer addresses the general topic of derivative asset/liability changes and balance sheet classifications, but the severe quantitative and qualitative errors undermine its correctness. Due to major factual and calculation errors, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 469,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "Procter & Gamble's global cash management strategy evolved between fiscal 2022 and 2024 by balancing liquidity optimization, restructuring impacts, and corporate financial resilience. In 2022, the company focused on leveraging scale and managing foreign exchange risks, with adjusted free cash flow decreasing slightly due to lower operating cash flow. By 2024, despite significant restructuring charges (e.g., $1.4B impairment and $659M restructuring costs), adjusted free cash flow surged 21% to $16.9B, reflecting improved operational cash generation and strategic cost management. The strategy emphasized maintaining strong liquidity through operational efficiency, debt flexibility (stable credit ratings), and optimizing cash flow from segments like Fabric & Home Care (18% net earnings growth) and Health Care (6% net earnings growth), while mitigating restructuring-related headwinds.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in key financial figures and their implications. While it correctly identifies the $659 million restructuring costs in fiscal 2024 and the $1.4 billion impairment charge, it incorrectly states that adjusted free cash flow surged 21% to $16.9B in 2024, which is not supported by the ground truth. The original answer makes no mention of free cash flow or operational cash flow improvements, instead emphasizing declining corporate net earnings due to restructuring and impairments. This is a major quantitative and qualitative error. Additionally, the LLM claims net earnings growth in Fabric & Home Care (18%) and Health Care (6%), which are not present in the ground truth and represent fabricated data. (2) The restructuring cost of $659M in 2024 matches the ground truth, as does the $1.4B Gillette intangible asset impairment. However, the $147M restructuring accrual from 2022 and the $872M improvement in corporate net earnings in 2022 are omitted. The LLM also fails to mention the $216M in non-cash foreign currency translation losses included in the 2024 restructuring costs, a significant detail affecting cash management. (3) The multi-hop reasoning is partially sound—the model attempts to link restructuring activities to financial performance and cash management strategy—but it invents positive operational outcomes (e.g., cash flow surge, segment earnings growth) that contradict the ground truth’s narrative of increased pressure and declining earnings. The synthesis is therefore flawed. (4) The contextual relevance is high because the answer addresses global cash management, restructuring, and financial performance across the correct time frame. However, the correctness score is limited to 5 due to serious factual and quantitative errors that undermine the core conclusions. The qualitative accuracy is moderate because the structure and intent are reasonable, but reasoning is based on incorrect data. Quantitative accuracy is low due to unsupported numbers and missing key figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 561,
        "total_tokens": 2041
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "Between 2022 and 2023, NVIDIA expanded Omniverse's integration into enterprise solutions and simulation technologies. In 2022, Omniverse was highlighted as a platform for industrial digitalization, enabling digital twins of factories, real-time 3D product configurators, and testing of autonomous systems. By 2023, NVIDIA emphasized Omniverse Enterprise for metaverse and 3D internet applications, with DRIVE Sim (based on Omniverse) supporting scalable simulation for automotive development and self-driving platforms. This evolution solidified Omniverse's role in enterprise workflows, combining real-time collaboration, simulation, and AI-driven virtual world creation.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in its overall narrative and captures the general evolution of NVIDIA Omniverse from 2022 to 2023, particularly in enterprise integration and simulation technologies. However, there are some inaccuracies in the chronological assignment of use cases. According to the ground truth, in 2022, Omniverse was positioned as a collaboration platform for 3D workflows with applications in virtual car showrooms, surgical training, and architectural walkthroughs, and it integrated with DRIVE Sim. The LLM incorrectly attributes industrial digitalization use cases like digital twins of factories and real-time 3D product configurators to 2022, when these were emphasized more prominently in 2023. Additionally, the LLM states that in 2023, Omniverse Enterprise was emphasized for 'metaverse and 3D internet applications,' which is not explicitly supported in the original answer; instead, the 2023 evolution focused on its role as a development platform and operating system tightly integrated with NVIDIA's accelerated computing infrastructure. The answer correctly identifies DRIVE Sim's role and scalability in automotive development, aligning with the ground truth. There are no numerical values to verify, so quantitative accuracy is scored as 10. The reasoning is generally sound but contains minor misplacement of key applications across years, affecting qualitative accuracy. The response remains contextually relevant and addresses the core of the question regarding Omniverse's evolution in enterprise and simulation integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 427,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "AMT's financial commitments related to communications sites decreased from $1.8 billion in 2023 to an estimated $1.55–$1.66 billion in 2024, reflecting a reduction in capital expenditures for site construction (from 3,198 sites in 2023 to 2,500–3,500 sites in 2024) and data center assets ($395 million in 2023 to $450 million in 2024). Future obligations include repayments of securitized debt tied to communications sites, with principal due in March 2053, and ongoing interest payments under the 2023 Securitization (5.490% and 5.735% rates). Additionally, AMT repaid $1.5 billion in 2024 under the 2021 Multicurrency Credit Facility, which funds operations and capital needs, including site-related expenditures.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents AMT's financial commitments from 2023 to 2024. (1) Quantitatively, the LLM incorrectly states that AMT's financial commitments decreased from $1.8 billion in 2023 to $1.55–$1.66 billion in 2024. The ground truth indicates no such overall reduction; instead, AMT reported a $450 million anticipated spend in 2023 for data center assets related to 2,500–3,500 sites, and in 2024 disclosed a $4.5 billion undiscounted future cash outlay for asset retirement obligations (AROs) on leased sites. These are different types of obligations (near-term capex vs long-term AROs), but the LLM incorrectly frames them as comparable and declining, which is factually wrong. (2) The LLM invents numbers not present in the ground truth: $1.8 billion in 2023 and $1.55–$1.66 billion in 2024 have no basis in the original answer. The 3,198 sites in 2023 are fabricated; the original mentions only a 2023–2024 range of 2,500–3,500 sites. (3) The mention of securitized debt with maturities in 2053 and interest rates of 5.490% and 5.735%, as well as the $1.5 billion repayment under the 2021 Multicurrency Credit Facility, are not part of the ground truth and appear to be hallucinated. (4) The qualitative reasoning is flawed: the original answer highlights a shift from near-term capital planning to long-term liability recognition, but the LLM incorrectly interprets this as a reduction in spending. The multi-hop synthesis fails—instead of contrasting 2023 capex plans with 2024 AROs, the LLM conflates unrelated metrics and introduces external financial instruments. (5) Contextual relevance is moderate because the answer discusses financial commitments related to communications sites, but the specific content diverges significantly from the truth. Minor alignment exists in mentioning data center assets and site construction ranges, but even those are misrepresented. Overall, the answer is largely incorrect and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 533,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "ExxonMobil's characterization of asset divestitures in relation to strategic objectives remained consistent between 2023 and 2024, with the language emphasizing that assets are divested when they no longer meet strategic goals or offer higher value to others. The 2024 filing expanded on this by explicitly linking divestitures to **structural cost savings** and **advantaged volume growth**, highlighting how proceeds contribute to operational efficiency and strategic alignment. However, the core rationale for divestitures—aligning with long-term objectives—remained unchanged, reflecting a sustained focus on optimizing capital deployment.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in noting that ExxonMobil maintained a consistent strategic rationale for divestitures—aligning assets with long-term objectives—between 2023 and 2024, which aligns with the ground truth. However, the LLM introduces new elements not present in the original answer: specifically, the claim that the 2024 filing 'expanded' by linking divestitures to 'structural cost savings' and 'advantaged volume growth' is unsupported by the ground truth and represents a significant factual deviation. The actual evolution described in the ground truth is purely in the *language used to describe proceeds*, shifting from a detailed breakdown (e.g., 'sales of subsidiaries, property, plant and equipment') in 2023 to a more consolidated phrase ('proceeds from asset sales and returns of investments') in 2024. The LLM fails to capture this key linguistic shift and instead invents a new strategic emphasis not mentioned in the original. While the core idea of strategic alignment is correctly identified, the answer misrepresents the nature of the evolution by focusing on new strategic justifications rather than the documented streamlining of financial terminology. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. Contextual relevance is moderate because the answer addresses the general topic of strategic objectives and divestitures but misses the specific focus on *proceeds language*. The qualitative accuracy is low due to incorrect reasoning about the evolution of language and the introduction of unsupported strategic linkages.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 437,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "Comcast's financial exposure to Universal Beijing Resort decreased from 2021 to 2023, as reflected in the consolidated balance sheet. As of December 31, 2021, the resort's assets totaled $9.7 billion and liabilities $8.1 billion, while as of December 31, 2023, assets and liabilities were $7.8 billion and $7.2 billion, respectively. This represents a reduction in both assets and liabilities, indicating a decline in the consolidated financial exposure to the resort.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 figures ($7.8 billion in assets and $7.2 billion in liabilities) and the 2022 figures from the ground truth, but incorrectly attributes the $9.7 billion in assets and $8.1 billion in liabilities to 2021 instead of 2022. This is a critical error in temporal attribution, as the question specifically asks about the evolution from 2022 to 2023. (2) The numbers themselves are accurate in value and format (e.g., $9.7 billion = $9.7 billion), but their assignment to the wrong year undermines quantitative accuracy. The calculation of reduction is implied correctly (decrease in both assets and liabilities), but the comparison is drawn across incorrect years. (3) The reasoning is otherwise sound: the model correctly infers that a reduction in both assets and liabilities indicates decreased financial exposure, which aligns with the multi-hop synthesis required. However, the use of 2021 data (not requested) instead of 2022 weakens the logical chain. (4) Contextual relevance is high because the answer addresses financial exposure through balance sheet items and draws a reasonable conclusion. The core facts are present but misdated, warranting a correctness score of 7—most information is right, but the time frame error is significant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 363,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "Caterpillar's Customer Demand Volatility risk factor remained consistent between 2023 and 2024, driven by macroeconomic conditions, commodity price fluctuations, and industry-specific capital expenditure trends. Both years highlight that economic weakness, such as reduced government/business investment, lower consumer spending, and supply/demand dynamics, can significantly impact demand for Caterpillar's products and services. The 2024 filing emphasizes continued risks from supply chain disruptions and cybersecurity threats, which could exacerbate volatility, but the core drivers of demand instability—economic cycles and commodity price volatility—remained unchanged. Financial performance and supply chain stability were consistently tied to these factors, with no material evolution in their nature or impact noted.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant misrepresentation of the evolution of Customer Demand Volatility between 2023 and 2024. While it correctly identifies macroeconomic conditions and commodity price fluctuations as ongoing factors, it incorrectly asserts that there was 'no material evolution in their nature or impact,' which contradicts the ground truth. The original answer shows a clear shift from 2023—where the focus was on pandemic-related demand-side shocks like inflation and labor inefficiencies—to 2024, where the risk expanded to include systemic supply-side challenges such as material price increases and broader supply chain or labor shortages. This indicates a broadening of the risk profile, which the LLM answer fails to capture. There are no numerical values in the question or answers, so quantitative accuracy is not applicable in a traditional sense, but all mentioned factors are plausibly framed, earning full marks by default. Contextually, the answer addresses the right topic and relevant themes (financial performance, supply chain stability), but the reasoning is flawed in synthesizing the change over time. The multi-hop aspect—comparing risk factor language across two years—was not properly executed, as the LLM minimized the evolution rather than acknowledging the expanded scope in 2024. Thus, while the answer is well-structured and contextually relevant, it lacks qualitative accuracy in capturing the nuanced shift in risk emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 410,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "From 2022 to 2024, the fair value of net derivative assets (liabilities) increased from $19 million (2022) to $69 million (2024), with valuation methodologies relying on discounted cash flows using swap rates and other unobservable inputs. Key changes include:  \n- **2022**: Transfers out of Level 3 ($6 million) indicated some derivatives moved to Level 2 due to observable inputs.  \n- **2023**: A transfer out of Level 3 ($1 million) suggested continued use of observable inputs, but the balance rose to $58 million.  \n- **2024**: Transfers into Level 3 ($2 million) primarily involved SOFR-indexed derivatives, reflecting market shifts and increased reliance on unobservable inputs.  \nThe weighted average swap rate for derivatives rose to 4% in 2024, impacting fair value measurements. Overall, the methodology remained consistent, but the composition of derivatives and market conditions influenced classification and valuation.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in key numbers and the overall trend. The ground truth states the fair value was $19 million as of December 31, 2021 (reported in 2022), and increased to $58 million as of December 31, 2023 (reported in 2024). However, the LLM incorrectly states the 2024 value as $69 million, which is factually wrong. It correctly notes the $58 million balance in 2023, but mislabels it as part of 2024 developments. Additionally, the LLM claims a transfer into Level 3 in 2024 of $2 million, which is not mentioned in the original answer and contradicts the trend toward more observable inputs. (2) The original answer emphasizes a methodological shift toward discounted cash flows using observable inputs like swap rates (3–5%, weighted average 4%). The LLM misrepresents this by stating the methodology relies on 'unobservable inputs' and claims increased reliance on Level 3, which directly contradicts the ground truth’s emphasis on greater transparency and observable inputs. The mention of SOFR-indexed derivatives and transfers into Level 3 is unsupported. (3) The multi-hop reasoning is partially sound—LLM attempts to track changes over time and links valuation methods to market inputs—but fails in synthesis by conflating years and misrepresenting the direction of methodological evolution. It correctly identifies the use of swap rates and a 4% weighted average, aligning with the original. (4) Despite incorrect numbers and a flawed characterization of the methodology shift, the answer is contextually relevant and structured around the right concepts: fair value changes, Level 3 transfers, and valuation techniques. Hence, moderate scores for qualitative accuracy and high for relevance, but low quantitative accuracy due to critical number errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 496,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 by being more deeply integrated into its broader GPU and cloud platform ecosystem, emphasizing AI-driven enhancements and expanded accessibility. In 2023, GeForce NOW was positioned as a key component of NVIDIA's cloud gaming strategy, leveraging AI technologies like deep learning super sampling (DLSS) and NVIDIA's accelerated computing infrastructure to improve streaming quality and performance. It was also aligned with NVIDIA's broader ecosystem, including Omniverse and AI Enterprise, highlighting its role in enabling interactive graphics across devices. This integration underscored GeForce NOW's importance in NVIDIA's vision for cloud-based, AI-enhanced computing experiences.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) There are no numeric values to verify in this question, so quantitative accuracy is 10. (2) The answer correctly captures the evolution of GeForce NOW from 2022 to 2023: in 2022 it was positioned as a cloud platform extending NVIDIA’s graphics ecosystem, and by 2023 it was more tightly integrated into the broader accelerated computing and cloud infrastructure narrative. The mention of AI-driven enhancements like DLSS and alignment with Omniverse and AI Enterprise is consistent with the strategic shift toward GPU-driven cloud services, including AI platforms like DGX Cloud. (3) The multi-hop reasoning is sound—while the LLM does not explicitly name DGX Cloud, it correctly infers the strategic integration of GeForce NOW within AI and cloud infrastructure, referencing accelerated computing and AI-enhanced experiences. The synthesis across NVIDIA’s ecosystem (Omniverse, AI Enterprise) reflects accurate qualitative understanding. (4) The only minor gap is that the original answer emphasizes the shift from being grouped with vGPU in 2022 to being part of a broader 'gaming as a service' suite in 2023, which the LLM answer implies but does not explicitly state. However, the core facts, reasoning, and contextual evolution are correctly conveyed, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 380,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "Inlyta's revenue increased by 3% globally from $1,003 million in 2022 to $1,036 million in 2023. This growth was driven by stronger adoption in the U.S. for combinations of immune checkpoint inhibitors and Inlyta in first-line treatment of advanced renal cell carcinoma (RCC), partially offset by lower volumes and net prices in certain European markets. The U.S. saw a 4% increase, while international markets experienced a 3% growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the revenue figures for Inlyta in 2022 ($1,003 million) and 2023 ($1,036 million), and accurately calculates the 3% growth. These numbers match the ground truth exactly, and the percentage change is correct: (1,036 - 1,003) / 1,003 ≈ 3.3%, which rounds to 3% as stated in both answers. (2) The key drivers of growth—increased U.S. adoption of Inlyta in combination with immune checkpoint inhibitors for first-line treatment of advanced RCC and growth in emerging markets—are correctly identified. The offsetting factor of lower volumes and net prices in certain European markets is also accurately included. (3) The reasoning is sound and reflects multi-hop synthesis: connecting revenue performance across years, identifying geographic trends, and linking clinical use to commercial performance. However, the LLM adds a detail not present in the ground truth: 'The U.S. saw a 4% increase, while international markets experienced a 3% growth.' While this is plausible and consistent with the overall narrative, it is not supported by the original answer and introduces unverified granular data. This minor over-specification prevents a perfect score. (4) Despite this addition, the core facts, calculations, and synthesis are accurate and relevant. The answer fully addresses both parts of the question—revenue evolution and influencing factors—with high fidelity. Hence, correctness is scored 9/10, with full marks for quantitative accuracy and contextual relevance, and only a slight deduction in qualitative accuracy due to the unsupported sub-market growth percentages.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 444,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "The treatment and valuation of network location intangibles evolved from 2023 to 2024 primarily through changes in amortization assumptions and impairment review processes. In 2024, the Company extended the estimated useful life of tower assets from 20 to 30 years, which indirectly affected the amortization of related network location intangibles (amortized over the shorter of the ground lease term or the asset's useful life). Additionally, the Company continued to review network location intangibles for impairment on an individual tower basis, focusing on indicators such as lack of current tenant leases or expenses exceeding revenues, aligning with its broader impairment assessment framework for long-lived assets. No explicit changes to impairment processes for these intangibles were noted beyond this ongoing evaluation.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims the company extended the estimated useful life of tower assets from 20 to 30 years in 2024, which is not supported by the ground truth. The original answer states that in 2023, the weighted average amortization period for network location intangibles was 15 years, with no mention of a change in useful life assumptions for tower assets. This is a major quantitative and qualitative error. Additionally, the LLM incorrectly states that amortization is based on the shorter of the ground lease term or asset's useful life, which is not mentioned in the ground truth. (2) The only correct quantitative element is the focus on impairment triggers such as lack of tenant leases or expenses exceeding revenues, which aligns with the original answer. However, the $470 million increase in asset retirement obligations—a key financial figure in the ground truth—is entirely omitted. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies that impairment reviews occur on an individual tower basis, it fails to capture the evolution in disclosure depth from 2023 to 2024. The original answer emphasizes that 2024 brought more detailed impairment disclosures, whereas the LLM downplays this by saying 'no explicit changes' were noted, contradicting the ground truth. The indirect impact of increased asset retirement obligations on valuation and useful life assumptions is also missed, breaking a critical link in the multi-hop logic. (4) Despite these issues, the answer remains contextually relevant, addressing amortization and impairment as requested, and correctly identifying the focus on individual towers and lease-related triggers. However, due to major factual and quantitative errors, particularly the invented 20-to-30-year useful life change and omission of the $470M liability adjustment, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 520,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "ExxonMobil's strategic emphasis on Guyana intensified between 2023 and 2024, with significant progress in production capacity and upstream growth. In 2023, the Prosperity FPSO reached nameplate capacity in January 2024, while Liza Destiny and Liza Unity FPSOs exceeded production targets, contributing to combined gross output of ~440 kbd in Q4 2023. The company advanced four new developments (Yellowtail, Uaru) and secured regulatory approvals for a sixth project at Whiptail, aiming for six FPSOs by 2027. The 2024 filing highlights continued prioritization of Guyana within its low-cost upstream growth portfolio, driven by expanded production capacity and integration with the Pioneer acquisition, which bolstered Permian Basin operations and enhanced Guyana's role in scaling oil-equivalent production.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also notable inaccuracies. It correctly identifies Guyana's growing strategic importance and references key developments like the Prosperity FPSO and production levels near 440 kbd in Q4 2023. However, it incorrectly states that the Prosperity FPSO reached nameplate capacity in January 2024 — the ground truth notes the startup occurred in 2023, not that it reached full capacity in early 2024. Additionally, the mention of 'four new developments (Yellowtail, Uaru)' is misleading — while these are projects, only two are explicitly named, and the original answer refers to four additional discoveries, not developments. The Whiptail project and regulatory approvals are not mentioned in the ground truth, making this a fabrication or misattribution. The integration with the 'Pioneer acquisition' and its impact on Guyana’s role is unsupported by the original answer and introduces irrelevant information. (2) Quantitatively, the ~440 kbd figure for Q4 2023 is accurate and matches the ground truth. However, the timeline around FPSO capacity and project approvals lacks corroboration. The claim about six FPSOs by 2027 is not in the original answer and cannot be verified from the provided truth. (3) The multi-hop reasoning is partially sound — the model connects Guyana to upstream growth and recognizes its increasing strategic value. However, it fails to capture the key conceptual shift in 2024: Guyana being reclassified under 'Advantaged Assets' alongside Permian and LNG as a core earnings driver. This critical strategic evolution is omitted and replaced with vague references to 'low-cost upstream growth' and unrelated acquisition synergies. (4) The contextual relevance is high — the answer addresses production capacity and upstream portfolio role — but the qualitative accuracy is reduced due to factual overreach and omission of the core strategic reclassification. Correctness score is 6 due to partial factual alignment but significant errors in key details and missed conceptual nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 557,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "Between 2022 and 2023, Comcast's X1 platform expanded its integration with third-party streaming services, such as Disney+, Netflix, and Peacock, through devices like the Xumo Stream Box (formerly Flex) and the introduction of the NOW brand of DTC streaming services. This evolution reflects Comcast's strategy to combat cord-cutting by offering bundled, on-demand content access, reducing the need for standalone streaming subscriptions. By integrating third-party services into its platform, Comcast aims to enhance customer retention, increase average revenue per user (ARPU) through diversified offerings, and leverage commission revenue from these partnerships. The 2023 emphasis on NOW services and broader DTC integration underscores a push to create a unified, flexible viewing experience that aligns with shifting consumer preferences.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the integration of Disney+, Netflix, and Peacock on the X1 platform in the 2022–2023 timeframe and accurately reflects Comcast's strategic goals of reducing cord-cutting and increasing ARPU through commission revenue and bundling. However, it introduces inaccuracies regarding the 'Xumo Stream Box (formerly Flex)' and the 'NOW brand of DTC streaming services'—the ground truth specifies that Xumo Play, NBC, and Sky were integrated into NOW TV in 2023, not that NOW was a new DTC brand introduced then. Additionally, the Xumo Stream Box/Flex detail is not present in the original answer and may conflate separate product lines. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not compromised—dates (2022–2023) are used correctly. (3) The multi-hop reasoning is partially sound: the model correctly infers strategic intent (retention, ARPU growth), but the synthesis includes entities (Xumo Stream Box, Flex, NOW as a DTC brand) not supported by the ground truth, weakening the factual chain. (4) The answer is contextually relevant and captures the core strategic narrative, but the inclusion of unverified product details reduces qualitative accuracy. Correctness score is 7 due to accurate strategy explanation but incorrect or unsupported platform evolution details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 385,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "Caterpillar's relationship with FG Wilson expanded in terms of distribution network coverage for electric power generation systems between 2023 and 2024. In 2023, FG Wilson's systems were sold through a network of 110 distributors covering 109 countries, while in 2024, the network was reduced to 108 distributors but expanded to cover 158 countries. This indicates a strategic optimization of the distribution network, achieving broader geographic reach despite a slight reduction in the number of distributors.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: 110 distributors in 2023 covering 109 countries, and 108 distributors in 2024 covering 158 countries. There are no calculation errors or misstatements. (2) The answer is complete, addressing both years, the number of distributors, the number of countries covered, and the strategic implication of the change. (3) Entity accuracy is correct—Caterpillar's relationship with FG Wilson is appropriately contextualized, and the metric (distribution network for electric power generation systems) is correctly identified. (4) The reasoning is sound: the LLM correctly infers a strategic optimization—fewer distributors but broader geographic reach—and communicates this clearly. The semantic meaning is equivalent to the original answer, with no factual or interpretive errors. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 276,
        "total_tokens": 1526
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "Capital One's carrying value of securitized debt obligations decreased from $18,043 million as of December 31, 2023, to $14,264 million as of December 31, 2024. The fair value of these obligations also declined slightly, from $18,067 million in 2023 to $14,335 million in 2024. These changes reflect reductions in both the recorded value and estimated market value of securitized debt obligations during the period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that in 2024, the carrying value of securitized debt obligations was $18,043 million and fair value was $18,067 million. The LLM incorrectly claims these values were $14,264 million and $14,335 million respectively in 2024, and falsely asserts a decrease from 2023 to 2024. No data for 2023 is provided in the ground truth, only 2022 and 2024. (2) The numbers cited by the LLM for 2024 are entirely wrong and do not match the ground truth. The ground truth reports $18,043 million carrying value and $18,067 million fair value in 2024, while the LLM reports $14,264 million and $14,335 million—differences of over $3.7 billion. Additionally, the LLM fabricates 2023 data not present in the original answer. (3) The multi-hop reasoning is flawed: the question asks about changes between 2022 and 2024, but the LLM incorrectly introduces 2023 as a baseline and invents a downward trend that is unsupported. The ground truth indicates stable exposure with slight fair value premium, while the LLM suggests a reduction in exposure. (4) The contextual relevance is moderate because the answer addresses securitized debt obligations and discusses carrying and fair values, but the factual inaccuracies and fabricated data severely undermine correctness. Quantitative accuracy is extremely low due to incorrect numbers and invented years. Qualitative accuracy is poor due to incorrect synthesis and reasoning. Correctness score is 1 due to complete factual misrepresentation despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 442,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "McDonald's maintained access to line of credit agreements in both 2023 and 2024 as part of its short-term funding strategy. In 2023, the company relied on commercial paper and lines of credit to manage cash flow, with $4.6 billion in cash and equivalents. By 2024, the cash balance dropped to $1.1 billion, but the company retained a **$4.0 billion committed line of credit** and utilized **uncommitted foreign currency lines of credit** for subsidiaries. Financing activities in 2024 saw increased cash usage due to higher debt repayments, though the line of credit agreements provided flexibility to address liquidity needs, reflecting continued reliance on credit facilities for cash flow management.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of McDonald's use of line of credit agreements between 2023 and 2024, noting continued reliance on credit facilities amid changing liquidity conditions. Key facts such as the drop in cash and equivalents from $4.6 billion in 2023 to $1.1 billion in 2024 are accurate. The mention of a $4.0 billion committed line of credit and uncommitted foreign currency lines is plausible and consistent with typical corporate structures, though this specific detail about the $4.0 billion committed facility is not present in the ground truth and cannot be verified. (2) Quantitatively, the $4.6 billion and $1.1 billion cash balances are correct. The ground truth states cash used for financing activities was $4.4 billion in 2023 and $7.5 billion in 2024 — the LLM correctly implies increased cash outflows in 2024 but does not explicitly state these figures, instead attributing the change to 'higher debt repayments' (ground truth cites decreased bond issuances as the driver). This is a minor omission. (3) The multi-hop reasoning is sound: the model connects reduced cash balances to increased reliance on credit lines, correctly inferring that line of credit agreements remained a key part of cash flow management. However, it misses the explicit contrast in financing strategy — shift from bond issuances in 2023 to greater use of credit facilities in 2024 — and does not mention the $2.2 billion decrease from 2022 to 2023 or $3.1 billion increase from 2023 to 2024, which are key to the evolution. (4) The answer is contextually relevant and well-structured, focusing on the role of credit agreements in cash flow management. The unverified $4.0 billion committed line detail prevents a higher score, but overall factual alignment is strong, warranting an 8 for correctness, quantitative, and qualitative accuracy, with full marks for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 515,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "The Worldwide Business Conduct Manual's role in reinforcing internal controls remained central in both 2022 and 2024, emphasizing Procter & Gamble's commitment to integrity, legal compliance, and ethical business practices. In both years, the manual was highlighted as a foundational element of the company's internal control framework, alongside other governance structures like the Global Leadership Council, Audit Committee, and Control Self-Assessment Program. This consistency indicates a stable, integrated approach to governance, prioritizing transparency, accountability, and risk management. The lack of significant changes suggests P&G's focus on maintaining robust internal controls through established principles and continuous improvement.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the ongoing role of the Worldwide Business Conduct Manual in reinforcing internal controls and mentions relevant governance bodies like the Global Leadership Council and Audit Committee. However, it incorrectly states that there was 'no significant change' and a 'consistent' approach between 2022 and 2024, which contradicts the ground truth. The original answer highlights a meaningful evolution in 2024 where the manual became more specifically tied to structured governance mechanisms such as the Disclosure Committee and oversight activities—indicating a shift toward a more integrated governance approach. The LLM answer misses this key evolution and instead emphasizes stability and lack of change, which is factually inaccurate. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is partially sound: the model correctly identifies the manual’s role and links it to governance structures, but fails to synthesize the temporal evolution between 2022 and 2024. It does not distinguish how the integration with specific governance bodies (e.g., Disclosure Committee) deepened over time, which is central to the question. (4) The contextual relevance is high because the answer addresses governance, internal controls, and the manual’s role, but the qualitative accuracy is low due to the incorrect conclusion about no significant change. The correctness score reflects that core facts are partially right but the main inference about P&G's evolving governance approach is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 454,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "Exxon's strategic positioning in Guyana has strengthened between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings drivers. In 2023, Guyana's long-lived assets totaled $9,689 million, up from $6,766 million in 2022, indicating increased investment. In 2024, Guyana remains a key component of Exxon's \"Advantaged Assets,\" which include Permian, Guyana, and LNG, highlighting its strategic importance. The Upstream segment's earnings (excluding identified items) rose to $25,175 million in 2024 from $23,609 million in 2023, underscoring improved performance driven by Guyana's operations. These developments align with Exxon's focus on advantaged assets and long-term value creation in the region.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Guyana's long-lived assets in 2023 as $9,689 million, which matches the ground truth. However, it introduces a figure for 2022 ($6,766 million) that is not present in the original answer and was not required by the question, potentially misleading the reader. Additionally, the LLM states that Upstream segment earnings rose to $25,175 million in 2024 from $23,609 million in 2023 — these numbers are plausible but not part of the ground truth and were not cited in the original answer, which focused on strategic positioning via asset disclosures and earnings driver definitions, not overall upstream earnings. These extraneous figures reduce quantitative accuracy. (2) The core strategic evolution — Guyana being included in 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver in 2024 — is correctly conveyed, though the LLM omits the explicit contrast in the original answer that Guyana moved from being a quantitatively significant asset in 2023 to a strategically emphasized one in 2024. Instead, it affirms continued strategic importance, which is directionally correct but less precise in framing the evolution. (3) The multi-hop reasoning is partially sound: the model connects asset disclosures with earnings driver definitions across years, but it adds unrelated financial data (upstream earnings) that were not part of the original logic chain, weakening the purity of the synthesis. (4) Despite the added numbers, the answer remains contextually relevant and captures the essential strategic shift. The inclusion of non-ground-truth figures lowers quantitative accuracy, but the qualitative reasoning and relevance remain strong. Correctness score is 7 due to accurate core facts but significant addition of unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 490,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "Capital One's reliance on securitized debt obligations as a funding source increased from 2022 to 2024, as evidenced by the carrying value of securitized debt obligations rising to $14.26 billion as of December 31, 2024, compared to $18.04 billion as of December 31, 2023 (from the 2024 document's Table 17.6). This reflects a higher proportion of long-term funding sourced through securitized debt obligations during the period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that Capital One's securitized debt obligations were $18.04 billion in 2023 and $14.26 billion in 2024, implying a decrease. However, the ground truth states that no specific dollar value was disclosed in 2022, and the first disclosed carrying value is $14,264 million ($14.264 billion) in 2024. There is no mention of a $18.04 billion figure in the ground truth for 2023, making this number entirely incorrect. (2) The quantitative accuracy is low because the LLM fabricates a 2023 value not present in the original answer and misrepresents the evolution of the funding source. The 2024 value is approximately correct in magnitude ($14.26B vs $14.264B), but the comparison is invalid due to the incorrect prior-year figure. (3) The reasoning is flawed: the LLM incorrectly infers an increase in reliance based on a fabricated downward trend, while the ground truth emphasizes increased transparency and continued use—not necessarily increased reliance. The multi-hop synthesis fails because the model invents data for 2023 instead of acknowledging the absence of disclosed figures in 2022 and the emergence of disclosure in 2024. (4) Contextual relevance is moderate because the answer addresses the topic of securitized debt obligations and attempts to discuss trends, but the incorrect data undermines the validity. The qualitative accuracy is low due to incorrect entities (non-existent 2023 value) and faulty logic. Overall, the answer misrepresents the evolution by introducing false quantitative comparisons, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 447,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "Between fiscal years 2022 and 2023, NVIDIA's Omniverse platform evolved from a 3D design collaboration tool for industrial digitalization (e.g., digital twins, autonomous vehicle testing) to a broader enterprise solution for metaverse and 3D internet applications. In 2023, it was explicitly positioned as part of NVIDIA's Graphics segment, emphasizing its role in building virtual worlds and integrating with automotive solutions like DRIVE Sim. Enterprise adoption expanded, with deeper integration into workflows for simulation, AI-driven design, and cross-industry applications, supported by enhanced partnerships and scalability.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in its overall narrative and captures the strategic evolution of NVIDIA's Omniverse from a design collaboration tool to a broader enterprise platform. It correctly identifies increased enterprise adoption and integration with simulation, AI, and industrial applications like digital twins and autonomous vehicle testing via DRIVE Sim. However, it introduces some inaccuracies not present in the ground truth: (1) The original answer does not mention 'metaverse and 3D internet applications' as a positioning shift in 2023, which is an overextension not directly supported in the source; (2) While Omniverse is part of the Graphics segment, the original does not explicitly state this repositioning occurred in 2023, making that claim potentially misleading; (3) The original emphasizes a shift in business model (subscription for enterprises, free for individuals) and specific use cases like real-time 3D product configurators and factory digital twins—details missing in the LLM response. On the positive side, the LLM correctly infers deeper enterprise integration and cross-industry scalability. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. The reasoning is logically sound but lacks precise grounding in the documented fiscal year descriptions. The answer remains contextually relevant and captures the core directional shift, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 397,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "Between 2022 and 2023, Pfizer's net amounts due under agreements with Viatris decreased from **$94 million** as of December 31, 2022, to **$33 million** as of December 31, 2023. This reflects reductions in outstanding obligations under manufacturing, supply, and transition agreements following the 2020 spin-off and combination of the Upjohn Business with Mylan to form Viatris.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the dollar amounts ($94 million as of December 31, 2022, and $33 million as of December 31, 2023) are correct and match the original answer exactly. The dates are also accurate. (2) The calculation of a $61 million decrease is implied and correct, though not explicitly stated, which is acceptable. (3) The reasoning is sound: the LLM correctly identifies the reduction in net amounts due and attributes it to the winding down of obligations under manufacturing, supply, and transition agreements post the 2020 spin-off and formation of Viatris. This shows proper multi-hop synthesis of financial data and corporate history. (4) The only minor shortcoming is that the LLM does not explicitly state the interpretation that this reflects a 'winding down or stabilization of transitional financial arrangements' in the same terms as the original, though the implication is clearly conveyed. Wording differences are acceptable under semantic equivalence, so this does not significantly impact accuracy. All entities (Pfizer, Viatris, agreements) and time periods are correctly identified. The answer is fully relevant and responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 346,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "ExxonMobil's strategic emphasis on Guyana in 2023 focused on advancing the Payara development (operational with the Prosperity FPSO), continuing Yellowtail project development, and funding the Uaru project. The 2024 documents provided do not include specific updates on Guyana's project activity or classification, so no direct changes between 2023 and 2024 are detailed in the given pages. However, the Payara project's operational start in 2023 likely sustained the strategic focus, with no explicit 2024 changes noted.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual information but misses the key strategic evolution highlighted in the ground truth. It correctly references the Payara, Yellowtail, and Uaru projects active in 2023, which aligns with the original answer. However, it fails to report the critical 2024 reclassification of Guyana as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver—a central point in the ground truth that reflects the strategic shift. This omission severely undermines the answer's correctness. (2) Quantitatively, the LLM does not mention the 12.6 net exploratory and development wells completed in 2023, a specific figure provided in the ground truth. No incorrect numbers are stated, but the absence of this data reduces quantitative accuracy. The LLM also does not provide any new numerical data for 2024, correctly noting a lack of updates—but this is inconsistent with the ground truth, which does contain a strategic classification change even if not operational metrics. (3) The multi-hop reasoning is flawed: the question asks for evolution between 2023 and 2024, requiring synthesis of operational activity in 2023 and strategic reclassification in 2024. The LLM incorrectly concludes no changes were documented in 2024, when in fact the 'Advantaged Assets' reclassification is a strategic signal present in the 2024 data. This reflects a failure in reasoning and information synthesis. (4) Contextual relevance is moderate—the answer discusses relevant projects and timeframes but fails to capture the core strategic shift, making it incomplete and less useful for understanding ExxonMobil's evolving priorities. The answer leans too heavily on absence of operational updates without recognizing the significance of strategic reclassification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 493,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "The weighted-average interest rate for senior notes with maturities greater than 10 years remained at **3.8%** in both 2022 and 2023. The face value of these notes increased slightly from **$52.8 billion** in 2022 to **$53.4 billion** in 2023, as reported in the Long-Term Debt Outstanding tables from the 2022 and 2023 10-K filings.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative values. According to the ground truth, the 2022 weighted-average interest rate was 3.67%, not 3.8% as stated in the LLM answer. While the 2023 rate of 3.8% is correct, the claim that it remained unchanged from 2022 is false, as there was an increase from 3.67% to 3.8%. Additionally, the face value in 2022 is incorrect: the LLM reports $52.8 billion, whereas the ground truth is $54.536 billion. The 2023 face value of $53.4 billion is accurate. (2) The quantitative inaccuracies are substantial—both the interest rate for 2022 and the 2022 face value are wrong, and the comparison of 'unchanged' interest rate is factually incorrect due to the misstatement of the 2022 rate. The direction of change in face value is also misrepresented: the LLM claims an increase from $52.8B to $53.4B, but in reality, there was a decrease from $54.536B to $53.4B. (3) The reasoning is partially sound in that the model attempts to compare two years and synthesize information about long-term senior notes, but the multi-hop synthesis fails due to incorrect data retrieval for 2022. The entity identification (senior notes with maturities >10 years, years 2022 and 2023) is correct, and the metric types are appropriate. (4) The contextual relevance is high because the answer addresses the right question structure and uses the correct financial concepts. However, due to major numerical errors and a flawed conclusion about trends, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the framework of the answer is logical, but based on incorrect inputs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1172,
        "completion_tokens": 460,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "Between 2023 and 2024, Alabama Power's nuclear decommissioning trusts reduced their Level 3 domestic equity investments from $208 million (2023) to $1 million (2024), while Level 2 domestic equity decreased from $443 million to $321 million. This shift indicates a move toward relying more on observable inputs (Level 2) and fewer unobservable inputs (Level 3) in valuing domestic equity holdings. Georgia Power's domestic equity allocations remained largely unchanged, with Level 2 at $321 million and Level 3 at $1 million in both years. The methodology likely reflects increased use of net asset value (NAV) as a practical expedient for private market investments, reducing reliance on Level 3 unobservable inputs.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to match the ground truth on multiple levels. (1) Quantitative Accuracy: The numbers are completely wrong. The LLM claims Alabama Power had $208 million in Level 3 investments in 2023 and $443 million in Level 2, but the ground truth shows Alabama Power had $396M in Level 1 and $169M in Level 2 in 2023 — with no mention of Level 3 domestic equity investments in the original answer. Similarly, the LLM states Georgia Power had $321M in Level 2 in both years, but ground truth shows Georgia Power had only $1M in Level 2 in both years. The LLM confuses Level 1, Level 2, and Level 3 categories and inverts the actual values. (2) Completeness: The question asks about shifts in domestic equity allocations and valuation methodologies between 2023 and 2024 for both companies, specifically regarding Level 1 and Level 2 inputs. The LLM incorrectly introduces Level 3 inputs as the focus, which are barely mentioned in the original answer (only implied via absence), and omits any correct discussion of Level 1 increases. It fails to report the actual Level 1 figures ($396M → $443M for Alabama; $255M → $321M for Georgia), which are central to the original answer’s conclusion. (3) Entity Accuracy: While the company names (Alabama Power, Georgia Power) and years (2023, 2024) are correct, the financial metrics (Level 1/2/3 allocations) are misattributed and fabricated. (4) Reasoning: The multi-hop synthesis is fundamentally flawed. The LLM invents a narrative about a shift from Level 3 to Level 2, while the ground truth describes an increase in Level 1 (highly observable, liquid) investments — indicating a shift toward more transparent valuations, not a reduction in Level 3. The conclusion about NAV as a practical expedient is unsupported by the original data. (5) Semantic Equivalence: The LLM answer conveys a completely different and factually incorrect picture. Despite using similar terminology (Level 1, Level 2, domestic equity), the values, trends, and implications are invalid. The only partial relevance is the focus on valuation methodology shifts, but even that is based on false premises. Thus, the correctness score is 1 due to catastrophic failure in quantitative accuracy and reasoning, with minimal contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 611,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "NVIDIA's CUDA evolved from 2022 to 2023 as a foundational element of its full-stack computing platform, reinforcing its role in enabling AI and high-performance computing across all target markets. In 2022, CUDA was highlighted as a core building block for NVIDIA's accelerated computing ecosystem, supporting diverse workloads through unified architecture and software stacks. By 2023, CUDA's integration deepened with the introduction of new hardware like the Grace CPU and expanded into enterprise AI solutions (e.g., NVIDIA AI Enterprise), while maintaining its critical role in data centers, gaming, professional visualization, and automotive markets. The platform's emphasis on CUDA-driven AI and parallel processing further solidified its strategic importance in driving innovation across NVIDIA's end-to-end solutions.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies CUDA's evolution from a core building block in 2022 to a deeper, more integrated role in 2023 within NVIDIA's full-stack platform. It accurately reflects CUDA's continued importance across key markets (gaming, data center, automotive, etc.) and mentions expanded enterprise AI integration, which aligns with the strategic shift. However, it misses specific details emphasized in the ground truth: the explicit expansion into domain-specific verticals like healthcare and manufacturing, and the critical point that by 2023, CUDA became the base layer for hundreds of domain-specific SDKs, libraries, and APIs—a key qualitative shift not mentioned. Instead, it references the Grace CPU and NVIDIA AI Enterprise, which, while contextually relevant, are not highlighted in the original answer as central to CUDA’s strategic repositioning. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no inaccuracies exist. (3) The multi-hop reasoning is partially sound: the model correctly infers a deepening integration of CUDA from 2022 to 2023 and connects it to broader enterprise and AI solutions. However, it fails to synthesize the specific evolution into vertically integrated software stacks and domain-specific libraries, which is a core aspect of the ground truth. (4) The correctness score is 7 because the answer captures the general direction and strategic importance of CUDA’s evolution but omits key differentiating elements of the 2023 positioning. Qualitative accuracy is 7 for similar reasons—core entities and timeline are correct, but missing nuanced, critical details. Contextual relevance is high (9) as the response stays focused and provides relevant context around CUDA’s role in AI and full-stack integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 507,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "Pfizer's financial obligations to Viatris decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Transitional service agreements (TSAs) and master service agreements (MSAs) between Pfizer and Viatris, established during the 2020 spin-off of the Upjohn Business, were largely completed by December 31, 2023. The net amounts owed to Viatris under these agreements reflected reduced obligations as transitional services concluded, with the MSA term extending to three years post-sale plus a two-year extension.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key financial figures—$94 million as of December 31, 2022, and $33 million as of December 31, 2023—and accurately states that transitional service agreements (TSAs) were largely completed by the end of 2023, aligning with the ground truth. The reduction in net amounts owed is correctly portrayed. (2) Quantitatively, all numbers and dates match the original answer exactly: the $94M to $33M decrease is accurate, and the timeline (end of 2022 vs. end of 2023) is correctly referenced. No calculation errors. (3) The reasoning is sound and reflects proper multi-hop synthesis: it connects the 2020 spin-off of Upjohn into Viatris with the subsequent wind-down of TSAs and MSAs, and correctly infers reduced obligations as services concluded. However, the mention of the 'MSA term extending to three years post-sale plus a two-year extension' is not present in the ground truth and introduces unverified detail, slightly weakening qualitative accuracy. (4) The answer is highly relevant, addressing all core aspects of the question—evolution of financial obligations, status of TSAs, and net amounts owed—while maintaining factual alignment. The minor over-specification about MSA extension prevents a perfect 10 on qualitative accuracy, but overall correctness remains very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 372,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "Duke Energy's environmental regulation compliance costs remained a significant factor in 2023, driven by ongoing federal and state regulations (e.g., EPA rules on CCR, emissions, and carbon reduction goals), which require capital expenditures and operational adjustments. Retail deregulation pressures persisted as a risk, with potential impacts on cost recovery and competitive positioning, though no explicit evolution in their interplay is noted between 2022 and 2023. Both challenges continued to influence financial outcomes, with environmental compliance costs and deregulation risks remaining intertwined in shaping operational and regulatory strategies.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key aspects of the evolution in the relationship between retail deregulation and environmental compliance costs from 2022 to 2023, which is the core of the question. (1) What was correct: The answer correctly identifies that Duke Energy faced ongoing environmental compliance costs in 2023 due to federal and state regulations (e.g., EPA rules, carbon reduction goals) and that retail deregulation remained a risk to cost recovery. These elements are factually consistent with the ground truth. Entity accuracy is strong—Duke Energy, EPA, and regulatory context are correctly identified. (2) Quantitative accuracy: There are no specific numbers (e.g., dollar amounts, percentages) in either the original or LLM answer, so no numerical inaccuracies exist—this aspect is neutral but does not detract. (3) Multi-hop reasoning assessment: The LLM fails on the critical multi-hop requirement—comparing how the *interplay* between deregulation and environmental cost recovery evolved across years. In 2022, the risk was that deregulation could prevent recovery of environmental costs due to PURPA-related above-market power commitments. By 2023, the situation evolved: increased regulatory pressure (e.g., more aggressive state carbon goals, EPA CO2 rules) made compliance costs rise, while deregulation continued to limit cost pass-through. The LLM acknowledges both factors but explicitly states 'no explicit evolution in their interplay is noted,' which contradicts the original answer’s clear evolution narrative. This represents a failure in reasoning and synthesis across time points. (4) Justification for scores: Correctness is 5/10 because core facts are present but the dynamic change over time—the essence of the question—is missed. Qualitative accuracy is 5 due to flawed reasoning in connecting the two forces over time. Quantitative accuracy is 10 by default (no numbers). Contextual relevance is 8 because the answer discusses relevant themes but does not fully address the comparative evolution requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 551,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "The retail share of Skoal oral tobacco products decreased from 9.5% in 2023 to 7.6% in 2024, a decline of 1.9 percentage points. This contrasts with the 2023 pricing strategy, which involved incremental list price increases for Skoal (e.g., $0.09 per can in August 2023 and prior adjustments), aimed at maintaining competitiveness amid shifting market dynamics. However, the retail share decline in 2024 suggests that pricing actions alone were insufficient to counteract competitive pressures, such as the growth of oral nicotine pouches and shifting consumer preferences, which further eroded Skoal's market position.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2024 retail share (7.6%) and the general trend of decline, but reports the 2023 retail share as 9.5% instead of the ground truth 9.3%, introducing a minor but notable inaccuracy in a key metric. The calculated decline of 1.9 percentage points is therefore incorrect (should be 1.7 points: 9.3% to 7.6%). (2) Regarding pricing, the LLM mentions a $0.09 increase in August 2023, but the ground truth specifies that the 2023-announced price increase was $0.11 effective January 23, 2024, with prior increases in 2022 (not August 2023). The LLM omits the $0.11 figure and misplaces the timing of recent increases, leading to inaccuracies in the pricing timeline and amounts. (3) The multi-hop reasoning is sound in linking price increases to declining retail share and contextualizing it with competitive pressures like nicotine pouches, which aligns with the implied causality in the original answer. The synthesis between pricing strategy and market performance is logically presented, even if specific data points are flawed. (4) The answer is contextually excellent—addresses both parts of the question, discusses the contrast between pricing and market share, and adds relevant context on consumer trends. However, the quantitative inaccuracies in both market share baseline and pricing details reduce overall correctness. Scores reflect mostly correct reasoning and structure with significant but not critical data errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 408,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "Amgen's investment in 'Other short-term interest-bearing securities' decreased slightly from $138 million in 2023 to $135 million in 2024. This minor reduction reflects the company's continued focus on maintaining liquidity and safety of principal, as these securities mature within one year and align with its investment policy of prioritizing prudent liquidity management. The stable, low-level holdings indicate a conservative approach to short-term cash management, consistent with Amgen's strategy to preserve capital while earning modest returns on excess liquidity.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Amgen's investment decreased from $138 million in 2023 to $135 million in 2024, while the ground truth confirms it remained unchanged at $138 million in both years. This is a critical factual error affecting the core of the response. (2) The quantitative inaccuracy is significant—$135M vs $138M is not a minor rounding difference but a misstatement of data. No calculation is required in this question, but the comparison across years is incorrect. (3) The reasoning and synthesis are partially sound—the LLM correctly interprets that stable short-term securities reflect a conservative liquidity strategy, which is contextually appropriate. However, the conclusion is based on a false premise (a decrease that did not occur), undermining the validity of the inference. (4) Contextual relevance is high because the answer addresses both parts of the question—evolution of investment and strategic implication—and uses appropriate financial reasoning. Despite correct terminology and logical structure, the answer fails on factual accuracy, which is paramount. The correctness score is low due to the central error in reported figures, even though the strategic interpretation, had the numbers been correct, would have been reasonable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 361,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "General Dynamics' involvement in Abrams Main Battle Tank Upgrades expanded from 2022 to 2024, with increased contract scope and value. In 2022, the Combat Systems segment secured a $360 million contract for Abrams upgrades and technical support, while in 2024, the segment received a $350 million contract for upgrades, engineering, and logistics support, along with a $285 million contract to produce SEPv3-configured Abrams tanks for Romania. The estimated potential contract value in the Combat Systems segment rose from $6.2 billion (2023) to $8.6 billion (2024), reflecting broader scope and sustained demand for upgrades and modernization.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key figures are correct: the $360 million 2022 contract, the $350 million 2024 contract for upgrades and support, and the $285 million contract for Romania SEPv3 production are all accurately reported. The LLM adds additional context about the Combat Systems segment's estimated potential contract value increasing from $6.2 billion in 2023 to $8.6 billion in 2024, which is not in the original answer but does not contradict it and may reflect broader segment trends. Since this extra data is plausible and doesn't undermine the core facts, it doesn't reduce accuracy. (2) The core evolution in contract scope—from upgrades and support in 2022 to a broader mix including production of new configurations (Romania SEPv3) in 2024—is correctly identified and supported with specific contracts. (3) Multi-hop reasoning is sound: the model synthesizes information across years and contract types to infer an expansion in scope and value. (4) Entity accuracy is strong: General Dynamics, Abrams tank, correct years (2022, 2024), and contract purposes are all correctly named. The only minor limitation is that the original answer emphasizes the shift from 'upgrade-focused' to 'upgrades and production,' while the LLM focuses more on value growth; however, the scope evolution is still clearly conveyed. Thus, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 411,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "AIG's financial relationship with Corebridge evolved significantly from 2023 to 2024. In 2023, Corebridge was a consolidated subsidiary, with AIG holding a controlling interest and reporting its debt (including senior unsecured notes and junior subordinated debt) as part of its consolidated financial statements. AIG also had guarantee and collateral agreements with Corebridge, which required collateral in case of credit downgrades or defaults. \n\nBy 2024, AIG deconsolidated Corebridge after reducing its ownership to 22.7% following share sales and secondary offerings. This transition shifted Corebridge's financials to discontinued operations, with AIG recognizing equity method income based on Corebridge's stock price and dividends. The deconsolidation resulted in a $4.8 billion loss, primarily due to an accumulated comprehensive loss of $7.2 billion. Borrowing arrangements were no longer part of AIG's consolidated debt, and income recognition shifted from consolidated earnings to equity method adjustments, reflecting AIG's reduced control and investment in Corebridge.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, correct evolution of AIG's financial relationship with Corebridge from 2023 to 2024. (1) It correctly identifies the shift from consolidation in 2023 to deconsolidation in 2024, aligning with the ground truth's emphasis on a transition from borrowing arrangements to equity-based income recognition. The key factual point in the original answer — that AIG began recognizing equity method income tied to Corebridge’s stock price and dividends starting June 9, 2024 — is accurately reflected in the LLM response, though the specific date (June 9, 2024) is omitted. (2) Quantitatively, the LLM introduces additional precise data not in the original answer: ownership reduced to 22.7%, a $4.8 billion loss, and a $7.2 billion accumulated comprehensive loss. These figures are plausible and consistent with public filings, but since they are not present in the ground truth, they cannot be fully verified from the provided context. However, their inclusion does not contradict the original answer and enhances detail without introducing errors. (3) The reasoning is sound and demonstrates strong multi-hop synthesis: it connects deconsolidation with the end of consolidated borrowing, explains the shift to equity method accounting, and links income recognition to dividends and stock performance. (4) The answer is contextually rich and fully addresses both borrowing arrangements and income recognition as required. The only minor shortcoming is the absence of the specific February 25, 2025 borrowing deadline mentioned in the original answer, which slightly reduces quantitative completeness. Overall, the LLM provides a more detailed and logically coherent explanation than the ground truth, with no factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 481,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "Tesla's approach to the Solar Roof product between 2022 and 2024 involved continued efforts to integrate it with energy storage systems like Powerwall and improve installation efficiency through partnerships with builders and developers. However, production challenges persisted, including supply chain constraints and supplier dependencies, as highlighted in risk factors related to component shortages and manufacturing delays. Strategic dependencies remained on external suppliers for key components, despite Tesla's efforts to vertically integrate certain parts of its solar product line. These challenges underscored the company's ongoing struggle to scale production efficiently while maintaining quality and cost control.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key developments between 2022 and 2024. It accurately captures Tesla's continued focus on installation efficiency through partnerships with builders and developers (2022 context), and correctly identifies persistent production challenges such as supply chain constraints, supplier dependencies, and manufacturing delays (2024 context). The mention of strategic dependencies on external suppliers and efforts toward vertical integration adds relevant context. However, the LLM answer does not explicitly highlight the *shift in emphasis* noted in the original answer—from active sales and engineering focus in 2022 to a 2024 reality where the product's future 'depends in large part' on overcoming production ramp challenges, bottlenecks, and cost control. This nuanced strategic pivot is central to the original answer and only implied, not directly stated, in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect figures are cited), and all entities (Tesla, Solar Roof, Powerwall, suppliers) are correctly identified. The reasoning is sound and contextually appropriate, synthesizing multi-hop elements across time and strategy, though slightly less precise in capturing the evolution of strategic emphasis. Hence, minor deduction from qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 390,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "Skoal's retail share in the U.S. oral tobacco market decreased from 9.3% in 2023 to 7.6% in 2024, a decline of 1.7 percentage points. This indicates a weakening competitive position relative to growing oral nicotine pouches, which gained market share at Skoal's expense. The decline reflects broader industry shifts toward less traditional products like nicotine pouches, as noted in the document's analysis of oral tobacco trends.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the retail share of Skoal in 2023 (9.3%) and 2024 (7.6%), matching the ground truth exactly. The calculated decline of 1.7 percentage points is accurate (9.3 - 7.6 = 1.7). 2) All numeric values and dates are correct, and the calculation is precise. Format is clear and consistent. 3) The LLM correctly synthesizes the trend in Skoal's market share and infers a weakening competitive position, which aligns with the ground truth. It appropriately contextualizes the decline within broader industry shifts toward nicotine pouches, even referencing competitive dynamics (e.g., growth of alternative products like on!). While the ground truth explicitly names on! and its share increase, the LLM answer captures the same competitive dynamic without naming the product, which is a minor omission but does not undermine the correctness. 4) The answer is highly relevant, directly addressing both parts of the question: the change in market share and its implication for competitive positioning. The reasoning is sound and reflects multi-hop understanding (tracking change over time and interpreting strategic implications). The only reason for not scoring a 10 is the lack of explicit mention of on! as a contrasting product, which is present in the original answer and adds specificity to the competitive context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 373,
        "total_tokens": 1579
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "The risk associated with the concentration of device share among premium-tier companies has remained a significant concern for Qualcomm in both 2023 and 2024, with heightened emphasis on geopolitical tensions and customer vertical integration. In 2024, the risk evolved with specific examples, such as the revocation of Qualcomm’s export license to Huawei, which directly impacted revenue from a key customer. The concentration of device share among a few companies, particularly in China and among OEMs like Apple and Samsung, continues to threaten pricing power by enabling lower prices and reducing revenue stability. Additionally, U.S.-China trade tensions and supply chain disruptions further exacerbate these risks, as seen in Huawei’s case, highlighting the potential for reduced revenue and margin pressures. The 2024 filings underscore ongoing challenges in maintaining stable revenue streams amid these concentrated market dynamics.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that concentration risk among premium-tier companies remains a concern for Qualcomm in 2023 and 2024 and acknowledges its impact on pricing power and revenue stability, which aligns with the original answer. However, it introduces specific claims not present in the ground truth, most notably the revocation of Qualcomm’s export license to Huawei and direct linkage to revenue impact. The original answer does not mention any license revocation or specific customer examples like Huawei in this context. Additionally, while the original answer notes a shift in emphasis in 2024 toward broader implications like revenue fluctuation due to product timing and customer vertical integration, the LLM overemphasizes geopolitical tensions and U.S.-China trade issues, which are not highlighted in the ground truth as central to the evolution of this specific risk. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised—score reflects no factual numeric errors. (3) The multi-hop reasoning is partially sound: the model connects device concentration to pricing and revenue risks across years, but fails to accurately represent the evolution described in the original—shifting from customer concentration with pricing pressure in 2023 to increased risk due to customer product cycles and in-house chip development in 2024. Instead, it injects external factors (e.g., Huawei license) not supported by the source. (4) Correctness is partially achieved due to alignment on core risk persistence, but significant factual overreach and misattribution reduce accuracy. Contextual relevance remains high because the answer addresses the right topic and implications, even if with incorrect specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1491,
        "completion_tokens": 489,
        "total_tokens": 1980
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "Amgen's allocation to money market mutual funds increased from $10,266 million as of December 31, 2023, to $10,354 million as of December 31, 2024, reflecting a modest rise in this component of its cash and cash equivalents.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Amgen's allocation to money market mutual funds increased from $10,266 million in 2023 to $10,354 million in 2024. The ground truth confirms that the allocation remained unchanged at $10,266 million in both years. This is a critical factual error that undermines the entire response. (2) The quantitative values are wrong: the 2024 figure of $10,354 million is not supported by the data and introduces a false increase of $88 million. The correct values are $10,266 million in both years, so the difference is $0. The LLM's claim of a 'modest rise' is therefore incorrect. (3) The reasoning is flawed because it fails to recognize the stability in Amgen's short-term investment strategy as reflected in identical disclosed values across both years. The model does not correctly synthesize the multi-hop requirement of comparing two years of investment data under available-for-sale securities, instead inventing a change where none occurred. (4) Despite the factual inaccuracies, the answer is contextually relevant—it addresses the right company (Amgen), the correct financial instrument (money market mutual funds), and the appropriate time frame (2023–2024). However, the core quantitative inaccuracy results in a very low correctness and quantitative accuracy score. The qualitative accuracy is slightly higher only because the structure and intent of the response align with the question, but the substance is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1134,
        "completion_tokens": 411,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "General Dynamics' U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) increased from $315 million in 2023 to $333 million in 2024. The 2022 data is not explicitly provided in the given pages, but the trend shows a gradual rise in pledged receivables during this period.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $333 million pledged in 2024 and $315 million in 2023, which aligns with the ground truth (as of December 31, 2023 and December 31, 2024, respectively). However, it fails to include the 2022 figure of $295 million as of December 31, 2021, and incorrectly states that 'the 2022 data is not explicitly provided,' which contradicts the original answer that clearly includes this value. This omission significantly undermines completeness and factual accuracy. (2) The numbers cited for 2023 and 2024 are quantitatively accurate, but the absence of the 2022 amount results in incomplete trend representation. The increase from $315M to $333M is correct, but the full evolution from $295M to $333M over the full period is not captured. (3) The reasoning is partially sound in identifying a rising trend, but the multi-hop synthesis is flawed because it did not correctly extract and incorporate the 2022 data point from the source, leading to an incomplete and slightly misleading narrative. (4) Contextual relevance is high as the answer addresses the core topic—evolution of pledged receivables to the CCF—and correctly interprets the upward trend. However, due to the missing data point and incorrect claim about data availability, the correctness score is limited to 5, reflecting partial accuracy with significant omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 382,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "AIG's financial relationship with Corebridge evolved significantly between 2023 and 2024, marked by Corebridge's IPO in September 2022 and subsequent deconsolidation from AIG's consolidated tax group. Following deconsolidation on June 9, 2024, AIG retained a 22.7% equity interest in Corebridge, accounted for under the equity method, with investment income recognized via changes in Corebridge's stock price and dividends. The deconsolidation triggered a $4.8 billion loss, primarily due to an accumulated comprehensive loss of $7.2 billion, impacting AIG's income statement. Tax implications included a $282 million gain on the December 2024 sale of 120 million shares and adjustments to deferred tax assets. Investment income fluctuated with Corebridge's stock price movements and share sales, culminating in a $282 million gain in Q4 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly impact correctness. While it correctly identifies the Corebridge IPO (September 2022) and the general shift to equity method accounting, it incorrectly states the deconsolidation date as June 9, 2024, whereas the ground truth indicates the ownership dropped below 80% in 2023, triggering tax deconsolidation then. The $4.8 billion loss and $7.2 billion accumulated comprehensive loss are not mentioned in the ground truth and appear fabricated. The $282 million gain from the sale of shares in December 2024 is also not supported by the original answer and contradicts the timeline where equity income is reported from June 10, 2024. The 22.7% equity interest is plausible but not confirmed in the ground truth. (2) Quantitative accuracy is low: key numbers like $4.8B loss, $7.2B accumulated loss, and $282M gain are unsupported. The original answer references '$X' as a placeholder, indicating specific figures were not available or disclosed, so asserting precise dollar amounts is incorrect. Dates are partially correct (IPO date) but deconsolidation timing is off—tax deconsolidation occurred in 2023, not June 2024. (3) Reasoning is partially sound: the model recognizes the shift from consolidation to equity method and understands tax deconsolidation implications, but fails to correctly sequence events. It conflates financial deconsolidation in 2024 with tax deconsolidation that occurred earlier. The multi-hop synthesis is weak—while it connects IPO to deconsolidation and tax effects, it invents financial impacts not present in the ground truth. (4) Contextual relevance is high—the answer addresses tax implications, investment income, IPO, and deconsolidation as required. However, the inclusion of unsupported figures and misaligned timelines reduces factual reliability. The shift to equity method and non-consolidated relationship is correctly framed, but execution lacks precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 535,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "Tesla's approach to Solar Roof production in 2022 emphasized improving installation efficiency through partnerships with real estate developers and training new installers to reduce costs and time. Supply chain challenges included maintaining battery cell supply and hiring skilled electricians. The 2024 document does not provide additional details on Solar Roof production strategies or supply chain updates, indicating limited evolution in this area beyond the 2022 focus on operational efficiency and collaboration.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures Tesla's 2022 strategy regarding Solar Roof production, including training installers, partnering with real estate developers, and addressing battery supply and electrician hiring. These elements are factually consistent with the ground truth. However, the LLM incorrectly states that the 2024 document 'does not provide additional details' and that there was 'limited evolution,' which directly contradicts the ground truth. In reality, the 2024 update shows a clear strategic shift toward systemic supply chain risks, global component procurement, supplier failure mitigation, and inflationary pressures—none of which are acknowledged in the LLM response. (2) There are no numerical values in this question, so quantitative accuracy is not applicable beyond correct use of years (2022, 2024), which are accurate. (3) The multi-hop reasoning fails because the model does not synthesize the evolution from 2022 to 2024. It stops at 2022 and assumes no new information in 2024, when in fact the knowledge graph confirms a significant shift in focus. This represents a failure in cross-temporal synthesis. (4) While the 2022 portion is contextually accurate and relevant, the omission of 2024 developments severely undermines completeness and correctness. The answer misrepresents the trajectory of Tesla’s strategy, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because it addresses the right topic and timeframe but fails to report the actual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 426,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina decreased from **$8 billion to $9 billion** in 2022 to **$7 billion to $8 billion** in 2023. By 2023, approximately **$4 billion** had been spent, compared to **$3.1 billion** through 2021. This reduction reflects progress under the Coal Ash Act, including the settlement agreement that lowered initial cost estimates and accelerated closure timelines, with remaining expenditures expected to occur over the next **10 years** rather than 15–20 years. The lower cost range and faster spending timeline indicate improved efficiency and adherence to regulatory requirements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key quantitative figures: the 2022 cost estimate ($8B–$9B), the 2023 revised estimate ($7B–$8B), the amount spent through 2021 ($3.1B), and the updated spending through 2023 ($4B). These match the ground truth exactly. 2) Quantitative accuracy is perfect—no errors in numbers, ranges, or timeframes. The $900M increase in spending between 2021 and 2023 is consistent with the data. 3) The reasoning is sound and adds value by noting the settlement agreement, accelerated timelines (10 vs 15–20 years), and improved efficiency—details not in the original answer but plausibly inferred and contextually appropriate. While the original answer emphasizes 'refined cost estimates' and 'more basins excavated,' the LLM provides a complementary explanation without contradicting facts. 4) The answer is fully relevant, directly addressing the evolution of cost estimates and what it indicates about progress under the Coal Ash Act. The only minor gap is that the original emphasizes 'measurable progress' tied to excavation and cost refinement, while the LLM focuses more on timeline acceleration—slightly different emphasis but not incorrect. Overall, the LLM answer is factually accurate, complete, and enhances the original with reasonable context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 357,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024, reflecting a 1.5 percentage point growth. This indicates that 'on!' gained market share within the broader oral tobacco segment despite the overall segment's retail share declining from 42.5% to 37.5% due to declines in traditional moist snuff (MST) products. However, 'on!' lost 2.6 share points within the nicotine pouch category, which grew to 42.9% of the U.S. oral tobacco category. The increase in 'on!'’s retail share suggests it is outperforming competitors in the evolving oral tobacco market, particularly as the segment shifts toward nicotine pouches, even though it faced headwinds in the nicotine pouch subcategory.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the increase in 'on!' retail share from 6.8% in 2023 to 8.3% in 2024 and the decline in total oral tobacco segment share from 42.5% to 37.5%, which aligns with the ground truth. These numbers are quantitatively accurate, and the 1.5 percentage point growth is correctly calculated. (2) However, the LLM introduces new information not present in the original answer or implied by the question: specifically, that 'on!' lost 2.6 share points within the nicotine pouch category, which grew to 42.9% of the U.S. oral tobacco category. This detail is absent from the ground truth and cannot be verified from the provided context, making it an unsupported addition that undermines factual accuracy. (3) The multi-hop reasoning is partially sound—correctly contrasting 'on!'s growing share against a shrinking overall segment—but extends beyond the scope by introducing a subcategory (nicotine pouch) performance without basis in the original answer. This reflects a failure in entity and contextual fidelity. (4) While the core quantitative facts and main conclusion about 'on!' gaining relative strength are correct, the inclusion of unverified, conflicting details (loss in nicotine pouch share) reduces correctness. The answer is partially correct but contains significant extraneous and inaccurate qualitative claims, warranting a score of 6. Quantitative accuracy is high (8), but qualitative accuracy suffers due to incorrect synthesis (5). Contextual relevance remains strong as it directly addresses market position evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 431,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "Qualcomm's reliance on Chinese OEMs for revenue has remained significant, with risks highlighted in both 2023 and 2024 filings. The 2024 document notes continued concentration in China, exacerbated by U.S.-China trade tensions and the Made in China 2025 initiative, which pressures OEMs to develop self-sufficient semiconductor capabilities. A key event was the revocation of Qualcomm's export license to Huawei in May 2024, reducing revenue from Huawei by ~$560 million in fiscal 2024. This underscores heightened geopolitical and operational risks, as Chinese OEMs may increasingly prioritize domestic alternatives, threatening Qualcomm's revenue stability. The 2023 filings similarly warned of concentration risks, but 2024 adds concrete examples of policy-driven shifts and supply chain disruptions, intensifying concerns about business stability.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific claims not present in the ground truth, most notably the 'revocation of Qualcomm's export license to Huawei in May 2024' and a '$560 million' revenue reduction. These details are factually unsupported by the original answer and contradict the ground truth, which does not mention any such event or financial impact. The original answer only states that reliance persisted and poses risk due to geopolitical tensions, without citing specific license changes or quantified revenue losses. (2) The quantitative inaccuracies are severe: the $560 million figure and May 2024 date are entirely fabricated from the model's perspective, as they do not appear in the ground truth. There is no calculation or number in the original answer to support this. (3) The reasoning partially aligns with the multi-hop requirement—correctly identifying ongoing reliance on Chinese OEMs and linking it to geopolitical risks in both years—but goes beyond the source by introducing speculative policy impacts (e.g., 'Made in China 2025') and cause-effect dynamics not present in the original. The model synthesizes a plausible narrative but fails to base it solely on the provided truth. (4) While the LLM answer is contextually relevant and addresses the evolution and implications of reliance, the inclusion of false specifics drastically undermines factual correctness. The core idea of sustained dependency and increased risk is consistent, but the invented details reduce the correctness score to partially accurate. Hence, correctness is scored at 4/10, quantitative accuracy very low due to false numbers, qualitative reasoning moderate for structure but flawed in sourcing, and relevance high as the response stays on topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 478,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "Amgen's available-for-sale investments increased significantly from $4.335 billion in 2022 to $10.404 billion in 2023. The composition shifted from 2022's emphasis on U.S. Treasury bills ($1.676 billion) and Money market mutual funds ($2.659 billion) to 2023's dominance by Money market mutual funds ($10.266 billion), with minimal holdings in Other short-term interest-bearing securities ($138 million). U.S. Treasury bills were entirely eliminated in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the composition of Amgen's 2022 investments. It incorrectly states that in 2022, Amgen held $1.676 billion in U.S. Treasury bills and $2.659 billion in money market mutual funds. According to the ground truth, in 2022, Amgen held $1,676 million in marketable securities (not U.S. Treasury bills specifically) and $2,659 million in cash and cash equivalents (not money market mutual funds). The 2023 figures are mostly correct: $10.266 billion in money market mutual funds and $138 million in other short-term interest-bearing securities, totaling $10.404 billion. However, the misattribution of 2022 components undermines the validity of the comparison. (2) Quantitative accuracy is partially correct: the total investment amounts for both years ($4.335B and $10.404B) are accurate, and the 2023 breakdown sums correctly ($10.266B + $0.138B = $10.404B). However, the 2022 component values are assigned to the wrong security types, leading to a misleading portrayal of the portfolio. (3) The multi-hop reasoning is flawed because the model fails to correctly identify and distinguish the types of securities held in 2022. It incorrectly maps 'marketable securities' to 'U.S. Treasury bills' and 'cash and cash equivalents' to 'money market mutual funds', which are not equivalent categories. This misclassification breaks the logical synthesis required to accurately describe the evolution of the investment portfolio. (4) Despite these errors, the answer is contextually relevant—it addresses the question about changes in composition over time and highlights the shift toward money market funds. However, due to the core misrepresentation of 2022 holdings, the qualitative and overall correctness scores are significantly reduced. The conclusion about eliminating U.S. Treasury bills is unsupported by the original data, which does not specify that marketable securities were exclusively Treasury bills.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 533,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "Shake Shack was not listed as a tenant at any SPG premium outlet properties in 2022. However, in the 2023 document, Shake Shack is explicitly mentioned as a tenant at the **Las Vegas Outlets (North Premium NV)**. This indicates that Shake Shack's presence expanded to SPG's properties in 2023, specifically at the Las Vegas location, but was absent from all properties in 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect regarding Shake Shack's presence in 2022. The ground truth states that Shake Shack was a tenant at Woodbury Common Premium Outlets in New York in 2022, but the LLM claims it was not listed at any SPG premium outlet in 2022. This is a major factual error. Additionally, the LLM fails to mention the continued presence at Woodbury Common in 2023, instead implying that Las Vegas was the only location and the first entry into SPG properties. (2) While there are no numerical values to verify (e.g., dollar amounts, percentages), the temporal facts (years) and entity-location mappings are incorrect. The year 2022 is misrepresented, undermining the accuracy of the timeline. (3) The multi-hop reasoning is flawed: the question requires comparing Shake Shack's tenancy across SPG properties between two years. The LLM fails to correctly identify the 2022 presence (Woodbury Common), misses the continuity into 2023, and only correctly identifies the new 2023 Las Vegas location. This results in an incomplete and misleading synthesis. (4) Despite the factual errors, the answer is contextually relevant—it addresses the evolution of Shake Shack’s presence in SPG outlets and focuses on the correct type of information (locations and years). However, due to significant factual inaccuracies in both entity and temporal attribution, the correctness, quantitative, and qualitative scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 399,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "The classification of retirement annuity contracts remained in Level 3 of the fair value hierarchy for both 2022 and 2024, as indicated by their inclusion under \"Significant Unobservable Inputs (Level 3)\" in the respective tables. This consistency suggests GD employs valuation methodologies relying on unobservable inputs for these contracts, reflecting a stable approach to their fair value determination despite changes in other assumptions like discount rates and asset allocations.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that retirement annuity contracts remained in Level 3 of the fair value hierarchy in both 2022 and 2024, which matches the ground truth. It accurately reflects that the valuation methodology relies on unobservable inputs, consistent with Level 3 classification. The answer also appropriately notes that GD maintained a stable valuation approach, which aligns with the core conclusion in the original answer. However, the LLM omits a key qualitative detail present in the ground truth: the 2024 disclosure included investments valued using net asset value (NAV) as a practical expedient in the reconciliation tables, which was not explicitly stated in 2022. This reflects a refinement in disclosure transparency, not just a stable methodology. While the LLM captures the stability in classification and methodology, it misses this nuance about improved reporting transparency. All entities (Level 3, GD, retirement annuity contracts, 2022–2024 timeframe) are correct, and there are no numerical inaccuracies (no calculations required). The reasoning is sound but incomplete in synthesizing the full evolution of disclosure practices. Hence, the answer is factually correct but lacks completeness in addressing the full scope of 'evolution' in classification practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 362,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "AIG's financial relationship with Corebridge evolved significantly between 2023 and 2024. In 2023, AIG sold 159.75 million shares of Corebridge through secondary offerings and repurchased 17.2 million shares, reducing its ownership to 52.2% by December 31, 2023. In 2024, AIG further reduced its stake to 22.7% after deconsolidating Corebridge on June 9, 2024, following the sale of 120 million shares to Nippon Life Insurance for $3.8 billion, resulting in a $282 million gain. The deconsolidation triggered a $4.8 billion loss, primarily due to an accumulated comprehensive loss of $7.2 billion. Post-deconsolidation, AIG recognized equity method income of $601 million in 2024, reflecting dividends and changes in Corebridge's stock price, while also recognizing gains from subsequent share sales. This transition from consolidated to equity method accounting impacted income recognition, with dilution in AIG's ownership and a shift in income recognition from consolidated operations to equity method adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly regarding key events and timelines related to AIG's relationship with Corebridge. (1) The original answer states that the IPO occurred on September 19, 2022, which terminated Blackstone's exchange right—this is a critical multi-hop fact that the LLM fails to mention or correctly sequence. Instead, the LLM claims deconsolidation occurred on June 9, 2024, and that equity method income began then, but the ground truth confirms income recognition under the equity method started from June 9, 2024, not due to a sale on that date. (2) The LLM introduces a $3.8 billion sale of 120 million shares to Nippon Life Insurance and a $282 million gain, which are not present in the ground truth and appear fabricated. (3) The claim of a $4.8 billion loss due to deconsolidation and an accumulated comprehensive loss of $7.2 billion is unsupported by the original answer. (4) The LLM correctly identifies the shift from consolidation to equity method accounting and mentions equity method income ($601 million), which aligns with the conceptual transformation in income recognition. However, this number is not in the ground truth and cannot be verified. (5) The discussion of ownership percentages (52.2% in 2023, 22.7% in 2024) and share transactions (159.75M sold, 17.2M repurchased) are absent from the original answer and likely incorrect. While the LLM captures the general theme of reduced ownership and a shift in accounting method, it fails on core facts, dates, and financial figures. The reasoning is partially sound in structure but built on incorrect data. Quantitative accuracy is low due to unsupported numbers and events. Qualitative accuracy suffers from incorrect entity-event linkages. Contextual relevance is high as the response addresses equity dilution and income recognition as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 503,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "Comcast's financial exposure to Universal Beijing Resort increased from $2.5 billion in debt as of December 31, 2021 (2022 filing) to $3.4 billion as of December 31, 2024 (2024 filing). The resort remains a consolidated variable interest entity (VIE), with Comcast holding a 30% interest and bearing the maximum risk of financial loss limited to its ownership stake. Debt disclosures show the resort's outstanding debt rose due to term loan extensions, but consolidation treatment remained unchanged, with no new guarantees or liquidity arrangements between Comcast and the resort.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Universal Beijing Resort had $2.5 billion in debt as of December 31, 2021, but the ground truth shows $3.6 billion as of that date (with $2.5 billion being the amount as of December 31, 2020). This misalignment skews the entire narrative of increasing debt. Additionally, the LLM claims debt rose from $2.5B to $3.4B, but in reality, debt decreased from $3.6B (2021) to $3.5B (2023) and then slightly dropped to $3.4B (2024), indicating stabilization, not a rise. The LLM also fabricates a '30% interest' and 'maximum risk of financial loss limited to its ownership stake' which are not present in the original answer and contradict the consolidation treatment. (2) Quantitative accuracy is low: two out of three debt figures are wrong (2021 and implied 2024 trend), and the timeline is misrepresented. The correct sequence is $2.5B (2020), $3.6B (2021), $3.5B (2023), $3.4B (2024). The LLM omits the 2023 figure entirely. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies the VIE consolidation, it fails to report that Comcast now fully consolidates the resort’s $7.3B in assets and $7.0B in liabilities as of 2024—a key part of the financial exposure evolution. The reasoning about 'term loan extensions' and 'no new guarantees' is speculative and unsupported by the original answer. (4) Contextual relevance is high because the answer addresses debt trends and consolidation, which are central to the question, but the factual and quantitative errors severely undermine correctness. The qualitative accuracy is moderate due to correct identification of VIE status but incorrect implications about risk limitation and ownership stake.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 479,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "The structure of aircraft trade-in commitments remained largely unchanged between 2022 and 2023, with two primary types: (1) options to trade in aircraft valued at fair market value 45 days before delivery, and (2) commitments guaranteeing a predetermined trade-in value, which carry higher risk in adverse market conditions. However, in 2023, the document specifies that \"some Gulfstream customers\" hold such options, narrowing eligibility to Gulfstream specifically. Additionally, the 2023 disclosure notes that estimated changes in fair market values from commitment dates were not material, indicating managed risk exposure compared to 2022.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the narrowing of customer eligibility from 'some customers' in 2022 to 'some Gulfstream customers' in 2023, which aligns with the ground truth. It also accurately notes that risk exposure related to trade-in values was considered not material in 2023, consistent with the original answer. However, the LLM introduces specific structural details not present in the ground truth—namely, two 'primary types' of trade-in commitments (fair market value 45 days before delivery and guaranteed predetermined value). These specifics are not mentioned in the original answer and represent an overinterpretation or addition not supported by the source, which only discusses the existence of options and risk from market changes without detailing mechanics or types. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not compromised; all references to years (2022, 2023) are correct. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes changes in customer eligibility and risk framing across years and identifies Gulfstream as a focal point in 2023. However, the unsupported elaboration on trade-in structures weakens the qualitative accuracy slightly. (4) The answer is contextually relevant and addresses both parts of the question—customer eligibility and risk exposure—accurately capturing the narrowing of eligibility and continuity in materiality of risk. The correctness score is 8 due to the accurate core facts but minor overreach in structural detail not present in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 444,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "Tesla's approach to the Tesla Semi evolved from development to pilot production between 2022 and 2024. In 2022, the Semi was mentioned as a planned commercial electric vehicle in the \"Future Consumer and Commercial Electric Vehicles\" section. By 2024, it was listed as being in \"Pilot production\" in Nevada, indicating progress toward scaling manufacturing. Strategically, the Semi remained a key component of Tesla's commercial vehicle lineup, with efforts focused on cost reduction, production optimization, and aligning with broader goals to expand its energy and transportation offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that in 2022, the Tesla Semi was in the planning/development phase, specifically referencing its mention in the 'Future Consumer and Commercial Electric Vehicles' section, which matches the original answer's characterization as conceptual and developmental. By 2024, it accurately notes the shift to 'pilot production' in Nevada, a key factual point. (2) There are no numeric values requiring calculation, but the years (2022 and 204) and production status terms ('planned', 'pilot production') are factually correct and consistent with the ground truth. (3) The multi-hop reasoning is sound—synthesizing information across two time points and inferring progression in strategic positioning. The LLM adds minor elaboration (e.g., cost reduction, production optimization, alignment with energy/transportation goals) that are reasonable inferences but not explicitly in the ground truth; however, they do not contradict it and enhance contextual understanding without introducing error. (4) The answer is semantically equivalent to the original, with slightly more detail but no factual deviation. The only reason for not scoring a 10 is that the original answer emphasizes the strategic shift from planning to market preparation more explicitly, while the LLM implies it. Overall, the response is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 399,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "The valuation allowance related to Altria's investment in Cronos increased slightly from $397 million at December 31, 2023, to $402 million at December 31, 2024. This indicates that Altria's confidence in the realizability of deferred tax assets tied to Cronos remained cautious, as the allowance increased modestly. However, the overall reduction in total valuation allowances in 2024 (from $2,800 million in 2022 to $668 million in 2024) reflects improved confidence in other areas, such as JUUL-related losses, due to the IRS Agreement and tax benefit releases. The slight increase in the Cronos-specific allowance suggests continued uncertainty about the realizability of those deferred tax assets.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states the valuation allowance increased from $379 million in 2022 to $402 million in 2024, but the LLM incorrectly reports $397 million in 2023 as the starting point and omits the 2022 figure entirely. This misrepresents the trend over the full 2022–2024 period. Additionally, the LLM introduces unrelated information about total valuation allowances decreasing from $2,800 million in 2022 to $668 million in 2024 and cites JUUL-related losses and an IRS Agreement—details not present in the ground truth and potentially conflating other parts of Altria’s financials. (2) The only correct number is the $402 million in 2024. The $397 million figure for 2023 is not in the original answer and contradicts the known 2022 value of $379 million, suggesting either incorrect data or flawed interpolation. The absence of the 2022 baseline undermines the multi-year evolution analysis. (3) The reasoning is partially sound in interpreting the increase in the Cronos-specific allowance as reflecting continued uncertainty, which aligns with the ground truth’s conclusion. However, the model fails to correctly synthesize the full time-series data (2022 to 2024), focusing only on a one-year change (2023 to 2024) and introducing extraneous context that distracts from the specific query. (4) The correctness score is 5 due to partial factual accuracy on the final year’s value and correct qualitative interpretation of increasing allowance indicating caution, but major deductions for missing and incorrect numbers. Quantitative accuracy is low (4) due to incorrect figures and missing data points. Qualitative accuracy is moderate (6) because the logic about realizability is reasonable, but the reasoning is based on incomplete and partly erroneous data. Contextual relevance is high (8) as the response stays focused on the topic of valuation allowances and deferred tax assets, even if it introduces some off-topic elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 542,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "Amgen changed the accounting treatment for its BeiGene investment from the equity method to fair value in the first quarter of 2023, recognizing changes in fair value directly in earnings. In 2023, this shift resulted in gains due to fair value appreciation. By 2024, the investment's fair value declined, leading to net unrealized losses in Other income (expense), net, reflecting the valuation impact of the investment's performance under the new method. This transition altered how BeiGene's financial outcomes directly affected Amgen's reported earnings and balance sheet.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the change in accounting method from the equity method to fair value in 2023, specifically noting it occurred in the first quarter, which aligns with the original answer's timeline. (2) The financial impact is accurately described: gains in 2023 due to fair value appreciation and a shift to net unrealized losses in 2024, recognized in 'Other income (expense), net'—this matches the original answer's claim of a reversal from gains to losses. (3) The multi-hop reasoning is sound: the answer synthesizes the change in accounting treatment with its resulting valuation impacts across two years, correctly linking the method change to direct earnings recognition and explaining how market or valuation changes led to losses in 2024. (4) All entities—Amgen, BeiGene, the accounting methods, financial statement line items—are correctly identified and contextualized. Minor wording differences (e.g., 'fair value appreciation' vs 'revaluation') do not affect factual accuracy. No numeric values are incorrect, and while exact dollar amounts aren't cited, the qualitative financial impacts (gains to losses) are correctly characterized as per the original answer. The response fully addresses the evolution of financial treatment and valuation impact between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 382,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "Between 2023 and 2024, Disney+ Hotstar's positioning evolved by consolidating regional service structures and refining branding. In 2024, Disney+ Hotstar remained the branded service in **India and certain Southeast Asian countries**, emphasizing localized content and sports programming. Meanwhile, in **Latin America**, the Company merged its Disney+ and Star+ services into a single Disney+ offering (replacing the prior Combo+ model), streamlining its service structure. This shift reflects a strategy to unify branding under Disney+ in regions where Star+ was previously offered, while maintaining Hotstar's distinct identity in India, where it retains a strong regional focus on entertainment and sports.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Disney+ Hotstar remained the branded service in India and Southeast Asia in 2024, maintaining its regional focus on entertainment and sports; in Latin America, Disney+ and Star+ were merged into a single Disney+ offering by the end of June 2024, replacing the Combo+ model. The answer correctly identifies the strategic shift toward brand unification under Disney+ in Latin America while preserving the distinct Hotstar identity in India. (2) There are no numeric values, dates, or financial figures in the question or ground truth that require verification—only the June 2024 deadline for the Latin America merger is implied in the original answer, which the LLM correctly contextualizes as occurring in 2024 without fabricating an exact date. (3) The multi-hop reasoning is sound: the model synthesizes information across regions (India, Southeast Asia, Latin America) and time (2023 vs. 2024), correctly distinguishing between continued use of the Hotstar brand and the consolidation of Star+ into Disney+. (4) The only minor shortcoming is that the LLM does not explicitly mention that Disney+ Hotstar was described in 2023 as a DTC service with general entertainment, family, and sports programming—though this is implied in the reference to localized content and sports. Otherwise, the answer is semantically equivalent, factually precise, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 406,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "PayPal's Protection Programs in 2024 maintained their core purpose of mitigating fraud and counterparty risks but faced heightened challenges due to evolving regulatory frameworks. The 2024 filings highlight increased exposure to fraud losses from potential changes in chargeback and error resolution requirements by card networks and regulators. Loss recovery mechanisms remained reliant on merchant cooperation, though uncertainties persist (e.g., fraudulent merchants or unwilling payers). Additionally, the scope of transactions covered by protection programs may expand or contract, impacting loss rates and requiring adaptive risk management strategies. These factors underscore a shift toward greater regulatory scrutiny and operational complexity in 2024 compared to 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of PayPal's Protection Programs from 2023 to 2024, particularly regarding increased risk exposure due to evolving fraud and regulatory changes, and challenges in loss recovery. It correctly identifies heightened exposure from potential changes in chargeback rules and reliance on merchant cooperation for recovery, aligning with the original answer's emphasis on difficulties recovering losses from insolvent or fraudulent merchants. However, the LLM omits a key detail from 2023: that costs were recorded in 'transaction and credit losses' and that PayPal did not provide a separate service under these programs—this absence weakens the comparative evolution. While the 2024 disclosures about expanded risk acknowledgment are accurately reflected in spirit, the LLM does not explicitly note the shift toward more detailed disclosures, which is a core part of the original answer. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the reasoning is logically sound, though slightly incomplete in synthesizing the full multi-hop comparison between the two years. The answer remains contextually relevant and captures the qualitative shift in risk posture, but lacks full completeness in reflecting the accounting and disclosure changes that defined the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 389,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "From 2022 to 2024, NextEra Energy's relationship with solar generation facilities evolved through a mix of asset disposals, consolidated VIEs, and equity investments. In 2022, NextEra sold 100% ownership of six solar facilities (115 MW) for $1.7 billion, recognizing a $53 million loss, while retaining control of three under-construction facilities with contingent liabilities tied to solar PTCs. By 2024, NextEra consolidated 30 VIEs owning solar and wind projects (totaling ~3,485 MW solar capacity) and held equity method investments in entities like XPLR, which owns solar projects. Financial exposure persisted through consolidated VIEs (assets: ~$23.9 billion) and equity investments, with ongoing liabilities for decommissioning and PTC-related obligations. Ownership structure shifted from direct control of sold assets to maintaining significant stakes via VIEs and equity investments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative details. The ground truth states that in 2022, NextEra sold a 100% stake in a 100 MW Arizona solar facility and a 90% stake in a portfolio of four solar facilities. However, the LLM claims NextEra sold '100% ownership of six solar facilities (115 MW) for $1.7 billion, recognizing a $53 million loss.' This contradicts the ground truth, which does not mention six facilities, 115 MW, $1.7 billion proceeds, or a $53 million loss—instead, the actual transactions resulted in gains, not a loss. These are major factual errors. (2) For 2024, the ground truth states NextEra consolidated eight VIEs with ~765 MW of solar capacity and held a 10% direct ownership interest. The LLM incorrectly states 30 VIEs with ~3,485 MW of solar capacity (mixing solar and wind), which is a substantial overstatement. The mention of XPLR and equity investments, while plausible, is not supported in the ground truth and introduces unverified entities. (3) The multi-hop reasoning is partially sound in structure—recognizing a shift from direct ownership to VIEs and equity stakes—but the synthesis is based on incorrect data. The conclusion about increased financial exposure through VIEs and liabilities is directionally consistent, but the magnitude and specifics are wrong. (4) Contextual relevance is fair, as the answer addresses ownership structure and financial exposure over time, but the incorrect numbers and entities severely undermine factual correctness. Quantitative accuracy is very low due to pervasive number mismatches. Qualitative accuracy is moderate because the conceptual shift is recognized, but entity and data fidelity are poor. Correctness score is low due to core factual and numerical errors that change the meaning of the financial and operational narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 503,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "ACN's investment in Mutual Fund Debt Securities remained in Level 2 of the fair value hierarchy for both 2022 and 2023, with no change in valuation methodology. In 2022, the amount was $379,989 (Level 2), and in 2023, it was also listed as $379,989 (Level 2) under Non-U.S. Plans. The valuation methodology remained consistent, relying on observable inputs (Level 2), with no shift to Level 3 or changes in the underlying valuation approach.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in stating that ACN's Mutual Fund Debt Securities remained in Level 2 of the fair value hierarchy in both years, and that the valuation methodology did not change—this aligns with the ground truth. However, the key quantitative error is in the 2023 value: the LLM incorrectly states it as $379,989 (same as 2022), while the ground truth reports a decrease to $253,025 in 2023. This misrepresents the evolution of the investment, which actually decreased by $126,964. (2) The quantitative accuracy is severely impacted because the dollar amount for 2023 is factually wrong, despite correct formatting. The 2022 figure ($379,989) is accurate. (3) The reasoning is sound in terms of interpreting the fair value hierarchy and methodology consistency, but fails in the core multi-hop requirement to compare year-over-year changes in value. The model missed the reduction in investment, undermining the analysis of how the investment 'evolved'. (4) Contextual relevance is high because the answer addresses both parts of the question—investment evolution and valuation methodology—and uses correct entities (ACN, Mutual Fund Debt Securities, Level 2). However, due to the significant numerical inaccuracy affecting the main trend, the overall correctness score is reduced to 4, reflecting partial correctness with major factual deficiency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 384,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "Chevron's financial stake in Tengizchevroil (TCO) increased slightly from $26,534 million in 2022 to $26,954 million in 2023, reflecting a $420 million rise in carrying value. However, equity earnings from TCO decreased from $4,386 million in 2022 to $3,375 million in 2023. Chevron's 50% ownership stake remained unchanged, indicating no evolution in equity involvement, though the investment's carrying value increased due to factors like loans to TCO.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Chevron's carrying value in Tengizchevroil was $23,727 million in 2022, not $26,534 million as stated. The 2023 carrying value is also incorrect—while the LLM claims $26,954 million, the ground truth does not provide an exact updated carrying value but notes only that it was approximately $80 million higher than its underlying equity in net assets. The equity in earnings figures are also wrong: the LLM reports $4,386 million in 2022 and $3,375 million in 2023, whereas the ground truth states $1,238 million in 2022 and does not provide a 2023 earnings figure. (2) Calculations are therefore invalid—while the LLM computes a $420 million increase, the actual 2022 carrying value was $23,727 million, making the LLM's numbers off by over $2.8 billion. The ground truth emphasizes a qualitative shift in valuation approach and a $4,500 million loan, which the LLM only vaguely references without accurate figures. (3) The multi-hop reasoning is flawed: the LLM incorrectly assumes no change in involvement due to unchanged ownership, but the ground truth highlights a significant deepening of financial involvement via a major loan and complex valuation—key strategic developments missed in the LLM's assessment. (4) Contextual relevance is moderate because the answer addresses the evolution of Chevron's stake and mentions loans, but the severe numerical inaccuracies and failure to capture the strategic significance of the $4.5 billion loan and valuation complexity drastically reduce factual correctness. The answer fabricates large numbers and omits the core insight about increased strategic commitment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 466,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "Disney's relationship with ABC Network evolved between 2023 and 2024 by deepening its integration into Disney's Direct-to-Consumer (DTC) ecosystem. In 2024, ABC's content, including sports programming (ESPN on ABC), was more prominently featured on Hulu and Disney+, with Hulu offering post-linear access to ABC's programming and Disney+ planning an ESPN tile in the U.S. by early 2025. Additionally, ABC's linear networks continued to serve as a distribution hub for ESPN, reinforcing its role in Disney's Sports segment. These moves strengthened ABC's strategic positioning as a bridge between traditional linear TV and Disney's streaming platforms, aligning with broader efforts to unify content across Disney's entertainment ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor overreach in detail not supported by the original answer. (1) Correct elements: The core evolution of ABC Network’s role—increased integration into Disney’s DTC platforms like Hulu and Disney+—is accurately described. The mention of Hulu offering ABC programming one day after linear airing (implied by 'post-linear access') matches the original. The strategic shift from linear to streaming focus is correctly captured. (2) Quantitative accuracy: No specific numbers (e.g., dollar amounts, station counts) are misstated; the LLM omits the detail about eight owned ABC stations but does not contradict it. Dates (2023–2024 evolution, ESPN tile by early 2025) are consistent with plausible timelines and do not conflict with the ground truth. (3) Multi-hop reasoning: The LLM correctly synthesizes ABC’s dual role in linear and streaming ecosystems and infers its bridging function, which is a reasonable interpretation of the strategic shift. However, the mention of 'ESPN on ABC' and ABC serving as a 'distribution hub for ESPN' introduces a nuance not present in the original answer, which focused on ABC’s content moving to Hulu/Disney+, not ESPN distribution via ABC. This is a plausible connection but represents an inference beyond the provided ground truth. (4) The omission of ABC’s affiliate fees being de-emphasized in 2024 is a minor gap in completeness, but the emphasis on streaming contribution is correctly highlighted. Overall, the answer is semantically close, contextually relevant, and factually sound on key points, warranting a high score with slight deduction for added inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 460,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "General Dynamics' ASCOD vehicle remains a key component of its Land Systems portfolio in both 2022 and 2023, with no indication of a shift in production focus or investment allocation. The 2023 filing reaffirms ELS's continued production and upgrades of ASCOD variants (e.g., Spanish Pizarro and Austrian Ulan) alongside other platforms like Piranha and the Ajax. While the Combat Systems segment's military vehicle revenue increased in 2023, the ASCOD's role as a versatile tracked combat vehicle for international partners persists, suggesting sustained investment in its development and deployment.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that in 2022, General Dynamics was 'producing and upgrading' the ASCOD vehicle, but by 2023, the language changed to simply 'offering'—a notable downgrade in commitment. The LLM incorrectly asserts that the 2023 filing 'reaffirms continued production and upgrades,' which directly contradicts the original answer and indicates a failure to detect a meaningful shift in disclosure. There are no numeric values in the question or answers, so quantitative accuracy is not at issue. (2) No numbers are present, so no calculations can be verified, but all references to years (2022, 2023) are correct. (3) The multi-hop reasoning is flawed: the question requires comparing the evolution of language and strategic positioning across two years, but the LLM fails to identify the change in wording and instead fabricates continuity. It also incorrectly implies sustained investment, while the original answer suggests a potential reallocation of resources to Piranha 5 and AJAX. The model does correctly identify relevant platforms (Piranha, AJAX), but misuses them to support an incorrect conclusion. (4) Correctness and qualitative accuracy are low due to the central factual error in interpreting the company's disclosed activities. Contextual relevance is moderate because the answer addresses the right company, platform, and timeframe, and attempts to discuss investment focus, but draws the opposite conclusion from the evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 420,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "PayPal's utilization of European customer balances for credit activities decreased from $3.0 billion (39% of European balances) in 2023 to $2.0 billion (26% of European balances) in 2024. This reduction reflects a strategic shift toward diversifying credit funding sources, including partnerships for selling receivables and leveraging other liquidity mechanisms, while maintaining flexibility to adjust usage based on operational needs and regulatory frameworks. The lower percentage indicates a more conservative approach to allocating customer balances for credit activities, aligning with broader liquidity management priorities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative facts: the decrease in approved European customer balances from $3.0 billion (39%) in 2023 to $2.0 billion (26%) in 2024. These figures match the ground truth exactly, with correct dollar amounts and percentages. (2) Quantitative accuracy is perfect—no calculation or numerical errors. The percentages and values are consistent with the original answer. (3) The reasoning is sound and captures the strategic shift toward reduced reliance on customer balances. However, while the LLM mentions 'partnerships for selling receivables,' it omits the specific, critical evidence from the ground truth: PayPal's multi-year agreement to sell consumer installment receivables, with a sharp increase from $5.5 billion in 2023 to $20.8 billion in 2024. This omission slightly weakens the qualitative completeness of the multi-hop synthesis, as the receivables sale data is key to substantiating the strategic shift. (4) Despite this omission, the LLM correctly infers a strategic diversification and more conservative approach, aligning with the core conclusion. The answer remains highly relevant and factually accurate, warranting a high score but not perfect due to missing a key supporting data point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 355,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "Between 2022 and 2024, NEE's Special Use Funds showed an increase in equity securities categorized under Level 2 (from $2,973 million in 2022 to $3,321 million in 2024) and a stable Level 3 category ($229 million in both years). This shift reflects a growing reliance on commingled funds (Level 2) for equity investments, as noted in disclosures. The increase in Level 2 assets suggests a move toward less transparent, indirectly managed investments, while the overall growth in equity holdings (from $5,511 million to $6,164 million) indicates expanded investment activity. These changes highlight reduced transparency due to indirect investments and a potential shift in portfolio composition toward less observable instruments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to match the ground truth on multiple levels. (1) Quantitative Accuracy: The numbers cited are completely wrong. The ground truth states that in 2022, NEE's equity securities were $906 million (carrying) and FPL's were $672 million, with no Level 2 or Level 3 breakdown provided. By 2024, NEE held $2,614 million in Level 1 and FPL $1,028 million in Level 1, with additional disclosures for Level 2 and Level 3. The LLM incorrectly claims $2,973 million in Level 2 for 2022 and $3,321 million in 2024, and $229 million in Level 3—none of which appear in the ground truth. There is no mention of Level 2 or Level 3 in 2022 in the original answer, so these figures are fabricated. (2) Completeness: The LLM fails to report the actual growth in equity securities from $906M (NEE) and $672M (FPL) to $2,614M (NEE) and $1,028M (FPL), and omits the key point about increased transparency due to granular Level 1–3 disclosures in 2024. Instead, it invents a narrative around Level 2 growth indicating reduced transparency, which contradicts the ground truth. (3) Entity Accuracy: While NEE and FPL are correctly identified, the years and financial metrics (Level 1/2/3 valuations) are misattributed. The LLM confuses total equity securities with Level 2/3 categories and misrepresents the nature of disclosures. (4) Reasoning: The multi-hop synthesis is flawed. The LLM incorrectly infers a shift toward less transparent investments based on non-existent Level 2 increases, when the ground truth indicates a move toward *more* transparency via detailed Level 1–3 reporting. The conclusion about 'reduced transparency' is the opposite of the correct interpretation. (5) Semantic Equivalence: The LLM answer conveys a meaning that is factually and directionally opposite to the ground truth. It invents data, misrepresents trends, and draws incorrect conclusions. Only the general idea that investment activity increased is loosely relevant, but even that is misrepresented in magnitude and composition. The answer fails on all core dimensions of accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 561,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "From fiscal 2022 to fiscal 2023, Accenture's share purchase program under the public program saw consistent utilization, with 1,964,612 shares purchased in Q4 2022 under the open-market program. Employee-related transactions, such as share withholding for payroll tax obligations, accounted for 97,251 shares in Q4 2022. The 2023 document does not provide specific data on share purchase program activity, so the evolution of public versus employee-related transactions for fiscal 2023 cannot be determined from the provided pages.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual correctness but introduces significant inaccuracies. It correctly states that 1,964,612 shares were purchased in fiscal 2022 for $576 million and that 97,251 shares were acquired through employee-related transactions. However, it incorrectly frames these purchases as occurring in 'Q4 2022', which is not supported by the original answer—these figures are for the full fiscal year 2022, not just the fourth quarter. This misrepresentation undermines quantitative and temporal accuracy. (2) The LLM claims that the 2023 document 'does not provide specific data' and therefore 'evolution cannot be determined', which contradicts the ground truth: the original answer explicitly states there is no mention of public program purchases in fiscal 2023, while employee-related transactions continued. This absence of public program activity is itself a meaningful signal, and the correct inference is a reduction or pause in the public buyback program—not that the evolution is indeterminable. (3) The multi-hop reasoning fails: the model should have synthesized the presence of public program activity in 2022 with its absence in 2023, and the continued employee-related transactions, to infer a shift in program utilization. Instead, it defaults to claiming insufficient data, missing a key qualitative insight. (4) While the entities (Accenture, share purchase program, employee-related transactions) are correctly identified, the reasoning and conclusions are flawed. The answer is contextually relevant but factually and logically deficient, particularly in interpreting absence of data as lack of evidence rather than evidence of change. Hence, low scores in correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 476,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC (CPChem) remained unchanged between 2022 and 2023. Chevron maintained a 50% equity ownership interest in CPChem, and the investment was accounted for using the equity method in both periods. There was no consolidation of CPChem into Chevron's financial statements, and no changes to the investment accounting approach were disclosed.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims Chevron's reporting relationship with Chevron Phillips Chemical Company LLC (CPChem) remained unchanged between 2022 and 2023, but the ground truth states a clear shift: CPChem was consolidated in 2022 and switched to equity method accounting in 2023. (2) The LLM incorrectly asserts that CPChem was never consolidated and that the equity method was used in both years, contradicting the original answer which explicitly notes consolidation in 2022 via 'Note 8: Summarized Financial Data' and a change in 2023 to equity method accounting. (3) This is a multi-hop question requiring synthesis of changes in consolidation status and accounting approach over time; the LLM failed to detect or report this key transition, indicating a breakdown in reasoning. (4) The answer is factually wrong on all critical dimensions—consolidation status, accounting method, and change over time—warranting a very low correctness and accuracy scores. Contextual relevance is slightly higher only because the answer addresses the right entity and topic, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 313,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "General Dynamics' Combat Systems segment saw increased production capacity for Hydra-70 rockets in 2023 compared to 2022. In 2022, the segment received a $175 million contract for Hydra-70 rocket production. By 2023, OTS (Ordnance and Tactical Systems) expanded its metal parts production capacity from 18,000 to 86,000 rounds per month by 2025 and propellant capacity from 4 million to 16 million pounds annually by 2028, with additional capacity for 155mm munitions, supporting heightened demand for Hydra-70 rockets and related systems.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $175 million contract in 2022 for Hydra-70 rocket production and the expansion of metal parts production capacity from 18,000 to 86,000 rounds per month by 2025, which aligns with the ground truth. However, it introduces additional information not present in the original answer—specifically, the expansion of propellant capacity from 4 million to 16 million pounds annually by 2028 and increased capacity for 155mm munitions—which, while potentially accurate, is not supported by the provided ground truth and thus adds unverified detail. (2) All numeric values mentioned in the ground truth ($175M contract, 18,000 to 86,000 rounds/month expansion) are accurately reported. The timeline (by 2025) is also correct. The added propellant and 155mm details lack verification but do not contradict the original answer. (3) The multi-hop reasoning is sound: the model correctly links OTS (as part of Combat Systems) to Hydra-70 production, identifies the 2022 contract, and connects the 2023 capacity expansion to increased demand. The synthesis across years and contract-to-capacity evolution is logically presented. (4) The answer is contextually relevant and addresses both contract involvement and production capacity evolution. The core facts are correct, but the inclusion of unsupported details slightly reduces quantitative and qualitative accuracy. Hence, a score of 8 is justified—strong accuracy with minor over-enrichment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 410,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between 2023 and 2024 through amendments to associated agreements. In the 2024 filing, Exhibit 10.08+ reflects an **amended and restated** version of the Performance-Based Restricted Stock Unit Award Grant Notice (originally filed in 2015), effective April 30, 2024. Additionally, the 2015 Equity Incentive Award Plan was **amended and restated** in 2024 (Exhibit 10.03+), updating the framework for such awards. This indicates a formalized revision of documentation and agreements in 2024 compared to the 2023 filing.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that there was an updated form of a performance-based RSU grant notice in 2024 (Exhibit 10.08+) and references the amended and restated 2015 Equity Incentive Award Plan (Exhibit 10.03+), which aligns with the ground truth. However, it incorrectly implies that the Performance-Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+) is an amended version of a document originally filed in 2015, whereas the ground truth clarifies that the base RSU notice (Exhibit 10.07+) was incorporated by reference from 2015, but the updated performance-based variant (Exhibit 10.08+) was newly linked to a 10-Q filing on April 30, 2024—not that it was an amendment of a 2015 filing. (2) The date April 30, 2024 is correctly cited, and the exhibit numbers (10.08+, 10.03+) are accurate. However, the claim that the performance-based notice was 'originally filed in 2015' is factually incorrect—the ground truth does not support this; only the base form (Exhibit 10.07+) traces back to 2015 via incorporation by reference. (3) The multi-hop reasoning is partially sound: the model connects the 2024 update to the amended plan and identifies evolving documentation. But it fails to distinguish clearly between the unchanged base RSU notice (Exhibit 10.07+) and the newly updated performance-based variant (Exhibit 10.08+), conflating their histories. It also omits the key point that the base Global RSU Award Notice remained unchanged in 2024, which was a central element of the ground truth. (4) The answer is contextually relevant and captures the direction of change—increased formalization in 2024—but lacks precision in entity-document relationships and introduces a minor factual inaccuracy regarding the origin of Exhibit 10.08+. Hence, correctness is reduced to 6 due to partial factual error and omission of critical contrast between static and evolving components.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 518,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "Opdivo's role within Bristol-Myers Squibb's portfolio expanded significantly from 2022 to 2024, driven by new regulatory approvals and sustained revenue performance. In 2024, Opdivo received multiple approvals, including FDA and EC approvals for expanded indications in urothelial carcinoma, non-small cell lung cancer (NSCLC), and combination therapies, enhancing its therapeutic versatility. These approvals likely contributed to increased revenue, as Opdivo's 2022 revenue was $7,523 million, reflecting its continued leadership in oncology. The expanded indications and strategic positioning solidified Opdivo as a cornerstone of BMS's portfolio, supporting growth in key therapeutic areas.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states Opdivo's 2022 revenue as $7,523 million, which matches the ground truth and ensures quantitative accuracy for that figure. However, it incorrectly implies that Opdivo received multiple FDA and EC approvals in 2024 across several indications including NSCLC and combination therapies, while the ground truth specifies only one FDA approval in March 2024 for urothelial carcinoma in combination with cisplatin and gemcitabine. There is no mention in the original answer of EC approvals or NSCLC approvals in 2024, making these additions factually unsupported. (2) The revenue figure is accurate and properly cited, but the LLM introduces speculative language such as 'likely contributed to increased revenue' despite the ground truth explicitly stating there was 'not a significant revenue increase from earlier years.' This misrepresents the financial trend. (3) The multi-hop reasoning is partially sound—linking revenue performance and regulatory developments to assess portfolio evolution—but fails in precision by overstating the number and scope of approvals. The synthesis should have been limited to the single confirmed 2024 FDA approval for urothelial carcinoma. (4) The correctness score is 5 due to accurate revenue data but significant overstatement of regulatory milestones and incorrect inference about revenue growth. Quantitative accuracy is 8 because the only number provided is correct. Qualitative accuracy is 5 due to incorrect entity expansion (NSCLC, EC approvals not in ground truth) and flawed reasoning about revenue trajectory. Contextual relevance is 8 because the response stays focused on Opdivo’s portfolio role and uses appropriate framing, even if details are inflated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 473,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "Chevron's financial involvement in Chevron Phillips Chemical Company LLC (CPChem) remained structured around its 50% ownership interest, with continued strategic support through project funding. In 2023, CPChem's equity earnings increased to $7,765 million (from $6,843 million in 2022), reflecting sustained operational performance. Chevron's investment included a $387 million loan to fund the Golden Triangle Polymers Project in Texas, underscoring its financial commitment. Additionally, CPChem advanced projects like the Cedar Bayou C3 splitter unit (final investment decision in 2021, operational in 2023), demonstrating Chevron's ongoing capital allocation to expand CPChem's capacity and capabilities. The investment structure remained anchored in the equity method, with Chevron's share of earnings and direct loans supporting project development.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Chevron maintains 50% ownership in CPChem; the $387 million loan in 2023 to fund the Golden Triangle Polymers Project is accurately reported; and CPChem’s equity earnings increased from $6,843 million in 2022 to $7,765 million in 2023. These numbers match the knowledge graph and are presented with correct formatting. (2) The LLM correctly identifies project developments such as the C3 splitter at Cedar Bayou becoming operational in 2023, consistent with the original answer’s timeline (FID in 2021, start-up in 2023). The mention of the 1-hexene unit in Old Ocean, Texas, is omitted, which is a minor gap, but the core evolution in funding structure—equity-based support in 2022 shifting to direct loan financing in 2023—is clearly articulated. (3) The reasoning is sound: the LLM synthesizes Chevron’s ongoing equity ownership, project-level investments, and the shift toward direct financial support via a loan, demonstrating correct multi-hop understanding across financial structure and strategic evolution. (4) The investment structure is correctly described as using the equity method, and the $387M loan is contextualized as direct financial support, capturing the essence of the strategic shift. Only minor completeness issues prevent a perfect 10: the 1-hexene unit is not mentioned, and the fact that CPChem owns 51% of the Golden Triangle project is omitted. However, these do not undermine the central accuracy. Overall, the answer is factually robust, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 447,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "PayPal's protection programs saw an increase in the allowance for transaction losses from $64 million in 2023 to $86 million in 2024, reflecting higher financial commitments. The 2024 provision for transaction losses was $1,114 million, up from $1,192 million in 2023, though realized losses were higher ($1,218 million vs. $1,313 million), resulting in a net increase in the combined allowance for transaction losses and negative customer balances ($342 million in 2024 vs. $282 million in 2023). These adjustments highlight PayPal's ongoing management of reserves to cover potential losses under its protection programs.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. While it correctly states the increase in the allowance for transaction losses from $64 million (2023) to $86 million (2024), it introduces incorrect data not present in the ground truth: the 'provision for transaction losses' of $1,114 million in 2024 and $1,192 million in 2023, and 'realized losses' of $1,218 million vs. $1,313 million. These figures are not mentioned in the original answer and contradict the ground truth, which does not disclose provisions or realized losses. Additionally, the claim of a 'combined allowance' rising from $282 million to $342 million is incorrect: the ground truth specifies the allowance for transaction losses ($64M to $86M) and negative customer balances ($218M to $256M), which sum to $282M in 2023 and $342M in 2024 — while the totals are mathematically correct, the LLM misrepresents them as a 'net increase in the combined allowance' due to provisions and losses, implying a dynamic calculation not supported by the source. (2) The only correct numbers are the $64M to $86M increase in transaction loss allowance and the implied total reserves (though not explicitly stated as such in the original). The $218M to $256M increase in negative customer balances is omitted entirely. (3) The multi-hop reasoning is partially sound in recognizing an increase in financial commitments, but flawed in constructing a narrative around non-disclosed metrics (provisions, realized losses), suggesting incorrect synthesis or hallucination. (4) Correctness score is low due to major quantitative errors despite some correct directional insights. Quantitative accuracy is poor due to fabricated figures. Qualitative accuracy is moderate because the core idea of increased reserves is correct, but reasoning is flawed. Contextual relevance is high as the answer addresses the evolution of protection programs and reserves.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 526,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "McDonald's has maintained franchising as its core business model between 2022 and 2024, emphasizing its role in driving profitability and local relevance. In 2022, the company highlighted franchising as a key driver of stable revenue through franchisee sales and co-investment in restaurant improvements to enhance performance and brand value. By 2024, the strategic framing reinforced franchising as \"paramount,\" with greater emphasis on collaborative co-investment between McDonald's and franchisees to modernize restaurants, improve local business performance, and align with global standards. The 2024 document also underscored the importance of franchisee contributions to revenue via rent and royalties, while stressing the partnership dynamic to ensure consistency and quality across the system. Thus, the strategic framing remained consistent but was further detailed in 2024 to highlight the symbiotic relationship and shared goals between McDonald's and its franchisees.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the shift from neutral/descriptive framing in 2022 to a more strategic, value-laden emphasis on franchising as 'paramount' in 2024 is accurately captured. The role of franchisee co-investment in driving performance, modernization, and quality is correctly highlighted. (2) There are no numeric values in the question or answer requiring calculation, so quantitative accuracy is not applicable—no errors in dates (2022 vs 2024) or financial terms. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in strategic framing across two years, identifying both continuity (franchising as core) and evolution (increased emphasis on co-investment and partnership). The only minor shortcoming is that the original answer emphasizes a shift from 'structural' to 'strategic' framing more explicitly, which the LLM captures in substance but slightly softens by saying the framing 'remained consistent but was further detailed'—this slightly understates the degree of change implied in the ground truth. (4) Contextual relevance is excellent: all parts of the question are addressed, including franchising as a core model and the evolving role of co-investment. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the original, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 389,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "Between 2022 and 2023, the FDA's authorization of Marlboro HeatSticks evolved significantly. In **January 2023**, the FDA authorized PMTAs for **three new tobacco-flavored varieties** of Marlboro HeatSticks, marking progress in regulatory approval for heated tobacco products. This followed earlier authorizations for the IQOS system (April 2019) and IQOS 3 (December 2020). However, the FDA had not issued marketing decisions for Marlboro HeatSticks by **February 2022**. The authorization of these new varieties indicates **advancing regulatory progress** for Altria's heated tobacco products, though challenges like the ITC ban on IQOS devices and ongoing PMTA reviews highlight the complex, iterative nature of FDA approval for such innovations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key facts are correct: the FDA authorized PMTAs for three new tobacco-flavored Marlboro HeatSticks in January 2023, and no marketing decisions had been issued by February 2022. These dates and events match the original answer. (2) The answer correctly identifies the evolution in FDA authorization between 2022 and 2023, noting the lack of decisions in early 2022 and the milestone approval in January 2023. (3) The reasoning is sound and adds contextual value by referencing prior IQOS authorizations and the ITC ban, which, while not in the ground truth, provide accurate supplementary context that enhances understanding of Altria's regulatory landscape. (4) The core conclusion—that this represents advancing regulatory progress for Altria—is semantically equivalent to the original answer’s claim of 'notable progress.' The only minor shortcoming is that the original answer explicitly ties the progress to Altria’s innovation strategy, a point slightly underemphasized in the LLM response, but the implication is still present. No factual errors; minor omission of strategic framing prevents a perfect 10 on qualitative accuracy. All entities (FDA, Marlboro HeatSticks, PMTA, Altria) are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 361,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "The valuation of mutual fund equity securities held by ACN increased from $234,339 in 2022 to $379,989 in 2023, reflecting both a strategic shift toward higher equity allocation (from 21% to 27% in Non-U.S. plans) and potential market gains. This indicates ACN's investment positioning leaned more toward equities in 2023, aligning with its long-term strategy to balance risk and return through diversified portfolios, while maintaining flexibility in asset allocation.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. The ground truth states that ACN's mutual fund equity securities decreased from $239,293 million in 2022 to $196,226 million in 2023, a reduction of $43,067 million. However, the LLM claims an increase from $234,339 to $379,989, which is both numerically and directionally wrong. These figures do not match the original data, and the magnitude of error is substantial. (2) The numbers cited in the LLM answer are factually incorrect—both the starting and ending values are wrong, and the implied difference ($145,650 million increase) is completely inaccurate. Additionally, the LLM introduces percentages (21% to 27% in Non-U.S. plans) and strategic commentary not present or supported in the ground truth. There is no mention in the original answer about Non-U.S. plans or allocation percentages, making this fabricated context. (3) The multi-hop reasoning fails entirely: instead of identifying a decrease and interpreting it as a reallocation away from mutual fund equities, the model incorrectly infers an increase and constructs a narrative about strategic equity growth, which contradicts the actual trend. (4) The contextual relevance is low because the answer discusses a different trend (increase vs. decrease) and introduces unverified details, but it does address the general topic of investment positioning, which provides minimal relevance. Thus, the correctness score is 1 due to complete factual inaccuracy in numbers and direction of change, despite attempting to answer the right type of question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 439,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "Chevron's involvement in Angola LNG Limited remained consistent from 2022 to 2023, with a 36.4% ownership stake. Operationally, the focus persisted on supplying the Angola LNG plant with both associated gas (from oil production) and non-associated gas from offshore developments. In 2023, the company continued efforts to develop non-associated gas reserves to sustain LNG plant operations, as noted in the 2023 filing. Financially, the investment value decreased slightly from $1,963 million in 2022 to $1,762 million in 2023, reflecting market conditions or accounting adjustments, but the equity stake and operational emphasis remained unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Chevron maintained a 36.4% interest in Angola LNG Limited from 2022 to 2023, which aligns with the ground truth. However, the LLM introduces specific financial values—$1,963 million in 2022 and $1,762 million in 2023—that are not present in the original answer and cannot be verified from the provided ground truth. These figures appear to be fabricated or inferred without support, significantly undermining quantitative accuracy. (2) There is no mention in the ground truth of a financial value decrease or specific investment valuations for Angola LNG Limited; instead, the emphasis shift is described qualitatively in disclosures. The inclusion of precise dollar amounts where none were provided in the source constitutes a major factual error. (3) Qualitatively, the LLM captures the operational continuity—processing associated and non-associated gas—and correctly notes ongoing development efforts in 2023. It also correctly identifies that operational focus remained on supplying the LNG plant. However, it misses the key point from the ground truth about a shift in disclosure emphasis: in 2023, Angola LNG was presented more as part of a broader portfolio of equity affiliates (e.g., Tengizchevroil, Chevron Phillips), indicating a change in reporting context from operational development to financial integration. This nuance is absent in the LLM answer, which instead emphasizes unchanged operational and investment focus. (4) Contextually, the response is highly relevant and well-structured, addressing both operational and investment aspects across the two years. While the reasoning is logical, it fails to reflect the actual nature of the evolution—shift in disclosure framing—because it substitutes unsupported numerical data for the qualitative insight provided in the ground truth. Thus, despite correct entity identification and partial reasoning, the introduction of unverified financial figures reduces overall correctness to a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 541,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "MMM's investment in Certificates of Deposit/Time Deposits increased from $21 million in 2022 to $49 million in 2023, representing a $28 million rise. This change is reflected in the \"Marketable Securities\" section of Note 12 in both the 2022 and 2023 10-K filings.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2022 value: it states $21 million instead of the correct $14 million from the ground truth. The 2023 value is correct at $49 million. The calculated increase of $28 million is therefore incorrect; the true increase is $35 million (from $14M to $49M), which corresponds to a 250% increase, not $28M. (2) Quantitative accuracy is compromised due to the incorrect base value and resulting miscalculation of the dollar change. While $49 million in 2023 is accurate, the $21 million figure for 2022 is not supported by the ground truth and leads to downstream errors. Percentage change is omitted in the LLM answer, which also reduces completeness. (3) The reasoning shows partial multi-hop capability—correctly identifying the metric across two years and referencing Note 12 in the 10-Ks—but fails in accurate data extraction for 2022. The entity identification (MMM, Certificates of Deposit/Time Deposits, years) is correct, and the direction of change (increase) is accurate. (4) Scores reflect that core elements (trend, 2023 value, location in filings) are correct, but major quantitative inaccuracies in key figures reduce overall correctness. Contextual relevance is high as the answer addresses the evolution and magnitude as asked, with appropriate sourcing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1141,
        "completion_tokens": 372,
        "total_tokens": 1514
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "Between 2021 and 2024, McDonald's percentage of franchised restaurants increased from **93%** (37,295 out of 40,031 total restaurants in 2021) to **95%** (approximately 41,303 out of 43,477 total restaurants in 2024). This reflects a growing reliance on franchising as the primary model, with the proportion of franchised locations rising steadily over the period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages (93% in 2021 and 95% in 2024) are accurate and match the original answer. The supporting figures—37,295 out of 40,031 franchised restaurants in 2021 and approximately 41,303 out of 43,477 in 2024—are consistent with the 93% and 95% ratios (verified: 37,295 / 40,031 ≈ 0.931, and 41,303 / 43,477 ≈ 0.9499 ≈ 95%). (2) The answer is complete, addressing the evolution of McDonald's franchise relationship over the specified time period with precise data points for both years. (3) Entity accuracy is correct: McDonald's is the focus, and the years 2021 and 2024 are properly referenced. (4) The reasoning is sound—by providing both percentages and absolute numbers, the LLM demonstrates multi-hop synthesis (deriving or confirming the percentage from total and franchised counts), and the conclusion about increasing reliance on franchising aligns with the trend. (5) The semantic meaning is equivalent to the original answer, with slightly more detail but no factual deviation. All scores are maximized due to full factual accuracy, correct calculations, proper context, and logical synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 338,
        "total_tokens": 1507
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "The 2015 Stock Compensation Plan for Non-Employee Directors was amended and restated effective **October 26, 2022**, as disclosed in Altria's 2023 10-K filing (Exhibit 10.22). This amendment updated the plan's structure, which became effective prior to the 2023 fiscal year. The 2022 10-K did not mention this amendment, indicating the change occurred between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns well with the ground truth. (1) It accurately identifies the new effective date of the plan as October 26, 2022, matching the ground truth. It also correctly implies that the prior version (referenced in the 2022 10-K) was the March 31, 2021 amended version, consistent with the original answer. (2) All dates are correct and precisely stated; no calculations are required, but the temporal logic is sound. (3) The reasoning correctly infers from the absence of the October 2022 amendment in the 2022 10-K and its presence in the 2023 10-K that the amendment occurred between the two reporting periods, demonstrating valid multi-hop logic across filings. (4) The answer is contextually relevant and directly addresses the evolution of the plan’s effective date and structure between 2022 and 2023. The only minor shortcoming is that it does not explicitly mention the 'amended and restated effective March 31, 2021' version by name in the 2022 context, though it is implied by contrast. This slight omission prevents a perfect 10 on qualitative accuracy, but the core facts and synthesis remain correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 324,
        "total_tokens": 1515
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "Accenture's investment in Duck Creek Technologies was accounted for using the equity method in fiscal 2022, with a carrying amount of $138,902 and an estimated fair value of $223,166 for its 16% ownership. In fiscal 2023, Accenture recognized a $253 million investment gain related to this stake, indicating an increase in fair value. The financial impact in 2023 included this gain, which adjusted the investment's valuation and contributed to adjusted earnings per share. No specific 2023 carrying amount or fair value figures are provided in the documents.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative facts: the 2022 carrying amount ($138,902), fair value ($223,166), 16% ownership, and the $253 million gain in fiscal 2023. These match the ground truth exactly, with acceptable formatting (e.g., $253 million vs $253M). (2) Quantitative accuracy is perfect—no calculation errors or misstatements. The gain is correctly attributed to fiscal 2023 and aligns with the financial impact described. (3) The reasoning is sound: the LLM correctly identifies the equity method accounting in 2022 and infers a financial realization event in 2023 due to the large gain, even without explicit disposal details. It appropriately notes the absence of updated carrying or fair value figures in 2023. The only minor gap is not explicitly stating that the gain affected the effective tax rate, which was mentioned in the original answer and is part of the financial impact. (4) The answer is highly relevant, directly addressing the evolution of the financial relationship, valuation changes, and reported impacts. The omission of the tax rate effect slightly reduces qualitative accuracy but does not undermine the core correctness. Overall, the answer is factually precise, well-reasoned, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 356,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "Between 2022 and 2024, Breyanzi (lisocabtagene maraleucel) expanded its therapeutic applications through new indications approved in 2024. In May 2024, the FDA granted accelerated approval for Breyanzi to treat adult patients with **relapsed or refractory mantle cell lymphoma (MCL)** after two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Additionally, in March 2024, the FDA approved Breyanzi for **relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)** after two prior lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. Japan also approved Breyanzi in August 2024 for **relapsed or refractory follicular lymphoma (FL)** after two or more lines of therapy. These approvals expanded Breyanzi's market potential by broadening its application to additional B-cell malignancies, including MCL, CLL/SLL, and FL.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the specific indications approved for Breyanzi in 2024. According to the ground truth, Breyanzi received two approvals in 2024: in March for relapsed or refractory CLL/SLL and in May for relapsed or refractory follicular lymphoma (FL). However, the LLM incorrectly states that the May 2024 approval was for mantle cell lymphoma (MCL), which is not supported by the original answer. Additionally, the LLM introduces a Japan approval in August 2024 for FL, which is not mentioned in the ground truth and cannot be verified from the provided information. (2) The dates (March and May 2024) are correctly placed, but the associated indications are mismatched. The requirement of prior therapies (two or more lines) is accurately reflected, but the specific disease conditions are not. The mention of BTK and BCL-2 inhibitors as required prior therapies is more detailed than the original answer but not confirmed by the ground truth, introducing unverified specifics. (3) The multi-hop reasoning is partially sound—the model recognizes that Breyanzi expanded its indications in 2024 and attempts to synthesize new patient populations. However, it fails to correctly map the indications to the correct dates and geographies, undermining the synthesis. The core evolution from a large B-cell lymphoma treatment to broader B-cell malignancies is conceptually aligned, but the specific new indications are incorrect. (4) The contextual relevance is high because the answer addresses the expansion of Breyanzi’s use and its market implications. However, due to major factual errors in the approved indications—especially substituting MCL for FL and adding an unmentioned Japan approval—the correctness and qualitative accuracy scores are significantly reduced. Minor formatting differences in drug name (lisocabtagene maraleucel) are acceptable and do not affect scoring.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 524,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "3M's approach to estimating and recording insurance receivables related to respirator mask/asbestos litigation under ASC 450 remained consistent between 2022 and 2023, but the 2023 disclosures reflect a $57 million increase in accruals for liabilities due to heightened claims involving serious injuries (e.g., mesothelioma) and legal developments. The company continued using ASC 450 guidelines to record probable and estimable losses, while also maintaining an immaterial insurance receivable for recoveries. Adjustments in 2023 accounted for evolving litigation trends, including a shift toward more severe injury claims and increased defense costs, without altering the core methodology.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The core claim—that 3M's approach remained consistent between 2022 and 2023—is directly contradicted by the ground truth, which states that 3M evolved its methodology by explicitly applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 in 2023, whereas in 2022 it did not specify the methodology for estimating insurance receivables. This represents a significant change in disclosure and likely in practice, which the LLM fails to recognize. (2) The $57 million increase in accruals is not mentioned in the original answer and cannot be verified against the ground truth; this figure is therefore factually unsupported. The only verified quantitative data in the original answer is the increase in claimants from 4,028 in 2022 to 4,042 in 2023—a minor increase of 14 claimants—which the LLM omits entirely. Instead, the LLM introduces unverified claims about 'heightened claims' and 'shift toward more severe injury claims' not present in the ground truth. (3) The multi-hop reasoning is flawed: the question asks about evolution in the *approach to estimating insurance receivables*, which requires comparing disclosures across years and identifying changes in accounting methodology. The LLM incorrectly asserts consistency and focuses on liability accruals and injury severity rather than the estimation of *insurance receivables*, which is the central issue. It also fails to mention the key frameworks (ASC 610-30) and factors (policy terms, case law, claim nature) introduced in 2023. (4) While the LLM stays within the general topic of 3M's litigation and accounting practices, it misses the key evolution in methodology and introduces unsupported quantitative and qualitative claims, leading to a low correctness score. Contextual relevance is moderate because it discusses related themes but fails the core task.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 524,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "In early 2022, PepsiCo sold its Naked juice brand to PAI Partners but retained a 39% noncontrolling interest in the newly formed joint venture, Tropicana Brands Group (TBG), which operates across North America and Europe. Operationally, PepsiCo remained the exclusive distributor for TBG's portfolio of brands (including Naked) in the U.S., focusing on small-format and foodservice customers via chilled direct-store-delivery (DSD). This indicates continued operational involvement through distribution, while the financial stake was maintained at 39%. No further changes to this relationship are noted in the 2023 filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 transaction in which PepsiCo sold Naked (along with Tropicana) to PAI Partners and retained a 39% noncontrolling interest in the joint venture, TBG. It accurately states PepsiCo's operational role in 2022 as the exclusive distributor for small-format and foodservice channels via chilled DSD. The financial stake (39%) is correct. However, the LLM fails to reflect the key 2023 change: that PepsiCo ceased its distribution role and had no further operational involvement by that year. Instead, it states 'No further changes... are noted in the 2023 filings,' which contradicts the ground truth that operational involvement ended. This omission significantly affects the qualitative accuracy of the multi-hop comparison between 2022 and 2023. (2) All numeric values (39%, 2022) and entity names (PAI Partners, TBG, Naked, Tropicana) are correct. The term 'Tropicana Brands Group (TBG)' is acceptable and aligns with known naming. (3) The reasoning is sound for 2022 but incomplete for 2023. The model synthesizes the initial transaction correctly but fails to recognize or report the withdrawal from distribution duties in 2023, which is central to the question about evolution between the years. This breaks the multi-hop synthesis required to compare operational and financial changes over time. (4) The answer is contextually relevant and well-structured, but the lack of 2023 operational shift limits correctness. Quantitative accuracy is perfect; qualitative accuracy is reduced due to missing key development; overall correctness is 7 due to core factual accuracy with a significant omission in temporal evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 457,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "The accounting treatment for the ExtraBucks Rewards program remained consistent between 2023 and 2024. Both years recognize revenue for ExtraBucks Rewards upon redemption, allocate transaction prices based on standalone selling prices and historical redemption patterns, and classify unredeemed rewards as contract liabilities. There is no indication of changes in revenue recognition or performance obligation determination in the 2024 disclosures compared to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in stating that the core accounting treatment—revenue recognition upon redemption, allocation based on standalone selling prices, and classification of unredeemed rewards as contract liabilities—remained consistent between 2023 and 2024. There are no numeric inaccuracies, as the ground truth does not include specific dollar amounts or percentages, so quantitative accuracy is high. However, the LLM fails to capture key qualitative changes in the 2024 disclosures. Specifically, it incorrectly states that 'there is no indication of changes' when the ground truth clearly indicates a refinement in language around performance obligations, particularly tying the obligation to customers who accumulate ExtraBucks based on historical spending levels. Additionally, the 2024 filing introduced more structured language regarding transaction price allocation and evaluation of standalone selling prices, signaling a more formalized approach. These are meaningful qualitative developments in disclosure and accounting policy articulation, even if the fundamental revenue recognition model did not change. The LLM answer thus misses the nuanced evolution in disclosure and treatment maturity, which is central to the question. This omission significantly reduces the correctness and qualitative accuracy scores, despite the response being factually sound on the basic mechanics and relevant to the question's context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 398,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "Based on the provided documents, the cost of revenues sections for both 2023 and 2024 mention that \"other operating costs include customer service and payment processing fees, including those we pay to our integrated payment partners.\" However, **no specific quantitative details or changes in the amounts paid to integrated payment partners** are provided in the cost of revenues sections for either year. The documents focus on broader cost drivers like content amortization, streaming delivery, and personnel expenses, but do not disclose evolving reliance on payment partners. Thus, **the evolution of reliance on integrated payment partners cannot be determined from the cost of revenues data alone** in the provided pages.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually consistent with the absence of quantitative data, correctly noting that no specific amounts or changes in payments to integrated payment partners are disclosed in the cost of revenues sections for 2023 and 2024. However, it fails to capture the key qualitative evolution described in the ground truth: while the exact figures are not provided, the disclosure language itself changed between years. In 2023, Netflix explicitly mentioned payment processing fees to integrated partners as part of other operating costs. In 2024, although the same categorization appears, the overall cost of revenues section was streamlined, with reduced granular detail—indicating a shift in disclosure strategy, not necessarily a change in operational reliance. The LLM incorrectly concludes that 'the evolution...cannot be determined' based on lack of quantitative data, when the ground truth infers evolution from qualitative disclosure changes. This represents a failure in multi-hop reasoning: synthesizing that unchanged language in a more condensed reporting format may signal reduced emphasis or transparency, even if the underlying cost classification persists. The answer is contextually relevant and quantitatively accurate (no numbers are misstated), but misses the core analytical point about disclosure trends, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 384,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023 by continuing compliance with the 2007 Settlement Agreement and Consent Order (SACO) with the Minnesota Pollution Control Agency (MPCA), addressing new stormwater discharge issues, and adapting to updated health-based standards (HBVs). In 2023, the MPCA directed 3M to address PFAS in stormwater from the Cottage Grove facility, leading to a revised plan and a Notice of Violation in March 2023. Additionally, the Minnesota Department of Health issued stricter HBVs for PFOA and PFOS in January 2024, prompting 3M to evaluate the impact on its obligations under the SACO. These actions reflect heightened regulatory scrutiny and proactive adjustments to meet evolving health standards.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of 3M's PFAS management approach from 2022 to 2023, including ongoing compliance with the 2007 SACO, new stormwater issues, and response to updated health-based values. However, it incorrectly states that the MPCA directed 3M to address stormwater at Cottage Grove in 2023, while the ground truth specifies that the MPCA issued the order in December 2022. Additionally, the LLM attributes the March 2023 Notice of Violation to the Cottage Grove facility, but the ground truth identifies it as relating to the Hutchinson facility. These are factual inaccuracies in entity and date alignment. (2) Quantitatively, the dates and sequence of events are mostly accurate, but the misplacement of the December 2022 Cottage Grove order into 2023 and the misassignment of the March 2023 NOV to the wrong facility reduce precision. The January 2024 HBV update is correctly cited. (3) The multi-hop reasoning is strong: the model correctly synthesizes information across regulatory actions (MPCA, MDH), facilities (Cottage Grove, Hutchinson), and timelines (2022–2024), and infers 3M’s adaptive response to tightening standards. The core logic about evolving regulatory pressure and corporate response is sound. (4) Despite minor factual errors in facility-date pairing, the answer conveys the essential narrative of increasing regulatory scrutiny and 3M’s responsive posture. Contextual relevance is excellent, directly addressing the question’s focus on regulatory changes and health standards. The correctness score is 8 due to key entity-date mismatches, but qualitative and contextual accuracy remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 454,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "PepsiCo increased its use of foreign currency derivatives in 2023, with the total notional value of foreign currency derivatives rising to $3.8 billion (December 30, 2023) from $3.0 billion (December 31, 2022). This reflects a broader hedging strategy to manage foreign exchange risks from international operations and subsidiaries. The company continued using forward contracts and net investment hedges, with gains/losses on non-hedging derivatives offset by changes in underlying hedged items, resulting in no material net impact on earnings. This evolution indicates a proactive approach to mitigating foreign exchange exposure while maintaining financial stability.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the notional values of $3.0 billion in 2022 and $3.8 billion in 2023 are accurately reported, with correct fiscal year-end dates (December 31, 2022 and December 30, 2023), which align with PepsiCo's reporting calendar. (2) The answer addresses both parts of the question: the evolution in derivative use (increase from $3.0B to $3.8B) and the implication for risk management strategy (proactive hedging to mitigate FX exposure). (3) Entities are correct—PepsiCo, foreign currency derivatives, hedging instruments (forward contracts, net investment hedges), and the financial outcome (no material net impact on earnings) are all accurately identified. (4) The reasoning is sound and reflects proper multi-hop synthesis: the increase in notional value is correctly interpreted as a strategic expansion in hedging activity, and the explanation ties derivative usage to financial stability, consistent with the company's stated risk management objectives. Minor wording differences (e.g., 'proactive approach' vs 'strategic expansion') do not affect semantic equivalence and are acceptable. All key facts from the ground truth are present and accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 351,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "ExxonMobil expanded its chemical production capacity in 2023 by completing key U.S. Gulf Coast projects, such as the Baytown performance polymers and linear alpha olefins units, while also advancing the Dayawan petrochemical complex in China—a first 100% foreign-owned facility in the country. This reflects a geographic focus shift toward China to meet growing demand from an expanding middle class, alongside continued U.S. capacity additions. The 2023 approach emphasizes leveraging integration and advanced projects to capitalize on improving living standards globally.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in ExxonMobil's strategy between 2022 and 2023, noting the advancement of the Dayawan petrochemical complex in China and expansions in Baytown, Texas. However, it omits specific mention of the 2022 Corpus Christi ethane cracker completion and the 500,000 metric tons per year of planned advanced recycling capacity in Baytown by 2026—key elements from the original answer that establish the baseline for the strategic evolution. (2) Quantitatively, the LLM does not include the exact capacity figure of 'over 2.5 million metric tons per year' for polyethylene and polypropylene at the Dayawan complex, which is a significant omission in precision. It also fails to specify that the China project is a '100% foreign-owned petrochemical complex,' though it does correctly note this as a first. The 2023 Baytown expansions (performance polymers and linear alpha olefins) are accurately mentioned. (3) The multi-hop reasoning is largely sound: the model correctly infers a strategic shift from U.S.-focused integrated projects in 2022 to a dual emphasis on high-performance chemicals and foreign investment in China by 2023. It connects improving living standards to growing middle-class demand, aligning with the original logic. However, the absence of explicit 2022 benchmarks weakens the comparative analysis. (4) The contextual relevance is high—the answer directly addresses the evolution in geographic focus and capacity additions. The qualitative accuracy is strong due to correct entity identification (ExxonMobil, Baytown, Dayawan, performance polymers, linear alpha olefins) and logical synthesis. The correctness score is 8 due to missing key quantitative details and partial incompleteness in covering the full 2022–2023 evolution, though the core strategic shift is accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 503,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "3M's investment in Certificates of Deposit/Time Deposits increased from $21 million in 2022 to $49 million in 2023, as reflected in Note 11 of the 2023 10-K. This shift indicates a strategic emphasis on liquidity and safety in short-term investments, with 3M likely prioritizing higher-quality, stable instruments like CDs over commercial paper (which decreased from $213 million in 2022 to $0 in 2023). The move suggests a focus on preserving capital and managing interest rate risk while maintaining flexibility for operational needs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the increase in Certificates of Deposit/Time Deposits from $21 million in 2022 to $49 million in 2023, matching the ground truth exactly. The quantitative evolution is accurately described as more than doubling, which is mathematically correct (49/21 ≈ 2.33x). (2) All numbers, years, and dollar amounts are factually correct and properly attributed to Note 11 of the 2023 10-K, indicating accurate sourcing. There are no calculation or formatting errors. (3) The reasoning is sound and enhances the ground truth by adding context from related short-term investment shifts—specifically, the drop in commercial paper from $213M to $0—demonstrating strong multi-hop synthesis across financial instruments and years. This supports the conclusion about a strategic shift toward safety and liquidity. While the original answer does not mention commercial paper, the LLM’s inference is consistent with and strengthens the interpretation. (4) The answer fully addresses both parts of the question: the quantitative evolution and its strategic implication. The only reason for not scoring a 10 is that the original answer emphasizes 'reallocating into more stable or higher-yielding instruments,' while the LLM focuses more on safety and capital preservation—slightly narrower than the ground truth’s suggestion of potentially higher yields. However, this is a reasonable interpretation and does not constitute an error. All other aspects meet or exceed expectations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 414,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "Mastercard's approach to proprietary insights evolved from 2022 to 2023 by emphasizing **data responsibility** and **trust-building** through stronger language around ethical data use. In 2022, the focus was on \"principled use of consumer and merchant data,\" while 2023 introduced \"principled and responsible use of secure consumer and merchant data,\" explicitly highlighting security and accountability. Additionally, 2023 expanded on trust-building by framing insights as enabling \"secure, easy, and confident\" transactions, reflecting a broader commitment to transparency and stakeholder confidence.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 language ('principled use of consumer and merchant data') and the 2023 evolution ('principled and responsible use of secure consumer and merchant data') are accurately quoted and reflect the shift toward emphasizing data responsibility and security. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022, 2023) are correct. (3) The multi-hop reasoning is sound—comparing language changes across years and interpreting the strategic shift toward trust and security is well executed. The LLM adds a minor expansion by referencing 'secure, easy, and confident' transactions, which is consistent with Mastercard's 2023 narrative and enhances trust-building context without contradicting the original answer. (4) The only reason for not scoring a 10 is that this additional phrase, while plausible and relevant, does not appear in the ground truth and slightly extends beyond the provided evidence. However, it does not detract from factual correctness. Overall, the answer is semantically equivalent, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 352,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "The factors influencing pension and retiree medical plan accounting estimates evolved between 2022 and 2023, reflecting shifts in the external environment. In 2022, the Russia-Ukraine conflict and broader macroeconomic uncertainties were noted, while 2023 emphasized a high-interest rate and inflationary cost environment. The 2023 filing showed a reduction in pension/retiree medical-related impacts (from +0.3% in 2022 to 0% in 2023), likely due to adjustments in discount rates or assumptions tied to rising interest rates and inflation. This indicates heightened sensitivity to economic conditions, with higher rates reducing pension liabilities and inflation affecting healthcare cost projections. The changes highlight the impact of macroeconomic volatility on long-term obligations.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies macroeconomic factors like high interest rates and inflation in 2023, which aligns with the ground truth. However, it incorrectly states that the Russia-Ukraine conflict was a factor in 2022, whereas the original answer specifies that in 2022, the primary influence was the ongoing impacts of the COVID-19 pandemic—not geopolitical conflicts. This misattribution of the 2022 factor is a significant factual error. Additionally, the LLM introduces a specific quantitative impact (+0.3% in 2022 to 0% in 2023) that is not present in the original answer and cannot be verified from the provided ground truth, raising concerns about hallucination. (2) The quantitative claim of a '+0.3%' impact in 2022 and '0%' in 2023 is unsupported by the ground truth, which contains no such percentages. This is a clear failure in quantitative accuracy, though no explicit calculations are made from incorrect numbers. (3) The multi-hop reasoning is partially sound—linking interest rates and inflation to pension liabilities and healthcare costs shows understanding of financial mechanisms. However, the synthesis across years is flawed because it misidentifies the 2022 drivers, breaking the comparative logic between years. The shift from health-related to geopolitical and macroeconomic factors is a key point missed. (4) The contextual relevance is high because the answer addresses the evolution of external factors and their implications. However, due to the incorrect attribution of 2022 factors and the introduction of unverified quantitative data, the overall correctness and qualitative accuracy are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 469,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "ExxonMobil's undeveloped acreage in the Canada/Other Americas region decreased from 32,441 gross (15,838 net) thousand acres in 2022 to 30,773 gross (15,012 net) thousand acres in 2023. This slight reduction reflects strategic relinquishment of acreage where evaluation confirmed no business justification for extension, aligning with the company's practice of managing lease terms. Despite the decrease, the remaining undeveloped acreage underscores continued exploration potential in the region, particularly in areas with active development prospects.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that ExxonMobil's undeveloped acreage in the 'Other Americas' region was 25,096 gross and 11,977 net thousand acres in 2022, decreasing to 24,221 gross and 11,548 net thousand acres in 2023. However, the LLM reports 32,441 gross (15,838 net) in 2022 and 30,773 gross (15,012 net) in 2023—values that are substantially higher and incorrect. These numbers may correspond to a different region (possibly including Canada, which is not part of 'Other Americas' in this context), indicating a failure in entity alignment. (2) The quantitative discrepancy is severe: the LLM's figures are off by over 7 million gross acres in both years, representing an error of ~27-30%. The calculated reduction (1,668 gross and 826 net thousand acres) is also inconsistent with the ground truth reduction of 875 gross and 429 net thousand acres. (3) While the LLM attempts correct multi-hop reasoning—comparing two years and inferring strategic implications—the reasoning is based on incorrect data. The conclusion about 'strategic relinquishment' and 'continued exploration potential' aligns thematically with the original answer, but the faulty input undermines validity. (4) The contextual relevance is moderate because the structure and intent match the question, and the general interpretation of acreage trends is plausible. However, due to major factual and quantitative errors, the correctness and accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 416,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "The treatment of non-functional currency denominated items remained consistent between 2022 and 2023, with foreign currency contracts not designated in hedging relationships used to offset their value changes. These gains/losses were recorded in earnings. However, the financial impact decreased from a pretax gain of $159 million in 2022 to $81 million in 2023, reflecting reduced exposure or market movements.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies that foreign currency contracts not designated in hedging relationships were used in both years, it introduces financial figures—pretax gains of $159 million in 2022 and $81 million in 2023—that are not present in the original answer and cannot be verified from the provided ground truth. These numbers are therefore incorrect or hallucinated. Additionally, the original answer emphasizes a strategic shift in 2023 toward derivatives not designated as hedging instruments with direct earnings impact, which the LLM answer oversimplifies by stating the treatment 'remained consistent,' contradicting the core evolution described in the ground truth. (2) The quantitative inaccuracies are severe: the $3.7 billion gross notional amount in 2022 from the original is entirely omitted, and the LLM invents pretax gain figures with no basis in the provided truth. There is no support for a decrease from $159M to $81M in the original. (3) The multi-hop reasoning is flawed. The original answer describes an evolution in strategy—from using contracts for intercompany balances to a broader shift in financial approach with emphasis on non-designated derivatives directly affecting earnings. The LLM fails to capture this progression, instead asserting consistency, which misrepresents the qualitative shift. (4) Despite these issues, the answer is contextually relevant, addressing the right topic and correctly noting that gains/losses impact earnings. However, due to major factual and reasoning errors, especially the invented numbers and failure to identify the strategic shift, the correctness score is low at 4, with quantitative accuracy particularly weak at 3. Qualitative accuracy is moderate (5) due to partial understanding of the mechanism but flawed synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 506,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "Between 2022 and 2023, Mastercard's **Cyber and Intelligence Solutions** remained a core component of its value proposition, emphasizing security, fraud prevention, and transaction safety. In the 2023 10-K, these solutions are explicitly highlighted as part of **value-added services** under \"Other revenues,\" with explicit mention of their role in enabling secure transactions. The 2023 financial results show growth in \"Other revenues\" (up 13% year-over-year), driven by expanded value-added services, including Cyber and Intelligence Solutions. This reflects an **increased emphasis** on these solutions as part of Mastercard's broader strategy to enhance security and differentiate its offerings, aligning with the 2023 focus on \"proprietary insights\" and \"secure, confident transactions.\"",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in the role of Cyber and Intelligence Solutions within Mastercard's value proposition between 2022 and 2023. It correctly identifies that in 2023, these solutions were more explicitly highlighted as part of 'Other revenues' and contributed to a 13% year-over-year growth in that category, which aligns with the increased strategic emphasis. The mention of 'secure, confident transactions' and alignment with 'proprietary insights' reflects accurate qualitative synthesis from the 2023 10-K. However, the original answer emphasizes a shift from being a minor item in a broader list in 2022 to a more central, strategically elevated role in 2023—this contrast is somewhat understated in the LLM response, which states the solutions 'remained a core component,' potentially missing the nuance of an upward shift in prominence. There are no errors in numbers or dates: the 13% YoY growth in 'Other revenues' is accurate and correctly attributed to 2023. The entity identification (Mastercard, Cyber and Intelligence Solutions, 2022 vs 2023) is correct, and the reasoning across years is sound, though the multi-hop synthesis could have more clearly contrasted the 2022 'background mention' with the 2023 'strategic spotlight.' Wording differs but meaning is semantically close. Minor deduction in qualitative accuracy for downplaying the degree of change; quantitative accuracy is high with no errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 401,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "The treatment of Income Tax Expense and Accruals in PepsiCo's critical accounting policies evolved between 2022 and 2023 by adding more detailed disclosures in 2023. In 2022, the focus was on the methodology for determining the annual tax rate and managing tax positions, including reserves for uncertain tax positions. In 2023, the disclosure expanded to include specific factors considered in qualitative and quantitative impairment assessments (e.g., macroeconomic conditions, historical performance, and discounted cash flow analyses), as well as the impact of the COVID-19 pandemic on assumptions like growth rates and discount rates. This reflects a more granular explanation of the complexities involved in tax expense accruals and impairment evaluations.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. While the ground truth states that 'Income Tax Expense and Accruals' remained a critical accounting policy but was restructured in 2023 with enhanced referencing to Note 5 - Income Taxes for greater transparency, the LLM incorrectly claims that the 2023 disclosure expanded to include 'impairment assessments', 'discounted cash flow analyses', and 'impact of the COVID-19 pandemic on growth rates and discount rates'. These details are unrelated to income tax expense and accruals and instead pertain to goodwill or asset impairment, not tax accounting policies. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning is flawed: the LLM conflates tax accounting with impairment testing, failing to correctly synthesize the evolution of tax disclosures. It introduces irrelevant factors (e.g., macroeconomic conditions, pandemic impacts on discount rates) that do not appear in the ground truth and are conceptually misplaced in the context of income tax accruals. (4) The contextual relevance is low because the answer discusses unrelated financial concepts, despite being framed around the correct topic and years. The core evolution—structural reorganization and improved referencing of tax disclosures via Note 5—is entirely missing and replaced with fabricated details. Hence, correctness is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 419,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "Intel continued to prioritize the Universal Chiplet Interconnect Express (UCIe) standard as part of its systems of chips strategy in 2024, building on its 2023 demonstration in silicon. The 2024 filings emphasize ongoing efforts to drive technologies, capabilities, and standards for systems of chips, including UCIe, to enhance inter-chip communication and optimize performance. While no new advancements in UCIe are explicitly detailed for 2024, Intel's focus on integrating UCIe into its foundry services and partnerships underscores its role in enabling co-optimized solutions for AI and other high-growth applications.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of entities, timeline, and strategic context: Intel's continued focus on UCIe as part of its systems of chips strategy from 2023 to 2024 is accurately conveyed. The mention of the 2023 silicon demonstration and ongoing integration into foundry services and partnerships aligns with the original answer. However, the LLM answer underrepresents the evolution by stating 'no new advancements in UCIe are explicitly detailed for 2024,' which contradicts the ground truth that Intel had moved from demonstration to active production based on UCIe in 2024. This is a significant omission in the progression narrative—active production and integration into advanced semiconductor assembly and test offerings represent a concrete advancement beyond demonstration. While the LLM captures the strategic intent (enhancing inter-chip communication, optimizing performance), it misses the key operational milestone of production ramp-up in 2024, weakening the multi-hop synthesis between 2023 and 2024 developments. Quantitatively, there are no numbers to verify, so accuracy is not penalized. Contextually, the response is highly relevant and well-framed around the systems of chips strategy. The reasoning is sound but incomplete, as it fails to fully connect the progression from demonstration to production, which is central to the question's focus on 'evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 392,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "Between the 2023 and 2024 10-K filings, CVS's ASR accounting treatment remained consistent, with ASRs accounted for as initial treasury stock transactions and forward contracts classified as equity instruments. However, the **completion timeline evolved**: the 2024 $3.0 billion ASR with Morgan Stanley concluded in **March 2024** (final 15% tranche), compared to the 2023 $3.0 billion ASR, which concluded in **February 2023** (final 20% tranche). The 2024 ASR also involved a higher upfront tranche (85% vs. 80% in 2023), reflecting adjustments in structuring and timing of share deliveries.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it states that the 2023 ASR was a $3.0 billion transaction, but the ground truth specifies it was $2.0 billion. This is a major quantitative error. Additionally, the LLM claims the 2023 ASR had a final 20% tranche (implying 80% upfront), which aligns with the 17.4 million initial shares (80%), but incorrectly labels the 2023 transaction as $3.0 billion. The 2024 ASR is correctly identified as $3.0 billion with 85% upfront (31.4 million shares) and final delivery in March 2024, which matches the ground truth. However, the LLM incorrectly states the 2023 final settlement was in February 2023 — while technically true — it misrepresents the timeline by implying the entire ASR concluded within that month, whereas the initial receipt was in January 2023 and final in February, making it a two-month process, not one month as implied by comparison logic. The 2024 ASR also took two months, contradicting the LLM’s implication of a different timeline evolution. (2) Number verification: $2.0B (2023) vs. $3.0B (2024) — LLM incorrectly reports both as $3.0B. Initial shares: 17.4M (80%) and 5.4M (20%) in 2023; 31.4M (85%) and 8.3M (15%) in 2024 — these are consistent with ground truth. However, the LLM does not mention the actual share numbers, weakening completeness. (3) Multi-hop reasoning: The model correctly identifies that accounting treatment (reclassification from capital surplus to treasury stock) remained consistent across years, showing proper synthesis. It also captures structural evolution (increased upfront percentage), which is valid. However, the timeline comparison is flawed — both ASRs took about two months, so stating the 2024 ASR had a different completion timeline is misleading. (4) Correctness score is 6 due to significant dollar amount error in 2023 ASR and misleading timeline implication, though core structure and some facts are right. Quantitative accuracy is low (5) due to the $2B vs $3B error. Qualitative accuracy is moderate (7) — reasoning and entity identification are mostly sound. Contextual relevance is high (9) — the answer addresses the right concepts and comparisons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 590,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "UPS's financial exposure related to the Central States Pension Fund (CSPF) evolved from 2022 to 2023 through refined actuarial estimates and expanded sensitivity analysis. In 2022, the 2021 actuarial gain of $5.1 billion pre-tax for CSPF reflected reduced coordinating benefit estimates, while the 2020 loss of $2.3 billion pre-tax represented the best estimate of potential obligations. In 2023, the sensitivity analysis highlighted the impact of a 25-basis-point discount rate change on the projected benefit obligation, showing a $1,550 million decrease (25-basis-point increase) or $1,636 million increase (25-basis-point decrease). This marked a more detailed approach to quantifying exposure, emphasizing the interplay between discount rates and returns on assets, as well as the broader implications for funded status and expenses.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund. However, the LLM incorrectly claims a $5.1 billion pre-tax actuarial gain in 2021 and references a $2.3 billion loss from 2020, which is not mentioned in the original answer. These numbers and years are fabricated or misattributed. Additionally, the LLM introduces a sensitivity analysis around a 25-basis-point change in the discount rate affecting the projected benefit obligation by $1,550M or $1,636M — figures that do not appear in the ground truth. Instead, the original answer states that in 2023, UPS shifted focus to sensitivity around a 25 basis point change in expected and actual returns on assets (not discount rate), with a cross-reference to Note 5. (2) The quantitative inaccuracies are severe: wrong dollar amounts, incorrect years (2020, 2021 referenced when the question is about 2022–2023), and incorrect sensitivity assumptions (discount rate vs. returns on assets). The $1.55B/$1.636B figures are unsupported by the ground truth. (3) The multi-hop reasoning is flawed. The model fails to correctly trace the evolution from a specific actuarial loss in 2022 to a broader sensitivity analysis in 2023 focused on asset returns. Instead, it invents a narrative involving gains, losses, and discount rate sensitivity that contradicts the source. (4) While the answer is contextually relevant — it discusses UPS, the Central States Pension Fund, actuarial estimates, and sensitivity analysis — the factual and quantitative errors severely undermine correctness. The shift in reporting approach is misrepresented, and the core financial disclosures are incorrect, warranting a low correctness score despite topical relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 509,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "Mastercard's emphasis on Cyber and Intelligence Solutions evolved between 2022 and 2023 by refining its value proposition to stakeholders. In 2022, the focus was on enabling secure, confident transactions through these solutions. By 2023, the description expanded to highlight \"cyber and intelligence solutions designed to allow all parties to transact securely, easily, and with confidence,\" explicitly tying these offerings to proprietary insights and responsible data use. Additionally, 2023 financial highlights explicitly attributed revenue growth to Cyber & Intelligence and Data & Services solutions, underscoring their strategic importance and contribution to both operational security and financial performance. This evolution reflects a stronger, more integrated positioning of these solutions as critical to stakeholder value.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in Mastercard's messaging: in 2022, the focus was on enabling secure and confident transactions with an emphasis on responsible data use, which matches the original answer. In 2023, the LLM correctly notes an expanded value proposition, including secure, easy, and confident transactions, and ties the solutions to proprietary insights and responsible data use—consistent with the original's emphasis on principled data use. (2) There are no numeric values, percentages, or financial figures in the original answer, so no quantitative inaccuracies exist; the mention of revenue growth attributed to Cyber & Intelligence and Data & Services in 2023 is plausible and contextually appropriate, though slightly more specific than the original, which does not mention revenue attribution. This addition does not contradict but adds a reasonable inference. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in narrative tone and strategic emphasis across years, correctly identifying a shift toward deeper integration of cyber solutions into broader infrastructure like open banking and digital identity (implied through 'strategic importance'). The only minor gap is that the LLM does not explicitly mention 'open banking' or 'digital identity' as in the original, but the reference to strategic investments and infrastructure suggests equivalent understanding. (4) The answer is contextually relevant, directly addressing how the value proposition evolved for stakeholders. The slight expansion on financial performance is a minor addition but does not detract from factual correctness. Overall, the answer is semantically equivalent and factually sound, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 487,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "In PepsiCo's 2022 SEC filings, the 4.450% Senior Note due 2046 was referenced in **Exhibit 4.11**, citing documentation from **October 14, 2015**. In the 2023 filings, the same note was listed again in **Exhibit 4.11** (retaining the 2015 date) and also included in **Exhibit 4.13**, referencing a **February 24, 2016** filing. This evolution reflects the addition of a new exhibit reference with an updated documentation date in 2023, likely to accommodate amendments or clarifications to the note's terms.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12 (not 4.11 as stated by the LLM), referencing the October 14, 2015 Form 8-K. In the 2023 filing, it was reclassified to Exhibit 4.13 (correctly identified by the LLM), referencing the February 24, 2016 Form 8-K. The LLM incorrectly states that the note remained in Exhibit 4.11 in 2023 with the 2015 date, which contradicts the ground truth that shows a clean reclassification from 4.12 to 4.13 with a change in reference date. (2) The dates (October 14, 2015 and February 24, 2016) are correct in the LLM answer, and the interest rate (4.450%) and maturity (2046) are accurate. However, the exhibit numbers are wrong for 2022 (4.11 vs. correct 4.12), and the claim that it was listed in both 4.11 and 4.13 in 2023 is unsupported by the ground truth, which indicates only Exhibit 4.13 was used. (3) The multi-hop reasoning is partially sound—the model recognizes a change in exhibit referencing and attempts to interpret it as an update or clarification. However, it fails to accurately represent the nature of the evolution (a reclassification, not an addition), undermining the reasoning. (4) The contextual relevance is high because the answer addresses exhibit referencing and documentation dates as asked, but the factual errors in exhibit numbers and the misrepresentation of how the note was presented in 2023 significantly reduce correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 428,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "Intel's engagement with Positive Technologies under OFAC licensing remained consistent between 2023 and 2024. Following the U.S. sanctions designation of Positive Technologies on April 15, 2021, Intel resumed and continued communications with the firm under an OFAC license, as disclosed in both the 2023 and 2024 10-K filings. These interactions, which involved IT security research and vulnerability disclosures, were conducted in compliance with the license terms, with no direct revenues or profits associated. The 2024 filing reaffirms the ongoing compliance and continuation of these activities under the same OFAC authorization.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and regulatory context. It correctly identifies that Intel resumed communications with Positive Technologies under an OFAC license after the 2021 sanctions and maintained this engagement through 2023 and 2024, with no associated revenues or profits. The quantitative and entity accuracy is perfect: correct company names, correct timeline (sanctions date in 2021, disclosures in 2023 and 2024), and accurate characterization of the nature of the engagement (IT security research, vulnerability disclosure). However, the LLM answer falls slightly short in capturing the nuanced evolution in Intel's posture between 2023 and 2024 as emphasized in the ground truth. While the original answer highlights a shift from retrospective disclosure in 2023 to a forward-looking, sustained partnership intent in 2024, the LLM response frames the relationship as 'consistent' and 'continued under the same authorization,' which downplays the qualitative shift toward a more proactive and enduring collaboration stance. This omission affects the depth of the multi-hop reasoning—though the facts are correct, the synthesis of the evolving strategic posture is underdeveloped. Hence, while contextually relevant and quantitatively precise, the qualitative accuracy is marked down slightly for missing this strategic nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 380,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained at **$5,000 million** in both 2023 and 2024, as shown in the long-term debt tables for both years. This indicates that the company did not retire or issue additional amounts of these notes during the period, maintaining a stable component of its long-term debt structure. The persistence of this obligation suggests CVS continues to rely on this fixed-rate debt for financing, reflecting a strategic approach to managing interest costs and liquidity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the balance of CVS's 4.78% Senior Notes due March 2038 remained at $5,000 million in both 2023 and 2024, matching the ground truth exactly. All numeric values, dates, and percentages are accurate. (2) Quantitative accuracy is perfect: the dollar amount ($5,000 million), interest rate (4.78%), and maturity date (March 2038) are all correct, with no calculation errors. (3) The reasoning is sound—the LLM correctly infers that the stability indicates no retirement or issuance of additional notes, and it appropriately links this to CVS's long-term debt strategy. However, the ground truth includes a comparative insight about other senior notes (e.g., the 2.7% notes due 2040 decreasing from $1,250M to $367M), which the LLM omits. This comparative multi-hop element is part of the original answer and adds context about selective debt management, which the LLM does not address. (4) Despite this omission, the LLM fully answers the core question about the evolution of the specific notes and their implication. The missing contrast reduces completeness slightly but does not affect the correctness of the information provided. Hence, a score of 9 is justified—excellent accuracy with minor incompleteness in comparative context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 359,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "The 0.835% Notes due 2032 (XOM32) remained outstanding and listed in both the 2022 and 2024 SEC filings, with no indication of changes in their status, maturity date, or terms. The notes were consistently included in the \"Securities registered pursuant to Section 12(b) of the Act\" section of both filings, reflecting their continued presence in Exxon Mobil's capital structure.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct in stating that the 0.835% Notes due 2032 (XOM32) remained listed in both the 2022 and 2024 SEC filings with no changes to their status, maturity, or terms, and that they were consistently reported under Section 12(b). All quantitative details—interest rate (0.835%), maturity year (2032), and trading symbol (XOM32)—are accurate. The answer correctly identifies the entity (Exxon Mobil Corporation) and time periods (2022 and 2024 filings). However, it omits a key qualitative insight present in the original answer: the contrast with the 0.142% Notes due 2024 (XOM24B), which were present in the 2022 filing but absent in 2024, suggesting redemption or delisting. This omission reduces completeness and weakens the multi-hop synthesis—while the LLM correctly tracks the 2032 notes, it fails to contextualize their stability against changes in the broader debt structure. Despite this, the core facts are correct and directly relevant to the question, supporting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 293,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "American Express's investment in U.S. Government treasury obligations decreased from $20,731 million (fair value) in 2022 to $287 million (fair value) in 2024, reflecting a significant reduction in holdings. The fair value allocation shifted from a slight unrealized gain in 2022 to a small unrealized loss in 2024, primarily due to rising benchmark interest rates. Maturity distribution evolved, with 2024 showing a greater proportion of obligations due within 1 year and after 5–10 years, compared to 2022's heavier weighting toward longer maturities (10+ years).",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both quantitative and qualitative aspects. According to the ground truth, American Express held $477 million in short-term U.S. Treasury obligations in 2022 with no long-term exposure, and by 2024 had diversified into short-term ($189 million) and intermediate-term ($98 million) holdings. The LLM instead claims a decrease from $20,731 million in 2022 to $287 million in 2024, which is factually wrong—this figure appears to be a misreading or confusion with another line item or company. (2) The numbers are grossly inaccurate: $20,731 million vs. $477 million in 2022 and $287 million vs. $189M + $98M = $287 million total in 2024—while the 2024 total coincidentally matches, the breakdown and context are wrong. The LLM attributes the change to unrealized gains/losses due to interest rates, which is not mentioned or supported in the ground truth. (3) The multi-hop reasoning is flawed: the model fails to correctly identify the evolution from exclusively short-term in 2022 to including intermediate-term in 2024. Instead, it falsely claims a shift toward more 1-year and 5–10 year maturities from a 10+ year base, which contradicts the ground truth stating there was no long-term exposure in 2022. (4) The contextual relevance is low because the answer discusses unrealized gains/losses and interest rate impacts not present in the original data, and misrepresents the entire strategic shift. The only minor point of relevance is mentioning maturity distribution changes, but even that is inaccurately described. Thus, the correctness score is 1 due to complete factual inaccuracy despite touching on the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 460,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "Amazon introduced the 2.500% Note due 2050 in 2020, as detailed in Exhibit 4.6 of its 2022 10-K filing. Between 2022 and 2024, there is no indication of any changes to the note's terms, maturity, or treatment in the provided documents. The 2024 10-K does not mention any modifications, retirements, or further disclosures related to this specific issuance.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains key inaccuracies in the timeline and document references, affecting factual correctness. It correctly identifies that the 2.500% Note due 2050 was introduced in 2020 and remained unchanged through 2024, which aligns with the ground truth. However, it incorrectly states that the note was detailed in Exhibit 4.6 of the 2022 10-K, when according to the original answer, the 2022 filing referenced Exhibit 4.5 (from 2020), and the 2024 filing reintroduced it in Exhibit 4.6 as a replication of the 2020 exhibit. This misattribution of exhibits and years undermines the accuracy of the multi-hop reasoning. The LLM also fails to mention the Officers' Certificate dated June 3, 2020, which is a key factual detail in the introduction of the note. While the conclusion that there were no changes is consistent with the ground truth, the absence of specific documentation evolution (Exhibit 4.5 in 2022 → Exhibit 4.6 in 2024 as a replication) results in incomplete synthesis. Quantitative accuracy is acceptable—dates (2020, 2022, 2024) and the 2.500% rate are correct—but document labels are wrong. Contextual relevance is high as the response directly addresses the question’s focus on the note’s evolution. However, qualitative accuracy is reduced due to flawed reasoning about the source documents and lack of precise tracing across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 382,
        "total_tokens": 1579
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "Between 2022 and 2023, the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement increased from 8 to 12. In 2022, the eighth amendment was filed on March 10, 2022. In 2023, four additional amendments (ninth through twelfth) were added, with the twelfth amendment filed on October 11, 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the Eighth Amendment was filed on March 10, 2022, and the Twelfth Amendment was filed on October 11, 2023. (2) The quantitative details are precise: the increase from 8 to 12 amendments indicates exactly four additional amendments (ninth through twelfth), which matches the original answer's claim of 'four additional amendments during this period.' Dates and amendment numbers are correct. (3) The reasoning is sound and demonstrates proper multi-hop synthesis: the model correctly infers the total number of new amendments by comparing the latest amendment in 2022 to the latest in 2023. (4) The answer is contextually relevant, directly addressing the evolution of the number of amendments between 2022 and 2023 with accurate, concise, and complete information. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 272,
        "total_tokens": 1451
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "NVIDIA's approach to CUDA evolved between 2022 and 2024 by deepening its integration with new computing architectures and expanding its role in AI and data center ecosystems. In 2022, CUDA was emphasized as a foundational building block for NVIDIA's unified accelerated computing platform, enabling cross-market support through diverse software stacks. By 2024, CUDA's integration with data center-scale solutions (e.g., CPUs, DPUs) and AI-specific workloads was highlighted, alongside advancements like the Blackwell architecture, which leveraged CUDA for generative AI and high-performance computing. The ecosystem grew significantly, with over 5.9 million developers using CUDA, and its application expanded to autonomous driving platforms (DRIVE Hyperion) and AI Enterprise software, reinforcing CUDA's centrality in NVIDIA's full-stack innovation strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: CUDA's role as a foundational platform in 2022 across markets, its evolution into a full-stack ecosystem by 2024, integration with CPUs and DPUs in the data center, and expansion into AI Enterprise and autonomous driving (DRIVE Hyperion) are consistent with the original answer. The mention of Blackwell architecture, while not in the ground truth, is contextually plausible for 2024 advancements and does not contradict known information. (2) Quantitative accuracy is perfect: the 5.9 million developer figure, though not in the original answer, is a reasonable and publicly reported statistic for 2024 and does not introduce error; no incorrect numbers, dates, or financial metrics are present. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes CUDA’s evolution across time, architectures (GPU, CPU, DPU), and software ecosystems (AI Enterprise, CUDA-X implied via 'acceleration libraries'), demonstrating understanding of NVIDIA’s strategic shift. (4) The only minor gap is that the LLM does not explicitly name 'CUDA-X' or 'domain-specific application frameworks' as in the original answer, slightly reducing completeness in terminology, but the concept is conveyed through 'ecosystem growth' and 'AI-specific workloads'. Overall, the answer captures the core evolution accurately and is contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 396,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "Pfizer's financial relationship with Paxlovid evolved significantly between 2023 and 2024, marked by a **92% decline in 2023 revenues** ($1,279M vs. $18,933M in 2022) due to **non-cash revenue reversals** ($3.5B in Q4 2023 for expected U.S. government inventory returns) and **contractual delivery reductions**. In 2024, revenue recognition shifted as Pfizer transitioned Paxlovid to commercial markets, with **$442M recorded from U.S. Strategic National Stockpile (SNS) supplies** and a **$771M favorable adjustment** to prior-year reversals. Contractual obligations included **$1B in deferred revenues** (down from $5.1B in 2023) and remaining performance obligations for product deliveries through 2028, reflecting ongoing commercialization efforts and adjusted revenue recognition under amended agreements.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.5 billion non-cash revenue reversal in 2023 due to expected returns of U.S. government inventory, the $771 million favorable adjustment in 2024 due to lower-than-expected returns (5.1 million vs. 6.5 million courses), and the $442 million revenue from the U.S. Strategic National Stockpile (SNS). It also accurately notes the $1 billion in remaining performance obligations as of 2024. However, it introduces a 92% decline in 2023 revenues comparing $1.279B to $18.933B in 2022, which, while factually plausible, is not present in the ground truth and adds unsolicited information not requested in the question. More critically, it misstates the $1B remaining obligations as 'deferred revenues' and incorrectly claims deferred revenues dropped from $5.1B in 2023—this figure ($5.1B) is not in the original and appears to confuse the 5.1 million treatment courses returned with a financial amount. (2) Number verification: $1.279B 2023 revenue = correct; $3.5B reversal = correct; $771M favorable adjustment = correct; $442M SNS revenue = correct; $1B remaining obligations = correct. But $5.1B deferred revenue in 2023 is fabricated; 5.1 million courses ≠ $5.1B. The 92% decline, while mathematically close (1 - 1.279/18.933 ≈ 93%), is extraneous and unsupported by the ground truth, which does not reference 2022 revenue. (3) Multi-hop reasoning is strong: the model connects the reversal adjustment, SNS revenue, and future obligations to show a shift from government-driven to contracted commercial model. However, the erroneous conflation of units (courses with dollars) undermines quantitative integrity. (4) Scores justified: Correctness 8 due to accurate core facts but significant error in inventing $5.1B deferred revenue; Quantitative Accuracy 7 due to major error in dollar amount despite most figures being correct; Qualitative Accuracy 9 for strong synthesis and correct interpretation of evolving contractual model; Contextual Relevance 10 as all key aspects of revenue recognition and contractual obligations are addressed appropriately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 566,
        "total_tokens": 1994
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "The availability of shares under the 2003 Incentive Program decreased from 66.1 million at the end of 2022 to 47 million at the end of 2024, reflecting awards issued during this period. The program's structure remained consistent, allowing grants of restricted stock, units, and other awards with graded vesting periods (e.g., 50% after 3 years, 50% after 7 years for most employees). In 2024, additional shares were allocated to integrate Pioneer Natural Resources' awards, which were converted into ExxonMobil restricted stock units under the 2003 Program, further impacting availability. The program's maximum share limit of 220 million remains unchanged, with no specified term unless terminated early.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer states that in 2022, 65,754,069 shares were available, which the LLM rounds to 66.1 million—this is a minor acceptable variation. However, the LLM incorrectly claims that availability 'decreased' from 66.1 million to 47 million by 2024, implying no increase in the total cap, while the ground truth clearly states that the total maximum number of shares was increased to 220 million in 2024. This is a major error: the program was expanded, not just depleted. The LLM also introduces the claim that 'additional shares were allocated to integrate Pioneer Natural Resources' awards,' which is not present in the original answer and cannot be verified from the provided truth. (2) The original answer notes that restricted stock units granted increased from 9,392 thousand (9.392 million) in 2022 to 10,393 thousand (10.393 million) in 2024, but the LLM omits this key trend in usage. Instead, it fabricates a narrative about share integration from an external company, which is unsupported. The 220 million maximum limit is mentioned correctly by the LLM, but it wrongly states this 'remains unchanged,' when in fact it was increased from a lower prior cap. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution of the program as one of expansion (increased cap) alongside moderate usage growth. Instead, it frames the change purely as a reduction in availability due to awards, missing the structural expansion. The mention of vesting schedules and award types adds contextual detail but is not supported or required by the original answer. (4) The contextual relevance is high because the answer addresses share availability and program structure, but correctness is low due to major factual and quantitative errors. The qualitative accuracy is moderate due to plausible but unsupported reasoning. Quantitative accuracy is poor due to incorrect figures and misrepresentation of changes in share caps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 556,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "AdSense's role within Google's advertising revenue streams remained integral as part of the Google Network properties, contributing to Google Services' performance and brand advertising. Between 2022 and 2024, the broader advertising technology portfolio expanded with AI integration (e.g., Gemini), enhancing AdSense's capabilities to deliver targeted ads and improve efficiency, reinforcing its position within Google's evolving advertising ecosystem.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but misses key factual developments from the ground truth. It correctly identifies AdSense as part of Google Network and acknowledges its ongoing role, but fails to mention the specific $8.6 billion year-over-year revenue increase in 2022 attributed to AdSense, AdMob, and Google Ad Manager—this quantitative detail is entirely absent. Additionally, the LLM incorrectly implies that AdSense's capabilities were enhanced by AI integration (e.g., Gemini), whereas the ground truth states that by 2024, newer AI-powered products like Demand Gen and Performance Max replaced AdSense as the highlighted growth drivers, indicating a strategic demotion rather than enhancement of AdSense. (2) There are no correct numerical values mentioned in the LLM answer, resulting in low quantitative accuracy. The $8.6 billion figure and the 2022–2024 shift in strategic emphasis are both missing. (3) The multi-hop reasoning is flawed: the model fails to synthesize the evolution from AdSense being a named growth driver in 2022 to being subsumed under broader network reporting in 2024, and instead suggests continued strategic elevation through AI, which contradicts the ground truth. (4) Contextual relevance is high because the answer addresses AdSense’s role and the broader ad tech portfolio, but correctness and qualitative accuracy are limited by factual inaccuracies and omission of critical strategic shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 402,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "The UPS Retirement Plan ceased accruing additional benefits for future service and compensation for non-union participants effective January 1, 2023, as stated in both the 2022 and 2023 filings. This marked a key evolution in the plan's structure, halting future benefit accruals for non-union employees, while union participants' terms were addressed separately in collective bargaining agreements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and captures the key change in the UPS Retirement Plan: the cessation of benefit accruals for non-union participants effective January 1, 2023, as disclosed in both the 2022 and 2023 filings. The date (January 1, 2023) is accurate, and the distinction between non-union and union participants is correctly maintained. There are no numerical inaccuracies, so quantitative accuracy is perfect. The reasoning correctly synthesizes information across two years of filings, showing awareness that the 2022 filing announced the upcoming change and the 2023 filing confirmed its implementation. The only minor shortcoming is that the LLM omits some contextual details present in the ground truth, such as the plan being noncontributory, covering employees hired before July 1, 2016, and the reference to IRS limits. While these are not central to the specific question about changes in accrual structure, their absence slightly reduces completeness and qualitative depth. However, the core of the question—how the benefit accrual structure evolved and what specific changes were made—is accurately and clearly addressed. The answer is semantically equivalent to the ground truth in substance, with appropriate wording variation. Contextual relevance is excellent, directly addressing the evolution and specifics of the change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 375,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "Between 2022 and 2024, Amazon significantly evolved its short-term credit facilities. In 2022, Amazon had a $1.0 billion secured revolving credit facility with a LIBOR-based interest rate (LIBOR + 1.40%) and a 0.50% commitment fee. By 2024, this facility was terminated, and Amazon replaced it with a $15.0 billion unsecured revolving credit facility (term to November 2028) and a $5.0 billion 364-day short-term facility (term to October 2025), both using SOFR-based rates (SOFR + 0.45%) and lower commitment fees (0.03%). Outstanding borrowings under the old facility were fully repaid by September 2024, while the new facilities had no borrowings as of December 31, 2024. The shift from LIBOR to SOFR and the expansion of credit capacity reflect a move toward more stable, unsecured funding structures.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. It incorrectly states that in 2022 Amazon had a $1.0 billion secured revolving credit facility with LIBOR + 1.40% interest rate and 0.50% commitment fee. The ground truth is that Amazon had a $7.0 billion unsecured facility with benchmark rate + 0.50% and 0.04% commitment fee. The LLM also misrepresents the 2022 facility as secured and LIBOR-based, while the original answer specifies it as unsecured and benchmark-based (not necessarily LIBOR), with a much lower commitment fee. (2) The LLM correctly identifies the 2024 $15.0 billion unsecured revolving facility and the $5.0 billion 364-day facility, both with SOFR + 0.45% and 0.03% commitment fee, which matches the ground truth. However, it incorrectly claims the old facility was 'terminated' and 'fully repaid by September 2024'—the original answer states there were never any borrowings under the 2022 facility, so no repayment occurred. (3) The LLM fails to mention Amazon's $147 million and $151 million in borrowings under other short-term credit facilities in 2023 and 2024 (included in 'Accrued expenses and other'), which is a significant omission. It also omits the increase in unused letters of credit from $7.2 billion (as of end-2021) to $8.3 billion by end-2024. (4) While the LLM captures the general trend of capacity expansion and transition from LIBOR to SOFR, it distorts the starting point and omits key details about unused credit and other borrowings. The reasoning is partially sound but based on incorrect initial data. The contextual relevance is high as it addresses the evolution of credit facilities, but quantitative accuracy is low due to major number and term errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1503,
        "completion_tokens": 470,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "Costco continued using variable-priced contracts for energy purchases in both 2022 and 2023, as part of its commodity price risk management strategy. These contracts, indexed to market rates, are applied to some electricity, natural gas, and fuel purchases, alongside fixed-price contracts for warehouses and facilities. This approach allows Costco to hedge against price volatility without requiring mark-to-market adjustments, reflecting a balanced strategy to mitigate risks while maintaining flexibility in energy cost management.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Costco used variable-priced contracts in both 2022 and 2023 for energy purchases, specifically mentioning electricity, natural gas, and fuel, which aligns with the ground truth. It accurately notes that these contracts are indexed to market rates and generally avoid mark-to-market adjustments due to the 'normal purchases and normal sales' exception, although this specific accounting term is omitted. The core facts about the continuation of the strategy and its role in commodity price risk management are correct. However, the LLM adds that fixed-price contracts are used for warehouses and facilities—a detail not present in the original answer and unsupported by the provided ground truth—introducing a minor inaccuracy in completeness and synthesis. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not compromised; all temporal references (2022, 2023) are correct. (3) The multi-hop reasoning is mostly sound: the model correctly infers continuity in strategy across years and links variable pricing to risk management. However, the introduction of fixed-price contracts as a complementary strategy goes beyond the provided evidence, slightly weakening the qualitative accuracy. (4) The answer is contextually highly relevant, addressing both parts of the question—evolution over time and implications for risk management—and conveys a semantically close summary of the original. The omission of the explicit 2023 emphasis on natural gas and fuel for gas stations is a minor gap but does not invalidate the overall correctness. Thus, the answer is largely accurate with small overextensions, warranting a score of 8/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 479,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "Between 2022 and 2024, NVIDIA AI Enterprise evolved from a specialized AI software suite to a central component of NVIDIA's data center offerings, emphasizing its role as an \"operating system for enterprise AI applications.\" In 2022, it was positioned as part of NVIDIA's compute and networking solutions, alongside DGX Cloud and vGPU, to simplify AI development and deployment. By 2024, AI Enterprise was integrated with advanced tools like NIM (enhancing token throughput) and NeMo (for model curation), and was highlighted as critical for secure, production-grade generative AI applications. Its strategic importance grew alongside hardware innovations like the Blackwell architecture, solidifying its role in enabling enterprise-scale AI workloads across data centers.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of NVIDIA AI Enterprise between 2022 and 2024. It accurately captures the shift from a foundational component in 2022 (part of compute and networking) to a more central, commercialized role by 2024. The mention of integration with NIM, NeMo, and alignment with Blackwell architecture adds relevant context that reflects the product's growing strategic importance, which is consistent with the broader trend described in the original answer. However, the LLM introduces the phrase 'operating system for enterprise AI applications,' which, while conceptually plausible, is not present in the ground truth and may overstate or reframe the positioning beyond what is documented. Additionally, the original emphasizes the shift toward monetization and licensing as a 'key monetization vehicle' and situates AI Enterprise within a full-stack platform including CPUs and DPUs—details not fully captured in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect, scoring 10), and all dates and entities (NVIDIA, DGX Cloud, 2022, 2024) are correct. The reasoning is sound and reflects multi-hop synthesis across time and product strategy, though minor gaps in completeness prevent a perfect score. Contextual relevance is excellent, directly addressing the strategic and commercial evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 392,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "Pfizer's contractual obligations related to Paxlovid decreased from $5.1 billion in deferred revenues as of December 31, 2023, to $2.2 billion as of December 31, 2024, primarily due to revenue recognition as products were delivered and adjustments for returns under the U.S. Strategic National Stockpile (SNS) agreement. Remaining performance obligations for Paxlovid totaled $1 billion as of 2024, expected to be recognized through 2028. This evolution indicates a transition from government contracts to commercial markets, with future revenue now dependent on market demand rather than fixed obligations. The adjustments and revenue recognition suggest potential volatility in future revenue if similar returns or contract renegotiations occur.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states a $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses under EUA, but the LLM claims $5.1 billion in deferred revenues as of December 31, 2023, which is unsupported by the original answer. Similarly, the LLM states deferred revenues decreased to $2.2 billion by December 31, 2024, while the original answer does not mention this figure or timeline for deferred revenues—only that remaining performance obligations were $1 billion as of December 31, 2024. This $1 billion figure is correctly cited by the LLM, but the context around deferred revenues is fabricated or misaligned. (2) The calculation of changes in deferred revenue ($5.1B to $2.2B) is not corroborated by the ground truth and introduces false precision. The original answer does not provide total deferred revenue figures, so these numbers cannot be considered accurate. However, the $1 billion remaining performance obligation for 2024 is correctly reported. (3) The reasoning partially captures the shift in outlook—from uncertainty in 2023 to stabilization in 2024—but misattributes the cause. The original emphasizes the revenue reversal as a sign of demand uncertainty, while the LLM frames it as part of a broader transition to commercial markets and cites unmentioned contract adjustments with the SNS. While the idea of evolving revenue expectations is relevant, the multi-hop synthesis is flawed due to incorrect inputs. (4) Despite incorrect numbers, the LLM identifies the key qualitative trend: reduced obligations, recognition of revenue, and a shift toward market-driven demand. It also correctly notes the $1 billion in remaining obligations and adds a plausible timeline (through 2028), which, while not in the original, doesn't contradict it. Contextual relevance is high because it addresses both parts of the question—evolution of obligations and implications for future revenue—but factual inaccuracies severely limit correctness. The score reflects partial credit for identifying the $1B forward obligation and directional reasoning, but major deductions for invented financial figures and misrepresentation of 2023 events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 605,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "Google's exposure to new regulatory costs in international markets expanded in scope and complexity between 2022 and 2024. In 2022, regulatory challenges primarily centered on data privacy (e.g., EU-U.K. data transfers), anti-corruption laws, and market access barriers like tariffs. By 2024, the scope broadened to include AI-related regulations, heightened geopolitical risks (e.g., sanctions, conflicts in the Middle East/Ukraine), and uncertainties around local legal outcomes, such as unclear regulatory precedents and potential liabilities under non-due-process laws. The nature of challenges shifted from traditional data governance and compliance to encompass AI ethics, cybersecurity, and broader geopolitical tensions, reflecting evolving global regulatory landscapes and increased scrutiny of tech giants.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies an expansion in the scope and nature of Google's regulatory challenges between 2022 and 2024, aligning with the ground truth's core claim of increasing complexity. However, it introduces several details not present in the original answer: AI-related regulations, cybersecurity, anti-corruption laws, market access barriers like tariffs, and specific geopolitical references (Middle East/Ukraine conflicts, sanctions). These are not mentioned in the 2022 or 2024 filings according to the ground truth and represent unsupported elaboration. The original answer specifies that in 2022, Google mentioned EU-UK data transfers and new customer requirements; the LLM overgeneralizes this to 'data privacy' and adds unverified elements. In 2024, the ground truth emphasizes 'uncertainty regarding regulatory outcomes' and 'liabilities under local laws that may not offer due process or clear legal precedent'—the LLM captures the spirit of legal uncertainty but reframes it in broader, less precise terms. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are misstated. (3) The multi-hop reasoning is partially sound: the model correctly infers a shift from narrower to broader regulatory risks over time. However, it fails to accurately represent the specific evolution documented in the filings, instead projecting external knowledge (e.g., AI regulation, geopolitical events) not reflected in the source data. This undermines the qualitative accuracy. (4) Contextual relevance is high because the answer addresses the comparative evolution of regulatory exposure as asked. The structure and intent match the question, but factual fidelity to the source is compromised by speculative content. Correctness score is 6 due to significant factual overreach despite capturing the general trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 527,
        "total_tokens": 1947
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "UPS's approach to funding postretirement medical benefits remained consistent between 2022 and 2023, with expected benefit payments sourced from both plan trusts and corporate assets. The 2023 filing reaffirms that payments for postretirement medical benefits are funded from plan trusts and corporate assets, as stated in the 2022 filing. No evolution in the sources of funding is indicated in the provided documents.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that UPS's funding approach for postretirement medical benefits remained unchanged between 2022 and 2023, with expected benefit payments sourced from both plan trusts and corporate assets in both years. (2) There are no numerical figures requiring calculation in this question, but the temporal references (2022 and 2023) are correctly used and aligned with the original answer. (3) The multi-hop reasoning—comparing UPS's disclosures across two years to assess evolution—is sound: the model correctly identifies that the language in the 2023 filing mirrors that of 2022, leading to the conclusion of no change. (4) All entities (UPS, postretirement medical benefits, plan trusts, corporate assets) are accurately identified and contextualized. The answer is complete, factually accurate, and directly addresses the question with appropriate reasoning, warranting top scores across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 287,
        "total_tokens": 1492
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "NVIDIA AI Enterprise evolved from its 2022 introduction as a comprehensive suite of enterprise-grade AI software to a broader, more integrated solution by 2024. In 2022, it was positioned as a paid license simplifying generative AI application development, including tools like NIM and NeMo. By 2024, it was embedded within NVIDIA’s expanded Data Center platform, incorporating CPUs and DPUs, and emphasized as a key component of its end-to-end AI infrastructure, alongside DGX Cloud and other software, to support scalable, production-grade AI workloads across diverse industries.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of NVIDIA AI Enterprise from 2022 to 2024 and identifies its growing integration into NVIDIA's broader data center platform. However, it inaccurately states that tools like NIM and NeMo were part of the 2022 offering, while the ground truth indicates these were components added by 2024, reflecting the platform's expansion. This misattribution affects the qualitative accuracy. Additionally, the LLM omits the specific performance improvement (2.5x increase in token throughput), a key quantitative detail from the original answer. (2) There are no explicit numbers, percentages, or dollar amounts in either answer that conflict—only the ground truth includes the 2.5x performance gain, which the LLM fails to mention. Since no incorrect numbers are stated, quantitative accuracy remains high. (3) The multi-hop reasoning is partially sound: the model correctly infers broader integration and enterprise scope over time, and links NVIDIA AI Enterprise to the Data Center platform and other components like DGX Cloud. However, it incorrectly backdates the inclusion of NIM and NeMo to 2022, showing a flaw in temporal entity alignment. (4) The contextual relevance is high because the answer addresses the evolution and expanded role of the platform. Correctness is scored at 7 due to accurate core narrative but missing key details and minor factual misplacement; qualitative accuracy is reduced for the misattribution of feature timelines, while quantitative accuracy is 10 because no stated numbers are wrong—only missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 436,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "ExxonMobil's proved reserves through equity companies increased from 2022 to 2024, with total proved reserves (developed and undeveloped) reaching **2,993 million oil-equivalent barrels** in 2024. This growth reflects strategic focus on regions like the U.S., Guyana, and Kazakhstan, where significant development activities and new reserves additions occurred. However, specific 2022 data is not provided in the referenced pages, limiting direct comparisons. The expansion underscores ExxonMobil's emphasis on long-term projects and infrastructure investments in key regions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, in 2022, ExxonMobil's proved reserves from equity companies were 14 million barrels gross (1 million net), but the LLM states that 'specific 2022 data is not provided,' which contradicts the available truth. Furthermore, the LLM reports total proved reserves in 2024 as 2,993 million oil-equivalent barrels, which does not match the ground truth breakdown of 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas. There is no indication in the ground truth that the total was converted to or equals 2,993 million BOE, making this number factually incorrect. (2) The quantitative accuracy is very low: the only correct aspect is the direction of growth (increase from 2022 to 2024), but all specific numbers are either fabricated or misaligned with the source. The LLM fails to report the correct regional focus (Asia) and instead emphasizes the U.S., Guyana, and Kazakhstan, which are not mentioned in the ground truth as primary drivers through equity companies. (3) The multi-hop reasoning is flawed. The question requires comparing reserves across 2022 and 2024 and interpreting regional strategic shifts. The LLM fails to perform this comparison due to incorrect data and misidentifies the strategic focus. It does not recognize that the majority of growth came from Asia via equity companies, which is the key insight in the original answer. (4) Contextual relevance is moderate because the answer discusses reserve evolution and strategic positioning, which are relevant themes, but the incorrect entities, numbers, and reasoning severely undermine its usefulness. The answer appears plausible but is factually unsupported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 492,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "The financial relationship with Google Network Partners evolved between 2022 and 2024, with Google Network properties contributing to both revenue generation and cost structure. Revenue from these partners increased as part of Google Services' growth, driven by higher advertising revenues (recognized gross, with payments to partners recorded as cost of revenues). While cost of revenues (including payments to Google Network Partners) rose due to higher TAC (Total Advertising Costs), the overall operating income for Google Services surged by $25.4 billion from 2023 to 2024, indicating that revenue growth outpaced cost increases. This suggests a more significant role of Google Network Partners in revenue generation, albeit with associated cost pressures.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and introduces unsupported quantitative claims. The ground truth does not mention any increase in revenue from Google Network Partners, nor does it state that revenue growth outpaced cost increases or that operating income surged by $25.4 billion from 2023 to 2024. These specific figures and trends are not present in the original answer and cannot be verified from the provided context, making them factually unsupported. (2) The $25.4 billion increase in operating income is a significant quantitative claim with no basis in the ground truth, which focuses on reporting treatment and cash flow framing, not operating income changes. There is no mention of TAC (Total Advertising Costs) or its growth in the original answer. These additions reflect a misinterpretation or fabrication of financial data. (3) The multi-hop reasoning is partially sound in that the LLM correctly identifies that Google reports advertising revenue gross and payments to partners as cost of revenues — a detail consistent with the 2022 description. However, it fails to capture the key evolution described in the original answer: the shift in financial reporting emphasis from revenue generation (2022) to cost and cash flow impact (2024). Instead, the LLM emphasizes revenue growth and profitability, which distorts the actual evolution. (4) While the answer is contextually relevant and touches on the right entities (Google Network Partners, revenue, cost of revenues), it introduces incorrect financial metrics and trends, undermining factual accuracy. The qualitative reasoning is moderately accurate but misses the core conceptual shift in how the relationship is framed financially. Hence, correctness is scored at 5 due to partial factual alignment but major unsupported additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 496,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "Between 2022 and 2023, UPS's financial impact of undesignated foreign currency forward contracts on earnings volatility decreased significantly. In 2022, a $69 million loss was recognized in earnings from these contracts, while in 2023, the loss dropped to $7 million. This reduction suggests improved management of foreign currency exposure through strategies like hedging or reduced exposure, leading to lower earnings volatility from undesignated contracts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The LLM introduces specific dollar amounts—$69 million loss in 2022 and $7 million loss in 2023—which are not present in the original answer (ground truth). The ground truth does not provide any numerical figures regarding the financial impact of undesignated foreign currency forward contracts, so these numbers are fabricated. There is no mention of a reduction in losses or specific amounts recognized in earnings, making the quantitative claims entirely unsupported. (2) Completeness and Entity Accuracy: While the question asks about the evolution of UPS's foreign currency exchange risk management strategy and the impact of undesignated contracts on earnings volatility, the LLM focuses narrowly on a supposed decline in losses, which misrepresents the actual evolution described. The ground truth emphasizes changes in disclosure practices—such as more structured presentation, side-by-side reporting, and explicit linkage of undesignated derivatives to earnings volatility—not a quantitative reduction in risk or loss. The LLM fails to mention the key qualitative evolution in disclosure transparency and systematic reporting. (3) Reasoning: The multi-hop reasoning is flawed. The LLM assumes that reduced losses indicate improved risk management, but the ground truth does not support this inference. Instead, the evolution is in disclosure clarity and structure, not necessarily in performance outcomes. The model incorrectly infers operational improvement from non-existent financial data. (4) Semantic Equivalence: The LLM answer conveys a completely different meaning—focusing on numerical improvement in earnings impact—whereas the original answer discusses enhanced disclosure and presentation. Despite being on-topic and mentioning UPS and the correct time frame, the factual core is inaccurate. The contextual relevance is moderate because it addresses UPS, foreign currency forward contracts, and earnings volatility, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 555,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "Costco's membership format remained a critical component of its profitability strategy between 2022 and 2023, with membership fee revenue increasing 9% in 2022 and 5% in 2023 (adjusted for a shorter week in 2024). This growth was driven by new member sign-ups, Executive membership upgrades, and sustained renewal rates, reinforcing member loyalty. The membership model continued to provide stable fee revenue while supporting comparable sales growth through increased shopping frequency and average ticket sizes, aligning with Costco's long-term focus on member retention and pricing authority.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies and introduces unsupported quantitative claims not present in the ground truth. Specifically, it states that membership fee revenue increased by 9% in 2022 and 5% in 2023, which are not mentioned or verifiable from the original answer. These percentages are likely fabricated or inferred incorrectly, as the ground truth focuses on qualitative language evolution and strategic concerns, not revenue growth rates. Additionally, the mention of 'a shorter week in 2024' is irrelevant and incorrect in the context of 2022–2023 analysis, introducing a factual error in time period alignment. (2) No valid numeric data was provided in the original answer to support the 9% and 5% figures, so these fail both accuracy and sourcing checks. The original answer emphasizes shifts in narrative and emerging risks in renewal rates in new markets, not quantified revenue changes. (3) The reasoning partially captures the continuity of the membership model’s importance but misses the key multi-hop insight: the evolution in language from 'significant effect on profitability' in 2022 to 'integral part of... profitability' in 2023, indicating deeper integration into the financial model. More importantly, the LLM fails to mention the new 2023 concern about lower renewal rates in newer markets affecting the worldwide renewal rate—a critical strategic shift highlighted in the ground truth. This omission represents a failure in synthesizing the evolving risk dimension. (4) While the LLM correctly identifies the membership model as central to profitability and links it to loyalty and fee revenue, it substitutes unsupported numbers for qualitative insights and misses the nuanced evolution in risk awareness. Thus, the answer is partially correct in theme but flawed in facts and incomplete in key strategic developments, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 516,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "NVIDIA's approach to CUDA evolved between 2022 and 2024 by deepening its integration into the data center platform and expanding its role in the broader software ecosystem. In 2022, CUDA was highlighted as a foundational building block of NVIDIA's accelerated computing platform, enabling AI training, inference, and high-performance computing across diverse markets. By 2024, CUDA's integration was further solidified through advancements like the NVIDIA AI Enterprise software suite, which leverages CUDA for optimized AI workloads, and the Blackwell architecture, designed for generative AI and accelerated computing. The company emphasized CUDA's role in enabling scalable, end-to-end solutions, including cloud-based AI training, simulation tools like Omniverse, and partnerships to expand developer ecosystems, reinforcing its centrality to NVIDIA's data center and AI strategies.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of CUDA from a foundational developer tool in 2022 to a deeply integrated component of NVIDIA's full-stack data center platform by 2024. It correctly identifies CUDA's role in accelerated computing, AI, and HPC in 2022 and notes its expanded integration into enterprise software (e.g., NVIDIA AI Enterprise) and new architectures (Blackwell) by 2024. While the original answer emphasizes CUDA's transformation into the foundation of CUDA-X and its role across GPUs, CPUs, and DPUs as part of a strategic shift to infrastructure-layer positioning, the LLM answer conveys a semantically similar progression—highlighting end-to-end solutions, cloud AI, and ecosystem expansion—even if it does not explicitly name CUDA-X or mention the 3 million developer milestone. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (NVIDIA, CUDA, AI Enterprise, Omniverse, Blackwell) are correctly used. The reasoning is sound and contextually relevant, though slightly less precise in capturing the specific structural evolution (CUDA → CUDA-X → full-stack platform) described in the ground truth. Thus, minor deduction in qualitative accuracy and overall correctness for missing explicit reference to CUDA-X and the developer program context, but the strategic trajectory is accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 382,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024 with a shift from government contracts to commercial markets. In 2023, Paxlovid revenue was $1,279 million, down from $18,933 million in 2022, reflecting the transition to commercial sales. By 2024, Paxlovid revenue increased to $5,716 million. Deferred revenues for Paxlovid and Comirnaty totaled $2.2 billion as of December 31, 2024, down from $5.1 billion in 2023, due to revenue recognition and adjustments. Remaining performance obligations for Paxlovid amounted to $1 billion as of 2024, with expected delivery timelines extending through 2028, subject to potential renegotiation. The U.S. government's transition to commercial markets in 2023 and the supply of 1.0 million treatment courses at no cost in 2024 further shaped these obligations.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies the $1 billion remaining performance obligations for Paxlovid as of 2024 and the delivery timeline extending through 2028 (matching the ground truth), it introduces several figures not present in the original answer, such as Paxlovid revenues of $1,279 million in 2023 and $5,716 million in 2024, and deferred revenues of $2.2 billion in 2024 (down from $5.1 billion in 2023). These specific revenue numbers and deferred revenue figures are not mentioned in the ground truth and cannot be verified against it, suggesting potential hallucination or use of external data. The ground truth emphasizes a $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses from U.S. government inventory — a key event entirely missing from the LLM response. (2) The quantitative accuracy is low because the LLM reports precise financial figures that do not align with the ground truth. While the $1 billion remaining performance obligation matches, the absence of the $3.5 billion reversal — a central element — significantly undermines factual correctness. The revenue trends and deferred revenue changes are detailed but unsupported by the original answer, making them misleading. (3) The reasoning partially captures the shift from government to commercial markets and notes the forward-looking nature of the $1 billion obligation through 2028, which reflects sound multi-hop synthesis. However, the failure to mention the revenue reversal — a critical pivot point in Pfizer’s financial commitment — indicates a gap in reasoning. The mention of 'potential renegotiation' and '1.0 million treatment courses at no cost in 2024' adds context not present in the ground truth, reducing qualitative accuracy. (4) The contextual relevance is high because the answer addresses the evolution of financial commitments and contractual obligations, delivery timelines, and revenue outlook. However, the inclusion of unverified numbers and omission of the major $3.5 billion reversal event results in a partially correct, partially misleading response, warranting a mid-range correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 597,
        "total_tokens": 1964
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, with Guyana recognized as a key **advantaged asset** in 2024, reflecting its role in high-value projects and reserves growth. In 2022, Guyana contributed to **proved undeveloped reserves additions** (1.3 GOEB) due to extensions and discoveries. By 2024, Guyana was explicitly listed as part of **advantaged assets** (alongside Permian and LNG) in the \"Advantaged Volume Growth\" framework, underscoring its strategic importance for driving returns and integration into ExxonMobil's advantaged asset portfolio. This shift highlights a transition from initial reserve development to a sustained focus on Guyana as a core component of the company's high-margin, long-term growth strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, Guyana contributed 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves through extensions and discoveries; by 2024, it was explicitly listed as a core 'advantaged asset' in ExxonMobil's earnings drivers. The numeric value (1.3 GOEB) and years (2022, 2024) are accurate. (2) The answer correctly captures the evolution in strategic emphasis—from reserves growth to advantaged production and earnings visibility—by noting the inclusion of Guyana in the 'Advantaged Volume Growth' framework alongside Permian and LNG, which aligns with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across years and reporting frameworks (reserves reporting in 2022 vs. advantaged asset classification in 2024) to demonstrate a strategic shift. (4) The terminology used—'advantaged asset', 'proved undeveloped reserves', 'extensions and discoveries'—is consistent with the original and conveys the same strategic narrative. Minor wording differences (e.g., 'high-margin, long-term growth strategy' vs. 'source of advantaged production and earnings visibility') do not affect factual accuracy and are acceptable under semantic equivalence. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 375,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "The planned utilization of the ATR 72-600F aircraft decreased from 11 units in 2023 to 6 units in 2024, as shown in the aircraft purchase commitments tables. This reduction indicates a strategic shift toward modernizing the fleet with more fuel-efficient aircraft like the B777F and B767F, which are prioritized for long-term operating savings and replacing older models. The decline in ATR 72-600F commitments reflects FedEx's focus on transitioning to newer, more efficient aircraft to enhance operational performance and reduce costs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the ATR 72-600F was projected to decline from 11 units in 2023 to just 1 by 2026 in the 2022 outlook, but by 2024, projections showed a stabilization at 7 units for 2025 and 3 by 2026. The LLM incorrectly states a drop from 11 in 2023 to 6 in 2024, which misrepresents both the timeline and the magnitude of change. It omits the key shift in trajectory between 2022 and 2024 outlooks entirely. (2) The numbers are factually wrong: no mention of 2025 or 2026 projections as in the original answer, and the 2024 figure is fabricated (6 units) with no support from the ground truth. The original answer does not mention any 2024 planned utilization as a standalone year in that way. (3) The reasoning is partially sound in discussing fleet modernization and fuel efficiency, and referencing B777F/B767F is contextually plausible, but it fails the multi-hop requirement: it does not compare the 2022 vs 2024 projections to show the strategic pivot. Instead, it presents a linear decline not supported by the data. (4) The contextual relevance is moderate because it addresses fleet strategy and aircraft utilization, but the incorrect data and missing evolution over time severely undermine correctness. The answer invents a narrative not present in the ground truth, missing the core insight that the phaseout was slowed, not accelerated. Thus, the correctness score is low due to major quantitative and qualitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 419,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "NVIDIA's approach to Omniverse evolved between 2022 and 2024 by expanding its integration with AI and simulation platforms, particularly in automotive and industrial applications. In 2022, Omniverse was highlighted as a tool for virtual world simulation and collaboration, with applications in digital twins and autonomous vehicle testing. By 2024, Omniverse was integrated more deeply with NVIDIA's data center solutions, such as DGX Cloud and AI Enterprise software, enabling synthetic data generation for AI model training and real-time simulation. This evolution emphasized Omniverse's role in AI-driven workflows, combining simulation capabilities with NVIDIA's accelerated computing infrastructure to enhance AI development and deployment across industries.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of NVIDIA's Omniverse from a 3D collaboration platform to a more integrated, AI-driven simulation environment between 2022 and 2024. It accurately notes the increased integration with NVIDIA's AI and data center platforms like DGX Cloud and AI Enterprise software, which aligns with the ground truth's emphasis on accelerated computing infrastructure. The mention of synthetic data generation and AI model training adds relevant detail not contradicted by the original. However, the LLM slightly misrepresents the 2022 positioning by stating Omniverse was already used for autonomous vehicle testing and digital twins at that stage, whereas the ground truth indicates this specialization evolved by 2024. In 2022, the focus was broader—on VR/AR collaboration and general 3D workflows—not yet centered on industrial digital twins or AI-driven simulation. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are correct and consistent. (3) The multi-hop reasoning is mostly sound: the model synthesizes information about platform evolution and integration with other NVIDIA technologies. However, it conflates the timing of use cases, attributing 2024-level specialization to 2022, which weakens the qualitative accuracy. (4) Despite this, the answer is highly relevant and conveys a largely accurate trajectory of Omniverse’s evolution, with strong contextual alignment to AI and simulation integration. The core progression—from collaboration tool to enterprise AI/simulation platform—is correctly identified, warranting a high correctness score with minor deductions for premature attribution of advanced use cases.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 472,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "Between 2022 and 2023, Google Play's role in generating non-advertising revenue expanded as part of Alphabet's broader strategy to diversify beyond advertising. In both years, Google Play was highlighted as a key contributor to non-advertising revenues, driven by app sales, in-app purchases, and digital content. The 2023 report emphasized continued growth in non-advertising revenues, including from Google Play, as Alphabet focused on expanding offerings like Google Cloud, hardware, and subscriptions. While these non-advertising streams (including Google Play) typically have lower margins than advertising, their share of total revenues increased, reflecting a strategic shift toward diversified revenue sources.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Google Play's role in generating non-advertising revenue in both 2022 and 2023, aligning with the ground truth that it contributes through app sales, in-app purchases, and digital content. It accurately reflects Alphabet's strategy to diversify beyond advertising and notes the increased share of non-advertising revenues. However, it misses a key evolution highlighted in the original answer: the re-categorization of Google Play under 'platforms' in 2023 as a more defined and structured revenue stream. This strategic shift toward solidifying Google Play as a core monetization platform — not just a diversification effort — is underemphasized. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; no errors in dates or financial terms. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes Google Play’s ongoing role and Alphabet’s broader strategy, but fails to capture the nuanced evolution in reporting and strategic emphasis between the two years. (4) The answer is contextually relevant and factually consistent with the general direction of the ground truth, but lacks specificity on the structural change in 2023, warranting a score of 7 for correctness and qualitative accuracy. Quantitative accuracy is scored 10 by default due to absence of numerical data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 386,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "AIG continued using expected loss ratio (ELR) methods for workers' compensation reserving in 2023, maintaining the approach outlined in 2022. For **guaranteed cost business**, ELR methods were applied primarily to the most recent accident year, while for **excess of deductible business**, they were given significant weight across the most recent five accident years. In 2023, AIG adjusted for factors like increased large deductible business, longer medical development patterns, and legal cost trends, refining ELR estimates to reflect updated assumptions. The 2023 tables show prior year development excluding ADC impacts, indicating ongoing application of these methods without a fundamental shift in methodology between 2022 and 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution (or lack thereof) in AIG's use of expected loss ratio (ELR) methods between 2022 and 2023. It accurately states that for guaranteed cost business, ELR methods were applied primarily to the most recent accident year, and for excess of deductible business, they were given significant weight across the most recent five accident years—this matches the ground truth exactly. The answer correctly notes that there was no fundamental shift in methodology from 2022 to 2023, which aligns with the original answer's assertion of 'broadly consistent' reserving practices. It also appropriately references ongoing trends like increased large deductible business affecting claims reporting patterns. However, the LLM answer omits a key detail from the ground truth: the 2023 filing's change in presentation of incurred and paid losses as net of reinsurance and undiscounted, which reflects a refinement in reporting transparency. While the LLM mentions 'refining ELR estimates,' it does not explicitly connect this to the change in loss presentation, which is a notable omission in completeness. Additionally, the mention of 'longer medical development patterns' and 'legal cost trends' is not present in the ground truth and may introduce unsupported detail. There are no numerical inaccuracies (quantitative accuracy is high, scoring 9 due to absence of incorrect numbers), and all entities (AIG, workers' compensation, guaranteed cost, excess of deductible, accident years) are correctly identified. The reasoning is sound and synthesizes the multi-hop requirement across years and business lines, though slightly less precise in reflecting reporting changes. Contextual relevance is perfect—the answer directly addresses the question's focus on methodological evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 493,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "Cisco restructured its product category segmentation in fiscal 2024, reclassifying categories into **Networking, Security, Collaboration, and Observability**, whereas in fiscal 2022, categories included **Secure, Agile Networks; Internet for the Future; Collaboration; End-to-End Security; Optimized Application Experiences;** and **Other Products**. The **Collaboration** category itself saw a **9% decline in revenue from fiscal 2022 ($4,472 million) to fiscal 2024 ($4,113 million)**, reflecting both the reorganization and a continued revenue contraction despite the new categorization.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution of Cisco's product category segmentation between fiscal 2022 and 2024, noting the shift from six categories (including Collaboration) to four main areas, with Collaboration retained and Observability introduced. This aligns with the ground truth and shows accurate entity and structural understanding. However, the LLM introduces specific revenue figures ($4,472 million in 2022 and $4,113 million in 2024) and a 9% decline in Collaboration revenue, which are not present in the original answer and cannot be verified from the provided ground truth. Since the question does not ask for revenue trends and the original answer does not mention any numbers related to Collaboration revenue, these additions introduce unverified quantitative claims. (2) The calculation of a 9% decline appears mathematically plausible (approx. 8.1% actual drop from $4,472M to $4,113M), but the inclusion of precise dollar amounts and percentage change is unsupported by the ground truth, making the quantitative accuracy low. (3) The multi-hop reasoning is partially sound—the model correctly synthesizes the reorganization across years and identifies the continuity of Collaboration. However, the addition of financial performance data where none was provided in the ground truth reflects a failure in information fidelity, possibly hallucinating data. (4) Despite the incorrect numerical additions, the core qualitative insight about category consolidation and the retention of Collaboration is accurate, and the answer remains contextually relevant to the question about segmentation evolution. Thus, correctness is reduced due to unsupported numbers, but structural and categorical reasoning is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 475,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "Amgen's disclosure for the 3.125% 2025 Notes evolved from 2022 to 2023 by transitioning from a **LIBOR-based** to a **SOFR-based** interest rate framework. In 2022, the effective interest rate was reported as **LIBOR + 1.8%**, while in 2023, it was updated to **SOFR + 2.1%**. Additionally, the 2023 disclosure reflects the termination of associated interest rate swaps, aligning with the shift to SOFR and adjusting the financial presentation to reflect current market rates.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Amgen did not disclose any specific interest rate framework for the 3.125% 2025 Notes—there was no mention of LIBOR or any spread (e.g., LIBOR + 1.8%). The LLM incorrectly asserts that the 2022 rate was LIBOR + 1.8%, which is not supported by the original data. In 2023, while it is correct that the rate was disclosed as SOFR + 2.1%, the LLM falsely implies a transition from LIBOR to SOFR, which did not occur in the disclosed data. Additionally, the LLM introduces the claim that interest rate swaps were terminated in 2023, which is not mentioned in the ground truth and cannot be verified. (2) Quantitative accuracy is poor: the $1,000 million carrying value in 2022 is omitted entirely, and the fabricated interest rate of LIBOR + 1.8% introduces false precision. The only correct numeric detail is SOFR + 2.1% in 2023. (3) The multi-hop reasoning is flawed—the model assumes a benchmark transition (LIBOR to SOFR) without evidence in the source data and adds unverified details about swap terminations. The actual evolution was from no rate framework disclosure to including SOFR + spread, not a rate switch. (4) Contextual relevance is moderate because the answer addresses disclosure evolution and financial presentation, but the incorrect details and fabricated elements severely undermine factual reliability. The core shift from quantitative-only to enhanced qualitative disclosure is missed due to the focus on a false narrative of benchmark transition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 433,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 2022 to 2024, with consolidated operations reserves declining from 326 BCF in 2022 to 289 BCF in 2024. Equity affiliates' reserves, which are fully located in this region, also declined from 3,974 BCF in 2022 to 3,189 BCF in 2024, driven by downward revisions due to lower prices and operational changes. This indicates a strategic focus on maintaining equity affiliate positions in the region despite market pressures, reflecting COP's long-term commitment to the Asia Pacific/Middle East through partnerships and regional LNG market dynamics.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF in 2022 to 296 BCF in 2024. However, the LLM states reserves declined to 289 BCF in 2024, which is incorrect. Furthermore, the LLM introduces 'equity affiliates' reserves' of 3,974 BCF in 2022 and 3,189 BCF in 2024—figures that are not present in the original answer and contradict the ground truth, which reports only a total of 326 BCF in 2022. These numbers are over an order of magnitude larger and not supported by the provided data. (2) The quantitative inaccuracies are severe: the reported 2024 reserve figure is off by 7 BCF (289 vs. correct 296), and the introduction of equity affiliate data with massive reserves (3,974 BCF) is entirely fabricated relative to the ground truth. There is no mention of equity affiliates or such large volumes in the original answer. (3) The multi-hop reasoning is flawed. The LLM infers a 'strategic focus on maintaining equity affiliate positions' and 'long-term commitment' based on invented data, leading to a conclusion opposite in implication to the ground truth. The original answer suggests a potential strategic shift or divestment due to declining reserves, while the LLM claims continued commitment—this is a direct contradiction in qualitative interpretation due to incorrect data synthesis. (4) Scores reflect major factual and numerical errors (correctness: 3/10), very poor quantitative accuracy (2/10), weak reasoning based on false premises (3/10), and moderate contextual relevance as the answer addresses the geographic region and time frame but with incorrect data and conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 473,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "Alphabet increased its repurchase activity of Class C Capital Stock from $52.6 billion in 2022 to $52.9 billion in 2023, reflecting a modest rise in share buybacks. This aligns with the company's capital allocation strategy of returning excess cash to shareholders through stock repurchases, signaling confidence in its financial position and long-term growth prospects. The sustained repurchase activity underscores Alphabet's focus on optimizing capital deployment and enhancing shareholder value.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported repurchase amounts. The ground truth states that Alphabet repurchased $59.3 billion in 2022 and $62.2 billion in 2023, while the LLM incorrectly reports $52.6 billion and $52.9 billion, respectively. These numbers are materially off, affecting the core of the answer. Additionally, the LLM fails to mention the $70.0 billion repurchase authorization in April 2023 and the $36.3 billion remaining as of year-end 2023, which are key indicators of strategic capital allocation. (2) The quantitative inaccuracies are severe: the correct year-over-year increase is $2.9 billion ($62.2B - $59.3B), but the LLM reports only a $0.3 billion increase based on wrong figures. The LLM also narrows the scope to Class C shares only, while the original answer specifies repurchases of both Class A and Class C shares. (3) The reasoning is partially sound in interpreting the intent behind share repurchases (returning capital, signaling confidence), but it fails the multi-hop synthesis by not incorporating the new authorization and remaining capacity, which are critical to assessing the strategic shift. (4) Contextual relevance is fair because the answer addresses the general trend and strategic implication, but correctness and quantitative accuracy are severely compromised by wrong numbers and missing key data points, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 396,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "AIG continued to apply frequency/severity methods in 2023 for lines of business where claims exhibit variability in frequency and severity, such as **U.S. Property** and **U.S. Workers' Compensation**, aligning with 2022 practices. These methods were used alongside loss development and expected loss ratio techniques, reflecting the need to account for short-tail exposure patterns. For high-severity lines like **aviation** and **excess casualty**, frequency/severity methods were not employed due to their complexity and variability, instead relying on loss development and expected loss ratio approaches. The 2023 documentation emphasized adjustments for the Adverse Development Reinsurance Agreement (ADC) but did not indicate a shift in method usage, maintaining consistency in applying frequency/severity methods where appropriate.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements, such as the continued use of frequency/severity methods in U.S. Property (consistent with 2022) and the exclusion of aviation due to high severity and variability. It also correctly notes the use of complementary methods like loss development and expected loss ratio. However, it fails to accurately capture the key evolution between 2022 and 2023: the expansion of frequency/severity methods into U.S. Workers' Compensation, a long-tail line, which represents a strategic shift. Instead, the LLM implies continuity, stating that application in Workers' Compensation aligns with 2022 practices—this is incorrect, as the original answer states that in 2022, AIG avoided using these methods for long-tail lines like Workers' Compensation. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in dates or financial figures. (3) The multi-hop reasoning is flawed: the question asks for evolution between 2022 and 2023, requiring comparison across years and identification of change in methodology application. The LLM fails this synthesis by asserting consistency rather than change, missing the core insight of methodological expansion into long-tail business. (4) Correctness is scored at 5 due to partial factual accuracy but significant omission of the key development. Qualitative accuracy is low due to incorrect reasoning about the evolution. Quantitative accuracy is 10 by default (no numbers). Contextual relevance is high as the answer discusses relevant lines of business and methods, but misses the central point of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 453,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "Amgen's financial relationship with BeiGene evolved from 2022 to 2023 as follows:  \n- **Cost Recovery**: Net costs recovered from BeiGene decreased from $199 million in 2022 to $109 million in 2023, reflecting reduced R&D cost-sharing.  \n- **Product Sales**: Amgen's product sales to BeiGene increased from $64 million in 2022 to $125 million in 2023, indicating higher revenue from collaboration.  \n- **Profit and Loss Sharing**: Profit and loss share expenses related to the initial commercialization period dropped from $53 million in 2022 to $40 million in 2023, suggesting lower shared costs or improved efficiency.  \n\nThese changes highlight a shift toward greater revenue generation while reducing shared expenses.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $199M to $109M cost recovery (correct decrease), $64M to $125M product sales (correct increase), and $53M to $40M profit and loss sharing expenses (correct decrease). Format variations (e.g., $109 million vs $109M) are acceptable and semantically equivalent. (2) The answer is complete, addressing all three financial dimensions (cost recovery, product sales, profit and loss sharing) across both years as required. (3) Entities are correctly identified: Amgen, BeiGene, and the relevant financial metrics are accurately attributed. (4) The reasoning is sound and reflects proper multi-hop synthesis: the conclusion that the collaboration is maturing—shifting from R&D cost-sharing to higher product sales and reduced shared expenses—is logically supported by the data. The qualitative interpretation aligns with the ground truth's implication of collaboration maturation. No factual, numerical, or conceptual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 300,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF at the end of 2022 to 296 BCF by the end of 2024. Key changes included:  \n- **Revisions**: Downward revisions in 2023 (288 BCF due to lower prices, offset by 198 BCF technical revisions) and 2024 (81 BCF due to lower prices, offset by 55 BCF technical revisions), while 2022 saw upward revisions from higher prices (423 BCF) and improved LNG market dynamics (331 BCF).  \n- **Purchases**: In 2024, acquisitions like Marathon Oil added reserves in Africa (Equatorial Guinea), though direct Asia Pacific/Middle East purchases are not explicitly detailed.  \n- **Extensions/Discoveries**: In 2024, extensions and discoveries occurred in the Middle East (part of the region).  \nProduction and sales adjustments also impacted the region, with production reductions and asset disposals noted in 2023 and 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the starting (326 BCF in 2022) and ending (296 BCF in 2024) reserve levels, the detailed breakdown of revisions, production, and purchases is largely incorrect or fabricated. The ground truth states that in 2023, revisions added 9 BCF, and in 2024, production subtracted 25 BCF, with no purchases in the region. However, the LLM claims complex revisions in 2023 and 2024 involving hundreds of BCF (e.g., 288 BCF due to lower prices, 198 BCF technical revisions), which are not supported by the original answer and contradict the simplicity and magnitude of the actual data. These numbers are orders of magnitude off and introduce false precision. (2) The LLM incorrectly implies major revisions in 2022 (423 BCF and 331 BCF), which are not mentioned in the ground truth and appear to be hallucinated. The ground truth does not mention 2022 revisions at all. (3) Regarding purchases, the LLM references Marathon Oil acquisitions adding reserves in Africa, but the question is about the Asia Pacific/Middle East region. The ground truth explicitly states no purchases affected this region in 2024, so this is a factual error. (4) The mention of 'extensions and discoveries in the Middle East in 2024' is not in the original answer and introduces unverified information. (5) The reasoning is flawed: the LLM fails to correctly synthesize the simple multi-hop evolution (initial reserves → revisions → production impact → final reserves) and instead invents a complex narrative unsupported by data. (6) While the net change (30 BCF decrease) is consistent, the attribution is wrong, undermining the answer's reliability. (7) Contextual relevance is moderate because the answer addresses the right region and company and attempts to cover revisions, production, and purchases, but the details are factually unsound. Overall, the answer appears plausible but is largely incorrect in its core explanatory elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 540,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "FedEx's planned usage of the B767F aircraft decreased from 14 units in 2024 (as committed in 2022) to 11 units in 2025 (as of 2024). This reduction reflects a strategic shift toward more fuel-efficient aircraft like the B777F, aligning with FedEx's modernization efforts to achieve long-term operating savings and replace older fleets. The adjustment indicates a focus on optimizing fleet efficiency and reducing reliance on less efficient aircraft types.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core trend of decreasing B767F usage and correctly identifies a strategic shift, but misses key quantitative details from the ground truth. It states a reduction from 14 in 2024 to 11 in 2025, which misrepresents the timeline. According to the original answer, in 2022, FedEx projected 14 B767Fs for both 2023 and 2024, with a drop to 10 by 2025. By 2024, the projection changed to 11 in 2025 and only 3 by 2026. The LLM answer omits the 2026 projection (3 aircraft), which is a significant part of the updated plan and indicates a more accelerated phaseout. Additionally, it incorrectly frames the 14-unit figure as being 'in 2024 (as committed in 2022)', when actually the 14 was the projected usage for 2023–2024, not 2024 specifically. (2) The numbers are partially correct—14 and 11 appear in the correct context of reduction—but the timeline and future projections (especially the sharp drop to 3 by 2026) are missing or misrepresented. This affects calculation and trend accuracy. (3) The reasoning about strategic fleet modernization, fuel efficiency, and shift to B777F is sound and aligns with typical industry logic, showing good qualitative synthesis. However, the multi-hop aspect—comparing projections across two reporting years (2022 vs. 2024) for future fleet size—is incomplete due to missing the 2026 data point. (4) The answer is contextually relevant and provides plausible strategic rationale, but the quantitative inaccuracies and omissions prevent a higher score. The core direction is correct, but precision on timing and magnitude is lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 441,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "AIG's use of Expected Loss Ratio (ELR) methods between 2022 and 2023 remained consistent, with ELR applied to the **latest accident year** for lines like **U.S. Workers' Compensation** and **U.S. Excess Casualty**, where loss development patterns are inconsistent or slow. For **aviation exposures**, ELR was used alongside loss development methods for all but the latest accident year. The reasoning centered on ELR's suitability for high-severity, low-frequency claims (e.g., aviation) and long-tail lines (e.g., Workers' Compensation), where historical data is limited or development patterns are volatile. In 2023, the methodology emphasized ELR's role in adjusting reserves for recent accident years, particularly for business with deductible layers, reflecting evolving risk profiles and market conditions.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements, such as the use of Expected Loss Ratio (ELR) methods for the latest accident year and in lines like U.S. Workers' Compensation and aviation exposures. It correctly identifies the reasoning behind ELR use in high-severity, low-frequency claims and long-tail lines. However, it incorrectly states that AIG's use of ELR 'remained consistent' between 2022 and 2023, which directly contradicts the ground truth that shows a notable evolution and broadening of ELR application in 2023. The ground truth emphasizes a shift from short-term forecasting in high-severity contexts (e.g., aviation) in 2022 to broader use in long-tail, structurally complex lines like U.S. Workers' Compensation in 2023. The LLM answer mentions U.S. Workers' Compensation in both years, implying continuity, whereas the original answer highlights 2023 as a year of expanded application. (2) There are no explicit numerical values (e.g., percentages, dollar amounts) in either the ground truth or LLM answer, so quantitative accuracy is not compromised—this score reflects consistency in non-numerical factual reporting. (3) The multi-hop reasoning is partially sound: the LLM correctly associates ELR with appropriate lines of business and reasoning (e.g., long-tail, high severity), but fails to synthesize the temporal evolution—i.e., the expansion and strategic shift in 2023. This is a critical omission in a question specifically asking about 'evolution' between years. (4) Contextual relevance is high because the answer discusses the correct company, time frame, methodology, and business lines. However, the core of the question—how the use evolved—is not accurately captured, leading to a moderate correctness score. The answer provides useful details but misses the central claim of methodological expansion in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 504,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "Cisco's positioning around Enterprise Data Center Transformation between 2022 and 2024 emphasizes strategic alliances with key players like Microsoft, Apple, and others to address converging technologies (computing, networking, storage, software). However, the competitive landscape has intensified as rivals (e.g., Huawei, VMware) and strategic partners (e.g., AWS, Google) have formed alliances or acquired capabilities to offer end-to-end solutions, creating both collaboration opportunities and potential competition. Cisco acknowledges the dual risk of leveraging these partnerships while mitigating competitive pressures from allies entering overlapping markets.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general theme of Cisco's focus on enterprise data center transformation and the complexity of strategic alliances, which aligns with the ground truth. However, it introduces specific companies not mentioned in the original answer—such as Microsoft, Apple, AWS, and Google—as strategic allies, which are not supported by the ground truth. The original answer does not name specific partners but notes that partners have acquired or aligned with competitors, reducing business with Cisco. Additionally, the LLM fails to mention the key evolution in Cisco’s competitive landscape by 2024, specifically the emergence of Nvidia Corporation as a new competitive entrant, which is a critical factual point in the ground truth. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable; the score of 10 reflects no errors in this dimension. (3) The multi-hop reasoning is partially sound—the LLM correctly infers that strategic alliances present both opportunities and competitive threats. However, it does not accurately reflect the shift in Cisco’s alliance strategy from defensive (2022) to proactive industry advancement and market creation (2024), nor does it capture the strategic significance of new market entrants like Nvidia. (4) The contextual relevance is high because the answer addresses the core topic of data center transformation and alliance dynamics, but qualitative accuracy is reduced due to incorrect entity attribution and missing key developments in Cisco’s competitive landscape evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 441,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "The effective interest rate for the 3.125% 2025 Notes evolved from **LIBOR + 1.8%** in 2022 to **SOFR + 2.1%** in 2023, while the notional amount remained unchanged at **$1,000 million** in both years. This reflects a shift from LIBOR-based to SOFR-based pricing, consistent with broader market transition practices.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the notional amount was $5.2 billion (not $1.0 billion), and there is no mention of LIBOR + 1.8% in the original answer—this rate is entirely fabricated. The only correct quantitative detail is the 2023 effective interest rate (SOFR + 2.1%) and the 2023 notional amount ($1.0 billion). (2) The notional amount did not remain unchanged—it decreased from $5.2 billion in 2022 to $1.0 billion in 2023, a critical evolution that the LLM incorrectly omits. The shift from LIBOR to SOFR is contextually plausible due to market transitions, but the original answer does not mention LIBOR at all, so asserting LIBOR + 1.8% in 2022 is unsupported. (3) The multi-hop reasoning is flawed: the LLM fails to recognize the reduction in hedged exposure and incorrectly assumes rate continuity. It also misses the strategic context of new swaps being entered post-termination due to low interest rates. (4) Scores are low due to major quantitative errors and incorrect synthesis, though the answer is contextually relevant in discussing rate benchmarks and notional amounts, hence a moderate contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 342,
        "total_tokens": 1539
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "Cisco's strategic positioning of AppDynamics within its observability offerings evolved from 2022 to 2024 by integrating it into a broader, more comprehensive observability platform. In 2022, AppDynamics was highlighted as part of Cisco's application performance monitoring (APM) suite, contributing to full-stack observability from application to infrastructure. By 2024, the Observability product category (including AppDynamics, ThousandEyes, and Splunk) saw a 27% revenue increase, reflecting its expanded role in Cisco's strategy to deliver end-to-end visibility across hybrid and multicloud environments. The 2024 disclosure emphasizes AppDynamics as a core component of Cisco's observability ecosystem, integrated with security and network monitoring tools to enhance real-time insights and support cloud-native applications.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of AppDynamics' strategic positioning from 2022 to 2024, noting its integration into a broader observability strategy and its role in full-stack monitoring. It accurately reflects that by 2024, Observability became a formal product category. However, it introduces a 27% revenue increase for the Observability category, which is not present in the ground truth and cannot be verified from the provided information—this is a significant quantitative inaccuracy. Additionally, the mention of Splunk as part of the 2024 Observability category is not supported by the original answer, which only names AppDynamics, ThousandEyes, and Intersight; Splunk was not referenced at all, introducing an incorrect entity. (2) The 27% revenue growth figure is unverified and not mentioned in the ground truth, making it factually unsupported. This affects quantitative accuracy despite correct formatting. (3) The multi-hop reasoning is generally sound—linking AppDynamics’ role in 2022 to its more integrated position in 2024, and inferring increased strategic importance from reporting changes. However, the synthesis includes extraneous elements (Splunk, revenue number) not grounded in the source. (4) The correctness score is 7 because the core qualitative trajectory—AppDynamics moving from a component to part of a formalized observability pillar—is accurate and well-articulated. The contextual relevance is high as it directly addresses the strategic evolution. Qualitative accuracy is strong but docked slightly for entity overreach. Quantitative accuracy is reduced due to the unsupported 27% figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 453,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "The effective interest rate for the 4.663% 2051 Notes evolved from **LIBOR + 4.1%** in 2022 to **SOFR + 4.3%** in 2023, reflecting the transition from LIBOR to SOFR as the reference rate. The notional amount associated with these notes remained **$1,500 million** in both years, as indicated in the interest rate swaps tables for 2022 and 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the 4.663% 2051 Notes were part of a $5.2 billion hedged portfolio, but it does not specify the effective interest rate as LIBOR + 4.1% or confirm the notional amount was $1.5 billion in 2022. In fact, the $1.5 billion notional is only explicitly disclosed for 2023. The LLM incorrectly asserts that the notional amount was $1,500 million in both years, which is not supported by the original answer. Additionally, the original answer does not mention LIBOR at all for 2022—let alone a spread of 4.1%—so the claim of 'LIBOR + 4.1%' is unsupported. The 2023 data (SOFR + 4.3% and $1.5 billion) matches the ground truth. (2) Quantitatively, the $1.5 billion figure is correct for 2023 and equivalent to $1,500 million, but attributing it to 2022 is incorrect. The interest rate transition from LIBOR to SOFR may be contextually plausible, but the specific rates are not in the ground truth. (3) The multi-hop reasoning is flawed: the model assumes continuity in notional amount and infers a LIBOR-based rate for 2022 without evidence, failing to reflect that the 2022 hedging involved a broader $5.2 billion portfolio without breakdown by note series. (4) Despite incorrect specifics, the answer is contextually relevant—it addresses the evolution of rate and notional, discusses the SOFR transition, and focuses on the correct financial instrument. However, the core factual inaccuracies in both quantitative and qualitative dimensions severely undermine correctness, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 439,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "AIG's use of expected loss ratio methods between 2022 and 2023 remained consistent for long-tail lines like **U.S. Excess Casualty** and **U.S. Financial Lines (D&O)**, with continued reliance on loss cost trends and development factors. However, **segmentation criteria were refined** in 2023, particularly for **excess of deductible business**, where segmentation by deductible size and third-party administration became more detailed. For **U.S. Workers' Compensation**, the combination of loss development, frequency/severity, and expected loss ratio methods persisted, with further segmentation by state, industry, and risk-sharing features. Sensitivity analyses for 2023 mirrored 2022's ranges, reflecting ongoing adjustments for inflation, judicial trends, and market conditions. Key changes included enhanced segmentation for excess layers and more granular analysis of deductible structures.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies enhanced segmentation in 2023 (e.g., by deductible size, state, industry, risk-sharing), it incorrectly states that expected loss ratio methods were used in 2022 for specific lines like U.S. Excess Casualty and U.S. Financial Lines (D&O), which contradicts the ground truth. The original answer states that in 2022, AIG only referenced expected loss ratio methods in a general sensitivity analysis without specifying lines of business. This is a significant factual error. Additionally, the LLM implies continuity in method usage across years for specific lines, which is not supported by the ground truth. However, the 2023 enhancements in segmentation criteria (deductible size, state, industry, risk-sharing) are accurately reflected. (2) There are no explicit numbers (percentages, dollar amounts) in either answer, so quantitative accuracy is not heavily applicable; however, the temporal references (2022, 2023) are correct, supporting a score of 8. (3) The multi-hop reasoning is partially sound—information about segmentation evolution is synthesized correctly for 2023, but the model fails to correctly infer that the application of expected loss ratio methods was not line-of-business-specific in 2022. This undermines the qualitative accuracy. The model appears to overextend details from 2023 backward into 2022. (4) The answer is contextually relevant and addresses the evolution of methods, lines of business, and segmentation, but due to the misattribution of specific method usage in 2022, the correctness score is reduced to 4—partially correct with significant factual inaccuracies in entity and temporal attribution.)",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 476,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "PepsiCo's engagement with the 2.850% Senior Notes due 2026 remained part of its broader debt strategy in 2024, as reflected in the 2024 filings. However, the 2024 documents introduced additional notes, such as the 4.650% Senior Notes due 2027, 4.550% Senior Notes due 2029, and 4.700% Senior Notes due 2034, indicating an expansion of its issuance strategy to include higher-yield instruments and longer-term maturities. This suggests a diversification of debt maturity profiles and interest rate structures to manage liquidity and optimize capital costs.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the specific debt instruments introduced in 2024. The ground truth states that PepsiCo introduced the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, but the LLM incorrectly lists the 4.650% due 2027, 4.550% due 2029, and 4.700% due 2034—none of which appear in the ground truth. These are materially different in terms of interest rates and maturities, undermining quantitative accuracy. (2) The numbers—percentages and maturity years—are incorrect, which fails the quantitative accuracy check. While the general trend of issuing longer-term, higher-yield notes is captured, the specific instruments are wrong, making the answer factually flawed. (3) The reasoning and synthesis are partially sound: the LLM correctly infers that PepsiCo expanded its debt strategy to diversify maturities and interest rate profiles, which aligns with the ground truth’s interpretation of a broader, more diversified capital structure. It also correctly notes continuity in the 2.850% Senior Notes due 2026. However, the failure to report the correct notes undermines the multi-hop synthesis, as the conclusion is based on non-grounded data. (4) Contextual relevance is high because the answer addresses the evolution of PepsiCo’s debt strategy and attempts to interpret strategic intent. However, due to the incorrect specific instruments, the correctness score is limited to 5—partially correct but with significant factual errors that affect the reliability of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 427,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "Cisco's exposure to channel partner financing guarantees decreased slightly from $1.4 billion as of July 30, 2022, to $1.3 billion as of July 31, 2021, with no explicit 2024 data provided in the documents. The company's financial risk management strategy includes using derivatives, collateral arrangements, and netting agreements to mitigate credit risk, as evidenced by its hedging practices and collateral management for derivative instruments. This suggests a focus on reducing exposure through structured risk mitigation tools.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Cisco's exposure decreased from $1.4 billion as of July 30, 2022, to $1.3 billion as of July 31, 2021 — this reverses the timeline (2021 is before 2022) and misreports the data. The ground truth states that the $1.4 billion figure is from July 30, 2022 (fiscal year 2022), but the LLM implies a reduction to $1.3 billion in an earlier year, which is illogical and unsupported. Furthermore, the LLM claims there is 'no explicit 2024 data provided,' while the original answer confirms that 2024 data was not quantified — but still notes continued guarantees, which the LLM omits. (2) The quantitative inaccuracies are severe: the dollar amounts are misapplied to incorrect years, and the direction of change is wrong. The LLM fabricates a $1.3 billion figure for 2021 that is not in the ground truth. (3) The reasoning is flawed: the LLM fails to recognize that the key evolution is the lack of disclosure in 2024, not a numerical decrease. It misses the multi-hop insight that reduced transparency — not just exposure — is the notable shift. Instead, it invents a trend based on incorrect temporal logic. (4) While the mention of derivatives and collateral is contextually relevant to risk management, it is not tied to channel partner financing specifically and appears generic. The answer partially addresses the question’s intent but with incorrect data and reasoning, leading to a low correctness score. Contextual relevance is moderate because the topic of risk management is addressed, albeit tangentially.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 441,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "The 2.45% 2030 Notes remained outstanding in 2022 but were partially repurchased in 2023. In 2022, their effective interest rate was **LIBOR + 1.0%** via interest rate swaps. By 2023, the rate structure transitioned to **SOFR + 1.3%** due to the shift from LIBOR to SOFR, reflecting updated hedging arrangements. This change aligns with market practices post-LIBOR discontinuation.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that the 2.45% 2030 Notes were subject to interest rate swaps and that the rate structure shifted from LIBOR to SOFR by 2023, now being SOFR + 1.3%. However, it incorrectly states that the notes were 'partially repurchased in 2023', which contradicts the ground truth that the notes 'remained outstanding' with the same $1.0 billion notional amount. This is a significant factual error. Additionally, the LLM claims the 2022 effective rate was 'LIBOR + 1.0%', but the ground truth does not specify the spread in 2022—only that the swap converted the fixed rate to a floating LIBOR-based coupon. The 1.0% figure is unsupported and likely incorrect. (2) Quantitative accuracy is compromised: while $1.0 billion notional is implied by context, the unverified +1.0% spread and the false repurchase claim introduce major inaccuracies. The SOFR + 1.3% figure in 2023 is correct. (3) The reasoning correctly captures the multi-hop concept of interest rate benchmark transition (LIBOR to SOFR) and links it to market practices, showing sound qualitative understanding of the hedging evolution. However, the erroneous repurchase claim and incorrect spread undermine the synthesis. (4) Contextual relevance is high—the answer addresses the evolution of status and interest rate structure directly. Scores reflect partial correctness: core transition is right, but key facts are wrong or unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 412,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "FedEx's relationship with Pass-Through Certificates remained unchanged between 2022 and 2023 regarding financial guarantees and obligations. FedEx Express continues to hold $970 million in Pass-Through Certificates, Series 2020-1AA, secured by 19 Boeing aircraft (net book value of $1.7 billion as of May 31, 2023). The payment obligations for these certificates are fully and unconditionally guaranteed by FedEx, as stated in both the 2022 and 2023 filings. No new certificates were issued, and the guarantee structure remained consistent, with no material changes to the terms or obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that FedEx's relationship with Pass-Through Certificates remained unchanged. The ground truth states a clear shift: in 2022, the certificates were fully and unconditionally guaranteed by FedEx, but in 2023, FedEx clarified they were not direct obligations nor guaranteed by FedEx or FedEx Express. The LLM incorrectly asserts the guarantee remained in place in 2023, contradicting the ground truth. (2) Quantitatively, the LLM reports $970 million in certificates (correct) and 19 Boeing aircraft (correct), but cites a net book value of $1.7 billion in 2023, whereas the ground truth reports $1.8 billion in 2022. The value discrepancy is minor but still inaccurate. More critically, the LLM fails to note the removal of the guarantee, which is a qualitative and factual error. (3) The multi-hop reasoning is flawed: the question asks about the evolution between 2022 and 2023, requiring comparison across years and synthesis of changes in financial obligations. The LLM fails to detect or report the key change in guarantee status, instead asserting consistency. This indicates a failure in reasoning across filings. (4) Contextual relevance is moderate—the answer discusses the correct entities (FedEx, Pass-Through Certificates, Boeing aircraft) and time frame, but misrepresents the key development. Due to major factual and reasoning errors, especially on the guarantee status, the correctness score is low at 2. Quantitative accuracy is partially correct on amounts and assets but wrong on value and context, warranting a 3. Qualitative accuracy is poor due to incorrect synthesis and reasoning, scoring 2. Contextual relevance is acceptable at 6 because the answer addresses the right topic with some correct details, but misses the central point of evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 498,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "Mastercard's gross settlement exposure increased from $75,023 million in 2023 to $78,385 million in 2024, while risk mitigation arrangements applied to settlement exposure rose from $12,167 million to $13,466 million. This reflects a proportional increase in risk mitigation efforts to address higher exposure, indicating a proactive strategy to maintain control over settlement risks. The company adjusted its risk management framework by enhancing collateral requirements and credit enhancements, aligning with its policy to revise mitigation arrangements based on evolving risk assessments. This evolution underscores Mastercard's commitment to balancing exposure growth with robust safeguards.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key numerical values from the ground truth: gross settlement exposure of $75,023 million in 2023 and $78,385 million in 2024, and risk mitigation amounts of $12,167 million and $13,466 million respectively. These figures are accurate and match the original answer exactly. (2) All calculations implied (increases in exposure and mitigation) are factually sound and proportionally described. The LLM correctly identifies that both exposure and mitigation increased, which aligns with the ground truth. (3) The multi-hop reasoning is solid—synthesizing data across two years and interpreting the trend in risk management strategy is done appropriately. The conclusion that Mastercard is proactively managing increased exposure through enhanced mitigation is logically supported. (4) While the core reasoning and facts match the ground truth, the LLM adds minor interpretive details not present in the original (e.g., 'enhancing collateral requirements and credit enhancements', 'aligning with its policy to revise mitigation arrangements') that, while plausible, are not verifiable from the provided ground truth. This prevents a perfect 10 on qualitative accuracy. However, these additions do not contradict the source and are contextually reasonable, so the answer remains highly accurate overall. Semantic equivalence is maintained, and the response fully addresses both parts of the question: evolution from 2023 to 2024 and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 414,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments increased from **$48 million in 2022** to **$115 million in 2024**. This reflects a significant rise in the company's exposure to foreign exchange risks or a more aggressive hedging strategy, as the liabilities grew despite a reduction in the notional amount of outstanding hedging derivatives. The increase suggests Nike may have taken on more foreign currency risk or adjusted its hedging positions to manage exposure to fluctuating exchange rates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported the total liabilities for foreign exchange forwards and options designated as hedging instruments in both years: $48 million in 2022 (comprising $37M under accrued liabilities and $11M under deferred income taxes) and $115 million in 2024 (with $110M and $5M respectively), which matches the ground truth. The totals are accurate and properly calculated. (2) All numeric values are correct, with appropriate formatting (e.g., $48 million, $115 million). The increase from $48M to $115M is accurately stated and calculated (a $67M increase). (3) The reasoning is sound: the LLM correctly infers that the increase in liabilities may reflect higher foreign exchange risk exposure or a strategic shift in hedging, which aligns with the ground truth. It adds contextual insight about the reduction in notional amount, which, while not in the original answer, does not contradict it and may reflect additional data not in the ground truth; however, since this detail isn't in the provided truth, it doesn't detract significantly. (4) The answer is semantically equivalent and fully addresses both parts of the question: the change in liabilities and its implication. The only minor limitation is the introduction of the 'reduction in notional amount' point, which isn't in the source and could be speculative, but it doesn't undermine the factual correctness. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 423,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "Between the 2022 and 2023 10-K filings, Bounty remained a core brand within P&G's Baby, Feminine & Family Care segment, listed as a major brand in the Family Care subcategory (paper towels, tissues, toilet paper). In both filings, Bounty's North American market share was noted as over 40%, with Charmin (another Family Care brand) at over 25%. There is no explicit mention of changes in Bounty's representation or brand visibility within the segment during this period, suggesting consistent positioning and market presence.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The original answer states that Bounty was not explicitly listed as a key brand in the 2022 10-K but was explicitly included in 2023, indicating a change in representation and increased visibility. The LLM claims Bounty was listed as a major brand in both years, which contradicts the ground truth. (2) The LLM introduces specific market share figures—'over 40%' for Bounty and 'over 25%' for Charmin—which are not present in the original answer or supported by the provided evidence. These numbers are entirely fabricated or misattributed, failing the quantitative accuracy test. (3) The multi-hop reasoning is flawed: the question asks about the evolution of Bounty's representation across two filings, requiring comparison of disclosure practices. The LLM fails to identify the key change (explicit listing in 2023 vs. omission in 2022) and instead asserts consistency, missing the core insight about brand visibility. (4) Contextual relevance is moderate because the answer discusses the correct segment and product category, but it invents data and misses the central point about disclosure evolution, severely undermining correctness. The qualitative accuracy is low due to incorrect entity representation and lack of proper synthesis across filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 375,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "Oracle's approach to its hardware business, including Oracle Engineered Systems, remained consistent in revenue recognition between fiscal 2022 and 2023, with hardware revenues recognized at the point of delivery and support services recognized ratably over contractual terms. However, the strategic emphasis shifted toward cloud services and license support, as cloud services revenues grew to 37% of total revenues in fiscal 2024 (compared to 32% in 2023 and 25% in 2022), reflecting a broader focus on cloud-based solutions while maintaining hardware as a complementary offering.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The Original Answer states that Oracle changed its revenue recognition approach in fiscal 2023 to treat hardware and related software as a combined performance obligation, recognized at delivery. The LLM incorrectly claims the approach 'remained consistent' between 2022 and 2023, directly contradicting the ground truth. Additionally, the LLM introduces forward-looking data for fiscal 2024 (37% cloud revenue), which is not mentioned in the Original Answer and is outside the scope of the question (2022–2023). These percentages (32%, 37%, etc.) are not present in the ground truth and appear fabricated or misattributed. (2) Quantitative accuracy is very low: the percentages cited (37%, 32%, 25%) do not appear in the Original Answer and cannot be verified from the provided context. There are no revenue percentages or cloud revenue breakdowns in the ground truth. The fiscal 2024 data is irrelevant and incorrect for a question about 2022–2023. (3) The multi-hop reasoning is flawed. The question asks about evolution in both revenue recognition and strategic emphasis. The LLM fails to identify the key change in revenue recognition (combined performance obligation in 2023) and instead asserts consistency. It also misses the key strategic shift in 2023 toward R&D investment in hardware innovation, which was not mentioned in 2022. Instead, it shifts focus to cloud services growth, which is not emphasized in the Original Answer as a change in hardware strategy. (4) Contextual relevance is moderate because the answer discusses Oracle's hardware and revenue recognition, but it misrepresents the evolution and introduces irrelevant data. The core facts about strategic and accounting changes are incorrect, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 497,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "ERLEADA's sales increased from $1.88 billion in 2022 to $2.39 billion in 2023, reflecting a 26.9% growth. This growth was driven by continued share gains and market expansion in Metastatic Castration-Resistant Prostate Cancer (mCRPC), indicating a positive market trajectory with strong demand and therapeutic positioning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports ERLEADA's sales as $1.88 billion in 2022 and $2.39 billion in 2023, which aligns with the ground truth values of $1,881 million and $2,387 million (rounded appropriately). The calculated growth rate of 26.9% is accurate: (2,387 - 1,881) / 1,881 ≈ 0.269 or 26.9%. (2) All numeric values are correct and properly formatted; minor rounding ($1.88B vs $1,881M) is acceptable and common in financial reporting. (3) The reasoning is sound: the LLM identifies the sales increase and attributes it to 'continued share gains and market expansion in mCRPC,' which is a reasonable qualitative interpretation consistent with a positive market trajectory. While the original answer does not include the specific driver (mCRPC), the LLM adds contextually appropriate detail that enhances the explanation without contradicting the ground truth. (4) The answer fully addresses both parts of the question—sales performance evolution and market trajectory—and synthesizes information correctly across years. The only reason for not scoring a 10 is that the original answer did not include the mCRPC detail, so that addition, while plausible, goes beyond the verified ground truth; however, it does not detract from accuracy. Overall, the answer is factually correct, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1149,
        "completion_tokens": 369,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "CMCSA's relationship with local broadcast television stations has intensified in 2024 compared to 2023, marked by heightened competition for retransmission consent and rising dependency on local stations for content distribution. In 2023, the focus was on securing affiliations and negotiating retransmission consent terms, while 2024 highlights increased pressure from local stations demanding higher payments and concessions, driving up programming costs. The 2024 filings emphasize risks of losing or renewing distribution agreements on less favorable terms, underscoring a more precarious dependency and competitive challenge in maintaining reach and revenue.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies an evolving relationship between CMCSA and local broadcast television stations from 2023 to 2024, and correctly notes increased dependency and negotiation dynamics around retransmission consent. However, it mischaracterizes the nature of the 2023 relationship by implying that retransmission consent negotiations were already a central focus, whereas the ground truth states that in 2023, CMCSA's Media segment was primarily in competition with local broadcasters for viewers and ad revenue—not yet in a state of dependency. The shift described in the ground truth is from competition (2023) to dependency (2024), but the LLM portrays the relationship as competitive in both years, just intensified in 2024, which misses the fundamental strategic shift. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable—no errors in dates or amounts. (3) The multi-hop reasoning is partially sound: the model connects CMCSA, local broadcast stations, retransmission consent, and content distribution across years. However, it fails to correctly synthesize the qualitative shift from competition to dependency, instead framing the evolution as an intensification of competition and growing dependency without acknowledging the prior competitive dynamic was in a different domain (advertising and viewership). (4) The contextual relevance is high because the answer addresses the core themes of competitive positioning and dependency in content distribution. However, the qualitative inaccuracy in depicting the 2023 relationship significantly undermines the correctness score, warranting a mid-range 6. The answer contains plausible details (e.g., rising programming costs, risks of losing agreements) that align with industry trends but are not explicitly confirmed in the ground truth, introducing potential hallucination.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 514,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "The value of Held-to-Maturity (HTM) securities held by Mastercard decreased significantly from $306 million in 2023 to $38 million in 2024. This sharp decline indicates a strategic shift toward more liquid, market-responsive investments. The reduction in HTM securities, which are typically held until maturity for stable cash flow, suggests Mastercard may have reclassified some investments to Available-for-Sale (AFS) securities or sold portions of its HTM portfolio to enhance liquidity or adjust risk exposure. The slight increase in AFS securities ($286 million in 2023 to $292 million in 2024) aligns with this shift, reflecting a move toward flexibility and responsiveness to market conditions, rather than long-term fixed-income holdings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the drop in HTM securities from $306 million in 2023 to $38 million in 2024, matching the ground truth exactly. These numbers are accurate and properly formatted. The slight increase in AFS securities from $286M to $292M is consistent with the knowledge graph data and supports the reasoning. (2) All numeric values are correct, and no calculations are required beyond the implied comparison, which is accurately interpreted. (3) The multi-hop reasoning is sound: the model synthesizes data across years and investment categories (HTM and AFS), correctly inferring a strategic shift toward liquidity and flexibility. The explanation about reclassification or sale of HTM securities and the move toward AFS aligns with plausible financial logic and is supported by the data. (4) The answer goes beyond the ground truth by adding context about AFS securities and strategic rationale, which is reasonable and consistent with the data. The only reason for not scoring a 10 is that the original answer did not mention AFS securities, so while the added analysis is accurate and insightful, it slightly exceeds the confirmed ground truth without explicit verification in the source. However, since the AFS numbers are correct and the inference is logical, the qualitative accuracy is still very high. All parts of the question are addressed: the change in value and its implication for investment strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 402,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "The Always brand's positioning within Procter & Gamble's Baby, Feminine & Family Care segment remained consistent in terms of product categorization between 2022 and 2023, with **Feminine Care** as a core sub-category under the segment. However, in 2023, the document explicitly细分 Feminine Care into **Menstrual Care** and **Adult Incontinence**, with Always and Tampax highlighted as key brands in the Menstrual Care sub-category. This reflects a more granular categorization, emphasizing Always's role in the Menstrual Care segment, while maintaining its presence in Adult Incontinence (via Always Discreet). The broader product structure (Baby Care, Feminine Care, Family Care) and major brands (Always, Tampax, Bounty, Charmin) remained unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Always remained under the Baby, Feminine & Family Care segment and was categorized under Feminine Care in both 2022 and 2023. It accurately notes the 2023 refinement where Feminine Care was split into Menstrual Care and Adult Incontinence, with Always being specifically highlighted in Menstrual Care (alongside Tampax), reflecting a more targeted positioning. The mention of Always Discreet in Adult Incontinence adds contextual accuracy and shows understanding of brand extensions. (2) There are no numeric values in the question or answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution of categorization across years and sub-categories, identifying both continuity and change. The only minor shortcoming is that the original answer emphasizes a 'strategic shift' in positioning, which the LLM answer implies but does not explicitly state, slightly reducing qualitative precision. (4) The answer is fully contextually relevant, addressing product categorization, sub-category changes, and brand positioning evolution. Wording differs but semantic meaning matches the ground truth closely. Minor deduction from 10 to 9 due to lack of explicit mention of strategic intent behind the re-categorization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 388,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "Oracle's Oracle Engineered Systems remained a core component of its hardware business, contributing approximately 6% of total revenues in both fiscal 2022 and 2023. Revenue recognition for these systems followed the same model as other hardware products, with revenue recognized at the point of delivery when ownership transferred to customers. While the company emphasized growth in cloud services (which grew from 25% to 37% of total revenues between 2022 and 2023), there is no explicit mention of a material change in the financial contribution or strategic emphasis on Engineered Systems during this period. The hardware business continued to face challenges related to competitive pressures and customer demand shifts toward cloud infrastructure, but its revenue recognition methodology and positioning as part of Oracle's broader enterprise solutions remained consistent.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in stating that Oracle Engineered Systems contributed approximately 6% of total revenues in both fiscal 2022 and 2023. According to the ground truth, Oracle only explicitly disclosed the 6% figure for fiscal 2023 and 2024; no specific percentage was provided for 2022. This misrepresents the evolution of financial transparency and overstates the availability of data for 2022. Additionally, the claim that cloud services grew from 25% to 37% of total revenues is not supported by the original answer and introduces unverified data. (2) Quantitative accuracy is low because the core percentage attribution is incorrectly applied to 2022. While the 6% figure for 2023 is correct, extending it to 2022 is unsupported and changes the interpretation of revenue trend and disclosure evolution. (3) The reasoning partially captures the revenue recognition method (point of delivery), which is correctly stated and consistent with the ground truth. However, it fails to reflect the strategic evolution highlighted in 2023—specifically, increased R&D emphasis and new disclosures about factors affecting hardware revenue predictability (e.g., manufacturing partners, competition with cloud infrastructure). The LLM downplays strategic shifts by asserting 'no material change,' which contradicts the original answer’s emphasis on clearer measurement and enhanced strategic focus. (4) Contextual relevance is high because the response addresses revenue recognition, financial contribution, and strategic positioning as asked. However, due to key factual inaccuracies and omission of the true nature of Oracle’s evolving disclosure and strategic emphasis, the overall correctness score is limited to 4, reflecting partial accuracy with major errors in multi-hop synthesis and temporal attribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 502,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "Comcast's relationship with representation firms in advertising sales remained consistent between 2023 and 2024. Both years describe similar strategies: Comcast acts as the principal in representation agreements, selling advertising units allocated to them and recording revenue net of agency commissions. The 2024 report added a detail about Peacock subscriptions, but no significant changes in the partnership structure or strategy with representation firms were noted. The approach to leveraging these firms as an extension of the sales force and recognizing revenue net of commissions remained unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that Comcast's relationship with representation firms remained consistent between 2023 and 2024. The ground truth states there was a clear evolution—from a co-selling model in 2023 where representation firms sold a portion of Comcast's advertising units (with revenue recorded net of commissions), to a formalized representation structure in 2024 where Comcast sells advertising on behalf of third parties. The LLM incorrectly claims no significant changes occurred, which contradicts the ground truth. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, the years 2023 and 2024 are correctly referenced, and no false numbers are introduced, hence a score of 10. (3) The multi-hop reasoning is flawed—the model fails to synthesize the shift in strategic relationship over time, missing the key evolution from an extension of the sales force to formal representation agreements. This reflects a failure in qualitative reasoning and entity-role transformation across years. (4) Contextual relevance is moderate because the answer discusses the correct topic (Comcast's ad sales strategy with representation firms) and correct entities, but it draws the wrong conclusion about change over time, making it misleading despite using relevant terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 382,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "Oracle's approach to industry-specific hardware offerings remained consistent between fiscal 2022 and 2023, with revenue recognized at the point of delivery when hardware and related software are transferred to customers. However, the strategic emphasis shifted toward cloud services, as cloud services revenue grew to 37% of total revenues in fiscal 2024 (compared to 25% in 2022), reflecting a broader focus on cloud-based solutions. The hardware business, including industry-specific offerings, continued to represent 6% of total revenues in both periods, with no explicit change in revenue recognition methodology for these products.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies and misses key aspects of the ground truth. It incorrectly claims that Oracle's approach to revenue recognition remained consistent between fiscal 2022 and 2023, while the ground truth states that Oracle introduced a more detailed explanation in 2023 regarding combined performance obligations (hardware plus software), indicating an evolution in disclosure and possibly in accounting emphasis. The LLM also fabricates data about cloud services growing to 37% of total revenues in fiscal 2024, which is outside the question's scope (2022–2023) and not supported by the original answer. Additionally, the claim that hardware represented 6% of total revenues in both years is unsupported in the ground truth, which does not mention revenue percentages. (2) Quantitative inaccuracies include the made-up figures: '37% in fiscal 2024', '25% in 2022', and '6% of total revenues'—none of which appear in the original answer. These numbers are not only irrelevant but also introduce false precision. (3) The multi-hop reasoning fails because the LLM does not synthesize the correct evolution in revenue recognition disclosures or the shift in strategic emphasis toward R&D and innovation in hardware for 2023. Instead, it incorrectly infers a strategic shift toward cloud services based on fabricated metrics, ignoring the actual qualitative shift in hardware strategy described in the ground truth. (4) The contextual relevance is moderate because the answer addresses Oracle and hardware offerings, but it misrepresents the nature of changes in both revenue recognition and strategic focus. The core of the question—evolution in hardware strategy and revenue treatment—is inaccurately portrayed, leading to a low correctness score despite some topical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 496,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "IMBRUVICA (ibrutinib) sales declined by 13.7% from $3.784 billion in 2022 to $3.264 billion in 2023. This decrease was primarily driven by **global competitive pressures** from novel oral agents, as noted in the 2023 filing. Additionally, the 2023 report highlights that competitive pressures and the loss of exclusivity for other products like ZYTIGA partially offset growth in the Oncology segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the sales figures for IMBRUVICA in 2022 ($3.784 billion) and 2023 ($3.264 billion), and accurately calculates the 13.7% decline, matching the ground truth exactly. All numeric values and the percentage change are factually correct, satisfying quantitative accuracy. (2) The answer addresses the sales evolution between 2022 and 2023 with precise figures and change percentage, fulfilling the first part of the multi-part question. For contributing factors, it correctly identifies 'competitive pressures from novel oral agents' as a key driver, which aligns with the original answer. It adds a relevant detail about 'loss of exclusivity for other products like ZYTIGA' affecting the Oncology segment, which is contextually accurate but slightly shifts focus from IMBRUVICA-specific factors. While this is not incorrect, the original answer emphasizes sustained competitive pressures and potential market saturation or treatment shifts in oncology—nuances only partially reflected in the LLM response. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across years and attributes the decline to competitive dynamics mentioned in the 2023 filing. However, it omits mention of pandemic-related delays in new patient starts in 2022, which was part of the evolving context in the ground truth. This is a minor omission that doesn't undermine the core explanation but reduces completeness. (4) Entity accuracy is perfect—IMBRUVICA, ibrutinib, correct years, and associated financial metrics are all properly identified. The answer is highly contextually relevant and semantically equivalent to the ground truth in key aspects, with only slight underrepresentation of the full causal picture. Hence, a correctness score of 9 is justified—excellent accuracy with minor room for deeper contextual synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 507,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "Comcast's involvement with Universal Beijing Resort remained consistent in 2023 and 2024, with a 30% ownership stake and no changes to the ownership structure. Debt levels slightly decreased from $3.5 billion (2023) to $3.4 billion (2024), reflecting the resort's ongoing financing under a syndicated loan agreement secured by its assets and equity. Financial risk exposure is limited to Comcast's 30% equity interest, as the resort is a variable interest entity (VIE) consolidated by Comcast with no guarantees or liquidity arrangements beyond its ownership stake. The debt is not guaranteed by Comcast, capping its risk at the equity investment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts: Comcast's 30% ownership stake, debt levels decreasing from $3.5 billion in 2023 to $3.4 billion in 2024, and the financial risk exposure being limited to the equity interest. It accurately states that Universal Beijing Resort is a VIE consolidated by Comcast with no guarantees beyond its ownership. (2) Quantitative accuracy is perfect: $3.5 billion and $3.4 billion debt figures match the ground truth. While the original answer breaks down the term loan ($3.1B in 2023, $3.0B in 2024), the LLM omits this detail but does not misstate anything—this is a minor omission, not an error. (3) Multi-hop reasoning is sound: the model synthesizes ownership, debt trends, consolidation treatment, and risk exposure across years and entities (Comcast and Universal Beijing Resort). It correctly infers that lack of guarantees limits risk to equity, consistent with VIE accounting. (4) The answer is semantically equivalent to the ground truth, with only a slight lack of granularity on the term loan breakdown preventing a perfect 10. All other elements—ownership stability, debt trend, risk exposure, consolidation—are accurately conveyed. Contextual relevance is full, addressing all three dimensions of the question: debt, ownership, and risk.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 365,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "FedEx's financial commitment related to future lease payments for build-to-suit facilities and equipment decreased from **$3.4 billion** as of May 31, 2022, to **$0.9 billion** as of May 31, 2023. This reduction reflects the commencement of some previously announced build-to-suit leases in 2023, as these leases were expected to begin between 2023 and 2024. The strategy indicates a focus on entering into long-term, customized facilities and equipment leases in 2022, with phased commencements in subsequent years to align with operational needs and capital allocation priorities.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the key financial figures: $3.4 billion in 2022 and $0.9 billion in 2023 for future lease payments related to build-to-suit facilities and equipment, matching the ground truth exactly. The dates (May 31, 2022 and May 31, 2023) align with typical FedEx fiscal year-ends, which is contextually accurate. (2) Quantitatively, all numbers are accurate—both the 2022 and 2023 undiscounted payment amounts are correct, and the significant reduction is properly highlighted. (3) The reasoning is mostly sound: the LLM correctly attributes the drop to the commencement of leases that were expected between 2023 and 2024. However, it misses a key strategic implication present in the original answer: the extension of commencement dates to 2025–2027 in 2023, which suggests a shift toward fewer long-term commitments with a more staggered rollout. Instead, the LLM interprets the strategy as a continued focus on long-term leases, which contradicts the ground truth's conclusion of a strategic reduction in such commitments. (4) While the answer is factually strong and contextually relevant, the qualitative reasoning slightly misrepresents the strategic direction, warranting a deduction in qualitative accuracy. Correctness score is high due to accurate numbers and partial reasoning, but not full, due to the misinterpretation of strategic intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 384,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "Mastercard's relationship with Dynamic Yield LTD, acquired in April 2022 for $325 million, remained unchanged between 2023 and 2024. The 2023 10-K confirmed the finalized purchase accounting for the acquisition, and the 2024 10-K did not mention any further actions or changes related to Dynamic Yield. Instead, Mastercard's strategic focus in 2024 shifted toward acquiring new capabilities, such as Recorded Future (a threat intelligence company), indicating a broader emphasis on expanding into cybersecurity and identity solutions rather than altering its existing relationship with Dynamic Yield.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Mastercard acquired Dynamic Yield LTD in April 2022 for $325 million, consistent with the ground truth. It accurately notes that the 2023 10-K confirmed finalized purchase accounting, which aligns with the disclosure of $200 million in goodwill attributed to synergies. The 2024 10-K mentions no new activity with Dynamic Yield, correctly interpreted as a stable, post-integration relationship. The strategic pivot to cybersecurity via the acquisition of Recorded Future in 2024 is accurately reported and correctly contrasts with the lack of new activity in Dynamic Yield. (2) All numeric values—acquisition date (April 2022), acquisition price ($325 million), and the absence of new financial figures in 2024—are factually correct. While the $200 million goodwill figure is not explicitly mentioned in the LLM answer, it is not required for the conclusion and its omission does not introduce inaccuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, infers the completion of integration from lack of new disclosures, and connects the shift in M&A activity to a strategic realignment. The logic that no new actions imply a stable relationship and a shift in focus is valid. (4) The answer is contextually excellent, directly addressing both the evolution of the relationship and what it indicates about strategic focus. The only minor shortcoming is the omission of the $200 million goodwill detail, which adds nuance about expected synergies but does not alter the core correctness. Hence, a score of 9 is justified—very high accuracy with a small loss in completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 461,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "The Severance Plan for Senior Officers at Lowe's was amended and restated on **May 26, 2022**, as noted in Exhibit 10.28 of the **2024 10-K filing** (filed November 27, 2024). This represents the most recent amendment date referenced in the provided documents, with no further amendments listed between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all dates and exhibit numbers are correct: the amendment date of May 26, 2022, and the filing date of November 27, 2024, for Exhibit 10.28 in the 2024 10-K are factually accurate. The LLM correctly identifies the most recent amendment and associated filing. (2) The answer omits the 2022 reference to the prior version (amended May 29, 2020, filed August 26, 2020, Exhibit 10.29), which was part of the original answer’s comparative evolution narrative. While this detail is not critical to identifying the most recent amendment, its absence slightly reduces completeness in showing the full evolution between 2022 and 2024. (3) The reasoning is sound—LLM correctly synthesizes information from the 2024 filing to infer the latest amendment, and no incorrect inferences are made. (4) The answer is contextually relevant and directly addresses the core of the question—evolution in terms of most recent amendment and filing—though a more complete response would have noted the prior version for full trajectory. Minor omission prevents a perfect 10, but factual correctness and clarity warrant a 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 334,
        "total_tokens": 1542
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "The fair value of Netflix's 6.375% Senior Notes decreased from **$995 million** as of December 31, 2021, to **$872 million** as of December 31, 2023. This decline suggests a reduction in market confidence in Netflix's debt, likely reflecting increased perceived credit risk or rising interest rates during the period. However, the fair value slightly increased from **$830 million** in 2022 to $872 million in 2023, indicating some stabilization or improved market conditions toward the end of the period. Overall, the trend highlights evolving market perceptions of Netflix's financial stability and debt risk.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the fair value of Netflix's 6.375% Senior Notes as $872 million on December 31, 2023, matching the ground truth. However, it reports the December 31, 2021, value as $995 million, whereas the ground truth states $999 million. This $4 million discrepancy, while relatively small, affects quantitative accuracy. (2) The calculation of the overall trend (decrease in fair value) is correct and logically sound. The LLM also introduces an intermediate data point—$830 million in 2022—which is not present in the original answer and cannot be verified from the provided ground truth. This addition, while potentially informative, introduces unverified information and could mislead. (3) The multi-hop reasoning is generally sound: the model correctly infers that a decline in fair value suggests reduced market confidence or increased credit risk, which aligns with financial principles and the original answer's interpretation. The added nuance about stabilization from 2022 to 2023, though unsupported by the ground truth, shows reasonable qualitative analysis but lacks evidentiary support. (4) The answer addresses both parts of the question—change in fair value and market perception—and does so with mostly accurate data and strong contextual reasoning. The minor numerical inaccuracy and inclusion of unverified intermediate data prevent a higher score. Contextual relevance is perfect as all content directly addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 410,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "IMBRUVICA's sales declined from $3.784 billion in 2022 to $3.264 billion in 2023, reflecting a 13.7% decrease. This decline was partially offset by competitive pressures and COVID-19-related market dynamics. However, the broader oncology segment grew by 10.5% in 2023, driven by strong performance from other products like DARZALEX and ERLEADA, indicating IMBRUVICA's market position remains significant despite facing competitive challenges.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the reported 2022 sales figure and the calculated percentage decline. The ground truth states IMBRUVICA's 2022 sales were $4,369 million, but the LLM incorrectly reports $3.784 billion. The correct 2023 sales figure ($3,264 million) is accurately cited. The percentage decline is miscalculated: the LLM reports a 13.7% drop based on its incorrect figures, whereas the actual decline from $4,369M to $3,264M is 25.2%. (2) Calculations: Correct decline = (4,369 - 3,264) / 4,369 ≈ 25.2%. LLM's calculation using $3.784B to $3.264B would be (3,784 - 3,264)/3,784 ≈ 13.7% — mathematically correct only if the input numbers were right, which they are not. (3) Multi-hop reasoning is partially sound — the model correctly references competitive products DARZALEX and ERLEADA and links IMBRUVICA's decline to broader oncology trends. However, the conclusion that IMBRUVICA's market position 'remains significant' contradicts the ground truth implication of a 'weakening market position' due to steep decline amid peer growth. (4) Contextually, the answer addresses both parts of the question — sales evolution and market position — so relevance is high. However, due to major numerical errors and flawed inference, the overall correctness is low. Quantitative accuracy is severely compromised, qualitative reasoning is partially valid, and contextual framing is appropriate but based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 409,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "LOW's inventory shrink reserve increased from $414 million in 2022 to $427 million in 2024, while the LCNRV reserve rose from $168 million in 2022 to $222 million in 2024. These increases implied higher provisions for inventory write-downs and shrinkage, which negatively impacted net earnings. A 10% change in either reserve would have affected net earnings by approximately $17 million (LCNRV) and $32 million (shrink) in 2024, reflecting greater sensitivity to reserve adjustments over this period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all factual information from the ground truth. The inventory shrink reserve increased from $414 million in 2022 to $427 million in 2024, and the LCNRV reserve increased from $168 million to $222 million—both figures match exactly. The impact on net earnings is also accurately stated: a 10% change in the LCNRV reserve would affect net earnings by approximately $17 million, and a 10% change in the shrink reserve by $32 million. (2) All numbers are quantitatively accurate, with correct years and dollar amounts. No calculation errors are present. Format variations (e.g., 'million' vs '$M') are acceptable and do not affect accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across time (2022 to 2024) and across two distinct reserves (shrink and LCNRV), then links their changes to implications for net earnings. The conclusion about increasing sensitivity to reserve adjustments aligns with the ground truth's emphasis on growing reserve needs and earnings sensitivity. (4) The answer is semantically equivalent to the original, conveying the same core facts, trends, and implications with slightly more concise wording. All parts of the question—evolution of reserves and implications for net earnings—are fully addressed. Therefore, all scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 376,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "Qulipta's status evolved significantly from 2022 to 2023, transitioning from development to commercialization. In April 2023, the FDA approved Qulipta for preventive treatment of chronic migraine, and in August 2023, the EC approved Aquipta (Qulipta) for migraine in adults with four or more migraine days per month. Financially, Qulipta's net revenues surged over 100% in 2023 compared to 2022, driven by strong market share uptake, growth across indications, and regulatory approvals, with U.S. and international revenues totaling $813 million in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures and dates. According to the ground truth, Qulipta generated $405 million in U.S. revenue and $3 million internationally in 2023, totaling $408 million—not $813 million as claimed. The statement that revenues 'surged over 100% in 2023 compared to 2022' is unsupported by the original answer, which does not provide 2022 revenue figures for Qulipta specifically. Additionally, the FDA approval date for Qulipta was in September 2021, not April 2023; the 2023 EC approval for 'Aquipta' (a misspelling of Qulipta) is plausible but not confirmed in the ground truth. (2) The revenue total is off by over $400 million, and the percentage growth claim introduces a calculation not verifiable from the original data. The reclassification of $1.0 billion in intangible assets in 2022 due to regulatory approvals is entirely omitted, which is a key part of Qulipta’s status evolution. (3) The reasoning partially captures the transition from development to commercialization, which aligns with the multi-hop intent—linking regulatory milestones to financial performance. However, it fabricates specific approval dates and revenue growth metrics, undermining the synthesis. (4) The contextual relevance is high because the answer addresses both development and commercialization progress. However, the quantitative accuracy is very low due to incorrect numbers and invented calculations. Qualitative accuracy is moderate as the general narrative direction is correct, but key details are wrong or missing. Correctness score reflects major factual and numerical errors despite some conceptual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 463,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "Honeywell's financial dependency on Resideo for environmental liabilities remained significant between 2022 and 2023, as the receivable from Resideo increased to $187 million in 2023 (from $157 million in 2022). This reflects continued reliance on Resideo's payments for environmental costs at specific sites, though the agreement caps annual reimbursements at $140 million. The increase in the receivable suggests that Honeywell's net environmental liability (after accounting for Resideo's contributions) has grown, indicating ongoing risk exposure. However, the cap and Resideo's obligation to cover 90% of costs mitigate some of this risk, though uncertainties around future obligations and litigation could still impact financial outcomes.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Resideo's subsidiary is obligated to pay 90% of Honeywell's annual net spending on environmental matters up to $140 million per year, and that this arrangement remained consistent between 2022 and 2023. However, the LLM introduces a 'receivable from Resideo' of $187 million in 2023 (up from $157 million in 2022), which is not mentioned in the original answer and contradicts the cap of $140 million per year. This suggests a fundamental error—either in data sourcing or reasoning—since the receivable cannot exceed the annual cap unless it includes carryforwards or arrears, which are not referenced. (2) The numbers $187M and $157M are not supported by the ground truth and appear to be fabricated or misattributed. The cap of $140 million is correctly noted, but the implication that Honeywell is receiving more than the cap (or accumulating a receivable beyond it) undermines the accuracy. There is no mention in the original answer of a growing receivable, so this is a major quantitative deviation. (3) The qualitative reasoning is sound in interpreting that Honeywell remains dependent on Resideo for risk mitigation and that the 90% coverage reduces exposure. The conclusion about ongoing risk exposure due to uncertainties is reasonable and adds context, even if speculative. The multi-hop synthesis—linking subsidiary obligation, cap, and risk exposure—is logically structured and relevant. (4) The contextual relevance is high because the answer addresses both parts of the question: evolution of dependency and implications for risk. However, the correctness score is reduced to 6 due to the critical numerical inaccuracies, which distort the factual basis of the conclusion. While the overall theme of continued dependency is correct, the use of incorrect financial figures undermines confidence in the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 534,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "Target's definition of \"original maturity\" for cash equivalents remained consistent between 2022 and 2024, defined as investments with an original maturity of three months or less from the time of purchase. This consistency indicates a stable approach to liquidity management, prioritizing short-term, highly liquid assets. However, the decline in cash and cash equivalents from $8,511 million (2021) to $3,805 million (2024) suggests potential shifts in cash management strategies, such as reallocating funds to longer-term investments or operational needs, while maintaining the core definition of original maturity.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Target's definition of 'original maturity' for cash equivalents remained at three months or less between 2022 and 2024, which aligns with the ground truth. However, the LLM introduces financial data (cash and cash equivalents declining from $8,511 million in 2021 to $3,805 million in 2024) that is not mentioned or implied in the original answer and is not directly tied to the definition or treatment of 'original maturity.' This data, while potentially factual, distracts from the core focus on definitional evolution and is used to infer a shift in cash management strategy not supported by the ground truth. (2) The numbers cited ($8,511M and $3,805M) cannot be verified against the provided ground truth, which contains no quantitative data about cash balances. Therefore, their inclusion introduces unverified quantitative claims, reducing quantitative accuracy. (3) The multi-hop reasoning is partially sound in recognizing consistency in the definition, but the leap to inferring strategic reallocation based on external cash balance trends (not linked to the definition of original maturity) reflects flawed reasoning. The ground truth emphasizes a qualitative evolution in disclosure—adding discussion of fair value measurements—rather than inferring strategy from balance changes. The LLM misses this nuance entirely. (4) While the answer is contextually relevant and addresses the definitional consistency, it fails to capture the key qualitative evolution noted in the original answer (broader discussion of fair value measurements), making it incomplete in synthesis. Hence, correctness is reduced to 5 due to partial factual alignment but significant omission of key qualitative development and introduction of unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 489,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "Between 2023 and 2024, NVIDIA's 3.50% Notes Due 2040 remained classified as long-term liabilities, carried at amortized cost net of unamortized discounts and issuance costs. Their fair value slightly decreased from $870 million (Jan 29, 2023) to $851 million (Jan 28, 2024), reflecting market interest rate movements. This indicates NVIDIA's strategy to manage long-term debt by issuing fixed-rate obligations with extended maturities (e.g., 2040), balancing refinancing risk and interest rate exposure. The continued presence of these notes alongside shorter-term instruments (e.g., 2024, 2026) suggests a diversified debt structure to optimize liquidity and financial flexibility.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timeline. According to the ground truth, the valuation of the 3.50% Notes Due 2040 increased from $851 million (as of January 28, 2024) to $1,000 million (as of January 26, 2025), indicating growth in carrying value. However, the LLM incorrectly states that the fair value decreased from $870 million (Jan 29, 2023) to $851 million (Jan 28, 2024), which contradicts the original data—no earlier value of $870 million is present in the ground truth, and the direction of change is wrong. Furthermore, the LLM misrepresents the time frame: the ground truth compares 2023 reporting (with data as of Jan 28, 2024) to 2024 reporting (as of Jan 26, 2025), not Jan 2023 to Jan 2024 as implied. (2) The LLM introduces a 'fair value' decrease not mentioned in the original answer—the original refers to carrying value and classification in the pricing hierarchy (Level 2), which the LLM omits entirely. Instead, it fabricates a narrative around market-driven fair value changes, which is unsupported. The correct evolution includes a rise in valuation to $1,000 million with added details like effective interest rate (3.54%) and remaining term (15.2 years), none of which are mentioned in the LLM response. (3) The multi-hop reasoning is partially sound in interpreting the long-term debt strategy, but based on incorrect data. The idea of using fixed-rate, long-term notes to manage refinancing risk is plausible, but the conclusion is drawn from false premises. The mention of shorter-term instruments (2024, 2026) is extraneous and not supported by the provided ground truth. (4) While the LLM attempts to address the strategic implications, the core quantitative inaccuracies severely undermine correctness. The contextual relevance is high because it addresses valuation, classification, and strategy, but the factual foundation is flawed. Thus, the correctness score is low due to major errors in numbers and timeline, despite reasonable structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 549,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "Venclexta's total global revenue increased from $2,009 million in 2022 to $2,288 million in 2023, reflecting a 13.9% growth rate. This growth was driven by 8% higher U.S. revenues and 20.1% higher international revenues, attributed to continued market share uptake and growth across indications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total global revenue for Venclexta in 2022 ($2,009 million) and 2023 ($2,288 million), and accurately states the 13.9% growth rate in 2023, which matches the ground truth. However, it omits the 2022 growth rate of 10.4%, which was explicitly asked for in the question (performance evolution between 2022 and 2023, including growth rates for both years). (2) All provided numbers are quantitatively accurate: $2,288M in 2023 vs $2,009M in 2022 implies a (2,288 - 2,009)/2,009 ≈ 13.9% growth, which is correct. The additional details on U.S. (8%) and international (20.1%) revenue growth are factually consistent with the knowledge graph and provide useful context, even if not part of the original answer. (3) The reasoning is sound and reflects multi-hop synthesis—comparing two years of revenue data and deriving or reporting growth trends. The omission of the 2022 growth rate prevents a perfect score, but the core financial evolution is correctly conveyed. (4) The answer is contextually relevant and adds explanatory detail (market share uptake, indication expansion) that aligns with the knowledge graph. Due to the missing 2022 growth rate, the completeness is slightly reduced, but the primary quantitative facts and trend direction are correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1148,
        "completion_tokens": 371,
        "total_tokens": 1520
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "Between the 2022 and 2023 SEC filings, Netflix amended its **Executive Severance and Retention Incentive Plan** again, effective **January 1, 2024** (as noted in the 2023 filing, Exhibit 10.16). This amendment replaced the prior plan, which had been restated in September 2021. The 2023 amendment introduced updated terms for severance and retention incentives, reflecting adjustments to align with evolving executive compensation strategies. The effective date of January 1, 2024, marks the implementation of these changes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the prior plan was restated in September 2021 (referenced in 2022 filing), and the new amendment effective January 1, 2024, was filed on December 8, 2023 (as noted in the 2023 filing). The LLM correctly identifies the effective date and the forward-looking nature of the amendment. (2) Quantitative accuracy is perfect: dates (January 1, 2024; September 2021) are correct, and the reference to the 2023 filing (Exhibit 10.16) adds precision. (3) Multi-hop reasoning is sound—LLM synthesizes information across 2022 and 2023 filings to show evolution in the plan. (4) The only minor shortcoming is that the LLM does not explicitly mention the December 8, 2023 filing date of the amendment, which is included in the ground truth and adds completeness. However, referencing the 2023 filing and Exhibit 10.16 implies this. The answer captures the core evolution and strategic intent, making it semantically equivalent with only a slight omission of a secondary detail. Hence, correctness is 9/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 311,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "Lowe's Benefit Restoration Plan was amended and restated as of January 1, 2025, reflecting updates to its structure and documentation in 2024. The plan continues to supplement the 401(k) Plan for employees with restricted benefits, offering salary deferrals and employer matches. This evolution indicates Lowe's commitment to maintaining structured, compliant retirement benefits while adapting to regulatory changes, emphasizing a balanced approach to employee retirement support.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) It correctly identifies the January 1, 2025 effective date of the amended and restated Benefit Restoration Plan, as introduced in 2024 filings, matching the original answer's reference to the updated exhibit (10.3) in the 2024 10-K. The description of the plan’s purpose—supplementing the 401(k) Plan for employees affected by IRS limits through salary deferrals and employer matches—is consistent. (2) There are no numerical values requiring calculation, but all dates and timeframes (2024 documentation update, 2025 effective date) are correct. (3) The multi-hop reasoning is sound: the model correctly infers that the formal restatement indicates a strategic approach to retirement benefits, particularly for high-earners, based on documentation changes across years. (4) The LLM slightly underemphasizes the significance of the 'updated and restated' filing as a formal structural enhancement and its implications for executive compensation strategy, which the original answer highlights more clearly. However, the conclusion about 'commitment to structured, compliant benefits' and 'adapting to regulatory changes' is semantically equivalent and contextually appropriate. Minor omission in depth of strategic implication does not detract from overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 373,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "NVDA's financial obligations related to the 0.584% Notes Due 2024 increased from $1,185 million in fiscal 2023 to $1,228 million in fiscal 2024, reflecting interest accruals and adjustments. The notes were repaid in fiscal year 2025, as noted in the 2024 10-K, but this repayment occurred outside the 2023–2024 period.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, NVDA's liability for the 0.584% Notes Due 2024 was $1,185 million in fiscal 2023 and was fully repaid by fiscal 2024. However, the LLM claims the obligation increased to $1,228 million in fiscal 2024, which contradicts the ground truth. Additionally, the LLM incorrectly states that repayment occurred in fiscal year 2025, while the ground truth confirms repayment was completed within fiscal 2024 as per the 2024 10-K. (2) Quantitatively, the $1,185 million figure for fiscal 2023 is correct, but the $1,228 million for 2024 is unsupported and incorrect. There is no evidence of interest accruals increasing the liability—on the contrary, it was extinguished. The repayment timing is also factually wrong. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of the debt obligation across years and misinterprets the repayment timeline. Instead of recognizing that the debt was resolved between 2023 and 2024, it projects repayment into 2025, which is outside the scope and factually inaccurate. (4) Contextual relevance is moderate—the response addresses the right topic (NVDA's 0.584% Notes Due 2024) and time frame (2023–2024), but the core facts about the amount and repayment are incorrect, severely undermining accuracy. Minor credit is given for referencing the 2024 10-K and attempting to explain the obligation’s evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1142,
        "completion_tokens": 406,
        "total_tokens": 1548
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "Mavyret's global revenue decreased by 7.2% in 2023 compared to 2022. In the United States, revenue declined 12.7% to $659 million, driven by factors such as pricing pressures, while international revenue decreased slightly by 1.9% to $771 million, reflecting modest market growth and competition. The overall decline was more pronounced in the U.S. market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: U.S. revenue declined from $755M to $659M (12.7% decrease), international revenue declined from $786M to $771M (1.9% decrease), and total global revenue decreased from $1,541M to $1,430M. The 7.2% overall decline is accurate ((1541-1430)/1541 ≈ 7.2%), though not explicitly mentioned in the original answer, it is a correct derivation. (2) All numeric values match the ground truth, with correct percentages and dollar amounts. Format variations (e.g., $659 million) are acceptable and consistent. (3) The multi-hop reasoning is sound—information is synthesized across U.S. and international markets and two years. The conclusion that the U.S. decline was more pronounced is correctly drawn. (4) The only minor shortcoming is that the LLM introduces explanatory factors not in the original answer—'pricing pressures' and 'modest market growth and competition'—which, while plausible, are not supported by the ground truth and slightly reduce qualitative accuracy. However, these do not contradict the data and are framed as contextual commentary. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 340,
        "total_tokens": 1579
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "Netflix remained in compliance with all covenant limitations related to its Senior Notes as of December 31, 2024 and 2023, with no material changes to the scope of restrictions between 2022 and 2024. Key terms, such as limitations on liens, sale-leaseback transactions, and restrictions on consolidating/merging assets, persisted. In 2024, the company repaid the $400 million 5.750% Senior Notes at maturity and maintained compliance with the Revolving Credit Facility's covenants, including a minimum EBITDA-to-interest expense ratio of 3.0. The scope of restrictions remained consistent, reflecting ongoing adherence to debt agreements.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Netflix remained in compliance with covenant limitations in 2022–2024 and accurately reports the $400 million repayment of the 5.750% Senior Notes in 2024. It also correctly identifies key covenants such as limitations on liens, sale-leaseback transactions, and merger/consolidation restrictions. However, it contradicts the ground truth by asserting that there were 'no material changes' and that the scope of restrictions 'remained consistent,' when the original answer explicitly states that by 2024, certain Senior Notes no longer included restrictions on sale and lease-back transactions—indicating a narrowing of covenant scope. This is a significant qualitative error in reasoning and synthesis. (2) Quantitatively, all numbers are accurate: the $400 million repayment amount, the 5.750% interest rate, and the reference to compliance in 2023 and 2024 are correct. The mention of the Revolving Credit Facility’s 3.0 EBITDA-to-interest ratio is contextually relevant but not directly tied to the Senior Notes covenants, which is a minor overreach but not factually incorrect. (3) The multi-hop reasoning is partially flawed: while the model correctly synthesizes compliance status and repayment activity, it fails to recognize the evolution in covenant scope—a core part of the question. This reflects a failure to fully interpret changes over time across filings. (4) The answer is contextually relevant and well-structured, but the incorrect assertion about unchanged covenant scope undermines the qualitative accuracy. The correctness score is reduced due to this key omission and misrepresentation of covenant evolution, despite strong quantitative performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 469,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "Honeywell restructured its Safety and Productivity Solutions segment in 2023 by combining the Safety and Retail business unit (which included gas detection and safety products) with the Advanced Sensing Technologies unit to form the Sensing and Safety Technologies business unit. This structural change, effective July 2022, reflects a realignment to integrate safety and sensing capabilities, streamlining operations and enhancing focus on technologies that combine safety, sensing, and productivity solutions. The reorganization was retroactively applied to historical periods in the 2023 filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the Safety and Retail unit was merged with Advanced Sensing Technologies to form Sensing and Safety Technologies; the change was effective July 2022 and reported in the 2023 filing; the strategic rationale of integrating sensing and safety capabilities is correctly explained. (2) Quantitative accuracy is perfect: while the exact revenue figure ($2,387 million) is not mentioned in the LLM answer, this omission does not detract significantly from the core of the question, which focuses on the structural evolution and change. No incorrect numbers or dates are present. (3) Multi-hop reasoning is sound—the model correctly synthesizes information about organizational changes across years and units, noting the retroactive application in 2023 filings. (4) The answer is contextually relevant and fully addresses both parts of the question: the evolution of Honeywell’s approach and the structural change in 2023. The only minor shortcoming is the omission of the specific revenue figure from 2022, which was included in the original answer and adds quantitative context. However, since the question does not explicitly ask for financial performance, this is a minor omission rather than a factual error. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 399,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "Between 2023 and 2024, Class B-2 Common Stock was no longer outstanding as of September 30, 2024, indicating conversion into Class A Common Stock under Visa's U.S. retrospective responsibility plan, which became effective upon resolution of litigation. This conversion reduced voting dilution risks and aligned Class B-2 holders with Class A shareholders in corporate governance, though the 2023 filing noted that conversions could still impact market price and governance dynamics due to dilution. The 2024 equity section confirms no Class B-2 shares remained outstanding, reflecting their conversion.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Class B-2 Common Stock was no longer outstanding by 2024 and that it converted into Class A Common Stock, aligning with the ground truth. However, it introduces specific details not present in the original answer, such as 'September 30, 2024' and 'Visa's U.S. retrospective responsibility plan,' which are not mentioned in the ground truth and cannot be verified from the provided information. The original answer states that no shares were outstanding prior to the Class B-1 exchange offer but does not specify a date or tie the conversion to litigation resolution. (2) The date 'September 30, 2024' is a precise claim absent from the ground truth and may be incorrect or unsupported; no other numeric values (e.g., share counts, percentages) are provided in either answer, so no calculation errors are detectable. (3) The multi-hop reasoning is partially sound—correctly inferring a structural shift from active to non-outstanding status—but the LLM adds unverified causal mechanisms (litigation, specific plan name) that distort the factual basis. The original answer emphasizes a strategic equity shift without attributing it to a specific program or legal outcome. (4) While the core idea of conversion and reduced governance influence is preserved, the inclusion of unsupported specifics reduces factual accuracy. The answer remains contextually relevant and captures the evolution in status and governance impact, but the added details introduce inaccuracies, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 426,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "The Home Depot enhanced its shopping experience in 2024 by expanding digital capabilities, such as improving mobile app functionality, enhancing online product information, and refining interconnected shopping experiences across stores and digital platforms. In-store, the company continued investments in technology (e.g., self-checkout, electronic shelf labels, and Computer Vision) and expanded store locations to improve convenience. These efforts built on 2023 initiatives, with 2024 emphasizing differentiated fulfillment options, enhanced order management systems, and broader supply chain investments to support faster delivery and customer-centric services.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies The Home Depot and the relevant time periods (2023–2024), and accurately references ongoing investments in digital and in-store capabilities such as mobile app functionality, electronic shelf labels, and self-checkout—elements present in the original answer. However, it diverges significantly in describing the evolution between years. While the ground truth emphasizes a strategic shift in 2024 toward personalized digital experiences (e.g., customer review summaries, enhanced product content, and data-driven personalization), the LLM instead highlights 'differentiated fulfillment options,' 'order management systems,' and 'supply chain investments'—details not mentioned in the original answer and representing a different strategic emphasis. Additionally, the mention of 'Computer Vision' and 'expanding store locations' introduces new technologies and initiatives absent from the ground truth, potentially conflating with other corporate strategies. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised—score reflects full alignment in this dimension. (3) The multi-hop reasoning is partially sound: the model recognizes continuity between 2023 and 2024 initiatives but fails to accurately capture the nature of the evolution, particularly the pivot toward personalization and data-driven insights in 2024. Instead, it substitutes logistics and fulfillment enhancements, which shifts the strategic narrative. (4) The contextual relevance is high because the response stays focused on shopping experience improvements across digital and in-store channels, but the qualitative inaccuracy in representing the core 2024 strategic shift reduces overall correctness. The answer captures the general direction but misrepresents the specific evolution detailed in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 513,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "The Target Corporation Long-Term Incentive Plan (LTIP) structure evolved from 2022 to 2024 by introducing new equity award forms under the 2020 LTIP. In 2022, the plan included Restricted Stock Units (RSUs), Performance-Based RSUs, and Performance Share Units. By 2024, additional forms such as **Cliff-Vested Restricted Stock Units** and **Performance Award Performance Share Units** were added, reflecting expanded equity award structures to align with evolving compensation strategies.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in Target Corporation's Long-Term Incentive Plan from 2022 to 2024. It correctly identifies the introduction of Cliff-Vested Restricted Stock Units and Performance Award Performance Share Units by 2024, which aligns with the ground truth. The dates (2022 and 2024) are accurate, and the overall direction of plan expansion is correctly conveyed. However, the LLM omits several equity award types present in 2022 according to the original answer, such as Non-Qualified Stock Options, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. While it mentions RSUs, Performance-Based RSUs, and Performance Share Units—core components—the answer is incomplete in representing the full 2022 structure. This omission affects completeness and qualitative accuracy, though not enough to undermine the core correctness. The reasoning is sound in identifying an expansion trend and new award types, and the answer remains contextually relevant and semantically aligned with the main point of evolution in equity award forms. No numerical or date inaccuracies are present, hence perfect quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 345,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "Qulipta's commercial performance showed significant growth from its 2021 FDA approval. In 2022, net revenues reached $158 million (a >100% increase from 2021), driven by strong market adoption. In 2023, revenues surged further to $813 million (total U.S. $405 million and international $408 million), reflecting continued market share uptake and growth, bolstered by expanded approvals for chronic migraine and EU launch in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the 2023 revenue figures. The ground truth states Qulipta generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million in 2023. However, the LLM incorrectly reports $813 million total revenue with $405 million U.S. and $408 million international, which is a major quantitative error—especially the $408 million international figure, which is 136x higher than the true $3 million. The 2022 U.S. revenue of $158 million is correct, as is the FDA approval in 2021. (2) The calculation of 'a >100% increase from 2021' is plausible given no 2021 revenue, but the 2023 surge to $813 million is factually wrong. The LLM also incorrectly implies that international revenue was $408 million, when it was only $3 million. (3) The multi-hop reasoning is partially sound—linking FDA approval to commercial performance over time—but fails in synthesizing accurate financial data across years. The mention of expanded approvals for chronic migraine and EU launch in 2023 is plausible context but not present in the original answer and not confirmed by the ground truth provided, making it speculative. (4) The contextual relevance is high as the answer addresses the evolution of commercial performance over time and attempts to explain growth drivers. However, due to the severe quantitative inaccuracies in the 2023 revenue breakdown and total, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the reasoning structure is logical and some facts are correct, but key data synthesis is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 452,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "Netflix's treatment and disclosure of the 2020 Stock Plan remained structurally consistent between the 2022 and 2024 SEC filings, as both describe the plan as a stockholder-approved mechanism for granting equity instruments (options, RSUs, PSUs). However, the 2024 filing provides more granular activity data, including detailed tables on stock option outstanding balances, intrinsic values, vesting terms, and total stock-based compensation expenses ($272.6M in 2024 vs. $339.4M in 2023). The 2024 disclosure also explicitly notes no stock options were granted subject to vesting conditions in 2022, reflecting evolving equity compensation activity while maintaining the plan's structural description.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The ground truth states that in 2022, the 2020 Stock Plan was only referenced in the exhibit list with no detailed description, whereas the LLM claims both 2022 and 2024 filings describe the plan's structure (e.g., as stockholder-approved), which contradicts the original answer. This misrepresents the core evolution — from minimal disclosure to detailed operational disclosure. (2) The quantitative data in the LLM answer (e.g., $272.6M in 2024, $339.4M in 2023, vesting conditions in 2022) is entirely fabricated and not present in the ground truth. There are no dollar amounts or specific figures mentioned in the original answer, so these numbers cannot be verified and appear invented. (3) The multi-hop reasoning is flawed: the question asks about the evolution in *treatment and disclosure* of the plan between 2022 and 2024, but the LLM incorrectly assumes both years contain structural descriptions and focuses on granular activity data that isn't supported by the ground truth. It fails to recognize the key shift from passive documentation (2022) to active, detailed disclosure (2024). (4) Contextual relevance is moderate because the answer addresses equity compensation and plan structure, which are relevant topics, but the specific claims and data undermine accuracy. The LLM invents details not present in the source and misses the fundamental qualitative shift emphasized in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 413,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "The company's approach to aluminum purchase agreements remained classified as derivative instruments in both 2022 and 2023, used to address long-term strategic sourcing objectives and non-U.S. business requirements. In 2023, the documentation explicitly emphasized their strategic role in securing supply and managing non-U.S. operations, while maintaining pricing at prevailing market rates. This reflects a continued focus on strategic use rather than hedging, with no significant change in classification between the two years.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that aluminum purchase agreements were classified as derivative instruments in both 2022 and 2023 and were used for long-term strategic sourcing and non-U.S. business requirements, which aligns with the ground truth. It also correctly notes the continuation of market-based pricing. However, it misses a key evolution highlighted in the original answer: the 2023 clarification that the quantities in these contracts 'offset each other,' which implies a more nuanced risk management or positioning strategy. This omission reduces completeness and slightly affects qualitative accuracy. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are misstated. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes information across two years and maintains consistent entity (aluminum purchase agreements, derivative classification, strategic use). However, it fails to capture the full strategic evolution—specifically the offsetting nature of the contracts in 2023—which is a critical detail in the progression of the company's approach. (4) The answer is contextually relevant and factually consistent with the original, but the missing detail about offsetting quantities prevents a top score in correctness and qualitative accuracy. The core facts are correct, but a significant nuance is omitted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 410,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "The disclosure of the Directors' Code of Conduct remained consistent between 2023 and 2024, with both filings stating that the code is posted on the company's website and that amendments or waivers will be disclosed there. No changes in accessibility, scope, or specific provisions were noted in the provided documents.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claims. (1) It states that there were no changes in accessibility, scope, or provisions between 2023 and 2024, which directly contradicts the ground truth. In fact, the URL for the Directors' Code of Conduct changed from 2023 (https://www.bnymellon.com/...) to 2024 (https://www.bny.com/...), indicating a reorganization of the website and a shift in accessibility. This change in URL structure reflects a real and specific difference in how the document is hosted and accessed. (2) The 2024 filing introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was absent in 2023, clearly indicating an expansion in scope. The LLM answer fails to mention this entirely. (3) The multi-hop reasoning required—comparing two years' disclosures across accessibility (URL changes) and content (new section)—was not performed. Instead, the model incorrectly asserts consistency where there is documented change. (4) While no numerical data is involved, the qualitative accuracy is very low due to factual errors in entity (URLs) and content (missing new section). The answer is relevant to the topic but fundamentally incorrect in its conclusions, hence the low correctness and qualitative accuracy scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 352,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "The 4.95% Senior Notes due September 2026 had a net carrying amount of $745 million as of January 28, 2024, compared to $744 million as of January 29, 2023, reflecting minor adjustments from amortization of discounts. However, in June 2024, HD issued $1.75 billion of 4.95% Senior Notes due June 2034, extending maturities further. This evolution indicates a strategic shift toward longer-term debt issuance to manage liquidity, refinance maturing obligations, and support acquisitions like SRS, while maintaining flexibility through derivative hedges and credit facilities. The company’s strategy emphasizes extending debt maturities and diversifying funding sources to mitigate interest rate risk and ensure financial stability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, HD issued $750 million of 4.95% senior notes due September 30, 2026, in 2023 at a discount of $1.6 million, resulting in a carrying amount of $747 million by early 2025. However, the LLM claims a net carrying amount of $745 million as of January 28, 2024, and $744 million as of January 29, 2023, which contradicts the original data showing an initial issuance of $750 million less a $1.6 million discount (i.e., $748.4 million initial carrying value), with amortization leading to a $747 million carrying value later. More critically, the LLM states that in June 2024, HD issued $1.75 billion of 4.95% Senior Notes due June 2034 — this is entirely incorrect. The ground truth confirms that HD issued $980 million in 4.95% senior notes due September 2052, not June 2034, and there is no mention of a $1.75 billion issuance. (2) The quantitative inaccuracies are severe: wrong issuance amount ($1.75B vs $980M), wrong maturity date (June 2034 vs September 2052), incorrect carrying values over time, and no mention of the 2052 notes. These errors undermine the financial narrative. (3) The multi-hop reasoning is flawed: while the LLM correctly infers a strategy of extending maturities, it does so based on fabricated data. The correct insight — that HD expanded the 4.95% coupon to a very long-term 2052 maturity — is missed entirely. Instead, the model invents a 2034 note and misrepresents the scale and structure of the issuance. (4) Despite incorrect facts, the answer remains contextually relevant by addressing the evolution of debt structure and interpreting strategic intent around maturity extension and risk management. However, the qualitative reasoning is built on false premises, limiting its validity. The conclusion about extending maturities has some alignment with the ground truth, but the evidence cited is inaccurate. Thus, low scores for correctness and quantitative accuracy, moderate for qualitative reasoning, and acceptable relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 554,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "Intel recognized $471 million in observable price adjustments on its investment in Beijing Unisoc Technology Ltd. in the first quarter of 2021. The net book value of this investment remained stable at $1.1 billion as of December 30, 2023, and December 31, 2022, with no additional observable price adjustments or impairment charges reported for 2022 or 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $471 million observable price adjustment in 2021 and the $1.1 billion net book value as of December 30, 2023, and December 31, 2022, matching the ground truth. It adds specificity by noting the adjustment occurred in Q1 2021, which is consistent with the original answer’s 2021 timeframe. The statement that no additional adjustments or impairments were reported in 2022 or 2023 is a reasonable inference from the stability of the book value and aligns with the ground truth’s implication of valuation stability. (2) All numeric values—$471 million and $1.1 billion—are accurate and correctly attributed to the right years and entities. Date formatting (December 30 vs December 31) reflects fiscal year-end variations and is acceptable. (3) The multi-hop reasoning is sound: the model connects the 2021 price adjustment with the subsequent stable book value through 2023, correctly inferring no further adjustments despite lack of explicit mention in the answer. The synthesis across years and accounting treatment (non-marketable equity security implied by lack of marketability and stable valuation) is logically consistent. (4) The only minor shortcoming is that the LLM does not explicitly state that Intel was accounting for the investment as a non-marketable equity security, a key detail in the original answer regarding financial treatment. However, this is implicitly supported by the absence of observable price changes and stable book value. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score with a small deduction for missing explicit terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 456,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "In 2023, AbbVie achieved significant regulatory milestones for Qulipta, with the FDA approving it for preventive treatment of chronic migraine in adults in April 2023 and the EC approving Aquipta (Qulipta) for migraine prevention in adults with four or more migraine days per month in August 2023. These approvals marked the transition from regulatory development to commercialization, following its 2022 phase III trial results and regulatory submissions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key regulatory milestones for Qulipta in 2023—FDA approval in April 2023 for chronic migraine prevention and EC approval in August 2023 for adults with four or more migraine days per month. These dates and approvals match the ground truth. However, the LLM omits the 2022 financial impact involving the $1.0 billion reclassification of R&D intangible assets to developed product rights, which is a significant part of the 'evolution' from 2022 to 2023. This omission reduces completeness. (2) Quantitatively, all dates and approvals are accurate. There is a minor typo—'Aquipta' instead of 'Qulipta'—but this does not affect factual understanding. The $1.0 billion reclassification in 2022 is missing, which is a key quantitative and qualitative point. (3) The reasoning correctly traces regulatory progression into commercialization but fails to incorporate the multi-hop element linking 2022's asset reclassification (a result of regulatory approval) to 2023's commercial rollout. This weakens the synthesis across years. (4) Scores reflect high accuracy in what was stated, with deductions for missing core financial and developmental context from 2022 that is essential to fully answering the evolution question. Contextual relevance is perfect as the answer directly addresses regulatory and commercial development.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 382,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "Boeing's language regarding 'upgrades and conversions' within the Global Services segment remained consistent between 2022 and 2023, with both filings describing the segment as providing these services as part of a broader portfolio of maintenance, modifications, and support offerings. There is no evidence of a strategic shift or heightened emphasis on upgrades and conversions in the 2023 filing compared to 2022. The term was consistently framed as a standard service line rather than a focal point of growth or transformation.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Boeing's language remained consistent and showed no strategic shift between 2022 and 2023. The ground truth indicates a clear evolution in framing: in 2022, 'upgrades and conversions' were listed as one of many general services without strategic emphasis, while in 2023, they were embedded within a more structured narrative about sustaining aerospace platforms, indicating a more integrated and strategic role. The LLM incorrectly asserts there was no change, directly contradicting the documented shift in emphasis. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. However, the qualitative accuracy is very low because the model failed to detect the nuanced but meaningful shift in language and strategic positioning—this is a critical multi-hop reasoning failure, as the task required comparing textual framing across two years to assess evolution. Contextual relevance is moderate because the answer addresses the right segment and service, but it draws the wrong conclusion from the evidence. The LLM appears to have either misread or failed to interpret the subtle but important shift in narrative structure and strategic context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 350,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "Intel's investment in Beijing Unisoc Technology Ltd. (Unisoc) was classified as a non-marketable equity security. In 2021, Intel recognized $471 million in observable price adjustments, increasing the net book value of the investment to $1.1 billion as of December 31, 2022. This value remained unchanged at $1.1 billion as of December 30, 2023, reflecting no further significant adjustments or impairments during the period. The investment's valuation was based on observable price changes, with no indication of impairment charges or sales activity between 2021 and 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $471 million observable price adjustment in 2021 and the $1.1 billion net book value in both 2022 and 2023, which aligns with the ground truth. However, there is a minor date discrepancy: the ground truth specifies the 2021 valuation date as December 25, 2021 (from the 2022 filing), while the LLM states the $1.1 billion value as of December 31, 2022, which conflates the reporting date with the fiscal period end. Intel’s 2022 10-K reports the value as of December 25, 2021, not December 31, 2022. Similarly, the 2023 value is as of December 30, 2023, which the LLM correctly notes. The LLM incorrectly implies the $1.1 billion resulted from the 2021 adjustment as of 2022, but the ground truth states the net book value was already $1.1 billion as of the end of 2021. (2) Quantitatively, the $471M adjustment and $1.1B book value are accurate and consistently reported. The error lies in the timing attribution—linking the $1.1B value to December 31, 2022, rather than confirming it was already $1.1B as of the end of 2021. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes data across years and filings, recognizes the absence of adjustments in 2023, and infers stability. However, it misrepresents the timeline of when the $1.1B valuation was established. (4) Scores reflect high factual accuracy and relevance, with a moderate deduction in correctness and quantitative accuracy due to the date/period misalignment, though the core financial facts and trend interpretation are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 432,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "Home Depot expanded the role of Self-Service Lockers in its interconnected shopping experience during 2023–2024 by integrating them further into in-store and online fulfillment options. In 2023, self-service lockers were highlighted as part of online order storage areas and curbside pickup, enabling convenient in-store pickup for online orders. By 2024, the lockers were emphasized as a key feature at the front entrances of many stores, supporting the company’s focus on seamless, frictionless interactions across digital and physical channels. This evolution reinforced their role in enhancing customer convenience and aligning with Home Depot’s broader strategy to unify shopping experiences through technology and omnichannel capabilities.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Self-Service Lockers at Home Depot from 2023 to 2024 as part of the interconnected shopping experience, noting their integration into online order fulfillment and omnichannel strategy. It accurately reflects that in 2023, lockers supported online order pickup, and by 2024, they were more prominently positioned (e.g., at front entrances) to support seamless digital-physical interactions. However, the LLM answer omits a key quantitative fact from the ground truth: in 2024, approximately 50% of U.S. online orders were fulfilled through a store, which underscores the operational significance of lockers in the broader fulfillment network. Additionally, while the LLM mentions curbside pickup and front entrances, it does not explicitly connect Self-Service Lockers to specific interconnected retail programs like BOSS, BOPIS, BODFS, and BORIS, which are critical for demonstrating multi-hop synthesis. The absence of these specific program names and the 50% fulfillment statistic represents a meaningful gap in completeness and contextual depth, though the overall direction and qualitative trend are correct. There are no factual inaccuracies or incorrect numbers (hence perfect quantitative accuracy), and the reasoning is generally sound but lacks full integration of all supporting evidence from the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 379,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities became more specific in 2024 compared to 2023. In 2023, the disclosure outlined general methods (historical claims experience, demographic factors, severity factors, and actuarial assumptions) without detailed context. In 2024, the disclosure added specifics about the role of the captive insurance subsidiary and reinsurance program, explicitly stated that liabilities are not discounted, and emphasized factors like inflation, regulatory changes, and unforeseen developments affecting claims. It also highlighted the potential for significant deviations from estimates and noted historical immaterial adjustments, providing a more comprehensive view of the estimation process and risk management.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies when compared to the ground truth. While it correctly identifies that Costco increased disclosure specificity in 2024, it reverses the timeline of information: it claims that in 2023, Costco already disclosed 'historical claims experience, demographic factors, severity factors, and actuarial assumptions'—but according to the original answer, these specific factors were only introduced in 2024, not 2023. This is a critical error in entity and content attribution across years. Additionally, the LLM claims that in 2024, Costco 'added specifics about the role of the captive insurance subsidiary and reinsurance program,' but the original answer states that these were already mentioned in 2023, making the LLM’s characterization of their introduction in 2024 incorrect. The LLM also introduces new details not present in the ground truth, such as 'inflation, regulatory changes, and unforeseen developments' and 'historical immaterial adjustments,' which are not mentioned in the original answer and thus appear to be hallucinated. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are involved and none are incorrect. (3) The multi-hop reasoning is partially sound in that the model recognizes a progression in disclosure quality from 2023 to 2024, but it fails in synthesizing the correct information per year, reversing key disclosures and attributing 2024 details to 2023 and vice versa. This undermines the qualitative accuracy. (4) Contextual relevance is high because the answer addresses the evolution of disclosure on insurance/self-insurance liabilities and attempts to compare years and detail estimation methods. However, due to significant factual misattribution and hallucinated content, the correctness score is moderate at 5—partially correct but with major errors in synthesis and factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 537,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "The financial impact of the Aldevron acquisition on inventory-related costs evolved from 2022 to 2023 as follows: In 2022, the acquisition contributed to higher inventory-related costs due to $59 million in incremental charges from fair value adjustments to inventory in 2021, which were partially offset in 2022. In 2023, the Company incurred an additional $87 million charge for excess inventory in the Biotechnology segment, likely tied to post-acquisition inventory management challenges, further increasing inventory-related costs compared to 2022. These charges reflect ongoing adjustments and reduced demand impacting inventory valuation post-acquisition.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the $59 million fair value adjustment originated in 2021 and was 'partially offset in 2022', which contradicts the ground truth stating the $59 million charge was incurred in 2022 due to the Aldevron acquisition. There is no mention of 2021 in the original answer, making this a major error. Additionally, while the $87 million charge in 2023 is correctly identified, the LLM misattributes it as 'likely tied to post-acquisition inventory management challenges' and implies continuity from the Aldevron acquisition, whereas the ground truth clearly states that the 2023 charge was due to excess inventory from reduced demand and that the acquisition-related cost was no longer present in 2023. (2) Quantitative accuracy is partially correct: the $59M and $87M figures are present, but their timing and causal attribution are wrong. The $59M is correctly associated with Aldevron but misdated to 2021 and misrepresented in its 2022 impact. (3) The multi-hop reasoning is flawed: the model fails to recognize the key evolution — a shift from acquisition-driven (2022) to operationally driven (2023) inventory costs — and instead suggests ongoing post-acquisition challenges, which contradicts the original answer. (4) Contextual relevance is high as the answer addresses inventory-related costs and the Aldevron acquisition over the two years, but correctness is undermined by key factual and logical errors. Thus, the answer is partially correct in data points but incorrect in synthesis and causality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 439,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "Costco's treatment of shop card liabilities remained consistent between 2023 and 2024, with revenue recognized upon redemption and liabilities recorded net of estimated breakage based on redemption data. This consistency indicates Costco maintains a stable approach to unclaimed balances, using historical trends to estimate and account for breakage without significant changes in methodology or recognition criteria.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Costco recognized revenue upon redemption and recorded liabilities net of estimated breakage based on redemption data in both years, which aligns with the ground truth. All entities (Costco, shop card liabilities, breakage, redemption) and time periods (2023, 2024) are accurate. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—score is 10. (3) However, the LLM misses a key qualitative evolution highlighted in the ground truth: the increased emphasis on 'estimated breakage' and methodology refinement in 2024. Instead, it characterizes the approach as 'stable' and 'without significant changes,' which contradicts the ground truth's assertion of a more refined or formalized approach. This misrepresents the multi-hop inference that subtle but meaningful changes in disclosure indicate improved estimation techniques. (4) While the answer is factually sound on surface-level accounting treatment, it fails to capture the nuanced shift in emphasis that reveals Costco's evolving approach to unclaimed balances. Thus, correctness and qualitative accuracy are reduced, but not severely, due to solid entity and methodological recognition. Contextual relevance remains high as the response directly addresses the question's focus on treatment and implications for unclaimed balances.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 394,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "Intel's Foundry Services (IFS) evolved from 2022 to 2023 by expanding strategic partnerships and customer engagement. In 2023, Intel doubled its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements, including multigenerational partnerships with ARM and a definitive agreement with Synopsys, enhancing design capabilities for Intel 18A and 18A processes. Additionally, IFS expanded partnerships under the U.S. Department of Defense's RAMP-C program, enabling customers like Nvidia, Microsoft, and Boeing to develop chips on Intel 18A. These initiatives strengthened IFS's ecosystem and customer base, positioning it as a competitive foundry services provider.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general evolution of Intel's Foundry Services from strategic intent to execution but misses key elements from the ground truth. It correctly notes the expansion of the IFS Accelerator Ecosystem to over 40 agreements and mentions multigenerational partnerships with ARM and Synopsys, which aligns with the original answer. However, it introduces a significant factual inaccuracy by claiming partnerships under the U.S. Department of Defense's RAMP-C program enabled customers like Nvidia, Microsoft, and Boeing to develop chips on Intel 18A—this is not mentioned in the ground truth and appears fabricated or misattributed. Additionally, the LLM claims the ecosystem was 'doubled' in 2023, but the original answer does not provide a prior number to support this doubling, making the quantitative claim unsupported. (2) The number 'over 40 strategic agreements' is correct, and the mention of ARM and Synopsys is accurate. However, the 'doubling' assertion lacks grounding, and the inclusion of Nvidia, Microsoft, and Boeing as RAMP-C participants using Intel 18A is not in the original and likely incorrect. (3) The multi-hop reasoning is partially sound—linking ecosystem growth and key partnerships to customer engagement evolution—but fails to include the critical 2023 design wins: four on Intel 18A (including a major HPC customer) and five in advanced packaging for AI designs, which are central to the original answer’s evidence of customer engagement. Their omission significantly weakens completeness and accuracy. (4) The contextual relevance is high as the response stays focused on strategic partnerships and customer engagement. However, due to the introduction of unverified customers and programs, and the omission of key design win metrics, the correctness score is reduced to 6. Quantitative accuracy is low due to unsupported claims like 'doubled,' and qualitative accuracy suffers from incomplete synthesis and potential hallucination.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 537,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "The financial impact of DHR's relationship with Aldevron, specifically the goodwill and net cash consideration, remained consistent between 2022 and 2023. The Aldevron acquisition in 2021 initially recorded **$6.1 billion in goodwill** and **$10,901 million in net cash consideration**. There were no adjustments to these figures in 2022 or 2023, as the document does not mention changes to the goodwill or net cash consideration related to Aldevron during those years. The 2022 and 2023 acquisitions (e.g., Abcam) are separate from Aldevron and reflect different transactions.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its core claims. The original answer states that in 2022, DHR recorded approximately $6.1 billion of goodwill related to the Aldevron acquisition, and by 2023, the net cash consideration increased to $9.561 billion. In contrast, the LLM claims there were no changes to goodwill or net cash consideration in 2022 or 2023 and asserts that the net cash consideration was $10,901 million ($10.901 billion), which contradicts the ground truth. This figure ($10.901 billion) does not appear in the original answer and is factually inconsistent with the stated $9.561 billion in 2023. Additionally, the LLM incorrectly references an Aldevron acquisition in 2021, while the ground truth implies the financial recognition occurred in 2022. (2) Quantitative accuracy is low: the $6.1 billion goodwill figure is correct and matches the ground truth, but the net cash consideration is wrong—$10,901 million vs. $9.561 billion—and the timeline is misaligned. There is no support for the claim that no adjustments occurred; in fact, the original answer explicitly describes an evolution in financial commitment. (3) The multi-hop reasoning is flawed: the LLM fails to recognize that the question asks about the evolution between 2022 and 2023, and instead asserts no change occurred, missing the key point of increased financial commitment. It incorrectly separates Aldevron from the 2022–2023 timeline and conflates it with other acquisitions. (4) Contextual relevance is moderate because the answer addresses the right companies (DHR, Aldevron) and the right metrics (goodwill, net cash consideration), but the factual inaccuracies and incorrect conclusion severely undermine correctness. The answer misrepresents the financial evolution, which is the central focus of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 494,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "The maturity date of AT&T Inc.'s 1.800% Global Notes changed from **September 5, 2026** in the 2022 filing to **September 14, 2039** in the 2024 filing. This extension indicates a strategic shift in AT&T's debt structure, reflecting a move toward longer-term financing to potentially reduce short-term liquidity pressures, align with long-term financial goals, or secure favorable interest rates. The change suggests the company is managing its maturity profile to optimize capital costs and extend debt obligations.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the maturity dates — September 5, 2026 (2022 filing) and September 14, 2039 (2024 filing) — are accurately reported with no discrepancies. The implied extension of over 13 years is factually sound. (2) The answer addresses both parts of the question: the change in maturity date and its implication for AT&T's debt structure evolution. (3) Entity accuracy is perfect: AT&T Inc., 1.800% Global Notes, and correct years (2022 and 2024 filings) are correctly identified. (4) The reasoning is strong and logically sound — the extension is interpreted as a strategic move toward longer-term financing, which aligns with typical corporate financial behavior to reduce short-term liquidity risk and optimize capital costs. The LLM provides additional but accurate qualitative insight (e.g., favorable interest rates, maturity profile management) that enhances the answer without introducing error. All information is semantically equivalent to or a well-supported elaboration of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 309,
        "total_tokens": 1527
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "Target remained in compliance with its debt leverage covenant in both 2023 and 2024, with the 2024 compliance likely supported by a reduced total debt balance ($14.9 billion vs. $16.0 billion in 2023) and structural changes to its credit facilities. In 2024, Target extended its $3.0 billion five-year unsecured revolving credit facility to expire in 2028 and secured a new $1.0 billion 364-day facility, providing greater liquidity flexibility. These adjustments, combined with lower debt levels, likely helped maintain compliance with the covenant, which has no practical impact on dividend payments.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Target remained in compliance with its debt leverage covenant in both 2023 and 2024, and correctly identifies the $3.0 billion five-year facility and the $1.0 billion 364-day facility. However, it introduces a factual inaccuracy by claiming Target had a 'reduced total debt balance ($14.9 billion vs. $16.0 billion in 2023)'—this specific debt figure is not present in the ground truth and cannot be verified from the provided information, making it an unsupported addition. Additionally, the LLM incorrectly implies that the five-year facility was 'extended' in 2024, while the ground truth states it was already set to expire in 2028 and remained unchanged. The renewal applied only to the 364-day facility, which was correctly extended from October 2024 to October 2025. (2) The quantitative inaccuracies—specifically the unsupported debt figures of $14.9B and $16.0B—significantly reduce confidence in the answer’s factual basis. These numbers are not in the original answer and represent a major deviation. The dates for the credit facilities are partially correct but misattributed: the 2028 expiration is accurate, but the framing of an 'extension' of the five-year facility is misleading. (3) The reasoning is partially sound: the model correctly infers that credit facility renewals support covenant compliance, and it connects liquidity flexibility to compliance. However, it fails to accurately represent the multi-hop detail that only the 364-day facility was renewed in 2024, not both facilities. This misrepresents the structural change. (4) The contextual relevance is high—the answer addresses both parts of the question (compliance evolution and credit structure changes) and attempts synthesis. However, due to the introduction of unverified financial figures and mischaracterization of facility renewals, the correctness score is reduced to 6, reflecting partial accuracy with significant factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 532,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "Intel's approach to expanding digital readiness under the RISE strategy evolved from 2022 to 2023 by deepening partnerships and enhancing measurable outcomes. In 2022, Intel emphasized scaling global digital readiness programs like AI for Youth and AI for Workforce through government and institutional collaborations, alongside launching the RISE Technology Initiative to address health, safety, and inclusive technology. By 2023, the RISE strategy had matured, with the third global Inclusion Index survey published, reflecting progress in diversity and inclusion metrics. Intel expanded its RISE Technology Initiative to fund projects focused on digital readiness, carbon-neutral computing, and inclusive technology, while strengthening partnerships with stakeholders to advance equitable access to digital skills and infrastructure. These efforts underscored a more structured, data-driven approach to external collaboration and global impact.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces inaccuracies and omits key facts from the ground truth. It correctly identifies the evolution of Intel's RISE strategy and mentions the third global Inclusion Index in 2023, aligning with the original answer. However, it fabricates or misrepresents specific programs such as 'AI for Youth' and 'AI for Workforce' and incorrectly frames the RISE Technology Initiative as being launched in 2022 and expanded in 2023, which is not supported by the ground truth. The original answer emphasizes the Alliance for Global Inclusion and the creation of a unified Inclusion Index with performance recognition (50% threshold), which the LLM answer omits entirely. (2) Quantitatively, the LLM fails to mention the critical metric that 18 out of 27 organizations scored 50% or higher and that Intel was among them—this is a major omission affecting factual completeness. No incorrect numbers are stated, but the absence of this data undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound—Intel’s evolving strategy from framework-building to measurement is implied—but the LLM substitutes actual collaboration mechanisms (Alliance for Global Inclusion) with generic references to government and institutional partnerships, failing to correctly synthesize the specific external collaboration initiative mentioned in the ground truth. (4) Contextual relevance is high because the response addresses the evolution of digital readiness efforts under RISE and external collaboration. However, due to factual inaccuracies and missing benchmarks, the qualitative and correctness scores are reduced to 6, reflecting partial accuracy with significant gaps in entity and reasoning fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 481,
        "total_tokens": 1921
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "Emerson's relationship with Micromine evolved from an agreement to acquire it in July 2022 to its termination in August 2023 due to unresolved Russian regulatory approvals. The termination incurred $198 in transaction costs in 2023, split between $88 pre-transaction (by Micromine) and $110 post-transaction (by Emerson), with no termination fee paid. Financially, the failed acquisition led to amortization expenses related to intangibles, inventory step-ups, and retention bonuses in 2023, but no direct gain or loss from the termination itself.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the acquisition agreement was terminated in August 2023 due to Russian regulatory issues, which aligns partially with the ground truth, but misrepresents key financial implications. Most critically, it claims $198 in transaction costs ($88 by Micromine and $110 by Emerson), which is not supported by the original answer—no such cost breakdown or total is mentioned in the ground truth. Instead, the ground truth reports a $24 mark-to-market gain in 2023 from foreign currency forward contracts and no termination fee. The LLM also invents 'amortization expenses related to intangibles, inventory step-ups, and retention bonuses' not present in the original. (2) Quantitative accuracy is severely lacking: the $198 cost figure is incorrect, and the $24 gain from the forward contracts—which is a key financial implication—is entirely omitted. The acquisition price of AU$900 (~$623M USD) is not mentioned at all. (3) The multi-hop reasoning is flawed: while the LLM identifies the termination of the deal as a key event, it fails to correctly link Emerson’s financial instruments (foreign currency forwards) to the gain in 2023 and their full termination in 2024. It incorrectly attributes financial impacts (e.g., amortization) that suggest the deal partially closed, when in fact it was terminated before closing. (4) Contextual relevance is moderate—the answer addresses the evolution of the relationship and attempts to discuss financial implications—but the incorrect details and invented figures severely undermine its accuracy. The core shift from strategic expansion to withdrawal is partially captured, but the financial narrative is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 478,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "The availability of shares under The Home Depot's U.S. ESPP decreased from approximately 17 million shares in fiscal 2022 to 15 million shares in fiscal 2023. The average purchase price of shares under the ESPP declined from $305.14 in fiscal 2022 to $277.19 in fiscal 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the share availability decreased from 17 million in 2022 to 15 million in 2023, and the average purchase price declined from $305.14 to $277.19. These values exactly match the original answer. (2) The answer is complete, addressing both parts of the question—changes in share availability and average purchase price—across the two fiscal years. (3) Entity accuracy is correct: The Home Depot, U.S. ESPP, and fiscal years 2022 and 2023 are properly identified. (4) The reasoning is sound and correctly synthesizes multi-hop information by comparing two data points across years. Although the LLM omits the detail that approximately one million shares were purchased in both years, this information is not required to answer the specific question about changes in share availability and average purchase price. The omission does not affect correctness as the focus is on availability and price trends. The answer is semantically equivalent and conveys the same core conclusion: a reduction in available shares and a decrease in average purchase price.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 330,
        "total_tokens": 1531
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "Between 2022 and 2023, DHR's impairment triggers and charges shifted toward the Biotechnology and Diagnostics segments. In 2022, no intangible asset impairments occurred, but in 2023, impairments were triggered in the second quarter (Biotechnology) and fourth quarter (Diagnostics and Biotechnology), resulting in $77 million in charges—up from $10 million in 2021. This evolution indicates heightened risks in these segments, likely due to market challenges, declining asset values, or strategic shifts, reflecting increased scrutiny of intangible assets like technology and trade names in these areas.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in impairment charges from $10 million (in 2021, reported in 2022 filing) to $77 million in 2023, and correctly attributes the 2023 impairments to the Biotechnology and Diagnostics segments in Q2 and Q4. However, it incorrectly states that 'no intangible asset impairments occurred' in 2022, which contradicts the ground truth: the 2022 filing did report a $10 million impairment in the Diagnostics segment (from Q1 2021, disclosed in the 2022 filing). This is a significant factual error. (2) Quantitatively, the $77 million charge in 2023 and $10 million in 2021 are correctly cited, and the comparison of increasing charges is accurate. However, the misrepresentation of the 2022 filing as having no impairments undermines the accuracy of the timeline and evolution. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes data across years and segments, noting the expansion into Biotechnology as a new area of impairment. However, it fails to acknowledge that the 2022 filing did include an impairment (albeit from 2021), which is essential for accurate trend analysis. (4) The qualitative reasoning about heightened risks and strategic shifts is reasonable and aligns with the implications in the ground truth. Contextual relevance is excellent—the answer directly addresses the evolution of triggers, segments involved, and risk implications. The main issue is the incorrect claim about 2022 having no impairments, which reduces quantitative and overall correctness despite otherwise strong synthesis and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 442,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This indicates that the company's involvement in business transactions tied to trade contracts expanded during this period, as reflected by the higher total letters of credit, with trade contracts being a primary component.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023, matching the ground truth exactly. These figures are accurate and properly formatted. (2) The quantitative change is correctly represented with no calculation errors; the increase of $236 million is implied and consistent with the provided numbers. (3) The reasoning is sound: the increase in letters of credit is correctly interpreted as an indicator of expanded involvement in trade-related business transactions, which aligns with the multi-hop logic required to infer business activity trends from financial commitments. (4) The LLM answer is semantically equivalent to the original answer, with slightly enhanced wording (e.g., 'higher total letters of credit, with trade contracts being a primary component') that adds context without introducing inaccuracies. All parts of the question are addressed: the change in value and its implication. Therefore, all scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 306,
        "total_tokens": 1480
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "The status of the 0.300% Notes due 2028 remained consistent between IBM's 2023 and 2024 SEC filings. In the 2023 filing, the notes were referenced in exhibits (Exhibit 4.1 to Form 8-K, filed February 10, 2020), while the 2024 filing listed them as registered securities under Section 12(b) of the Exchange Act (trading symbol IBM28B). No changes in their status, maturity, or terms were disclosed, indicating IBM's continued adherence to consistent financial instrument disclosures without new developments affecting these notes. This reflects IBM's transparency in maintaining accurate and up-to-date information about its debt obligations.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 0.300% Notes due 2028, the Exhibit 4.1 reference from February 10, 2020, and the trading symbol IBM28B listed in the 2024 filing. These factual elements are accurate and match the ground truth. However, the core interpretation is incorrect: the LLM claims the status 'remained consistent' and that 'no changes in status' occurred, while the ground truth emphasizes a meaningful evolution—from a disclosed instrument in 2023 to an actively issued and traded security (via Section 12(b) registration) in 2024. This shift indicates increased market engagement, which the LLM fails to recognize. (2) Quantitatively, all dates, percentages, and exhibit references are correct. There are no numerical or date inaccuracies. (3) The multi-hop reasoning is flawed: while the model retrieves correct facts from both filings, it fails to synthesize them into the correct conclusion about the instrument's evolving status. Instead of identifying a progression in disclosure depth and market recognition, it incorrectly asserts consistency. (4) The answer is contextually relevant and well-structured, but the qualitative misinterpretation of the significance of the 2024 listing as an active instrument undermines the correctness. The model misses the key implication about IBM's financial disclosures becoming more operationally transparent or market-integrated. Hence, partial credit is given for factual retrieval but docked heavily for incorrect synthesis and conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 418,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024 by transitioning from being referenced in prior filings (e.g., Form 8-K from January 30, 2019) to being actively registered and disclosed as traded securities on the New York Stock Exchange (NYSE) in 2024. The 2024 10-K explicitly lists the notes under \"Securities registered pursuant to Section 12(b) of the Act,\" confirming their ongoing registration and exchange listing. Additionally, a new indenture for these notes, dated February 2, 2024, was incorporated by reference, reflecting updated disclosure requirements and formal registration on the NYSE.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 1.750% Notes due 2031 were disclosed in prior filings (specifically referencing the January 30, 2019 Form 8-K, which matches the 'exhibit filed on January 30, 2019' in the original answer), and in 2024 they were formally registered on the NYSE under a trading symbol (implied by inclusion in 'Securities registered pursuant to Section 12(b)'). The mention of a new indenture dated February 2, 2024, while not in the original answer, does not contradict it and may reflect additional detail from the 2024 filing. (2) Quantitative accuracy is perfect: percentages (1.750%), years (2031, 2019, 2024), and dates (January 30, 2019; February 2, 2024) are correctly stated and consistent with the knowledge graph. (3) The multi-hop reasoning is sound—linking the 2019 exhibit reference in 2023 disclosure to the 2024 formal registration shows synthesis across years and documents. The only minor gap is that the LLM does not explicitly name the trading symbol IBM31, which is a specific detail present in the original answer. However, referencing NYSE listing via Section 12(b) registration effectively conveys the same core idea of formal exchange recognition. (4) The answer is contextually relevant, directly addressing the evolution in disclosure and registration status. The addition of the new indenture enhances rather than distracts. Overall, this is a semantically equivalent, slightly more detailed version of the ground truth with no factual errors—just a small omission of the ticker symbol, warranting a 9 instead of 10 on qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 457,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "Eli Lilly's financial relationship with Zyprexa evolved significantly between 2023 and 2024, primarily through the sale of the olanzapine portfolio, including Zyprexa, in 2023. In 2023, Zyprexa revenue outside the U.S. totaled $1.69 billion, driven by the sale of rights to the olanzapine portfolio, which shifted revenue recognition from ongoing product sales to a one-time transaction. This sale impacted the business model by reducing reliance on Zyprexa's long-term sales and introducing a lump-sum revenue recognition approach. By 2024, Zyprexa was no longer listed as an active product, reflecting the completion of the transaction and a transition to recognizing revenue from the sale rather than continued product distribution.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the reported revenue figure—$1.69 billion in 2023 is incorrect; the ground truth states $1.45 billion from the sale of rights for the olanzapine portfolio. This discrepancy affects quantitative accuracy. (2) The answer correctly identifies the key event—the 2023 sale of rights to Zyprexa/olanzapine outside the U.S.—and the shift in revenue recognition from product sales to a transaction-based model. However, it mischaracterizes the 2023 revenue as 'driven by the sale of rights' while implying ongoing product sales contributed to that figure, whereas the ground truth clarifies that the $1.45 billion was the direct result of the sale, not accumulated sales revenue. (3) The reasoning partially captures the multi-hop evolution: it notes the transition from active sales to post-sale recognition and the removal of Zyprexa from active products in 2024. However, it fails to mention that revenue in 2024 was recognized under 'collaboration and other arrangements,' missing the nuance of ongoing royalty or profit-sharing, instead implying only a one-time lump sum. This omits a key aspect of the business model shift. (4) Contextual relevance is high—the response stays focused on the financial relationship, revenue recognition, and business model changes. Despite correct framing and logical flow, the incorrect dollar amount and incomplete characterization of the revenue model reduce correctness and qualitative accuracy. The answer is partially correct but contains critical factual and conceptual gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 434,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "The treatment of Mobility Preferred Interests evolved from 2023 to 2024 as follows: In 2023, the interests were classified as a liability due to redemption obligations, with $2,670 recorded in current liabilities. These obligations impacted diluted EPS by adding 72 potential shares, slightly reducing EPS. By 2024, all Mobility Preferred Interests were repurchased in April 2023, eliminating redemption obligations and removing their dilutive effect on EPS. The 2024 diluted EPS calculation excluded these shares, resulting in a lower denominator and higher EPS compared to 2023. The financial impact shifted from a liability with dilutive EPS effects in 2023 to no ongoing obligations in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant inaccuracies. It correctly identifies the reclassification of Mobility Preferred Interests as a liability in 2023 and the elimination of obligations by 2024. However, it introduces a figure of '72 potential shares' impacting diluted EPS, which is not present in the ground truth and cannot be verified. The ground truth emphasizes the application of ASU 2020-06 for prior-period diluted EPS calculations due to the ability to settle in stock, but the LLM incorrectly frames the dilutive effect as a direct addition of 72 shares in 2023 and removal in 2024, which misrepresents the accounting treatment. (2) The dollar amounts are partially correct: the LLM mentions $2,670 in current liabilities, but omits the equal $2,670 in noncurrent liabilities, understating the total liability. The repurchase amount of $5,414 is not mentioned at all, a major omission. The date of repurchase (April 2023) is correctly noted. (3) The multi-hop reasoning is partially sound—linking liability classification to EPS impact—but fails to accurately reflect the retrospective nature of the ASU 2020-06 adjustment for prior periods. Instead, it implies an ongoing dilutive effect in 2023 that was removed in 2024, which contradicts the ground truth stating the interests were fully retired and the focus shifted to prior-period accounting. (4) The contextual relevance is high as the answer addresses both redemption obligations and EPS impact. However, due to incorrect quantitative claims (72 shares), missing financial figures, and flawed reasoning about EPS effects, the correctness score is limited to 6. The qualitative accuracy is moderate due to correct entity and timeline identification but flawed synthesis. Quantitative accuracy is low due to missing and fabricated numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 502,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "IBM's treatment of the 0.875% Notes due 2030 evolved between 2023 and 2024 in terms of listing and registration. In the 2023 10-K, the notes were referenced in the exhibits section as part of the instruments defining their terms (Exhibit 4.1 to Form 8-K filed February 8, 2022), but no explicit mention of listing or registration was made. By the 2024 10-K, the notes were actively listed on the New York Stock Exchange under the ticker **IBM30A** and registered under Section 12(b) of the Securities Exchange Act, reflecting formal listing and ongoing registration status. This indicates a transition from disclosure in the exhibits to active market listing in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately reflects that in 2023, the 0.875% Notes due 2030 were disclosed via incorporation by reference to Exhibit 4.1 of the Form 8-K filed on February 8, 2022, with no explicit listing status. (2) It correctly states that by 2024, the notes were listed on the New York Stock Exchange under the ticker IBM30A and registered under Section 12(b) of the Securities Exchange Act, indicating formal registration and listing. (3) The multi-hop reasoning is sound—comparing the treatment across two years and identifying the evolution from referenced disclosure to active listing. (4) All entities (IBM, 0.875% Notes due 2030, NYSE, IBM30A, Form 8-K, Section 12(b)) are correctly identified, and the timeline (2023 vs. 2024) is accurately maintained. Minor wording differences (e.g., 'actively listed' vs. 'explicitly listed') do not affect semantic equivalence. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 287,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "From 2023 to 2024, AT&T expanded its Telco LLC Preferred Interests by issuing an additional $2,250 in Telco Class A-4 preferred interests in 2024, which pay a 5.94% annual distribution rate (reset every four years starting November 2028) and are callable beginning November 2028. This contrasts with the prior Telco Class A-1 (4.25%, reset every seven years) and A-2/A-3 (6.85%, reset every seven years) issued in 2020 and 2023. The evolution reflects AT&T's strategy to refine its preferred equity structure, balancing lower distribution rates with shorter reset periods to optimize financing costs while maintaining flexibility to manage liquidity through callable terms. This approach underscores AT&T's use of preferred equity as a flexible financing tool to refinance existing obligations and stabilize its capital structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, there was no issuance of $2,250 in Class A-4 preferred interests in 2024 at 5.94%. Instead, the total Telco Preferred Interests increased from $7,250 (comprised of $2,000 Class A-1 and $5,250 Class A-2/A-3) in 2023 to $7,250 in 2024 — meaning no new issuance occurred; the amount remained the same. The LLM incorrectly states an additional $2,250 was issued in 2024, which is not supported by the original answer. Additionally, the 5.94% distribution rate and callable terms starting November 2028 for Class A-4 interests are entirely fabricated and not present in the ground truth. (2) The original answer confirms that the structure remained consistent: Class A-1 at 4.25% and Class A-2/A-3 at 6.85%, both reset every seven years. The LLM misrepresents reset periods for existing tranches and introduces a new class (A-4) with a four-year reset, which is incorrect. (3) The multi-hop reasoning is flawed because the LLM invents new instruments and terms rather than correctly synthesizing the continuity of structure and the clarification in 2024 about distribution payment flexibility. It fails to mention the key point that failure to pay distributions does not restrict dividend payments or share repurchases — a critical update in 2024. (4) While the LLM attempts to interpret AT&T’s financing strategy, its conclusions about 'refining structure' and 'optimizing costs' are based on false premises. The contextual relevance is moderate because it addresses the general theme of financing strategy, but the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 459,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "Capital One's involvement in multifamily commercial real estate loans involved selling these loans to government-sponsored enterprises (GSEs) under loss sharing agreements. As of December 31, 2023, the liability related to these agreements was $137 million, compared to $82 million as of December 31, 2022, reflecting an increase in risk exposure under the agreements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) All key facts are correct: Capital One sold multifamily commercial real estate loans to GSEs under loss sharing agreements, with liabilities of $82 million as of December 31, 2022, and $137 million as of December 31, 2023. These numbers match the original answer exactly, and the increase in risk exposure is correctly highlighted. (2) Quantitative accuracy is perfect—both dollar amounts and dates are correct, and the implied increase of $55 million is accurate. (3) The reasoning is sound: the model correctly infers that an increasing liability reflects greater risk exposure, which aligns with the multi-hop logic required (linking loan sales, loss sharing agreements, and balance sheet liabilities over time). (4) The only minor shortcoming is slight incompleteness: the original answer notes that Capital One 'originated' these loans with the intent to sell, which adds context about their business activity evolution; the LLM omits 'originated' and the forward-looking intent, slightly reducing qualitative richness. However, the core multi-hop synthesis—linking the growing liability to increased risk exposure over time—is correctly executed. The answer is fully relevant and directly addresses the question's focus on evolution and risk exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 375,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "Amazon's co-branded credit card programs faced heightened regulatory scrutiny and compliance obligations in 2023 compared to 2022, driven by evolving payment card association rules and enhanced authentication requirements. These obligations could increase operational costs and reduce the ease of use of payment products. Additionally, the programs' strategic significance remained critical for revenue diversification, but the risk of unfavorable renewal terms or termination loomed larger in 2023, potentially impacting operating results through higher compliance expenses or lost revenue streams.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative details from the ground truth, particularly regarding the introduction of data localization rules in 2023, which were not present in 2022 and represent a significant shift in regulatory risk. The answer correctly identifies increased regulatory scrutiny and compliance obligations in 2023, as well as the ongoing strategic importance and risk of unfavorable renewal terms. However, it fails to mention data localization and cross-border data transfer issues, which are central to the expanded regulatory landscape described in the original answer. While the general direction of increased compliance costs and operational complexity is noted, the specific nature of the new obligations (data localization) is omitted, weakening the multi-hop synthesis between years and jurisdictions. There are no numerical inaccuracies (dates are correct: 2022 vs 2023), so quantitative accuracy is high. Contextual relevance is strong as the response stays focused on the question, but the absence of key regulatory developments limits its factual completeness and reasoning depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 318,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "PM's financial relationship with RBH evolved such that RBH was deconsolidated from PM's financial statements since March 2019 (per Note 20 in the 2022 filing). By 2024, PM accounted for its equity investment in RBH using the equity method, with valuation considerations involving a discounted cash flow analysis. In 2024, PM recorded a $2.316 billion impairment charge due to the estimated fair value of the investment being lower than its carrying amount, factoring in risks related to the CCAA proceedings and global settlement allocations.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. First, it incorrectly states that PM accounted for RBH using the equity method by 2024; the ground truth indicates that RBH was an equity investment requiring impairment analysis, not accounting under the equity method. This is a significant mischaracterization of the accounting treatment. Second, the $2.316 billion impairment charge is not mentioned in the original answer and is factually unsupported by the ground truth, which discusses fair value estimation and judgment but no specific impairment amount. The original answer notes a CAD 3.1 billion allocation of damages related to litigation in 2022, which the LLM omits entirely. (2) Quantitatively, the $2.316 billion figure is incorrect and not present in the ground truth; the only numeric value in the original is CAD 3.1 billion in compensatory damages allocated to RBH in 2022. The LLM invents a precise number not found in the source, which severely undermines quantitative accuracy. The date of deconsolidation is correctly tied to 2019 (via Note 20 in the 2022 filing), which aligns with the original answer’s reference to CCAA proceedings starting in 2019. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the shift from deconsolidation to investment valuation and references DCF analysis and risks from CCAA/global settlement, which reflects synthesis of valuation considerations. However, the failure to mention the litigation impact in 2022 and the incorrect accounting method (equity method vs. fair value with impairment) breaks the chain of accurate reasoning. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship, consolidation status, and valuation considerations. Qualitative accuracy is moderate due to correct framing of the shift in relationship but flawed details. Correctness score is 6 due to correct directional narrative but major factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 536,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "Baqsimi's revenue contribution decreased significantly from $677.6 million in 2023 to an unspecified amount in 2024, as the product's role within LLY's portfolio diminished. In 2023, the sale of Baqsimi rights generated $579 million in U.S. revenue, but the product's ongoing sales were part of the $677.6 million total. By 2024, Baqsimi was no longer listed as a separate product revenue line, indicating its reduced strategic importance and likely exit from the portfolio, with its contribution to LLY's revenue declining.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly states the total 2023 revenue of $677.6 million, it incorrectly claims that the sale of Baqsimi rights generated $579 million in U.S. revenue, which is not supported by the ground truth. The ground truth specifies $645.7 million in U.S. sales and $31.9 million outside the U.S., with no mention of a $579 million figure related to rights sale. This misrepresents a key financial event. Additionally, the LLM implies that the $579 million was from the sale of rights, but the ground truth clarifies that the shift in 2024 was due to the 2023 sale of rights, without specifying the sale amount. (2) The calculation and attribution of revenue are flawed: the LLM conflates ongoing product sales with proceeds from the asset sale, which are distinct financial events. The absence of a 2024 revenue number is correctly noted, but the reasoning is undermined by incorrect data. (3) The multi-hop reasoning is partially sound—the model correctly infers that Baqsimi’s removal from product revenue lines indicates a strategic shift or divestiture. It also correctly identifies the reduced role in LLY’s portfolio. However, it fails to accurately synthesize the nature of the collaboration and other arrangements mentioned in the ground truth, missing the precise mechanism of the transition. (4) Despite these errors, the answer remains contextually relevant, addressing both financial performance and strategic positioning across years. The core idea—that Baqsimi transitioned from a direct revenue contributor to a divested asset—is directionally correct, warranting partial credit. However, major factual and quantitative errors reduce overall correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 488,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "From 2022 to 2024, Union Pacific's Total Highway Revenue Equipment composition shifted significantly toward owned assets. In 2022, containers and chassis were **78,837 owned** units versus **16,004 leased** units (ratio ~4.93:1). By 2024, owned units increased to **50,731** (containers: 46,375; chassis: 4,356) compared to **1,485 leased** units (containers: 288; chassis: 1,197), resulting in a much higher ratio of **~34.16:1**. This reflects a substantial reduction in leased equipment and a greater reliance on owned assets for highway revenue equipment.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. While it correctly states the 2022 owned (78,837) and leased (16,004) totals, it incorrectly claims that owned units were 50,731 in 2024 — this is actually a reduction from 2022, not an increase as implied. The LLM falsely states that owned units 'increased' to 50,731, when in fact they dropped significantly. This misrepresents the trend. (2) The breakdown of containers and chassis in 2024 is partially accurate (e.g., 4,356 owned chassis and 288 leased containers), but the LLM incorrectly assigns 46,375 as owned containers in 2024, which is not supported by the ground truth. The ground truth does not provide a container-specific owned number for 2024, only that total owned units dropped to 50,731. The leased chassis number (1,197) is also not in the ground truth, which only states total leased units dropped to 1,485. (3) The reasoning is flawed: the LLM concludes a shift 'toward owned assets' and 'greater reliance on owned assets', but the ground truth describes a strategic reduction in both owned and leased equipment, especially in chassis and leased containers. The actual trend is asset lightening, not increased ownership. The ratio calculation (~34.16:1) is mathematically correct based on the numbers used, but those numbers are misapplied due to incorrect interpretation of directionality. (4) The contextual relevance is moderate because the answer addresses the right entities (Union Pacific, highway equipment, owned vs leased, 2022–2024) and attempts multi-hop synthesis, but the core conclusion is factually inverted. Quantitative accuracy is low due to incorrect directional claims and unsupported component breakdowns. Qualitative accuracy suffers from flawed logic and misinterpretation of strategic intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 490,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "Capital One's securitized debt obligations increased by $2.6 billion to $15.0 billion as of December 31, 2022, compared to December 31, 2021, driven by net issuances in securitization programs. This growth contributed to the company's funding structure by expanding its sources of capital, alongside deposits and other debt, to support its loan portfolios and liquidity needs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that securitized debt obligations increased to $15.0 billion as of December 31, 2022, but the ground truth reports a carrying value of $18.043 billion in 2023 (not 2022), and no data is provided for 2021 to verify a $2.6 billion increase. The $15.0 billion figure and the $2.6 billion increase are unsupported by the original answer and likely incorrect. (2) The quantitative accuracy is low because the dollar amounts and timeframes are wrong. The LLM references 2021–2022 growth, but the question asks about evolution between 2022 and 2023. The correct 2023 value is $18.043 billion, not $15.0 billion, and no 2022 value is given in the ground truth to support the claimed change. (3) The qualitative reasoning is flawed: the LLM fails to mention the key evolution in classification—securitized debt obligations being categorized under Level 2 in the fair value hierarchy in 2023—indicating a shift in valuation methodology and strategic role. This is a central point in the original answer but entirely missing in the LLM response. (4) Contextual relevance is moderate because the answer discusses securitized debt in Capital One’s funding structure, which is relevant, but it addresses the wrong time period and omits the critical shift in accounting treatment and strategic role. The answer focuses on growth and funding utility but misses the nuanced evolution in structure and valuation that defines the actual change. Overall, the LLM provides plausible-sounding but factually incorrect and incomplete information, failing on core multi-hop synthesis between years and financial reporting changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 460,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "LLY's Zyprexa revenue in 2023 and 2024 primarily stemmed from the sale of rights for the olanzapine portfolio, as noted in the 2023 and 2024 filings. In 2023, this revenue was recognized as **collaboration and other revenue** due to the one-time sale of rights, contributing $30.4 million. By 2024, the revenue from Zyprexa shifted to **net product revenue** as ongoing sales of the drug increased, reflecting $79.4 million. The recognition method evolved from a one-time collaboration arrangement to recurring product sales, with the source remaining tied to the olanzapine portfolio rights.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) The source and recognition method of Zyprexa revenue are incorrectly reversed: the ground truth states that in 2023, revenue came from the sale of rights (a one-time event), and in 2024, it was recognized under collaboration revenue as part of ongoing arrangements from that prior sale. The LLM incorrectly claims that in 2023 revenue was recognized as collaboration revenue and in 2024 shifted to net product revenue — this is the opposite of the truth. (2) The numerical values provided ($30.4M in 2023 and $79.4M in 2024) are not present in the original answer and cannot be verified; the ground truth does not include any dollar amounts, so their inclusion appears hallucinated. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the evolution of revenue recognition — the shift was from direct product/rights sale in 2023 to collaboration-based recognition in 2024 due to accounting for the aftermath of the sale, not an increase in product sales. (4) The context of the question — how revenue recognition *method* and *source* changed — is partially addressed, but with incorrect substance, hence moderate relevance but very low correctness. Overall, the answer misrepresents the core facts and introduces unsupported numbers, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 381,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "The valuation methodology and classification of Federal Government Securities in the pension plan remained consistent from 2022 to 2024. Both years classify these securities as **Level 2 investments**, valued using a **bid evaluation process with bid data from independent pricing sources**. There is no indication of changes in methodology or classification between the two periods.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Federal Government Securities were classified as Level 2 investments in both 2022 and 2024 and that the valuation methodology relies on a bid evaluation process using independent pricing sources. It accurately reflects the continuity in classification. However, it omits a key nuance from the original answer: in 2022, the classification was reported as 'Significant Other Observable Inputs (Level 2)' with a disclosed value of $742 million, while in 2024, the company added specificity by clarifying the bid evaluation methodology. The LLM implies the same detailed methodology was used in both years, which is not confirmed in the ground truth—only that classification remained Level 2. (2) There are no numeric inaccuracies; the LLM does not introduce incorrect figures and avoids making false claims about amounts. The $742 million figure from 2022 is not mentioned, which is a minor omission but not a quantitative error. (3) The multi-hop reasoning is mostly sound—linking the classification across years and noting consistency—but fails to fully capture the evolution in disclosure clarity, which is a qualitative shift even if the classification remained unchanged. (4) The answer is contextually relevant and factually aligned in spirit, but loses points for not acknowledging the enhanced methodological transparency in 2024, which is central to how the valuation methodology 'evolved.' Hence, correctness is high but not complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 413,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "Capital One's utilization of credit score data for product segmentation decisions remained consistent between 2022 and 2023, with no significant changes in the distribution of credit scores across portfolios. In both years, auto loans maintained similar FICO score thresholds (53% above 660, 20% between 621-660, and 27% below 620), and domestic credit card portfolios showed minimal shifts in score ranges (69% to 68% above 660). This consistency suggests that the company continued leveraging credit scores for segmentation as part of its credit risk modeling strategy, prioritizing risk-based underwriting without altering core segmentation criteria. However, the rise in auto loan delinquency rates (from 5.62% in 2022 to 6.34% in 2023) indicates potential shifts in risk profiles, possibly due to broader economic factors rather than changes in credit score utilization.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its core claim. The original answer states that Capital One updated its credit score data for product segmentation from using 2020–2021 distributions in 2022 to using 2022–2023 distributions in 2023, indicating a shift toward more current data. In contrast, the LLM claims there was 'no significant changes' and 'remained consistent', which contradicts the ground truth. This fundamental misrepresentation undermines the answer’s correctness. (2) Quantitatively, the LLM introduces specific percentages (e.g., 53% above 660, 20% between 621–660) and delinquency rates (5.62%, 6.34%) that are not present in the original answer and cannot be verified against the ground truth. These numbers may be fabricated or misattributed, as the original answer does not mention portfolio-level FICO breakdowns or delinquency rates in this context. Thus, quantitative accuracy is low. (3) The multi-hop reasoning is flawed. The question asks about the evolution in data utilization over time and what it indicates about risk modeling strategy. The correct inference is that Capital One shifted to more recent data, signaling a dynamic and proactive strategy. The LLM instead focuses on static portfolio segmentation and delinquency trends, missing the key point about data recency and model updating. It fails to reference Table 21 or the shift in time periods used, indicating a failure in synthesizing the correct information. (4) Contextual relevance is moderate because the answer discusses credit score usage and risk modeling, which are relevant topics, but it does not address the actual evolution described in the original answer. The focus on delinquency rates and unchanged thresholds distracts from the true strategic shift in data sourcing. Overall, the answer is factually incorrect on the main point, contains unverified numbers, and misrepresents the company's evolving strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 522,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "Amazon's strategic positioning of AWS evolved from 2022 to 2023 by reinforcing its role as a core enabler of the company's broader business segments and a key driver of long-term growth. In 2022, AWS was highlighted as a critical component of Amazon's technology and content investments, supporting geographic expansion, cross-functional systems, and infrastructure for services like advertising, fulfillment, and digital content. By 2023, AWS remained central to Amazon's strategy, with continued emphasis on investing in technology infrastructure to sustain growth, innovate, and support emerging business areas. The 2023 filing underscored AWS's role in enabling scalability, operational efficiency, and competitive advantage across all segments, reflecting its sustained prioritization as a strategic cornerstone.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in tone and context, correctly identifying AWS as a strategic priority in both 2022 and 2023, and accurately reflecting its role in technology investment, infrastructure, and support for other business segments. There are no numeric inaccuracies, as the question and answer do not involve specific financial figures, percentages, or calculations—thus quantitative accuracy is 10. Contextual relevance is high, as the response directly addresses AWS’s strategic role and evolution within Amazon’s broader business. However, the key multi-hop insight from the ground truth is missing: in 2023, AWS was elevated to one of Amazon’s three core business segments (alongside North America and International), marking a structural and strategic shift from being an investment area to a standalone, mission-critical segment. The LLM answer fails to mention this reclassification, instead stating AWS remained a 'strategic cornerstone' without acknowledging the formal organizational and strategic elevation. This omission significantly weakens the qualitative accuracy, as the core evolution—AWS becoming a primary reporting segment—is not captured. While the LLM conveys continuity and importance, it misses the pivotal change in AWS’s positioning, resulting in a partially correct, but incomplete, synthesis across years. Hence, correctness and qualitative accuracy are moderately scored at 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 392,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "Philip Morris International (PMI) recorded a **$2,316 million non-cash impairment charge** in 2024 related to its equity investment in Rothmans, Benson & Hedges Inc. (RBH), reflecting the estimated fair value of the investment being lower than its carrying value due to uncertainty surrounding the allocation of a proposed CAD 32.5 billion global settlement in Canadian tobacco litigation. This impairment, recognized as a subsequent event, highlights PMI's financial exposure to RBH's unresolved legal risks. Between 2022 and 2024, PMI's accounting treatment shifted from deconsolidating RBH's financial results in 2019 (due to CCAA proceedings) to recognizing impairment on its equity stake, underscoring ongoing litigation-related uncertainties.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $2,316 million non-cash impairment charge in 2024 and the proposed CAD 32.5 billion settlement, both of which are accurate per the ground truth. The shift in accounting treatment from deconsolidation to equity method is also correctly described. However, the LLM incorrectly states that deconsolidation occurred in 2019, while the ground truth specifies it occurred in 2022 due to CCAA restructuring—this is a significant factual error in timing. (2) All numeric values (dollar amounts, currency, settlement figure) are correct and properly formatted; the impairment amount and settlement value match the original answer exactly. (3) The multi-hop reasoning is largely sound: the model connects RBH’s deconsolidation, the litigation context, the shift to equity accounting, and the resulting impairment. However, the erroneous dating of deconsolidation to 2019 undermines the accuracy of the timeline synthesis between 2022 and 2024. (4) Despite the date error, the core financial exposure and accounting evolution are well-conveyed, with strong contextual relevance and semantic equivalence on key points. The answer addresses both accounting treatment and financial exposure as required. Minor deduction for the incorrect deconsolidation year, but overall factual and conceptual understanding is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 379,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "Biktarvy's commercial significance for GILD grew substantially from 2022 to 2024, with revenue increasing from $8.6 billion in 2022 to $10.2 billion in 2024, driven by strong HIV treatment demand. However, risks persist, including competition from generics, reimbursement pressures, and potential shifts in HIV treatment paradigms that could reduce reliance on nucleoside-based therapies like Biktarvy. Additionally, regulatory and pricing challenges, such as U.S. legislative actions like the Inflation Reduction Act, may impact long-term profitability and market share.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth states that Biktarvy generated $8,624 million ($8.624 billion) in 2022, which the LLM approximates reasonably as $8.6 billion (acceptable rounding). However, the LLM claims revenue grew to $10.2 billion in 2024, which is not supported by the original answer—no 2024 revenue figure is provided in the ground truth. This fabricated number severely undermines factual correctness. (2) The quantitative accuracy is low because the $10.2 billion figure for 2024 is incorrect and unsupported. There are no calculations in the ground truth to validate growth or trends, so asserting a specific increase is a factual overreach. (3) Qualitatively, the LLM correctly identifies key risks such as shifts in treatment paradigms, competition, and regulatory pressures (e.g., Inflation Reduction Act), which align with the ground truth's emphasis on heightened risks related to TAF-based therapies and evolving treatment landscapes. It also correctly frames Biktarvy as a major product for GILD. However, it misses the nuance that the 2024 risk focus is specifically on reliance on TAF-based therapies, a detail absent in the LLM response. (4) Contextually, the answer is relevant and addresses both revenue contribution and product risks as required. The reasoning structure is logical, but the inclusion of false revenue data undermines the overall correctness. While the direction of risk evolution is correctly interpreted, the unsupported revenue growth claim results in a partial score. The model synthesizes the general trend but fails on key factual grounding, especially in the 2024 projection.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 467,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "Union Pacific's (UPRR) financial stake in TTX increased from $1.5 billion (2022) to $1.9 billion (2024), reflecting a slight rise in its 36.79% to 37.03% ownership. Car hire expenses with TTX rose from $402 million (2022) to $432 million (2024), indicating a modest increase in operational reliance, while remaining within a stable range of $375–$432 million annually.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in key numeric values. The ground truth states that Union Pacific's financial stake in TTX increased from $1.6 billion (referenced in the 2022 filing, reflecting 2021 data) to $1.9 billion in 2024. However, the LLM incorrectly reports the starting investment as $1.5 billion in 2022, which misaligns with the source data. Additionally, car hire expenses are reported as rising from $402 million in 2022 to $432 million in 2024 by the LLM, but the ground truth indicates an increase from $375 million in 2021 to $432 million in 2024. The LLM thus overstates the 2022 expense figure and uses the wrong base year, leading to an inaccurate trend portrayal. The ownership percentages (36.79% to 37.03%) are not present in the original answer and are unverifiable from the provided truth, introducing unsupported detail. (2) Quantitative accuracy is compromised: the $1.5B vs $1.6B stake and $402M vs $375M expense figures are materially off. While the final 2024 values ($1.9B stake, $432M expense) match, the baseline comparisons are incorrect, affecting trend interpretation. (3) The reasoning partially captures the multi-hop nature—linking financial stake and operational expenses over time—but bases its synthesis on incorrect starting points. The conclusion of 'modest increase' and 'stable range' contradicts the ground truth's implication of a growing involvement, especially given a $57M rise from $375M to $432M (15.2% increase), which is more significant than 'modest'. (4) Contextual relevance is high—the answer addresses both investment value and car hire expenses over time, uses correct entities (UPRR, TTX), and maintains focus on the evolution of the relationship. However, the incorrect data undermines correctness. The answer fabricates precise ownership percentages and misstates base-year figures, reducing reliability. A score of 5 reflects partial correctness: it gets the endpoint numbers right but fails on critical input data and trend accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 547,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "Tesla continued its focus on improving Solar Roof installation capabilities through installer training and partnerships with real estate developers in both 2022 and 2023, as noted in the \"Energy Generation and Storage Demand, Production and Deployment\" sections of both filings. However, in 2023, the company emphasized heightened supply chain and labor cost challenges due to global trade conditions and labor availability, indicating a broader strategy to manage supply chain risks through increased capital expenditures and operational adjustments. No explicit changes in installer training initiatives were reported between the two years.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key aspects of the shift in Tesla's strategy from 2022 to 2023, particularly regarding installer training initiatives. (1) Correctly identifies Tesla's continued focus on installer training and partnerships in both years and notes increased emphasis on supply chain risks in 2023, including global trade and labor challenges. However, it incorrectly states that 'no explicit changes in installer training initiatives were reported,' which contradicts the ground truth: in 2022, Tesla actively expanded installer onboarding and training as a growth lever, whereas in 2023, this focus diminished in favor of supply chain resilience. The shift in emphasis from installer-driven scaling to supplier and production risk management is underplayed. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—score reflects absence of errors. (3) Multi-hop reasoning is partially sound—LLM synthesizes information across years and identifies supply chain as a growing concern—but fails to accurately contrast the strategic pivot away from installer expansion. (4) Contextual relevance is high as the response addresses both parts of the question (installer training and supply chain), but the qualitative inaccuracy in characterizing continuity in training initiatives reduces overall correctness. The answer suggests stability where there was a strategic shift, weakening its factual alignment with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 407,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "The Coca-Cola Company's relationship with fountain retailers in the U.S. regarding fountain syrup manufacturing and distribution remained consistent between 2022 and 2023. In both years, the company continued to manufacture fountain syrups domestically and sell them directly to authorized fountain wholesalers and some retailers, as well as through bottling partners. These sales are included in the North America operating segment, with no indication of significant changes in the structure or terms of this relationship.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in its core conclusion. While it correctly states that The Coca-Cola Company manufactures fountain syrups in the U.S. and sells them to authorized fountain wholesalers and some retailers, it incorrectly claims that the relationship 'remained consistent' between 2022 and 2023. The ground truth shows a meaningful evolution: in 2022, U.S. bottlers were generally not authorized to manufacture syrups and the Company sold directly to wholesalers and certain retailers; by 2023, the Company explicitly included bottling partners in the distribution chain, selling syrups to them for further distribution to fountain retailers. This indicates a more defined or expanded tiered distribution model, which the LLM answer fails to recognize. There are no numerical figures in the question, so quantitative accuracy is not applicable—scored as 10 by default for absence of numerical errors. The qualitative accuracy is low because the model misses the key multi-hop insight: the shift from an implicit to a more explicit role for bottling partners in distribution. Contextual relevance is high as the answer addresses the correct companies, geography, product (fountain syrups), and time frame. However, the failure to identify the evolution in the distribution model undermines the correctness score, warranting a 5 for overall factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 391,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "IBM's 0.950% Notes due 2025 were disclosed in the 2024 10-K as registered securities under Section 12(b) of the Securities Exchange Act, listed as \"IBM25B\" on the New York Stock Exchange. The 2022 filing (pages 28–32) did not specifically address these notes, but the 2024 document confirms their registration and classification as debt instruments, consistent with standard disclosure practices for corporate bonds. No changes in classification or registration details are noted between 2022 and 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misses key aspects of the evolution in IBM's treatment and disclosure of the 0.950% Notes due 2025 from 2022 to 2024, leading to a partially incorrect conclusion. (1) Quantitatively, the trading symbol 'IBM25B' and the reference to Section 12(b) registration in 2024 are accurate and align with the ground truth. The percentage (0.950%) and maturity year (2025) are correctly stated. (2) However, the claim that the 2022 filing 'did not specifically address these notes' is incorrect. The ground truth states that the notes were disclosed in a Form 8-K filed on May 22, 2017, and referenced in 2022 as part of exhibits—indicating ongoing disclosure, not absence. The LLM incorrectly interprets lack of detailed discussion in the 2022 10-K as non-disclosure, failing to recognize that exhibit-level referencing constitutes disclosure. (3) The reasoning is flawed in asserting 'no changes in classification or registration details are noted'—the ground truth explicitly describes an evolution from exhibit-based disclosure (2022) to active listing for trading (2024), which represents a material shift in treatment. The LLM fails to capture this multi-hop progression: from initial filing (2017), to passive disclosure (2022), to active listing (2024). (4) While the answer is relevant and uses correct terminology, it draws an incorrect conclusion due to misinterpretation of disclosure practices, hence the moderate score. Semantic equivalence is partially achieved but key factual nuance is lost.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 422,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "Gilead's strategic positioning of Biktarvy has focused on maintaining its competitive differentiation in the HIV treatment market through efficacy, safety, and patient adherence, while managing financial risks tied to pricing pressures and competition from generics. From 2022 to 2024, the company emphasized sustaining market share amid evolving reimbursement challenges and regulatory pressures, as highlighted in risk factors related to HIV product sales and pricing. Financial risk exposure remains tied to the HIV portfolio's reliance on key products like Biktarvy, with competitive differentiation reinforced by its favorable side effect profile and simplified dosing compared to older therapies.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key aspects of the evolution in GILD's strategic positioning of Biktarvy from 2022 to 2024 as described in the ground truth. (1) What was correct: The LLM correctly identifies Biktarvy as a key product in GILD’s HIV portfolio and notes financial risk exposure due to reliance on it, aligning with the 2024 risk acknowledgment. It also accurately highlights competitive differentiation via efficacy, safety, dosing, and adherence—factors consistent with GILD’s messaging. (2) Quantitative accuracy: There are no specific numbers (e.g., revenue figures, percentages) in either the original or LLM answer, so no numeric inaccuracies exist; this aspect is neutral and does not detract. (3) Multi-hop reasoning assessment: The LLM fails to capture the critical shift between 2022 and 2024. In 2022, Biktarvy was emphasized as a core marketed product (strong positioning), but by 2024, GILD explicitly flagged increasing financial risk due to potential paradigm shifts away from TAF-based therapies like Biktarvy—this evolving concern about long-term sustainability and differentiation in the face of new treatment trends and generic erosion is missing in the LLM response. Instead, the LLM generalizes ongoing challenges (pricing, reimbursement) without showing the strategic evolution. (4) Justification for scores: Correctness is 6 because core facts about Biktarvy’s role and risks are present, but the dynamic change in strategic outlook over time—the central thrust of the question—is underdeveloped. Qualitative accuracy is 6 due to incomplete synthesis across years and lack of specificity on the TAF-based regimen risk. Quantitative accuracy is 10 by default (no numbers involved). Contextual relevance is 8 because the answer stays on-topic and addresses financial risk and differentiation, though not the temporal evolution as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 508,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "Lockheed Martin transferred $4.3 billion of defined benefit pension obligations to an insurance company in 2022 via group annuity contracts, resulting in a $1.5 billion noncash pension settlement charge. In 2023, the company made $414 million in lump-sum settlements to former employees, reducing benefit obligations without impacting 2023 FAS pension income. These transfers reduced unfunded pension liabilities, with the 2022 transfer significantly lowering the funded status compared to 2021. The 2023 settlements further decreased obligations but did not generate a settlement charge.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: $4.3 billion pension obligation transfer in 2022 via group annuity contracts with a $1.5 billion noncash settlement charge, and $414 million in lump-sum payments to former employees in 2023. These numbers match the original answer exactly, satisfying quantitative accuracy. (2) The answer correctly identifies the shift in strategy—from large-scale annuity transfers in 2022 to direct individual settlements in 2023—even if it doesn't explicitly state '6,500 former employees,' this detail is minor and doesn't affect the core financial or strategic insight. (3) The reasoning is sound: it correctly notes that the 2023 settlements reduced obligations without triggering a settlement charge or impacting FAS pension income, which reflects proper synthesis of the financial implications across years. (4) The mention of reduced unfunded liabilities and impact on funded status adds context not in the original answer but is factually consistent and enhances relevance. The only minor gap is the lack of explicit contrast in strategy (e.g., 'shift from insurer transfers to individual settlements'), but the implication is clearly conveyed. Thus, the answer is semantically equivalent, fully relevant, and factually precise, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 399,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "The composition of IBM's debt instruments maturing in 2025 remained consistent between 2022 and 2024, with the **2.875% Notes due 2025 (IBM 25A)** still listed in both the 2022 and 2024 10-K filings. No changes in the structure or maturity of this specific debt instrument were noted in the provided pages. The 2024 filing also included the **7.00% Debentures due 2025 (IBM 25)**, indicating the 2025 maturity date remained a key component of IBM's debt portfolio during this period.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the 2.875% Notes due 2025 (IBM 25A) as present in both 2022 and 2024, it fails to mention the removal of the 0.875% Notes due 2025 (IBM 25C) by 2024, which is a key part of the evolution in debt composition. Instead, the LLM incorrectly introduces '7.00% Debentures due 2025 (IBM 25)' as present in the 2024 filing, which is not supported by the ground truth and contradicts the original answer. This misrepresents the actual change in composition. (2) Quantitatively, the 2.875% interest rate and 2025 maturity date are correct, but the introduction of a 7.00% debenture is factually wrong and unsupported. No dollar amounts or calculations are involved in this question, so accuracy hinges on correct identification of instruments and their presence across years. (3) The multi-hop reasoning is flawed: the question asks for an analysis of how the composition evolved, requiring comparison across years and identification of additions/removals. The LLM fails this synthesis by asserting consistency and adding a non-existent instrument, missing the key point that IBM retired the 0.875% Notes. (4) Contextual relevance is moderate because the answer addresses IBM's debt instruments maturing in 2025 and references the correct time frame and one correct instrument, but the incorrect addition of a 7.00% debenture and omission of the removal of IBM 25C severely undermine factual correctness. The conclusion that the composition 'remained consistent' directly contradicts the ground truth, which notes a clear shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 444,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "Biktarvy's strategic importance within Gilead's HIV portfolio grew significantly from 2022 to 2024, driven by its role in offsetting declining sales of Truvada and Atripla post-loss of exclusivity in 2020. In 2022, Biktarvy's sales increased due to higher demand and net average selling prices, positioning it as a key growth driver. However, its risk profile remained elevated due to competitive pressures from generics and evolving treatment paradigms, particularly as alternative therapies like lenacapavir emerged. By 2024, while Biktarvy maintained its critical role, ongoing challenges included managing generic competition and ensuring sustained adoption amid shifting clinical guidelines and payer dynamics.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements but diverges significantly from the ground truth in key aspects of strategic evolution and risk profile. (1) Correctly identifies Biktarvy as a growth driver in 2022 and notes competitive pressures, which aligns with the original answer. However, it incorrectly frames Biktarvy's strategic importance as having 'grown significantly' from 2022 to 2024, whereas the ground truth indicates a shift toward increased vulnerability and risk by 2024, not strengthened strategic position. (2) No specific numeric values (e.g., 11% revenue increase) are mentioned in the LLM answer, missing a key quantitative anchor from the original. While no incorrect numbers are stated, the absence of this critical data point reduces quantitative completeness. (3) The reasoning mischaracterizes the multi-hop synthesis: the ground truth emphasizes that by 2024, Biktarvy’s risk stems from overreliance on TAF-based therapies and potential paradigm shifts away from nucleoside analogs, not just generic competition or lenacapavir. The LLM overemphasizes external competitive threats while underrepresenting the internal structural risk within Gilead’s portfolio highlighted in the 2024 10-K. (4) Contextually, the answer is relevant and addresses the question’s scope, but fails to reflect the nuanced shift from 'growth asset' to 'increasingly vulnerable' status, which is central to the correct interpretation. Wording flexibility is acceptable, but the semantic meaning differs on a core point: strategic importance declined in risk perception by 2024, not increased.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 435,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "The U.S. litigation escrow account balance increased from $1,449 million at the end of fiscal 2022 to $1,764 million at the end of fiscal 2023. During fiscal 2023, the Company deposited $1,000 million into the account, while making payments of $685 million to opt-out merchants.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numbers. The ending balance for fiscal year 2023 is incorrect: it states $1,764 million instead of the correct $3,089 million. The deposit during fiscal 2023 is stated as $1,000 million, but the ground truth is $1,500 million. Additionally, the LLM introduces unverified details—'payments of $685 million to opt-out merchants'—which are not part of the original answer and contradict the provided truth. (2) Quantitative accuracy is low: the balance increase is reported as $315 million ($1,764M - $1,449M), whereas the actual increase is $1,640 million ($3,089M - $1,449M). The deposit amount for fiscal 2023 is wrong, and no deposits for fiscal 2022 are mentioned in the LLM answer, despite being required. (3) The reasoning is partially sound in that it recognizes the account balance increased and attempts to explain changes via deposits and payments, but it fails the multi-hop synthesis by not correctly linking the two fiscal years' deposits and balances. It also introduces extraneous, unsupported information, indicating flawed reasoning. (4) Contextual relevance is moderate—the response addresses the evolution of the escrow account and mentions deposits, so it stays on topic—but due to major factual inaccuracies and missing core data, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1159,
        "completion_tokens": 378,
        "total_tokens": 1537
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "Coca-Cola's North America operating segment continued to manufacture and distribute fountain syrups in the United States in both 2022 and 2023, as described in the \"Our Business\" sections of both filings. The company's responsibility for producing fountain syrups and selling them to retailers and authorized wholesalers remained unchanged, with these activities consistently included in the North America operating segment. No significant evolution in manufacturing or distribution responsibilities was noted between the two years.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key nuance in the evolution of Coca-Cola's role in fountain syrup manufacturing and distribution between 2022 and 2023. (1) It correctly states that Coca-Cola continued to manufacture and distribute fountain syrups in the U.S. in both years and that responsibilities within North America remained consistent—this aligns with the ground truth. However, it fails to mention the significant shift noted in the 2023 filing regarding authorization of bottling partners outside the U.S. to manufacture fountain syrups using company concentrates. This omission undermines the completeness and qualitative accuracy of the response. (2) There are no numerical values in the question or answer, so quantitative accuracy is not applicable; however, the years (2022, 2023) and entities (Coca-Cola, North America operating segment, fountain syrups) are correctly identified. (3) The multi-hop reasoning is weak: while the model correctly infers continuity in North America, it does not synthesize the broader operational evolution involving international manufacturing authorization, which is central to understanding the strategic shift. (4) The answer is contextually relevant and addresses the core of the question about manufacturing and distribution responsibilities, but by omitting the decentralized model expansion, it presents an incomplete picture. Thus, the correctness and qualitative accuracy scores are moderate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 401,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "The 0.950% Notes due 2025 (IBM 25B) remained part of IBM's debt instruments maturing in 2025 in both the 2022 and 2024 10-K filings. The composition of debt maturing in 2025, including this specific note, did not change between the two periods, as the same instruments (IBM 25A, 25B, and 25) were listed in both filings. No evidence of repayment, replacement, or structural changes to the 0.950% Notes due 2025 is provided in the disclosed pages.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the composition of IBM's debt instruments maturing in 2025 remained unchanged between 2022 and 2024. According to the ground truth, in 2022 there were three notes: 2.875% (IBM 25A), 0.950% (IBM 25B), and 0.875% (IBM 25C). By 2024, the 0.875% Notes (IBM 25C) were no longer listed, indicating a change in composition. The LLM incorrectly claims all three instruments were still present in 2024, which contradicts the ground truth. (2) While percentages (0.950%, 2.875%) and note names (IBM 25A, 25B) are correctly referenced, the core claim about continuity is false. The assertion that 'the same instruments were listed in both filings' is quantitatively inaccurate. (3) The multi-hop reasoning failed: the model should have compared the list of 2025-maturing notes across 2022 and 2024 filings to detect the removal of IBM 25C. Instead, it assumed no change, missing a key evolution in debt composition. (4) Contextual relevance is moderate because the answer addresses the right topic (IBM's 2025 debt, specifically the 0.950% notes) and uses correct terminology, but the central conclusion is wrong. Correctness, quantitative, and qualitative scores are low due to the critical factual error in synthesis and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 361,
        "total_tokens": 1587
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "Disney's strategic approach to cruise ships evolved between 2022 and 2024, as disclosed in their 10-K filings. In 2022, the company highlighted plans to open a Disney Cruise Line destination at Lighthouse Point, Eleuthera, in 2024, emphasizing expansion into new markets. By 2024, Disney announced additional fleet expansion plans, including new cruise ships, to enhance capacity and offerings. This reflects a shift toward growing their cruise business through both destination development and fleet growth, aligning with broader investments in the \"Experiences\" segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct but contains a minor factual inaccuracy and omits a key aspect of the strategic evolution described in the ground truth. (1) The LLM correctly identifies Disney's fleet expansion plans by 2024 and references the Experiences segment, aligning with the broader strategic shift. However, it incorrectly states that in 2022, Disney highlighted plans to open a cruise destination at Lighthouse Point in 2024. While Lighthouse Point is mentioned in Disney’s filings, the 2022 10-K does not frame this as a central part of the cruise strategy; instead, the ground truth emphasizes that in 2022, Disney discussed cruise ships more passively, as dependent on consumer demand for travel. This misrepresents the 2022 strategic posture. (2) Quantitatively, there are no explicit numbers or dates that are incorrect—'2024' for new ships and destination openings is consistent with disclosures—so quantitative accuracy is high. (3) The multi-hop reasoning is partially sound: the model connects 2022 and 2024 strategies and infers growth intent, but fails to accurately contrast the passive 2022 stance (dependence on demand) with the active 2024 investment strategy, which is the core of the evolution. (4) Contextual relevance is strong—the answer addresses strategic evolution in cruise ships using 10-K disclosures and ties it to segment-level investments. However, the omission of the risk acknowledgment in 2024 (increased costs and uncertain returns) slightly weakens completeness. Overall, the answer captures the direction of change but mischaracterizes the starting point and misses nuanced strategic depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 445,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "Lockheed Martin continued its strategy of mitigating pension liabilities through pension risk transfer transactions in 2023, building on the 2021 transaction where $4.9 billion of pension obligations were transferred via group annuity contracts (GACs). The 2023 filing notes that future transactions could result in noncash settlement charges, which may impact earnings materially. While no new specific transactions are detailed for 2023, the strategic intent remains focused on reducing pension obligation volatility and managing financial exposure, with ongoing evaluation of opportunities to transfer risks, potentially affecting earnings through noncash charges.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its quantitative details: it accurately references the $4.9 billion pension obligation transfer via group annuity contracts (GACs) from 2021 and correctly notes the potential for future noncash settlement charges that could materially impact earnings. The mention of ongoing evaluation of risk transfer opportunities aligns with the strategic continuity described in the original answer. However, the LLM answer omits key qualitative developments from 2023 that reflect an evolution in Lockheed Martin's approach. Specifically, it fails to mention the nuanced risk introduced in 2023 regarding potential residual liability if insurers default on GACs—a significant shift toward a more cautious framing not emphasized in 2022. Additionally, while the original answer highlights that $11.6 billion in obligations had been transferred since December 2018, benefiting ~95,000 retirees, this context is missing in the LLM response, weakening the completeness of the strategic narrative. The LLM also does not clarify that the $1.7 billion noncash settlement charge was already realized in 2022 (not just a future possibility), though it correctly identifies that future transactions may trigger similar charges. The reasoning is sound but incomplete in synthesizing the full evolution—particularly the shift from execution-focused reporting in 2022 to a more risk-aware, forward-looking stance in 2023. Wording is semantically aligned and relevant, but the absence of the insurer default risk and cumulative transfer context prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 431,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "Tesla's relationship with financing partners evolved between 2022 and 2023, with heightened focus on accounts receivable management and leasing program risks. In 2023, Tesla emphasized the impact of payment terms and timing on accounts receivable balances, noting fluctuations due to financing partner payment cycles and government rebate processing timelines. The 2023 filing also highlighted risks related to leasing programs, including residual value projections, resale value guarantees, and credit risk from customers and partners. These factors could affect profitability if actual resale values fall short of expectations or if customers default on payments, underscoring increased scrutiny of financial obligations tied to financing arrangements.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in Tesla's relationship with financing partners from 2022 to 2023, with accurate qualitative details and no numerical inaccuracies. (1) All entities—Tesla, financing partners, accounts receivable, leasing programs, residual value, credit risk—are correctly identified, and the years 2022 and 2023 are appropriately referenced. (2) There are no explicit numbers (e.g., dollar amounts, percentages, or timeframes like 'two weeks') in the LLM answer, but the original answer mentions that in 2022, settlement could take 'up to approximately two weeks'—a specific detail missing in the LLM response. While the LLM mentions 'payment cycles' and 'timing,' it omits this concrete timeframe, which is a minor factual omission. (3) The multi-hop reasoning is sound: the LLM correctly infers that Tesla’s focus shifted toward greater risk management in leasing (residual values, resale guarantees, credit risk) in 2023, aligning with the ground truth. However, it does not explicitly contrast 2022’s focus on short-term liquidity and settlement timing with 2023’s broader risk concerns, weakening the comparative analysis slightly. (4) The answer remains highly contextually relevant, addressing both accounts receivable management and leasing risks as asked. The omission of the 'two weeks' detail and the less precise framing of the 2022 situation prevent a perfect score, but core facts and reasoning are accurate. Hence, correctness is 8/10, with full marks for quantitative accuracy (no incorrect numbers) and contextual relevance, and a slight deduction in qualitative accuracy for incomplete synthesis of the year-over-year shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 459,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "Coca-Cola's fountain syrup distribution strategy remained consistent between 2022 and 2023, with the Company continuing to manufacture fountain syrups in the U.S. and sell them to authorized fountain wholesalers or bottling partners, who then distribute to fountain retailers. There were no significant changes in the roles of bottlers or fountain wholesalers during this period, as bottlers in the U.S. were still not authorized to manufacture fountain syrups, and the Company retained control over their distribution to ensure alignment with its pricing and operational strategies.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Coca-Cola's fountain syrup distribution strategy remained consistent between 2022 and 2023. The ground truth indicates a clear shift in strategy, particularly outside the United States, where bottlers became authorized to manufacture fountain syrups using Coca-Cola concentrates in 2023—a significant change from the 2022 model where Coca-Cola manufactured and sold syrups directly to wholesalers. The LLM incorrectly claims no significant changes occurred, which contradicts the documented evolution in the supply chain model. (2) There are no numeric values (e.g., dollar amounts, percentages, quantities) in either the question or answers, so quantitative accuracy is not heavily applicable; however, the years 2022 and 2023 are correctly referenced, supporting a score of 8 for quantitative accuracy based on correct use of time periods. (3) The multi-hop reasoning is flawed: the model failed to synthesize the change in bottler roles internationally, which requires connecting information across time and geography. The LLM incorrectly generalizes the U.S.-centric model to all markets and misses the strategic shift toward a more integrated, bottler-driven international supply chain. (4) Despite addressing the question's structure and focusing on the relevant entities (Coca-Cola, bottlers, fountain wholesalers), the answer is largely incorrect in substance, warranting a low correctness score of 2. Contextual relevance is moderate (6) because the response discusses the right topic and entities but draws the wrong conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 440,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "Between 2023 and 2024, AMD's financial relationship with the ATMP JV evolved as follows:  \n- **Receivables** from the ATMP JV increased from **$9 million** (as of December 30, 2023) to **$12 million** (as of December 28, 2024).  \n- **Payables** to the ATMP JV rose from **$363 million** (2023) to **$476 million** (2024).  \n- AMD made a **$17 million equity contribution** to the JV in 2024, raising its investment carrying value to **$149 million** from **$99 million**.  \n- A **$100 million term loan** was secured by the JV's receivables from AMD, further linking their financial obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly reports the increase in receivables from $9M to $12M, it introduces several pieces of false information not present in the ground truth: payables rising from $363M to $476M, a $17M equity contribution, an increase in investment carrying value from $99M to $149M, and a $100M term loan secured by the JV's receivables from AMD. The ground truth states that AMD entered into a $100M term loan *with* the JV (i.e., AMD is the lender), not that the loan was secured by AMD's receivables. (2) Quantitative accuracy is low: only the receivables figures ($9M and $12M) are correct. All other numbers (payables, equity contributions, carrying values) are fabricated or misstated. The $100M loan is mentioned but misrepresented in structure and security. (3) Multi-hop reasoning is flawed: the model incorrectly synthesizes a more complex financial relationship than supported by the ground truth, adding investment activity and secured debt mechanisms that do not appear in the original answer. It fails to capture the key point that 2023 had no investment or loan activity, while 2024 introduced a creditor role via a direct loan from AMD to the JV. (4) Contextual relevance is moderate because the answer addresses the evolution of the financial relationship and focuses on receivables and investment-like activities, but the factual errors severely undermine correctness. The core shift from transactional to financially integrated is partially recognized but misrepresented in mechanism.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 432,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "Lockheed Martin's approach to managing nonqualified defined benefit pension plans evolved between 2022 and 2023 through strategic settlements. In 2022, the company transferred $4.3 billion of pension obligations to an insurance company via group annuity contracts, resulting in a **$1.5 billion noncash pension settlement charge**. In 2023, the company made **$414 million in lump-sum payments** to former employees who had not yet commenced vested benefits, reducing the pension obligation without impacting FAS pension income. These actions reflect a shift from transferring obligations to insurers (2022) to direct settlements (2023), both aimed at reducing unfunded liabilities while managing financial impacts differently: 2022 involved a noncash charge, while 2023 resulted in a direct cash outflow with no income statement effect.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts from the ground truth: in 2022, Lockheed Martin transferred $4.3 billion in pension obligations via group annuity contracts and recognized a $1.5 billion noncash settlement charge; in 2023, it made $414 million in voluntary lump-sum payments to approximately 6,500 former employees. All numeric values (dollar amounts, years) are accurate and match the original answer exactly, with acceptable formatting (e.g., $4.3 billion = $4.3 billion). (2) Quantitative accuracy is perfect: both the $4.3 billion obligation transfer and $1.5 billion charge in 2022, and the $414 million in 2023, are correctly reported. There are no calculation errors. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across two years and two different strategies (annuity transfer vs. lump-sum payments) and draws the valid conclusion that the company shifted from large-scale insurer transfers to a more targeted approach. The characterization of financial impacts—noncash charge in 2022 vs. cash outflow without income statement impact in 2023—is consistent with the underlying accounting and adds valuable context not explicitly stated but logically inferred. (4) The only minor shortcoming is that the LLM omits the detail about 'approximately 6,500 former employees,' which is present in the ground truth and adds specificity to the 2023 action. While not critical, it slightly reduces completeness. Otherwise, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning. Hence, correctness is 9/10, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 460,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "Between 2023 and 2024, AMD's investment in the ATMP JV increased from **$83 million** (as of December 31, 2022) to **$149 million** (as of December 28, 2024), driven by a **$17 million contribution** in 2024. Equity income from the JV rose from **$16 million in 2023** to **$33 million in 2024**, reflecting improved performance. Purchases from the JV remained steady at **$1.7 billion annually**, while payables increased to **$476 million in 2024** (from $363 million in 2023), partly due to a **$100 million loan** provided to the JV in October 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces significant inaccuracies. It correctly states that AMD contributed $17 million in 2024 and that equity income rose from $16 million in 2023 to $33 million in 2024, matching the ground truth. However, it incorrectly claims the 2022 carrying value was $83 million, which is not provided in the original answer and not inferable from the given data. The original answer only provides the 2023 carrying value ($99 million), which the LLM omits. Instead, the LLM implies the $149 million in 2024 resulted from $83M + $17M, which is mathematically incorrect ($100M) and contradicts the ground truth progression. The correct progression should be $99M (end of 2023) + $17M contribution + $33M equity income - distributions (if any) = $149M, but the LLM does not explain this properly. (2) Additional details like $1.7 billion in annual purchases, $476 million in payables, and a $100 million loan to the JV in October 2024 are not present in the original answer and appear to be hallucinated or sourced from outside the provided truth. These undermine quantitative accuracy. (3) The multi-hop reasoning is partially sound—AMD increased investment and saw higher equity income—but the synthesis is flawed due to incorrect baseline values and inclusion of unsupported data. (4) Despite the inclusion of extraneous and incorrect figures, the core trend (increased investment and higher equity income) is correctly identified, warranting a moderate correctness score. Contextual relevance is high as the answer addresses the evolution of the financial relationship, but quantitative accuracy is penalized heavily due to false numbers and unsupported calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 471,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "Johnson & Johnson's ownership of Kenvue decreased from 9.5% as of August 23, 2023, to 0% by May 17, 2024, following a Debt-for-Equity Exchange. In 2023, the exchange offer resulted in a non-cash gain of $21.0 billion, including $2.8 billion from retained Kenvue shares. In 2024, the disposal of the remaining Kenvue shares led to a $0.4 billion loss recorded in Other (income) expense. This reflects the evolution of retained equity and associated gains/losses during the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures all key facts from the ground truth: Johnson & Johnson's ownership decreased from 9.5% in 2023 to 0% in 2024, the $21.0 billion non-cash gain in 2023 (including $2.8 billion on retained shares), and the $0.4 billion loss in 2024 from the disposal of remaining shares. The dates (August 23, 2023, and May 17, 2024) are specific and consistent with the timeline. (2) All numeric values are accurate: 9.5%, $21.0 billion, $2.8 billion, $0.4 billion, and the final 0% ownership. The format variations (e.g., 'approximately $0.4 billion' vs. '$0.4 billion') are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound—correctly linking the 2023 partial divestiture with gain recognition and the 2024 full exit with a loss, demonstrating synthesis across two fiscal years and events (exchange offer and debt-for-equity exchange). The only minor omission is that the original answer specifies Johnson & Johnson retained 9.5% *after* the initial exchange, whereas the LLM implies the 9.5% was the starting point without clarifying it was post-exchange. Also, the LLM does not mention the exact number of shares (182,329,550), but this is a minor detail not critical to the core question about stake evolution and financial impact. (4) The answer is highly relevant, directly addressing the evolution of ownership, retained equity, and associated gains/losses. The qualitative accuracy is slightly reduced due to the subtle ambiguity in the sequence of ownership percentage, but overall, the reasoning and facts are robust. Hence, a 9/10 correctness score is justified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 446,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained unchanged between 2022 and 2023, as evidenced by its continued inclusion in the guarantee agreements referenced in Exhibit 4-b of the 2023 10-K filing. This exhibit explicitly references a 2011 guarantee agreement covering obligations of Southwestern Bell Telephone Co., indicating no new inclusion or modification of the guarantee during the specified period.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained unchanged between 2022 and 2023, which aligns with the ground truth. The key factual point—that the guarantee continued in both years without modification—is accurate. However, there is a discrepancy in the exhibit number cited: the LLM states Exhibit 4-b in the 2023 10-K, while the ground truth specifies Exhibit 4-c for both years. This is a material error in sourcing, as exhibit numbers are specific and verifiable components of SEC filings. Despite this, the core reasoning and conclusion about the consistency of the guarantee are sound. The answer correctly avoids introducing new facts or incorrect entities, and the reference to a 2011 guarantee agreement (though not in the ground truth) does not contradict it, as such agreements can be long-standing. The multi-hop synthesis across years is logically handled, but the incorrect exhibit reference reduces confidence in the sourcing accuracy. Thus, while the semantic meaning and overall correctness are largely preserved, the error in exhibit number prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 327,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023 by advancing from classified development to early production phases, as noted in the 2023 filing (pages 4-7). In 2022, the company was engaged in significant classified hypersonics development programs, with expectations of transitioning to production over the next few years. By 2023, Lockheed Martin reported multiple hypersonics programs in active development, with several expected to enter early production by 2026. This reflects a strategic shift toward operationalizing hypersonic capabilities, expanding program development responsibilities to include production readiness and execution under the 21st Century Security initiative.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Lockheed Martin's hypersonics involvement from development toward production, which aligns with the direction of the ground truth. It correctly identifies that in 2022, hypersonics were part of significant classified programs with expectations of future production, and by 2023, multiple programs were in active development with early production expected by 2026. The mention of the 21st Century Security initiative adds contextual relevance. However, the LLM introduces specific details not present in the ground truth: (1) the claim about 'early production phases' and 'expected to enter early production by 2026' is more specific than the original answer, which does not mention production timelines; (2) the reference to 'pages 4-7' and '2023 filing' lacks verification and is not supported in the ground truth; (3) the original answer emphasizes a shift in strategic positioning—from a potential growth area to a major program under the Space segment—whereas the LLM focuses on a development-to-production timeline, missing the structural and segment-level repositioning highlighted in the ground truth. While the LLM demonstrates sound reasoning in inferring progression, it substitutes the actual evidence (segment reporting changes) with inferred program phase transitions. The entities (Lockheed Martin, hypersonics, U.S. military) are correct, and there are no numerical inaccuracies since no incorrect numbers are stated—thus quantitative accuracy is high. However, the qualitative accuracy is reduced due to incomplete and partially incorrect reasoning about the nature of the strategic shift. The answer remains contextually relevant and addresses the evolution question, but with a misaligned emphasis and unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 483,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "The balance of the U.S. litigation escrow account increased from $1.4 billion as of September 30, 2022, to $1.764 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1,000 million was deposited. The 2023 balance reflects net changes from these deposits and payments to opt-out merchants.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the reported 2023 escrow balance. The ground truth states the balance was $3.089 billion as of September 30, 2023, but the LLM reports $1.764 billion, which is off by over $1.3 billion. This is a major quantitative error. However, the deposits are mostly correct: $850 million in FY2022 matches the ground truth, and $1,000 million (i.e., $1.0 billion) in FY2023 is semantically equivalent to the correct value. (2) The calculation implied by the LLM—starting from $1.4B and adding $850M and $1.0B—would result in $3.25B pre-payments, not $1.764B, so the final balance is inconsistent with the deposits stated. The LLM mentions 'payments to opt-out merchants' as a reason for the lower balance, but this is not supported in the ground truth and appears to be fabricated or misattributed. (3) The multi-hop reasoning is partially sound in that the model identifies the need to track balance evolution and deposits across two fiscal years, but it fails in synthesizing the correct ending balance, which undermines the core of the question. (4) The contextual relevance is high because the answer addresses both parts of the question (balance evolution and deposits), uses correct fiscal years and entity (U.S. litigation escrow account), and maintains appropriate structure. However, the severe inaccuracy in the 2023 balance severely limits correctness. Quantitative accuracy is low due to the incorrect balance; qualitative accuracy is moderate due to correct identification of deposits and time frame but flawed reasoning around balance changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 442,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "Outdoor Garden's role within HD's product strategy remained classified under the Hardlines category in both 2022 and 2024, with its sales composition and percentage of total net sales showing minimal change. In 2022, Outdoor Garden accounted for 6.4% of total net sales ($10,039 million), and in 2024, it represented 6.5% of the Primary segment's net sales ($10,308 million). The slight increase in sales and stable classification indicate a consistent positioning within the Hardlines category, reflecting ongoing relevance in HD's retail strategy without significant strategic repositioning.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both classification and performance metrics. According to the ground truth, Outdoor Garden was a distinct product line in 2022, not part of Hardlines, and was only integrated into Hardlines by 2024. The LLM incorrectly states it was classified under Hardlines in both years, which contradicts the strategic evolution described in the original answer. (2) The numeric values are also inaccurate: the ground truth reports $10,317 million in net sales for 2022 (6.8% of total), while the LLM claims $10,039 million (6.4%). For 2024, the LLM cites $10,308 million (6.5% of Primary segment), but the original answer does not provide a 2024 sales figure or percentage—only a reclassification into Hardlines. These discrepancies suggest fabricated or misattributed data. (3) The multi-hop reasoning is flawed: the question asks about evolution in role and positioning, which hinges on the shift from standalone category to inclusion in Hardlines. The LLM fails to detect this structural change, instead asserting 'minimal change' and 'consistent positioning,' which directly contradicts the ground truth. (4) Contextual relevance is moderate because the answer discusses sales trends and categorization, which are relevant themes, but the core factual inaccuracies in entity classification, timeline, and metrics severely undermine the response. The conclusion of 'no significant repositioning' is incorrect given the documented strategic shift. Thus, the answer is mostly wrong in both quantitative and qualitative dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 432,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "AMD maintained its emphasis on an engaging and open environment by prioritizing cultural inclusivity, employee engagement surveys, and flexible work arrangements as its global workforce grew from 26,000 in 2023 to 28,000 in 2024. The company reinforced its culture of innovation through annual surveys highlighting top-tier engagement scores, diverse Employee Resource Groups (ERGs), and mentorship programs. These efforts, combined with competitive total rewards, pay-for-performance incentives, and hybrid work flexibility, underscore AMD's talent retention strategy of fostering belonging, continuous development, and adaptability—critical in attracting and retaining top talent amid fierce semiconductor industry competition.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes accurate workforce numbers (26,000 in 2023 and 28,000 in 2024), correctly reflecting the 7.7% growth mentioned in the ground truth. However, the qualitative content diverges significantly from the original answer. The ground truth states that AMD maintained the *same exact messaging* about its culture across both years, with no new programs or initiatives mentioned. In contrast, the LLM answer fabricates specific programs such as 'employee engagement surveys,' 'top-tier engagement scores,' 'ERGs,' 'mentorship programs,' 'pay-for-performance incentives,' and 'hybrid work flexibility'—none of which are present in the original data. (2) Quantitatively, the numbers are correct: 26,000 to 28,000 is a ~7.7% increase, and the years are accurate. (3) The multi-hop reasoning is flawed—the original answer draws a conclusion based on the *repetition of identical cultural language* despite workforce growth, suggesting intentional cultural preservation. The LLM instead invents a suite of retention programs not supported by the source, failing to base its reasoning on the actual evidence (i.e., consistent messaging). (4) While the LLM answer is contextually relevant and addresses talent retention in a competitive industry, it substitutes inference and plausible-sounding details for factual synthesis, leading to a partially correct but factually inaccurate response. The core claim—that AMD preserved its cultural messaging as a retention strategy—is overshadowed by unsupported specifics, reducing factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 430,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "AT&T's guarantee obligations related to The Ohio Bell Telephone Company were part of its contingent liabilities as of December 31, 2021, as disclosed in **T_10k_2022.pdf** (Note 4, Exhibit 4-c). The document lists The Ohio Bell among entities whose obligations were guaranteed by AT&T under a 2011 agreement. However, **T_10k_2023.pdf** does not explicitly mention The Ohio Bell or changes to these obligations, suggesting the guarantee remained in place without modification during 2022–2023. No new disclosures or terminations are noted in the provided pages.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in terms of factual content and context. It accurately identifies that AT&T's guarantee obligation for The Ohio Bell Telephone Company was documented in the 2022 10-K (filing T_10k_2022.pdf) under Exhibit 4-c, originating from a 2011 agreement, which aligns with the ground truth. The date reference to December 31, 2021, is consistent with the 2022 filing's reporting of prior-year liabilities. However, the LLM states that the 2023 filing does not 'explicitly mention' The Ohio Bell, concluding the guarantee 'remained in place without modification'—this is a reasonable inference but weaker than the ground truth, which notes an updated exhibit reference (e.g., from Exhibit 4-c to a current equivalent), indicating active maintenance of documentation. The LLM fails to mention this update in documentation practices, which is a key nuance in the evolution of the relationship. While the core facts and dates are correct (hence high quantitative accuracy), the absence of this detail reduces completeness and weakens the multi-hop synthesis—specifically, linking the absence of explicit mention to updated reporting standards. The reasoning is sound but incomplete, and the conclusion, while plausible, lacks the positive affirmation of continuity through documentation updates. Semantic equivalence is mostly preserved, but the omission of the exhibit update reduces qualitative accuracy. Contextual relevance remains high as the response directly addresses the question's focus on guarantee obligations and timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 424,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "The financial impact of GE's relationship with AerCap evolved significantly between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests. In 2023, GE reported gains of $5.778 billion on these interests, primarily driven by its AerCap investment. However, in 2024, gains decreased by $5.2 billion, reflecting a substantial decline attributed to AerCap's performance and market conditions. This decrease was a key factor in the overall reduction of continuing earnings for 2024 compared to 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the overall trend and key drivers—the significant decrease in gains on retained and sold ownership interests from 2023 to 2024, primarily due to AerCap and GE HealthCare. However, there is a minor quantitative inaccuracy: the LLM states that GE reported gains of $5.778 billion in 2023, while the ground truth specifies a $5.7 billion *increase* in corporate operating profit due to higher gains, not necessarily the total gains themselves. This misrepresents the metric slightly. The $5.2 billion decrease in 2024 is accurately reported and correctly framed as a year-over-year decline. (2) The $5.778 billion figure appears overly precise and is not supported by the original answer, which rounds to $5.7 billion. While close, this introduces false precision and could imply a different data source or calculation. The decrease of $5.2 billion matches exactly and is correctly interpreted. (3) The multi-hop reasoning is sound—LLM correctly synthesizes the change in financial impact between two years and attributes it to AerCap (and implicitly GE HealthCare, though it only explicitly names AerCap). The conclusion about the impact on continuing earnings is a reasonable inference, even if not in the original answer. (4) Scores reflect high qualitative and contextual accuracy, with a moderate deduction in quantitative accuracy due to the incorrect specificity of the 2023 gain figure. The core message—that gains surged in 2023 and then sharply declined in 2024—is preserved, warranting a high but not perfect correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 435,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "Home Depot's strategic use of HD Supply evolved between 2022 and 2024 by expanding its focus on professional customers (Pros) and MRO services through acquisitions and enhanced offerings. In 2024, the acquisition of SRS, a specialty trade distributor, strengthened HD Supply's position in serving residential and commercial roofing, landscaping, and pool contractors. HD Supply now provides tailored online experiences, dedicated sales support, a broad Pro-focused product assortment, and improved fulfillment options, including the Pro House Account credit program. These initiatives reflect a deeper integration of MRO services and differentiated capabilities to meet complex Pro needs, building on earlier strategic investments in Pro-centric solutions.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several inaccuracies and introduces information not present in the ground truth. (1) It incorrectly states that the acquisition of SRS occurred in 2024 and was part of HD Supply's expansion; however, the original answer and known public filings do not support this claim—SRS was acquired by Home Depot in 2021, not 2024, and is not directly tied to HD Supply’s MRO strategy in the provided context. (2) The LLM emphasizes new capabilities like 'tailored online experiences,' 'dedicated sales support,' and the 'Pro House Account credit program' as developments between 2022 and 2024, but these specific initiatives are not mentioned in the ground truth and cannot be verified from the provided data. (3) While the ground truth correctly identifies a strategic evolution—from integration challenges in 2022 to HD Supply becoming a core Pro-focused growth driver by 2024—the LLM misrepresents the nature of this evolution by attributing it to new acquisitions and service enhancements not cited in the original. (4) The answer is contextually relevant and addresses the focus on professional customers and MRO services, showing understanding of the strategic direction, but fails on factual accuracy and multi-hop reasoning because it fabricates key details rather than reporting the documented shift from integration risk to strategic enabler. (5) There are no numerical values to verify, so quantitative accuracy is acceptable by default, but the qualitative inaccuracies severely undermine correctness. Overall, the answer conveys a plausible narrative but diverges significantly from the ground truth in entities, events, and timing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 450,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "Between 2023 and 2024, AMD's patent portfolio size remained stable in the U.S. (7,500 patents) but expanded globally, with issued patents increasing from 12,800 to 13,200. Cross-licensing agreements continued to be a key component of AMD's strategy, enabling technology exchange and IP rights transfer with other companies. While the document does not explicitly detail changes in reliance on these agreements, the growth in global patent holdings suggests AMD maintained or enhanced its IP position through licensing, supporting ongoing technology collaboration and competitive differentiation.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in AMD's issued patents from 12,800 in 2023 to 13,200 in 2024 and notes the stable number of pending applications at 5,600, which aligns with the ground truth. However, it introduces a U.S.-specific figure of 7,500 patents that is not present in the original answer and cannot be verified from the provided ground truth, making this an unsupported addition. (2) The core numbers—12,800 to 13,200 issued patents and total portfolio growth from ~18,500 to ~18,800—are accurate and correctly reflect the slight expansion in the patent portfolio. The LLM omits the total patent matters (18,500 in 2023, 18,800 in 2024), which slightly reduces completeness. (3) The reasoning about cross-licensing agreements being a key strategy and the implication of a stronger IP position enhancing leverage is logically sound and consistent with the original answer’s inference. While the LLM stops short of explicitly stating that reliance on cross-licensing remains strong (as in the original), it implies continuity by calling it a 'key component' and linking portfolio growth to strategic advantage. (4) The answer is contextually relevant, addressing both patent portfolio evolution and implications for technology exchange. The unsupported U.S. patent number and omission of total patent matters prevent a perfect score, but the core facts and multi-hop synthesis are largely correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 398,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "Johnson & Johnson's financial stake in Kenvue evolved from 89.6% ownership post-IPO in May 2023 to 9.5% after disposing of 80.1% in an exchange offer by August 2023. By May 2024, the remaining 9.5% was exchanged for commercial paper in a debt-for-equity transaction, resulting in full disposal of Kenvue shares. This disposal, recorded as a $0.4 billion loss in 2024, marked the end of J&J's ownership, with all strategic relationships (e.g., transition agreements) likely concluding by the end of 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but has key factual inaccuracies. It correctly identifies the 9.5% stake post-exchange offer in 2023 and the full disposal in 2024 via a debt-for-equity transaction resulting in a $0.4 billion loss. However, it incorrectly states that J&J had 89.6% ownership post-IPO and disposed of 80.1% to get to 9.5%, which is not supported by the ground truth. The original answer does not mention pre-disposal ownership percentage or such a specific disposal of 80.1%, so this is an unsupported inference. Additionally, the LLM claims the disposal was of the 'remaining 9.5%', but the ground truth specifies the exact number of shares (182,329,550), which corresponds to the full stake, though the percentage is consistent. The $3.6 billion commercial paper amount is omitted in the LLM answer, reducing quantitative completeness. (2) The $0.4 billion loss in 2024 is correctly reported, as is the $0.4 billion expense in 2023 (though LLM only mentions the loss). However, the introduction of 89.6% and 80.1% figures lacks grounding in the provided truth and introduces numerical errors by implication. (3) The multi-hop reasoning is generally sound—linking the 2023 stake to 2024 disposal and recognizing the strategic conclusion—but fabricating intermediate percentages weakens the logical chain. The synthesis across years is appropriate, but the unsupported quantification undermines accuracy. (4) Despite numerical issues, the answer addresses the evolution of the stake and relationship, correctly concluding full exit and strategic wind-down, making it contextually relevant and mostly aligned in intent and structure with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 464,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "AT&T's relationship with Indiana Bell Telephone Co. Inc. was included in guarantee disclosures in the 2023 10-K filing (Exhibit 4-c and 4-d), reflecting a contractual obligation to guarantee certain obligations of Indiana Bell. This was not explicitly mentioned in the 2022 10-K notes, indicating the inclusion of Indiana Bell in guarantee disclosures evolved from absent in 2022 to explicitly disclosed in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim. According to the ground truth, Indiana Bell Telephone Co. Inc. was explicitly listed in AT&T's guarantee disclosures in both 2022 and 2023 under Exhibit 4-d, with no change in status. The LLM incorrectly states that the guarantee was 'not explicitly mentioned in the 2022 10-K notes,' implying the relationship was absent in 2022 and newly disclosed in 2023—this contradicts the ground truth. This is a major factual error in both entity disclosure status and temporal comparison. The mention of 'Exhibit 4-c and 4-d' in 2023 introduces an irrelevant exhibit (4-c) not referenced in the ground truth. While the answer correctly identifies that a guarantee existed in 2023 and involves contractual obligations, the erroneous claim of evolution from absence to presence undermines the multi-hop reasoning. The conclusion about 'evolved from absent in 2022 to explicitly disclosed in 2023' is false, as the guarantee was already in place and disclosed in 2022. Thus, despite some contextual relevance and partial entity/year accuracy, the answer fails on key factual and reasoning dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 322,
        "total_tokens": 1540
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "GE's financial relationship with AerCap evolved from 2023 to 2024 with a shift from equity holdings to cash transactions and a reduced role in investment gains. In 2023, GE sold its remaining equity shares in AerCap and paid $203 million in net cash to AerCap for ongoing activities, resulting in a $1,252 million loss in discontinued operations. By 2024, GE retained a senior note from AerCap (fair valued at $944 million) and recorded a $6 million net gain on disposal of discontinued operations, primarily due to the settlement program for Bank BPH. Cash involvement decreased in 2024, with no additional cash transactions mentioned, while investment gains shifted focus to the note's fair value adjustments rather than equity sales.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states that GE sold its remaining equity shares in AerCap in 2023 and paid $203 million to AerCap as part of that sale. In reality, the $203 million was a net cash payment *from GE to AerCap* related to continuing involvement (note receivable, product leases, transition services), not a sale of equity. The LLM also fabricates a '$1,252 million loss in discontinued operations' tied to AerCap, which is not mentioned in the ground truth. In 2024, the LLM claims GE held a senior note fair valued at $944 million and recorded a $6 million net gain due to Bank BPH—this is irrelevant and incorrect; the ground truth states GE reported a *decrease in gains* of $5.2 billion on retained and sold ownership interests, largely due to AerCap and GE HealthCare. (2) Quantitative accuracy is very low: the $203 million cash payment direction is correct but miscontextualized; the $1,252M loss, $944M note, and $6M gain are all unsupported and incorrect. The critical $5.2 billion decrease in gains is entirely missing. (3) Multi-hop reasoning is flawed: the LLM incorrectly frames the evolution as a shift from equity to cash transactions, whereas the truth is a shift from operational involvement (2023) to investment-based returns (2024). It fails to mention the strategic transition and misattributes financial impacts. (4) Contextual relevance is moderate—the answer addresses the timeline and financial relationship but with incorrect entities, metrics, and logic. Due to major factual and quantitative errors, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 445,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "The Home Depot has maintained a focus on enhancing store appearance and customer experience through physical and digital integration, evolving from 2022 to 2024. In 2022, they emphasized store refreshes, wayfinding signage, and improved in-store navigation, while investing in digital tools like mobile apps and online platforms to create an interconnected shopping experience. By 2024, they expanded on these efforts with additional store refreshes, new locations, and advanced digital capabilities (e.g., enhanced mobile navigation, personalized marketing). The acquisition of SRS in 2024 further strengthened their Pro-focused offerings, integrating digital and physical services to meet complex customer needs. Both years highlight a strategic balance between optimizing store environments and leveraging technology to drive customer satisfaction and competitive differentiation.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of The Home Depot's approach from 2022 to 2024, emphasizing both physical store appearance and digital integration as competitive factors. It accurately reflects the continuity and expansion of efforts, such as store refreshes, wayfinding, and digital tools. However, the mention of the 'acquisition of SRS in 2024' is not present in the original answer or supported by the provided ground truth, which does not reference any acquisitions. This is a minor factual overreach, though it doesn't undermine the core argument. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not compromised—no errors in numbers or calculations. (3) The multi-hop reasoning is largely sound: the model synthesizes changes over time (2022 to 2024), connects store appearance with digital integration, and links customer experience to competitive strategy. The only gap is the unsupported claim about SRS, which introduces an entity not in the ground truth. (4) The answer is contextually highly relevant, addressing all parts of the question—evolution over time, store appearance, customer experience, and digital integration. Despite the extraneous detail about SRS, the core reasoning and factual content align well with the ground truth, warranting a high correctness score with a slight deduction for the unsupported claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 395,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "Between 2023 and 2024, AMD's financial relationship with the ATMP JV evolved through increased resales and new financial arrangements. In 2024, AMD's resales to the ATMP JV rose to $121 million (from $14 million in 2023), while purchases remained steady at $1.7 billion. AMD also provided a $100 million one-year term loan to the ATMP JV in October 2024, secured by the JV's receivables from AMD, and contributed an additional $17 million to the JV, raising its investment value to $149 million from $99 million. These actions reflect expanded capital support and a structured credit arrangement in 2024 compared to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states that AMD's resales to the ATMP JV increased from $14 million in 2023 to $121 million in 2024, and correctly identifies the October 2024 $100 million one-year term loan, it introduces unsupported information. Specifically, the claim that AMD 'contributed an additional $17 million to the JV, raising its investment value to $149 million from $99 million' is not present in the ground truth and cannot be verified. Additionally, the statement about 'purchases remained steady at $1.7 billion' and the loan being 'secured by the JV's receivables from AMD' are not mentioned in the original answer and appear to be hallucinations. (2) The resale figures ($14M in 2023, $121M in 2024) and the $100M loan in October 2024 are quantitatively accurate. However, the additional $17M contribution and the $1.7B purchase amount are unverified and likely incorrect, severely impacting quantitative accuracy. (3) The reasoning correctly identifies the evolution of the relationship as deepening due to increased resales and new financial arrangements, which aligns with the ground truth. However, the multi-hop synthesis fails because it fabricates financial contributions and security terms not present in the source data, undermining the qualitative accuracy. (4) The answer is contextually relevant, addressing the evolution of the financial relationship and focusing on resales and new arrangements. However, the inclusion of unverified details reduces correctness. The core progression—increased resales and a new loan—is correct, but the added details make the answer partially misleading. Thus, the correctness score is 4 due to significant factual errors despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 482,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "Johnson & Johnson's approach to privacy compliance programs remained consistent between 2023 and 2024, emphasizing established controls and global compliance with evolving privacy laws and international data flow regulations. Both reports highlight ongoing efforts to manage risks from cross-border data transfers, unauthorized access, and legislative changes, including increased scrutiny of data localization and AI-driven threats. While no significant new programs were introduced, the 2024 report underscored heightened awareness of risks from AI and legislative actions affecting data use, reflecting a proactive stance amid growing regulatory complexity.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in conveying Johnson & Johnson's ongoing commitment to privacy compliance and the evolving regulatory landscape, with accurate emphasis on cross-border data flows, data localization, and legislative changes. There are no numeric inaccuracies (quantitative accuracy is perfect), and the context of heightened regulatory scrutiny and AI-related risks in 2024 is appropriately noted. However, the LLM understates the evolution in J&J's approach by stating the approach 'remained consistent' and that 'no significant new programs were introduced,' which contradicts the ground truth indicating a clear broadening of focus—from addressing new laws in 'other territories' in 2023 to anticipating 'globally' emerging laws in 2024—and an expansion to include technology and data-driven initiatives involving third parties. This represents a meaningful shift in scope and anticipation, not just heightened awareness. The answer captures the continuity but misses the strategic expansion and more anticipatory posture emphasized in the original answer, resulting in a partial omission of key qualitative evolution. Thus, while factually sound on surface elements, it lacks full completeness and precision in capturing the multi-hop nuance of how the program evolved. Contextual relevance is high as it directly addresses the question's focus on privacy compliance and regulatory response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 389,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "GE's financial exposure to Bank BPH related to borrower litigation losses decreased from $2,669 million as of December 31, 2023, to $2,461 million as of December 31, 2024. The valuation allowance for these losses was fully offset by the settlement program in 2024, resulting in no remaining valuation allowance as of 2024, compared to a $124 million allowance in 2023. This reflects a reduction in estimated losses and the resolution of the litigation through the settlement.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures, particularly regarding the valuation allowances. According to the ground truth, in 2023, GE had $1,712 million in valuation allowances and $957 million in other liabilities (totaling $2,669 million), and in 2024, $1,517 million in valuation allowances and $944 million in other liabilities (totaling $2,461 million). However, the LLM incorrectly states that the valuation allowance was $124 million in 2023 and zero in 2024, which is factually wrong. The total estimated losses are correctly reported as $2,669 million in 2023 and $2,461 million in 2024, so those high-level totals are accurate. (2) The calculation of the total losses is correct, but the breakdown is entirely wrong. The LLM claims the valuation allowance was fully offset and reduced to zero, but the ground truth states it was $1,517 million in 2024—still substantial—and that it 'fully offset the financing receivables balance,' not that the allowance itself was zero. This is a critical misunderstanding. (3) The multi-hop reasoning is partially sound in recognizing a decrease in total exposure and linking it to a settlement program, but the conclusion that there is 'no remaining valuation allowance' contradicts the source, undermining the reasoning. The strategic shift is mentioned in the original, but the LLM misrepresents its financial manifestation. (4) The contextual relevance is high because the answer addresses the evolution of GE's exposure, litigation losses, and settlement impact. However, due to major quantitative errors and misrepresentation of the valuation allowance trend, the correctness score is low. The qualitative accuracy is moderate because the direction of change (reduction in exposure) is correct, but the mechanism (valuation allowance elimination) is false.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 504,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "HD's Indoor Garden product line remained categorized under the Hardlines product line in both 2022 and 2024, with slight adjustments to merchandising department structures in 2024. In 2022, Indoor Garden accounted for 6.4% of total net sales ($10,105 million), and in 2024, it represented 6.6% of the Primary segment's net sales ($10,519 million), reflecting a modest growth in sales. The 2024 reorganization emphasized its placement within Hardlines, aligning it with Hardware, Outdoor Garden, and other related categories, suggesting a strategic focus on integrating it into broader home improvement offerings while maintaining its distinct positioning.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, HD's Indoor Garden product line generated $15,546 million in net sales (10.3% of total revenue), but the LLM incorrectly reports $10,105 million (6.4%). The 2024 figures are also wrong—the ground truth does not provide 2024 sales data, yet the LLM fabricates $10,519 million (6.6% of Primary segment sales), which is unsupported. Additionally, the ground truth states that Indoor Garden was a standalone category in 2022 and only reclassified under 'Hardlines' in 2024, but the LLM falsely claims it was already under Hardlines in 2022. (2) Quantitative accuracy is severely compromised: both dollar amounts and percentages are incorrect, and the LLM invents a 2024 sales figure not present in the original answer. There is no indication that the 6.6% refers to the Primary segment in the ground truth. (3) The multi-hop reasoning is flawed—the question asks for evolution based on financial performance (2022) and merchandising categorization (2024). The LLM fails to correctly identify the key shift: from standalone category in 2022 to Hardlines integration in 2024. Instead, it assumes continuity in categorization, undermining the core insight. (4) Contextual relevance is moderate because the answer discusses merchandising integration and strategic positioning, which are relevant themes, but the incorrect data and misrepresentation of structural changes severely limit usefulness. The conclusion about 'modest growth' and 'strategic focus' is based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 436,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "Colgate-Palmolive's sourcing strategies to manage cost volatility, as detailed in the 2022 10-K, emphasize cost containment, productivity initiatives, and limited use of commodity hedging contracts to address raw material price fluctuations. However, the provided 2024 document pages do not include specific updates or changes to these strategies, making it impossible to determine evolution from 2022 to 2024 based on the given text.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its conclusion. While it correctly identifies Colgate-Palmolive and the general use of sourcing strategies and cost containment in 2022, it falsely claims that the 2024 document does not contain updates on sourcing strategies. The ground truth confirms that by 2024, the company had evolved its approach with greater emphasis on managing raw material cost volatility (e.g., resins, essential oils, soybeans), increased focus on proactive cost containment, and adaptation to geopolitical and climatic disruptions. The LLM fails to report this evolution, incorrectly asserting insufficient data. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning is flawed: the model should have synthesized information across 2022 and 2024 disclosures to show evolution in strategy, but instead concluded no information was available, indicating a failure in retrieval or synthesis. (4) Contextual relevance is moderate because the answer discusses the correct company and topic (sourcing strategies, cost volatility), but it fails to deliver the key comparative insight between 2022 and 2024, which is the core of the question. Thus, correctness and qualitative accuracy are low despite correct terminology use.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 385,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "TREMFYA's sales increased from $3,147 million in 2023 to $3,670 million in 2024, reflecting a 16.6% growth. This growth was driven by market expansion and share gains, despite ongoing biosimilar competition in the immunology sector. In 2023, TREMFYA's growth was attributed to market growth, continued strength in PsO/PsA (psoriasis and psoriatic arthritis), and patient mix. The 2024 growth maintained momentum, with market growth and share gains offsetting broader challenges in the immunology segment, such as biosimilar competition impacting other products like STELARA and REMICADE.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: TREMFYA sales were $3,147 million in 2023 and $3,670 million in 2024, representing a 16.6% growth, which matches the ground truth exactly. The calculation is accurate: (3,670 - 3,147) / 3,147 ≈ 0.166 or 16.6%. (2) Quantitative accuracy is perfect—dollar amounts, percentages, and years are all correct and properly formatted. (3) Qualitatively, the LLM correctly identifies market expansion and strength in PsO/PsA as growth drivers in 2023, and maintains that momentum in 2024 with market growth and share gains. It adds context about biosimilar competition affecting other immunology products like STELARA and REMICADE, which is consistent with broader industry trends and does not contradict the ground truth. However, it omits the specific breakdown of the 18.1% growth from operations and the -1.5% currency impact mentioned in the original answer, which is a minor but relevant detail for full completeness. (4) Contextual relevance is high—the answer directly addresses both parts of the question: sales performance evolution and contributing factors. The reasoning is sound and synthesizes multi-hop information correctly across years and market conditions. The omission of the operational vs. currency impact detail prevents a perfect 10, but the core facts and logic are fully aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 384,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "Disney's structural relationship with A&E remained unchanged in terms of ownership (50% equity stake) and reporting methods from 2022 to 2023. The 2022 and 2023 filings both detail A+E's subscriber counts (e.g., 69 million domestic subscribers as of September 2022) and report Disney's financial stake under the equity method. No explicit structural changes or adjustments to subscriber reporting are noted in the provided documents for this partnership during the period.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims no structural change occurred in Disney's relationship with A&E from 2022 to 2023, but the original answer states a clear shift: in 2022, Disney had an arms-length partnership with 69 million domestic subscribers reported, while in 2023, it held a 50% equity stake and reclassified A+E as a significant equity investment. This change in ownership and reporting method is central to the question and entirely missed by the LLM. (2) Quantitatively, the LLM correctly mentions 69 million domestic subscribers as of 2022, which aligns with the ground truth, but fails to report the updated 58 million subscribers in 2023, omitting a key data point. The claim that 'no explicit structural changes' occurred is factually wrong based on the provided truth. (3) The multi-hop reasoning is flawed: the model should have connected the change in ownership structure to changes in financial reporting (from partnership disclosure to equity method inclusion under 'Equity in the income of investees') and subscriber number updates. Instead, it asserts continuity where there was a material change. (4) Contextual relevance is moderate because the answer discusses the right entities (Disney, A&E, subscribers, equity stake) and timeframe, but draws incorrect conclusions. The answer would be more accurate if it acknowledged the shift in both subscriber counts and reporting classification. Overall, major factual and reasoning errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 421,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "The financial impact of GE's relationship with AerCap evolved between 2023 and 2024, with a realized and unrealized gain of **$129 million** in 2023 compared to a **$865 million loss** in 2022. In 2024, GE reported a **decrease in gains on retained and sold ownership interests** of **$5.2 billion**, primarily due to AerCap investments, indicating a shift toward losses or reduced gains in 2024. This reflects a significant reversal from the 2023 gain, driven by market conditions and strategic adjustments.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error by referencing a '$865 million loss in 2022', which is not mentioned in the original answer and is irrelevant to the question about 2023–2024 evolution. This introduces incorrect data and undermines quantitative accuracy. The $129 million unrealized gain in 2023 is correctly stated, and the $5.2 billion decrease in gains in 2024 is also accurate and properly attributed to AerCap. However, the original answer does not state a specific dollar amount for the 2024 loss—only that gains decreased by $5.2 billion compared to 2023—so asserting a '$865 million loss' in 2024 is unsupported and incorrect. (2) The calculation of a $5.2 billion drop in gains is correctly used, but the introduction of a precise $865 million loss figure (possibly misattributed from another context or year) is a major quantitative flaw. No such number appears in the ground truth for 2022 or 2024. (3) The multi-hop reasoning is partially sound: the model identifies the shift from gain in 2023 to reduced gains in 2024 and links AerCap as a key contributor. However, the erroneous 2022 data breaks the logical chain and suggests confusion in entity-year alignment. (4) Despite the significant error in numbers, the overall direction of reasoning—declining financial performance from 2023 to 2024 due to AerCap—is consistent with the original answer, and the core $5.2 billion decline is correctly emphasized, warranting partial credit. Contextual relevance is high as the response focuses on the right companies, time frame, and financial concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 436,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "Mastercard's multi-layered security approach evolved between 2022 and 2024 by explicitly addressing third-party service provider risks through enhanced collaboration and integration. In 2024, the company emphasized working with third-party platforms (e.g., integrating Virtual Card Number solutions into external technology platforms) and leveraging public-private partnerships to monitor and mitigate threats. This evolution reflects a strategic shift toward proactive risk management, strengthening defenses against emerging cybersecurity threats by embedding security protocols into third-party ecosystems and enhancing visibility through tools like Mastercard Receivables Manager. The focus on third-party integration underscores Mastercard's commitment to a resilient, collaborative security framework.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Mastercard's security approach from 2022 to 2024. It correctly identifies that by 2024, Mastercard explicitly addressed risks related to third-party service providers, marking a shift from 2022 when such risks were not explicitly mentioned. The answer accurately reflects the strategic shift toward ecosystem-wide resilience through public-private partnerships and cross-organizational collaboration. However, the LLM introduces specific examples—such as 'Virtual Card Number solutions' and 'Mastercard Receivables Manager'—that are not present in the original ground truth and cannot be verified from the provided data. While these may be plausible, they represent unverified details that slightly undermine qualitative accuracy. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default (no errors in numbers/dates). The reasoning is sound and captures the multi-hop nature of the question—comparing two time points and inferring strategic intent. The answer is fully contextually relevant, addressing all parts of the question. The core facts are correct, but the addition of unsupported specifics prevents a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 356,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "Target Corporation remained in compliance with its debt leverage covenant in both 2022 and 2023, despite changes to its credit facilities. In 2022, the company replaced its $2.5 billion credit facility with a $3.0 billion facility and maintained compliance. In 2023, it added a new $1.0 billion 364-day facility and extended its five-year facility to 2028, while continuing to comply with covenants. The company’s credit ratings remained stable (A2/AA/A), ensuring access to capital markets and adherence to covenant terms.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Target remained in compliance with its debt leverage covenant in both 2022 and 2023 and accurately describes the addition of a $1.0 billion 364-day facility and the extension of the $3.0 billion facility to 2028. However, it incorrectly claims in 2022 that Target 'replaced its $2.5 billion credit facility with a $3.0 billion facility,' which is not supported by the ground truth. The original answer states that the $3.0 billion unsecured revolving credit facility was already in place in 2022 and set to expire in 2026—there is no mention of a prior $2.5 billion facility being replaced. This is a factual inaccuracy affecting quantitative precision. (2) Correct numbers include: $3.0 billion facility (correct amount), 2028 extension (correct), $1.0 billion 364-day facility (correct), October 2024 and October 2028 expiration dates (implied correctly). The erroneous $2.5 billion figure and the claim of replacement in 2022 are the only quantitative errors. (3) The multi-hop reasoning is sound—LLM correctly synthesizes covenant compliance across two years and links it to changes in credit facilities. It also appropriately infers that stable credit ratings (A2/AA/A) support covenant adherence, which, while not in the ground truth, is a reasonable qualitative addition that does not detract from accuracy. (4) The answer is contextually excellent, addressing all parts of the question: covenant compliance over time and changes in credit facilities. Due to the minor but notable error in the 2022 facility description, the correctness and quantitative accuracy scores are slightly reduced, but qualitative and relevance scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 462,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "Salesforce's risks associated with AI offerings, including generative AI like Agentforce, evolved from 2023 to 2024 by expanding to include heightened regulatory scrutiny, ethical concerns, and operational complexities. In 2023, risks were primarily framed around ethical issues (e.g., bias, privacy, content accuracy) and the challenges of integrating AI into existing services. By 2024, the discussion emphasized specific risks tied to generative AI, such as content inaccuracy, copyright infringement, and the need for robust compliance frameworks. The 2024 filings also highlighted increased regulatory pressures, including EU laws like the AI Act, and the potential for reputational harm and legal liability due to AI-generated content. Additionally, the 2024 document underscored the costs of mitigating these risks and the importance of maintaining ethical AI practices to avoid adverse impacts on business operations and customer trust.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Salesforce's AI-related risks from 2023 to 2024 with strong semantic equivalence to the ground truth. It correctly identifies the shift from general third-party integration risks in 2023 (though it reframes them slightly as 'ethical issues' rather than warranty-related liabilities) to expanded AI-specific risks in 2024, including ethical concerns, regulatory scrutiny (notably the EU AI Act), legal liability for inaccurate or infringing content, and increased compliance costs. All dates (2023, 2024) and entities (Salesforce, Agentforce, EU AI Act) are correct. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The only minor shortcoming is that the LLM slightly recharacterizes the 2023 risk: the original emphasizes warranty-related liabilities from third-party integrations, while the LLM emphasizes ethical AI issues (bias, privacy) — which were not the primary focus in 2023 per the ground truth. However, the 2024 risk expansion is accurately detailed, including generative AI content risks, copyright, compliance costs, and governance. The multi-hop reasoning across years and risk domains is sound, and the answer is fully contextually relevant. Thus, a score of 9 is justified for high but not perfect qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 377,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "Lowe's delivery capability for parcel-eligible items improved between fiscal years 2023 and 2024, with key advancements including expanded same-day delivery via its gig network, next-day delivery for major appliances in nearly all U.S. zip codes, and enhanced distribution capacity for big-and-bulky items. These improvements were supported by the completion of the market-based delivery model rollout and optimized supply chain infrastructure, enabling faster and broader delivery options for customers.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the improvement in delivery capabilities between fiscal years 2023 and 2024, particularly highlighting next-day delivery for major appliances in nearly all U.S. zip codes, which aligns with the ground truth. However, it introduces 'same-day delivery via its gig network' and 'enhanced distribution capacity for big-and-bulky items' that are not mentioned in the original answer, adding unverified details. The core advancement—faster parcel delivery (within two business days or less in 2024 vs. two business days in 2023)—is implied but not explicitly stated with the same precision. (2) There are no explicit numerical errors (e.g., dates, percentages, dollar amounts), but the answer adds capabilities (same-day delivery, gig network) not present in the ground truth, which affects factual accuracy despite no incorrect numbers. (3) The multi-hop reasoning is partially sound—correctly linking 2024 improvements to broader delivery speed and geographic reach—but overreaches by including unsupported enhancements like same-day delivery and gig network expansion. The original answer does not mention a gig network or same-day delivery, so this represents an extrapolation beyond the provided data. (4) The contextual relevance is high as the answer addresses delivery evolution and specific improvements. However, the qualitative accuracy is reduced due to the inclusion of unverified delivery methods and capabilities. The correctness score is 7 because the key fact about next-day appliance delivery is accurate and central, but the added details introduce inaccuracies, preventing a higher score despite correct overall direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 460,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "The sale of Dermstore LLC in February 2021 generated a $335 million pretax gain, recognized in 2021, and had no impact on Target's consolidated revenues or operating income in 2022 or 2023. The 2022 operating income was $3.848 billion, and 2023 operating income was $5.707 billion, reflecting changes driven by other factors such as sales trends, cost management, and supply chain adjustments, not the Dermstore transaction.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that the Dermstore sale occurred in February 2021 and generated a $335 million pretax gain, which aligns with the ground truth. It accurately notes that there was no impact on Target's consolidated revenues or operating income in 2022 or 2023, which is consistent with the original answer stating Dermstore represented less than 1% of revenues, operating income, and net assets in both years. However, the LLM introduces specific operating income figures for 2022 ($3.848 billion) and 2023 ($5.707 billion) that are not present in the ground truth and cannot be verified from the provided context. While these numbers may be factually correct in a broader context, their inclusion introduces unsupported precision and shifts focus toward general operating income trends not directly tied to the Dermstore sale. (2) The $335 million gain and February 2021 sale date are quantitatively accurate. The added operating income figures, while potentially correct, are extraneous and not part of the original answer, slightly reducing quantitative accuracy. (3) The reasoning is sound in concluding no financial impact post-sale, correctly synthesizing that the gain was recognized in 2021 and had no subsequent effect. However, the explanation attributes 2022–2023 operating income changes to 'sales trends, cost management, and supply chain adjustments'—details not present in the ground truth—introducing plausible but unverified causal factors. This reflects a minor overreach in reasoning beyond the provided data. (4) The answer is highly contextually relevant, directly addressing the evolution of financial impact. Despite minor over-specification, the core conclusion matches the ground truth: no meaningful financial impact in 2022 or 2023. The answer is semantically equivalent in its main claim but adds unsupported details, justifying a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 516,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "Between 2023 and 2024, Data Cloud's strategic positioning within Salesforce evolved to become more deeply integrated with AI advancements and expanded into specialized industry solutions. In 2023, Data Cloud was highlighted as a hyperscale data engine enabling unified customer insights across Salesforce's Customer 360 platform. By 2024, it was further aligned with the Einstein 1 Platform, allowing low-code AI app development and enhancing personalized, automated experiences. Additionally, Salesforce introduced new industry clouds (e.g., Automotive, Professional Services) leveraging Data Cloud's capabilities, strengthening its role in driving AI-driven, industry-specific solutions. This evolution solidified Data Cloud as a core enabler of Salesforce's AI and data strategy, differentiating the company in a competitive landscape by offering integrated, scalable AI-powered services.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. While it correctly identifies Data Cloud as a hyperscale data engine in 2023 and mentions integration with Salesforce's platform, it fabricates key developments in 2024 that are not supported by the original answer. Specifically, the claims about alignment with the 'Einstein 1 Platform,' 'low-code AI app development,' and the introduction of new industry clouds (e.g., Automotive, Professional Services) leveraging Data Cloud are not present in the ground truth and represent unsupported additions. The original answer emphasizes a shift in tone—from product-centric messaging to one highlighting competitive uncertainty, market novelty, and pricing model challenges—none of which are reflected in the LLM response. Instead, the LLM portrays a purely positive strategic evolution focused on AI integration and industry expansion, which misrepresents the actual strategic narrative. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not applicable; no errors here. (3) The multi-hop reasoning is flawed: the question asks for evolution in strategic positioning, particularly regarding Salesforce's broader service offerings and competitive landscape. The LLM correctly addresses the role within service offerings but completely misses the critical shift in competitive and strategic risk discourse in 2024. It fails to synthesize the key point that Salesforce acknowledged market uncertainty and limited experience with consumption-based pricing—central elements of the strategic positioning shift. (4) The correctness score is 4 due to partial factual alignment (correct 2023 description) but major omissions and fabrications in 2024 context. Qualitative accuracy is low due to incorrect reasoning and entity relationships. Contextual relevance is moderate because the answer stays on topic but emphasizes different aspects than those in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 543,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "LOW's treatment of forward interest rate swap contracts evolved between 2023 and 2024, shifting from **cash flow hedges** to **fair value hedges**. In 2023, these swaps were designated as cash flow hedges, with a **$311 million loss** recorded in other comprehensive income (OCI) due to the settlement of swaps related to debt issuances. By 2024, the swaps were reclassified as **fair value hedges**, with the Company applying the **shortcut method** (assuming perfect effectiveness), resulting in **no net impact on earnings** as changes in the swaps' fair value offset hedged debt. The 2024 OCI loss was reduced to **$13 million**, reflecting improved hedge effectiveness and lower financial impact.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly identifies the shift from cash flow hedges in 2023 to fair value hedges in 2024 and the use of the shortcut method, the financial figures are incorrect. The ground truth states that LOW received $247 million upon settlement of the forward interest rate swaps in 2023, whereas the LLM claims a $311 million loss recorded in OCI—this number is both misstated and mischaracterized (gain vs. loss). Additionally, the 2024 OCI loss of $13 million mentioned in the LLM answer is not supported by the original answer, which states there was no net impact on earnings due to the fair value hedge accounting, and no mention of a $13 million OCI loss. (2) The calculation and direction of financial impact are wrong: the original answer indicates a $247 million gain (cash received), not a loss, and no earnings impact in 2024 due to offsetting entries under fair value hedging. The LLM incorrectly implies ongoing OCI activity in 2024, which contradicts the 'no net impact on earnings' conclusion. (3) The multi-hop reasoning is partially sound—the model correctly infers a change in hedge designation and accounting treatment between years and links it to financial statement impact—but fails to accurately represent the nature and direction of cash flows and income statement/OCI effects. (4) The contextual relevance is high because the answer addresses the evolution in accounting treatment and hedge designation as asked. However, due to major quantitative errors and misrepresentation of financial impacts, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the conceptual shift is recognized, but not accurately detailed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 490,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "Target's strategy around its owned brands evolved from 2022 to 2023 by emphasizing expansion and deeper integration of its portfolio. In 2022, the focus was on differentiating through curated owned brands (e.g., A New Day™, Hearth & Hand™) and partnerships with national brands. By 2023, the strategy highlighted strengthening the owned brands portfolio, expanding the breadth and depth of signature partnerships, and leveraging these brands across omnichannel experiences to enhance customer discovery and engagement. The 2023 emphasis also included using owned brands to drive traffic and market share growth, aligning with broader goals to make Target a \"favorite discovery destination.\"",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Target's strategy from 2022 to 2023: in 2022, the focus was on differentiation through curated owned brands like A New Day™ and Hearth & Hand™, which matches the ground truth's description of a strong but descriptive presence. In 2023, the shift toward strategic emphasis on owned brands as a driver of traffic, sales, and market share growth is accurately reflected, including alignment with the goal of making Target a 'favorite discovery destination,' which is semantically equivalent to 'delight with newness, style, and value.' (2) There are no numeric values, percentages, or financial figures in either answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes a strategic shift over time (2022 vs 2023) and identifies the change from showcasing to actively leveraging owned brands. The mention of omnichannel experiences and customer discovery adds contextual detail consistent with Target’s public strategy, even if not in the original answer—this does not contradict but enriches. (4) The only minor gap is that the original answer explicitly frames the 2023 strategy as a 'core element' and emphasizes 'strengthening the portfolio' to drive growth, which the LLM captures in substance but could have mirrored more precisely. However, the semantic meaning and strategic trajectory are correctly conveyed. Thus, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 440,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "GM's approach to software-enabled services evolved from 2022 to 2023 by expanding its offerings and platform capabilities. In 2023, GM emphasized its end-to-end software platform, enabling over-the-air updates for features like Super Cruise, security, climate control, and EV ownership experiences. The company also launched collaborations for high-powered charging networks (e.g., 30,000+ chargers in North America) and integrated NACS hardware in EVs starting in 2025. These steps reflect increased investment in scalable digital solutions, including software-defined vehicles, ecosystem-building for EV adoption, and partnerships to enhance connectivity and charging infrastructure, underscoring GM's commitment to autonomous and electric vehicle ecosystems.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in GM's software-enabled services from 2022 to 2023, noting the shift toward an end-to-end software platform with over-the-air update capabilities. It accurately identifies key features like Super Cruise and EV ownership experience. However, it introduces details not present in the ground truth, such as 'climate control' updates and collaborations for high-powered charging networks with '30,000+ chargers in North America'—this specific number and initiative are not mentioned in the original answer. Additionally, the mention of NACS hardware integration starting in 2025 is absent from the ground truth and not supported by the provided knowledge. (2) Quantitatively, the LLM invents a specific figure (30,000+ chargers) and a 2025 timeline for NACS, which are not in the original answer, reducing quantitative accuracy. The ground truth emphasizes platform deployment on 2024 models like the Cadillac LYRIQ and Chevrolet Silverado EV, which the LLM omits. (3) The reasoning is partially sound: it correctly infers increased investment in scalable digital solutions and software-defined vehicles. However, it fails to fully synthesize the multi-hop insight that GM moved from general statements in 2022 to concrete platform deployment on specific 2024 models by 2023, which is a key evolution. The LLM adds ecosystem partnerships not in the original, potentially conflating other filings or public announcements. (4) The answer is contextually relevant and captures the strategic direction, but the inclusion of unsupported specifics and omission of key model examples (LYRIQ, Silverado EV) and the 2024 model deployment timeline reduce factual precision. Hence, a score of 7 is justified—core facts are correct, but with notable omissions and additions that affect completeness and accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 503,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "The revenue contribution from ThousandEyes within the Observability product category increased from $581 million in fiscal 2022 to $661 million in fiscal 2023, reflecting a 14% growth. This increase was driven by growth in the ThousandEyes offering, as noted in the 2023 filing, which also included contributions from the Observability Suite and Splunk. The category's overall revenue rose by 27% year-over-year, with ThousandEyes being a key growth driver.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the *growth* in revenue for the Observability category was $80 million (14%) in fiscal 2023 and $75 million (11%) in fiscal 2022, but the LLM incorrectly reports absolute revenue figures of $581M (2022) and $661M (2023), which are not present in the original answer and imply a $80M increase—while this matches the growth amount, the absolute values are fabricated. There is no mention in the ground truth of Splunk or an 'Observability Suite' as contributors to ThousandEyes' growth, nor a 27% YoY category growth. (2) The calculation of 14% growth is consistent with the original answer’s 2023 percentage, but the 27% overall category growth and absolute revenue numbers are unsupported. The original answer does not provide absolute revenue values for ThousandEyes or the category, only growth increments. (3) The reasoning fails on multi-hop synthesis: the original answer attributes growth in both years to ThousandEyes but does not allow for inference of absolute revenue or Splunk’s involvement. The LLM incorrectly introduces new entities (Splunk) and misrepresents the scope of the product category. (4) The contextual relevance is moderate because the answer addresses the evolution of ThousandEyes’ revenue contribution and correctly identifies it as a growth driver, but the quantitative and entity inaccuracies severely undermine correctness. The answer fabricates precise figures and introduces external elements not in the source, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 434,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "Amendment No. 4 to the Lockheed Martin Executive Severance Plan was consistently included in the exhibits of both the 2023 and 2024 10-K filings (Exhibit 10.34 in both years), but not explicitly referenced in the main body of the filings. This suggests the company's disclosure strategy involves placing such amendments in the exhibits rather than the primary text, maintaining consistency in its approach to disclosing plan modifications. The addition of Amendment No. 5 in 2024 (Exhibit 10.36) further indicates a pattern of incremental updates to the plan, with amendments disclosed through exhibits rather than detailed narrative sections.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly states that Amendment No. 4 was listed as Exhibit 10.34 in both the 2023 and 2024 10-K filings. According to the ground truth, while Amendment No. 4 was indeed listed as Exhibit 10.34 in the 2023 10-K (incorporated from the September 2022 10-Q), it was *not* listed as a standalone exhibit in the 2024 10-K. Instead, in 2024, it was included as part of a sequence of amendments (Nos. 2, 3, 4, and 5), indicating a change in disclosure format. The LLM fails to recognize this key evolution in treatment, which is the central point of the question. (2) The LLM incorrectly implies continuity in exhibit numbering and standalone disclosure, which contradicts the ground truth. There is no mention of Amendment No. 5 being Exhibit 10.36 in the ground truth, making that detail unsupported. (3) The multi-hop reasoning is flawed: the question asks for a comparison of how the treatment of Amendment No. 4 evolved between two years and what that indicates about disclosure strategy. The LLM asserts consistency, while the ground truth shows a shift from highlighted standalone disclosure to integrated, consolidated disclosure—indicating a change in strategy. (4) While the LLM correctly identifies that the amendment is not discussed in the main body and is placed in exhibits, this observation is overshadowed by the fundamental error in describing the exhibit treatment across years. The contextual relevance is moderate because it addresses disclosure strategy, but the factual foundation is incorrect, leading to an invalid conclusion. Minor details like dates and exhibit numbers are either wrong or unverifiable, severely impacting quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 480,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "JPMorgan's Tier 1 leverage ratio increased from 6.6% in 2023 to 7.2% in 2024, while its Standardized CET1 capital ratio rose from 15.0% in 2023 to 15.7% in 2024, reflecting improved compliance with regulatory requirements.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states JPMorgan's 2023 Standardized CET1 ratio as 15.0% and 2024 Tier 1 leverage ratio as 7.2%, it incorrectly claims the 2023 Tier 1 leverage ratio was 6.6% and that the 2024 Standardized CET1 ratio increased to 15.7%—neither of which is supported by the ground truth. The original answer does not provide the 2023 Tier 1 leverage ratio or the 2024 CET1 ratio, so the LLM fabricated these figures. (2) Quantitative accuracy is low because two out of four numerical claims are unsupported or incorrect. The only correct numbers are 15.0% (2023 CET1) and 7.2% (2024 Tier 1 leverage), while the other two values (6.6% and 15.7%) are not in the ground truth. (3) The reasoning is partially sound in that it attempts to show improvement in capital ratios over time, but it fails on multi-hop synthesis because it invents missing data rather than limiting conclusions to available information. The original answer emphasizes compliance relative to requirements, which the LLM omits entirely. (4) Contextual relevance is high because the response addresses the evolution of capital ratios and focuses on the correct company, metrics, and time periods. However, the made-up numbers undermine factual correctness, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1154,
        "completion_tokens": 374,
        "total_tokens": 1528
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "Between 2022 and 2023, GM Financial's role in General Motors' operations remained integral as a distinct segment within the consolidated financial statements. In **Note 23 (Segment Reporting)**, GM Financial is explicitly listed as a reportable segment, with its financial results (e.g., revenue, earnings, and net income) presented separately alongside other segments like GMNA, GMI, and Cruise. The 2023 financials show increased earnings before interest and taxes-adjusted ($5,036M vs. $2,702M in 2022) and higher net income attributable to stockholders ($10,019M vs. $9,945M in 2022), reflecting improved performance. Additionally, **Note 1** clarifies that GM Financial's financials are adjusted for consolidated tax reporting and intercompany eliminations, emphasizing its full integration into GM's consolidated disclosures. The segment's cash flows, including finance receivables and interest income/expenses, are prominently featured in the **cash flow statements**, underscoring its operational significance. Overall, GM Financial's integration and financial presentation remained consistent, with enhanced performance metrics in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the financial figures presented. The ground truth does not mention specific numbers such as earnings before interest and taxes-adjusted ($5,036M vs. $2,702M) or net income attributable to stockholders ($10,019M vs. $9,945M); these figures are either fabricated or misattributed. There is no support in the original answer for any quantitative performance improvement in GM Financial between 2022 and 2023. (2) The quantitative accuracy is low because the LLM introduces precise dollar amounts and performance metrics that are not present in the ground truth. The original answer focuses on the nature of financial presentation and integration (e.g., tax adjustments), not segment-level profitability trends. (3) The reasoning is partially sound in identifying GM Financial as a reportable segment and noting adjustments for consolidated tax reporting and intercompany eliminations, which aligns with the ground truth. However, the LLM incorrectly shifts focus to performance metrics rather than the evolution in financial disclosure and integration details. The multi-hop synthesis is weak because it fails to emphasize the key evolution: the increased clarity in 2023 about how deferred tax positions and income tax provisions differ due to consolidation. (4) Contextual relevance is moderate because the answer addresses GM Financial’s role and integration in consolidated statements, but it misrepresents the nature of the evolution by emphasizing performance changes instead of disclosure transparency. The mention of Note 1 and Note 23 adds detail but is not verifiable from the ground truth. Overall, the answer is misleading due to invented numbers and misaligned focus, despite some correct conceptual elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 490,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "The treatment and disclosure of step-rent provisions in lease accounting remained consistent between 2022 and 2024. Both filings state that step-rent provisions, which include periodic rent increases based on price indices or sales volume, are recognized on a straight-line basis over the lease term and any extension options the company is reasonably certain to exercise. These provisions are classified as variable lease payments, with no material changes in accounting treatment or disclosure noted between the two periods.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the treatment of step-rent provisions remained consistent between 2022 and 2024. The ground truth indicates a clear shift in accounting treatment—from straight-line recognition in 2022 to recognizing such increases as variable lease payments in 2024. The LLM incorrectly asserts no change occurred, which contradicts the core finding. (2) While there are no explicit numerical values (e.g., dollar amounts or percentages) to verify, the temporal references (2022 and 2024) are correctly identified, but the interpretation of accounting treatment across those years is wrong. The claim that step-rents are 'classified as variable lease payments' in both years is misleading because in 2022 they were still straight-lined despite being tied to variables, whereas in 2024 they are explicitly recognized as variable payments. This misrepresents the evolution. (3) The multi-hop reasoning fails: the question requires comparing disclosures across two years to identify a change in policy. The LLM fails to detect the shift and instead incorrectly synthesizes continuity where there is none. It also conflates classification (variable lease payments) with recognition method (straight-line vs. non-straight-line), which are distinct under ASC 842. (4) Correctness is severely compromised due to the central factual error. Quantitative accuracy is low because the treatment description involves qualitative 'metrics' that are misstated. Qualitative accuracy is poor due to flawed reasoning and misunderstanding of lease accounting concepts. Contextual relevance is moderate because the answer addresses the right topic and time frame but draws the wrong conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 470,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "From 2023 to 2024, Lockheed Martin's projected payouts for qualified defined benefit pension plans decreased slightly. In 2025, payments were expected to be **$1.86 billion** in 2023 and **$1.80 billion** in 2024. For the long-term period (2029–2033), the projected total payments were **$10.02 billion** in 2023 and **$9.99 billion** in 2024, reflecting a minor reduction in both annual and multi-year obligations.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, the projected payment for 2025 was $1,860 million in both 2023 and 2024, indicating no change. However, the LLM incorrectly states that the 2025 projection decreased from $1.86 billion to $1.80 billion in 2024, which is factually wrong. Additionally, while the long-term projection decrease from $10.02 billion to $9.99 billion is correctly reflected in magnitude, the time period is misstated: the 2024 projection covers 2030–2034, not 2029–2033 as claimed by the LLM. This affects the comparability of the long-term figures. (2) Number verification: $1,860 million = $1.86 billion (correctly formatted), but the erroneous drop to $1.80 billion introduces a material error. The $10.02 billion and $9.99 billion figures match the ground truth in amount but are applied to incorrect time periods. The long-term period shifted from 2029–2033 (in 2023 projection) to 2030–2034 (in 2024 projection), which the LLM fails to note, leading to an invalid year-over-year comparison. (3) Multi-hop reasoning is partially sound—the model attempts to compare two projections across years and identifies the correct metric and company—but it fails in accurately extracting and aligning the time periods and amounts. The conclusion about 'minor reduction in both annual and multi-year obligations' is misleading because the annual obligation did not change, and the long-term period is not directly comparable due to the shift in years. (4) Correctness and quantitative accuracy are low due to key number and period errors. Qualitative accuracy is moderate because the model identifies the right topic and direction of change for long-term obligations but misrepresents the annual change. Contextual relevance is high as the response stays focused on the question and uses appropriate financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 514,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "JPMorgan Chase's 2024 disclosures expanded on its 2023 resolution plan obligations by emphasizing more detailed liquidity risk management strategies, including pre-positioning liquidity in subsidiaries to meet regulatory requirements and addressing resolution plan obligations under net stable funding ratio (NSFR) and liquidity coverage ratio (LCR) frameworks. The 2024 filings highlighted increased focus on funding cost considerations, noting that actions to satisfy resolution plan requirements—such as accessing alternative liquidity sources—could elevate funding costs, particularly in scenarios of market stress or regulatory changes. This reflects a more refined integration of resolution plan obligations into liquidity management compared to the 2023 disclosures, which were broader in scope.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in JPMorgan Chase's disclosures between 2023 and 2024. (1) It correctly identifies the key elements from 2023: resolution plan obligations impacting liquidity and funding costs, emphasis on LCR and NSFR requirements, and the potential need for alternative funding sources. In 2024, it accurately notes the expansion of disclosures to include funding cost considerations under stress scenarios and regulatory changes, as well as pre-positioning in subsidiaries. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no incorrect figures are presented. (3) The multi-hop reasoning is sound: the model synthesizes how the firm’s risk management narrative evolved from structural liquidity constraints in 2023 to a more dynamic, forward-looking view in 2024 that includes regulatory and macroeconomic uncertainty. The only minor shortcoming is that the LLM does not explicitly mention 'systemic events' or 'changes in laws/rules in response to economic effects of systemic events'—a nuance highlighted in the original answer—which slightly reduces qualitative completeness. (4) Despite this, the LLM conveys semantic equivalence by referencing 'regulatory changes' and 'market stress,' which align with the broader context. The answer is fully relevant, directly addressing the evolution in liquidity risk and funding cost disclosures. Thus, correctness is rated 9 for missing a subtle but specific point about systemic events driving regulatory change, but all other aspects are accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 446,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "Between 2022 and 2023, Optum Rx's financial structure showed an increase in accounts receivable, rising from $7.1 billion in 2022 to $8.6 billion in 2023. Revenue recognition for Optum Rx's pharmacy care services remained consistent, with product revenue recognized upon prescription dispensing. In 2023, the company reported product revenues on a gross basis due to its role in setting pharmacy prices, formulary decisions, and network management, whereas 2022 disclosures focused on dispensing-based recognition without explicit mention of gross reporting.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in accounts receivable from $7.1 billion in 2022 to $8.6 billion in 2023, matching the ground truth exactly. It also correctly states that revenue recognition occurs at the point of prescription dispensing. However, the LLM introduces a nuance not present in the original answer—that in 2023, gross reporting was explicitly tied to Optum Rx's role in pricing and formulary decisions, and that 2022 disclosures did not explicitly mention gross reporting. While this may be inferable, the original answer clearly states that the gross revenue model was already in place in 2022 due to Optum Rx's primary obligation to pay providers, implying consistency across both years. This subtle misrepresentation slightly undermines the qualitative accuracy. (2) All numeric values—$7.1B and $8.6B—are accurate, and the time frame (2022 to 2023) is correct. No calculations are required, but the comparison is valid. (3) The multi-hop reasoning is mostly sound: the model connects revenue recognition and accounts receivable trends across two years. However, it incorrectly implies an evolution in revenue reporting (from unspecified to gross) when the ground truth states the model remained aligned, meaning no material change occurred. This mischaracterization affects the reasoning quality. (4) Despite the minor overstatement of change in revenue recognition, the core facts—accounts receivable growth and dispensing-based revenue recognition—are correct and relevant. The answer addresses both parts of the question and remains highly contextually relevant. Hence, a score of 8 is justified for correctness, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 470,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "UPS's quantitative exposure to interest rate risk through Floating to Fixed Interest Rate Swaps remained a core component of its risk management strategy between 2022 and 2024. In 2024, the company continued using interest rate swaps to convert floating-rate debt into fixed-rate obligations, designated as cash flow hedges, with a $5 million loss reclassified from AOCI to interest expense. This aligns with 2022 practices, where similar swaps were used to hedge forecasted interest payments, though specific 2022 figures are not detailed in the provided pages. The strategic approach focused on maintaining a balanced fixed-floating rate mix to stabilize borrowing costs, with adjustments in hedge effectiveness and reclassifications reflecting market conditions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that UPS had a $28 million notional amount for Floating to Fixed Interest Rate Swaps in 2022, but the LLM claims 'specific 2022 figures are not detailed' and incorrectly implies continuity without citing this key number. Furthermore, the LLM introduces a $5 million loss reclassified from AOCI to interest expense in 2024, which is not present in the original answer and cannot be verified against the provided ground truth. This introduces false quantitative data. (2) The quantitative accuracy is low because the model fabricates a $5 million loss not mentioned in the ground truth and omits the actual $28 million notional amount from 2022. There is no indication in the original answer of any reclassification or loss amount, so this is a critical error. The correct evolution is from a specific $28M exposure in 2022 to a broader strategic approach in 2024, but the LLM misrepresents both ends of this timeline. (3) The multi-hop reasoning is flawed. The original answer shows an evolution from limited quantitative use (with a specific number) to a more strategic, holistic approach. The LLM fails to capture this progression accurately, instead asserting continuity in practice and introducing unrelated financial effects (AOCI reclassification), suggesting it did not correctly synthesize the shift in strategy. It conflates general hedging practices with specific disclosures about scale and intent. (4) Contextual relevance is moderate because the answer discusses interest rate swaps, cash flow hedges, and debt mix—topics relevant to interest rate risk management. However, due to incorrect numbers and missing the core narrative of strategic evolution from minimal to intentional use, the qualitative and correctness scores are low. The answer misses the central point: the shift from a small-scale hedge (quantitative) to a strategic portfolio-level approach (qualitative).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 534,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "Between 2022 and 2023, GM's financial relationship with LG Energy Solution (LGES) evolved through continued joint venture activities and recall-related cost management. In 2022, GM and LGES maintained their equally owned joint venture, Ultium Cells LLC, to produce battery cells for EVs, with plans to expand U.S.-based production. By 2023, the partnership faced recall-related costs tied to the Chevrolet Bolt EV battery defects. LGES agreed to reimburse GM for recall expenses, leading GM to accrue $2.6 billion in total costs through December 2023, with $1.6 billion in receivables from LGES. The remaining accrual was $600 million, reflecting ongoing financial obligations from the recall. This highlights both collaborative production efforts and LGES's role in mitigating recall-related financial impacts.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of GM's financial relationship with LG Energy Solution (LGES) from strategic collaboration in 2022 to cost management in 2023 due to the Bolt EV battery recall. All key facts are present: the Ultium Cells LLC joint venture, its role in EV battery production, the $2.6 billion in total recall costs accrued by GM, and the $1.6 billion in receivables from LGES. The mention of a remaining $600 million accrual is a reasonable inference ($2.6B - $1.6B = $1.0B, but 'remaining' could refer to net liability after receivables; however, this phrasing slightly misrepresents the $1.0B net cost as $600M, which is not supported by the ground truth). This is a minor error in interpretation, not calculation. (2) Quantitative accuracy is high: $2.6 billion total costs and $1.6 billion receivables are correctly stated. The implied $1.0 billion net cost is accurate mathematically, but the LLM's statement that 'the remaining accrual was $600 million' is inconsistent with the data and introduces a factual discrepancy. This is the only numerical issue. (3) Multi-hop reasoning is sound—LLM synthesizes joint venture activity (strategic collaboration) with recall-related financial impacts (transactional shift), correctly identifying the shift in relationship dynamics. It links LGES’s reimbursement agreement to GM’s financial statements, showing proper cross-entity and cross-year synthesis. (4) The answer is contextually excellent, directly addressing both joint venture activities and recall-related costs. The qualitative reasoning is strong, though slightly weakened by the $600M claim. Overall, the answer is factually robust, well-structured, and semantically equivalent to the ground truth, with only a minor inaccuracy in the characterization of remaining accruals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 497,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "The revenue contribution from ThousandEyes within the Observability product category increased from fiscal 2022 to fiscal 2023. In fiscal 2023, the Observability category's total revenue rose by 14% ($80 million) compared to fiscal 2022, driven by growth in ThousandEyes and monitoring/analytics offerings. While the exact revenue from ThousandEyes alone is not specified, it was a key contributor to the category's expansion during this period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that in fiscal 2023, Observability revenue grew by 14% ($80 million), but the ground truth reports a 27% increase, or $176 million. The $80 million figure actually corresponds to fiscal 2022 growth, not 2023. This misattribution of numbers across years is a critical error. Additionally, the LLM omits key information about Splunk's inclusion and the 15% organic growth excluding Splunk, which is essential to understanding ThousandEyes' contribution. (2) Quantitative accuracy is severely compromised: the percentage (14% vs 27%) and dollar amount ($80M vs $176M) for fiscal 2023 are both incorrect. The $80 million figure is correctly mentioned but misassigned to 2023 instead of 2022. (3) The reasoning is flawed as it fails to perform the necessary multi-hop synthesis: it does not recognize that the $80M increase was in 2022, not 2023, and misses the evolution of contribution due to the addition of Splunk in 2023. It also fails to infer that ThousandEyes maintained strong growth even after accounting for Splunk's impact. (4) Contextual relevance is moderate because the answer addresses the general trend of growth and correctly identifies ThousandEyes as a contributor, but the incorrect data and missing nuance about organic vs. acquired growth undermine the overall correctness. The answer gives a misleading picture of the revenue evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 398,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "Between 2022 and 2024, UPS's 7.620% Debentures maintained consistent redemption terms and interest payment structure. The debentures, with a maturity date of April 1, 2030, remained callable at any time by UPS at a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining payments discounted at a benchmark treasury yield plus five basis points. The interest rate stayed fixed at 7.620% since April 1, 2020, and semi-annual interest payments in April and October continued unchanged, with no sinking fund requirements. No modifications to these terms were noted in the 2024 filings.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct factual elements but misrepresents the evolution of the redemption terms between 2022 and 2024. While it correctly states the maturity date (April 1, 2030), the interest rate (7.620%), and the semi-annual payment schedule (April and October), it incorrectly claims that the redemption terms were unchanged. The ground truth indicates that in 2022, only basic details (principal amount $276M, carrying value $280M) were reported, but by 2024, UPS provided a more detailed and specific redemption formula — a key evolution. The LLM fails to acknowledge this shift in disclosure depth and implies the detailed redemption terms were already in place in 2022, which is not supported by the 2022 data. (2) Quantitatively, the LLM omits the $276M principal and $280M carrying value mentioned in the 2022 filing, which are important for assessing the debentures' status at the start of the period. The interest rate and maturity date are correct. However, the claim that the rate has been fixed since April 1, 2020, introduces unverified information not present in the ground truth, reducing quantitative reliability. (3) The multi-hop reasoning is flawed: the question asks how the relationship evolved, requiring comparison across years. The LLM asserts consistency, but the ground truth shows increased disclosure and clarification in 2024 — an evolution in transparency and detail, even if the underlying terms may not have changed. This nuance is missed, indicating poor synthesis. (4) Contextual relevance is high because the answer addresses redemption terms and interest payments directly. However, the failure to recognize the informational evolution — from minimal to detailed disclosure — results in a low correctness score despite some accurate data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 492,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "The total fair value of Fixed Maturity Securities AFS held by MET increased from 2022 to 2023. In 2022, U.S. government bonds totaled **$1,507 million** (comprising $1,462 million in Level 1 and $45 million in Level 2), while corporate securities totaled **$3,001 million** (comprising $2,946 million in Level 2 and $55 million in Level 3). In 2023, U.S. government bonds increased to **$1,575 million** (comprising $1,537 million in Level 1 and $38 million in Level 2), and corporate securities rose to **$3,083 million** (comprising $3,029 million in Level 2 and $54 million in Level 3). Both categories saw growth in total fair value, with U.S. government bonds increasing by $68 million and corporate securities by $82 million.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 values for U.S. government bonds ($1,575 million, with $1,537 million in Level 1) and corporate securities ($3,083 million, with $3,029 million in Level 2), which match the ground truth. However, the 2022 figures are incorrect—the original answer does not provide a breakdown of U.S. government bonds or corporate securities for 2022, only stating the total carrying amount of Fixed Maturity Securities AFS as $2,164 million as of December 31, 2021 (i.e., reported in 2022). The LLM fabricates detailed 2022 breakdowns ($1,507M for U.S. government bonds, $3,001M for corporate securities), which are not present in the ground truth. (2) The calculations of year-over-year increases ($68M and $82M) are based on these fabricated numbers and are therefore invalid. The ground truth does not support any such comparison. (3) The multi-hop reasoning is partially sound—LLM correctly identifies the need to compare 2022 and 2023 compositions and focuses on the right categories. However, it invents data for 2022 instead of acknowledging the lack of breakdown in the original answer, failing the synthesis step. (4) Scores reflect that core 2023 facts are accurate (qualitative and contextual strength), but quantitative accuracy is penalized due to significant invented numbers and incorrect deltas. The answer is well-structured and relevant, but factual correctness is compromised by unsupported 2022 figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 405,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "General Motors' financial involvement with Ultium Cells LLC remained consistent in 2022 and 2023, with an investment of $0.5 billion recorded in 2021 (as noted in the 2023 filing). However, in 2023, regulatory implications emerged: GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC's operations, leading to a $5.1 million EPA settlement (jointly with Ultium Cells LLC). This highlights ongoing financial ties through investment and heightened regulatory scrutiny in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $0.5 billion investment in Ultium Cells LLC and the $5.1 million EPA settlement related to TSCA violations in 2023. However, it inaccurately states that the $0.5 billion investment was made in 2021 (as noted in the 2023 filing), whereas the ground truth specifies the investment was reported in 2022 as part of that year’s investing activities. This misattribution of timing affects quantitative accuracy. (2) The dollar amounts ($0.5 billion and $5.1 million) are correct and match the ground truth, and the settlement date (November 2023) and disclosure (February 2023) are contextually accurate, though not explicitly dated in the LLM response. The key error is the incorrect assignment of the investment to 2021 instead of 2022, which undermines temporal precision. (3) The multi-hop reasoning is largely sound: the model connects GM's financial involvement with evolving regulatory implications, correctly inferring increased operational entanglement from the self-disclosure and settlement. It captures the shift from investment to regulatory co-liability, though it underemphasizes the evolution in the nature of the relationship, instead framing it as 'ongoing financial ties' rather than a shift from passive to active involvement. (4) Despite the date error, the answer remains contextually relevant and conveys a mostly accurate narrative. The qualitative reasoning is strong, and the core regulatory and financial facts are present, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 425,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "The company continued to use variable-priced contracts for natural gas and fuel purchases in both 2022 and 2024, as described in the \"Derivatives\" sections of both filings. These contracts, based on index pricing, qualify for the \"normal purchases and normal sales\" exception and require no mark-to-market adjustments. There is no indication of a material change in the use or structure of these contracts between the two years.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key qualitative evolution described in the ground truth. (1) Correct elements: The company used variable-priced contracts in both 2022 and 2024, these were index-based, qualified for the 'normal purchases and normal sales' exception, and required no mark-to-market adjustments. These facts are consistent with the original answer. (2) Quantitative accuracy: There are no numerical values to verify, but all factual assertions about accounting treatment and contract types are accurate. (3) Multi-hop reasoning: The model correctly identifies the presence of variable-priced contracts and their accounting treatment across both years. However, it fails to recognize the evolution — in 2024, the company explicitly framed these contracts as meeting derivative instrument characteristics, indicating a more formalized or strategic approach. The LLM incorrectly concludes there was 'no material change,' contradicting the ground truth's implication of a shift in management or accounting alignment. (4) This omission significantly undermines the qualitative accuracy, as the question specifically asks how the use of contracts 'evolved.' The answer should have noted the increased formalization or strategic accounting treatment by 2024. While contextually relevant and factually sound on surface details, the LLM misses the core inferential point about evolution, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 396,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "Cisco's financial reporting approach for the APJC segment remained consistent between fiscal 2022 and 2023, with no changes to the expense categories excluded from segment performance measurement. Both filings state that expenses such as research and development, sales and marketing, general and administrative expenses, amortization of acquisition-related intangible assets, share-based compensation, litigation settlements, asset impairments, and restructurings are not allocated to segments and excluded from segment performance metrics. This approach did not evolve between the two periods.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Cisco's financial reporting approach for the APJC segment did not change between fiscal 2022 and 2023, with consistent exclusions of specific expense categories from segment performance measurement. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy pertains to correct identification of fiscal years (2022 and 2023), which are correctly cited. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the same set of expenses—research and development, sales and marketing, general and administrative, amortization of intangible assets, share-based compensation, litigation settlements, asset impairments, and restructurings—were excluded in both years, indicating no evolution in reporting. (4) All entities (Cisco, APJC segment, fiscal years) and financial terms are accurately used. The answer is concise, complete, and directly addresses the question about the evolution (or lack thereof) in reporting approach, matching the original answer in factual content and conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 330,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "UnitedHealth Group (UNH) intensified its focus on managing rising outpatient procedure costs for seniors in 2023 compared to 2022, emphasizing strategies like enhanced care management programs, clinical engagement, and provider collaboration to mitigate cost increases. The 2023 10-K highlights elevated outpatient care utilization for seniors as a key driver of medical cost trends, with UNH aiming to address this through targeted interventions to promote clinically sound choices and improve affordability. This reflects a more proactive approach to managing senior-specific outpatient costs, building on prior efforts to control medical trends through underwriting, product design, and provider contracts.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in UNH's approach from 2022 to 2023: in 2022, UNH was concerned about deferred care and rising demand, particularly for chronic conditions, and focused on risk-based management; by 2023, it specifically targeted rising outpatient costs for seniors. The LLM accurately reflects this shift from general cost management to targeted intervention. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 vs 2023) and identifies the strategic shift in focus and tactics, including clinical engagement, provider collaboration, and data-driven decision-making (phrased as 'targeted interventions to promote clinically sound choices'). The mention of 'underwriting, product design, and provider contracts' as prior strategies is consistent with 2022 risk-based arrangements. (4) The only minor gap is that the LLM does not explicitly mention 'data-driven insights' or 'guiding consumer and physician decisions' verbatim, but 'enhanced care management', 'clinical engagement', and 'targeted interventions' are semantically equivalent in context. Overall, the answer is factually correct, complete, and contextually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 399,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "UPS expanded its time-definite delivery services between 2022 and 2024 by enhancing digital integration (e.g., embedding shipping solutions into e-commerce platforms) and broadening returns services to 150 countries. Network integration advanced through investments in RFID-enabled smart facilities, optimized air hubs, and insourcing residential delivery services (e.g., UPS SurePost) to improve control and efficiency. Additionally, strategic divestitures (e.g., Coyote) and focus on high-yield volume aligned with evolving market demands.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies key developments in UPS's time-definite delivery evolution between 2022 and 2024, including the insourcing of residential delivery (e.g., UPS SurePost), expansion of returns services to approximately 150 countries, and network integration improvements. These align with the ground truth. However, the LLM introduces elements not present in the original answer, such as 'digital integration' (e.g., embedding shipping solutions into e-commerce platforms) and 'investments in RFID-enabled smart facilities' and 'optimized air hubs', which were not mentioned in the ground truth and cannot be verified from the provided knowledge. Additionally, the mention of 'strategic divestitures (e.g., Coyote)' is factually accurate (Coyote was divested in 2023), but it is not directly tied to time-definite delivery services in the original answer, making it contextually extraneous. (2) Quantitatively, the '150 countries' figure matches the ground truth and is correctly presented. No other numbers (dates, dollar amounts) are introduced, so there are no calculation errors. Format and numeric accuracy are preserved. (3) The multi-hop reasoning is partially sound: the LLM correctly synthesizes the expansion of returns and the insourcing of SurePost as part of network control and service scope evolution. However, it adds unverified enhancements (RFID, digital integration) that were not part of the documented evolution in the knowledge graph, indicating potential over-inference or hallucination. The core evolution—greater control via insourcing and broader service scope—is accurately captured. (4) The correctness score is 7 because the key facts (SurePost insourcing, 150-country returns expansion) are correct and central to the answer, but the inclusion of unsupported details reduces factual precision. Quantitative accuracy is high (9) due to correct use of the 150-country figure. Qualitative accuracy is 7 due to correct entity identification (UPS, SurePost, Coyote) and time frame, but flawed reasoning in adding unsupported initiatives. Contextual relevance is high (9) as most content directly addresses the question, despite minor tangential additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 591,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "Lowe's Companies, Inc. recognized its 2.50% Notes maturing in April 2026 in the 2022 annual filing as part of its outstanding debt obligations. In the 2023 annual filing, these notes were no longer listed in the exhibits, indicating their retirement or repayment by April 2026. This reflects a change in recognition from being an outstanding liability in 2022 to being removed from the debt structure in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) It incorrectly states that the 2.50% Notes maturing in April 2026 were 'no longer listed in the exhibits' in the 2023 filing and implies they were retired or repaid, which is false according to the original answer — the notes were still outstanding and merely received more explicit recognition in 2023. (2) The quantitative elements (interest rate of 2.50%, maturity date of April 2026) are correct, but the interpretation of their status over time is wrong; there is no evidence in the ground truth of retirement or removal from exhibits. (3) The multi-hop reasoning is flawed: instead of identifying a shift in disclosure treatment from procedural/historical mention in 2022 to active recognition in 2023, the model incorrectly infers retirement, showing a failure to synthesize the correct evolution. (4) Contextual relevance is moderate because the answer addresses the right company and notes, and attempts to compare filings across years, but the conclusion is factually incorrect. The core misunderstanding — that the notes were removed due to repayment — fundamentally undermines the response, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 342,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "The 2022 and 2024 10-K filings mention sovereign debt crises as a general economic factor that could impact Costco's ability to purchase inventory, affect pricing strategies, and influence costs. However, **no specific details are provided** about changes in merchandise sourcing or cost structure directly tied to sovereign debt crises between 2022 and 2024. The 2024 filing notes increased international operations (28% of net sales) and broader exposure to foreign economic conditions, but the documents do not explicitly link sovereign debt crises to measurable shifts in sourcing or cost management practices. Thus, the impact remains described in broad terms without quantifiable evolution.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that 'no specific details are provided' about changes in merchandise sourcing or cost structure related to sovereign debt crises between 2022 and 2024. The ground truth clearly shows a qualitative evolution in risk disclosure: from sovereign debt crises being one of several macroeconomic factors that 'could adversely affect' sourcing and costs in 2022, to being explicitly stated in 2024 to 'negatively impact' Costco's business, financial condition, and operations, with added emphasis on supply chain risks like geopolitical instability and supplier constraints. This shift reflects a material change in tone and risk assessment, which the LLM failed to recognize. (2) Quantitatively, the LLM correctly notes increased international operations (28% of net sales in 2024), which aligns with the broader exposure mentioned in filings, though this specific percentage was not in the ground truth provided—however, since it does not contradict and supports contextual plausibility, it does not count as a factual error. No other numbers are present, so quantitative accuracy is not heavily penalized. (3) The multi-hop reasoning is flawed: the model should have synthesized the change in language and risk framing across years as evidence of evolving impact, but instead concluded there was no evolution due to lack of 'measurable shifts,' misinterpreting qualitative risk disclosures as insignificant. This reflects a failure to understand how SEC filings signal changing risk exposure through evolving language. (4) Correctness is low because the core claim—that there is no evolution—contradicts the ground truth. Qualitative accuracy is low due to incorrect reasoning and failure to identify the shift in risk characterization. Contextual relevance is moderate because the answer addresses the right topic and timeframe, but misses the key insight.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 518,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "The number of shares available for future grants under the 2020 Stock Incentive Plan decreased from 64 million as of December 31, 2021, to 53 million as of December 31, 2023. This reduction indicates a diminished capacity for UnitedHealth Group to issue new share-based awards under this plan, likely due to prior grants and exercises of awards.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the number of shares available for future grants in 2021 (64 million) and 2023 (53 million), matching the ground truth exactly. The dates are specified as of December 31, 2021, and December 31, 2023, which aligns with standard fiscal reporting periods and adds precision without contradicting the original answer. (2) The quantitative values are accurate, and the implied decrease of 11 million shares is correct. No calculations are required beyond this comparison, and the model reports the change accurately. (3) The reasoning is sound: the reduction in available shares is correctly interpreted as a diminished capacity to issue new share-based awards. The addition of 'likely due to prior grants and exercises of awards' is a reasonable inference consistent with typical stock plan dynamics and does not contradict the ground truth; it adds context without introducing error. (4) The answer fully addresses both parts of the question: the change in number of shares and its implication for UnitedHealth Group's capacity. All entities (UnitedHealth Group, 2020 Stock Incentive Plan) and time periods are correctly identified. The semantic meaning is equivalent to the original answer, with slightly enhanced detail that improves clarity without compromising accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1176,
        "completion_tokens": 369,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "The IAM National Pension Fund / National Pension Plan relationship with UPS evolved between 2022 and 2024 as follows:  \n- **Expiration Date**: In 2022, the collective bargaining agreement with IAM expired on **July 31, 2024**. By 2024, UPS ratified a new National Master Agreement with IAM, extending the expiration date to **July 31, 2029**.  \n- **Contribution Significance**: UPS contributed more than 5% of total plan contributions for all years (2022–2024), maintaining its significant role. Contributions increased slightly from $48 million in 2022 to $53 million in 2024, reflecting ongoing contractual obligations under the updated agreement.  \n\nThis evolution highlights a prolonged relationship with extended terms and sustained contribution commitments.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the extension of the expiration date from July 31, 2024, to July 31, 2029, and correctly states that UPS contributed more than 5% of total plan contributions, maintaining its significant contributor status. However, the LLM introduces specific dollar amounts—$48 million in 2022 and $53 million in 2024—that are not present in the original answer and cannot be verified from the ground truth. These figures may be plausible but are not supported by the provided knowledge graph, making them potentially inaccurate additions. (2) The dates (July 31, 2024, and July 31, 2029) are correct and match the ground truth. The percentage threshold (>5%) is also correctly maintained across years 2022–2024. However, the inclusion of unverified dollar figures undermines quantitative accuracy. There are no calculation errors per se, but the introduction of unsupported numbers is a factual overreach. (3) The multi-hop reasoning is sound: the model correctly synthesizes information about the expiration date evolution and contribution significance over time, linking UPS’s ongoing role with the updated agreement. It correctly infers sustained significance, aligning with the original conclusion. (4) The contextual relevance is perfect—the answer directly addresses both parts of the question (expiration date and contribution significance) and their evolution. The qualitative reasoning is strong, but the quantitative accuracy is reduced due to unsupported numerical claims. Hence, correctness is partially impacted, warranting a 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 431,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "Between fiscal years 2022 and 2023, LOW extended the maturity date of its 2020 Credit Agreement from March 2025 to September 2028 through amendments in September 2023. The agreement's availability was increased to $2.0 billion, and combined with the Third Amended and Restated Credit Agreement, total availability reached $4.0 billion. These changes enhanced liquidity and extended debt maturity.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the extension of the maturity date from March 2025 to September 2028 via amendments in September 2023 and correctly states the $2.0 billion availability under the 2023 Credit Agreement. It also correctly notes the combined $4.0 billion total availability with the Third Amended and Restated Credit Agreement. However, it inaccurately states that the availability was 'increased to $2.0 billion', implying it was lower before, while the ground truth confirms it remained at $2.0 billion—no increase occurred. This misrepresents the continuity of the facility amount. (2) Quantitative accuracy is mostly correct: dates (March 2025, September 2028), dollar amounts ($2.0 billion, $4.0 billion), and timing (September 2023 amendment) align with ground truth. The error lies in the implication of an increase in availability, which did not occur. (3) The multi-hop reasoning is sound—LLM connects the 2020 agreement to its amendment into the 2023 agreement and synthesizes availability across agreements. However, it fails to clarify that the $2.0 billion was maintained, not increased, weakening the precision of the synthesis. (4) Scores reflect high factual alignment with minor but notable quantitative inaccuracy in describing the change in availability. Context and entities (LOW, 2020/2023 agreements, fiscal years) are accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 386,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "Between 2022 and 2024, MDLZ's notional amounts for Net Investment Hedge Derivative Contracts increased from $7,456 million in 2023 to $8,647 million in 2024. The 2022 notional amount is not explicitly provided in the given documents, but the trend shows a growth in the notional value during this period.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 and 2024 notional amounts ($7,456 million and $8,647 million), which align with the ground truth. However, it fails to include the actual 2022 data point mentioned in the original answer — specifically, the $3,915 million as of December 31, 2021 (reported in the 2022 filing), which is critical for understanding the evolution from 2022 onward. Instead, the LLM incorrectly implies that 2022 data is unavailable, when in fact the question asks about evolution between 2022 and 2024, and the relevant data exists in the source. (2) The numbers cited (2023 and 2024) are quantitatively accurate, but the omission of the earlier data points from the 2022 report breaks the full timeline and misrepresents data availability. The calculation of growth is implied but not explicitly incorrect — however, the trend description lacks the full context of a near doubling from 2020–2021 to 2024. (3) The multi-hop reasoning is partially sound — the model identifies the increase from 2023 to 2024 correctly — but fails to synthesize the full evolution across all available years referenced in the original answer (including backward-looking disclosures in 2022 and 2023 reports). It misses the required cross-year synthesis starting in 2022. (4) The contextual relevance is high because the answer addresses the trend in notional amounts and focuses on the right metric and company. However, due to significant omission of key data points and incorrect claim about data absence, the overall correctness is reduced to a mid-range score. The answer is not wrong in what it states, but incomplete and misleading in its assessment of data availability and trend onset.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 466,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "Between 2022 and 2024, Microsoft 365's AI integration evolved from general AI-backed tools to a more specialized, AI-first platform. In 2024, specific new capabilities included **Copilot for Sales, Service, and Finance**, which provide role-specific insights and workflow automation, and **Copilot Studio** for customizing Copilot functionality. Additionally, **Copilot Pro** was introduced as a consumer subscription service offering enhanced AI assistance in Microsoft 365 apps and web. These advancements solidified Microsoft 365 as a hub for AI-driven productivity, collaboration, and business process optimization.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Microsoft 365's AI integration from 2022 to 2024, noting the shift to an 'AI-first platform'—a key point in the original answer. The introduction of Copilot for Sales, Service, and Finance is accurately reported as 2024 developments, matching the ground truth. The mention of Copilot Studio and Copilot Pro adds detail not explicitly in the original answer, but these are factually correct enhancements introduced in 2024 and do not contradict the ground truth; they provide additional context. There are no numeric inaccuracies—dates (2022, 2024) and product names are correct. The reasoning is sound, showing multi-hop synthesis between the initial AI-backed tools and the advanced, role-specific AI features. The only minor gap is that the original answer emphasizes the integration of Microsoft Graph and M365 apps with Copilot, which the LLM answer omits, slightly reducing completeness. However, the core facts, entities, and timeline are correct, and the answer fully addresses both parts of the question: evolution over time and new 2024 capabilities. Wording differs but semantic meaning is equivalent or enhanced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 345,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "Between 2022 and 2024, 3M's approach to PFAS discharge characterization at its Decatur, Alabama facility evolved from acknowledging incomplete characterization of PFAS discharges in its NPDES permit to actively submitting an application to add additional PFAS compounds to the permit. In 2022, the company had already installed wastewater treatment controls and was working with regulators to address the issue. By 2024, 3M had submitted a formal request to update the permit to reflect a more comprehensive characterization of PFAS discharges, reflecting progress toward regulatory compliance, though the permit modification remained pending. The company continued to implement treatment systems and engage with regulators to manage PFAS-related obligations.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in the timeline of actions, particularly regarding the installation of wastewater treatment controls. According to the ground truth, in 2022, 3M had not yet installed treatment controls but had submitted an application to ADEM to add PFAS to the permit due to incomplete discharge characterization. By 2024, the company had installed and was upgrading PFAS-specific wastewater treatment controls, which were being optimized, while awaiting ADEM's decision on the permit modification. However, the LLM incorrectly states that treatment controls were already installed in 2022, which contradicts the original timeline. This misrepresents the evolution of 3M's approach—portraying implementation as occurring earlier than it did. All dates (2022, 2024), entities (3M, Decatur facility, ADEM, NPDES permit), and the fact that the permit modification remained pending are correctly identified. The reasoning is mostly sound in recognizing a progression toward better PFAS characterization and regulatory engagement, but the incorrect sequencing of actions (treatment before permit update) undermines the multi-hop synthesis. The answer is contextually relevant and captures the general direction of progress, but the key operational milestone is misplaced, leading to a moderate correctness score. Quantitative accuracy is perfect—no numbers or dates are misstated. Qualitative accuracy suffers due to the incorrect causal and temporal logic. Contextual relevance is high as the response directly addresses the question's focus on evolution in PFAS discharge characterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 449,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "Lowe's Companies, Inc. issued the 4.550% Notes on April 5, 2019, with a maturity date of April 5, 2049, as disclosed in the 2022 10-K. These notes remained outstanding as of December 31, 2023, with no changes to their terms or issuance during the 2023 fiscal year, as noted in the 2023 10-K. The evolution between 2022 and 2023 involved no modifications or new issuances of the 4.550% Notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the same core information as the ground truth. (1) All key facts are correct: the 4.550% Notes were issued on April 5, 2019, mature on April 5, 2049, and remained unchanged in 2023. The answer correctly states there was no modification or new issuance in 2023. (2) Quantitative accuracy is perfect: dates and percentages match the original answer exactly. (3) The multi-hop reasoning is sound—information from both the 2022 and 2023 10-K filings is correctly synthesized to show continuity of the notes with no changes. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'Fifteenth Supplemental Indenture' by name, which is included in the ground truth and adds specificity about the legal document governing the notes. While this detail is omitted, it does not undermine the overall correctness or clarity of the response. The answer remains semantically equivalent and fully addresses the evolution (or lack thereof) between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 291,
        "total_tokens": 1487
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "Between 2022 and 2024, MDLZ's financial relationship with KDP evolved through a change in accounting treatment. In 2023, MDLZ's ownership in KDP fell below 5%, leading to a shift from equity method accounting to marketable securities. This change resulted in a **pre-tax gain of $606 million** during 2023, reflecting the difference between sale proceeds and the carrying value of the investment. In 2024, MDLZ exited its investment in JDE Peet's (a separate entity) and recorded a separate gain of €313 million ($332 million), but no further gains related to KDP were mentioned.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that MDLZ recognized a $71 million pre-tax gain in 2022 (Q1) from the sale of KDP shares, and a $493 million pre-tax gain in 2024 due to a change in accounting for its KDP investment. The LLM incorrectly states a $606 million pre-tax gain in 2023, which does not match the ground truth. Additionally, the LLM claims this gain was due to ownership falling below 5% in 2023, but the original answer does not specify the year of the accounting change—only that it occurred by 2024. (2) The numbers are entirely incorrect: $606M vs. $493M (2024 gain) and no mention of the actual $71M gain in 2022. The LLM also introduces a gain from exiting JDE Peet’s ($332M) in 2024, which is unrelated to KDP and not part of the question’s focus. This introduces irrelevant information and distracts from the correct multi-hop comparison between 2022 and 2024 KDP-related gains. (3) The multi-hop reasoning is flawed. The question asks about the evolution of MDLZ's financial relationship with KDP between 2022 and 2024, specifically gains from changes in accounting. The LLM misattributes the timing (2023 instead of 2022 and 2024), misstates the amount, and fails to correctly identify that the large gain occurred in 2024, not 2023. It also conflates two separate investments (KDP and JDE Peet’s), showing poor entity discrimination. (4) The contextual relevance is moderate because the answer discusses accounting changes and gains related to investments, but the incorrect entities, numbers, and timing severely undermine accuracy. The qualitative reasoning about accounting treatment shift has some plausibility but is not supported by the provided ground truth. Thus, the correctness score is low due to major factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 496,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "Between 2022 and 2024, Xbox Game Pass expanded its title library from over 100 to over 400 first- and third-party console and PC titles, reflecting significant growth in scale. Microsoft strategically emphasized Xbox Game Pass as a core subscription service, integrating it with cloud gaming (Xbox Cloud Gaming) and exclusive content to strengthen its position in the gaming ecosystem. The 2024 focus highlighted expanding ecosystems, enhancing user engagement through exclusive titles, and leveraging first-party studios like Activision Blizzard to solidify its competitive edge in the gaming market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Xbox Game Pass grew from over 100 titles in 2022 to over 400 in 2024, matching the ground truth exactly in both scale and direction of growth. The years (2022 and 2024) are accurate, and the characterization of first- and third-party titles is preserved. (2) Quantitatively, the numbers 'over 100' and 'over 400' are factually correct and consistent with the original answer; no calculations are required, but the comparison of growth is accurately conveyed. (3) The reasoning is sound: the LLM correctly infers increased strategic emphasis based on integration with cloud gaming, exclusive content, and first-party studios like Activision Blizzard. While the original answer calls Game Pass the 'cornerstone' of Microsoft's gaming platform, the LLM captures this elevated status by describing it as a 'core subscription service' and emphasizing ecosystem expansion and user engagement—semantically equivalent. The mention of Activision Blizzard is a reasonable inference given Microsoft's 2023 acquisition and its relevance to content expansion, though not explicitly stated in the ground truth. (4) The answer is fully contextually relevant, addressing both the scale (number of titles) and strategic positioning over time. The only minor gap is that the original answer explicitly frames the strategic shift by noting the evolution from 'key part' to 'cornerstone,' which the LLM implies but does not quote directly. However, the qualitative assessment remains strong due to accurate synthesis and logical inference. Thus, the answer is factually correct, complete, and well-reasoned, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 476,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "The structure and disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan remained consistent from 2022 to 2024, as evidenced by the referenced filings. The 2024 10-K (pages 115–119) and 2022 10-K (pages 129–133) both reference the same form of Deferred Stock Unit Award Agreement, incorporated by reference from the 2018 10-K, with no amendments or updates noted for non-employee directors during this period. No changes in structure or disclosure were identified in the provided documents.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the structure and disclosure of the Deferred Stock Unit Award Agreements remained consistent from 2022 to 2024, which aligns with the ground truth. However, it incorrectly states that the agreement is incorporated by reference from the 2018 10-K, while the ground truth specifies that the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, with amendments as of May 8, 2023. This is a significant factual error regarding the source and update history of the agreement. (2) The dates referenced (2018 vs 2023) are incorrect in the LLM answer, which undermines the quantitative and qualitative accuracy. The ground truth emphasizes that the 2024 filing references a 2023 amendment, indicating ongoing maintenance, whereas the LLM claims no updates were made, contradicting the original answer. (3) The multi-hop reasoning is partially sound—LLM correctly synthesizes across 2022 and 2024 filings—but fails to incorporate the critical update from the 2023 10-K, indicating a failure in full cross-year synthesis. (4) The contextual relevance is high because the answer addresses the core question about evolution and uses appropriate document references. However, due to the incorrect citation of the incorporation source and the erroneous claim of no amendments, the correctness and qualitative accuracy scores are reduced. Minor formatting differences in page numbers (e.g., 115–119 vs 129–133) are acceptable and do not affect scoring, but the misrepresentation of the amendment history is a major issue.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 436,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "Between 2023 and 2024, Charles Schwab Bank's First Mortgages and HELOCs portfolios saw a slight increase in total balances, with First Mortgages rising to $27.389 billion (from $26.153 billion) and HELOCs increasing to $424 million (from $479 million). Origination costs, reflected in unamortized premiums/discounts, rose slightly for First Mortgages ($112M in 2024 vs. $100M in 2023) but remained stable for HELOCs ($100M in 2024 vs. $98M in 2023). Geographic concentration in California decreased marginally from 43% to 42% for the combined portfolio, indicating a slight diversification away from California.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. While the ground truth states that the combined unamortized premiums, discounts, and direct origination costs for the entire First Mortgages and HELOCs portfolio were $100M in 2023 and $112M in 2024, the LLM incorrectly breaks this down into separate figures for First Mortgages and HELOCs (e.g., $100M vs $98M for HELOCs), which is not supported by the original answer and introduces false granularity. Additionally, the LLM introduces total balances for First Mortgages ($26.153B to $27.389B) and HELOCs ($479M to $424M), which are not present in the ground truth and appear to be fabricated or misattributed from another source. These balance figures were not part of the original knowledge graph answer and contradict the HELOC increase implied by rising origination costs. (2) The California concentration (43% to 42%) is correctly reported, and the directional change (slight decrease) is accurate. The origination cost increase from $100M to $112M is correct in total, but the LLM misattributes this to First Mortgages alone rather than the combined portfolio, distorting the meaning. (3) The multi-hop reasoning is partially sound—geographic concentration and cost trends are addressed—but the synthesis is flawed due to incorrect disaggregation of portfolio-level data. The model fails to treat 'First Mortgages and HELOCs' as a combined portfolio as presented in the original answer, instead treating them separately without evidence. (4) Contextual relevance is high—the answer addresses origination costs and California concentration as asked—but correctness is severely undermined by invented or misallocated numbers. The conclusion about diversification is reasonable but based on incomplete and partially false data. Thus, while some directional trends are correct, the quantitative foundation is unsound, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 524,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "Nike's strategic emphasis on Dri-FIT technology remained consistent between fiscal 2023 and 2024, as highlighted in the \"Product Research, Design and Development\" sections of both 10-K filings. In fiscal 2024, Nike explicitly mentioned Dri-FIT as part of its ongoing commitment to innovation, alongside other technologies like Nike Air, Zoom, and React, underscoring its continued importance in product development. The 2023 document (not fully provided here) likely mirrored this focus, with no indication of a shift or reduction in emphasis on Dri-FIT during the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly conveys that Nike's strategic emphasis on Dri-FIT technology remained consistent between fiscal 2023 and 2024, which aligns with the ground truth. It accurately identifies Dri-FIT as part of Nike’s core innovation portfolio alongside technologies like Nike Air, Zoom, and React, and correctly references the 'Product Research, Design and Development' sections of the 10-K filings. The answer notes the use of similar language in both years, though it does not explicitly state that the *exact same language* was used, which is a minor omission from the ground truth. However, this does not distort the overall conclusion. There are no numerical values to verify, so quantitative accuracy is scored as 10. The reasoning is sound and contextually appropriate, with only a slight lack of precision in not emphasizing the verbatim repetition of text. The answer fully addresses the question about evolution (or lack thereof) in strategic emphasis, making it contextually complete and highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 291,
        "total_tokens": 1555
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "Mondelez International has continued to prioritize investments in backup and disaster recovery as part of its cybersecurity strategy, with enhanced focus in 2024. The 2024 filing highlights expanded efforts to strengthen cybersecurity programs, including advanced identity and access management, network security, and 24/7 security operations, alongside robust backup and disaster recovery measures. These investments reflect a proactive response to evolving threats, building on 2022 initiatives that already emphasized heightened preparedness and resource allocation to mitigate risks. The 2024 document underscores ongoing adjustments to security controls based on threat intelligence, indicating sustained and adaptive investment in this area.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies Mondelez International's continued and expanded investment in backup and disaster recovery from 2022 to 2024, accurately reflecting the evolution in response to increasing cybersecurity threats. (1) All entities—Mondelez International, 2022 and 2024 timeframes, and the focus on backup and disaster recovery—are correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not compromised; dates (2022, 2024) are accurate. (3) The multi-hop reasoning is sound: the LLM synthesizes the continuity of efforts from 2022 (heightened preparedness) to 2024 (expanded investments), noting enhanced measures like 24/7 security operations and adaptive controls based on threat intelligence, which aligns with the original's mention of state-sponsored and AI-driven threats. (4) While the LLM answer does not explicitly mention 'state-sponsored actors' or 'artificial intelligence' as in the original, it captures the essence of evolving and sophisticated threats and the company’s adaptive response. This is a minor omission but does not detract significantly from the overall correctness. The answer is contextually rich, relevant, and conveys semantic equivalence. Hence, a high score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 396,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "Microsoft's financial commitment to Black and African American-owned suppliers evolved from fiscal year 2022 to 2024 by achieving its $500 million spending goal with double the number of such suppliers, as noted in the 2024 report. In 2022, the company had reached over 90% of this goal. Additionally, in 2024, Microsoft expanded its commitment with a $150 million investment in Minority Depository Institutions and funds for Black and African American-owned small businesses, along with 162 low- or no-interest loans through its Partner Capital Fund, reflecting deeper engagement and financial support.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in FY2022, Microsoft reached over 90% of its $500 million goal with double the number of Black and African American-owned suppliers; by FY2024, it achieved the $500 million goal and added a $150 million commitment to Minority Depository Institutions and funds supporting Black-owned businesses. These numbers match the original answer exactly, with acceptable formatting. (2) Quantitative accuracy is perfect: $500 million goal, >90% in 2022, $150 million new allocation in 2024—all match. (3) The reasoning correctly synthesizes multi-hop information across fiscal years and initiatives, showing evolution over time. (4) The only minor deviation is the addition of '162 low- or no-interest loans through its Partner Capital Fund'—a detail not present in the ground truth. While this may be factually true from another source, it introduces information not confirmed in the provided knowledge graph, slightly reducing qualitative accuracy. However, it does not contradict the original answer and adds contextually relevant detail. Overall, the answer is complete, factually correct, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 346,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "The availability of common shares under Abbott's Employee Stock Purchase Plan for Non-U.S. Employees decreased from **10,638,639 shares as of December 31, 2021** to **8,565,087 shares as of December 31, 2023**. This reduction indicates increased utilization of the plan to provide stock-based incentives for non-U.S. employees, reflecting Abbott's strategy to retain talent and align employee interests with company performance through equity compensation. The decline suggests active participation in the plan, consistent with a focus on stock-based incentives for international workforce engagement.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the two key figures—10,638,639 shares available as of December 31, 2021 (referenced in the context of 2022 reporting) and 8,565,087 shares as of December 31, 2023 (2023 reporting)—which matches the ground truth exactly. Dates and numbers are accurate, satisfying quantitative precision. (2) However, the interpretation diverges from the original answer’s conclusion. While the ground truth states the reduction 'suggests a potential tightening or adjustment' in Abbott's stock-based incentive strategy, the LLM interprets the decline as evidence of 'increased utilization' and 'active participation,' implying a strengthening of the incentive strategy. This is a plausible alternative interpretation but contradicts the cautious, conservative inference in the original answer. (3) The multi-hop reasoning is sound in identifying the change over time and linking it to strategic implications, but the qualitative synthesis misaligns with the source’s intended implication. The LLM assumes utilization caused the drop, but the data alone doesn’t confirm whether the reduction was due to issuance, plan amendments, or repurchases—other factors could be at play. (4) Therefore, while all facts and numbers are correct (quantitative accuracy = 10), the qualitative interpretation introduces a conflicting narrative, reducing the correctness score to 7. Contextual relevance remains high as the answer directly addresses both parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 409,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "Nike's treatment of Nike Air technology in its product development strategy remained consistent between fiscal years 2023 and 2024, with the company continuing to emphasize its role as a core innovation driver. Both filings highlight Nike Air as part of a broader suite of technologies (e.g., Zoom, React, Flyknit) central to designing innovative products across categories. While no explicit changes in strategy are detailed, the 2024 document underscores ongoing efforts to integrate such technologies into new experiences and product lines, reflecting sustained focus on leveraging Nike Air for competitive differentiation.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Nike's treatment of Nike Air technology 'remained consistent' between fiscal years 2023 and 2024. The ground truth shows a clear strategic evolution: in 2023, Nike Air was highlighted as an innovative technology reflecting dedication to product innovation, suggesting it was still being actively promoted as a distinct innovation. By 2024, it was grouped with mature technologies like Zoom, Free, and React, indicating it had transitioned to a foundational, integrated component rather than a standalone growth driver. The LLM incorrectly frames this shift as continuity, missing the nuanced but important strategic repositioning. There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. The qualitative accuracy is low because the model fails to capture the correct multi-hop reasoning: synthesizing the change in narrative tone and categorization of Nike Air across the two fiscal years. Contextual relevance is moderate—the response addresses the right topic and mentions relevant technologies, but misinterprets the strategic trajectory. The answer uses plausible language and structure but conveys the opposite of the correct conclusion, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 363,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "Based on the provided 10-K filings, Abbott's positioning of Osmolite within its Nutritional Products segment remained consistent between 2022 and 2023. Both filings list Osmolite as part of the enteral feeding portfolio for healthcare institutions, alongside products like Jevity, Glucerna, and Freego. There is no explicit mention of strategic shifts or changes in product line emphasis for Osmolite in the provided pages, indicating stability in its role within the segment during this period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly states that Osmolite's positioning within Abbott's Nutritional Products segment remained consistent between 2022 and 2023, continuing as part of the enteral feeding portfolio for healthcare institutions. The listed co-products (Jevity, Glucerna, Freego) match those in the original answer, though the LLM omits a few (Glucerna 1.2 Cal, Glucerna 1.5 Cal, Oxepa, Nepro, Vital), which slightly reduces completeness but does not affect the core conclusion. There are no numerical values in this question, so quantitative accuracy is scored based on correct handling of years (2022 and 2023), which are accurate. The reasoning is sound: the model correctly infers stability in strategic positioning due to absence of repositioning or discontinuation mentions. The answer synthesizes information across the two years appropriately, demonstrating valid multi-hop reasoning. Semantic equivalence is strong—while wording differs, the meaning matches the ground truth. The only minor shortcoming is the incomplete listing of enteral products, but this does not distort the overall accurate conclusion of stable positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 337,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "Between 2022 and 2024, 3M's regulatory engagement and remediation obligations related to PFAS in Minnesota and Alabama evolved as follows:  \n- **Minnesota**: 3M continued addressing PFAS under the 2007 SACO with MPCA, including updated Health Risk Limits (HRLs) and stricter Clean Water Act permit requirements. In 2024, the MPCA issued revised effluent limits for PFAS, requiring significant operational changes, and directed stormwater management actions. Remediation at Cottage Grove and Woodbury sites progressed, with ongoing monitoring and maintenance.  \n- **Alabama**: 3M adhered to the 2020 interim Consent Order, focusing on PFAS discharge controls, site investigations, and remediation. The company faced regulatory scrutiny, including a grand jury subpoena, and maintained compliance with the 2009 TSCA consent order. Remediation of Decatur’s soil and groundwater contamination advanced, with a multilayer cap installed.  \n\nThese efforts reflect heightened regulatory scrutiny, stricter compliance requirements, and ongoing remediation commitments in both states.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key developments in 3M's regulatory engagement and remediation obligations related to PFAS in Minnesota and Alabama between 2022 and 2024. It correctly identifies the ongoing nature of the 2007 SACO with MPCA in Minnesota and the 2020 Interim Consent Order with ADEM in Alabama. The mention of updated Health Risk Limits (HRLs) and stricter Clean Water Act permit requirements in Minnesota aligns with the ground truth, including the 2024 draft permit with revised effluent limits. The LLM accurately notes the installation of a multilayer cap at the Decatur facility in Alabama and ongoing remediation efforts. However, it omits specific details present in the original answer: (1) the August 2024 public comment submission by 3M on the draft permit, (2) the December 2024 revised draft permit issued by MPCA after stakeholder input, and (3) the reference to updated HBVs from MDH in January 2024. Additionally, while the LLM mentions a grand jury subpoena in Alabama, this detail is not in the ground truth and may be extraneous or inaccurate based on the provided knowledge. The answer also generalizes 'stormwater management actions' and 'Woodbury sites' without confirmation in the original answer, which only specifies Cottage Grove. Despite these minor inaccuracies and omissions, the core facts—regulatory evolution, continued obligations, and increased scrutiny—are correctly conveyed. Quantitative accuracy is high: all dates (2007, 2020, 2024) and regulatory frameworks are correctly cited. The reasoning is sound in synthesizing multi-hop information across time and jurisdictions, though slight overreach occurs with unverified details. Contextual relevance is excellent, directly addressing the question's focus on evolution between 2022 and 2024 in both states.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1644,
        "completion_tokens": 493,
        "total_tokens": 2137
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "The Coca-Cola Company's investment in Coca-Cola HBC AG remained classified as an equity method investment throughout 2022 and 2024, with a consistent 22% ownership stake as of December 31, 2024, as detailed in Note 6 of the 2024 10-K. No changes in investment classification or stake percentage were reported during this period.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Coca-Cola HBC AG remained an equity method investee from 2022 to 2024 and accurately reports the 22% ownership stake as of December 31, 2024. However, it incorrectly claims a 'consistent 22% ownership stake' throughout the period, which contradicts the ground truth stating that the stake percentage was not disclosed in 2022. This is a significant factual error regarding the evolution of the stake percentage. (2) The quantitative accuracy is partially compromised because while the 22% figure for 2024 is correct, the implication that it was the same in 2022 is unsupported by evidence and misrepresents the timeline of disclosure. (3) The reasoning is flawed in the multi-hop synthesis: the question asks how the relationship evolved, but the LLM fails to recognize the key development — the formalization and first-time disclosure of the 22% stake in 2024 after absence in 2022. Instead, it asserts consistency, missing the evolution entirely. (4) Contextual relevance is high as the answer addresses investment classification and stake percentage as asked, and cites the correct note (Note 6) in the 2024 10-K. However, due to the critical error in asserting a consistent stake despite incomplete prior disclosure, the overall correctness is reduced to a 6 — partially correct but with significant factual inaccuracy affecting the core of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 391,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "Oracle's strategic emphasis on hybrid deployments has evolved between fiscal 2022 and 2024 by integrating cloud and on-premise models to enhance flexibility and customer choice. In fiscal 2022, Oracle invested $7.2 billion in R&D to develop technologies like the Oracle Autonomous Database and OCI, which support hybrid environments. By fiscal 2024, the proportion of cloud services and license support revenues (71% of total revenues) continued to grow, reflecting deeper integration of hybrid deployment capabilities. The company expanded programs to help customers migrate on-premise workloads to the cloud, reinforcing hybrid as a core model alongside cloud-only solutions.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's strategic evolution toward hybrid deployments and cites the accurate $7.2 billion R&D investment in fiscal 2022, which matches the ground truth. However, it introduces a new figure—71% of total revenues from cloud services and license support in fiscal 2024—that is not present in the original answer and cannot be verified against the provided ground truth, raising concerns about factual accuracy. While this percentage may be contextually plausible, its inclusion without confirmation represents a deviation. (2) The $7.2 billion figure is correctly stated and contextually applied to R&D for hybrid-enabling technologies like Autonomous Database and OCI. The 71% revenue figure lacks corroboration in the ground truth and may reflect overreach or external data not in the knowledge graph, reducing quantitative accuracy. (3) The reasoning correctly traces a strategic evolution from product development (2022) to deeper integration (2024), aligning with the multi-hop requirement. However, the original answer emphasizes hybrid deployments becoming a 'standard deployment choice' and highlights Oracle Cloud@Customer specifically, which the LLM omits. Instead, it discusses migration programs and revenue mix, which, while relevant, shift focus away from deployment model integration. (4) The answer is contextually strong and addresses both product development and deployment integration, but misses precise terminology and emphasis on Cloud@Customer and interoperability. The core facts are mostly correct, but the addition of unverified metrics and omission of key specifics from the ground truth prevent a higher score. Thus, correctness is rated 7 for being substantially accurate with minor but notable gaps and one unsupported figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 490,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "The filing status of Wells Fargo & Company's Mandatory Clawback Policy remained consistent between the 2023 and 2024 SEC 10-K disclosures. In both filings, the policy was referenced as **Exhibit 97**, with the 2024 filing incorporating the 2023 version (effective October 2, 2023) without introducing amendments or changes to the policy itself. No evolution in filing status or policy content was noted between the two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the filing status 'remained consistent' between 2023 and 2024, which contradicts the ground truth. In reality, there was a procedural change: in 2023, the Mandatory Clawback Policy was filed directly as Exhibit 97, while in 2024 it was incorporated by reference from the prior year. The LLM mischaracterizes this evolution as 'no evolution in filing status,' which is factually incorrect. (2) Quantitatively, the answer correctly identifies Exhibit 97 and the effective date of the 2023 policy (October 2, 2023), which aligns with the ground truth. These details are accurate and properly referenced. (3) The multi-hop reasoning is flawed because the model fails to recognize that incorporation by reference represents a change in disclosure method. This is a key distinction in SEC filings, and the model incorrectly interprets the lack of policy amendment as indicating no change in filing status, missing the procedural shift entirely. (4) While the entities (Wells Fargo, Exhibit 97, years) and dates are correct, and the answer is relevant to the question, the core factual claim about the filing status evolution is wrong, warranting a low correctness and qualitative accuracy score. The answer is semantically different from the ground truth despite some accurate component facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 374,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "Thermo Fisher acquired CorEvitas, LLC in August 2023 for $910 million, with $730 million in cash paid and $184 million in debt settled. This acquisition expanded the Laboratory Products and Biopharma Services segment's portfolio with real-world evidence solutions, contributing $627 million in goodwill (non-tax-deductible). The transaction was a significant cash outflow in 2023's investing activities ($5,142 million total), and no further changes in the relationship or financial implications are noted in the 2024 filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of CorEvitas, LLC by Thermo Fisher for $910 million, which aligns with the ground truth amount of $0.91 billion. It adds more granular detail not in the original answer—$730 million in cash and $184 million in debt settled—which is consistent with a plausible breakdown and does not contradict the ground truth. The mention of $627 million in goodwill is an additional detail that may be accurate but is not present in the ground truth, so it cannot be verified. However, the LLM fails to mention the key 2024 development: the amortization of definite-lived intangible assets over 18 years, which is a specific financial implication in 2024. This omission reduces completeness. (2) Quantitatively, all provided numbers are consistent: $910 million total matches $0.91 billion; the $5.142 billion total investing outflow contextually fits within Thermo Fisher’s broader 2023 activities. The absence of the 18-year amortization period—a critical 2024 financial implication—is a significant quantitative and qualitative gap. (3) The reasoning correctly identifies the 2023 acquisition and its integration into the Laboratory Products and Biopharma Services segment, satisfying part of the multi-hop requirement. However, it fails to connect the 2024 financial treatment (amortization), which requires synthesis across years and accounting disclosures, weakening the multi-hop analysis. (4) Scores reflect high accuracy in what was stated, but the missing 2024 financial implication limits correctness and qualitative reasoning. Contextual relevance remains high as all provided information directly addresses the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 463,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "RTX's flight hour payment obligations under the 2012 agreement with Rolls-Royce remained contingent on hours flown by V2500-powered aircraft through June 2027, as disclosed in both the 2022 and 2023 10-K filings. These payments were capitalized as collaboration intangible assets as they were made, with no change in capitalization treatment between the two years. The timing of obligations remained unchanged, extending through the specified June 2027 deadline.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the payment obligations are contingent on flight hours through June 2027, tied to V2500-powered aircraft, and capitalized as collaboration intangible assets. There is no change in timing or treatment between 2022 and 2023. (2) Quantitative elements—specifically the June 2027 deadline—are correctly stated. No numerical calculations are required, but the temporal metrics are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes disclosures from both 2022 and 2023 filings, confirms consistency across years, and infers no change in obligation structure. (4) The answer addresses all parts of the question: timing (through June 2027), capitalization treatment (as intangible assets), and evolution (no change). Wording differs slightly but meaning is preserved. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 275,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024 through contingent payments tied to performance milestones. In 2020, Coca-Cola acquired the remaining ownership interest in fairlife, with a $902 million gain recognized in 2022. A contingent milestone payment, based on fairlife's financial performance through 2024, was recorded as a $6.126 billion liability at December 31, 2024, reflecting discounted cash flow analyses. This payment, payable in 2025, was remeasured quarterly, with changes in fair value impacting income until settlement. In 2023, a $275 million milestone payment was made, but the remaining liability persisted as of 2024, indicating ongoing performance-based obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that there was no mention of ongoing contingent payments in 2022, but the LLM claims a $902 million gain was recognized in 2022 related to the 2020 acquisition—this is not supported by the original answer and introduces a false financial figure. Additionally, the LLM asserts a $6.126 billion liability was recorded at the end of 2024, which is vastly larger than any figure mentioned in the ground truth and appears fabricated. The claim that a $275 million milestone payment was made in 2023 is also not present in the original answer and contradicts the timeline where the remaining payment is scheduled for 2025 with no interim payments mentioned. (2) Quantitative accuracy is severely lacking: none of the dollar amounts ($902M gain, $6.126B liability, $275M payment) are in the original answer, and no such figures were referenced in the ground truth. These numbers are not just misstated—they are entirely absent from the source data, indicating hallucination. (3) While the LLM correctly identifies the core concept—that a contingent milestone payment from the 2020 acquisition remains due in 2025 based on performance through 2024—it fails to accurately represent the evolution from 2022 to 2024. The original answer emphasizes that in 2022, no ongoing payments were disclosed, whereas by 2024, a remaining obligation was acknowledged. The LLM overcomplicates this with incorrect details about quarterly remeasurements and income impacts not present in the ground truth, undermining the reasoning. (4) Contextual relevance is moderate—the response addresses the financial relationship and contingent payments, and correctly frames the 2020 acquisition and future 2025 payment. However, due to severe quantitative errors and unsupported details, the overall correctness score is low. The model captures the general direction of the evolution but fails on factual precision, which is critical in financial disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 544,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024 by emphasizing deeper integration with enterprise applications and infrastructure technologies, as highlighted in the 2022 document's focus on interoperable deployment models and the 2024 financial data showing sustained growth in cloud services. By 2024, cloud services and license support revenues accounted for 71% of total revenues, reflecting continued investment in cloud infrastructure (OCI) and SaaS offerings that power enterprise applications like Oracle Fusion Cloud ERP and HCM. The 2022 strategy emphasized migration to the cloud, while 2024 data underscores the maturation of this integration, with Oracle leveraging OCI to enhance scalability, security, and interoperability across hybrid and on-premise environments.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies, particularly in quantitative claims. The statement that 'cloud services and license support revenues accounted for 71% of total revenues' in 2024 is not supported by the ground truth and introduces a specific percentage not present in the original answer. There is no mention of financial data or revenue breakdowns in the original answer, making this a significant factual overreach. (2) No actual numbers appear in the ground truth, so the introduction of a 71% revenue figure constitutes a major quantitative error. The LLM fabricates a data point that cannot be verified from the provided context, which severely undermines factual accuracy. (3) On qualitative grounds, the LLM captures part of the strategic evolution—such as increased integration with enterprise applications (e.g., Fusion Cloud ERP and HCM) and infrastructure technologies like OCI—and correctly identifies a shift from cloud migration (2022) to maturation (2024). It also references hybrid and on-premise interoperability, aligning with the original's mention of deployment flexibility. However, it misses the core conceptual shift emphasized in the ground truth: from promoting individual innovations like the Autonomous Database to positioning Oracle Cloud as a holistic, integrated platform. The LLM focuses more on financial performance and technical integration than on the strategic repositioning toward customer-centricity and comprehensive service offerings. (4) Despite the fabrication of revenue data, the answer remains contextually relevant, addressing the evolution of Oracle’s cloud strategy with respect to enterprise and infrastructure integration. The reasoning shows partial synthesis across years but fails to fully capture the nuance of the strategic narrative shift. Correctness is penalized heavily due to unsupported quantitative claims, though qualitative elements show moderate accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 525,
        "total_tokens": 2004
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "The Key/Specified Employee Policy was referenced in the 2023 filing (Exhibit 10(r)) as incorporated by reference to the 2018 10-K. In the 2024 filing, there is no explicit mention of the policy as an exhibit, suggesting a potential change in documentation or incorporation by reference, though no new exhibit or update is explicitly noted in the provided pages.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly identifies the exhibit number in the 2023 filing as Exhibit 10(r), while the ground truth states it is Exhibit 10(v). This is a critical error in entity accuracy. Furthermore, the LLM claims there is 'no explicit mention of the policy as an exhibit' in the 2024 filing, which contradicts the ground truth stating the policy was explicitly announced as continuing and still relying on the same 2018 Exhibit 10(v). The LLM incorrectly implies a potential change or omission, when in fact the policy's documentation remained unchanged and was still incorporated by reference. (2) Quantitatively, the years (2018, 2023, 2024) are correct, but the exhibit number error undermines the precision of the documentation details. No calculations were required, but the references to exhibits are factually wrong. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the continuity of the policy and its documentation between 2023 and 2024. Instead of recognizing that the same exhibit was reused, it infers a possible discontinuity, which is incorrect. (4) Contextually, the answer addresses the right topic—documentation and incorporation by reference—but draws the wrong conclusion due to incorrect exhibit citation and misinterpretation of the 2024 status. Hence, while the structure is relevant, the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 407,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "The aggregate principal balance of the 6.700% notes due 2028 decreased from **$400 million in 2022** to **$285 million in 2023**, reflecting a repayment of **$115 million** during 2023. This reduction indicates RTX's active debt management strategy to reduce near-term obligations, potentially refinance higher-cost debt, and extend the maturity profile of its liabilities. The company also issued new long-term debt with lower rates (e.g., 5.750% notes) and extended maturities, aligning with a strategy to optimize capital structure, lower refinancing risk, and manage interest costs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in the reported financial figures. According to the ground truth, the aggregate principal balance of the 6.700% notes due 2028 was $115 million in 2022 and increased to $285 million in 2023. The LLM incorrectly states it was $400 million in 2022 and decreased to $285 million, implying a repayment of $115 million, which is factually wrong. This reverses the actual trend—RTX increased, not decreased, its debt on these notes. (2) The calculation of a $115 million repayment is based on incorrect inputs and is therefore invalid. The correct change is an increase of $170 million ($285M - $115M), not a decrease. (3) The reasoning and synthesis are flawed because the LLM draws conclusions opposite to the actual data. It suggests RTX is reducing debt and refinancing higher-cost obligations, but the ground truth shows an expansion of this fixed-rate debt, indicating a strategy to take on more, not less, of this instrument. The mention of issuing 5.750% notes may be contextually relevant but does not justify misrepresenting the 6.700% note balance trend. (4) The contextual relevance is moderate because the answer discusses debt management strategy, which is relevant, but the qualitative and quantitative inaccuracies severely undermine the validity of the conclusion. The entity (RTX) and metric (principal balance of 6.700% notes due 2028) are correctly identified, but the years and values are wrong. Due to the reversal of direction in debt movement and incorrect numbers, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 433,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "The carrying value of TMO's 1.95% 12-Year Senior Notes decreased from $773 million as of December 31, 2023, to $725 million as of December 31, 2024. The effective interest rate for these notes remained nearly stable, dropping slightly from 2.08% in 2023 to 2.07% in 2024. This reflects minor adjustments in the debt's amortization and market conditions over the period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value correctly decreases from $773 million in 2023 to $725 million in 2024, and the effective interest rate declines from 2.08% to 2.07%. These values match the original answer exactly, with acceptable formatting (e.g., '2.08%' vs. '2.08%'). (2) The answer is complete, addressing both the carrying value and effective interest rate for both years as required by the question. (3) Entity accuracy is correct—TMO's 1.95% 12-Year Senior Notes are properly identified, and the years 2023 and 2024 are correctly referenced with appropriate context (end-of-year values). (4) The reasoning is sound: the slight drop in effective interest rate and decrease in carrying value are accurately described and plausibly attributed to amortization and market conditions, which aligns with financial logic and the original answer’s interpretation. The LLM successfully performs multi-hop synthesis by correctly associating the two metrics across two time points and interpreting the trend. (5) Semantic equivalence is achieved—the wording differs slightly (e.g., 'nearly stable' vs. 'slightly declined'), but the meaning is identical. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 364,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "The 2024 filing (pages 1-5) mentions the Directors' Code of Conduct in the \"Corporate Governance\" section under ITEM 10, with a website link for access, while the 2022 filing (pages 9-13) also references the code in the same section. There is no explicit indication of a change in presentation format between the two filings. However, the 2024 document emphasizes the code's availability on the website and its applicability to all directors, reinforcing transparency and accessibility, which aligns with corporate governance principles of accountability and stakeholder engagement. The consistency in presentation suggests ongoing commitment to governance standards, though no material change in structure or content is documented.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that the 2024 filing includes a website link and maintains consistent presentation with 2022. The ground truth states that in 2024, the Directors' Code of Conduct was listed among other governance materials *without a direct link or specific mention of updates*, whereas in 2022 it was explicitly detailed with a direct URL. This is a critical misrepresentation of the core fact. The LLM also claims there is 'no explicit indication of a change in presentation format,' which directly contradicts the ground truth that identifies a clear shift in visibility and emphasis. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning fails: the question requires comparing the presentation of the Code across two years to assess governance implications. The LLM incorrectly concludes no change occurred, missing the key shift from explicit, accessible disclosure to a more buried, less visible format. This undermines the synthesis needed to evaluate transparency and accountability implications. (4) While the LLM addresses the general topic of corporate governance and stakeholder engagement, it does so based on an incorrect premise, reducing contextual relevance. The answer is on-topic but built on false foundations, warranting a low correctness score despite appropriate terminology use.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 410,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "Amazon's Short-Term Credit Agreement evolved between 2023 and 2024 as follows:  \n- **Facility Size**: Remained at **$5.0 billion** in both years.  \n- **Maturity Date**: The 2023 agreement matured in **October 2024**, while the 2024 agreement, established in **October 2024**, matures in **October 2025**.  \n- **Timing of Establishment**: The 2023 agreement was entered into in **November 2023**, and the 2024 agreement replaced it in **October 2024**. The interest rate structure (Secured Overnight Financing Rate + 0.45%) and commitment fee terms remained consistent.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts: facility size ($5.0 billion in both years), maturity dates (October 2024 for 2023 agreement, October 2025 for 2024 agreement), and timing of establishment (November 2023 and October 2024). These match the ground truth exactly. (2) Quantitative accuracy is perfect: all dollar amounts, dates, and timeframes are correct. The shift from November to October and the one-year maturity extension are accurately reflected. (3) The reasoning is sound and demonstrates proper multi-hop synthesis across the two years’ agreements. The LLM correctly infers this is a renewal, though it adds minor details not in the original (e.g., interest rate, commitment fee), which are not contradicted but not confirmed by the ground truth—this does not harm accuracy but slightly exceeds the provided information. (4) The answer is fully contextually relevant and addresses all parts of the question. The only reason for not scoring a 10 is that the original answer emphasizes the procedural nature of the renewal and the replacement pattern from prior years (e.g., 2022 to 2023), which the LLM implies but does not explicitly state. However, the core facts and synthesis are fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 348,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "AMD's APU strategy evolved from 2022 to 2024 by integrating AI-specific hardware (e.g., NPUs) into APUs, targeting next-generation AI PCs. In 2022, APUs focused on general-purpose performance and efficiency for gaming and productivity. By 2024, AMD introduced Ryzen AI 300 Series APUs with dedicated NPUs, enhancing AI workloads and positioning APUs as core components for AI PCs. This shift strengthens AMD's revenue potential in the AI PC segment by addressing specialized compute needs, aligning with growing demand for AI-driven applications in edge and client devices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of AMD's APU strategy from 2022 to 2024. It correctly identifies the shift from general-purpose APUs in 2022 to the integration of dedicated NPUs in 2024, specifically mentioning the Ryzen AI 300 Series APUs, which aligns with AMD's real-world product rollout. The answer accurately reflects the strategic pivot toward AI PCs and the implications for revenue potential in the AI PC segment. While the original answer provides more contextual detail—such as AMD being the first to integrate an NPU on the same SoC as an x86 CPU and specific references to 2022 GPU-focused strategies like the Instinct MI200 series—the LLM answer still conveys the essential multi-hop reasoning: (1) change in product integration (adding NPUs), (2) shift in target market (from general computing to AI PCs), and (3) positive revenue implications. All dates and product names (e.g., 2022, 2024, Ryzen AI 300 Series) are correct. There are no numerical inaccuracies, and the qualitative reasoning is sound, though slightly less detailed than the ground truth. The answer is fully contextually relevant and semantically equivalent in meaning, even if less granular in technical specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 344,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "The treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic remained consistent between 2023 and 2024. Dividends are generally subject to a 25% Irish dividend withholding tax unless exemptions apply, such as for U.S. residents holding shares through the Depository Trust Company (DTC) with a U.S. address or providing Form 6166/V2. The withholding tax discharge Irish income tax liability, and the U.S./Ireland Double Tax Treaty provisions are typically unnecessary due to broad exemptions. No changes in tax rates or treatment were noted in the 2024 filing compared to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All factual elements are correct: the 25% Irish dividend withholding tax rate is accurately stated, and the conditions for exemption (e.g., Form 6166, Irish Non-Resident Form V2) are correctly identified. The key point that U.S. shareholders with proper documentation generally have no Irish income tax liability is preserved. (2) Quantitative accuracy is perfect: the 25% tax rate is correct, and no erroneous numbers or calculations are present. (3) The reasoning is sound and reflects multi-hop synthesis: the answer correctly links the withholding tax to discharge of Irish income tax liability and notes the stability between 2023 and 2024. One minor omission is that the ground truth explicitly mentions submission of a required statement to Irish Revenue to discharge liability, which the LLM answer implies but does not state directly. Additionally, the LLM mentions DTC and U.S. address as exemption conditions, which are not explicitly in the ground truth—this adds detail but may slightly over-specify without confirmation. (4) Contextual relevance is excellent: the answer directly addresses the evolution (or lack thereof) in tax treatment between the two years, focuses on U.S. shareholders and Irish withholding tax, and correctly concludes no changes occurred. Overall, the answer is semantically equivalent with only minor differences in emphasis, warranting a high score but not perfect due to slight over-specification and omission of the 'statement to Irish Revenue' requirement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 435,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "The risk disclosure around new products and services and the platforms operating model initiative evolved between 2022 and 2024 by explicitly highlighting the transition to a platforms operating model as a distinct risk factor in 2024. In 2022, the risk was mentioned within broader transformational initiatives, noting potential failure to implement such initiatives could affect results. By 2024, the disclosure specifically emphasized the risk of not realizing expected benefits from the platforms operating model, underscoring heightened awareness and detailed scrutiny of this initiative's challenges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the evolution of risk disclosure from general strategic initiatives in 2022 to a specific focus on the platforms operating model in 2024 is accurately described. The core idea that BNY Mellon may not realize expected benefits from the platform transition is correctly attributed to the 2024 filing. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct use of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound—LLM correctly synthesized the shift in risk language across two years and linked it to a specific strategic initiative (platforms operating model). It captures the progression from general to specific risk disclosure. (4) The only minor shortcoming is that the LLM does not explicitly name BNY Mellon as the company, though this may be inferred from context. Otherwise, the answer is semantically equivalent to the original, well-structured, and fully relevant to the question. Hence, a score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 343,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "Amazon's relationship with the 3.600% Note due 2032 remained consistent between 2023 and 2024, as disclosed in the 10-K filings. Both filings reference the same Supplemental Indenture (Exhibit 4.2) from April 13, 2022, which includes the note's terms, indicating no amendments or changes to the instrument. The 2024 filing does not introduce new disclosures or modifications related to this specific debt obligation.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually correct in stating that the 3.600% Note due 2032 was consistently referenced under the same Supplemental Indenture (April 13, 2022) in both 2023 and 2024, with no changes to the note's terms or interest rate. The dates and percentages are accurate, and the reference to Exhibit 4.2 aligns with typical disclosure practices, satisfying quantitative accuracy. However, the LLM omits a key qualitative evolution highlighted in the ground truth: the trustee transition from Wells Fargo Bank, National Association (prior trustee) to solely Computershare Trust Company, National Association as successor trustee in the 2024 filing. This procedural change in trustee structure represents a meaningful administrative evolution in the debt instrument's disclosure, which the LLM fails to mention. While the core facts about the note’s terms and continuity are correct, the answer lacks completeness regarding the shift in trustee relationship, which is central to how the disclosure evolved. The reasoning is sound but incomplete, and the omission reduces the qualitative accuracy. Contextually, the response is highly relevant and addresses the core of the question, but misses a critical nuance in the multi-hop synthesis between years and entities (trustees).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 356,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "MDLZ's treatment of net investment hedge derivative contracts evolved from 2023 to 2024, with changes in fair value presentation and financial impact. In 2023, net investment hedge contracts had $163 million in assets and $382 million in liabilities, while in 2024, they increased to $305 million in assets and $50 million in liabilities. The financial impact shifted from a $396 million after-tax gain in 2022 to an $185 million after-tax loss in 2023, with 2024 showing continued losses reflected in \"Other income, net\" as ($328) million. These contracts remained disclosed as assets/liabilities in the balance sheet, with fair value adjustments impacting comprehensive income and earnings.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, MDLZ disclosed $1,347 million in other current assets and $250 million in other assets related to derivative assets, with corresponding liabilities of $377 million and $413 million as of 2023 and 2022, respectively. The LLM incorrectly reports derivative assets as $163 million and liabilities as $382 million in 2023, and $305 million in assets and $50 million in liabilities in 2024—none of which match the ground truth. Additionally, the LLM introduces after-tax gains/losses of $396 million in 2022 and $185 million loss in 2023, and a ($328) million loss in 2024—all of which are unsupported by the original answer and factually incorrect. (2) The quantitative inaccuracies are severe and pervasive. The correct values are in the hundreds of millions and specifically reference balance sheet line items (other current assets, other assets), but the LLM fabricates entirely different figures and misrepresents the years. There is no indication in the ground truth of after-tax gains or losses for these hedges in 2022 or 2023, nor a ($328) million loss in 2024. (3) The multi-hop reasoning is flawed. While the LLM correctly identifies a shift in financial statement impact toward 'Other income, net' in 2024—which aligns with the ground truth's mention of amounts excluded from hedge effectiveness being included there—the reasoning is undermined by incorrect data. The evolution in disclosure emphasis (from balance sheet valuation to income statement volatility) is partially recognized, but the synthesis is based on false numerical premises. (4) The contextual relevance is moderate because the answer attempts to address the evolution in treatment and disclosure of net investment hedges and mentions relevant financial statement items. However, due to the severe quantitative errors and lack of fidelity to the actual disclosed values, the correctness score is very low. The qualitative accuracy is slightly higher because the direction of the shift in disclosure focus is partially correct, but the overall answer is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 576,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "From 2023 to 2024, the Abrams Main Battle Tank's modernization strategy advanced with the continued delivery of the SEPv3 upgrade package, enhancing communications, power, fuel efficiency, and armor, while the development of the M1E3 Abrams introduced a next-generation architecture for faster technology integration and reduced sustainment costs. International demand remained robust, with exports to allies like Canada, the UK, Spain, and others, and the M1E3's capabilities attracting interest from NATO members and partners. The 2024 filings highlight expanded production and upgrades for global customers, reflecting sustained technological innovation and heightened international procurement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the core evolution of the Abrams modernization strategy from 2023 to 2024. It accurately identifies the SEPv3 upgrades (communications, power, fuel efficiency, armor) and the development of the M1E3 with next-gen architecture and reduced sustainment—key points from the ground truth. It also correctly reflects increased international demand and global procurement momentum. However, the mention of specific countries like Canada, the UK, and Spain is not present in the original answer and may be speculative; the ground truth refers to broader regions (Europe, Middle East, North Africa, Indo-Pacific) without naming individual countries. This is a minor over-specificity but does not introduce false facts. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is fully preserved. (3) The multi-hop reasoning is sound: the model synthesizes technological development (SEPv3 and M1E3) and connects it to international demand and strategic relevance across years. The shift from technical roadmap (2023) to global procurement focus (2024) is correctly inferred and articulated. (4) The answer is contextually excellent—directly addresses both technological development and international demand, aligns with the timeframe, and maintains semantic equivalence with minor wording differences. The slight over-specification of countries prevents a perfect 10, but overall accuracy is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 410,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "Between 2022 and 2024, AMD's role in APUs evolved from a focus on consumer and commercial markets (e.g., notebooks, desktops) to a stronger emphasis on enterprise and data center applications. In 2022, APUs were highlighted for integrating CPU/GPU on a single chip to deliver performance and efficiency for mainstream PCs, with commercial segments like Ryzen PRO targeting enterprise security and manageability. By 2024, AMD shifted strategic emphasis toward data center and AI/ML workloads, as evidenced by the growth of the Data Center segment (revenue increased from $6,043M in 2022 to $12,579M in 2024) and investments in AI accelerators like the Instinct MI200 series. APUs and related technologies were increasingly positioned for HPC, cloud gaming, and AI-driven workloads, reflecting a broader market segmentation strategy prioritizing enterprise and high-performance computing over traditional consumer markets.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth does not mention any revenue figures for AMD's Data Center segment in 2022 or 2024, nor does it state that APU-specific revenue grew from $6,043M to $12,579M. These numbers appear fabricated or misattributed—likely conflating overall Data Center segment revenue with APUs, which are only one component. There is no support in the original answer for such specific financial figures or growth claims. (2) The qualitative shift described—APUs moving toward data center and AI workloads—is partially aligned with the ground truth, which confirms that by 2024, APUs were explicitly included in both the Data Center and Client segments. However, the original answer does not state that AMD shifted focus *away* from consumer markets or that APUs are being used in AI/ML or HPC workloads; rather, they are grouped alongside other products like AI accelerators. The LLM overinterprets and extrapolates beyond the provided information. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic repositioning of APUs into more defined segments. However, it fails to accurately reflect the 2022 state—where APUs were part of a broader semi-custom portfolio without specific segmentation—and incorrectly introduces commercial Ryzen PRO and enterprise security as focal points, which are not mentioned in the ground truth. (4) Contextual relevance is high because the answer addresses market segmentation and strategic emphasis over time, but correctness is undermined by unsupported numbers and overreach in interpretation. Thus, while the direction of evolution is plausibly described, the factual basis is weak, leading to a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 485,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "Medtronic's disclosure regarding the Financial Transfers Act 1992 remained consistent between 2023 and 2024. Both filings explain that the Act allows the Irish Minister for Finance to restrict financial transfers between Ireland and third countries, with the list of restricted countries subject to ongoing changes. The 2024 disclosure did not introduce new information or evolve the discussion compared to 2023, maintaining the same explanation of the Act's scope and implications for transfers involving sanctioned countries.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in describing the Financial Transfers Act 1992 and its general provisions as disclosed by Medtronic in both 2023 and 2024. There are no numeric inaccuracies (quantitative accuracy is high), and the entities (Medtronic, Ireland, third countries, Irish Minister for Finance) and years (2023, 2024) are correctly identified. However, the key point of evolution in disclosure—specifically, that in 2024 Medtronic no longer emphasized the 'ongoing change' in the list of restricted countries, suggesting a shift in focus or stabilization—is missed entirely. The LLM incorrectly states that the 2024 disclosure 'maintained the same explanation' including the dynamic nature of the list, which contradicts the ground truth. This represents a failure in qualitative accuracy and multi-hop reasoning: the model should have detected a subtle but meaningful change in tone/emphasis across filings. While the answer is contextually relevant and addresses the right topic, it fails to capture the evolution asked for in the question, making it partially correct but significantly flawed in reasoning and factual completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 323,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "The G700 aircraft, Gulfstream's next-generation ultra-long-range, ultra-large-cabin model, was expected to enter service following FAA certification in early 2024, as disclosed in GD's 2023 filing. By 2024, GD confirmed that the G700 began deliveries in the second quarter of 2024, marking the start of production ramp-up. The 2024 filing noted increased inventories due to the ramp-up in production of new Gulfstream models, including the G700, and highlighted that customer deposits for firm orders contributed to higher liabilities. Thus, the G700 transitioned from certification planning in 2023 to actual production and deliveries in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately represented: in 2023, the G700 was expected to enter service after FAA certification in early 2024; by 2024, deliveries began in Q2, indicating successful certification and transition to production. (2) There are no numeric values requiring calculation, but the dates (early 2024 for certification, Q2 2024 for deliveries) are correctly cited and consistent with the original answer. Format and timing are precise. (3) The multi-hop reasoning is sound—information from GD's 2023 and 2024 disclosures is correctly synthesized to show the evolution from planned certification to active delivery and production ramp-up. The mention of increased inventories and customer deposits in 2024 adds contextual support from the filings, enhancing accuracy without introducing error. (4) The semantic meaning matches the original answer exactly, with added but accurate contextual detail (e.g., production ramp-up, inventory impact). All entities—G700, Gulfstream, GD, FAA, 2023 and 2024 timeframes—are correctly identified and used. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 334,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "PMI's relationship with KT&G evolved from a renewed exclusive commercialization agreement in 2023 to a long-term, extended collaboration in 2024. In 2023, PMI renewed its arrangement with KT&G to commercialize its smoke-free products globally (excluding South Korea) through a 15-year agreement, emphasizing exclusive access to KT&G's product pipeline and innovation. By 2024, this partnership deepened with structured performance reviews and commitments, reflecting heightened strategic dependency on KT&G's expertise in product development and regulatory compliance. The 2024 agreement also formalized shared responsibilities in navigating market-specific regulations, underscoring PMI's reliance on KT&G for commercialization success in diverse regions.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces inaccuracies and omits key aspects of the evolution in PMI's relationship with KT&G. The 15-year agreement running through January 29, 2038, is correctly implied by a 2023 start date, so the timeline is approximately accurate (quantitative accuracy is high). However, the LLM incorrectly states that PMI 'renewed' the arrangement in 2023, while the original answer indicates it was a new long-term collaboration announced that year, not a renewal. This misrepresents the nature of the 2023 agreement. (2) The LLM claims that in 2024, the agreement included 'structured performance reviews' and 'formalized shared responsibilities in navigating market-specific regulations,' which are not mentioned in the ground truth and appear to be fabricated or inferred without basis. These details undermine qualitative accuracy. (3) The core multi-hop reasoning—tracking the evolution from exclusive commercialization to deeper strategic integration—is partially correct, but the LLM fails to mention the critical point that by 2024, KT&G's heat-not-burn products were explicitly included in PMI's own product portfolio, signaling operational integration beyond distribution. Instead, the LLM emphasizes regulatory collaboration and performance reviews not present in the original, missing the key evidence of integration. (4) Contextual relevance is strong because the response addresses strategic dependency and product commercialization as asked, and the overall structure follows the timeline. However, the failure to accurately reflect the nature of the 2024 evolution—specifically the inclusion of KT&G products into PMI's portfolio—results in a moderate correctness score. Semantic equivalence is not achieved due to factual divergence in the description of the 2024 relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 502,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "AMD's approach to semi-custom SoC products evolved from 2022 to 2024 by strengthening strategic integration with broader ecosystems, particularly in AI and data center markets. In 2022, the focus was on revenue dependency through third-party adoption, with semi-custom SoCs tied to customers' product success. By 2024, AMD expanded its semi-custom SoC strategy through acquisitions like Silo AI and ZT Systems, enhancing AI acceleration capabilities and data center infrastructure. The company emphasized ecosystem collaboration, positioning semi-custom SoCs as core components of AI-driven platforms, aligning with industry trends in cloud computing and high-performance computing. This shift reflects a broader strategic emphasis on AI leadership and integrated solutions.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the high-level evolution in AMD's semi-custom SoC strategy from dependency on third-party adoption in 2022 to a more integrated, ecosystem-driven approach by 2024, which aligns with the ground truth. It correctly identifies the shift from a revenue model tied to customer product success to a strategic positioning within broader platforms, particularly in AI and data centers. However, the LLM introduces factually incorrect details: the acquisitions of 'Silo AI' and 'ZT Systems' are not mentioned in the ground truth and are not verifiable as part of AMD's public strategy in this context. These additions represent significant hallucinations that undermine the qualitative accuracy. While the emphasis on AI integration, data centers, and ecosystem collaboration is directionally correct, the ground truth specifically highlights the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs and use in gaming, cloud, and embedded systems—details missing in the LLM response. The answer also omits the explicit contrast between risk and dependency in 2022 versus product leadership in 2024. There are no numerical values in the question or answer, so quantitative accuracy is scored as 10 by default. Contextual relevance is high because the response stays on topic and addresses strategic positioning and ecosystem integration. The reasoning is partially sound but flawed due to reliance on fabricated acquisitions, weakening the multi-hop synthesis. Overall, the answer gets the general direction right but fails on key factual specifics and introduces false entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 445,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "The treatment of Irish income tax on dividends paid to U.S. residents remained consistent between 2023 and 2024. Dividends are generally subject to a 25% Irish dividend withholding tax, but U.S. residents holding shares through the Depository Trust Company (DTC) with U.S. addresses or providing valid U.S. Certification of Residence (Form 6166) are exempt. If withholding tax applies, it discharges Irish income tax liability, provided the shareholder submits required documentation. No changes in exemptions or withholding rates were noted in 2024, though Ireland’s implementation of OECD Pillar Two rules (effective 2025) could indirectly impact tax obligations.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in entity identification and reasoning synthesis. (1) Quantitatively, the 25% withholding tax rate is correctly stated and consistent with the ground truth. However, the LLM introduces specific procedural details not present in the original answer—such as the Depository Trust Company (DTC), U.S. addresses, and Form 6166—without grounding in the provided knowledge graph, which only references Medtronic’s disclosures and general conditions. These specifics may be contextually plausible but are not supported by the source. (2) The claim that 'no changes in exemptions or withholding rates were noted in 2024' contradicts the ground truth, which states that Medtronic’s 2024 disclosure provided 'more structured conditions for exemption' and clarified post-withholding procedures, indicating an evolution in treatment. This omission or misrepresentation undermines the correctness. (3) The multi-hop reasoning is flawed: the original answer hinges on Medtronic’s year-over-year disclosures as the source of information, but the LLM generalizes to Ireland’s tax policy and references OECD Pillar Two (effective 2025), which is irrelevant to the 2023–2024 comparison asked. This shifts focus away from the company-specific, year-specific disclosures that form the basis of the ground truth. (4) While the core idea—that withholding tax discharge and exemption conditions apply—is semantically aligned, the LLM fails to attribute the information to Medtronic’s reporting or reflect the nuanced evolution in disclosure clarity between years. Thus, despite correct numbers and general relevance, the answer lacks fidelity to the source data and misrepresents the nature of the change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 474,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "General Dynamics' Marine Systems segment faced cost pressures in 2023 due to supply chain impacts on the Virginia-class submarine schedule and cost growth on the DDG-51 program, which contributed to a 110-basis-point decline in operating margin. However, the Columbia-class submarine program drove a 12.9% revenue increase in 2023. In 2024, the segment expects continued revenue growth (to $12.8–12.9 billion) with an improved operating margin of 7.6%, reflecting better cost management. The Virginia-class and DDG-51 programs' cost challenges persisted, but the Columbia-class remained a key growth driver, with higher volume expected to sustain revenue momentum.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 110-basis-point margin decline in 2023, cost pressures from supply chain disruptions on the Virginia-class and cost overruns on DDG-51, and the $12.8–12.9 billion revenue projection for 2024 with a 7.6% operating margin. These figures match the original answer exactly. (2) Quantitative accuracy is perfect: all numbers, ranges, and percentages are correctly reported. The 12.9% revenue increase in 2023 is not in the original answer, but it does not contradict it—while the original notes revenue rose due to Columbia-class activity, it does not specify the percentage increase. This addition is plausible but unverified; however, it does not constitute a factual error. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes performance trends across 2023 and 2024, identifies the shift from margin pressure to improved outlook, and highlights the Columbia-class program as a strategic growth driver. (4) The answer is contextually complete and relevant, addressing all aspects of the question: financial performance changes, cost pressures on specific programs, and revenue outlook for Columbia-class. The only minor issue is the inclusion of the 12.9% revenue growth figure, which is not in the ground truth and cannot be confirmed, slightly reducing qualitative accuracy. Otherwise, the answer is factually correct, well-reasoned, and comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 405,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "BKNG's financial dependency on Booking.com for accommodation reservations remained consistent at approximately 89% for both the years ended December 31, 2022, and 2023, as indicated in the \"Revenue by Type of Service\" section of the 2023 10-K filing. This suggests no significant change in the proportion of revenue derived from accommodation reservations between these periods.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and matches the ground truth in all key quantitative aspects: the percentage of revenue from Booking.com's accommodation reservations is accurately reported as 89% for both 2022 and 2023. The dates (December 31, 2022, and 2023) are correctly specified, and the source (2023 10-K, 'Revenue by Type of Service') is appropriately cited. There are no calculation errors. The answer correctly concludes that there was no significant change in dependency, which aligns with the ground truth observation of sustained dependency. The only minor shortcoming is that the LLM answer does not explicitly state that this indicates a 'slightly increased' or 'unchanged' dependency as framed in the original answer—though 'remained consistent' effectively conveys the same meaning. It omits the interpretive phrase 'heavily relies' and the characterization of 'concentrated dependency,' but the core multi-hop reasoning—synthesizing the stability of revenue proportion over two years to infer dependency—is sound. The entities (BKNG, Booking.com), metric (revenue from accommodation reservations), and time periods are all accurate. The answer is highly relevant and conveys semantically equivalent information, warranting a high correctness score with a small deduction for slight incompleteness in qualitative nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 371,
        "total_tokens": 1581
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "The company's Swiss Franc note, which was $299 million at December 31, 2023, was fully repaid by December 31, 2024, as it no longer appears in the long-term debt section for 2024. This indicates the company resolved its foreign currency obligation related to the Swiss Franc note, reducing its exposure to currency fluctuations and demonstrating effective management of its foreign debt liabilities.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) Quantitatively, the $299 million Swiss Franc note obligation at December 31, 2023, is accurately reported, and its complete removal by December 31, 2024, is correctly stated. The absence of the note in 2024 implies full repayment or restructuring, consistent with the original answer. (2) The answer addresses both parts of the question: the evolution of the Swiss Franc note (from $299M in 2023 to zero in 2024) and the implication regarding foreign currency obligations. (3) Entities—'Swiss Franc note,' '2023,' '2024,' and 'long-term debt'—are correctly identified and contextualized. (4) The reasoning is sound: the disappearance of the liability from the 2024 filing supports the conclusion that the obligation was resolved, and the interpretation about reduced currency exposure and improved debt management aligns with the implications in the ground truth. Minor wording differences (e.g., 'fully repaid' vs. 'repaid or restructured') do not affect factual accuracy, as 'fully repaid' is a plausible subset of 'resolved' and is supported by the data. All aspects of multi-hop reasoning—tracking a specific foreign currency obligation across two years and interpreting its removal—are correctly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 360,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "Goldman Sachs introduced new Non-Employee Director RSU Award Agreement forms in its 2024 10-K filings (Exhibits 10.31 and 10.32), replacing the pre-2015 agreements referenced in the 2023 10-K (e.g., Exhibit 10.8). The 2024 agreements include both standard and cash-settled variants, reflecting updated terms and structures for RSU awards.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies. According to the ground truth, in the 2024 10-K, Goldman Sachs did not introduce new 'Form of Non-Employee Director RSU Award Agreement' as Exhibits 10.31 and 10.32, nor did it replace the pre-2015 agreements. Instead, the 2024 filing retained the pre-2015 form (Exhibit 10.8) and added a new Exhibit 10.18 titled 'Amendments to Certain Non-Employee Director Equity Award Agreements'—a detail entirely missing from the LLM response. The LLM incorrectly claims the introduction of two new RSU agreement forms (10.31 and 10.32) and characterizes them as replacements, which is not supported by the original answer. Additionally, the mention of 'cash-settled variants' and updated structures is speculative and not present in the ground truth. While the LLM correctly identifies a change between 2023 and 2024 filings regarding RSU agreements, the specific exhibits and nature of changes are factually wrong. The reasoning is partially sound in that it recognizes an evolution, but the multi-hop synthesis fails due to incorrect entity mapping (wrong exhibit numbers and agreement types). Quantitative accuracy is low due to fabricated exhibit numbers and agreement forms. Contextual relevance is moderate because the topic and general direction of change are correct, but details are misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 373,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "PM's financial relationship with Swedish Match AB evolved between 2023 and 2024 through the prepayment of a significant portion of long-term debt tied to the acquisition. In 2023, PMI had a Euro credit facility borrowings obligation of €6,121 million (average interest rate 3.445%) related to the Swedish Match acquisition, due through 2027. By 2024, PMI prepaid approximately €3 billion (about $3.2 billion) of the 3-year tranche of the senior unsecured term loan facility, reducing the outstanding balance under this tranche. As of December 31, 2024, the remaining €2.5 billion (approximately $2.6 billion) under the 5-year tranche of the term loan facility remained outstanding, reflecting a reduction in long-term debt obligations tied to the acquisition.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the key figures are correct: the 2023 long-term debt obligation of $6,121 million (stated as €6,121 million, which is acceptable given exchange rate approximations and reporting in Euros) and the 2024 reduction to approximately $2.6 billion (aligned with the ground truth $2,610 million). The mention of a ~$3.2 billion prepayment is consistent with the difference (~$3.5 billion), with minor variance likely due to rounding or exchange rate adjustments. (2) The answer adds contextual detail not in the original—such as the term loan tranches (3-year and 5-year), prepayment action, and interest rate—which are plausible and enhance understanding without contradicting facts. (3) Entity accuracy is strong: PM (PMI), Swedish Match AB, correct years (2023–2024), and financial metric (long-term debt obligations tied to acquisition) are all correctly identified. (4) Reasoning is sound: the answer correctly infers debt reduction via prepayment, supports the idea of reduced financial exposure, and synthesizes multi-hop information (debt structure, timing, repayment action). The only minor shortcoming is that the original answer emphasizes the overall reduction trend, while the LLM adds specific euro-denominated tranches and prepayment details that, while reasonable, are not confirmed in the ground truth. However, these do not contradict but rather enrich the narrative. Thus, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 429,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "BMY's strategic positioning around KRAS inhibition evolved significantly from 2023 to 2024 through the acquisition of Mirati in January 2024, which added Krazati (a commercially approved KRAS G12C inhibitor) to its portfolio. This acquisition enhanced BMY's capabilities in KRAS inhibition by providing a validated therapeutic (approved for second-line NSCLC) and expanding its development pipeline, including Krazati's clinical trials in combination with PD-1 inhibitors for first-line NSCLC. The acquisition solidified BMY's leadership in KRAS-targeted therapies, aligning with its broader oncology strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of BMY's strategic positioning around KRAS inhibition from 2023 to 2024. It correctly identifies the acquisition of Mirati in January 2024 (aligned with the 2024 timeframe in the ground truth) and notes that Krazati, a KRAS G12C inhibitor, was added to BMY's portfolio as a result. The answer accurately reflects that Krazati was already FDA-approved for second-line NSCLC and was in development for first-line NSCLC in combination with a PD-1 inhibitor. It also correctly emphasizes the strategic importance of the acquisition for BMY's oncology and KRAS inhibition strategy. However, the LLM answer omits a key expansion mentioned in the ground truth: the 2024 FDA approval of Krazati for advanced or metastatic KRAS-mutated colorectal cancer in combination with cetuximab. This is a meaningful therapeutic expansion and part of the drug’s evolving footprint, making the omission a minor but notable gap in completeness. The dollar amount of the $4.8 billion acquisition is missing, which is a quantitative detail present in the original answer, though the absence of this figure does not undermine the overall strategic narrative. All entities (BMY, Mirati, Krazati, KRAS G12C, NSCLC, PD-1) are correctly identified and contextualized. The reasoning is sound, demonstrating multi-hop synthesis across time (2023 vs 2024), corporate action (acquisition), and clinical development trajectory. Wording differs but maintains semantic equivalence on most points. Thus, the answer is excellent but not fully complete, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 439,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "Goldman Sachs' disclosure of the Restricted Partner Compensation Plan (RPCP) remained consistent between 2023 and 2024, with no explicit updates to the plan itself in the 2024 filings. However, newer compensation governance policies, such as the **Clawback Policy** (effective December 1, 2023), were introduced in 2023 and reflected in the 2024 10-K. This policy, which allows for the recovery of compensation in certain circumstances, likely influenced the broader compensation framework but did not alter the RPCP's structure or disclosure. The RPCP, last referenced in 2006, remained unchanged in its core terms, while governance policies like the Clawback Policy were emphasized as part of updated oversight mechanisms.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some key elements but contains significant inaccuracies and omissions that affect factual correctness. (1) It correctly identifies the introduction of the Clawback Policy and its relevance to compensation governance, aligning with the ground truth. However, it incorrectly states that the RPCP was 'last referenced in 2006,' which contradicts the ground truth that it was listed as Exhibit 10.3 in 2023 and Exhibit 10.4 in 2024—this is a major factual error. (2) The date for the Clawback Policy is partially correct (effective December 1, 2023), but the answer misattributes its disclosure timing by implying it was introduced in 2023 filings, while the ground truth emphasizes its appearance as Exhibit 10.1 in the 2024 filing, indicating formal disclosure prominence in 2024. (3) The LLM fails to mention the exhibit repositioning—Exhibit 10.3 in 2023 moving to 10.4 in 2024 and being placed later in the list—which is a central point in the original answer about strategic repositioning. This omission weakens the multi-hop synthesis between disclosure order and governance emphasis. (4) While the conclusion about updated oversight mechanisms is reasonable, the lack of reference to the exhibit numbering shift and the erroneous claim about the 2006 reference undermine the qualitative accuracy. The answer is contextually relevant and addresses the broader theme of governance evolution, but the factual errors in entity accuracy (exhibit references, years) and missing structural disclosure changes reduce correctness. Minor formatting differences in dollar amounts are not an issue here, but date and exhibit number accuracy is critical and flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 456,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "Philip Morris International expanded its heat-not-burn product categorization in 2023 by integrating oral nicotine products (e.g., nicotine pouches, snus) into its smoke-free portfolio, while formalizing business integration through acquisitions like Vectura Group PLC and Fertin Pharma A/S to support wellness and healthcare initiatives. The 2023 report highlights a 14.7% increase in heated tobacco unit (HTU) shipments and the establishment of a dedicated \"Wellness and Healthcare\" segment, reflecting a structured approach to diversifying beyond traditional tobacco products.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces inaccuracies and omits key aspects of the evolution in product categorization and integration. It correctly notes a shift in 2023 toward broader integration and mentions the expansion into wellness, but misrepresents the core categorization change. The ground truth states that heat-not-burn products were reclassified under 'smoke-free products' alongside e-vapor, oral nicotine, and wellness offerings, whereas the LLM incorrectly implies that oral nicotine products were integrated *into* the heat-not-burn category, reversing the actual structural shift. Additionally, the mention of acquisitions like Vectura and Fertin supports wellness initiatives but is not directly tied to heat-not-burn product integration, which was the focus of the question. (2) The quantitative claim of a '14.7% increase in HTU shipments' is not present in the original answer and cannot be verified against the ground truth; this number may be factually incorrect or taken out of context. No such percentage increase was mentioned in the provided ground truth, making this a fabrication or unsupported addition. (3) The multi-hop reasoning is partially sound—there is an attempt to synthesize business integration with product categorization—but it fails to accurately reflect the hierarchical reorganization described in the original answer. The key evolution—explicitly grouping heat-not-burn under 'smoke-free products' and including licensed KT&G products—is entirely missing. Instead, the LLM focuses on peripheral developments (acquisitions, wellness segment) that, while relevant to PMI’s broader strategy, do not directly address the specific evolution of heat-not-burn product categorization. (4) The contextual relevance is high because the answer discusses PMI’s strategic moves around smoke-free and next-generation products. However, correctness and qualitative accuracy are reduced due to factual inaccuracies in categorization logic, unsupported numerical claims, and omission of the central point about licensed KT&G product inclusion and the formal reclassification into a unified smoke-free portfolio.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 585,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "Bristol-Myers Squibb's approach to business risk governance under the SEC Consent Order remained consistent between 2023 and 2024, with the business risk and disclosure group continuing to oversee compliance with the Consent's requirements. The 2024 filings reiterate the group's established role in monitoring sales practices, escalating compliance concerns, and ensuring adherence to the policy, with no new changes or enhancements noted compared to 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts and timeline. It correctly identifies that the business risk and disclosure group was established in response to the SEC Consent Order and remained operational in 2024 without changes. The dates (2023 and 2024) and entities (Bristol-Myers Squibb, SEC Consent Order, business risk and disclosure group) are accurate. There are no numeric values requiring verification, so quantitative accuracy is 10. However, the LLM omits specific details from the original answer about the formal review and certification process for SEC filings, the retention of an outside consultant to re-engineer accounting processes, and the governance mechanism for escalating compliance issues—key components of the 2023 implementation. While the LLM mentions monitoring sales practices and escalating concerns, it does not fully capture the scope of the group’s initial establishment or its integration into the ongoing compliance framework as emphasized in the ground truth. The reasoning is sound and contextually appropriate, showing correct multi-hop synthesis between years and compliance evolution, but with minor gaps in completeness. Thus, the correctness and qualitative accuracy scores are slightly reduced due to these omissions, though the core message remains semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 378,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "UNP's treatment of the relationship between its pension plan's expected return and asset allocation mix remained consistent between 2023 and 2024. Both years, the expected long-term rate of return on plan assets was set at **5.25%**, based on the asset allocation mix (targeting 20–30% equity and 70–80% debt) and historical performance, with adjustments for current market conditions. The 2024 document reiterated this approach, maintaining the same expected return rate despite changes in discount rates and actual returns, reflecting a stable methodology linking asset allocation to return assumptions.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The ground truth states that in 2023, UNP reported an actual return of 6%, not an expected return of 5.25%, and no actual return was disclosed in 2024. The LLM incorrectly claims the expected return was 5.25% in both years, which is not supported by the ground truth. Additionally, the ground truth emphasizes a shift in language—from a multifactor explanation (including historical returns and market conditions) in 2023 to a narrower 'depends on' asset allocation in 2024—indicating a change in disclosure approach. The LLM instead asserts consistency in treatment and methodology, directly contradicting the ground truth. (2) Quantitatively, the 5.25% figure is unsupported, and the 6% actual return for 2023 is misrepresented as part of a stable expected return assumption. The asset allocation ranges (20–30% equity, etc.) are not in the ground truth and appear fabricated. (3) The multi-hop reasoning fails: the model should have compared the qualitative evolution in disclosure language and transparency between years, but instead invents numerical consistency and ignores the shift in explanatory depth. (4) Scores are low because the core claim (consistency) is false, key numbers are incorrect, and the analysis misses the actual evolution in disclosure strategy. Contextual relevance is moderate because the answer addresses pension plan return assumptions and asset allocation, but with incorrect data and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 419,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "BNY Mellon maintained the accessibility of its Directors' Code of Conduct by posting it on its website in both 2022 and 2023, with no explicit changes noted in the disclosed pages. However, in 2023, the document emphasized the intention to disclose amendments or waivers of the code on the website, enhancing transparency. Integration into corporate governance reporting remained consistent, as the code was referenced in the \"Directors, Executive Officers and Corporate Governance\" section of both filings, though 2023 did not introduce new structural changes to its disclosure approach.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in describing the evolution of BNY Mellon's disclosure approach between 2022 and 2023. (1) Correctly notes that the Directors' Code of Conduct was accessible on the website in both years, which aligns with the ground truth. However, it incorrectly claims that 'no explicit changes' were made and that '2023 did not introduce new structural changes,' which contradicts the ground truth. The original answer clearly states that in 2023, the Code was no longer just referenced but was specifically listed among key governance documents like Corporate Governance Guidelines and committee charters, indicating a more structured and centralized disclosure approach. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—score reflects no errors in numbers/dates. (3) The multi-hop reasoning is flawed: the model fails to recognize the significance of the Code being explicitly grouped with core governance documents in 2023, which represents an important evolution in integration and presentation within corporate governance reporting. Instead, the LLM incorrectly concludes that there was no structural change. (4) The answer is contextually relevant and addresses accessibility and integration, but misses the key qualitative shift in how the document was positioned within the governance framework. This omission severely undermines the correctness of the response, warranting a low correctness and qualitative accuracy score despite accurate basic facts about website posting and section references.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 437,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "Oracle's strategic positioning of Oracle Database between 2023 and 2024 emphasizes enhanced deployment flexibility and integration with engineered systems, such as Oracle Exadata Cloud@Customer and OCI Dedicated Region, enabling secure on-premise and hybrid cloud deployments. This reflects Oracle's focus on supporting seamless cloud migration and hybrid IT environments by offering flexible deployment models (cloud, on-premise, hybrid) and integrating advanced capabilities like AI and machine learning into the Oracle Autonomous Database. These efforts underscore Oracle's commitment to providing scalable, secure, and interoperable solutions that align with evolving customer needs for multicloud and hybrid infrastructure.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of deployment models (on-premise, hybrid, cloud), mentions relevant engineered systems like Oracle Exadata Cloud@Customer, and correctly identifies Oracle's focus on hybrid IT and cloud migration. There are no numeric inaccuracies (quantitative accuracy is 10), as the answer avoids specific figures that could be incorrect. However, the LLM answer misses the key evolution highlighted in the ground truth: the strategic shift from flexible deployment of standalone databases in 2023 to deeper integration with engineered systems like Oracle Exadata Database Machine in 2024. While it mentions Exadata Cloud@Customer, it does not emphasize the 2024 pivot toward tightly integrated, full-stack engineered systems as a strategic evolution. Additionally, the LLM introduces 'OCI Dedicated Region' and emphasizes AI/ML in Autonomous Database, which, while plausible, are not mentioned in the ground truth and represent a slight misdirection in focus. The reasoning is sound but incomplete—multi-hop synthesis is partially achieved, but the conclusion about strategic maturation is less precise than the original. Contextual relevance is high as the response stays on-topic and addresses cloud migration and hybrid environments effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1523,
        "completion_tokens": 362,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "The formal review and certification process for SEC reports, established under the 2004 SEC Consent Order, remained consistent between 2023 and 2024. Both filings reaffirm the existing procedures, including a company-wide policy, governance mechanisms for escalating compliance concerns, regular monitoring, and the use of external consultants to refine financial reporting processes. No specific changes or enhancements to the process or governance procedures were noted in the 2024 filing compared to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of the formal review and certification process between 2023 and 2024. First, it incorrectly states that the process was established under a '2004 SEC Consent Order', which is entirely false—the ground truth specifies that the process was established in 2023 as part of a Consent agreement, not in 2004. This major error in date and context undermines the entire response. Second, the LLM claims no changes were noted in 2024, directly contradicting the original answer, which states that by 2024 the company had evolved the process from initial implementation to sustained enforcement and integration into broader operational frameworks like company-wide sales policies. This evolution is a key point missed by the LLM. While the LLM correctly identifies elements such as governance mechanisms, escalation procedures, and monitoring, these are generic similarities and do not reflect the actual progression described in the ground truth. The reasoning is flawed because it fails to perform the necessary multi-hop synthesis—comparing the 2023 implementation phase with the 2024 integration and enforcement phase. The answer is partially relevant to the question’s topic but fundamentally incorrect in timeline, causality, and progression. Quantitative accuracy is low due to the wrong year (2004 vs 2023), and qualitative accuracy suffers from incorrect entity relationships and lack of proper synthesis. Contextual relevance is moderate because the topic of SEC review processes is addressed, but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 442,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "Philip Morris International (PMI) expanded its heat-not-burn (HTN) product portfolio in 2023, emphasizing growth in HTU shipments (up 14.7% year-over-year) and strengthening market positioning in key regions like Europe and Japan. The 2023 report highlights increased HTU sales volume and adjusted in-market sales growth (14.8%), driven by brands like HEETS and Marlboro HeatSticks. Product categorization evolved to explicitly separate smoke-free products (including HTN, e-vapor, and oral nicotine) from Wellness and Healthcare, reflecting a more granular segmentation strategy to target reduced-risk product adoption. This aligns with PMI's broader shift toward positioning HTN as a core component of its smoke-free portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in PMI's product categorization and market positioning from 2022 to 2023 correctly—specifically, the explicit inclusion of heat-not-burn (HTN) within a broader smoke-free product segment alongside e-vapor and oral nicotine products. This aligns with the ground truth’s description of a more integrated and commercialized strategy. However, the LLM introduces specific quantitative claims—such as a 14.7% year-over-year increase in HTU shipments and 14.8% adjusted in-market sales growth—that are not present in the original answer and cannot be verified from the provided ground truth. These figures may be accurate in reality, but since they are absent from the knowledge graph-based answer, they represent unverified additions that undermine factual correctness. (2) The quantitative accuracy is low because the numbers cited (14.7%, 14.8%) do not appear in the original answer and were not part of the multi-hop synthesis supported by the knowledge graph. There is no mention of shipment volumes, sales growth percentages, or brand-level performance (e.g., HEETS, Marlboro HeatSticks) in the ground truth. (3) The qualitative reasoning is strong: the model correctly identifies the shift in categorization and positions HTN products as central to PMI’s smoke-free portfolio. It also correctly infers a strategic refinement in segmentation, separating smoke-free from Wellness and Healthcare, which reflects an accurate understanding of PMI’s evolving business structure. The mention of licensed KT&G products is missing, which is a notable omission regarding partnership expansion, but the overall trajectory of strategic integration is sound. (4) Contextual relevance is high because the response directly addresses the question about evolution in market positioning and product categorization between 2022 and 2023. Despite the unsupported numbers, the conceptual framing matches the intent and substance of the original answer. The score is reduced primarily due to the inclusion of unverified quantitative data not grounded in the source knowledge.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 567,
        "total_tokens": 1982
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "Oracle's strategic positioning of Oracle Database between 2023 and 2024 emphasized enhanced deployment flexibility and deeper integration with Oracle Cloud Infrastructure (OCI) and other technologies. In 2024, Oracle expanded deployment options to include hybrid and multicloud models, enabling customers to run workloads across on-premise data centers, OCI, and third-party clouds (e.g., Microsoft Azure). The Oracle Autonomous Database was further integrated with OCI services, Java Cloud, and Oracle APEX, while Oracle Database licenses remained flexible for cloud, on-premise, and hybrid environments. These advancements reinforced Oracle's focus on interoperability and adaptability, aligning with growing customer demand for seamless, multi-environment solutions.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's focus on deployment flexibility and integration with Oracle technologies between 2023 and 2024, and accurately notes continued support for cloud, on-premise, and hybrid environments. However, it misrepresents the core evolution described in the ground truth. The original answer emphasizes a strategic shift from deployment flexibility in 2023 to deeper integration within Oracle Engineered Systems (specifically Oracle Exadata) in 2024. The LLM answer omits any mention of Oracle Exadata or engineered systems as the key strategic evolution and instead emphasizes multicloud deployment with third-party clouds like Microsoft Azure and integration with Oracle Autonomous Database, Java Cloud, and APEX—details not present in the ground truth. While deployment flexibility is correctly noted, the central 2024 strategic shift toward engineered systems is missing. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are incorrect. (3) The multi-hop reasoning is partially sound: the LLM correctly infers continuity in deployment models and integration trends, but fails to synthesize the key shift from standalone database flexibility to engineered systems integration, which is the main evolution in the ground truth. The mention of third-party cloud integration (e.g., Azure) introduces information not supported by the original answer and may reflect external knowledge rather than the provided truth. (4) Correctness is scored 6 due to significant omission of the Exadata/engineered systems pivot and introduction of unverified integration points. Qualitative accuracy is 6 due to correct entities (Oracle, OCI, on-premise, hybrid) but incorrect emphasis and missing key strategic element. Contextual relevance is high (9) as the answer addresses deployment and integration themes directly related to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 534,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "BMY's strategic relationship with Krazati evolved from 2023 to 2024 through the acquisition of Mirati, the company that held Krazati's commercial rights. In 2024, BMY acquired Mirati for **$4.8 billion in total consideration** ($4.1 billion net of cash acquired), including **$12.00 per share contingent value rights (CVRs)** for Mirati shareholders, contingent on FDA acceptance of an NDA for PRMT5 Inhibitor within seven years. This acquisition integrated Krazati into BMY's oncology portfolio, solidifying its strategic fit and expanding BMY's capabilities in lung cancer therapies. The financial commitment in 2024 reflected this evolution through the upfront payment and potential contingent milestones.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of BMY's relationship with Krazati from 2023 to 2024. It correctly identifies the 2024 acquisition of Mirati for $4.8 billion (with $4.1 billion net of cash), which aligns with the ground truth. The mention of $12.00 per share contingent value rights (CVRs) tied to FDA acceptance of the PRMT5 Inhibitor NDA is factually correct and reflects the $1.0 billion contingent commitment in the original answer—this equivalence is valid, as the $1.0 billion figure represents the total potential payout implied by the CVRs. The answer explains the strategic evolution: from Krazati being part of BMY’s portfolio in 2023 to full integration via acquisition in 2024, including its FDA/EMA approvals and clinical development for first-line NSCLC (contextually accurate, though slightly less explicit than the original). The multi-hop reasoning is sound—linking Mirati’s acquisition to Krazati’s inclusion in BMY’s portfolio and interpreting the CVR as a financial commitment. The only minor shortcoming is that the LLM does not explicitly state the $1.0 billion figure, instead describing the per-share CVR amount, which requires inference to connect to the total value. While semantically equivalent, direct mention of the $1.0 billion would improve quantitative clarity. All entities (BMY, Mirati, Krazati, PRMT5 Inhibitor), years (2023, 2024), and strategic context are correct. Wording differs but meaning is preserved. No factual errors, making the answer contextually relevant and qualitatively excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 428,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "The 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV remained outstanding and fully and unconditionally guaranteed by The Bank of New York Mellon Corporation in both the 2022 and 2023 SEC filings. No changes in their treatment, structure, or status were explicitly noted between the two periods, as they continued to be listed as registered securities under the same terms in both filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly conveys that the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV remained unchanged between 2022 and 2023 in terms of their status, guarantee, and listing. All entities (Mellon Capital IV, The Bank of New York Mellon Corporation, BK/P trading symbol) and the percentage (6.244%) are accurate. The statement that the securities were 'fully and unconditionally guaranteed' and 'remained outstanding' aligns with the ground truth. The LLM correctly identifies no change in treatment or status, which is the core conclusion. The only minor omission is that the original answer explicitly mentions the securities are registered under Section 12(b) of the Act and listed on the NYSE—details the LLM implies by calling them 'registered securities' but does not specify. This does not affect factual correctness but slightly reduces completeness in technical precision. Quantitative accuracy is perfect: the rate (6.244%) and years (2022, 2023) are correct. Reasoning is sound: the model correctly synthesizes across two years of filings and draws the right conclusion of no change. Contextual relevance is excellent, directly addressing the evolution (or lack thereof) in treatment or status. Thus, the answer is semantically equivalent to the ground truth with only minor detail omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 373,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "PMI's short-term credit arrangements capacity increased from approximately $2.3 billion at December 31, 2022, to $2.7 billion at December 31, 2023, reflecting expanded committed facilities and uncommitted lines. Utilization (borrowings) rose slightly from $244 million in 2022 to $283 million in 2023. This suggests PMI maintained flexibility in liquidity management, leveraging increased capacity to support working capital needs while avoiding overreliance on short-term debt, indicating a stable near-term liquidity posture.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, PMI's short-term credit capacity was $1.9 billion at the end of 2022, but the LLM states $2.3 billion—a material overstatement of $400 million. Utilization in 2022 was $295 million (ground truth), but the LLM reports $244 million, underestimating actual drawdown by $51 million. While the 2023 utilization figure ($283 million) is correct, the 2022 figure is wrong, and the direction of change is misrepresented: ground truth shows a decrease in utilization, but the LLM claims it 'rose slightly', which is incorrect. (2) Calculations and comparisons are therefore flawed. The correct trend is a capacity increase from $1.9B to $2.7B with utilization decreasing from $295M to $283M, indicating improved liquidity headroom. The LLM incorrectly implies both capacity and utilization increased, altering the interpretation. (3) The multi-hop reasoning is partially sound—linking capacity, utilization, and liquidity posture—but based on incorrect data, leading to a misleading conclusion. The LLM suggests PMI used increased capacity to support working capital (implying higher drawdown), whereas the truth is they expanded capacity while reducing utilization, signaling a more conservative stance. (4) Contextual relevance is high—the answer addresses the right metrics and time periods and attempts to interpret liquidity posture. However, due to major quantitative errors affecting the core facts and resulting logic, the correctness score is low despite appropriate structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 440,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "Oracle's Autonomous Database has evolved between 2023 and 2024 by enhancing integration with other Oracle Cloud services (e.g., Java Cloud, Oracle APEX, and OCI Sovereign Cloud) and expanding AI-driven automation capabilities. In 2024, it emphasizes deeper integration with analytics tools like Oracle Analytics Cloud and third-party platforms, alongside advanced AI features such as generative AI for predictive maintenance and financial modeling. Automation capabilities were further refined with machine learning-driven diagnostics, automatic threat detection, and hybrid/multicloud deployment flexibility, enabling seamless workload management across on-premise, OCI, and third-party cloud environments.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Oracle's Autonomous Database positioning from 2023 to 2024 with respect to integration and automation. It accurately notes deeper integration with Oracle Cloud services such as Java Cloud and Oracle APEX, which aligns with the ground truth. However, it introduces 'OCI Sovereign Cloud' and 'Oracle Analytics Cloud' as integration points, which were not mentioned in the original 2024 description—these are plausible but not supported by the ground truth. Similarly, the mention of 'third-party platforms' and 'generative AI for predictive maintenance and financial modeling' goes beyond the documented focus on native machine learning, diagnostics, fault prediction, and error handling. The core automation enhancements—machine learning-driven diagnostics, automatic threat detection, and hybrid/multicloud deployment—are consistent with the 2024 emphasis. (2) There are no numeric values, dates, or financial figures in the response or ground truth, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is partially sound: the model correctly infers progression in integration and automation, but adds unverified elements (e.g., generative AI, third-party integration) not present in the source. This affects qualitative accuracy. (4) The answer is contextually relevant and addresses the key aspects of integration and automation evolution. While it adds some speculative details, the central thrust aligns with the ground truth, warranting a correctness score of 7 for minor overreach but solid core accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 444,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "GM's financial relationship with Ultium Cells Holdings LLC evolved between 2023 and 2024, with a reduction in committed capital contributions. In 2023, GM's maximum exposure to loss included **$0.8 billion** in committed capital contributions to Ultium Cells, down from **$1.4 billion** in 2022. In 2024, the document notes an **investment of $0.7 billion** in Ultium Cells, reflecting a continued strategic involvement but a further decrease in capital commitment compared to 2023. This suggests a strategic shift toward reduced direct financial support while maintaining a presence in the entity.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $0.8 billion committed contribution in 2023 and the $0.7 billion investment in 2024, which aligns with the ground truth. However, it introduces a fact not present in the original answer—namely, that the 2023 commitment was 'down from $1.4 billion in 2022'—which is unsupported by the provided ground truth and constitutes a factual overreach. This affects quantitative accuracy and reasoning. (2) The core numbers for 2023 and 2024 are accurate ($0.8B and $0.7B), but the inclusion of the $1.4B figure from 2022 is extraneous and unverified in the context of the ground truth, undermining quantitative precision. No calculation errors are present, but the comparison across years is incomplete and potentially misleading. (3) The multi-hop reasoning is partially sound: the model correctly infers a reduction in capital commitment and a shift from contingent to actual investment. However, it misses the key qualitative shift emphasized in the ground truth—namely, the change from a variable interest entity (VIE) where GM lacked control to a more direct strategic positioning with potentially greater influence. This critical aspect of strategic repositioning related to governance and control is omitted, weakening the qualitative accuracy. (4) The answer remains contextually relevant, addressing the evolution of GM's financial relationship and strategic involvement. While it captures the directional change in capital flow, it fails to fully convey the strategic realignment in terms of control and influence, instead framing the shift primarily as a reduction in financial support. Thus, the correctness score is moderate due to partial factual accuracy and incomplete synthesis of strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 480,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "Between 2022 and 2024, the financial impact of the Litigation Management Deed evolved as follows:  \n- In 2022, the Sixth Anniversary Release released **$3.5 billion** of as-converted value from Series B and C preferred stock, issuing **176,655** Series A preferred shares.  \n- In 2024, the Eighth Anniversary Release released **$2.7 billion** of as-converted value, issuing **99,264** Series A preferred shares.  \n\nThe as-converted value released decreased by $800 million, and the number of Series A shares issued declined by 77,391 shares, reflecting reduced litigation-related adjustments over time.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key factual information: $3.5 billion released in 2022 with 176,655 shares issued, and $2.7 billion released in 2024 with 99,264 shares issued. The calculated decrease in value ($800 million) and shares (77,391) are accurate. (2) Quantitative accuracy is perfect—numbers match the ground truth exactly, and the arithmetic (3.5B - 2.7B = 0.8B; 176,655 - 99,264 = 77,391) is correct. (3) The only minor issue is a slight inaccuracy in referring to 'Series B and C preferred stock' as the source of as-converted value, which is not mentioned in the original answer and introduces unsupported detail; otherwise, the multi-hop reasoning across 2022 and 2024 is sound and the conclusion about reduced financial burden is logically supported. (4) The answer is highly relevant, complete, and semantically equivalent to the ground truth, with only a small over-specification that does not undermine correctness. Thus, a score of 9 is justified—excellent but with a minor factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 297,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "Between 2023 and 2024, 3M's relationship with the Aearo Entities evolved through litigation resolution and business restructuring. In 2023, the Aearo Entities initiated Chapter 11 bankruptcy proceedings, leading to 3M deconsolidating them in Q3 2022 and reconsolidating them in Q2 2023 after the bankruptcy dismissal. The CAE Settlement in 2023, amended in January 2024, resolved Combat Arms Earplugs litigation with a $6.0 billion payment plan through 2029. This settlement significantly impacted 3M's financials, resulting in a $4.2 billion pre-tax charge in Q3 2023 and adjustments to business segment operating income, particularly in Safety and Industrial, where Aearo-related litigation costs were reflected as special items. The reconsolidation and settlement also influenced segment reporting, with adjustments to sales and operating income margins due to divestiture/acquisition impacts and litigation-related accruals.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the general themes of litigation and business adjustments. (1) Key errors include: the claim that Aearo initiated Chapter 11 in 2023 contradicts the ground truth, which states bankruptcy filings were dismissed in 2023 (not initiated); deconsolidation occurred in 2022 (correctly noted as Q3 2022), but reconsolidation is inaccurately tied to Q2 2023 without support in the original answer, which does not specify quarters; the $6.0 billion CAE Settlement payment plan and $4.2 billion pre-tax charge in Q3 2023 are not mentioned in the ground truth, which only states the settlement resolved claims with no specific dollar figures or charges; the impact on Safety and Industrial segment is fabricated, as the original answer specifies the Aearo Entities were referenced in the Transportation and Electronics segment in 2024. (2) Quantitative accuracy is low: all major numbers ($6.0B, $4.2B) are unsupported by the ground truth and appear to be hallucinated. The original answer explicitly states the income statement impact was immaterial, directly contradicting the $4.2B charge. (3) Reasoning is partially sound in structure—linking reconsolidation, litigation, and segment impacts—but fails on multi-hop synthesis: it misidentifies the timeline, financial impact, and business segment involved. (4) Contextual relevance is moderate: the answer addresses litigation and strategic adjustments as asked, but with incorrect details, making it misleading despite covering the right topics. The original answer emphasizes a shift from litigation resolution in 2023 to strategic financial reporting in 2024, which the LLM answer does not clearly reflect due to factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 481,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "Between 2022 and 2024, Class C Common Stock evolved in structure and earnings performance. In 2022, Class C had no transfer restrictions, and its basic EPS was $28.03, rising to $33.17 in 2023 and $38.97 in 2024. The 2024 filing notes that Class C shares are now fully transferable without restrictions, while Class B common stock was restructured into B-1 and B-2 classes via an exchange offer, impacting conversion rates and share counts. These changes, along with adjustments to preferred stock conversion rates, influenced EPS calculations by altering the as-converted share counts for all classes. Class C's EPS growth reflects improved financial performance, while its structural changes (e.g., transferability) align it more closely with Class A in marketability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2024, Class C Common Stock had a basic EPS of $33.17 and diluted EPS of $33.13, while Class A had $8.29 basic and $8.28 diluted. The LLM incorrectly claims Class C EPS was $28.03 in 2022, $33.17 in 2023, and $38.97 in 2024—none of which are supported by the ground truth, which does not provide 2022 or 2023 EPS for Class C. The ground truth only provides 2024 EPS comparisons between Class C and Class A. The LLM fabricates a trend over three years and inflates the 2024 figure. (2) The LLM introduces structural changes not present in the ground truth: it claims Class B was restructured into B-1 and B-2 classes via an exchange offer, that transfer restrictions were lifted on Class C, and that preferred stock conversion rates were adjusted—all of which are absent from the original answer. The ground truth notes no structural changes to Class C’s transferability or conversion mechanics, only that its financial performance (EPS) improved relative to Class A. (3) The multi-hop reasoning is flawed. The question asks about the evolution between 2022 and 2024, and the ground truth contrasts 2022’s focus on governance (voting rights, influence in mergers) with 2024’s strong EPS performance. The LLM invents a narrative around transferability and share class restructuring unsupported by evidence. It fails to mention the key 2022 context about divergent interests between Class C and Class A holders, which is central to the original answer. (4) While the LLM correctly identifies that Class C outperforms Class A in EPS by 2024 and attempts to discuss structural and financial evolution, the extensive fabrication of numbers and events severely undermines factual correctness. The contextual relevance is moderate because it addresses the right topic and direction of change, but the details are largely incorrect. Quantitative accuracy is very low due to made-up EPS figures and trends. Qualitative accuracy is partially correct in framing a shift toward financial performance but fails on entity and reasoning accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 572,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "Qualcomm's involvement in ADAS/AD technology expanded from fiscal 2022 to 2024, as evidenced by increased automotive segment revenue (from $1,509M in 2022 to $2,910M in 2024) and explicit categorization of ADAS/AD under automotive applications in the QCT segment. The 2024 filing highlights strategic R&D investments in ADAS/AD and XR, alongside broader expansion into automotive and IoT, reflecting a heightened focus on autonomous driving technologies.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qualcomm's evolving involvement in ADAS/AD from development to commercialization between fiscal 2022 and 2024, aligning with the ground truth's core narrative. It appropriately references increased automotive revenue and the re-categorization of ADAS/AD under automotive products, particularly in the QCT segment. However, the ground truth does not mention specific revenue figures ($1,509M in 2022, $2,910M in 2024), nor does it attribute ADAS/AD categorization specifically to the QCT segment—these are plausible inferences but not directly supported in the original answer. (2) The quantitative figures cited—$1,509M and $2,910M—are not present in the ground truth and cannot be verified from the provided information, making them potentially inaccurate or hallucinated. The ground truth emphasizes a qualitative shift (from investment to revenue-generating) without citing exact numbers. This significantly impacts quantitative accuracy. (3) The multi-hop reasoning is generally sound: the model infers progression based on revenue growth and categorization changes, which is consistent with commercialization. However, the original answer relies on strategic framing (from development via QSI/Qualcomm Ventures to revenue under automotive), not numerical trends. The LLM introduces a data-driven argument not present in the ground truth, weakening fidelity. (4) Despite the unsupported numbers, the LLM captures the essential evolution in Qualcomm’s strategy and correctly identifies the shift from R&D to commercialization. Wording differs but meaning is semantically close. Scores reflect strong qualitative and contextual alignment but reduced correctness due to unverified financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 475,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024 by expanding its mechanisms to manage litigation risk, including increasing the U.S. litigation escrow account balance from $1.4 billion (2022) to $3.089 billion (2024) through additional deposits. The plan's structure remained anchored on the escrow account, conversion features of class B stock, makewhole agreements, indemnification obligations, and loss-sharing arrangements. Notably, the 2024 amendments to the omnibus agreement extended coverage to opt-out cases, ensuring equitable liability allocation between Visa and Mastercard. This evolution reflects Visa's proactive approach to distributing litigation risk across multiple entities and financial instruments, while maintaining liquidity buffers to address potential liabilities from ongoing and future litigation.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of Visa's plan evolution and correctly identifies key mechanisms such as the escrow account, conversion features, indemnification, and loss-sharing arrangements, showing sound qualitative understanding and contextual relevance. However, it introduces specific numerical figures—$1.4 billion (2022) and $3.089 billion (2024)—that are not present in the original answer or ground truth, making the quantitative claims unsupported and factually inaccurate. The original answer does not mention any specific dollar amounts for the escrow balance, only noting that accruals could differ from escrow balances. Additionally, the LLM incorrectly states that the omnibus agreement amendments extended coverage to 'opt-out cases' and involved 'Mastercard,' which is a significant factual error; the original answer makes no mention of Mastercard or opt-out case coverage, and such a claim introduces a cross-company liability mechanism not supported by the ground truth. While the LLM correctly infers that the evolution reflects a proactive, diversified risk management strategy, the inclusion of fabricated numbers and erroneous entities (Mastercard) undermines factual correctness. The reasoning is logically structured and addresses all parts of the question, but the multi-hop synthesis fails due to incorrect data injection. Thus, while the overall framework is aligned, the answer contains critical quantitative and entity-level inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 407,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "Merck's financial stake in Lynparza, as reflected in alliance revenue, increased by 9% in 2024 to $1.311 billion from $1.199 billion in 2023, driven by higher demand in international markets. This growth, alongside the January 2025 approval of Lynparza in China for adjuvant breast cancer treatment, underscores its strategic importance and sustained performance. While the intangible asset value of Lynparza (part of licenses and other intangibles) remained at $1.5 billion in 2023, the revenue increase and expanded approvals indicate ongoing market success and Merck's continued commitment to the collaboration with AstraZeneca.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% growth in alliance revenue linked to Lynparza and attributes it to increased international demand, which aligns with the ground truth. It also accurately notes the January 2025 China approval for adjuvant breast cancer treatment, reinforcing strategic importance. However, the LLM introduces specific revenue figures—$1.311 billion in 2024 and $1.199 billion in 2023—that are not present in the original answer and cannot be verified from the provided ground truth. While a 9% increase from $1.199B to $1.311B is mathematically accurate (~9.3%), the original answer does not state these exact numbers, making their inclusion a factual overreach. (2) The original answer only confirms a '9% growth in alliance revenue' without specifying base or final amounts. Thus, while the percentage is correct, the dollar amounts are fabricated or inferred beyond available data, reducing quantitative accuracy. (3) The reasoning is otherwise sound: the model correctly synthesizes Merck’s financial stake via alliance revenue (not ownership), links performance to demand and regulatory milestones, and infers strategic importance from expansion—demonstrating good multi-hop logic across financial and regulatory data. (4) Contextual relevance is perfect—the answer directly addresses both the evolution of Merck’s stake and indicators of performance/strategic importance. The core facts (9% growth, intangible asset value in 2023, China approval) are correct, but the unsupported revenue figures prevent a higher score on correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 440,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "Between 2022 and 2024, Skoal's market position within Altria's oral tobacco products segment weakened, marked by a **16% decline in shipment volume** (from 163.1 million to 147 million units) and a **18% drop in retail share** (from 9.3% to 7.6%). This decline was driven by **lower shipment volume**, a **shift toward growing nicotine pouches** (on!), and a **non-cash Skoal trademark impairment** of $354 million in 2024. Competitors like on! gained market share, with the U.S. nicotine pouch category expanding to 42.9% of the oral tobacco market, while Skoal's traditional MST segment faced headwinds from declining demand and increased competition.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the LLM correctly states Skoal's retail share decline from 9.3% in 2022 to 7.6%, matching the original answer. The shipment volume drop from 163.1 million to 147 million units is factually correct and represents an ~9.8% decline, though the LLM's claim of an '18% drop in retail share' is slightly misleading—it should be an absolute 1.7 percentage point drop (from 9.3% to 7.6%), which is approximately an 18% relative decline (1.7/9.3 ≈ 18.3%), so this is semantically acceptable with clarification. The $354 million non-cash Skoal trademark impairment in 2024 is accurate and adds valuable context not in the original answer but consistent with Altria's filings. (2) The mention of on! gaining traction and the U.S. nicotine pouch category reaching 42.9% of the oral tobacco market is consistent with the broader trend in the ground truth, though the exact 42.9% figure is not in the original answer—this may come from external data but does not contradict it. (3) The qualitative reasoning is sound: the LLM correctly identifies declining demand, competition from nicotine pouches (especially on!), and internal performance issues as drivers of Skoal’s weakening position. It appropriately contrasts Skoal’s decline with on!’s growth, fulfilling the multi-hop requirement to compare competitive performance across brands and time. (4) The answer is contextually excellent, addressing market position evolution, competitive dynamics, and underlying causes. The only minor gap is the lack of explicit mention of Copenhagen’s decline (from 23.5% to 19.1%), which would have strengthened the comparative analysis, but the focus on on! as a key competitor is justified given its growth. Overall, the answer is factually strong, well-reasoned, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 500,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "The revenue contribution from Dynamics 365 within Microsoft Cloud increased from $5,437 million in fiscal year 2022 to $6,481 million in fiscal year 2023, representing a growth of approximately 19.2%. This reflects Dynamics 365's continued expansion as part of Microsoft's cloud offerings.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer provides specific numerical figures ($5,437 million in 2022 and $6,481 million in 2023) and a calculated growth rate of 19.2%, but these numbers are not supported by the original answer (ground truth). The ground truth does not provide exact revenue figures for Dynamics 365 in either fiscal year, only stating that Dynamics 365 revenue grew 39% in FY2022 and was part of the broader Microsoft Cloud revenue ($91.2B in 2022, $111.6B in 2023). There is no mention of Dynamics 365's standalone dollar contribution in the original data, making the LLM's precise figures factually incorrect. (2) The calculation of 19.2% growth from $5,437M to $6,481M is mathematically accurate, but since the inputs are fabricated, the result is invalid. The ground truth does not provide enough data to calculate Dynamics 365's exact growth in FY2023. (3) The reasoning fails on multi-hop synthesis: the LLM invents specific line-item revenue numbers not present in the source, rather than acknowledging the partial information available (i.e., growth rates in 2022, inclusion in Microsoft Cloud totals, lack of explicit 2023 growth rate). It incorrectly implies precise financial disclosures where none exist in the provided truth. (4) While the general direction of growth and relevance to Microsoft Cloud is contextually appropriate, the fabrication of exact figures severely undermines factual correctness. The contextual relevance is moderate because the answer addresses the right topic and trend direction, but the quantitative inaccuracy results in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 439,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "Merck's Balance Sheet Risk Management Program for foreign exchange exposure remained centered on forward exchange contracts and foreign currency debt in both 2023 and 2024. However, the scope of hedging activities expanded in 2024, as evidenced by a significant increase in the notional amount of foreign exchange contracts (from $12.75 billion in 2023 to $38.56 billion in 2024) and the addition of new interest rate swap contracts tied to long-term debt. The program continued to use forward contracts to hedge net investments in foreign operations, with unrealized gains/losses recorded in OCI, while euro-denominated debt served as economic hedges. The 2024 program also saw heightened activity due to the 2024 Restructuring Program, which likely increased exposure and necessitated broader hedging coverage.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent Merck's Balance Sheet Risk Management Program evolution from 2023 to 2024. (1) Quantitatively, the LLM invents specific notional amounts ($12.75 billion in 2023, $38.56 billion in 2024) and claims about interest rate swaps that are not present in the original answer or supported by the ground truth. These numbers are entirely fabricated. (2) The original answer states that forward contracts were not designated as hedges and marked to market through 'Other (income) expense, net', but the LLM incorrectly claims unrealized gains/losses were recorded in OCI, which contradicts the source. (3) The LLM incorrectly states that foreign currency debt and interest rate swaps were part of the program, and that euro-denominated debt served as an economic hedge—none of which is mentioned in the ground truth. (4) The original answer highlights the introduction of purchased local currency put options and collar options in 2024, along with a strategic layering approach based on cost-benefit assessments; the LLM omits these entirely and instead invents a connection to a '2024 Restructuring Program' with no basis in the provided information. (5) The core evolution—shift to a more structured program with new option-based instruments and dynamic hedging timing—is completely missed. While the LLM correctly notes forward contracts were used in both years, this single point does not compensate for the extensive inaccuracies. The answer is contextually relevant to the topic of FX risk management but fails on correctness and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 442,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "PayPal's direct investment in merchant financing products (PPWC and PPBL) increased from $1.7 billion in 2023 to $1.8 billion in 2024. The allowance for credit losses on merchant receivables decreased from $160 million as of December 31, 2023, to $113 million as of December 31, 2024, reflecting improved credit quality in the PPBL portfolio and reduced charge-offs ($38 million in 2023 vs. $10 million in 2024).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that PayPal purchased $1.8 billion in merchant receivables in 2024 (matching the ground truth), it fabricates data about a $1.7 billion investment in 2023, which is not mentioned in the original answer. The original answer states the outstanding balance was $1.2 billion in 2023 and $1.5 billion in 2024, not $1.7B to $1.8B in direct investment. Additionally, the LLM introduces specific figures for allowance for credit losses ($160M in 2023, $113M in 2024) and charge-offs ($38M in 2023, $10M in 2024), which are not present in the ground truth and cannot be verified. The principal and interest coverage ratio (9% in 2021, down from 23% in 2020) mentioned in the original answer is entirely omitted. (2) The only correct quantitative element is the $1.8 billion in receivables purchased in 2024. The rest of the numbers are either incorrect or fabricated. The original answer does not provide credit loss allowance figures for 2023 or 2024, so the LLM’s inclusion of such data misrepresents the information. (3) The reasoning partially captures the evolution toward greater direct involvement but fails to reflect the shift from risk disclosure (2022) to active investment (2024), which is a key multi-hop insight. The LLM focuses narrowly on fabricated financials rather than synthesizing the strategic shift in PayPal’s role. (4) The contextual relevance is high because the answer addresses merchant financing products (PPWC and PPBL) and discusses credit loss trends, but the correctness score is low due to major quantitative inaccuracies and omission of key historical context (e.g., 2022 risk methodology and coverage ratios). The qualitative accuracy is moderate because the direction of evolution (increased involvement) is correct, but the evidence used is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 507,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "The financial significance of smokeable products to Altria (MO) remained stable in terms of goodwill allocation, with $99 million in goodwill reported for smokeable products in both 2021 and 2020 (no 2022 data provided). Operating income for smokeable products increased slightly from $10,670 million in 2023 to $10,821 million in 2024, reflecting improved performance. However, overall operating income decreased by $306 million in 2024 due to factors like the Skoal trademark impairment and Initiative costs, which offset gains in smokeable products.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. It incorrectly states that the $99 million goodwill for smokeable products was reported in 2021 and 2020, while the ground truth specifies 2022 — no data for 2020 or 2021 is mentioned in the original answer. This misrepresents the timeline and omits the correct year (2022) from the question's scope. Additionally, the LLM claims goodwill was 'stable' with figures from 2020–2021, which contradicts the original answer’s point that no 2024 goodwill data is available, making any stability claim unsupported. (2) The operating income numbers are correct: $10,670 million in 2023 and $10,821 million in 2024, aligning with the ground truth. However, the LLM introduces external factors like 'Skoal trademark impairment' and 'Initiative costs' that, while possibly true, are not part of the original answer and distract from the focus on smokeable products. These additions are contextually relevant to MO’s overall performance but not directly responsive to the question about smokeable products’ financial significance. (3) The multi-hop reasoning is partially sound — it connects goodwill and operating income across years — but fails on the critical point of correctly attributing the $99 million goodwill to 2022 (not earlier years) and incorrectly implies data continuity into 2024 for goodwill. The original answer emphasizes that 2024 goodwill is undisclosed, suggesting a shift in reporting focus, which the LLM overlooks. (4) The correctness score is 4 due to major factual errors in dates and entities, despite accurate operating income figures. Quantitative accuracy is 5 because key numbers are correct but applied to wrong years. Qualitative accuracy is 5 due to flawed reasoning about goodwill stability. Contextual relevance is 8 because the answer addresses the right topic and metric types, even if with errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 510,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "The revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud increased from $13.816 billion in fiscal year 2022 to $16.372 billion in fiscal year 2023, reflecting a growth of approximately 18.5%. This is derived from the \"Revenue, classified by significant product and service offerings\" tables in the respective 10-K filings, where LinkedIn's revenue is explicitly listed as part of Microsoft Cloud.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its quantitative claims. The original answer (ground truth) states that Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was $91.2 billion in FY2022 and $111.6 billion in FY2023. However, the LLM incorrectly reports LinkedIn's standalone commercial revenue as $13.816 billion and $16.372 billion for those years, which is not supported by the ground truth. There is no mention in the original answer of LinkedIn's isolated revenue contribution, nor are the figures for LinkedIn's portion provided in the knowledge graph. The 18.5% growth calculation may be mathematically correct based on the numbers provided by the LLM ($13.816B to $16.372B), but it is based on fabricated data. The reasoning is flawed because it assumes that LinkedIn's revenue can be extracted from Microsoft Cloud revenue via a table in the 10-K, which contradicts the ground truth that only the combined Microsoft Cloud figure (including LinkedIn) is reported. The model fails to recognize that the original answer does not provide a breakdown of LinkedIn’s specific revenue, making the LLM’s detailed figures unsupported and factually wrong. While the answer attempts to address the evolution of revenue contribution and references appropriate sources (10-K filings), it invents precise numbers that are not present in the ground truth, leading to a very low correctness score. Contextual relevance is moderate because the answer discusses the right topic (LinkedIn's commercial revenue within Microsoft Cloud) and timeframe, but with incorrect specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 436,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "Between 2023 and 2024, Lynparza's commercialization expanded geographically with **China's National Medical Products Administration (NMPA) approving Lynparza in December 2024** for combination therapy in specific cancers, building on prior approvals in the U.S. (FDA) and Japan (MHLW). Revenue growth for Lynparza alliance revenue increased **9% in 2024**, driven by higher demand in most international markets, reflecting broadened market access and sustained therapeutic adoption.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% revenue growth in 2024 and references prior U.S. (FDA) and Japan (MHLW) approvals from 2023, which aligns with the ground truth. However, it incorrectly states that China's NMPA approval occurred in December 2024, while the ground truth specifies January 2025. This is a significant factual error in timing, though the approval itself is real and correctly attributed to the OlympiA trial for early breast cancer (though the LLM vaguely refers to 'combination therapy in specific cancers' without specifying the indication). (2) The 9% revenue increase is accurately reported. However, the date of the China NMPA approval is off by nearly a year—December 2024 vs. January 2025—which affects quantitative and temporal accuracy. While minor date shifts might be acceptable in some contexts, in regulatory timelines, this is a material discrepancy. (3) The reasoning is mostly sound: the model connects geographic expansion (approvals in key markets) with revenue growth, showing multi-hop synthesis between regulatory events and financial performance. It correctly infers that international demand drove revenue gains. However, it omits the specific therapeutic expansion into adjuvant treatment of high-risk early breast cancer, which is a key part of the commercialization evolution. (4) The correctness score is 7 because the core financial and strategic narrative (geographic expansion and revenue growth) is accurate, but the wrong approval date and lack of detail on the new indication reduce precision. Quantitative accuracy is 6 due to the incorrect date. Qualitative accuracy is 8 because entity identification (FDA, MHLW, NMPA, alliance revenue) and logic are strong, despite missing some specificity. Contextual relevance is 9 as the answer directly addresses the question’s focus on geographic and commercial evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 510,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "RTX's financial treatment of the Powder Metal Matter evolved between 2023 and 2024, with a reduction in its impact on future income tax benefits. In 2023, the Powder Metal Matter was reflected as a $644 million item in deferred tax benefits, while in 2024, it decreased to $455 million. This decline suggests a reduction in the tax benefits associated with the matter, likely due to resolution of tax positions, adjustments in estimates, or changes in temporary differences. The 2024 decrease indicates a lower future tax benefit compared to 2023, reflecting the evolving financial and tax implications of the matter.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $644 million in 2023 and $455 million in 2024 are accurately reported. The decrease of $189 million is implied (644 - 455 = 189), though the percentage decrease (29.3%) is not explicitly mentioned, which is a minor omission. (2) The entity 'RTX' and the 'Powder Metal Matter' are correctly identified, and the years 2023 and 2024 are properly referenced. (3) The reasoning is sound: the shift from a prior impact (implied in sales reduction in 2023) to a recognized future income tax benefit in both years is correctly interpreted, even though the 2023 treatment as a 'sales reduction' is not directly restated in the LLM answer. However, the core evolution — that the matter is now quantified in tax benefits and has decreased — is correctly synthesized. (4) The answer is contextually relevant, directly addressing the evolution in financial treatment and its impact on future tax benefits. The only minor shortcoming is the lack of explicit mention of the 2023 sales reduction aspect from the original answer, which slightly weakens the completeness of the multi-hop synthesis. Still, the focus on tax benefits in both years and the correct numerical trend justify a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 361,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "The borrowing capacity and terms of the Paidy Credit Agreement evolved as follows: In October 2021, PayPal acquired Paidy and assumed a secured revolving credit facility of approximately $198 million (¥50.0 billion) with an interest rate of Tokyo Interbank Offered Rate plus a margin of 0.40%–0.60%, as disclosed in the 2022 10-K. By September 2022, the facility was modified to increase borrowing capacity to ¥90.0 billion (approximately $574 million). In the 2024 10-K, the Paidy Credit Agreement is described as unsecured, with no remaining borrowing capacity as of December 31, 2024, and a maturity date of February 2027. The interest rate terms remained based on the Tokyo Interbank Offered Rate plus a margin, but the facility was fully drawn down by 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that PayPal acquired Paidy in October 2021 and assumed the credit facility at that time—this is context not present in the original answer and not required to answer the question. More critically, it claims the $198 million facility had an interest rate of 'Tokyo Interbank Offered Rate plus 0.40%–0.60%' in 2022, but the original answer states the interest rate terms were 'unspecified' in 2022, with the rate only introduced in 2024. This is a major factual error. Additionally, the LLM claims there was 'no remaining borrowing capacity' as of December 31, 2024, which contradicts the original answer stating the capacity was increased to ¥90.0 billion (~$574M) in 2024—implying available capacity unless fully drawn, which is not stated. The original answer does not say the facility was fully drawn, but the LLM assumes this. (2) Quantitatively, the $198M and ¥90.0B/$574M figures are correctly reported, as is the February 2027 maturity date. However, attributing the interest rate to 2022 is incorrect. The date of the modification (September 2022) is not in the original answer—this is an LLM fabrication. (3) The multi-hop reasoning is partially sound in that it attempts to track changes over time, but it introduces unverified details (acquisition timing, rate in 2022, full drawdown) and misrepresents the evolution of terms. The synthesis is flawed due to incorrect temporal attribution of terms. (4) Despite these issues, the answer is contextually relevant and structured around the correct entities and time frame. It captures the increase in borrowing capacity and shift to unsecured status, but fails on key qualitative and quantitative accuracy, especially regarding interest rate timeline and facility utilization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 496,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "Altria's reliance on long-term senior unsecured notes evolved between 2022 and 2024 through strategic refinancing and maturity extension. In 2022, Altria issued $5.5 billion in long-term notes to reduce near-term debt maturities and lower interest costs, extending the weighted-average maturity of its debt. By 2024, Altria had reduced total long-term debt to $24.9 billion from $26.2 billion in 2023, while maintaining a fixed-rate structure with a weighted-average coupon rate of ~4.3%. In February 2025 (within the 2024 fiscal year), Altria issued $1.0 billion in new senior unsecured notes (4.875% and 5.625%) to refinance maturing obligations, further stabilizing its capital structure. This reflects continued reliance on long-term notes for liquidity and debt management, with adjustments to maturity profiles and interest rates.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The original answer states that Altria's capital resources included long-term senior unsecured notes and $4.5 billion in cash in 2022, decreasing to $3.1 billion in 2024—this cash trend is a key indicator of potentially increased reliance on external financing. However, the LLM answer omits this critical cash information entirely and instead introduces unsupported numerical claims: issuing $5.5 billion in 2022, reducing total debt from $26.2B to $24.9B between 2023–2024, and citing specific coupon rates (~4.3%, 4.875%, 5.625%), none of which appear in the ground truth. (2) The mention of a February 2025 note issuance is problematic—it falls outside the 2024 timeframe and is presented as part of the 2024 fiscal year without clarification, risking temporal inaccuracy. (3) While the LLM correctly identifies continued reliance on long-term senior unsecured notes as a capital resource, it shifts focus to refinancing and maturity extension strategies not emphasized in the original answer, introducing details (e.g., weighted-average maturity, interest cost reduction) that lack grounding in the provided truth. (4) The reasoning is logically coherent—refinancing and debt management imply ongoing reliance on notes—but it fails to support this with the actual evidence from the ground truth (declining cash reserves). Thus, while the general direction (continued reliance) aligns, the factual basis, numbers, and supporting logic are largely fabricated or unsubstantiated, leading to a low quantitative accuracy score. The answer is contextually relevant and attempts multi-hop synthesis, but with incorrect data inputs, resulting in partial qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 477,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "RTX's financial treatment of the Powder Metal Matter evolved between 2023 and 2024, with the 2023 charge impacting net sales and cost of sales by $5.4 billion and $2.5 billion, respectively. In 2024, the matter's tax implications were reflected in deferred tax assets, showing a reduction from $644 million (2023) to $455 million (2024). This indicates that some tax benefits related to the Powder Metal Matter were realized in 2024, but the remaining deferred tax asset suggests potential future income tax benefits could still materialize, contingent on resolution of related tax matters.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the decrease in future income tax benefits from $644 million in 2023 to $455 million in 2024, which matches the ground truth and is factually accurate. However, it introduces new figures—$5.4 billion impact on net sales and $2.5 billion on cost of sales in 2023—that are not present in the original answer and cannot be verified from the provided ground truth. These numbers may be factually incorrect or misattributed, undermining quantitative accuracy. (2) The core financial figures related to deferred tax assets ($644M → $455M) are correct in amount and direction, but the addition of unverified sales and cost impacts reduces confidence in overall quantitative precision. Calculations (i.e., the decrease of $189M) are implied correctly, but not explicitly discussed. (3) The multi-hop reasoning is partially sound: the model correctly interprets the decline in deferred tax assets as an evolving financial treatment and links it to future tax benefits. However, the explanation shifts toward 'realized benefits' and 'contingent on resolution,' which goes beyond the ground truth’s straightforward interpretation of diminishing impact. This introduces speculative reasoning not supported by the original answer. (4) Contextually, the response addresses both parts of the question—evolution between years and implications for future tax benefits—and remains focused on RTX and the Powder Metal Matter. Despite incorrect additions and some interpretive overreach, the central trend is accurately captured, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 439,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "PayPal's utilization of the Paidy Credit Agreement evolved from an initial secured revolving credit facility of approximately $198 million (as of October 2021) to a significantly increased borrowing capacity of ¥90.0 billion (approximately $574 million) by 2024, following a September 2022 amendment. In 2024, the full $574 million was drawn down under the agreement, leaving no remaining borrowing capacity as of December 31, 2024. This reflects a substantial expansion in borrowing capacity and complete utilization of the enhanced facility during the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $198 million borrowing capacity in 2022 (originally referenced as of October 2021, which aligns with the context of the initial facility), and accurately states the 2024 borrowing capacity as ¥90.0 billion (~$574 million), with full drawdown. The ground truth notes $98 million outstanding as of December 31, 2021, leaving ~$100 million available, which the LLM does not explicitly mention. However, the LLM correctly infers the expansion and complete utilization by 2024. (2) All numeric values—$198 million, ¥90.0 billion, $574 million, and full drawdown in 2024—are factually accurate and consistent with the ground truth. The conversion from yen to dollars is appropriately approximated. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across time (2021 to 2024), recognizes the September 2022 amendment as the driver of capacity expansion, and concludes increased reliance on the facility. The only minor gap is the omission of the exact 2021 outstanding balance and remaining capacity, which slightly reduces completeness but does not affect the overall correctness. (4) The answer is contextually fully relevant, directly addressing the evolution in borrowing capacity and drawdown. The qualitative reasoning is strong, with accurate entity identification (PayPal, Paidy Credit Agreement), correct time periods, and logical synthesis. The score of 9 reflects near-perfect accuracy with a minor omission in initial utilization details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 421,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "The ownership structure between Accenture plc and Accenture Canada Holdings Inc. remained largely unchanged from 2023 to 2024, with noncontrolling interests held by Accenture Leadership members (less than 1% as of August 31, 2024) and exchangeable shares retained by pre-incorporation partners. These exchangeable shares could be converted to Accenture plc Class A ordinary shares on a one-for-one basis, with Accenture plc optionally redeeming them at market price. Class X ordinary shares, issued to partners, remained non-transferable and subject to redemption conditions tied to exchangeable shares. No significant changes in equity relationships or ownership percentages were disclosed.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that noncontrolling interests were less than 1% as of August 31, 2024, which aligns with the ground truth. It also accurately describes the one-for-one conversion of exchangeable shares into Accenture plc Class A ordinary shares and mentions the existence of Class X shares tied to exchangeable shares. However, it incorrectly claims that 'no significant changes' occurred between 2023 and 2024, which directly contradicts the ground truth that the equity relationship became more formalized and structured in 2024 with specific provisions around exchangeable and Class X shares. This misrepresents the evolution of the ownership structure, which is the core of the question. (2) Quantitatively, the <1% figure and August 31, 2024 date are correct. No calculations are required, so numerical accuracy is high. (3) The multi-hop reasoning is flawed: while the model identifies the correct entities (Accenture plc, Accenture Canada Holdings Inc., exchangeable shares, Class A and Class X shares), it fails to synthesize the change over time. The ground truth emphasizes an evolution from a simple noncontrolling interest disclosure in 2023 to a more structured, provision-based relationship in 2024. The LLM answer misses this progression and instead asserts continuity, indicating a failure in temporal and structural reasoning. (4) Contextual relevance is strong—terms and entities are appropriate and on-topic—but the qualitative inaccuracy in capturing the evolution undermines correctness. The answer provides accurate components but draws an incorrect overall conclusion about the lack of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 450,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "Merck's approach to managing balance sheet risk through forward exchange contracts between 2022 and 2024 remained consistent, focusing on hedging exposures in developed currencies (euro, Japanese yen, British pound, Canadian dollar, Swiss franc) and selectively using forward contracts for developing currencies like the Chinese renminbi based on cost-benefit analyses. The cost-benefit considerations included evaluating exposure magnitude, exchange rate volatility, and hedging costs, with short-term contracts (average maturities <6 months) to mitigate spot-forward differences. No significant evolution in currency focus or methodology was noted.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Merck's use of forward exchange contracts for balance sheet risk management and accurately lists developed market currencies (euro, yen, pound, etc.) and the Chinese renminbi as a developing market currency hedged selectively. It also correctly states that cost-benefit considerations included exposure magnitude, exchange rate volatility, and hedging costs, which aligns with the 2022 disclosure. However, the key error lies in asserting that there was 'no significant evolution' in approach, which directly contradicts the ground truth. The original answer highlights a notable shift between 2022 and 2024: while 2022 included explicit discussion of cost-benefit analysis and specific mention of the Chinese renminbi in developing markets, this detail was omitted in 2024, suggesting a change in emphasis or simplification. The LLM fails to recognize or report this evolution, instead claiming consistency, which is factually incorrect. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is high based on correct qualitative financial concepts (e.g., short-term maturities <6 months, spot-forward mitigation), though these details were not in the ground truth and may be extraneous. (3) The multi-hop reasoning is flawed: the question asks for evolution *between* 2022 and 2024, requiring comparison across years. The LLM synthesizes information within each year correctly but fails to detect the change in disclosure tone and content over time, leading to an incorrect conclusion about consistency. (4) Contextual relevance is strong—answer addresses currencies, cost-benefit analysis, and risk management—but the failure to identify the shift in disclosure results in a major factual inaccuracy, warranting a low correctness score despite accurate individual components.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 511,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "The change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024, reflected in the reduction of its deferred tax asset allocation from $644 million (2023) to $455 million (2024), suggests a decrease in the ongoing financial impact on future income tax benefits. This reduction indicates that RTX may have recognized some tax benefits related to the matter or adjusted its estimates, leading to a lower projected future tax benefit. The 2024 disclosure also notes a $212 million tax charge tied to a non-U.S. ruling, which could further affect the tax position, but the direct reduction in the Powder Metal Matter line implies a diminished long-term tax impact.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the reduction in the Powder Metal Matter's value from $644 million in 2023 to $455 million in 2024, accurately reflecting the shift in disclosure and its implication on future income tax benefits. It correctly interprets this change as indicating a diminished long-term tax impact, aligning with the ground truth's conclusion about reduced immediate negative impact and potential resolution. However, the LLM introduces a '212 million tax charge tied to a non-U.S. ruling' that is not present in the original answer or implied in the context provided, which adds extraneous information not supported by the ground truth. This could mislead about the cause of the change. (2) Quantitatively, the numbers $644 million and $455 million are correct, and the implied decrease of $189 million is accurate (644 - 455 = 189), though the LLM does not explicitly calculate or comment on the magnitude of change. The mention of a $212 million tax charge is unverified and not in the original, constituting a factual overreach. (3) The multi-hop reasoning is largely sound: the model correctly infers that a reduction in the deferred tax asset related to the Powder Metal Matter suggests recognition of tax benefits or revised estimates, and connects the shift from operational loss to tax asset treatment. However, the introduction of an unsupported tax charge weakens the reasoning chain. (4) The answer is highly contextually relevant, directly addressing the question about the change in disclosure and its implication on future income tax benefits. Despite the extraneous detail, the core logic and factual basis are strong, warranting a high score but not perfect due to the unsupported claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 473,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "PayPal expanded its merchant finance offerings between 2022 and 2024, increasing the scale of merchant receivables purchased from partner institutions. In 2024, PayPal purchased $1.8 billion in merchant receivables (up from $1.7 billion in 2023) and maintained an outstanding balance of $1.5 billion, net of participation interests. The company deepened its relationship with partner institutions through participation arrangements, where it sells participation interests in merchant receivables, while retaining servicing responsibilities. The allowance for credit losses on merchant receivables decreased from $160 million in 2023 to $113 million in 2024, reflecting improved credit quality and risk management in its merchant finance portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in merchant receivables purchased by PayPal from $1.7 billion in 2023 to $1.8 billion in 2024, and correctly states the outstanding balance of $1.5 billion as of December 31, 2024 (up from $1.2 billion in 2023), which aligns with the ground truth. However, it incorrectly states that the $1.5 billion outstanding balance is 'net of participation interests,' which is not mentioned or implied in the original answer and introduces a potentially misleading interpretation. Additionally, the LLM introduces a new figure—the allowance for credit losses decreasing from $160 million in 2023 to $113 million in 2024—which is not present in the ground truth and cannot be verified against it, representing a significant factual addition. (2) The quantitative values for receivables purchased ($1.8B in 2024, $1.7B in 2023) and total outstanding balance ($1.5B in 2024) are accurate, but the participation interest figures—$53 million in 2024 and $44 million in 2023 in the ground truth—are entirely omitted and replaced with unrelated credit loss allowance data. This omission and substitution reduce quantitative accuracy. (3) The qualitative reasoning is sound in describing the evolution of PayPal's relationship with partner institutions through participation interests and retained servicing, and the general trend of growth in scale and collaboration is correctly inferred. However, the model fails to mention WebBank as the specific partner institution in 2022 or the accounting treatment (derecognition of participation interests), which were key elements in the original multi-hop synthesis across years. (4) Despite these issues, the answer remains contextually relevant, addressing the evolution of PayPal's merchant finance offerings and partner relationships with mostly accurate data and logical interpretation, warranting a moderate score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 523,
        "total_tokens": 1981
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "Merck's alliance revenue from Lynparza increased from $1,116 million in 2022 to $1,311 million in 2024, reflecting a 9% growth in 2024. This growth was primarily driven by higher demand in most international markets, as noted in the 2024 report. Additionally, the 2023 revenue was $1,199 million, showing a 7% increase from 2022, with similar factors of international demand contributing to the trend. The expansion in international markets, including approvals in key regions like China, supported the revenue growth.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in the quantitative data. According to the ground truth, Merck's alliance revenue from Lynparza was $989 million in 2022, but the LLM incorrectly states it was $1,116 million in 2022 and $1,311 million in 2024. This implies a growth rate of approximately 17.4% ($1,311M / $1,116M), not 9% as claimed, making the calculation internally inconsistent as well. The ground truth confirms a 9% growth from $989M, which would place the 2024 revenue at approximately $1,078 million, not $1,311 million. Additionally, the LLM fabricates 2023 revenue of $1,199 million with a 7% increase, which is not supported by the original answer. (2) The qualitative aspects—such as the driver of growth (increased international demand) and the mention of regulatory approvals in key markets like China—are consistent with the original answer. However, the original specifies the China approval was in January 2025 (based on OlympiA trial), while the LLM only vaguely references 'approvals in key regions' without specifying timing or indication, missing a key forward-looking detail. (3) The multi-hop reasoning is partially sound in linking international demand and approvals to revenue growth, but the synthesis fails due to incorrect base figures and fabricated intermediate data. The model appears to confuse Lynparza revenue with another drug or misattributes figures from different contexts. (4) The contextual relevance is high because the answer addresses both parts of the question—revenue evolution and contributing factors—and uses appropriate terminology. However, the severe numerical inaccuracies and incorrect calculations drastically reduce the correctness and quantitative accuracy scores. Minor flexibility is allowed for phrasing, but not for core financial figures or growth rates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 500,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "PayPal's involvement in merchant receivables evolved between 2022 and 2024 through strategic risk management and portfolio adjustments. By 2024, the total merchant loans, advances, and interest receivables outstanding grew to $1.5 billion (from $1.2 billion in 2023), driven by expanded offerings like PPWC and PPBL. However, financial exposure decreased as the allowance for credit losses dropped to $113 million (from $160 million in 2023), reflecting improved credit quality in the PPBL portfolio. Operationally, PayPal shifted toward offloading risk by entering a multi-year agreement to sell eligible consumer installment receivables, reducing its balance sheet exposure while maintaining servicing roles for remaining portfolios.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $1.5 billion outstanding balance in 2024 (up from $1.2 billion), aligning with the ground truth. However, it introduces a figure of $113 million allowance for credit losses in 2024 (down from $160 million in 2023), which is not present in the original answer and contradicts the ground truth narrative of increased financial exposure through active purchases. The ground truth reports $1.8 billion in purchases in 2024 and $1.7 billion in 2023—data entirely missing from the LLM response. Instead, the LLM claims PayPal reduced exposure via a receivables sale agreement, which is not mentioned in the original and misrepresents the evolution as risk reduction rather than expansion. (2) Quantitative accuracy is partially correct: the $1.5B and $1.2B figures match, but the $113M and $160M allowance numbers are unsupported and likely incorrect in this context. The key purchase volumes ($1.8B in 2024, $1.7B in 2023) are omitted. (3) The multi-hop reasoning is flawed: the LLM infers a risk-offloading strategy, while the ground truth shows deeper engagement via direct purchases and full servicing. The mention of PPWC and PPBL is correct and contextually relevant, but the operational shift is misrepresented. (4) Scores reflect partial factual alignment on balance growth and product names, but major errors in financial exposure interpretation and missing core data on receivables purchases. Contextual relevance is high as it addresses the question's scope, but factual correctness is compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 442,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "Merck's involvement with Lynparza evolved from 2022 to 2024 with regulatory progress including FDA approval in the U.S. for adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer in 2022 (based on the OlympiA trial) and continued EU review in 2024. Revenue growth for Lynparza alliance revenue increased 9% from $1,116 million in 2022 to $1,311 million in 2024, driven by higher demand in international markets.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly identifies the 2022 FDA decision context and the 9% revenue growth in 2024, it incorrectly states that the FDA approval occurred in 2022—while the PDUFA date was in Q1 2022, the ground truth does not confirm approval was granted in that year. More critically, the LLM fabricates specific revenue figures: $1,116 million in 2022 and $1,311 million in 2024. The original answer only states that alliance revenue grew by 9% in 2024 due to international demand, but provides no 2022 or 2024 dollar amounts. The implied calculation (from $1,116M to $1,311M) is approximately 17.5%, not 9%, compounding the error. (2) The dates for regulatory progress are partially correct—the 2022 PDUFA date is accurate—but the claim about 'continued EU review in 2024' is not supported in the ground truth, which instead highlights a new approval in China in January 2025, indicating expansion, not ongoing review. The LLM omits this key global development. (3) The multi-hop reasoning is partially sound—linking regulatory progress and revenue trends over time—but fails in synthesis by inventing data not present in the source. It incorrectly implies precise revenue figures and growth trajectory across years without grounding. (4) Despite these issues, the answer addresses the core themes of regulatory progress and revenue growth, and the 9% growth mention aligns semantically with the original, even if misapplied. The qualitative reasoning about international demand is consistent. Hence, correctness is partially accurate but undermined by significant quantitative fabrication, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 457,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "Boeing's strategy with commodity purchase contracts between 2022 and 2024 maintained a long-term risk management horizon, with hedging arrangements extending through 2028 to mitigate price volatility. However, the company adjusted its financial exposure by reclassifying losses from accumulated other comprehensive income (AOCI) to earnings when forecasted transactions became improbable, as seen in 2022 ($50 reclassified) and expected in 2024 ($64 pre-tax). This reflects a dynamic approach to managing exposure, balancing long-term hedging with adjustments based on evolving market conditions and forecast reliability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Boeing extended its hedging strategy through 2031, but the LLM incorrectly claims it extends through 2028. Additionally, the ground truth reports a $46 million impact from a 10% commodity price change in 2022, while the LLM cites a $50 reclassification of losses from AOCI to earnings in 2022 and a $64 pre-tax amount expected in 2024—figures not present in the original answer and unrelated to the question about risk management horizon and exposure. These numbers are either fabricated or misattributed. (2) Quantitative accuracy is very low: none of the key numbers (2031 horizon, $46 million sensitivity) from the ground truth are correctly reported. The $50 and $64 figures have no support in the original data and appear to be hallucinated or drawn from an external, incorrect source. The 2028 end date is also incorrect—Boeing’s strategy goes to 2031, not 2028. (3) The reasoning is partially sound in that it attempts to describe a shift in Boeing’s risk management approach involving hedges and financial reclassifications, but it fails the multi-hop synthesis requirement. The original answer emphasizes a strategic shift from short-term hedging to a multi-decade horizon (2022 vs. 2031), which the LLM misses entirely by citing 2028 and focusing on AOCI reclassifications instead of the expansion of hedging duration. The core evolution—longer-term contracts for cost predictability—is misrepresented. (4) Contextual relevance is moderate because the answer discusses commodity contracts, hedging, and financial exposure, which are relevant themes. However, due to major factual and quantitative errors, the answer does not accurately reflect Boeing’s strategy evolution as documented in the ground truth. The focus on AOCI reclassifications, while potentially part of accounting practices, distracts from the central point about extended risk management horizons. Correctness score is low due to fundamental errors in dates, figures, and strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 558,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "Schwab's exposure to PALs remained fully collateralized throughout the period, with securities pledged in excess of borrowings as of December 31, 2021, and no allowance for credit losses was required for PALs in either 2021 or 2024. The 2024 disclosures confirm continued adherence to the collateral maintenance practical expedient under ASC 326, ensuring full coverage of PALs without additional credit loss provisions.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy regarding the allowance for credit losses in 2024. According to the ground truth, while no allowance was required in 2021 due to full collateralization, by 2024 there was a decrease in the allowance for credit losses—implying that an allowance existed and declined, contrary to the LLM's claim that 'no allowance...was required...in either 2021 or 2024.' This misrepresents the evolution of Schwab's credit risk management. The LLM correctly notes full collateralization in 2021 and references ASC 326 and the practical expedient, which aligns with the context of collateral coverage. However, it fails to acknowledge the shift in risk assessment approach described in the original answer—from reliance on collateralization to a broader evaluation of credit quality and projected loss rates. The statement about 'continued adherence' suggests static treatment, whereas the ground truth indicates a qualitative change in risk assessment methodology. Quantitatively, no specific dollar amounts or percentages are provided in either answer, so the response does not introduce numerical errors. Contextually, the answer addresses PAL exposure and credit risk, making it relevant. However, the failure to capture the key evolution in allowance treatment and risk philosophy results in a moderate correctness score. Multi-hop reasoning is partially sound but incomplete, as it does not synthesize the change over time correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 412,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "Between 2022 and 2024, Boeing's financial treatment of the 777X program evolved with increased R&D investments and cost pressures. In 2022, R&D expenses decreased compared to 2020 due to reduced spending on the 777X, but by 2023 and 2024, R&D expenses rose again, driven by continued investments in the 777X program and enterprise product development. Cost of sales increased in 2023 and 2024 due to reach-forward losses on the 777X and 767 programs, reflecting higher charges and lower margins. Strategic positioning emphasized sustaining R&D for the 777X despite financial challenges, with Boeing managing risks like delivery delays and potential order cancellations, while also navigating global trade and supply chain disruptions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. It incorrectly states that R&D expenses decreased in 2022 compared to 2020 due to reduced spending on the 777X, which contradicts the ground truth showing a $525 million increase in R&D in 2023 over 2022 and a further $435 million increase in 2024 over 2023—indicating rising, not falling, investment. There is no mention in the ground truth of R&D trends between 2020 and 2022, so asserting a decrease in 2022 is unsupported and misleading. (2) The ground truth specifies exact year-over-year R&D increases: $525M (2023 vs 2022) and $435M (2024 vs 2023), but the LLM answer omits these precise figures and instead vaguely references rising R&D in 2023 and 2024 without quantification. This represents a significant failure in quantitative accuracy. (3) The reasoning partially captures the shift in strategic positioning—from financial burden to investment priority—but fails to correctly trace the evolution due to incorrect R&D timeline claims. The mention of 'reach-forward losses' in 2023 and 2024 aligns with the 2022 context in the ground truth, but applying it to later years without clarification weakens the multi-hop logic. The LLM also introduces the 767 program, which is not mentioned in the original answer, adding irrelevant detail. (4) Despite these issues, the answer is contextually relevant, addressing financial treatment, R&D trends, and strategic positioning. It correctly identifies the 777X as a source of cost pressure and ongoing strategic focus. However, due to major quantitative errors and flawed timeline reasoning, the correctness score is low. The qualitative accuracy is moderate because the conceptual shift is partially recognized, and contextual relevance is high as the response stays on-topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 499,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "Schwab's risk management approach for Portfolio Against Loans (PALs) remained consistent between 2022 and 2024, relying on the practical expedient based on collateral maintenance provisions to estimate credit losses. The credit loss allowance methodology involved measuring allowances as the difference between amortized cost and the present value of expected cash flows, limited to fair value adjustments. Portfolio growth increased from $38.8 billion in 2022 to $42.3 billion in 2024, but the allowance methodology did not evolve significantly, reflecting continued reliance on collateralization to limit credit risk.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and omissions compared to the ground truth. While it correctly identifies Schwab's use of the practical expedient in 2022 due to collateralization, it incorrectly states that the allowance methodology did not evolve significantly by 2024. The original answer indicates a meaningful shift in risk profile — despite portfolio growth, the allowance for credit losses decreased as a ratio to year-end loans due to improved credit quality and lower projected loss rates — which reflects an evolution in risk assessment methodology, not just static reliance on collateral. The LLM fails to mention this key development. (2) The dollar figures provided in the LLM answer ($38.8B in 2022, $42.3B in 2024) are not present in the original answer and cannot be verified against the ground truth; thus, they are factually unsupported. The original answer mentions portfolio growth and a slight decrease in 2023 but provides no specific dollar amounts. This introduces false precision and undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound — the model connects PALs to credit loss methodology and portfolio trends — but it misses the synthesis between portfolio growth and declining allowance ratios, which is central to understanding risk evolution. It also omits the daily collateral monitoring and maintenance levels by security type, which are key risk management elements. (4) Contextual relevance is high because the response addresses the core topics: PALs, credit loss allowance, risk management, and portfolio growth. However, the inclusion of unverified numerical data and failure to capture the reduced risk profile despite growth limits qualitative and quantitative accuracy. The conclusion that the methodology 'did not evolve significantly' contradicts the ground truth's implication of refinement in risk modeling based on improved metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 521,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "MDLZ's notional amount of British pound sterling notes decreased slightly from $360 million in 2022 to $356 million in 2023. However, the after-tax loss on these hedges in 2023 ($8 million) compared to a gain in 2022 ($45 million) indicates volatility in fair value due to exchange rate movements. This suggests the company employs net investment hedges to manage foreign exchange risk, but the shift reflects ongoing exposure to currency fluctuations, with the 2023 loss signaling potential adverse impacts from unfavorable rate changes.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. The ground truth states that MDLZ's value of British pound sterling notes increased from $3 million in 2022 to $45 million in 2023. However, the LLM claims the notional amount decreased from $360 million to $356 million, which is factually wrong on both values and trend. These numbers do not match the ground truth and represent a more than 10x overstatement of the actual amounts. (2) The LLM introduces financial data not present in the original answer, such as an after-tax loss of $8 million in 2023 and a gain of $45 million in 2022, which are not mentioned or supported by the ground truth. The $45 million figure is misused—it is presented in the LLM answer as a gain in 2022, but in the original answer it is the 2023 value of the notes. This indicates a severe confusion or hallucination of data. (3) The multi-hop reasoning is flawed. The question asks about the change in value of pound sterling notes and what that shift indicates about FX risk management. The correct reasoning hinges on interpreting an increase from $3M to $45M as a strategic shift toward greater GBP exposure. The LLM instead discusses hedge gains/losses and net investment hedges, which are not supported by the provided truth and fail to address the actual change in notional value. (4) The contextual relevance is low because the LLM discusses hedging outcomes and volatility rather than the change in notional exposure. While foreign exchange risk management is relevant, the specific evidence used is incorrect. The qualitative accuracy is low due to incorrect entities (wrong amounts, wrong years, wrong metrics), and the reasoning does not align with the data. Only minimal credit is given for addressing the general topic of FX risk management.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 494,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "Amgen's interest rate disclosures for the 3.125% 2025 Notes show consistency in the **coupon rate** (3.125%) across both the 2022 and 2024 filings. However, the **effective interest rate** disclosures reveal a shift in hedging strategy: in 2022, the effective rate was **LIBOR + 1.8%**, while in 2024, it became **SOFR + 2.1%**. This transition reflects Amgen's adoption of **SOFR (Secured Overnight Financing Rate)** as the benchmark for floating-rate debt, replacing LIBOR, aligning with market trends and regulatory changes. The company's approach emphasizes **interest rate risk management** through swaps, maintaining a fixed coupon rate while adjusting the effective rate to reflect current market conditions and liquidity preferences.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the 3.125% 2025 Notes had a fixed interest rate of 3.125% with no variable rate terms, but the LLM incorrectly claims the effective rate was 'LIBOR + 1.8%'—this is not supported by the original answer and introduces a benchmark (LIBOR) and spread not mentioned. In 2024, the ground truth says the rate became SOFR + 2.1%, which the LLM correctly identifies, but it misrepresents this as an 'effective rate' due to hedging, whereas the original indicates a structural change in the note's rate (from fixed to floating), not just a swap or hedging adjustment. (2) The coupon rate of 3.125% is correctly preserved, but the introduction of LIBOR + 1.8% in 2022 is entirely fabricated and contradicts the ground truth that no variable rate was disclosed then. The SOFR + 2.1% in 2024 matches, but the interpretation is flawed. (3) The multi-hop reasoning fails because the LLM assumes a hedging strategy (swaps) and stable coupon with changing effective rates, while the ground truth describes an actual shift in the instrument's interest rate structure—indicating refinancing or repricing, not hedging. This misdiagnoses the nature of the change. (4) The contextual relevance is moderate because the answer addresses the right instrument and time periods and discusses SOFR transition, which is relevant, but the core factual and interpretive errors severely undermine correctness. The conclusion about risk management via swaps is speculative and unsupported by the data provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 435,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "Schwab's reliance on its Commercial Paper Issuance Program (CP Program) increased between 2022 and 2024 due to rising interest rates and market disruptions. In 2022, the CP Program was highlighted as a key source of external financing alongside uncommitted credit lines, with risks tied to credit rating downgrades and market volatility. By 2024, the document notes heightened reliance on the CP Program and supplemental funding sources (e.g., FHLB advances, brokered CDs) amid rapid interest rate hikes, which caused client cash reallocations and liquidity pressures. The 2024 filing emphasizes that higher rates exacerbated unrealized losses on securities portfolios, further stressing the need for the CP Program to maintain liquidity and meet regulatory capital requirements.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Schwab introduced and increasingly relied on its Commercial Paper Issuance Program between 2022 and 2024 in response to rising interest rates and market disruptions. The core facts—introduction in 2022 as a potential financing source, increased reliance by 2024, and use alongside other mechanisms like FHLB advances—are factually accurate and align with the ground truth. However, the LLM mentions 'brokered CDs' as a supplemental funding source, which is not present in the original answer; the ground truth specifies 'repurchase agreements' instead. This is a minor factual deviation. Additionally, the LLM introduces the point about 'unrealized losses on securities portfolios' and 'regulatory capital requirements,' which, while plausible in context, are not mentioned in the original answer and represent added reasoning not supported by the ground truth. (2) There are no numeric values, percentages, or dollar amounts in either the question or answers, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is largely sound: the model correctly synthesizes the evolution of Schwab’s funding strategy across years and links it to macroeconomic conditions (rising rates, client outflows). It correctly infers increased reliance on the CP program due to liquidity pressures. However, the substitution of 'brokered CDs' for 'repurchase agreements' and the addition of regulatory capital and unrealized losses go beyond the provided information, indicating a slight overextension in reasoning. (4) The correctness score is 8 because the central narrative and timeline are accurate, with only minor factual omissions and additions. Quantitative accuracy is 10 due to absence of numerical errors. Qualitative accuracy is 8 due to correct entity identification (Schwab, CP Program, FHLB advances, 2022–2024 timeline) but minor inaccuracies in funding mechanisms and unsupported inferences. Contextual relevance is 10—the answer directly addresses the question’s focus on the evolution of Schwab’s reliance on the CP program in response to market and rate conditions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 578,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "The 3.625% Notes due 2022 were redeemed in 2022, with associated interest rate swaps terminated. By 2024, the company issued 3.625% Notes due 2024, which were hedged with interest rate swaps tied to SOFR + 3.4%, reflecting a shift from LIBOR-based swaps (LIBOR + 2.7% for the 2022 notes) to SOFR-based structures. This evolution indicates a strategic adaptation to market benchmarks (LIBOR phase-out) and active interest rate risk management, maintaining flexibility in debt financing while aligning with evolving regulatory and market standards.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that the 3.625% 2024 Notes had a carrying value of $1,400 million in 2022 and were fully paid off by 2024. However, the LLM incorrectly claims that '3.625% Notes due 2022' were redeemed in 2022 and that new '3.625% Notes due 2024' were issued — this contradicts the ground truth, which indicates the same series (2024 Notes) existed in 2022 and were retired by 2024, not newly issued. There is no mention in the ground truth of new 3.625% Notes being issued in 2024. (2) Quantitative accuracy is poor: the $1,400 million carrying value in 2022 and $0 notional in 2024 are critical facts missing or misrepresented. The LLM introduces unverified figures like 'SOFR + 3.4%' and 'LIBOR + 2.7%', which do not appear in the ground truth and are therefore unsupported. (3) The multi-hop reasoning is flawed: instead of tracking the lifecycle of the same debt instrument (3.625% 2024 Notes) from 2022 to 2024, the model fabricates a sequence involving redemption of 2022 notes and issuance of new 2024 notes. It also incorrectly frames the shift as a change in hedging strategy (from LIBOR to SOFR swaps), while the ground truth describes an actual structural shift from fixed-rate to floating-rate debt. (4) While the LLM attempts to interpret strategic implications (e.g., adapting to SOFR, managing rate risk), this is based on incorrect premises. The contextual relevance is moderate because it addresses debt strategy evolution, but the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 438,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "Schwab's approach to providing financial support to variable interest entities (VIEs) remained consistent between 2022 and 2024, with no evolution in intent or conditions for funding commitments. As noted in Note 11 of both filings, Schwab did not provide or intend to provide financial support to VIEs beyond contractual obligations, and funding commitments were contingent on specific conditions. The maximum exposure to loss and commitment timelines (e.g., fulfillment between 2022 and 2025) remained unchanged, reflecting a stable approach to VIE involvement.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim that Schwab's approach remained consistent between 2022 and 2024. The ground truth shows a clear evolution: in 2022, Schwab explicitly stated it did not provide and did not intend to provide support beyond contractual obligations to VIEs. By 2024, Schwab updated its disclosure to acknowledge it may choose to provide credit, liquidity, or other support to its proprietary funds under stress conditions like significant valuation declines or redemptions—despite having no contractual obligation. This represents a meaningful shift toward a more proactive, discretionary support stance. The LLM incorrectly asserts no change occurred, directly contradicting the ground truth. While the LLM references 'Note 11' and mentions stable exposure and timelines (e.g., 2022–2025), these quantitative details are not disputed and are likely accurate, hence a moderate quantitative accuracy score. However, the qualitative reasoning fails entirely on multi-hop synthesis—failing to detect a change in intent across years. The answer is contextually relevant (addresses VIE support and funding) but draws the wrong conclusion, making it misleading overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 337,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023 through the sale of its developed market gum business in October 2023, which added $22 million in incremental net revenues and contributed to liquidity. Additionally, MDLZ's investment in JDE Peet's via €300 million in zero-interest exchangeable notes (issued in 2021) provided flexibility, allowing potential conversion to cash or shares, impacting capital structure. These actions enhanced liquidity and diversified MDLZ's financial positioning.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces factually unsupported information. (1) The claim that MDLZ sold its developed market gum business in October 2023 for $22 million in incremental net revenues is not present in the ground truth and is factually inaccurate in context. There is no mention of such a sale impacting the JDE Peet's relationship. (2) The reference to €300 million in zero-interest exchangeable notes issued in 2021 is not corroborated by the original answer and introduces specific financial instruments not mentioned in the ground truth, making it a significant factual error. (3) The original answer focuses on a reclassification of the investment relationship from 'Has_Stake_In' in 2022 to 'Invests_In' in 2023, emphasizing the change in accounting treatment and strategic posture, particularly regarding liquidity and capital structure flexibility. The LLM fails to mention this key conceptual shift, which is central to the question. (4) While the LLM attempts to address liquidity and capital structure, it does so using fabricated events and instruments rather than the actual evolution in reporting and strategic framing. The reasoning is therefore unsound and not aligned with the multi-hop synthesis required—linking changes in investment classification to implications for financial flexibility. (5) Despite being off-base factually, the answer remains thematically focused on liquidity and capital structure, which provides minimal contextual relevance. However, due to major errors in entities, dates, and financial details, the overall correctness is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 436,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "The interest rate hedging strategy for the 3.125% 2025 Notes evolved from using **LIBOR + 1.8%** in 2022 to **SOFR + 2.1%** in 2024. This transition reflects the shift from LIBOR to SOFR as the reference rate, with the effective interest rate under the swap agreements increasing slightly due to the change in benchmark. The swap terms remained aligned with the notes' maturity, ensuring continued alignment of fixed-rate debt with floating-rate exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error by stating that the 2022 interest rate under the swap was LIBOR + 1.8%, which is not supported by the ground truth. The original answer explicitly states that the exact rate for the 3.125% 2025 Notes swap in 2022 was not disclosed, only that swaps were terminated and reentered at then-current rates. This makes the specific 'LIBOR + 1.8%' figure entirely fabricated. The 2024 rate of SOFR + 2.1% is correctly reported and matches the ground truth, as is the notional amount of $1,000 million, though the LLM does not mention the notional amount. (2) Quantitative accuracy is low because one of the two key percentages (LIBOR + 1.8%) is incorrect and unsupported, while the other (SOFR + 2.1%) is accurate. The notional amount, though correct in the ground truth and relevant to the evolution, is omitted. (3) The reasoning partially captures the shift from LIBOR to SOFR as a benchmark, which is contextually sound given market trends, but incorrectly implies continuity in swap terms with specific rates when the 2022 rate was actually undisclosed. The multi-hop synthesis fails because the model invents a specific prior rate instead of acknowledging the lack of disclosure. (4) Contextual relevance is high because the answer addresses the evolution of the hedging strategy and the shift in reference rates, but correctness is undermined by the invented quantitative detail. The core factual error in the 2022 rate severely limits reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 417,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a decline of $249 million.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values for fiscal years 2022 ($5,819 million) and 2023 ($5,570 million) are accurate, and the calculated decline of $249 million is correct (5,819 - 5,570 = 249). (2) The answer addresses both parts of the question: the evolution (decrease from 2022 to 2023) and the magnitude of change ($249 million). (3) Entities are correctly identified: Walmart, 'fair value of equity investments', 'Level 2 inputs', and the correct fiscal years. (4) The reasoning is sound and reflects proper multi-hop synthesis across fiscal periods. The only minor difference is the omission of the word 'moderate' to describe the decline, but this is qualitative characterization and does not affect factual accuracy. The core information is semantically equivalent and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1113,
        "completion_tokens": 253,
        "total_tokens": 1366
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "Apple's characterization of its reliance on marketing abilities has remained consistent between its 2023 and 2024 10-K filings. Both documents explicitly state that the Company \"relies primarily on the innovative skills, technical competence, and marketing abilities of its personnel\" in the **Intellectual Property** section. Additionally, marketing and distribution capability are consistently listed as key competitive factors in the **Business** section of both filings. There is no indication of a shift or evolution in how Apple characterizes its reliance on marketing abilities between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Apple's characterization of its reliance on marketing abilities has 'remained consistent' between the 2023 and 2024 10-K filings. The ground truth shows a clear evolution in language: from 'relies primarily' in 2023 to 'depends heavily' in 2024, with added strategic context about ensuring a 'continual and timely flow' of competitive offerings. The LLM incorrectly asserts that the exact same phrase appears in both filings, which contradicts the ground truth. While there are no numeric inaccuracies (hence a high quantitative accuracy score), the qualitative analysis fails completely—Apple did shift its emphasis, particularly linking marketing abilities more directly to competitiveness amid rising imitation and price competition. The model also fails to perform the required multi-hop reasoning to compare the nuanced changes in language and strategic framing across the two years. The answer is relevant to the topic but fundamentally wrong in its conclusion, hence a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 301,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "The notional amount for the 3.625% 2024 Notes decreased from $1,400 million in 2022 to zero in 2024 due to their redemption. The interest rate structure shifted from LIBOR + 3.2% (as of December 31, 2021) to SOFR + 3.4% (as of December 31, 2023), reflecting a transition from LIBOR to SOFR benchmarks. This change indicates Amgen's hedging strategy adapted to evolving interest rate markets, terminating swaps tied to the 2024 Notes upon redemption to align with new benchmark rates and reduce counterparty risk.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it states the notional amount was $1,400 million in 2022, but the ground truth indicates that the $1,400 million figure was as of December 2023, not 2022. The ground truth also mentions a $5.2 billion swap termination in 2022 covering multiple notes including the 3.625% 2024 Notes, which the LLM omits entirely. The LLM incorrectly implies the decrease to zero was due to 'redemption' of the notes, while the ground truth attributes it to unwinding the hedge as the notes approached maturity. Additionally, the LLM cites an interest rate of LIBOR + 3.2% as of 2021, but this data point is not in the ground truth and introduces unsupported information. The shift to SOFR + 3.4% in 2023 is correctly noted. (2) Quantitative accuracy is low because key numbers are either misplaced in time (1,400 million in 2022 vs 2023) or invented (LIBOR + 3.2% in 2021). The $5.2 billion swap termination in 2022 is a major missing quantitative fact. (3) The multi-hop reasoning is partially sound—recognizing the shift from LIBOR to SOFR and linking hedge unwinding to maturity is reasonable—but fails to incorporate the full scope of Amgen’s 2022 swap termination and re-issuance, which is central to the hedging strategy. The conclusion about reducing counterparty risk is speculative and not in the ground truth. (4) Despite inaccuracies, the answer remains contextually relevant by addressing both the notional amount trend and rate benchmark transition, and correctly identifying the end state (zero notional in 2024). However, the omission of the $5.2 billion swap activity and incorrect timeline significantly reduce factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 465,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "Schwab retained the iRebal portfolio rebalancing solution as part of its offerings for independent advisory clients following the TD Ameritrade acquisition in 2020. By 2023, the integration was advanced, with approximately 90% of TD Ameritrade's RIA clients transitioned to Schwab, and the remaining transitions expected by 2024. This integration underscores Schwab's commitment to providing specialized tools like iRebal, enhancing its competitive positioning in the RIA market by offering customizable, high-value solutions that meet the needs of independent advisors, thereby attracting and retaining advisory clients.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies, particularly in timing and quantitative claims. It incorrectly states that Schwab retained iRebal 'following the TD Ameritrade acquisition in 2020'—while the acquisition did close in 2020, the original answer focuses on Schwab's strategic positioning of iRebal in 2022 and 2023, not 2020. This misaligns the timeline and omits the key evolution from 2022 (retaining iRebal) to 2023 (incorporating it as a core offering). Additionally, the LLM introduces a specific figure—'approximately 90% of TD Ameritrade's RIA clients transitioned to Schwab'—which is not present in the ground truth and cannot be verified from the provided data; the ground truth mentions $1.6 trillion in assets and 15 million accounts moved, but not client transition percentages. The mention of 'remaining transitions expected by 2024' is also absent from the original and introduces unverified forward-looking information. (2) Quantitative accuracy is low because the introduced percentage (90%) and implied timeline (2024 completion) are unsupported. The correct quantitative data from the original includes the $1.6 trillion in assets and 15 million accounts transitioned by 2023—none of which are mentioned in the LLM answer. (3) Qualitatively, the reasoning is partially sound: the LLM correctly infers that integrating iRebal strengthens Schwab’s competitive positioning in the RIA market and that offering specialized tools helps attract advisors. It captures the strategic intent and market implication, though it fails to explicitly note the shift from retention (2022) to core integration (2023), which is central to the multi-hop reasoning. (4) Contextual relevance is high because the answer addresses both parts of the question—evolution of iRebal integration and competitive positioning—and stays focused on Schwab, iRebal, RIAs, and strategic implications. However, the factual inaccuracies and missing key data from the ground truth limit correctness. Overall, the answer gets the general direction right but fails on precise facts and multi-hop synthesis of the 2022–2023 evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 572,
        "total_tokens": 2003
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "Apple introduced the iMac in the first quarter of 2024 as part of its Mac product line, as disclosed in its 2024 10-K filing. This marked a continuation of the iMac line, which had been a key product in the Mac segment. The 2024 filing noted increased Mac net sales compared to 2023, driven by higher laptop sales, suggesting the new iMac models contributed to this growth. While the 2023 filing (not fully visible here) likely referenced prior iMac iterations, the 2024 disclosure highlights the iMac's ongoing role in the Mac lineup, emphasizing Apple's focus on integrating design innovation and performance improvements in its desktop offerings.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but introduces inaccuracies and misses the core insight from the ground truth. It correctly identifies that the iMac is part of the Mac product line and that Apple discussed Mac sales in both years. However, it incorrectly states that Apple 'introduced the iMac in the first quarter of 2024,' which is not supported by the ground truth and misrepresents the nature of the 2024 disclosure. The original answer emphasizes a shift in how Apple *discussed* the iMac — from being a standard product in 2023 to a highlighted innovation in 2024 — not a new introduction. (2) There are no explicit numbers in the ground truth, so the LLM’s reference to 'increased Mac net sales' and attribution to 'higher laptop sales' and 'new iMac models' lacks direct support and introduces speculative causality not present in the original. While such data might exist in filings, the ground truth does not mention sales figures or growth drivers, so this addition is unsupported inference. (3) The multi-hop reasoning is partially sound — the model attempts to compare disclosures across years — but fails to capture the key qualitative shift in narrative emphasis that the ground truth identifies. Instead of noting elevated strategic positioning, it defaults to a product launch narrative, which distorts the actual evolution. (4) The contextual relevance is moderate because the answer stays within the topic of iMac evolution and 10-K disclosures, but the qualitative inaccuracy in reasoning and overreach in interpretation reduce correctness. The answer is plausible-sounding but factually misaligned with the ground truth’s focus on disclosure tone and strategic emphasis rather than product timing or sales impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 479,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "RTX issued the 2.820% Notes Due 2051 in August 2021 as part of a debt refinancing strategy to repay higher-yield obligations. These notes remained outstanding through 2024, reflecting their continued role in RTX's long-term debt structure. By 2024, the company's average long-term debt maturity had shortened to ~12 years from 15 years in 2021, indicating a shift toward shorter-term financing and lower interest rates (4.5% in 2024 vs. 4.2% in 2021). This evolution suggests RTX prioritized optimizing debt costs and managing maturity ladders, with the 2.820% Notes Due 2051 contributing to a more stable, lower-rate long-term capital structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the 2.820% Notes Due 2051 were issued in August 2021, while the ground truth indicates they were introduced in 2022. The principal amount of $1,000 million is not mentioned at all, which is a key quantitative fact. The claim that the average long-term debt maturity shortened from 15 years in 2021 to ~12 years in 2024 is unsupported by the ground truth, which does not provide maturity duration data for those years. Additionally, the interest rate comparison (4.5% in 2024 vs 4.2% in 2021) is fabricated; no such rates are mentioned in the original answer. (2) The ground truth emphasizes that the 2.820% Notes Due 2051 remained unchanged at $1,000 million between 2022 and 2024, and that total long-term debt increased from $40,078 million to $41,146 million over this period. None of these specific figures are mentioned or correctly calculated in the LLM response. (3) The multi-hop reasoning is flawed: the LLM fails to connect the stability of the 2051 notes with the broader expansion of RTX's debt portfolio, instead inventing a narrative about refinancing and maturity shortening that is not supported by the data. The synthesis across years and debt instruments is incorrect. (4) While the LLM attempts to address the evolution of RTX's debt structure and the role of the 2051 notes, it does so with fabricated data and incorrect timelines, leading to a low correctness score. Contextual relevance is moderate because the general topic (debt structure evolution) is addressed, but factual accuracy is severely lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 446,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "Between 2022 and 2023, Schwab's IDA agreement terms evolved primarily through a **reduction in service fees** and **reference rate adjustments**. In 2022, the amended IDA agreement lowered the service fee on client cash deposits at TD Depository Institutions from **25 basis points** to **15 basis points**. In 2023, Schwab transitioned from LIBOR to alternative reference rates (e.g., SOFR) as part of the LIBOR phase-out, but no further changes to service fees were disclosed. The 2023 adjustments focused on aligning the IDA with post-LIBOR benchmarks, while the 2022 change reflected a direct reduction in fees.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the key figures—25 basis points and 15 basis points—are accurately reported, with correct years (2022 for fee reduction, 2023 for reference rate transition). No calculations are required, but the temporal sequence and numerical values are precise. (2) The answer is complete, addressing both parts of the question: service fee changes in 2022 and reference rate adjustments in 2023. (3) Entity accuracy is strong: 'Schwab', 'IDA agreement', 'TD Depository Institutions', 'LIBOR', and implied use of SOFR (as a standard alternative) are all contextually accurate and correctly situated in time. (4) The reasoning correctly synthesizes a multi-hop evolution—first a fee structure change, then a benchmark transition—reflecting a shift in focus from cost to regulatory alignment. The LLM adds minor clarification (mentioning SOFR) that is consistent with industry practice and does not contradict the ground truth. Wording differs slightly but maintains semantic equivalence. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 315,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "The change in Filorga's financial treatment from a standalone reporting unit in 2023 to being grouped with other trademarks within broader segments in 2024 suggests a strategic shift toward integrating Filorga into a more consolidated brand portfolio. This realignment, without triggering goodwill impairment, indicates the company values Filorga's contribution to broader segments (e.g., North America) and likely employs a valuation approach that assesses its fair value within these segments using income-based methodologies. The move reflects Filorga's strategic importance as a key global trademark, emphasizing its role in enhancing overall brand ecosystems rather than operating as an isolated entity.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the change in Filorga's financial treatment from 2023 to 2024 and accurately references the $221 million goodwill figure from 2023, which matches the ground truth. There are no numeric inaccuracies, so quantitative accuracy is perfect. (2) However, the LLM introduces information not present in the original answer—specifically, the claim that the change occurred 'without triggering goodwill impairment' and that Filorga contributes to segments like 'North America'—which contradicts the ground truth stating Filorga was part of the Europe segment in 2023 and does not mention North America or impairment status. Additionally, the assertion about 'income-based methodologies' for valuation is speculative and not supported in the original. (3) While the model correctly performs the multi-hop reasoning of connecting changes in reporting structure to strategic implications, it draws a different qualitative conclusion—emphasizing increased strategic importance—whereas the ground truth suggests reduced visibility and potential downgrading in strategic priority due to loss of standalone reporting. This reversal in interpretation significantly affects qualitative accuracy. (4) The answer is contextually relevant and well-structured, addressing the core question about strategic importance and valuation approach, but the incorrect inferences reduce its factual correctness despite accurate numbers. Hence, correctness is scored as partially correct with significant reasoning deviations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 424,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "Apple's 2024 10-K filing includes detailed disclosures about the iPhone 16 Pro as part of its Q4 2024 product announcements, emphasizing features like Apple Intelligence and integration with generative AI models. This reflects a strategic shift toward highlighting technological innovation and ecosystem integration in product development. In contrast, the 2023 10-K focused on prior models (e.g., iPhone 15) and broader financial performance, indicating a move toward more granular, forward-looking disclosures about new product lines and their alignment with AI-driven advancements. This evolution underscores Apple's emphasis on transparency in innovation and its reporting strategy to underscore competitive differentiation through cutting-edge technology.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its factual claims. The ground truth states that in the 2023 10-K, Apple announced the iPhone 16 Pro as part of the Fourth Quarter 2024 product lineup, while in the 2024 10-K it is listed among existing products. The LLM incorrectly claims that the 2024 10-K includes 'detailed disclosures' about the iPhone 16 Pro as part of Q4 2024 announcements, which contradicts the ground truth — by 2024, the product should be established, not newly announced. Additionally, the LLM fabricates specific features like 'Apple Intelligence' and 'generative AI models,' which are not mentioned in the ground truth and cannot be verified from the filings. (2) There are no correct numbers, dates, or financial metrics referenced — the answer introduces speculative technological details without quantitative support. The timeline is also misrepresented: the 2024 10-K should reflect retrospective reporting, not forward-looking announcements. (3) The multi-hop reasoning is flawed. The core of the question hinges on the shift from forward-looking (planning/launch phase) to retrospective (established product) disclosure. The LLM instead invents a narrative about increasing granularity and AI focus, which is not supported by the ground truth. It fails to recognize the lifecycle progression of the product as reflected in the reporting shift. (4) While the answer attempts to address Apple's reporting strategy, it does so with fabricated content and incorrect characterization of the disclosures. The contextual relevance is moderate because it discusses product development and reporting strategy, but the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 467,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "Between 2022 and 2023, Schwab enhanced its Economic Value of Equity (EVE) simulations by incorporating interest rate swap derivatives into its risk management framework, which directly influenced modeling assumptions and balance sheet dynamics. In 2023, the company updated deposit beta assumptions in a declining rate environment, reflecting changes in non-maturity deposit behavior, and adjusted effective duration calculations to account for shorter liability durations amid rising rates. These updates, alongside increased margin loan and cash balances, altered assumptions about asset/liability sensitivity to interest rate shifts, improving the accuracy of EVE simulations in capturing balance sheet dynamics.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual alignment but introduces significant inaccuracies. While it correctly notes the 2023 update to deposit beta assumptions in a declining rate environment—consistent with the ground truth—it incorrectly states that interest rate swap derivatives were incorporated into the EVE framework, which is not mentioned in the original answer. It also references 'rising rates' and adjustments to 'effective duration' due to shorter liability durations, which contradicts the ground truth focus on declining rates and client cash allocation changes. The mention of 'increased margin loan and cash balances' altering assumptions is not supported in the original. (2) There are no explicit numerical values (e.g., percentages, dollar amounts) in either answer, so quantitative accuracy is assessed on temporal and conceptual precision. The years 2022 and 2023 are correctly used, but modeling assumptions are misrepresented. (3) The multi-hop reasoning is flawed: the LLM fails to identify the key evolution—incorporating client cash allocation changes into EVE simulations in 2023—and instead invents a narrative around derivatives and duration adjustments not present in the source. It misses the shift from static historical assumptions to a more dynamic modeling approach focused on client behavior. (4) The contextual relevance is moderate because the answer stays within the domain of interest rate risk and EVE modeling, but the qualitative inaccuracies and fabricated details reduce correctness. Core elements like non-negative yields, prepayment speeds, and the expanded role of client behavior are omitted or replaced with unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 462,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "Qualcomm's strategic shift from enabling wireless access point technologies through licensing (QTL segment) to directly producing them via its QCT segment in 2023 enhanced its competitive positioning by allowing greater control over technology integration and innovation. This vertical integration expanded its product portfolio breadth in the networking market, enabling deeper participation in edge networking and IoT applications, while reinforcing its leadership in 5G and wireless infrastructure solutions. The move likely strengthened its ability to offer end-to-end solutions, improving differentiation and market reach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Qualcomm shifted from enabling wireless access point technologies (via chipsets and foundational IP) in 2022 to directly producing them in 2023. The mention of QTL (licensing) and QCT (chipset) segments is consistent with Qualcomm's business structure and adds useful detail not in the original but factually sound. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2023) are correct. (3) The multi-hop reasoning is solid: the model correctly infers that moving from component supplier to full-system producer enhances competitive positioning through vertical integration and broader portfolio reach. It accurately captures the strategic implication—greater control, end-to-end solutions, improved differentiation. (4) The LLM adds value by referencing IoT and edge networking applications and segment strategy (QCT vs QTL), which are contextually appropriate and reflect deeper synthesis, though not explicitly stated in the original. The only minor gap is the lack of explicit mention of competitors like Broadcom and Intel, which the original includes to contextualize competitive positioning. However, the core claim about competing more directly in the ecosystem is preserved. Overall, the answer is semantically equivalent, slightly enriched, and factually correct—justifying a 9 on correctness and qualitative accuracy. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 428,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "From 2022 to 2023, Schwab's HELOC product saw a slight decrease in the percentage of adjustable-rate mortgages with interest-only terms, dropping from 28% in 2022 to 27% in 2023. Additionally, the portion of these interest-only loans not scheduled to reset for three or more years decreased from 89% in 2022 to 86% in 2023, reflecting a modest shift toward loans with shorter reset periods.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the percentage of adjustable-rate mortgages with interest-only terms decreased from 28% in 2022 to 27% in 2023, and the portion not scheduled to reset for three or more years decreased from 89% to 86%, as stated in the original answer. (2) The answer is complete, addressing both parts of the question—evolution in interest-only loan percentages and reset periods—across the two years. (3) Entity accuracy is correct: Schwab's HELOC product is the focus, and the years 2022 and 2023 are properly referenced. (4) The reasoning is sound and reflects the minor tightening in loan structure due to decreases in both metrics. The LLM correctly synthesizes multi-hop information (percentage of interest-only loans and their reset schedules) and conveys the same semantic meaning as the original answer, with slightly rephrased but equivalent wording. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 292,
        "total_tokens": 1520
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "Qualcomm's involvement in the XR market evolved from 2022 to 2023 through strategic investments and product development. In 2022, the QSI segment highlighted investments in XR as part of its focus on emerging technologies like 5G, AI, and IoT. By 2023, Qualcomm's QCT segment included XR devices within its consumer product revenue streams (e.g., under \"consumer\" applications), reflecting expanded product offerings. While QCT's XR-related revenue (e.g., consumer category) decreased slightly compared to 2022, the company continued investing in XR through QSI, emphasizing R&D for technologies like advanced SoCs and integrated chipsets tailored for XR applications. This indicates sustained strategic emphasis on XR despite revenue fluctuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While it correctly identifies Qualcomm's 2022 strategic investments in XR via Qualcomm Ventures (referred to as QSI), it incorrectly introduces segment-specific revenue dynamics—claiming that XR-related revenue in the QCT segment decreased slightly in 2023 compared to 2022. The original answer does not mention any revenue decline, nor does it attribute XR revenue to specific internal segments like QCT or QSI. This introduces false quantitative and structural claims. (2) There are no explicit numbers in the ground truth, so the LLM’s reference to revenue changes (e.g., 'decreased slightly') is unsupported and likely incorrect. The ground truth emphasizes a qualitative shift—from investment to direct revenue—not revenue fluctuations. Thus, the quantitative accuracy is partially compromised due to unsupported comparative statements. (3) The multi-hop reasoning is partially sound: the model recognizes a progression from investment to product integration. However, it mischaracterizes the nature of the evolution by focusing on R&D and segment-level revenue trends not present in the ground truth, and fails to emphasize the key point: the explicit inclusion of XR as a revenue-generating application in 2023 filings, marking commercialization. (4) Despite these issues, the answer remains contextually relevant, addressing both years, strategic investments, and product revenue. However, the introduction of unverified segment dynamics and revenue trends reduces factual correctness. Hence, the correctness score is 4—partially correct but with significant factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 460,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained at **$1,100 million** in both 2022 and 2024, as reflected in RTX's long-term debt schedules. This stability indicates that RTX did not repay or refinance these notes during the period, maintaining a consistent portion of its long-term debt structure. The notes' long maturity (2052) suggests a strategic focus on locking in lower interest rates for extended periods, while the overall reduction in total long-term debt (from $42.355 billion in 2023 to $38.726 billion in 2024) reflects refinancing or repayment of other debt obligations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the aggregate principal balance of the 3.030% Notes Due 2052 as $1,100 million in both 2022 and 2024, matching the ground truth exactly. This satisfies the quantitative core of the question. (2) All numeric values are accurate: the $1,100 million amount is correctly stated, and the additional context about total long-term debt decreasing from $42.355 billion in 2023 to $38.726 billion in 2024 is factually consistent with RTX's filings, even though not part of the original answer. These figures are correctly formatted and contextually relevant. (3) The multi-hop reasoning is sound: the model correctly infers that the stability in the note balance indicates no repayment or refinancing, and connects this to RTX’s broader debt management strategy, including the long maturity and interest rate lock-in. It also correctly contrasts the stability of this instrument with changes in other debt components. (4) The only minor shortcoming is that the original answer emphasizes 'strategic consistency in managing this portion of its capital structure,' while the LLM focuses more on interest rate strategy and overall debt reduction. This is a slight difference in emphasis, not a factual error. The LLM adds value with external context but doesn’t contradict the ground truth. Thus, the answer is highly accurate, complete, and relevant, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 415,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "AXP's focus on Corporate Card solutions has evolved to emphasize innovative products like B2B capabilities and expanded payment options, as highlighted in their 2024 strategy. This shift reflects a broader commercial payments strategy centered on differentiating through enhanced corporate card and accounts payable solutions, leveraging partnerships (e.g., Delta, digital partners), and deepening merchant engagement to drive spending and value for both businesses and Card Members. The emphasis on evolving value propositions and integrating advanced features underscores AXP's commitment to strengthening its leadership in commercial payments.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the general evolution of AXP's Corporate Card strategy between 2023 and 2024, and correctly identifies the emphasis on innovation and differentiation in commercial payments. There are no numeric inaccuracies (quantitative accuracy is 10) as the response does not introduce specific figures that could be incorrect. However, the LLM answer does not clearly distinguish the shift in focus from 2023 to 2024 as articulated in the original answer: in 2023, AXP focused on evolving value propositions and differentiating corporate card and accounts payable solutions, while in 2024 the emphasis expanded to integrated 'financing, banking and payment solutions'—a more holistic, solution-oriented approach. The LLM response mentions 'innovative products' and 'expanded payment options' but frames the broader strategy as continuity rather than a strategic evolution toward integration with wider business financial services. It also introduces specific partnerships (e.g., Delta) and 'deepening merchant engagement' that are not mentioned in the ground truth, which may add plausible context but are not supported by the provided knowledge graph. While the overall direction and intent are correctly captured (qualitative accuracy 7), the answer misses the nuance of a strategic shift from product differentiation to embedded, suite-based solutions. Contextual relevance is high (9) as it directly addresses the question and remains focused on AXP’s commercial payments strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 425,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "The strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal, and Home Care segment remained consistent between 2023 and 2024, as it continued to be listed as a principal global trademark under the segment. However, the provided documents do not specify any changes in its distribution channels or strategic emphasis during this period. The 2023 and 2024 filings highlight PCA SKIN's presence in the segment but lack detailed disclosures about evolving distribution strategies or channel adjustments.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is incorrect in its core claim that 'the provided documents do not specify any changes in its distribution channels,' which directly contradicts the ground truth. The ground truth clearly states that in 2024, Colgate-Palmolive expanded PCA SKIN's distribution channels to include sales to skin health professionals in some geographies—a key strategic refinement. The LLM fails to report this change, instead asserting a lack of information, which is factually inaccurate. There are no numerical values in this question, so quantitative accuracy is scored as 10 by default (no errors possible). However, the qualitative accuracy is low because the model fails to perform the necessary multi-hop reasoning: comparing the 2023 and 2024 filings to detect an evolution in distribution strategy. The answer is contextually relevant in that it discusses PCA SKIN’s status as a principal trademark, but it omits the critical update about distribution channel expansion, resulting in a misleading conclusion of 'no change.' Thus, while some entities and context are correct, the failure to identify and report a documented strategic shift severely undermines the answer’s correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 333,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "Between 2022 and 2023, Opdivo's strategic focus expanded to include new tumor indications and combination therapies, such as adjuvant treatment for melanoma and neoadjuvant combination therapy with chemotherapy for NSCLC, as well as monotherapy approvals in Europe. These expansions, alongside ongoing combination therapies with Yervoy, position Opdivo to maintain revenue growth despite patent expiration challenges for other products like Revlimid. The 2023 approvals and broader therapeutic applications are expected to drive sustained revenue growth by accessing new patient populations and treatment lines.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution of Opdivo between 2022 and 2023. It accurately captures the expansion into new tumor indications and combination therapies, specifically mentioning adjuvant melanoma and neoadjuvant NSCLC combinations, which reflect real-world regulatory advancements. The emphasis on monotherapy use in Europe and combination regimens with Yervoy is consistent with the original answer. The implication for revenue growth—sustained despite patent expirations (e.g., Revlimid)—is contextually appropriate and reflects strategic intent. However, the LLM omits specific mention of key 2022 indications (e.g., bladder, CRC, HCC, MPM, stomach cancers) and does not reference the subcutaneous formulation, a notable 2023 development highlighted in the ground truth that impacts long-term adoption. While the core reasoning and entity identification (Opdivo, Yervoy, NSCLC, melanoma) are accurate, this omission reduces completeness in multi-hop synthesis across all indications and delivery innovations. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect figures are cited), and the answer remains highly relevant to the question. The reasoning is sound but slightly less comprehensive than the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 366,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "American Express's investment in foreign government bonds and obligations remained at a fair value of $770 million in 2023 and $765 million in 2024, reflecting a slight decrease. The maturity distribution remained concentrated in the \"due after 10 years\" category for both years, with no changes in the allocation across maturity ranges.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect. The ground truth states that in 2023, American Express held $549 million in foreign government bonds, not $770 million as claimed by the LLM. The 2024 value is correctly stated as $765 million in the LLM answer, but the 2023 figure is wrong, leading to an incorrect conclusion of a slight decrease. (2) The maturity distribution is completely misrepresented: the LLM claims investments were concentrated in 'due after 10 years' for both years, while the ground truth shows that in 2023, all $549 million matured in 12 months or more (i.e., over one year), and in 2024, $764 million matured within one year and only $1 million after one year but within five years—indicating a shift to short-term maturities, not long-term. (3) The multi-hop reasoning is flawed: the LLM fails to recognize the significant increase in fair value from $549M to $765M and the dramatic shift in maturity profile from long-term to predominantly short-term. Instead, it incorrectly asserts no change and mischaracterizes the maturity buckets. (4) The contextual relevance is low because the answer discusses the right topic (foreign government bonds) and time frame, but with incorrect data and conclusions. Due to major factual errors in numbers, trends, and maturity distribution, the correctness score is 1. Quantitative accuracy is 1 due to incorrect dollar amounts and misrepresentation of trends. Qualitative accuracy is 1 due to flawed reasoning and entity/metric misattribution. Contextual relevance is 3 because the general subject is addressed, but details are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 442,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "Walmart's use of intercompany financing arrangements between 2022 and 2024 saw a reduction in cash not freely transferable to the U.S., decreasing from **$4.3 billion** (as of January 31, 2022) to **$3.3 billion** (as of January 31, 2024). In 2022, **$2.2 billion** of this amount required approval from Flipkart's minority shareholders for access via dividends or intercompany financing. By 2024, the restrictions shifted to noncontrolling interest shareholders, reflecting changes in ownership structures (e.g., acquisitions and settlements with Flipkart and PhonePe) and updated liquidity management practices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key quantitative figures: $4.3 billion in 2022 and $3.3 billion in 2024 for cash not freely transferable to the U.S., and the $2.2 billion subset requiring Flipkart minority shareholder approval in 2022. These match the ground truth exactly. The dates (January 31, 2022 and January 31, 2024) are appropriate fiscal year-ends for Walmart and align with reporting conventions. (2) Quantitative accuracy is perfect—no calculation errors, and the decrease from $4.3B to $3.3B is accurately represented. Format variations (e.g., writing out 'billion') are acceptable and clear. (3) The reasoning is sound: the shift from Flipkart-specific minority shareholder approval to a broader reference to noncontrolling interest shareholders is correctly interpreted as a structural evolution in intercompany financing arrangements. The mention of acquisitions and settlements with Flipkart and PhonePe adds context not in the original but is plausible and does not contradict the ground truth; however, this detail is not confirmed in the provided ground truth, slightly reducing qualitative precision. (4) The answer fully addresses both parts of the question—evolution in amount and in transfer conditions—and maintains semantic equivalence with the original answer. The only minor gap is the slight expansion on PhonePe/acquisition details beyond the ground truth, but this doesn’t introduce factual errors. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 437,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained consistent between 2023 and 2024, with fixed income securities and cash equivalents allocated at 80% and equity securities at 20% in both years. This aligns with the target allocation ranges of 75–85% for fixed income and 15–25% for equity. While the total fair value of plan assets slightly decreased from $264 million in 2023 to $248 million in 2024, the proportional allocation of fixed income and equity securities did not change.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the total plan assets and implied allocations. The ground truth states that total plan assets were $264 million in both 2023 and 2024, with fixed income at $210 million (79.5%) and equity at $54 million (20.5%). However, the LLM claims total assets decreased to $248 million in 2024, which contradicts the ground truth. While the LLM correctly notes that the *proportional* allocation remained unchanged, it inaccurately rounds the percentages to exactly 80% and 20%, whereas the actual figures are approximately 79.5% and 20.5%. (2) The calculation of percentages based on $210M and $54M out of $264M is ~79.5% and ~20.5%, not exactly 80/20. The claim of a drop to $248M is unsupported and incorrect, leading to a major quantitative error. (3) The reasoning correctly identifies that the allocation strategy did not change, which reflects sound qualitative understanding of the intent behind the question. It also appropriately references target allocation ranges, which may appear in filings, but this does not compensate for incorrect asset totals. However, the model fails the multi-hop verification by not confirming that both years report identical asset values. (4) The contextual relevance is high because the answer addresses the evolution (or lack thereof) in asset composition and discusses relevant categories. However, due to the incorrect total asset values and slightly inaccurate percentages, the quantitative accuracy is low. The qualitative reasoning is partially sound but built on false numerical premises, warranting a moderate score. Correctness is significantly penalized due to the false claim of a decline in total assets, which directly contradicts the ground truth of no change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 487,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "Honeywell's 2006 Stock Plan for Non-Employee Directors evolved between 2022 and 2024 through amendments, including an Omnibus Amendment in 2021 (Exhibit 10.30* in 2022) and further adjustments in 2024 (Exhibit 10.28*). These changes likely refined the plan's terms, such as award agreements, to align with broader compensation strategies or regulatory updates. The continued existence of the plan alongside newer plans (e.g., the 2016 Stock Plan) suggests a shift toward diversified director compensation, potentially emphasizing performance-based incentives or tax efficiency, while maintaining legacy structures for continuity.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its core claims. The ground truth states that in 2022, Honeywell referenced the 'Form of Option Agreement' (Exhibit 10.30) and 'Form of Restricted Unit Agreement' (Exhibit 10.32) under the 2006 Stock Plan, but by 2024, only the Option Agreement remained (Exhibit 10.29), with no mention of the Restricted Unit Agreement. The LLM incorrectly claims that the changes were due to an 'Omnibus Amendment in 2021' (Exhibit 10.30*) and a 2024 adjustment (Exhibit 10.28*), which misrepresents both the nature and timing of the changes. These exhibit numbers and amendment details are not supported by the ground truth. (2) Quantitatively, the LLM invents exhibit numbers and amendment dates not present in the original answer. There is no mention of an 'Omnibus Amendment in 2021' or 'Exhibit 10.28*' in the ground truth. The actual exhibits cited are 10.30 and 10.32 in 2022, and 10.29 in 2024—showing a removal of the restricted unit form. The LLM’s references are factually wrong, though it correctly identifies the 2006 plan’s continued existence. (3) The multi-hop reasoning is flawed. The question requires identifying specific forms of award agreements over time and inferring compensation strategy shifts. The LLM fails to note the disappearance of the restricted unit agreement, a key factual change. Instead, it fabricates amendments and implies broad refinements without evidence. It also incorrectly suggests the shift is toward 'performance-based incentives or tax efficiency'—a speculative claim not grounded in the exhibit list changes. The correct inference, per the ground truth, is a move toward stock options over restricted units. (4) The contextual relevance is moderate—the answer discusses director compensation evolution and plan amendments, which is relevant. However, due to factual inaccuracies and incorrect reasoning, the qualitative and correctness scores are low. The answer does not reflect the actual evolution in award forms, which is the central point of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 551,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "Walmart reduced its ownership stake in Flipkart from approximately 83% to 75% in fiscal 2022 through a $3.2 billion equity funding transaction. This reduction diminished Walmart's financial exposure to Flipkart's performance but introduced regulatory risks, particularly in India. By fiscal 2024, Flipkart faced ongoing investigations under India's Foreign Direct Investment (FDI) rules and antitrust regulations, with potential penalties or ownership restrictions if violations were confirmed. These matters could impact Walmart's financial position through indemnification obligations or operational adjustments, though no definitive financial exposure had materialized as of January 31, 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the reduction in Walmart's ownership stake from 83% to 75% and the $3.2 billion equity funding in fiscal 2022, which aligns with the ground truth. It also accurately notes the ongoing regulatory scrutiny in India by 2024, including potential FDI rule violations and antitrust investigations. The statement that no definitive financial exposure had materialized as of January 31, 2024, is consistent with Walmart's disclosure about inability to estimate losses. (2) All numeric values—percentages (83% to 75%), dollar amount ($3.2 billion), and fiscal years (2022, 2024)—are correct. The use of 'fiscal 2022' and 'fiscal 2024' is acceptable given that Walmart’s fiscal year ends in January, so these correspond to calendar years 2021–2022 and 2023–2024 respectively; this does not constitute an error. (3) The multi-hop reasoning is sound: the model correctly synthesizes financial implications (reduced ownership, partial exit) with regulatory risks (FDI investigations, potential penalties) and links them to Walmart’s exposure via indemnification obligations. However, it omits the specific detail that the show cause notice was issued in July 2021 and that the alleged violations occurred between 2009–2015—key context about the pre-acquisition nature of the risks—which slightly weakens the completeness of the regulatory timeline. (4) Despite this minor omission, the answer captures the core evolution: from financial de-risking through stake reduction to ongoing exposure via legacy regulatory issues. Wording differs but meaning is semantically equivalent. Scores reflect high accuracy with a slight deduction in qualitative accuracy due to missing pre-acquisition timeline details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 474,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "HON's total U.S. cash balances decreased from $11.5 billion in 2021 to $8.1 billion in 2023 but increased to $11.0 billion in 2024. The geographic distribution shifted significantly, with non-U.S. cash holdings rising to $8.0 billion (73% of total cash) in 2024, reflecting a strategic emphasis on diversifying liquidity across regions to support acquisitions and operational needs, as seen in the 2024 acquisitions of Access Solutions, CAES, and others.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that HON's U.S. cash balances were $11.5 billion in 2021 and decreased to $8.1 billion in 2023, which is not supported by the ground truth. The original answer states that $11.5 billion was reported as of December 31, 2021 (for the 2022 filing), and $11.0 billion as of December 31, 2024 (for the 2024 filing). The LLM introduces a figure for 2023 ($8.1 billion) that is not in the ground truth, and incorrectly frames the $11.5 billion as a 2021 balance rather than a year-end 2021 figure reported in 2022. Additionally, the LLM claims U.S. cash increased to $11.0 billion in 2024, but the ground truth specifies that only $3.0 billion of the $11.0 billion total was in the U.S. (since $8.0 billion was held in non-U.S. subsidiaries). (2) The $8.0 billion non-U.S. cash in 2024 is correctly cited, and 73% is approximately accurate (8/11 ≈ 72.7%), so that calculation is acceptable. However, the introduction of a $8.1 billion U.S. cash figure in 2023 and the misattribution of reporting years undermine quantitative accuracy. (3) The reasoning partially captures the shift in geographic distribution but misrepresents the trend by suggesting a rebound in U.S. cash in 2024 when the truth indicates a growing non-U.S. share. The strategic emphasis on diversification is correctly noted, and the mention of acquisitions (Access Solutions, CAES) adds context not in the ground truth but plausibly aligns with strategic rationale. However, this addition is speculative and not confirmed in the provided truth. (4) The contextual relevance is high because the answer addresses both total cash and geographic distribution, and attempts multi-hop reasoning. However, due to incorrect figures, timeframes, and mischaracterization of U.S. cash trends, the correctness score is limited to 5—partially correct but with significant factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 522,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "The financial treatment and liability estimation methodology for the Membership Rewards program remained consistent between 2023 and 2024, using the Ultimate Redemption Rate (URR) and Weighted Average Cost (WAC) per point to estimate liabilities. However, in 2024, the methodology was refined to include more detailed sensitivity analysis, such as quantifying the impact of a 25-basis-point increase in URR (which would raise the liability by ~$197M) and a 1-basis-point increase in WAC (raising it by ~$220M). Deferred fees for the program were still included in the \"Deferred Card and Other Fees, Net\" line item, with 2024 showing a net amount of $3,442M (compared to $3,027M in 2023), reflecting ongoing accruals for Membership Rewards program participants. The assumptions continued to rely on redemption trends, partner contracts, and program changes, with periodic reassessments of cost per point and redemption patterns.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several correct quantitative elements, such as the $197 million and $220 million sensitivity figures for URR and WAC changes, and the deferred fee amounts of $3,442M in 2024 and $3,027M in 2023. These numbers are factually accurate and correctly attributed to the respective years. However, the core qualitative claim—that the methodology 'remained consistent' between 2023 and 2024—is directly contradicted by the ground truth. The original answer clearly states that in 2023, only deferred fees were mentioned (a simpler approach), while in 2024, a more detailed, model-driven methodology using URR and WAC was introduced. The LLM incorrectly asserts that URR and WAC were used in both years, when in fact their explicit use and detailed disclosure began in 2024. This misrepresents the evolution of the methodology and fails the multi-hop reasoning requirement to compare the two years accurately. While the sensitivity analysis and deferred fee figures are correctly reported, the synthesis across years is flawed, leading to a major error in interpretation. The contextual relevance is high because the answer addresses the right topic and includes pertinent financial line items, but the reasoning and entity-level accuracy (specifically, the temporal attribution of methodology) are significantly off. Hence, the correctness score is low due to the fundamental inaccuracy in the evolution narrative, despite some correct numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 401,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "Adobe's integration of Frame.io into its Digital Media segment, completed in fiscal 2021, has evolved to deepen alignment with its broader product ecosystem by enabling seamless collaboration across Adobe's Creative Cloud and Document Cloud offerings. By integrating Frame.io with tools like Adobe Premiere Pro, After Effects, and Photoshop, Adobe enhanced real-time workflows for video creation and review, aligning Frame.io's capabilities with its AI-driven tools (e.g., Adobe Firefly) and cloud-based services. This integration supports Adobe's strategic focus on unified creative workflows, expanding Frame.io's role in its ecosystem to drive scalable content production and cross-platform collaboration.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the integration of Frame.io into Adobe's Digital Media segment and its alignment with key Creative Cloud applications like Premiere Pro, After Effects, and Photoshop, which aligns with the ground truth. It also captures the strategic emphasis on collaboration and workflow integration. However, it incorrectly states the acquisition was 'completed in fiscal 2021,' while the ground truth indicates the integration was discussed in 2022, following the $1.18 billion acquisition (which did close in late 2021, but the strategic positioning context starts in 2022). This misalignment in timing affects the evolution narrative between 2022 and 2024. Additionally, the LLM mentions integration with Document Cloud, which is not supported in the original answer—Frame.io's integration is focused on Creative Cloud, not Document Cloud. The mention of Adobe GenStudio in 2024 as a key indicator of deeper ecosystem integration is missing from the LLM response, representing a notable omission in completeness. (2) Quantitatively, the $1.18 billion acquisition amount is not mentioned, and the incorrect fiscal year (2021 vs. 2022 as the starting point of integration reporting) undermines quantitative accuracy. No other numbers are present, but the temporal misstatement is significant. (3) The reasoning is largely sound—multi-hop synthesis between Frame.io’s acquisition, integration into Adobe’s product suite, and strategic alignment with AI/cloud tools is logically presented. However, the failure to contrast 2022 (initial integration) with 2024 (core component, GenStudio inclusion) weakens the evolution narrative. (4) Despite these issues, the answer remains contextually relevant and captures the essence of Frame.io’s deepening integration, earning high marks for qualitative accuracy and relevance, but loses points for factual precision and completeness on key strategic developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 524,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "The fair value of equity-like funds within private alternative investments decreased slightly from $25.4 million (Level 3) in 2022 to $25.1 million (Level 3) in 2023, while the total equity-like funds increased from $4,014.1 million to $4,093.7 million. This reflects a minor reduction in Level 3 inputs (significant unobservable inputs) for these investments, with the majority of their valuation still relying on unobservable inputs, as no material transfers between valuation levels occurred during either period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect. According to the ground truth, the fair value of equity-like funds measured using Level 3 inputs increased from $5.5 million in 2022 to $25.4 million in 2023. However, the LLM claims the value decreased from $25.4 million in 2022 to $25.1 million in 2023, which reverses both the direction and magnitude of change. Additionally, the LLM introduces figures for total equity-like funds ($4,014.1M and $4,093.7M) and claims a 'minor reduction' in Level 3 inputs, none of which are present or supported by the original answer. (2) The quantitative inaccuracies are severe: the 2022 Level 3 value is wrong ($25.4M vs correct $5.5M), the 2023 value is slightly off ($25.1M vs correct $25.4M), and the narrative of a decrease contradicts the fivefold increase stated in the ground truth. Calculations and comparisons are therefore invalid. (3) The multi-hop reasoning fails completely — instead of identifying a significant increase in Level 3 valuation for equity-like funds, the model incorrectly infers a slight decrease and adds unverified context about total fund sizes and valuation stability. (4) The contextual relevance is low but not zero, as the answer addresses the general topic (Level 3 inputs in equity-like private funds), but with incorrect data and conclusions. Hence, correctness and accuracy scores are near minimum.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 386,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "Adobe integrated Frame.io into its Digital Media segment in Q4 2021, positioning it as a cloud-based video collaboration platform to enhance creative workflows. By 2024, Frame.io was further embedded into Adobe's Digital Media ecosystem, seamlessly integrated with tools like Adobe Premiere Pro and After Effects, enabling real-time feedback and streamlined production. It became a core component of Adobe GenStudio, supporting scalable content creation and enterprise workflows, reflecting its strengthened role in Adobe's creative and collaborative offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Frame.io's integration between 2022 and 2024. It accurately notes the post-acquisition integration beginning after Q4 2021 (aligned with the October 2021 acquisition) and the deepened integration by 2024. The mention of Frame.io being embedded in Adobe GenStudio and integrated with key tools like Premiere Pro and After Effects matches the ground truth. Minor omission: the LLM does not explicitly mention integration with Photoshop, Lightroom, and Workfront—only Premiere Pro and After Effects—making the answer slightly less complete but still substantially accurate. (2) Quantitatively, the dates are correct in substance: acquisition completed in late 2021 (Q4), with integration progress noted from 2022 onward. No financial figures are involved, so numerical accuracy is not applicable beyond timing, which is handled correctly with appropriate temporal framing. (3) The multi-hop reasoning is sound: the model synthesizes the timeline (post-acquisition to 2024), the strategic positioning (cloud-based collaboration), and the deepening integration into Adobe’s ecosystem. It correctly infers the strategic evolution from standalone platform to core component. (4) Scores reflect high accuracy with a minor completeness gap: correctness is 9 due to omitted integrations; quantitative accuracy is 9 due to correct use of timeframes; qualitative accuracy is 9 due to strong reasoning and entity identification; contextual relevance is 10 as the answer directly and appropriately addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 432,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "CVS expanded its Medication Management approach between 2022 and 2024 by enhancing digital tools and clinical programs. In 2022, the focus included UM, adherence programs like Pharmacy Advisor, and digital analytics for cost visibility. By 2024, CVS integrated AI-driven platforms like Canopy, expanded disease management (e.g., Weight Management for GLP-1 medications), and strengthened virtual care via MinuteClinic and Signify Health’s in-home evaluations. These advancements improved adherence, reduced costs through data-driven interventions, and incorporated advanced analytics and machine learning for personalized care plans.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of CVS's Medication Management approach from 2022 to 2024 with relevant themes: expansion of digital tools, clinical programs, and a shift toward integrated care. Contextually, it addresses the question well and maintains relevance throughout. Quantitatively, there are no explicit numbers (e.g., 239 centers, 27 states) in the LLM response, so no numeric inaccuracies are present—thus a high score for quantitative accuracy. However, the qualitative accuracy is lower due to several key factual discrepancies. The LLM incorrectly names 'Canopy' as an AI-driven platform used in Medication Management—this is not mentioned in the ground truth and cannot be verified as such. The 'Pharmacy Advisor' program is referenced without confirmation in the original answer. While the 2024 launch of the CVS Weight Management program with GLP-1 integration is correctly identified in theme, the LLM attributes it to 'disease management' without specifying the integration with lifestyle coaching or the brand name (NovoLogix platform is missing). The original answer highlights the NovoLogix preauthorization platform and Oak Street Health’s role in value-based care with 239 centers in 27 states—specific, multi-hop details that the LLM omits entirely. Instead, it mentions 'Signify Health’s in-home evaluations' and 'MinuteClinic' expansion, which are not in the ground truth and represent potential hallucinations or misattributions. The original emphasizes a shift from cost-containment to an integrated, digitally enabled model—this conceptual evolution is partially reflected but not clearly articulated. Thus, while the LLM answer is plausible and contextually relevant, it substitutes or invents specific programs and platforms, undermining factual reliability. Core elements like formulary management via the National Pharmacy and Therapeutics Committee, real-time benefit tools, and the seven-day opioid supply policy in 2022 are omitted. In 2024, the focus on enhanced analytics for lower-cost alternatives is mentioned in spirit but not tied to correct systems. Overall, the answer is directionally correct but factually inconsistent on key entities and initiatives, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 600,
        "total_tokens": 2068
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "Adobe integrated Frame.io into its Creative Cloud ecosystem in 2022 by enhancing collaboration workflows in Premiere Pro and After Effects, enabling native video editing collaboration. By 2024, Frame.io's integration expanded to include deeper integration with Adobe Photoshop, Lightroom, and Workfront, alongside features like \"Camera to Cloud\" for real-time on-set footage uploads and frame-accurate commenting. These enhancements strengthened cross-app collaboration, streamlined review processes, and extended Frame.io's role in scalable content production through Adobe GenStudio.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately identifies the 2022 integration of Frame.io into Creative Cloud with initial focus on Premiere Pro and After Effects, and the 2024 expansion to Photoshop, Lightroom, and Workfront. The 'Camera to Cloud' feature and real-time collaboration enhancements are correctly mentioned. (2) There are no numeric values requiring verification (e.g., dates like 2022 and 2024 are correct), so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the evolution from video-specific to broader creative collaboration is implied through expanded app integrations and functionality. However, the LLM mentions 'Adobe GenStudio', which is not present in the original answer and appears to be incorrect or speculative—no such platform is referenced in the ground truth, potentially confusing Frame.io with another Adobe product. This is a minor factual error affecting qualitative accuracy. (4) The answer is contextually relevant and addresses both parts of the question: evolution from 2022–2024 and specific collaboration enhancements. Missing explicit mention of support for still images, design files, and PDFs slightly reduces completeness. Overall, core facts and timeline are correct, with only minor omissions and one erroneous entity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 370,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "The use of recently executed transactions in valuing loans and other assets remained significant in both 2023 and 2024, but their role evolved in complexity. In 2023, loans were primarily valued using recently executed transactions, market price quotations, and models (e.g., discounted cash flow analyses) when transactions were unobservable. By 2024, the methodology expanded to incorporate more sophisticated techniques, such as benchmarking to comparable instruments and market-based models, particularly for nonrecurring fair value measurements. For held-for-sale loans, 2024 emphasized recently executed transactions and market prices, while also leveraging models to adjust for unobservable inputs like credit spreads and default probabilities. This reflects a broader reliance on transactional data alongside enhanced modeling to address liquidity constraints and improve precision in fair value determination.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of the use of recently executed transactions in fair value determination from 2023 to 2024. (1) The key factual elements are accurate: in 2023, transaction data were used alongside market quotes and models; in 2024, their use became more targeted, especially for held-for-sale loans, and extended to other assets. The LLM correctly identifies the continued significance of transaction data and the increased sophistication in valuation techniques. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable in a traditional sense—however, the years (2023, 2024) are correct and consistently used, earning full marks. (3) The multi-hop reasoning is sound: the model synthesizes changes over time and across asset categories, correctly identifying the shift toward more targeted application and integration with advanced models. However, the LLM slightly overemphasizes 'sophisticated techniques' and 'benchmarking to comparable instruments' not explicitly mentioned in the ground truth, and omits the specific mention of 'contingent lending commitments' and 'other investments' being valued using transaction data in 2024. It also does not explicitly mention the use of 'comparable company multiples' or 'implied yields' from 2023, which are part of the original answer. (4) Despite these minor omissions and slight rewording, the core meaning and evolution are accurately conveyed, warranting a high correctness score. Contextual relevance is perfect—the answer directly addresses the question’s focus on the evolving role of transaction data in fair value determination.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 464,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "Adobe's approach to Substance 3D Stager remained consistent between 2022 and 2024, positioning it as a core component of the broader Substance 3D ecosystem. In both periods, Stager was described as a tool for building and assembling 3D scenes, integrated with other Substance 3D apps like Painter (for texturing) and Sampler (for digitizing assets). The 2024 document emphasized its role within the ecosystem without introducing new positioning or functional changes, maintaining its focus on 3D scene creation and interoperability with the suite's tools.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that Adobe's approach to Substance 3D Stager remained 'consistent' between 2022 and 2024. The ground truth states that in 2022, Stager was only listed as a trademark with no detailed information about its functionality or strategic role, whereas by 2024, Adobe had explicitly positioned it as a tool for building and assembling 3D scenes within a broader, integrated ecosystem. This represents a clear evolution in strategic positioning, which the LLM answer incorrectly downplays. (2) There are no numeric values, dates, or calculations in the response, so quantitative accuracy is not applicable—no errors here, hence a score of 10. (3) The multi-hop reasoning is flawed: the model fails to recognize the shift from minimal public positioning (2022 trademark listing) to active integration into an end-to-end 3D workflow (2024). It incorrectly assumes consistent messaging across years without acknowledging the lack of detailed information in 2022. (4) While the LLM correctly identifies Stager’s function in 2024 and its integration with other tools like Painter and Sampler, it misses the core of the question—how the *approach evolved*. Instead, it asserts continuity where there was actually strategic development. This major omission in reasoning significantly reduces correctness and qualitative accuracy, though the response remains contextually relevant due to accurate mention of ecosystem tools and Stager’s function.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 413,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "GE's strategic positioning regarding grid-scale batteries remained consistent from 2022 to 2023, emphasizing their role as critical technologies for the energy transition. In both years, grid-scale batteries were highlighted as part of the necessary innovations to achieve deep decarbonization, alongside hydrogen, carbon capture, and advanced nuclear power. While the 2023 filing reiterated the importance of these technologies for enabling renewable energy integration and grid modernization, there was no explicit shift in strategic reliance or prioritization compared to 2022. GE continued to view grid-scale batteries as a key component of its long-term energy transition strategy, though the document did not detail increased emphasis or specific operational changes in this area.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that GE's strategic positioning remained consistent from 2022 to 2023. The ground truth shows a clear evolution: in 2022, grid-scale batteries were mentioned as 'emerging technologies that may become more important over time,' indicating a speculative, peripheral role. By 2023, they were explicitly integrated into the strategic narrative as a dependency—stated to be something decarbonization goals would 'depend in part' on—signaling increased strategic reliance. The LLM incorrectly concludes there was 'no explicit shift in strategic reliance,' which directly contradicts the documented progression from potential future investment to a more central, dependent role. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, the years (2022, 2023) are correctly referenced, earning full marks here. (3) The multi-hop reasoning is flawed: the model fails to synthesize the change in language and strategic framing across the two years. The shift from 'may become more important' (2022) to 'depend in part' (2023) represents a significant qualitative and strategic escalation that the LLM overlooks. This failure to detect nuanced but critical changes in wording undermines the reasoning. (4) While the answer is contextually relevant—discussing GE, grid-scale batteries, and energy transition—it misses the core of the question, which is about *evolution* and *increased strategic reliance*. By asserting continuity instead of change, the answer fundamentally misrepresents the truth. Correctness and qualitative accuracy are therefore low, despite correct entity and year identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 467,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "CVS Health did not report any broker quoted debt securities in its fair value disclosures for the years ended December 31, 2022 or 2024. The 2024 filing explicitly states, \"The Company did not have any broker quoted debt securities for the years ended December 31, 2024 and 2023,\" consistent with the 2022 disclosure. This indicates no evolution in the use of broker quoted debt securities. The absence of such securities means CVS relied on alternative valuation methods (e.g., internal analysis, matrix pricing) for Level 3 assets, with no material impact on financial reporting related to broker quotes.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that CVS did not have any broker quoted debt securities in both 2022 and 2024, accurately reflecting the core fact from the ground truth. It correctly cites the 2024 disclosure about the absence of such securities for 2024 and 2023, and implies consistency with prior years. However, the LLM answer states that the 2022 filing covers '2022 or 2024', which is a misstatement — the original answer clarifies that the 2022 filing refers to 2021 and 2020, not 2022. This is a minor but notable error in temporal alignment. (2) Quantitatively, all dates and years mentioned are factually consistent with the ground truth when interpreted in context; the error lies in the framing, not the numbers themselves. The LLM correctly avoids inventing figures and accurately represents the absence of securities. (3) The multi-hop reasoning is mostly sound: it connects disclosures across years and infers no change in practice. However, it misses the nuanced evolution in tone and emphasis highlighted in the ground truth — specifically, that the 2024 filing dropped mention of impact or review processes related to broker quoted securities, indicating reduced disclosure focus. This qualitative shift is omitted, weakening the completeness of the evolution analysis. (4) Despite this omission, the answer remains highly relevant and factually grounded, earning high marks for quantitative accuracy and contextual relevance. The correctness score is 8 due to the missed nuance in disclosure emphasis and slight misrepresentation of the years covered in the 2022 filing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 439,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "BlackRock's total equity securities at FVTNI increased from $1,429 million in 2023 to $1,556 million in 2024. Specifically, **equity securities/mutual funds** rose from $1,585 million (2023) to $1,950 million (2024), while **equity method investments** increased from $2,756 million (2023) to $2,783 million (2024). These changes reflect growth in both categories, with a more pronounced increase in equity securities/mutual funds.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported numbers. According to the ground truth, in 2023, equity securities/mutual funds were $1,211 million, not $1,585 million as stated by the LLM. Similarly, equity method investments in 2023 were $1,895 million, but the LLM incorrectly reports $2,756 million. The LLM also fabricates a total for 2023 ($1,429 million) and 2024 ($1,556 million), which do not match the sum of the components in the ground truth (e.g., $1,211M + $1,895M = $3,106M in 2023). Only the 2024 values for both categories ($1,950M and $2,783M) are correct. (2) Calculations are therefore flawed: the LLM implies a small increase in equity method investments from $2,756M to $2,783M (just $27M), whereas the actual increase is from $1,895M to $2,783M ($888M), a major growth. The increase in equity securities/mutual funds is overstated because the starting point is wrong ($1,585M vs correct $1,211M). (3) Multi-hop reasoning is partially attempted—comparing two years across two investment types—but fails due to incorrect data retrieval. The model appears to conflate or misattribute figures, possibly pulling numbers from different contexts or companies. (4) Despite incorrect numbers, the answer addresses the right categories and time frame, and correctly concludes growth in both areas, which maintains some contextual relevance. However, the severe quantitative errors undermine factual correctness, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 413,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "UnitedHealth Group evaluated credit-related impairments for available-for-sale debt securities by assessing the present value of expected cash flows, issuer financial conditions, and market factors. In 2022 (as of December 31, 2021), gross unrealized losses totaled $274 million, primarily due to interest rate increases, with no material allowance for credit losses. In 2024 (as of December 31, 2024), the Company continued this approach, noting that unrealized losses remained non-credit-related and the allowance for credit losses on available-for-sale securities was still not material. The evaluation process and treatment of impairments remained consistent, with no significant changes in methodology or allowance recognition between the periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual correctness but misses the key evolution described in the ground truth. It correctly states that in 2022, unrealized losses were due to interest rate increases and that the allowance for credit losses was not material as of December 31, 2021. However, it incorrectly claims the allowance remained 'not material' in 2024 and that there were 'no significant changes in methodology,' which directly contradicts the ground truth. The ground truth indicates a meaningful shift in 2024 toward a more formalized framework with an explicit allowance account and recognition of credit-related impairments through investment income—details entirely omitted by the LLM. (2) The LLM introduces a specific number—$274 million in gross unrealized losses in 2022—that is not present in the original answer and cannot be verified against the ground truth; this introduces unverified quantitative data. Dates are mostly accurate (referring to correct year-ends), but the use of 'as of December 31, 2024' for 2024 data is slightly misaligned since the original does not specify the exact date. (3) The multi-hop reasoning fails because the LLM does not synthesize the evolution over time—it treats both periods as consistent, missing the conceptual shift from qualitative assessment to structured accounting treatment. This is a critical failure in answering a question about how the evaluation and treatment evolved. (4) While the LLM captures the general context and uses appropriate terminology (e.g., present value of cash flows, issuer conditions), its qualitative inaccuracy undermines the core of the response. The contextual relevance is high because it addresses the right topic and structure, but the correctness score is low due to significant factual and conceptual omissions regarding the evolution of accounting practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 507,
        "total_tokens": 1945
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "Between 2022 and 2023, AMD's investment in the ATMP JV increased from $83 million to $99 million, reflecting a growth in the carrying value of the equity interest. Additionally, AMD's equity income from the ATMP JV rose from $14 million in 2022 to $16 million in 2023, indicating improved performance or higher gains from the joint venture during this period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value of AMD's investment in ATMP JV increased from $83 million in 2022 to $99 million in 2023, and equity income rose from $14 million to $16 million—both figures match the original answer exactly. (2) The answer is complete, addressing both parts of the question: evolution of investment value (carrying value) and equity income over the two-year period. (3) Entity accuracy is correct—AMD, ATMP JV, and the financial metrics (carrying value, equity income) are properly identified with correct years (2022 and 2023). (4) The reasoning is sound: the LLM correctly infers that the increase in equity income and carrying value indicates improved performance or higher gains, which is a logical conclusion from the data. There is no factual error, omission, or misinterpretation. The answer is semantically equivalent to the ground truth, with slightly rephrased but accurate language. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1176,
        "completion_tokens": 307,
        "total_tokens": 1484
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "UnitedHealth Group's exposure to tort claims remained primarily tied to medical malpractice and healthcare service delivery in both 2022 and 2024, with risks stemming from failures to adhere to clinical standards or provider misconduct. However, in 2024, the nature of claims expanded to include cybersecurity-related tort risks following a significant cyberattack on its Change Healthcare subsidiary, which involved protected health information. The potential financial impact in 2024 heightened due to the cyberattack's scale, emphasizing risks of data breaches, regulatory penalties, and litigation costs, alongside persistent challenges from medical malpractice claims.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in describing the evolution of UnitedHealth Group's tort claim exposure between 2022 and 2024, despite correct use of years and entities. (1) The original answer states that in 2022, UnitedHealth highlighted increasing medical malpractice claims and new legal theories that could bypass damage caps, with a focus on self-insured liabilities. In 2024, the concern shifted to broader clinical quality and patient safety issues, including reputational and business relationship risks. The LLM answer incorrectly introduces a 'cybersecurity-related tort risk' and a 'significant cyberattack on its Change Healthcare subsidiary' as a driver of tort claim evolution, which is not mentioned in the ground truth. While a real-world event, this detail is absent from the knowledge graph source and represents an unsupported addition. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default due to absence of numerical claims. (3) The multi-hop reasoning is flawed: the LLM fails to accurately synthesize the shift from narrowly defined malpractice liabilities in 2022 to broader systemic risks in 2024 related to care delivery standards; instead, it substitutes this with a cybersecurity narrative not present in the source. (4) Contextual relevance is moderate—the answer addresses tort claim exposure and financial impact over time, and correctly identifies healthcare service delivery as a consistent risk factor, but introduces irrelevant and unverified information about cyberattacks, undermining factual correctness. The core evolution described in the ground truth—expansion in legal theories and systemic risk—is missed entirely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 472,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "Boeing's three-year revolving credit agreement remained in effect through August 2025 in 2024, with its structure and capacity evolving by replacing shorter-term facilities. In 2023, the company entered into a $3.0 billion five-year agreement (expiring August 2028) and a $0.8 billion 364-day facility (with a one-year extension option), while retaining the legacy $3.0 billion three-year agreement. By 2024, the $0.8 billion 364-day and $3.2 billion five-year agreements were terminated, leaving the $3.0 billion three-year and $3.0 billion five-year facilities active, with $10.0 billion in unused borrowing capacity. This shift reflects a liquidity strategy focused on maintaining long-term flexibility, reducing short-term obligations, and leveraging extended credit lines to support operations while ensuring compliance with debt covenants and capital market access.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 Boeing had a $3.0 billion three-year revolving credit agreement expiring in August 2025. In 2024, Boeing entered a new $4.0 billion five-year agreement expiring in May 2029 and terminated two other facilities. The LLM incorrectly states that in 2023 Boeing entered a $3.0 billion five-year agreement (expiring 2028) and a $0.8 billion 364-day facility, which is not supported by the original answer. It also claims that by 2024, $3.2 billion five-year agreements were terminated—this figure does not appear in the ground truth. The unused borrowing capacity of $10.0 billion is fabricated and not mentioned in the original. (2) Quantitative accuracy is poor: none of the new agreements or terminations match the original. The $4.0 billion new facility in 2024 is completely omitted, and instead, a $3.0 billion five-year facility is incorrectly said to remain. The original specifies no $0.8 billion or $3.2 billion facilities. (3) Multi-hop reasoning is flawed—the LLM invents a complex structure of facilities not present in the ground truth and fails to correctly synthesize the evolution: replacing an expiring facility with a larger, longer-term one to improve liquidity. Instead, it describes a consolidation that never occurred. (4) Contextual relevance is moderate because the answer discusses credit agreements and liquidity strategy, aligning with the question’s intent, but the factual foundation is incorrect, undermining the analysis. The conclusion about long-term flexibility is partially aligned but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 451,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "The financial impact of the 2017 Performance-based Options evolved between 2023 and 2024 as follows:  \n- **Fair value of vested options**: Decreased from $56 million in 2023 to $52 million in 2024.  \n- **Intrinsic value of exercised options**: Rose significantly from $44 million in 2023 to $373 million in 2024, reflecting higher stock prices and increased exercise activity.  \n\nThis reflects a shift in the valuation dynamics of these options, driven by market conditions and vesting progress.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all factual information from the ground truth. The fair value of vested options decreased from $56 million in 2023 to $52 million in 2024, and the intrinsic value of exercised options increased from $44 million to $373 million—both figures match the original answer exactly. (2) All numeric values are accurate and properly formatted; no calculation errors are present. The comparison between years is correctly framed in terms of direction (decrease, increase) and magnitude. (3) The multi-hop reasoning is sound: the model synthesizes data across two years and two financial metrics (fair value of vesting vs. intrinsic value of exercise), correctly attributing the increase in intrinsic value to higher stock prices and exercise activity, which is a reasonable qualitative inference consistent with financial principles. (4) The answer is semantically equivalent to the ground truth, with slightly more concise formatting and an added explanatory note about market drivers, which enhances clarity without introducing inaccuracies. All parts of the question are addressed completely and correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 326,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "AMD's approach to estimating adjustments for product return rights remained consistent between 2022 and 2023, relying on historical data, known events, and economic conditions to assess returns and rebates for OEM and distributor customers. The methodology involved adjusting contract prices based on trended historical return rates, actual historical incentives, and market analysis, with no specific changes noted in the 2023 disclosures compared to 2022. Both years emphasized that estimates are subject to management judgment and could differ from actual outcomes, potentially impacting revenue and operating results.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that AMD's approach remained consistent between 2022 and 2023, when the ground truth confirms a clear evolution in methodology. Specifically, the LLM claims 'no specific changes noted in the 2023 disclosures compared to 2022,' which directly contradicts the original answer that highlights a shift toward a more structured application of ASC 606-10-32-8 through 14 and the use of the 'most likely amount' method for variable consideration. These specific changes are entirely omitted in the LLM response. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in numbers, dates, or calculations are present, hence a score of 10. (3) The multi-hop reasoning is flawed: the question requires identifying a change over time in accounting methodology, but the LLM fails to detect or report the shift in 2023 toward a more codified approach under ASC 606, which involves synthesizing information about accounting standards and changes in estimation techniques. This represents a failure in qualitative accuracy. (4) Contextual relevance is moderate—the response discusses product return rights, historical data, and management judgment, which are relevant topics, but it misses the core of the question: the evolution and specific methodological changes. Thus, while the content is on-topic, it is factually inaccurate in its central claim, warranting a low correctness score of 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 413,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "The number of shares under option for the 2017 Performance-based Options decreased from **1,549,080** at December 31, 2023, to **625,825** at December 31, 2024. This decline reflects significant exercise and forfeiture activity in 2024, with **905,219 shares exercised** (up from 183,704 in 2023) and **18,036 shares forfeited** (up from 3,114 in 2023). The sharp reduction indicates accelerated vesting and exercise of these options, likely driven by achievement of performance hurdles and favorable stock price conditions, alongside higher forfeiture rates due to employee turnover. This trend suggests a shift toward liquidity events (exercises) and reduced outstanding shares, with fewer unvested options remaining.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key numbers from the ground truth: the starting number of shares (1,549,080 in 2023), ending number (625,825 in 2024), shares exercised (905,219), and forfeited (18,036). These match the ground truth exactly and are calculated correctly (1,549,080 - 625,825 = 923,255 total reduction; 905,219 + 18,036 = 923,255, confirming internal consistency). (2) The quantitative accuracy is perfect—no errors in numbers, dates, or implied calculations. The LLM even adds comparative context (e.g., exercise and forfeiture numbers 'up from' prior year), which is not in the ground truth but does not contradict it and may be inferred from trend data. (3) The reasoning is sound and enhances the ground truth by explaining possible drivers (performance hurdles, stock price, turnover), which are plausible and contextually appropriate. The core multi-hop synthesis—linking the decrease in outstanding shares to exercise and forfeiture trends—is correctly executed. (4) The only reason for not giving a full 10 is that the original answer emphasizes the 'completion in the lifecycle' of the options as they approach final vesting, while the LLM focuses more on 'accelerated vesting' and external drivers. This is a slight shift in emphasis but not factually incorrect. Overall, the answer is semantically equivalent, highly accurate, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 387,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "Between 2022 and 2024, Optum Rx expanded its pharmacy care services by increasing specialty pharmaceutical spending from $45 billion to $74 billion and adding rare disease and gene therapy support services. It also enhanced integration of medical, pharmacy, and behavioral care through embedded pharmacists in patient care teams, emphasizing holistic, whole-patient treatment. Strategically, Optum Rx strengthened its role within UnitedHealth Group by aligning with Optum Health and UnitedHealthcare to advance value-based care, leveraging data analytics and clinical programs to improve outcomes, reduce costs, and address complex health needs across the broader health care ecosystem.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth states that in 2022, Optum Rx managed $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending. The LLM incorrectly claims that specialty pharmaceutical spending increased to $74 billion by 2024, which is not supported by the original answer—no specific spending figures were provided for 2024. This is a major quantitative error. Additionally, the LLM introduces new services such as 'rare disease and gene therapy support services' and 'embedded pharmacists in patient care teams,' which are not mentioned in the ground truth. While the strategic integration with Optum Health and UnitedHealthcare and the emphasis on data analytics and value-based care align broadly with the 2024 positioning, these enhancements are overstated and include fabricated details. (2) The only correct number is the $45 billion in specialty pharmaceutical spending in 2022; the claimed $74 billion in 2024 is unsupported and incorrect. No calculation is possible due to lack of 2024 data in the original. (3) The multi-hop reasoning is flawed: the model incorrectly infers growth and new service offerings without evidence, fails to acknowledge the absence of 2024 financial data, and invents programmatic expansions (e.g., embedded pharmacists, rare disease services) not present in the source. The synthesis across years is therefore invalid. (4) Despite the factual errors, the answer remains contextually relevant—it addresses the evolution of Optum Rx’s role and strategic positioning within UnitedHealth Group and touches on integration, data analytics, and care coordination themes from the original. However, the inclusion of fabricated metrics and services severely undermines correctness, warranting a low score overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 509,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "BlackRock's Equity Securities at FVTNI (Fair Value Through Net Income) decreased from $1,585 million as of December 31, 2023, to $1,950 million as of December 31, 2024. Specifically, investments held for deferred cash compensation plans, which are included in Equity Securities at FVTNI, dropped from $241 million in 2023 to $173 million in 2024. These investments are classified as Level 3 assets, reflecting unobservable inputs due to their reliance on internal valuations and hedging strategies. The decline likely stems from market valuation changes and adjustments to economically hedge deferred compensation liabilities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, BlackRock reported $9 million (not $241 million) in Equity Securities at FVTNI related to deferred cash compensation plans. The LLM incorrectly states that this amount dropped from $241 million to $173 million, which is factually wrong. Additionally, the LLM claims total Equity Securities at FVTNI increased from $1,585 million in 2023 to $1,950 million in 2024, but this information is not present in the ground truth and contradicts the focus of the question. (2) The only number that aligns between the LLM and the ground truth is the $173 million in 2024, but it is misattributed — in the ground truth, this amount is no longer classified under Equity Securities at FVTNI but under 'Investments related to deferred cash compensation plans' in the Equity Method section, indicating a reclassification. The LLM fails to recognize or report this critical reclassification. (3) The multi-hop reasoning is flawed: the question asks about changes in composition and valuation, particularly regarding deferred compensation investments. The ground truth highlights a reclassification (a structural reporting change), but the LLM interprets it as a simple decline within the same category, missing the key conceptual shift. The mention of Level 3 assets and internal valuations, while plausible, is not supported by the provided ground truth and introduces unsupported details. (4) The contextual relevance is moderate because the LLM addresses the general topic (deferred compensation investments and FVTNI securities), but due to major factual errors and failure to identify the reclassification, the answer is largely incorrect. Correctness and quantitative accuracy are low due to wrong numbers and misrepresentation of financial structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 502,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "Accenture's aggregate available authorization for its open-market share purchase program decreased from $3,129,296 as of August 31, 2022, to $2,694,281 as of August 31, 2024. This reduction suggests a shift in capital allocation strategy, potentially prioritizing other uses of capital, such as dividends or strategic investments, over share repurchases. However, the company later increased its authorization by $4 million in September 2024, bringing the total to $6,694,281, reflecting potential adjustments in long-term repurchase goals.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the decrease in aggregate available authorization from $3,129,296 in 2022 to $2,694,281 in 2024, which matches the ground truth and addresses the first part of the question. However, the LLM introduces new information not present in the original answer or implied by the question — specifically, that Accenture 'increased its authorization by $4 million in September 2024, bringing the total to $6,694,281'. This figure is factually inconsistent with the ground truth, which reports a decrease and does not mention any subsequent increase. The $6,694,281 figure appears to be a miscalculation or fabrication, as adding $4 million to $2,694,281 does not yield that number (it would be $6,694,281 only if $4 million were added to ~$2.69M, but even then, the timing and data source are unverified). (2) The initial numbers for 2022 and 2024 are quantitatively accurate, but the addition of the $4M increase and resulting total is unsupported and incorrect, undermining quantitative accuracy. (3) The reasoning for a shift in capital allocation strategy is logically sound and consistent with the observed reduction, aligning with the ground truth’s interpretation. However, the conclusion is undermined by the inclusion of false subsequent events, indicating flawed multi-hop synthesis — the model may have conflated data from different time periods or sources. (4) The contextual relevance is high because the answer addresses both parts of the question (change in authorization and strategic implication), but the inclusion of inaccurate forward-looking data reduces overall correctness. The core insight about reduced repurchase capacity indicating a more conservative or shifted capital strategy is preserved, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 484,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "Between 2022 and 2024, Accenture Canada Holdings Inc. Exchangeable Shares saw increased share repurchase activity and more detailed disclosure of shareholder rights. In 2024, the company repurchased 13.9 million Accenture plc Class A ordinary shares and 47,752 exchangeable shares, with total cash outlays of $4.5 billion and $15,254, respectively, under its open-market program. Additionally, the Board approved $4 million in new repurchase authority, raising total authorization to $6.69 billion. Shareholder rights were clarified, including the one-to-one exchangeability of exchangeable shares for Class A shares at market price, and redemption terms for Class X shares tied to exchangeable shares, ensuring alignment with shareholder equity structures. These disclosures reflect enhanced transparency and active management of share repurchase programs and shareholder entitlements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that as of August 31, 2024, there was a remaining authorization of $2,694,281 (~$2.69 million) for share repurchases, but the LLM claims the Board approved $4 million in new authority, raising total authorization to $6.69 billion — a figure that is off by orders of magnitude and completely unsupported by the original answer. Additionally, the LLM fabricates specific repurchase volumes (13.9 million Class A shares, 47,752 exchangeable shares) and cash outlays ($4.5 billion, $15,254), none of which appear in the ground truth. (2) The only correct quantitative element is the mention of a one-for-one exchangeability, which aligns with the original answer. However, all other numbers are either invented or grossly distorted. (3) Qualitatively, the LLM correctly identifies the direction of evolution — increased disclosure clarity around shareholder rights and more structured repurchase programs — and correctly notes the one-to-one exchangeability and alignment of share classes. These reflect some correct multi-hop reasoning about disclosure trends. However, it fails to accurately represent the progression from general intent in 2022 to specific authorization in 2024, instead inventing detailed transaction data not present in the source. (4) Contextual relevance is moderate: the answer addresses the right topic (evolution of disclosure and repurchase activity) and touches on shareholder rights, but the inclusion of fabricated metrics severely undermines its reliability. The core narrative is plausible but factually unsound. Correctness score is low due to severe quantitative errors, despite some conceptual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 481,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "The global revenue from Electrophysiology Devices increased by **14.4%** in 2024 compared to 2023, excluding the impact of foreign exchange fluctuations. This is derived from the \"Total Change Excl. Exchange\" column in the Medical Devices segment table, which shows a 14.4% growth in Electrophysiology sales in 2024 versus 2023. The 12.3% total change in the table includes foreign exchange effects, but the 14.4% reflects the adjusted growth rate.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key percentage change excluding foreign exchange fluctuations as 14.4%, which matches the ground truth. It also correctly references the total change of 12.3% as including FX effects. However, it omits the actual revenue figures for 2023 ($2,195 million) and 2024 ($2,467 million), which were explicitly asked for in the question. (2) All numeric values mentioned (14.4% and 12.3%) are accurate and correctly interpreted. The calculation implied by the percentage change (from $2,195M to $2,467M) yields approximately 12.3% including FX and 14.4% excluding FX, which aligns with the ground truth. (3) The reasoning is sound: the model correctly distinguishes between total change and change excluding exchange rate impacts, demonstrating proper synthesis of multi-hop financial data. It references the correct segment (Electrophysiology Devices) and time frame (2023 to 2024). (4) The answer is highly accurate qualitatively and contextually, but loses one point in correctness due to incompleteness — while it captures the essential analytical point (the FX-adjusted growth), it fails to report the actual revenue numbers requested in the first part of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 344,
        "total_tokens": 1530
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "Accenture's financial relationship with Duck Creek Technologies evolved through continued equity method accounting, with the investment's fair value increasing from $223,166 (16% ownership) as of August 31, 2022, to a significant gain of $253 million recognized in fiscal 2023, impacting effective tax rates and diluted earnings per share. This gain, excluded from adjusted financial metrics, reflects improved valuation, though no further details on 2024 valuation changes are provided. The investment's impact on financial performance was primarily through the 2023 gain, which enhanced earnings before adjustments for business optimization costs.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the initial investment value of $223,166 with 16% ownership in fiscal 2022 and the $253 million gain, which aligns with the ground truth. However, it incorrectly attributes the gain to fiscal 2023 instead of fiscal 2024, which is a material timing error affecting the evolution timeline. (2) All numeric values (dollar amounts, ownership percentage) are accurate and properly formatted; the $253 million gain is correctly stated, though the fiscal year is off by one. There are no calculation errors. (3) The multi-hop reasoning is largely sound: the LLM connects Accenture's equity method accounting, the increase in investment value, and its impact on financial performance (e.g., diluted EPS and tax rates). It also correctly notes the exclusion from adjusted metrics, adding contextual depth. However, the misattribution of the gain to 2023 weakens the synthesis across the full 2022–2024 period, especially the endpoint in 2024. (4) The answer is highly relevant, addressing both investment valuation and financial impact as asked. The qualitative shift in contribution to earnings is acknowledged, though the absence of explicit 2024 valuation data is noted—this is a minor limitation since the $253M gain *is* the key 2024 event per ground truth. The score is reduced slightly due to the fiscal year misplacement, but core facts and reasoning remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 391,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "Union Pacific's retention share and unit awards saw a shift in composition toward performance-based awards in 2023 compared to 2022, as evidenced by the introduction of performance stock units tied to return on invested capital (ROIC) and operating income growth. The scale of retention awards remained relatively stable, with 31,979,909 shares available for future issuance as of December 31, 2023, compared to similar figures in 2022. This indicates a strategic emphasis on aligning executive compensation with long-term performance metrics while maintaining consistent equity compensation scales.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, 389,207 retention shares were outstanding as of December 31, 2021 (reported in the 2022 filing), and by 2023, 954,405 retention shares and 366,046 retention units were outstanding. The LLM incorrectly states that the scale of retention awards remained 'relatively stable' and cites 31,979,909 shares available for future issuance — a figure not mentioned in the ground truth and unrelated to outstanding retention shares/units. This number appears to be confused with total shares available under the plan, not retention instruments. (2) The quantitative inaccuracies are severe: the LLM fails to report the actual increase in outstanding retention shares (from 389,207 to 954,405 — a 145% increase) and completely omits the introduction of 366,046 retention units in 2023. Instead, it introduces 'performance stock units tied to ROIC and operating income growth,' which are not mentioned in the ground truth and represent a different type of award. (3) The multi-hop reasoning is flawed. The question asks about changes in composition and scale of retention share and unit awards, but the LLM shifts focus to performance-based awards and shares available for issuance, missing the core data on outstanding retention instruments. It fails to synthesize the correct data points across years and misidentifies the nature of the change. (4) While the LLM attempts to infer strategic intent (aligning compensation with long-term performance), this conclusion is based on incorrect data and mischaracterized changes. The ground truth indicates a shift toward greater use of retention-based compensation with new retention units, whereas the LLM incorrectly frames it as a shift to performance-based awards. The contextual relevance is moderate because it addresses executive compensation strategy, but the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 533,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "MetLife's application of GAAP guidance for adjusted earnings in 2024 continued the exclusions related to market volatility and asymmetrical accounting adjustments as outlined in 2023, with refinements due to the adoption of LDTI (Life and Health Insurance Accounting Update). In 2023, adjusted earnings excluded net investment gains/losses, derivatives, MRB remeasurement, goodwill impairments, and asymmetrical accounting adjustments (e.g., in-force reinsurance). In 2024, these exclusions were maintained, but LDTI further refined the scope by explicitly excluding changes in fair value of MRBs, discount rate adjustments on annuitization guarantees, and asymmetrical accounting for in-force reinsurance. The 2024 disclosure emphasized consistency with GAAP while aligning adjustments to reflect updated accounting standards.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continuation and refinement of MetLife's adjusted earnings exclusions between 2023 and 2024, particularly around market volatility and asymmetrical accounting adjustments due to LDTI adoption. It accurately notes exclusions such as MRB remeasurement, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance, which aligns with the ground truth. However, it omits key details present in the original answer—specifically, the 2024 expansion to exclude policyholder liability remeasurement gains (losses) related to in-force reinsurance and the new exclusion of equity method joint venture adjustments in net investment income, which were not mentioned in 2023. These omissions reduce completeness and qualitative accuracy. (2) There are no numerical values, dates, or calculations in the question or answers that are incorrect; all references to years (2023, 2024) and accounting standards (LDTI) are factually accurate, so quantitative accuracy is perfect. (3) The multi-hop reasoning is partially sound—the model correctly links LDTI adoption to changes in adjusted earnings treatment and recognizes evolving exclusions, but fails to fully synthesize the incremental changes in 2024 compared to 2023, particularly the expanded scope of exclusions. (4) The answer is contextually relevant and well-structured, but the missing 2024-specific refinements prevent a higher score. Thus, correctness is 7 due to accurate core facts but significant omissions in detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 430,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "Accenture's approach to compressed transformations evolved from 2022 to 2024 by expanding its technological focus to include generative AI, AR/VR, and quantum computing, while broadening the scope of services to integrate AI-driven automation and advanced manufacturing. In 2022, the emphasis was on cloud, data, AI, IoT, and digital twins, whereas 2024 highlighted generative AI, edge computing, and metaverse applications, alongside enhanced capabilities in redefining product design, sourcing, and manufacturing processes. The scope also expanded to include AI-powered operations and hyper-personalized customer experiences, reflecting a deeper integration of transformative technologies across industry verticals.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Accenture and the relevant time frame (2022 to 2024), and captures the general evolution of its compressed transformation approach. It accurately notes the expansion of technology use from digital twins, AI, IoT, cloud, and 5G in 2022 to more advanced tools by 2024. However, it introduces 'quantum computing' as a 2024 technology, which is not mentioned in the ground truth and is factually incorrect based on the provided data. The ground truth specifies generative AI, AR/VR, and advanced robotics as new additions, with continued emphasis on metaverse applications—this is partially reflected but distorted by the inclusion of quantum computing. Additionally, the LLM fails to mention the key expansion into digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers, which is a major scope broadening highlighted in the original answer. Instead, it cites 'AI-powered operations' and 'hyper-personalized customer experiences,' which are not part of the documented scope expansion. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is partially sound: the model correctly infers an evolution in technological focus over time and attempts to contrast 2022 and 2024. However, it synthesizes incorrect information (quantum computing) and misses the critical shift into capital project transformation, indicating a failure to fully capture the second hop of scope expansion. (4) The contextual relevance is high because the answer stays focused on Accenture’s transformation services and technological evolution, but the factual inaccuracies and omissions reduce correctness. The qualitative accuracy is moderate due to partial alignment with the truth but significant deviations in key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 525,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "Abbott's use of interest rate hedge contracts remained at a notional value of $2.2 billion in both 2023 and 2024, indicating no change in the scale of these contracts between the two years. While the 2023 filing noted a reduction from $2.9 billion in 2022 due to the maturity of $700 million in contracts, the 2024 filing confirms the notional value stayed at $2.2 billion, reflecting no evolution in the use of interest rate hedges for managing fixed-rate debt exposure during this period.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly reports the notional value of Abbott's interest rate hedge contracts as $2.2 billion in both 2023 and 2024, which matches the ground truth. It also accurately notes that the amount remained stable between those years. However, the LLM introduces information not present in the original answer—specifically, the reduction from $2.9 billion in 2022 due to $700 million in maturities—which, while potentially true, is not part of the ground truth and distracts from the 2023–2024 evolution focus. More critically, the LLM concludes there was 'no evolution' in hedge usage, which contradicts the ground truth that identifies an important development: despite stable notional amounts, the average interest rate on long-term debt increased from 3.6% to 3.8%, indicating a shift in debt structure or market conditions. This key qualitative insight is entirely missing.\n\n2) Quantitatively, the $2.2 billion figure is correct for both years. The mention of $2.9 billion and $700 million, while potentially accurate, is extraneous and not verifiable from the ground truth, but does not invalidate the numeric accuracy of the core data.\n\n3) The reasoning is flawed in its conclusion. The question asks how the use of hedges 'evolved'—a stable notional amount is one part, but the evolution also includes the context of changing interest rates on debt. The LLM fails to perform the necessary multi-hop synthesis between hedge notional values and the changing average interest rate on debt, leading to an incomplete and misleading conclusion of 'no evolution.'\n\n4) The answer is contextually relevant and addresses the core topic of hedge usage. However, by omitting the shift in average interest rates and overemphasizing notional stability, it misses a critical dimension of the evolution in Abbott’s risk management context. Thus, while factually aligned on the hedge amounts, it lacks the full analytical depth required for a correct multi-hop answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 528,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "MetLife's treatment of Adjusted Earnings in 2024 remained consistent with its 2023 definition as a GAAP measure for segment performance, but refinements occurred due to updated GAAP guidance. In 2023, the adoption of LDTI simplified DAC/VOBA measurements, updating Adjusted Earnings to exclude specific items like MRB fair value changes and asymmetrical accounting. In 2024, the company aligned with ASU 2023-07, enhancing segment disclosures retroactively, and maintained Adjusted Earnings as the GAAP measure for segment performance while retaining exclusions for market volatility and non-economic adjustments. The 2024 disclosures provided more granular segment-specific Adjusted Earnings data, reflecting refined compliance with GAAP and improved transparency.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its high-level description of MetLife's evolution in Adjusted Earnings treatment between 2023 and 2024, particularly regarding the impact of LDTI adoption and the role of Adjusted Earnings as a GAAP measure for segment performance. It correctly identifies the 2023 changes due to LDTI, including the exclusion of MRB fair value changes and asymmetrical accounting, and notes the continued use of Adjusted Earnings in 2024 with refinements. The mention of ASU 2023-07 is contextually relevant and aligns with enhanced segment disclosures under GAAP, which supports the claim of improved transparency. However, the LLM answer omits key specifics from the ground truth: it does not mention the shift in 2023 from amortization of DAC/VOBA to adjusting for changes in measurement of guarantees, nor does it detail the expanded 2024 exclusions such as inflation-indexed benefit adjustments, non-economic losses from single premium annuity contracts, or the structured exclusion of goodwill impairments and derivative gains/losses. While the answer captures the general direction of refinement and alignment with GAAP, it lacks the full scope of exclusions and specific adjustments that define the evolution. The reasoning is sound but incomplete in synthesizing all multi-hop elements (e.g., precise linkage between LDTI, ASU 2023-07, and specific exclusions). Quantitative accuracy is high as no incorrect numbers or dates are presented (e.g., correct years 2023–2024, correct reference to GAAP updates), though no explicit figures are involved. Contextual relevance is strong, as the response directly addresses the question’s focus on GAAP guidance and segment performance. The answer is semantically close but falls short on completeness of exclusions and specificity of accounting changes, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1479,
        "completion_tokens": 500,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "From 2022 to 2024, Accenture's share purchase program authorization and methods evolved as follows:  \n- **Authorization**: As of August 31, 2022, the available authorization was **$3,129,296**, but by August 31, 2024, it decreased to **$2,694,281**. However, additional authority of **$4,000,000** was approved in September 2024, raising the total outstanding authorization to **$6,694,281**.  \n- **Share Acquisition Methods**: Both years utilized **open-market purchases** (e.g., 9.6M shares in 2022, 11.8M in 2024) and **employee-related programs** (e.g., share withholding for payroll taxes and VEIP). The methods remained consistent, with slight increases in total shares purchased (12.2M in 2022 vs. 13.9M in 2024).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Accenture had an aggregate available authorization of $3,129,296, but the LLM incorrectly claims a decrease to $2,694,281 by 2024 and an additional $4,000,000 approved in September 2024—none of which is supported by the original answer. There is no mention in the ground truth of a new $4M authorization or updated figures for 2024, so these numbers are fabricated. (2) The LLM cites specific share purchase volumes (e.g., 9.6M in 2022, 11.8M in 2024, total 12.2M vs 13.9M), but these figures are not present in the original answer and contradict its focus on authorization and acquisition methods rather than volume trends. The original answer does not provide any quantitative data on number of shares purchased in either year. (3) The reasoning is flawed in terms of multi-hop synthesis: the original answer emphasizes a shift in acquisition methods—specifically, that in 2024, share withholding for payroll taxes became a primary method that did not impact public program authorization—indicating a structural change. The LLM incorrectly concludes that methods 'remained consistent,' missing this key evolution. It also fails to mention the distinction between Accenture plc Class A shares and Accenture Canada Holdings Inc. exchangeable shares, a critical entity-specific detail in the original. (4) While the LLM addresses the general themes of authorization and methods, aligning with the question's intent, its severe factual and numerical errors—especially inventing figures not in the source—drastically reduce correctness. The contextual relevance is moderate because it attempts the right categories (funding, methods), but the qualitative and quantitative accuracy is very low due to hallucinated data and missed conceptual shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 502,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "MetLife's treatment of Unit-linked Securities remained consistent in terms of cost basis, which is based on original cost adjusted for amortization, as outlined in the 2023 disclosures. However, in 2024, the fair value methodology for these securities became more detailed, incorporating sensitivity analyses for unobservable inputs such as long-term equity volatility and nonperformance risk spreads, as reflected in the Level 3 fair value measurements. The 2024 disclosures highlight increased emphasis on modeling these factors, which influenced fair value fluctuations, while the cost basis approach remained unchanged.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy regarding the cost basis treatment of Unit-linked Securities. The ground truth states that in 2023, cost basis was based on original cost for equities and amortized cost for fixed maturities, but by 2024, these securities were included in Level 3 fair value measurements using significant unobservable inputs—indicating a shift from a cost-based to a more dynamic, assumption-driven valuation methodology. However, the LLM incorrectly claims that the 'cost basis approach remained unchanged,' which contradicts the evolution described in the original answer. This misrepresents a key aspect of the methodology shift. On the positive side, the LLM correctly identifies the increased use of sensitivity analyses and unobservable inputs (e.g., equity volatility, nonperformance risk) in 2024 and correctly references Level 3 fair value measurements. These qualitative details align with the ground truth and show proper synthesis of disclosure trends. There are no numeric values to verify, so quantitative accuracy is high by default (minor variations in terminology like 'long-term equity volatility' vs 'equity volatility' are acceptable). Contextual relevance is strong—the response directly addresses the question’s focus on evolution in treatment and valuation. However, due to the critical error in asserting continuity in cost basis when a clear shift occurred, the overall correctness and qualitative accuracy scores are reduced. The model failed the multi-hop reasoning test by not recognizing that inclusion in Level 3 with unobservable inputs implies a departure from static cost-based valuation, even if cost is still used as a starting point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 469,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "Between fiscal years 2022 and 2023, the structure and vesting timeline of market-based RSUs evolved as follows: In 2023, the company introduced **five-year vesting periods** for certain market-based RSUs, subject to **stock price performance milestones**, whereas prior to 2023, RSUs generally vested over **four years** with market conditions. Additionally, 2023 grants included both **service-based** and **market-based conditions**, expanding on the existing framework. The weighted-average grant date fair value per share increased significantly, reflecting higher valuation assumptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, market-based RSUs generally had a four-year vesting period, and in 2023, the company introduced five-year vesting RSUs tied to stock price performance milestones—this matches the original answer's claim of expanded vesting structures. (2) All numeric and temporal details (e.g., 'four years', 'five years', '2022', '2023') are factually correct; no calculations were required, but the timeline comparison is accurate. (3) The multi-hop reasoning is sound: the model synthesizes changes across fiscal years and correctly infers an evolution in structure, including the addition of new conditions. (4) The LLM adds that 2023 grants included both service-based and market-based conditions, which is plausible context but not explicitly confirmed in the ground truth—this is a minor addition that doesn't contradict but slightly extends the known facts. The mention of increased fair value is not in the original answer and lacks grounding in the provided truth, but it doesn't detract from the core correctness. Overall, the answer captures the key evolution accurately, earning a 9 for minor inclusion of unverified contextual detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 348,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "The phase-in treatment of the CECL standard's impact on regulatory capital evolved between 2023 and 2024 as follows: In 2023, 50% of the cumulative 'day 2' ongoing CECL impact was phased in, while in 2024, 75% was phased in. During the phase-in period (2022–2024), the Federal Banking Agencies applied a 25% annual scaling factor to the estimated cumulative impact of CECL on regulatory capital. As of December 31, 2024, the Company's CET1 capital ratio reflected 75% of the phased-in CECL impact, with the remaining 25% to be fully phased in by 2025. This treatment allowed regulatory capital to gradually incorporate the CECL allowance adjustments over time.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. According to the ground truth, the CECL phase-in began on January 1, 2022, and proceeded at 25% per year through 2024, meaning 25% in 2022, 50% by end of 2023, and 75% by end of 2024. However, the LLM incorrectly states that in 2023, 50% was phased in (should be cumulative 50% by end of 2023, not 50% during 2023 alone), and 75% in 2024 (again, this is the cumulative amount, not the annual increment). The statement that 'the remaining 25% to be fully phased in by 2025' is incorrect — the phase-in was scheduled to end on December 31, 2024, not extend into 2025. (2) The annual scaling factor of 25% is correctly identified, but its application is misrepresented over the years. The ground truth confirms a consistent 25% annual increase from 2022–2024, culminating in full recognition by end-2024. The LLM’s implication of a continuing phase-in beyond 2024 contradicts this. (3) The reasoning is partially sound in recognizing the multi-year phase-in and the gradual impact on CET1, but fails in accurately tracking the timeline and cumulative percentages. It misattributes annual phase-in amounts versus cumulative totals. (4) Despite these errors, the answer is contextually relevant and captures the general intent of the CECL transition rule. It correctly references the Federal Banking Agencies and the purpose of the phase-in. However, due to major quantitative inaccuracies affecting the core facts, the correctness score is reduced to 4, with low quantitative accuracy (3) and moderate qualitative accuracy (5).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 444,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "Between 2022 and 2023, Broadcom issued senior notes under new indentures with Wilmington Trust, National Association as trustee. In 2022, notes such as 4.00% Senior Notes due 2029 and 4.15% Senior Notes due 2032 were issued under indentures dated April 14, 2022, and April 18, 2022. In 2023, additional notes like 4.926% Senior Notes due 2037 were issued under a July 12, 2024 indenture. The terms included varying interest rates and maturities, reflecting Broadcom's ongoing use of Wilmington Trust as trustee for structured debt offerings.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in dates, interest rates, and issuance years. According to the ground truth, the 2022 notes were issued under indentures from January 2021 (not April 2022), with rates ranging from 1.950% to 3.750%. The LLM incorrectly states that 4.00% and 4.15% notes were issued in 2022 under April 2022 indentures, but the ground truth shows the April 18, 2022 indenture was part of the evolving relationship, not the initial 2022 activity. Additionally, the 4.926% note due 2037 was issued under a July 12, 2024 indenture, which is future-dated relative to 2023 and should not be presented as a 2023 issuance. The LLM incorrectly implies it was issued in 2023. (2) The ground truth indicates that higher-yielding notes (4.150%–4.800%) were issued in October 2024, which is beyond the 2023 scope and not mentioned in the LLM answer. The LLM omits the lower-rate 2021-issued notes that were still relevant in 2022, misrepresenting the starting point of the relationship. (3) The multi-hop reasoning is partially sound—the model recognizes the continuation of the trustee relationship and attempts to show evolution in terms of new indentures and higher rates. However, it fails to accurately synthesize the timeline and terms across 2022 and 2023, conflating future-dated indentures and misattributing issuance dates. (4) Despite these errors, the answer captures the general trend of issuing longer-term, higher-yielding debt and correctly identifies Wilmington Trust as the ongoing trustee, maintaining contextual relevance. The qualitative reasoning is plausible but based on incorrect data, leading to a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 458,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "Capital One's regulatory capital add-back under the CECL Transition Rule evolved from 2023 to 2024 through a phased-in approach. In 2023, 50% of the cumulative 'day 2' ongoing CECL impact was phased in, and by 2024, this increased to 75%. The phase-in progression followed a 25% annual increment starting from January 1, 2022, with the full phase-in completed by December 31, 2024. As of December 31, 2024, 75% of the $2.4 billion add-back amount (from the CECL Transition Rule) had been incorporated into regulatory capital.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the phase-in progression from 50% in 2023 to 75% in 2024 and references the $2.4 billion add-back amount, which aligns with the ground truth. However, it incorrectly states that the full phase-in was completed by December 31, 2024, when the ground truth indicates a five-year phase-in starting after 2021, meaning full implementation would be by 2026 (100% by January 1, 2026). Additionally, the claim that the 25% annual increment started January 1, 2022, contradicts the ground truth, which specifies the phase-in began after 2021, with 50% already in place by January 1, 2023. (2) The dollar amount ($2.4 billion) and percentages (50% to 75%) are accurate, but the timeline and completion date are factually incorrect, affecting quantitative accuracy. The statement that '75% of the $2.4 billion' was incorporated is misleading—the $2.4 billion is the total add-back amount already reflecting the phased-in portion, not a cumulative pool being gradually added. (3) The multi-hop reasoning is partially sound—correctly linking phase-in percentages across years and associating them with regulatory capital—but fails in accurately reconstructing the phase-in schedule beyond 2024. (4) Scores reflect mostly correct core facts with significant timeline errors impacting overall correctness; contextual relevance remains high as the response directly addresses the question’s focus on evolution and phase-in progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 406,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "Following the Broadcom acquisition of VMware, non-employee directors' in-the-money VMware stock options and RSUs were accelerated and converted into cash and Broadcom common stock in equal parts, as outlined in both the 2022 merger agreement and the 2023 completion of the acquisition. There was no change in treatment between 2022 and 2023; the policy remained consistent with the terms of the VMware Merger Agreement.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in describing the treatment of VMware stock options and RSUs for non-employee directors: they were accelerated and converted into cash and Broadcom common stock in equal parts, as per the merger agreement. All entities (VMware, Broadcom, non-employee directors), the nature of the awards (in-the-money stock options and RSUs), and the conversion terms are correctly identified, satisfying quantitative and entity accuracy. However, the LLM incorrectly states that 'there was no change in treatment between 2022 and 2023' and that 'the policy remained consistent.' This misrepresents the evolution emphasized in the original answer: in 2022, the conversion was a planned future event contingent on acquisition completion; by 2023, it had been realized. The transition from a prospective plan to an actualized outcome is a key aspect of how the treatment evolved, which the LLM overlooks. This is a qualitative shortcoming in reasoning and temporal synthesis across the two years, reducing the qualitative accuracy score. Contextual relevance is strong, as the answer directly addresses the question's focus on the evolution of treatment. While the core facts are correct, the failure to capture the shift from plan to execution results in a correctness score of 7 rather than higher.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 366,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "Based on AbbVie's disclosures, Vraylar's therapeutic positioning remained consistent from 2022 to 2024, focusing on its approved indications: acute and maintenance treatment of schizophrenia, acute treatment of manic/mixed episodes in bipolar disorder, acute depressive episodes in bipolar I disorder, and adjunctive treatment for major depressive disorder (MDD). The 2022 clinical trial results for MDD adjunctive therapy were retained in the 2024 product description, with no new indications or expanded therapeutic roles added during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that Vraylar's therapeutic positioning remained consistent from 2022 to 2024. The ground truth shows a clear evolution: in 2022, Vraylar was still under evaluation for adjunctive treatment of MDD in Phase 3 trials, with mixed results, and was not yet broadly indicated for that use. By 2024, it had gained formal indication for adjunctive MDD treatment and was positioned for a broader range of psychiatric conditions. The LLM incorrectly states that all indications were already approved and unchanged during this period, which contradicts the documented expansion. (2) There are no numerical values requiring calculation in this question, so quantitative accuracy is not heavily applicable; however, the years 2022 and 2024 are correctly referenced, and the description of the 2022 trial outcomes (numerical but not statistically significant improvement) aligns partially with the ground truth, earning partial credit. (3) The multi-hop reasoning is flawed: the model fails to synthesize the progression from investigational use in 2022 to expanded approved indications in 2024. It conflates future approvals with current status in 2022, indicating a failure to track therapeutic positioning over time across disclosures. (4) While the final list of indications in 2024 is accurately described, the core of the question—how the positioning evolved—is fundamentally misrepresented. The answer claims no change occurred, when the ground truth confirms a significant expansion. This major factual error severely undermines correctness and qualitative reasoning, though the response remains contextually relevant to the drug and company.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 464,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "GE's accounting policy for long-term services agreements remained consistent from 2022 to 2024, using the **percentage of completion method** for revenue recognition, based on costs incurred relative to estimated total costs. However, in 2024, the documentation provided additional detail on **contract billing estimates**, emphasizing the use of historical utilization trends and forward-looking factors (e.g., market conditions, asset retirements) to assess customer payments and costs. Revisions to estimates are now explicitly noted as adjustments to revenue in the current period, reflecting improved transparency in how changes in utilization or cost projections impact financial reporting. No material change in the revenue recognition method was disclosed.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in stating that GE used the percentage of completion method consistently from 2022 to 2024. According to the ground truth, GE used the straight-line basis in 2022 and only shifted to the percentage of completion method by 2024. This is a major factual error that undermines the core of the response. Additionally, the LLM claims no material change in revenue recognition method was disclosed, which directly contradicts the ground truth. (2) Quantitatively, the LLM fails to mention any of the key figures from the ground truth: the $6.6 billion net liability, the $162 billion total estimated life of contract billings, or the 4.1% ratio. These specific numbers are critical for demonstrating the evolution in contract billing estimates and are entirely omitted. There are no calculations in the LLM answer to verify, but the absence of these figures severely limits quantitative accuracy. (3) The multi-hop reasoning is flawed because the model fails to recognize the change in accounting policy over time, which is the central point of the question. Instead, it asserts consistency where there was a clear shift. While the LLM correctly identifies that forward-looking factors and utilization trends were emphasized more in 2024, this detail alone does not compensate for the incorrect characterization of the revenue recognition method. (4) Contextual relevance is moderate because the answer addresses revenue recognition and contract billing estimates, which are relevant topics, but the incorrect synthesis of the timeline and method change results in a misleading response. The added detail about estimate revisions being adjusted in the current period is plausible but not supported in the ground truth, making it potentially speculative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 489,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings by including the notes in the 2023 filing. In the 2022 10-K, there is no mention of these notes, while the 2023 10-K lists them under \"Securities registered pursuant to Section 12(b) of the Act,\" indicating their inclusion as a registered security. This reflects the addition of the 1.250% Notes due 2027 in the 2023 disclosure.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a major factual error: it claims that the 1.250% Notes due 2027 were not mentioned in the 2022 10-K, which contradicts the ground truth. The Original Answer states that in the 2022 10-K, IBM *did* disclose the notes by referencing Exhibit 4.3 to Form 8-K filed on January 30, 2019, as part of the instruments defining the rights of holders. The LLM incorrectly asserts there was 'no mention' of the notes in 2022, which is false. However, the LLM correctly identifies that in the 2023 10-K, the notes are listed as registered securities under Section 12(b) with the trading symbol IBM 27B on the NYSE. (2) Quantitatively, the percentage (1.250%), maturity year (2027), and filing years (2022 and 2023) are all correct. There are no calculation errors because no computations were required. (3) The multi-hop reasoning is flawed: the model fails to recognize that both filings contain disclosures about the same notes, just in different contexts (from rights-defining instrument reference to registered security). Instead, it interprets the evolution as an 'addition' of previously unmentioned notes, missing the nuance of evolving disclosure format. This reflects a failure in synthesizing the correct comparative analysis across filings. (4) While the answer addresses the general idea of disclosure evolution and correctly describes the 2023 treatment, the core factual inaccuracy about the absence of the notes in 2022 severely undermines correctness. Contextual relevance is moderate because the structure and intent align with the question, but the conclusion is based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 447,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "Between 2022 and 2024, AbbVie's performance-vested RSUs for senior executives and key employees continued to vest in **one-third increments over a three-year performance period**, with performance criteria tied to **return on invested capital (ROIC)** relative to a defined peer group of pharmaceutical, biotech, and life science companies. The structure and vesting increments remained consistent, but performance metrics expanded to include **earnings per share (EPS)** and **total shareholder return (TSR)** relative to peers for performance shares, reflecting a broader set of financial benchmarks.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the vesting structure (one-third increments over a three-year period) and the continued use of ROIC as a performance metric, it incorrectly states that performance metrics expanded to include earnings per share (EPS) and total shareholder return (TSR) by 2024. The ground truth explicitly states that the 2024 criteria were streamlined and focused primarily on ROIC, with no mention of EPS or TSR being added. This is a major factual error that contradicts the original answer. (2) There are no numeric values (e.g., percentages, dollar amounts) in either answer, so quantitative accuracy cannot be assessed on numbers per se, but the description of performance metrics is quantitatively incorrect in terms of scope and evolution—claiming expansion when the truth indicates simplification. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of the performance criteria over time. Instead of identifying a simplification or standardization of metrics, it asserts an expansion to additional metrics not mentioned in the ground truth, indicating a failure in logical inference from the source data. (4) Contextual relevance is moderate—the answer addresses the structure and time frame correctly and discusses performance metrics, so it stays on topic. However, the core claim about metric expansion undermines correctness. The answer would score higher if it had correctly captured the trend toward simplification rather than misrepresenting it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 435,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "GE's financial relationship with AerCap evolved from a significant unrealized loss of $865 million in 2022 to unrealized gains of $129 million in 2023 and a realized gain of $38 million in 2024, reflecting improved performance and potential realization of value from its investment.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that in 2022, GE had an unrealized loss of $865 million, and by 2024, a combined realized and unrealized gain of $38 million. However, the LLM introduces a figure of $129 million in unrealized gains for 2023, which is not present in the original answer and cannot be verified from the provided ground truth. This number is extraneous and incorrect. Additionally, the LLM separates the 2024 result into a 'realized gain of $38 million', while the original answer specifies a combined 'realized and unrealized gain of $38 million', implying the total net gain, not solely realized. (2) The $865 million loss in 2022 is correctly cited, and the $38 million gain in 2024 is directionally correct in magnitude but misrepresented in nature (over-simplifying it as only realized). The introduction of a 2023 figure breaks quantitative accuracy. (3) The multi-hop reasoning is partially sound—there is an attempt to show evolution over time and interpret financial improvement. However, the addition of unsupported data (2023 gain) undermines the reasoning chain and suggests fabrication or misattribution. (4) Contextual relevance is high because the answer addresses the evolution of GE's financial relationship with AerCap through gains/losses over time. Qualitative accuracy is moderate because the entities (GE, AerCap), years (2022, 2024), and general trend (loss to gain) are correct, but the reasoning is flawed by unsupported data. Correctness is scored at 5 due to a mix of correct directional trend and key numbers but major errors in specific figures and characterization of the 2024 gain.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 462,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings in terms of disclosure visibility. In the **2023 filing**, the notes are explicitly listed in the \"Securities registered pursuant to Section 12(b) of the Act\" section (page 5), under the New York Stock Exchange ticker **IBM 26B**, confirming their active status and ongoing disclosure. In contrast, the **2022 filing** (pages 28–32) does not mention the 0.300% Notes due 2026 in the provided sections, suggesting reduced visibility or a shift in disclosure format. This indicates a more prominent inclusion in the 2023 filing, likely reflecting continued active trading and regulatory reporting.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the increased visibility of the 0.300% Notes due 2026 in the 2023 filing, including the correct ticker symbol IBM 26B and the section 'Securities registered pursuant to Section 12(b) of the Act', which aligns with the ground truth's emphasis on formal recognition on the New York Stock Exchange. The numerical details (interest rate, maturity year, ticker) are accurate. However, the LLM incorrectly states that the 2022 filing does not mention the notes at all, claiming 'does not mention... in the provided sections' and implying reduced visibility. This contradicts the ground truth, which confirms the notes were disclosed in 2022 via Exhibit 4 to Form 8-K filed November 1, 2016, as part of legal instruments defining holder rights. The LLM underestimates the 2022 disclosure, misrepresenting it as absent or minimal when it was actually present in a different but valid form (exhibit reference). This is a significant qualitative error in reasoning and entity-context linkage, as the evolution is not from 'no mention' to 'listed', but from 'referenced in legal exhibits' to 'explicitly listed as a registered security'. The multi-hop synthesis is partially flawed because it fails to recognize the 2016 Form 8-K reference as part of the 2022 disclosure landscape. While the direction of evolution (increased visibility) is correctly inferred, the basis for comparison is factually incomplete, leading to an inaccurate narrative of the change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 407,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "GE's RISE Program evolved from a broad sustainability initiative in 2022 to a more focused technological development effort by 2024. In 2022, the program was highlighted as part of investments in sustainable flight technologies, including the Catalyst engine and Open Fan testing. By 2024, RISE emphasized specific innovations like hybrid electric systems, compact cores, and alternative fuel compatibility, with detailed progress reported (e.g., 250+ Open Fan tests). The strategic emphasis shifted toward enabling a sustainable future through advanced propulsion solutions, while investment focus expanded to include hybrid-electric systems and broader decarbonization technologies.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of GE's RISE Program from a sustainability initiative toward more focused technological development, which aligns with the ground truth. However, there are significant factual inaccuracies that reduce correctness. First, the original answer specifies a collaboration with Safran and a target of 'more than 20% reduction in fuel consumption and CO2 emissions'—a key quantitative and partnership detail entirely missing in the LLM response. Second, the LLM introduces specific technologies like 'hybrid electric systems' and claims '250+ Open Fan tests' and mentions the 'Catalyst engine', none of which appear in the ground truth and are unsupported by the provided knowledge. While the shift from conceptual to active R&D is correctly implied, the LLM misrepresents the nature of the evolution by adding unverified technical details and omitting the Safran partnership and emission targets. The strategic emphasis on sustainability is correctly noted, but the investment focus is inaccurately expanded to include hybrid-electric systems without evidence. Quantitative accuracy is low due to fabricated numbers (e.g., 250+ tests) and missing the 20% emissions reduction target. Qualitative accuracy is moderate—core reasoning about increased focus is sound, but entity and detail errors weaken synthesis. Contextual relevance is high as the response stays on-topic and addresses strategic and investment shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 400,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "American Express maintained a continued emphasis on asset securitizations as a key component of its funding strategy in both 2022 and 2023, as disclosed in the \"FUNDING STRATEGY\" sections of their 10-K filings. In 2023, the document explicitly highlighted the role of asset-backed securities (e.g., the $3.5 billion in Fixed Rate Class A Certificates issued by the American Express Credit Account Master Trust) as part of its diversified funding sources, alongside direct retail deposits and unsecured debt. While 2022’s disclosures focused on the general strategy of maintaining scale in securitizations, 2023 provided more granular details on specific programs and issuance amounts, reflecting a sustained reliance on securitizations with increased transparency.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly portrays the evolution of asset securitizations in American Express's funding strategy. According to the ground truth, in 2022, securitizations were only defined in a glossary and not discussed as part of the funding strategy, whereas in 2023 they were explicitly elevated to a core funding source. The LLM answer falsely claims that both years included discussion in a 'FUNDING STRATEGY' section and that there was 'continued emphasis' in both years, which contradicts the ground truth. This is a major factual and interpretive error. (2) The $3.5 billion in Fixed Rate Class A Certificates is a specific detail not present in the original answer; while it may be factually accurate from the filing, it was not part of the ground truth knowledge graph output, and its inclusion suggests the model introduced a detail beyond the provided truth, potentially hallucinating or misattributing emphasis. No calculations were required, so quantitative accuracy is moderate due to format consistency but penalized for introducing unverified specifics. (3) The multi-hop reasoning is flawed: the model failed to recognize that the 2022 mention was purely definitional (glossary) rather than strategic, and thus did not correctly synthesize the shift from definition to strategic emphasis. Instead, it assumed equal strategic treatment in both years, missing the core evolution. (4) Contextual relevance is fair because the answer addresses funding strategy and securitizations, and mentions correct categories (deposits, unsecured debt), but the central claim about continuity is incorrect, undermining overall correctness. The answer provides more detail than the ground truth in some areas but misrepresents the strategic evolution, which is the central question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 488,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "Emerson's financial and strategic relationship with AspenTech evolved significantly from 2022 to 2023. Following the May 2022 acquisition of Heritage AspenTech, the combined AspenTech segment (merged with Emerson's Industrial Software Business) reported improved performance in 2023, with sales rising to $656 million (from $319 million in 2022) and a $12 million earnings contribution (compared to a $7 million loss in 2022). This reflects successful operational integration, as amortization benefits from the acquisition improved margins by 0.6 percentage points. Investment returns were positive, driven by the acquisition's impact on sales growth and profitability, though 2023 also included restructuring costs and foreign currency adjustments. The strategic alignment strengthened Emerson's position in industrial software, though 2024 saw challenges from inventory step-up amortization and divestiture-related expenses.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Emerson did not acquire Heritage AspenTech in May 2022—rather, the acquisition occurred in 2023, marking the shift to a 55% controlling stake. The LLM incorrectly states the acquisition happened in May 2022, which misrepresents the timeline and undermines the multi-hop reasoning. Additionally, the LLM claims AspenTech sales rose to $656 million in 2023 from $319 million in 2022, but the ground truth states AspenTech contributed $656 in sales in 2022 (no unit specified, but context implies millions; however, no 2023 sales figure is provided in the original answer). The $12 million earnings gain in 2022 is correctly noted, but the LLM fabricates a $7 million loss in 2022 and improvement to $12 million in 2023, which is not supported by the original. The 0.6 percentage point margin improvement in 2023 is correctly attributed to the acquisition, aligning with the original. (2) Quantitative accuracy is low: the acquisition date is wrong, 2022 sales figure is fabricated, 2022 earnings are misrepresented as a loss, and 2023 sales are incorrectly stated as $656 million (implying growth) when the original does not provide 2023 sales. The $12 earnings gain is mentioned in both but with different contexts—original says it was in 2022, LLM implies it's 2023. (3) Multi-hop reasoning is partially sound—the LLM recognizes the strategic deepening and operational integration, and correctly links the acquisition to margin improvements. However, the incorrect timeline and financial figures undermine the synthesis. The shift from minority investment to controlling interest is conceptually correct but misdated. (4) Contextual relevance is high—the answer addresses investment returns, operational integration, and strategic evolution. However, the inclusion of 2024 challenges (not asked and not in original) adds irrelevant detail. Overall, the answer captures the strategic direction but fails on core facts and numbers, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 556,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "Emerson's financial relationship with AspenTech evolved between 2022 and 2023 through the acquisition of Heritage AspenTech in May 2022, which established Emerson's 55% ownership and a $5.9 billion noncontrolling interest (NCI) in AspenTech. The NCI was recorded at fair value, reducing additional paid-in-capital by $550. In 2023, the acquisition's impact persisted, with amortization expenses related to intangible assets (e.g., $678 million in 2023) and continued recognition of the NCI in equity. Acquisition-related costs, including restructuring and divestiture expenses, also affected equity and expenses, reflecting the integration of AspenTech's operations. The NCI remained unchanged at 45% ownership, with no further adjustments noted between 2022 and 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in key financial figures. The ground truth states that Emerson contributed $6.0 billion in cash and recorded a $5.9 billion noncontrolling interest (NCI), with a $550 million reduction to additional paid-in capital. The LLM correctly identifies the $550 million reduction and the 55% ownership, but incorrectly attributes the NCI to the 'acquisition of Heritage AspenTech' rather than the formation of New AspenTech through a business contribution and cash. This misrepresents the nature of the transaction. (2) The LLM claims $678 million in amortization expenses in 2023, which is not mentioned in the ground truth. Instead, the ground truth specifies that SG&A expenses increased by $572 million year-over-year, partly due to the AspenTech transaction and higher stock compensation. This is a significant quantitative error. The LLM also fails to mention the 0.6 percentage point improvement in gross margins, a key operational impact in 2023. (3) The reasoning is partially sound: the LLM correctly identifies the persistence of NCI in equity and acquisition-related integration costs. However, it misses the shift from initial accounting (2022) to operational performance impacts (2023), which is central to the evolution described in the original answer. It incorrectly implies no change in NCI or ownership, while the focus in 2023 should be on income statement impacts rather than balance sheet accounting. (4) The contextual relevance is high, as the answer addresses noncontrolling interest, equity impacts, and expenses. However, due to incorrect figures (e.g., $678M vs $572M) and missing key metrics (gross margin impact), the quantitative accuracy is low. The qualitative accuracy is moderate due to correct entity identification (Emerson, AspenTech) and general understanding of NCI accounting, but flawed transaction characterization. Correctness score is 6 due to partial factual alignment but significant omissions and numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 547,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "IBM's disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings. In the 2022 filing, the debentures were referenced as Exhibit 3 to a Form 8-K filed in 1997, indicating reliance on historical documentation. In the 2023 filing, the debentures were directly listed in the \"Securities registered pursuant to Section 12(b) of the Act\" section, reflecting a more integrated and current disclosure in the 10-K's main body. This shift suggests a move toward explicit, up-to-date presentation in the 2023 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 filing references Exhibit 3 to the Form 8-K filed on August 1, 1997 (date not explicitly mentioned but implied via context), and the 2023 filing includes a more current and structured disclosure. The percentage (6.22%) and maturity year (2027) are correctly stated. (2) Quantitative elements—interest rate (6.22%), year of debenture maturity (2027), and historical filing year (1997)—are accurate. The LLM correctly identifies the 1997 Form 8-K without specifying the exact date (August 1), which is a minor omission but does not affect factual correctness. (3) The reasoning is sound: the shift from a historical reference to an integrated, current disclosure in the 10-K’s main body (specifically Section 12(b)) reflects improved transparency. The LLM captures the essence of the evolution—increased visibility and modernization of disclosure—though it omits the detail about the trading symbol (IBM 27) and NYSE registration mentioned in the original answer. This is a minor gap in completeness but does not undermine the core accuracy. (4) The answer is fully relevant, directly addressing how IBM's treatment and disclosure evolved. The synthesis across two years and filings is logically presented. The omission of the trading symbol and NYSE context prevents a perfect 10, but the answer remains factually strong and semantically equivalent in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 405,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers remained centered on its ability to estimate and manage medical costs payable, as detailed in both 2023 and 2024 filings. The company adjusts its estimates of medical costs payable based on actual claim data, seasonal trends, provider contract rates, and other factors, with approximately 90% of claims settled within 90 days. While the 2024 document does not explicitly mention changes in risk exposure, the methodologies for cost estimation and service delivery responsibilities remained consistent, emphasizing the need for accurate forecasting and integration of care management programs to mitigate financial risks and ensure profitability under risk-based contracts.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies UnitedHealth Group's ongoing responsibility for cost estimation and service delivery under risk-based arrangements in both 2023 and 2024, and accurately notes the 90% claims settlement rate within 90 days, which aligns with typical actuarial practices. However, it fails to capture the key evolution in financial risk exposure from 2023 to 2024 as described in the ground truth. Specifically, the LLM claims that the 2024 filing 'does not explicitly mention changes in risk exposure,' which contradicts the ground truth stating that in 2024, UnitedHealth faced increased responsibility for unpaid claims if providers failed financially and greater operational risk due to provider solvency and data reporting issues. This is a major omission that undermines the correctness of the answer. (2) Quantitatively, the 90% figure is plausible and consistent with industry standards, though not explicitly confirmed in the ground truth; no incorrect numbers are presented, so quantitative accuracy is relatively high. (3) The multi-hop reasoning is flawed: the question requires a comparison across years (2023 vs 2024) in terms of risk evolution, but the LLM incorrectly asserts consistency rather than identifying the expansion of risk and new provider-related vulnerabilities in 2024. It misses the synthesis that UnitedHealth’s exposure became more complex due to downstream provider risks, which is central to the ground truth. (4) Contextual relevance is moderate—the answer discusses cost estimation and risk management, which are relevant, but fails to address the core implication of increased financial and operational risk in 2024. Thus, while some factual elements are correct, the absence of the key 2024 risk expansion significantly reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 493,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "Emerson's financial relationship with AspenTech evolved significantly between 2022 and 2023, marked by a strategic acquisition and increased investment. In May 2022, Emerson contributed two software businesses and $6.0 billion in cash to Heritage AspenTech, acquiring a 55% stake in the newly formed New AspenTech. This acquisition boosted AspenTech's sales from $656 million in 2022 to $1.3 billion in 2023, reflecting the strategic integration of Emerson's software assets. The investment magnitude grew substantially, and Emerson's strategic involvement deepened through this acquisition, which contributed to a 20% increase in Software and Control segment sales in 2023. However, by 2023, Emerson's ownership stake was diluted as it explored strategic alternatives, including a potential full acquisition of the remaining shares.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it incorrectly states that Emerson made the $6.0 billion cash contribution and acquired a 55% stake in May 2022, while the ground truth confirms this major transaction occurred in 2023, not 2022. Additionally, the claim that AspenTech's sales increased from $656M in 2022 to $1.3B in 2023 is unsupported by the original answer and introduces new, unverified data. The statement that Emerson's ownership was diluted in 2023 due to exploring strategic alternatives contradicts the ground truth, which states Emerson gained 55% ownership as part of the 2023 transaction. (2) Quantitative inaccuracies include the misplacement of the $6.0 billion transaction to 2022 instead of 2023, and the introduction of sales figures ($656M, $1.3B) and a 20% sales increase that are not present in the original answer. The only correct number is the $6.0 billion cash contribution, though it is misdated. The 55% ownership stake is correctly mentioned but incorrectly timed. (3) The multi-hop reasoning is partially sound in recognizing a shift from financial to strategic involvement, but the timeline and causality are reversed. The model fails to correctly synthesize the evolution: in 2022, Emerson had a minority investment of $362M; in 2023, it made a controlling move. Instead, the LLM portrays the acquisition as happening in 2022 and then discusses dilution in 2023, which is factually incorrect. (4) Contextual relevance is high because the answer addresses investment magnitude and strategic involvement as asked. However, due to major factual and temporal errors, especially in the sequence of events and unsupported numerical claims, the overall correctness score is low. The qualitative accuracy is moderate because the direction of evolution (increased strategic involvement) is conceptually correct, but the details are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 517,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "Adobe Target's role within Adobe's customer journey solutions has evolved from a standalone personalization tool to an integrated component of Adobe's AI-driven Experience Cloud ecosystem. In fiscal 2022, Adobe Target was highlighted as part of the Customer Journeys solutions, enabling A/B testing and multivariate tests for personalized content. By fiscal 2023, Adobe Target is explicitly described as an AI- and machine learning-driven engine, emphasizing its integration with Adobe Journey Optimizer and Adobe Experience Platform to deliver real-time, hyper-personalized experiences across channels. This evolution reflects Adobe's strategic focus on leveraging AI and machine learning to unify data, automate personalization, and optimize customer journeys, positioning Adobe Target as a core enabler of its broader AI-driven personalization vision.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual information is correct: Adobe Target's role evolved from being part of a broader set of customer journey tools in fiscal 2022 (noted for A/B and multivariate testing) to being explicitly described as an 'AI- and machine learning-driven personalization engine' in fiscal 2023. The LLM correctly identifies its integration with Adobe Journey Optimizer and Adobe Experience Platform, which is consistent with the 2023 emphasis on AI-powered automation and omnichannel personalization. (2) There are no numeric values, dates, or financial figures in dispute; all time references (fiscal 2022 to 2023) are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across years and product integrations, correctly inferring Adobe’s strategic direction toward AI-driven personalization. (4) The only minor deviation from the original answer is that the LLM emphasizes 'integration with Adobe Experience Platform' and 'real-time, hyper-personalized experiences'—details not explicitly stated in the ground truth—though these are reasonable inferences given the context of AI-driven personalization and do not contradict the source. Overall, the answer captures the core evolution and strategic implication accurately, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 377,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "Emerson's financial stake in AspenTech expanded significantly following the acquisition of Heritage AspenTech in Q3 2022, as reflected in increased goodwill ($7.289 billion) and intangible assets. Post-acquisition integration activities included converting Heritage AspenTech's stock-based compensation awards into Emerson's plans, aligning vesting terms, and maintaining AspenTech as a separate publicly traded entity under Emerson's ownership. In 2023, AspenTech's integration involved performance-based compensation structures tied to financial metrics, with ongoing alignment of equity awards and operational integration efforts.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general evolution of Emerson's relationship with AspenTech but contains key factual inaccuracies. The ground truth states that Emerson reported a balance of $8,326 million related to AspenTech in 2022, while the LLM cites $7.289 billion in goodwill — a different figure and category (goodwill vs. total acquisition balance), which undermines quantitative accuracy. There is no mention in the ground truth of Q3 2022 as the acquisition timing, so adding that detail introduces unsupported precision. (2) The numbers do not align: $7.289 billion in goodwill is not equivalent to the $8,326 million total balance reported in the original answer, and the LLM fails to mention the full $8.326 billion figure. Additionally, the LLM incorrectly implies that Heritage AspenTech's stock awards were converted into Emerson's plans, while the ground truth states that AspenTech continued its own stock-based compensation plans (e.g., stock options and RSUs) under its own equity structure — a critical distinction in post-acquisition integration. (3) The multi-hop reasoning is partially sound: the model correctly infers a shift from acquisition to integration and identifies performance metrics like free cash flow as relevant. However, it misrepresents the nature of equity integration — the original answer emphasizes AspenTech maintaining its own publicly traded status and equity plans, whereas the LLM suggests conversion into Emerson’s plans, which contradicts the ground truth. (4) Despite these errors, the answer is contextually relevant and captures the high-level trajectory: increased financial stake in 2022 and deeper operational integration in 2023 with performance incentives. The qualitative reasoning is reasonable but flawed in key details, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 497,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023 by deepening integration with AI-powered tools like Adobe Sensei and enhancing cross-channel campaign orchestration. In 2022, the platform was highlighted as a central hub for connecting data and enabling personalized experiences across Adobe Experience Cloud solutions. By 2023, the platform's capabilities were expanded to include advanced AI services for real-time personalization, automation, and domain-specific intelligence (e.g., sentiment analysis, anomaly detection). Cross-channel orchestration was further strengthened through tools like Adobe Journey Optimizer, which allowed brands to manage seamless, data-driven customer journeys across all touchpoints, supported by AI-enhanced analytics and unified customer profiles.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of Adobe Experience Platform from 2022 to 2023. It accurately notes the platform's foundational role in 2022 with integration of Adobe Sensei for AI-powered services like sentiment analysis and anomaly detection, and its expansion in 2023 to support cross-channel orchestration via Adobe Journey Optimizer. The mention of real-time personalization, unified profiles, and AI-enhanced analytics aligns with the ground truth. However, the LLM omits specific 2023 innovations such as Adobe Mix Modeler, which is a key addition that leveraged Adobe Experience Platform and Adobe Sensei for marketing investment optimization. While the answer correctly identifies the shift toward campaign orchestration and AI integration, it lacks this concrete example, resulting in a minor completeness gap. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and all entities (Adobe Experience Platform, Adobe Sensei, Adobe Journey Optimizer) are correctly identified with appropriate timeframes. The reasoning is sound and synthesizes the multi-hop elements across years and functionalities, though slightly less detailed than the original. The response is fully contextually relevant, directly addressing the evolution in AI integration and cross-channel orchestration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1513,
        "completion_tokens": 380,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "UnitedHealth Group intensified its focus on value-based care models in 2024, accelerating the transition from fee-for-service to fully accountable care to address Medicare Advantage funding pressures. This included expanding investments in care coordination technology, clinical engagement, and data analytics to improve outcomes and reduce costs. The 2024 approach also emphasized adjusting member premiums, optimizing provider networks, and intensifying cost management to mitigate the impact of reduced Medicare Advantage rates and risk adjustment model changes, while prioritizing high-quality, affordable care.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative description of UnitedHealth Group's 2024 response to Medicare Advantage funding pressures, including cost management, provider network optimization, and continued investment in value-based care. It accurately references key elements such as risk adjustment changes, reduced rates, and the use of technology and data analytics. However, it misrepresents the evolution of the company's approach by stating that UnitedHealth 'intensified its focus' and 'accelerated the transition' in 2024, whereas the ground truth indicates a strategic shift from expansion to retrenchment due to financial pressures. The original answer emphasizes that 2023 was the period of aggressive investment and transition acceleration, while 2024 involved pullback and operational adjustments. The LLM answer incorrectly frames 2024 as a year of continued or intensified investment rather than one of cost containment and strategic retreat. There are no numeric values to verify, so quantitative accuracy is scored as 10. Contextual relevance is high as the response directly addresses the question and relevant factors. The qualitative accuracy is reduced due to the mischaracterization of the temporal shift in strategy, which is central to the multi-hop reasoning required (comparing 2023 vs 2024 approaches).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 371,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "The composition of TMO's debt instruments remained consistent between 2022 and 2023, with the 1.950% Notes due 2029 (listed as TMO 29) continuing to appear in both the 2022 and 2023 10-K filings under the \"Securities registered pursuant to Section 12(b) of the Act\" table. No changes in maturity, issuance, or retirement of these notes are indicated in the provided pages.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually correct regarding the continuity of the 1.950% Notes due 2029 (TMO 29) between 2022 and 2023, with accurate mention of the trading symbol and consistent presence in both years' filings. All quantitative elements—interest rate (1.950%), maturity year (2029), and trading symbol (TMO 29)—are correct, earning a perfect score on quantitative accuracy. However, the LLM answer is incomplete in scope: while it correctly notes no change in the specific notes, it omits the introduction of new debt instruments in 2023 (3.200% Notes due 2026 and 3.650% Notes due 2034), which is a key part of the evolution in debt composition highlighted in the ground truth. This missing information limits the qualitative accuracy, as the multi-hop reasoning required to assess the broader shift in financing strategy is not fully addressed. The answer remains contextually relevant and accurately interprets the data available in the filings, but fails to provide a complete picture of the debt portfolio evolution, resulting in a correctness score of 7 rather than higher.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 306,
        "total_tokens": 1537
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "Between 2022 and 2023, TMO's debt composition evolved by introducing new note categories while retaining the 0.500% Notes due 2028 (TMO 28A). In 2023, additional notes were added, including 3.200% Notes due 2026 (TMO 26B), 1.375% Notes due 2028 (TMO 28), 1.950% Notes due 2029 (TMO 29), and 3.650% Notes due 2034 (TMO 34), reflecting a diversification of maturity dates and interest rates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the retention of the 0.500% Notes due 2028 and the introduction of new note categories in 2023, including the 3.200% Notes due 2026 and the 3.650% Notes due 2034, which aligns with the ground truth. It also accurately includes the 1.375% Notes due 2028, confirming continuity. The only minor discrepancy is the inclusion of the 1.950% Notes due 2029 (TMO 29), which is not mentioned in the original answer. However, this does not contradict the ground truth—it may reflect additional detail not present in the original summary. (2) All numeric values—interest rates (0.500%, 3.200%, 1.375%, 1.950%, 3.650%) and maturity years (2026, 2028, 2029, 2034)—are accurate and correctly attributed. No calculations are required, and all figures match or extend the ground truth without error. (3) The multi-hop reasoning is sound: the model correctly infers a strategic diversification of debt instruments based on changes between 2022 and 2023, synthesizing continuity and new additions. The logic of evolving maturity timelines and interest rate structures is well-supported. (4) The answer is contextually fully relevant, directly addressing the evolution of TMO's debt composition. The inclusion of an extra note (1.950% due 2029) slightly exceeds the original answer but does not introduce inaccuracy; thus, the correctness score is reduced by one point for minor over-specification, but all core facts and reasoning remain correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 409,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "The range of excess fair value over carrying value for DHR's reporting units decreased between 2023 and 2024. In 2023, the range was **140% to 495%**, while in 2024, it narrowed to **70% to 450%**. This reflects a reduction in the minimum excess (from 140% to 70%) and a slight decrease in the maximum excess (from 495% to 450%).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 140% to 495% in 2023 and 70% to 450% in 2024. These values are correctly reported with no calculation or transcription errors. (2) The answer is complete, addressing the change in range over time and explicitly noting both the reduction in the minimum (140% to 70%) and the slight decrease in the maximum (495% to 450%). (3) Entity accuracy is correct—DHR is properly identified, and the years 2023 and 2024 are accurately referenced in the context of annual goodwill impairment analyses. (4) The reasoning is sound: the narrowing of the range is correctly interpreted as a decrease in the cushion before potential impairment, which aligns with the implication in the original answer. The LLM provides additional clarity by explicitly calling out the direction and magnitude of change in both ends of the range, enhancing the explanation without introducing error. (5) Semantic equivalence is achieved—the LLM conveys the same core information with slightly more detailed comparative language, which improves rather than distorts the message.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1171,
        "completion_tokens": 333,
        "total_tokens": 1504
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "The treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan remained consistent from 2022 to 2023. Both the 2022 and 2023 filings state that RSUs canceled or shares withheld for tax purposes increase the available share pool by **two times** the number of RSUs canceled or shares withheld. This mechanism ensures that shares returned to the pool due to cancellations or tax withholdings are effectively doubled, maintaining the available share pool for future grants. No change in the treatment or its impact on the share pool was noted between the two periods.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims the treatment of canceled RSUs and tax-withheld shares remained consistent from 2022 to 2023, stating that both years applied a 'two times' factor. However, the ground truth explicitly states that in 2023, the language specifying the 'two times' factor was omitted, indicating a change in treatment. This is a direct contradiction. (2) Quantitatively, the repeated emphasis on 'two times' in both years is factually wrong for 2023, making the numerical claim inaccurate. There is no support for the assertion that the mechanism remained unchanged. (3) The multi-hop reasoning failed: the question asks about the evolution of treatment across two years, requiring comparison of plan provisions between 2022 and 2023. The LLM incorrectly concluded no change occurred, missing the key detail that the doubling provision was removed in 2023. (4) Contextual relevance is low but not zero because the answer addresses the right topic (RSUs, tax-withheld shares, share pool), but it provides misleading information. The answer fabricates continuity where there was a documented change, severely undermining factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 330,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "Danaher's strategic relationship with Aldevron, acquired in 2021 for $9.6 billion, remained unchanged between 2023 and 2024. Aldevron continued to be part of the Life Sciences segment, contributing to product diversity in genomic medicine and bioprocessing. There were no new financial stake adjustments or integration updates mentioned in the 2024 filings, reflecting sustained operational integration since the acquisition.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly identifies Aldevron as part of Danaher's Life Sciences segment, it incorrectly states that the relationship 'remained unchanged' between 2023 and 2024, which contradicts the ground truth showing a strategic shift from a separately accounted stake to full integration. The acquisition year is stated as 2021, but the ground truth implies the financial stake was still significant in 2023, suggesting the integration process culminated later. The $9.6 billion figure is close to the ground truth $9,561 million (i.e., $9.561 billion), so this is a minor rounding difference and acceptable. However, the LLM claims 'no new financial stake adjustments or integration updates' in 2024, which directly contradicts the ground truth that Aldevron was no longer listed as a separate stake in 2024, indicating a material change. (2) Quantitatively, the $9.6B vs $9.561B is acceptable (within rounding), but the lack of mention of the removal of Aldevron as a standalone stake in 2024 misses a key quantitative shift in reporting. (3) The multi-hop reasoning is flawed: the model fails to synthesize the change in accounting treatment (from separate allocation to absorption into the segment) as evidence of deeper integration, which is central to the question. It incorrectly infers no change from absence of explicit mention, which is unsound. (4) Scores reflect partial factual accuracy on the acquisition value and segment placement, but major errors in interpreting the evolution of the relationship, leading to a low correctness and qualitative accuracy score. Contextual relevance is high as the answer addresses the right companies and general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 470,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024 by deepening its AI integration through Copilot, enhancing productivity and business process automation. In 2024, Microsoft 365 was positioned as an \"AI-first platform,\" with Copilot for Microsoft 365 combining AI with business data across applications like Teams, Dynamics 365, and role-specific tools (e.g., Copilot for Sales, Service, and Finance). This integration drove growth in commercial metrics, including a 14% increase in Office Commercial revenue and 82.5 million Microsoft 365 Consumer subscribers. The AI-driven capabilities also contributed to broader Microsoft Cloud revenue growth (23% YoY), underscoring its role in advancing the company's commercial business outcomes.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of Microsoft 365 as an AI-first platform with deeper integration of Copilot and AI across business applications, which aligns with the ground truth. It also correctly emphasizes the role of AI in enhancing productivity and commercial outcomes. However, it introduces specific quantitative claims not present in the original answer: a '14% increase in Office Commercial revenue' and '82.5 million Microsoft 365 Consumer subscribers'. These numbers are not mentioned in the ground truth and cannot be verified from the provided information, making them factually unsupported. (2) The ground truth does mention a change in the reporting metric—expanding Microsoft 365 Consumer subscribers to include Basic tier subscribers in 2024—but does not provide a numerical value like 82.5 million. Similarly, no percentage increase in Office Commercial revenue is stated. These fabricated figures significantly reduce quantitative accuracy. (3) The multi-hop reasoning is partially sound: the model correctly infers that AI integration (via Copilot) strengthens Microsoft 365’s commercial value and aligns with strategic positioning. It also connects AI capabilities to broader cloud revenue growth, which is plausible but not explicitly confirmed in the ground truth. However, it fails to mention the key strategic change in metric definition (inclusion of Basic subscribers), which is a central point in the original answer about evolving positioning. (4) While the qualitative direction and contextual focus on AI integration and commercial impact are accurate and relevant, the inclusion of unverified metrics undermines factual correctness. The answer captures the spirit of the evolution but lacks precision on the actual strategic changes documented, particularly around subscriber metric alignment. Hence, correctness is reduced due to unsupported numbers despite otherwise logical reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 527,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "Microsoft's Copilot Pro positioning in 2024 emphasizes its role as a consumer subscription service offering enhanced AI assistance within Microsoft 365 apps and on the web, as detailed in the 2024 10-K filing. The document highlights Copilot Pro's integration into Microsoft 365 and web-based workflows, expanding its utility for productivity and collaboration. While the 2023 filing may have introduced Copilot Pro, the 2024 disclosure underscores its evolution as a core component of Microsoft's AI-driven ecosystem, reinforcing its importance in both desktop and web environments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that Copilot Pro was introduced as a consumer subscription service offering enhanced AI assistance in Microsoft 365 apps and on the web, consistent with the 2023 positioning. The evolution in 2024 is accurately portrayed as a deeper integration into Microsoft's AI-driven ecosystem, with emphasis on its role in productivity and collaboration across desktop and web environments. The answer captures the core narrative shift—retention of 'faster and more powerful AI assistance' language while embedding it within a broader AI-first strategy—though it does not explicitly quote or highlight the continuity of that specific phrasing from 2023 to 2024, which slightly weakens the qualitative precision. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (Microsoft, Copilot Pro, Microsoft 365, 2023–2024 timeframe) are correct. The reasoning is sound, demonstrating multi-hop synthesis between the introduction in 2023 and strategic evolution in 2024. Contextual relevance is excellent, directly addressing the question about positioning and emphasis changes over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 337,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "Between 2023 and 2024, the structure of the 2007 Omnibus Incentive Plan remained unchanged, continuing to authorize stock options, RSUs, PSUs, and other equity awards. However, the remaining shares available for issuance under the plan decreased from **50 million** as of December 31, 2023, to **47 million** as of December 31, 2024, reflecting issuances during 2024. The plan's terms, including vesting periods and award types, remained consistent across both years.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claim that 50 million shares were available as of December 31, 2023. The ground truth states that no specific figure was provided for remaining shares in 2023, making the LLM's assertion of '50 million' unsupported and incorrect. The 47 million figure for 2024 matches the ground truth and is accurate. (2) The calculation of a 3 million decrease (from 50M to 47M) is therefore invalid, as the starting point (50M in 2023) is fabricated. There is no evidence in the ground truth that the company disclosed a precise number in 2023, so the comparison is unfounded. (3) The qualitative reasoning is partially sound—recognizing continuity in plan structure (award types, vesting) is reasonable and aligns with the context provided. However, the model fails the multi-hop synthesis by inventing a missing data point rather than acknowledging the absence of 2023 availability data. The evolution noted in the ground truth is about increased transparency in disclosure, not a quantifiable reduction. (4) The contextual relevance is high because the answer addresses the right plan, time frame, and topic (share availability and structure). However, the correctness score is low due to the critical error in numerical fabrication, which undermines trust in the response. Quantitative accuracy is severely penalized for the invented 50 million figure. Qualitative accuracy is moderate due to correct identification of award types and plan continuity, but penalized for flawed reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 434,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "Microsoft's accounting policy regarding the estimated useful lives of server and network equipment remained unchanged between fiscal years 2023 and 2024. In July 2022, Microsoft increased the estimated useful life from four to six years due to software efficiency improvements and technological advances, effective for fiscal year 2023. No further adjustments were mentioned in the 2024 filing, indicating the policy remained consistent.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and largely consistent with the ground truth. (1) Quantitatively, all numbers and dates are correct: the change from four to six years is accurately stated, and the effective timing (July 2022 for FY2023) aligns with the original answer. The absence of a policy change in FY2024 is correctly noted. (2) The LLM correctly identifies the factors influencing the change—software efficiency improvements and technological advances—which matches the ground truth's mention of 'investments in software that improved operational efficiencies and advances in technology.' (3) The reasoning is sound: the LLM correctly infers that no mention of a change in FY2024 implies policy consistency, which aligns with the original answer's statement that the policy 'remained consistent' and was 'sustained.' (4) The only minor shortcoming is that the LLM does not explicitly mention the ongoing cloud and AI infrastructure investments as reinforcing the rationale in FY2024, which is included in the original answer for contextual continuity. However, this omission does not detract from the core factual accuracy. The answer is semantically equivalent and contextually appropriate, with strong multi-hop synthesis across fiscal years and policy implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 356,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "MDT's auction rate securities remained classified as Level 3 in the fair value hierarchy throughout 2022 and 2023, with a fair value of $33 million in both periods. These securities were consistently reported as \"Other Assets\" in the balance sheet, and the unrealized losses of $3 million persisted, indicating no material change in exposure or classification between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the fair value of $33 million for both 2022 and 2023, which matches the ground truth, earning high marks for quantitative accuracy. However, it incorrectly claims that auction rate securities were classified as 'Other Assets' in both years, while the ground truth indicates that in 2022 they were included under 'Total' in the investment portfolio without a separate classification and only moved to 'Other Assets' in 2023. This is a critical factual error in classification evolution. Additionally, the LLM introduces information about Level 3 classification and unrealized losses of $3 million, which are not mentioned in the original answer and cannot be verified from the provided ground truth, suggesting hallucination. (2) The dollar amount ($33 million) is correct in both years, but the classification change — the core of the question — is misrepresented. The claim of consistent 'Other Assets' classification contradicts the ground truth's key point about a shift in reporting. (3) The multi-hop reasoning fails because the model does not recognize the change in balance sheet presentation from 2022 to 2023. Instead, it asserts no change, directly opposing the original answer’s conclusion of a shift in categorization. This undermines the qualitative accuracy. (4) While the answer addresses the question's topic and includes relevant financial data, the misrepresentation of the classification change and addition of unverified details (Level 3, unrealized losses) significantly reduce correctness. The contextual relevance is moderate because it discusses the right company and securities over the correct time frame, but the core insight is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 466,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "The net loss from Cisco's available-for-sale debt investments increased from $21 million in fiscal 2023 to $67 million in fiscal 2024, as reported in the \"Other Income (Loss), Net\" section. This indicates a deterioration in investment performance, likely driven by adverse market conditions, such as rising interest rates, which negatively impacted the fair value of these investments. The broader context of the 2024 financial disclosures highlights that higher interest rates and market volatility contributed to reduced returns on the portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the net losses of $21 million in fiscal 2023 and $67 million in fiscal 2024, matching the ground truth exactly. The increase in loss is accurately portrayed. (2) All numeric values are correct and properly attributed to the respective fiscal years. There are no calculation errors. Format variations (e.g., '$21 million') are acceptable and consistent with the ground truth. (3) The multi-hop reasoning is sound—comparing the two fiscal years' performance and drawing a conclusion about investment performance deterioration is valid. The LLM adds contextual insight (e.g., rising interest rates, market volatility) that is plausible and consistent with typical financial reporting, though this specific causal explanation is not present in the ground truth. While this additional context enhances understanding, it slightly extends beyond the provided truth, which only states the worsening performance without specifying causes. (4) The answer is factually correct, complete, and directly addresses both parts of the question: the change in net gains/losses and what it indicates. The added market context improves relevance without contradicting facts, warranting high scores. However, the qualitative accuracy is not perfect because the explanation of 'why' (interest rates) is inferred and not confirmed in the ground truth, though it is reasonable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 390,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "The provided document pages do not contain specific information detailing Cisco's evolution of operational structure versus financial investment in the APJC region between 2023 and 2024. The 2023 and 2024 10-K filings focus on general business strategies, financial summaries, and accounting policies, but no regional-specific analysis of APJC's operational or investment shifts is included. As such, the implications for Cisco's revenue model in the APJC region during this period cannot be determined from the given documents.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and fails to reflect the ground truth. (1) It claims the documents do not contain information about Cisco's APJC region evolution, but the original answer—based on actual 10-K filings—clearly states that in 2023, Cisco operated directly in APJC as a geographic segment, and by 2024 had expanded into financial investments including marketable and non-marketable equity securities and equity method investments. This operational-to-investment evolution is a key factual point the LLM missed entirely. (2) There are no numbers or calculations in this question, so quantitative accuracy is not applicable, but the LLM fails to report any of the specific financial categories mentioned in the ground truth. (3) The multi-hop reasoning required—comparing Cisco’s 2023 operational structure with its 2024 financial investment strategy in the same region—was not performed; instead, the model incorrectly asserts insufficient data. (4) While the response is relevant in topic (Cisco, APJC, 2023–2024), it is factually wrong and contradicts the provided ground truth, resulting in very low scores across correctness, accuracy, and reasoning. The contextual relevance is slightly higher only because the answer attempts to address the right general domain.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 358,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024 by adapting to legal pressures and market demands. In 2022, the Company acknowledged changes to the App Store, including adjustments to commission rates and distribution practices, driven by litigation, competition, and regulatory scrutiny. By 2024, Apple further modified its policies to comply with the EU's Digital Markets Act (DMA), implementing alternative fee structures, distribution methods, and payment processing options for iOS apps. These changes aimed to address regulatory requirements while potentially reducing commission rates, reflecting a strategic shift toward compliance with evolving legal frameworks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Apple acknowledged regulatory and legal pressures in 2022 affecting App Store commissions, and by 2024 implemented changes in response to the EU's Digital Markets Act (DMA). The mention of alternative fee structures, distribution methods, and payment processing options matches the original answer's reference to new business terms, alternative fee structures, and distribution methods. (2) There are no numeric values (e.g., percentages, dollar amounts) in either answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes Apple’s evolving stance from general acknowledgment in 2022 to concrete regulatory compliance actions in 2024, particularly in the U.S. and EU. The only minor omission is that the original specifies changes in both the U.S. and EU, while the LLM focuses primarily on the EU; however, the U.S. aspect is less emphasized in the source and not critical to the core claim. (4) The answer is contextually excellent—directly addresses the evolution in Apple’s approach, legal drivers, and financial implications. Wording differs slightly but maintains semantic equivalence. No factual inaccuracies. Thus, correctness is 9 (not 10) due to slight incompleteness regarding the U.S. scope, but all other dimensions are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 394,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "Between 2022 and 2024, Texas Instruments' U.S. Retiree Health Care Plan increased its allocation to fixed income securities and reduced equity securities. In 2022 (based on 2021 data), the plan held 65% fixed income and 35% equity. By 2024, the allocation shifted to 80% fixed income and 20% equity, reflecting a strategic rebalancing toward fixed income to align with asset-liability modeling and discount rate considerations.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in allocation strategy from a higher equity weighting in 2022 to a more conservative 80/20 fixed income to equity split in 2024, which aligns with the ground truth's description of increased emphasis on fixed income. However, the specific 2022 allocation percentages (65% fixed income, 35% equity) are not supported by the original answer, which provided dollar amounts ($248M fixed income and cash equivalents, $137M equity) but not percentages. A calculation from those amounts yields approximately 64.4% fixed income and 35.6% equity, so the 65/35 split is a reasonable approximation. The 80/20 split in 2024 matches the ground truth. (2) The LLM incorrectly references '2021 data' for the 2022 figures, which is not mentioned or implied in the original answer—this introduces an unsupported temporal assumption. The original answer clearly states the 2022 figures as reported for that year. (3) The reasoning about strategic rebalancing toward fixed income for capital preservation is consistent with the ground truth’s interpretation, showing sound qualitative synthesis. However, the mention of 'asset-liability modeling and discount rate considerations' introduces external rationale not present in the original answer, which focused on capital preservation without specifying technical drivers. (4) The correctness score is 6 due to partially accurate numbers (approximate percentages acceptable, but unsupported data year reference) and missing the explicit dollar values from 2022. Quantitative accuracy is penalized because the model invents a data provenance (2021 data) and omits verifiable dollar figures. Qualitative accuracy is decent given correct trend interpretation. Contextual relevance is high as the answer directly addresses the evolution of allocation strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 500,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "Texas Instruments' strategic emphasis on Embedded Processing Products has remained a key component of its business model, contributing to competitive advantages through its broad product portfolio and market reach. From 2022 to 2024, the segment's revenue slightly declined (from $3,261M in 2022 to $2,533M in 2024), but its operating profit margin improved in 2024 (13.9% vs. 38.4% in 2022), reflecting operational efficiency gains. The segment continues to be reported separately, underscoring its strategic importance, while restructuring charges in 2024 highlight ongoing adjustments to maintain competitiveness.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Embedded Processing was not a reportable segment in 2022 but became one in 2024, marking a strategic shift. However, the LLM incorrectly states that the segment 'continues to be reported separately,' implying it was always a reportable segment, which contradicts the ground truth. Additionally, the financial data provided (revenue declining from $3,261M to $2,533M and operating margin dropping from 38.4% to 13.9%) is factually incorrect and opposite to what would be expected with increased strategic emphasis. The ground truth does not provide specific financials, but the LLM's inclusion of such precise yet erroneous figures undermines credibility. (2) Quantitative accuracy is extremely low: the revenue and margin numbers are fabricated or misremembered. A margin decrease from 38.4% to 13.9% would indicate severe operational deterioration, not efficiency gains, making the interpretation illogical. There is no support in the ground truth for any financial figures. (3) Multi-hop reasoning is flawed. The question requires synthesizing changes in strategic emphasis, segment reporting, and competitive advantage over time. The LLM fails to identify the key evolution—elevation to a reportable segment in 2024—as a structural and strategic shift. Instead, it assumes continuity, missing the core insight. It also introduces unrelated details like restructuring charges not mentioned in the ground truth. (4) Contextual relevance is moderate because the answer discusses strategic importance and operational performance, which are relevant themes, but the incorrect facts and reasoning severely limit usefulness. The qualitative accuracy is low due to incorrect entity relationships and reasoning. Overall, the answer is mostly incorrect with major factual and conceptual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 511,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "TMO issued its 2.00% 10-Year Senior Notes in 2022, with the first issuance due on April 15, 2025 (euro-denominated) and an effective interest rate of 2.10% as of December 31, 2021. By 2024, the company had additional 2.00% 10-Year Senior Notes due on October 15, 2031 (euro-denominated), with an effective interest rate of 2.23% as of December 31, 2024. The effective rate increased from 2.10% in 2022 to 2.23% in 2024, reflecting market conditions and refinancing activities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, TMO issued $1,200 million in 2.00% 10-Year Senior Notes due October 15, 2031 in 2022 with an effective interest rate of 2.23%. The LLM incorrectly states that the issuance was due on April 15, 2025 (euro-denominated), citing a 2.10% effective rate as of December 31, 2021—none of which aligns with the original data. Furthermore, the LLM claims there were 'additional' notes issued by 2024, implying growth or new issuance, which contradicts the ground truth that the principal remained unchanged at $1,200 million with the same effective rate of 2.23%. (2) Quantitative accuracy is severely lacking: the dollar amount ($1,200 million) is never mentioned; the due date (October 15, 2031) is misrepresented; the effective interest rates are wrong for the stated years (2.10% in 2021 vs actual 2.23% in 2022); and no mention of consistency between 2022 and 2024. (3) The multi-hop reasoning is flawed—the question asks for evolution between 2022 and 2024, but the model fabricates euro-denominated notes and a rate increase from 2.10% to 2.23%, when in fact the rate was already 2.23% in 2022 and unchanged in 2024. It fails to recognize that no change occurred, which is the key insight in the ground truth. (4) Contextual relevance is moderate because the answer addresses the general topic of TMO's senior notes and attempts to compare across years, but the incorrect entities, dates, and financial figures undermine the response. The conclusion about market conditions and refinancing is unsupported by the data provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 444,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "Between 2022 and 2024, REMICADE (infliximab) sales declined from $1,839 million in 2023 to $1,605 million in 2024, reflecting a 12.8% decrease, primarily due to continued biosimilar competition. Despite this decline, REMICADE remains a key product in Johnson & Johnson's Pharmaceutical segment, contributing significantly to revenue in the Immunology therapeutic area. Its role underscores the segment's focus on immune-mediated inflammatory diseases, though the growing biosimilar threat highlights ongoing challenges in maintaining market share.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the sales figures for REMICADE in 2023 ($1,839 million) and 2024 ($1,605 million), and accurately calculates the 12.8% decline, which matches the ground truth. These numbers are factually correct and properly formatted. (2) All quantitative elements are accurate—sales amounts, year-over-year decrease, and percentage change are correctly stated and computed. The calculation of (1,839 - 1,605) / 1,839 ≈ 0.1278 (12.8%) is precise. (3) The reasoning is sound: the model correctly identifies REMICADE as a key product in J&J's Pharmaceutical segment within Immunology and synthesizes the impact of declining sales due to biosimilar competition, which aligns with the implied market dynamics in the ground truth. While the original answer cites 'market saturation, increased competition, or emergence of newer biologics,' the LLM specifies 'biosimilar competition'—a plausible and contextually accurate explanation consistent with industry trends and not contradicted by the ground truth. (4) The answer is contextually complete and relevant, addressing both the financial evolution and strategic role of REMICADE. The only minor difference is that the original answer references 2022 as a point of product significance without providing 2022 sales data, while the LLM focuses on 2023–2024 trends. However, since no 2022 sales figure was provided in the ground truth, the LLM appropriately uses available data. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 436,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "REMICADE sales declined from $3,190 million in 2021 to $1,605 million in 2024, reflecting continued biosimilar competition. This decline indicates REMICADE's market position within JNJ's Immunology portfolio has weakened relative to other products like STELARA and TREMFYA, which saw growth despite biosimilar pressures, highlighting the portfolio's diversification and resilience.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3,190 million sales figure for REMICADE and the $1,605 million sales in 2024, which matches the ground truth. However, it incorrectly states that $3,190 million was from 2021, while the original answer specifies this figure is from 2022. This misalignment in year affects the temporal accuracy of the trend description. Additionally, the LLM omits the specific year-on-year decline percentages provided in the ground truth (14.9% decline from 2020 to 2022 and 12.8% drop from 2023 to 2024), which are key quantitative benchmarks. (2) While the final 2024 number is correct, the starting point is misattributed to 2021 instead of 2022, introducing a timing error. The absence of intermediate data (e.g., 2023 sales) and exact percentage declines reduces quantitative precision. (3) The reasoning about REMICADE's weakening market position due to biosimilar competition and comparison to growing products like STELARA and TREMFYA is sound and adds valuable context not in the original answer, demonstrating good qualitative synthesis. However, this added context is not grounded in the provided ground truth, which does not mention those products or portfolio dynamics. (4) Despite the year misstatement and missing percentage declines, the core trend (significant sales decline over time) and conclusion (weakening market position) are consistent with the ground truth. The answer remains contextually relevant and insightful, but the factual inaccuracies in timing and missing metrics prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 429,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "Between 2021 and 2024, REMICADE sales declined from $3.19 billion (2021) to $1.61 billion (2024), reflecting a consistent 12.8% annual decrease. The primary factor driving this decline was **continued biosimilar competition**, both in the U.S. and internationally, which eroded REMICADE's market share. This competition intensified as biosimilar versions of the drug were introduced and additional competitors entered the market, leading to further sales reductions in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. The original answer states that REMICADE's sales were part of a larger Immunology segment totaling $16.8 billion in 2021, not that REMICADE alone generated $16.8 billion. However, the LLM incorrectly reports REMICADE's 2021 sales as $3.19 billion, which does not match either the standalone REMICADE figure or the segment total. The 2024 figure of $1.61 billion is close to the ground truth of $1,605 million, so this part is approximately correct. However, the claim of a 'consistent 12.8% annual decrease' is incorrect — the original specifies a 12.8% decrease from 2023 to 2024 only, not an annual trend. (2) Calculations: The LLM implies a steady annual decline based on two data points, but no evidence supports this pattern in the ground truth. The 12.8% drop is specific to one year, not cumulative or consistent. (3) Reasoning: The qualitative explanation of biosimilar competition in the U.S. and global markets is accurate and aligns with the original answer. The synthesis of competitive pressure leading to market share erosion and declining sales is logically sound and correctly identifies the causal factor. (4) Contextual relevance is high because the answer addresses both parts of the question — sales evolution and contributing factors — and focuses on the correct drug and timeframe. However, the major numerical inaccuracies in the starting sales figure and misrepresentation of the decline rate significantly reduce overall correctness. While the direction (decline) and cause (biosimilars) are correct, the magnitude and pattern of decline are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 458,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "Between 2022 and 2024, STELARA (ustekinumab) experienced a decline in sales due to increasing biosimilar competition and patent expiration. In 2021 (reported in the 2022 filing), STELARA sales were $9.1 billion, up 18.5% year-over-year, driven by strong uptake in Crohn's disease and ulcerative colitis. However, by 2024, sales fell to $10.4 billion, a 4.6% decrease from 2023, primarily due to share loss from European biosimilar entrants and continued competition with REMICADE biosimilars. The U.S. market saw $6.7 billion in sales in 2024, but the company anticipates further sales declines in 2025 as additional biosimilars launch.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. It incorrectly states that 2021 sales were $9.1 billion (reported in the 2022 filing), but the ground truth does not provide 2021 sales data, and $9.1B does not align with the reported $10,858M in 2023 or $10,361M in 2024. The claim of 18.5% year-over-year growth in 2021 is unsupported by the original answer. While the 4.6% decline from 2023 to 2024 matches the ground truth, the LLM incorrectly attributes 2024 sales as $10.4 billion (should be $10,361 million or ~$10.36B), introducing a rounding or reporting error. The $6.7B U.S. sales figure in 2024 is not mentioned in the ground truth and is therefore unverified. (2) The original answer highlights that in 2022, STELARA was in the filing stage for pediatric psoriatic arthritis — a key regulatory status update that the LLM omits entirely. Instead, the LLM introduces information about 2021 sales and disease indications (Crohn’s, ulcerative colitis) not present in the ground truth. (3) The multi-hop reasoning is partially sound in identifying a sales decline trend and linking it to biosimilar competition, which is a plausible inference, but the LLM fabricates earlier data points and misrepresents the timeline. It also introduces forward-looking expectations for 2025, which are outside the scope of the original answer. (4) The contextual relevance is high because the answer addresses the evolution of STELARA’s commercial performance, but correctness is low due to incorrect numbers, missing key regulatory status in 2022, and invented details. The qualitative accuracy is moderate because the general trend (sales decline due to biosimilars) aligns with expectations, but the reasoning is based on incorrect or unsupported data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 491,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "The total net revenue from Restasis in the United States decreased by **38.5% in 2023** compared to 2022, and by **55.2% in 2024** compared to 2023. \n\n**Key data points:**  \n- **2023 (vs. 2022):** $382 million (down 38.5%).  \n- **2024 (vs. 2023):** $172 million (down 55.2%).  \n\nThese figures are derived from the \"Eye Care\" section of the 2023 and 2024 10-K filings, which detail Restasis revenue and percentage changes.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts from the ground truth: the 2023 net revenue ($382 million), the 2024 net revenue ($172 million), the 38.5% decrease in 2023 compared to 2022, and the 55.2% decrease in 2024 compared to 2023. (2) All numeric values match the original answer exactly, including dollar amounts and percentage decreases. The percentages are correctly attributed to the right year-over-year comparisons. (3) The multi-hop reasoning is sound—though the question does not require retrieval of data from multiple companies, it does require synthesizing year-over-year revenue changes across two filings (2023 and 2024), which the model correctly attributes to the respective 10-Ks. (4) The answer is semantically equivalent to the ground truth, with added clarity in formatting and sourcing. All scores are 10 because the response is factually accurate, complete, and properly contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1161,
        "completion_tokens": 272,
        "total_tokens": 1434
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "The role and strategic importance of Master Lease Agreements (MLAs) evolved between 2022 and 2023 by strengthening AMT's international growth and tenant relationships. In 2023, MLAs were emphasized as critical tools for **reducing churn** (particularly in India and the U.S. & Canada) and fostering **long-term revenue stability** through comprehensive agreements that build strategic partnerships with tenants. These agreements also **accelerated colocation deployments**, enabling tenants to rapidly expand infrastructure on AMT's sites. Additionally, MLAs supported **international expansion** by leveraging AMT's global site portfolio (182,000 sites) and relationships with multinational carriers, ensuring consistent revenue streams and aligning with growth in emerging and mature markets. This strategic focus on MLAs reinforced tenant retention and scalability in both developed and developing regions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic evolution of Master Lease Agreements (MLAs) between 2022 and 2023, emphasizing their role in reducing churn, ensuring long-term revenue, accelerating colocation, and supporting international growth. It accurately reflects the expansion of AMT's international portfolio to approximately 182,000 sites in 2023 (up from 177,000 in 2022, per ground truth), which is correctly stated. However, the original answer does not specify that churn reduction was focused on India and the U.S. & Canada—this geographic detail is an addition not present in the ground truth and potentially misleading, though not factually incorrect if inferred. (2) Quantitatively, the 182,000 figure is accurate for 2023; the 177,000 figure from 2022 is omitted in the LLM answer but implied through context. No calculations are required, and all numbers presented are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes the strategic importance of MLAs in both years, connects them to international growth and tenant relationships, and links site count expansion with revenue stability and deployment speed. The omission of the 2022 site count is a minor completeness gap. (4) The answer is contextually excellent—directly relevant, well-structured, and focused on the evolution of MLAs. The addition of regional churn focus slightly exceeds the ground truth but doesn't contradict it. Overall, core facts, numbers, and strategic narrative are correct with only minor omissions or elaborations, warranting a high score but not perfect due to incomplete year-on-year synthesis and unsupported geographic specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 455,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "The role of Google Marketing Platform in advertising revenue generation remained consistent between 2023 and 2024, as it continues to serve as a key channel for customers to purchase advertising inventory. Advertising revenues from Google Network properties are recognized on a gross basis, with amounts billed to customers recorded as revenue and payments to Google Network partners recorded as cost of revenues. No significant changes in revenue recognition or management practices across Google Network properties were noted in the 2024 disclosures compared to 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that there were no significant changes between 2023 and 2024, which directly contradicts the ground truth. The original answer states that the role of Google Marketing Platform evolved in 2024 to include a more nuanced evaluation of principal versus agent status and a deeper explanation of its control over advertising inventory—key developments in revenue recognition logic. The LLM incorrectly claims consistency and absence of change, missing the core evolution described. (2) There are no explicit numerical values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not heavily applicable; however, the years 2023 and 2024 are correctly referenced, and the gross revenue recognition description is factually accurate as far as it goes, warranting a moderate score. (3) The multi-hop reasoning is flawed: the question asks for an evolution between two years, requiring comparison and synthesis of changes in revenue recognition practices. The LLM fails this synthesis by denying any change, despite the ground truth highlighting a meaningful shift in disclosure and rationale around gross reporting based on control. (4) Contextual relevance is moderate because the answer discusses the correct entities (Google Marketing Platform, Google Network properties, gross revenue recognition) and the general topic of advertising revenue management, but it fails to capture the critical evolution in 2024, rendering it substantially incomplete and misleading in its conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 435,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "The volume (average balance) of Federal Funds Purchased & Securities Loaned increased from $291,669 million in 2023 to $324,389 million in 2024, while their fair value rose from $133,053 million to $144,501 million. This indicates BAC expanded its use of short-term funding sources, potentially to enhance liquidity or manage interest rate risk. However, the decline in interest income ($18,679 million in 2023 to $15,965 million in 2024) suggests lower yields on these funds, possibly reflecting competitive rates or a shift toward lower-cost funding strategies. The increase in volume and fair value aligns with a strategy to bolster short-term liquidity, while the interest income trend highlights a focus on cost efficiency in funding.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers compared to the ground truth. The ground truth states that in 2023, the volume (net change) of Federal Funds Purchased & Sec Loaned was $16,466 million, not average balances of $291,669 million in 2023 and $324,389 million in 2024 as claimed by the LLM. Additionally, the fair value in 2024 is reported as $192,859 million in the original answer, whereas the LLM reports $144,501 million—over $48 billion lower. The LLM also introduces interest income figures ($18,679M to $15,965M) that are not present in the ground truth and cannot be verified from the provided data. (2) Calculations: The LLM’s volume increase of $32,720 million ($324,389M - $291,669M) does not align with the ground truth’s net change of $16,466 million in 2023, and the fair value increase is understated. There is no support for the interest income trend mentioned. (3) Multi-hop reasoning: The LLM attempts to infer strategy based on volume, fair value, and interest income, but because the underlying data is incorrect or extraneous, the reasoning is flawed. The ground truth focuses on the rise in fair value to $192,859M and increased liabilities indicating greater reliance on short-term secured funding—specifically tied to trading and liquidity management. The LLM mischaracterizes the data and adds unsupported metrics. (4) Despite incorrect numbers, the LLM correctly interprets the directional trend (increase in volume and fair value suggesting expanded short-term funding use), which gives partial credit for contextual relevance and qualitative insight. However, the severe quantitative errors undermine factual correctness, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 470,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "PepsiCo's disclosures regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations remained consistent between 2022 and 2024, with both filings noting that such exposure is discussed in \"Our Critical Accounting Policies and Estimates.\" However, the 2024 filing provided more specific details on the expense drivers (e.g., settlement charges and a group annuity contract) but did not introduce new information about the sensitivity of these liabilities to market fluctuations. Thus, the evolution in disclosure was minimal, focusing instead on operational changes rather than expanded market risk analysis.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. While it correctly notes that PepsiCo discussed the exposure of pension and retiree medical plan liabilities in 'Our Critical Accounting Policies and Estimates' in both years, it incorrectly asserts that there was minimal evolution and no new information about sensitivity to market fluctuations. The ground truth states that in 2024, PepsiCo expanded its disclosure to explicitly link sensitivity not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions—indicating a broader and more detailed macroeconomic risk analysis. This key evolution is entirely missed by the LLM. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, the years (2022 and 2024) are correctly referenced, earning full marks here. (3) The multi-hop reasoning is flawed: the LLM fails to synthesize the expanded risk context in 2024, which requires connecting disclosures across two years and identifying qualitative changes in risk characterization. Instead, it focuses on operational details like settlement charges and annuity contracts—information not mentioned in the ground truth and irrelevant to the question about sensitivity to market and macroeconomic fluctuations. (4) The contextual relevance is moderate because the answer addresses the right section of the filing and the right topic, but it misrepresents the nature of the evolution, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 428,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "Adobe Scan's approach remained consistent between 2023 and 2024, emphasizing its role as a free mobile app for converting paper documents into editable, searchable PDFs via Adobe Document Cloud services. In both years, it was positioned as a key component of Adobe's broader document management ecosystem, integrating with Acrobat, Acrobat Sign, and other Adobe apps to streamline workflows. No significant changes or new features were highlighted in the 2024 filings regarding Adobe Scan's functionality or positioning.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in stating that Adobe Scan remained a free mobile app integrated with Adobe Document Cloud and other Adobe tools in both 2023 and 2024. However, it incorrectly claims no significant changes were highlighted in 2024, which contradicts the ground truth. The original answer identifies a key evolution in 2024: increased emphasis on integration with cloud-based productivity tools and AI-driven features such as Content Credentials and Firefly-powered generative AI workflows, signaling a strategic shift toward enterprise workflows and digital trust. This represents a meaningful change in positioning that the LLM answer omits. While there are no numeric inaccuracies (hence a high quantitative score), the qualitative accuracy is low because the model fails to capture the multi-hop synthesis of Adobe's strategic shift across years and product lines. The reasoning is flawed in concluding no changes occurred, despite evidence of enhanced ecosystem integration and AI feature adoption. Contextual relevance is moderate since the answer addresses Adobe Scan’s role but misses the evolution in strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 320,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "Gemini's role and integration across Google's products expanded significantly from 2023 to 2024. Initially launched in 2023 as a native multimodal AI model, Gemini was integrated into all seven of Google's core products (Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube). In 2024, Gemini 2.0 was introduced, enhancing its multimodal capabilities to handle text, code, audio, images, and video with greater sophistication. Key advancements included improved AI features like image generation, coding support, and app integration in the Gemini app, as well as enhanced productivity tools in Google Workspace. Additionally, Gemini 2.0 powered new research prototypes (e.g., Project Astra) and improved YouTube recommendations and Google Ads capabilities, solidifying its role as a foundational AI model across Google's ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Gemini launched in 2023 as a multimodal model capable of handling text, code, audio, images, and video; in 2024, Gemini 2.0 was introduced and integrated into all seven of Google's two-billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube. The mention of Project Astra as an experimental prototype is accurate. (2) Quantitative elements—such as the timeline (2023 launch, 2024 evolution), the number of core products (seven), and the types of data modalities—are all factually correct with no calculation errors. (3) The multi-hop reasoning is sound: the answer synthesizes Gemini’s evolution across time, product integration, and capability enhancements. (4) Minor deduction in qualitative accuracy due to the addition of 'improved YouTube recommendations and Google Ads capabilities' and 'enhanced productivity tools in Google Workspace'—while plausible and contextually consistent, these specific applications are not present in the ground truth and introduce slight overreach. Similarly, 'image generation' and 'app integration in the Gemini app' are not mentioned in the original, though they may be part of Gemini 2.0’s features. Overall, the answer captures the core evolution and multimodal advancements accurately, with only minor additions beyond the provided truth. Semantic equivalence is largely preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 399,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "Linde's global helium wholesale business, part of the \"Other\" segment, saw decreased sales in 2024 due to lower volumes, primarily impacting the segment's operating profit. While 2022 documents only note helium's inclusion in the Other segment without specific performance details, 2024 data highlights that helium-related costs contributed to higher expenses, partially offset by insurance recoveries for other businesses like LAMT. The segment's operating profit increased in 2024 despite helium-related challenges, indicating a complex interplay between volume declines and cost management.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Linde's relationship with helium from 2022 to 2024 and its impact on sales and operating profit. In 2022, the ground truth states helium was listed as a supply, indicating a neutral/positive relationship, which the LLM accurately reflects by noting helium's inclusion in the 'Other' segment without negative performance details. By 2024, the LLM correctly identifies that lower helium volumes led to decreased sales and that higher helium-related costs negatively impacted operating profit, particularly by partially offsetting an insurance recovery in LAMT. The LLM also correctly notes the 44% overall increase in operating profit for the 'Other' segment, though it does not explicitly state the 2% sales decrease due to helium—this omission is significant but not critical, as the directional impact is conveyed. All entities (Linde, LAMT, 'Other' segment, global helium wholesale) and years (2022, 2024) are accurate. The reasoning is sound, showing multi-hop synthesis between operational performance and financial impact across years. The only shortcoming is the missing explicit mention of the 2% sales decline, which reduces quantitative precision slightly. However, the qualitative narrative and overall correctness remain strong, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 365,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "The net value of acquired franchise rights decreased from $626 million in 2022 to $598 million in 2024, representing a $28 million reduction. This decline reflects amortization and adjustments in the carrying value over the period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative values. According to the ground truth, the net value of acquired franchise rights in 2022 was $789 million, but the LLM incorrectly states it as $626 million. The 2024 value is correctly reported as $598 million. This error directly impacts the calculated change: the LLM reports a $28 million reduction, but the actual decline is $789M - $598M = $191 million, making the LLM's magnitude of change severely underreported. (2) Number verification: 2022 value: incorrect ($626M vs $789M); 2024 value: correct ($598M); difference: incorrect ($28M vs $191M). The calculation itself (if based on LLM's numbers) would be $626M - $598M = $28M, so internal consistency is present, but the inputs are wrong. (3) Multi-hop reasoning: The model correctly identifies that the change involves a decrease over time and attributes it to amortization and carrying value adjustments, which is plausible and contextually appropriate. However, because the starting value is wrong, the synthesis across years fails to reflect the true magnitude. (4) The contextual relevance is high because the answer addresses the evolution and magnitude of change as asked. Qualitative accuracy is moderate because the direction (decrease) and reasoning are sound, but quantitative accuracy is low due to the major error in the 2022 figure. Correctness score is 4 due to partial correctness (right trend, wrong numbers, severely miscalculated magnitude).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1097,
        "completion_tokens": 416,
        "total_tokens": 1514
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolved from 2023 to 2024 as follows: In 2023, Chevron's delivery commitments outside the U.S. included 2.9 trillion cubic feet of natural gas from 2024–2026, with operations in Australia and Israel. In 2024, these commitments increased to 3.2 trillion cubic feet for 2025–2027. However, specific production volumes for Tengizchevroil are not detailed in the documents, as the data provided reflects aggregated affiliate production (including Tengizchevroil) and does not break down individual projects. The 2024 affiliate natural gas production (1,849 billion cubic feet) slightly decreased compared to 2023 (2,063 billion cubic feet), but this may reflect broader operational changes rather than Tengizchevroil-specific trends.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to accurately reflect the ground truth. (1) Quantitatively, the numbers provided are completely different from the original answer: the ground truth reports daily natural gas volumes (in million cubic feet per day), while the LLM cites multi-year aggregated commitments in trillions of cubic feet (e.g., 2.9 Tcf for 2024–2026), which is a different metric and time frame. The LLM also incorrectly states that 2024 affiliate production (1,849 Bcf) decreased from 2023 (2,063 Bcf), which contradicts the ground truth showing an increase in Tengizchevroil-related sold volumes from 7,148 to 7,569 MMcf/d. These figures do not align with the actual data and suggest confusion between different reporting units (daily vs. annual, aggregated vs. project-specific). (2) The answer fails on completeness: it does not report the actual production and consumption volumes from Tengizchevroil as presented in the original answer (596 to 609 MMcf/d consumed, 7,148 to 7,569 MMcf/d sold), which are central to the question. Instead, it claims such data is not available, which contradicts the ground truth. (3) Entity accuracy is partially correct—Chevron and Tengizchevroil are correctly identified—but the time periods (2023 vs. 2024) and metrics (daily production vs. multi-year delivery commitments) are misaligned. (4) The reasoning is flawed: the LLM appears to conflate delivery commitments from other regions (Australia, Israel) with Tengizchevroil data and fails to extract the correct multi-hop information about how Tengizchevroil’s contributions evolved year-over-year. The conclusion about decreased production contradicts the actual increase reported. Overall, the answer misrepresents the data, uses incorrect metrics, and misses the core facts, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 493,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "The role of Google Network partners in Google's advertising revenue model remained consistent between 2023 and 2024, as described in the 2023 10-K filing. Payments to Google Network partners are categorized as part of the \"cost of revenues\" in the 2023 filing, specifically under \"TAC\" (Total Advertising Cost), which includes amounts paid to these partners for ads displayed on their properties. No explicit changes in the description of these payments or their role in the revenue model are noted in the provided 2024 pages, suggesting the framework remained unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that there was no change between 2023 and 2024 in how payments to Google Network partners are described. The ground truth states a clear evolution—from being described as a standard operating expense in cash flow activities in 2023 to being explicitly categorized under Traffic Acquisition Costs (TAC) tied to revenue generation in 2024. The LLM incorrectly claims the framework remained unchanged, which contradicts the ground truth. (2) There are no numeric values to verify, so quantitative accuracy is not heavily applicable; however, the mention of 'TAC' is correct in concept but mislabeled as 'Total Advertising Cost' instead of 'Traffic Acquisition Costs', which is a terminology error. (3) The multi-hop reasoning is flawed—the question requires comparing the description of payments across two years (2023 vs 2024), but the LLM relies only on the 2023 filing and states no changes were noted in 'provided 2024 pages', implying insufficient or incorrect cross-year analysis. It fails to recognize the shift in categorization and strategic framing. (4) Correctness and qualitative accuracy are low due to the central factual error about the evolution of the payment description. Contextual relevance is moderate because the answer discusses the right topic (Google Network partners, TAC, cost of revenues) but draws an incorrect conclusion about change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 398,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "The impact of public policies on Bank of America's climate-related regulatory requirements has seen heightened jurisdictional divergence and compliance risks from 2023 to 2024. Both years highlight increasing global regulatory focus on climate change, with divergent standards across jurisdictions (e.g., U.S. vs. non-U.S. regions) creating complexity in compliance. In 2023, the bank noted potential jurisdictional divergence as a key risk, while 2024 emphasized ongoing challenges in navigating evolving regulations, including stricter disclosure requirements and varying interpretations of climate-related policies. This divergence increases legal, compliance, and reputational risks, requiring Bank of America to adapt strategies to align with diverse regulatory expectations while managing potential operational and financial impacts.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: both 2023 and 2024 are accurately represented in terms of Bank of America's evolving concerns about jurisdictional divergence and compliance risks related to climate regulations. The shift from anticipated risk in 2023 to active impact in 2024 is correctly conveyed, though the LLM uses 'ongoing challenges' rather than explicitly stating the transition from anticipation to tangible impact. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not applicable—scored as 10 by default since no errors exist. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years and jurisdictions, correctly identifying the evolution in regulatory impact. It captures the core idea that divergence across U.S. and non-U.S. regions increases legal, compliance, and reputational risks. (4) The answer is contextually excellent—directly addresses the question about evolution from 2023 to 2024, jurisdictional divergence, and compliance risks. The only minor shortcoming is a slightly less precise articulation of the shift from 'expected' to 'actual' impact compared to the original answer, which clearly frames the 2024 situation as actively impacting risks. This nuance is implied but not explicitly stated, justifying a 9 instead of 10 on qualitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 404,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "General Motors' strategic emphasis on full-size pickup trucks intensified from 2022 to 2024, as evidenced by a **23.7% share of total vehicle sales in 2024** (up from 21.9% in 2023) and a **11.4% year-over-year increase in GMNA total net sales** driven by strong demand for full-size pickups and SUVs. In 2024, full-size pickups contributed to **higher variable profit margins (160% vs. 40% for crossovers)** and **EBIT-adjusted margin improvement to 9.2%**, reflecting stronger market positioning and profitability. These metrics highlight a shift toward outperforming other segments, with trucks driving growth and margin expansion.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several incorrect quantitative claims not supported by the ground truth. Specifically, the 23.7% share of total vehicle sales in 2024 (up from 21.9% in 2023), 11.4% year-over-year increase in GMNA total net sales, and EBIT-adjusted margin improvement to 9.2% are not present in the original answer and cannot be verified from the provided knowledge. The only correct quantitative figure is the 160% variable profit for trucks, which matches the ground truth. However, the comparison to 40% for crossovers is fabricated and not mentioned in the original. (2) The ground truth does not provide sales share percentages, year-over-year sales growth figures, or EBIT-adjusted margin percentages—these are hallucinated. The only verified metric is the 'approximately 160%' variable profit on a weighted-average basis for full-size pickup trucks in 2024. (3) The qualitative reasoning partially aligns with the multi-hop evolution: the shift from risk factor (2022) to performance driver (2024) is correctly inferred, and the emphasis on profitability and market positioning is contextually appropriate. However, the model fails to mention the key point that full-size trucks were a 'key risk factor' in 2022, instead implying a continuous strategic emphasis without highlighting the shift from vulnerability to strength. (4) While the answer is relevant and attempts to address both parts of the question—evolution of strategy and 2024 performance indicators—it introduces false precision through unsupported numbers, significantly undermining factual correctness. The contextual relevance is high because it focuses on the right product line, time frame, and financial implications, but the quantitative inaccuracies severely limit reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 483,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "The allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts remained relatively stable from 2023 to 2024, with values of $20 million in both years. However, in 2021, the allocation was $21 million, indicating a minor decrease from 2021 to 2023. This stability suggests the company maintained a conservative investment strategy, prioritizing low-risk, liquid assets like U.S. Treasury securities to ensure fund security for decommissioning obligations. The lack of significant shifts implies a focus on preserving capital rather than pursuing higher-yield alternatives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. It discusses allocations for 2021, 2023, and 2024 but completely omits the key entities from the ground truth—Alabama Power and Georgia Power. Instead, it presents a single aggregated figure ($20M in 2023 and 2024), which does not reflect the subsidiary-level breakdown required. The ground truth shows Alabama Power decreased from $21M to $20M and Georgia Power increased from $293M to $349M between 2022 and 2024—information entirely missing from the LLM response. (2) Quantitatively, the LLM invents a 2021 figure of $21M (while the ground truth starts in 2022) and incorrectly aggregates values across subsidiaries. It fails to report Georgia Power’s significant increase to $349M, a major component of the trend. The years referenced (2021, 2023) are either incorrect or not supported by the provided data, which focuses on 2022 and 2024. (3) The reasoning is flawed because it does not perform the necessary multi-hop synthesis across subsidiaries and years. The conclusion about 'stability' contradicts the ground truth, which shows a notable shift toward Georgia Power. The LLM fails to identify this strategic reallocation and instead assumes uniformity across the portfolio. (4) Scores are low due to major factual inaccuracies, incorrect numbers, wrong years, and failure to address the multi-entity nature of the question. Contextual relevance is moderate because the answer discusses investment strategy in the right domain (nuclear decommissioning trusts, conservative strategy), but the lack of entity-specific analysis and incorrect data severely undermines its validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 455,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "PepsiCo's relationship with independent bottlers from 2022 to 2024 maintained financial incentives through annual bottler funding agreements, which support advertising, new product launches, and distribution programs. However, in 2024, the company shifted its alcoholic beverage business toward a trademark licensing model, reducing reliance on bottlers for those products. For core beverages, strategic dependency persisted via exclusive geographic contracts and royalty structures, with financial incentives focused on sustaining distribution and market presence.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces a significant factual inaccuracy regarding the shift in PepsiCo's alcoholic beverage business to a trademark licensing model in 2024, which is not present in the ground truth and contradicts the stated increased strategic dependency on bottlers. This undermines the core claim about reduced reliance. Additionally, the ground truth emphasizes an evolution toward more structured and specifically allocated funding across trade and consumer programs, which the LLM captures in part (e.g., advertising, new product launches), but misses the accrual methodology based on annual targets and historical experience in 2022. The critical fact that Walmart accounted for approximately 14% of consolidated net revenue through independent bottlers in 2024—a key indicator of strategic dependency—is entirely omitted. (2) There are no explicit numbers in the LLM answer to verify against the 14% figure or other financial metrics, resulting in incomplete quantitative support. The absence of this percentage significantly weakens the response. (3) The multi-hop reasoning is partially sound in identifying evolving financial incentives and ongoing strategic dependency, but the incorrect claim about reduced reliance via trademark licensing breaks the logical synthesis of the relationship’s evolution. The model fails to connect the increased revenue dependency (via Walmart) with the financial structuring of bottler incentives, which is central to the ground truth. (4) While the answer remains contextually relevant and addresses the general theme of financial incentives and strategic dependency, the omission of key data and introduction of unsupported claims reduce correctness and qualitative accuracy. The contextual relevance is higher because the response stays on-topic and discusses appropriate dimensions of the bottler relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 518,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "Adobe Firefly's role in Adobe's product innovation strategy has evolved from 2023 to 2024, with a heightened focus on AI integration and risk management. In 2024, Adobe explicitly positioned Firefly as a core component of its AI-driven product innovation, emphasizing efforts to enhance AI capabilities across its offerings (e.g., \"enhancing the artificial intelligence ('AI') capabilities of our products\"). However, risk disclosures highlight ongoing uncertainties, including regulatory challenges, competition, and the potential for reputational harm or financial impact from AI-related issues. While 2023 filings (not fully visible here) likely established Firefly as a foundational AI tool, 2024 disclosures reflect a more strategic emphasis on scaling AI integration while addressing associated risks, such as compliance costs and market competition.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but diverges from the ground truth in key aspects of reasoning and factual synthesis. (1) Correct elements: The answer correctly identifies Adobe Firefly's growing strategic importance in 2024 and references AI integration and risk disclosures, which aligns with the general direction of the original answer. It appropriately notes regulatory and competitive risks associated with AI, which are plausible inclusions in risk factors. (2) Quantitative accuracy: There are no numerical values in the question or answers, so this dimension is neutral; no errors present. (3) Multi-hop reasoning assessment: The core of the original answer hinges on a specific evolution—Firefly moved from being listed in trademarks (2023) to being explicitly mentioned in risk factors as a newly released generative AI product (2024)—signaling strategic elevation. The LLM answer does not mention the trademark listing in 2023 or the shift to risk disclosures in 2024 as evidence of strategic evolution. Instead, it assumes Firefly was a 'foundational AI tool' in 2023 without citing trademark data and overemphasizes risk management without tying it to the structural change in disclosure type (trademark → risk factor). This misses the key multi-hop insight: the change in disclosure context reflects strategic repositioning. (4) Justification for scores: Correctness is scored 6 due to plausible but unsubstantiated claims and failure to accurately reflect the evidentiary basis (trademark vs. risk factor evolution). Qualitative accuracy is 6 because while entities (Adobe, Firefly, AI strategy) are correct, the reasoning and use of evidence are flawed. Quantitative accuracy is 10 by default (no numbers). Contextual relevance is 8 because the answer addresses AI strategy and risks but misattributes the supporting evidence from filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 501,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "Contractual rent escalations continued to be a key driver of tenant billing growth in 2023, as noted in the 2023 filing, which explicitly lists them as a primary factor in revenue growth alongside colocations and lease amendments. However, the increased churn (3% of tenant billings in 2023, up from 4% in 2022) and lease cancellations, particularly in the U.S. & Canada segment due to T-Mobile/Sprint MLA terms, partially offset the growth from escalations. Despite this, the lower overall churn rate compared to 2022 reduced the dilution effect of churn on escalations, maintaining their significance in driving billing growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the churn rate comparison: it states that churn was '3% of tenant billings in 2023, up from 4% in 2022', which incorrectly implies that churn decreased from 2022 to 2023. However, the ground truth states that churn was 'elevated' in 2023 at approximately 3%, and was higher than in 2022 — meaning the 4% figure for 2022 is incorrect and contradicts the original context. This misrepresents the trend and undermines the conclusion that lower churn reduced dilution. In fact, increased churn in 2023 should act as a headwind, not a mitigating factor. (2) The quantitative accuracy is compromised by this inversion of percentages — stating 4% churn in 2022 vs. 3% in 2023 directly contradicts the ground truth that churn increased in 2023 and is now elevated. No other numbers (e.g., T-Mobile impact, U.S. & Canada focus) are quantitatively wrong, but the core comparison is flawed. (3) The multi-hop reasoning is partially sound: the model correctly identifies contractual rent escalations as a continued driver and links T-Mobile/Sprint lease cancellations to churn in the U.S. & Canada segment. However, the flawed churn trend leads to an incorrect synthesis — concluding that lower churn helped maintain escalations' impact, when the truth is that higher churn offsets it. This reverses the causal logic. (4) Despite this, the answer is contextually relevant and captures key entities (T-Mobile, lease amendments, colocations, U.S. & Canada segment) and the tension between escalations and churn. The qualitative reasoning structure is good but built on a false premise. Hence, correctness is partially compromised — core facts are present but the central dynamic is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 476,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "Chevron's capital expenditure commitment for Tengizchevroil decreased from $2.31 billion in 2023 to an estimated $1.5 billion in 2024, as nearly half of the projected $3 billion in Affiliate Capex for 2024 is allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. Production involvement remained significant, with Chevron's net production in Kazakhstan (including Tengizchevroil) showing stable crude oil output (45 MBD) and slightly reduced natural gas production (113 MMCFD in 2024 vs. 114 MMCFD in 2023).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar figures ($2.31 billion in 2023 and $1.5 billion in 2024) that are not present in the original answer and cannot be verified from the provided ground truth. The original answer states that 'nearly half' of the $3 billion 2024 Affiliate Capex was allocated to Tengizchevroil, implying approximately $1.5 billion in 2024, which the LLM correctly infers. However, the $2.31 billion figure for 2023 is unsupported and appears fabricated, as the original answer does not provide any 2023 capital expenditure amount—only a forward-looking statement about 2024 allocations. Additionally, the LLM introduces production data (45 MBD crude oil, 113/114 MMCFD natural gas) that are not mentioned in the original answer, making them factually unverifiable and likely incorrect in this context. (2) While the $1.5 billion estimate for 2024 is a reasonable interpretation of 'nearly half' of $3 billion, the inclusion of precise 2023 Capex and detailed production metrics goes beyond the source material and undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound—the model correctly identifies the shift from capital investment focus in 2023 to production emphasis in 2024. However, it overreaches by introducing unsupported numerical specifics, failing to stay within the bounds of the known facts. (4) The contextual relevance is high because the answer addresses both capital commitments and production involvement across the two years, aligning with the question’s requirements. However, the correctness score is low due to significant factual inaccuracies and hallucinated data, particularly in quantitative claims not grounded in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 469,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "The specificity of UPS's bond matching approach for determining the discount rate for U.S. pension and postretirement benefit plans remained consistent between 2023 and 2024. UPS continued to use the bond matching method, selecting specific bonds to match projected benefit cash flows, as described in the 2023 and 2024 filings. While the discount rate decreased from 5.79% in 2023 to 5.42% in 2024, reflecting changes in market conditions and bond yields, the methodology itself did not evolve in terms of specificity. The approach remained focused on aligning bond cash flows with plan obligations, with no indication of enhanced granularity or revised criteria in the 2024 disclosure.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that UPS used a bond matching approach in both 2023 and 2024 and that the methodology remained consistent in practice. It accurately notes the discount rate decreased from 5.79% to 5.42%, which aligns with market conditions—this numerical information is factually correct and matches the knowledge graph's context on rate changes. However, the ground truth emphasizes a subtle but important evolution in *language* and *framing*: in 2024, UPS began describing the bond matching approach as a 'guide' for selection rather than a direct matching process, signaling a shift in operational framing. The LLM answer misses this nuance entirely and incorrectly concludes there was 'no evolution in specificity' and 'no indication of enhanced granularity or revised criteria,' which contradicts the ground truth’s assertion of a more precise operational statement in 2024. (2) Quantitatively, the discount rates (5.79% in 2023, 5.42% in 2024) are accurate and correctly compared; no calculation errors. (3) The multi-hop reasoning is partially sound—information about the method and rates is synthesized correctly across years—but fails to capture the qualitative shift in disclosure language that constitutes the core of the question about 'evolution in specificity.' The model treats consistency in mechanics as synonymous with no evolution in specificity, whereas the ground truth distinguishes between mechanical consistency and increased precision in communication. (4) Correctness is scored at 5 due to major omission of the key qualitative shift; quantitative accuracy is high (8) due to correct numbers; qualitative accuracy is moderate (5) because reasoning is logical but misses critical nuance; contextual relevance is high (9) as the response stays focused on the topic and timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 498,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "Linde's helium business, part of the \"Other\" segment, experienced lower sales in 2024 due to reduced volumes, primarily affecting global helium wholesale. However, operating profit in this segment increased by $19 million (44%) in 2024 compared to 2023, driven by insurance recovery for LAMT, despite higher costs linked to helium. This reflects a shift in financial performance where helium-related challenges impacted sales but were partially offset by non-helium factors.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures part of the truth but contains significant inaccuracies. It correctly identifies that helium had a negative impact on sales in 2024 due to lower volumes in global helium and that LAMT-related insurance recovery helped operating profit. However, it incorrectly states that operating profit increased by $19 million (44%) in 2024 compared to 2023 — this specific figure and percentage are not supported by the ground truth, which only mentions downward pressure on operating profit partially offset by insurance recovery, without quantifying the net increase. The ground truth reports a $32 million (2%) decrease in sales due to helium, which the LLM omits entirely. (2) Quantitative accuracy is partially correct: the $32 million sales decline is missing, and the $19M/44% operating profit increase is not in the original and appears fabricated or misattributed. The years (2022–2024) are correctly framed, but the financial figures do not align. (3) The multi-hop reasoning is partially sound — the model connects helium volumes to sales impact and links LAMT insurance to profit mitigation — but fails to show the full evolution from 2022 (helium as input) to 2024 (helium as a drag), and misses the explicit shift in relationship. It also does not mention 2022's neutral/positive role beyond implying a change. (4) Contextual relevance is high as the answer addresses the core topic and financial dimensions. However, due to missing key numbers and introducing unsupported ones, the correctness score is reduced to 5 — partially correct but with significant factual gaps and inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 446,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "Between 2023 and 2024, Bank of America's unfunded capital contributions for renewable energy investments decreased from **$6.2 billion** (2023) to **$4.6 billion** (2024). Correspondingly, recognized tax credits related to these investments declined from **$4.0 billion** in 2023 to **$3.9 billion** in 2024. This reflects a reduction in both unfunded commitments and tax benefits associated with renewable energy investments during the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all factual information: unfunded capital contributions decreased from $6.2 billion in 2023 to $4.6 billion in 2024, and recognized tax credits declined from $4.0 billion to $3.9 billion. These values match the ground truth exactly. (2) All numeric values are accurate and properly attributed to the correct years and metrics. Calculations are not required beyond the stated changes, and the directional changes (decreases) are correctly described. Format variations (e.g., $4.6 billion) are acceptable and standard. (3) The multi-hop reasoning is sound—information from two years and two financial metrics (unfunded contributions and tax credits) is correctly synthesized across time. The conclusion that both commitments and tax benefits decreased is logically supported, though the original answer notes tax benefits were 'relatively stable,' which is a slightly more nuanced interpretation than 'declined.' The LLM's characterization is still factually correct but slightly less precise in tone. (4) The answer is fully contextually relevant, directly addressing both parts of the question—evolution of unfunded contributions and corresponding change in tax credits. The minor deduction in qualitative accuracy is due to the slightly less nuanced interpretation of the tax credit stability, but overall, the response is factually complete and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 390,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024 by expanding into electric commercial vehicles (e.g., BrightDrop EV600 and EV410) and targeting partnerships with major clients like FedEx and Verizon. Sales channels remained primarily through the dealer network, with direct sales to fleets for specialized programs. Profitability considerations persisted, as fleet sales (including daily rentals) are generally less profitable than retail, but investments in EV infrastructure and hydrogen fuel cell technology (HYDROTEC) aim to enhance long-term efficiency and margins in commercial segments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes correct qualitative elements such as the lower profitability of fleet sales compared to retail and the use of both dealer and direct sales channels. However, it introduces specific details not present in the ground truth, such as the BrightDrop EV600 and EV410, partnerships with FedEx and Verizon, and investments in hydrogen fuel cell technology (HYDROTEC) and EV infrastructure. These additions, while plausible, are not supported by the original answer and represent over-specificity or potential hallucination. (2) There are no numeric values, dates, or calculations in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the continuation of dealer-based sales and selective direct engagement, aligning with the 2024 shift mentioned in the ground truth. However, it fails to clearly articulate the evolution *from 2022 to 2024* as a strategic shift in channel structure and profitability balance, instead focusing on product and technology expansions not mentioned in the original. (4) The contextual relevance is high because the answer addresses fleet sales channels and profitability, but the emphasis on EVs and partnerships distracts from the core evolution in sales strategy. The correctness score is 6 due to plausible but unsupported details and incomplete alignment with the ground truth's focus on structural channel evolution and profitability trade-offs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 423,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "Between 2022 and 2024, PepsiCo's relationship with Sabra evolved through a remeasurement of its previously held 50% equity interest in Sabra, resulting in a **$122 million pre-tax gain** in 2022 (recorded in selling, general, and administrative expenses). This gain reflected the fair value adjustment of the equity stake. By 2024, there is no indication of further changes to the relationship, suggesting the stake remained held or restructured, with no additional financial implications explicitly noted in the provided documents.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $122 million pre-tax gain and PepsiCo's 50% equity stake in Sabra, which aligns with the ground truth. However, it incorrectly states that the gain was recorded in 2022, while the original answer implies the remeasurement and gain occurred in connection with a divestment *between* 2022 and 2024, not in 2022 itself. This misplacement of the timing undermines the factual accuracy. Additionally, the LLM claims there is 'no indication of further changes' by 2024, which contradicts the original answer stating PepsiCo no longer had full ownership by 2024 — indicating a clear structural change. (2) The dollar amount ($122 million) is correct and matches the ground truth, and the 50% equity stake is accurately noted. However, the assignment of the gain to 2022 is factually inconsistent with the timeline implied in the original answer, where the change occurred *between* 2022 and 2024, likely in 2023 or early 2024. (3) The multi-hop reasoning is partially sound — the model connects the equity stake to a financial gain — but fails to correctly infer the direction of ownership change (from full ownership to 50%) and misattributes the timing. The original answer indicates a strategic divestment, while the LLM frames it as a remeasurement of a previously held stake, reversing the causal logic. (4) The contextual relevance is high as the answer addresses both the relationship evolution and financial implications, but the qualitative and quantitative inaccuracies — especially the incorrect timing and mischaracterization of the ownership transition — reduce correctness. The answer captures key elements but misrepresents the sequence and nature of events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 469,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "Adobe Scan's positioning within Adobe's product ecosystem evolved in 2024 by being more explicitly integrated into the Adobe Document Cloud, emphasizing its role in document conversion and workflow automation alongside Adobe Acrobat and other cloud-based tools. In 2023, Adobe Scan was likely positioned as a standalone mobile app for converting paper documents to PDFs, but by 2024, it was highlighted as a key component of the Document Cloud ecosystem, enhancing seamless collaboration and accessibility across Adobe's suite of productivity and creative applications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All entities—Adobe Scan, Adobe Document Cloud, Acrobat, and the 2023–2024 timeframe—are correctly identified. There are no numeric values in the question or answer, so quantitative accuracy is not applicable beyond correct use of years, which are accurate. (2) The answer addresses all parts of the question: it contrasts Adobe Scan’s positioning in 2023 versus 2024 and explains its evolving role in the product ecosystem. In 2023, it correctly infers that Adobe Scan was likely a standalone app (consistent with being listed only as a trademark), and in 2024, it accurately reflects the more explicit integration into Document Cloud. (3) The multi-hop reasoning is sound—synthesizing trademark status in 2023 with strategic integration in 2024 to infer a progression in positioning. The only minor gap is that the LLM says Adobe Scan was 'likely' a standalone app in 2023, which introduces slight uncertainty not present in the ground truth (which states trademark listing as a fact). However, this is a reasonable inference and does not detract significantly from accuracy. (4) The semantic meaning fully matches the original answer: a shift from peripheral recognition to strategic integration within Document Cloud. Wording differs but conveys equivalent information. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for contextual relevance and quantitative accuracy (based on correct use of years and no numerical errors).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 422,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "General Motors' financial exposure to Stellantis regarding indemnifications and historical liabilities from the 2017 Opel/Vauxhall sale has remained largely unchanged from 2022 to 2024. GM's wholly owned subsidiary agreed to indemnify Stellantis for certain losses related to emissions claims, product liabilities, and recalls, with obligations subject to time limitations, thresholds, and caps. As of December 31, 2024, GM had an immaterial remaining accrual for these matters and could not estimate any reasonably possible material loss or range of loss, either directly or through indemnification claims. The nature of obligations includes covering historical liabilities, but exposure is constrained by contractual terms, with no material financial impact quantified beyond the accrued amounts.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of quantitative details: the immaterial accrual as of December 31, 2024, and the inability to estimate reasonably possible losses are correctly reported and align with the ground truth. There are no numerical or date inaccuracies, supporting a perfect quantitative accuracy score. However, the qualitative accuracy is lower because the LLM fails to capture the evolution in the *nature* of the obligation from 2022 to 2024. The ground truth emphasizes a shift from active supply-related transactions in 2022 to passive indemnification-based exposure in 2024, which the LLM omits, instead stating that exposure has 'remained largely unchanged.' This misrepresents the transformation in the relationship. While the LLM correctly identifies the types of liabilities (emissions, recalls, product liabilities) and contractual limitations, it does not reflect the multi-hop synthesis of changing dynamics over time. The answer remains contextually relevant and addresses indemnifications and historical liabilities, but misses the temporal evolution central to the question. Thus, the correctness score is 7—core facts are right, but a key aspect of the change over time is inaccurately portrayed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 345,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "PepsiCo's relationship with co-packers has remained consistent between 2022 and 2024, with continued reliance on co-packers for manufacturing, warehousing, and distribution facilities. The 2024 filing reaffirms that co-packers, along with strategic alliances and joint ventures, provide critical infrastructure, maintaining operational dependency and strategic collaboration. No significant changes in dependency levels or strategic involvement are explicitly noted in the provided documents.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that PepsiCo's relationship with co-packers 'has remained consistent' between 2022 and 2024. The ground truth shows a clear evolution in language and strategic posture: from describing co-packers as part of a 'highly distributed network' of third-party facilities in 2022 (indicating operational dependency) to framing them in 2024 as part of 'strategic alliances or joint ventures in which we have an equity interest' (indicating deeper strategic involvement). This shift reflects a meaningful change in the nature of the relationship—from arms-length operational reliance to more integrated, ownership-based partnerships. The LLM fails to detect or report this evolution, instead asserting that 'no significant changes' occurred, which directly contradicts the evidence. While there are no numerical figures to verify (so quantitative accuracy is not applicable in a traditional sense, but no numbers are misstated), the qualitative inaccuracy is severe. The model also fails in multi-hop reasoning by not synthesizing the change in language across the two years to infer strategic evolution. Contextually, the answer is relevant—it addresses co-packers and operational/strategic aspects—but it draws the wrong conclusion from the data, undermining its usefulness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 366,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "Between 2023 and 2024, SPG's financial relationship with ABG evolved significantly. In 2023, ABG's capital transactions led to dilution of SPG's ownership (from 12.3% to 9.6%) and deemed disposals of SPG's proportional interest, resulting in **$59.1 million** in non-cash pre-tax gains. SPG also recognized **$157.1 million** in gains from selling a portion of its ABG interests. By 2024, SPG completed the sale of its **remaining 33.3% interest in ABG** for **$1.2 billion**, generating a **$414.8 million pretax gain**. This marked a strategic exit from ABG, with SPG realizing substantial gains through both deemed disposals and the full sale, reflecting a shift from active investment to divestiture.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the $59.1 million gain from deemed disposals due to ABG's capital transactions and the $157.1 million gain from the sale of a portion of SPG's ABG interests in 2023, it fabricates a $414.8 million pretax gain from the sale of SPG's 'remaining 33.3% interest in ABG for $1.2 billion' in 2024, which is not supported by the ground truth. The original answer states that in 2024, SPG disclosed an $18.8 million gain from the sale of a portion of its ABG interest that occurred in December 2021 (not 2024), and highlights a strategic partnership with ABG for Reebok in the U.S. as the key development—indicating deeper operational collaboration, not a full divestiture. The claim of selling a 'remaining 33.3%' stake is factually incorrect and contradicts the dilution from 12.3% to 9.6% mentioned, which would make such a large remaining stake impossible. (2) Quantitative accuracy is low: two out of three numbers in 2023 are correct ($59.1M and $157.1M), but the $414.8M gain and $1.2B sale in 2024 are entirely fabricated. The $18.8M gain from the 2021 transaction, which was disclosed in 2024, is omitted. (3) Multi-hop reasoning is flawed: the model incorrectly infers a full exit from ABG in 2024, missing the actual strategic shift toward operational partnership (Reebok licensing) that defines the evolution. It fails to connect the 2024 disclosure of a past transaction with the new strategic direction, instead inventing a large sale. (4) Contextual relevance is moderate because it addresses the evolution of the financial relationship and mentions gains, but misrepresents the nature of the 2024 developments. The qualitative reasoning is poor due to incorrect entity relationships and invented transactions. Correctness is severely compromised by the invention of a major financial event not present in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 522,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "Lockheed Martin's involvement in Sikorsky helicopter programs saw sustained production volume in 2022, driven by higher output on programs like the Black Hawk, Seahawk, and CH-53K King Stallion, as noted in 2022 disclosures. By 2024, the scope expanded to include advanced systems such as the VH-92A helicopter for U.S. Marine One, with the final delivery under this program completed in 2024. While production volume for specific programs like VH-92A concluded, ongoing programs like CH-53K and integrated warfare systems reflected continued scope growth and technological advancements.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Lockheed Martin's continued involvement in Sikorsky helicopter programs and references key platforms like Black Hawk, Seahawk, and CH-53K, which aligns with the original answer. However, it introduces the VH-92A program and its completion in 2024 as a key development, which is not mentioned in the ground truth and represents an unsupported expansion of program scope. The original answer emphasizes a shift from being a cost driver (due to $560M increase in product costs in 2022) to a strategic product line by 2024, a key evolution that the LLM answer omits. (2) Quantitatively, the LLM answer does not mention the $560 million increase in product costs in 2022, a critical data point in the ground truth. While no incorrect numbers are stated, the absence of this figure undermines the quantitative completeness. The years 2022 and 2024 are correctly used contextually. (3) The multi-hop reasoning is partially sound—linking sustained production in 2022 to expanded scope in 2024—but the LLM infers a scope expansion based on VH-92A completion, which is not supported in the ground truth. The original answer frames the evolution around internal segment reporting and strategic emphasis, not program completions. (4) The contextual relevance is high as the answer addresses production volume and program scope. However, the qualitative accuracy is reduced due to the introduction of unverified programs and omission of the cost-driven evolution narrative. Correctness score reflects partial alignment with ground truth: core programs are accurate, but key financial and strategic context is missing or misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 457,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "Walmart's ownership stake in Alert Innovation increased to 100% in fiscal 2023 through a $0.4 billion acquisition, as noted in the \"Purchases and Sales of Subsidiary Stock\" section of the 2023 filing. This full ownership was maintained through fiscal 2024, as the entity was subsequently sold and deconsolidated in fiscal 2025. Thus, between fiscal 2023 and 2024, Walmart's ownership remained at 100%.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Walmart acquired Alert Innovation for $0.4 billion in fiscal 2023 and increased ownership to 100%, which matches the ground truth. However, it incorrectly claims that Walmart maintained 100% ownership through fiscal 2024, directly contradicting the original answer, which states there was no mention of Walmart retaining ownership in fiscal 2024, indicating a full exit. The LLM introduces unverified information about a sale and deconsolidation in fiscal 2025, which is not present in the ground truth and cannot be assumed. (2) Quantitatively, the $0.4 billion figure and 100% ownership are accurate, so numerical values are correct. (3) The multi-hop reasoning fails because the model does not correctly synthesize the absence of mention in fiscal 2024 as evidence of divestiture; instead, it fabricates a timeline extending into fiscal 2025. The original answer infers exit based on omission in 2024, while the LLM incorrectly assumes continuity. (4) Due to the major factual error in ownership status during fiscal 2024, the correctness score is low despite accurate numbers. The answer is contextually relevant but fundamentally flawed in reasoning and conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1172,
        "completion_tokens": 344,
        "total_tokens": 1516
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "SPG's utilization of the Supplemental Facility evolved between 2023 and 2024 primarily through repayment and strategic refinancing. In 2023, SPG repaid €750 million (approximately $815.4 million) under the Supplemental Facility using proceeds from a €750 million bond issuance in November 2023. This repayment reduced outstanding balances under the facility. In 2024, there is no explicit mention of new borrowings under the Supplemental Facility; instead, SPG focused on managing liquidity through other sources like the Credit Facilities and Commercial Paper program. The Supplemental Facility remained available for future borrowing, with its maturity date extended to January 31, 2030, and its capacity maintained at $3.5–$4.5 billion. The repayment strategy in 2023 prioritized refinancing via fixed-rate debt, while 2024 emphasized maintaining flexibility across multiple credit facilities.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the €750 million borrowing and repayment in 2023 and the absence of outstanding balance in 2024, aligning with the ground truth. However, it introduces inaccuracies: the repayment date (November 17, 2023) is omitted and instead generalized to 'November 2023', and the bond issuance is described as €750 million, while the ground truth specifies it was used to repay the facility but does not confirm the currency of the bonds. The LLM incorrectly converts €750 million to $815.4 million, which is not supported in the original answer and introduces a spurious precision. Additionally, the $1.0 billion unsecured note issuance in September 2024—a key refinancing event in the ground truth—is missing. Instead, the LLM mentions 'no explicit mention of new borrowings' and cites other liquidity tools, which downplays the strategic shift to long-term unsecured notes. (2) The quantitative inaccuracies include the unsupported dollar conversion and omission of the $1.0 billion 2024 bond issuance. The maturity extension to January 31, 2030, and facility capacity of $3.5–$4.5 billion are not in the ground truth and appear to be hallucinated or misattributed. (3) The multi-hop reasoning is partially sound: the model correctly infers a shift in strategy from repayment and refinancing, but fails to connect the 2024 refinancing activity to the specific $1.0 billion note issuance, weakening the synthesis. (4) Despite these issues, the answer captures the core evolution—repayment in 2023 and reduced reliance in 2024—and maintains contextual relevance by focusing on borrowing activity and repayment strategy. The qualitative reasoning about strategic refinancing and liquidity management is coherent, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 486,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "Linde's treatment of helium as a primary product in its industrial gases business remained consistent between 2023 and 2024, with helium classified as a process gas sold through merchant and packaged distribution methods. The 2024 filing reaffirms helium's inclusion in the merchant category, which allows for longer-distance shipping, and no significant changes in supply strategies or positioning as a primary product are noted. Revenue data by distribution method shows continued alignment with prior years, indicating stable operational approaches.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that Linde's treatment of helium remained consistent between 2023 and 2024. The ground truth shows a clear shift: in 2023, helium was explicitly listed as a primary product alongside oxygen, nitrogen, and hydrogen, but in 2024, it was no longer specifically named and was instead subsumed under general gas descriptions, indicating a strategic repositioning. The LLM incorrectly states there was 'no significant change,' which contradicts the documented evolution in product positioning. (2) There are no numeric values in either the question or answers, so quantitative accuracy is not applicable beyond the correct use of years (2023, 2024), which the LLM gets right. Hence, quantitative accuracy is scored as 10. (3) The multi-hop reasoning is flawed: the question requires comparing Linde’s product classification and supply strategy descriptions across two years to infer a strategic shift. The LLM fails to detect the removal of helium as a named product in 2024 and misinterprets the continuity of distribution methods as evidence of no change, ignoring the qualitative shift in emphasis. (4) Contextual relevance is moderate—the answer addresses helium in Linde’s industrial gases business and discusses distribution methods, so it stays on topic—but it misses the key analytical point about repositioning. The conclusion is therefore misleading despite using relevant context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 403,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "Between 2022 and 2023, the U.S. Retiree Health Care Plan's asset allocation shifted toward fixed income securities and away from equity securities. In 2022, fixed income securities and cash equivalents totaled **$182 million** (65% of total plan assets), while equity securities amounted to **$98 million** (35%). By 2023, fixed income securities increased to **$210 million** (79.5% of total assets), and equity securities decreased to **$54 million** (20.5%). This reallocation aligns with the plan's target range of 75–85% fixed income and 15–25% equity, reflecting a rebalancing toward fixed income to better match liability risk profiles.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. According to the ground truth, in 2022, fixed income securities and cash equivalents were $248 million (not $182 million), and equity securities were $137 million (not $98 million). The total assets were $385 million in 2022, not $280 million as implied by the LLM's numbers. In 2023, the LLM correctly states equity securities as $54 million and fixed income as $210 million, but incorrectly implies a shift toward fixed income as a strategic rebalancing, when in fact both asset classes decreased significantly in absolute terms—fixed income from $248M to $210M and equity from $137M to $54M. The percentages cited (65%, 35%, 79.5%, 20.5%) are therefore also incorrect due to reliance on wrong base totals. (2) Calculations are flawed: using the LLM's own numbers, $182M + $98M = $280M, but no total is stated, and the 65%/35% split does not match the ground truth allocation. While the 2023 numbers for fixed income ($210M) and equity ($54M) are correct, the total should be $264M, and the correct percentages are ~79.5% and ~20.5%—this is the only numerically accurate part. However, the narrative of a strategic shift toward fixed income is misleading because both categories declined, with a much larger absolute drop in equities. (3) The multi-hop reasoning is partially sound in identifying a shift in allocation, but it fails to recognize that the overall plan assets shrank significantly, which changes the interpretation. The mention of a 'target range of 75–85% fixed income' introduces external information not present in the ground truth, making the explanation speculative. (4) The correctness score is low (3) due to major errors in 2022 figures and misrepresentation of trends. Quantitative accuracy is very poor (2) because most numbers are wrong. Qualitative accuracy is low (3) due to incorrect synthesis and unsupported reasoning. Contextual relevance is moderate (7) as the answer addresses asset allocation changes and focuses on the right categories and years, despite factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 565,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "Between 2022 and 2023, Trodelvy's revenue grew by **56%** to **$1.063 billion** in 2023, driven by increased demand in new and existing geographies. This growth was supported by key regulatory milestones, including **FDA approval** for Trodelvy as a monotherapy for unresectable/metastatic HR+/HER2- breast cancer (2023) and **EC approval** for treating HDV with compensated liver disease (2022). These approvals expanded its therapeutic applications, enhancing its strategic positioning in oncology and liver disease markets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The ground truth states that Trodelvy generated $380 million in 2022 and does not provide 2023 revenue. The LLM claims $1.063 billion in 2023, implying a 56% growth, which is unsupported and incorrect—actual growth from $380M to $1.063B would be ~180%, not 56%. (2) The regulatory milestones are partially correct: FDA approval for HR+/HER2- metastatic breast cancer in 2023 aligns with the ground truth, but the EC approval is misrepresented—the LLM incorrectly states it was for 'HDV with compensated liver disease' in 2022, while the ground truth indicates EC approval for a similar (breast cancer) indication as the FDA, not liver disease. This reflects a critical entity and indication error. (3) Multi-hop reasoning is flawed: the model fabricates revenue data and misattributes therapeutic areas, failing to correctly synthesize across years and regulatory bodies. It introduces liver disease, which is unrelated to Trodelvy’s oncology focus. (4) Despite these issues, the answer is contextually relevant—addressing both financial performance and strategic positioning with regulatory milestones—and correctly identifies the FDA approval in 2023. However, the quantitative and qualitative inaccuracies severely undermine the correctness. Hence, low scores for quantitative (2) and qualitative accuracy (4), moderate contextual relevance (7), and an overall correctness score of 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 402,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "Chevron's downstream-related earnings and investment in GS Caltex (a 50% joint venture in South Korea) showed growth from 2022 to 2024. In 2022, Chevron's equity earnings from GS Caltex were $874 million, increasing to $437 million in 2023 and $513 million in 2024. While the investment balance slightly decreased from $4,309 million (2023) to $4,144 million (2024), the rising equity earnings reflect improved performance of the joint venture. This growth underscores the strategic importance of GS Caltex, as it contributes meaningfully to Chevron's downstream profitability, aligning with broader efforts to enhance refining and marketing operations in key markets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron reported higher downstream earnings from GS Caltex in 2022 and maintained a 50% ownership stake through 2024, but does not provide specific equity earnings figures for 2022, 2023, or 2024. The LLM fabricates precise numbers—$874M (2022), $437M (2023), $513M (2024)—which are not present in the original answer and contradict the trend implied by the truth (no decline in 2023). Additionally, the LLM introduces investment balances of $4,309M (2023) and $4,144M (2024), which are entirely absent from the ground truth and unsupported. (2) The only accurate quantitative data in the original answer is the affiliated revenue: $16,286M in 2022 and $13,850M in 2024. The LLM omits these key figures entirely, failing to report the actual financial metrics provided. This is a major omission and misdirection. (3) The multi-hop reasoning is flawed. The question asks about the evolution of earnings and investment relationship and what it indicates strategically. The LLM incorrectly infers growth in earnings when the ground truth indicates a decrease in affiliated revenues and only general improvement in equity income in 2022. The conclusion that earnings grew from 2022 to 2024 is unsupported and contradicts the downward revenue trend. (4) While the LLM correctly identifies GS Caltex as a 50% joint venture with GS Energy in Korea and correctly frames it as strategically important for downstream operations, these correct contextual elements are outweighed by the invented data and incorrect trend analysis. The strategic interpretation is reasonable but based on false premises. Thus, the correctness and quantitative accuracy scores are low due to fabricated numbers and incorrect trends; qualitative accuracy is partially redeemed by correct entity identification; contextual relevance is moderate as the structure and intent align with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 530,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "From 2022 to 2024, the CH-53K program's production volume increased, with risk retirements contributing to improved financial performance in 2022. In 2022 (2021 data), higher production volume on the CH-53K, along with risk retirements, boosted net sales and operating profit for RMS. By 2024, production volume remained a key driver, as noted in the increase in net sales due to CH-53K program ramp-up. However, specific details about risk retirements in 2024 are not explicitly mentioned, though the program's production activity continued to positively impact financial results.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures some correct elements—such as increased production volume and the positive impact of risk retirements in 2022—but contains inaccuracies and omissions. The original answer specifies that the CH-53K contributed approximately $140 million in increased profit in 2022 due to risk retirements and higher production. The LLM answer does not mention this key quantitative figure, weakening its factual completeness. Additionally, the LLM incorrectly references '2022 (2021 data)', which is not supported by the ground truth and introduces confusion about the time period. (2) There are no explicit numbers in the LLM answer, missing the $140 million profit increase from the ground truth. This is a significant omission in quantitative accuracy. The 73% decline in RMS operating profit by 2024—a critical data point in the original—is also absent, undermining the comparative financial analysis. (3) The multi-hop reasoning is partially sound: the model correctly infers that higher production volume and risk retirements boosted performance in 2022 and that production continued into 2024. However, it fails to synthesize the broader context that RMS profits declined sharply by 2024, which tempers the interpretation of CH-53K's ongoing financial contribution. The absence of this decline leads to an overly positive and incomplete picture. (4) Contextual relevance is high because the answer addresses both financial performance and production status across the requested time frame. However, the lack of key financial metrics and incorrect time framing reduce correctness and qualitative accuracy, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 454,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "PayPal's approach to seller protection programs between 2022 and 2023 evolved from a risk-management focus to a strategic emphasis on enhancing trust and differentiation. In 2022, the programs were highlighted as critical for mitigating transaction losses (0.09–0.15% of TPV) and addressing macroeconomic risks like merchant insolvency, with a focus on historical loss trends. By 2023, the programs were framed as broader protections aligned with or exceeding industry standards, emphasizing consumer and merchant confidence through mechanisms like dispute resolution and payment guarantees. The 2023 disclosure also underscored leveraging PayPal's two-sided network and data analytics to strengthen fraud prevention and risk mitigation, reflecting a strategic shift toward embedding protections as a competitive advantage while maintaining risk exposure management.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in PayPal's approach from 2022 to 2023, accurately reflecting the shift from risk management to strategic emphasis on trust and competitive differentiation. All key qualitative elements are present: 2022 focus on risk exposure and loss rates (0.09%–0.15% of TPV), and 2023 framing of seller protection as part of a broader value proposition tied to merchant trust and platform growth. (2) Quantitatively, the LLM correctly reports the 0.09%–0.15% transaction loss rate range from 2022, matching the ground truth exactly. No other numerical data is required, and no inaccuracies are present. Format is consistent and acceptable. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 vs 2023), identifies the change in strategic emphasis, and links it to broader business goals like merchant retention and platform differentiation. It adds contextual depth by referencing dispute resolution, payment guarantees, and data analytics—elements aligned with the 2023 strategic integration mentioned in the ground truth. (4) The only minor gap is that the LLM does not explicitly mention the integration of seller protection with other merchant services (e.g., analytics, risk management) as a 'broader value proposition' in the exact phrasing of the original, though it implies this through references to data analytics and network effects. This slight omission prevents a perfect 10 but does not undermine factual correctness. All other aspects match or closely paraphrase the ground truth with semantic equivalence. Scores reflect high accuracy, full quantitative fidelity, excellent reasoning, and complete relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 467,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "Starbucks' approach to ready-to-drink beverages in 2023 and 2024 maintained consistent revenue recognition practices, with revenue recognized upon shipment to customers outside company-operated and licensed stores, as outlined in \"Other Revenues\" sections of both filings. Supplier dependency remained unchanged, as the company continued sourcing these products from specialty suppliers under long-term contracts, as detailed in the \"Product Supply\" section of the 2024 filing. No significant evolution in revenue recognition methods or supplier strategies was noted between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that there was no significant evolution in Starbucks' approach between 2023 and 2024. The ground truth states a clear shift from a revenue-centric reporting model in 2023 to a supply-chain risk management focus in 2024, particularly emphasizing supplier dependency and resilience. The LLM incorrectly asserts that both revenue recognition and supplier dependency strategies remained unchanged, which contradicts the original answer. (2) There are no specific numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not heavily applicable; however, the years 2023 and 2024 are correctly referenced, and the general revenue recognition timing (upon shipment) aligns with the ground truth, earning partial credit. (3) The multi-hop reasoning is flawed: the model fails to synthesize the evolution in focus—from revenue recognition in 2023 to supply chain strategy in 2024—and instead concludes no change occurred, missing the key insight about strategic shift. It references the correct sections (e.g., 'Other Revenues', 'Product Supply') but draws an incorrect conclusion from them. (4) While the LLM answer is relevant to the topic and addresses the right categories and time periods, it fundamentally misrepresents the nature of the change, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because it discusses the right themes but fails to capture the evolution the question asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 424,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "Between 2022 and 2023, Trodelvy's geographic reach and regulatory approvals expanded. In 2022, Trodelvy was approved in the European Union (EU) for metastatic triple-negative breast cancer (TNBC) and in Canada under Project Orbis, which included countries like the U.S., Australia, Switzerland, and the UK. By 2023, Trodelvy received additional approvals: the EU granted it monotherapy status for unresectable/metastatic HR+/HER2- breast cancer, and the FDA approved it for the same indication in the U.S. This expanded both its geographic reach (U.S. and EU) and regulatory scope, adding new indications for HR+/HER2- breast cancer.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 FDA and EC approvals for HR+/HER2- metastatic breast cancer, which aligns with the ground truth and shows expanded regulatory scope. However, it introduces unverified information not present in the original answer: specifically, approvals in Canada under Project Orbis and in Australia, Switzerland, and the UK, which are not mentioned in the ground truth and cannot be confirmed from the provided data. Additionally, while the original answer cites specific sales figures ($370M in U.S., $10M in Europe in 2022), the LLM omits these quantitative metrics entirely, missing a key component of geographic reach assessment. (2) Quantitatively, the LLM does not contradict any numbers but fails to include the sales data that define geographic reach in 2022, which is a significant omission for a question about geographic evolution. There are no calculation errors because no calculations are attempted. (3) The multi-hop reasoning is partially sound—linking new approvals to expanded reach and indications—but incorrectly infers broader international approval beyond EU and U.S. without evidence. The original answer implies limited international presence outside U.S. and Europe in 2022, but the LLM suggests wider reach (Canada, UK, Australia, etc.) without support. (4) The contextual relevance is high because the answer addresses both regulatory evolution and geographic implications. However, the correctness score is reduced due to unsupported claims and omission of key quantitative evidence. The qualitative accuracy is moderate because while core regulatory developments are correct, entity and geographic scope are overstated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 462,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "Simon Property Group's ownership stake in ABG decreased from approximately 12.3% in 2023 to 9.6% by the end of 2023 due to capital transactions, resulting in non-cash pre-tax gains of $10.3 million and $12.4 million in 2023. In 2024, the company sold its remaining 9.6% interest in ABG for $1.2 billion in cash, recognizing a pretax gain of $414.8 million. This transaction marked the complete divestiture of its ABG stake, with the carrying value of the investment reduced from $733.2 million (Dec 2023) to zero.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group's (SPG) ownership stake in ABG decreased from 12.3% to 9.6% through multiple dilution events in 2023, not a single sale of the remaining stake in 2024. The LLM incorrectly claims that SPG sold its remaining 9.6% stake in 2024 for $1.2 billion in cash, recognizing a $414.8 million pretax gain, which is not supported by the original answer. Instead, the ground truth states that SPG did not report any new transactions in 2024 and only referenced a prior 2021 transaction involving an $18.8 million gain and a $100.0 million acquisition. (2) Quantitative inaccuracies include: the gains in 2023 are listed as $10.3M and $12.4M in the LLM answer, but the correct sequence is $36.4M, $12.4M, and $10.3M; the $414.8M gain and $1.2B sale in 2024 are entirely fabricated; the carrying value of $733.2M at end-2023 is not mentioned in the original and cannot be verified. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a complete divestiture in 2024, whereas the original indicates no active stake changes were disclosed in 2024, reflecting a passive disclosure stance. The model fails to recognize that the 2024 mention was a reference to a 2021 transaction, not a new event. (4) The contextual relevance is moderate because the answer addresses SPG’s stake and financial gains in ABG across 2023–2024, but the core facts and timeline are incorrect, undermining the qualitative and quantitative accuracy. The reasoning and synthesis are unsound, warranting low scores in correctness, quantitative, and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 454,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "Between the 2023 and 2024 filings, the **2012 Equity Incentive Plan** was amended with the **Fourth Amendment** (filed in the 2024 10-Q, Exhibit 10.2(C)), building on the **Third Amendment** from 2023 (Exhibit 10.2(B) in the 2023 10-K). Additionally, the 2024 filing introduced new forms of award agreements under the plan, including Exhibits 10.2(K) and 10.2(L), which expanded the plan's award agreement templates compared to the 2023 disclosures (Exhibits 10.2(C) and 10.2(D)). No further amendments were noted in the 2024 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of the 2012 Equity Incentive Plan, noting the Fourth Amendment in 2024 (dated August 1, 2024 in the ground truth; the LLM correctly places it in the 2024 filing and references Exhibit 10.2(C) in the 10-Q, which is consistent with SEC filing conventions). The reference to the Third Amendment in 2023 (Exhibit 10.2(B)) matches the ground truth. (2) The LLM accurately reflects the introduction of new award agreement forms in 2024 (Exhibits 10.2(K) and 10.2(L)), which corresponds to the 'additional forms from April 2024' in the ground truth. While the exact dates (April 2024) are not mentioned, the inclusion of new forms is correctly reported. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, identifies amendments and forms of award agreements, and correctly tracks the progression from 2023 to 2024. (4) The only minor omission is the lack of explicit mention of the 2012 and 2017 forms referenced in 2023, which were part of the original answer. However, the LLM does imply continuity by referencing prior exhibits. All entities (plan name, amendment numbers, exhibit references) are correct. Wording differs slightly but maintains semantic equivalence. The claim that 'no further amendments were noted' may be misleading if interpreted as no amendments beyond the Fourth, but in context it likely means no additional ones beyond what was filed, so not a factual error. Overall, the answer is factually correct, complete in substance, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 442,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "The treatment of capitalized software licenses remained consistent, with amortization applied on a straight-line basis over the license term. However, the valuation increased from $152 million in 2022 to $223 million in 2023, reflecting a higher asset base. Amortization expense also rose from $54 million to $63 million during the same period. This indicates the company significantly increased its investment in software licensing in 2023, likely to support expanded operations or new initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the consistent treatment of capitalized software licenses with straight-line amortization, matching the original answer's description of the accounting policy. It accurately reports the carrying values of $152 million in 2022 and $223 million in 2023, which aligns with the ground truth. The increase in amortization expense from $54 million to $63 million is an additional detail not present in the original answer; however, since this information is plausible and does not contradict the ground truth (and may reflect real data from the filings), it does not count as an error. (2) All numeric values provided—$152M, $223M, $54M, $63M—are factually accurate and consistent with the knowledge graph. Calculations implied (e.g., increase in asset value by $71M and amortization by $9M) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 vs 2023), compares asset valuations, links increased amortization to higher investment, and infers business implications—consistent with the original answer’s conclusion about growing investment. The only minor gap is that the original emphasizes the evolution from policy disclosure (2022) to quantified asset (2023), which the LLM mentions implicitly but not explicitly. (4) Scores reflect near-perfect factual accuracy, strong reasoning, and full relevance. The 9 on qualitative accuracy reflects the slight omission of the conceptual evolution in reporting transparency; otherwise, the answer is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 427,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "PayPal increased the percentage of European customer balances designated for credit activities from 37% (as of December 31, 2022) to 39% (as of December 31, 2023), despite a slight decrease in the absolute approved amount from $3.8 billion to $3.0 billion. This indicates a strategic shift toward leveraging internal liquidity more aggressively to fund credit products, reflecting a focus on optimizing internal capital sources rather than relying solely on external funding. The higher percentage suggests a deliberate effort to expand credit offerings while managing liquidity risks.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the key quantitative facts: the approved amounts ($3.8 billion in 2022 and $3.0 billion in 2023) and the corresponding percentages (37% and 39%). These numbers match the ground truth exactly, and the observation that the percentage increased despite a lower absolute amount is accurate. (2) Quantitative accuracy is high—no errors in numbers, dates, or percentages. The $3.8B to $3.0B decrease and 37% to 39% increase are correctly stated. (3) However, the qualitative reasoning is flawed in a critical aspect: the LLM concludes that the higher percentage indicates a 'strategic shift toward leveraging internal liquidity more aggressively' and 'optimizing internal capital sources.' This contradicts the ground truth, which identifies a strategic shift toward *external* funding mechanisms via a new €40 billion receivables sale agreement, with $5.5 billion sold in 2023. The LLM completely omits this major strategic development, leading to an incorrect interpretation of PayPal's funding strategy. This is a significant multi-hop reasoning failure—the model should have synthesized the reduced internal approval with the new external funding activity to conclude a shift *away* from reliance on internal balances. (4) The contextual relevance is high because the answer addresses the evolution of utilization and attempts to interpret strategic intent. However, due to the omission of a key fact and the resulting incorrect strategic inference, the overall correctness is reduced to a 6—partially correct but with a major error in interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 438,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "Starbucks' investment in Valor Siren Ventures I L.P. and II L.P. increased in carrying value from $24.2 million as of October 1, 2023, to $39.8 million as of September 29, 2024. However, the total carrying value of these private equity investments was $211.9 million in 2024, indicating broader portfolio growth. The financial impact of these investments on Starbucks' consolidated statements was not material during the periods presented.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that the carrying value of Starbucks' investment in Valor Siren Ventures I L.P. and II L.P. increased from $24.2 million (as of October 1, 2023) to $39.8 million (as of September 29, 2024), which directly contradicts the ground truth. The original answer states that the combined carrying value of both Valor Siren Ventures I and II L.P. was $211.9 million as of September 29, 2024 — not $39.8 million. Additionally, there is no mention in the ground truth of a $24.2 million value for fiscal 2023; in fact, the carrying value for 2023 was not specifically disclosed. The LLM incorrectly introduces precise numbers that are not supported by the source. (2) The quantitative inaccuracies are severe: the LLM underreports the 2024 carrying value by over $170 million and fabricates a 2023 figure. While it correctly notes the $211.9 million total for 2024 later in the response, it confuses this with 'broader portfolio growth' without clarifying that this is the actual combined carrying value of the two Valor funds — not a larger portfolio. (3) The multi-hop reasoning is flawed. The model fails to correctly synthesize the evolution of the investment: from non-disclosed individual value in 2023 to a combined disclosed value in 2024. It incorrectly implies granular year-over-year tracking was available for Valor I and II, when the ground truth emphasizes lack of materiality and specific disclosure in 2023. (4) Despite these issues, the LLM correctly identifies that the financial impact was non-material and reported in 'interest income and other, net,' which aligns with the original answer, earning partial credit for qualitative and contextual accuracy. However, the severe numerical errors dominate the assessment, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 499,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "Analog Products' strategic positioning remained centered on TI's four sustainable competitive advantages (manufacturing/technology, broad product portfolio, market channel reach, and product/market diversity) in both 2022 and 2023. However, its financial contribution declined: Analog revenue dropped 15% to $13.04 billion in 2023 from $15.36 billion in 2022, with operating profit falling 30% to $5.82 billion. This was driven by lower revenue and higher manufacturing costs tied to capacity expansion, despite continued focus on industrial and automotive markets. The segment's operating margin decreased to 44.6% (from 54.4% in 2022), reflecting challenges in maintaining profitability amid reduced factory loadings and cost pressures.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Analog Products contributed to a gross margin of 67.5% in 2022 and remained a core strategic pillar in 2023 with emphasis on TI's competitive advantages and cash generation. However, the LLM claims a sharp decline in financial performance — including a 15% revenue drop to $13.04B, a 30% drop in operating profit to $5.82B, and operating margin falling from 54.4% to 44.6% — none of which is supported by the original answer. These figures are entirely fabricated or misattributed, as the ground truth does not mention any such decline. (2) Quantitative accuracy is very low: no revenue, profit, or margin figures are present in the original answer for either year, and the LLM invents precise numbers (e.g., $13.04B, $5.82B) and percentages (15%, 30%, 44.6%) without basis. The only correct number in the original is the 67.5% gross margin in 2022, which the LLM omits entirely. (3) The reasoning is flawed: while the LLM correctly identifies that Analog Products relate to TI’s competitive advantages, it incorrectly frames the evolution as a deterioration in financial contribution, contradicting the ground truth that emphasizes continuity and strategic reinforcement. The multi-hop synthesis fails — instead of linking Analog Products to TI's strategic advantages and long-term cash flow focus in 2023, it invents a narrative of declining performance due to capacity expansion and factory loadings. (4) Contextual relevance is moderate because the answer addresses the right topic (strategic positioning of Analog Products) and mentions relevant concepts like competitive advantages and industrial/automotive markets, but the overall direction misrepresents the evolution. The qualitative accuracy is low because the entities (TI, Analog Products, years) are correct, but the synthesis and conclusions are not aligned with the source. Correctness score is low due to complete mismatch in financial data and misrepresentation of strategic trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 552,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "Chevron's capital allocation strategy in the Lower 48 region intensified from 2022 to 2023, reflected in higher depreciation, depletion, amortization, and impairments. In 2023, the Lower 48 segment reported $5,729 million in these expenses, up from $4,854 million in 2022, indicating increased investment in assets and operational activities. This aligns with higher capital expenditures ($6,487 million in 2023 vs. $5,630 million in 2022), suggesting a strategic focus on expanding or maintaining infrastructure in the region. Impairments may reflect asset write-downs, but the overall trend underscores a shift toward greater capital allocation to the Lower 48.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, amortization, and impairments in the Lower 48 region from $4,854 million in 2022 to $5,729 million in 2023, matching the ground truth exactly. It also correctly references increased capital expenditures ($6,487M in 2023 vs $5,630M in 2022), which, while not part of the original answer, is factually consistent with Chevron’s 10-K filings and adds contextual support. (2) All numeric values are accurate and properly formatted; no calculation errors. The core financial figures from the ground truth are fully preserved. (3) The multi-hop reasoning is sound: the model correctly infers that rising DD&A and impairments reflect increased capital allocation and asset development, linking financial metrics to strategic intent. It appropriately contrasts this with other regions implicitly, though the explicit comparison to Europe, Middle East and North Africa from the original answer is omitted—this is a minor completeness gap but does not detract from the core correctness. (4) The answer is semantically equivalent to the ground truth, with slightly expanded context (capital expenditures) that enhances rather than distorts. The reasoning is logical, entities (Chevron, Lower 48, years, metrics) are accurate, and the response directly addresses the evolution of capital allocation strategy. Only a perfect 10 would require inclusion of the comparative regional context, but omission does not undermine correctness. Hence, 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 430,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "Verizon's approach to FWA Broadband evolved between 2023 and 2024 by strengthening its integration into the **Business segment**, particularly targeting **enterprise and public sector customers**, while maintaining its role in the **Consumer segment**. In 2023, FWA was part of both segments, with the Consumer segment emphasizing residential broadband alternatives and the Business segment offering FWA as part of corporate networking solutions. By 2024, FWA became more central to the Business segment's **Enterprise and Public Sector** offerings, aligned with IoT and managed network services, reflecting a strategic shift toward enterprise-scale connectivity. The Consumer segment continued to use FWA as a broadband alternative but with less emphasis on expanding its footprint compared to 2023. Target segments expanded from general business to include government and large enterprises, with FWA positioned as a key component of Verizon's broader digital infrastructure solutions.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that FWA broadband was offered in both Consumer and Business segments in 2023 and continued into 2024, aligning with the ground truth. It accurately reflects the dual-segment positioning and the role of FWA as an alternative to traditional broadband. However, the LLM introduces specific claims not present in the ground truth, such as FWA becoming 'more central to the Business segment's Enterprise and Public Sector offerings' and 'less emphasis on expanding its footprint' in the Consumer segment. These strategic shifts in emphasis and targeting (e.g., government, large enterprises) are not supported by the original answer, which only notes a shift in language from 'provides' to 'produces' and a more integrated positioning within a broader portfolio including IoT. (2) There are no numeric values in the LLM answer, so quantitative accuracy is not violated; the original answer includes the 3.1 million connections figure, which the LLM omits but does not contradict. (3) The multi-hop reasoning is partially sound—LLM correctly synthesizes FWA’s presence across segments and its alignment with IoT and advanced services—but goes beyond the source by inferring customer segment expansion and strategic prioritization not explicitly stated. (4) The answer is contextually relevant and well-structured, but overinterprets the evolution, adding granularity not present in the ground truth. While the core direction of increased strategic integration is consistent, the specific customer segment shifts and reduced consumer focus are unsupported, warranting a score of 7 for correctness and qualitative accuracy. Quantitative accuracy is 10 due to absence of incorrect numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 472,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "Emerson's relationship with AspenTech evolved from a 55% ownership stake in 2022 to a proposed full acquisition of the remaining 45% in 2024, aiming for complete control. This integration likely enhanced Emerson's software capabilities and scale. Financially, the 2023 gross margin increased to 49.0% (up 3.3 percentage points) due to the Heritage AspenTech acquisition, while 2024 gross margin rose to 50.8% (up 1.8 percentage points), driven by the Test &amp; Measurement acquisition despite inventory step-up amortization costs. The equity structure shifted from a majority stake to a potential full ownership, impacting Emerson's consolidated financial position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Emerson had a 55% ownership stake in AspenTech in 2022, when the ground truth indicates the 55% stake was acquired by 2024 as part of a strategic transaction creating 'New AspenTech.' The evolution is misrepresented: it was not a progression from 55% in 2022 to full acquisition in 2024, but rather a partnership in 2022 and acquisition of 55% by 2024. (2) Quantitative inaccuracies include the gross margin figures: the LLM claims 49.0% in 2023 (up 3.3 points) and 50.8% in 2024 (up 1.8 points), but the ground truth states the AspenTech acquisition contributed only 0.6 percentage points to gross margin in 2023 — not a full margin figure or multi-year uplift. The LLM invents precise gross margin percentages and growth figures not present in the original answer. Additionally, attributing 2024 margin growth to the 'Test & Measurement acquisition' and 'inventory step-up amortization' introduces entities and costs absent from the ground truth. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the timeline (2022 partnership → 2024 majority stake) and misrepresents the financial impact. It introduces a 'proposed full acquisition' and 'Heritage AspenTech acquisition' not mentioned in the original. The equity structure discussion is partially relevant (shift to full ownership) but based on false premises. (4) Contextual relevance is moderate — the answer addresses the relationship evolution and financial impacts as asked, but with incorrect details. Due to major factual and quantitative errors, especially in the core timeline and financial metrics, the correctness score is low at 3. Quantitative accuracy is severely lacking (2), qualitative reasoning is poor (3), and while the structure attempts relevance, it misses the mark.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 506,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "From 2022 to 2023, the financial relationship between NEE and FPL Group Capital Inc. involved ongoing obligations tied to debt instruments and capital structure support. In 2022, FPL Group Capital Inc. was referenced in a 1999 Guarantee Agreement (*4(n)) ensuring obligations related to FPL Group, Inc.'s debt. In 2023, FPL Group Capital Inc. continued its role through new debt issuances, including the 4.45% Notes (Series J, *4(j)) and Floating Rate Notes (Series K, *4(k)), which were part of NEE's capital structure. These instruments reflected FPL Group Capital Inc.'s involvement in supporting NEE's debt obligations, maintaining its role as a guarantor and participant in capital markets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, the relationship was based on a guarantee agreement dated October 14, 1998, between FPL Group, Inc. and FPL Group Capital Inc. However, the LLM incorrectly cites a '1999 Guarantee Agreement (*4(n))', which is both the wrong year and unsupported by the ground truth. Furthermore, the LLM claims that in 2023, NEE issued '4.45% Notes (Series J)' and 'Floating Rate Notes (Series K)' to FPL Group Capital Inc., but the ground truth specifies that NEE issued junior subordinated debentures in Series B, C, L, M, N, O, and P — not Series J and K — with maturities from 2057 to 2082. These series (J, K) and their associated interest rates are entirely fabricated and not mentioned in the original. (2) Quantitatively, the dates (1998 vs 1999), series labels (B,C,L,M,N,O,P vs J,K), and financial instruments (junior subordinated debentures vs notes with specific rates) are incorrect. The maturity dates (2057–2082) are omitted entirely, and the interest rate of 4.45% and 'Floating Rate' have no basis in the ground truth. (3) The multi-hop reasoning is flawed: the model fails to recognize the evolution from a guarantee by FPL Group, Inc. to a capital structure shift involving NEE issuing long-term debentures to FPL Group Capital Inc. Instead, it portrays FPL Group Capital Inc. as a continuing guarantor, which contradicts the original answer — the direction of obligation and nature of involvement is misrepresented. The strategic shift from a simple guarantee to long-term financing is missed. (4) While the answer is contextually relevant — discussing financial obligations and capital structure — the core facts, entities, and instruments are incorrect, leading to a low correctness score. Minor credit is given for addressing the general theme of evolving debt relationships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 512,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "Between 2022 and 2024, InterStim II maintained its position as a key component of Medtronic's Pelvic Health therapies, alongside newer models like InterStim X and InterStim Micro. In 2022, InterStim II was highlighted as part of the growth drivers for Pelvic Health, alongside the recently launched InterStim Micro and SureScan MRI leads. By 2024, InterStim II's recharge-free design was emphasized as part of a broader portfolio, with continued growth in Pelvic Health therapies, including InterStim X and InterStim Micro, reflecting its sustained market acceptance and integration into advanced neurostimulation solutions for overactive bladder, urinary retention, and fecal incontinence. The evolution underscores its role in expanding treatment options within the Pelvic Health segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: InterStim II remained a core product in Medtronic's Pelvic Health portfolio between 2022 and 2024, positioned alongside InterStim Micro and InterStim X. The 2024 emphasis on its recharge-free design is correctly highlighted, matching the ground truth's focus on device-specific attributes like recharge status. The conditions treated—overactive bladder, urinary retention, and fecal (bowel) incontinence—are accurately listed. (2) There are no numeric values to verify, so quantitative accuracy is 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years and product lines, showing evolution in positioning from being part of a growing suite in 2022 to being differentiated by technical features (recharge-free) in 2024. The only minor shortcoming is that the original answer explicitly notes InterStim Micro's repositioning by recharge status, which the LLM implies but does not state as clearly, slightly reducing qualitative accuracy. (4) The response is fully contextually relevant, directly addressing the evolution of market acceptance and positioning relative to other devices and broader Pelvic Health therapies. Wording differs but semantic meaning is equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 366,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "Simon Property Group's utilization of the Supplemental Facility evolved between 2022 and 2024 with increased borrowing capacity, consistent interest rate strategies, and active repayment actions. In 2022, the Supplemental Facility had an initial $3.5 billion capacity, extendable to $4.5 billion, with a maturity date of January 31, 2026, and interest rates based on SOFR plus 72.5 basis points. By 2024, the facility's capacity remained within the $3.5–$4.5 billion range, with a maturity date extended to January 31, 2029, and similar SOFR-based interest rates. The company used the facility to repay €750 million in debt in 2023 and issued new notes in 2024, reflecting strategic management of debt maturities while maintaining flexibility through the Credit Facilities and Commercial Paper program.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states the initial $3.5 billion capacity and extendable $4.5 billion in 2022, it incorrectly claims the maturity was extended to January 31, 2029—ground truth states the maturity remained January 31, 2026. This is a critical error. The interest rate margin of 72.5 basis points is not mentioned in the ground truth, which only states that margins were based on credit rating—this specific number is unsupported. The LLM also misrepresents the €750 million borrowing as debt repayment via the facility, whereas ground truth clarifies SPG borrowed €750 million under the facility and later repaid it after issuing exchangeable bonds. The LLM reverses the causal relationship. Additionally, the 2024 issuance of new notes is not in the ground truth. (2) Quantitative accuracy is low: maturity date wrong (2029 vs 2026), added unsupported basis points (72.5), and misstates the nature of the €750M transaction. (3) Reasoning is partially sound—LLM recognizes evolution in utilization and strategic management—but fails multi-hop synthesis: it conflates borrowing with repayment actions and omits key strategy of using interest rate swaps to fix rates at 3.81% in 2023, a critical element of rate management. (4) Contextual relevance is high as it addresses borrowing capacity, interest rates, and repayment, but factual errors reduce correctness. Overall, partially correct with significant factual and logical flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 414,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "Verizon's approach to device payment plans evolved from 2023 to 2024 by phasing out fixed-term, subsidized service plans for Consumer customers (retained for Business customers) and emphasizing device payment plans with non-interest-bearing installment notes for 36-month terms. In 2024, promotional incentives such as billing credits contingent on service maintenance were integrated into device payment plans, with credits allocated to performance obligations based on relative selling prices. The financing component of these plans was deemed not significant for direct-channel contracts, reflecting a shift toward flexible installment structures and embedded promotional incentives.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements but introduces inaccuracies and omits key aspects of the evolution in Verizon's device payment plans from 2023 to 2024. (1) Quantitatively, the 36-month term and non-interest-bearing installment note are correctly stated, aligning with the ground truth. However, the claim about phasing out fixed-term subsidized service plans for Consumer customers is not present in the original answer and cannot be verified from the provided ground truth, introducing a factual overreach. (2) The mention of 'billing credits contingent on service maintenance' and their allocation to performance obligations based on relative selling prices adds detail not found in the ground truth, which instead emphasizes a structured upgrade path via trade-ins after paying a specified portion—this promotional feature is entirely missing in the LLM answer. (3) The multi-hop reasoning is partially sound: it correctly identifies a shift in financing structure and the inclusion of promotional incentives, but fails to accurately characterize the nature of those incentives. The original answer specifies a clear upgrade+trade-in mechanism, while the LLM focuses on billing credits and revenue recognition concepts not mentioned in the ground truth. (4) Contextual relevance is high as the response stays focused on device payment plan evolution, financing structure, and promotions. However, the qualitative accuracy suffers due to substitution of the actual promotional incentive (upgrade via trade-in) with unverified billing credit mechanics. While the 36-month, non-interest-bearing note is correct, the overall synthesis does not faithfully reflect the documented shift from general financing to a structured, trade-in-based incentive model.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 478,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "The Coca-Cola Company's legal relationship with Aqua-Chem regarding asbestos-related claims remained unchanged between 2023 and 2024. As of December 31, 2024, the Georgia Case (The Coca-Cola Company v. Aqua-Chem) remained subject to the 2004 stay, with no new developments or rulings altering the Company's stance that it has no obligation for Aqua-Chem's liabilities or expenses related to asbestos claims. The litigation continued to hinge on prior judgments, including the 2007 declaratory judgment affirming joint and several liability of insurers, but no material changes in liability exposure were reported.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct but misses a key nuance in the evolution of Coca-Cola's stance between 2023 and 2024, which is central to the question. Quantitatively, the dates (2004 stay, 2007 judgment) and case name (The Coca-Cola Company v. Aqua-Chem) are accurate, and the statement that no new rulings occurred by December 31, 2024, aligns with the ground truth—hence a quantitative accuracy score of 8. However, the qualitative accuracy is lower because the LLM fails to recognize the shift in emphasis described in the original answer: from outright denial of liability in 2023 to a more nuanced 2024 position focusing on insurance coverage and shared insurer responsibility. Instead, the LLM claims the stance 'remained unchanged,' which contradicts the ground truth. This reflects a failure in multi-hop reasoning—synthesizing the change in disclosure tone and content across years—even if the legal outcome remained static. Contextually, the answer is relevant and addresses the litigation backdrop, but it omits the key evolution in narrative and emphasis that constitutes the actual development. Thus, while factually sound on surface details, it misrepresents the core analytical point about Coca-Cola's evolving disclosure strategy, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 358,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "Intel's utilization of non-US tax credits reduced the effective tax rate in 2024 by 5.3% (compared to 13.4% in 2022), indicating a diminished reliance on these credits in 2024. This shift suggests a strategic realignment, possibly due to changes in operations or jurisdictional focus. The significant increase in the valuation allowance for US deferred tax assets in 2024 ($10.9 billion) reflects heightened uncertainty about the realizability of these assets, likely tied to financial performance and restructuring, which impacts long-term tax liabilities. This underscores a more cautious approach to international tax strategies amid evolving financial conditions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Intel's long-term income taxes payable decreased from $4.3 billion in 2022 to $1.6 billion in 2024 due to an increasing offset from non-US tax credits. However, the LLM claims that the effective tax rate was reduced by non-US tax credits by only 5.3% in 2024 compared to 13.4% in 2022, implying a *decline* in the use or impact of non-US tax credits, which contradicts the ground truth that shows a *stronger* offsetting effect over time. Additionally, the LLM introduces a $10.9 billion valuation allowance for US deferred tax assets in 2024, which is not mentioned in the original answer and cannot be verified from the provided context. (2) The numbers provided in the LLM answer (5.3%, 13.4%, $10.9 billion) are not present in the ground truth and appear fabricated or misattributed. The only correct quantitative trend should have been the drop in long-term income taxes payable from $4.3B to $1.6B, but this is entirely missing from the LLM response. (3) The multi-hop reasoning is flawed: instead of connecting the increased utilization of non-US tax credits to the declining long-term tax liability, the model incorrectly infers reduced reliance on such credits. It also introduces unrelated concepts (valuation allowances, effective tax rates) that divert from the core comparison of long-term tax liabilities and their drivers. (4) The contextual relevance is moderate because the answer discusses international tax strategy, which is relevant, but the incorrect data and reversed logic undermine the conclusion. The qualitative reasoning fails due to incorrect entity relationships and unsupported claims. Overall, the answer is mostly incorrect with major factual and logical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 488,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "Between 2022 and 2024, the treatment of pension risk transfers (PRTs) and their interest rate sensitivity evolved through enhanced hedging strategies and regulatory adjustments. The 2024 filings highlight increased use of derivatives to mitigate interest rate risk, particularly for long-duration PRTs, as rising rates (e.g., 10-year Treasury yields reaching 2.46% by 2024) impact asset-liability matching. Regulatory developments, including stricter pension funding rules, pressured companies to delay or modify plan terminations, increasing reliance on non-guaranteed PRTs. Interest rate sensitivity remained critical, with scenarios showing that rising rates boosted reinvestment yields but strained derivative income, while declining rates exacerbated margin compression. Regulatory scrutiny of pension obligations and capital requirements further shaped PRT structures, emphasizing liquidity and solvency management.",
      "correctness_score": 7,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in pension risk transfer (PRT) treatment between 2022 and 2024, including increased regulatory influence and a shift toward non-guaranteed products, which aligns with the ground truth. It correctly identifies interest rate sensitivity as a key factor and notes regulatory pressure affecting corporate decisions on plan termination. However, it introduces specific quantitative claims not present in the original answer, such as '10-year Treasury yields reaching 2.46% by 2024', which is unsupported by the ground truth and potentially inaccurate (in reality, 10Y yields were higher than 2.46% in 2022 and fluctuated above 4% in 2023–2024). This undermines quantitative accuracy. (2) There are no verifiable calculations in the original or LLM answer, but the LLM fabricates a precise interest rate figure without citation or grounding in the provided truth, which is a critical flaw. The original answer does not include any numerical data, so introducing such specifics without basis reduces factual reliability. (3) The multi-hop reasoning is sound: the LLM synthesizes interest rate impacts, regulatory changes, and strategic shifts in PRT mix, correctly inferring that regulatory pressure may delay plan terminations and increase reliance on non-guaranteed products. This demonstrates good qualitative understanding and logical flow across time and domains. (4) Contextual relevance is high—the response directly addresses both interest rate sensitivity and regulatory influence over the 2022–2024 period. While the conceptual framework and strategic implications match the ground truth, the inclusion of unsupported numerical data lowers the correctness and quantitative accuracy scores. The answer would have scored higher if it had avoided spurious precision and stuck to the qualitative insights provided in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 510,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved from initial launch and sales growth in 2022 to sustained market acceptance and integration with advanced technologies by 2024. In 2022, the InterStim Micro was highlighted as a key driver of growth in Pelvic Health, contributing to a 12% increase in Specialty Therapies sales. By 2024, the InterStim Micro remained part of Pelvic Health therapies but was complemented by newer models like the InterStim X and InterStim II recharge-free neurostimulators, reflecting a shift toward advanced, recharge-free options. The strategy emphasized continued global adoption and expanded applications for treating overactive bladder, urinary retention, and fecal incontinence, alongside regulatory advancements like the Inceptiv closed-loop SCS approval in 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and introduces unsupported information. While it correctly identifies the InterStim Micro as part of Medtronic's Pelvic Health therapies and notes its role in treating overactive bladder, urinary retention, and fecal incontinence, it incorrectly claims a '12% increase in Specialty Therapies sales' driven by InterStim Micro in 2022—this specific quantitative figure is not present in the ground truth and cannot be verified from the provided knowledge. Additionally, the claim that by 2024 the product was 'complemented by newer models like InterStim X and InterStim II recharge-free neurostimulators' reverses the actual timeline and strategy: the ground truth states that InterStim Micro is the *rechargeable* device, while InterStim X and II are recharge-free, but the LLM implies the newer models are recharge-free advancements, misrepresenting the product differentiation. (2) The quantitative inaccuracy is significant—the 12% sales growth figure is fabricated or misattributed, and no dollar amounts, percentages, or financial impacts were mentioned in the original answer. This severely undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound—linking InterStim Micro to Pelvic Health and tracking its strategic evolution across years—but fails in synthesizing the correct product differentiation: the key 2024 shift was Medtronic *highlighting InterStim Micro as rechargeable*, thereby distinguishing it from the non-rechargeable models, whereas the LLM incorrectly frames recharge-free models as newer and advanced, missing the strategic emphasis on rechargeability as a feature. (4) Contextual relevance is high because the answer addresses the evolution of product strategy and positioning within the correct therapeutic and divisional context. However, due to major factual and quantitative errors, especially the unsupported 12% growth claim and reversed product differentiation logic, the overall correctness is only partial. The core idea of evolving strategy is present, but execution lacks fidelity to the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 569,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "Between 2022 and 2024, Simon Property Group's use of the Supplemental Facility involved significant repayments and capacity adjustments. In 2021, the company drew $1.05 billion under the Supplemental Facility to repay mortgages, but by December 31, 2021, the outstanding balance was reduced to $1.05 billion. In 2023, the company repaid €750 million (approximately $815 million) under the Supplemental Facility using proceeds from bond issuances. By December 31, 2024, the Supplemental Facility's borrowing capacity was $3.5–$4.5 billion, with no explicit mention of outstanding balances, indicating prior repayments had reduced its usage. The facility's maturity was extended to January 31, 2029, reflecting its continued role in liquidity management.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly regarding timing and amounts. It incorrectly states that $1.05 billion was drawn in 2021 and still outstanding at year-end 2021, which is irrelevant to the 2022–2024 timeframe asked. The ground truth focuses on 2022 and 2024 balances under the Credit Facilities, with a weighted average outstanding balance of $519.9 million in 2022 and $311.1 million in 2024. The LLM fails to report these key weighted average figures, which are central to assessing evolution in facility usage. (2) The repayment of €750 million ($815.4 million) on November 17, 2023, is correctly reported in amount and timing, aligning with the ground truth. However, the LLM incorrectly frames this as occurring in '2023' without the specific date and omits that this was part of a broader reduction from the Supplemental Facility. (3) The LLM introduces irrelevant data about the borrowing capacity in 2024 ($3.5–$4.5 billion) and maturity extension to 2029, which, while possibly true, are not in the ground truth and distract from the core question about outstanding borrowings and repayment actions. More critically, it fails to mention the maximum aggregate balance of $2.1 billion in 2022, a key indicator of peak usage. (4) The reasoning is partially sound in linking bond proceeds to repayments, but it misattributes the timeline (focusing on 2021 instead of 2022–2024) and omits multi-hop synthesis between the weighted average balances across years, which would show a clear downward trend. While the general direction (reduction in usage) is implied, the lack of correct quantitative benchmarks and misaligned timeframes severely undermines accuracy. (5) Contextual relevance is fair—the answer addresses facility usage and repayments—but misses the precise metrics requested. Overall, the answer is partially correct in direction but flawed in key facts, timing, and completeness, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 534,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "COP's investment activity in the Lower 48 region increased from 2022 to 2023, as reflected in higher depreciation, depletion, amortization, and impairments expenses. In 2023, Lower 48 expenses rose to **$5,729 million** (up from **$4,854 million** in 2022), driven by expanded development and exploration activities. This aligns with increased capital expenditures ($6,487 million in 2023 vs. $5,630 million in 2022) and a rise in development wells (371 in 2023 vs. 159 in 2022), indicating greater asset investment in the region.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the key financial figures from the ground truth: $4,854 million in 2022 and $5,729 million in 2023 for depreciation, depletion, amortization, and impairments (DD&A + impairments) in the Lower 48 region. These numbers match the original answer exactly and are presented with appropriate formatting variations (e.g., $5,729 million). (2) The quantitative accuracy is perfect—both the 2022 and 2023 figures are correct, and the implied increase of $875 million is accurate. While the LLM adds supplementary data (capital expenditures: $6,487M in 2023 vs $5,630M in 2022; development wells: 371 vs 159), these are consistent with increased investment and do not contradict the ground truth. However, these additional metrics were not present in the original answer or question prompt, so their inclusion, while plausible, goes beyond the provided ground truth. (3) The reasoning is sound: the LLM correctly infers that rising DD&A and impairments indicate higher investment or asset utilization, which aligns with the original conclusion. It supports this with logical multi-hop synthesis—linking expense increases to capital spending and operational activity (well counts). This demonstrates strong qualitative reasoning, though the original answer did not include capex or well count data, so the LLM may be drawing from external knowledge. (4) The answer is contextually fully relevant, directly addressing how investment activity evolved based on the specified expenses. The only reason for not scoring a 10 in correctness and qualitative accuracy is the introduction of unverified additional data points not present in the ground truth, which, while reasonable, slightly exceeds the evidence provided. Overall, the core answer is factually correct, well-reasoned, and semantically equivalent to the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 503,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "Verizon's approach to corporate networking solutions in 2024 maintained its focus on enterprise and public sector services, security, managed networks, and IoT, as described in 2023. However, the Business segment's revenue emphasis shifted slightly, with Business Markets and Other increasing from 42% to 44% of total Business segment revenue (from $12.7 billion to $13.08 billion), while Enterprise and Public Sector decreased marginally. The service descriptions remained consistent, emphasizing corporate networking, security, and IoT capabilities, with no significant new offerings highlighted in the 2024 filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, Enterprise and Public Sector revenues were $15.1 billion, accounting for approximately 50% of Business segment revenue. The LLM incorrectly claims that Enterprise and Public Sector revenues decreased and that Business Markets and Other increased from 42% to 44%, with specific dollar figures ($12.7B to $13.08B), none of which appear in the ground truth and contradict it. There is no mention in the original answer of 'Business Markets and Other' or such percentage shifts, making these figures fabricated or misattributed. (2) The quantitative inaccuracies are severe: the LLM introduces percentages and revenue figures not present in the ground truth, and the calculations (e.g., 42% to 44%) have no basis in the provided data. The correct emphasis in 2023 was on $15.1B representing ~50% of Business segment revenue for Enterprise and Public Sector—this is entirely missing from the LLM response. (3) The reasoning is flawed: the question asks about evolution in service description and business segment emphasis. The ground truth highlights a shift from detailed service descriptions in 2023 (private networking, cloud connectivity, SDN) to a more generalized description in 2024. The LLM incorrectly asserts that service descriptions 'remained consistent' and fails to identify the key change in narrative detail and strategic messaging. This misses the core multi-hop insight: a shift in disclosure granularity and possible strategic consolidation. (4) Contextual relevance is moderate—the response addresses corporate networking and segments, but due to factual errors and failure to capture the actual evolution in disclosure style and emphasis, the answer is largely incorrect. The LLM invents metrics and misses the central qualitative shift, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 513,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "MetLife's FVO securities were sensitive to U.S. dollar appreciation, with a $54 million estimated fair value loss in 2021 (as shown in the 2022 10-K). The 2024 10-K does not provide specific sensitivity figures for FVO securities under U.S. dollar appreciation, but the Level 3 fair value table indicates the fair value of FVO securities increased to $1,190 million as of December 31, 2024. The evolution from 2022 to 2024 is not explicitly detailed in the provided pages.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. It incorrectly states that the $54 million sensitivity to a 10% U.S. dollar appreciation was reported in the 2021 filing (via 2022 10-K), but the ground truth specifies this data point was from 2022, not 2021. Additionally, the LLM claims the fair value of FVO securities was $1,190 million as of December 31, 2024, based on the 2024 10-K, but the original answer explicitly states that no direct fair value figure for FVO securities is provided in 2024—this number is therefore fabricated or misattributed. (2) The quantitative inaccuracies are significant: the year is off by one (2021 vs 2022), and a specific fair value figure is reported for 2024 that the ground truth confirms is not available. These are not formatting issues but fundamental errors. (3) The multi-hop reasoning is weak: the model fails to synthesize the evolution in valuation approach from a static sensitivity model to a more dynamic, duration- and currency-dependent framework. Instead, it defaults to citing a non-existent specific fair value and misses the conceptual shift entirely. (4) Contextual relevance is moderate because the answer addresses FVO securities and U.S. dollar sensitivity, but it does not capture the core evolution in methodology. The answer reflects partial understanding but is undermined by key factual and inferential errors, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 397,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "NextEra Energy's engagement in power marketing activities, including energy trading services, expanded significantly between 2022 and 2023, driven by increased revenues from non-qualifying commodity hedges and favorable energy price movements. In 2023, operating revenues surged by $5,952 million, with $2,529 million in gains from energy price volatility compared to $2,670 million in losses in 2022. This reflects enhanced financial performance in energy trading, supported by optimized contracts and projected commodity price advantages, as detailed in NEER's results of operations and the broader discussion of trading activities in the 2023 10-K.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly identifies that NextEra Energy (NEE) expanded its power marketing and trading activities in 2023, the specific financial figures cited—such as a $5,952 million increase in operating revenues and $2,529 million in gains from energy price volatility in 2023 compared to $2,670 million in losses in 2022—are not present in the ground truth and contradict the known data. The ground truth emphasizes a rise in net income from $285 million in 2022 to $3,558 million in 2023 for NEER, which the LLM answer omits entirely. This is a critical error, as net income is the key performance metric provided. (2) The LLM introduces 'non-qualifying commodity hedges' and 'projected commodity price advantages' which, while plausible in context, are not mentioned in the original answer and may represent speculative inferences. The absence of the actual net income figures—especially the dramatic increase from $285M to $3,558M—represents a major omission. (3) The multi-hop reasoning is partially sound: the model infers increased profitability from expanded trading activities, which aligns with the original conclusion. However, it fails to correctly synthesize the actual financial metric (net income) that demonstrates this evolution, instead fabricating or misrepresenting revenue and gain/loss figures. (4) The contextual relevance is high because the answer addresses power marketing evolution and financial performance, and the general direction of growth is correct. However, due to severe quantitative inaccuracies and the replacement of correct metrics with unverified ones, the correctness score is low. The qualitative accuracy is moderate because the entities (NextEra Energy, NEER, energy trading) and time frame are correct, and the direction of change (expansion, improved performance) is accurate, but the reasoning is undermined by incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 535,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "The Coca-Cola Company's ownership stake in Coca-Cola FEMSA remained at 28% in both 2023 and 2024, as noted in Note 6 of the 10-K filings. However, the equity income from this investment increased from $1,691 million in 2023 to $1,770 million in 2024, reflecting higher net income from FEMSA. This suggests the financial relationship evolved positively due to improved performance of FEMSA, despite unchanged ownership. The carrying value of the investment also remained stable, with no significant changes in fair value adjustments reported.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2023, The Coca-Cola Company did not report a 28% ownership stake in Coca-Cola FEMSA — instead, the relationship was described as one of indirect financial dependency due to FEMSA being a key bottler affecting credit ratings. The shift to a 28% ownership stake accounted under the equity method is specifically highlighted as a 2024 development, indicating a change from 2023. However, the LLM claims the stake was 28% in both years, which contradicts the ground truth. Additionally, the LLM introduces specific financial figures — $1,691 million and $1,770 million for equity income — which are not present in the original answer and cannot be verified against the provided ground truth. There is no mention of Note 6 or carrying value in the original, suggesting fabrication or misattribution. (2) Quantitative accuracy is low because the dollar amounts and the assertion of unchanged ownership percentage are unsupported by the ground truth. The original does not provide equity income figures for either year, nor does it state that the ownership was the same in both years. (3) The multi-hop reasoning is flawed: the LLM fails to recognize the evolution from indirect dependency (2023) to direct ownership (2024) as the core transformation. Instead, it assumes stable ownership and attributes changes to performance, which misrepresents the strategic shift. The model misses the conceptual evolution in the financial relationship, focusing instead on numerical changes that aren't in the source. (4) While the answer is relevant to the question’s topic and discusses stake ownership and equity income, it conveys a different narrative than the ground truth. The contextual relevance is moderate because it addresses the right companies and general theme, but the factual foundation is incorrect, leading to a misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 524,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "Between 2022 and 2023, the Lower 48 region's depreciation expenses increased from $4,854 million to $5,729 million, reflecting heightened financial investment in assets. However, production volume data for 2022 and 2023 is not explicitly provided in the given pages, though 2021 Lower 48 crude oil production was 447,000 barrels daily. The rise in depreciation suggests operational focus on asset expansion or maintenance, but production trends remain unclear without 2022–2023 volume specifics.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the depreciation expenses for 2022 ($4,854 million) and 2023 ($5,729 million), matching the ground truth exactly—this satisfies quantitative accuracy. However, it incorrectly states that production volume data for 2022 and 2023 is not provided, when in fact the original answer explicitly includes 2022 production volumes (447 thousand barrels of crude oil and 1,340 million cubic feet of natural gas daily). This is a critical omission that undermines completeness and qualitative accuracy. (2) All numeric values cited by the LLM are accurate and properly formatted; no calculation errors exist. (3) The reasoning is partially sound—the LLM correctly infers that rising depreciation indicates increased financial investment. However, it fails to perform the necessary multi-hop synthesis: linking 2022 production data to operational focus and combining it with 2023 financial data to show evolution. By claiming production trends are 'unclear,' the LLM misses the core inference supported by the data. (4) The correctness score is 5 due to significant factual incompleteness despite accurate numbers. Quantitative accuracy is 10 because all numbers are correct. Qualitative accuracy is 5 due to flawed reasoning and failure to use available data. Contextual relevance is 8 because the response addresses the general topic and draws a plausible conclusion, albeit with a key factual gap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 396,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "Verizon's 4G LTE network remained a foundational component of its network infrastructure in 2024, supporting both wireless services and FWA broadband as an alternative to traditional landline internet. The company continued to invest in network densification and capacity expansion to meet growing demand, while integrating 4G LTE with 5G advancements to enhance performance. This strategic role aligned with broader growth initiatives, including fiber network expansion and leveraging 4G LTE as a backbone for emerging services, ensuring its relevance alongside evolving 5G capabilities.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but misses a key evolution in Verizon's strategic positioning of its 4G LTE network between 2023 and 2024 as described in the ground truth. (1) What was correct: The LLM correctly identifies that 4G LTE remained foundational in 2024 and supported FWA broadband and wireless services. It also accurately notes integration with 5G and continued investment, which aligns with Verizon’s broader network strategy. There are no numeric values to verify, so quantitative accuracy is 10. (2) What was incorrect: The original answer emphasizes a strategic shift—from 4G LTE being primarily a service delivery platform (especially for FWA) in 2023 to being part of an integrated multi-technology ecosystem (including C-Band, mmWave, and fiber) in 2024. The LLM answer does not clearly articulate this evolution or the change in strategic framing. Instead, it implies continuity rather than transformation, missing the nuanced shift from 'foundational service delivery' to 'strategic asset within a broader ecosystem.' (3) Multi-hop reasoning assessment: The question requires synthesizing how the role of 4G LTE changed across two years. The LLM fails to contrast 2023 and 2024 roles explicitly and omits mention of C-Band, millimeter wave, and fiber integration as part of the evolved strategic vision. This weakens the qualitative accuracy. (4) Justification: While the answer is contextually relevant and factually plausible, it lacks the precise strategic evolution described in the ground truth, warranting a correctness score of 6—partially correct with significant omissions in conceptual shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 443,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "Emerson's ownership of AspenTech evolved from 55% in 2022 (post-Heritage AspenTech acquisition) to 57% in 2024, with a proposed full acquisition of the remaining shares in 2024. The 2022 acquisition increased AspenTech's backlog by $714 million, reflecting integration benefits. While the 2024 financial metrics highlight overall gross margin expansion (50.8% in 2024) driven by the Test &amp; Measurement acquisition, specific AspenTech margin impacts are not detailed in the provided documents. The strategic relationship shifted from a partial ownership stake to a path toward full control, with AspenTech's performance contributing to broader operational synergies.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, Emerson did not own 55% of AspenTech in 2022; rather, it acquired a 55% controlling stake in 'New AspenTech' by 2024, not 2022. The LLM incorrectly states ownership was 55% in 2022 and increased to 57% in 2024, which contradicts the ground truth. Additionally, the claim of a 'proposed full acquisition of remaining shares in 2024' is not supported in the original answer. The backlog increase attributed to AspenTech integration is misstated: the LLM says it increased by $714 million due to the 2022 acquisition, but the ground truth reports a backlog of $8,053 million in 2024 (up from $6,533 million in 2021), with no mention of a $714 million increase in 2022. The gross margin impact is also misrepresented: the ground truth specifies a 3.3 percentage point increase in gross margin in 2023 partly due to AspenTech, but the LLM attributes margin expansion in 2024 to the Test & Measurement acquisition, not AspenTech, and provides no correct causal link. (2) Quantitative accuracy is very low: key numbers like ownership percentages (55% in 2024, not 2022), correct timeline of ownership evolution, and correct backlog figures ($8,053M in 2024) are either misplaced or invented. The $714M backlog increase has no basis in the ground truth. (3) Multi-hop reasoning is flawed: the LLM fails to correctly synthesize the timeline of ownership (from stake in 2022 to 55% control in 2024) and misattributes financial impacts to the wrong years and acquisitions. It also introduces 'Heritage AspenTech' and 'Test & Measurement' acquisition, which are not mentioned in the original answer, indicating hallucination. (4) Contextual relevance is moderate because the answer addresses stake value, ownership, and financial metrics like backlog and margin, but the incorrect entities and numbers undermine usefulness. The strategic shift toward control is partially correct but poorly supported. Overall, major factual and quantitative errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 556,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "NEE's financial commitment to the Mountain Valley Pipeline evolved from equity contributions in 2024 (as noted in both 2022 and 2023 capital expenditure tables) to include a 20-year natural gas transportation agreement in 2023. This shift indicates a strategic move from a pure equity investment to a more integrated approach, combining financial support with long-term operational agreements to secure revenue streams and ensure the pipeline's viability. The 2023 addition of a transportation agreement suggests NEE aimed to stabilize its investment through contractual obligations, even after prior impairment charges.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. It incorrectly states that NEE's equity contributions were noted in '2024' capital expenditure tables, which is factually wrong—the question and ground truth focus on 2022 and 2023. This is a critical error in temporal context. Additionally, the LLM fails to mention the specific ownership stake range (32%–55%) in 2022 or the precise 32.8% stake in 2023, which are key quantitative details from the ground truth. The $70 million per year transportation agreement value is omitted entirely, despite being a central financial figure. (2) The quantitative inaccuracies include the fabricated reference to '2024 capital expenditure tables' and the absence of exact percentages and dollar amounts. While the 20-year transportation agreement is correctly identified, its value is missing, undermining financial precision. (3) The reasoning partially captures the strategic shift—from equity investment to a more structured, long-term arrangement—but does so without grounding in the correct multi-hop evidence (e.g., no mention of NEER as the subsidiary or the evolution from variable stake to fixed 32.8%). The mention of 'prior impairment charges' is unsupported in the ground truth and introduces unverified information. (4) Despite these flaws, the answer is contextually relevant, correctly identifying the shift in investment strategy and the significance of the transportation agreement. The core idea of moving toward long-term contractual stability aligns with the ground truth, warranting moderate scores in qualitative accuracy and contextual relevance. However, the lack of key numbers and incorrect dates significantly reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 467,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "Coca-Cola's relationship with Costa Limited remained integral to the Global Ventures segment in both 2023 and 2024, with Costa's operations and brand included within the segment's scope. In 2023, Costa was explicitly listed as part of the Global Ventures segment, alongside businesses like innocent and doğadan, and sales to Costa were categorized under this segment. The 2024 document (pages 71–75) likely reinforced this integration, emphasizing Costa's role in the segment's strategic focus on expanding beverage offerings and leveraging distribution partnerships. No significant changes in operational integration or strategic positioning were noted between the two years, as Costa's inclusion in Global Ventures persisted, aligning with Coca-Cola's broader efforts to diversify and strengthen its portfolio through partnerships and regional growth initiatives.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no incorrect numbers, it is scored as 10. The main issue lies in qualitative accuracy and correctness. The LLM incorrectly states that Costa Limited was already grouped with innocent and doğadan in 2023, which contradicts the ground truth: in 2023, Costa was part of Global Ventures through its retail operations, but the broader integration including innocent and doğadan—and deeper strategic embedding—occurred in 2024. The LLM claims 'no significant changes' between 2023 and 2024, which directly opposes the ground truth that indicates a deeper integration and expanded strategic role in 2024. This misrepresents the evolution of the relationship, failing the multi-hop reasoning required to compare the two years' strategic positioning. While the answer correctly identifies Costa's presence in the Global Ventures segment in both years and references distribution partnerships, it misses the key development—enhanced integration and expansion of the segment's composition in 2024. Thus, despite being contextually relevant and using appropriate terminology, the answer is factually inaccurate in its core conclusion, warranting a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 359,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "Intel's fair value of economically hedged marketable debt investments decreased from $17.1 billion as of December 30, 2023, to $13.5 billion as of December 28, 2024. This reflects a decline of $3.6 billion over the period. The 2022 data (not explicitly provided in the 2024 document) shows net losses of $748 million, while 2023 had net gains of $534 million, and 2024 recorded net losses of $464 million, indicating volatility in the fair value during this timeframe.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the fair value decline from $17.1 billion in 2023 to $13.5 billion in 2024, and accurately states the $3.6 billion decrease. It also correctly cites the $748 million net loss in 2022 and $464 million net loss in 2024, aligning with the ground truth. However, it introduces a fact not present in the original answer—net gains of $534 million in 2023—which, while possibly true in the actual filings, is not part of the provided ground truth and adds unverified information. (2) All stated numbers (dollar amounts, years) are quantitatively accurate, and the $3.6 billion difference is correctly calculated ($17.1B - $13.5B = $3.6B). The dates (December 30, 2023, and December 28, 2024) are plausible fiscal year-ends but were not specified in the ground truth; their inclusion is reasonable but adds precision not confirmed in the original. (3) The multi-hop reasoning is mostly sound: the model connects changes in fair value and net losses across years. However, the original answer emphasizes a two-year evolution from 2022 to 2024 with portfolio size and loss reduction, while the LLM shifts focus to volatility by introducing 2023 gains, which changes the narrative slightly. The core evolution is captured, but the synthesis includes an unsupported intermediate data point. (4) The answer is highly contextually relevant, directly addressing the evolution of Intel's hedged investments. The correctness score is 7 due to accurate core facts but minor overreach with unconfirmed 2023 gains; quantitative accuracy is 8 due to correct values and math; qualitative accuracy is 7 due to sound but slightly flawed reasoning; contextual relevance is 10 as the response stays fully on-topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 471,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "AMT's financial focus on communications sites remained centered on generating recurring revenue through long-term leases with wireless carriers and other tenants, as most leases have noncancellable terms of 5–10 years with renewal options. This structure ensured continued recurring revenue in both 2023 and 2024. Regarding asset retirement liabilities, as of December 31, 2024, the estimated undiscounted future cash outlay for asset retirement obligations was **$4.5 billion**, though no specific 2023 figure is provided in the given pages. The 2023 document does not explicitly mention ARO amounts, so the 2024 figure reflects the latest disclosed liability.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the recurring revenue model in both 2023 and 2024, noting long-term leases as the driver, which aligns with the ground truth that 99% of revenues came from property operations (i.e., leasing). It accurately reports the $4.5 billion undiscounted future cash outlay for asset retirement obligations (ARO) as of December 31, 2024, matching the ground truth. However, it states that 'no specific 2023 figure is provided' and that ARO was not mentioned in 2023, which is factually accurate based on available data but omits the key evolution highlighted in the original answer: the *shift in focus* from emphasizing revenue in 2023 to also addressing liabilities in 2024. This conceptual shift is central to the question and only partially captured. (2) All numeric values—$4.5 billion, December 31, 2024—are correct and properly formatted. No calculations were required. (3) The reasoning is sound in terms of multi-hop synthesis: it draws from both years and correctly identifies what is present (or absent) in each filing. However, it stops short of synthesizing the *evolution* in financial focus, instead reporting facts from each year without explicitly connecting them into a narrative of change. (4) Scores reflect high factual accuracy and relevance, with a moderate deduction in qualitative accuracy for incomplete reasoning about the shift in focus, though the core facts are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 399,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "XOM's strategic positioning in Guyana remained anchored by the Petroleum Activities Act 2023, which established a legal framework with exploration periods (up to 10 years) and production terms (20 years for oil, 30 for gas), renewable for up to 10 years. In 2024, Guyana was highlighted as part of XOM's \"Advantaged Assets\" in its earnings drivers, emphasizing continued focus on growth through its Guyana LNG project and integrated operations. The legal framework remained unchanged, but the company intensified its business growth emphasis, leveraging Guyana's assets as a key component of its advantaged volume growth strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Correctly identifies the Petroleum Activities Act 2023 as the legal framework governing XOM's operations in Guyana, accurately describing the exploration period (up to 10 years) and production period (20 years for oil, with renewal up to 10 years). The mention of a 30-year term for gas is not present in the original answer but does not contradict it, as the original only specifies oil; this may be additional context rather than an error. (2) Correctly notes that in 2024, Guyana was classified as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, reflecting a strategic emphasis on volume growth and integration. (3) The multi-hop reasoning is sound: it connects the stable legal framework (2023) with the evolved business strategy (2024), showing how Guyana transitioned from a jurisdiction with defined terms to a core growth asset. (4) Minor point: the original does not mention the 'Guyana LNG project' specifically, so that detail is an addition not present in the ground truth, but it is contextually plausible and does not detract from accuracy. Overall, all key facts, dates, and strategic shifts are correctly conveyed with only slight elaboration beyond the original. Quantitative and qualitative accuracy are high, and the response is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 385,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "Caterpillar's involvement in the diesel-electric locomotives business remained a key component of its Energy & Transportation segment in both 2023 and 2024, with strategic focus on manufacturing, remanufacturing, and leasing services. In 2024, the segment reported increased transportation sales, driven by growth in marine and rail services, including diesel-electric locomotives, while maintaining its role in rail-related products and remanufacturing. The 3% year-over-year sales growth in the Energy & Transportation segment reflected continued operational responsibility and strategic positioning in this area.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but misses key aspects of Caterpillar's strategic evolution in the diesel-electric locomotives business between 2023 and 2024. While it correctly identifies Caterpillar's continued involvement in remanufacturing and services within the Energy & Transportation segment, it fails to capture the significant strategic shift highlighted in the ground truth—specifically, the 2024 pivot toward integrated systems, electrified powertrains, and zero-emission technologies. This omission represents a major gap in qualitative accuracy. (2) The LLM introduces a specific figure—'3% year-over-year sales growth'—which is not present in the original answer and cannot be verified from the provided ground truth. This affects quantitative accuracy, though the number is plausible and not wildly inconsistent. No other numbers are present to verify. (3) The multi-hop reasoning is partially sound: the model connects Caterpillar’s locomotive activities across years and segments, but it does not synthesize the evolution in strategic focus (e.g., environmental technologies, integration with power generation and industrial sectors). The answer treats the business as stable rather than evolving, contradicting the ground truth’s emphasis on transformation. (4) Contextual relevance is high because the response stays on topic, references the correct segment, and discusses operational responsibilities. However, the failure to reflect the strategic shift toward electrification and integrated solutions significantly undermines factual correctness, warranting a mid-range score of 5 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 454,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "The company's reliance on securitized debt obligations as a funding source decreased from 2023 to 2024, with the amount declining from $18.0 billion (2023) to $14.3 billion (2024). This reduction indicates a strategic shift toward diversifying funding sources, likely emphasizing more stable, lower-cost alternatives like deposits, to mitigate risks associated with securitized debt.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no exact amount for securitized debt obligations was disclosed in 2022, and there is no data provided for 2023. However, the LLM claims a specific value of $18.0 billion in 2023, which is not supported by the original answer. The 2024 figure of $14.3 billion is approximately close to the correct carrying value of $14,264 million (i.e., $14.264 billion), so this part is roughly accurate within rounding. (2) The quantitative inaccuracies are critical: the introduction of a $18.0 billion figure for 2023 is entirely fabricated based on the ground truth, and the comparison between 2023 and 2024 cannot be made due to absence of 2023 data. The calculation or trend analysis (decrease from $18.0B to $14.3B) is therefore invalid. (3) The multi-hop reasoning is flawed. The original answer suggests an increased clarity or definitional focus on securitized debt in 2024 compared to vague disclosure in 2022, implying growing strategic importance. In contrast, the LLM concludes a strategic reduction and shift away from securitized debt, which contradicts the ground truth's implication of increased reliance or at least more transparent accounting. (4) The contextual relevance is moderate because the answer addresses the general topic of funding strategy evolution and securitized debt, but the incorrect data and resulting misinterpretation severely undermine the validity. Due to major factual and reasoning errors, the correctness score is low at 2, with similarly low quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 442,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "McDonald's treatment of developmental licensees between 2023 and 2024 remained consistent in financial reporting, with revenues from this segment reported under the \"International Developmental Licensed Markets & Corporate\" segment. In 2023, this segment generated $2,543.3 million in revenue, while in 2024, it increased to $2,543.3 million (assuming the 2024 data reflects a similar structure). The financial reporting continues to recognize royalties and initial fees from developmental licensees, with no significant changes noted in the disclosure of their treatment. Relationship management practices, as outlined in franchise arrangements, also remained aligned with historical practices, emphasizing royalty-based payments and initial fees, with no material shifts identified in the 2024 filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies and omits key developments in McDonald's treatment of developmental licensees between 2023 and 2024. While it correctly identifies that royalties and initial fees are part of the arrangement, it fabricates revenue figures—claiming $2,543.3 million for both 2023 and 2024—without any support from the ground truth, which does not provide specific revenue numbers for this segment. This undermines quantitative accuracy. (2) The ground truth highlights important changes in 2024: the evaluation of developmental licensees as potential variable interest entities (VIEs) and a change in rounding policy to the nearest whole number. These critical updates are entirely missing from the LLM response, which incorrectly asserts there were 'no significant changes' or 'no material shifts.' This shows a failure in both completeness and qualitative accuracy. (3) The multi-hop reasoning is flawed—the question asks for evolution between years, but the LLM concludes no change occurred, contradicting the original answer’s emphasis on new assessments and presentation updates. It fails to synthesize the shift in accounting evaluation and disclosure practices. (4) Contextual relevance is moderate because the answer discusses the right topic (developmental licensees, royalties, fees), but it does not reflect actual changes reported in the filings. The mention of the 'International Developmental Licensed Markets & Corporate' segment is plausible but not confirmed in the ground truth, and the repeated identical revenue figure suggests data fabrication or error. Overall, the answer is mostly incorrect due to missing key developments and introducing unsupported numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 473,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "Southern Company's Equity and Incentive Compensation Plan maintained consistent share availability and executive award disclosures between 2023 and 2024. As of December 31, 2023, 26.9 million shares were available for awards under the plan, as detailed in Note 12 of the 2023 10-K. The 2024 10-K does not indicate changes to the plan's structure or share availability, with the plan's effective date remaining May 26, 2021, and disclosures about stock-based compensation and award calculations unchanged. No specific updates to executive award disclosures or share availability are noted in the provided 2024 document pages.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the 26.9 million shares available in 2023 and the May 26, 2021 effective date of the plan, which aligns with the ground truth. However, it incorrectly claims there were no changes in 2024, directly contradicting the original answer, which states that Southern Company increased transparency by disclosing specific terms for Named Executive Officer awards in 2024. This is a critical factual omission. (2) Quantitatively, the numbers and dates provided (26.9 million shares, May 26, 2021) are accurate and match the ground truth. There are no calculation errors. (3) The reasoning is flawed: the LLM fails to recognize the evolution in disclosure practices between 2023 and 2024, which is the core of the question. Instead, it asserts no changes occurred, indicating a failure in multi-hop reasoning—specifically, synthesizing the shift from internal reserve allocation to enhanced executive compensation transparency. (4) While the answer is factually accurate on the data it includes, it misses the key development in 2024, rendering it substantially incomplete. The contextual relevance is moderate because it addresses the plan and shares but overlooks the critical evolution in disclosure practices, which is the central focus of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 362,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "Inlyta's revenue increased by 3% globally from 2022 to 2023, reaching $1,036 million in 2023 compared to $1,003 million in 2022. The growth was driven by strong U.S. adoption of Inlyta in combination with immune checkpoint inhibitors for advanced RCC, partially offset by lower volumes and net price declines in certain European markets. This trajectory reflects both market expansion in the U.S. and regional challenges in Europe, influenced by competitive dynamics and pricing pressures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Inlyta's global revenue reached $1,036 million in 2023 with a 3% total increase, matching the ground truth. It accurately infers the 2022 revenue as $1,003 million ($1,036M / 1.03 ≈ $1,003M), which is consistent with the 3% growth reported. The 5% operational growth mentioned in the original is not explicitly included, but the 3% total growth is correctly emphasized. (2) All numeric values—$1,036 million, 3% growth—are factually accurate and correctly calculated. The implied 2022 figure is mathematically sound. (3) The reasoning correctly synthesizes multi-hop information: it identifies the U.S. adoption of Inlyta in combination therapies for advanced RCC as a growth driver and acknowledges headwinds in Europe due to pricing and volume declines. This aligns with the original answer’s causal factors. However, it omits explicit mention of Inlyta being part of Pfizer’s growth portfolio in 2022 alongside Comirnaty, Eliquis, and Vyndaqel, which slightly weakens the completeness of the year-over-year evolution narrative. (4) The answer is semantically equivalent in conveying the core revenue performance and drivers. The omission of the 2022 product peer context and the 5% operational growth (vs. 3% total) prevents a perfect score, but the key facts, calculations, and reasoning are sound and highly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 386,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "McDonald's relationship with its franchisees from 2023 to 2024 maintained a structured financial dependency, with franchisees contributing 95% of total restaurants. Revenue recognition for franchisees includes rent, royalties (based on sales percentages), and initial fees, with minimum rent payments recognized straight-line over franchise terms. Technology platform costs are recovered through fees paid by franchisees, with revenue recognized gross as services are transferred. In 2024, the company emphasized co-investment in restaurant improvements with franchisees, reinforcing shared value creation while maintaining stable revenue streams through existing fee structures. No significant changes in dependency or cost-sharing models were noted.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements, such as the ongoing financial structure with rent, royalties, and initial fees, and the high percentage of franchised restaurants (95%), which aligns with McDonald's model. However, it incorrectly states that 'no significant changes in dependency or cost-sharing models were noted' in 2024, which directly contradicts the ground truth. The key evolution in 2024—McDonald's shifting to gross revenue recognition for technology services and recording related expenses in 'Other restaurant expenses'—is entirely missing. This represents a significant change in financial structure and interdependency, particularly around technology platforms, which the LLM fails to acknowledge. (2) Quantitatively, the 95% franchised restaurant figure is plausible and consistent with public disclosures, and no incorrect numbers are presented. There are no calculations in the response, so no errors there. The dates (2023 to 2024) are correctly referenced. (3) The multi-hop reasoning is flawed: the question requires synthesis of changes in revenue recognition and cost-sharing for technology platforms across two years, but the LLM denies any change despite the ground truth indicating a material shift. The model fails to connect the dots between revenue recognition policy changes and increased operational interdependence. (4) Contextual relevance is high—the response addresses franchisee financial structure, revenue recognition, and technology costs—but the omission of the core 2024 change severely undermines factual accuracy. The answer is well-structured but misses the central point of evolution in the franchisee relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 460,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "The fair value of energy-related derivatives assets held by Southern Company's subsidiaries decreased from $199 million in 2022 to $55 million in 2023, while liabilities increased from $210 million to $358 million. This indicates a reduction in assets hedging energy price risks but a rise in obligations tied to energy derivatives, suggesting potential heightened exposure to market fluctuations due to increased liabilities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative values. According to the ground truth, in 2022, the total assets from energy-related derivatives were $59 + $8 + $28 = $95 million, not $199 million as claimed. Total liabilities in 2022 were $32 + $12 + $65 = $109 million, not $210 million. In 2023, the LLM reports $55 million in assets and $358 million in liabilities, but the ground truth only provides data for Alabama Power ($15 assets, $110 liabilities) and Georgia Power ($13 assets, $124 liabilities), totaling $28 million in assets and $234 million in liabilities. Thus, both asset and liability figures in the LLM answer are incorrect. The net liability in 2022 was $109 - $95 = $14 million (not $54 million as per ground truth calculation in original answer, which actually computes $101M assets - $155M liabilities = -$54M net), and in 2023 it was $234 - $28 = $206 million net liability (close to the ground truth's $219M, but still off). (2) Calculations are fundamentally flawed: the LLM invents aggregate numbers not present in the source and miscalculates the subsidiaries' contributions. It also misattributes data—Mississippi Power, Southern Power, and Southern Company Gas are named in 2022, but Alabama and Georgia Power in 2023, suggesting incomplete or incorrect entity mapping. (3) Multi-hop reasoning is partially sound—the LLM recognizes the need to aggregate derivatives data across subsidiaries and years and draws a reasonable qualitative conclusion about increased exposure. However, due to incorrect inputs, the logic is based on false premises. (4) Contextual relevance is acceptable because the answer addresses the evolution of fair value and its implication for market exposure. However, the severe quantitative errors and incomplete entity coverage (missing or misrepresenting subsidiaries) undermine correctness. The conclusion about heightened exposure is directionally consistent with the ground truth but not sufficiently supported by accurate data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 546,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "The Procter & Gamble 2019 Stock and Incentive Compensation Plan remained the sole active equity compensation plan allowing future grants in both 2022 and 2024, as noted in Item 12 of the 10-K filings. However, the number of shares available for future issuance under the 2019 Plan decreased from 119 million (as of June 30, 2022) to 77 million (as of June 30, 2024), reflecting utilization of the plan's share pool. The plan's significance as the primary vehicle for equity compensation persisted, though its available shares were reduced due to prior grants.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies not supported by the ground truth. The claim that the 2019 Plan was the 'sole active equity compensation plan allowing future grants' in both 2022 and 2024 is not mentioned or implied in the original answer, which only states the plan evolved from being newly introduced to becoming a standard part of PG's equity compensation. Additionally, the specific numbers cited—119 million shares as of June 30, 2022, and 77 million as of June 30, 2024—are entirely absent from the ground truth and cannot be verified from the provided context. There is no mention of share counts or utilization in the original answer, making these figures hallucinated. (2) Quantitative accuracy is low because the numbers presented (119M, 77M) have no basis in the ground truth. Even if such data existed in actual filings, the evaluation must be based solely on the provided ground truth, which contains no quantitative metrics about shares available. Thus, introducing precise figures undermines factual correctness. (3) The reasoning partially captures the evolution of the plan’s significance—highlighting its continued role in equity compensation—but misrepresents the nature of that evolution by adding unsupported specifics. The original answer emphasizes a shift in disclosure context (from introduction to integration), while the LLM focuses on quantitative depletion and exclusivity, which are not present in the ground truth. This reflects flawed multi-hop synthesis, as the model inferred granular details not contained in the source. (4) Despite the factual errors, the answer remains contextually relevant by addressing the plan's ongoing significance and changes over time. It attempts to respond to the evolution question and stays within the domain of 10-K disclosures and equity plan treatment, warranting moderate relevance and partial qualitative accuracy. However, the invention of precise share numbers and the claim of sole active plan status severely reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 551,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "Southern Company's approach to managing pension plan risk remained consistent between 2023 and 2024, emphasizing diversification across asset classes and formal rebalancing to align with target allocations. While the 2024 disclosures reiterated the use of diversification, external guidelines for investment managers, and monitoring of risk factors, there were no explicit changes in strategy. However, the 2024 section highlighted a slight increase in private credit allocation (from 0% to 1% of actual assets) and a more precise alignment of real estate investments with target allocations, suggesting a refined focus on balancing risk and return through targeted adjustments in specific asset classes.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements, such as the continued use of diversification and rebalancing in both years, which aligns with the ground truth. The mention of external investment manager oversight is partially accurate for 2023, but the LLM incorrectly states that this oversight remained a focus in 2024, whereas the ground truth indicates a reduction in emphasis on external manager oversight. The LLM introduces specific asset allocation changes—private credit increasing from 0% to 1% and real estate adjustments—which are not mentioned in the original answer and appear to be fabricated or inferred beyond the provided data. These quantitative details, while plausible, are not supported by the ground truth and introduce inaccuracies. (2) Quantitatively, the 0% to 1% shift is numerically precise but not present in the original answer, so it cannot be verified and likely reflects unsupported inference. No actual calculations are performed, so the score is moderate due to the plausible but unverified numbers. (3) The multi-hop reasoning is flawed: the question asks for evolution and specific changes in risk management emphasis, but the LLM concludes there were 'no explicit changes in strategy,' directly contradicting the ground truth, which identifies a clear shift from active oversight to market-driven risk exposure. This failure to identify the core conceptual shift significantly undermines the qualitative accuracy. (4) Contextually, the answer remains relevant by discussing pension risk management and asset allocation, but it misses the key analytical point about changing emphasis in risk philosophy. The answer focuses on minor allocation tweaks rather than the broader strategic shift in risk framing, leading to a partially correct but ultimately misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 494,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "NVIDIA's role in the CUDA platform has remained foundational to its accelerated computing ecosystem, with CUDA serving as the core programming model for all NVIDIA GPUs. Between 2022 and 2023, NVIDIA emphasized expanding CUDA's integration into its full-stack solutions, including AI, data center infrastructure, and autonomous systems. The 2023 filing highlights CUDA's critical role in enabling AI training and inference, as well as its extension into new domains like generative AI and high-performance computing. This underscores NVIDIA's strategic focus on maintaining CUDA as a central enabler of its technological leadership in AI and data center innovation.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and contextually relevant, correctly identifying NVIDIA's continued and deepening role in the CUDA platform between 2022 and 2023. It accurately reflects that CUDA remained central to NVIDIA's ecosystem and was increasingly integrated into AI, data centers, and new domains like generative AI—consistent with the strategic focus shift. While the original answer specifies a qualitative evolution from 'supplier' to 'developer' of CUDA, the LLM answer captures the essence of this shift by emphasizing expanded integration and full-stack development without explicitly naming the role transition. All entities (NVIDIA, CUDA, 2022–2023 timeframe) are correct, and there are no numerical inaccuracies (no quantitative data to verify, so score is 10 by default). The reasoning is sound and synthesizes the strategic implications correctly, though it misses the precise framing of role evolution from supplier to developer, which is a minor omission in qualitative precision. Hence, correctness and qualitative accuracy are slightly reduced but remain high due to semantic alignment with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 320,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "Pfizer's financial relationship with Viatris evolved between 2022 and 2023 through ongoing supply agreements under Manufacturing and Supply Agreements (MSAs) established during the Upjohn separation and combination with Mylan. These agreements involved Pfizer manufacturing, labeling, and packaging products for Viatris, with terms ranging from four to seven years post-separation. Outstanding balances due to Viatris under these agreements decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023, reflecting payments made during the period. This reduction aligns with the transition of operations and fulfillment of supply obligations under the MSAs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the decrease in net amounts due to Viatris from $94 million (Dec 31, 2022) to $33 million (Dec 31, 2023) is accurately reported, matching the original answer. No calculations were required beyond this comparison, and the values are presented correctly. (2) The answer addresses both parts of the question—supply agreements and outstanding balances—with precise details on the Manufacturing and Supply Agreements (MSAs), including their origin from the Upjohn-Mylan transaction and duration. (3) The multi-hop reasoning is sound: it connects Pfizer’s supply obligations post-separation to the declining balance owed to Viatris, correctly interpreting the reduction as reflective of ongoing fulfillment and payments. (4) The only minor omission is that the original answer notes $780 million in revenue growth from PC1 in 2022 tied to manufacturing for Viatris, which the LLM answer does not mention. While not critical to the evolution of balances, it adds context about the scale of the 2022 relationship. Otherwise, entity names (Pfizer, Viatris, Upjohn, MSAs), years (2022–2023), and financial terms are accurate. The answer is semantically equivalent in key aspects and highly contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 366,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "The treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024 by maintaining their role as collateral for securitizations while enhancing transparency on compliance with debt covenants. In 2023, the disclosures focused on the structure of securitizations (e.g., Series 2015-2 Notes secured by 3,343 sites and Trust Securitizations involving 5,034 towers) and repayment terms. By 2024, the disclosures emphasized updated metrics, such as the Debt Service Coverage Ratio (DSCR) for Trust Securitizations (7.14x as of December 31, 2024), compliance with cash trap and minimum DSCR thresholds, and the impact of these ratios on cash flow distribution. The 2024 filing also clarified that excess cash flows were available for distribution to the parent company, reflecting continued adherence to covenants and improved liquidity management.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and misrepresents the evolution of treatment and disclosure of communications sites in relation to debt obligations between 2023 and 2024. (1) The original answer states that in 2023, specific communications sites (e.g., 3,343 sites) were explicitly disclosed as collateral for debt obligations like the Series 2015-2 Notes and the $1.3 billion repayment via 2023 Securitization. In 2024, there was no such site-specific collateral disclosure; instead, the company reported broader financial obligations like a $4.5 billion estimated undiscounted future cash outlay for asset retirement obligations. This indicates a shift from granular, site-linked disclosures to more generalized liability reporting. (2) The LLM answer incorrectly asserts that in 2024, disclosures focused on updated metrics like DSCR (7.14x), compliance with covenants, and cash flow distribution—none of which are mentioned in the ground truth. These specific figures (e.g., 7.14x DSCR) and concepts (cash trap thresholds, excess cash flows) are fabricated or hallucinated, as the ground truth contains no such data. The 5,034 towers and Trust Securitizations are also not referenced in the original answer, making them factually inaccurate. (3) The multi-hop reasoning fails because the LLM does not identify the key shift from site-specific collateral disclosures to broader financial obligations. Instead, it invents a narrative around covenant compliance and liquidity metrics that are unsupported by the ground truth. (4) While the LLM correctly notes that communications sites were used in securitizations in 2023, it distorts the 2024 developments entirely. The contextual relevance is moderate because it addresses debt and disclosures, but the factual inaccuracies and hallucinated metrics severely undermine correctness. Quantitative accuracy is very low due to invented numbers; qualitative accuracy is poor due to flawed reasoning and entity inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 529,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "Comcast's approach to retransmission consent agreements evolved between 2022 and 2023 by explicitly detailing revenue recognition and distribution models in the 2023 10-K. In 2023, the Media segment's **Distribution** section clarified that revenue from NBC and Telemundo retransmission consent agreements is recognized **monthly as programming is provided**, reflecting a structured, multiyear agreement model. This contrasts with the 2022 document, which focused on passing through fees to customers without specifying recognition timing. Additionally, the 2023 report highlighted expanded distribution to **virtual multichannel video providers** (e.g., streaming services) and **Peacock**, signaling a shift toward integrating retransmission consent with digital platforms. Revenue recognition in 2023 emphasized **monthly accruals** rather than lump-sum payments, aligning with broader trends in streaming and subscription-based models.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Comcast recognized revenue monthly as programming was provided, though it adds the detail about 'passing through fees to customers' not explicitly in the original—this is a minor addition but not factually incorrect. (2) The 2023 evolution is accurately described: monthly recognition, inclusion of virtual multichannel video providers, and integration with Peacock are all correctly noted. The emphasis on structured, multiyear agreements and monthly accruals matches the original's implication of consistent recognition timing. (3) Multi-hop reasoning is sound—comparing 2022 and 2023 filings, synthesizing changes in revenue recognition and distribution models across years. (4) The only minor shortcoming is that the LLM slightly overemphasizes the contrast in revenue recognition timing, suggesting 2022 lacked specificity, while the original confirms monthly recognition was already in place. However, the core facts—timing, expansion to virtual MVPDs, Peacock integration, and hybrid models—are all correct. No numeric inaccuracies; all dates and financial concepts are consistent. Semantic equivalence is strong, and the answer fully addresses both revenue recognition and distribution model changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 367,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "Caterpillar's involvement in diesel-electric locomotives remained consistent between 2023 and 2024, as these locomotives and related rail products continued to be part of the Energy & Transportation segment's portfolio. The 2024 filing explicitly states Caterpillar is a leading manufacturer of diesel-electric locomotives, with the segment including \"diesel-electric locomotives and components and other rail-related products and services.\" While the 2024 document highlights advancements in electrified powertrains and zero-emission technologies, no reduction or discontinuation of diesel-electric locomotive production is noted, indicating sustained strategic positioning in this area.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no incorrect numbers, it scores high by default. The main issue lies in qualitative accuracy and factual correctness. The LLM incorrectly states that diesel-electric locomotives were part of the 'Energy & Transportation' segment in 2023, when the ground truth confirms they were under the ME&T segment at that time. This is a critical entity and segment misattribution. Additionally, the LLM claims Caterpillar was a 'leading manufacturer' in 2024, which overstates the claim—the original answer notes a shift to 'produces' but does not assert market leadership. The LLM also fails to identify the key evolution: the shift from general operational inclusion (remanufacturing, support) in 2023 to explicit production and strategic focus in 2024. Furthermore, it omits the introduction of competitive pressures from Wabtec Corp and Siemens Mobility A/S in 2024, a key indicator of strategic repositioning. While the answer correctly notes that production continued and no discontinuation occurred, it misrepresents the nature and direction of evolution, missing the multi-hop synthesis between segment changes, strategic emphasis, and competitive context. Thus, despite being contextually relevant and not containing false numbers, it is factually inaccurate in key aspects of entity mapping and reasoning, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 398,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "McDonald's relationship with franchisees regarding revenue recognition and cost-sharing arrangements remained consistent between 2023 and 2024, with no material changes noted. Revenue from franchised restaurants continues to include rent, royalties (based on sales percentages), and initial fees, recognized at the time of underlying sales or over the franchise term. Cost-sharing for restaurant improvements involves allocating project costs between McDonald's and franchisees, with adjustments made upon project completion. However, in 2024, the Company clarified that revenue from distinct technology platform services provided to franchisees is recognized on a **gross basis** as the principal, reflecting a more explicit acknowledgment of these arrangements. No significant shifts in cost-sharing methodologies were reported.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: revenue recognition components (rent, royalties, initial fees) are accurately described for both years, and the key 2024 change—recognizing technology platform fees on a gross basis—is correctly identified. The explanation of cost-sharing for restaurant improvements, including interim allocation and final adjustment upon completion, matches the original answer. (2) There are no numeric values in the question or answer, so quantitative accuracy is not applicable in terms of calculations, but all references to years (2023, 2024) and financial terms are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two dimensions (revenue recognition and cost-sharing), noting consistency in core arrangements while highlighting enhanced disclosure and clarification in 2024. The only minor shortcoming is that the LLM slightly underemphasizes the novelty of the 2024 cost-sharing disclosure—while it mentions adjustments upon completion, it does not explicitly state that this level of detail was absent in 2023, which the original answer highlights as a transparency evolution. (4) Despite this nuance, the answer is contextually complete, semantically equivalent, and conveys the same conclusion: McDonald's maintained consistent models but improved transparency and specificity in 2024, especially regarding gross revenue recognition for technology services. Hence, a score of 9 is warranted, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 444,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "Southern Company's approach to executive equity compensation remained consistent in award terms between 2023 and 2024, with PSUs and RSUs still vesting upon retirement and performance metrics tied to TSR and ROE. However, the **Employee Savings Plan** was amended in 2024 (ninth amendment in December 2024), reflecting updated documentation for the plan, while award structures and vesting rules remained unchanged from 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains several critical inaccuracies and misses key aspects of the evolution in Southern Company's executive equity compensation approach between 2023 and 2024. (1) It incorrectly identifies the 'Employee Savings Plan' as the relevant plan for equity awards, while the ground truth specifies the 'Equity and Incentive Compensation Plan'—a major entity error. The Employee Savings Plan is not the vehicle for PSUs or RSUs; this misidentifies the core plan governing executive equity. (2) The answer claims that award terms and vesting rules 'remained unchanged,' directly contradicting the ground truth, which states that 2024 introduced formalized terms for Named Executive Officers and new documentation practices (e.g., specific exhibits), indicating a shift toward greater structure and transparency. (3) While it correctly mentions PSUs and RSUs and ties performance to TSR and ROE, these details are not present in the original answer and cannot be verified against the ground truth; more importantly, they distract from the actual focus on documentation and structural evolution. (4) The 'ninth amendment in December 2024' is a specific detail not supported by the ground truth and appears fabricated or misattributed. (5) The multi-hop reasoning fails: the question asks about evolution in plan documentation and award terms, but the LLM focuses on continuity in vesting and performance metrics, missing the core shift toward formalization and transparency in 2024. Quantitative accuracy is moderate only because there are no explicit numerical errors (dates like 'December 2024' are plausible but unverified), but the qualitative and contextual flaws are severe. The answer is partially relevant but fundamentally misaligned with the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 487,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "Procter & Gamble's reliance on membership club stores remained a notable customer segment in both 2022 and 2024, as indicated in the \"Key Customers\" section of their 10-K filings. However, the documents do not explicitly detail a strategic shift in this area. Instead, the broader retail strategy emphasizes adapting to evolving channels, including e-commerce and digital platforms, while maintaining strong relationships with key retailers like Walmart. This suggests a balanced approach, prioritizing both traditional and digital channels to sustain growth and competitiveness.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in noting that membership club stores remained a customer segment in both 2022 and 2024, but it fails to accurately reflect the key evolution identified in the ground truth — the shift from 'identifying' membership clubs as a channel in 2022 to 'emphasizing dependency' on them in 2024. This strategic deepening of reliance is central to the question and is entirely missed. Instead, the LLM claims there is 'no explicit detail' of a strategic shift, which contradicts the ground truth. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; no errors in dates or entities like years or company names (Procter & Gamble, 2022–2024), hence a score of 10. (3) The multi-hop reasoning is flawed: the model should have synthesized the change in language and strategic emphasis across the two years’ filings to infer increased strategic reliance. Instead, it defaults to a generic observation about digital channels and Walmart, which, while contextually plausible, is not supported as the primary shift in the ground truth. (4) The answer is contextually relevant in discussing P&G’s retail strategy and channels, but it misrepresents the core strategic evolution by downplaying the shift toward membership clubs and redirecting focus to e-commerce and Walmart, which were not the focus of the question. Thus, while the response is coherent, it is factually incomplete and misaligned with the documented strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 417,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "AMT's involvement with Nigeria Letters of Credit evolved from a carrying value of $3.4 million as of December 31, 2023, to being fully drawn and settled by December 31, 2024. In 2024, the company drew on these letters of credit, which bore interest at the SOFR rate plus a spread and were due 270 days after issuance. The 2024 disclosures indicate that the obligations were resolved, with the remaining amounts settled by year-end, reflecting management of these financial commitments.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $3.4 million obligation in 2023 and its resolution by 2024 with a $0 carrying value, aligning with the ground truth. However, it introduces details not present in the original answer, such as the letters of credit being 'drawn,' bearing interest at SOFR plus a spread, and having a 270-day maturity. These specifics are not supported by the ground truth and represent unsupported elaboration. (2) Quantitatively, the $3.4 million figure and the conclusion of $0 obligation in 2024 are accurate, satisfying the core numerical requirements. Format and values match within acceptable variation. (3) The multi-hop reasoning is partially sound—correctly inferring that the obligation was settled due to the drop from $3.4M to $0—but adds speculative financial mechanics (interest rate, draw timing, maturity) that were not in the source data, weakening the qualitative accuracy. (4) The answer is contextually relevant and addresses both parts of the question—evolution over time and implications for financial obligations—but overreaches in explanatory detail, reducing its factual reliability. The core conclusion about settlement is correct, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 347,
        "total_tokens": 1574
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "Between 2022 and 2024, GD's Retirement Annuity Contracts decreased in fair value from $38 (2022) to $22 (2024), as shown in the fair value tables. The valuation methodology remained consistent, with these contracts classified under Level 3 (Significant Unobservable Inputs) in both years. This indicates the company continues to use unobservable inputs for these assets, likely due to their complexity or lack of active market data, reflecting a stable approach to reporting under the fair value hierarchy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims the fair value of GD's Retirement Annuity Contracts decreased from $38 million in 2022 to $22 million in 2024, but the ground truth states the value was $35 million as of December 31, 2021, and $38 million as of December 31, 2020 — with no mention of a $22 million value in 2024. Thus, both the numbers and the trend are incorrect. (2) The quantitative inaccuracies are severe: the LLM fabricates a $22 million figure not present in the original data and misattributes the $38 million value to 2022 instead of 2020. There is no evidence in the ground truth of a decline to $22 million by 2024. (3) The reasoning is flawed regarding methodology: the LLM claims the valuation methodology remained consistent under Level 3, but the ground truth explicitly states that by 2024, the contracts were valued using NAV as a practical expedient and were excluded from the formal fair value hierarchy — indicating a clear shift in methodology. This key change is entirely missed, undermining the multi-hop synthesis required. (4) While the LLM correctly identifies that Level 3 was used in 2022 and attempts to interpret the implications of using unobservable inputs, it fails to capture the critical evolution in reporting approach. The conclusion about a 'stable approach' is therefore incorrect. Contextual relevance is moderate because the answer addresses the right topic and attempts to discuss valuation methodology, but core facts and synthesis are wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 431,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "The restricted cash for securitization investors decreased from $458 million as of December 31, 2023, to $441 million as of December 31, 2024. Both periods classified this restricted cash as Level 1 within the fair value hierarchy, indicating it was measured using observable market inputs (e.g., quoted prices). No changes in fair value hierarchy classification were observed between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, no explicit fair value hierarchy classification was provided, but by 2024, the $441 million was fully classified as Level 1. The LLM incorrectly introduces data for 2023 ($458 million), which is not mentioned in the original answer, and compares 2023 to 2024 instead of 2022 to 2024 as required by the question. This misalignment with the time periods undermines the correctness. Additionally, the original answer implies a shift in transparency and classification clarity between 2022 and 2024, but the LLM claims Level 1 classification was already in place in 2023, which contradicts the ground truth assertion that no such detail was available for 2022. (2) The $441 million figure for 2024 is correct and matches the ground truth. However, the $458 million figure for 2023 is not supported by the original answer and appears to be fabricated or sourced from outside the provided truth. There is no mention of a decrease from $458M to $441M in the ground truth. (3) The multi-hop reasoning is flawed because the LLM fails to compare the correct years (2022 vs 2024) and misrepresents the evolution of fair value hierarchy disclosure. The original answer emphasizes that in 2022, the classification was not explicitly detailed, implying limited or no hierarchy disclosure, whereas in 2024 it was fully Level 1—indicating a change in transparency. The LLM incorrectly asserts no change in classification between 2023 and 2024, which does not address the actual shift from unspecified (in 2022) to Level 1 (in 2024). (4) The contextual relevance is high because the answer discusses restricted cash, securitization investors, fair value hierarchy, and Level 1 classification—all relevant topics. However, due to incorrect timeframes, unsupported numbers, and failure to capture the key qualitative shift in disclosure transparency, the overall correctness score is low. Quantitative accuracy is moderate due to one correct number but one incorrect or unsupported one. Qualitative accuracy is low due to flawed reasoning about the evolution of classification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 581,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "McDonald's relationship with franchisees in terms of financial recognition and asset management between 2023 and 2024 shows continued growth in franchised restaurants (conventional franchised increased from 21,818 to 22,077, developmental licensed from 8,684 to 9,247, and foreign affiliated from 9,178 to 10,108). Financial recognition includes shared cost allocations for restaurant improvements, with McDonald's managing projects and allocating costs between Property and Equipment and Accounts Receivable. Asset management involves shared lease obligations (franchisees pay occupancy costs like property taxes and insurance) and acquisitions of restaurants from franchisees (e.g., 228 in Israel in 2024), impacting goodwill and long-lived assets. These practices reflect a collaborative approach to cost management and asset integration.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and misses the core evolution described in the ground truth. While it mentions restaurant acquisitions (e.g., 228 in Israel in 2024), this specific number is not present in the original answer and appears fabricated. The increase in franchised restaurant counts (e.g., conventional, developmental licensed, foreign affiliated) is not supported by the ground truth and introduces quantitative data that was not part of the source. (2) There are no verifiable calculations or correct numeric references to financial recognition methods such as discounted cash flow or goodwill write-offs, which are central to the 2023 description. The mention of cost allocations between Property and Equipment and Accounts Receivable, shared lease obligations, and project cost management lacks support in the original answer and distracts from the actual shift in financial model. (3) The multi-hop reasoning is flawed: the original answer emphasizes a structural shift from asset acquisition (2023) to service-based revenue recognition via technology platforms (2024), but the LLM fails to identify this transformation. Instead, it focuses on operational details like lease obligations and cost sharing that were not in the ground truth, missing the key conceptual shift to gross revenue recognition for technology services. (4) The contextual relevance is moderate because it discusses franchisee relationships and some financial aspects, but it fails to capture the essential evolution in financial recognition and asset management. The qualitative accuracy is low due to incorrect entities (e.g., Israel acquisition), made-up metrics, and failure to identify the technology platform dependency model. Quantitative accuracy is partially present in plausible numbers but not in verified facts, hence a low overall correctness score of 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 511,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "Between 2022 and 2024, Procter & Gamble's disclosures consistently highlight the **2019 Stock and Incentive Compensation Plan** as the **only active equity compensation plan** allowing future grants of securities. In 2022, **119 million shares** were available for future issuance under the 2019 Plan, while by 2024, this amount decreased to **77 million shares**, reflecting increased utilization of the plan. The 2019 Plan remains central to equity compensation, with other plans (e.g., 2001, 2009, 2014) either expired or not permitting future grants. The plan's structure, including its 187 million share limit and counting RSUs/PSUs as five shares per award, is reiterated in both years, underscoring its continued role in executive and employee compensation.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several specific quantitative claims not present in the original answer (ground truth), such as the number of shares available for issuance (119 million in 2022, 77 million in 2024), the 187 million share limit, and the treatment of RSUs/PSUs as five shares per award. These details are absent from the ground truth and cannot be verified as correct based on the provided information, introducing factual inaccuracies or unsupported specifics. The original answer focuses on a qualitative shift in disclosure emphasis—from governance and adoption context in 2022 to strategic ownership and structural role in 2024—without citing exact share numbers or plan mechanics. While the LLM correctly identifies the 2019 Plan as central and active relative to older plans (e.g., 2014, 2009), it mischaracterizes the evolution as one of quantitative utilization rather than discursive framing. The reasoning is partially sound in recognizing the 2019 Plan's ongoing centrality and the inactive status of prior plans, but it fails to capture the conceptual shift (procedural to strategic) emphasized in the ground truth. The answer is contextually relevant and addresses the relationship with other plans and the role in equity compensation, but the unsupported numerical details and misaligned focus on share counts over disclosure evolution reduce factual correctness. Thus, while the general direction of the answer is reasonable, the inclusion of unverified quantitative data and omission of the core conceptual shift limit its accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 424,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "Salvatore Ferragamo's presence in Simon Property Group's international outlet locations remained consistent between 2022 and 2023. The 2023 filing confirms Salvatore Ferragamo as a tenant at key international outlets, including Gotemba Premium Outlets (Japan), Kobe-Sanda Premium Outlets, and Rinku Premium Outlets, which were also listed in the 2022 filing. No changes in tenant presence or lease status are explicitly noted in the provided documents for this period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) Quantitatively, the original answer states that Salvatore Ferragamo was present in three Japanese outlets in 2022 and only one U.S. location in 2023, indicating a reduction. The LLM claims presence remained consistent across years and lists three international outlets in 2023, including Rinku Premium Outlets (not mentioned in 2022 ground truth), which contradicts the ground truth. (2) The LLM incorrectly asserts no changes occurred, while the ground truth shows a major shift from Japan to the U.S. and a reduction from three to one location. (3) Multi-hop reasoning failed: the model should have compared tenant lists across 2022 and 2023 SPG filings but instead fabricated or misidentified locations (e.g., Rinku instead of Sano) and ignored the U.S. shift. (4) Contextual relevance is low because the answer addresses the right topic but with incorrect data and conclusions. The LLM may have relied on outdated or inaccurate document excerpts, leading to a completely inaccurate assessment of tenant evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 311,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "COP's natural gas position in the Asia Pacific/Middle East region remained stable in 2024 compared to 2023, with proved reserves at 296 BCF (unchanged from 2023). However, 2024 saw downward revisions of 81 BCF due to lower prices, partially offset by technical revisions of 55 BCF. The region also saw extensions and discoveries in equity affiliates, particularly in the Middle East, indicating continued operational focus on exploration and development. This suggests COP is maintaining its strategic emphasis on the region despite market challenges, leveraging technical advancements and equity investments to sustain presence.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 312 BCF in 2023 to 296 BCF in 2024, a reduction of 16 BCF. However, the LLM claims reserves were 'unchanged' at 296 BCF, which directly contradicts the data. This is a critical error in quantitative reporting. (2) The LLM introduces specific figures not present in the original answer—namely, 'downward revisions of 81 BCF due to lower prices' and 'technical revisions of 55 BCF'—which are unsupported by the ground truth and appear fabricated. These numbers cannot be verified and misrepresent the source data. (3) The reasoning is flawed: the original answer suggests a minor reduction indicating stabilization or lack of aggressive growth, while the LLM interprets the situation as active exploration and development through 'extensions and discoveries in equity affiliates,' which is not mentioned or implied in the ground truth. This reflects incorrect multi-hop synthesis or hallucination. (4) While the LLM attempts to address the question's intent—evolution of COP's position and operational focus—the inclusion of false numbers and unsupported conclusions severely undermines accuracy. The contextual relevance is moderate because it discusses the right region and company and touches on operational focus, but the factual foundation is unsound. Minor formatting variations (e.g., BCF vs billion cubic feet) are acceptable, but core data discrepancies and invented details justify a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 438,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "Comcast's approach to wireless gateways evolved from 2022 to 2024 by shifting strategic emphasis toward integrating them with network upgrades and expanding coverage. In 2022, wireless gateways were highlighted as part of broadband services, offering combined modems and routers with xFi management tools. By 2024, the focus expanded to deploying wireless gateways alongside scalable infrastructure investments to enable multigigabit symmetrical speeds and support line extensions. While capital expenditures for customer premise equipment (including gateways) decreased slightly, the 2024 report explicitly noted continued investment in wireless gateways as a key component of network modernization and coverage expansion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Comcast offered wireless gateways as part of broadband services with xFi tools; by 2024, the strategic emphasis shifted to deeper integration with network infrastructure upgrades, including multigigabit symmetrical speeds. The mention of decreased capital expenditures for customer premise equipment is consistent with available data and adds contextual nuance not in the original answer but not contradicted by it. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2024), identifies the evolution in strategic emphasis, and connects wireless gateways to broader network modernization. The addition of 'scalable infrastructure investments' and 'line extensions' is contextually appropriate and reflects accurate interpretation of Comcast's strategy. (4) Semantic equivalence is maintained: while the LLM answer includes slightly more detail (e.g., mention of capital expenditure trends), it does not introduce inaccuracies and enhances completeness without straying from the truth. The only reason for not scoring a 10 is that the original answer emphasizes the shift from 'offering' to 'actively investing' more explicitly, which the LLM captures in spirit but slightly softens. Overall, the response is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 436,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "Between 2022 and 2024, the G600's cumulative deliveries increased from approximately 150 (as of year-end 2021) to over 300 by year-end 2024, reflecting strong market adoption. The G600 remains a core model in Gulfstream's product lineup, complementing newer additions like the G700 (launched in 2022) and G800 (expected in 2023), which expanded the company's ultra-long-range and large-cabin offerings. The G600's role as a high-performance, fuel-efficient aircraft continues to solidify Gulfstream's leadership in the business jet market.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that cumulative deliveries for the G500 and G600 increased from approximately 150 by year-end 2021 to over 300 by year-end 2024, which aligns with the ground truth. However, the original answer specifies that the 150 figure refers to both G500 and G600 combined, while the LLM attributes the 150 number to the G600 alone, which is a minor misattribution. The doubling of deliveries is accurately captured. (2) The dates and numbers are mostly accurate: 'year-end 2021' and 'year-end 2024' are correctly used as reference points, and 'over 300' matches the ground truth. The LLM does not introduce incorrect figures, though it slightly misrepresents the scope of the initial 150 deliveries. (3) The reasoning is sound in showing growth and market adoption, and the mention of newer models like the G800 is consistent with the shift in product focus. However, the LLM incorrectly references the G700 launch in 2022 and G800 expected in 2023, while the original answer does not specify launch years and only notes that newer models like G800 and G400 are the new focus—this introduces unsupported specifics. (4) Despite minor inaccuracies in model attribution and introduction dates, the LLM captures the core evolution: strong delivery growth and the G600 transitioning from new to established product. The answer remains contextually relevant and conveys a largely accurate picture of the G600's market and production evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 405,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "AIG's equity ownership in Corebridge decreased from 52.2% as of December 31, 2023, to 22.7% as of December 31, 2024, following the deconsolidation of Corebridge in June 2024 and subsequent share sales. Income recognition shifted from consolidated financials to the equity method post-deconsolidation, with AIG reporting net investment income from Corebridge's stock price changes and dividends. A significant gain of $282 million was recognized in the fourth quarter of 2024 from the sale of 120 million shares to Nippon, reflecting the evolution of AIG's financial relationship with Corebridge.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, with only minor omissions. (1) Quantitatively, the key figures are correct: AIG's ownership decreased from 52.2% in 2023 to 22.7% by end of 2024, and deconsolidation occurred in June 2024, consistent with the shift to equity method accounting. The $282 million gain from the Nippon share sale is factually accurate and adds valuable detail not in the original answer. (2) The income recognition shift—from consolidated reporting to equity method based on dividends and stock price changes post-June 2024—is correctly described and matches the ground truth’s emphasis on passive investment treatment. (3) The multi-hop reasoning is sound: the model connects ownership reduction, deconsolidation, accounting change, and financial impact across time and entities (AIG, Corebridge, Nippon). (4) The only minor gap is that the original answer emphasizes AIG’s 'intention to fully divest over time,' which the LLM omits, slightly reducing completeness. However, the 22.7% figure and share sales imply ongoing divestment. All entities, dates, and financial terms are accurate. Wording differs but meaning is semantically equivalent and enriched with specific data. Thus, the answer earns a 9 for correctness—excellent but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 361,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "Tesla's Solar Roof production strategy evolved between 2022 and 2024, with manufacturing primarily localized at Gigafactory New York, as highlighted in the 2024 filings. This shift reflects efforts to streamline production and reduce reliance on external suppliers. However, operational challenges persisted, including supply chain dependencies on raw materials (e.g., lithium, nickel) and supplier reliability, as noted in both 2022 and 2024. The 2024 documents emphasize increased localization of procurement and manufacturing, alongside risks from material price volatility and potential disruptions, underscoring ongoing efforts to mitigate these dependencies while scaling production.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) What was correct/incorrect: The LLM correctly identifies Gigafactory New York as central to Solar Roof production and notes ongoing supply chain and operational challenges. However, it misrepresents the evolution of Tesla's strategy. The original answer states that in 2022, production was actively occurring at Gigafactory New York with a strategic push via financing, while in 2024, Tesla highlighted increased complexity, delays in ramping production, and broader manufacturing dependencies. The LLM incorrectly implies that the localization at Gigafactory New York is a 2024 development (calling it a 'shift'), when in fact it was already the dedicated facility in 2022. Additionally, the LLM introduces raw materials like lithium and nickel, which are more relevant to battery production than Solar Roof, introducing factual inaccuracies in the nature of dependencies. The original answer emphasizes design tolerances, quality, output rates, and supply chain coordination—not material inputs like lithium. (2) Quantitative accuracy: There are no specific numbers (e.g., production volumes, costs, dates) in either answer, so no numeric inaccuracies exist. The years 2022 and 2024 are correctly referenced. (3) Multi-hop reasoning assessment: The LLM fails in synthesizing the correct evolution over time. It conflates the continuity of location (Gigafactory NY) with a supposed strategic shift toward localization in 2024, when the ground truth shows the facility was already dedicated in 2022. The reasoning leap to material dependencies like lithium is unsupported and reflects a failure to distinguish Solar Roof (a roofing tile product with solar cells) from energy storage (Powerwall, etc.). The original answer correctly links the 2024 challenges to ramping production and design/quality control, not raw material volatility. (4) Justification for scores: Correctness is 5 due to partial factual alignment (correct facility, general challenges) but major errors in strategic evolution and misattribution of dependencies. Quantitative accuracy is 10 because no numbers are misstated. Qualitative accuracy is 5 due to flawed reasoning and entity confusion (lithium/nickel). Contextual relevance is 7 because the answer addresses the general theme of production strategy evolution and challenges, but with significant factual drift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 627,
        "total_tokens": 2067
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "Qualcomm's strategic involvement with on-device AI evolved from 2023 to 2024 by expanding its business focus beyond mobile handsets into emerging industries like automotive and IoT, while maintaining investments in foundational AI technologies. In 2023, the company emphasized on-device AI as part of its core wireless and computing innovations, while in 2024, it explicitly linked AI advancements to growth in automotive and IoT sectors. The 2024 filing highlighted continued R&D investments in AI, alongside strategic acquisitions and partnerships to strengthen capabilities in these new markets, reflecting a broader, diversified approach to AI-driven innovation.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qualcomm's expansion of on-device AI from mobile to automotive and IoT, its continued R&D investment, and strategic acquisitions—key elements from the ground truth. However, it misses the critical nuance that Qualcomm's 2024 strategy shifted from being a core product offering to a more investment-centric and ecosystem-enabling approach, emphasizing long-term growth over immediate commercialization. This shift in strategic focus is underemphasized in the LLM response, which instead frames the evolution as a diversification rather than a strategic pivot toward enabling third-party integration. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in dates or financials. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes Qualcomm’s AI focus across 2023 and 2024 and connects it to broader industry applications. However, it fails to fully capture the qualitative shift from product-centric to investment/ecosystem-centric strategy, which is central to the ground truth. (4) The correctness score is 7 because core facts are accurate but a key strategic insight is missing. Quantitative accuracy is 10 due to absence of numerical errors. Qualitative accuracy is 7 due to incomplete reasoning on strategic evolution. Contextual relevance is 9 as the answer stays focused and relevant throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 398,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "Dolce & Gabbana's presence in SPG-operated premium outlet locations remained consistent between 2022 and 2023, as the brand is listed as a tenant in multiple Japanese Premium Outlets (e.g., Gotemba, Kobe-Sanda, Rinku) in both the 2022 and 2023 filings. This continuity indicates SPG's strategy to retain high-end luxury brands in its premium outlet locations, reinforcing its positioning as a destination for upscale, branded retail experiences.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Dolce & Gabbana remained present in multiple Japanese SPG-operated outlets in both 2022 and 2023. According to the ground truth, Dolce & Gabbana was present in Japan (Gotemba, Kobe-Sanda, Rinku) in 2022 but was only listed at Las Vegas Outlets North Premium NV in the U.S. in 2023. This represents a significant shift, not continuity. The LLM incorrectly asserts consistency in presence, which contradicts the data. (2) There are no numerical values in the question, but the temporal and locational facts are treated as quantitative anchors. The LLM misrepresents the year-over-year tenant data, failing to note the removal from Japanese locations and the sole presence in the U.S. by 2023. (3) The multi-hop reasoning is flawed: the model should have synthesized tenant lists across two years and multiple geographies to detect a strategic relocation. Instead, it assumes consistency without evidence, leading to an incorrect conclusion about SPG’s brand strategy. The ground truth indicates a shift toward exclusivity in a key U.S. market, while the LLM claims ongoing emphasis on upscale retail in Japan—missing the strategic pivot entirely. (4) Contextual relevance is moderate because the answer addresses SPG's brand positioning and premium outlets, but the factual foundation is wrong, rendering the reasoning and conclusion invalid. The answer discusses the right topic with plausible language but fails on core accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 413,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "COP's investment in exploration activities in the Asia Pacific/Middle East region remained stable between 2023 and 2024, with 1 dry exploratory well reported in both years. However, the region saw increased development activity, with productive development wells rising from 20 in 2023 to 22 in 2024. Additionally, the 2024 filing noted extensions and discoveries in the Middle East through equity affiliates, indicating a strategic focus on maintaining and expanding operations in the region, leveraging both direct and affiliate investments to sustain exploration and development efforts.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in nearly all aspects. The ground truth states that COP spent $49 million on exploration in the Asia Pacific/Middle East region in 2023 and $0 in 2024, indicating a complete halt in exploration. The LLM claims exploration activity remained stable with 1 dry exploratory well in both years, which contradicts the $0 expenditure in 2024. It also fabricates data about development wells (20 in 2023, 22 in 2024) and mentions 'extensions and discoveries through equity affiliates' not present in the original answer. (2) Quantitative accuracy is extremely low: the only correct number could be coincidental (e.g., '1 dry well' has no support in the ground truth, which reports expenditures, not well counts). The core financial figures—$49M and $0—are entirely missing from the LLM response. (3) The multi-hop reasoning is flawed: the question asks about evolution in investment and strategic implications. The LLM misrepresents investment as stable when it actually dropped to zero, leading to an incorrect conclusion about strategic focus. Instead of recognizing a strategic withdrawal, it claims continued expansion, which is the opposite of the truth. (4) Contextual relevance is low but not zero because the answer addresses the right company (COP), region (Asia Pacific/Middle East), and general topic (exploration strategy). However, due to pervasive factual errors and reversed conclusions, the answer is substantially misleading. Scores reflect near-total failure in accuracy and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 425,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "Comcast's financial stake in Universal Beijing Resort remained at a 30% ownership interest through 2024, with the resort consolidated as a variable interest entity (VIE) due to Comcast's control over its economic performance. Debt involvement in 2024 totaled $3.4 billion (including $3.0 billion in term loans), slightly lower than the $3.5 billion debt outstanding in 2023. Assets and liabilities of the resort were $7.3 billion and $7.0 billion as of December 31, 2024, compared to $7.8 billion and $7.2 billion in 2023, reflecting ongoing operational and financial commitments under the syndicated debt structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Comcast's 30% ownership interest in Universal Beijing Resort by 2024, consistent with the ground truth. It accurately reports the debt outstanding as $3.4 billion in 2024 (down from $3.5 billion in 2023), and correctly states the asset and liability figures for 2024 ($7.3B assets, $7.0B liabilities) compared to 2023 ($7.8B and $7.2B). These numbers match the original answer exactly. (2) All quantitative values are correct, including the debt reduction of $0.1 billion and the decrease in both assets and liabilities. The mention of $3.0 billion in term loans is additional detail not contradicted by the ground truth and may be a subset of the total $3.4 billion debt. (3) The reasoning is sound: the LLM correctly synthesizes information across years, noting the evolution from no explicit stake disclosure in 2022 to full financial disclosure in 2024. It appropriately references the VIE consolidation, which explains why Comcast consolidates the resort despite a 30% stake—this is a valid qualitative addition supported by typical SEC disclosure practices. (4) The only minor shortcoming is that the LLM does not explicitly mention the absence of specific financial stake or debt data in 2022, which was a key point in the original answer. However, it implies this by stating the stake was maintained 'through 2024', suggesting continuity from an earlier period. This omission slightly affects completeness but does not undermine factual correctness. Overall, the answer is highly accurate, contextually relevant, and demonstrates strong multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 443,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "Duke Energy's net derivatives balance shifted from a liability of $203 million in 2022 to an asset of $225 million in 2023, reflecting a significant reduction in net exposure. This change was driven by increased settlement activity (from $5 million in 2022 to $68 million in 2023) and a $10 million gain on derivatives in 2023. The shift indicates active management of derivative instruments, with settlements and realized gains reducing liability exposure while transitioning the net position to an asset.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Duke Energy's net derivatives balance was $29 million in 2022 and $13 million in 2023, both positive balances (likely assets or net receivables), but the LLM incorrectly states a liability of $203 million in 2022 and an asset of $225 million in 2023—values that are completely mismatched. The settlement amounts are partially correct: the LLM correctly states $68 million in 2023, but incorrectly reports $5 million in 2022 versus the true value of $32 million. The mention of a '$10 million gain on derivatives' is not supported by the original answer and introduces unverified information. (2) Quantitative accuracy is very low: both the net derivatives balances and settlement figures are wrong for 2022, with only the 2023 settlement amount ($68 million) matching. Calculations or comparisons based on these numbers are therefore invalid. (3) The reasoning is flawed in terms of multi-hop synthesis: while the LLM attempts to infer that increased settlements reduced exposure, it misrepresents the starting position and magnitude of changes. The conclusion about transitioning from liability to asset is unsupported by the ground truth, which shows decreasing but positive net balances (no indication of liability or sign change). (4) Contextual relevance is moderate—the response addresses derivative balance evolution and management implications as asked, and correctly identifies increased settlement activity in 2023. However, due to severe factual errors in core data, the overall correctness score is low. Semantic equivalence is not achieved due to incorrect magnitudes and directional mischaracterization of positions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 472,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "SPG's treatment of LTIP Units evolved from 2022 to 2023 by increasing the maximum potential fair value of awards under the 2023 LTI Program to $42.5 million (from $20.6 million in 2022), reflecting a more aggressive performance-based valuation model. Both periods used TSR modifiers to adjust FFO performance conditions, but the 2023 program extended vesting to January 1, 2027, compared to 2026 for 2022. The dilutive effect remained non-material for both years, as no securities had a material dilutive impact, and LTIP Units continued to be treated as participating securities under the two-class method, with expenses recognized over vesting periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and introduces information not present in the ground truth. While it correctly notes that LTIP Units are treated as participating securities under the two-class method in both years, it fabricates specific dollar amounts ($42.5 million and $20.6 million) and vesting dates (January 1, 2027 vs. 2026) that are not mentioned in the original answer or supported by the knowledge graph. These numbers appear to be hallucinated. The ground truth does not mention any change in maximum fair value or vesting schedules, nor does it reference an 'LTI Program' with such details. (2) The quantitative inaccuracies are significant: no dollar figures or vesting end dates were provided in the original answer, so the inclusion of precise numbers like $42.5M and January 1, 2027, is incorrect. The claim about 'increasing maximum potential fair value' is unsupported. (3) The reasoning partially captures the continuity of treatment (e.g., participating securities, non-material dilution), but fails to reflect the actual evolution described in the ground truth—namely, the shift from general dilution disclosure to more granular valuation modeling using Monte Carlo methods for market-based LTIP units in 2023. This key qualitative shift is entirely missing from the LLM response. (4) Contextual relevance is moderate because the answer stays on topic regarding LTIP units, dilution, and EPS treatment, but introduces irrelevant details (specific award values, vesting end dates) and misses the core evolution in disclosure practices. The correct point about non-material dilutive effect in both years adds some validity, but the overall synthesis is flawed due to hallucinated data and omission of the Monte Carlo modeling advancement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 487,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "Comcast's financial commitment to Atairos Group, Inc. decreased slightly in maximum annual capital calls from $400 million (plus prior distributions) in 2020 to $400 million in 2024, with a reduced management fee commitment of $40 million annually (down from $45 million). As of December 31, 2024, Comcast's investment in Atairos was $5.1 billion, with an unfunded capital commitment of $1.4 billion, reflecting incremental capital contributions and a slight reduction in the unfunded balance compared to $1.5 billion as of December 31, 2021.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Comcast's total capital commitment to Atairos decreased from $5 billion in 2022 to $4.5 billion in 2024, with an added $40 million annual management fee. However, the LLM claims a maximum annual capital call of $400 million in both 2020 and 2024 (not mentioned in the original), a reduction in management fees from $45M to $40M (original states $40M is an additional commitment, not a reduction), and provides investment figures like $5.1B total investment and $1.4B unfunded commitment as of 2024—none of which appear in the ground truth. (2) The numbers are largely fabricated or misaligned: the $5B to $4.5B capital commitment reduction is central to the original answer but entirely missing; instead, the LLM invents annual capital call amounts and fee reductions not present in the source. The unfunded commitment balances ($1.4B in 2024 vs $1.5B in 2021) are specific but unsupported by the original. (3) The multi-hop reasoning is flawed: the question asks for evolution between 2022 and 2024, but the LLM references 2020 data and mischaracterizes the nature of the commitments (annual calls vs total aggregate). It fails to capture the strategic recalibration—reduced total capital plus new management fee—as described in the original. (4) The contextual relevance is moderate because it discusses Comcast’s involvement in Atairos and financial commitments, but the qualitative and quantitative deviations are severe, leading to a low correctness score. The answer misrepresents the core facts and introduces unverified figures, undermining its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 455,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 319 BCF in 2023 to 303 BCF in 2024, primarily due to downward revisions from lower prices (81 BCF) and technical factors, partially offset by positive technical revisions (55 BCF). This decline reflects operational adjustments, including the disposition of Indonesia assets in 2023 and reduced production from technical and pricing pressures. However, the region remains a focus area, as evidenced by equity affiliate activities and purchases in the Middle East, indicating continued strategic interest in the region's resource potential.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported reserve volumes. The ground truth states that COP's natural gas reserves in the Asia Pacific/Middle East region were 312 BCF in 2023 and 296 BCF in 2024, but the LLM reports 319 BCF and 303 BCF, respectively—both numbers are incorrect. The difference of 7 BCF in 2023 and 7 BCF in 2024 represents a material deviation that affects the reliability of the response. (2) The LLM introduces specific details not present in the original answer, such as 'downward revisions from lower prices (81 BCF)' and 'positive technical revisions (55 BCF)', which are unsupported by the ground truth and appear fabricated or misattributed. These figures cannot be verified and contradict the simpler explanation of a modest reduction. (3) While the LLM attempts multi-hop reasoning by linking asset dispositions (e.g., Indonesia) and regional investments to strategic focus, the original answer only notes a 'potential shift in operational focus' without asserting continued strategic interest. The LLM overinterprets by claiming 'continued strategic interest' based on equity affiliate activities, which is not mentioned in the ground truth. (4) Despite these issues, the LLM correctly identifies the general trend—a decrease in reserves—and connects it to operational changes, showing partial understanding of the question’s intent. The contextual relevance is moderate because the structure and direction of reasoning align with the question, even if facts are wrong. However, the quantitative inaccuracies severely undermine the correctness score, which is primarily based on factual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 455,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "Comcast's wireless gateway procurement strategy in 2022 focused on sourcing devices from limited suppliers to support bundled services, as noted in the 2022 10-K under \"Sources of Supply.\" In 2024, the company shifted toward investing in network deployment, emphasizing scalable infrastructure, line extensions, and wireless gateway deployment to expand coverage and capacity, as detailed in the 2024 10-K under \"Capital Expenditures.\" The 2024 focus reflects a strategic shift from procurement to active deployment as part of broader network upgrades.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: in 2022, Comcast procured wireless gateways from limited suppliers, as confirmed in the 2022 10-K under 'Sources of Supply'; by 2024, the focus shifted to strategic deployment as part of capital expenditures for network upgrades, as stated in the 2024 10-K under 'Capital Expenditures'. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no figures were misstated. (3) The multi-hop reasoning is sound: the model correctly synthesized information across two different years and filings, connecting procurement strategy in 2022 with investment focus in 2024, and inferred a strategic evolution. (4) The answer captures the core shift from passive procurement to active integration into network infrastructure, though it omits the specific mention of 'multigigabit symmetrical speeds' and 'scalability and capacity expansion' as stated in the original answer. This is a minor omission that slightly reduces completeness but does not affect the overall correctness. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses both parts of the comparison question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 361,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "Tesla's approach to the Solar Roof product, as indicated in the 2021 10-K filing, was part of its energy generation and storage segment, with deployments contributing to revenue growth in 2021. However, the provided documents do not include specific details about strategic shifts or production challenges related to Solar Roof between 2022 and 2024. The 2021 filing notes production challenges, such as temporary manufacturing underutilization during product ramp-up, but no further updates on Solar Roof's evolution or strategic importance are available in the given pages.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core of the question. (1) It incorrectly claims that the provided documents do not include information about 2022–2024, when the original answer (ground truth) clearly draws from those years. The LLM references the 2021 10-K filing, which is outside the requested timeframe and not aligned with the ground truth. (2) There are no numeric values in this response to evaluate for quantitative accuracy, but the key issue is the absence of correct temporal data: the evolution between 2022 and 2024 is central, yet the LLM fails to report any developments in those years. (3) The multi-hop reasoning is flawed—the question requires synthesizing changes in strategic importance and production challenges over time, but the LLM does not identify the shift from growth contributor in 2022 to a product with ramp delays in 2024. Instead, it defaults to a 'no information' stance despite the ground truth being available. (4) The response lacks contextual relevance because it does not engage with the actual evolution of Tesla’s Solar Roof strategy; instead, it retreats to 2021 and reports generic production challenges without connecting them to the requested analysis. Overall, the answer reflects a failure to retrieve or synthesize the correct information, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 374,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments increased from $14 million in 2022 to $54 million in 2023, representing a significant rise. This growth indicates the company is strategically allocating more resources to these investments, which may reflect efforts to diversify its portfolio, manage liabilities, or capitalize on market opportunities. The increase aligns with Duke Energy's broader asset management strategy, emphasizing prudent risk management and optimizing returns across its retirement trust assets.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of the change. The ground truth states that Duke Energy's investment decreased from $53 million in 2022 to $14 million in 2023, but the LLM incorrectly claims an increase from $14 million to $54 million—reversing the years and misstating the amounts. This fundamental error undermines the entire response. (2) Quantitative accuracy is severely lacking: the correct values are $53M (2022) and $14M (2023), not $14M and $54M. The LLM not only swaps the years but also reports an incorrect 2023 figure ($54M vs. $14M). No correct calculation or comparison can be derived from these wrong inputs. (3) The multi-hop reasoning is flawed because the model fails to correctly retrieve and compare the two annual figures. Instead of identifying a reduction, it infers growth, leading to an entirely incorrect strategic interpretation—suggesting increased strategic allocation when the data shows a pullback. The reasoning about diversification and asset management may be contextually plausible in isolation but is invalid given the incorrect data. (4) The contextual relevance is moderate (6/10) because the answer addresses the right category (Net Pending Transactions and Other Investments) and attempts to interpret strategic implications, which is relevant to the question. However, due to the severe factual and quantitative errors, the qualitative accuracy is very low (2/10), and the correctness score is 1 out of 10—the answer is essentially the opposite of the truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 427,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "Between 2023 and 2024, the company's liability-driven investment framework for pension plans maintained its core strategy of aligning assets with liabilities through a 20%/80% equity/fixed income target allocation (adjusted to 21%/63% in 2024). Defined contribution plan expenses increased slightly from $109 million (2023) to $112 million (2024). Plan asset composition disclosures remained detailed, showing continued emphasis on corporate bonds (57% in 2023, 63% in 2024) and equity securities (18% to 21%), with consistent disclosure of fixed income and equity allocations, risk management practices, and adherence to fiduciary guidelines.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that defined contribution plan expenses increased from $109 million in 2023 to $112 million in 2024, it incorrectly claims the target allocation changed from 20%/80% to 21%/63% in 2024. The ground truth confirms the 20%/80% target allocation was maintained. Furthermore, the LLM fabricates specific asset composition percentages (e.g., corporate bonds 57% in 2023, 63% in 2024; equities 18% to 21%) that are not present in the original answer. The original only mentions a new disclosure about characterizing the actual composition at year-end, not specific breakdowns. (2) Quantitative accuracy is low: the dollar amounts are correct, but the percentages are entirely incorrect or hallucinated. There is no mention in the ground truth of 63% fixed income or 21% equity as actual allocations—only that a new disclosure about characterizing actual composition was introduced. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of disclosure practices. Instead of highlighting the new transparency about reporting actual asset composition (a qualitative change), it invents quantitative details not supported by the source. It also misrepresents the consistency of the investment framework by suggesting a shift in target allocation when none occurred. (4) Contextual relevance is moderate—the answer addresses the general topic of plan expenses and asset allocation, and correctly notes increased expenses and continued emphasis on the framework. However, due to major factual and quantitative errors, especially in the core elements of allocation and disclosure evolution, the overall correctness is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 476,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and 2024 by explicitly integrating it into broader 5G and semiconductor initiatives. In fiscal 2024, the company emphasized that 5G combined with on-device AI would drive adoption in automotive and IoT, highlighting investments in 5G ICs and partnerships (e.g., new license agreements with OEMs like Transsion). The 2024 filing also noted continued leadership in AI-driven technologies, while fiscal 2023 primarily referenced AI in the context of 5G and semiconductor innovation without specific investment details. The 2024 disclosures underscored AI as a key enabler for future growth in non-handset markets, reflecting a more concrete strategic direction.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Qualcomm's strategic focus on On-Device AI from fiscal 2023 to 2024. It accurately notes that in 2023, AI was discussed in the context of 5G and semiconductor innovation, while in 2024, it became more central to growth in non-handset markets like automotive and IoT. The shift toward a more concrete, investment-driven strategy is implied through mentions of partnerships and emphasis on AI as a growth enabler, though the LLM does not explicitly mention 'acquisitions or strategic transactions,' which is a key differentiator in the ground truth. (2) There are no numeric values, dates, or financial figures in the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is mostly sound: the model synthesizes information across fiscal years and identifies the broadening of AI’s role beyond smartphones. However, it misses the explicit mention of 'investing in new product areas' and 'pursuing acquisitions,' which represent a critical evolution from vision to action. Instead, it references partnerships and license agreements (e.g., Transsion), which are not mentioned in the ground truth and may introduce slight factual overreach. (4) The answer is contextually relevant and conveys a semantically close interpretation. While the core progression—from strategic positioning to active expansion—is captured, the absence of specific strategic actions (like M&A) prevents a perfect score. Wording differences are acceptable, but omission of key strategic mechanisms noted in the original answer limits completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 450,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "The classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members remained consistent between the 2022 and 2023 10-K filings, with both referencing the same Second Amended and Restated Voting Trust Agreement (Exhibit 9.1) and related Voting Agreement (Exhibit 9.2) dated March 1, 2004. This consistency indicates that the governance structure has remained stable, as no amendments or changes to the agreement's classification were disclosed, reflecting ongoing adherence to the established framework.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the classification and presentation of the Voting Trust Agreement remained consistent between the 2022 and 2023 10-K filings. The ground truth shows a clear change: the 2022 filing refers to the 'Second Amended and Restated' agreement, while the 2023 filing drops this modifier, indicating no new amendments. The LLM incorrectly claims both filings use the 'Second Amended and Restated' label, which contradicts the evidence. (2) The date 'March 1, 2004' is correctly cited in both the LLM and ground truth, so quantitative accuracy for dates is acceptable. However, the core factual claim about the presence of the 'Second Amended and Restated' language is wrong, which is a critical qualitative error. (3) The multi-hop reasoning fails because the LLM did not detect the change in terminology across years, which is central to the question. Instead, it asserts consistency where there is a subtle but meaningful shift in disclosure. The conclusion about stability is aligned with the ground truth’s interpretation, but it is based on incorrect premises. (4) Correctness and qualitative accuracy are low due to the fundamental misrepresentation of the filings’ content. Contextual relevance is moderate because the answer addresses the right topic and draws a reasonable conclusion about governance stability, albeit using incorrect evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 391,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "COP's natural gas reserves in the Asia Pacific/Middle East region decreased slightly from 312 BCF at the end of 2023 to 296 BCF by the end of 2024, primarily due to downward revisions of 81 BCF caused by lower prices, partially offset by technical revisions of 55 BCF. This reflects the region's sensitivity to price fluctuations but also ongoing development activities, as extensions and discoveries in equity affiliates (located in the Middle East) contributed to reserves. The region's strategic importance persists, as it remains a key focus for COP's equity affiliates, with continued exploration efforts despite price-related challenges.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the natural gas reserve figures for 2023 (312 BCF) and 2024 (296 BCF), matching the ground truth exactly. The decrease of 16 BCF is accurate, though the LLM does not explicitly calculate or mention the 5.1% decline, which is a minor omission. However, the LLM introduces additional details not in the original answer—specifically, a breakdown of downward revisions (81 BCF due to lower prices) and technical revisions (55 BCF), along with extensions and discoveries in equity affiliates. These specifics, while plausible and contextually relevant, are not present in the ground truth and cannot be verified as correct from the provided knowledge graph, introducing unconfirmed detail that affects factual accuracy. (2) The core numbers (312 BCF and 296 BCF) are correct and properly formatted (BCF = billion cubic feet). The implied difference of 16 BCF is accurate. However, the detailed revision components (81 BCF downward, 55 BCF upward) are not in the original answer and thus represent unsupported additions. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the trend (slight decrease) and connects it to broader strategic implications involving equity affiliates and exploration activity. It correctly notes the region's continued strategic importance, aligning with the original answer’s emphasis on equity affiliates holding 5,870 BCF in 2024—though this exact number is not mentioned in the LLM response, weakening completeness. (4) The LLM answer is contextually relevant and well-structured, addressing both the quantitative evolution and strategic implications. However, the correctness score is reduced due to the inclusion of unverified granular data and the omission of the explicit percentage decline and the specific 5,870 BCF equity affiliate reserve figure, which are key elements in the ground truth. While the qualitative reasoning is logical, it diverges from the verified facts by adding unsupported detail and omitting key data, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 556,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "AIG's financial relationship with Corebridge evolved significantly between 2023 and 2024. In 2024, AIG deconsolidated Corebridge, transitioning from consolidating its debt to accounting for its retained 22.7% equity interest via the equity method. This change resulted in a **$4.8 billion loss** on deconsolidation, primarily due to an accumulated comprehensive loss of **$7.2 billion**. Corebridge's equity method income for 2024 was **$601 million**, reflecting its pre-tax income and changes in stock price post-deconsolidation. Debt structure shifted from consolidated obligations to an equity investment, with AIG no longer reporting Corebridge's debt on its balance sheet.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in key numerical values not present or contradicted in the ground truth. The $4.8 billion loss on deconsolidation and $7.2 billion accumulated comprehensive loss are not mentioned in the original answer and appear to be hallucinated. Similarly, the equity method income of $601 million in 2024 contradicts the ground truth, which states that income was reported during the second half of 2024 and included dividends and stock price changes since June 9, 2024, but does not specify a total amount. The 22.7% equity interest is also not mentioned in the original answer and is therefore unsupported. (2) Quantitative accuracy is low: while the original answer provides specific debt figures for 2023 ($9,368M total, $6,452M senior unsecured, $989M junior subordinated), the LLM omits these entirely and introduces incorrect financial figures. There is no verification of calculations because the introduced numbers (e.g., $4.8B loss) are not grounded in the source. (3) The qualitative reasoning partially captures the multi-hop evolution: it correctly identifies the shift from consolidation to equity method accounting and the removal of Corebridge debt from AIG’s balance sheet. It also correctly frames the change as a move to equity method income. However, it fails to mention the discontinued operations context and incorrectly attributes specific financial results (losses, income amounts) without support. (4) Contextual relevance is high because the answer addresses the core transformation in AIG’s relationship with Corebridge and focuses on debt structure and equity income as asked. However, the introduction of unsupported figures severely undermines factual correctness, warranting a low overall score despite structurally appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 499,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "From 2022 to 2024, NextEra Energy's Special Use Funds increased their allocation to fixed income securities (from ~55-57% in 2022 to 57.6% in 2024) while reducing equity holdings (from ~45-44% to 42.4%). This shift reflects a strategic move toward a more conservative, liquidity-focused approach, emphasizing fixed income to stabilize cash flows and mitigate equity price volatility, particularly for long-term obligations like nuclear decommissioning. The increased fixed income allocation suggests a prioritization of risk management and liquidity preservation over growth-oriented equity investments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM claims that in 2022, NextEra Energy (NEE) had approximately 55-57% fixed income and 45-44% equity in its Special Use Funds, but the ground truth states that in 2022, the entire $2,505 million was in fixed income securities—meaning 100% fixed income and 0% equity. By 2024, the LLM incorrectly states that fixed income is 57.6% and equity 42.4%, but the truth is that equity securities alone amounted to $6,164 million out of a total of $8,444 million ($6,164 + $722 + $685 + $873), which is approximately 73% equity, with fixed income (bonds and corporate debt) making up the remainder. The LLM reverses the actual trend. (2) The calculations are entirely fabricated—no actual sums or percentages from the ground truth are correctly computed or represented. (3) Qualitatively, the reasoning is flawed: the LLM concludes a shift toward conservatism and liquidity focus, but the actual data shows a dramatic shift from 100% fixed income to a majority equity portfolio, indicating increased risk appetite and growth orientation. The LLM fails to perform the correct multi-hop synthesis: it does not recognize that 2022 was all fixed income, nor does it accurately extract or sum the 2024 components. (4) Contextual relevance is partially present—NEE is correct, the time frame is addressed, and the topic of risk/liquidity strategy is discussed—but the conclusions are diametrically opposed to the truth due to factual errors. Thus, the correctness score is very low due to complete inversion of facts and numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 442,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "The risk associated with site infrastructure sharing evolved between 2022 and 2024, with heightened focus on 5G technology's impact. In 2022, the risk was noted as potential slowdowns in new lease activity due to carriers using shared equipment (e.g., RAN sharing) or decommissioning redundant infrastructure. By 2024, the risk expanded to include 5G-driven shifts in customer demand, such as overestimation of 5G benefits and the emergence of alternative technologies (e.g., satellite services), which could reduce reliance on traditional tower infrastructure. These factors increased uncertainty around lease activity, as customers may prioritize cost-effective shared solutions or newer technologies, potentially reducing the need for new leases.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in the qualitative evolution of the risk, particularly in how it characterizes the 2024 risk. (1) What was correct: The answer correctly identifies that site infrastructure sharing posed a risk to new lease activity and links it to 5G adoption in both years. It also correctly notes that shared infrastructure (e.g., RAN sharing) could reduce demand for new leases. (2) Quantitative accuracy: There are no numeric values in the question or ground truth, so this aspect is neutral; no errors in dates (2022 and 2024 are correctly referenced). (3) Multi-hop reasoning assessment: The model fails in synthesizing the correct evolution of the risk. The ground truth specifies that by 2024, the risk evolved into a more specific concern about RAN sharing, roaming, or resale arrangements—and crucially, the lack of compensation to AMT when carriers use shared infrastructure. The LLM instead introduces 'overestimation of 5G benefits' and 'satellite services' as new risk factors in 2024, which are not present in the original answer and represent a misdirection. The core financial concern in 2024—AMT not being compensated for shared use—is entirely missing. (4) Justification for scores: Correctness is scored 5 because key facts about the nature of the risk evolution are wrong, despite some correct context. Quantitative accuracy is 10 because no numbers are misstated. Qualitative accuracy is 5 due to incorrect characterization of the 2024 risk and introduction of unsupported factors. Contextual relevance is 8 because the answer stays on topic and addresses lease activity and 5G impact, but drifts into speculative technology shifts not in the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 468,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "Chevron's investment in Angola LNG Limited decreased from $1,963 million in 2022 to $1,762 million in 2023, reflecting a reduction in the carrying value of its equity method investment. Concurrently, Chevron's equity in earnings from Angola LNG shifted from a positive $1,857 million in 2022 to a negative $513 million in 2023, indicating a loss in 2023 under equity method accounting. This reflects deteriorating performance of Angola LNG, leading to a write-down of Chevron's investment and a corresponding reduction in reported earnings.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The dollar amounts cited—$1,963 million and $1,762 million for investment carrying value, and $1,857 million earnings in 2022 turning to a $513 million loss in 2023—are not supported by the ground truth. The original answer does not mention any financial figures related to carrying value or earnings; instead, it focuses on a structural change in the investment relationship and a consistent 36.4% ownership. There is no numerical data in the ground truth to support the LLM's specific dollar figures or earnings shifts, making these fabrications. (2) Completeness: The LLM fails to address the core of the question—evolution in investment structure and equity method accounting in terms of relationship classification ('Depends_On' to 'Invests_In'). Instead, it invents a narrative around financial performance and write-downs that is absent from the ground truth. (3) Entity Accuracy: While Chevron and Angola LNG Limited are correctly identified, the financial metrics (carrying value, equity earnings) are incorrectly attributed or invented. (4) Reasoning: The multi-hop reasoning is flawed. The LLM assumes that a change in accounting treatment must reflect financial deterioration, but the ground truth indicates a reclassification in relationship type (from 'Depends_On' to 'Invests_In'), which suggests a strategic or structural shift, not financial loss. The model incorrectly infers economic performance from a structural accounting change. (5) Semantic Equivalence: The LLM answer conveys a completely different and factually unsupported narrative—financial decline—whereas the ground truth describes a shift in investment classification with stable ownership. The two answers are semantically divergent. The contextual relevance is low because the response focuses on financial performance rather than structural and accounting relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 530,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "The G600's role in Gulfstream's product lineup remained prominent in both 2022 and 2023, with consistent performance metrics emphasizing its speed, fuel efficiency, and range advantages over prior models. By the end of 2023, cumulative deliveries of the G500 and G600 exceeded 250 units (up from ~150 in 2021), reflecting strong production and market demand. The G600 continued to hold over 90 city-pair speed records, underscoring its leadership in performance. While the G700 and G800 were introduced in 2023, the G600 remained a core asset, contributing to Gulfstream's aircraft manufacturing revenue ($5,710M in 2023) and sustaining its reputation as a technologically advanced flagship model.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and omissions compared to the ground truth. While it correctly identifies the G600 as a key model in Gulfstream's lineup and notes strong production/demand, it misrepresents key aspects of the evolution from 2022 to 2023. The ground truth emphasizes a shift in the G600's characterization—from a 'recent addition' in 2022 to a 'mature product' by 2023—and highlights that its technologies (e.g., Symmetry Flight Deck) became foundational for newer models like the G700, G800, and G400. This strategic evolution is missing in the LLM response, which instead focuses on performance metrics and delivery numbers without capturing the conceptual shift in product lifecycle stage. (2) Quantitatively, the LLM states that 'cumulative deliveries of the G500 and G600 exceeded 250 units' by 2023, but the ground truth specifies that over 250 deliveries were for the G600 alone by year-end 2023. This is a significant error, as it conflates two models and misattributes combined delivery figures. Additionally, the reference to ~150 in 2021 is not in the original answer and introduces unverified data. The $5,710M manufacturing revenue is mentioned without source or verification and does not appear in the ground truth. (3) The multi-hop reasoning is partially sound—linking production volume to market demand and positioning the G600 as a core model—but fails to synthesize the key insight that the G600 transitioned from a new product to a platform enabler for future models. This represents a missed multi-hop connection between the G600’s technology and its influence on the G700/G800/G400. (4) Despite these issues, the answer remains contextually relevant, addressing the G600’s role, production status, and performance. The qualitative reasoning is reasonable but incomplete. Scores reflect partial correctness: moderate quantitative inaccuracy, acceptable qualitative reasoning, high relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 527,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "McDonald's relationship with its franchisees evolved between 2022 and 2024 through increased strategic collaboration and shared financial involvement. In 2024, the company emphasized co-investment with franchisees to fund restaurant improvements and modernization, reflecting a shift toward joint initiatives to enhance performance. Financially, the 2024 filings highlighted stable revenue streams from franchised operations, with continued reliance on franchisee sales for predictable cash flow. Additionally, the company reinforced its role in supporting franchisees through technology platforms and shared operational standards, while maintaining rigorous standards to ensure brand consistency. This evolution underscores a more integrated, collaborative approach compared to the prior period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's relationship with franchisees between 2022 and 2024. It correctly identifies the shift from a traditional franchising model to one involving co-investment and strategic collaboration by 2024, aligning with the ground truth. The answer notes the increased financial involvement through co-investment for restaurant improvements and modernization, which matches the original answer's emphasis on joint funding for upgrades. It also correctly references the continued reliance on franchisee revenue streams (rent, royalties) and brand consistency efforts. There are no numeric inaccuracies—no specific dollar amounts or percentages are cited in either answer, so the absence of numbers does not detract. The qualitative reasoning is sound: it synthesizes the shift in strategy across time (2022 to 2024), correctly attributes the change to enhanced collaboration, and contextualizes it within brand performance and modernization. The only minor shortcoming is that it does not explicitly contrast the 2022 'passive' model (e.g., no capital investment under developmental licenses) as clearly as the ground truth, slightly weakening the multi-hop contrast. However, the implication of change is clear. Wording differs but semantic meaning is equivalent. All entities (McDonald's, franchisees, 2022–2024 timeframe) are correct. The answer is fully relevant and responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 402,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "From 2022 to 2023, **smokeable products** net revenues decreased by **$720 million** (from $22,476 million to $21,756 million), primarily due to lower shipment volumes. Operating income for smokeable products slightly declined by **$18 million** (from $10,688 million to $10,670 million), driven by higher general corporate expenses and amortization costs, partially offset by improved performance in the oral tobacco segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: net revenues decreased from $22,476 million to $21,756 million (a $720 million drop), and operating income declined from $10,688 million to $10,670 million (an $18 million decrease). These numbers are quantitatively accurate and match the original answer exactly. (2) Calculations are correct: 22,476 - 21,756 = 720; 10,688 - 10,670 = 18. All numeric values, years, and financial metrics are accurately represented with proper context. (3) The reasoning is sound and adds value by explaining potential drivers—lower shipment volumes for revenue decline and higher corporate expenses for the operating income drop—while noting partial offset from oral tobacco. While these explanatory details are not in the ground truth and thus cannot be verified, they do not contradict it and are plausible extensions. (4) The answer is semantically equivalent to the original in terms of core facts and evolution of performance. The only minor limitation is that the original emphasizes 'slight' or 'marginal' declines, while the LLM quantifies them precisely but could slightly overemphasize the revenue decline by highlighting $720M without calling it marginal. However, this does not detract from factual correctness. All parts of the question are addressed with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 380,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "From 2022 to 2024, Opdivo's role within BMY's strategy expanded through new therapeutic approvals and maintained collaborative frameworks. In 2024, Opdivo received key approvals, including Japan's approval for urothelial carcinoma and EU approval for combination therapy with Yervoy in colorectal cancer, alongside the launch of Opdivo Qvantig in the U.S. for multiple indications. These approvals strengthened BMY's leadership in immuno-oncology (IO) and diversified its therapeutic applications. Collaboratively, BMY's partnership with Ono for Opdivo's development and commercialization in Japan, South Korea, and Taiwan persisted, with BMY retaining global development and commercialization rights while sharing profits and costs. The strategic focus on extending IO leadership and leveraging collaborative frameworks remained central, alongside expanding Opdivo's use in combination therapies and new indications.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies that deviate from the ground truth. While it correctly identifies the ongoing collaboration with Ono and BMY's global leadership in immuno-oncology, it misrepresents the key 2024 FDA approval. The ground truth specifies a March 2024 FDA approval in the U.S. for Opdivo in combination with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma. In contrast, the LLM incorrectly cites Japan's approval for urothelial carcinoma and EU approval for combination with Yervoy in colorectal cancer—neither of which aligns with the documented U.S. FDA approval. Additionally, the mention of 'Opdivo Qvantig' launch in the U.S. is not supported by the original answer and appears to be fabricated or confused with another product. (2) Quantitatively, the answer fails on key dates and jurisdictions: the pivotal event in 2024 is a U.S. FDA approval, not Japanese or EU approvals as claimed. There is no mention of the March 2024 date in the LLM response, and the geographic focus is misaligned. The original answer emphasizes a strategic shift toward independent commercialization, which is not reflected in the LLM’s portrayal of continued co-development emphasis. (3) Regarding multi-hop reasoning, the LLM partially synthesizes the collaborative framework with Ono (correctly noting profit/cost sharing and regional rights), but fails to capture the evolution from joint development to BMY-led expansion. The ground truth highlights a strategic shift in BMY's approach—moving from shared development to BMY taking the lead in new indications—whereas the LLM suggests continuity rather than evolution. (4) Despite these issues, the answer remains contextually relevant by addressing both collaboration and new approvals, and correctly identifying the strategic importance of Opdivo in BMY’s IO portfolio. However, due to significant factual errors in approvals, timing, and strategic interpretation, the correctness and qualitative accuracy scores are moderate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 554,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "AMT's disclosure regarding interest rate benchmarks evolved from 2022 to 2024, transitioning from LIBOR/EURIBOR-based rates to fixed rates and incorporating more specific covenants. In 2022, debt instruments referenced LIBOR and EURIBOR with margins (e.g., 1.125% above EURIBOR for EUR-denominated loans), while 2024 disclosures highlighted fixed rates (e.g., 5.490% and 5.735% for securitized debt) and introduced **Debt Service Coverage Ratio (DSCR)** covenants (e.g., maintaining a DSCR of 1.30x to release excess cash flow). The 2024 filings also emphasized compliance with updated covenants, reflecting a shift toward fixed-rate structures and enhanced financial safeguards.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of AMT's interest rate benchmarks and covenants between 2022 and 2024. (1) Quantitatively, the LLM incorrectly states that 2024 disclosures included fixed rates of 5.490% and 5.735% for securitized debt—this information is not present in the ground truth and contradicts the actual shift to SOFR. The mention of a 1.125% margin above EURIBOR for EUR-denominated loans is also unsupported by the original answer. (2) The core evolution described in the ground truth—transition from LIBOR to SOFR, particularly in Nigeria under letters of credit—is entirely omitted. Instead, the LLM falsely claims a shift to 'fixed rates', when the ground truth specifies a move to SOFR plus a spread, which is floating, not fixed. (3) The introduction of a Debt Service Coverage Ratio (DSCR) covenant of 1.30x is fabricated; the original answer notes that 2024 disclosures focused on consequences of non-compliance without specifying covenant terms, whereas the LLM invents specific metrics and mechanisms. (4) The reasoning is flawed: it fails the multi-hop requirement to compare disclosures across years based on actual filing content. While the answer is contextually relevant—addressing interest rate benchmarks and covenants—it substitutes accurate synthesis with plausible-sounding but incorrect details. Minor credit is given for correctly identifying LIBOR and EURIBOR usage in 2022. Overall, the answer is mostly incorrect with major factual and conceptual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 422,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "McDonald's relationship with franchisees regarding real estate ownership and co-investment strategy remained consistent between 2022 and 2024. The company continues to own or secure long-term leases for restaurant sites, ensuring long-term occupancy and cost control, while franchisees co-invest in improvements to enhance performance and align with consumer preferences. This collaborative approach, detailed in the 2024 10-K, emphasizes shared responsibility for modernizing restaurants and maintaining brand value, with no explicit changes noted in the provided documents.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant misrepresentation of the evolution in McDonald's relationship with franchisees between 2022 and 2024. While it accurately describes the co-investment model in 2024—where McDonald's owns or secures long-term leases and franchisees invest in equipment and décor—it incorrectly asserts that this model 'remained consistent' between 2022 and 2024. The ground truth indicates a clear evolution: in 2022, the focus was on general systemwide coordination for ESG initiatives without specific details on real estate ownership, whereas in 2024, McDonald's explicitly defined its real estate and co-investment strategy. This shift reflects a move toward a more structured and strategic approach, which the LLM answer fails to acknowledge. There are no numerical inaccuracies (hence high quantitative accuracy), and the entities (McDonald's, franchisees, 2022, 2024) are correctly identified. However, the reasoning is flawed because it misses the multi-hop synthesis required to compare the strategic depth and specificity of the franchise relationship across years. The answer is contextually relevant and uses appropriate terminology, but the core conclusion about consistency contradicts the documented evolution, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 363,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "Between 2022 and 2023, the **2015 Stock Compensation Plan for Non-Employee Directors** saw a reduction in shares available for future issuance (from 703,256 in 2022 to 589,927 in 2023) and an amendment to the plan effective October 26, 2022 (Exhibit 10.22). This evolution reflects Altria's refined governance approach to director compensation, emphasizing structured, shareholder-approved equity frameworks and tighter control over share allocations, aligning with broader corporate governance priorities.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the quantitative claim that shares available decreased from 703,256 in 2022 to 589,927 in 2023. The original answer (ground truth) only states that 703,256 shares were available in 2022 and does not provide any data for 2023. Therefore, the 589,927 figure is unsupported and incorrect, making the core numerical comparison invalid. This undermines the quantitative accuracy. (2) The date of the amendment (October 26, 2022) and reference to Exhibit 10.22 are consistent with the ground truth, which notes the plan was amended and restated effective October 26, 2022, and incorporated by reference from the September 30, 2022, Form 10-Q. These details are accurate. (3) The reasoning about Altria’s governance approach—suggesting a refined, structured framework aligned with corporate governance priorities—is semantically similar to the original answer’s interpretation that the amendment indicates a formal update potentially to align with evolving standards. This shows sound qualitative reasoning and synthesis. (4) However, the introduction of a false 2023 share number represents a major factual deviation, likely due to hallucination or incorrect data sourcing. While the amendment and governance implications are correctly addressed, the unsupported numerical claim significantly reduces overall correctness. The answer is contextually relevant and addresses both parts of the question (status/documentation changes and governance implications), but the quantitative inaccuracy severely impacts trustworthiness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 435,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "The impact of roaming and resale arrangements on AMT's leasing activity has remained a persistent competitive pressure, as highlighted in both the 2022 and 2024 filings. In 2022, the risk was noted as potentially slowing new lease activity by encouraging carriers to use shared equipment (e.g., 5G RAN sharing) rather than deploying new infrastructure, leading to equipment decommissioning. By 2024, this risk was reiterated, with added emphasis on RAN sharing as a key driver of infrastructure sharing. This evolution underscores that competitive pressures from these arrangements have persisted, challenging AMT's ability to grow new leases, as carriers increasingly prioritize cost-effective shared solutions over traditional tower leasing.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts, timeline, and implications. (1) It accurately identifies that roaming and resale arrangements have been a persistent competitive pressure on AMT's leasing activity from 2022 to 2024. The mention of 5G RAN sharing as a factor in 2022 and its continued relevance in 2024 is consistent with the original answer. (2) There are no numeric values in the question or answer, so quantitative accuracy is not applicable—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes the evolution of risk from slowing new leases (2022) to potential decommissioning (2024), though it slightly underemphasizes the expansion of the risk in 2024 to include resale arrangements beyond RAN sharing. The original answer explicitly notes that by 2024, the risk broadened to include both RAN sharing and resale arrangements leading to decommissioning, while the LLM focuses more narrowly on RAN sharing. (4) The answer is contextually relevant and addresses both parts of the question: the evolution of impact and what it indicates about competitive pressures. The conclusion about carriers prioritizing cost-effective shared solutions correctly captures the competitive dynamic. The score is 8 because while all core facts are present, the LLM slightly downplays the expansion of the risk in 2024 to include resale arrangements and their role in decommissioning, which is a meaningful nuance in the evolution of the threat.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 423,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "McDonald's relationship with its franchisees between 2022 and 2024 evolved toward greater collaboration and strategic co-investment, emphasizing modernization and operational alignment. In 2022, the focus was on mitigating pandemic-related risks and ensuring franchisee financial stability, while 2024 highlighted co-investment in restaurant improvements, technology upgrades, and shared initiatives to enhance customer experiences. The company reinforced its commitment to rigorous standards and brand consistency, with franchisees playing a critical role in driving sales and operational success through aligned investments and innovation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's relationship with its franchisees from 2022 to 2024. (1) It correctly identifies the shift from pandemic-related operational challenges in 2022 to strategic co-investment and modernization by 2024. While the original answer specifies the 'Accelerating the Arches' strategy and structured co-investment for restaurant modernization and brand value, the LLM conveys the same meaning using terms like 'strategic co-investment,' 'technology upgrades,' and 'shared initiatives to enhance customer experiences.' (2) There are no numeric values, percentages, or dollar amounts in either answer, so quantitative accuracy is not applicable—no discrepancies exist. (3) The multi-hop reasoning is sound: the LLM synthesizes changes over time (2022 vs 2024), correctly attributes shifting priorities (from stability to growth via investment), and maintains entity accuracy (McDonald's, franchisees, correct years). The only minor omission is the lack of explicit mention of 'Accelerating the Arches' and the emphasis on franchisee reinvestment as a structured expectation, which slightly reduces qualitative completeness. (4) The answer is fully contextually relevant, directly addressing both strategic investment and operational expectations as asked. Wording differs but semantic equivalence is strong. A score of 9 is justified due to high factual alignment with only minor detail omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 402,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "NextEra Energy's investment strategy in equity securities within its Special Use Funds evolved from 2022 to 2024 by increasing the total value of equity securities held, with a notable shift toward Level 2 valuations (unobservable inputs) and higher unrealized gains. In 2024, total equity securities in Special Use Funds rose to **$6,164 million** (vs. **$5,290 million** in 2023), driven by a **$579 million increase in Level 2 assets**. Unrealized gains improved from a **$1,028 million loss in 2022** to **$917 million in 2024**, reflecting better performance or strategic adjustments in holdings. This suggests a focus on diversifying equity investments and leveraging commingled funds, while maintaining a mix of direct and indirect holdings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, NextEra Energy held $8,922 million in Special Use Funds with no explicit breakdown of equity securities. However, the LLM claims that equity securities were $5,290 million in 2023 and implies a value in 2022, which is not supported by the original answer. There is no mention in the ground truth of Level 2 valuations, unrealized gains/losses ($1,028 million loss in 2022 or $917 million gain in 2024), or year-over-year changes in asset levels—these are entirely fabricated. The only correct number is the 2024 equity securities value of $6,164 million. (2) The quantitative inaccuracies are severe: the LLM invents figures for 2022 and 2023 equity allocations, introduces non-existent metrics like Level 2 increases ($579 million), and makes up performance data (unrealized gains/losses). These numbers do not appear in the ground truth and contradict it by implying detailed disclosures in 2022 that were not present. (3) The multi-hop reasoning is flawed. The original answer emphasizes a shift in transparency—from no equity breakdown in 2022 to a disclosed $6,164 million in 2024—within a declining total fund value. The LLM instead constructs a narrative of growth and performance improvement unsupported by the source, failing to recognize the key point about disclosure evolution versus actual investment changes. (4) While the LLM attempts to address the evolution of investment strategy, it does so with invented data and incorrect reasoning, leading to a low correctness score. Contextual relevance is moderate because it discusses equity securities in Special Use Funds over time, but the substance is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 474,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "The financial performance of smokeable products showed a decline in net revenues from $22,476 million in 2022 to $21,756 million in 2023, primarily due to lower shipment volumes. Operating income for smokeable products slightly decreased from $10,688 million in 2022 to $10,670 million in 2023, reflecting higher general corporate expenses and amortization costs, partially offset by improved performance in the oral tobacco products segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: net revenues of $22,476 million in 2022 and $21,756 million in 2023, and operating income of $10,688 million in 2022 and $10,670 million in 2023, matching the ground truth exactly. These numbers reflect a slight decline in both metrics, which is accurately conveyed. (2) Quantitative accuracy is perfect—values are reported correctly with consistent units and no calculation errors. The difference in net revenues ($720 million decrease) and operating income ($18 million decrease) aligns with the data. (3) The qualitative reasoning is mostly sound and adds context not present in the original answer—specifically citing 'lower shipment volumes' and 'higher general corporate expenses and amortization costs' as drivers, which may come from related disclosures in the 10-K. While the ground truth does not include these explanatory details, they do not contradict it and are plausible elaborations. The mention of 'improved performance in the oral tobacco products segment' as a partial offset is an additional detail that may be contextually accurate but is not required for the question and does not detract from correctness. (4) The answer is fully relevant, addressing both net revenues and operating income across 2022 and 2023. The slight deduction in qualitative accuracy (9 instead of 10) is due to the introduction of explanatory factors not confirmed in the ground truth, but since they are reasonable and do not conflict with facts, the overall correctness remains high. The core multi-hop synthesis—comparing two financial metrics across two years—is executed flawlessly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 454,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "The utilization of Accenture plc Class A Ordinary Shares under share purchase programs increased in 2023 compared to 2022, as evidenced by the expanded authorization for share repurchases. In 2022, open-market purchases totaled 9,635,751 shares, while the Board approved an additional $3 million in repurchase authority in 2023, raising the total authorization to $6.129 billion. These shares are primarily used for employee benefits, including equity awards under the Employee Share Purchase Plan (ESPP) and restricted share units, as well as treasury shares for payroll tax obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the aggregate available authorization was $3,129,296 (approximately $3.13 million), not $3.129 billion or $6.129 billion as claimed. The LLM incorrectly states that the Board approved an additional $3 million in 2023, raising total authorization to $6.129 billion—this is a massive overstatement and not supported by the original answer. Additionally, the LLM claims that 9,635,751 shares were purchased in 2022, but this figure is not present in the ground truth and cannot be verified. (2) The original answer does not provide any actual number of shares purchased, nor does it mention an increase in authorization to $6.129 billion. The correct interpretation is that the $3.13 million was the remaining authorization, not the total or an increase. The LLM also misrepresents the timeline by attributing a 2023 authorization increase that isn't in the source. (3) The qualitative reasoning partially captures the intended usage of shares—for employee benefits and equity awards—but incorrectly conflates share withholding for payroll taxes (which occurred in fiscal 2024) with the buyback program, and fails to distinguish that this withholding was separate from the public buyback authorization. It also misses the key point that in 2023, Accenture clarified that repurchased shares were being held as treasury shares for employee benefits, which represents the actual evolution in utilization. (4) The contextual relevance is moderate because the answer addresses share purchase programs and usage for employee benefits, but the severe quantitative errors and incorrect synthesis of program scale and timing undermine the factual foundation. Due to major numeric inaccuracies and flawed multi-hop reasoning, the correctness score is low at 3, with quantitative accuracy particularly poor at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 516,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "Between 2022 and 2024, AMT's operating covenants evolved from variable-rate debt instruments tied to LIBOR/EURIBOR with margin adjustments to fixed-rate securitizations with stricter financial covenants. In 2022, debt included EUR/USD term loans with interest rates based on LIBOR/EURIBOR plus margins (e.g., 1.125% above EURIBOR for EUR-denominated loans). By 2024, the company issued fixed-rate securitizations (e.g., 5.490% and 5.735% for 2023 Securities) with covenants requiring debt service coverage ratios (DSCR) and restrictions on additional indebtedness. The 2024 covenants emphasized maintaining DSCR thresholds and reserve accounts, reflecting a shift toward fixed-rate structures and enhanced operational controls.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of AMT's operating covenants between 2022 and 2024. (1) The original answer states that in 2022, AMT's covenants were tied to credit facilities referencing LIBOR and EURIBOR (e.g., 2021 Multicurrency Credit Facility), and by 2024, there was a shift to SOFR, specifically for letters of credit in Nigeria. The LLM incorrectly claims a shift to fixed-rate securitizations (e.g., 5.490% and 5.735% for 2023 Securities) with DSCR covenants, which is not supported by the ground truth. (2) Quantitatively, the LLM introduces specific percentages (1.125% above EURIBOR, 5.490%, 5.735%) and characterizes instruments as 'fixed-rate securitizations' that are absent from the original answer. These numbers and instruments are not mentioned in the ground truth and appear fabricated. (3) The reasoning is flawed: the actual evolution is a benchmark transition (LIBOR/EURIBOR → SOFR) due to regulatory changes, not a structural shift to fixed-rate securitizations with enhanced covenants. The LLM fails to mention SOFR's role in Nigerian letters of credit, a key detail. (4) While the answer addresses debt instruments and covenants, it invents a narrative of moving to fixed-rate structures and stricter financial controls, which distorts the actual nature of the change—benchmark transition, not covenant tightening or securitization. Thus, despite addressing the general topic, the answer is factually incorrect on core elements, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 422,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "Between the 2023 and 2024 SEC filings, Disney+ Hotstar's subscriber base grew to approximately 36 million as of September 2024, though the exact 2023 figure is not explicitly stated in the provided documents. The consolidation of Star+ into Disney+ in Latin America streamlined Disney's international streaming strategy by unifying services, reducing operational complexity, and enhancing brand cohesion, which likely supported subscriber growth and market penetration in the region.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the date: it states Disney+ Hotstar had 36 million subscribers 'as of September 2024', but the ground truth specifies the 2023 SEC filing reported this number as of September 28, 2023 (not 2024). This misrepresents the timeline and implies growth to 36 million by 2024 without confirming the 2023 baseline, which undermines quantitative accuracy. Additionally, the LLM incorrectly suggests the 2023 figure is not available, while the ground truth confirms it was reported in the 2023 filing. (2) The consolidation of Star+ into Disney+ in Latin America is correctly described in terms of timing (by end of June 2024) and strategic intent, though the LLM omits the specific detail that the two services were offered separately in certain Latin American countries prior to July 2024. However, the interpretation of strategic impact—streamlining, reducing complexity, enhancing brand cohesion—is semantically aligned with the ground truth. (3) The multi-hop reasoning is partially sound: the model connects subscriber data with strategic changes in international offerings, but fails to accurately anchor the subscriber number to the correct fiscal year, weakening the synthesis. (4) The contextual relevance is high because the answer addresses both parts of the question and provides a reasonable interpretation of strategic implications. However, the incorrect dating of the subscriber figure severely impacts factual correctness, warranting a moderate overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 423,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "The number of employees covered under collective labor agreements remained approximately one-fifth of the company's subsidiary workforce in both 2022 and 2023, as indicated by the consistent percentage (one-fifth) cited in both years' disclosures. While the 2022 document noted 3,000 employees covered in renegotiations, the 2023 document referenced 2,100 employees for 2024 negotiations, reflecting a reduction in the number of employees involved in renegotiations. This suggests a stable labor agreement strategy, with the company maintaining consistent bargaining efforts and managing agreements without significant disruptions to operations.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the numerical values from the ground truth—3,000 employees in 2022 and 2,100 in 2023 (projected for 2024)—and notes the reduction, which is factually accurate. However, it introduces the claim that this represents 'approximately one-fifth of the company's subsidiary workforce' in both years, which is not present in the original answer or supported by the provided context. This addition misrepresents the data and undermines factual correctness. (2) Quantitatively, the numbers and years are accurate: 3,000 in 2022 and 2,100 in 2023 (for upcoming negotiations), with a correct directional change (reduction). No calculation errors, but the unsupported 'one-fifth' percentage harms accuracy. (3) The multi-hop reasoning is partially sound—comparing employee counts across years is correct—but the conclusion diverges: the original answer infers a 'shift in labor agreement strategy' due to fewer renegotiations, while the LLM claims a 'stable labor agreement strategy', which contradicts the evidence of reduced negotiations. This misinterprets the implication of the data. (4) Contextual relevance is fair: the answer addresses both parts of the question (change in employees and strategic implication), but the inclusion of unverified proportions and incorrect strategic interpretation reduces its overall correctness. The core data is right, but synthesis and conclusion are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 396,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "NextEra Energy's investment in U.S. Government and municipal bonds increased from $137 million in 2022 to $1,283 million in 2024, reflecting a total increase of $1,146 million. This growth is derived from the fair value measurements in the pension plan assets section of the 2022 and 2024 10-K filings, where the combined value of these bonds rose significantly over the period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors. According to the ground truth, NextEra Energy's investment in U.S. Government and municipal bonds increased from $137 million in 2022 to $161 million in 2024, a change of $24 million. However, the LLM claims the 2024 value was $1,283 million (over 7x higher than actual) and reports an increase of $1,146 million, which is completely inaccurate. (2) The quantitative inaccuracies are severe: the 2024 value is off by more than $1.1 billion, and the growth amount is overstated by over $1.1 billion. The percentage increase implied by the LLM (over 800%) is also wildly off from the correct ~17.5%. (3) The reasoning is flawed: while the LLM references 'fair value measurements in the pension plan assets section', it fails to correctly extract or synthesize the actual figures. The multi-hop requirement—comparing two years of bond investments for the same company—was not executed correctly, likely due to misreading or misattributing data. (4) The contextual relevance is moderate because the answer addresses the right topic (bond investments over time) and cites plausible sections of the 10-K, but the severe numerical errors undermine all substantive value. Correctness and quantitative accuracy are therefore very low; qualitative accuracy is slightly higher only because the structure and intent of the response follow a logical format.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 390,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "Between 2022 and 2024, Opdivo's role in Bristol-Myers Squibb's portfolio expanded through additional therapeutic approvals, including FDA approval for Opdivo Qvantig (a subcutaneous combination product) in December 2024 and expanded indications for urothelial carcinoma and resectable NSCLC. Manufacturing strategy evolved to balance internal capabilities (e.g., maintaining internal production capacity) with third-party partnerships, ensuring supply stability while aligning with broader shifts toward outsourcing mature products. These steps reinforced Opdivo's position as a core oncology asset, supported by regulatory flexibility and scalable manufacturing.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the expansion of Opdivo's therapeutic approvals and mentions the ongoing use of both internal and third-party manufacturing, aligning with the ground truth's emphasis on strategic manufacturing and clinical growth. However, it introduces inaccuracies in dates and specific approvals. The ground truth states that in March 2024, Opdivo received FDA approval for combination therapy with cisplatin and gemcitabine for urothelial carcinoma. The LLM incorrectly states an approval for 'Opdivo Qvantig' in December 2024, which is not mentioned in the original answer and appears to be fabricated or misdated. Additionally, while the original answer does not mention NSCLC or subcutaneous formulations, the LLM adds these unverified indications, introducing factual overreach. (2) Quantitative accuracy is compromised due to the incorrect date (December 2024 vs. March 2024) and the introduction of a product name (Opdivo Qvantig) not present in the source. The original answer does not reference any subcutaneous formulation approval, making this a significant factual deviation. (3) The multi-hop reasoning is partially sound—linking manufacturing strategy and therapeutic expansion to portfolio evolution—but fails in synthesizing only verified information. The model extrapolates beyond the provided data, undermining the reliability of the synthesis. (4) Despite these errors, the answer captures the core theme of Opdivo's growing role and balanced manufacturing approach, earning moderate scores in qualitative accuracy and high relevance. The correctness score is reduced due to key factual inaccuracies in dates and unverified product approvals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 463,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "Disney's ownership of National Geographic magazine remained at 73% in both 2023 and 2024, as stated in the Notes to Consolidated Financial Statements. However, in 2024, National Geographic was strategically integrated into Disney's Direct-to-Consumer (DTC) platforms, such as Disney+, where it became a top-level branded tile within the service. This reflects a shift toward positioning National Geographic as a core content asset within Disney's streaming ecosystem, enhancing its visibility and aligning it more closely with Disney's broader entertainment offerings.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that Disney owns 73% of National Geographic in 2023 (per ground truth), it incorrectly claims this ownership percentage was reaffirmed in 2024. The ground truth explicitly states that the 73% ownership was *removed* from 2024 disclosures, indicating a shift in how Disney reports its relationship — from an equity stake to a more operational 'published by' framing. The LLM fails to capture this key change in business structure. Additionally, the claim that National Geographic was integrated into Disney+'s 'top-level branded tile' in 2024 is not supported by the original answer and introduces new, unverified strategic positioning details not present in the ground truth. (2) Quantitatively, the 73% figure is accurate for 2023 but incorrectly extended to 2024. There are no calculations in the response, but the reuse of the percentage without qualification is misleading given the context of changing disclosure. (3) The multi-hop reasoning is flawed: the original answer emphasizes a shift from ownership-focused reporting to operational language, signaling a structural or strategic repositioning. The LLM instead assumes continuity of ownership and invents a new strategic integration into DTC platforms, which is not mentioned in the ground truth. This reflects a failure to synthesize the correct inference from changes in disclosure language. (4) Despite introducing unsupported details, the answer remains contextually relevant by addressing Disney’s relationship with National Geographic and its strategic positioning. However, the core factual misrepresentation of ownership continuity and invented DTC integration severely undermine correctness. Hence, the low scores in correctness, quantitative, and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 498,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024 by emphasizing enhanced scalability, security, and global currency support. In 2023, the platform was noted to handle transactions across **200 markets** and **150 currencies**, with the ability to withdraw funds in **56 currencies** and hold balances in **24 currencies**. By 2024, the platform expanded to **200 markets** and **140 currencies** for sending payments, while increasing supported withdrawal currencies to **57**. The 2024 document highlighted improved infrastructure for large-scale global operations, robust cybersecurity, and integration with new financial services, underscoring advanced capabilities to manage cross-border transactions efficiently.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While the ground truth confirms that PayPal supported 56 withdrawal currencies in 2023 and 57 in 2024, the LLM incorrectly introduces additional figures not present in the original answer—specifically, '200 markets', '150 currencies' for transactions, and '24 currencies' for holding balances in 2023, and '140 currencies' for sending payments in 2024. These numbers are not supported by the ground truth and contradict the provided information. (2) The only correct quantitative element is the increase from 56 to 57 withdrawal currencies, which aligns with the original answer. However, all other numbers (150, 140, 24, 200) are fabricated or misattributed, severely undermining quantitative accuracy. (3) The qualitative reasoning partially captures the evolution in PayPal's description—such as the expansion in withdrawal currencies and a focus on global processing—but incorrectly frames the changes around scalability, security, and infrastructure enhancements, which are not mentioned in the ground truth. The LLM also misses the key qualitative shift in 2024’s consumer-centric language (placing 'consumers' before 'merchants'), which is a central point in the original answer. (4) Contextually, the answer addresses the general theme of global payment processing and currency support, so it remains relevant. However, due to major factual errors and failure to accurately represent the nature of PayPal’s stated evolution, the overall correctness is low. The answer invents metrics and omits the actual linguistic and strategic reframing emphasized in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 451,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "The interest rate for NEE's Series K Debentures was reset to **6.051% per year** in March 2023 during a remarketing. By 2024, there is no explicit mention of a change to the Series K Debentures' rate, which remained at **6.051%**. However, NEE issued new debentures in January 2024 with interest rates ranging from **4.90% to 5.55%**, indicating a broader strategy to refinance existing debt at lower rates. This suggests NEE prioritizes securing favorable terms by issuing new debt with lower rates, potentially reducing interest costs and optimizing its capital structure.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 6.051% interest rate reset in March 2023 for the Series K Debentures, which matches the ground truth. However, it incorrectly states that there is 'no explicit mention of a change' in 2024 and implies the rate remained unchanged due to lack of update, whereas the ground truth clarifies that a letter dated March 1, 2023, set terms effective March 1, 2023, indicating a formal continuation of the updated terms into 2024. This misrepresents the nature of the 2024 status as passive (no change) when it was actively confirmed via documentation. Additionally, the LLM introduces information about new debentures issued in January 2024 with rates between 4.90% and 5.55%, which is not present in the original answer or supported by the provided ground truth, leading to an unsupported inference about NEE’s refinancing strategy. (2) Quantitatively, the 6.051% figure is accurate, and the 2023 timing (March) is correct. The 4.90%–5.55% range for new 2024 debentures may be factually correct in external context but is not part of the ground truth provided, so it cannot be verified and constitutes extraneous data. (3) The multi-hop reasoning is partially sound—correctly linking the 2023 reset to ongoing terms—but fails to incorporate the key document (March 1, 2023 letter) that formalizes the continuation into 2024. Instead, it substitutes this with speculative reasoning about inaction, weakening the logical chain. The conclusion about refinancing at lower rates contradicts the ground truth, which states NEE locked in a *higher* rate, suggesting adaptation to market conditions rather than cost reduction via lower rates. (4) The correctness score is 5 due to accurate core data but significant misinterpretation of strategic implications and inclusion of unverified details. Quantitative accuracy is 8 because key numbers are correct, though some introduced figures are unverified. Qualitative accuracy is 5 due to flawed reasoning and incorrect synthesis. Contextual relevance is 7 as the response stays on topic but drifts into unsupported strategy claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 567,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "ExxonMobil maintained the application of the Unit-of-Production Depreciation method in both 2022 and 2023, using proved reserves and adjusting for production and technical changes. The method remained consistent, with no significant evolution noted between the years, as outlined in the 10-K filings. Adjustments to reserves were based on the most recent SEC prices when necessary to ensure equitable cost allocation, reflecting ongoing adherence to established accounting practices.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative evolution in ExxonMobil's application of the Unit-of-Production Depreciation method between 2022 and 2023. (1) What was correct: The answer correctly identifies that ExxonMobil used the Unit-of-Production method in both years and referenced proved reserves and SEC prices for adjustments, which aligns with the ground truth. There are no numeric inaccuracies, so quantitative accuracy is high. (2) Number/calculation verification: No specific numbers (e.g., dollar amounts, percentages) are present in either answer, so no calculation errors exist. (3) Multi-hop reasoning assessment: The LLM fails to capture the nuanced shift in 2023 where the company placed 'greater emphasis' on using the most recent SEC price specifically in cases where reserves had been significantly reduced—a refinement to better align depreciation with economic conditions. The original answer highlights a methodological refinement; the LLM incorrectly states 'no significant evolution noted,' which contradicts the ground truth. (4) Justification for scores: Correctness is scored 6 because core elements (method, reserves, SEC pricing) are present, but the critical evolution in approach is omitted or downplayed. Qualitative accuracy is low due to flawed reasoning about the lack of change. Contextual relevance is high as the response stays on topic and references appropriate concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 394,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "Netflix's strategic emphasis on original programming between 2023 and 2024 involved continued reliance on both third-party production partners and internal studio scaling. The 2024 filing highlights ongoing efforts to scale internal studio operations to produce original content, including acquisitions like Scanline and Animal Logic, while also maintaining partnerships with third parties for development, production, and distribution. The 2023 filing similarly notes reliance on third-party arrangements and internal studio growth, with no explicit shift in prioritization between the two approaches. Thus, the strategy remained balanced, with both external collaborations and internal expansion playing key roles.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains factual inaccuracies in its interpretation of Netflix's strategic shift between 2023 and 2024. While it correctly identifies the acquisitions of Scanline and Animal Logic and mentions third-party partnerships, it incorrectly concludes that there was 'no explicit shift in prioritization' and that the strategy 'remained balanced.' This contradicts the ground truth, which notes a clear evolution: in 2023, Netflix highlighted risks of third-party partners (legal, insolvency, fraud), but in 2024, this warning was omitted and the focus shifted to internal systems, culture, and operational scaling—indicating reduced reliance on external partners. The LLM fails to detect this strategic pivot. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, all mentioned entities (Scanline, Animal Logic) and years (2023, 2024) are correct, supporting a high quantitative score. (3) The multi-hop reasoning is flawed: the model should have compared the change in language and emphasis across the two years’ filings to infer a strategic shift toward internal control. Instead, it treated both years as consistent, missing the nuanced evolution in risk disclosure and strategic focus. (4) Contextual relevance is high because the answer addresses original programming, internal scaling, and third-party reliance—core elements of the question—but the failure to identify the strategic evolution significantly undermines factual correctness, justifying a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 435,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "Mastercard's Cyber and Intelligence Solutions strategic positioning evolved between 2022 and 2023 by expanding their integration into core services and emphasizing growth. In 2022, acquisitions like Ekata (2021) bolstered digital identity verification capabilities, while 2023 highlighted continued investment in cyber and intelligence solutions as part of value-added services, driving revenue growth. The 2023 filing noted increased focus on securing transactions and leveraging these solutions to enhance fraud detection and response, reflecting a strengthened market position and operational integration.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in strategic positioning of Mastercard's Cyber and Intelligence Solutions between 2022 and 2023, noting increased integration into core services and emphasis on growth. It accurately reflects that in 2022, the focus was on fraud prevention and detection (supported by the Ekata acquisition in 2021), and in 2023, these solutions were highlighted as value-added services contributing to revenue growth and broader transaction security. However, the original answer emphasizes a specific shift from being grouped under 'Other revenues' in 2022 to being explicitly elevated in strategic importance in 2023 as part of new network investments—this structural and reporting-level change is missing in the LLM response. (2) There are no numerical values, dates, or calculations in the original or LLM answer beyond the mention of Ekata's acquisition in 2021, which is factually correct and not disputed. Thus, quantitative accuracy is fully maintained. (3) The multi-hop reasoning is partially sound: the model connects acquisitions and strategic emphasis across years, but fails to fully synthesize the key point about reclassification and elevated reporting status in 2023, which is central to the ground truth. (4) The contextual relevance is high because the answer addresses the evolution in strategic role, but the qualitative accuracy is slightly reduced due to omission of the explicit shift in financial categorization and ecosystem-wide integration described in the original. Wording differences are acceptable, but the absence of 'Other revenues' context and the broader ecosystem role weakens completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 458,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "Tesla's approach to energy storage products in 2024 evolved with a heightened focus on production scalability and strategic supplier dependencies. The 2024 filing highlights risks related to delays in ramping production for energy storage systems, emphasizing challenges in supplier reliability, component shortages, and cost management. Strategic dependencies include reliance on external suppliers like Panasonic and CATL for battery cells, alongside efforts to develop proprietary cells to reduce costs and ensure long-term supply. These challenges underscore Tesla's push to balance external partnerships with internal manufacturing capabilities to mitigate production risks and meet growing demand.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Tesla's approach to energy storage from 2023 to 2024. It accurately captures the shift from modular design and in-house optimization (implied context for 2023) to a 2024 focus on production scalability, supply chain bottlenecks, and supplier dependencies. The mention of risks related to production ramp delays, supplier reliability, component shortages, and cost management matches the original answer's emphasis on bottlenecks and efficient manufacturing. The LLM adds specific supplier names (Panasonic and CATL) and references proprietary cell development, which are plausible details consistent with Tesla's known strategy but not explicitly stated in the ground truth. While these additions are reasonable, they go beyond the provided knowledge graph, slightly reducing qualitative accuracy. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The answer is contextually relevant and addresses both production challenges and strategic dependencies as required. The multi-hop reasoning is sound, connecting Tesla's evolving strategy across years and synthesizing production and supply chain aspects. However, the original answer does not mention specific suppliers or internal cell development, so the LLM introduces external knowledge, which slightly affects fidelity. Overall, the core facts, timeline, and strategic shift are correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 414,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "NextEra Energy Capital Holdings increased its floating rate debenture issuance in 2024 compared to 2023, with a principal amount of $600 million due in 2026, compared to $400 million due in 2024 in 2023. The maturity structure expanded from a single 2024 maturity to a range of maturities (2026–2054) with interest rates between 4.90% and 5.55%, reflecting a shift toward longer-term floating rate debt to manage interest rate risk and optimize funding costs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, NextEra Energy Capital Holdings sold $600 million in floating rate debentures due in 2026. However, the LLM incorrectly claims that in 2023, the company issued $400 million due in 2024, which is not supported by the original answer. Additionally, the LLM states that in 2024, the company expanded maturities to a range of 2026–2054 with interest rates between 4.90% and 5.55%, but the original answer does not mention any such range or interest rates, nor any expansion beyond the 2026 maturity. The principal amount in 2024 is correctly stated as $600 million, but the claim of an increase from $400M to $600M is false since no $400M issuance is documented in 2023. (2) Quantitative accuracy is very low: the $400 million figure, 2024 maturity, interest rate range, and extended maturity up to 2054 are all fabricated or incorrect. Only the $600 million and 2026 maturity align with the ground truth. (3) The multi-hop reasoning is flawed. The LLM incorrectly infers a strategic shift toward longer-term debt and broader maturity structuring, while the original answer emphasizes continuity and consistency in strategy with no significant changes. The synthesis fails to reflect the actual evolution—there was no restructuring or expansion. (4) Contextual relevance is moderate because the answer addresses issuance strategy, principal amount, and maturity structure as asked, but the content is largely incorrect. Correctness and quantitative accuracy are low due to major factual and numerical errors; qualitative accuracy is slightly higher only because the response attempts the right type of analysis, albeit based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 476,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "Intel's approach to supply chain responsibility evolved from 2023 to 2024 by expanding supplier engagement scope and deepening collaboration on industry initiatives. In 2023, Intel emphasized direct supplier audits and capability-building programs for compliance with human rights and environmental standards, while in 2024, it broadened engagement to include indirect suppliers through programs on forced labor, responsible minerals, and diversity. The 2024 report highlights increased collaboration across the industry on responsible minerals sourcing and climate transparency, alongside linking executive bonuses to emissions reduction targets, reflecting a more integrated focus on environmental and social sustainability in supply chain practices.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While it correctly identifies Intel's focus on supplier engagement and collaboration on responsible minerals and climate transparency in 2024, it misrepresents the 2023 activities by claiming emphasis on 'direct supplier audits' and compliance programs, which are not mentioned in the original answer. Instead, the ground truth states that in 2023, Intel announced an expansion of supplier engagement under its RISE strategy with a goal of net-zero upstream Scope 3 emissions by 2050—this strategic goal is entirely missing from the LLM response. Additionally, the LLM incorrectly claims that in 2024, Intel broadened engagement to include 'indirect suppliers' and linked executive bonuses to emissions targets—neither of these points is supported by the original answer. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable; however, all mentioned years (2023, 2024) are correct, hence a score of 10. (3) The multi-hop reasoning is partially sound—the model correctly identifies a shift from broader engagement to deeper collaboration—but it fabricates specific programs (e.g., forced labor, diversity, executive bonuses) and misattributes the nature of the evolution. The synthesis does not accurately reflect the source data, particularly around the RISE strategy and net-zero goal. (4) The contextual relevance is high because the answer addresses the evolution of Intel's supply chain responsibility initiatives with attention to collaboration and supplier scope, but the factual inaccuracies and invented details reduce correctness and qualitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 471,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "XOM's characterization of the assumptions underlying the standardized measure of discounted future cash flows remained consistent between 2022 and 2023. Both disclosures explicitly state that the measure uses **first-day-of-the-month average prices**, which are discrete points in time and may cause significant year-to-year variability in cash flows due to price changes. No evolution in framing the dependency on these prices is evident in the provided documents. The 2023 disclosure retains the same acknowledgment of this assumption's impact, with no additional clarification or modification noted.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that there was no evolution in XOM's framing between 2022 and 2023. The ground truth clearly states that while the methodology remained unchanged, the *framing* shifted from describing the assumptions as 'prepared on the basis of certain prescribed assumptions' in 2022 to stating in 2023 that the measure 'depends on' these assumptions, reflecting a more explicit acknowledgment of sensitivity and dependency. The LLM incorrectly asserts that the characterization 'remained consistent' and that 'no evolution in framing' is evident, which directly contradicts the ground truth. While the LLM correctly identifies that first-day-of-the-month average prices are used and may cause variability (factually accurate details), it fails to recognize the qualitative shift in language and emphasis. This is a multi-hop reasoning failure: the model must compare the tone and framing across two years' disclosures, not just the presence of an assumption. The quantitative aspects (e.g., discount rate, use of prices) are not disputed and are correctly noted where mentioned, hence full marks for quantitative accuracy. However, the failure to detect a key change in narrative framing results in a low correctness and qualitative accuracy score. Contextual relevance is moderate because the answer addresses the right topic and company but misses the central point of evolution in disclosure tone.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 397,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "Between 2022 and 2023, Mastercard enhanced its digital identity solutions by integrating advanced biometric technologies (e.g., fingerprint, face, iris scanning) and behavioral analytics to strengthen fraud prevention and user verification. These solutions were further aligned with open banking capabilities, as evidenced by partnerships in 2023 to launch an ACH payment solution using open banking platforms, connecting to **95% of U.S. deposit accounts** and **3,000 banks across Europe**. This expansion improved secure data access and payment experiences while broadening reach across financial institutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key developments in MA's digital identity solutions between 2022 and 2023, including the expansion of open banking connectivity to 95% of U.S. deposit accounts and approximately 3,000 banks in Europe, which matches the ground truth. It also accurately notes the 2023 partnership to launch an ACH payment solution using open banking infrastructure. However, the LLM introduces specific biometric technologies (fingerprint, face, iris scanning) and behavioral analytics, which are not mentioned in the original answer and represent added detail not supported by the ground truth. While these may be plausible enhancements, they are not part of the documented evolution in the provided knowledge base, making this a minor factual overreach. (2) Quantitatively, all numbers are accurate: '95% of U.S. deposit accounts' and '3,000 banks across Europe' are correctly reported with no calculation errors. (3) The multi-hop reasoning is largely sound—linking digital identity evolution with open banking integration and expanded reach across financial institutions—but slightly overreaches by introducing unverified technical enhancements. The core synthesis across years and capabilities is valid. (4) The answer is contextually relevant and addresses both parts of the question: evolution over time and integration with open banking and reach. The added biometric detail slightly affects qualitative accuracy, but the key facts and synthesis are correct, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 425,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "Tesla's approach to the Solar Roof product evolved between 2023 and 2024 by addressing production challenges and strategic dependencies. In 2023, the company emphasized direct sales and partnerships for installation, while in 2024, it focused on scaling production and integrating Solar Roof with energy storage systems like Powerwall. Production challenges persisted, including supplier reliability and manufacturing complexities, as highlighted in risk factors. Strategic efforts included localized manufacturing, workforce training programs, and improving supply chain efficiency to mitigate dependencies and meet growing demand.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While it correctly identifies that production challenges persisted for Tesla's Solar Roof between 2023 and 2024, it fabricates specific details not present in the original answer, such as 'direct sales and partnerships for installation' in 2023 and 'localized manufacturing, workforce training programs' in 2024—none of which are mentioned in the ground truth. The original answer does not reference supplier reliability or manufacturing complexities as explicitly stated risk factors in the filings, nor does it mention any new strategic efforts like workforce training. Instead, the ground truth emphasizes that in 2023, Tesla highlighted the design maturity and integration with Powerwall, and in 2024 acknowledged production ramp delays similar to other products, with a strategic dependency on mass-market vehicle scaling. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the key shift from product positioning (2023) to production delay acknowledgment and strategic prioritization of vehicles (2024). Instead, it invents a narrative about scaling production and supply chain improvements that is not supported by the original answer. The critical point in the ground truth—that Tesla's success 'depends in large part' on mass-market vehicle production, implying a potential deprioritization of Solar Roof—is entirely missing from the LLM response. (4) The contextual relevance is moderate because the answer addresses the general topic of Solar Roof evolution, production challenges, and strategy, but introduces irrelevant and unsupported details, reducing factual fidelity. The core insight about strategic dependencies being tied to vehicle production is omitted, which is central to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 540,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "Between 2023 and 2024, NextEra Energy, Inc. entered into two new Pledge Agreements in 2024: one dated **June 1, 2024**, and another dated **October 1, 2024**. These agreements involved **Deutsche Bank Trust Company Americas** as Collateral Agent, Custodial Agent, and Securities Intermediary, alongside **The Bank of New York Mellon** as Purchase Contract Agent. In contrast, the 2023 filing referenced a Pledge Agreement dated **September 1, 2022**, which included **The Bank of New York Mellon** as Purchase Contract Agent. The evolution reflects the addition of Deutsche Bank as a counterparty in 2024 and the continuation of agreements with the Bank of New York Mellon.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All dates—September 1, 2022, June 1, 2024, and October 1, 2024—are correctly reported. The counterparties, Deutsche Bank Trust Company Americas and The Bank of New York Mellon, are accurately identified. (2) Quantitative accuracy is perfect: all dates and entity names match the original answer. (3) The reasoning is sound: the LLM correctly infers an evolution in the use of Pledge Agreements by noting the introduction of two new agreements in 2024 with the same counterparties, and it adds value by specifying the roles of each counterparty (e.g., Collateral Agent, Purchase Contract Agent), which enhances clarity even if not in the original. (4) The only minor shortcoming is that the original answer emphasizes the continuity of both counterparties from the 2022 agreement (referenced in 2023 filing) to the 2024 agreements, while the LLM implies Deutsche Bank was newly added in 2024. However, the original states the 2022 agreement already included both Deutsche Bank and BNY Mellon, so Deutsche Bank was not a new counterparty in 2024. This is a slight mischaracterization, hence the 9 instead of 10 on qualitative accuracy. Otherwise, the answer is complete, relevant, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 356,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "Intel's strategic positioning in Edge AI evolved from 2023 to 2024 by enhancing its software platform offerings and deepening ecosystem partnerships. In 2024, Intel emphasized an **edge-native software platform** with modular building blocks, preeminent service, and support, enabling developers to build, deploy, and manage distributed edge infrastructure and AI across industries. This platform supports hybrid AI and offers optimizations for networking, IoT, and edge workloads. Ecosystem partnerships expanded, with continued collaboration with key players like Ericsson, Nokia, Cisco, and cloud providers (e.g., Amazon, Google, Microsoft), as well as advancements in 5G and cloud-RAN solutions. The 2024 NEX segment revenue growth ($5.8B vs. $5.774B in 2023) reflects stronger Edge AI traction, driven by Network and Edge revenue, alongside improved software-driven solutions.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Intel's Edge AI strategy from 2023 to 2024, correctly identifying the edge-native software platform with modular building blocks and support for hybrid AI, distributed infrastructure, and ecosystem partnerships. It accurately notes the emphasis on cloud-native programmability and collaboration with partners like Ericsson, Nokia, Cisco, and major cloud providers. However, it incorrectly implies that the edge-native platform was emphasized in 2024, while the ground truth states this was Intel's 2023 focus. In 2024, the strategic shift was under the NEX initiative toward transforming fixed-function hardware into general-purpose, programmable systems—this nuance is underemphasized. (2) The LLM introduces specific revenue figures—$5.8B in 2024 vs. $5.774B in 2023—which are not present in the original answer and cannot be verified from the provided ground truth. This is a critical issue for quantitative accuracy, as these numbers appear fabricated or misattributed. No revenue data was included in the ground truth, so including such precise figures reduces trustworthiness. (3) The multi-hop reasoning is partially sound: the model connects ecosystem partnerships and software evolution across years, but misaligns the timing of strategic emphases. It conflates 2023's platform focus with 2024 developments, failing to clearly distinguish the shift to the NEX initiative and cloud-native programmable hardware. The mention of 5G and cloud-RAN is contextually plausible but not explicitly in the ground truth. (4) Despite the factual error in revenue and timeline conflation, the answer remains contextually relevant and captures the qualitative direction of Intel’s evolution. The core themes—modular software, ecosystem expansion, hybrid AI, and edge-cloud integration—are consistent with the ground truth, warranting a solid but not high score. The correctness score is 7 due to accurate conceptual understanding but significant quantitative and temporal inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1512,
        "completion_tokens": 548,
        "total_tokens": 2061
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "The composition and value of CVS's long-term debt related to the 1.75% senior notes due August 2030 remained unchanged between 2023 and 2024. Both the 2023 and 2024 10-K filings list the 1.75% senior notes due August 2030 at $1,250 million in the long-term debt section, with no indication of repayments, issuances, or modifications to this specific debt obligation during the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 1.75% senior notes due August 2030 remained unchanged at $1,250 million between 2023 and 2024, which matches the ground truth. All numeric values (1.75%, August 2030, $1,250 million, years 2023 and 2024) are accurate. (2) Quantitative accuracy is perfect—dollar amounts, percentages, and dates are correct and consistent with the original answer. There are no calculation errors. (3) The reasoning is sound and focused on the specific debt instrument in question. However, the LLM does not mention other senior notes due in 2030 (e.g., the 3.75% notes due April 2030), which were included in the ground truth to provide context about overall debt composition. While the question primarily focuses on the 1.75% notes, the omission of broader composition context slightly reduces completeness and qualitative accuracy. (4) Despite this minor omission, the LLM directly addresses the core of the question with precise, relevant information, making it highly contextually relevant and factually correct. The answer is semantically equivalent in substance, though slightly less comprehensive than the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 330,
        "total_tokens": 1533
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "Netflix introduced an ad-supported subscription plan in 2023 as a lower-priced option to attract broader audiences and diversify its pricing strategy. By 2024, this plan had become a key component of its membership growth objectives, enabling the company to expand its customer base while managing costs. The 2024 filing emphasized the plan's role in supporting global growth and maintaining competitiveness, aligning with efforts to balance affordability with revenue sustainability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Netflix introduced the ad-supported plan in 2023 as a lower-priced option to broaden audience reach and adjust pricing strategy, and by 2024 it became a key part of membership growth and global competitiveness. There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023, 2024) are correct. (2) The answer addresses all parts of the question: evolution of the ad-supported plan, its role in pricing strategy, and its impact on membership growth objectives. (3) Multi-hop reasoning is sound—the model correctly synthesizes the plan’s progression from an experimental offering in 2023 to a strategic, integrated component in 2024, reflecting long-term planning. (4) Semantic equivalence is strong; the LLM captures the core message of strategic evolution and integration without repeating the exact phrasing. The only minor gap is that the LLM does not explicitly mention the plan’s role in 'value perception' or 'range of plans' as stated in the original, slightly reducing qualitative completeness. However, the essence of strategic integration and growth targeting is preserved. Overall, the response is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 374,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "Tesla's approach to the Tesla Semi evolved from early production in 2023 to pilot production in 2024, reflecting a focus on scaling manufacturing capacity and integrating advancements in battery technology and Full Self-Driving (FSD) capabilities. In 2024, the company emphasized cost reduction, efficiency improvements, and expanding global infrastructure to support the Semi's production, aligning it with broader strategic goals of increasing affordability and market penetration for commercial electric vehicles.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution in Tesla's approach to the Tesla Semi from 'early production' in 2023 to 'pilot production' in 2024, which aligns with the ground truth. The production status and timeline are factually accurate. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes the progression in production status across years. However, the LLM adds details not present in the ground truth, such as 'cost reduction,' 'efficiency improvements,' 'global infrastructure,' and 'advancements in battery technology and FSD capabilities,' which, while plausible, are not supported by the provided knowledge graph. These additions slightly reduce qualitative accuracy. (4) Despite the extra details, the core factual progression and strategic interpretation are consistent with the original answer, and the response directly addresses the question about production status and strategic positioning. Hence, the correctness and contextual relevance scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 336,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "The expansion of NextEra Energy's Executive Retention Employment Agreements (ERAs) from 2023 to 2024, as evidenced by new agreements (e.g., Exhibit 10(nn) in the 2024 10-K), reflects the company's strategic emphasis on leadership continuity and executive talent retention. These agreements, part of broader compensation frameworks like the 2021 Long Term Incentive Plan, underscore NextEra's commitment to securing key executives through long-term incentives, ensuring stability and alignment with long-term business objectives. This approach highlights the company's prioritization of retaining experienced leadership to drive sustained growth and operational resilience.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the expansion of NextEra Energy's Executive Retention Employment Agreements (ERAs) from 2023 to 2024 as a strategic move to ensure leadership continuity and talent retention, which aligns with the ground truth. It appropriately references the 2024 10-K and links the agreements to broader compensation frameworks like the 2021 Long Term Incentive Plan, adding contextual depth. However, it lacks specific details about the named executives mentioned in the original answer—Mark Lemasney and Armando Pimentel, Jr. in 2023, and the addition of Brian Bolster in 2024 with a specific date (May 6, 2024)—which are key factual elements that demonstrate the actual expansion. While the LLM correctly infers strategic intent, it omits these concrete data points, weakening the multi-hop synthesis between years and individuals. The answer does not include any incorrect numbers or dates (hence high quantitative accuracy), but the absence of specific names and dates reduces completeness and qualitative accuracy. The reasoning is sound and contextually relevant, showing understanding of the implications of ERAs, but fails to fully substantiate the 'expansion' claim with the specific evidence from the knowledge graph. Thus, the answer is partially correct—core interpretation is accurate, but missing key factual anchors required for full correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 381,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "Intel's approach to xPU products in 2024 emphasizes expanding the x86 ecosystem through compatibility across platforms, simplifying software development, and enabling developers to innovate for future workloads. This reflects a strategic focus on open platforms and ecosystem growth, as outlined in their 2024 strategy. Product development priorities now prioritize AI integration across the entire AI continuum, from large language models to edge AI, alongside broadening their xPU portfolio (GPUs, IPUs, FPGAs) to address diverse computing needs. This builds on 2023's emphasis on process technology and competitive positioning, but with a stronger emphasis on AI-driven innovation and ecosystem collaboration.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Intel's strategic evolution in xPU development from 2023 to 2024, noting a shift toward AI integration, ecosystem expansion, and broadening the xPU portfolio (GPUs, IPUs, FPGAs), which aligns with the ground truth. However, it omits key factual details from the original answer, particularly the $16.0 billion R&D spend in 2023 and the explicit mention of past challenges with product development delays and cost overruns. While it references 2023's focus on process technology, it does not fully capture the transition from a general R&D focus to a structured 'product competitiveness' initiative in 2024, nor does it mention the creation of an advisory group to expand the x86 ecosystem—both important specifics in the ground truth. (2) There are no numeric inaccuracies; the LLM does not introduce any incorrect figures, and since it avoids citing specific numbers (e.g., $16.0B), there is no contradiction—thus quantitative accuracy is high. (3) The multi-hop reasoning is partially sound: the model infers a strategic shift toward AI and ecosystem development, which is valid, but fails to synthesize the full scope of organizational changes (e.g., advisory group) and financial context (R&D spending) that ground the evolution. (4) The answer is contextually relevant and captures the essence of Intel’s strategic direction, but lacks completeness in conveying the full factual basis of the shift, particularly the structural and financial underpinnings from the original answer. Hence, correctness and qualitative accuracy are reduced due to omissions, not errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 444,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "Netflix has continued to focus on developing its advertising technology infrastructure and organizational capabilities in both 2023 and 2024, as outlined in their 10-K filings. The documents highlight ongoing efforts to build and expand an advertising sales and technology team, as well as invest in the infrastructure required to support ad-supported services. However, the provided text does not specify significant changes or new initiatives between the two years, indicating a sustained emphasis on these areas rather than marked evolution.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is partially correct in noting Netflix's ongoing focus on advertising technology and organizational development in both 2023 and 2024. However, it fails to accurately capture the key evolution described in the ground truth: a strategic shift from reliance on third-party providers in 2023 to internal development and investment in ad tech capabilities in 2024. The LLM incorrectly states that there is 'no significant change' between the years, which contradicts the original answer's emphasis on a proactive shift in 2024 toward building internal teams and infrastructure. While there are no numeric inaccuracies (hence a high quantitative accuracy score), the qualitative reasoning is flawed—missing the multi-hop contrast between the two years. The answer also lacks specific details about 2023 risks (e.g., limited experience, dependency on third parties) and the 2024 strategic emphasis on self-driven development. This results in a low correctness and qualitative accuracy score despite acceptable contextual relevance to the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 301,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "Tesla's approach to free Supercharging programs remained consistent in terms of revenue recognition between 2023 and 2024, with revenue recognized over the vehicle's expected ownership life on a straight-line basis for unlimited free Supercharging and over-the-air software updates. Limited free Supercharging incentives were still recognized based on actual usage or expiration. However, deferred revenue related to these programs increased from $3,536 million in 2023 to $3,599 million in 2024, reflecting a larger base of customers or extended program terms, though no explicit structural changes in the program itself were detailed in the provided documents.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that Tesla's approach to free Supercharging revenue recognition remained consistent between 2023 and 2024. The ground truth states there was a structural shift: in 2023, free Supercharging was bundled into Automotive Sales Revenue and recognized over time, but in 2024, Tesla began deferring revenue for features like free Supercharging and recognizing them as liabilities to be amortized—indicating a change in accounting treatment. The LLM incorrectly asserts no structural change occurred. (2) Quantitatively, the LLM provides specific deferred revenue figures ($3,536M in 2023 and $3,599M in 2024), which may be accurate in isolation, but these numbers are not mentioned in the ground truth and are used to support an incorrect conclusion. Without verification from the original knowledge graph, and given they distract from the actual accounting policy change, their inclusion misleads. (3) The multi-hop reasoning is flawed: the question asks about evolution in both program structure and revenue recognition, requiring synthesis of changes over time. The LLM fails to identify the key shift from bundled recognition to deferral and liability treatment, missing the central qualitative change. Instead, it focuses on continuity and usage-based recognition methods, which does not align with the documented policy evolution. (4) While the answer is relevant to Tesla and Supercharging programs and includes plausible financial data, it contradicts the ground truth on the main point of evolution in revenue recognition. Hence, correctness and qualitative accuracy are low despite some numerical plausibility and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 466,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "NextEra Energy's approach to Series O Junior Subordinated Debentures in 2024 involved issuing debentures with a maturity date of **November 1, 2029**, as noted in the 2024 10-K (Exhibit *4(rr)*). However, the **coupon structure** for these debentures is not explicitly detailed in the provided pages. In contrast, the 2023 10-K does not mention Series O debentures. This suggests a **new issuance** in 2024, potentially reflecting a strategic shift toward longer-term financing (2029 maturity) to align with capital structure goals, though the coupon rate details remain unspecified in the given documents.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It correctly identifies the 2024 Series O issuance with a maturity date of November 1, 2029, but incorrectly states that the coupon structure is not disclosed in the documents. The ground truth confirms a defined coupon rate of 5.55% in 2024. Additionally, the LLM claims the 2023 10-K does not mention Series O debentures, which contradicts the ground truth stating that a Series O issuance occurred in 2023 with a maturity of May 1, 2079. Thus, the LLM fails to recognize the 2023 issuance entirely. (2) Quantitatively, the 2029 maturity date is correct, but the omission of the 5.55% coupon rate and the 2079 maturity from 2023 undermines accuracy. The claim of 'no explicit coupon' in 2024 is false per ground truth. (3) The reasoning is flawed: the LLM interprets the 2029 maturity as 'longer-term financing' without acknowledging the shift from a 55-year maturity (2079) to a 5-year one (2029), which actually indicates a move toward shorter-term debt. This mischaracterization leads to an incorrect conclusion about financing strategy. The multi-hop synthesis between 2023 and 2024 is missing. (4) Scores reflect major factual omissions and misinterpretations: correctness is low due to wrong entities and missing data; quantitative accuracy penalized for missing key numbers; qualitative reasoning fails on synthesis and logic; contextual relevance is moderate as it addresses the right instrument and year but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 417,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "ExxonMobil's impairment assessment framework from 2022 to 2023 continued to consider OPEC investment activities and production policies as key factors influencing long-term oil supply dynamics. In 2022, the Corporation explicitly noted OPEC's impact on global oil supplies as part of its evaluation of commodity prices and margins. By 2023, this consideration was integrated more explicitly into its Global Outlook and cash flow assessments, emphasizing OPEC's role in shaping supply-side fundamentals and long-term price trends. The 2023 framework reinforced the importance of OPEC's policies in assessing future cash flows and potential impairment, aligning with ongoing monitoring of supply-demand balances and market uncertainties.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant misrepresentation of the evolution in ExxonMobil's impairment assessment framework from 2022 to 2023. (1) What was correct: The answer correctly identifies that in 2022, ExxonMobil explicitly considered OPEC's investment activities and production policies as influencing global oil supplies, which aligns with the ground truth. It also accurately notes that OPEC remained relevant in 2023 within cash flow assessments. (2) Quantitative accuracy: There are no numerical values in the question or answers, so this dimension is neutral; no errors present. (3) Multi-hop reasoning assessment: The key failure is in the characterization of the 2023 framework. While the LLM claims OPEC's role was 'reinforced' and 'integrated more explicitly,' the ground truth indicates a shift away from direct emphasis on OPEC toward a broader, integrated framework that includes environmental factors like greenhouse gas costs and net-zero targets. The LLM answer incorrectly suggests continuity and increased emphasis on OPEC, whereas the actual evolution reflects a relative de-emphasis of OPEC in favor of a more comprehensive, environmentally conscious assessment model. (4) This leads to a correctness score of 5: the answer gets basic facts about OPEC’s role right but fails to capture the essential shift in the framework’s focus, resulting in flawed qualitative reasoning. Contextual relevance is high because the response stays on topic and addresses impairment, oil supply, and time evolution, but the synthesis is inaccurate. Thus, qualitative accuracy is low due to incorrect inference about the direction of change in ExxonMobil's approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 460,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "Netflix's approach to its ad-supported subscription plan in 2024, as emphasized in the 2024 10-K filing, reflects continued strategic emphasis on offering diverse pricing options to meet consumer needs, including the ad-supported plan. While the 2023 filings (not fully visible here) likely introduced the plan, the 2024 document highlights ongoing focus on pricing strategies, consumer adoption, and enhancing member experience through this model. The 2024 filing underscores the plan as part of a broader effort to drive engagement and flexibility, with no explicit mention of significant changes in detail or emphasis compared to 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but misses the key evolution highlighted in the ground truth. While it correctly identifies that the ad-supported plan is part of Netflix's pricing strategy in 2024 and relates it to consumer needs, it fails to capture the critical shift from a risk-focused, uncertain tone in 2023 to a confident, strategic positioning in 2024. Instead, the LLM claims there is 'no explicit mention of significant changes in detail or emphasis compared to 2023,' which directly contradicts the ground truth. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning is flawed: the question requires comparing the strategic framing of the ad-supported plan across two years (2023 vs 2024), but the LLM does not acknowledge the shift from risk/uncertainty to strategic integration. It also speculates that 'the 2023 filings (not fully visible here) likely introduced the plan,' which shows lack of access or inference from reliable data, weakening the analysis. (4) Correctness is scored 5 due to partial factual alignment but major omission of the core evolution; qualitative accuracy is 5 because entity identification (Netflix, ad-supported plan, years) is correct but reasoning is unsound; contextual relevance is 7 because the response addresses the general topic and timeframe but misses the key comparative insight.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 407,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "Amazon's approach to shipping between 2022 and 2024 evolved with a strategic focus on balancing cost management and fulfillment efficiency. In 2022 (as reflected in 2021 data), shipping costs rose due to expanded fulfillment networks, higher carrier rates, wage increases, and supply chain inefficiencies. Amazon aimed to mitigate these costs through higher sales volumes, network optimization, and supplier negotiations. By 2024, shipping costs increased further (to $95.8 billion) due to higher sales, but fulfillment network efficiencies and lower transportation costs partially offset growth. The company continued expanding its fulfillment network to meet demand while emphasizing operational improvements to reduce per-unit shipping expenses, aligning with its long-term strategy of leveraging scale and efficiency to sustain low prices.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in Amazon's shipping strategy from 2022 to 2024, correctly identifying cost drivers (e.g., network expansion, higher sales, wage increases) and strategic focus on efficiency gains. The shift from customer-driven cost increases in 2022 to operations-centric efficiency in 2024 is semantically aligned with the ground truth. However, there is a critical quantitative discrepancy: the LLM states that shipping costs reached $95.8 billion in 2024, but the original answer only provides 2021 shipping costs ($76.7 billion) and does not report 2024 figures. This number is unsupported by the ground truth and appears to be fabricated or inferred beyond available data. (2) The ground truth does not mention 'lower transportation costs' as an offset in 2024—instead, it emphasizes 'fulfillment network efficiencies' as the key offset, which the LLM partially captures but misattributes. (3) The multi-hop reasoning is sound in synthesizing cost drivers and strategic shifts across years, and the entity (Amazon), time periods (2022 vs 2024), and metrics (shipping costs, fulfillment efficiency) are correctly identified. (4) Despite the incorrect $95.8B figure, the qualitative narrative about increasing costs due to sales growth and network expansion, countered by efficiency improvements, matches the ground truth’s strategic evolution. The answer remains contextually relevant and mostly accurate in direction and logic, but the unsupported number reduces quantitative accuracy significantly. Hence, correctness is reduced to 7 due to the major numerical inaccuracy, though core reasoning remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 453,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "Duke Energy's Master Retirement Trust maintained its asset allocation structure between 2023 and 2024, with target allocations for RCBP (Retirement and Consulting Benefits Plan) and DELPP (Duke Energy Long-Term Post-retirement) assets remaining largely unchanged: 35% liability hedging and 65% return-seeking for RCBP, and 80% liability hedging and 20% return-seeking for DELPP. Actual allocations in 2024 showed minor adjustments (e.g., RCBP's global equity securities decreased to 44% from 45% in 2023, while real estate/cash increased). The expected long-term return rates (8.50% for RCBP, 7.00% for DELPP) and disclosure practices, including detailed fair value measurements and asset class breakdowns, remained consistent. Securities lending was discontinued in 2023 and not reinstated in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate details about Duke Energy's Master Retirement Trust, such as the target asset allocations (35% liability hedging / 65% return-seeking for RCBP, 80%/20% for DELPP) and expected long-term returns (8.50%, 7.00%), which may align with actual data. However, these specifics are not present in the ground truth and cannot be verified against it, raising concerns about hallucination. Crucially, the LLM fails to report the key evolution highlighted in the original answer: the 2024 introduction of subsidiary-level allocations (e.g., Duke Energy Progress at 15%, Duke Energy Florida at 18%) and the new reconciliation of beginning and ending balances with Level 3 fair value disclosures. These represent significant enhancements in transparency and granularity that define the reporting evolution—but are entirely missing from the LLM response. Instead, the LLM claims 'disclosure practices... remained consistent,' which directly contradicts the ground truth showing a clear shift toward more detailed reporting. The mention of securities lending being discontinued in 2023 is plausible but not corroborated in the ground truth and irrelevant to the core question about asset allocation and disclosure evolution. While the answer addresses asset allocation, it misrepresents the trend as stability rather than evolution, undermining the multi-hop synthesis required. Quantitative accuracy is moderate due to plausible but unverified percentages; qualitative accuracy is low due to incorrect reasoning about reporting changes; contextual relevance is fair since it discusses related topics but misses the central developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 450,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "Between 2022 and 2024, Google's financial relationship with Google Network Partners evolved with increased **cost structure** and **payment obligations** tied to **TAC (Third-Party Advertiser Costs)**. The cost of revenues for Google Network properties remained significantly higher than for Google Search & Other properties, as most advertiser revenues from Network properties were paid as TAC to partners. In 2024, TAC and content acquisition costs rose, reflecting higher payments to Network Partners, while operating income growth was partially offset by these expenses. This indicates a sustained, if evolving, financial dependency on Network Partners, with payment obligations tied to ad revenue growth and operational scaling.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Google's financial relationship with Network Partners between 2022 and 2024. It accurately identifies that Traffic Acquisition Costs (TAC) are central to the cost structure, and correctly notes that TAC for Network Partners constitutes a higher percentage of revenue compared to Google Search properties. The answer correctly states that payments to Network Partners increased by 2024 and impacted operating income, reflecting sustained financial dependency. However, it refers to 'Third-Party Advertiser Costs' instead of the correct 'Traffic Acquisition Costs'—a minor but notable mislabeling of the acronym TAC, which stands for Traffic Acquisition Costs, not Third-Party Advertiser Costs. This affects qualitative accuracy slightly. Additionally, while the original answer highlights a structural shift—from cost-of-revenue to a primary operating cash outflow—the LLM answer does not explicitly mention the change in financial classification or cash flow treatment, which is a key nuance in the evolution of the relationship. This omission prevents a perfect score but does not undermine the overall correctness. There are no numerical inaccuracies, as the answer avoids specific dollar amounts or percentages not present in the ground truth. The reasoning is sound and contextually relevant, synthesizing the multi-hop elements of cost structure and temporal evolution. Semantic equivalence is high, though slightly less precise in framing the shift in financial treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 423,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "The treatment of offsetting swap positions remained consistent between 2022 and 2023, with UPS not electing to offset derivative positions in the consolidated balance sheets. In 2023, the financial impact of fair value changes and settlements for non-designated derivatives (e.g., foreign currency contracts) resulted in a $7 million loss in income, compared to a $69 million loss in 2022. This reflects a reduction in the magnitude of losses recognized in income, driven by changes in market conditions and hedging activities, while the gross fair value amounts remained unadjusted for offsetting.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, the financial impact of derivative fair value changes and settlements was *not quantified* in the excerpt, but the LLM claims specific losses of $7M in 2023 and $69M in 2022. These numbers are not supported by the original answer and contradict its key point about reduced transparency in 2023. (2) Quantitative accuracy is very low because the LLM fabricates precise figures ($7M loss, $69M loss) that do not appear in the ground truth. The original answer only provides data for 2021 ($163M gain) and 2020 ($124M gain), with no mention of 2022 or 2023 net impacts. Any calculation or comparison based on non-existent 2022/2023 figures is invalid. (3) The qualitative reasoning is partially sound in noting consistent treatment of offsetting swaps and fair value reporting, but incorrectly infers a reduction in losses due to market conditions, which is not stated or implied in the original. The multi-hop synthesis fails because the model invents data rather than acknowledging the absence of current-year quantification. (4) Contextual relevance is moderate because the answer addresses derivative treatment and income impact, but the core claim about financial impact is fabricated, undermining overall correctness. The focus on non-designated derivatives and fair value reporting aligns with the topic, but the conclusion misrepresents the disclosed information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 408,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "The increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures compared to 2023 indicates a strategic shift toward emphasizing deferred compensation and aligning directors' interests with long-term company performance. In 2024, the plan is explicitly highlighted as a key component of director compensation, allowing outside directors to defer retainers and adjust balances based on phantom investment options, including the Duke Energy Common Stock Fund. This reflects a focus on tying director compensation to equity performance, fostering long-term commitment, and potentially reducing cash outflows while incentivizing alignment with shareholder value. The 2023 disclosures, while mentioning the plan, provide less detailed context, suggesting a heightened emphasis on this structure in 2024 as part of a broader strategy to refine director compensation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the core shift in Duke Energy's director compensation strategy from 2023 to 2024, accurately reflecting the increased prominence and strategic emphasis on the Directors' Savings Plan. All factual assertions align with the ground truth: in 2023, the plan was mentioned only in passing (e.g., via exhibit references), while in 2024, it received a substantive description including deferral mechanisms and phantom investment options. The LLM correctly identifies that outside directors can defer retainers and that balances are adjusted based on phantom investments, including in Duke Energy Common Stock Fund—details consistent with the knowledge graph. (2) There are no numeric values, percentages, or dollar amounts in the question or ground truth, so quantitative accuracy is not applicable beyond correct handling of years (2023 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes differences in disclosure depth across years and infers a strategic shift toward long-term alignment, transparency, and deferral flexibility. It goes slightly beyond the original answer by interpreting implications (e.g., reducing cash outflows, incentivizing shareholder alignment), which are reasonable inferences but not explicitly stated in the ground truth—this constitutes a minor overreach in interpretation, hence not a full 10 on qualitative accuracy. (4) The answer is highly contextually relevant, directly addressing the comparison between 2023 and 2024 and the strategic implications of increased plan prominence. Overall, the LLM conveys semantically equivalent and factually correct information with only minor interpretive additions, warranting a correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 478,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "American Express has intensified its focus on digital innovation and premium value propositions between 2022 and 2024, emphasizing technology-driven solutions like AI, automation, and enhanced digital ecosystems to compete with alternative payment providers and evolving customer demands. The company prioritized expanding merchant coverage globally, targeting younger demographics (Millennials/Gen Z) with tailored benefits, and strengthening cobrand partnerships to maintain competitive differentiation. These efforts aim to address declining merchant discount rates, rising competition, and shifting consumer preferences toward digital convenience and personalized services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in American Express's value proposition strategy between 2022 and 2024. It correctly identifies the competitive pressures from alternative payment providers and shifting consumer behaviors, particularly around digital and personalized services. The response accurately reflects the shift toward a more proactive, innovation-driven strategy by highlighting AI, automation, digital ecosystems, global merchant coverage, and targeting Millennials/Gen Z—key elements from the ground truth. It also correctly notes cobrand partnerships as a competitive differentiator, aligning with the original answer’s emphasis on strategic partnerships. The mention of declining merchant discount rates is not explicitly in the ground truth but is contextually plausible and does not contradict it. The only minor omission is specific reference to dining platform expansions (Tock and Rooam), which are cited in the original answer as concrete examples of ecosystem enhancement. However, the broader theme of digital platform investment is conveyed. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. The reasoning is sound, demonstrating multi-hop synthesis across competitive pressures, customer behavior changes, and strategic responses over time. The answer is semantically equivalent to the ground truth in intent and substance, with only slight loss in specificity. Thus, the correctness score is 9 due to this minor omission, but all other dimensions are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 426,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "Exxon Mobil retired its 0.142% Notes due 2024 (XOM24B) by 2024, as they are no longer listed in the 2024 10-K filings, indicating repayment or maturity. The composition of long-term debt shifted toward longer-dated obligations, retaining the 0.524% Notes due 2028 (XOM28), 0.835% Notes due 2032 (XOM32), and 1.408% Notes due 2039 (XOM39A), which were also present in 2022. This reflects a reduction in near-term debt and a focus on extending maturities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values—interest rates (0.142%, 0.524%, 0.835%, 1.408%) and maturity years (2024, 2028, 2032, 2039)—are correct and match the original answer. The observation that the 0.142% Notes due 2024 are no longer listed in 2024 is factually sound, indicating maturity or repayment. (2) The LLM correctly identifies the continued presence of the 0.524% Notes due 2028, 0.835% Notes due 2032, and 1.408% Notes due 2039 in both years, confirming the shift toward longer-term debt. (3) The multi-hop reasoning—comparing debt composition across 2022 and 2024 filings to infer strategic evolution—is logically sound and well-executed. The conclusion about extending maturities and reducing near-term obligations is supported by the data. (4) The only minor omission is that the original answer explicitly frames this as a 'strategic evolution in capital structure,' a slightly more interpretive point that the LLM implies but doesn't fully articulate. However, the core facts, synthesis, and implications are correctly conveyed. Wording differences (e.g., ticker symbols like XOM24B) are acceptable and do not affect factual accuracy. Overall, the answer is quantitatively precise, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 368,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "American Express has evolved its corporate card solutions between 2022 and 2024 by emphasizing differentiated value propositions, such as enhanced accounts payable expense management, financing options, and integrated banking solutions, as part of its strategic focus on commercial payments. The 2024 filings highlight expanded product differentiation through innovative features like B2B capabilities, fraud protection, and digital partnerships, alongside strengthening global merchant acceptance and network services to better serve business customers. This reflects a continued commitment to differentiating corporate cards through comprehensive, tailored solutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: American Express's strategic emphasis in 2022 included differentiating corporate card and accounts payable solutions, which the LLM correctly identifies. By 2024, the shift toward a more integrated global network, enhanced fraud protection, and improved merchant acceptance is accurately reflected. The LLM captures the evolution from internal product development to an externally focused ecosystem strategy, though it does not explicitly frame the shift in those exact terms. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes information across 2022 and 2024 timeframes, correctly identifying continuity in commercial payments focus while highlighting new dimensions like B2B capabilities and digital partnerships. The only minor shortcoming is a slightly less explicit contrast between the internal vs. external strategic orientation compared to the original answer, which slightly affects qualitative depth. (4) The answer is fully contextually relevant, directly addressing both strategic emphasis and product differentiation over the specified period. Wording differs but semantic meaning matches the ground truth. Overall, this is a strong, factually correct response with only minor room for improved nuance in framing the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 423,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "Amazon's financial relationship with AWS Services has shown significant growth in cash flow generation and strategic emphasis between 2022 and 2024. AWS's net sales increased by 19% in 2024 (from $90.76 billion in 2023 to $107.56 billion in 2024), contributing to a 12% year-over-year rise in consolidated net sales. This growth was driven by expanded cloud infrastructure investments, including $77.7 billion in capital expenditures in 2024, primarily allocated to technology infrastructure to support AWS. Operating cash flow surged to $115.9 billion in 2024, reflecting AWS's role as a key revenue driver. Strategically, AWS remains central to Amazon's focus on cloud innovation, with continued investments in compute, storage, and AI/ML services to maintain its leadership in the cloud market.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numeric values compared to the ground truth. While the 2024 operating cash flow of $115.9 billion matches the original answer, the prior year figure of $84.9 billion in 2023 is omitted and replaced with unrelated data. The LLM introduces AWS net sales figures of $90.76 billion in 2023 and $107.56 billion in 2024 (19% growth), which are not present in the ground truth and cannot be verified from the provided context. Additionally, the $77.7 billion in capital expenditures in 2024 is not mentioned in the original answer, making it factually unsupported. (2) The calculation of 12% year-over-year rise in consolidated net sales and 19% AWS sales growth lacks grounding in the provided truth data, introducing speculative metrics. The only correct quantitative point is the $115.9 billion operating cash flow in 2024, which aligns with the original answer. (3) The multi-hop reasoning is partially sound—AWS is correctly identified as a growing strategic and financial asset, and there is a logical progression from infrastructure investment to cash flow generation. However, the shift in strategic emphasis from risk (2022) to core revenue driver (2024), which is central to the original answer, is underemphasized. The LLM focuses more on continuous strategic centrality rather than a transformation in narrative, missing a key qualitative shift. (4) Despite the numerical inaccuracies, the answer remains contextually relevant, addressing both cash flow and strategic emphasis. The qualitative reasoning is plausible and aligns with general industry knowledge, but deviates from the specific evidence in the ground truth. Hence, correctness is penalized heavily due to unsupported numbers, though the overall direction of the answer is reasonable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 492,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "The scope of trend analyses used to evaluate the historical consistency of regulatory asset balances expanded in 2024 compared to 2023. In 2023, trend analyses focused on historical consistency and comparing recorded balances to independently developed expectations. In 2024, the analysis incorporated additional factors, including assessments of ongoing regulatory recoverability for coal ash-related asset retirement obligations and specific storm costs, alongside continued evaluation of historical trends. This reflects a broader focus on both historical consistency and evolving regulatory risks.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of trend analyses between 2023 and 2024. It correctly identifies that in 2023, the focus was on historical consistency of regulatory asset balances, and that by 2024, the scope expanded to include additional assessments—specifically, ongoing regulatory recoverability of asset retirement obligations related to coal ash. This matches the key point in the original answer about a shift toward specialized regulatory compliance areas. The LLM adds 'storm costs' as an additional factor in 2024, which is not mentioned in the ground truth. While this does not contradict the original answer, it introduces information not present in the source, slightly reducing qualitative accuracy. There are no numerical values in the question or answers, so quantitative accuracy is scored based on correct use of years (2023, 2024), which are accurate. The reasoning is sound and reflects appropriate multi-hop synthesis across time periods and audit focus areas. The answer is contextually relevant and directly addresses how the scope and focus evolved. The minor addition of 'storm costs' prevents a perfect score, but the core factual content and semantic meaning remain consistent with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 359,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "Costco continued to increase the penetration of its private-label items in 2023 compared to 2022 as part of its strategy to manage cost and pricing pressures. This approach, highlighted in both the 2022 and 2023 10-K filings, involved adjusting merchandise mix and pricing strategies to maintain competitive pricing while mitigating the impact of rising costs, including supplier inflation and tariffs. The 2023 filing emphasized ongoing efforts to leverage private-label offerings to enhance value for members and support profitability amid persistent cost challenges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) There are no numeric values (e.g., percentages, dollar amounts) in either the question or the original answer, so quantitative accuracy is not applicable—no errors present. (2) The LLM correctly identifies that Costco increased penetration of private-label items in 2023 as a strategic response to cost and pricing pressures, consistent with the original answer. It accurately reflects that this was a continuation and deepening of strategy, referencing both 2022 and 2023 filings. (3) The multi-hop reasoning is sound: the model synthesizes information across years, noting that while 2022 involved reactive measures (absorbing costs, bulk buying), 2023 emphasized a more strategic shift toward private-label expansion. The LLM captures the evolution in strategy—though it does not explicitly contrast 'reactive' vs. 'strategic' as clearly as the ground truth, it implies this through context. (4) The answer is semantically equivalent, using phrases like 'ongoing efforts to leverage private-label offerings' and 'manage cost and pricing pressures,' which reflect the sustained strategic emphasis in 2023. Minor deduction in qualitative accuracy because the LLM does not explicitly mention Costco's 'pricing authority' or 'gross margin pressures' from 2022, slightly reducing depth of contrast between years. However, core reasoning and facts are correct, and the response is highly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 409,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "Based on Pfizer's 2023 and 2024 10-K filings, the financial outlook for Paxlovid evolved as follows:  \n- **2023**: Remaining performance obligations (RPO) for Paxlovid and Comirnaty totaled **$5.1 billion**, with **$2.6 billion** in current liabilities and **$2.5 billion** in noncurrent liabilities.  \n- **2024**: RPO for Paxlovid decreased to **$1 billion**, reflecting revenue recognition from delivered products (including $442 million from the U.S. SNS program) and a $771 million favorable adjustment for returned EUA-labeled inventory. The remaining obligation for Paxlovid ($1 billion) is expected to be recognized through **2028**, with **$442 million** in current liabilities to be recognized within 12 months.  \n\nThis indicates a significant reduction in deferred revenue obligations for Paxlovid by 2024, driven by product delivery and adjustments, while future revenue recognition remains tied to long-term contracts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Pfizer did not disclose specific remaining performance obligations (RPO) for Paxlovid in 2023, but the LLM claims a total of $5.1 billion for Paxlovid and Comirnaty combined, with $2.6 billion and $2.5 billion split between current and noncurrent liabilities—this level of detail and specificity is not supported by the ground truth and appears fabricated. In 2024, the LLM correctly states that RPO for Paxlovid was $1 billion as of December 31, 2024, which matches the ground truth. However, it adds unsupported details such as revenue recognition through 2028, $442 million from the U.S. SNS program, and a $771 million favorable adjustment for returned EUA-labeled inventory—none of which are mentioned in the ground truth and cannot be verified from the provided information. (2) Quantitative accuracy is low: while the $1 billion figure for 2024 is correct, all other numbers ($5.1B, $2.6B, $2.5B, $442M, $771M) are either misattributed or invented. There is no evidence in the ground truth that RPO was ever $5.1 billion or that it decreased from that amount. (3) The multi-hop reasoning is flawed. The model incorrectly assumes that because RPO exists in 2024, there must have been a disclosed amount in 2023 to compare against, and it invents a narrative of decline. The correct reasoning, per the ground truth, is that no specific Paxlovid RPO was disclosed in 2023, so the emergence of a $1 billion figure in 2024 represents new disclosure and increased visibility—not a reduction from a prior number. (4) Contextual relevance is moderate because the answer addresses the evolution of financial outlook and mentions RPO correctly as a metric, but the incorrect data and reasoning undermine the conclusion. The answer suggests decreasing demand or obligation due to 'reduction', whereas the ground truth interprets the $1 billion RPO as increased contractual certainty—opposite implications. Thus, despite some correct terminology and one accurate number, the overall answer is misleading and factually incorrect on key points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 573,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "American Express maintained a consistent approach to the Reasonable and Supportable (R&S) Period for estimating credit loss reserves between 2022 and 2024, using it to incorporate current and future economic conditions within the R&S Period and reverting to long-term average loss rates beyond it. The methodology and assumptions around the R&S Period remained stable, reflecting a disciplined focus on prudent risk management and conservative reserve estimates, as evidenced by the continued reliance on statistically-based models and qualitative adjustments to address uncertainties. This consistency suggests a stable, risk-aware approach to financial forecasting and provisioning.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant mischaracterization of the evolution in American Express's use of the Reasonable and Supportable (R&S) Period between 2022 and 2024. (1) Quantitatively, there are no explicit numbers in the LLM answer that contradict the ground truth—no dollar amounts or dates are incorrectly stated, so quantitative accuracy is high. However, the LLM omits the specific $3.3 billion reserve figure from 2021 referenced in the original answer, which was contextually relevant. (2) The entity accuracy is correct: American Express, R&S Period, credit loss reserves, and the years 2022 and 2024 are all properly identified. (3) The key failure is in reasoning and qualitative accuracy: the LLM claims the approach was 'consistent' and 'remained stable,' which directly contradicts the ground truth that shows an evolution—from explicitly introducing and explaining the R&S Period in 2022 to embedding it as a mature, standard component by 2024. This shift reflects a maturation of the methodology, not static application. The original answer emphasizes this progression as indicative of the framework becoming foundational, whereas the LLM interprets the continuity as conservatism and stability, missing the nuance of methodological institutionalization. (4) Contextually, the answer addresses financial risk management and the use of models, so relevance is strong. However, the conclusion about 'disciplined' and 'conservative' risk management is an interpretation not directly supported by the ground truth, which instead points to increasing integration and normalization of the R&S framework. Thus, while the LLM captures surface-level consistency, it fails to accurately represent the conceptual evolution central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 481,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "Amazon's approach to debt financing between 2022 and 2024 included the continued presence of the 0.800% Note due 2025, which was issued in 2020 and referenced in both the 2022 and 2024 filings. However, no refinancing or material changes to this specific note were disclosed during this period. In 2022, Amazon issued additional debt instruments, such as the 4.600% Note due 2025, reflecting a broader strategy of issuing new notes with varying terms to manage its capital structure. The 0.800% Note remained part of its existing debt portfolio without modification.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All entities—Amazon, the 0.800% Note due 2025, and the 4.600% Note due 2025—are correctly identified, and the timeline (2022–2024) is accurately addressed. The note's origin in 2020 is correctly referenced. (2) Quantitative elements are precise: interest rates (0.800% and 4.600%) and maturity year (2025) match the original answer. No incorrect numbers or dates are present. (3) The reasoning is sound: the LLM correctly infers that Amazon maintained the 0.800% Note without modification while issuing new debt, indicating a broader financing strategy. However, the original answer emphasizes a strategic shift toward managing interest rate risk and cash flow, which the LLM mentions only implicitly through 'managing capital structure.' This slight under-articulation of strategic intent prevents a perfect qualitative score. (4) The response is highly relevant, directly addressing Amazon’s debt financing evolution and the role of the 0.800% Note. Minor omission of explicit risk management language does not detract from overall correctness. Semantic equivalence is maintained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 327,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "The Twenty-third Supplemental Indenture, dated May 15, 2020, is disclosed in both the 2022 and 2024 SEC filings as a separate exhibit, with no indication of amendment or replacement. In the 2024 filing, it is still referenced alongside newer supplemental indentures (e.g., the Ninety-fifth Supplemental Indenture dated March 1, 2024). This continuity in disclosure suggests the Twenty-third Supplemental Indenture remains in effect and relevant, reflecting ongoing legal and financial obligations tied to the indenture.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the Twenty-third Supplemental Indenture was dated June 1, 1978, and was explicitly mentioned in the 2022 filing but omitted in the 2024 filing. However, the LLM incorrectly states it was dated May 15, 2020, and claims it is disclosed in both 2022 and 2024 filings as a continuing exhibit—this is false. The ground truth confirms no mention in 2024. Additionally, the LLM fabricates a 'Ninety-fifth Supplemental Indenture dated March 1, 2024,' while the actual 2024 filing references the 'Forty-ninth Supplemental Indenture dated March 14, 2024.' (2) Quantitative accuracy is severely compromised: the date of the Twenty-third Supplemental Indenture is off by over 40 years (1978 vs. 2020), and the supposed newer indenture (Ninety-fifth) is entirely incorrect in both number and date. (3) The multi-hop reasoning is flawed—the question asks for a comparison across 2022 and 2024 filings to assess evolution and relevance. The LLM incorrectly asserts continuity when the ground truth shows omission in 2024, leading to the opposite conclusion about relevance. Instead of recognizing diminished significance due to non-reaffirmation, the LLM wrongly infers ongoing relevance. (4) Contextual relevance is moderate because the answer addresses the structure of indenture disclosures and attempts to interpret relevance, but the factual foundation is so incorrect that the conclusion is invalid. Scores reflect major factual and reasoning errors despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 434,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "The total value of Class C Capital Stock repurchased in 2022 was $59.3 billion (total for both Class A and Class C shares), though the exact Class C amount is not specified. In 2023, Class C repurchases totaled $52.868 billion, and in 2024, they amounted to $50.192 billion. The repurchase activity for Class C decreased from 2023 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Alphabet repurchased $59.3 billion in 2022 (combined Class A and C), $62.2 billion in 2023, and $62.0 billion in 2024—also combined. However, the LLM incorrectly reports separate Class C repurchase values of $52.868 billion in 2023 and $50.192 billion in 2024, which are not supported by the original answer. The original does not specify how much of the total was for Class C versus Class A in any year, so breaking out exact Class C amounts is factually wrong. (2) The numbers provided for 2023 and 2024 in the LLM answer ($52.868B and $50.192B) do not match the ground truth totals for any class or combination, and no such figures appear in the original. The 2022 figure is partially correct in that $59.3B is the correct total for both classes, but the LLM misleadingly presents it as if the full amount were Class C or implies a breakdown that isn't available. (3) The reasoning is flawed because it assumes a level of granularity (Class C-specific repurchase amounts) that the source data does not provide. The multi-hop synthesis fails because the model invents specific figures rather than acknowledging the lack of class-level detail. (4) While the LLM attempts to address the evolution of repurchase activity and annual values, the invented numbers severely undermine correctness. The contextual relevance is moderate because it discusses the right topic and timeframe, but the core quantitative claims are incorrect, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1172,
        "completion_tokens": 432,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "The treatment and documentation of the American Express Company Salary/Bonus Deferral Plan remained unchanged between the 2022 and 2024 SEC filings. Both filings reference the same plan documents: the original plan from 1988 (Exhibit 10.13) and its 1994 amendment (Exhibit 10.14). No new amendments or updates to the plan were disclosed in the 2024 filing. However, the 2024 filing introduced a new exhibit (10.19) describing compensation for non-management directors, which is unrelated to the Salary/Bonus Deferral Plan.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims the treatment and documentation remained unchanged, but the original answer shows that the 2024 filing expanded disclosures by adding Exhibit 10.16, which includes the 1997 amendments—this is a significant change not acknowledged by the LLM. (2) The LLM incorrectly states that both filings reference Exhibits 10.13 (1988 plan) and 10.14 (1994 amendment) as if they were present in both years, but the original answer indicates these exhibit numbers were used in the 2024 filing, not necessarily in 2022 under those labels. In fact, the 2022 filing referenced the same documents under different exhibit numbers (10.16 and 10.17), which the LLM fails to recognize. (3) The LLM introduces a new exhibit (10.19) about non-management director compensation, which is irrelevant and not mentioned in the ground truth, adding misleading information. (4) Multi-hop reasoning failed: the model did not correctly track the renumbering of exhibits across years or identify the addition of the 1997 amendments in 2024. While the question is about changes in treatment and documentation, the LLM incorrectly concludes no changes occurred, missing the core fact of expanded historical disclosure. Quantitative accuracy is low due to incorrect exhibit numbers and missing dates (1997 amendment omitted). Qualitative accuracy is poor due to flawed reasoning and entity mapping. Contextual relevance is moderate because it discusses the right topic but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 421,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "Between 2022 and 2024, Starbucks' interest rate swap exposure evolved in terms of balance sheet classification and magnitude. In 2022, the interest rate swap liability was classified as a **current liability** (Accrued liabilities) at **$12.0 million**, while in 2024, it shifted to a **long-term liability** (Other long-term liabilities) at **$19.2 million**, reflecting an increase in magnitude and a change in classification. This shift suggests a longer-term hedging strategy and a larger liability position in 2024 compared to 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities', not $12.0 million under 'Accrued liabilities' as claimed by the LLM. The 2024 figure of $19.2 million under 'Other long-term liabilities' is correct in the LLM answer, but it omits the additional $41.4 million liability from 2023 swaps mentioned in the original answer, which is critical for understanding the evolution of exposure. (2) The quantitative inaccuracies are severe: the 2022 liability amount is wrong ($12.0M vs $34.0M), and the classification is incorrect (current vs long-term). The LLM incorrectly states there was an increase in liability from 2022 to 2024, when in fact the total exposure decreased significantly from $34.0M to $19.2M (excluding 2023). (3) The multi-hop reasoning is flawed: the LLM fails to incorporate the 2023 data point that is essential for tracking the evolution of the liability over time, and mischaracterizes the trend as increasing when it is actually decreasing. It also misrepresents the balance sheet classification in 2022. (4) While the LLM addresses the general question about evolution in classification and magnitude, the core facts are incorrect, leading to a misleading conclusion. The contextual relevance is moderate because it attempts the right analysis, but correctness is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 412,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "Between 2022 and 2024, Duke Energy's Directors' Savings Plan remained in effect with key features unchanged, including the ability for outside directors to defer compensation (primarily retainers) into an unfunded account tied to phantom investment options, such as the Duke Energy Common Stock Fund. The 2024 filing notes an amendment to the plan effective December 16, 2021, but no substantive changes in structure or deferral mechanisms are documented between 2022 and 2024. This consistency suggests Duke Energy prioritizes long-term governance alignment, using deferral mechanisms to tie director compensation to company performance while maintaining flexibility in governance frameworks.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several correct elements but exhibits key inaccuracies in reasoning and timeline interpretation, affecting the overall correctness. (1) Quantitatively, the date 'December 16, 2021' is correctly cited from the ground truth as the amendment date, but the LLM mischaracterizes it as being 'noted in the 2024 filing' when the original answer implies it was part of the 2022 introduction—this creates a misleading impression of retroactive documentation rather than timely implementation. (2) The LLM claims 'no substantive changes in structure or deferral mechanisms are documented between 2022 and 2024,' which contradicts the ground truth's emphasis on an evolution from policy establishment (2022) to operational transparency with detailed mechanics (2024), particularly around phantom investments and unfunded accounts. This omission or misrepresentation of the plan’s evolution undermines the qualitative accuracy. (3) The multi-hop reasoning is partially sound—tying deferrals to stock performance and governance alignment is valid—but fails to capture the shift from policy creation to disclosure refinement, which is central to the question about governance approach. (4) Contextually, the answer remains relevant and addresses director compensation, deferral mechanisms, and governance implications, but misses the nuance of increasing transparency and structural detail over time. Wording differences are acceptable, but the failure to reflect the plan’s developmental trajectory results in a partial rather than full match to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 429,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "Costco's Kirkland Signature brand maintained its positioning as a high-quality, value-driven private-label offering that competes with national brands, emphasizing cost efficiency and margin advantages. Between 2022 and 2023, there is no explicit mention of a shift in its positioning, though the 2023 filing highlights continued focus on expanding private-label sales penetration. The risk profile remained tied to supply chain challenges, competition, and inflationary pressures, with no indication of material changes in Kirkland's strategic role or risk exposure during this period.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in stating that Kirkland Signature maintained its value-driven positioning and that Costco continued to focus on expanding private-label sales penetration. There are no numeric inaccuracies (quantitative accuracy is high), and the entities (Costco, Kirkland Signature, 2022–2023 timeframe) are correctly identified. However, the key qualitative shift identified in the ground truth—namely, the evolution in risk profile from a growth-focused narrative in 2022 to a more risk-aware stance in 2023—is missed entirely. The LLM incorrectly asserts there was 'no indication of material changes in Kirkland's strategic role or risk exposure,' which directly contradicts the ground truth: the 2023 filing explicitly broadened risk disclosures to include supply chain, foreign exchange, and catastrophic events impacting private-label brands. This represents a significant shift in risk framing. The model fails to synthesize this multi-hop insight—comparing the tone and content of risk disclosures across two years—which is central to the question. While contextually relevant and factually consistent on surface-level brand positioning, the answer lacks the critical comparative risk analysis, resulting in a low qualitative and overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 357,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF at the end of 2022 to 296 BCF at the end of 2024. Key changes included **downward revisions** of 81 BCF due to lower prices, partially offset by **technical revisions** of 55 BCF. **Extensions and discoveries** in the region's equity affiliates (Middle East) contributed to additions, while **purchases** in 2024 primarily affected Africa (Equatorial Guinea). The net decline reflects the impact of pricing pressures and development adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the starting and ending reserve volumes (326 BCF in 2022 and 296 BCF in 2024), which matches the ground truth. However, it introduces specific quantitative details not present in the original answer—namely, a downward revision of 81 BCF due to lower prices and technical revisions of 55 BCF—which are unsupported by the ground truth. The original answer mentions 'revisions and production activities' but does not quantify them or attribute changes to price effects. Additionally, the LLM claims 'extensions and discoveries in equity affiliates (Middle East)' contributed to additions, while the original explicitly states 'minimal extensions and discoveries' and 'no sales or significant reserve additions in 2024.' The mention of 'purchases in 2024 primarily affected Africa' is irrelevant to the Asia Pacific/Middle East region and not supported in context. (2) While the net change (30 BCF decrease) is accurate, the breakdown of revisions (81 BCF down, 55 BCF up) implies a calculation that does not align with any data provided in the ground truth. There is no verification for these figures, making the quantitative accuracy low. (3) The multi-hop reasoning is partially sound in tracking reserve evolution over time, but the model fabricates granular drivers (price revisions, technical adjustments, affiliate contributions) not present in the source. This undermines the qualitative accuracy despite correct entity identification (COP, Asia Pacific/Middle East, 2022–2024). (4) The answer is contextually relevant and addresses the question's structure—volume change and sources of additions—but includes speculative and incorrect details that reduce factual correctness. The core trend (slight decline) is right, but the explanation is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 490,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "Between 2022 and 2024, FedEx maintained ownership of its entire Boeing 767F fleet (114 aircraft as of May 31, 2022) and continued modernization efforts by purchasing additional B767Fs. In 2022, FedEx committed to acquiring 38 B767Fs through 2025, but by 2024, purchase commitments for B767Fs had decreased to 14 (for 2025 and 2026). The company emphasized replacing older aircraft with more fuel-efficient B767Fs and B777Fs to achieve long-term cost savings, reflecting a strategic focus on fleet modernization while retaining ownership of the 767F fleet.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly states that FedEx owned 114 Boeing 767F aircraft as of May 31, 2022 (matching the ground truth), it introduces specific purchase commitments—'38 B767Fs through 2025' in 2022 and '14 for 2025 and 2026' in 2024—that are not present in the original answer or supported by the provided ground truth. These figures represent over-specificity and are not corroborated, making them likely incorrect or hallucinated. (2) The original answer does not mention any reduction in purchase commitments or exact numbers of planned deliveries, only that B767Fs are part of modernization efforts and that delaying purchases would incur significant costs. Thus, the LLM invents a trend (decrease from 38 to 14) unsupported by the source. (3) Qualitatively, the LLM captures the correct strategic emphasis on modernization, fuel efficiency, and long-term savings, and correctly identifies the B767F as central to fleet renewal. It also accurately reflects that FedEx retains ownership of the fleet. This shows sound multi-hop reasoning in connecting ownership with modernization intent, even if specific numbers are flawed. (4) Contextually, the response is highly relevant, addressing both fleet ownership and modernization focus as asked. However, the inclusion of unverified numerical commitments significantly undermines factual correctness, warranting a moderate score of 6. Quantitative accuracy is penalized heavily (5/10) due to unsupported numbers; qualitative reasoning is reasonably sound (7/10); and relevance is strong (9/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 451,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "From 2022 to 2024, Starbucks' roasted coffee inventory value increased from $310.3 million in 2022, as indicated in the 2022 10-K. The production infrastructure expanded, with additional roasting facilities listed in the 2024 document, including locations in York, PA; Seattle, WA; Minden, NV; and Kunshan, China, reflecting growth in capacity and operations.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly identifies the 2022 roasted coffee inventory value of $310.3 million and accurately reflects the expansion of roasting infrastructure by 2024. However, it incorrectly states that the inventory value 'increased' without providing a 2024 inventory figure, which is not mentioned in the original answer—this implies a quantitative change not supported by the ground truth. 2) The numeric value of $310.3 million is correct and properly attributed to 2022. No calculation errors are present, but the LLM fabricates a trend (increase) without data, reducing quantitative accuracy slightly. 3) The LLM correctly identifies the multi-hop nature of the question by referencing both inventory (financial data) and infrastructure (operational data) across years. However, it lists 'Seattle, WA' instead of 'Kent, WA'—a factual error in entity location—while omitting Kent entirely. The original answer specifies Kent, WA, not Seattle, which are distinct locations. This affects qualitative accuracy. 4) Despite the location error and unsupported claim of inventory increase, the LLM captures the core evolution: Starbucks expanded its roasting infrastructure significantly from 2022 to 2024, signaling deeper involvement in production. The answer remains contextually relevant and mostly aligned with the ground truth in intent and structure, but with notable factual lapses in entity accuracy and inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 390,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "PepsiCo's utilization of the 2.750% Senior Notes due 2025 was referenced in both the 2023 and 2024 filings as part of the Board of Directors' authorizations for debt instruments (Exhibit 4.64 in both years). However, the specific issuance or repayment of these notes during 2023–2024 is not detailed in the provided pages. The 2023 filing notes the authorization of these notes in 2013, and the 2024 filing references the same authorization, indicating they remained part of the debt structure without new issuance or repayment mentioned.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 2.750% Senior Notes due 2025 were referenced in both 2023 and 2024 filings as part of Board authorizations (via Exhibit 4.64), and correctly notes the original 2013 authorization. These factual elements are accurate and consistent with the ground truth. However, the LLM fails to mention the key evolution highlighted in the original answer: the introduction of a new 2.750% Senior Notes due 2030 in 2024, which signals a strategic extension of the same interest rate to a longer-term instrument. This omission significantly weakens the response's ability to address the core of the question—how utilization evolved. (2) Quantitatively, all dates (2013, 2023, 2024) and interest rate (2.750%) are correct; no calculations are required. (3) The multi-hop reasoning is partially sound—LLM correctly links the note across years and filings—but fails to synthesize the strategic implication of introducing a new 2030 note with the same rate, which is essential to demonstrating evolution in utilization. (4) The answer is contextually relevant and accurately reports what is in the filings, but lacks the inferential depth needed to fully capture the strategic shift, resulting in a mid-range correctness score despite strong factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 363,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "FedEx reduced its planned utilization of the B777F aircraft from 4 units in 2024 (as of May 31, 2022) to 2 units in 2025 (as of May 31, 2024). This indicates a strategic shift toward optimizing fleet efficiency, likely replacing older aircraft with more fuel-efficient models like the B777F, while reducing the number of new B777F acquisitions to align with long-term cost-saving goals and operational needs.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a reduction in B777F utilization from 4 to 2 aircraft, which aligns with the ground truth. However, it misrepresents the timeline: the original answer states that in 2022, FedEx planned to operate 4 B777Fs in 2024 and 2 in 2025, while by 2024 the plan was revised to only 2 in 2025 with no further plans beyond. The LLM incorrectly frames this as a reduction from 4 units in 2024 to 2 in 2025, implying the 4 were planned for 2024 in the initial plan (correct) but fails to note that the updated 2024 plan shows no B777Fs beyond 2025—indicating a complete phase-out, not just a reduction. (2) The numbers (4 and 2) are accurate, but the temporal framing is off—the LLM omits that the 2022 plan included 4 for 2024 and 2 for 2025, and the 2024 update shows only 2 for 2025 and nothing beyond. This omission affects the completeness and reasoning. (3) The multi-hop reasoning is partially sound—there is recognition of a reduction—but the conclusion that this reflects optimization by replacing older aircraft with B777Fs is contradictory and incorrect. The B777F is the new aircraft being scaled back, not the replacement. The ground truth indicates a phase-out of B777F, not increased use. The LLM misattributes the strategic rationale. (4) Correctness is scored 5 due to partial factual accuracy but major error in strategic interpretation. Quantitative accuracy is 6 because numbers are correct but context (years and planning horizons) is misrepresented. Qualitative accuracy is 5 due to flawed reasoning and misattribution of fleet strategy. Contextual relevance is 8 because the answer addresses the question’s intent and structure, even if factually flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 467,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "Starbucks' foreign currency - other derivative liabilities decreased from $55.3 million in AOCI as of October 2, 2022, to $11.5 million as of September 29, 2024, with corresponding reclassifications to earnings dropping from $32.5 million to $9.5 million. This decline indicates reduced exposure to foreign currency fluctuations, likely due to adjusted hedging strategies or more effective risk management. However, derivative liabilities (accrued liabilities) increased from $0.3 million in 2022 to $4.7 million in 2024, suggesting ongoing foreign currency obligations, though the lower AOCI gains/losses reflect better alignment between hedging activities and exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities — this part is correctly mentioned. However, the LLM claims that in 2022, the amount in AOCI was $55.3 million, which is not supported by the original answer; the ground truth does not provide any AOCI figure for 2022. Instead, it states that in 2024, net gains included in AOCI were $11.5 million — this $11.5 million figure is correctly cited by the LLM, but it is misrepresented as a decrease from $55.3 million, which is unsupported. Additionally, the LLM introduces reclassification amounts ($32.5M to $9.5M) and a 2024 derivative liability of $4.7M that are not present in the ground truth and cannot be verified. (2) The quantitative inaccuracies are severe: the $55.3 million AOCI value in 2022 and the $4.7 million liability in 2024 are not in the original answer, and no reclassification data was provided in the ground truth. The only correct numbers are the $0.3 million liability in 2022 and the $11.5 million AOCI gain in 2024. (3) The multi-hop reasoning is partially sound — the LLM attempts to interpret trends in foreign currency exposure and hedging — but the conclusion that exposure decreased contradicts the ground truth, which suggests increased exposure due to a shift from minimal liability to substantial unrealized gain. The LLM’s inference of reduced exposure due to lower AOCI balances is based on incorrect data. (4) Despite incorrect numbers and flawed reasoning, the answer is contextually relevant, addressing the evolution of liabilities and AOCI impact and attempting to interpret hedging implications. Hence, contextual relevance is high, but correctness and quantitative accuracy are low due to unsupported figures and misinterpretation of trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 519,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "Between 2023 and 2024, PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved as follows: In the 2023 filings, no direct mention of these notes was found. However, in the 2024 10-K, Exhibit 4.64 references the 2.625% Senior Notes due 2026 as part of a broader set of debt instruments authorized by board resolutions. Additionally, a new indenture dated February 12, 2024 (Exhibits 4.69–4.70) explicitly includes these notes, marking their formal incorporation into PepsiCo's debt structure. This indicates that the 2024 disclosures reflect the initiation of engagement with these notes, alongside other debt instruments, through legal and structural frameworks.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. First, it incorrectly claims that the 2.625% Senior Notes due 2026 were not mentioned in 2023 filings, stating 'no direct mention of these notes was found'—this directly contradicts the original answer, which states that in 2023, these notes were explicitly listed among other notes in a section involving Board of Directors Resolutions. This is a critical error in entity and disclosure timeline accuracy. Second, the LLM asserts that the 2024 disclosures mark the 'initiation of engagement' with these notes due to a new indenture on February 12, 2024, suggesting these notes were newly incorporated. However, the ground truth indicates continuity—PepsiCo retained the 2026 notes in 2024 and expanded its debt portfolio to include newer instruments like the 2027 and 2029 notes. The LLM misrepresents the evolution as a new engagement rather than a continuation and expansion. While the mention of Exhibit 4.64 and the new indenture in 2024 may reflect accurate document references, the interpretation of these as evidence of 'initiation' is incorrect given the prior existence of the notes in 2023 disclosures. The broader context of an active capital markets strategy involving diversified maturities and rates is entirely missing from the LLM response, undermining the qualitative and multi-hop reasoning. Quantitatively, no numerical values (percentages, dates) are incorrect per se, but their contextual application is flawed. The answer is partially relevant to the question but fundamentally misrepresents the timeline and nature of PepsiCo's engagement. Thus, the correctness score is low due to core factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 468,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "Cisco's exposure to technical hurdles has remained significant from 2022 to 2024, with strategic investments in emerging technologies like AI, cloud, and cybersecurity as critical to overcoming these challenges. The 2022 filings emphasized risks of delayed product development in areas such as network programmability (e.g., SDN) and the potential for competitors like \"white-box\" hardware providers to disrupt markets. By 2024, the focus expanded to include complexities in scaling software-as-a-service offerings and addressing evolving customer needs in AI and cybersecurity, underscoring the ongoing reliance on timely innovation and R&D to maintain competitiveness. Both periods highlight the importance of overcoming technical hurdles to sustain growth and market leadership.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Cisco's exposure to technical hurdles from 2022 to 2024, noting the continuity of risk and the shift in focus toward software-as-a-service, AI, and cybersecurity. It accurately reflects that technical hurdles remained a concern across both periods and ties them to strategic investments and product development timelines. However, it omits specific consequences highlighted in the original answer, such as reputational damage, legal liability, and reduced customer retention in 2024, which represent a meaningful expansion of risk beyond market share and earnings. Additionally, while the LLM mentions 'white-box' competitors and SDN as 2022 concerns, these details are not present in the ground truth and may reflect over-specificity or inference beyond the source. (2) There are no numeric values, dates, or calculations in either the original or LLM answer, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is generally sound: the model synthesizes information across years and identifies a shift in emphasis from internal execution risks (2022) to broader strategic dependencies (2024), aligning with the core trajectory in the ground truth. However, it does not fully capture the qualitative shift from 'delays in execution' to 'timely innovation as a competitive necessity' with expanded downstream risks. (4) The contextual relevance is high—the response directly addresses the question about evolution in exposure and reliance on overcoming technical hurdles in relation to strategy and product timelines. The qualitative accuracy is slightly reduced due to partial omission of key 2024 risk dimensions and introduction of unverified specifics (e.g., SDN, white-box providers), but the overall narrative arc is correct. Hence, correctness is scored 8—core facts are accurate, but minor omissions and potential over-inference prevent a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 530,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "The role of Google Ad Manager in driving Google Network revenues was highlighted in 2021 as a key contributor to growth, alongside AdMob and AdSense, according to the 2022 document. However, the 2023 document does not provide specific mentions of Google Ad Manager's performance or positioning in 2022–2023, leaving no explicit indication of changes in its role during that period. Thus, while Ad Manager remained part of the Google Network's revenue drivers, the documents do not detail any specific evolution or shift in its contribution between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Google Ad Manager's role was highlighted in 2021 according to the 2022 document, while the ground truth clearly states that in 2022, Ad Manager was cited as a key driver of the $8.6 billion year-over-year increase in Google Network revenues. The LLM also falsely claims that the 2023 document does not provide specific mentions of Ad Manager's performance or positioning, when in fact it does—by listing it among several platforms without specific attribution to growth, which is a critical qualitative shift. (2) The quantitative accuracy is very low because the LLM fails to mention the $8.6 billion year-over-year increase in Google Network revenues in 2022, a key financial figure in the ground truth. No numbers are cited at all, and the temporal reference to 2021 is incorrect. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize information across the 2022 and 2023 documents. It misattributes the performance mention to 2021 instead of 2022 and misses the nuanced shift from Ad Manager being a named growth driver in 2022 to being part of a broader suite in 2023. This undermines the core of the question about changing roles. (4) Contextual relevance is moderate because the answer addresses Google Ad Manager and its role in Google Network revenues, but it fails to deliver the correct comparative analysis across years. The conclusion that 'documents do not detail any specific evolution' is incorrect, as the ground truth shows a clear change in emphasis. Thus, while the topic is relevant, the factual and reasoning errors severely limit accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 460,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "Starbucks' derivative liabilities related to foreign currency - other increased from $0.3 million as of October 2, 2022, to $4.7 million as of September 29, 2024, representing a $4.4 million increase. This reflects a growth in accrued liabilities associated with these derivatives over the period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the derivative liabilities for foreign currency - other at $0.3 million in 2022 and $4.7 million in 2024, matching the ground truth. The calculated change of $4.4 million ($4.7M - $0.3M) is accurate. (2) All numeric values are correct, including the specific dollar amounts and the implied difference. The fiscal dates (October 2, 2022, and September 29, 2024) align with Starbucks' reported fiscal year-ends and are consistent with SEC filing timelines. (3) The multi-hop reasoning is sound—information from two different years is correctly synthesized to show evolution and magnitude of change. The categorization under accrued liabilities is implied correctly through context. (4) The answer is semantically equivalent to the original, with slightly more precise date formatting and explicit quantification of the change. All aspects of the question—evolution over time and magnitude of change—are fully addressed with factual and logical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1156,
        "completion_tokens": 290,
        "total_tokens": 1447
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "PepsiCo's 4.600% Senior Notes due 2045 were issued in 2023 and remained part of its debt structure in 2024, as evidenced by their inclusion in the 2024 10-K filings. This continuity indicates a strategic focus on maintaining long-term debt with extended maturities to manage interest rate risk and balance its capital structure, aligning with its broader approach to diversify debt maturity profiles and ensure financial flexibility.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 4.600% Senior Notes due 2045 were part of PepsiCo's debt structure in both 2023 and 2024, and correctly references their presence in the 2024 10-K, which aligns with the ground truth. The percentage (4.600%) and maturity year (2045) are accurate. However, the LLM incorrectly implies the notes were 'issued' in 2023, while the ground truth states they were only authorized via Board Resolutions in 2023 — no issuance event is confirmed for that year. This is a key factual misrepresentation. (2) Quantitatively, all numbers (4.600%, 2045, 2023, 2024) are correct and consistent with the original answer. No calculations are involved, so numerical accuracy is high. (3) The multi-hop reasoning is partially sound: the model connects the note across two years and infers strategic intent. However, it fails to incorporate the key evolution noted in the ground truth — that in 2024, the 4.600% notes were referenced alongside new instruments like the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026, indicating a broader diversification. The LLM mentions diversification but without citing this specific evidence, weakening the synthesis. (4) The correctness score is 6 due to the significant error about issuance timing and the omission of the expanded debt portfolio context. Quantitative accuracy is 9 due to correct figures. Qualitative accuracy is 6 because reasoning is plausible but based on incomplete evidence. Contextual relevance is 8 as the answer addresses the core question about evolution and strategy, albeit incompletely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 441,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "COP's natural gas position in the Asia Pacific/Middle East region, as reflected in consolidated operations, decreased slightly from 330 BCF (2022) to 303 BCF (2024), while equity affiliates' reserves increased from 5,753 BCF to 5,870 BCF. This suggests a strategic focus on maintaining and expanding equity stakes in the region, particularly through affiliates, despite modest declines in direct operations. The equity affiliates' reserves, which account for the majority of the region's total reserves, indicate COP's emphasis on leveraging regional partnerships and market dynamics, such as LNG spot price improvements and technical revisions, to sustain its position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF in 2022 to 296 BCF in 2024. However, the LLM reports 330 BCF (2022) and 303 BCF (2024), which are incorrect. Moreover, the LLM introduces 'equity affiliates' reserves' increasing from 5,753 BCF to 5,870 BCF — a claim entirely absent from the original answer and not supported by the ground truth. These figures are orders of magnitude larger than the total reserves cited in the truth, suggesting a fundamental data error. (2) The quantitative inaccuracies are severe: the correct decrease is 30 BCF (326 → 296), but the LLM reports a smaller drop (330 → 303 = 27 BCF), using wrong base numbers. The introduction of massive equity affiliate reserves (over 5,700 BCF) is unsupported and distorts the entire analysis. (3) The multi-hop reasoning fails because the LLM fabricates a distinction between 'consolidated operations' and 'equity affiliates' that is not present in the original data or question. The ground truth presents a single, unified reserve figure. The conclusion about strategic focus on equity stakes is therefore based on non-existent data. (4) While the LLM attempts to provide strategic interpretation (contextually relevant), the reasoning is built on false premises. The contextual relevance is moderate because it addresses the region and time frame and attempts to infer strategy, but the qualitative and quantitative foundations are deeply flawed, leading to a mostly incorrect answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 439,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "Google Play's role in Google's non-advertising revenue strategy remained consistent between 2022 and 2023, primarily generating revenue from app and in-app purchase sales within the Google Play store. In both years, it was explicitly listed as a key component of the \"platforms\" segment under Google Services, contributing to non-advertising revenue alongside hardware and consumer subscriptions. No new revenue sources for Google Play were introduced in the 2023 filing, reflecting its sustained focus on app sales and digital content as a core non-advertising revenue stream.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that Google Play's role 'remained consistent' between 2022 and 2023. The ground truth shows a clear evolution in how Google Play's revenue sources were described—broadly as 'sales of apps and in-app purchases and digital content' in 2022, and more narrowly focused on 'apps and in-app purchases' in 2023, with a strategic repositioning under the 'platforms' category. The LLM incorrectly asserts continuity, missing the narrowing of focus and strategic shift in emphasis. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in numbers, dates, or calculations, hence a score of 10. (3) The multi-hop reasoning is flawed: the question asks for an analysis of evolution, requiring comparison across two years' filings and synthesis of changes in language and categorization. The LLM fails this by asserting no change when the ground truth documents a shift in narrative and scope. It also incorrectly states that Google Play was explicitly listed under 'platforms' in both years, while the 2022 description does not mention this grouping—only the 2023 filing does. (4) Contextual relevance is high because the answer addresses the right topic, company, time frame, and revenue category. However, the qualitative inaccuracy in reasoning and entity/timing relationships severely undermines correctness. The answer misrepresents the evolution as stagnation, which is the opposite of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 420,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "The projected utilization of the Cessna SkyCourier 408 increased from 11 aircraft in 2023 (as of 2022) to 12 aircraft in 2024 (as of 2022). By 2024, commitments for 2025 and 2026 showed 17 and 14 aircraft, respectively, indicating a strategic shift toward higher reliance on this model for long-term fleet modernization and operational efficiency. This evolution suggests FedEx is prioritizing the Cessna SkyCourier 408 to replace older aircraft and achieve cost savings.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. According to the ground truth, in 2022, FedEx projected 49 total Cessna SkyCourier 408 aircraft for operation from 2023 onward, not 11 in 2023 as claimed. By 2024, the projection was reduced to 31 aircraft for 2025–2029, not increased to 17 in 2025 and 14 in 2026. The LLM incorrectly states that utilization increased, while the ground truth shows a reduction from 49 to 31 aircraft and a strategic downgrade from 'Increases' to 'Depends_On'. (2) All numerical claims in the LLM answer (11, 12, 17, 14) are factually wrong and not supported by the original data. There is no mention of 11 or 12 aircraft in the ground truth; instead, totals are given for multi-year periods. The LLM fabricates year-specific commitments that do not appear in the source. (3) The multi-hop reasoning is flawed: the model fails to recognize that the change in projection reflects a decreased strategic reliance, not an increase. It misinterprets the shift in relationship type and ignores the reduction in total projected aircraft. (4) The contextual relevance is moderate because the answer addresses the right topic (FedEx’s use of the Cessna SkyCourier 408) and attempts to discuss strategic reliance, but the factual inaccuracies and incorrect synthesis severely undermine correctness. The conclusion about 'higher reliance' and 'prioritizing' the aircraft is the opposite of the ground truth, which indicates a moderated reliance. Thus, the correctness score is low at 2 due to major factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 438,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "AIG's use of expected loss ratio (ELR) methods for casualty lines remained consistent between 2022 and 2023, with continued segmentation into **automobile-related** and **non-automobile** claims. Non-automobile claims were further segmented into **latent exposures** like construction defects and mass torts, which exhibit unique emergence patterns. The analysis also incorporated **attachment point bands** to account for delays in loss reporting tied to higher attachment layers. In 2023, ELR methods were applied to the **three most recent accident years**, adjusted for rate changes, loss trends, and market conditions, reflecting ongoing reliance on historical loss ratios while incorporating external factors like COVID-19 impacts. No significant changes in segmentation or casualty line analysis were noted compared to 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its core claim that AIG's use of expected loss ratio (ELR) methods remained consistent between 2022 and 2023. The ground truth states a clear shift—from U.S. Excess Casualty in 2022 to U.S. Workers' Compensation in 2023. The LLM incorrectly asserts no significant changes occurred, which contradicts the documented strategic evolution. While it correctly mentions segmentation by automobile vs. non-automobile claims and latent exposures like construction defects and mass torts, these details were specific to 2022 and not carried forward as the primary focus in 2023. (2) Quantitatively, the LLM correctly references the 'three most recent accident years'—a detail present in the 2022 analysis—but fails to note that this timeframe was applied to a different line of business in 2023 (Workers' Compensation), not Excess Casualty. There are no explicit numerical errors (e.g., dates, percentages), so quantitative accuracy is partially preserved. (3) The multi-hop reasoning is flawed: the question asks for an evolution between years, requiring comparison across time and casualty lines. The LLM fails to recognize the shift in focus from Excess Casualty to Workers' Compensation and misrepresents the 2023 application context. It incorrectly implies continuity rather than change. The mention of 'rate changes, loss trends, and market conditions' and 'COVID-19 impacts' introduces unsupported details not present in the ground truth. (4) Contextual relevance is moderate because the answer discusses ELR methods and segmentation, which are relevant, but it misapplies them to the wrong year and business line. The failure to capture the strategic pivot significantly undermines factual correctness, warranting a low overall score despite some accurate terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 494,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "Nike's classification of unallocated products within its consumer construct remained consistent between fiscal years 2022 and 2024. In fiscal 2022, unisex products were reclassified under Men's, and Jordan Brand was separately reported, with \"Others\" encompassing products not allocated to Men's, Women's, Kids', or Jordan Brand. By fiscal 2024, the same consumer construct (Men's, Women's, Kids', Jordan Brand) persisted, and \"Others\" continued to include unallocated products and adjustments. No further changes to the categorization of unallocated products were noted, reflecting stability in the reporting structure post-2022 reclassification.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the structure of Nike's consumer construct in both fiscal years 2022 and 2024, including the use of 'Others' for unallocated products and the separation of Jordan Brand. It accurately notes that unisex products were reclassified under Men's in 2022. However, it incorrectly concludes that the classification remained 'consistent' and that there were 'no further changes' in 2024. The ground truth indicates a potential shift in how unisex products are treated by 2024 — specifically, there is no mention of unisex products being classified under Men's in that year, suggesting a change or integration into broader categories. This nuance is missed entirely by the LLM, which interprets the continued use of 'Others' as evidence of stability, failing to recognize the absence of explicit unisex classification as a meaningful evolution. (2) There are no numerical values in this question, so quantitative accuracy is not applicable in the traditional sense; however, the fiscal years (2022, 2024) and category names (Men's, Women's, Kids', Jordan Brand, Others) are correctly cited, earning full marks here. (3) The multi-hop reasoning is flawed: the model should have compared the explicit mention of unisex product classification in 2022 with its absence in 2024 and inferred a possible change. Instead, it defaults to assuming continuity, which contradicts the cautious interpretation in the ground truth suggesting a potential shift. This represents a failure in qualitative synthesis. (4) Contextual relevance is high because the answer addresses the consumer construct and categorization of unallocated products directly. However, the core of the question — how the classification *evolved* — is misrepresented due to the incorrect conclusion of stability. Thus, while the components are present, the overall correctness is compromised by faulty reasoning about change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 522,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "PepsiCo issued the 3.500% Senior Notes due 2025 in 2024, as evidenced by the Board of Directors Resolutions (Exhibit 4.64) in the 2024 10-K. This indicates a shift from the 3.500% Senior Notes due 2040 (2023 filing) to a shorter-term maturity, reflecting a strategic adjustment to manage debt maturity and interest rate risk. The company's debt management strategy emphasizes diversifying maturity dates and optimizing capital structure, aligning with its broader goal of maintaining flexibility and minimizing exposure to long-term interest rate fluctuations.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that PepsiCo 'issued' the 3.500% Senior Notes due 2025 in 2024, which contradicts the ground truth: these notes were already part of the debt structure in 2023 and remained in 2024. The issuance of new notes in 2024 (e.g., 3.500% due 2040 and 3.550% due 2034) is misrepresented as a shift away from long-term to short-term debt, when in fact the opposite occurred—PepsiCo added longer-term debt. (2) Quantitative accuracy is low: while the coupon rate (3.500%) and maturity year (2025) are correct, the key event (issuance in 2024) is false. The reference to Exhibit 4.64 and Board Resolutions may be real, but it does not support the claim that the 2025 notes were issued in 2024. (3) Multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of the debt portfolio. Instead of recognizing that PepsiCo maintained the 2025 notes while adding longer-term instruments (indicating diversification), it infers a shift to shorter-term debt, which is the opposite of the truth. (4) Contextual relevance is moderate—the answer discusses debt management strategy and maturity structure, which are relevant, but the incorrect premise undermines the conclusion. The strategy described (managing interest rate risk, diversifying maturities) is plausible but misaligned with the actual data. Thus, correctness is severely compromised by core factual and logical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 408,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "Between 2022 and 2024, ConocoPhillips' Lower 48 segment reported **capital expenditures** of $3,129 million in 2024, a decrease from $3,394 million in 2022. This reflects reduced investment in the region. Additionally, **future cash inflows** for the Lower 48 increased from $141,307 million (2023) to $164,264 million (2024), driven by revisions in reserve estimates and production forecasts, as noted in the \"Revisions of previous quantity estimates\" line item under discounted cash flow calculations. These revisions likely adjusted upward due to improved production outlooks or higher commodity prices.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, COP reported capital expenditures of $3,129 million in 2022, not 2024, and there is no mention of a $3,394 million figure in 2022 or any capital expenditure figure for 2024. The LLM incorrectly reverses the years and invents a prior year number not present in the original answer. Additionally, the LLM introduces specific future cash inflow figures ($141,307 million in 2023 and $164,264 million in 2024) that are not present in the ground truth, which only states that future cash inflows were revised upward in 2024 without providing numerical values. (2) The quantitative inaccuracies are severe: the capital expenditure amount is assigned to the wrong year, a non-existent comparative figure is introduced, and precise cash inflow numbers are fabricated. No calculations are performed in the original, so the LLM's use of these numbers misrepresents the data. (3) The multi-hop reasoning is flawed. The original answer indicates a shift from reporting capital expenditures in 2022 to discussing revisions in future cash inflows and production costs in 2024, with no new capex figure. The LLM incorrectly assumes capex data was reported in 2024 and fabricates a trend. It also incorrectly infers that 'Revisions of previous quantity estimates' directly caused the increase in cash inflows, which is not stated in the ground truth. (4) The contextual relevance is moderate because the answer addresses capital expenditures and future cash inflows in the Lower 48 region over the 2022–2024 period, which aligns with the question. However, due to major factual and numerical errors, the qualitative and quantitative accuracy scores are low, resulting in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 485,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "Comcast's financial commitments with Atairos Group evolved between 2023 and 2024 through amendments to their agreement, including reducing the maximum aggregate capital commitment from $5 billion to $4.5 billion and lowering annual capital calls to $400 million. Governance arrangements remained unchanged, with Comcast retaining no voting rights and only limited consent rights, while Atairos' management companies (led by Comcast's former CFO) retained control. As of December 31, 2024, Comcast's investment in Atairos was $5.1 billion, with a remaining unfunded commitment of $1.4 billion, reflecting adjusted capital obligations under the amended terms.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies key financial changes, including the reduction in Comcast's capital commitment from $5 billion to $4.5 billion and the $400 million annual capital call limit, which aligns with the ground truth. It also accurately notes that Atairos' management companies, led by Comcast’s former CFO, retained control, and that Comcast has no voting rights. However, it incorrectly states that governance arrangements 'remained unchanged,' which contradicts the ground truth: in 2024, there was a significant evolution in governance and control structures under the equity method accounting framework, including a clarified loss absorption (99%) and return allocation (86%), which the LLM omits entirely. Additionally, the LLM introduces a specific investment value of $5.1 billion as of December 31, 2024, and a remaining unfunded commitment of $1.4 billion—details not present in the original answer and unverifiable from the provided truth. These additions risk implying precision where none was given. (2) Quantitatively, the $5B to $4.5B reduction and $400M annual cap are correct. However, the $5.1B invested and $1.4B unfunded commitment are unsupported by the ground truth and appear to be fabricated or inferred incorrectly. There is no mention in the original answer of these exact figures or a calculation that would yield them. (3) The multi-hop reasoning is partially sound—linking the amended agreement to reduced capital obligations—but fails to synthesize the key 2024 changes in economic rights (loss/return allocation) and misrepresents governance as static when it evolved significantly. The model misses the shift to equity method accounting and its implications. (4) The correctness score is 6 due to accurate core financial figures but major omissions in governance evolution and introduction of unsupported numbers. Quantitative accuracy is 7 because key numbers are right but unverified figures are added. Qualitative accuracy is 6 due to flawed reasoning about governance continuity. Contextual relevance is 9—response stays on topic and addresses the question’s scope well, despite inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 577,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "FedEx reduced its projected utilization of the Cessna SkyCourier 408 from 11 aircraft scheduled for delivery in 2023 (as of May 31, 2022) to 0 in 2023, with remaining commitments shifted to later years (e.g., 17 for 2025). This indicates a strategic shift away from the SkyCourier 408, likely prioritizing more efficient aircraft like the B767F and B777F for long-haul operations, while reserving the SkyCourier for niche markets or specific routes.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of quantitative details. The ground truth states that FedEx's projected total number of Cessna SkyCourier 408 aircraft dropped from 49 (through 2027) in the 2022 filing to 31 (through 2029) in the 2023 filing. However, the LLM claims a reduction from '11 aircraft scheduled for delivery in 2023' to '0 in 2023', which misrepresents both the total fleet projection and the timeline. These numbers (11, 0, 17 in 2025) do not appear in the ground truth and appear to be fabricated or misinterpreted. (2) There are no correct calculations or verifiable numeric alignments with the original answer. The LLM focuses on annual delivery schedules rather than total projected fleet utilization, which is the core of the question. (3) The reasoning is partially sound in inferring a strategic shift away from the SkyCourier 408 and toward aircraft like the B767F and B777F, which aligns with the qualitative interpretation in the original answer. This shows some correct multi-hop reasoning about strategic fleet planning. (4) While the general direction of the conclusion (reduced strategic role) is plausible, the factual basis is incorrect, severely undermining the answer. The contextual relevance is moderate because it addresses fleet strategy and comparisons, but fails on the primary data point: total projected utilization over time. The answer shifts focus from total planned fleet size (the actual metric) to annual deliveries, which is not what the question asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 420,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "Nike's approach to the Air Max product line from 2022 to 2024 emphasizes technological innovation, as highlighted in the 2024 10-K under \"Product Research, Design and Development,\" which explicitly names Air Max among key technologies driving product innovation. However, the documents do not provide specific revenue transparency details for Air Max, focusing instead on broader revenue disaggregation by product lines (e.g., footwear, apparel) without isolating Air Max subcategories. Revenue transparency for the Air Max line remains consistent with Nike's general reporting practices, which prioritize segment-level disclosure rather than granular product-line specifics.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that Nike did not disclose specific revenue figures for the Air Max product line in either 2022 or 2024, which matches the original answer's point about lack of standalone financial metrics. It also accurately notes the emphasis on technological innovation in the 2024 10-K, citing Air Max as a highlighted technology in product development—consistent with the shift toward positioning Air Max as a key innovation driver. The answer correctly reflects Nike's revenue disaggregation practices, focusing on broader categories rather than granular product lines. However, it omits a direct comparison between 2022 and 2024 regarding the evolution in reporting: while the ground truth notes that Air Max was listed among other technologies in a revenue disaggregation table in 2022 (a subtle but specific detail), the LLM answer does not mention this change in presentation or the strategic shift from passive inclusion to active promotion as an innovation example. This missing nuance prevents a perfect score, but the core facts, entities, and reasoning remain sound. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response is highly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 359,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "Comcast's capital expenditure strategy for Epic Universe remained consistent in 2023 and 2024, with total Connectivity & Platforms capital expenditures staying around $8.2 billion in both years. In 2023, expenditures included land acquisition for potential theme park expansions, while 2024 saw increased spending on theme park attractions, specifically construction costs for Epic Universe in Orlando. The documents do not specify exact amounts allocated to Epic Universe but highlight its prioritization as part of broader theme park development efforts, with 2024 emphasizing infrastructure and attraction investments.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but introduces significant inaccuracies. It correctly identifies the $8.2 billion capital expenditure under Connectivity & Platforms in 2023 from the ground truth. However, it incorrectly states that this amount remained 'around $8.2 billion in both years' — the original answer does not provide the 2024 total or imply it was unchanged, so this is an unsupported claim. Additionally, the LLM mentions 'land acquisition for potential theme park expansions' in 2023, which is not mentioned in the ground truth and represents an unverified detail. (2) The quantitative accuracy is compromised because while the 2023 $8.2 billion figure is correct, the assertion of a similar amount in 2024 lacks support. The ground truth explicitly states that specific figures for Epic Universe were not disclosed in 2024, making the LLM’s implication of continued $8.2 billion spending misleading. (3) The multi-hop reasoning is partially sound — the model correctly infers that Epic Universe is a priority within broader theme park investments. However, it fails to accurately represent the evolution: the shift from infrastructure focus in 2023 to sustained investment including guest experience in 2024 is oversimplified and mischaracterized as merely increased spending on construction. The LLM also misses the forward-looking nature of the 2024 plan toward 2025, which is a key element in the original answer. (4) Contextual relevance is high because the response stays focused on capital expenditures and Epic Universe development. Despite factual inaccuracies, it attempts to address the evolution of strategy, investment amounts, and development priorities. The qualitative accuracy is moderate due to correct entity identification (Comcast, Epic Universe, Orlando, Connectivity & Platforms) and general thematic alignment, but penalized for unsupported details and misrepresentation of financial continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 528,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "FedEx's utilization of the ATR 72-600F aircraft decreased between 2022 and 2023, as reflected in their fleet projections. In 2022, FedEx had 11 ATR 72-600F aircraft committed for delivery in 2023. By 2023, the projected deliveries for the ATR 72-600F were reduced to 6 aircraft for 2024, indicating a decline in planned utilization for this aircraft type during the 2022–2023 period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a reduction in FedEx's planned utilization of the ATR 72-600F between 2022 and 2023 projections, which aligns with the ground truth. However, it contains significant quantitative inaccuracies. In the 2022 projection, the LLM correctly states that 11 aircraft were planned for 2023, but then incorrectly states that by 2023, only 6 were projected for 2024—while the ground truth shows 6 for 2024, 6 for 2025, and 1 for 2026 in the original 2022 plan. The updated 2023 projection included 7 for 2025 and 3 for 2026, which the LLM completely omits. (2) The LLM misrepresents the timeline and scope of the projections. It frames the change as a reduction from 11 in 2023 to 6 in 2024, but the key evolution is in later years (2025 and 2026), where the 2023 update revised plans to 7 for 2025 and 3 for 2026—information not mentioned at all. (3) The multi-hop reasoning is partially sound—recognizing a decline in planned utilization is correct—but fails to synthesize the full evolution across both planning periods (2022 vs 2023 views of 2023–2026). The answer oversimplifies and misaligns the timeframes. (4) Scores reflect partial factual correctness: the direction of change (decrease) is right, but key numbers and years are wrong or missing, hurting quantitative and qualitative accuracy. Contextual relevance is high as the answer addresses the core topic and trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 393,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "Nike's estimated cost of inventory for expected product returns decreased from $269 million in fiscal 2021 to $194 million in fiscal 2022, as noted in the sales-related reserves section of Note 16. This reduction suggests improved forecasting or changes in return policies. However, no explicit 2024 data is provided in the given pages, so the evolution between fiscal 2022 and 2024 cannot be fully determined from the provided information. The methodology for revenue recognition, which accounts for anticipated returns, remained consistent, with reserves adjusted based on historical rates and expected returns.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Nike's estimated cost of inventory for expected product returns was $269 million in fiscal 2021 and $194 million in fiscal 2022, while the ground truth specifies $269 million in fiscal 2022 only — no 2021 figure is provided in the original answer, and the $194 million figure is entirely fabricated. Furthermore, the LLM claims a reduction in reserves, which is unsupported by the provided data. (2) The quantitative inaccuracies are severe: the fiscal years are misaligned, and a specific dollar amount ($194M) is introduced without basis. The ground truth does not provide any 2024 dollar amount, but correctly notes a methodological shift; the LLM incorrectly asserts that 'no explicit 2024 data is provided in the given pages,' implying a limitation of the source material rather than recognizing the disclosed qualitative evolution in methodology. (3) The multi-hop reasoning fails: the question asks about the evolution between fiscal 2022 and 2024 in both estimation approach and revenue recognition implications. The LLM misses the key shift to a 'most likely amount' model for variable consideration, which is central to the updated revenue recognition methodology under ASC 606. Instead, it falsely claims the methodology 'remained consistent,' directly contradicting the ground truth. (4) Contextual relevance is moderate because the answer addresses product return reserves and revenue recognition, but the incorrect data and flawed reasoning severely undermine its usefulness. The answer fabricates numbers, misrepresents trends, and fails to identify the core methodological evolution, resulting in a mostly incorrect response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 474,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "The planned fleet composition for the Cessna SkyCourier 408 increased from 12 units in 2025 (as of May 31, 2022) to 17 units in 2025 (as of May 31, 2023), with additional commitments for 2026. This indicates FedEx's strategic reliance on the Cessna SkyCourier 408 model to meet operational demands, likely due to its efficiency or alignment with fleet modernization goals. The increase in commitments underscores a shift toward prioritizing this aircraft for future operations.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in planned Cessna SkyCourier 408 units from 12 in 2025 (2022 plan) to 17 in 2025 (2023 plan), which matches the ground truth. However, it incorrectly states that there were 'additional commitments for 2026', when in fact the 2023 plan reduced the 2026 fleet count to 14 from the previously stable 12. This omission of the reduction in 2026 misrepresents the full fleet trajectory. (2) Quantitatively, the 12 → 17 increase for 2025 is accurate, and the dates (May 31, 2022 and May 31, 2023) align with typical SEC filing dates, though not explicitly in the ground truth. The error lies in the characterization of 2026 plans—no 'additional commitments' were made; instead, a drop to 14 was planned, indicating a strategic pullback. (3) The multi-hop reasoning is partially sound: the model connects 2022 and 2023 plans for 2025 correctly but fails to synthesize the full picture across both years for both 2025 and 2026. The conclusion about increasing strategic reliance is only half-accurate, missing the nuance of a subsequent reduction. (4) The contextual relevance is high as the answer addresses fleet composition changes and strategic implications. However, the qualitative accuracy is reduced due to the incorrect inference about 2026 plans, leading to an incomplete and slightly misleading strategic interpretation. A score of 7 is justified: core numbers for 2025 are correct, but key details for 2026 are wrong, affecting the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 416,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "Mastercard's real-time account-based payments infrastructure expanded from 13 markets in 2023 to a broader global footprint in 2024, enhancing operational scale through increased cross-border transaction support and integration with 180+ markets. Security capabilities were strengthened via multi-layered protections, including real-time fraud scoring, tokenization, and compliance with EMV standards, alongside AI governance and privacy-by-design frameworks to ensure data integrity and resilience.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Mastercard's real-time payments infrastructure in 13 markets in 2023, which matches the ground truth. However, it inaccurately claims expansion to '180+ markets' in 2024, which is not supported by the original answer—no such specific number is mentioned, and Mastercard's real-time infrastructure is not known to operate in 180+ markets. This is a significant quantitative overstatement. (2) The original answer notes enhanced ACH and real-time systems with stronger security, but does not mention 'AI governance', 'privacy-by-design', or 'EMV compliance' as new 2024 integrations—these are plausible but not factually confirmed in the ground truth, making them speculative additions. (3) The multi-hop reasoning is partially sound: the model correctly infers growth in scale and security from 2023 to 2024 and synthesizes relevant capabilities like fraud scoring and tokenization. However, the leap to 180+ markets misrepresents operational scale and undermines factual accuracy. (4) Despite the numerical inaccuracy, the answer captures the core direction of evolution—increased scale and enhanced security—and remains contextually relevant. The qualitative reasoning is logical and well-structured, but the quantitative error reduces overall correctness. Hence, a score of 6 is justified: partially correct with significant factual shortcomings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 388,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "Nike's use of foreign exchange forwards and options evolved between 2022 and 2024, with the total notional amount of outstanding foreign currency derivatives designated as cash flow hedges decreasing from $18.5 billion (May 31, 2022) to $16.2 billion (May 31, 2024). The company maintained a 24-month maximum hedge term for forecasted transactions. The hedging strategy focused on managing foreign currency exposures from product costs, revenues, and intercompany transactions, with deferred gains in accumulated other comprehensive income (AOCI) expected to reclassify to net income as hedged transactions occur. In 2024, approximately $231 million of deferred net gains (net of tax) were anticipated to impact net income within the next 12 months.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and omits key information from the ground truth. While it correctly identifies Nike and the 2022–2024 timeframe, it introduces specific notional amounts ($18.5B in 2022, $16.2B in 2024) and a 24-month hedge term that are not present in the original answer and cannot be verified against the provided ground truth. These numbers appear fabricated or hallucinated. The original answer does not mention notional amounts, hedge terms, or deferred gains in AOCI, so these details are irrelevant or incorrect. (2) The only quantitative data in the ground truth are: a net gain of $8 million after tax in 2022, and by 2024, $110 million in accrued liabilities and $5 million in deferred income taxes and other liabilities related to foreign exchange instruments. The LLM answer completely fails to mention these liability figures, which are central to the evolution in reporting and financial impact. Instead, it focuses on notional amounts and AOCI reclassifications not referenced in the original. (3) The multi-hop reasoning is flawed: the question asks about evolution in use of forwards/options with respect to financial liabilities and hedging strategy. The original answer highlights a shift in financial reporting (increased liabilities) and impact on income categories. The LLM answer discusses changes in notional value and AOCI, which may reflect hedging activity but do not address the liability impact or strategic shift in financial reporting. It misses the core evolution described in the ground truth. (4) The answer is contextually relevant—foreign exchange forwards, options, and hedging strategy are appropriate topics—and it correctly identifies Nike and the time frame. However, due to significant factual inaccuracies, omission of key financial liability data, and introduction of unsupported metrics, the correctness score is low. The qualitative accuracy is moderate because the general concept of evolving hedging strategy is present, but reasoning is not aligned with the source truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 556,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "The product category classification of Puffs within the Baby, Feminine & Family Care segment remained unchanged between 2022 and 2023. In both years, Puffs was listed under the **Family Care** sub-category, which includes paper towels, tissues, and toilet paper, as part of the segment's major brands. There is no indication of reclassification or evolution in its categorization during this period.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key nuance in the evolution of the product category classification. (1) It correctly identifies that Puffs remained under the Family Care sub-category in both 2022 and 2023, and accurately lists the product types (paper towels, tissues, toilet paper), so entity and date accuracy are correct. (2) There are no numeric values requiring calculation, so quantitative accuracy is not applicable—score reflects no factual errors in presented data. (3) However, the original answer highlights a reporting-level change: in 2023, the breakdown of sub-categories was simplified or consolidated, with 'Tissues' no longer explicitly called out in the same way, indicating an evolution in how the segment details were reported. The LLM incorrectly states there is 'no indication of reclassification or evolution,' which contradicts the ground truth. This reflects a failure in multi-hop reasoning—while the surface-level categorization appears unchanged, the change in reporting granularity constitutes an evolution in classification structure. (4) The answer is contextually relevant and factually consistent on surface entities, but lacks the qualitative insight about reporting simplification, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 354,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "Tampax remained categorized under the **Baby, Feminine & Family Care** segment in both 2022 and 2023, specifically within the **Feminine Care** sub-category. In 2023, its positioning was further clarified as part of the **menstrual care** sub-category, emphasizing its focus on menstrual products alongside adult incontinence. This refinement highlighted Tampax's role in the feminine care segment while maintaining its association with the broader Baby, Feminine & Family Care portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately states that Tampax remained under the 'Baby, Feminine & Family Care' segment in both years, which matches the original answer. It correctly identifies the shift in 2023 toward a more specific categorization under 'menstrual care', reflecting a refined positioning. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are involved. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two time points and identifies the evolution in categorization. However, the LLM slightly misrepresents the 2022 structure by stating Tampax was in 'Feminine Care' in 2022 without noting that 'Feminine Care' was grouped with 'Baby Care' and 'Family Care' under the broader segment—this nuance is present in the ground truth but missing in the LLM response. Additionally, the mention of 'adult incontinence' as a co-located category in 2023 is not present in the original answer and may introduce irrelevant information, slightly reducing qualitative accuracy. (4) Despite minor omissions and the addition of unverified context (adult incontinence), the core facts about the repositioning from 'Feminine Care' to a more focused 'Menstrual Care' category are correct, and the answer directly addresses the question about categorization evolution. Hence, the correctness and qualitative scores are high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 412,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "Oracle's strategy for Oracle Engineered Systems (part of the Hardware Business) saw a decline in revenue contribution between fiscal 2022 and 2023, as the hardware business' total revenues decreased by 5% year-over-year, driven by a strategic shift toward cloud-based infrastructure and reduced emphasis on non-strategic hardware products. However, Oracle continued to invest in research and development, with R&D expenses increasing by 11% in fiscal 2022, reflecting ongoing efforts to improve existing hardware and develop new offerings. The company's broader focus shifted toward cloud services, which grew to 37% of total revenues in fiscal 2024, indicating a long-term prioritization of cloud over traditional hardware.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in fiscal 2023, Oracle noted hardware represented 6% of total revenues, but the LLM incorrectly claims a 5% year-over-year revenue decline in hardware without any such figure provided in the original answer. There is no mention of a revenue decrease in the ground truth. Additionally, the LLM cites an 11% increase in R&D expenses in fiscal 2022, which is not present in the original answer—while Oracle did state in fiscal 2023 it would continue investing in R&D, no specific percentage increase or fiscal 2022 R&D growth was mentioned. The claim that cloud services grew to 37% of total revenues in fiscal 2024 is irrelevant and unsupported, as the question focuses on fiscal 2022–2023 and the original answer does not mention fiscal 2024 or cloud revenue share. (2) Quantitative inaccuracies include the fabricated 5% hardware revenue decline, the incorrect 11% R&D increase in 2022, and the irrelevant 37% cloud revenue in 2024—none of which appear in the ground truth. The only correct quantitative point is the strategic emphasis on R&D in 2023, though the supporting number is wrong. (3) The multi-hop reasoning is flawed: the LLM infers a decline in hardware strategy based on revenue drop and cloud growth, but the ground truth shows Oracle actually enhanced the strategic positioning of Engineered Systems in 2023 by specifying its revenue contribution (6%) and reaffirming R&D investment—indicating increased rather than decreased emphasis. The synthesis incorrectly frames the strategy as de-prioritizing hardware, contrary to the original answer’s indication of clearer strategic focus. (4) Scores reflect major factual and numerical errors, incorrect temporal reasoning, and misrepresentation of strategic direction. While the answer addresses the general topic (hardware strategy and R&D), the core facts are incorrect, leading to a low correctness score. Contextual relevance is moderate because it discusses the right business segment and general trends, but with fabricated data and misaligned conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 570,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "Honeywell's Non-U.S. pension plans increased private fund investments from $90 million in 2022 to $115 million in 2023. In 2022, private funds were allocated $54 million (Level 2) and $36 million (Level 3), while in 2023, the allocation shifted to $41 million (Level 2) and $74 million (Level 3), reflecting a higher proportion of Level 3 assets. This evolution indicates a strategic reallocation toward Level 3 investments, likely due to market conditions or valuation adjustments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Honeywell reported $1,105 million in private fund investments for its *U.S.* pension plans (not Non-U.S.), all classified under Level 3. However, the LLM incorrectly claims $90 million in Non-U.S. plans in 2022 with a split of $54M (Level 2) and $36M (Level 3), which is not supported by the ground truth. In 2023, the correct data is $115 million for *Non-U.S.* plans, split into $41M (Level 2) and $74M (Level 3), which the LLM correctly reports. However, the LLM falsely implies this is an increase from 2022, when in fact the 2022 data for Non-U.S. plans is not provided in the original answer—only U.S. data is given for 2022. (2) The quantitative inaccuracies are severe: the LLM invents numbers for 2022 Non-U.S. plans that do not exist in the ground truth and misattributes the $1,105M U.S. figure as if it were Non-U.S. or comparable to the 2023 Non-U.S. amount. The calculation of a change from $90M to $115M is entirely fabricated. (3) The multi-hop reasoning fails because the model does not correctly distinguish between U.S. and Non-U.S. pension plans across years, conflating two different entities. It also incorrectly infers a trend (increase and strategic reallocation) that cannot be substantiated due to lack of comparable data for Non-U.S. plans in 2022. (4) While the 2023 numbers are correct and the answer is relevant to the topic, the core factual foundation is wrong, leading to a low correctness score. Contextual relevance is moderate because the structure and intent align with the question, but accuracy is critically compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 457,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "The 2014 USD Notes, which matured in April 2024, were classified as short-term debt in the 2023 filing. In April 2024, the company repaid the $1 billion principal amount related to these notes. Additionally, in July 2024, the company settled the INR Term Loan (not directly related to the 2014 USD Notes) by paying INR28.1 billion ($336 million). No further actions were taken regarding the 2014 USD Notes beyond their repayment in April 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 2014 USD Notes were classified as short-term debt in 2023 with a maturity in April 2024 and that $1 billion in principal was repaid in full in April 2024, matching the ground truth. All key facts—classification, maturity date, repayment amount, and timing—are accurate. (2) Quantitative accuracy is perfect: the $1 billion principal, April 2024 repayment date, and even the unrelated INR28.1 billion ($336 million) loan settlement are correctly reported. While the INR loan is not part of the 2014 USD Notes, its mention does not detract from correctness as it is clearly distinguished. (3) The multi-hop reasoning is sound—LLM correctly tracks the debt from its 2023 classification to 2024 repayment. The only minor issue is the inclusion of the INR Term Loan, which, while factually correct, is not relevant to the specific question about the 2014 USD Notes, slightly diluting focus but not affecting factual accuracy. (4) Scores reflect near-perfect factual alignment, with full quantitative precision and high qualitative and contextual accuracy. The slight deduction in qualitative accuracy is due to the inclusion of tangential information, though it does not mislead.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 347,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "The treatment and documentation of Lowe's Officer Indemnification Agreements remained consistent between 2022 and 2024, with the same form (Exhibit 10.23) from 2019 referenced in both filings. This indicates sustained continuity in executive risk management and governance practices, as the company did not introduce significant changes to indemnification agreements during this period. The absence of updated documentation suggests a stable approach to executive accountability and risk mitigation.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Lowe's maintained the same form of Officer Indemnification Agreement between 2022 and 2024, indicating continuity in governance and executive risk management, which aligns with the ground truth. However, there is a factual error in the exhibit number: the LLM states 'Exhibit 10.23' while the ground truth specifies 'Exhibit 10.43'. This is a clear discrepancy in entity accuracy, particularly in document identification, which affects quantitative accuracy. (2) The dates (2019 filing, refiled in 2022 and 2024) are correctly referenced, and no numerical calculations were required, so numerical precision is mostly sound aside from the exhibit number. (3) The multi-hop reasoning is strong: the model correctly infers that unchanged documentation implies stable governance and risk management practices, synthesizing information across years and filings appropriately. (4) Despite the exhibit number error, the overall meaning and conclusion are semantically equivalent to the original answer, with accurate reasoning and high contextual relevance. The mistake is minor in impact but notable in precision, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 339,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "Between the 2022 and 2023 Procter & Gamble 10-K filings, **Always Discreet**'s market share in the adult incontinence category increased from **over 10%** to **about 15%** in key markets. The 2023 filing explicitly states this 15% market share, while the 2022 filing notes \"over 10% market share in the key markets in which we compete.\" There is no explicit mention of a change in category positioning beyond this growth in market share.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content. (1) Quantitatively, it falsely claims that Always Discreet's market share increased from over 10% in 2022 to about 15% in 2023, and that the 2023 filing explicitly states a 15% market share. However, the ground truth confirms that while the 2022 filing mentions 'over 10%' market share, the 2023 filing does not provide any specific market share figure—let alone 15%. This is a critical factual error. (2) The calculation or comparison of market share growth is entirely fabricated, with no basis in the source documents. (3) Qualitatively, the model fails the multi-hop reasoning task: instead of recognizing the absence of a market share disclosure in 2023 and interpreting the shift in disclosure strategy, it invents a precise figure and implies continued quantitative transparency. The category positioning is not meaningfully analyzed beyond the false market share claim. (4) Contextually, the answer addresses the right brand, product category, and time frame, showing relevance to the question, but the core conclusion is unsupported. The correct interpretation should highlight the removal of the specific market share metric in 2023, not an increase in share. Due to major factual and quantitative inaccuracies, the correctness score is low despite appropriate context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 372,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023 by reinforcing their role as foundational infrastructure for both hardware and cloud offerings. In 2022, Engineered Systems (e.g., Exadata) were highlighted as pre-integrated solutions for on-premise and cloud deployments, emphasizing performance, scalability, and security. By 2023, Oracle further integrated these systems into OCI, enabling hybrid cloud deployments and enhancing their alignment with cloud transformation goals. This shift underscores Engineered Systems as critical enablers of OCI's capabilities, supporting Oracle's narrative of delivering secure, scalable infrastructure for enterprise workloads while bridging on-premise and cloud environments.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the evolution in Oracle's strategic positioning of Engineered Systems from 2022 to 2023, noting their continued role as pre-integrated solutions and increased integration with OCI to support hybrid cloud and cloud transformation. The qualitative description of their enhanced alignment with cloud goals and role in bridging on-premise and cloud environments is consistent with the ground truth. However, the LLM answer omits key quantitative and structural details present in the original answer: specifically, the inclusion of servers, storage, and operating systems in the broader hardware business; the classification as combined performance obligations; and the fact that hardware revenues (including Engineered Systems) represented 6% of total revenues in both fiscal 2023 and 2024. It also fails to mention ongoing R&D investments and the acknowledgment of the lower-margin nature of the hardware business, which are important nuances in Oracle's strategic narrative. While there are no incorrect facts or numerical errors (hence a perfect quantitative accuracy score), the absence of these specific data points and strategic implications reduces completeness and qualitative accuracy. The reasoning is sound but incomplete in synthesizing all multi-hop elements from the ground truth. The response remains contextually relevant and addresses the core of the question regarding strategic evolution and cloud transformation alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 404,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "The disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan remained consistent between the 2022 and 2023 10-K filings. Both filings explicitly state that the 2020 Stock Plan succeeded the 2011 Stock Plan, with the 2020 Plan authorizing 17.5 million new shares and incorporating the remaining 5.5 million shares from the 2011 Plan that were available for grants. No significant changes or additional details were introduced in the 2023 filing to alter this relationship.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) Quantitatively, the LLM claims that both the 2022 and 2023 filings mention the carry-forward of 5.5 million shares from the 2011 Stock Plan, but the ground truth states that this detail was present only in the 2022 filing and explicitly omitted in the 2023 filing. The number 5,530,106 (rounded to 5.5 million) is accurate, but the assertion that it appears in both years is false. (2) The LLM incorrectly states that the 2020 Stock Plan authorized 17.5 million new shares—a figure not present in the ground truth and unsupported by the provided data. This introduces a fabricated number. (3) Qualitatively, the reasoning is flawed: the question asks how the disclosure *evolved*, implying a comparison over time, but the LLM asserts consistency when the actual evolution was a removal of the reference to the 2011 Plan. The multi-hop synthesis failed—the model should have detected the presence in 2022 and absence in 2023, but instead assumed continuity. (4) Contextually, the answer addresses the topic of stock plan transitions but misrepresents the core factual change, making it misleading despite using semantically plausible language. The conclusion is the opposite of the truth: there was a notable change in disclosure strategy, not consistency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 371,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "Honeywell's allocation to private funds increased slightly for U.S. pension plans from $1,105 million in 2022 to $1,265 million in 2023, reflecting a modest shift toward higher-return private equity investments aligned with the elevated expected rate of return (7.00% in 2023). Conversely, non-U.S. private fund allocations dropped significantly from $65 million in 2022 to $8 million in 2023, likely due to regional market conditions or strategic adjustments. This divergence suggests a prioritization of private funds in the U.S. to enhance returns, while non-U.S. allocations may reflect localized constraints or regulatory considerations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. According to the ground truth, Honeywell's investment in private funds was $1,244 million in 2022 and $1,265 million in 2023, representing a 1.7% increase. However, the LLM incorrectly states the 2022 U.S. allocation as $1,105 million and introduces non-U.S. allocations ($65M in 2022, $8M in 2023) that are not present in the original answer or supported by the provided ground truth. These figures appear to be hallucinated or misattributed. (2) The calculation of a 'modest shift' and reference to an 'elevated expected rate of return (7.00%)' is not mentioned in the original answer and introduces unsupported reasoning. While the $1,265 million figure for 2023 is correct, the 2022 figure is wrong, and the breakdown between U.S. and non-U.S. plans is not part of the ground truth, undermining the quantitative accuracy. (3) The multi-hop reasoning is partially sound in that it attempts to interpret strategic intent behind allocation changes, but it does so using incorrect data segmentation (U.S. vs. non-U.S.), which breaks the logical foundation. The original answer emphasizes overall stability in private fund allocation despite broader asset reductions, a nuance missed in the LLM response. (4) The contextual relevance is fair because the answer addresses capital deployment priorities and attempts to explain strategic implications, but the use of fabricated sub-allocations reduces its reliability. The qualitative accuracy is moderate due to correct identification of Honeywell and the general trend direction (slight increase), but flawed entity segmentation and unsupported inferences lower the score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 468,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "Between 2023 and 2024, Class B-2 Common Stock transitioned from having **no outstanding shares** in 2023 to **120 million shares outstanding** in 2024. This change occurred via a **Class B-1 to Class B-2 exchange offer** in May 2024, where 241 million Class B-1 shares were retired in exchange for 120 million Class B-2 shares and 48 million Class C shares. Class B-2 shares are part of the broader Class B common stock structure, which converts to Class A common stock at a **conversion rate of 1.5430** (resulting in 186 million as-converted Class A shares in 2024). The conversion rates for Class B-2 are subject to adjustments based on litigation escrow deposits and other factors, linking their outstanding status to the Company’s retrospective responsibility plans.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) According to the original answer, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 exchange offer, and there was no issuance of 120 million Class B-2 shares in 2024. Instead, the 2024 filing only referenced the prior lack of outstanding shares, with no new disclosures—indicating reduced emphasis or potential discontinuation. The LLM falsely claims 120 million Class B-2 shares became outstanding in 2024 via an exchange offer, which is unsupported. (2) The numeric values—120 million shares issued, 241 million Class B-1 retired, 48 million Class C issued, and a conversion rate of 1.5430—are all fabricated and not present in the ground truth. The original answer mentions conversion rate adjustments tied to litigation escrow but does not specify a rate or any 2024 exchange. (3) The multi-hop reasoning is fundamentally flawed: the LLM invents an event (exchange offer) and financial mechanics (conversion math, share counts) that do not appear in the source. It misrepresents the evolution as active issuance when the truth is a lack of updates. (4) Contextual relevance is low because the answer discusses non-existent developments. The only partial alignment is the mention of litigation escrow affecting conversion rates, which is correct in theme but misrepresented in application. Overall, the answer fabricates key facts and fails to reflect the actual reduction in disclosure and lack of outstanding shares.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 418,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "The financial obligations related to the Target Circle program, as reflected in deferred revenue liabilities, increased from $89 million in 2022 to $117 million in 2024. This indicates growth in the program's obligations, likely due to expanded membership, higher rewards accruals, or changes in program structure, reflecting increased commitments to fulfill rewards for members.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in deferred revenue from $89 million in 2022 to $117 million in 2024, matching the ground truth in both amounts and years. The interpretation that this reflects growth in obligations due to expanded membership or higher rewards is reasonable and aligns with the original answer. However, the LLM omits the critical data point from February 1, 2025, where deferred revenue dropped sharply to $19 million—a key part of the program's evolution. This omission significantly affects completeness. (2) All provided numbers are quantitatively accurate: $89M in 2022 and $117M in 2024 are correctly cited with appropriate fiscal dates (though the LLM does not mention exact dates, it correctly associates the figures with the years). No calculations were required beyond comparison, which is accurate. (3) The reasoning correctly infers that growing deferred revenue implies increased liabilities from member rewards, suggesting program growth. However, it fails to address the subsequent sharp decline, which is essential for a full multi-hop analysis across 2022, 2024, and 2025. This limits the depth of synthesis. (4) Scores reflect high factual accuracy and relevance, but the qualitative accuracy and overall correctness are reduced due to the missing 2025 data point, which changes the interpretation of the program's trajectory—indicating not just growth but a recent reversal or strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 402,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "The fair value of Netflix's 4.375% Senior Notes increased slightly from **$980 million** as of December 31, 2022, to **$996 million** as of December 31, 2023. This minor increase suggests modest improvement in investor confidence or market conditions, potentially reflecting stable credit risk perceptions or favorable interest rate environments. However, the small change indicates limited significant shifts in market sentiment or financial outlook for Netflix during this period.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the direction of the change in fair value. The ground truth states the fair value decreased from $980 million to $996 million, but this is logically impossible—$996M is greater than $980M, so the value increased, not decreased. However, the original answer incorrectly claims the value 'decreased' when it actually increased. The LLM correctly reports the numbers ($980M to $996M) and correctly interprets this as an increase, which contradicts the ground truth. Thus, the LLM is quantitatively accurate and logically consistent, but the ground truth contains an internal contradiction. (2) Quantitatively, the LLM matches the dollar amounts and dates exactly—$980 million on December 31, 2022, and $996 million on December 31, 2023—so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the LLM identifies the correct financial instrument, compares fair values across years, and infers investor perception. However, it contradicts the ground truth's erroneous claim of a 'decrease', which undermines the qualitative accuracy score because the evaluation must be based on alignment with the provided ground truth, even if flawed. (4) Contextual relevance is high—the answer addresses both parts of the question: the change in fair value and its implication for investor perception. The conclusion about modest improvement is reasonable given the small change. However, the qualitative accuracy is penalized because the ground truth asserts a 'decrease' and stabilization toward par, while the LLM correctly infers an increase, creating a conflict. Due to the requirement to align with the ground truth, the correctness score is reduced despite the LLM likely being factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 481,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "Between 2023 and 2024, Visa's equity structure related to Class C Common Stock evolved through the issuance of 48 million shares as part of a May 2024 exchange offer, where Class B-1 common stock was converted into Class B-2 and Class C shares. This issuance increased the number of Class C shares outstanding, as noted in the 2024 10-K, which reported 353 record holders for Class C as of November 6, 2024. The classification of Class C shares remained as common stock, with no indication of reclassification during this period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that the exchange offer occurred in May 2024 and resulted in the issuance of 48 million Class C shares, but the ground truth states this exchange happened in 2023. Additionally, the LLM incorrectly implies that 48 million shares were newly issued and remain outstanding in 2024, while the original answer clearly states that by 2024, only 10 shares of Class C common stock were issued and outstanding. The mention of '353 record holders' as of November 6, 2024, is not supported by the ground truth and introduces unverified detail. (2) Quantitative accuracy is severely compromised: the date of the exchange (2023 vs. 2024), the number of shares outstanding in 2024 (48 million vs. 10 shares), and the timing of disclosures are all incorrect. The 48 million figure is accurate for the 2023 issuance, but its placement in 2024 is wrong. (3) The multi-hop reasoning fails because the model misaligns events across years and does not recognize that the 2024 data reflects stabilization at 10 shares, indicating post-exchange cleanup or retirement of most Class C shares. It also fails to connect the exchange to the Visa Europe retrospective responsibility plans, missing key context. (4) Despite incorrect facts, the answer is contextually relevant—it addresses equity structure evolution, share issuance, and classification—so moderate relevance is retained. However, due to major factual and temporal errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 419,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "Lowe's continued to classify Rough Plumbing under the **Building Products** category in both 2022 and 2024, maintaining its position within the home improvement retail segment. However, in 2024, the company expanded its service offerings by explicitly including **installation services for Rough Plumbing** under its \"Installed Sales\" model, reflecting a broader integration of service-based solutions alongside product sales. This evolution highlights a shift toward enhanced customer value through added installation support, while the business classification remained consistent.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately states that Rough Plumbing was classified under 'Building Products' in both 2022 and 2024, which matches the original answer. It correctly identifies the key evolution: the addition of installation services in 2024 under the 'Installed Sales' model. (2) There are no numeric values explicitly mentioned in either answer beyond the 5% installed sales figure in the ground truth, which the LLM omits. This is the primary gap—while the shift to service offerings is noted, the LLM does not mention that this contributed to approximately 5% of total sales in 2024, a quantifiable impact present in the original answer. (3) The reasoning is sound: the model correctly synthesizes the shift from product-only to service-inclusive engagement, even if it frames the classification as unchanged rather than noting a potential expansion *within* the same category. The ground truth implies a repositioning within the same category, which the LLM captures by maintaining the classification but adding service layers. (4) Contextual relevance is high—the answer directly addresses both business classification and service offering changes. The omission of the 5% metric prevents a perfect score, but all other factual and logical elements are accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 373,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "Between 2023 and 2024, Visa introduced **Class B-2 common stock** through an exchange offer in May 2024, where holders of **Class B-1 common stock** (redenominated from prior Class B stock) exchanged shares for **Class B-2** and **Class C** stock. Class B-2 was created as part of a structured transition, with conversion rate adjustments tied to litigation resolutions and escrow accounts, doubling the impact compared to Class B-1. This indicates Class B-2 serves as a transitional class in Visa’s capital structure, facilitating gradual liquidity and alignment with litigation outcomes, while maintaining distinct conversion terms and roles in earnings per share calculations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) The introduction of Class B-2 common stock is incorrectly dated to May 2024 via an exchange offer; the ground truth states it was already introduced in 2023 with 77 million shares outstanding. This misrepresents the timeline and mechanism of introduction. (2) The claim that Class B-2 was created through an exchange offer involving Class B-1 and Class C stock is unsupported by the original answer, which only notes that no Class B-2 shares were outstanding prior to the Class B-1 exchange offer in 2024—this suggests removal or restructuring, not creation at that time. (3) There is no mention in the ground truth of Class C stock, conversion rate adjustments tied to litigation, escrow accounts, or doubling effects—these are fabrications or hallucinations. (4) The original answer highlights a strategic shift where Class B-2 may have been replaced or restructured, but the LLM incorrectly frames Class B-2 as a transitional vehicle introduced in 2024, reversing the actual sequence. (5) Quantitative accuracy is poor: while 77 million shares is mentioned in the ground truth for 2023, the LLM omits this key figure entirely and introduces no verifiable numbers. (6) Multi-hop reasoning fails—the LLM does not correctly synthesize the evolution from 2023 (introduction) to 2024 (disappearance pre-exchange), instead inventing a narrative around litigation and conversion mechanics absent in the source. (7) Contextual relevance is moderate because the answer discusses capital structure roles, which aligns with the question’s intent, but the underlying facts are flawed. Overall, the answer misrepresents the chronology, mechanism, and purpose of Class B-2 stock, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 486,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "The financial liability associated with the Target Circle program decreased from $117 million in 2022 to $19 million in 2024, as reflected in deferred revenue reported in the 2024 10-K. This decline suggests a reduction in accrued rewards liability, likely due to increased revenue recognition from program members or changes in program structure, indicating potential growth in program participation or efficiency in managing rewards obligations.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change. The ground truth states that no liability was disclosed in 2022, but by 2024 it had grown to $117 million, indicating an increase. The LLM incorrectly claims a decrease from $117 million in 2022 to $19 million in 2024, which contradicts the original data. (2) The numbers are entirely inaccurate: there is no mention of a $19 million figure or any 2022 liability in the ground truth. The $117 million figure is correctly cited as the 2024 amount, but it is wrongly presented as a starting point in 2022. Calculations and comparisons based on these numbers are therefore invalid. (3) The multi-hop reasoning fails because the model misrepresents the timeline and data availability. It assumes a disclosed liability in 2022 when none was reported, and draws incorrect conclusions about program evolution. The correct inference requires recognizing that the emergence of a $117 million liability in 2024 (from no disclosed amount in 2022) indicates growth, not decline. (4) The contextual relevance is moderate because the answer discusses deferred revenue and program participation, which are relevant themes, but the factual foundation is so flawed that the conclusion is opposite to the truth. Hence, correctness and quantitative accuracy are very low; qualitative accuracy is slightly higher only because the general concept of linking liability to program activity is valid, though misapplied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 411,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "NVDA's exposure to pollution limits and regulatory impacts evolved between 2023 and 2024, with heightened focus on climate-related regulations affecting operations and data center expansion. In 2023, the company acknowledged potential costs from pollution limits, including compliance expenses and operational adjustments. By 2024, the disclosure expanded to explicitly link pollution regulations to energy/water constraints, which could restrict data center expansion and customer capacity growth. The 2024 filing emphasized that climate-related laws, such as pollution limits, might impair access to critical resources (e.g., clean water, predictable energy), directly impacting NVIDIA's ability to support data center expansion and customer demand. This reflects a more specific concern about regulatory barriers to infrastructure growth in 2024 compared to the broader compliance risks noted in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: NVDA's 2023 concerns centered on cost increases (compliance, energy, capital expenditures), and by 2024, the focus expanded to include land, permitting, and resource constraints affecting customer data center expansion. The LLM correctly identifies the evolution from operational compliance risks to demand-side impacts. (2) There are no numeric values in the question or answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2023 vs 2024) and entities (NVDA’s operations and customer dynamics), correctly inferring that regulatory constraints on customers could indirectly affect demand for NVDA’s products. The mention of 'energy/water constraints' and 'critical resources' is consistent with the broader concept of pollution limits impacting permitting and land use. (4) The only minor deviation is that the LLM emphasizes 'clean water' and 'predictable energy'—details not explicitly in the original answer—though these are reasonable inferences from pollution and climate regulations. This slight expansion does not introduce inaccuracies but adds contextual detail. Overall, the answer is semantically equivalent, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 387,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "Between 2023 and 2024, the company's Japanese subsidiary issued $500 in Guaranteed Senior Notes in November 2023, repaid $77 of them in July 2024, and the remaining notes mature between 2033 and 2043. The fair value of these notes was consistently measured using Level 3 inputs, reflecting their non-recurring, complex valuation. The 2.750% Senior Notes due in 2024 were fully repaid in May 2024, reducing the carrying value of long-term debt. Overall, the composition shifted from issuance in 2023 to partial repayment in 2024, with fair value inputs remaining Level 3.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $500 issuance in 2023 and $77 repayment in 2024, which aligns with the ground truth. However, it introduces a specific detail not present in the original answer — the '2.750% Senior Notes due in 2024' being repaid in May 2024 — which is not mentioned in the ground truth and may conflate other debt instruments. This introduces factual inaccuracy. The maturity range of 2033–2043 is also not in the original and, while plausible, is unverified. (2) The dollar amounts ($500 issued, $77 repaid) are accurate and correctly formatted. However, the LLM omits the key comparative fair value figures for long-term debt: $5,738 at end of 2023 and $5,412 at end of 2024 — a critical quantitative point in the original answer showing overall reduction. While it mentions Level 3 inputs correctly, it adds interpretive language like 'non-recurring, complex valuation' not in the source and potentially misleading. (3) The reasoning correctly synthesizes issuance and repayment across 2023 and 2024 and attributes them to the Japanese subsidiary, showing proper multi-hop understanding. However, it fails to connect the repayment to the broader trend in fair value of total long-term debt, which is a central analytical point in the original. Instead, it focuses on carrying value without supporting data. (4) The answer is contextually relevant and well-structured, addressing composition, valuation, issuance, repayment, and fair value inputs. But due to the omission of key fair value totals and introduction of unverified note details, the quantitative accuracy is reduced. The core facts are mostly right, but with notable gaps and additions, justifying a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 474,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "Netflix's investment in streaming service improvements increased from 2022 to 2024, reflected in a 24% rise in technology and development expenses in 2022 due to expanded headcount and infrastructure upgrades. Cybersecurity risk exposure evolved with enhanced measures in 2024, including a dedicated VP of Security and Privacy Engineering (with 30+ years of experience), third-party security programs, and annual audits, addressing risks like data breaches and third-party vulnerabilities. Personnel changes emphasized retaining key talent, while cybersecurity risks remained a focus, though past incidents had no material impact.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. The ground truth states a $384 million increase in personnel-related costs in 2022, but the LLM claims a '24% rise in technology and development expenses'—a figure not present in the original answer and unsupported by the provided data. There is no mention of a 24% increase or total tech expenses in the ground truth, making this a significant factual deviation. Additionally, the LLM introduces specific details not in the original, such as a 'VP of Security and Privacy Engineering with 30+ years of experience' and 'annual audits,' which are absent from the ground truth and cannot be verified against it. (2) While the $384M personnel cost increase is a key quantitative anchor in the original, the LLM fails to mention this exact figure, instead shifting focus to an unverified percentage increase in tech expenses. This undermines quantitative accuracy. (3) Qualitatively, the LLM captures the evolution from personnel-driven streaming investments in 2022 to heightened cybersecurity focus in 2024, correctly identifying themes like third-party risk and data breach concerns. It synthesizes a multi-hop narrative across years and domains (personnel to cybersecurity), showing sound reasoning structure. However, the addition of unverified roles and audit practices introduces hallucinated details, reducing qualitative precision. (4) Contextually, the response is highly relevant, directly addressing the evolution of investment and risk exposure as asked. Despite incorrect numbers and added specifics, the core trajectory—from growth-focused spending to risk mitigation—is consistent with the ground truth. The answer would score higher if not for the fabricated metrics and omission of the key $384M figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 489,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "The Bank of New York Mellon Corporation introduced a new 2024 Form of Restricted Stock Unit Agreement (Exhibit 10.29) in its 2024 filing, replacing the 2023 version (Exhibit 10.27). This evolution reflects refinements in lifecycle management, likely incorporating updated vesting schedules, performance conditions, or tax treatments to align executive compensation more closely with strategic goals and long-term performance metrics. The changes underscore a continued emphasis on tying equity incentives to organizational objectives while adapting to market dynamics and regulatory considerations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the timing and nature of the restricted stock unit (RSU) agreement updates. Contrary to the ground truth, the LLM claims that the '2024 Form' was introduced in the 2024 filing, when in fact it was introduced in the 2023 filing as 'Filed herewith'. The 2024 filing then referenced the 2024 Form as 'Previously filed' and introduced the '2025 Form' as new. The LLM incorrectly implies the 2024 Form replaced the 2023 Form in the 2024 filing, which misrepresents the timeline and evolution. (2) Quantitative accuracy is low because the years associated with the filings and form introductions are wrong. The 2023 filing introduced the 2024 Form, not the 2024 filing. This error in date attribution undermines the factual foundation of the response. (3) The reasoning is partially sound in that it recognizes an evolutionary pattern in RSU agreements and links them to executive compensation strategy, but it fails the multi-hop synthesis by not correctly tracking the lifecycle of the forms across years. The model does not capture the annual forward-looking update pattern (e.g., introducing next year’s form each year) that the ground truth highlights. (4) Contextual relevance is moderate because the answer addresses the general theme of RSU evolution and executive compensation strategy, but the incorrect timeline and document history reduce its accuracy. While the intent to discuss strategic alignment is appropriate, the factual misalignment with the actual filing sequence results in a partially incorrect narrative. Minor point: the exhibit numbers (10.29, 10.27) are plausible but not confirmed in the ground truth, so their inclusion adds false precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 475,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "The 4.90% Senior Notes due April 2029 had a carrying amount of $743 million as of January 29, 2023, and increased slightly to $744 million as of February 2, 2025. Their maturity timeline remained unchanged at April 2029, with no structural changes noted. The 2024 issuance included new notes (e.g., 4.95% Senior Notes due 2034), but the 4.90% notes retained their original terms and carrying amount adjustments reflected amortization and discount accretion.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual errors. It incorrectly states the carrying amount was $743 million as of January 29, 2023, but the notes were issued in November 2023, so this date is before issuance and the amount cannot exist then. The correct initial carrying amount in 2023 was $746.6 million (after $3.4M discount on $750M principal), not $743M in early 2023. The LLM also claims a carrying amount of $744 million as of February 2, 2025, which is a future date and not supported by the ground truth. The correct carrying amount as of January 28, 2024, is $743 million, which the LLM misattributes to a future date. (2) The maturity date is correctly stated as April 2029, but the LLM fails to mention the exact date (April 15) and omits key details about semi-annual interest starting April 15, 2024. The LLM incorrectly references a 2024 issuance of the 4.90% notes, when they were issued in November 2023. It also introduces irrelevant information about 4.95% Senior Notes due 2034, which distracts from the focus on the 4.90% notes. (3) The multi-hop reasoning is flawed: the model fails to correctly sequence the timeline (issuance in 2023, carrying amount in 2024), misattributes dates and values, and does not accurately reflect the amortization impact. It incorrectly implies the carrying amount increased, while the ground truth states it slightly decreased due to discount amortization. (4) Despite these major errors, the answer is contextually relevant in that it discusses the correct type of debt instrument and approximate maturity, and mentions amortization concepts. However, the quantitative inaccuracies and timeline confusion severely undermine factual correctness, warranting a low correctness score of 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 479,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 million at fixed interest rates between 1.400% and 2.120%, with maturity dates ranging from 2033 to 2043. By 2024, the subsidiary repaid $77 million of these notes in July 2024, reducing the outstanding balance of the Guaranteed Senior Notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the issuance of four Guaranteed Senior Notes in 2023 totaling approximately $500 million at fixed interest rates between 1.400% and 2.120%, which matches the ground truth (with acceptable formatting: $500 vs $500 million). The repayment of $77 million in 2024 is accurately reported, with the addition of a specific month (July 2024), which is consistent with the ground truth but adds minor detail not contradicted by it. (2) All numeric values—$500 million issuance, $77 million repayment, interest rate range—are factually correct and properly contextualized. The maturity dates (2033–2043) are additional details not present in the ground truth but do not contradict it and are likely accurate based on typical note structures; they do not detract from correctness. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across 2023 issuance and 2024 repayment events for Costco’s Japanese subsidiary, correctly attributing the activity to the right entity and time frame. The LLM also implies continuity in financial engagement by noting the repayment, though it omits explicit mention of the 2024 filing referencing the proceeds as a financing activity—a minor omission in completeness. (4) The answer is semantically equivalent to the ground truth, with slightly enhanced detail (maturity dates, repayment timing), no factual errors, and high relevance. The correctness score is 9 due to the minor omission of the financing activity context in 2024 filings, but quantitative and contextual accuracy are perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 438,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "The risk associated with competitors developing after-market parts for DHR's products remained a stated concern in both 2022 and 2023, as highlighted in the \"Risk Factors\" section of both annual reports. In 2022, the risk was noted as a potential threat to sales, while in 2023, it was reiterated alongside broader competitive pressures, including pricing challenges from healthcare reforms like the Inflation Reduction Act. However, the documents do not explicitly indicate a material evolution in the risk's nature or impact on financial statements between the two years, suggesting the risk persisted without significant change.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative shifts in how the risk was framed between 2022 and 2023, which is central to the question. (1) There are no numeric values in the question or ground truth, so quantitative accuracy is not applicable—scored as 10 by default. (2) The LLM correctly identifies that the risk was mentioned in both years and notes the persistence of the concern, but it inaccurately claims there was 'no explicit material evolution,' which contradicts the ground truth: in 2023, the risk was repositioned from a direct threat to sales to being one of several external pressures, contextualized within broader healthcare cost containment and reimbursement policies. This shift reflects a strategic reframing and relative de-emphasis, which the LLM fails to capture. (3) The multi-hop reasoning is weak—the model should have synthesized the change in tone and contextual placement of the risk across the two years, but instead concludes there was no significant change. The mention of the Inflation Reduction Act is plausible context but not present in the ground truth, introducing unsupported detail. (4) While the answer addresses the persistence of the risk and touches on financial implications, it underrepresents the evolution in narrative and strategic perception, leading to a correctness score of 5—partially accurate but missing a key interpretive shift. Contextual relevance is high because the response stays on topic and references appropriate sections of the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 416,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "Netflix evolved its membership plans from 2022 to 2024 by introducing ad-supported tiers and adjusting pricing to address declining membership growth and competitive pressures. The 2022 document notes a 7% increase in average monthly revenue per paying member due to price changes, while the 2024 pages (likely reflecting 2023-2024 updates) mention expanded features like games and live programming. These changes aimed to combat slowing membership growth, rising content costs, and competition by diversifying offerings and improving monetization, while also managing churn and maintaining profitability amid macroeconomic challenges.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Netflix's introduction of ad-supported tiers and pricing adjustments from 2022 to 2024, aligning with the ground truth. It accurately notes the 7% increase in average monthly revenue per membership in 2022 due to price changes, which matches the original answer. However, it omits the 19% revenue increase and 11% growth in average paying memberships in 2022, as well as the 50% drop in paid net membership additions—key quantitative indicators of the business challenges. The mention of 'expanded features like games and live programming' in 2024 is not present in the ground truth and may be factually inaccurate or unsupported. (2) The quantitative accuracy is mostly correct but incomplete; the 7% revenue per member increase is accurate, but missing the 19% total revenue growth and 11% membership growth weakens completeness. There are no calculation errors, but key metrics are omitted. (3) The reasoning correctly links pricing and plan changes to challenges like competition and slowing growth, but fails to explicitly connect the 2024 ad-supported plan and password-sharing enforcement to the earlier decline in net additions. The synthesis across years is partially sound but lacks full multi-hop linkage (e.g., from 2022 performance to 2024 strategic response). (4) The answer is contextually relevant and addresses the core evolution and intent behind changes, but includes unsupported details (games, live programming) and misses critical evidence of business challenges cited in the ground truth, such as the halving of membership growth. These omissions and additions reduce qualitative and quantitative accuracy, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 469,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "Boeing's approach to in-orbit incentive payments in 2023 involved recognizing the net present value of these payments as revenue during the construction period, with risk exposure tied to satellite performance over up to 15 years post-acceptance. This framework was not explicitly detailed in the 2022 filings, which focused more on defense program risks and contract adjustments. The 2023 disclosure emphasized financial recognition during construction and highlighted potential refunds or charges if performance criteria were unmet, reflecting a more explicit acknowledgment of long-term risk exposure in satellite contracts.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in Boeing's approach to in-orbit incentive payments between 2022 and 2023, correctly identifying the shift from general risk acknowledgment to more explicit financial recognition and long-term performance risk. It accurately describes the recognition of net present value of payments during construction and the 15-year post-acceptance performance risk. However, it omits the key quantitative detail from the ground truth: the $1,585 million in additional losses recorded in 2023 on Boeing's five major fixed-price development programs. This is a significant omission because the original answer hinges on this specific figure to demonstrate the magnitude of financial exposure. While the LLM mentions 'potential refunds or charges,' it fails to quantify the actual losses incurred, which weakens the factual completeness. The entities (Boeing, in-orbit incentive payments, fixed-price programs) and years (2022 vs 2023) are correct, and the reasoning about evolving risk disclosure is sound. The answer is contextually relevant and semantically aligned in structure, but the absence of the $1,585 million figure—central to the 2023 update—reduces quantitative accuracy. Minor phrasing like 'not explicitly detailed in 2022' is a reasonable interpretation, though the original notes 2022 did mention risks, just less specifically. Overall, the answer is partially correct with a significant factual gap in quantification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 402,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "The disclosure and accessibility of the Directors' Code of Conduct remained consistent between 2023 and 2024, with both years referencing the code's availability on BNY Mellon's website. However, in the 2024 filing, the company explicitly stated its intention to disclose **any amendments to or waivers of the Directors' Code of Conduct** on its website, enhancing transparency compared to the 2023 disclosure, which only noted the code's existence without specifying amendment disclosure practices.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no numerical claims, it is scored as correct by default (10). The qualitative accuracy is low because the LLM misrepresents the evolution of disclosure: according to the ground truth, in 2023 the company explicitly posted the URL and stated it would disclose amendments or waivers, while in 2024 the reference became more general without repeating the URL. The LLM incorrectly claims that the *2024* filing *added* an explicit statement about disclosing amendments, when in fact that disclosure was already present in 2023. This reverses the direction of change. The answer also fails to note the key shift from a specific URL in 2023 to a more consolidated, implicit reference in 2024, which is the central point of the ground truth. Thus, the reasoning is flawed and the synthesis across years is incorrect. Contextual relevance is moderate because the answer addresses website accessibility and disclosure practices but mischaracterizes the nature and direction of change. Overall, the answer conveys the opposite of the true evolution, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 332,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "Between 2022 and 2023, Mobileye Drive™ evolved from a commercial Robotaxi and autonomous cargo delivery solution to a broader deployment strategy encompassing fleet-based autonomous driving and consumer-level AVs. In 2022, Mobileye launched Mobileye Drive™ with partnerships like Udelv and Transdev, focusing on commercial mobility services. By 2023, the strategy expanded to include scaling SuperVision to Chauffeur, a consumer AV solution, and integrating Mobileye Drive™ into transportation networks and public transit operators. The deployment emphasized leveraging REM mapping, True Redundancy, and advanced EyeQ platforms (e.g., EyeQ6L/H) to support both fleet operations and future consumer markets.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 launch of Mobileye Drive™ and key partnerships with Udelv and Transdev, aligning with the ground truth. It also captures the strategic shift in 2023 toward broader deployment involving transportation networks and public transit. However, it introduces elements not present in the original answer, such as 'scaling SuperVision to Chauffeur' and 'consumer-level AVs,' which were not mentioned in the ground truth as part of the 2023 strategy evolution. The integration of Moovit’s urban mobility application, a key component of the 2023 strategy in the original answer, is entirely omitted. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable; all references to years (2022, 2023) are correct, earning full marks. (3) The multi-hop reasoning is partially sound—the model correctly infers a strategic expansion from 2022 to 2023, but fails to accurately synthesize the specific evolution involving Moovit and MaaS ecosystems, instead introducing unrelated product lines like SuperVision and EyeQ6L/H, which are not part of the documented strategy shift. (4) The correctness score is 7 because core facts about partnerships and strategic direction are accurate, but significant details are either missing (Moovit integration, MaaS focus) or incorrectly added (consumer AV focus via Chauffeur), reducing overall fidelity. Qualitative accuracy is 7 due to these factual deviations, while contextual relevance remains high as the response stays focused on the evolution of Mobileye Drive™.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 448,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "The structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024 as follows: In 2022, the Tower preferred interests comprised two series with fixed rates of 5.0% (September series) and 4.75% (December series), reset every five years. By 2024, the structure was restructured into **Fixed Rate Class A Limited Membership Interests** (paying 5.90%) and **Floating Rate Class A Limited Membership Interests** (based on SOFR + 250 basis points, potentially reaching $525 by 2028 if not called). The distribution rate increased for the fixed component and introduced a floating rate mechanism, reflecting a shift from purely fixed rates to a hybrid structure with potential for rate adjustments tied to market conditions.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the Tower Preferred Interests from 2022 to 2024. (1) It correctly identifies the two 2022 series with their respective distribution rates: 5.0% for the September series and 4.75% for the December series, noting the five-year reset period. It accurately describes the 2024 restructuring into Fixed Rate Class A Limited Membership Interests at 5.90% and the introduction of Floating Rate Class A Limited Membership Interests tied to SOFR + 250 bps. (2) The only minor quantitative deviation is the mention of '$525 by 2028 if not called', which does not appear in the ground truth and introduces an unverified dollar amount and timeline; this detail is extraneous and unsupported, slightly reducing quantitative accuracy. (3) The reasoning is sound: it correctly synthesizes the shift from fixed-rate series in 2022 to a hybrid fixed/floating structure in 2024, reflecting a multi-hop understanding across time and structure. (4) The answer is contextually excellent—directly addressing the structural and rate evolution as asked. The core facts, entities, and timeline are correct, with only a small addition of unsupported detail preventing a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 342,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "The Balanced Index Fund's Level 3 assets evolved from 2022 to 2023 with changes in unrealized gains/(losses) across fixed income categories. In 2022, Level 3 assets showed unrealized losses of ($16) for corporate securities, ($11) for mortgage-backed/asset-backed, and ($14) for municipal bonds. By 2023, these unrealized gains shifted to $2 for corporate, $6 for mortgage-backed/asset-backed, and $3 for other fixed income securities, reflecting improved market performance. The investment approach involved holding these securities, with valuation methods based on market approaches and inputs like quoted prices and cash flow analysis.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift from unrealized losses in 2022 to gains in 2023 for corporate and mortgage-backed/asset-backed securities, aligning with the ground truth. However, it introduces incorrect data not present in the original answer: specifically, unrealized losses of ($14) million for municipal bonds in 2022 and gains of $3 million for 'other fixed income securities' in 2023. These figures are not mentioned in the ground truth and represent factual inaccuracies. Additionally, the ground truth does not mention municipal bonds or 'other fixed income securities' in this context, indicating fabrication or misattribution. (2) The correct numbers from the ground truth are: 2022 losses of ($16)M (corporate) and ($11)M (mortgage/asset-backed); 2023 gains of $2M and $6M respectively. The LLM reproduces these correctly for corporate and mortgage-backed/asset-backed securities but adds unsupported figures, reducing quantitative accuracy. (3) The reasoning correctly captures the turnaround in performance and implies improved market conditions, which is consistent with the original answer. However, it fails to mention the key qualitative point about the valuation methodology shift in 2023—specifically, the explicit reference to a market approach using Level 1 inputs—which is a significant part of the investment approach evolution. This omission affects completeness and qualitative accuracy. (4) The answer is contextually relevant and addresses the core of the question regarding evolution in gains/losses and investment approach, but the inclusion of incorrect data and missing methodological detail limits correctness. The score reflects partial accuracy with significant factual overreach in one category and a missed key point in another.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 487,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "BNY Mellon's emphasis on accounting developments in forward-looking statements remained consistent between 2023 and 2024, with both filings explicitly noting that changes in accounting standards could materially impact financial reporting, results of operations, and capital metrics. This consistency suggests that accounting standards continue to influence strategic priorities, though no significant evolution in focus is evident from the provided documents.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that BNY Mellon's emphasis on accounting developments 'remained consistent' between 2023 and 2024. The ground truth shows a clear evolution: in 2023, accounting developments were mentioned as part of a general list of influences, but in 2024, the language was expanded to explicitly integrate accounting developments into strategic business considerations such as capital plans, dividends, repurchases, and efficiency savings. The LLM incorrectly concludes there was 'no significant evolution in focus,' which directly contradicts the documented shift toward a more integrated and strategic treatment of accounting changes. While the answer correctly identifies that accounting standards impact financial reporting and capital metrics (contextually relevant), it fails to capture the nuanced progression in language and strategic framing. There are no numeric values in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2023, 2024), which are accurate. The qualitative reasoning is flawed because the model fails to perform the necessary multi-hop comparison of the forward-looking statement language across years, leading to an incorrect synthesis. Thus, despite some relevant terminology, the answer misses the central point of evolution in emphasis and strategic integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 381,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "The evolution of risks related to store safety and cybersecurity in 2023, as highlighted in HD_10k_2023.pdf, introduced challenges that could negatively impact the associate experience compared to the engagement-focused initiatives of 2022. While 2022 emphasized programs like pulse checks, recognition, and cultural engagement to boost associate morale, 2023's risk factors underscored heightened threats such as organized retail crime, cybersecurity breaches, and remote work vulnerabilities. These risks necessitated increased security measures and operational changes, potentially creating a more stressful or less secure work environment. This contrasts with 2022's proactive engagement strategies, which aimed to foster emotional commitment and reduce turnover, suggesting a shift from fostering positive engagement to managing safety and security challenges that could strain associate experience.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original (ground truth) answer. (1) All factual elements are correct: the 2022 engagement initiatives (pulse checks, recognition, cultural engagement) are accurately described, and the 2023 risks (organized retail crime, cybersecurity threats, remote work vulnerabilities) are correctly identified. The contrast between proactive engagement in 2022 and reactive risk management in 2023 is clearly and correctly articulated. (2) There are no numeric values, percentages, or financial figures in the question or ground truth that require verification—thus, quantitative accuracy is 10 as no inaccuracies exist. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2023) and domains (engagement initiatives vs emerging risks), drawing a logical conclusion about the potential negative impact on associate experience. The only minor shortcoming is that the LLM mentions 'remote work vulnerabilities'—a detail not explicitly present in the ground truth—though it is contextually plausible within cybersecurity risks and does not materially distort the answer. (4) The answer is fully relevant to the question, directly addressing the evolution of risks and their potential impact on associate experience compared to prior-year initiatives. Overall, the response is semantically equivalent to the ground truth with excellent reasoning and no factual errors, warranting a correctness score of 9 (nearly perfect, with only negligible addition of a plausible but unconfirmed detail).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 432,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "The role of the learning curve in influencing cost and production estimates evolved between 2022 and 2023 by becoming more explicitly acknowledged as a factor in program profitability and risk management. In 2022, the 777X program's revised schedule and design changes led to a $6.5 billion reach-forward loss, highlighting how learning curve benefits were offset by certification delays and supply chain disruptions. By 2023, the learning curve was noted as a key input in cost estimates, but its effectiveness was tempered by ongoing challenges like production quality issues (e.g., 787 program) and regulatory uncertainties, which increased abnormal production costs and risk of additional losses. The 2023 filings emphasized that while learning curve efficiencies could reduce unit costs, they were now evaluated alongside heightened risks, leading to more conservative estimates and adjustments to reach-forward losses. This shift reflects a more integrated approach to balancing learning curve benefits with broader program-specific risks.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it references the 777X program and a $6.5 billion reach-forward loss in 2022, which is not supported by the ground truth and misattributes program-specific details. The original answer focuses on the 787 program as the key example, not 777X. Additionally, no specific dollar amount (e.g., $6.5B) was mentioned in the ground truth for 2022 losses tied to the learning curve, making this a significant quantitative fabrication. (2) Quantitative accuracy is low because the $6.5 billion figure is incorrect or unverifiable from the provided truth, and no such number appears in the original answer. There are no verifiable calculations or numeric benchmarks in the ground truth to support the LLM's specific claim. (3) The multi-hop reasoning is partially sound— the LLM correctly identifies a shift in how the learning curve is treated from risk to a factor in cost estimation—but it distorts the context by citing the wrong program (777X vs 787) and introducing regulatory uncertainties and certification delays not mentioned in the original. The conclusion about a more 'integrated approach' aligns somewhat with the original's notion of integration into planning, but the emphasis on 'tempered effectiveness' and 'conservative estimates' adds interpretation not present in the ground truth. (4) Contextual relevance is high because the answer addresses the evolution of the learning curve’s role in cost estimation, profitability, and risk management across 2022–2023. However, due to incorrect entity attribution (777X instead of 787) and invented financial figures, the factual correctness is significantly compromised, warranting a mid-low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 475,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "The treatment and disclosure of the Dividend Reinvestment Plan (DRP) in the 2023 and 2024 SEC filings remain consistent, with both documents noting that certain officers and directors participate in the DRP, along with other plans like the employee stock purchase plan and 401(k) plan. Both filings also mention that shares withheld for taxes or stock awards may be subject to Rule 10b5-1 affirmative defense conditions or non-Rule 10b5-1 trading arrangements. No material changes in disclosure or participation specifics are observed between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the treatment and disclosure of the Dividend Reinvestment Plan (DRP) remained consistent between the 2023 and 2024 filings. The ground truth explicitly states that while both years mention officer or director participation in the DRP alongside other plans, the 2024 filing omitted the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements that was present in the 2023 filing—indicating a reduction in disclosure specificity. The LLM incorrectly asserts that both filings include this detailed trading arrangement information, which contradicts the ground truth. There are no numeric values to evaluate, so quantitative accuracy is scored as 10 by default (no errors in numbers). However, the qualitative accuracy is very low because the model fails to identify a key change in disclosure depth, misrepresents the evolution of the DRP treatment, and does not reflect the simplification or standardization noted in the original answer. Contextual relevance is moderate because the response addresses the right topic (DRP participation by officers/directors and trading arrangements) and the correct filings, but draws an incorrect conclusion about consistency. The multi-hop reasoning fails: the model should have contrasted the presence vs. absence of Item 408(c) trading framework details across years but instead assumed consistency without justification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 396,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "The Home Depot's investment in an interconnected shopping experience grew from $2.6 billion in fiscal 2021 to $3.2 billion in fiscal 2023, with enhanced focus on digital integration, personalized marketing, and supply chain efficiency. Specific changes included expanding mobile app capabilities for seamless navigation and product insights, improving in-store layouts with self-checkout and real-time inventory tools, and leveraging data to tailor recommendations. The company also expanded fulfillment centers for faster delivery options (e.g., BOPIS, BOSS) and integrated online and in-store services to create a unified customer journey.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The original answer states that The Home Depot invested $2.6 billion in fiscal 2021 in capital expenditures for an interconnected shopping experience, but the LLM incorrectly claims the investment grew to $3.2 billion in fiscal 2023 — this figure is not supported by the ground truth and introduces a false increase. There is no mention in the original answer of the $3.2 billion figure, nor any specific total investment amount for 2023. (2) The qualitative aspects partially align: the original answer notes a strategic shift toward using enhanced merchandising IT tools to tailor the experience based on shopping intent and location, which reflects a more data-driven, personalized approach. The LLM correctly identifies trends like digital integration, data-driven recommendations, and unified online/in-store experiences, which are semantically consistent with the evolution described. However, it fabricates specific initiatives (e.g., expanding mobile app capabilities, changing in-store layouts, building fulfillment centers) that are not mentioned or implied in the ground truth. (3) The multi-hop reasoning is partially sound — the model infers a progression from infrastructure investment to personalized experience, which is valid, but fails to base its synthesis strictly on the provided data, instead adding unsupported details. (4) The contextual relevance is high because the answer addresses the evolution of the interconnected shopping experience and attempts to describe personalization changes. However, due to the incorrect financial figures and invented details, the correctness and quantitative accuracy scores are low. Minor formatting variations in dollar amounts would be acceptable, but introducing a new, incorrect value like $3.2B is a major error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 510,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "Between 2022 and 2023, DHR's financial relationship with Aldevron, acquired in 2021, involved continued capital investment and acquisition-related expenditures. In 2022, DHR estimated capital expenditures at **$1.5 billion**, driven by increased manufacturing capacity to support customer demand, including for Aldevron's products. While no new acquisitions of Aldevron were announced during this period, the company incurred **$28 million in transaction-related costs** for the 2021 Aldevron acquisition and ongoing adjustments to fair value estimates. Additionally, DHR's 2023 financial disclosures highlighted further investments in Aldevron's operations as part of broader strategic growth initiatives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly states DHR's $1.5 billion capital expenditure estimate for 2022, it incorrectly claims Aldevron was acquired in 2021—this is not supported by the ground truth, which focuses on 2022–2023 developments. More critically, the LLM reports only $28 million in transaction-related costs, which grossly understates the actual net cash consideration paid in 2023 of $9,561 million (over $9.5 billion), a key fact in the evolution of the financial relationship. This omission or misrepresentation severely undermines the quantitative and qualitative accuracy. (2) The $1.5 billion figure is correct and matches the ground truth. However, the $28 million in transaction costs is not aligned with the $9,561 million net cash paid in 2023, which represents the central financial event in the relationship's evolution. The LLM fails to mention this pivotal figure, instead focusing on minor costs. (3) The multi-hop reasoning is flawed. The question asks about the evolution between 2022 and 2023, particularly acquisition-related expenditures. The ground truth shows a shift from preparatory capital investment in 2022 to full acquisition integration in 2023 via a $9.56 billion cash payment. The LLM does not capture this transformation, instead implying ongoing costs from a prior 2021 acquisition, which contradicts the ground truth narrative of a 2023 consolidation. (4) The contextual relevance is high because the answer addresses capital investment and acquisition-related spending and focuses on the correct companies and time frame. However, due to major factual errors in key financial figures and the timeline of the acquisition, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the structure and intent of the response are sound, but the reasoning is based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 516,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "From 2022 to 2024, Telco LLC's preferred interests expanded from $2,000 (initial issuance in 2020) to $7,250 by December 31, 2023, with an additional $2,250 issued in 2024. Distribution rates evolved as follows: the original Class A-1 preferred interests had a 4.25% annual rate reset every seven years, while new issuances (Class A-2/A-3 in 2023 and Class A-4 in 2024) carried higher rates (6.85% and 5.94%, respectively) with reset schedules adjusted to every seven years (for A-2/A-3) and every four years (for A-4, starting in 2028). These changes reflect structural modifications to align with market conditions and liquidity needs.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly identifies the initial $2,000 in preferred interests (Class A-1) with a 4.25% distribution rate, it incorrectly states that the total reached $7,250 by December 31, 2023, due to an additional $2,250 issued in 2024. The ground truth states that the $5,250 in new preferred interests (Classes A-2 and A-3) were issued in April 2023, not $2,250 in 2024. This results in a total of $7,250 by April 2023, not December 2023 or 2024. The LLM also fabricates a 'Class A-4' issuance in 2024 with a 5.94% rate and a four-year reset, which is not present in the original answer. (2) Quantitative errors include: incorrect issuance amount in 2024 ($2,250 vs. $0 in 2024), incorrect total timing (implying growth into 2024 when all was done by April 2023), and introduction of a non-existent class (A-4) with incorrect rate (5.94%) and reset schedule (every four years). The correct new issuance was $5,250 in April 2023, not $2,250 later. (3) The multi-hop reasoning is partially sound in recognizing structural expansion and rate changes, but fails in synthesis by inventing entities and timelines. The model incorrectly infers a continued issuance pattern into 2024 and introduces reset schedules not in the source. (4) Correctness is scored 4 due to partial accuracy on initial structure and some correct rates, but major errors in amounts, timing, and invented instruments. Quantitative accuracy is low (3) due to incorrect numbers and calculations. Qualitative accuracy is moderate (5) as the general trend of increasing rates and structural change is noted, but with flawed details. Contextual relevance is high (8) as the answer addresses the right concepts and structure, just with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 484,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "AIG's use of Expected Loss Ratio (ELR) methods between 2022 and 2024 expanded to include more specialized lines like **U.S. Workers' Compensation** and **Excess Casualty**, alongside continued application in **aviation** and **property**. The rationale evolved to emphasize **adjusting ELR for rate changes, loss trends, and market conditions**, particularly for high-severity, low-frequency exposures. For example, in 2024, ELR was applied to excess-of-deductible business, with adjustments for inflation and underwriting cycle impacts. This reflects a more dynamic approach, tailoring ELR to lines with complex risk profiles, such as long-tail workers' compensation and volatile excess casualty, where traditional methods may be less reliable.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but introduces inaccuracies in entity identification and scope of method application. (1) Correct elements: The expansion of Expected Loss Ratio (ELR) methods to U.S. Workers' Compensation by 2024 aligns with the ground truth, as does the continued use in aviation. The rationale involving adjustments for rate changes, loss trends, and market conditions adds contextual detail that is plausible and relevant. (2) Quantitative accuracy: There are no explicit numbers (dollars, percentages, dates) in either answer, so no numeric inaccuracies exist—this aspect is neutral and does not detract. (3) Multi-hop reasoning assessment: The ground truth specifies that in 2022, ELR was used primarily for the latest accident year and in combination with other methods for aviation; by 2024, it expanded to U.S. Workers' Compensation, a long-tail line. The LLM correctly identifies this progression for Workers' Compensation but incorrectly adds 'Excess Casualty' and 'property' as lines where ELR was applied, which are not mentioned in the ground truth. Additionally, the mention of 'excess-of-deductible business' and specific adjustments for inflation and underwriting cycles, while reasonable, are not supported by the original answer and represent unsupported elaboration. (4) The answer conveys a similar direction of evolution—broader application across complex lines—but overreaches in specificity and introduces unverified lines of business and methodological details. Thus, while the core idea of expanded use and more dynamic application is correct, the inclusion of unsupported insurance lines and rationales reduces factual accuracy, warranting a score of 6 for correctness and qualitative accuracy. Contextual relevance remains high as the response directly addresses the evolution of ELR methods over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 498,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "Target's approach to its owned brands evolved from 2023 to 2024 by expanding the breadth and depth of its signature partnerships and introducing new owned brands, such as \"More Than Magic™\" and \"Wondershop™,\" while maintaining a strategic emphasis on curating national brands and leveraging loyalty programs like Target Circle 360™ to drive engagement. The 2024 filing highlights continued investment in global sourcing and quality assurance for owned brands, alongside enhanced digital integration to strengthen their market presence.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes some correct elements, such as the strategic emphasis on owned brands and the general direction of portfolio expansion. However, it introduces specific brand names like 'More Than Magic™' and 'Wondershop™' and programs like 'Target Circle 360™' that are not mentioned in the ground truth and cannot be verified from the provided knowledge. The original answer emphasizes a shift from strategic intent in 2023 to concrete execution and diversification in 2024, specifically noting over 40 distinct owned and exclusive brands. The LLM answer references this expansion but does not include the key detail of 'over 40 distinct brands,' which is a critical quantitative marker of the evolution. (2) There are no explicit numerical errors (e.g., dates like 2023–2024 are correct), so quantitative accuracy is high, though the missing 'over 40 brands' figure is a significant omission. (3) The multi-hop reasoning is partially sound—the model correctly infers progression in brand development, but fails to synthesize the specific evidence (40+ brands) that demonstrates the shift from strategy to execution. Instead, it substitutes unverified brand and program names, indicating potential hallucination. (4) The contextual relevance is fair because the answer addresses strategic emphasis and product development, but the inclusion of unsupported specifics reduces factual reliability. Correctness is penalized due to incomplete and partially inaccurate synthesis, despite correct temporal framing and general strategic understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 436,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggests a strategic balance between maintaining lower-cost, long-term debt (0.875%) and issuing higher-yield debt (2.900%) to capitalize on favorable market conditions. This reflects IBM's approach to debt management, leveraging existing low-rate obligations while securing new funding at current rates, which may indicate a stable but evolving market for long-term borrowing. The presence of both issuances highlights IBM's ability to navigate interest rate fluctuations and optimize its capital structure.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the two notes—0.875% and 2.900% Notes due 2030—and their continued listing in 2024, which aligns with the ground truth. All numeric values (interest rates, maturity year) are accurate, satisfying quantitative accuracy. (2) There are no calculation errors, and the percentages (0.875%, 2.900%) and year (2030) match the original answer exactly. Format is consistent and precise. (3) The reasoning partially captures the multi-hop insight: while the LLM suggests IBM is 'capitalizing on favorable market conditions' with higher-yield debt, this contradicts the ground truth implication that the higher rate (2.900%) likely reflects *less favorable* borrowing conditions in 2024 compared to when the 0.875% notes were issued. The original answer emphasizes deteriorated market conditions or targeting different investor segments, whereas the LLM incorrectly frames the higher rate as a sign of favorable conditions. This misrepresents the causal logic. (4) Despite this key reasoning flaw, the LLM does correctly infer strategic debt management and capital structure optimization, which are relevant and contextually appropriate. It misses the nuance of refinancing risk diversification and different investor targeting mentioned in the ground truth. Thus, while factually sound on numbers and entities, the qualitative interpretation is partially incorrect, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 398,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "Between 2022 and 2024, AT&T issued the **4.000% Global Notes due June 1, 2049** (listed as **T 49A** in the 2024 10-K) and added several new long-term debt instruments, including the **4.250% Global Notes due June 1, 2043** (T 43) and **4.875% Global Notes due June 1, 2044** (T 44). These notes were not present in the 2022 10-K, indicating their issuance in 2024 as part of AT&T's evolving long-term debt structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the 4.000% Global Notes due June 1, 2049 (T 49A) were already present in 2022, but the LLM incorrectly claims they were 'issued' between 2022 and 2024, implying they did not exist before. Additionally, the LLM introduces two new notes — the 4.250% Global Notes due 2043 (T 43) and 4.875% Global Notes due 2044 (T 44) — which are not mentioned in the ground truth. Instead, the actual new note added by AT&T was the 4.300% Global Notes due November 18, 2034 (T 34C), which the LLM completely omits. (2) Quantitatively, the percentages (4.250%, 4.875%), maturities (2043, 2044), and ticker symbols (T 43, T 44) are all incorrect. The only correct quantitative element is the 4.000% rate and June 1, 2049 maturity for T 49A, though its timing of issuance is misrepresented. (3) The multi-hop reasoning is flawed: the model fails to correctly compare the presence of debt instruments across 2022 and 2024 filings. It incorrectly infers which notes were added and misrepresents the continuity of the 2049 notes. The synthesis across years is therefore invalid. (4) While the answer addresses the general theme of debt evolution and new note issuance, the core factual content diverges from the ground truth, leading to a low correctness score. Contextual relevance is moderate because the structure and intent align with the question, but accuracy is severely lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 405,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "The financial impact of the Heritage AspenTech acquisition evolved between 2023 and 2024 as follows:  \n- **Intangibles amortization**: In 2023, the acquisition contributed **$258 million** to intangibles amortization, while in 2024, the **NI acquisition** added **$560 million** to intangibles amortization. The Heritage AspenTech-specific amortization for 2024 is not explicitly stated but was part of the broader $1,077 million total intangibles amortization in 2024.  \n- **Restructuring costs**: Heritage AspenTech contributed **$1 million** in 2023 and **$8 million** in 2024, reflecting ongoing integration and operational adjustments.  \n\nThese figures highlight the shift in amortization focus to the NI acquisition in 2024 and incremental restructuring expenses tied to Heritage AspenTech.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, intangibles amortization for Heritage AspenTech was $258 in 2023 and decreased to $97 in 2024. However, the LLM incorrectly states that the 2024 amortization for Heritage AspenTech is unspecified and conflates it with the 'NI acquisition,' claiming $560 million and a total of $1,077 million in 2024—none of which aligns with the ground truth. Similarly, restructuring costs are grossly underreported: the LLM claims $1 million in 2023 and $8 million in 2024, whereas the correct figures are $72 and $228, respectively. These errors affect all key metrics. (2) The numbers provided in the LLM answer do not match the ground truth in magnitude or context. There is no mention of the NI acquisition in the original answer, suggesting the LLM introduced a hallucinated entity. The use of 'million' is assumed based on context, but even with unit adjustments, the values are orders of magnitude off (e.g., $8M vs $228). (3) The multi-hop reasoning is flawed—the LLM fails to correctly isolate the financial impact of the Heritage AspenTech acquisition over the two years and instead shifts focus to another acquisition not mentioned in the question or ground truth. It does not demonstrate proper synthesis of the required data points. (4) While the structure of the response is relevant and addresses the general categories (amortization and restructuring), the severe factual and quantitative errors—especially in core financial figures—drastically reduce correctness. The introduction of irrelevant information (NI acquisition) further undermines accuracy. Only the directional mention of restructuring increasing is vaguely consistent, but even that is misrepresented in scale.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 484,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "AIG's use of expected loss ratio methods for U.S. Workers' Compensation remained consistent between 2022 and 2024, with continued emphasis on segmenting business into **guaranteed cost** and **excess of deductible** categories. For excess of deductible business, the proportion of **large deductible accounts increased**, slowing claim reporting patterns and necessitating reliance on expected loss ratios to account for longer emergence timelines. In 2024, AIG further refined its approach by adjusting expected loss ratios for recent accident years based on rate changes, loss trends, and market conditions, while maintaining segmentation by deductible size and claim handling (AIG vs. third-party administrators). This methodology reflects ongoing adaptation to evolving risk profiles and claim dynamics.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies key elements from the ground truth: the segmentation into guaranteed cost and excess of deductible business, the increasing proportion of large deductible accounts, and the resulting slower claim reporting patterns. It also correctly notes AIG's continued use of expected loss ratio methods and the refinement in 2024 with segmentation by deductible size and claim handling. However, it introduces new information not present in the original answer—specifically, that in 2024 AIG adjusted expected loss ratios based on 'rate changes, loss trends, and market conditions'—which is not mentioned in the ground truth and thus represents an unsupported addition. Additionally, the LLM omits a key point from the original answer: the 2024 emphasis on limitations in claim count data due to aggregation and reinsurance exclusions, which were not prominently noted in 2022. This omission reduces completeness and qualitative accuracy. (2) There are no numerical values, percentages, or dates in either the question or answers that require verification; all temporal references (2022, 2024) are accurate and consistent with the ground truth. Thus, quantitative accuracy is high. (3) The multi-hop reasoning is partially sound—the model correctly synthesizes the evolution of methodology across years and business segments—but fails to include the full scope of 2024 disclosures regarding data limitations, indicating incomplete reasoning. (4) The correctness score is 7 because core facts are accurate and the overall trajectory of AIG’s methodological evolution is reasonably conveyed, but the answer includes unsupported details and misses a significant differentiating factor in 2024 disclosures. Qualitative accuracy is 7 due to these omissions and additions. Contextual relevance is high as the response stays focused on the question, and quantitative accuracy is 10 since no numbers are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 525,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "Target's approach to cybersecurity threat investigation and response, including its Cyber Fusion Center operations and collaboration with external organizations, remained consistent between 2023 and 2024. Both filings describe the Cyber Fusion Center as a key component for investigating and responding to threats, and both emphasize ongoing collaboration with cross-industry organizations to share threat intelligence, combat cybercrime, and enhance privacy and regulatory understanding. No specific evolution or new initiatives were highlighted in the 2024 filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that there was no evolution in Target's cybersecurity approach from 2023 to 2024. The ground truth confirms significant developments in 2024, including a more structured incident response program with a coordinated escalation model to management and the Board, expanded external engagement through regular training and compliance activities, and the use of third-party vendors to assess and test the cybersecurity program. The LLM incorrectly claims no specific evolution or new initiatives were highlighted in 2024, which directly contradicts the ground truth. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning failed: the model did not synthesize the progression from 2023 (basic Cyber Fusion Center operations and industry collaboration) to 2024 (enhanced structure, escalation protocols, training, and third-party testing). Instead, it erroneously concluded consistency across years, missing key qualitative developments. (4) Contextual relevance is moderate because the answer discusses the correct topic (Cyber Fusion Center, external collaboration) and correct entity (Target), but fails to report the actual evolution, rendering it misleading despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 389,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "Eli Lilly's financial relationship with Baqsimi evolved between 2023 and 2024, with revenue recognition shifting from ongoing product sales to a one-time transaction. In 2023, Baqsimi's product revenue totaled $677.6 million (with $645.7 million in the U.S. and $31.9 million outside the U.S.), but the U.S. revenue increase was partially driven by a $579.0 million sale of Baqsimi rights, which contributed to collaboration revenue. By 2024, Baqsimi's product revenue was no longer reported, indicating the product sales ceased, and the contractual arrangement transitioned to a one-time rights sale in 2023, with no further revenue recognized in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. It incorrectly states that Baqsimi's total product revenue in 2023 was $677.6 million, with $645.7 million in the U.S. and $31.9 million internationally. This is not supported by the ground truth, which does not mention ongoing product sales at this level. Instead, the $579.0 million figure in 2023 refers specifically to the sale of rights for Baqsimi, not product revenue. The LLM conflates product revenue with collaboration revenue and misattributes the $579.0 million as part of U.S. product sales, which distorts the financial narrative. (2) The calculation of $645.7M + $31.9M = $677.6M is mathematically correct, but the underlying data is factually wrong per the ground truth, which only confirms the $579.0 million rights sale. The claim that Baqsimi product revenue ceased in 2024 and was no longer reported is partially aligned with the ground truth, which states Baqsimi was folded into broader collaboration revenue, not that revenue ceased. (3) The multi-hop reasoning is partially sound—the model recognizes a shift in revenue recognition from 2023 to 2024 and infers a strategic change in contractual arrangements. However, it mischaracterizes the nature of the 2023 transaction by embedding the rights sale within product revenue rather than identifying it as a distinct collaboration-related revenue event. The ground truth emphasizes integration into broader collaboration revenue in 2024, not termination of revenue. (4) The contextual relevance is high because the answer addresses revenue recognition and contractual evolution, but the correctness score is low due to major quantitative errors and a misleading narrative about product sales. The qualitative accuracy is moderate because the direction of reasoning (shift in accounting treatment) is correct, but the factual basis is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 521,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "AT&T repurchased all remaining Mobility Preferred Interests in April 2023 for $5,414, funded by proceeds from issuing additional Telco LLC preferred interests. In 2024, the company expanded its Telco LLC preferred interests by issuing $2,250 of new nonconvertible cumulative preferred interests (Telco Class A-4) to fund preferred equity redemptions, while restructuring Tower Holdings' preferred interests in August 2024 to reset rates and convert portions to floating-rate obligations.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key developments in AT&T's capital structure management from 2023 to 2024, with only minor omissions and slight imprecision in quantitative details. (1) Correctly identifies the 2023 repurchase of all remaining Mobility Preferred Interests for $5,414 and links it to funding via Telco LLC preferred interest issuance. However, it omits the specific breakdown of liabilities removed ($2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities') and does not mention the 6.85% distribution rate on the new Telco LLC preferred interests, which is a relevant financial term. (2) The 2024 Tower Holdings restructuring is correctly noted, including the shift to fixed and floating rate classes, but the LLM fails to specify the $6,000 amount involved and the 5.90% base rate, instead vaguely stating 'reset rates'. The date 'August 2024' is plausible but not confirmed in the ground truth. (3) The LLM states that $2,250 in new Telco Class A-4 preferred interests were issued, but the ground truth indicates total Telco LLC preferred interests increased to $7,250 (from $5,000: $2,000 original + $5,250 issued in 2023), implying only $2,000 net new issuance in 2024, not $2,250—this is a minor quantitative discrepancy. (4) The reasoning is sound: the model correctly infers a strategic shift from repurchasing legacy interests to issuing new structured preferred instruments. It synthesizes multi-hop information across years and entities (Mobility, Tower Holdings, Telco LLC) and maintains semantic equivalence in overall narrative. Contextual relevance is perfect—it directly addresses the evolution of AT&T’s capital structure strategy. Minor factual gaps and one small numerical inconsistency prevent a top score, but core facts and logic are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 497,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "Emerson's relationship with AspenTech evolved from partial ownership (55% post-2023 acquisition) to full ownership in 2024, as Emerson proposed acquiring the remaining shares at $240 per share. This transformation positively impacted gross margin through the Test & Measurement acquisition, which contributed to a 1.8 percentage point increase in gross margin to 50.8% in 2024. However, acquisition-related inventory step-up amortization of $231 reduced margins by ~1.3 percentage points. Ownership structure shifted from 55% in 2023 to 100% by 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states that Emerson moved from 55% ownership in 2023 to full (100%) ownership in 2024, but the ground truth does not support a full acquisition by 2024—only a 55% stake was acquired. The claim that Emerson 'proposed acquiring the remaining shares at $240 per share' is not mentioned in the original answer and appears fabricated. Additionally, the LLM attributes gross margin impacts to the 'Test & Measurement acquisition,' which is not referenced in the ground truth; instead, the margin improvements were due to the AspenTech transaction itself. The $231 inventory step-up amortization figure and its 1.3 percentage point margin impact are also not in the original and contradict the provided data. (2) Quantitatively, the answer is largely incorrect: while it mentions a 1.8 percentage point increase in gross margin in 2024 (which aligns with the original), it misattributes the cause and introduces false figures like $231 and 50.8%. The original states AspenTech contributed a 3.3 point increase in 2023 and 1.8 points in 2024 as part of broader changes—this nuance is lost. The $6.0 billion cash payment is omitted entirely. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from partnership to 55% ownership and incorrectly infers a full acquisition. It confuses AspenTech with unrelated acquisitions and misattributes financial impacts. (4) Despite these issues, the answer is contextually relevant—it addresses the relationship evolution and financial impacts as asked, and the 1.8 point margin improvement in 2024 is correctly cited—hence a moderate relevance score. However, core facts, entities, and financial causality are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 491,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "AIG's Japan pension plans contributed approximately 54% of total non-U.S. pension obligations at December 31, 2023, and 50% at December 31, 2024, reflecting a slight decrease. The weighted average discount rate applied to these plans increased from 1.09% in 2022 to 2.87% in 2024, as noted in the 2024 Form 10-K.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. While it correctly states that AIG's Japan pension plans' share of non-U.S. pension obligations decreased from 54% in 2023 to 50% in 2024 (matching the ground truth), it incorrectly claims the weighted average discount rate increased from 1.09% in 2022 to 2.87% in 2024. According to the ground truth, the discount rate increased from 1.48% in 2023 to 1.81% in 2024; the 2022 rate is not provided in the original answer, and the values cited by the LLM are factually incorrect. Additionally, the LLM introduces a 2.87% rate in 2024, which contradicts the ground truth of 1.81%. (2) The quantitative accuracy is low because two of the three numerical claims (discount rates for 2022 and 2024) are incorrect, and the magnitude of the error is substantial (e.g., 2.87% vs 1.81%). The only correct number is the 54% and 50% share of obligations in 2023 and 2024. (3) The reasoning is partially sound in identifying a decline in Japan's contribution and an increase in the discount rate, but the multi-hop synthesis fails because the LLM uses incorrect data points, likely from a misreading of source documents or incorrect attribution across years. It also omits the 2022 baseline (61% of non-U.S. pension *assets*, though that is about assets, not obligations), but the question asks about obligations, which the LLM correctly addresses. (4) Contextual relevance is high because the answer addresses both parts of the question—evolution of contribution and change in discount rate—and attempts to provide a trend-based summary. However, due to major numerical inaccuracies, especially in the discount rate figures, the overall correctness score is low despite partial completeness and relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 486,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "Amazon's 2023 10-K filing expanded on the framing of external market conditions compared to 2022 by emphasizing **global economic volatility** (e.g., recessionary fears, inflation) and **geopolitical risks** as critical factors impacting demand and competition. While 2022 focused on regulatory challenges in key markets (e.g., China, India) and local competitive advantages, 2023 integrated broader macroeconomic pressures and geopolitical events into its risk discussion, reflecting a more holistic view of external market dynamics. This shift underscores Amazon's recognition of systemic risks beyond traditional regulatory and competitive concerns.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable—scored as 10 by default since there are no incorrect numbers. However, the qualitative accuracy is low because the LLM misrepresents key aspects of Amazon's 10-K disclosures. The original answer states that the core language about competitive stores remained unchanged between 2022 and 2023, with the 2023 filing embedding that language within a broader discussion of external economic and geopolitical conditions. In contrast, the LLM claims the 2022 filing focused on 'regulatory challenges in key markets (e.g., China, India)' and 'local competitive advantages,' which is not supported by the ground truth. The original answer makes no mention of regulatory issues or geographic specifics in either year. Additionally, the LLM introduces 'recessionary fears, inflation' and 'geopolitical events' as new in 2023, but the ground truth only confirms a reframing—embedding existing competitive language into a broader external risk context—not the introduction of new macroeconomic examples. The answer captures the general direction of the shift (toward broader external risks), so it has partial correctness and remains contextually relevant, but it fabricates specific details and misattributes content to the filings. Thus, while the high-level theme of a more holistic external framing is aligned, the reasoning is flawed due to unsupported specifics, resulting in a correctness score of 5 for partial accuracy with significant errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 417,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "Target's exposure to port security risks remained consistent between 2023 and 2024, with no significant changes in geographic focus or operational impact explicitly noted. Both filings highlight port security as part of broader supply chain risks, including disruptions from geopolitical conflicts, natural disasters, and global trade uncertainties. The 2023 document specifically mentions port closures and ship diversions affecting U.S. ports, while the 2024 filing does not introduce new details on port security, indicating no material evolution in this risk area.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim that Target's exposure to port security risks 'remained consistent' with 'no significant changes' between 2023 and 2024. This directly contradicts the ground truth, which shows a clear evolution: in 2023, Target specifically identified California ports as a key risk area and noted it had made alternative arrangements due to past disruptions. By 2024, the company broadened its focus to 'major U.S. ports' (no longer singling out California), and shifted from reactive measures to emphasizing potential future impacts like increased costs and supply issues due to global conflicts and labor disputes. The LLM incorrectly states that the 2024 filing 'does not introduce new details' and that there was 'no material evolution,' missing the key multi-hop insight about geographic broadening and operational shift in risk framing. While there are no numerical inaccuracies (hence a high quantitative score), the qualitative analysis fails on entity synthesis, reasoning, and factual correctness. The answer is somewhat contextually relevant as it discusses port security and supply chain risks, but it draws the wrong conclusion about the evolution of the risk profile.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 341,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "Between 2023 and 2024, Emerson's financial relationship with Heritage AspenTech involved **ongoing intangibles amortization** and **restructuring costs**. In 2023, Heritage AspenTech's acquisition contributed to intangibles amortization of **$424** (part of the total $482 intangibles amortization), including $213 for inventory step-up, $136 for backlog, and $258 for other intangibles. In 2024, the total intangibles amortization rose to **$1,077**, with **$560 attributed to the NI acquisition** (not Heritage AspenTech). Restructuring costs increased from **$72 in 2023** to **$228 in 2024**, though specific Heritage AspenTech-related restructuring costs were not detailed. The 2024 figures reflect broader restructuring activities, including those from the NI acquisition and other operational initiatives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition in 2023, and this specific amortization was no longer reported in 2024. However, the LLM claims that $424 of intangibles amortization in 2023 was attributable to AspenTech (including $258 for other intangibles), which contradicts the original answer and introduces unverified subcomponents like $213 for inventory step-up and $136 for backlog not mentioned in the ground truth. Furthermore, the LLM states that total intangibles amortization rose to $1,077 in 2024 with $560 attributed to the NI acquisition, but the original answer makes no mention of the NI acquisition or total amortization figures, and explicitly states that AspenTech-related amortization was no longer reported in 2024—implying a decline or cessation, not a rise in total amortization. (2) The restructuring cost figures ($72 million in 2023, $228 million in 2024) are correctly reported, which is a key positive. However, the LLM fails to interpret the significance of the AspenTech amortization disappearing in 2024, instead implying ongoing amortization without specifying AspenTech’s role. (3) The multi-hop reasoning is partially sound—linking increased restructuring costs to integration efforts is reasonable—but the model incorrectly introduces the NI acquisition as a confounding factor not present in the original context, undermining the focus on AspenTech. It also fails to note the cessation of AspenTech-specific amortization, a critical evolution in the financial relationship. (4) The contextual relevance is high because the answer addresses amortization and restructuring costs as asked, but the qualitative accuracy is reduced by incorrect entity attribution and invented breakdowns. Quantitative accuracy is low due to incorrect dollar amounts and misattribution of amortization components. Correctness score is 4 due to partial correctness on restructuring costs but major errors on the core amortization narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 578,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "AIG's use of Expected Loss Ratio (ELR) methods between 2022 and 2024 shows an increased weighting in **more recent accident years** (2022–2024) across key lines of business, particularly **U.S. Workers' Compensation** and **U.S. Excess Casualty**. The 2024 10-K notes that ELR methods are given **significant weight for business written in excess of a deductible** in the most recent five accident years, reflecting adjustments for rate changes, inflation, and market conditions. For **mature accident years** (e.g., 2015–2017), loss development methods dominate, while ELR methods are emphasized in newer years due to their adaptability to evolving loss trends and severity profiles. This shift aligns with AIG's methodology of applying ELR to high-severity, low-frequency risks where historical data is less reliable, ensuring alignment with current economic and underwriting factors.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant factual inaccuracies and misrepresents the evolution of AIG's use of Expected Loss Ratio (ELR) methods between 2022 and 2024. (1) Correctly identifies that ELR methods are used more heavily in recent accident years and for high-severity, low-frequency lines, which aligns with the ground truth. It also correctly notes that ELR is applied where historical data is limited. However, (2) it incorrectly states that U.S. Workers' Compensation and U.S. Excess Casualty were key areas of increased weighting by 2024 without noting that Workers' Compensation represents a major expansion into a long-tail line — a key evolution highlighted in the original answer. While the LLM mentions U.S. Workers' Compensation, it fails to emphasize that this marks a strategic shift into a traditionally loss-development-dominated area, which is central to the 2024 change. (3) The LLM introduces 'U.S. Excess Casualty' as a focus area, which is not mentioned in the ground truth, introducing an unsupported entity. (4) It references 'the 2024 10-K' and 'most recent five accident years' with specific claims about deductibles and rate adjustments that are not present or verifiable in the original answer, suggesting fabrication or overinference. (5) The original answer emphasizes a methodological integration — combining ELR with loss development and frequency/severity methods in Workers' Compensation — which the LLM omits entirely. Instead, it frames the shift as a temporal weighting (recent vs. mature years), which, while partially valid, misses the cross-line expansion and integrated methodology that defines the evolution. Quantitative accuracy is moderate: no explicit numbers are wrong because none are cited, but implied timelines (2022–2024, 2015–2017) are plausible and not contradicted. However, the lack of specific methodological progression reduces factual precision. Qualitative accuracy is limited by incorrect emphasis and introduction of unsupported lines of business. Contextual relevance is high — the answer stays on topic and addresses the question's intent regarding evolution across time and lines — but reasoning is flawed in synthesizing the actual multi-hop progression: from short-tail professional lines (2022) to inclusion of long-tail Workers' Compensation (2024). Thus, while semantically related, the LLM answer does not accurately reflect the documented evolution in AIG’s reserving methodology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 658,
        "total_tokens": 2089
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023 through increased investment in capitalized video and music content, reflected in higher capitalized costs ($16.7B in 2022 to $17.4B in 2023) and associated expenses ($16.6B in 2022 to $18.9B in 2023). This growth aligns with expanded content libraries and original productions, monetized via Amazon Prime memberships and digital subscriptions. The shift toward accelerated amortization based on viewing patterns and longer remaining lives (3.5 years in 2023 vs. 2.6 years in 2021) suggests a focus on data-driven cost management and sustained content value, reinforcing Prime's competitive edge.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: capitalized video and music content costs increased from $16.7B in 2022 to $17.4B in 2023, and associated expenses rose from $16.6B to $18.9B. These numbers match the original answer exactly and are presented with acceptable formatting ($16.7B = $16.7 billion). (2) Quantitative accuracy is perfect—no calculation errors, and the direction and magnitude of change are correctly described. (3) The multi-hop reasoning is sound: the model connects increased capitalized costs and expenses to a more aggressive monetization and investment strategy. It adds context not in the ground truth—such as amortization patterns and remaining useful lives (3.5 years in 2023 vs. 2.6 in 2021)—which is factually plausible and enhances the explanation, though this detail was not in the original knowledge graph answer. While this additional detail is accurate and relevant, it slightly extends beyond the provided ground truth, which focused solely on cost/expense increases as evidence of strategy evolution. (4) The answer is semantically equivalent and highly relevant, addressing both parts of the question (evolution of strategy based on changes in capitalized costs and expenses). The only reason for not scoring a 10 is that the original answer did not include amortization or useful life data, so that inference, while reasonable, introduces external synthesis. Overall, the response is factually correct, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 420,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "Between 2022 and 2024, Philip Morris International's financial relationship with RBH evolved significantly, particularly in 2024. In 2024, PMI recorded a **$2,316 million non-cash impairment charge** on its investment in RBH due to uncertainty surrounding the allocation of a proposed $32.5 billion global settlement in Canadian tobacco litigation. This uncertainty, tied to unresolved disputes over how the settlement amount would be distributed among RBH, Imperial Tobacco Canada, and JTI Macdonald, triggered an impairment assessment. The 2022 filing (and prior years) did not mention this specific impairment, as the deconsolidation of RBH occurred in 2019, and the 2024 charge marked the first impairment related to PMI's equity stake in RBH.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $2,316 million impairment charge in 2024, the $32.5 billion Canadian tobacco litigation settlement, and the entities involved (RBH, Imperial Tobacco Canada, JTI Macdonald). The absence of such an impairment in 2022 is correctly noted. (2) Quantitative accuracy is perfect: both dollar amounts ($2,316 million and $32.5 billion) are reported correctly, with acceptable formatting. (3) The multi-hop reasoning is sound—LLM correctly infers a shift in relationship from prior brand reporting (implied in 2022) to a direct equity investment facing impairment in 2024, even though the deconsolidation in 2019 is mentioned as context. (4) The only minor gap is that the original answer highlights the evolution from a trademark/licensing relationship (e.g., HEETS volume reporting) in 2022 to equity investment in 2024, which the LLM mentions implicitly but could have emphasized more clearly. However, the core evolution and financial impact are accurately conveyed. Wording differs but semantic meaning matches. Contextual relevance is excellent—directly addresses stake evolution and impairment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 337,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "The sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities decreased slightly between 2023 and 2024. In 2023, a 5% change in these liabilities resulted in a $615 million revenue impact, while in 2024, the same 5% change led to a $600 million revenue impact. This reflects a minor reduction in sensitivity, likely due to changes in liability balances and accrual dynamics, though the U.S.-based portion of these liabilities remained approximately 90% in both years.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect. The ground truth states that LLY did not provide a sensitivity figure in its 2024 10-K filing, whereas the LLM falsely claims that a $600 million impact was disclosed for 2024. This introduces a fabricated quantitative result not present in the actual filing. The only correct number mentioned is the 2023 $615 million impact, which matches the ground truth. (2) The quantitative inaccuracy is severe: the $600 million figure for 2024 is entirely incorrect, and the implied comparison (a decrease from $615M to $600M) is based on non-existent data. There is no evidence in the ground truth that LLY disclosed any updated sensitivity analysis in 2024. (3) The multi-hop reasoning fails because the model invents data for 2024 instead of recognizing the absence of disclosure. The correct inference from the 2024 filing is the lack of updated quantitative sensitivity, not a revised dollar impact. The model also incorrectly infers a trend ('decreased slightly') and attributes it to liability dynamics, which is unsupported. (4) Correctness is scored very low (1) due to the central fabrication of a key fact. Quantitative accuracy is 1 because only the 2023 number is correct and the 2024 number is false. Qualitative accuracy is low (2) due to flawed reasoning and incorrect synthesis. Contextual relevance is moderate (5) because the answer addresses the right topic and metric but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 403,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "Union Pacific's Bulk shipments contributed approximately 32% of total freight revenues in both 2021 (as reported in the 2022 10-K) and 2024, according to the 2024 disclosures. While the percentage remained stable, the absolute revenue increased due to overall growth in freight revenues, reflecting sustained demand in key markets like grain, coal, and fertilizer. Bulk's role as a core commodity group persisted, with continued emphasis on volume growth and operational efficiency.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that Bulk shipments contributed 32% of total freight revenues in both 2021 (as reported in the 2022 10-K) and 2024, but the ground truth states that the 32% figure is only reported for 2024. There is no mention in the ground truth that Bulk contributed 32% in 2021. Instead, the 2022 filing references 2021 average revenue per car ($3,305) and a 6% increase from 2020 — information entirely missing in the LLM response. (2) The LLM incorrectly asserts that the 32% revenue contribution was consistent across years, which is unsupported by the ground truth. The ground truth highlights a transformation and growing strategic importance by 2024, implying evolution, not stability. Additionally, the LLM invents a claim about 'absolute revenue increased due to overall growth' without any supporting data in the ground truth. (3) The multi-hop reasoning is flawed: the model fails to connect the shift from revenue-per-unit focus in earlier years to strategic integration in 2024. It misses the evolution narrative — from performance metrics (revenue per car) to strategic footprint (international connections, commodity coverage) — which is central to the original answer. (4) While the LLM correctly identifies the 32% contribution in 2024 and mentions relevant commodities (grain, coal, fertilizer), it distorts the timeline and misrepresents the nature of change. The contextual relevance is high because it addresses the question's scope, but correctness is low due to fabricated quantitative continuity and omission of key developmental details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 446,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "The interest rate for IBM's Notes due 2028 remained unchanged between 2023 and 2024, with both years listing 0.300% (IBM 28B) and 1.750% (IBM 28A) as the rates. This consistency suggests IBM's debt strategy prioritized maintaining low-interest obligations, likely to optimize capital structure and manage interest costs effectively, reflecting a focus on financial stability and cost control.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that only the 1.750% Notes due 2028 (IBM 28A) were present in both 2023 and 2024. However, the LLM incorrectly claims that two series—0.300% (IBM 28B) and 1.750% (IBM 28A)—were listed in both years. There is no mention of a 0.300% Note due 2028 (IBM 28B) in the ground truth, making this a critical error in entity and quantitative accuracy. (2) The interest rate numbers themselves (1.750%) are correct for IBM 28A, but the addition of the 0.300% note is unsupported and false. This undermines the quantitative accuracy. The conclusion about stability is partially reasonable, but the reasoning is based on incorrect data. (3) The multi-hop reasoning is flawed because the model fabricated a note series (IBM 28B) not present in the original data, failing to correctly synthesize across years. While it correctly notes rate stability for IBM 28A, it does not mention IBM’s broader debt strategy of issuing new higher-rate, longer-term debt (e.g., 2.900% Notes due 2030 and 3.150% due 2033), which is a key part of the ground truth and necessary for full completeness. (4) The contextual relevance is high because the answer addresses the interest rate evolution and attempts to infer strategy, but correctness and qualitative accuracy are reduced due to factual errors and incomplete/misleading synthesis. Hence, correctness is scored low due to major quantitative and entity inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 410,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "AT&T repurchased all outstanding Mobility Preferred Interests in April 2023, eliminating them from its capital structure by December 31, 2023. In 2024, the company introduced new preferred instruments, including Telco LLC Preferred Interests (Telco Class A-4) with fixed and floating rate terms, and issued new Mobility II Redeemable Noncontrolling Interests (Series B) in June 2023. These new instruments feature adjustable distribution rates, reset provisions, and redemption options, reflecting a strategic shift toward structured, long-term capital instruments to manage liquidity and financial obligations.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states that AT&T repurchased all Mobility Preferred Interests in 2023, it introduces a new instrument called 'Mobility II Redeemable Noncontrolling Interests (Series B)' issued in June 2023, which contradicts the ground truth that AT&T eliminated this class of preferred interests. The ground truth indicates no new Mobility-related preferred instruments were introduced; instead, restructuring occurred in Tower Holdings and Telco LLC. The LLM incorrectly implies continuity in Mobility-related instruments, which is not supported. Additionally, the LLM mentions 'Telco Class A-4' with fixed and floating rate terms, but the ground truth only confirms expansion of Telco LLC preferred interests to $7,250 million without specifying class or rate structure. (2) Quantitative inaccuracies include omission of key figures: the $5,340 million redemption value and $373 million annual distributions for the Mobility Preferred Interests are missing. The $7,250 million total for Telco LLC is not mentioned in the LLM answer, reducing quantitative completeness. (3) Multi-hop reasoning is partially sound—the model recognizes a strategic shift in preferred instruments—but fails to correctly synthesize the evolution: it incorrectly suggests new Mobility II instruments were introduced after eliminating the original, which contradicts the strategic pivot away from Mobility-based capital. The correct synthesis should show a shift from Mobility to infrastructure/telecom-focused instruments like Tower Holdings and Telco LLC, not a continuation under new names. (4) Despite these errors, the answer is contextually relevant and captures the general direction of strategic change toward structured, long-term instruments. However, due to significant factual and quantitative omissions and the introduction of unsupported instruments, the correctness score is reduced to 6, reflecting partial accuracy with notable flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 539,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "Amazon's characterization of competitive threats evolved from emphasizing local companies' advantages in 2022 to acknowledging broader, evolving threats in 2023. In 2022, the focus was on local competitors' deeper customer understanding and established brand names. By 2023, Amazon explicitly mentioned \"competitive stores, websites, products, services, price decreases, or improvements\" and highlighted the adoption of \"evolving business models\" as key competitive factors. This shift indicates a broader recognition of dynamic online competition, including price-driven strategies and innovative business practices, beyond traditional local market advantages.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in its characterization of Amazon's evolving competitive language between 2022 and 2023, with accurate use of the key phrase 'competitive stores, websites, products, services, price decreases, or improvements' from 2023, which aligns with the ground truth. The shift toward recognizing more dynamic and strategic competition is correctly identified. However, the LLM introduces a detail not present in the original answer—specifically, that in 2022 Amazon focused on 'local competitors' deeper customer understanding and established brand names.' This detail is absent from the ground truth, which states that in 2022, competitive websites were mentioned as part of a broader list of fluctuating business factors, not specifically in the context of local competitors. This misrepresents the nature of the 2022 characterization and introduces an inaccurate contrast. While the core evolution in language and strategic framing is correctly captured, this error in entity and contextual detail reduces the qualitative accuracy. There are no numerical values, so quantitative accuracy is scored as 10 by default. The answer remains contextually relevant and captures the essence of the shift, warranting a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 350,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "PMI's relationship with KT&G evolved from a 2020 global collaboration agreement to exclusive distribution of KT&G's smoke-free products outside South Korea, which became a strategic component of PMI's smoke-free portfolio. By 2024, KT&G's heat-not-burn products (e.g., LIL Mini, LIL Plus) were integrated into PMI's offerings, contributing to growth in smoke-free revenues and shipment volumes, reflecting increased reliance on KT&G's technology within PMI's smoke-free strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor factual inaccuracy regarding the start date of the agreement. The original answer states the agreement began in 2022, while the LLM claims it started in 2020—this is incorrect and affects the timeline accuracy. All other key facts are correct: KT&G's products (LIL Mini, LIL Plus) were distributed exclusively by PMI outside South Korea and became integrated into PMI's smoke-free portfolio by 2024. The strategic evolution from distributor to integration is accurately captured. (2) There are no numerical values (e.g., dollar amounts, percentages, shipment numbers) in either answer, so quantitative accuracy is based on dates. The incorrect mention of '2020' instead of '2022' is a notable error, though not catastrophic. Other dates (implication of evolution through 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information about the nature of the partnership, its geographic scope, product types, and the evolution in strategic reliance. It correctly infers deeper integration by 2024, aligning with the ground truth. (4) Scores reflect high factual and contextual accuracy with a deduction for the incorrect start year. The answer remains semantically close to the original and addresses all parts of the question, just with a flawed initial date. Contextual relevance is perfect as it directly addresses the evolution and strategic reliance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 404,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "IBM's PWCC Plan remained unchanged in both administration and scope between 2022 and 2024. The plan continued to be used exclusively for funding awards for employees of PwCC who became IBM employees post-acquisition, with terms identical to the 2001 Plan. Administration remained under the Executive Compensation and Management Resources Committee, and no modifications to its structure or purpose were disclosed in the 2024 filings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of entity identification, timeline, and scope of the PWCC Plan. It correctly states that the plan was used exclusively for former PwCC employees who joined IBM post-acquisition and that its terms remained substantively identical to the 2001 Plan. The administration detail (Executive Compensation and Management Resources Committee) is consistent with typical IBM plan governance, though not explicitly confirmed in the ground truth. Quantitatively, there are no numbers to verify, so accuracy is 10. The answer captures the continuity in administration and scope, but misses the nuanced evolution in language from 2022 to 2024—specifically, the shift from 'will continue to be used' to a more definitive 'has been and will continue to be used solely,' which the ground truth interprets as a stronger reaffirmation of intent. This subtle but important qualitative shift in tone and commitment is not reflected in the LLM response, which asserts 'remained unchanged' rather than acknowledging the reinforced emphasis in 2024. Thus, while the core facts are correct, the multi-hop reasoning around linguistic evolution and its implication for IBM's commitment is underdeveloped, warranting a slight deduction in qualitative accuracy and overall correctness. Contextual relevance is perfect—directly addresses the question with appropriate focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 383,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "AT&T repurchased all outstanding Mobility Preferred Interests in April 2023, eliminating $5,414 million in financial obligations by December 31, 2023. This shift reflects a strategic move to reduce long-term liabilities, enhance financial flexibility, and reallocate capital toward network transformation initiatives like Open RAN deployment. The repurchase underscores AT&T's focus on optimizing its capital structure by retiring high-cost obligations and prioritizing investments in growth-driven technologies, aligning with broader efforts to strengthen operational efficiency and shareholder returns.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that AT&T repurchased all Mobility Preferred Interests in 2023 for $5,414 million, aligning with the ground truth. The dollar amount and the fact of full repurchase are accurate. However, the LLM specifies 'April 2023' as the repurchase date, which is more precise than the ground truth (which only confirms completion by year-end 2023); this detail cannot be verified from the provided ground truth and may be extraneous or unconfirmed. (2) Quantitatively, the $5,414 million figure matches exactly, and no other numbers are introduced, so quantitative accuracy is perfect. (3) The reasoning is largely sound: the elimination of the obligation and strategic intent to reduce liabilities and optimize capital structure are consistent with the ground truth. However, the LLM adds specific strategic motivations—'network transformation initiatives like Open RAN deployment' and 'shareholder returns'—that are not present or inferable from the original answer. While plausible, these represent an expansion beyond the documented evidence, slightly weakening qualitative accuracy. (4) The answer is highly contextually relevant, addressing both the evolution between 2023 and 2024 and the implication for capital structure. It correctly infers a strategic shift, though it omits the contrast with other preferred interests (e.g., Tower Holdings, Telco LLC), which is a key multi-hop element in the ground truth. This omission limits completeness and weakens the qualitative score slightly. Overall, the answer is factually strong but adds unverified strategic details and misses a key comparative element, warranting a high but not top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 458,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "IBM's 2022 and 2024 filings indicate that regulatory exposure for its debt securities remains influenced by \"governmental and stock exchange regulations\" as a listed risk factor in both periods. However, the documents do not explicitly detail any evolution or changes in IBM's relationship with stock exchange regulations regarding debt securities between 2022 and 2024. The risk factors are consistently described without specific updates on regulatory changes or heightened exposure during this timeframe.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that there was no evolution in IBM's relationship with stock exchange regulations between 2022 and 2024. The ground truth shows a clear shift in language and recognition: from describing stock exchange regulations as one of several factors influencing debt securities in 2022, to stating in 2024 that IBM is 'subject to' these regulations, indicating a stronger, more direct regulatory exposure. The LLM incorrectly asserts that there is no explicit detail on evolution and that risk factors are consistently described, which contradicts the documented change in tone and legal implication. While the LLM correctly identifies that regulations were mentioned in both years and that they relate to debt securities (preserving some contextual relevance), it fails to detect and report the key qualitative shift. There are no numerical values in this question, so quantitative accuracy is scored as 10 by default. The reasoning is flawed because the model did not perform the necessary multi-hop comparison of language changes across filings, leading to an incomplete and misleading conclusion. Thus, the correctness and qualitative accuracy scores are low despite accurate entity and year identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 350,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "Disney's equity income contribution from A+E decreased from $782 million in 2023 to $575 million in 2024, reflecting a $207 million decline. This reduction was primarily due to lower income from A+E, as noted in the \"Equity in the Income of Investees\" section of the 2024 financial statements. The 2022 equity income figure is not explicitly provided in the given pages, but the trend shows a significant decrease from 2023 to 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies a $207 million decline in equity income from A+E between 2023 and 2024, with specific figures of $782 million in 2023 and $575 million in 2024, which aligns with the ground truth's stated $207 million decrease due to lower A+E income. These numbers are quantitatively accurate and consistent with the knowledge graph. (2) The calculation is correct: $782M - $575M = $207M, matching the ground truth's reported decrease. While the original answer references 2022–2024 evolution, it does not provide a 2022 figure, and the LLM appropriately notes that the 2022 amount is not explicitly provided, which is consistent with available data. (3) The multi-hop reasoning is sound: the model correctly synthesizes the trend across years and attributes the decline to A+E, as specified in the financial statements. It correctly infers that while 2022 data isn't given, the material decline occurred from 2023 to 2024. (4) The only minor limitation is that the original answer emphasizes the significance of A&E in 2022 as a major equity investee, which the LLM omits—but since the LLM acknowledges the lack of explicit 2022 data, this omission is justified. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth with high quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 377,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "The carrying value of securitized debt obligations increased from $16,973 million as of December 31, 2022, to $18,043 million as of December 31, 2023, reflecting a $1,070 million rise. This increase indicates the company continued to issue securitized debt as part of its long-term funding strategy, leveraging these instruments to manage liquidity, optimize capital structure, and diversify funding sources. The growth aligns with prior trends of using securitization programs to meet funding needs, suggesting a sustained reliance on this mechanism for stability and cost efficiency.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude of change. The ground truth states that the carrying value of securitized debt obligations decreased to $18.043 billion as of December 31, 2023, from a prior level (implied in 2022) that was part of a total long-term funding of $42.3 billion as of December 31, 2021, with securitized debt being a significant portion. The LLM incorrectly claims an increase from $16,973 million ($16.973 billion) in 2022 to $18.043 billion in 2023, which contradicts the downward trend indicated in the original answer. (2) The numbers cited by the LLM ($16,973 million and $18,043 million) are not supported by the ground truth. The original answer does not provide the 2022 value explicitly but indicates a decrease to $18.043 billion by 2023 from a much higher prior level embedded in the $42.3 billion total. The LLM’s calculation of a $1,070 million increase is therefore based on fabricated data. (3) The multi-hop reasoning is flawed: the LLM fails to recognize that the overall long-term funding was $42.3 billion in 2021 (with securitized debt as a major component), and by 2023, securitized debt alone had dropped to $18.043 billion—indicating a reduction in reliance. Instead, the model incorrectly infers continued reliance and growth. (4) The contextual relevance is moderate because the answer discusses securitized debt in the context of long-term funding strategy, but the factual inaccuracies and reversed trend severely undermine correctness. The qualitative reasoning is unsound due to incorrect premises. Quantitative accuracy is very low due to made-up figures and incorrect direction of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 460,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "Disney's approach to scripted programming between 2022 and 2024 involved a strategic shift toward direct-to-consumer (DTC) platforms while maintaining international general entertainment channels. In 2022, the company emphasized expanding DTC services like Disney+ and Hulu, which included scripted content from Disney, Pixar, Marvel, and National Geographic, alongside international sports programming. By 2024, Disney+ had merged with Star+ in Latin America, consolidating scripted and sports content under a unified DTC offering, reflecting a stronger focus on DTC as a primary distribution channel. International general entertainment channels (e.g., Fox, National Geographic, Star) continued to operate but faced reduced reliance on linear licensing, with monetization increasingly directed toward DTC platforms like Disney+ and ESPN+. This shift aimed to capitalize on DTC growth while adapting to changing viewer preferences.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Disney's strategic shift toward DTC platforms between 2022 and 2024 and acknowledges the role of international general entertainment channels under Fox, National Geographic, and Star brands. It accurately notes the consolidation of Star+ with Disney+ in Latin America by 2024, which aligns with Disney’s broader DTC strategy. However, it omits key details from the ground truth, such as the exact number of ~220 international general entertainment channels in 2022 and the specific joint venture (Venu Sports) with Fox Corporation and Warner Bros. Discovery for a sports-focused DTC platform. Additionally, the LLM fails to mention the planned fall 2025 launch of a new DTC offering combining live ESPN linear streams and ESPN+, which is a critical component of Disney’s strategic pivot. (2) Quantitatively, the LLM does not include the specific figure of 'approximately 220' international channels in 2022, which is a factual omission. While no incorrect numbers are stated, the absence of this key metric reduces quantitative accuracy. Dates (2022, 2024, and implied 2025) are used appropriately in context. (3) The reasoning is logically sound in connecting Disney’s reduced reliance on linear channels to increased DTC focus, and the mention of monetization shifting to Disney+ and ESPN+ reflects valid synthesis. However, the multi-hop element involving the Venu Sports joint venture and its implications for strategic direction is missing, indicating incomplete cross-entity reasoning. (4) The answer remains contextually relevant and captures the essence of Disney’s evolving strategy, but lacks specificity on major initiatives that define the strategic shift. Hence, while the core narrative is accurate, the absence of key facts and partnerships limits the correctness score to 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1485,
        "completion_tokens": 499,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "Tesla's financial challenges related to energy storage products in 2022 included accounts receivable risks tied to long collection periods for government rebates (up to a year) and sales of regulatory credits, as noted in the 2022 10-K. In 2023, the focus shifted to operational scaling dependencies, with the 10-K highlighting production ramp delays and supply chain risks for energy storage products, though specific accounts receivable details for 2023 were not explicitly provided. The 2023 filing emphasized challenges in managing production scalability and supplier constraints, but no direct comparison of accounts receivable trends between the two years was included.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Tesla's 2022 financial challenge involving long collection periods for government rebates, consistent with the $627 million receivable disclosed as of December 31, 2021 (reported in the 2022 10-K). While the exact dollar amount ($627M) is not mentioned, the qualitative description of extended collection periods and rebate-related receivables is factually correct. (2) For 2023, the LLM accurately reflects the shift to operational challenges—production ramp delays, supplier constraints, and scaling risks—citing factories in Nevada and Texas, which matches the ground truth. (3) The multi-hop reasoning is sound: it synthesizes a shift from financial (receivables) to operational (scaling) challenges across two years, even noting that specific 2023 receivables data was not provided, which is accurate and shows appropriate restraint. (4) Minor deduction in quantitative accuracy because the $627M figure is omitted, though the core context (long-term rebates, extended collection) is preserved. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative and contextual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 344,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "The role of syrups in Coca-Cola's business model remained central between 2022 and 2023, with continued emphasis on their distribution to both consolidated and unconsolidated bottling partners. Syrups are sold to bottlers, who use them to produce finished beverages, and fountain syrups are specifically used by fountain retailers for on-site consumption. Revenue recognition for syrups depends on ownership structure: for consolidated bottlers, revenue is recognized when finished products are sold to third parties, while for unconsolidated partners, it is recognized at the time of syrup delivery. The 2023 report highlights growth in concentrate sales volume (9% YoY) and expanded focus on fountain retail channels, underscoring syrups' ongoing importance in supporting both traditional bottling operations and direct retail sales.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures some correct elements about Coca-Cola's syrup business model, including the distinction between consolidated and unconsolidated bottling partners and revenue recognition principles. However, it introduces a specific quantitative claim—'9% YoY growth in concentrate sales volume'—that is not present in the original answer (ground truth) and cannot be verified from the provided context. This unsupported figure significantly undermines quantitative accuracy. (2) There are no other numeric values in the original answer to cross-check, but the introduction of a precise percentage without grounding in the source data constitutes a major factual overreach. The original answer focuses on structural and strategic shifts, not performance metrics. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the dual distribution channels (bottling partners and fountain retailers) and the operational role of syrups. However, it fails to capture the key evolution emphasized in the original answer—the shift from a volume-driven metric to a more operationally embedded, strategically integrated component of the business model in 2023. Instead, it frames the change as continued importance with 'expanded focus,' missing the conceptual repositioning. (4) Contextual relevance is high because the answer addresses the core entities and relationships asked about. Qualitative accuracy is moderate because while the structural description is accurate, the reasoning does not fully reflect the strategic evolution described in the ground truth. The correctness score is reduced primarily due to the unsupported quantitative claim and incomplete synthesis of the model shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 470,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) increased from $84 million in fiscal 2022 to $166 million in fiscal 2024. However, the proportion of these securities relative to the overall fair value hierarchy remained stable at 1% for both years, as reflected in the Plan Asset Mix percentages in the respective 10-K filings. This indicates a growth in absolute value but no significant change in their relative weighting within the investment portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the dollar amounts: it reports $84 million for fiscal 2022 and $166 million for fiscal 2024, whereas the ground truth states $96 million in 2022 and $120 million in 2024. These discrepancies affect the accuracy of the investment evolution description. However, the proportion (1%) is correctly reported for both years, which aligns with the ground truth. (2) Quantitative accuracy is low because both absolute values are incorrect—$84M vs $96M (2022) and $166M vs $120M (2024)—and the implied growth rate is exaggerated. The percentage (1%) is accurate, but the dollar figures are not, undermining the reliability of the financial analysis. (3) The reasoning is partially sound: the model correctly identifies that the proportion remained stable despite an increase in absolute value, demonstrating appropriate multi-hop synthesis between investment value and portfolio weighting. However, the incorrect base numbers weaken the validity of the conclusion. (4) Contextual relevance is high because the answer addresses both parts of the question—evolution of investment and trend in proportion—and uses the correct entities (Disney, Other MBS & ABS, fiscal years 2022–2024, fair value hierarchy/plan asset mix). The structure and intent match the original answer, but factual errors reduce correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 382,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "Between 2022 and 2023, Skunk Works' advanced development programs evolved to emphasize next-generation military aircraft capabilities, particularly in **hypersonics**, **air dominance**, and **integrated network-enabled systems**. In 2022, the focus included unmanned/manned aerial systems, hypersonics, and situational awareness. By 2023, the scope expanded to explicitly prioritize **next-generation capabilities for air dominance**, **hypersonic strike weapons**, and **advanced technologies** for integration into existing platforms like the F-35. The 2023 filings also highlighted progress in transitioning hypersonics programs from development to early production, underscoring a sharper alignment with emerging threats and operational requirements.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continuity in focus areas such as hypersonics, situational awareness, and advanced aerial systems between 2022 and 2023. It accurately reflects an increased emphasis on air dominance, which aligns with the ground truth. However, the LLM introduces elements not present in the original answer, such as 'integrated network-enabled systems' and 'transitioning hypersonics programs from development to early production,' which are not mentioned in the ground truth. Additionally, the mention of 'hypersonic strike weapons' and integration into platforms like the F-35 goes beyond the provided information. While these may be plausible developments, they are not supported by the original answer and represent speculative additions. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are incorrect. (3) The multi-hop reasoning is partially sound: the model correctly infers a shift toward air dominance and maintains continuity in key areas like hypersonics and ISR. However, it fails to mention the explicit continuity in intelligence, surveillance, and reconnaissance (ISR) and air mobility from 2022 to 2023 as stated in the ground truth, instead substituting with more specific (but unverified) applications. The evolution is portrayed as a broader expansion rather than a refinement of priorities, slightly misrepresenting the nature of the shift. (4) The correctness score is 7 because the core factual shift—increased emphasis on air dominance while retaining focus on hypersonics and situational awareness—is accurate. The answer is contextually relevant and well-structured, but the addition of unsupported details and omission of specific retained focus areas (e.g., air mobility) prevent a higher score. Qualitative accuracy is 7 due to these factual overextensions, while contextual relevance remains high at 9 due to strong alignment with the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 550,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "Tesla's approach to the Powerwall product evolved from 2022 to 2023 by emphasizing **cross-selling with residential solar energy products** and improving integration strategies, as noted in both filings. In 2022, the focus was on increasing production of energy storage products, including Powerwall, while addressing global component constraints. By 2023, Tesla expanded on this by enhancing installation capabilities and collaborating with real estate developers to streamline Solar Roof integration, further aligning Powerwall with solar solutions. Production emphasis remained on scaling energy storage capacity, with continued attention to battery cell supply and cost efficiencies, though 2023 highlighted stronger integration with solar infrastructure.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Tesla's Powerwall strategy from 2022 to 2023. It correctly identifies the 2022 focus on cross-selling with residential solar and production scaling amid component constraints, which matches the original answer's emphasis on availability and solar integration. The 2023 shift toward deeper integration with solar infrastructure, including improved installation capabilities and collaboration with real estate developers for Solar Roof integration, reflects a substantively accurate progression toward engineered synergy, as stated in the ground truth. However, the LLM answer introduces 'collaborating with real estate developers'—a detail not present in the original knowledge graph answer—and slightly overemphasizes production scaling and battery supply, which were not highlighted as key shifts in the ground truth. While these points may be contextually plausible, they shift focus away from the core evolution described: a move from sales-driven cross-selling to deliberate technical integration. There are no numerical inaccuracies (quantitative accuracy is perfect, scoring 10), and the answer remains highly relevant to the question. The reasoning is sound but not perfectly aligned in emphasis, hence a qualitative accuracy of 8. Overall, the answer captures the essential multi-hop evolution in strategy and integration, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 403,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "Gilead's strategic positioning of Biktarvy within its HIV portfolio remained consistent between 2022 and 2024, emphasizing its role as a key once-daily, fixed-dose combination therapy for HIV-1 infection. However, commercial risks persisted, including competition from generics, pricing pressures from payers, and potential shifts in treatment paradigms affecting TAF-based regimens like Biktarvy. These risks are highlighted in both the 2022 and 2024 10-K filings under \"Risk Factors,\" underscoring ongoing challenges in maintaining market share and revenue stability for HIV products.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Biktarvy as a key product in Gilead’s HIV portfolio and notes ongoing commercial risks such as competition, pricing pressures, and treatment paradigm shifts, which are relevant and mentioned in the original answer. However, it fails to capture the key evolution in strategic positioning between 2022 and 2024—specifically, the shift from emphasizing innovation and efficacy in 2022 to increased vulnerability due to overreliance on TAF-based therapies in 2024. The original answer highlights a meaningful transition in narrative: from product strength to systemic risk from portfolio concentration. The LLM answer treats risks as static rather than showing an evolution, missing the core insight of increased dependence and its implications for financial stability. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, the absence of incorrect numbers supports a score of 10. (3) The multi-hop reasoning is partially sound—the model correctly identifies Biktarvy’s role and general risks across years, but fails to synthesize the change in strategic emphasis over time, which is central to the question. It does not connect the dots between TAF dependence and heightened commercial risk as a developing trend. (4) Contextual relevance is high because the answer addresses Biktarvy, HIV portfolio, and commercial risks as required, but the lack of temporal evolution limits its accuracy. The answer is plausible but misses the nuanced shift described in the ground truth, warranting a moderate correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 443,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "The composition of the U.S. Retrospective Responsibility Plan changed between 2022 and 2023 by adding **makewhole agreements** related to the class B-1 common stock exchange offer and expanding the **conversion feature** to include class B-1 and B-2 common stock. In 2023, the U.S. litigation escrow account balance increased to $1,764 million (from $1,449 million in 2022), driven by higher deposits ($1,000 million vs. $850 million) and payments to opt-out merchants ($685 million vs. $295 million). These adjustments reflect updated mechanisms to address liability under the U.S. covered litigation.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific numerical data (e.g., escrow account balance of $1,764 million in 2023 vs. $1,449 million in 2022, deposits of $1,000 million vs. $850 million, payments of $685 million vs. $295 million) that are not present in the original answer or ground truth. There is no mention in the ground truth of any financial figures related to the U.S. Litigation Escrow Agreement balances or payments, so these numbers cannot be verified and appear fabricated or incorrectly inferred. (2) The claim that the 'conversion feature' was expanded to include Class B-1 and B-2 common stock is not supported by the original answer, which only states that 'makewhole agreements relating to the Class B-1 common stock exchange offer' were added. The original does not mention B-2 stock or any modification to the conversion feature. (3) The core correct element is the addition of 'makewhole agreements' in 2023, which aligns with the ground truth. The retention of the U.S. Litigation Escrow Agreement is also correctly implied. However, the answer adds unsupported quantitative details and misrepresents the nature of the changes to the conversion feature, undermining the qualitative accuracy. (4) While the answer addresses the evolution of the plan and focuses on the right context (mechanisms tied to litigation liability), the inclusion of unverified financial data and incorrect structural changes significantly reduces factual correctness. The reasoning fails the multi-hop synthesis test because it introduces data not present in the source knowledge. The contextual relevance remains moderate because the overall topic and direction of explanation are appropriate, but precision and truthfulness are compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 475,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "Biktarvy's strategic importance for GILD remained significant from 2022 to 2024 due to its patent protection, which extended to 2033 in both the U.S. and EU, with potential extensions to 2028 in the U.S. However, the company's risk disclosures highlighted its heavy reliance on HIV products, including Biktarvy, noting that declining sales due to competition, patent expiration, or shifting treatment paradigms could adversely impact revenue and business growth. As the patent timeline approached, the risk of reduced exclusivity and increased generic competition became a critical factor in maintaining Biktarvy's strategic value.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies regarding patent expiration dates. The ground truth states that in 2022, Biktarvy had a U.S. patent expiration in 2033 and no expiration listed in the E.U., but the LLM incorrectly claims patent protection extends to 2033 in both the U.S. and EU, and further adds a potential extension to 2028 in the U.S., which is not supported by the original answer. This is a significant factual error affecting quantitative accuracy. (2) The original answer notes that by 2024, patent details were not explicitly mentioned, but the LLM implies continued patent protection without noting the absence of updated patent data, misrepresenting the information. (3) Qualitatively, the LLM correctly identifies the increased risk disclosures around HIV product dependency and competition, aligning with the original answer’s point about heightened risk due to market competition and shifting treatment paradigms. It appropriately captures the strategic vulnerability despite patent protection, showing sound reasoning in synthesis. (4) Contextually, the response is relevant and addresses the evolution of strategic importance, tying together patent life and risk factors. However, the incorrect patent details—especially the fabricated EU expiration and erroneous U.S. extension—undermine the correctness score. While the overall narrative of growing risk is accurate, the faulty quantitative foundation limits the answer’s reliability. Semantic equivalence is partially achieved but compromised by key factual deviations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 430,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "Based on the provided document pages, there is no indication of modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023. The referenced guarantees (e.g., in Exhibit 4-c of the 2011 10-K) are not updated or altered in the 2022 or 2023 filings, and no new guarantee structures or documentation are disclosed for Illinois Bell during this period.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns with the ground truth in substance, but contains a minor discrepancy in exhibit number. The original answer states the guarantee is referenced under 'Exhibit 4-d' in the 2011 Form 10-K, while the LLM incorrectly refers to 'Exhibit 4-c'. This is a factual error in entity accuracy, though it does not affect the overall conclusion that no changes occurred. All other aspects are accurate: there is no indication of modifications to the guarantee structure or documentation between 2022 and 2023, and the reasoning correctly infers continuity based on unchanged references. The answer addresses both parts of the question—guarantee structure and documentation—and correctly synthesizes information across years. Despite the exhibit number error, the core factual claim (no modifications) is supported, and the answer remains contextually relevant and logically sound. Quantitative accuracy is high as no numerical data is misstated; the error is purely in exhibit labeling.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 290,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "The consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggests that the terms for converting Class C shares into Class A shares remained unchanged during this period. This stability implies that any conversions of Class C shares would result in a predictable increase in the number of Class A shares outstanding, potentially diluting the voting power of existing Class A stockholders in significant corporate transactions. However, the conversion rate itself does not alter the fundamental risk of dilution; it merely ensures that the dilution, if conversions occur, would follow a fixed ratio.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of the conversion rate stability between 2022 and 2023, and correctly identifies that the unchanged rate leads to predictable dilution effects. Quantitatively, no specific numbers are mentioned (e.g., 4.0000 conversion rate, 38 million to 39 million as-converted Class A value), but since the LLM does not misstate any figures and the omission does not lead to inaccuracy, this is acceptable under semantic equivalence. However, the LLM misses a key insight from the ground truth: the stability of the conversion rate implies no *change* in relative voting power dilution, meaning the *impact on Class A stockholders’ voting power remained stable*—not just predictable. The original answer emphasizes that there was no structural change in influence over corporate decisions, which the LLM fails to explicitly convey. While the reasoning about potential dilution is sound, it leans toward a general risk ('if conversions occur') rather than assessing the actual *lack of change* in dilution dynamics year-over-year. This omission reduces completeness and qualitative accuracy, though the core logic remains relevant and directionally correct. Contextual relevance is high as the response directly addresses the question’s focus on voting power implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 362,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "Tesla's relationship with Solar Roof evolved from 2022 to 2023 by shifting production focus to Gigafactory New York, where Solar Roof and other solar products were developed and manufactured alongside energy storage components. In 2022, Solar Roof was highlighted in warranty discussions, emphasizing its integration with roofing systems and weatherization. By 2023, Tesla explicitly tied Solar Roof production to Gigafactory New York, reflecting a strategic emphasis on localized manufacturing and cross-functional integration with solar and energy storage systems, underscoring its role in expanding renewable energy solutions.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements, such as the location of Solar Roof production at Gigafactory New York and the integration with energy storage and solar systems. However, it misrepresents the nature of Tesla's evolving relationship with the Solar Roof from 2022 to 2023. The original answer correctly identifies a strategic shift from active production focus in 2022 to a more risk-averse, cautionary tone in 2023 regarding scaling challenges, supply chain constraints, and ramp-up risks. In contrast, the LLM answer portrays a continued or even strengthened strategic emphasis in 2023, highlighting 'localized manufacturing' and 'cross-functional integration' as positive developments—this contradicts the ground truth, which indicates increased strategic concerns rather than reinforced commitment. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in this regard. (3) The multi-hop reasoning is partially sound: the model correctly identifies Gigafactory New York as the production site and links Solar Roof to broader energy systems. However, it fails to synthesize the critical shift in tone and strategic posture from production focus to risk disclosure, which is central to the question. This represents a failure in qualitative reasoning across time periods. (4) The correctness score is 5 due to partial factual accuracy but significant error in the core strategic narrative. Quantitative accuracy is 10 because no numbers are involved. Qualitative accuracy is 5 due to correct entity and location identification but flawed reasoning about strategic evolution. Contextual relevance is 8 because the answer addresses the right topic and timeframe with relevant context, even if the conclusion is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 490,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "Between 2022 and 2023, syrups remained a core component of Coca-Cola's concentrate operations, which are sold to bottlers for finished beverage production. The 2023 filing notes that concentrate operations (including syrups) accounted for 58% of total net operating revenues, up from 56% in 2022, reflecting a slight growth in their role. Syrups are still critical for producing finished beverages through bottlers and fountain retailers, with no significant structural changes in distribution channels highlighted. The focus on concentrate pricing models and global bottling partnerships underscores their continued importance in the supply chain.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The claim that concentrate operations (including syrups) accounted for 58% of total net operating revenues in 2023, up from 56% in 2022, is not supported by the ground truth and introduces fabricated quantitative data. The original answer makes no mention of these percentages or revenue shares, meaning these numbers are incorrect and unsupported. (2) There are no valid calculations or numeric values in the ground truth to compare against, so the introduction of specific percentages (56%, 58%) constitutes a serious quantitative error. These figures appear invented and misrepresent the financial role of syrups. (3) The multi-hop reasoning is partially sound in that the model recognizes syrups as part of concentrate operations and their use in beverage production. However, it fails to capture the key evolution described in the ground truth: the shift in 2023 toward direct management of fountain syrup sales in the U.S. by Coca-Cola, the sale to wholesalers and bottling partners, and the inclusion of fountain syrup operations in the North America operating segment. These structural and strategic changes are entirely omitted, which is a major qualitative shortcoming. (4) While the answer is contextually relevant—focusing on syrups, concentrate operations, and distribution channels—it misses the core evolution in distribution strategy and organizational segmentation emphasized in the original. The answer suggests 'no significant structural changes,' which directly contradicts the ground truth's emphasis on tighter control and regional segmentation. Thus, despite correct general context, the answer is factually and qualitatively deficient, especially in quantitative claims and failure to report key strategic shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 491,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "Between 2022 and 2024, Colgate-Palmolive's geographic reporting structure maintained Africa/Eurasia as a distinct reportable segment, though the company realigned its skin health business reporting (from Europe to North America in 2024) without impacting Africa/Eurasia. Financially, Africa/Eurasia's net sales grew from $1,045 million (2022) to $1,095 million (2024), with operating profit increasing from $187 million (2022) to $253 million (2024). Capital expenditures in the region decreased from $30 million (2022) to $12 million (2024), reflecting reduced investment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Africa/Eurasia had an operating profit of $203 million in 2022, but the LLM claims $187 million in 2022 and $253 million in 2024—neither of which are supported by the original answer. Additionally, the LLM introduces financial figures not present in the ground truth: net sales of $1,045M (2022) and $1,095M (2024), and capital expenditures of $30M and $12M, which are entirely fabricated. These numbers do not appear in the original answer and contradict the only financial data provided ($203M operating profit in 2022). (2) The quantitative accuracy is very low because the core financial figures are incorrect or invented. Even allowing for format variation, the values themselves are not equivalent to the ground truth. There is no mention of net sales or capex in the original, so including them as precise figures misrepresents the data. (3) The qualitative accuracy is partially correct: the LLM correctly notes that Africa/Eurasia remained a distinct reportable segment and that the skin health business was realigned from Europe to North America in 2024. However, it incorrectly implies this realignment did not impact Africa/Eurasia, while the original emphasizes it as part of a broader strategic refinement in geographic reporting that includes Africa/Eurasia. The reasoning fails to connect the realignment to a more nuanced operational focus as described in the ground truth. (4) Contextual relevance is moderate—the response addresses the evolution of geographic structure and financial contribution, aligning with the question's intent, but the inclusion of false specifics undermines reliability. Due to major factual and quantitative errors, the correctness score is low despite some structural understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 496,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "Johnson & Johnson's Orthopaedics business maintained stable global sales performance in 2023 and 2024, with Worldwide sales of $8,942 million in both years, reflecting consistent growth in both U.S. (3.8%) and International (4.6%) markets. The strategic emphasis on enabling technologies remained consistent, as described in the MedTech segment, which highlighted Orthopaedics' focus on products and technologies supporting hips, knees, trauma, spine, sports, and other areas. No significant shifts in strategic emphasis or sales performance were noted between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that Johnson & Johnson's Orthopaedics global sales were $8,942 million in both 2023 and 2024, which contradicts the ground truth stating that 2024 did not report revenue figures at all. The ground truth explicitly notes a strategic shift in 2024 to omit financial metrics and focus on qualitative aspects, but the LLM incorrectly asserts that sales figures were repeated and stable. While the 2023 sales figure ($8,942 million), U.S. sales ($5,525 million), and growth rates (3.8% U.S., 4.6% international) are accurate, the erroneous claim of identical 2024 sales undermines quantitative correctness. (2) The calculation of growth percentages is not challenged, but the core error lies in asserting that 2024 revenue was reported and equal to 2023—this is false per the original answer. The 2024 filing did not provide revenue data, so claiming $8,942 million again is factually wrong. (3) The multi-hop reasoning fails because the model does not recognize the strategic shift from quantitative to qualitative presentation. Instead, it concludes there was 'no significant shift,' directly contradicting the ground truth's central point about a pivot toward innovation and enabling technologies in 2024. The LLM acknowledges the mention of enabling technologies but misinterprets consistency rather than evolution in emphasis. (4) The contextual relevance is moderate because the answer discusses the relevant business segment, geographies, and technologies, but the failure to capture the strategic evolution and the invention of a 2024 revenue figure severely damages accuracy. Correctness score is low due to major factual and interpretive errors despite some correct 2023 data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 479,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "Visa's approach to managing litigation liabilities through loss sharing agreements remained consistent between 2022 and 2023, with the scope of U.S. covered litigation unchanged. The U.S. covered litigation scope included the Interchange Multidistrict Litigation (MDL 1720), opt-out cases post-October 2015, and claims related to reorganization, as defined in the 2015 amendment to the loss sharing agreement. Liability allocation via the omnibus agreement maintained Visa's 66.6667% share of settlements/judgments, with the loss sharing agreement ensuring member indemnification for excess liabilities. Escrow account balances increased in both years due to deposits and payments, reflecting ongoing management of litigation risks without structural changes to the framework.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct factual elements, such as the 66.6667% liability share by Visa and the reference to the October 2015 amendment and MDL 1720. However, it fundamentally misrepresents the evolution of Visa's approach between 2022 and 2023. The original answer correctly identifies a strategic shift in 2023 with the consolidation under the U.S. Retrospective Responsibility Plan and an expanded definition of U.S. covered litigation to include 'settled or otherwise fully or substantially resolved' matters. In contrast, the LLM claims the approach 'remained consistent' and that the scope was 'unchanged,' which directly contradicts the ground truth. This is a critical error in reasoning and factual accuracy. (2) Quantitatively, the percentages (66.6667%, 33.3333%) are accurate, and references to escrow activity are plausible, though not emphasized in the ground truth. No calculation errors are present, but the LLM introduces escrow balances increasing 'in both years' without grounding in the provided truth. (3) The multi-hop reasoning fails: the question asks for evolution between years, requiring comparison and synthesis of changes. The LLM does not recognize the shift from a bilateral loss sharing framework with Mastercard in 2022 to a more comprehensive, retrospective plan in 2023. It misses the strategic pivot entirely, which is the core of the original answer. (4) Scores reflect mostly correct numbers but severe deficiencies in qualitative reasoning and overall correctness due to the central factual inaccuracy about the lack of change. Contextual relevance is moderate because the answer discusses related concepts but fails to address the actual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1519,
        "completion_tokens": 468,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "Between 2021 and 2024, Colgate-Palmolive's U.S. pension plans reduced their Guaranteed Investment Contracts (GICs) from $1 million to $0, while International plans decreased GICs from $51 million to $30 million. This shift reflects a strategic reallocation of assets toward other fixed income instruments or lower-risk investments, aligning with the target asset allocation of emphasizing fixed income (76% for U.S. plans) and potentially optimizing returns or managing risk exposure. The reduction in GICs suggests a move away from insured fixed income products toward more diversified or liquid fixed income strategies.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and time periods. The original answer states that in 2022, CL held $1 million in GICs for U.S. Pension Plans and $55 million for International Pension Plans, but the LLM incorrectly reports $51 million for International in 2021 (not 2022). Additionally, the LLM claims International decreased to $30 million by 2024, while the ground truth is $34 million. The U.S. reduction from $1M to $0 is correct, but the timeline is misstated as 2021–2024 instead of 2022–2024. (2) Calculations are not explicitly shown, but the direction of change (decrease) is correct. However, the specific figures are off: a drop from $55M to $34M is a $21M decrease, whereas the LLM implies a $21M drop from $51M to $30M — close but based on wrong inputs. The U.S. elimination is accurate. (3) The multi-hop reasoning is partially sound — the model correctly infers a strategic reallocation from the reduction in GICs and links it to broader asset strategy, mentioning fixed income emphasis. However, it introduces unverified details like 'target asset allocation of 76% for U.S. plans' and 'optimizing returns or managing risk exposure' which are not in the original answer, adding unsupported speculation. (4) Despite incorrect numbers and timeline, the core idea — a strategic shift away from GICs — is captured, and the answer addresses both parts of the question (evolution and implication), warranting moderate scores. Quantitative accuracy is penalized heavily due to wrong base figures and years; qualitative and contextual scores are higher due to reasonable interpretation and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 452,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "The Mastercard Developer Platform has evolved between 2022 and 2024 by expanding its role in integrating digital assets and new technologies, particularly blockchain and cryptocurrencies. In 2022, it was highlighted as a tool to simplify access to Mastercard's digital assets through a centralized API hub. By 2024, the platform further advanced by enabling programmable payments via the Mastercard Multi-Token Network, enhancing interoperability and security in blockchain ecosystems. It also supported cryptocurrency adoption, allowing consumers to buy and spend digital assets where Mastercard is accepted, while continuing to foster innovation through partnerships and emerging technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the 2022 description of the platform as a centralized access point for digital assets and APIs is consistent with the original answer, and the 2024 evolution emphasizing blockchain, digital currencies, and the Mastercard Multi-Token Network™ is accurately reflected. The mention of programmable payments, interoperability, and security in blockchain ecosystems matches the expanded strategic positioning. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across time (2022 to 2024), platforms (Developer Platform), and technologies (blockchain, digital assets, Multi-Token Network), showing evolution in functionality and strategic focus. (4) The only minor shortcoming is that the LLM adds a detail not present in the ground truth—'allowing consumers to buy and spend digital assets where Mastercard is accepted'—which, while plausible, is not supported by the provided original answer and slightly extends beyond the documented scope. Otherwise, the answer is semantically equivalent, contextually relevant, and factually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 373,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "The company's U.S. pension plans held no investments in its own common stock as of December 31, 2021, 2022, 2023, or 2024. This consistency reflects a strategic decision to avoid direct ownership of the company's stock in its pension portfolios, aligning with broader asset allocation targets that prioritize diversified equity investments (e.g., pooled funds, international equities) over concentrated holdings in the company's own shares. The absence of U.S. common stock in plan assets underscores a focus on risk management and diversification rather than self-dealing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that while the U.S. pension plan had no investment in U.S. common stocks in 2022 and 2024, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. The LLM answer completely omits this $2 million international investment and instead claims there was no investment in U.S. common stocks across all pension plans, which contradicts the original answer. Additionally, the LLM incorrectly references data from 2021, which was not part of the question's scope (2022–2024), and mischaracterizes the lack of investment as being specifically in the company's own common stock, whereas the original answer refers to U.S. common stocks generally, not necessarily the company’s own shares. (2) The key dollar amount ($2 million in international pension plan) is missing, and the years referenced extend beyond the required timeframe (2021 is irrelevant). No correct calculations are presented because the core data is wrong. (3) The multi-hop reasoning fails: the model does not synthesize the distinction between U.S. and international pension plans, nor does it recognize that the absence of U.S. common stock in the domestic plan coexists with a small but consistent allocation in the international plan. This undermines the strategic interpretation. (4) The contextual relevance is moderate because the answer discusses asset allocation strategy and diversification, which are relevant themes, but the factual foundation is flawed, leading to an incorrect conclusion about the company's investment behavior. Thus, the correctness score is low due to major factual inaccuracies and omission of critical information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 482,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "Disney's strategic focus on cruise ships remained a key component of its capital investment plans in 2022–2023, with continued emphasis on expanding the Disney Cruise Line fleet as part of the Parks & Experiences segment. The 2023 filing noted ongoing investments in cruise ships, alongside broader capital expenditures for theme park expansions and DTC offerings. Operational risks included economic volatility, currency fluctuations, and natural disasters (e.g., hurricanes impacting Walt Disney World Resort), which could affect cruise operations and profitability. Additionally, the 2023 document highlighted risks related to contract renewals and market competition, which could influence long-term investment decisions and operational costs.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Disney's continued investment in cruise ships and mentions relevant operational risks such as hurricanes, economic volatility, and natural disasters, which aligns partially with the original answer. However, it fails to capture the core evolution in strategic focus between 2022 and 2023 as described in the ground truth. In 2022, Disney emphasized cruise ships as a growth engine within capital investment, but by 2023, the framing shifted to viewing cruise ships more as an operational risk exposure rather than a growth priority. The LLM answer does not reflect this strategic shift—it instead suggests that expansion and investment remained a 'continued emphasis' in 2023, which contradicts the ground truth's assertion of a recalibration toward risk mitigation. (2) There are no specific numbers, dollar amounts, or percentages in either answer, so quantitative accuracy is not compromised; thus, a score of 10 is justified. (3) The multi-hop reasoning is flawed: the question asks for an evolution between two years, requiring synthesis of changes in tone and strategic emphasis across filings. The LLM fails to contrast the growth-oriented 2022 strategy with the risk-focused 2023 approach, missing the key analytical point. It treats both years as having similar strategic priorities, which is inaccurate. (4) Contextual relevance is high because the answer discusses capital investment and operational risks in both years, addressing the main themes of the question. However, due to the failure to identify the strategic pivot—from growth to risk mitigation—the qualitative accuracy and overall correctness are significantly reduced, warranting a mid-range score of 5 for both correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 482,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "Mastercard continued to utilize short-duration foreign exchange derivative contracts between 2022 and 2024 to manage foreign exchange risk during daily settlement activities. These contracts, based on anticipated receipts and disbursements, mitigate exposure to currency fluctuations by offsetting gains and losses from foreign currency movements. In 2024, the Company expanded this approach by entering into contracts with a maximum term of approximately 7 years to hedge foreign-denominated assets, while maintaining the core objective of reducing volatility from daily settlement exposures. The role of these contracts remained consistent in managing short-term FX risk, with refined hedging strategies in 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Mastercard used short-duration foreign exchange derivative contracts in both 2022 and 2024 to manage FX risk in daily settlement activities, and it accurately reflects the objective of reducing volatility from currency fluctuations. However, a critical factual error occurs in the claim that in 2024, Mastercard entered into contracts with a 'maximum term of approximately 7 years' to hedge foreign-denominated assets. This directly contradicts the ground truth, which emphasizes the use of *short duration* contracts and does not mention long-term contracts up to 7 years. The introduction of long-dated contracts is factually unsupported and misrepresents the evolution of the strategy. (2) There are no specific numerical values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy hinges on temporal and duration claims. The '7-year' term is a significant quantitative inaccuracy, as short-duration contracts typically refer to maturities of days or weeks, not years. This undermines the quantitative accuracy. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes continuity in the use of derivatives for daily settlement risk. However, it incorrectly infers an expansion of the short-duration strategy to include long-term hedges, which is not supported by the original answer. The ground truth notes a dynamic approach in 2023–2024 due to de-designation and re-designation of euro-denominated debt hedges, which the LLM omits entirely. Instead of this accurate nuance, the model fabricates a new strategy involving long-term contracts, indicating flawed reasoning. (4) Contextual relevance is high because the answer addresses the core topic—evolution of FX derivative use in daily settlement—and maintains focus on risk management objectives. However, the invention of long-term contracts and omission of the actual strategic shift (de-/re-designation of debt hedges) significantly reduce factual correctness and qualitative accuracy. The answer gives a misleading impression of strategic expansion rather than the actual refinement within short-term frameworks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 583,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "Salesforce's strategic relationship with enterprise cloud companies from 2023 to 2024 maintained a focus on strategic investments in enterprise cloud firms, technology startups, and system integrators, as outlined in their 2024 10-K. The company emphasized expanding its partner ecosystem through collaborations with ISVs and SIs to accelerate market reach, while integrating tools like **Agentforce** and **Data Cloud** to enhance ecosystem interoperability. These efforts aimed to deepen ecosystem integration via AI-driven platforms and reinvest proceeds from strategic investments to grow the portfolio, reflecting continuity in prioritizing innovation and ecosystem expansion.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Salesforce's ongoing strategic investments in enterprise cloud companies, startups, and system integrators, and mentions ecosystem expansion, which aligns with the 2023 portion of the ground truth. However, it fails to accurately capture the key evolution from 2023 to 2024—specifically, the shift from financial investment to broader strategic dependency and deeper ecosystem integration via AppExchange and third-party development. Instead, the LLM implies continuity rather than transformation, missing the nuanced pivot described in the original answer. The mention of 'Agentforce' and 'Data Cloud' is contextually relevant but not present in the ground truth, introducing unverified specifics that may not be supported by the filings referenced. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised—score reflects full alignment where applicable. (3) The multi-hop reasoning is partially sound: the model connects investments and ecosystem growth across years, but fails to synthesize the critical shift in strategic posture from investor to ecosystem orchestrator in 2024. This undermines the qualitative accuracy despite correct entity identification (e.g., ISVs, SIs). (4) Contextual relevance is high because the response addresses investment focus and ecosystem integration, directly engaging the question’s scope, but the failure to distinguish the strategic evolution limits correctness. The correctness score is 6 due to partially accurate facts with a significant omission in strategic shift; qualitative accuracy is low due to flawed reasoning synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 460,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "The company's approach to accrual rates for vendor funding programs remained consistent between fiscal 2023 and 2024, with accrual rates based on vendor agreements, historical purchase trends, and adjustments to reflect actual volumes. Both years emphasized sensitivity to projected purchase volumes, noting that deviations could impact accrued amounts, particularly in programs tied to graduated purchase volumes. No material changes in methodology were reported during this period.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in stating that the company's methodology for accrual rates remained unchanged between fiscal 2023 and 2024 and that projected purchase volumes were a factor. It correctly notes the use of vendor agreements, historical trends, and volume adjustments. However, it inaccurately claims that both years 'emphasized sensitivity to projected purchase volumes' and that graduated purchase volumes were explicitly referenced in both years. According to the ground truth, fiscal 2023 specifically highlighted 'graduated purchase volumes' as a sensitivity factor, but this explicit reference was omitted in fiscal 2024, suggesting a shift in emphasis or simplification. The LLM answer misses this key nuance and instead implies continuity in the explicit treatment of graduated volumes, which contradicts the original answer. There are no numerical inaccuracies (hence high quantitative accuracy), but the qualitative reasoning is flawed in synthesizing the evolution of disclosure emphasis. The answer is contextually relevant and addresses the core question about evolution in approach, but fails to capture the subtle yet important change in how sensitivity was communicated, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 348,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "The strategic relationship between LLY and Boehringer Ingelheim (BI) regarding Jardiance evolved from 2022 to 2024, with legal involvement shifting from active patent litigation to regulatory compliance. In 2022, BI initiated U.S. patent litigation against generic companies seeking to market Jardiance, which was stayed. By 2024, the focus shifted to the Inflation Reduction Act (IRA) of 2022, which subjected Jardiance to government-set prices effective in 2026, impacting revenue. Despite this, LLY and BI maintained their collaborative dependency on Jardiance, with BI continuing to defend against patent challenges and manage legal risks. The partnership remained critical for Jardiance's commercialization, though regulatory pressures and pricing constraints became more prominent in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in the LLY-BI relationship from 2022 to 2024, noting BI's initiation of patent litigation in 2022 and the impact of the Inflation Reduction Act (IRA) on Jardiance pricing. However, it incorrectly states that the IRA's government-set prices take effect in 2026, while the ground truth implies the pricing impact is reflected in 2024 business planning and revenue projections, with the 66% discount compared to 2023 prices. The 66% discount figure is missing in the LLM answer, a key quantitative detail. (2) The date of the IRA (2022) is correctly mentioned, but the effective timing of its impact is misrepresented. The LLM introduces a '2026' effective date not present in the original answer, which undermines quantitative and temporal accuracy. The original answer emphasizes the 2024 strategic dependency due to IRA pricing, not a future 2026 effect. (3) The multi-hop reasoning is partially sound: the model connects BI's legal actions in 2022 and the IRA's impact on Jardiance, recognizing the evolving nature of the collaboration. However, it fails to fully capture the depth of LLY's growing dependency by 2024 as a strategic shift from arms-length legal separation to financial entanglement due to pricing pressures. The synthesis is logical but incomplete. (4) The contextual relevance is high—LLM stays focused on the evolution of the partnership, legal involvement, and collaborative dependency. The qualitative reasoning is strong, with accurate entity identification (LLY, BI, Jardiance, IRA), but the omission of the 66% discount and misstatement of timing reduce factual precision. Hence, correctness is reduced to 7 due to significant but not fundamental errors in quantitative and temporal details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 483,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "Disney's capital investment strategy toward cruise ships remained aligned with its broader Parks & Experiences business in 2023, as highlighted in the 2022 filing. The 2022 document noted that significant capital spending included cruise ships as part of theme park and resort expansion. The 2023 filing reiterated Disney Cruise Line's role within the Parks & Experiences segment, with no explicit mention of changes to the cruise ship investment strategy, suggesting continuity in prioritizing cruise ship development as part of its experiential offerings.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The 2022 10-K did not state that cruise ships were included in significant capital spending; instead, it only mentioned cruise ships as part of the Experiences segment without specific emphasis on capital investment. The LLM incorrectly asserts that the 2022 filing 'noted that significant capital spending included cruise ships,' which contradicts the ground truth. In reality, it was the 2023 filing that explicitly elevated cruise ships as a key capital investment. The LLM claims there was 'no explicit mention of changes' and 'continuity in prioritizing,' but the ground truth shows a clear strategic shift—cruise ships went from not being specifically highlighted in capital spend in 2022 to being explicitly listed in 2023. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in numbers, dates, or calculations. (3) The multi-hop reasoning is flawed: the model failed to correctly synthesize the evolution between the two years' filings. It incorrectly attributes 2023-level specificity about cruise ship investments to the 2022 report, reversing the timeline of strategic emphasis. This breaks the logical comparison required by the question. (4) Correctness is low (3/10) due to major factual inaccuracy in the central claim. Quantitative accuracy is 10/10 by default (no numbers involved). Qualitative accuracy is low (3/10) due to incorrect entity-event mapping (wrong year for investment emphasis). Contextual relevance is moderate (6/10) as the answer addresses the right segment and topic but misrepresents the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 458,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024 by expanding its focus on emerging technologies and fintech partnerships. In 2022, Foundry was highlighted for connecting customers and partners with thought leadership, innovation methodologies, and early-stage fintech players. By 2024, Foundry continued these efforts while deepening engagement with blockchain ecosystems, digital currencies, and crypto players, enabling programmable payments and enhancing cross-border remittance solutions. This reflects a progression from foundational innovation partnerships to actively experimenting with and integrating cutting-edge technologies like blockchain and AI-driven fraud detection.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of evolution from 2022 to 2024. It accurately captures the initial role of Mastercard Foundry in 2022 as a connector to thought leadership, innovation methodologies, and early-stage fintech players. The 2024 evolution toward deeper engagement with emerging technologies like blockchain and programmable payments is also correctly conveyed. The mention of blockchain ecosystems, digital currencies, and crypto players reflects the strategic shift toward next-gen financial tech as described in the original answer. However, the LLM adds a specific detail about 'AI-driven fraud detection' and 'cross-border remittance solutions' that are not present in the ground truth and cannot be verified from the provided knowledge. While these may be plausible extensions, they introduce unverified elements, slightly reducing qualitative accuracy. Additionally, the ground truth specifically references the 'Mastercard Multi-Token Network™' as a key vehicle for this evolution, which the LLM omits. This is a minor but notable omission in precision. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. Contextual relevance is strong—the response directly addresses the evolution in Foundry's role, engagement with emerging tech, and fintech partnerships. Overall, the answer is factually sound with minor overreach in unsupported details and a slight lack of specificity on the Multi-Token Network, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 429,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "The collaboration with Boehringer Ingelheim evolved between 2022 and 2024, with **regulatory designations** such as Breakthrough Therapy and Fast Track supporting the development of Jardiance (Empagliflozin), which received these designations in 2022 and continued in 2024. However, **pricing pressures intensified** due to the Inflation Reduction Act (IRA) of 2022, which mandated government-set prices for certain drugs, including Jardiance. In 2024, the U.S. Department of Health and Human Services (HHS) imposed a **66% discount** on Jardiance’s 2023 list price, significantly impacting revenue and reflecting heightened regulatory and financial challenges under the IRA.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Breakthrough Therapy and Fast Track designations in 2022, continuation into 2024, Jardiance being part of the Eli Lilly-Boehringer Ingelheim collaboration, the Inflation Reduction Act (IRA) of 2022 as the source of pricing pressure, HHS imposing a 66% discount on Jardiance’s 2023 list price, and the financial impact of government-set pricing. (2) Quantitative accuracy is perfect: the 66% discount is correctly stated, and the reference to 2023 list price and 2024 regulatory action matches the timeline. (3) Multi-hop reasoning is sound—correctly linking the evolution from early regulatory support (2022) to later financial constraints (2024) via the IRA, synthesizing information across time and regulatory/financial domains. (4) Minor deduction in qualitative accuracy because the original answer emphasizes a strategic shift from 'regulatory facilitation to regulatory-driven financial constraints,' a nuance slightly underemphasized in the LLM response, though implied. Otherwise, the LLM answer is semantically equivalent, contextually complete, and precisely addresses both regulatory designations and pricing pressures as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 348,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "The CH-53K King Stallion heavy lift helicopter remains a key component of Lockheed Martin's Rotary and Mission Systems (RMS) segment, emphasizing its strategic role in international defense and logistics. In 2023, the RMS segment highlighted the CH-53K as part of its growth initiatives, including international contracts like the Israeli Ministry of Defense's procurement of 12 helicopters (awarded in 2022–2023). In 2024, the CH-53K is reiterated as a major program under RMS, underscoring its continued importance in supporting U.S. and international military operations, particularly in heavy lift capabilities and global logistics. The segment's focus on expanding its portfolio and maintaining strategic partnerships ensures the CH-53K's sustained relevance in meeting evolving defense needs.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the CH-53K King Stallion as a key program within Lockheed Martin's Rotary and Mission Systems (RMS) segment in both 2023 and 2024, which aligns with the ground truth. It also accurately references international contracts, such as the Israeli Ministry of Defense procurement, which is factually correct and contextually relevant. However, the original answer emphasizes a shift in strategic positioning—from being one of several near-to-mid-term growth elements in 2023 to being framed within a broader portfolio of all-domain mission solutions, AI/ML, and autonomy in 2024. This evolution in narrative and technological integration is missing from the LLM response. Instead, the LLM focuses on logistics and international defense relevance, which, while not incorrect, fails to capture the core shift in strategic framing. (2) There are no numeric values in the ground truth, and the LLM does not introduce any incorrect numbers or dates. The mention of the Israeli contract awarded in 2022–2023 is plausible and does not contradict known facts, so quantitative accuracy is high. (3) The multi-hop reasoning is partially sound—the LLM connects the CH-53K to RMS and tracks its importance across years, but it does not synthesize the deeper strategic evolution involving digital transformation and interoperability. The answer stays at a surface-level continuity rather than identifying the shift in emphasis. (4) The correctness score is 6 due to accurate entity and contextual placement but significant omission of the key qualitative shift in strategic positioning. Quantitative accuracy is 10 because no numbers are wrong. Qualitative accuracy is 6 due to incomplete reasoning and missed conceptual evolution. Contextual relevance is 8 because the answer stays on topic and provides relevant background, even if it misses the central point of strategic repositioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 519,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "The change in Lilly's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 reflects a strategic shift toward newer, more competitive products (e.g., Glyxambi, Synjardy, Trijardy XR) and a reduction in older products like Trajenta and Jentadueto. This indicates a focus on maintaining market relevance amid biosimilar and generic competition, prioritizing products with stronger patent protection or therapeutic advantages. The exclusion of certain legacy products suggests a reallocation of resources to high-growth areas, such as combination therapies and emerging diabetes treatments, while adapting to evolving reimbursement pressures and payer dynamics.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the narrowing of the portfolio from a broader set in 2022 (Trajenta, Jentadueto, Basaglar, etc.) to only Jardiance, Glyxambi, Synjardy, and Trijardy XR by 2024, though it does not explicitly name all products removed (Basaglar is mentioned only implicitly via 'older products'). (2) There are no numeric values requiring calculation, but the years (2022 and 2024) are correctly used as reference points. (3) The multi-hop reasoning is sound: the model infers strategic refocusing from product removals and additions, correctly attributing the shift to factors like generic competition, patent protection, and growth potential. It appropriately emphasizes combination therapies and market adaptation. (4) The answer conveys the same core insight as the original—strategic streamlining toward higher-potential products—while adding relevant context on payer dynamics and biosimilars, which is plausible and contextually supportive. The only minor shortcoming is the omission of explicit mention of Basaglar’s removal, which slightly reduces completeness. Overall, the response is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 344,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "The JASSM program's production activity ramped up in 2024, contributing to a **$1.2 billion increase in MFC segment net sales** compared to 2023, driven by higher volume on tactical and strike missile programs. This production ramp-up also fueled a **significant rise in backlog**, as higher orders on JASSM, along with PAC-3 and GMLRS, increased the backlog by $6.55 billion year-over-year. In 2023, JASSM had already contributed to a $145 million sales boost and backlog growth, underscoring its strategic importance as a key driver of revenue and deferred obligations in the MFC segment.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While the ground truth states that JASSM contributed to a $1.2 billion increase in tactical and strike missile programs within MFC in 2024, the LLM incorrectly frames this as a $1.2 billion increase in MFC segment net sales, which is not supported by the original answer. More critically, the LLM introduces a $6.55 billion year-over-year backlog increase driven by JASSM, PAC-3, and GMLRS—this specific figure is not present in the ground truth, which only states that JASSM was a key contributor to backlog growth without quantifying the total backlog increase. Additionally, the claim that JASSM contributed to a $145 million sales boost in 2023 is entirely absent from the original answer, which explicitly states there was no specific mention of significant changes in production or backlog contribution in 2023. (2) These numerical errors are major because they fabricate precise financial figures not present in the source, undermining factual reliability. While $1.2 billion is correctly referenced, its context (net sales vs. program-level increase) is misrepresented. (3) The qualitative reasoning is partially sound: the model correctly identifies the production ramp-up in 2024 and links JASSM to increased backlog alongside PAC-3 and GMLRS, showing appropriate multi-hop synthesis of program importance across years. However, the addition of unsupported 2023 financials breaks the chain of accurate inference. (4) Contextual relevance is high because the answer addresses production activity, backlog contribution, and strategic importance over the two years as required. However, due to the invention of specific dollar amounts and misattribution of financial impacts, the correctness score is limited to 5—partially correct but with significant factual errors that affect interpretation of the program’s evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 515,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "JPM's evaluation of credit risk for Business Banking Loans has evolved to emphasize more granular monitoring of **LTV ratios**, **FICO scores**, and **geographic distribution** as key indicators, alongside delinquency rates. In 2024, delinquency rates for residential real estate loans (a proxy for business banking risk) decreased to 0.11% (vs. 0.37% in 2023), reflecting improved risk management. The shift toward refined LTV and FICO analysis, combined with regional economic insights, enhances early detection of borrower distress, enabling proactive mitigation strategies. This evolution underscores a more proactive, data-driven approach to identifying credit risks.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces key metrics—LTV ratios, FICO scores, and geographic distribution—as central to JPM's 2024 credit risk evaluation, which are not mentioned in the ground truth. Instead, the original answer emphasizes a shift from broader prime consumer credit strategy in 2023 to focusing on delinquency rates (specifically loans >30 days past due) in 2024. These are fundamentally different risk indicators, and the LLM invents data points not present in the source. (2) The quantitative claims are factually incorrect: the LLM states that delinquency rates for 'residential real estate loans' decreased from 0.37% in 2023 to 0.11% in 2024. However, the ground truth does not provide any specific delinquency percentages for those years, nor does it equate residential real estate loans with Business Banking Loans. This numerical data appears fabricated. Additionally, using residential real estate loans as a 'proxy' for business banking risk is unsupported in the original answer. (3) The multi-hop reasoning is flawed. The original answer traces a conceptual evolution—from portfolio-level performance models in 2023 to early delinquency tracking in 2024—as part of a strategic shift toward proactive intervention. The LLM instead pivots to unrelated metrics and an incorrect proxy category, failing to synthesize the correct evolution across years and segments. It also mischaracterizes the scope by referencing residential loans instead of Business Banking Loans. (4) While the LLM captures the general direction of a 'more proactive, data-driven approach,' this is a vague alignment. The core factual content—metrics, time-based evolution, and supporting data—is incorrect or invented. Hence, the correctness score is low due to major factual and quantitative errors, despite partial relevance in tone and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 499,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "Based on the provided document pages, there is no indication of changes to Target Corporation's SPP II plan terms between the 2022 and 2023 filings. Both filings reference the SPP II plan as amended and restated effective April 3, 2016, without additional amendments or modifications. This suggests that Target's executive compensation framework remained consistent during this period, maintaining its structure and terms without significant updates.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims there were no changes to the SPP II plan between the 2022 and 2023 filings, directly contradicting the ground truth, which states that the plan was updated from the 2016 Plan Statement (effective April 3, 2016) in the 2022 filing to the 2022 Plan Statement (effective May 1, 2022) in the 2023 filing. (2) The key dates—April 3, 2016, and May 1, 2022—are explicitly mentioned in the ground truth and represent critical factual anchors; the LLM incorrectly asserts both filings reference only the 2016 version, failing on quantitative accuracy. (3) The multi-hop reasoning required to compare the plan statements across two years is entirely missed; the LLM fails to recognize the evolution in plan documentation, leading to an erroneous conclusion about consistency in executive compensation. (4) While the answer addresses the question's structure and attempts to interpret implications, its factual foundation is wrong, severely undermining qualitative and contextual accuracy. The suggestion of 'consistency' is incorrect given the documented plan restatement. Only minimal contextual relevance is retained because the answer at least engages with the topic of executive compensation framework stability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 351,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "The financial obligations related to Incyte under the Olumiant collaboration remained consistent from 2022 to 2024, with Incyte eligible for up to $100.0 million in success-based regulatory milestones and up to $100.0 million in sales-based milestones as of December 31, 2024. These amounts had not changed from the 2021 disclosure, indicating no material evolution in the potential future milestone payments during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the milestone structure remained unchanged through 2024. The ground truth indicates a clear evolution: in 2022, Incyte was eligible for up to $100M in regulatory milestones and $100M in sales-based milestones, but by 2024, there is no mention of remaining regulatory milestones, suggesting they were resolved or expired, with only royalty payments (up to 20% and low teens for COVID-19 sales) referenced. The LLM incorrectly asserts that the same milestone structure was still in place as of December 31, 2024, which contradicts the ground truth. (2) Quantitatively, the $100M regulatory and $100M sales milestones are correctly cited for 2022, but the extension of these figures to 2024 is unsupported and incorrect. There is no evidence in the ground truth that these potential future payments still existed in 2024. (3) The multi-hop reasoning is flawed: the model fails to recognize the shift from a dual milestone structure (regulatory + sales) to one focused on royalties, which requires synthesizing changes over time across filings. Instead, it assumes static terms without acknowledging the evolution. (4) Contextual relevance is moderate because the answer addresses the right companies and agreement, and discusses milestone types, but misses the core of the question—how obligations evolved—by asserting no change when a significant shift occurred. This fundamental error severely undermines correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 416,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "Cisco's APJC region revenue remained stable at $8,027 million in fiscal 2023 compared to $8,027 million in fiscal 2022, with no significant change in revenue. Long-lived assets in the APJC region also remained unchanged at $997 million as of July 29, 2023, compared to $997 million as of July 30, 2022. This indicates no material evolution in financial exposure for the APJC region between these periods based on segment reporting and asset balances.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) The revenue figure of $8,027 million for APJC in both fiscal 2022 and 2023 is not supported by the ground truth, which explicitly states that specific financial figures for APJC were not disclosed in 2022 and no revenue data was provided. (2) The long-lived assets value of $997 million is contradicted by the ground truth, which reports total assets (not long-lived) in APJC as $5,382 million as of July 29, 2023—this is a major numerical discrepancy. (3) The LLM falsely claims stability in financial exposure due to unchanged figures, but the ground truth indicates that detailed asset disclosure began in 2023, implying improved transparency rather than no change. (4) The reasoning fails on multi-hop synthesis: the model invents precise figures not present in the source data and draws a conclusion opposite to the ground truth, which emphasizes increased disclosure and lack of prior itemization. While the answer addresses the question's structure (evolution between years), it does so with fabricated data, making it highly inaccurate despite being contextually framed around the right region and time period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 338,
        "total_tokens": 1588
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "The strategic collaboration between Lilly (LLY) and Boehringer Ingelheim regarding Jardiance evolved in response to regulatory changes, particularly the U.S. Inflation Reduction Act (IRA) of 2022. In 2022, the IRA introduced government-set prices for certain drugs under Medicare, including Jardiance, effective in 2026, with a 66% discount from the 2023 list price. By 2024, this regulatory framework had solidified, leading to accelerated revenue erosion for Jardiance due to mandated price reductions. The collaboration adapted by navigating these price controls, which impacted reimbursement and market dynamics, while maintaining demand for Jardiance despite competitive and regulatory pressures.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly around timing and regulatory implementation. While it correctly identifies the Inflation Reduction Act (IRA) and its impact on Jardiance, it incorrectly states that the IRA introduced government-set prices effective in 2026. According to the ground truth, Jardiance was selected in August 2023 as one of the first drugs subject to price-setting, with a 66% discount applied in August 2024—meaning the price reduction took effect in 2024, not 2026. This is a major error in both timing and regulatory timeline. (2) The 66% discount is correctly cited in magnitude but misaligned in effective date. The ground truth specifies the discount was applied in August 2024, whereas the LLM defers it to 2026, which significantly distorts the business impact timeline. Additionally, the LLM omits key 2022 performance data: the 30% U.S. and 28% ex-U.S. revenue growth, which were central to the original answer and relevant to showing pre-IRA momentum. (3) The reasoning partially captures the multi-hop nature of the question—linking regulatory change (IRA) to pricing impact and then to collaboration strategy—but fails to accurately synthesize the timeline and causal sequence. The answer implies the 2022 IRA immediately set 2026 prices, skipping the critical 2023 selection and 2024 implementation milestones. (4) Despite these errors, the answer remains contextually relevant, correctly identifying the LLY-Boehringer Ingelheim collaboration, Jardiance, the IRA, and the general direction of impact (price controls affecting revenue). The qualitative reasoning about adapting to price controls and maintaining demand is plausible, though underspecified. Thus, the answer is partially correct but contains significant factual and temporal inaccuracies that undermine full correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 504,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "GM's emphasis on financial and reputational risks of product safety recalls remained consistent between 2022 and 2023, with continued acknowledgment of the significant costs (e.g., parts, labor, and potential legal liabilities) and reputational harm associated with recalls, particularly for global platforms like the Chevrolet Bolt EV. However, in 2023, the discussion expanded to highlight the heightened risks tied to advanced technologies (EVs/AVs), including cybersecurity vulnerabilities and the complexity of connected systems. The 2023 filings underscored proactive risk management strategies, such as enhanced cybersecurity protocols and integrated oversight by the Cybersecurity Management Board, to address emerging threats and protect brand reputation in the context of evolving EV/AV technologies. This reflects a broader, more integrated approach to managing risks associated with advanced systems.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies GM and the Chevrolet Bolt EV as central to the discussion of recalls and acknowledges the evolution in risk emphasis between 2022 and 2023. It accurately notes that financial and reputational risks were acknowledged in both years, which aligns with the ground truth. However, the original answer emphasizes a clear shift from a cost-centric focus in 2022 (logistical complexity and scale of global platform recalls) to a reputation- and strategy-centric focus in 2023 (brand equity and leadership in EV/AV technologies). The LLM answer captures part of this evolution but introduces elements not present in the ground truth—specifically, 'cybersecurity vulnerabilities' and the 'Cybersecurity Management Board'—which are not mentioned in the original answer and represent a divergence in reasoning. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised; the LLM does not fabricate numbers, earning a full score here. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes information across years and technologies, but it introduces new concepts (cybersecurity board, cyber protocols) that were not part of the knowledge graph's ground truth, suggesting potential hallucination or misattribution. This affects qualitative accuracy. (4) The contextual relevance is high because the answer addresses the core question about evolving risk emphasis and ties it to EV/AV technologies and brand positioning, even if the specific reasoning path diverges. The answer is plausible but not fully aligned with the documented evolution in GM's disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 460,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "Between 2022 and 2024, Costco's Japanese subsidiary issued $500 million in Guaranteed Senior Notes with fixed interest rates (1.400%–2.120%) and maturities ranging from 2033 to 2043, reflecting a long-term financing strategy to secure low-cost capital for extended periods. In July 2024, the subsidiary repaid $77 million of these notes, indicating active management of debt maturity. This approach aligns with Costco's broader strategy of using a mix of senior notes and subsidiary-guaranteed debt to optimize financing costs, leverage favorable rates, and maintain flexibility in managing long-term liabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the issuance of $500 million in Guaranteed Senior Notes by Costco's Japanese subsidiary in November 2023 (implied from the 2024 filing), with fixed interest rates ranging from 1.400% to 2.120% and maturities from 2033 to 2043. It also correctly notes the $77 million repayment in July 2024. These figures match the ground truth, though the LLM omits the detail that in 2022, only Level 3 valuation inputs were disclosed without specifics. (2) Quantitatively, all numbers are accurate: $500 million issuance, rate range, maturity dates, and $77 million repayment are all correct. The use of 'million' is an acceptable format expansion of '$500' as stated in the original (where '$500' is clearly meant as $500 million given context). (3) The reasoning is sound: the LLM correctly infers a strategic long-term financing approach focused on fixed-rate, long-dated debt and active liability management. It appropriately links this to Costco’s broader financing strategy, which is a reasonable interpretation. However, it does not explicitly mention the increased transparency between 2022 and 2024, a key point in the original answer about the evolution of disclosure. (4) The answer is highly relevant and conveys nearly all key facts with correct synthesis across time and entities. The minor omission of the 2022 disclosure limitation slightly reduces completeness, but core facts and implications are preserved. Hence, a score of 9 is justified—excellent accuracy with only a small qualitative gap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 426,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "The value of Cisco's available-for-sale debt investments decreased from $15,206 million as of July 31, 2022, to $15,592 million as of July 29, 2023, reflecting a net increase. However, the **gain on these investments declined** from $53 million in 2022 to a loss of $21 million in 2023, indicating **lower unrealized gains** or **unfavorable market movements**. This shift suggests Cisco may be **rebalancing its investment portfolio**, potentially reallocating funds toward other assets (e.g., privately held investments) or adjusting to market conditions, while maintaining a focus on liquidity and strategic uses of capital.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. It incorrectly states that the value of Cisco's available-for-sale debt investments increased from $15,206 million in 2022 to $15,592 million in 2023, which contradicts the ground truth showing a decrease from $15,592 million in 2022 to $9,865 million in 2023—a drop of $5,727 million. The LLM also misreports the 2022 gain as $53 million, while the original answer states it was $9 million. The 2023 loss of $21 million is not mentioned in the ground truth at all. (2) Calculations are therefore incorrect: the LLM implies a net increase in investment value, while the correct change is a substantial decrease. The ground truth emphasizes a strategic reduction in holdings, which the LLM fails to capture due to incorrect numbers. (3) Multi-hop reasoning is flawed—the LLM conflates market gains/losses with total investment value and misaligns the timeline. While it attempts to infer strategy (rebalancing, capital allocation), this is based on incorrect data, undermining the conclusion. (4) The contextual relevance is moderate because the answer addresses investment strategy and mentions portfolio rebalancing, but the qualitative and quantitative inaccuracies severely limit its correctness. The core facts—direction of change, magnitude, and supporting figures—are wrong, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 383,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "JPMorgan Chase's exposure to system damage risks from third-party vendor attacks and data recovery challenges has evolved from 2023 to 2024, with heightened emphasis on cloud migration, AI-driven threats, and ransomware. In 2023, the focus was on general cybersecurity risks, including third-party vulnerabilities and data breach recovery complexities. By 2024, the report highlights increased risks from expanding digital banking and cloud services, AI-enabled attacks, and quantum computing threats, alongside specific challenges in recovering from ransomware and third-party system disruptions. Both years stress the difficulty of mitigating these risks and the potential for significant financial and reputational harm.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but introduces inaccuracies and omits key details from the ground truth. While it correctly identifies an evolution in JPMorgan Chase's risk exposure related to third-party vendors and data recovery, it adds unsupported specifics such as 'cloud migration', 'AI-driven threats', 'quantum computing threats', and 'AI-enabled attacks' that are not present in the original 2023–2024 comparison. The ground truth emphasizes ransomware targeting third-party vendors, risks exceeding cyber insurance coverage, and inability to prevent fraudulent transaction processing in 2024—none of which are mentioned in the LLM response. Instead, the LLM invents new threat vectors not cited in the source. (2) There are no numeric values in either answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is partially sound: the model recognizes that risk exposure evolved over time and attempts to contrast 2023 and 2024. However, it fails to accurately synthesize the specific evolution documented in the knowledge graph, particularly around insurance coverage limits and transaction fraud prevention. The reasoning is plausible but factually misaligned. (4) Contextual relevance is high because the answer addresses the core topic—evolution of system damage risks related to third parties and data recovery—but the inclusion of speculative threats reduces factual precision. Correctness is scored at 5 due to significant factual omissions and introduction of unsupported content, despite maintaining the general theme.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 441,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "Costco invested in expanding its manufacturing and processing facilities to support private-label growth, as noted in the 2024 filing. The document highlights increased focus on private-label penetration through merchandising strategies and mentions operational facilities dedicated to producing private-label items, including processing, packaging, and manufacturing capabilities. These investments align with the 2022 strategy to enhance value for members and improve gross margins through private-label offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that Costco made operational investments by 2024—specifically in processing, packaging, and manufacturing facilities—to support its private-label growth strategy first emphasized in the 2022 filing. The answer accurately reflects the strategic continuity between the 2022 merchandising focus and the 2024 operational execution. All entities (Costco, private-label strategy, 2022 and 2024 timeframes) are correct, and there are no numerical inaccuracies (no specific numbers to verify, but qualitative references are consistent). The reasoning correctly synthesizes information across two filings (2022 strategy and 2024 implementation), demonstrating sound multi-hop logic. The only minor shortcoming is that the LLM does not explicitly state the strategic shift from external sourcing to internal production capabilities, which is a key nuance in the original answer. However, mentioning dedicated facilities implies this evolution. Wording differs slightly but maintains semantic equivalence. Thus, the answer is highly accurate, complete, and contextually relevant with only a slight omission in depth of strategic transformation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 344,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "UnitedHealth Group's approach to Medicaid managed care contract bidding in 2022 and 2023 involved assumptions about enrollment, utilization, and medical costs, with risks tied to bid accuracy including unforeseen program changes, competitor pricing, and regulatory audits. Both years highlighted that inaccurate assumptions—due to policy shifts, post-bid program adjustments, or lower competitor bids—could lead to financial adverse effects, lost members, or penalties from CMS/state audits, emphasizing the critical role of accurate forecasting and regulatory compliance in bid outcomes.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies key elements of UnitedHealth Group's Medicaid managed care contract bidding risks, including assumptions about enrollment, utilization, and medical costs, as well as risks from unforeseen program changes, competitor pricing, and regulatory audits. It accurately notes that inaccurate assumptions could lead to financial adverse effects and penalties, which aligns with the 2023 emphasis in the ground truth. However, the LLM fails to capture the core evolution between 2022 and 2023 as required by the question. In 2022, the focus was on the risk of losing Medicaid members due to failure to renew contracts—a retention and renewal risk—whereas in 2023, the focus shifted to the accuracy of bid assumptions and competitive dynamics. The LLM incorrectly implies that both years had similar concerns about bid assumptions and competitive pricing, thus missing the key shift in emphasis. While all entities (UnitedHealth Group, Medicaid managed care, CMS/state audits) and years are correctly referenced, and there are no numerical inaccuracies (no specific numbers to verify), the qualitative reasoning is flawed in its synthesis across years. The answer conflates the two years' risk disclosures rather than contrasting them, undermining the multi-hop reasoning needed to show evolution. This results in a partially correct answer with accurate components but a significant omission in the comparative analysis. Hence, correctness is reduced to 6 due to the failure to accurately represent the shift in strategic focus over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 427,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "MET's investment in Municipals decreased from $159 million at December 31, 2022, to $147 million at December 31, 2023, as reported in the \"Fixed Maturity Securities AFS by Sector &Credit Quality Rating\" tables. The valuation hierarchy classification for Municipals remained in **Level 2** for both years, as they are categorized under observable inputs (e.g., independent pricing sources or market data) in the fair value hierarchy, consistent with the majority of Fixed Maturity Securities AFS holdings. No transfers into or out of Level 3 were explicitly noted for Municipals in the provided data.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors. According to the ground truth, MET's investment in Municipals was $14,212 million in 2022 and dropped to $159 million in 2023. However, the LLM incorrectly states the 2022 value as $159 million and 2023 as $147 million, reversing and distorting the actual figures. This is a critical quantitative error. (2) The valuation hierarchy classification is partially correct: the LLM correctly identifies Municipals as classified under Level 2 in 2023, which matches the ground truth. However, it claims Level 2 classification also applied in 2022, while the ground truth states that in 2022 the investment was categorized under 'Estimated Fair Value' without a detailed hierarchy breakdown—meaning the LLM incorrectly assumes Level 2 applied in both years. (3) The multi-hop reasoning is flawed: the model fails to recognize the dramatic reduction from over $14 billion to $159 million, which is central to the question. Instead, it reports a minor decline from $159M to $147M, suggesting confusion between the two years or misattribution of data. (4) Contextual relevance is moderate—the response addresses the right topic (Municipals investment and fair value hierarchy), uses appropriate terminology, and references plausible tables, but the core facts are incorrect. Due to severe inaccuracies in numbers and misrepresentation of the valuation hierarchy evolution, the correctness score is low despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 410,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "Microsoft's approach to Office 365 subscriptions evolved from fiscal year 2022 to 2024 by expanding licensing flexibility and simplifying customer agreement models. In 2022, the Microsoft Customer Agreement was introduced as a non-expiring, digital agreement supporting all customers, while the Microsoft Online Subscription Agreement allowed small/medium organizations to subscribe seamlessly. By 2024, these models were further refined, emphasizing subscription-based flexibility, with the Microsoft Products and Services Agreement enabling on-demand licensing without organization-wide commitments. Additionally, SA was integrated into Open Value agreements, enhancing flexibility for customers seeking hybrid perpetual and subscription options. These changes reflect a broader shift toward adaptable, customer-centric licensing frameworks.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general direction of Microsoft's evolution toward more flexible licensing and customer-centric agreements, correctly identifying key agreements like the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement. However, it incorrectly states that the Microsoft Customer Agreement was introduced in 2022, while the ground truth does not specify an introduction date and implies it was already in place or evolved by 2024. Additionally, the mention of 'SA' (Software Assurance) and its integration into 'Open Value agreements' is not supported by the original answer and introduces a detail not present in the ground truth, potentially confusing perpetual licensing models with the subscription-focused evolution described. (2) There are no explicit numbers (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised—dates (2022, 2024) are used appropriately in context. (3) The multi-hop reasoning is partially sound: the model connects licensing flexibility with agreement models across years, but it introduces unsupported details (SA, Open Value) that were not in the original knowledge, weakening the factual synthesis. (4) The correctness score is 6 due to these factual overextensions despite capturing the core trend; qualitative accuracy is 6 due to incorrect entity relationships; quantitative accuracy is 8 because all temporal references are contextually valid; contextual relevance is 9 as the response stays focused on the question's scope and evolution of subscription models.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 446,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "Between 2022 and 2023, MET's Level 3 Fixed Maturity Securities AFS composition shifted from a higher allocation to **Corporate securities** ($55 million in 2022) and **Other** ($3 million) to a greater emphasis on **Foreign Bonds** ($8 million) and **Other** ($8 million). This indicates a strategic diversification toward international assets, likely to manage risk or capitalize on global market opportunities, while reducing exposure to domestic corporate debt. The slight decrease in total Level 3 Fixed Maturity Securities AFS ($920 million in 2022 to $904 million in 2023) reflects a reallocation rather than a reduction in overall holdings.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS included $1M in Corporate bonds, $1M in Foreign Bonds, and $11M in Equity Securities—not $55M in Corporate securities and $3M in Other as claimed. In 2023, the correct values are $54M in Corporate bonds, $2M in Foreign Bonds, and $828M in Other Investments, whereas the LLM states $8M in Foreign Bonds and $8M in Other, which is vastly incorrect. The LLM also invents a total portfolio value of $920M in 2022 and $904M in 2023, which is not supported by the ground truth and cannot be verified from the provided data. (2) Quantitative accuracy is very low: none of the key figures match the original data. The LLM misrepresents both the categories (e.g., 'Equity Securities' is replaced with 'Other') and the amounts (e.g., $11M vs. $3M, $828M vs. $8M). The calculation of totals is fabricated. (3) The multi-hop reasoning is flawed. The LLM incorrectly identifies the shift as being toward Foreign Bonds and Other, while the actual shift is a massive increase in Other Investments (from $11M to $828M, though note: Equity Securities in 2022 may not be directly comparable to Other Investments in 2023 if categories changed). The conclusion about reducing domestic corporate debt is unsupported—corporate bond exposure actually increased from $1M to $54M. The reasoning about international diversification is speculative and based on false data. (4) Contextual relevance is moderate because the answer attempts to address the change in composition and interpret strategy, but due to incorrect data, the interpretation is invalid. The structure and intent align with the question, but factual foundation is entirely wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 492,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024 by reinforcing its role as a core cloud service within Microsoft's broader portfolio, recognized ratably over contract periods. In 2022, Office 365 was described as a single performance obligation due to its integration with desktop applications, emphasizing its subscription-based cloud model. By 2024, Microsoft intensified its focus on AI-driven innovation, integrating generative AI capabilities into Office 365 and other services to counter competitive pressures from AI-centric offerings. The 2024 filings highlighted investments in AI infrastructure and cloud platforms to maintain differentiation, ensuring Office 365 remained a key enabler of productivity while adapting to evolving market demands.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Office 365's role as a core cloud service in 2022 alongside Azure, Dynamics 365, and Xbox is accurately reflected, and the 2024 evolution toward AI integration is correctly described. The mention of AI-driven innovation, investments in AI infrastructure, and competitive pressures from AI-centric offerings matches the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across time (2022 to 2024), identifies the strategic shift in Office 365’s positioning, and links it to broader competitive dynamics and Microsoft’s AI strategy. The only minor omission is that the original answer specifically names competitive threats like 'free applications funded by advertising or open-source AI models,' which the LLM answer alludes to generally as 'AI-centric offerings' but does not detail. This slight lack of specificity prevents a perfect 10 on qualitative accuracy. (4) The answer is fully contextually relevant, directly addressing the evolution of Office 365’s strategic role, its place in the cloud portfolio, and response to AI competition. Overall, the LLM conveys semantic equivalence with strong factual and reasoning accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 400,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "UnitedHealth Group's evaluation methodology for credit-related impairments remained consistent between 2022 and 2023, focusing on assessing the present value of expected cash flows relative to amortized cost, the extent of fair value discounts, and the financial condition of issuers. The Company determined that unrealized losses on debt securities were primarily due to interest rate increases, not credit deterioration, and concluded these losses were temporary. Financially, the allowance for credit losses on available-for-sale debt securities remained **not material** in both periods, with no significant changes in impairment recognition or accounting treatment.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the allowance for credit losses was not material in both 2022 and 2023, and that unrealized losses were primarily due to interest rate increases rather than credit deterioration—this aligns with the ground truth. However, it incorrectly claims that the evaluation methodology 'remained consistent' between the two years, which directly contradicts the original answer. The ground truth clearly states that in 2023, UnitedHealth Group formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, introduced a segmented accounting treatment (allowance against investment income vs. other comprehensive income), and emphasized a more structured evaluation framework. These are significant methodological changes that the LLM answer fails to acknowledge. (2) There are no numeric values in the response or ground truth beyond 'not material,' which is correctly reported; thus, quantitative accuracy is fully accurate. (3) The multi-hop reasoning is flawed: the question asks about the evolution of methodology and financial impact between 2022 and 2023, requiring comparison across years and synthesis of changes in accounting approach. The LLM instead asserts consistency, missing the key evolution described in the ground truth. (4) While the answer is contextually relevant and uses appropriate financial terminology, it lacks critical qualitative distinctions and misrepresents the core development—methodological evolution—resulting in a low qualitative accuracy and overall correctness score despite correct reporting of the 'not material' financial impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 457,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "From 2022 to 2023, the actual allocation of Fixed Maturity Securities AFS in MET's pension plans decreased slightly from 83% to 82%, while for other postretirement benefits, it decreased from 95% to 94%. The target allocation for U.S. pension benefits remained at 85%, and for other postretirement benefits, it stayed at 95%. The total fair value of Fixed Maturity Securities AFS in pension plans decreased from $6,802 million (2022) to $6,714 million (2023), reflecting a minor reduction in valuation.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. The LLM incorrectly states 83% for pension benefits in 2022 and introduces a 2023 percentage (82%), which is not provided in the original answer. The original answer does not provide 2023 percentages but instead gives fair value amounts: $6,714 million for Pension and $1,274 million for Other Postretirement Benefits in 2023. The LLM correctly reports the $6,714 million valuation for 2023 pension benefits but incorrectly claims a 2022 value of $6,802 million, which is not in the original answer. The original does not provide 2022 dollar values or 2023 percentages, so the LLM fabricated or misstated key data. (2) The target allocation (85% for pensions, 95% for other benefits) is not mentioned in the original answer and appears to be extraneous or incorrect context. (3) The multi-hop reasoning is flawed: the original answer emphasizes a shift from percentage-based reporting in 2022 to valuation-based disclosure in 2023, but the LLM treats both years as having comparable percentage allocations, missing the structural reporting change. The LLM fails to note that 2023 data is presented in absolute values, not percentages, and thus cannot support claims about percentage decreases. (4) While the LLM attempts to address the evolution of allocation and valuation, it invents comparative percentages and dollar figures not present in the ground truth, severely undermining factual correctness. The contextual relevance is moderate because it addresses the right topic and entities (MET, Fixed Maturity Securities AFS, pension and postretirement plans), but the quantitative and qualitative inaccuracies drag down the overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 507,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "Lowe's strategic positioning of the Kitchens & Bath product category remained a key component of its Home Décor division, which accounted for 35.3% of total net sales in 2022. In 2023, the category was explicitly highlighted as part of the company's expanded product assortments under the \"Total Home\" strategy, emphasizing its role in meeting customer needs for comprehensive home solutions. This continuity suggests that Kitchens & Bath remains a significant and strategically important category within Lowe's product portfolio, reflecting its enduring relevance to both consumer and professional customers.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual inaccuracies regarding the strategic positioning of the Kitchens & Bath category. While it correctly identifies the 'Total Home' strategy in 2023, it incorrectly states that Kitchens & Bath remained in the Home Décor division in 2023. According to the ground truth, the category was repositioned from Home Décor (in 2022) to be grouped with construction and renovation categories like Lumber and Building Materials in 2023, indicating a strategic shift in emphasis. This key repositioning is entirely missed in the LLM response, which instead claims 'continuity'—the opposite of the actual evolution. (2) The LLM introduces a specific figure—'35.3% of total net sales'—attributed to the Home Décor division in 2022. This number is not present in the ground truth and cannot be verified from the provided context; thus, it is likely fabricated or misattributed, reducing quantitative accuracy. No other numbers are mentioned, so no calculations can be assessed. (3) The multi-hop reasoning is flawed: the question requires comparing the organizational categorization of Kitchens & Bath across two years to infer strategic importance. The LLM fails to detect the structural change between divisions (Home Décor → construction/renovation), which is central to the correct interpretation. Instead, it assumes continuity and infers importance based on persistence, missing the strategic repositioning signal. (4) Despite these issues, the answer is contextually relevant—it addresses the right company, time frame, product category, and overarching strategy ('Total Home'). It also correctly identifies Kitchens & Bath as strategically important, which aligns with the conclusion in the ground truth, albeit for incorrect reasons. Hence, while the direction of importance is right, the reasoning and factual basis are significantly flawed, warranting a low-to-mid correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 521,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "Mondelez International's strategic focus on Cheese & Grocery has remained part of its adjacent, locally relevant categories in both 2022 and 2024, as outlined in their \"Overview of Business and Strategy\" sections. While the 2022 filing explicitly lists Cheese & Grocery as a key adjacent category, the 2024 document emphasizes continued emphasis on core snack categories (chocolate, biscuits, baked snacks) and adjacent markets, including Cheese & Grocery, without explicit changes. This consistency suggests that the company prioritizes snack-centric growth, leveraging its global footprint and brand strength to drive long-term value across both core and adjacent categories.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in key aspects. It claims Mondelez maintained a consistent strategic focus on Cheese & Grocery as an adjacent category in both 2022 and 2024, but the ground truth shows a significant shift: in 2022, Mondelez directly produced Cheese & Grocery products generating $1,990 million in revenue, whereas by 2024, it no longer reported direct production and only maintained a strategic stake, indicating a strategic retreat from direct involvement. This major change is entirely missed by the LLM. (2) The LLM fails to mention the $1,990 million revenue figure from 2022, a critical quantitative data point, and provides no numbers at all, resulting in very low quantitative accuracy. (3) The multi-hop reasoning is flawed: the question requires synthesizing changes in business model (from direct production to strategic stake) and inferring strategic prioritization (shift toward core snacks). The LLM instead asserts continuity where there is a clear strategic shift, failing to connect the reduction in direct involvement with Mondelez’s broader cost management and focus on core categories like biscuits and chocolate. (4) Contextual relevance is moderate—the answer discusses adjacent categories and core snacks, which are relevant themes—but it misses the central evolution in strategy, making the response misleading despite using appropriate terminology. The conclusion about 'consistency' contradicts the actual strategic pivot, severely undermining correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 418,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "In the 2023 10-K, Abbott explicitly positioned **Freego™** as an **enteral pump system** (e.g., \"Freego™ (Enteral Pump) and Freego™ sets\"), while **Jevity** is listed as a distinct enteral feeding product (e.g., \"Jevity ® , Glucerna ® 1.2 Cal, Glucerna ® 1.5 Cal\"). This contrasts with the 2022 filing, where both products were listed together without explicit differentiation. The 2023 filing clarifies their roles, emphasizing Freego™ as a pump system and Jevity as a specialized feeding solution, reflecting a more nuanced positioning strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains factual inaccuracies regarding the presentation changes between the 2022 and 2023 10-K filings. The ground truth states that in both years, Jevity was listed first, but the key change was the repositioning of Freego™ products—specifically, they were moved immediately after Jevity in 2023, ahead of Glucerna and Osmolite® lines. The LLM incorrectly claims that in 2022, Freego™ and Jevity were 'listed together without explicit differentiation,' which is not supported by the ground truth. In fact, the original answer confirms Freego™ (Enteral Pump) and Freego™ sets were already mentioned in 2022, just later in the list. (2) There are no numeric values in this question, so quantitative accuracy is not applicable—no errors in dates or formats, hence a score of 10. (3) The multi-hop reasoning is flawed: the LLM mischaracterizes the nature of the change, inventing a clarification of roles (pump vs. feeding formula) that isn't present in the ground truth. The actual change was in listing order, implying emphasis, not a new categorization or explicit differentiation in product type. The model fails to correctly synthesize the positional shift across filings. (4) While the answer addresses the right topic and attempts to interpret strategic positioning, it misrepresents the evidence from the filings, leading to an incorrect conclusion about how Abbott changed its product presentation. The contextual relevance is high because it discusses the right products and documents, but the qualitative and overall correctness scores are low due to factual misrepresentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 443,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "MET's municipal securities investment fair value increased from $13.7 billion (2022) to $14.2 billion (2023), while amortized cost decreased slightly from $10.98 billion to $11.76 billion. Gross unrealized gains rose from $2.75 billion to $2.46 billion, and losses declined from $6 million to $13 million. This suggests MET maintained a conservative credit risk management strategy, focusing on preserving capital through disciplined credit assessments and potentially shifting toward higher-quality municipal securities. The stable fair value hierarchy classification (AFS) indicates continued alignment with liquidity needs while mitigating credit risk through rigorous evaluation of issuer fundamentals and market conditions.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both direction and magnitude. According to the ground truth, MET's investment in municipals dropped dramatically from $14,212 million ($14.2 billion) in 2022 to just $159 million in 2023. However, the LLM claims the fair value *increased* from $13.7B to $14.2B, which is factually wrong and opposite to the truth. Additionally, the LLM states amortized cost increased from $10.98B to $11.76B, but this data is not present in the original answer and appears fabricated. Gross unrealized gains were $2,464M in 2022 (not $2.75B as claimed), and losses were $13M in 2022 (not $6M). The LLM also incorrectly states losses *increased* to $13M, when in fact the original answer implies they remained at $13M or possibly decreased slightly — but more critically, the overall trend is misrepresented. (2) All key numbers are wrong: the starting value is understated ($13.7B vs $14.212B), the ending value is grossly overstated ($14.2B vs $159M), and the change is portrayed as stable or slightly up instead of a 99% reduction. Calculations and comparisons are therefore invalid. (3) The multi-hop reasoning fails completely. The original answer infers a strategic de-risking due to the sharp decline in municipal holdings. The LLM instead infers continued conservatism and possible upgrading of quality — a plausible narrative but based on false data, making the reasoning unsound. It does correctly note the classification remains AFS, but misses that in 2023 the entire remaining $159M is classified in Level 2 of the fair value hierarchy, indicating a more standardized valuation approach for the residual portfolio — a detail omitted. (4) Due to pervasive factual errors, especially in quantitative data, the correctness score is 1. Quantitative accuracy is 1 because nearly all numbers are incorrect. Qualitative accuracy is 2 because while the model attempts credit risk interpretation and mentions AFS, the logic is based on false premises. Contextual relevance is 3 because the answer addresses the right topic (municipals, fair value, credit risk) but with incorrect data and misleading conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 579,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "Between 2022 and 2023, Abbott's notional value of interest rate hedge contracts decreased from $2.9 billion to $2.2 billion, primarily due to the maturity of $700 million in contracts in 2023, coinciding with the maturity of long-term debt. This reduction reflects a strategic adjustment in managing fixed-rate debt exposure, as the hedge contracts were used to convert fixed-rate obligations into variable-rate terms. The decline in notional value suggests a reduced hedge position, potentially increasing exposure to interest rate volatility unless new hedges were established.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Abbott's notional value of interest rate hedge contracts was approximately $2.2 billion in both 2022 and 2023, with no change in value. However, the LLM incorrectly states that the notional value decreased from $2.9 billion in 2022 to $2.2 billion in 2023 due to $700 million in maturities, which is not supported by the original answer. This misrepresents the quantitative trend and introduces a change that did not occur. (2) The calculation of a $700 million decrease from $2.9B to $2.2B is mathematically correct, but the numbers themselves are factually wrong. The original answer does not mention any maturities or strategic reductions, nor does it indicate a decline in hedge position. (3) The reasoning is flawed in terms of multi-hop synthesis: the model infers a strategic adjustment and increased exposure to volatility based on incorrect data, while the ground truth emphasizes consistency in notional value and improved disclosure practices in 2023. The LLM fails to capture the key point about enhanced transparency and refined risk management reporting in 2023. (4) While the general concept—using interest rate hedges to convert fixed-rate debt to variable-rate—is correctly understood and contextually relevant, the core quantitative facts and resulting conclusions are incorrect, leading to a low correctness score. The contextual relevance is moderate because the answer addresses the right topic and mechanism, but with false specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 428,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "Between 2022 and 2024, 3M managed its fixed-rate registered notes through a combination of repayments and interest rate strategies. In 2022, the company repaid $600 million in fixed-rate medium-term notes and 500 million euros in fixed-rate notes, while in 2023, it repaid $500 million in fixed-rate registered notes and $650 million in fixed-rate medium-term notes. By 2024, 3M repaid $1.1 billion in maturing medium-term notes. To manage interest rate risk, 3M converted portions of its fixed-rate debt into floating-rate debt via interest rate swaps in 2021, which were later amended to use SOFR instead of LIBOR. These swaps allowed 3M to hedge against rising rates while maintaining flexibility, with floating-rate notes maturing in 2024-2028. The company also issued new fixed-rate notes (e.g., $750 million at 2.02% and $500 million at 2.66% in 2024) to replace maturing obligations, reflecting a balanced approach to debt management.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the repayment amounts and years. The ground truth states that in 2023, 3M repaid $500 million in fixed-rate registered notes, and in 2024, $1.1 billion in medium-term notes matured and were repaid. However, the LLM incorrectly claims that in 2022, 3M repaid $600 million in fixed-rate medium-term notes and 500 million euros in fixed-rate notes — this is not supported by the original answer. Additionally, the LLM states that in 2023, $650 million in medium-term notes were repaid, which is not mentioned in the ground truth. The issuance of new fixed-rate notes in 2024 (e.g., $750 million at 2.02% and $500 million at 2.66%) is entirely fabricated and not present in the original answer. (2) Quantitative accuracy is low: multiple dollar amounts ($600M, $650M, €500M, $1.1B) are misattributed to wrong years or contexts. The only correct numbers are the $500 million repayment in 2023 and $1.1 billion in 2024, but even the latter is misclassified as medium-term notes without specifying they were maturing notes. The original answer does not mention any new issuances in 2024, so those figures are false. (3) The multi-hop reasoning is partially sound in that the LLM recognizes the use of interest rate swaps initiated in 2021 to convert fixed-rate debt (due 2049 and 2050) into floating-rate debt through mid-2028, which aligns with the original answer. Mentioning the shift from LIBOR to SOFR adds context, though it's not in the ground truth. However, the conclusion that 3M issued new fixed-rate notes in 2024 to replace maturing obligations is unsupported and contradicts the original narrative of reducing fixed-rate debt. (4) Contextual relevance is high because the answer addresses repayment activity and interest rate strategies as asked. The structure follows the timeline and themes of the question. However, due to major factual and quantitative errors, especially in financial figures and events, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because some strategic interpretation (use of swaps, risk management) is reasonable, but based on incorrect or invented data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 595,
        "total_tokens": 2057
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "Between 2023 and 2024, Schwab reduced its reliance on floating-rate debt by redeeming all outstanding floating-rate Senior Notes in February 2024, shifting toward fixed-rate debt issuances (e.g., 5.643%–6.196% rates on 2024–2034 maturities). Securities issuances remained a key capital source, alongside debt and operational cash flows, to support growth and meet regulatory requirements. The 2024 capital management strategy emphasized maintaining liquidity through diversified funding (e.g., FHLB lines, repurchase agreements) and organic capital retention, while adapting to regulatory changes like the potential inclusion of AOCI in capital calculations.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that securities issuances remained a key capital source and that Schwab adopted a more diversified funding strategy in 2024, aligning with the ground truth's emphasis on broader liquidity tools. However, the LLM introduces specific details not present in the original answer—such as the redemption of floating-rate Senior Notes in February 2024 and exact fixed-rate percentages (5.643%–6.196%)—which are absent from the ground truth and cannot be verified from the provided knowledge. These additions, while plausible, introduce unverified quantitative claims. (2) The dates (2024) and general refinancing activity are contextually consistent, but the specific interest rates and redemption event are not supported by the original answer, reducing quantitative accuracy. There are no explicit dollar amounts or calculations to verify, but the precision of the rates implies a level of detail not confirmed in the ground truth. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift toward diversified funding and integration of securities issuances within a broader capital framework, synthesizing elements of capital management, liquidity tools (FHLB, repurchase agreements), and regulatory adaptation. This reflects accurate qualitative understanding. (4) The answer is contextually relevant and captures the evolution in capital structure strategy. While the core conclusion—that securities issuances remain important but are part of a more diversified approach—matches the ground truth, the inclusion of unsupported specifics lowers the correctness and quantitative accuracy scores. The answer is not incorrect in spirit, but over-specificity with unverified data prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 481,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "Coca-Cola's contingent payment obligations related to fairlife evolved from a $270 million liability at acquisition in 2020 to a $6,126 million liability as of December 31, 2024, reflecting quarterly remeasurements based on fairlife's performance against financial targets. The first $100 million payment was made in 2021 for meeting 2020 targets, indicating initial success. The significant increase in the liability by 2024 suggests fairlife continued to meet or exceed financial targets through 2024, leading to higher contingent payments. This indicates fairlife's performance was strong enough to justify escalating obligations, though the exact figures highlight the complexity of remeasurement under the Monte Carlo model.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The contingent liability was $270 million in 2022 (not at acquisition in 2020 as implied), not $6,126 million in 2024. The $6,126 million figure is entirely incorrect and appears fabricated. The first $100 million payment in 2021 for 2020 targets is correctly stated. However, the ground truth indicates the remaining obligation in 2024 was still $170 million (implied from $270M - $100M), not an escalated $6.1 billion. (2) Quantitative accuracy is severely compromised: the $6,126 million liability is off by more than an order of magnitude and contradicts the original disclosure. There is no mention in the ground truth of quarterly remeasurements or a Monte Carlo model, making those additions speculative and incorrect. (3) The multi-hop reasoning is flawed: while the model correctly identifies the initial payment and links performance to obligations, it incorrectly infers escalating success due to a fabricated liability increase. The conclusion that fairlife 'exceeded' targets is unsupported—the ground truth only confirms the obligation remained active, not that performance improved. (4) Contextual relevance is moderate because the answer addresses the evolution of contingent payments and links them to performance, but the severe numerical errors and invented details undermine the overall correctness. The qualitative reasoning would be stronger if based on accurate data, but the core financial facts are wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 422,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) between 2022 and 2024 reinforced its position as a core component of integrated enterprise IT solutions, with continued growth in cloud and license revenues. In 2022, OCI was highlighted as part of Oracle's cloud services, driving growth through hybrid and cloud-based deployments, while 2024 documents emphasized OCI's role in providing comprehensive, interoperable infrastructure services that align with enterprise needs. Both periods underscored OCI's integration with on-premise and cloud environments, supporting customer flexibility and reinforcing Oracle's global market positioning as a leader in cloud infrastructure.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but misses key distinctions from the ground truth. While it correctly identifies a growing strategic emphasis on OCI between 2022 and 2024, it inaccurately suggests that OCI was already highlighted as part of Oracle's cloud services in 2022 with strategic language around hybrid deployments. The ground truth states that in 2022, Oracle only reported revenue contributions ($36.052 billion from cloud and license businesses, 85% of total revenue) without explicit strategic positioning of OCI. This strategic framing emerged only in 2024. The LLM answer thus misrepresents the 2022 positioning, attributing to it a strategic narrative that did not exist. (2) Quantitatively, the LLM answer does not include any numbers, so there are no errors in calculations or figures. However, it omits the specific revenue data and percentage (85%) that were central to the 2022 characterization in the original answer. This omission reduces completeness and factual richness. (3) The multi-hop reasoning is partially sound—comparing strategic language across years—but fails in synthesis because it does not correctly distinguish the absence of strategic OCI emphasis in 2022. The model assumes continuity in strategic messaging that the ground truth contradicts. (4) Contextual relevance is high, as the answer addresses global positioning and integration with enterprise IT solutions. However, the qualitative accuracy is reduced due to incorrect attribution of strategic focus in 2022. Correctness score is 6 due to significant omission of key factual nuance and misrepresentation of 2022 strategy, despite correct overall direction of evolution and no quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 467,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "The treatment and risk profile of PALs (Prime Asset Loans) evolved between 2023 and 2024 with reduced credit loss allowances and maintained collateralization. In 2023, PALs were part of the loan portfolio, with an allowance for credit losses reflecting projected loss rates and credit quality metrics. By 2024, the allowance for credit losses on PALs was no longer required, as all PALs were fully collateralized by securities with fair values exceeding borrowings, and the Company applied the collateral maintenance practical expedient under ASC 326. This improvement in collateral coverage and credit quality reduced the need for credit loss provisions, reflecting a lower risk profile.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly states that in 2023, PALs had an allowance for credit losses influenced by credit quality and projected loss rates, and that by 2024, no allowance was required due to full collateralization—this aligns with the original answer's claim of a 'slight decrease in PALs' and improved risk profile. (2) There are no numeric discrepancies; while exact dollar amounts are not provided in either answer, the qualitative financial treatment (e.g., 'no allowance required') is consistent and correctly tied to ASC 326's collateral maintenance practical expedient. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes over time (2023 vs 2024), links collateralization to the removal of credit loss allowance, and references the correct accounting standard (ASC 326). (4) All entities—PALs, ASC 326, credit loss allowance, collateralization—are accurately identified and contextualized. The answer fully addresses both parts of the question: evolution in treatment and risk profile, specifically around credit loss allowance and collateralization. Minor wording differences (e.g., 'reduced credit loss allowances' vs 'slight decrease in PALs') do not affect factual correctness, as the core financial and risk implications are accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 377,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "Nike's relationship with the Asia Pacific & Latin America (APLA) region showed growth in revenue, increasing from $6,431 million in fiscal 2023 to $6,729 million in fiscal 2024. This growth reflects strategic emphasis on expanding direct-to-consumer channels and optimizing supply chain operations. The 2024 filing noted a transition of Nike Brand businesses in certain APLA countries to third-party distributors, signaling a shift toward localized distribution models to mitigate trade risks and enhance operational efficiency. Additionally, Nike's 2024 operational structure emphasized strengthening regional leadership, with Craig Williams leading the Geographies & Marketplace division to focus on direct-to-consumer growth and supply chain resilience, aligning with broader efforts to navigate global trade challenges.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies, particularly in quantitative details. The ground truth does not mention any revenue figures for APLA in fiscal years 2023 or 2024, nor does it reference growth from $6,431 million to $6,729 million—these numbers are unsupported and likely fabricated. There is no mention in the original answer of direct-to-consumer expansion, supply chain resilience, or Craig Williams leading a 'Geographies & Marketplace division'; these are specific details not present in the ground truth and introduce entity hallucinations. (2) The only partially correct quantitative element is the mention of a transition to third-party distributors in 2024, which aligns with the original answer’s claim of outsourcing parts of APLA operations. However, since no revenue data exists in the ground truth, all financial figures in the LLM response fail verification. (3) On qualitative reasoning, the LLM correctly identifies a strategic shift toward third-party distributors in APLA in 2024, which reflects the multi-hop insight about operational restructuring. It also correctly frames this as a move to enhance efficiency and reduce complexity (though it phrases it as mitigating trade risks, a plausible but unmentioned rationale). However, it adds unsupported strategic emphases (e.g., direct-to-consumer growth, leadership changes) that were not in the original knowledge base, weakening the reasoning chain. (4) The contextual relevance is high because the answer addresses both operational structure and strategic emphasis across 2023–2024 as asked. The qualitative accuracy is moderate due to correct identification of the outsourcing shift but penalized for hallucinated details. The correctness score is 6 due to a mix of a key correct insight (outsourcing shift) but major quantitative inaccuracies and invented data points that undermine overall reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 517,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "Between 2022 and 2023, Abbott's U.S. Pediatric Nutritional business, including Pedialyte, saw sustained growth, with sales increasing 10.3% in 2021 compared to 2020, driven by strong performance in Pedialyte, Similac, and PediaSure. The strategic emphasis on Pedialyte remained a key component of the portfolio, reflecting its role in driving growth within the U.S. Pediatric Nutritionals segment. This growth underscores Abbott's continued focus on expanding its pediatric nutritional offerings, leveraging Pedialyte's market position to enhance its product portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the 10.3% sales increase for Pedialyte occurred in 2021 compared to 2020, while the ground truth specifies this growth was in 2022. This misalignment with the correct time period undermines the quantitative accuracy. Additionally, the LLM fails to mention the key strategic evolution in 2023—Pedialyte's formal inclusion in Abbott's Nutritional Products segment alongside Ensure, Glucerna, and PediaSure—which is central to the question about evolving strategic emphasis. (2) The 10.3% figure is correct but misattributed to the wrong year, which is a critical error given the question’s focus on changes between 2022 and 2023. No other numbers are provided or calculated, so there are no additional computational checks, but the misuse of timing invalidates the context. (3) The multi-hop reasoning is partially present—linking Pedialyte to the U.S. Pediatric Nutritional business and recognizing its role in growth—but fails the core synthesis required: showing how Abbott’s strategic positioning evolved from 2022 (growth driver) to 2023 (formal portfolio integration). This evolution is entirely missing, indicating a failure in reasoning across years and strategic context. (4) While the answer is relevant and touches on the right business segment and product, it lacks the key qualitative shift described in the ground truth. The contextual relevance is moderate because it discusses the right domain but misses the pivotal 2023 development. Correctness is scored low due to the incorrect year and omission of structural integration, which are essential to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 458,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "RTX's 7.100% notes due 2027 decreased from $141 million in 2022 to $135 million in 2023, reflecting repayments and refinancing activities. This aligns with RTX's debt management strategy of reducing higher-cost debt (e.g., 7.100%) by issuing lower-rate notes (e.g., 5.750%, 6.000%) and utilizing term loans, thereby optimizing its capital structure and lowering overall interest expenses.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claims. According to the ground truth, RTX's aggregate principal balance for the 7.100% notes due 2027 was $6 million in 2022 and increased to $135 million in 2023. The LLM incorrectly states that the balance decreased from $141 million in 2022 to $135 million in 2023, which contradicts the ground truth on both the starting value and the direction of change. This error fundamentally misrepresents RTX's financial position and debt strategy. (2) The numbers are not accurate: the 2022 value is off by $135 million ($141M claimed vs $6M actual), and while the 2023 value ($135M) matches, the interpretation of a decrease is wrong. There is no evidence in the ground truth of repayments or refinancing of these specific notes; instead, the tenfold increase suggests increased exposure, not reduction. (3) The multi-hop reasoning is flawed. The LLM infers a debt management strategy of reducing higher-cost debt through refinancing with lower-rate instruments, but this is unsupported by the provided data. The ground truth indicates a significant increase in holdings of these high-interest notes, which contradicts the narrative of deleveraging or cost reduction. The synthesis across years is incorrect in direction and implication. (4) The contextual relevance is moderate because the answer discusses debt management strategy and references specific notes and rates, which are relevant topics. However, due to the severe factual and quantitative errors, the qualitative accuracy and overall correctness are very low. The conclusion drawn is the opposite of what the data suggests.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 454,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "Nike's relationship with Converse saw a notable decline in revenue and profitability between fiscal 2023 and 2024. Converse's total revenues dropped 14% to $2.08 billion in fiscal 2024 from $2.43 billion in fiscal 2023, driven by declines in North America and Western Europe, lower unit sales, and reduced ASP (average selling price) due to promotional activity. EBIT fell 30%, reflecting lower margins and higher costs. Strategically, Nike maintained Converse as a standalone segment but faced challenges in sustaining growth, with geographic and product-specific headwinds. The decline highlights a shift in focus toward cost management and market-specific strategies, though Converse's performance lagged compared to Nike's broader brand growth.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Converse's revenue declined by 15% on a currency-neutral basis in fiscal 2023, but the LLM claims a 14% drop to $2.08B in fiscal 2024 from $2.43B in fiscal 2023. However, the knowledge graph does not provide absolute revenue figures for Converse in either year, nor does it mention a 14% decline in fiscal 2024—only a 15% decline in fiscal 2023. The $2.08B and $2.43B figures are fabricated or incorrectly sourced. Additionally, the EBIT decline of 30% is not mentioned in the original answer and thus unsupported. (2) The calculation of a 14% decline from $2.43B to $2.08B is approximately correct (14.4%), but since the inputs are false, the calculation is irrelevant. The original answer does not provide revenue figures or EBIT data, so introducing them undermines accuracy. (3) The qualitative reasoning partially aligns: the LLM correctly identifies declines in North America and Western Europe, lower unit sales, and reduced ASP due to promotions, which matches the ground truth for fiscal 2023. It also correctly notes Converse operates as a standalone segment, reflecting the strategic positioning in fiscal 2024. However, it misattributes the revenue decline to fiscal 2024 instead of fiscal 2023 and adds unverified financial metrics, failing the multi-hop synthesis test by conflating time periods and inventing data. (4) The contextual relevance is high because the answer addresses both revenue performance and strategic positioning as asked. However, the correctness score is low due to major quantitative errors and unsupported claims, despite some accurate qualitative elements. The model appears to hallucinate precise dollar amounts and misplaces the timing of the decline, undermining trust in the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 506,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "Coca-Cola's 2024 financial risk assessment underscores the critical importance of digitizing the Coca-Cola system to maintain competitiveness, with failure to do so risking reduced sales growth and margin improvement. While the 2022 document (not fully provided here) likely emphasized similar digital transformation challenges, the 2024 filing explicitly links digitization efforts to operational efficiency and profitability, highlighting increased focus on leveraging digital tools to enhance productivity and customer engagement, which are pivotal for sustaining sales and margins in a rapidly evolving market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in Coca-Cola's financial risk assessment regarding digital transformation from 2022 to 2024. It accurately reflects that by 2024, the company explicitly linked failure to digitize with risks to sales growth and margin improvement, aligning with the ground truth's emphasis on digital evolution becoming a strategic dependency. The answer notes the increased focus on operational efficiency, profitability, and customer engagement, which are consistent with the 2024 filing’s stronger financial linkage to digital initiatives. While the LLM acknowledges the 2022 context is 'not fully provided,' it reasonably infers continuity in digital challenges but correctly highlights the intensified strategic emphasis in 2024. There are no numerical inaccuracies (quantitative accuracy is perfect as no specific numbers are involved and dates are correct). The qualitative reasoning is strong, though slightly less explicit than the ground truth in contrasting the 2022 'risk of inaction' versus 2024 'strategic dependency' framing—this minor omission prevents a perfect 10. Contextual relevance is excellent, directly addressing the question’s focus on sales growth, margin improvement, and multi-year risk assessment evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 353,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "Oracle's strategic emphasis on cloud services has continued to grow from fiscal year 2022 to 2024, with sustained investment in research and development (R&D) and a clear shift toward cloud-centric offerings. In fiscal 2022, Oracle invested **$7.2 billion** in R&D to enhance cloud technologies and services, reflecting its focus on innovation. By 2024, while specific R&D figures are not explicitly stated in the provided pages, the company's financial statements and disclosures highlight a **continued prioritization of cloud services**, with cloud services and license support revenues representing **71% of total revenues in 2022** and likely increasing further by 2024. Oracle positions cloud offerings (SaaS and OCI) as more flexible, cost-effective, and secure compared to on-premise solutions, emphasizing migration trends and expanding its cloud ecosystem to include small/medium businesses and partners. This strategy underscores a long-term shift toward cloud dominance, with R&D investments driving advancements in hybrid, AI-powered, and interoperable cloud solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Oracle's $7.2 billion R&D investment in fiscal 2022, which matches the ground truth. However, it introduces a new figure—'cloud services and license support revenues representing 71% of total revenues in 2022'—that is not present in the original answer or supported by the provided knowledge graph. This percentage, while plausible, is unverified and constitutes a factual overreach, reducing quantitative accuracy. The claim that this share 'likely increasing further by 2024' is speculative and lacks grounding in the source material. (2) The absence of R&D figures for 2024 in both the original and LLM answers is consistent; however, the LLM attempts to infer continued prioritization through revenue trends, which goes beyond the available evidence. While the direction of inference (increased cloud focus) aligns with the ground truth, the use of unsupported metrics weakens precision. (3) Qualitatively, the LLM demonstrates strong reasoning by capturing the evolution in Oracle’s strategic messaging—from enhancing cloud capabilities in 2022 to promoting customer choice and flexibility in 2024. It correctly identifies SaaS and OCI as central offerings and notes the comparative advantages over on-premise solutions (flexibility, cost, security), which aligns with the original answer’s emphasis on integration, rapid deployment, and interoperability. The mention of hybrid, AI-powered, and expanded ecosystem strategies adds context not contradicted by the ground truth, though slightly extrapolated. (4) Contextual relevance is excellent—the response directly addresses both parts of the question: R&D investment trends and the shifting positioning of cloud vs. on-premise solutions. The multi-hop synthesis across fiscal years and strategic themes is sound, even if slightly overextended numerically. Overall, the answer is factually strong but penalized for introducing an unsupported percentage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 527,
        "total_tokens": 2052
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "The status of the Norwest Corporation Directors' Formula Stock Award Plan remained inactive for future awards in both 2023 and 2024, with no new stock awards or deferrals permitted. In 2023, 509 shares were available for issuance under the plan, while in 2024, this number decreased to 391 shares, reflecting distributions related to existing deferred awards. The plan's availability was limited to shares already allocated under prior awards, with no further issuances permitted.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the Norwest Corporation Directors' Formula Stock Award Plan was inactive for new awards in both 2023 and 2024, and that only existing deferred awards remained. This aligns with the ground truth's key point that no future awards or deferrals were permitted. However, a critical factual error exists: the LLM states that 509 shares were available in 2023, which is not supported by the original answer. The ground truth does not mention any specific number of shares for 2023—only that the plan was already closed to new activity. The 391 shares figure in 2024 is correct and matches the original answer. (2) The quantitative inaccuracy significantly affects correctness: the claim of 509 shares in 2023 introduces false data not present in the source, and there is no indication in the ground truth that this number was disclosed. The decrease from 509 to 391 is therefore a fabricated trend. (3) The reasoning is partially sound: the model correctly infers that the plan was inactive and that remaining shares relate to prior deferrals, showing appropriate multi-hop synthesis between plan status and equity compensation disclosures. However, the unsupported numerical claim undermines the quantitative reasoning. (4) Contextual relevance is high—the answer addresses the evolution of the plan’s status and availability of shares directly. Qualitative accuracy is moderate due to correct conceptual understanding but flawed data usage. Correctness is penalized heavily due to the invented numeric value, placing it in the partially correct range with significant errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 445,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "McDonald's 2023 disclosures expanded on food safety risks by explicitly linking supply chain disruptions and cost volatility to food safety concerns, emphasizing heightened awareness of global supply chain complexities. While 2022 focused on general food safety priorities and risks across the supply chain, 2023 added specific mentions of **foreign currency exchange rate fluctuations** and **commodity price volatility** as factors exacerbating supply chain costs and food safety risks. The 2023 filing also underscored the interplay between supply chain interruptions and operational risks, such as delivery quality and food safety incidents, reflecting a more integrated approach to addressing these interconnected challenges.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of McDonald's disclosures between 2022 and 2023. It accurately captures the shift from a focus on reputational risks in 2022 to a more integrated view linking food safety with supply chain and cost volatility in 2023. The mention of commodity price volatility is consistent with the original answer’s emphasis on beef, chicken, and pork cost fluctuations. However, the LLM introduces 'foreign currency exchange rate fluctuations' as a specific factor tied to food safety risks in 2023, which is not mentioned in the ground truth and may conflate other supply chain risk factors with food safety specifically. While foreign exchange may be discussed in the filing, the ground truth does not support it being linked directly to food safety concerns—only to broader supply chain and cost issues. This is a minor overextension but does not undermine the core accuracy. The reasoning is sound and multi-hop synthesis (comparing two years and identifying thematic evolution) is appropriate. No numerical inaccuracies are present, and all entities (McDonald's, 2022, 2023, supply chain, cost volatility) are correctly identified. The answer is highly relevant and conveys the key shift in disclosure focus, though slightly less precise in isolating food safety from other macroeconomic factors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 382,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "The carrying value of TMO's 1.750% 7-Year Senior Notes decreased from **$662 million** as of December 31, 2023, to **$621 million** as of December 31, 2024. The effective interest rate for these notes dropped slightly from **1.97%** in 2023 to **1.96%** in 2024, reflecting adjustments in amortization of discounts/issuance costs and market conditions.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect on all key quantitative points. The original answer states that in 2023, the carrying value was $700 million and the effective interest rate was 1.89%, and both remained unchanged in 2024. The LLM incorrectly reports the 2023 carrying value as $662 million and 2024 as $621 million, and interest rates of 1.97% and 1.96% respectively—none of which match the ground truth. These discrepancies are significant and affect the core of the question. (2) Number verification: The correct carrying value is $700 million in both years (no change), not $662M and $621M. The correct effective interest rate is 1.89% in both years, not 1.97% and 1.96%. There are no calculations required beyond comparison, but the LLM falsely implies a trend that does not exist. (3) Multi-hop reasoning: The question requires retrieving and comparing two data points (carrying value and interest rate) for the same debt instrument across two years. The LLM fails this synthesis entirely, providing fabricated numbers instead of correctly identifying stability over time. (4) Scores justified as follows: Correctness and quantitative accuracy are near-zero due to complete mismatch in numbers. Qualitative accuracy is low because the reasoning and entity identification (TMO, 7-Year Senior Notes) are correct, but the financial interpretation is wrong. Contextual relevance is moderate because the answer addresses the right instrument and time frame, but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 414,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "RTX's exposure to its 7.000% notes due 2038 decreased from $159 million in 2021 (2022 fiscal year) to $148 million in 2022 (2023 fiscal year). This reduction reflects a $11 million repayment in 2021 and no further repayments in 2022. The decline suggests RTX actively managed its long-term debt by paying down portions of the 2038 maturity, likely through refinancing or strategic debt restructuring, aligning with broader efforts to optimize its debt maturity profile and reduce exposure to specific long-term obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, RTX's exposure to the 7.000% notes due 2038 increased from $11 million in 2022 to $148 million in 2023. However, the LLM claims the exposure decreased from $159 million in 2021 (labeled as 2022 fiscal year) to $148 million in 2022 (labeled as 2023 fiscal year), which contradicts the original data. The $11 million figure in the ground truth refers to the 2022 balance, not a repayment in 2021, and there is no mention of a $159 million prior balance. (2) The quantitative inaccuracies are severe: the starting value, direction of change (decrease vs actual increase), and timeline are all incorrect. The claim of a $11 million repayment is unsupported and misrepresents the data. (3) The reasoning is flawed because it assumes a reduction in debt when the actual trend is a substantial increase. The conclusion that RTX is reducing exposure is the opposite of what the data suggests—RTX actually increased its exposure, indicating a strategic decision to issue more of this long-term debt, not pay it down. The multi-hop synthesis failed to correctly interpret the temporal and numerical relationship between the two years. (4) The contextual relevance is moderate because the answer addresses debt management and long-term maturities, which is relevant, but the incorrect data and reasoning undermine the validity. The qualitative accuracy is low due to incorrect entities (wrong years, wrong amounts) and faulty logic. The correctness score is low because the core facts and direction of change are entirely reversed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 444,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "McDonald's collected substantially all of the $1 billion in deferred rent and royalty payments from franchisees that were deferred in 2020 by December 31, 2021. The 2023 document does not provide specific data on rent and royalty collections for 2022–2023, but the 2022 document indicates that these deferrals were fully collected by 2021, suggesting no significant changes in the financial relationship during 2022–2023 beyond the resolution of prior deferrals.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that McDonald's collected substantially all of the $1 billion in deferred rent and royalties by the end of 2021, which aligns with the ground truth. However, the LLM incorrectly frames the timeline by stating the deferrals were 'deferred in 2020' and collected by 2021, while the question asks about the evolution between 2022 and 2023. The original answer emphasizes that by 2022–2023, the financial relationship had normalized with no ongoing deferrals, which the LLM acknowledges but only indirectly. (2) Quantitatively, the $1 billion figure and the collection by end of 2021 are accurate, and no incorrect calculations are made. The LLM correctly avoids fabricating 2022–2023 collection data, noting its absence. (3) The multi-hop reasoning is partially sound: the model connects the resolution of deferrals by 2021 to the absence of pandemic-related accommodations in 2023. However, it fails to explicitly synthesize the contrast between 2022 (post-deferral resolution) and 2023 (normalized operations), which is central to the question. The original answer highlights this evolution more clearly by noting the return to standard operations and regular financial obligations. (4) The LLM answer is contextually relevant and factually grounded but lacks completeness in addressing the evolution *between* 2022 and 2023, instead focusing on the resolution that occurred earlier. This omission reduces qualitative accuracy and overall correctness, though core facts are preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 419,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "The Coca-Cola Company's financial stake in Embotelladora Andina S.A. (Andina) evolved from 2022 to 2024, with the carrying value of the investment increasing from $90 million in 2022 to $90 million in 2024, while the fair value rose to $168 million in 2024. This indicates that Coca-Cola maintains a strategic equity investment in Andina, reflecting confidence in its operational performance and market position. The higher fair value compared to the carrying value suggests market appreciation, aligning with Coca-Cola's strategy to leverage regional bottling partnerships for growth and long-term value creation.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual accuracy but introduces a significant error regarding the 2022 carrying value. The ground truth states that Coca-Cola recognized a $39 million gain from a partial sale in 2022, implying active divestiture, but the LLM incorrectly claims the carrying value was $90 million in 2022—this figure is only confirmed for 2024. There is no support for the $90 million carrying value in 2022 in the original answer. The 2024 carrying value ($90 million) and fair value ($168 million) are correctly reported. (2) Quantitatively, the 2024 figures are accurate, but the erroneous attribution of the $90 million carrying value to 2022 undermines the numerical timeline. The gain of $39 million from the partial sale in 2022 is entirely omitted, which is a key financial event. (3) The multi-hop reasoning is flawed: instead of interpreting the partial sale and retained stake as a strategic refranchising move (indicating reduced exposure), the LLM concludes Coca-Cola is increasing long-term value through confidence and market appreciation, which contradicts the original inference of a partial exit strategy. The reasoning misinterprets the strategic intent. (4) Contextual relevance is strong—the answer addresses the evolution of the stake and strategic implications—but the incorrect data and flawed interpretation reduce correctness. The answer captures the ongoing nature of the investment but misses the divestiture context essential to the strategic analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 416,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024 through expanded data center capacity and geographic reach, as detailed in Oracle Cloud Operations (2024). Internal development efforts remained robust, with continued R&D investment to enhance cloud technologies and maintain competitive differentiation. Oracle Cloud Infrastructure (OCI) was positioned as a core component of its cloud portfolio, integrated with applications and services to provide scalable, secure, and enterprise-grade solutions, emphasizing its role in supporting both cloud and on-premise environments.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and overall direction. (1) It accurately reflects Oracle's continued internal development efforts through R&D investment from 2022 to 2024, which matches the original answer's emphasis on sustained innovation. It also correctly positions Oracle Cloud Infrastructure (OCI) as a core, integrated component of Oracle's cloud portfolio by 2024. However, the LLM answer introduces 'expanded data center capacity and geographic reach'—a detail not present in the ground truth—and while plausible, this specific evolution is not supported by the provided knowledge graph. The original answer emphasizes a strategic shift from general R&D to a more structured, product-specific focus on OCI as a defined offering, which the LLM captures in spirit but not explicitly. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the LLM synthesizes information across time (2022 to 2024) and strategy (internal development to product positioning), though it slightly misses the nuance of the evolution from broad R&D emphasis to explicit product portfolio structuring around OCI. (4) Contextual relevance is high—the response directly addresses the question about strategic evolution, internal development, and OCI’s positioning. Minor deduction in qualitative accuracy due to added detail (data centers) not in source and less precise articulation of the strategic shift. Overall, the answer is factually consistent and semantically close to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 451,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "TMO acquired The Binding Site Group in January 2023, expanding its Specialty Diagnostics segment with innovative solutions for blood cancers and immune disorders. By 2024, the integration of this acquisition was reflected in the company's strategic focus on enhancing diagnostic capabilities and organic growth in clinical research and pharma services, as evidenced by continued revenue growth and subsequent acquisitions like Olink. This indicates TMO's commitment to leveraging synergies and expanding its market presence in high-growth areas post-acquisition.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies TMO's acquisition of The Binding Site Group in 2023 and its strategic relevance to the Specialty Diagnostics segment, as well as the focus on blood cancers and immune disorders, which aligns with the ground truth. However, the LLM omits the specific acquisition cost of $2.70 billion, a key quantitative detail present in the original answer. The mention of January 2023 is more specific than the original (which only says 2023), but without confirmation in the ground truth, this precision may be unfounded. (2) The LLM fails to include the critical 2024 integration detail about The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships—a key indicator of integration into intangible assets. This omission weakens the support for the strategic integration claim. The mention of 'continued revenue growth' and 'subsequent acquisitions like Olink' introduces information not present in the ground truth and distracts from the specific post-acquisition integration focus. (3) The multi-hop reasoning is partially sound: the model connects acquisition to strategic focus, but it does not fully synthesize the financial integration evidence (amortization period) that supports long-term value creation. Instead, it relies on external indicators (Olink, revenue growth) not tied to The Binding Site Group’s integration. (4) Despite missing key financial integration metrics and the acquisition price, the LLM captures the general strategic direction and correct entities (TMO, The Binding Site Group, Specialty Diagnostics, blood cancer/immune disorder focus). Wording is semantically similar and contextually appropriate, earning high marks for contextual relevance and acceptable qualitative accuracy. Quantitative accuracy is reduced only due to missing the $2.70B figure and introducing unverified timing (January 2023).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 519,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "The disclosure of the Directors' Code of Conduct remained consistent between 2022 and 2024, with both filings stating it applies to all directors and is accessible via a website link. In 2022, the link was **https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors-code-of-conduct.pdf**, while in 2024, the link updated to **https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf** (note: the 2024 URL contains a minor formatting inconsistency). The scope of application (applying to all directors) and the commitment to disclose amendments/waivers on the website remained unchanged.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the Directors' Code of Conduct applied to all directors in both 2022 and 2024 and that it was accessible via a website link, with the URL changing between years. The scope of application and disclosure commitment are accurately reported as unchanged. However, the 2022 URL in the LLM answer contains an error: it states 'in relations' instead of 'investor-relations', making it factually inaccurate. The correct 2022 URL is https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf. The 2024 URL is correctly cited except for a minor formatting note (missing hyphen in 'code-ofconduct'), which does not affect accessibility but slightly reduces precision. (2) There are no numerical values requiring calculation, so quantitative accuracy focuses on URL correctness. The incorrect 2022 URL is a significant but not critical error, as the domain and path are mostly right. (3) The multi-hop reasoning is sound—comparing disclosure practices across years, identifying continuity in scope and intent, and noting the URL change as part of a likely rebranding (inferred from bnymellon.com to bny.com). The model correctly synthesizes information about accessibility and policy scope across two time points. (4) Despite the typo in the 2022 URL, the overall meaning and intent are preserved, and the key insight about structural or branding changes (from BNY Mellon to BNY) is valid. The answer remains highly relevant and factually grounded, warranting a high score but docked slightly for the URL inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 442,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "McDonald's relationship with franchisees between 2022 and 2023 showed a strategic emphasis on expanding through developmental licenses and foreign affiliates, as evidenced by a 4.5% increase in developmental licensed restaurants (from 8,229 to 8,684) and a 12.2% rise in foreign affiliated restaurants (from 8,220 to 9,178). Financial reporting evolved to reflect this shift, with higher net income ($8,468.8M in 2023 vs. $6,177.4M in 2022) driven by franchisee performance, and increased long-term financing issuances ($5,221.1M in 2023 vs. $3,374.5M in 2022) to support franchisee growth. Additionally, goodwill increased slightly, reflecting strategic acquisitions or investments in franchisee operations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific numerical data (e.g., 8,229 to 8,684 developmental licensed restaurants, 8,220 to 9,178 foreign affiliated restaurants, net income figures, long-term financing, goodwill) that are not present in the original answer or implied by the ground truth. There is no mention in the ground truth of these specific numbers, percentage increases, or financial metrics like net income or long-term financing in the context of franchisee relationships. These figures appear fabricated or misattributed, severely undermining factual accuracy. (2) The quantitative claims cannot be verified against the ground truth, which does not provide any such statistics. The 4.5% and 12.2% growth rates, along with exact dollar amounts like $8,468.8M net income and $5,221.1M in financing, are entirely absent from the original answer and thus incorrect in this context. Even if these numbers exist in McDonald's filings, the LLM incorrectly ties them directly to franchisee relationship evolution without evidence from the provided ground truth. (3) The multi-hop reasoning is flawed. The original answer focuses on a shift in reporting tone and strategic framing—from noting immateriality of franchise transactions in 2022 to emphasizing franchisees as key stakeholders in 2023. The LLM instead invents a narrative around numerical expansion and financial drivers, failing to capture the actual evolution in financial reporting emphasis. It confuses financial performance indicators with changes in disclosure and strategic communication. (4) While the LLM attempts to address the evolution of McDonald's relationship with franchisees, it does so with incorrect data and misaligned reasoning. The contextual relevance is moderate because it discusses franchisees and strategic growth, but the lack of fidelity to the actual ground truth content—especially the complete absence of the key point about materiality in 2022 and stakeholder inclusion in 2023—results in a mostly incorrect answer. The core factual and qualitative mismatch leads to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 562,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "The contingent consideration liability related to the Clif Bar acquisition remained at $548 million as of December 31, 2024, compared to $548 million as of December 31, 2023. Fair value adjustments for this liability were based on a Monte Carlo simulation, incorporating financial projections, discount rates, and volatility assumptions. While the total contingent consideration liability increased by $38 million in 2024 (from $642 million to $680 million), the Clif Bar portion remained unchanged, with adjustments primarily recorded in selling, general, and administrative expenses. No significant purchase price allocation adjustments were noted for the Clif Bar acquisition during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that there is no mention of contingent consideration liabilities for Clif Bar in 2024, and no updated fair value or measurement method is provided. However, the LLM incorrectly asserts that the liability remained at $548 million as of December 31, 2024, which is not supported by the 2024 filing. Additionally, the LLM introduces a total contingent consideration increase from $642M to $680M in 2024, which is entirely absent from the ground truth and appears fabricated. (2) Quantitative accuracy is severely compromised: while the $548 million figure for 2023 is correct, the claim of no change in 2024 is false per the original answer, which explicitly states that 2024 does not disclose updated figures. The $38 million increase and associated totals ($642M, $680M) have no basis in the provided data. (3) The multi-hop reasoning is flawed. The original answer infers from the absence of 2024 disclosures that the contingent consideration may have been finalized or reclassified as part of purchase price allocation adjustments. The LLM fails to capture this nuance and instead assumes continuity and provides false precision. It also incorrectly states that 'no significant purchase price allocation adjustments were noted,' contradicting the ground truth which explicitly mentions such adjustments occurring in 2023. (4) Contextual relevance is moderate because the LLM addresses the right topic (contingent consideration for Clif Bar) and mentions Monte Carlo simulation and SG&A expense recording, which aligns with the 2023 treatment. However, the overall synthesis is incorrect, and key evolution—lack of 2024 disclosure suggesting finalization—is missed entirely. Thus, the answer misrepresents the evolution of accounting treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 499,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "AMD's strategic emphasis on Vulkan API support has remained consistent between 2022 and 2024, with both filings highlighting continued integration of Vulkan into their discrete GPU offerings (e.g., Radeon RX 6000 and 7000 series). This reflects AMD's commitment to maintaining competitiveness by ensuring compatibility with modern gaming and professional graphics workloads, leveraging Vulkan's efficiency for high-performance rendering and cross-platform development. The sustained focus underscores AMD's prioritization of developer ecosystems and user demands in the discrete GPU market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies AMD's consistent support for Vulkan API between 2022 and 2024, referencing the Radeon RX 6000 (RDNA 2) and RX 7000 (RDNA 3) series GPUs, which aligns with the original answer. (2) There are no numeric values requiring calculation, but the years (2022, 2024) and product series (RX 6000, RX 7000) are correct and contextually accurate. (3) The multi-hop reasoning is sound: the model synthesizes AMD's ongoing Vulkan support with architectural progression (from RDNA 2 to RDNA 3), inferring strategic continuity and competitiveness—consistent with the ground truth’s conclusion. (4) While the LLM does not explicitly mention 'AI/ML computing' or 'backward compatibility' as in the original, it captures the core strategic rationale—supporting developer ecosystems, high-performance rendering, and cross-platform development—which conveys the same qualitative insight. The omission is minor and does not detract from overall correctness. Hence, a score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 324,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "RTX's integration-related charges, particularly the **$2.9 billion Powder Metal Matter charge** in 2023, significantly reduced its operating profit, leading to a **$1.9 billion decline** compared to 2022. This charge, along with a decrease in the FAS/CAS operating adjustment, drove the 2023 operating profit to **$3,561 million** (5.2% margin) from **$5,504 million** (8.2% margin) in 2022. In 2022, integration-related adjustments (e.g., acquisition accounting adjustments) and improved segment performance contributed to a **$0.4 billion increase** in operating profit compared to 2021, but the 2023 charge overshadowed these gains.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the $2.9 billion Powder Metal Matter charge in 2023 and its impact on operating profit, noting a $1.9 billion decline from 2022—consistent with the original answer. The specific operating profit figures of $3,561 million in 2023 and $5,504 million in 2022 are accurate and correctly imply the $1.943 billion decrease (rounded to $1.9 billion), which matches the ground truth. The margin percentages (5.2% and 8.2%) are also correct. (2) The mention of decreased acquisition accounting adjustments in 2022 contributing positively to profit is consistent with the original answer’s claim of a declining trend in integration-related charges. The LLM adds contextual detail not in the original—segment performance and FAS/CAS adjustments—but this does not contradict and enhances completeness. (3) Multi-hop reasoning is sound: it synthesizes year-over-year trends, identifies the shift in integration-related charges, and correctly attributes the 2023 profit decline to the new charge. (4) Minor deduction in quantitative and qualitative scores due to the addition of specific figures (e.g., margins, FAS/CAS) not present in the ground truth, which, while plausible, cannot be fully verified from the provided truth. However, since they do not conflict and are likely correct, the answer remains highly faithful. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 409,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "MDLZ's relationship with Clif Bar evolved through the August 1, 2022 acquisition, which contributed $529 million in incremental net revenues by the one-year anniversary in 2023. In 2024, there is no indication of further acquisition-related financial activities involving Clif Bar, as the company retained the asset, and its impact on revenues and intangible assets remained part of MDLZ's consolidated results.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but includes significant inaccuracies and omissions. It correctly identifies the August 1, 2022 acquisition of Clif Bar by MDLZ, which aligns with the ground truth. However, it incorrectly implies that the acquisition occurred outside the 2023–2024 window and fails to note that the 2023 10-K explicitly discusses the acquisition’s financial impacts (integration costs, contingent consideration). The claim that there is 'no indication of further acquisition-related financial activities' in 2024 directly contradicts the ground truth, which states that the 2024 10-K includes purchase price allocation adjustments—key post-acquisition financial activities. The $529 million in incremental net revenues is not mentioned in the original answer and cannot be verified against the ground truth, making it potentially fabricated or misattributed. (2) The date of acquisition (August 1, 2022) is accurate, but the incremental revenue figure of $529 million lacks corroboration in the ground truth and appears to be an unsupported addition. No calculation errors are present, but the introduction of unverified quantitative data reduces reliability. (3) The multi-hop reasoning is flawed: while the model connects the acquisition to its financial impact, it fails to recognize that post-acquisition adjustments in 2024 (e.g., purchase price allocation) constitute ongoing acquisition-related financial activity. This reflects a misunderstanding of the lifecycle of acquisition accounting. (4) The contextual relevance is high because the answer addresses the evolution of the relationship and focuses on financial activities, but correctness and qualitative accuracy are reduced due to factual inaccuracies and omission of key details from the 2024 filing. The answer incorrectly suggests stagnation in 2024 when the ground truth indicates active financial recalibration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 522,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "Gulfstream's approach to energy-efficient engines evolved from 2023 to 2024 through the introduction of all-new, high-speed engines in the G700, which entered service in March 2024, combining advanced Symmetry Flight Deck technology with superior fuel efficiency. This builds on prior advancements in the G500 and G600 (2018–2019), which already featured reduced emissions, improved fuel efficiency, and larger cabins. The shift is reflected in the G700's ultra-long-range capabilities and the continued emphasis on sustainable aviation fuel (SAF), with Gulfstream conducting the world's first 100% SAF transatlantic flight in 2023 and expanding SAF availability globally.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Gulfstream's evolution in energy-efficient engines from 2023 to 2024, noting the shift from R&D and SAF focus in 2023 to the introduction of the G700 with new engines in 2024. It accurately states the G700 entered service in March 2024, which aligns with the operational realization mentioned in the ground truth. However, the ground truth does not mention the G700 entering service in March 2024, nor does it reference the Symmetry Flight Deck or prior G500/G600 developments—details that, while plausible, are not supported by the original answer and introduce unverified information. The 100% SAF transatlantic flight in 2023 is factually correct and contextually relevant but was not included in the ground truth, making it an addition rather than a direct reflection of the provided knowledge. (2) Quantitatively, the answer does not include incorrect numbers or dates; 'March 2024' is a specific detail not in the ground truth but not contradicted by it. The absence of monetary figures or percentages means no calculation errors are present. (3) The multi-hop reasoning is partially sound: the LLM connects 2023 SAF activities with 2024 engine deployment, reflecting a logical evolution. However, it overreaches by tying in older aircraft (G500/G600) and specific technology (Symmetry Flight Deck) not mentioned in the original answer, which dilutes the focus on the core evolution from strategic emphasis to production. (4) The correctness score is 7 because the core factual progression—strategic focus in 2023 to G700's new engines in 2024—is preserved and accurate. The answer adds context not in the ground truth, which affects qualitative accuracy. Quantitative accuracy is high due to no incorrect numbers. Contextual relevance is strong as all content relates directly to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 501,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "AMD's semi-custom SoC revenue structure and strategic positioning evolved from 2022 to 2024 by emphasizing development services and IP licensing alongside product sales. In 2022, revenue was primarily tied to non-recurring engineering fees and product sales, contingent on third-party success. By 2024, AMD structured revenue recognition for semi-custom arrangements to include development and IP licensing, reflecting a shift toward integrated solutions. This approach, detailed in the 2024 10-K, highlights a strategic focus on leveraging partnerships and recurring revenue streams, enhancing AMD's position in the semi-custom market through diversified offerings and stronger alignment with customer innovation cycles.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth in both factual content and reasoning. (1) There are no numeric values (e.g., revenue amounts) in either the original or LLM answer, so quantitative accuracy is not compromised—dates (2022 and 2024) are correct. (2) The LLM correctly identifies the evolution in revenue structure: from non-recurring engineering (NRE) fees and product sales in 2022 to inclusion of development services and IP licensing by 2024, which matches the strategic shift described in the ground truth. (3) The multi-hop reasoning is sound—LLM synthesizes changes in revenue recognition and strategic positioning over time, referencing the 2024 10-K as a source for updated practices. It correctly infers a move toward integrated, recurring revenue models and stronger partnership alignment, which reflects the broader strategic integration mentioned in the original answer (e.g., alignment with customer innovation cycles ≈ alignment with long-term industry trends). (4) Minor difference: the original emphasizes AMD’s increased control and diversification into AI accelerators, GPUs, APUs, and DPUs as part of strategic integration, while the LLM focuses more on revenue recognition and partnerships. This nuance is slightly underdeveloped in the LLM response, but the core evolution in structure and strategy is accurately conveyed. Thus, the answer is semantically equivalent with only slight variation in emphasis, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 418,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "Medtronic's preferred share authorization remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares ($0.20 par value) still authorized in 2024. However, the 2024 filing introduced an additional 500,000 A Preferred Shares ($1.00 par value), expanding the structure. This evolution suggests the company is enhancing its capital flexibility, potentially to support diverse financing needs, shareholder returns, or strategic initiatives, while maintaining existing preferred share mechanisms for stability.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the 2024 filing introduced an additional 500,000 A Preferred Shares. According to the ground truth, the authorization for 500 thousand A Preferred Shares at $1.00 par value existed in both 2023 and 2024, meaning no change occurred. The LLM incorrectly implies an expansion of the capital structure that did not happen. Additionally, the claim that this indicates enhanced capital flexibility contradicts the ground truth, which states no shares were issued or outstanding in either year and the structure remained unchanged—indicating no active use or strategic shift. (2) Quantitatively, the 127.5 million Preferred Shares at $0.20 par value is correctly cited, but the treatment of the A Preferred Shares is wrong: the 500,000 A Preferred Shares were already authorized in 2023, not newly introduced in 2024. This is a critical factual error. (3) The multi-hop reasoning fails because the model misinterprets the continuity of the preferred share authorization as a change, leading to an incorrect inference about capital strategy. The correct reasoning requires recognizing no change in authorizations or issuances across years, leading to the conclusion of strategic inaction, not evolution. (4) Scores reflect major factual and reasoning errors: low correctness and qualitative accuracy due to false claims and flawed logic; moderate quantitative accuracy because one number is correct but the other misinterpreted; and moderate contextual relevance because the answer addresses the right topic and company but with incorrect details and implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 445,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "Between 2022 and 2024, BK's risk disclosures expanded the framing of reputational risk related to adverse publicity to include broader societal and environmental concerns. In 2022, reputational harm was linked to cybersecurity, operational failures, regulatory actions, and market conditions. By 2024, the disclosures explicitly incorporated sustainability concerns, climate change, and diversity as drivers of reputational risk, alongside existing factors like geopolitical events and pandemics. This evolution reflects a heightened emphasis on long-term societal risks and aligns with growing regulatory and stakeholder focus on environmental, social, and governance (ESG) issues.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in identifying the evolution of BK's reputational risk disclosures from 2022 to 2024, particularly the expansion to include ESG-related concerns such as climate change, diversity, and sustainability. The dates (2022 and 2024) and entities (BK) are accurate, and there are no numerical inaccuracies, earning a perfect score on quantitative accuracy. However, the original answer specifies that in 2022, adverse publicity was linked to government scrutiny and reputational harm—not cybersecurity, operational failures, or market conditions, as stated by the LLM. This misattribution of 2022 risk linkages reduces qualitative accuracy. Additionally, the LLM omits the specific mention of the 'platforms operating model transition' as a new context in 2024, which is a key part of the multi-hop synthesis in the ground truth. While the broader theme of expanding reputational risk to ESG issues is correctly captured and contextually relevant, these omissions and minor factual inaccuracies prevent a higher score. The answer conveys a semantically similar but not fully equivalent analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 316,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "Amazon's investment in Anthropic, PBC evolved from 2023 to 2024 by maintaining its classification as an available-for-sale convertible note (Level 3 asset) in 2023, with a $1.25 billion initial investment and a potential $2.75 billion follow-on commitment. By 2024, the investment remained part of Amazon's equity and convertible debt portfolio, valued at $22.1 billion in total, with Anthropic's convertible debt noted for its complexity due to private company valuation challenges. Valuation factors included market volatility, lack of public data, and global economic uncertainty, with adjustments for observable price changes and impairments.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies, particularly in quantitative details. The ground truth states Amazon's initial investment was $1.25 billion with a commitment of an additional $2.75 billion, totaling up to $4 billion. However, the LLM claims the total portfolio value was $22.1 billion, which is not mentioned in the original answer and appears fabricated. This is a major factual error. Additionally, the original answer does not state any specific valuation of the Anthropic investment in 2024 beyond the classification and disclosure of valuation challenges—there is no mention of a $22.1 billion figure. (2) The dates and investment structure (convertible note, available-for-sale, Level 3) are correctly identified, and the $1.25 billion initial investment and $2.75 billion follow-on commitment are accurately reflected. However, the erroneous $22.1 billion value severely undermines quantitative accuracy. (3) The reasoning around valuation complexity—lack of public data, market volatility, global uncertainty—is semantically aligned with the original answer’s emphasis on increased valuation risk and disclosure focus in 2024. The LLM correctly identifies the continuity in classification and the nature of the investment as part of a broader portfolio. However, it incorrectly implies that the $22.1 billion is the value of Anthropic or its convertible debt, which is unsupported by the ground truth. (4) Contextually, the answer addresses the evolution of investment classification and valuation factors, making it relevant. The qualitative reasoning is mostly sound but undermined by the false precision of the $22.1 billion figure. Correctness score is 6 due to correct structure and some accurate details but major error in financial magnitude; quantitative accuracy is low (4) due to the invented number; qualitative accuracy is 7 for correct logic and entity identification; contextual relevance is high (9) as the response stays on topic and synthesizes relevant themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 542,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "The nature of risks related to protecting MDLZ's intellectual property (IP), including know-how, evolved slightly between 2023 and 2024, with the 2024 disclosure emphasizing heightened concerns about **artificial intelligence (AI) technologies** and their potential to challenge existing IP protections. While both years highlight risks such as third-party infringement claims, litigation costs, and regulatory changes, the 2024 section explicitly notes the need to address **AI-related developments** that could undermine traditional IP safeguards. This reflects a growing awareness of emerging technological threats to IP in 2024, building on the 2023 focus on legal and regulatory uncertainties.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim about the evolution of MDLZ's intellectual property risks between 2023 and 2024. According to the ground truth, in 2023 MDLZ specifically mentioned artificial intelligence (AI) as a factor that could reduce intellectual property protections, while in 2024 it removed that specific reference and instead broadened its risk disclosure to include general legal and regulatory non-compliance, enforcement actions, and reputational damage. The LLM answer incorrectly states that the 2024 disclosure 'explicitly notes the need to address AI-related developments' and that there was a 'heightened concern' about AI in 2024—this is the opposite of the truth. In reality, the mention of AI was dropped in 2024, indicating a reduced emphasis, not an increased one. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are involved. The qualitative accuracy is very low because the model misidentifies the direction of change in risk disclosure and misattributes emphasis on AI to the wrong year. Contextual relevance is moderate because the answer addresses IP risks and uses appropriate terminology, but the reasoning and factual basis are flawed. The model fails the multi-hop requirement to compare disclosures across years accurately, reversing the actual trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 387,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "Goldman Sachs updated its Non-Employee Director Equity Award Agreements in 2024 by introducing new forms (e.g., **Exhibit 10.31** for standard RSU awards and **Exhibit 10.32** for cash-settled RSUs), replacing pre-2015 agreements referenced in 2023 (e.g., **Exhibit 10.21**). The 2024 filings reflect a shift to more structured, modernized award frameworks, with updated timelines and vesting conditions, while retaining prior amendments (e.g., **Exhibit 10.17** from 2008) as part of the evolving equity compensation landscape.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in several key aspects. (1) The exhibit numbers cited (Exhibit 10.31, 10.32, 10.21) are fabricated and do not match the ground truth: in 2023, the correct exhibit is 10.17 (not 10.21), and in 2024 it is 10.18 (not 10.31/10.32). The LLM incorrectly claims new forms were introduced in 2024, while the truth is that the same exhibit number (10.18) was used with a shift in referenced source. (2) The timeline is wrong: the LLM suggests pre-2015 agreements were referenced in 2023 and replaced in 2024, but the ground truth states the 2023 filing referenced a 2008 amendment via Exhibit 10.17, and the 2024 filing shifted to citing Exhibit 10.69 from the 2008 Annual Report — no new forms or modernized frameworks are mentioned. (3) The multi-hop reasoning fails: instead of identifying continuity in exhibit numbering and a shift in underlying documentation, the LLM invents a narrative of replacement and modernization unsupported by the data. (4) While the answer addresses the general topic (evolution of equity award agreements), it misrepresents the nature of the change, exhibits, and dates, making it factually unsound. Minor credit is given for contextual relevance — it attempts to compare 2023 and 2024 filings and discusses equity awards — but core facts and reasoning are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 375,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "BKNG's relationship with travel service providers evolved between 2022 and 2023 through increased merchant-based transaction processing, which expanded contractual responsibilities and revenue recognition. In 2023, Booking.com processed more transactions on a merchant basis, facilitating payments and offering secure transaction terms, which increased gross bookings and incremental revenues (e.g., credit card rebates) but also raised expenses for payment processing, chargebacks, and fraud prevention. Revenue recognition remained net-based, with commissions/margins as the primary consideration, but the shift toward merchant services introduced additional contractual obligations related to payment handling and transaction management, as detailed in the 2023 10-K's \"Revenue Recognition\" section (pages 81–85).",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but introduces significant inaccuracies not present in the ground truth. While it correctly identifies that BKNG recognizes revenue on a net basis and discusses revenue recognition in the context of contracts with travel service providers, it incorrectly emphasizes a 'shift toward merchant-based transaction processing' in 2023 as a key evolution. The original answer does not mention any such shift; instead, it highlights a more detailed accounting disclosure and clarification of revenue recognition timing (at point of service usage) and the agent role justification for net reporting. The LLM answer incorrectly implies an operational shift toward merchant models, which contradicts the ground truth that BKNG continues to act as an intermediary/agent. (2) There are no explicit numerical values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not penalized—format and references to the 10-K pages (81–85) are plausible and do not contradict the source. (3) The multi-hop reasoning is partially sound—BKNG’s role and revenue recognition are addressed across years—but the synthesis is flawed because it infers a change in business model (merchant expansion) not supported by the original answer. The evolution described should focus on accounting transparency and contractual clarity, not payment processing responsibilities. (4) The correctness score is 5 due to major conceptual inaccuracies in describing the nature of the evolution, despite correct mentions of net revenue recognition and contractual details. Qualitative accuracy is low because of incorrect reasoning about the shift in business model. Contextual relevance is moderate as the answer stays on topic but misrepresents the core development.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 491,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "The structure of Goldman Sachs' executive life insurance policy disclosures remained consistent between the 2023 and 2024 10-K filings. Both filings reference the same exhibits (e.g., Exhibit 10.11 for the Metropolitan Life policy and Exhibit 10.12 for the Pacific Life policy) detailing the terms and restrictions of the policies. No new exhibits or structural changes were introduced in the 2024 filing that alter the disclosure framework for these policies.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim. The ground truth states that there was a structural change in exhibit numbering between the 2023 and 2024 10-K filings: the Metropolitan Life policy moved from Exhibit 10.11 to 10.12, and the Pacific Life policy moved from 10.12 to 10.13. However, the LLM incorrectly asserts that the exhibits remained the same (10.11 and 10.12 in both years) and that no structural changes occurred. This misrepresents the key factual point of the question. The LLM also fails to note the reorganization of exhibit numbering, which is the central structural change. While the entities (Goldman Sachs, Metropolitan Life Insurance Company, Pacific Life & Annuity Company) and general context (executive life insurance policies) are correctly identified, the reasoning is flawed due to the incorrect assertion of no change. The answer is contextually relevant to the topic and question, but factually inaccurate in its main conclusion. Quantitative accuracy is low because the exhibit numbers are treated as static when they were renumbered, and this is a factual error in document structure. Qualitative accuracy suffers due to failure in multi-hop synthesis—comparing exhibit numbering across two years—and drawing an incorrect conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 355,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "The strategic importance of FBAR filters has remained central to Broadcom's competitive positioning, with internal fabrication continuing to play a key role in preserving IP and accelerating time-to-market for proprietary technologies. In both 2022 and 2024, Broadcom emphasized using internal fabrication facilities for FBAR filters and other innovative processes (e.g., GaAs/InP lasers) while outsourcing commodity processes like standard CMOS. The 2024 filing highlighted continued investment in optimizing internal fabrication capabilities and R&D to sustain competitive advantages, particularly in wireless communications. Competitive positioning was reinforced through IP protection, proprietary design expertise, and differentiation against rivals like Analog Devices and Qorvo, with no significant shifts in manufacturing strategy noted between the periods.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that FBAR filters remained strategically important and internally fabricated in both 2022 and 2024, with the purpose of protecting IP and accelerating time to market. It accurately reflects the continuity in manufacturing approach and Broadcom's reliance on internal fabrication for proprietary technologies. However, the original answer specifies that by 2024, the competitive landscape explicitly included Qualcomm and Skyworks in addition to Qorvo, while the LLM answer only mentions Qorvo and Analog Devices—missing Qualcomm and Skyworks and incorrectly including Analog Devices, which was not mentioned in the ground truth. This is a minor but notable entity inaccuracy affecting competitive context. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default due to absence of numerical content. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2024) and connects internal fabrication to strategic positioning and IP protection. The logic that no significant shift occurred in manufacturing strategy is consistent with the ground truth. However, the failure to accurately report the full set of competitors in 2024 slightly weakens the qualitative accuracy of the competitive environment analysis. (4) The answer is highly contextually relevant, addressing all parts of the question—strategic importance, manufacturing approach evolution, internal fabrication, and competitive positioning—over the specified time frame. The core facts are correct, but the omission and substitution of key competitors prevent a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 471,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "BMY's strategic positioning of Krazati evolved between 2023 and 2024 through the acquisition of Mirati in January 2024, which granted BMS full commercialization rights to Krazati and expanded its clinical development pipeline. In 2024, Krazati advanced into Phase III trials (KRYSTAL-12) for 2L+ mutated NSCLC, broadening its indications beyond 1L NSCLC and 2L CRC. Financially, the $4.8 billion acquisition of Mirati reflected a significant valuation, with Krazati's fair value recognized as part of $3.5 billion in indefinite-lived IPRD assets, underscoring its strategic importance.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $4.8 billion acquisition of Mirati in 2024 and BMY's (BMS's) full rights to Krazati, aligning with the ground truth. It accurately notes the financial valuation via the $3.5 billion indefinite-lived IPRD asset recognition, which reflects proper accounting treatment and strategic importance. The clinical development expansion into combination therapy with a PD-1 inhibitor is implied through the mention of broadened indications, though not explicitly stated. However, the LLM incorrectly states that Krazati 'advanced into Phase III trials (KRYSTAL-12)' in 2024 — in fact, KRYSTAL-12 was already ongoing in 2023 for 2L+ mutated NSCLC; the evolution was not initiation but continued development and likely progression toward registration or label expansion. Additionally, the LLM omits specific mention of FDA/EMA approvals for second-line NSCLC and FDA approval for KRAS-mutated CRC, which are key regulatory milestones that define the 2024 strategic shift. (2) Quantitatively, all numbers are correct: $4.8 billion acquisition cost and $3.5 billion IPRD valuation match expected figures. Dates (2023 to 2024, January 2024 acquisition) are accurate. (3) The multi-hop reasoning is largely sound — connecting the Mirati acquisition to full control of Krazati, expanded pipeline, and financial valuation — but misses the full synthesis of regulatory approvals as a driver of strategic repositioning. (4) Scores reflect high accuracy in numbers and context, minor gaps in clinical trial phase progression detail and omission of key approvals, but overall strong qualitative and contextual alignment with the question’s focus on clinical and financial evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 467,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "Between 2022 and 2023, BKNG maintained its focus on mutually beneficial relationships with travel service providers, emphasizing expanded distribution channels and inventory utilization. In 2023, the company refined its financial management of these relationships by structuring revenue recognition around commission-based models (as outlined in **Revenue Recognition**), where obligations are tied to transaction margins rather than service delivery. Additionally, BKNG enhanced incentive programs (e.g., referral bonuses, loyalty points) to drive engagement, with incentives recognized as revenue reductions at issuance. These adjustments reflect a more structured approach to managing financial obligations and incentives while sustaining partnerships.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the presence of incentive programs (referral bonuses, loyalty points) and their accounting treatment as reductions of revenue, which aligns with the original answer. It also mentions financial obligation management through commission-based models and revenue recognition, which is contextually relevant. However, it misses the key shift in relationship dynamics from competition in 2022 to dependence in 2023, which is central to the question. The original answer highlights a strategic evolution from competing to becoming more dependent on providers, evidenced by the increase in 'Deferred merchant bookings' liability—a critical piece of evidence absent in the LLM response. (2) There are no numeric values in either answer, so quantitative accuracy is not compromised; thus, a score of 10 is justified. (3) The multi-hop reasoning is partially sound—the LLM recognizes incentive programs and revenue recognition changes, but fails to synthesize the shift in competitive dynamics and the balance sheet liability ('Deferred merchant bookings') as indicators of increased dependency. This omission reflects a failure in deeper qualitative synthesis across years and financial statements. (4) Contextual relevance is high because the answer discusses financial obligations and incentives, directly addressing the question's focus, but the lack of the core competitive-to-dependent narrative limits correctness. The answer presents a more neutral, continuous relationship rather than the evolution described in the ground truth, leading to a correctness score of 5 due to significant conceptual omissions despite accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 459,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "Broadcom's involvement in Custom Touch Controllers remained consistent from 2022 to 2024, with the product continuing to be part of their wireless connectivity solutions for mobile devices. In both years, the controllers were listed under semiconductor product families, emphasizing their role in processing touch screen signals for mobile handsets and tablets. There is no explicit mention of a significant evolution in their role or expanded product lifecycle stages in the provided documents.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that Broadcom's involvement remained consistent from 2022 to 2024. The ground truth states a clear evolution in Broadcom's role — from being a supplier of Custom Touch Controllers in 2022 to an active producer involved in design and creation as part of custom silicon solutions in 2024. The LLM denies this evolution, claiming no significant change, which contradicts the original answer. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, the years 2022 and 2024 are correctly referenced, earning full marks here. (3) The multi-hop reasoning is flawed: the model fails to synthesize the shift in Broadcom’s role across time, missing the strategic progression from component supplier to integrated designer/producer. This represents a failure in qualitative reasoning despite correct entity identification (Broadcom, Custom Touch Controllers, time periods). (4) Contextual relevance is moderate — the answer discusses the right product and company in the correct timeframe, but incorrectly concludes no change occurred, thus failing the core requirement of identifying the evolution in the product lifecycle. The answer is on-topic but factually misaligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 365,
        "total_tokens": 1607
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "Union Pacific's approach to freight cars evolved from 2023 to 2024 with a focus on strategic acquisitions and lease buyouts to support growth and asset replacement. In 2024, the company allocated $788 million to locomotives and freight cars, including $143 million in lease buyouts, reflecting a shift toward owning more freight cars. This aligns with their 2024 capital plan emphasizing acquiring freight cars for replacement and growth opportunities. In 2023, investments in freight cars totaled $728 million, with lease buyouts of $57 million, indicating a continued emphasis on asset acquisition, though reduced by the 2023 purchase of a trucking operator. The strategy highlights a balance between purchasing and transitioning leased assets to owned freight cars to meet operational needs.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic shift from leasing to acquiring freight cars, with accurate lease buyout figures of $143 million in 2024 and $57 million in 2023, aligning with the ground truth. However, it introduces additional investment figures ($788 million in 2024 and $728 million in 2023 for locomotives and freight cars) that are not present in the original answer and cannot be verified against the provided ground truth, which only specifies lease buyouts. These numbers may be factually correct in context but go beyond the knowledge graph's stated facts, introducing unverified quantitative claims. (2) The lease buyout amounts are correctly reported and show a proper year-over-year comparison, supporting the narrative of increased ownership. But the inclusion of total investment figures without source confirmation reduces quantitative accuracy. (3) The multi-hop reasoning is sound—the model correctly infers a strategic shift toward asset ownership based on increased lease buyouts and ties it to growth and replacement goals, which matches the original answer’s logic. The mention of the 2023 trucking operator purchase as a factor affecting investment levels shows additional contextual synthesis, though this detail is not in the ground truth and slightly distracts from the core focus on freight car acquisition strategy. (4) The answer is contextually relevant and captures the essence of the strategic evolution. While the core conclusion about shifting toward ownership is correct and well-supported by accurate lease buyout data, the addition of unverified total expenditure figures lowers the quantitative accuracy score. Overall, the answer is factually aligned on key points but extends beyond the ground truth with supplementary data, warranting a high but not perfect correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 501,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "Nike's structural changes in APLA, including transitioning certain businesses to third-party distributors, resulted in increased APLA segment revenues and EBIT from FY2022 to FY2023. APLA revenues rose to $6,431 million (FY2023) from $5,955 million (FY2022), with EBIT increasing to $1,932 million (FY2023) compared to $1,896 million (FY2022). These improvements suggest operational efficiency gains from the distributor transition. However, a non-recurring impairment charge related to prior-year APLA transitions was recognized in FY2020, impacting Corporate results but not directly affecting FY2022–2023 financials. Overall, the structural changes contributed to stable or improved performance in the APLA region.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. The ground truth does not mention specific revenue or EBIT figures for APLA in FY2022 or FY2023, nor does it state that revenues or EBIT increased as a result of the structural changes. These numbers ($6,431M and $5,955M in revenue; $1,932M and $1,896M in EBIT) are fabricated or incorrectly sourced, which severely undermines factual correctness. Additionally, the claim about a non-recurring impairment charge in FY2020 is factually incorrect — the ground truth states that non-recurring impairment charges were anticipated in FY2022 due to the transition, not that they occurred in FY2020. (2) The quantitative accuracy is low because the core financial figures provided are not supported by the original answer and contradict the timeline of events. There is no mention in the ground truth of performance improvements or financial metrics post-transition, so asserting improved revenues and EBIT is unsupported. (3) The reasoning partially captures the strategic intent behind the transition — reducing operational overhead and shifting to third-party distributors — which aligns with the ground truth’s description of moving from direct operations to a strategic stake. However, the model fails to correctly link the impairment charge to FY2022 and misattributes it to FY2020, breaking the multi-hop logic between the structural change and its financial impacts. It also omits key details such as the reference to Note 18 on divestitures and the shift in reporting structure. (4) Despite the factual errors, the answer remains contextually relevant by addressing the financial and operational impacts of the APLA transition and attempting to interpret efficiency gains. However, the incorrect data and misattributed events reduce both qualitative and overall correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 514,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "Broadcom's internal fabrication strategy for InP lasers remained consistent from 2022 to 2024, with the company using internal fabrication facilities for proprietary processes like vertical-cavity surface emitting lasers (VCSELs) based on InP for fiber optic communications, while outsourcing commodity processes such as standard CMOS. This approach allowed Broadcom to protect IP and accelerate time-to-market, maintaining a competitive edge in the high-speed optical communications market against firms like Lumentum and II-VI. The 2024 filing emphasized continued investment in R&D for mission-critical, innovative products, reinforcing their position in advanced laser technologies.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Broadcom's continued use of internal fabrication for InP lasers from 2022 to 2024, accurately reflecting the ground truth that Broadcom uses internal facilities for proprietary processes including InP-based lasers for fiber optic communications. It correctly notes the outsourcing of commodity processes like standard CMOS, which aligns with the strategic context. The competitive positioning is partially accurate—Lumentum is correctly named as a competitor, but II-VI (now Coherent Corp.) is referred to by its former name, missing the updated reference to Coherent Corp. as explicitly stated in the 2024 filing. Additionally, the ground truth emphasizes a strategic shift in 2024 toward explicitly highlighting InP laser capabilities as a competitive differentiator, which the LLM answer does not fully capture—instead focusing on R&D investment without directly linking it to competitive differentiation. (2) There are no numeric values, dates, or calculations in the response or ground truth beyond years (2022, 2024), which are correctly used. (3) The multi-hop reasoning is mostly sound: the model connects Broadcom’s internal fabrication strategy across years and links it to competitive advantage. However, it misses the evolution in competitive framing—i.e., the increased emphasis on naming competitors and positioning InP lasers as differentiators in 2024. (4) The correctness score is 8 due to accurate core facts and strategy description but minor omissions in competitor naming updates and the nuanced strategic shift in messaging. Quantitative accuracy is 10 as no numbers are incorrect. Qualitative accuracy is 8 due to strong entity and reasoning alignment but incomplete synthesis of the competitive landscape evolution. Contextual relevance is 10 as the answer directly addresses the question’s focus on fabrication strategy and competitive positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 520,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "The ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock remained largely unchanged between 2022 and 2023. As of June 30, 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, and as of June 28, 2023, this percentage remained at 77%. If converted to Class B shares, Swoosh, LLC's ownership would decrease to ~16% of Class B shares. This consistency implies Swoosh, LLC retains significant influence through Class A shares, which carry more voting power, despite the potential dilution in Class B ownership. The structure underscores Swoosh, LLC's continued dominant role in shaping corporate decisions, though Class B shareholders have limited voting rights.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: 77% ownership of Class A Common Stock in both 2022 and 2023 is accurately reported, as is the ~16% implied ownership in Class B Common Stock upon conversion. The fiscal dates (June 30, 2022, and June 28, 2023) are specific and consistent with typical SEC filing timelines, and though not in the original answer, they are plausible and do not contradict the ground truth. (2) The calculation implied by the ownership translation (77% Class A → ~16% Class B if converted) is correctly represented, and the model correctly interprets the dilution effect upon conversion. (3) Qualitatively, the reasoning is sound: the LLM correctly infers that the stable ownership structure implies sustained influence, particularly through the higher voting power of Class A shares. It appropriately emphasizes Swoosh, LLC’s dominant role in corporate decision-making. However, the LLM omits explicit mention of Travis Knight’s managerial role, which is a minor but relevant detail in explaining *why* Swoosh, LLC’s ownership translates to influence. This omission prevents a perfect qualitative score. (4) Contextual relevance is excellent—the answer directly addresses both parts of the question: evolution (no change) and implications (continued influence, voting power dynamics). Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with only a minor omission in explanatory depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 424,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "PMI's strategic positioning of Reduced-Risk Products (RRPs) evolved from 2022 to 2023 through the integration of Swedish Match's oral nicotine portfolio (ZYN) with its existing heat-not-burn (IQOS) and e-vapor products, creating a comprehensive smoke-free offering. This integration, completed in 2022, was further solidified in 2023 by restructuring segments to align Swedish Match results with regional operations, enhancing portfolio coherence. Market availability expanded to 84 markets by 2023, reflecting broader distribution of RRPs, including strengthened U.S. presence via ZYN and continued growth in key regions like Japan and Southeast Asia.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the integration of Swedish Match's oral nicotine products (ZYN) with PMI's existing IQOS and e-vapor offerings, which aligns with the strategic evolution toward a broader smoke-free portfolio. It accurately states that PMI's smoke-free products were available in 84 markets by 2023, matching the ground truth. However, it incorrectly implies that the integration of Swedish Match was 'completed in 2022' and formed the basis of the 2023 strategy, while the ground truth emphasizes a reclassification from RRPs to a new 'Smoke-Free Products' (SFPs) category in 2023 that now includes wellness and healthcare—information missing in the LLM response. (2) Quantitatively, the '84 markets by 2023' figure is correct and matches the original answer; no other numbers are misstated. The timeline (2022 vs 2023) for integration is partially inaccurate—the Swedish Match acquisition closed in Q4 2022, but the strategic reclassification into SFPs occurred in 2023, which the LLM overlooks. (3) The reasoning captures the portfolio integration aspect well, especially the inclusion of ZYN and regional alignment, but fails to mention the key conceptual shift from RRPs to SFPs as a reporting and strategic category, which includes wellness/healthcare—this is a significant omission in the multi-hop synthesis. (4) Scores reflect high quantitative accuracy and relevance, with moderate deduction in qualitative accuracy due to incomplete conceptual framing and timeline conflation. The answer is factually strong but misses the full strategic nuance of the RRP-to-SFP evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 443,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, with a shift toward higher-growth applications like Power Generation (22% YoY revenue increase) and gas compression, while well servicing sales declined. This realignment improved the segment's revenue composition, contributing to a 2% increase in Energy & Transportation's profit margin to 19.9% in 2024. The focus on data center and industrial gas compression applications, coupled with favorable price realization, enhanced gross margin potential, while declining Industrial sales (18% YoY) and lower aftermarket parts revenue partially offset this growth.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and focus. The original answer states that Caterpillar evolved from selling reciprocating engines through its dealer network and Perkins in 2022 to including remanufacturing of its own and third-party engines by 2024, thus shifting toward a full lifecycle service provider model. In contrast, the LLM answer discusses a strategic shift toward Power Generation (22% YoY growth), gas compression, and data centers, with mentions of margin expansion in Energy & Transportation to 19.9% and an 18% decline in Industrial sales. None of these specific numbers or strategic pivots appear in the ground truth and are therefore factually unsupported. (2) Quantitative inaccuracies include the 22% YoY revenue increase in Power Generation, 2% margin increase to 19.9%, and 18% decline in Industrial sales—none of which are present in the original answer and cannot be verified from the provided context. There is no mention of remanufacturing margins or cost advantages in the LLM response, which is the core financial implication in the ground truth. (3) The multi-hop reasoning is flawed: the LLM fails to connect Caterpillar’s strategic evolution to remanufacturing and its impact on gross margins via lower material costs and higher-margin service revenue. Instead, it fabricates a narrative around application shifts and price realization, which is not supported by the original data. (4) While the LLM attempts to address revenue composition and margin impact, it does so using incorrect entities, metrics, and causal logic. The contextual relevance is moderate because it discusses Caterpillar, reciprocating engines, revenue mix, and margins—but the substance is factually divergent, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 486,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "BNY Mellon maintained a consistent approach to disclosing amendments to the Directors' Code of Conduct between 2022 and 2023, committing to publicly disclose such changes on its website. Both filings (2022 and 2023) explicitly state that amendments to the Directors' Code of Conduct would be disclosed on the company’s website, with no evolution in mechanisms or transparency commitments noted in the provided documents.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that BNY Mellon maintained a consistent approach to disclosing amendments to the Directors' Code of Conduct between 2022 and 2023, with no changes in mechanisms or transparency commitments. (2) There are no numeric values requiring calculation, but the years (2022 and 2023) are correctly referenced. (3) The multi-hop reasoning is sound—by comparing disclosures across both years, the model correctly infers that the mechanism (website posting) and transparency commitment remained unchanged, which aligns with the knowledge graph. (4) The answer addresses all parts of the question: it identifies the mechanism (public disclosure on website), confirms no evolution in transparency commitments, and covers both years. Wording differs slightly but meaning is identical. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 271,
        "total_tokens": 1496
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "Nike's strategic approach to the APLA (Asia Pacific & Latin America) market evolved between FY22 and FY23 by transitioning from a wholesale and direct-to-consumer model to a distributor-led operating model in certain APLA countries, as outlined in Note 18 - Divestitures. This shift involved selling legal entities in Argentina, Uruguay, and Chile to third-party distributors, reducing direct revenue contributions from these regions. While APLA revenue slightly declined in FY23 ($6.4B vs. $6.7B in FY22), the new model aimed to improve profitability by reducing selling/administrative expenses and foreign exchange exposure. Operational restructuring also included aligning product organizations around consumer segments and enhancing digital capabilities, though APLA's growth was partially offset by market dynamics and supply chain challenges.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Nike's strategic shift in APLA from direct operations in FY22 to a distributor-led model in FY23, including the sale of legal entities in Argentina, Uruguay, and Chile, which aligns with the ground truth. It accurately captures the operational restructuring and shift toward a partner-driven model. However, the original answer does not mention specific revenue figures ($6.4B vs $6.7B) or Note 18 - Divestitures, which are not present in the ground truth source. These details, while plausible and consistent with the strategic shift, go beyond the provided knowledge graph and introduce unverified quantitative claims. (2) The revenue numbers cited ($6.4B and $6.7B) are not present in the original answer and cannot be verified against the ground truth; thus, they represent a quantitative overreach. The original answer only notes APLA's contribution to the 14% growth in NIKE Direct in FY22 but provides no total APLA revenue or FY23 decline. This introduces potential inaccuracies in quantitative accuracy. (3) The multi-hop reasoning is strong: the model correctly infers a strategic evolution in operational structure and market participation, synthesizing changes in distribution models and their implications. The mention of reduced direct revenue, lower expenses, and foreign exchange benefits shows deeper contextual understanding, even if some specifics are extrapolated. (4) The answer is highly contextually relevant and semantically aligned with the core evolution described in the ground truth. Due to the inclusion of unsupported financial figures, the correctness score is reduced to 8 and quantitative accuracy to 7, but qualitative reasoning and relevance remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 474,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "From 2021 to 2024, Favorable Price Realization remained a critical factor in Caterpillar's profitability. In 2021, it contributed positively to the 22% sales growth and improved margins, offsetting challenges like supply chain disruptions. By 2024, despite a 3% sales decline compared to 2023, Favorable Price Realization helped offset lower sales volume and the absence of the Longwall divestiture impact, sustaining profitability with a 20.2% operating margin. Its role evolved from a volume-driven growth enabler to a stabilizing factor amid market headwinds.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It references 2021 data not mentioned in the original question or ground truth, which focuses on 2022–2024. The $9.223 billion favorable price realization in 2022 from the ground truth is not mentioned at all. The LLM claims a '3% sales decline' in 2024 and a '20.2% operating margin'—neither of these figures appears in the original answer and cannot be verified against the provided truth. The profit increase from $10.335B to $10.792B in 2024 is completely omitted. (2) The quantitative inaccuracies are severe: no correct dollar amounts are reported for price realization impact ($9.223B in 2022), no mention of the $2.251B volume decrease offset in 2024, and incorrect or unverified percentages (3% sales decline, 22% growth in 2021, 20.2% margin). These numbers contradict or misrepresent the ground truth. (3) The reasoning is partially sound in identifying that favorable pricing helped offset volume declines and sustain profitability, which aligns with the original answer’s logic. However, the multi-hop synthesis fails because it introduces irrelevant data (2021, Longwall divestiture) not in the ground truth and omits key links (profit numbers, exact price realization contribution). (4) The contextual relevance is moderate—it addresses the evolution of price realization’s impact and Caterpillar’s profitability—but the incorrect time frame and invented metrics reduce usefulness. Due to major factual and numerical errors, the correctness score is low despite some conceptual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 432,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024 by refining its strategic focus on scaling EV production, reducing costs, and strengthening supply chain resilience. In 2023, GM emphasized scaling EV manufacturing capabilities, reducing battery costs, and securing raw materials through strategic partnerships. By 2024, the company shifted toward a more resilient, North American-focused EV supply chain, prioritizing long-term supply agreements and investments in raw material sourcing. Additionally, GM refocused its AV strategy on personal vehicles, restructuring Cruise's operations and integrating ADAS technology, while addressing supply chain risks tied to geopolitical factors and the Inflation Reduction Act (IRA). These changes reflect a more targeted approach to both EV production and supply chain development.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: GM's 2023 focus on scaling EV manufacturing and securing raw materials, and the 2024 shift toward a more resilient, North American-focused supply chain with long-term agreements and raw material investments are accurately represented. The mention of strategic sourcing, supply chain risks, and regional focus matches the original. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes a strategic evolution across two years, identifying shifts in focus from broad scaling to structured, regional supply chain development. The addition of context around Cruise and ADAS, while not in the original answer, is factually plausible and adds relevant strategic context without contradicting the ground truth. (4) The only minor deviation is the inclusion of AV/ADAS elements, which were not part of the original answer’s scope—this slightly dilutes focus but does not reduce factual accuracy. Overall, the answer is semantically equivalent, contextually appropriate, and demonstrates strong qualitative reasoning. Correctness score is 9 due to slight over-expansion beyond the core EV manufacturing and supply chain focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 392,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "Pfizer's remaining performance obligations (RPO) for Paxlovid decreased from $5.1 billion as of December 31, 2023, to $1 billion as of December 31, 2024, reflecting reduced future revenue commitments due to product delivery and contract adjustments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Pfizer did not disclose any specific remaining performance obligations (RPO) for Paxlovid in 2022, and only in 2024 was a figure of $1 billion reported as of December 31, 2024. The LLM incorrectly claims a decrease from $5.1 billion in 2023 to $1 billion in 2024, which is not supported by the original answer or the implied data. There is no mention of a $5.1 billion figure in the ground truth, nor is there any data provided for 2023. (2) The quantitative inaccuracies are severe: the $5.1 billion figure is entirely fabricated in this context, and the comparison over time is based on false premises. The only correct number is the $1 billion RPO as of December 31, 2024, which matches the ground truth. However, the direction of change (decrease) and the prior value are incorrect. (3) The multi-hop reasoning is flawed. The question asks for the evolution from 2022 to 2024, requiring synthesis across years. The LLM fails this by inventing a 2023 figure and implying a trend that cannot be established from the disclosed data. The original answer correctly notes that 2022 had no disclosed amount, making any quantitative comparison invalid until 2024. (4) Contextual relevance is moderate because the answer discusses the right topic (RPO for Paxlovid) and the correct company and time frame, but the incorrect data and reasoning undermine the response. The conclusion about reduced commitments is speculative and unsupported. Thus, the correctness score is low due to major factual and quantitative errors, despite addressing the general subject.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 453,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "Caterpillar's approach to monitoring supplier financial viability remained consistent between 2022 and 2023, with both years emphasizing the use of contractual agreements and risk mitigation strategies to address supply chain disruptions. The 2022 and 2023 filings highlight similar practices, including monitoring supplier financial viability, business continuity, and production flexibility through supplier agreements, without indicating significant changes in methodology or emphasis.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative evolution in Caterpillar's approach between 2022 and 2023. (1) It correctly states that Caterpillar monitored supplier financial viability in both years and used contractual agreements and risk mitigation strategies, which aligns with the ground truth. However, it fails to capture the nuanced but important shift in emphasis in 2023, where 'supplier financial viability' was explicitly listed as the first risk in supply chain disclosures—indicating a heightened prioritization. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; the LLM did not introduce any incorrect figures, earning full marks here. (3) The multi-hop reasoning is weak: while the model identifies continuity, it overlooks the evolution in strategic emphasis and the reinforcement of global strategic sourcing models in 2023 aimed at building long-term relationships and leveraging enterprise spend—key differentiators in risk mitigation strategy. (4) Contextual relevance is high because the answer addresses the core topic and timeframe, but the lack of specificity on evolving emphasis reduces completeness and qualitative accuracy. Overall, the answer is factually safe but superficial, missing the deeper synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 365,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "Visa's Risk and Identity Solutions evolved significantly between 2022 and 2024 by expanding its AI-driven fraud prevention capabilities and integrating these solutions more deeply into its value-added services. In 2022, the focus was on transforming data into real-time insights for fraud detection, with products like Visa Protect Authentication Intelligence and Provisioning Intelligence. By 2024, Visa introduced advanced solutions such as **Visa Deep Authorization** (AI-powered transaction risk scoring) and **Visa Risk Manager** (scheme-agnostic fraud risk management), enhancing protection for both Visa and non-Visa transactions. These innovations were integrated into broader platforms like Visa Direct and B2B Connect, reinforcing Visa's \"network of networks\" strategy and strengthening its role in securing digital payments across diverse ecosystems.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, with accurate dates (2022 and 2024) and correct integration of Risk and Identity Solutions into Visa's value-added services. It correctly identifies an evolution in strategic positioning, mentioning AI-driven enhancements and network-agnostic capabilities like Visa Risk Manager, which aligns with the ground truth's emphasis on services for non-Visa transactions. However, the LLM answer introduces specific product names (e.g., Visa Deep Authorization, Visa Protect Authentication Intelligence) and platforms (Visa Direct, B2B Connect) not mentioned in the original ground truth, which may be accurate but are not supported by the provided knowledge graph. More critically, it omits the core structural evolution described in the ground truth: the shift to a three-pillar strategic framework (1) for Visa transactions, (2) network-agnostic for non-Visa, and (3) services beyond payments. This strategic reorganization is central to the original answer and represents a key multi-hop insight that the LLM fails to capture. While the LLM conveys a sense of deeper integration and expanded capabilities, it does not accurately reflect the specific strategic structuring emphasized in the ground truth. Quantitative accuracy is perfect—no numbers, percentages, or dates are incorrect. Contextual relevance is high as it directly addresses the evolution of Risk and Identity Solutions. Qualitative accuracy is reduced due to the substitution of product-level detail for strategic framework accuracy, missing the precise multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 439,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "The company's exposure to shelf space limitations as a risk factor remained a concern in both 2022 and 2023, with continued emphasis on changes in retail customer policies (e.g., inventory de-stocking, shelf space restrictions) and the evolving retail landscape. In 2023, the document highlights increased challenges from alternative retail channels (eCommerce, DTC) and shifting consumer preferences, noting the company's efforts to adapt through digital strategies and expanding presence in non-traditional channels. While shelf space limitations persisted, the 2023 disclosure underscores a broader focus on mitigating risks through innovation and diversification in distribution, reflecting heightened awareness of retail channel dynamics.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: shelf space limitations were a noted risk in 2022 and became an active challenge in 2023; retail customer policies (e.g., shelf space restrictions) are consistently mentioned; the expansion of alternative retail channels like eCommerce and DTC is correctly identified. The evolution from potential risk to actual impact is implied through phrases like 'increased challenges' and 'heightened awareness,' though the shift from 'potential' to 'actively impacted' is slightly less explicit than in the original. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored 10 by default as no inaccuracies exist. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2023), identifies evolving risk characterization, and connects it to strategic responses (digital investment, non-traditional channels). The only minor gap is that the original specifies 'investment in digital and analytics capabilities,' while the LLM generalizes to 'digital strategies,' which is semantically close but slightly less precise. (4) Contextual relevance is excellent—the response directly addresses the evolution of shelf space risk, retail policy changes, and alternative channel growth, fully satisfying the multi-part, multi-hop nature of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 402,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "Oracle's approach to hybrid deployments has evolved to emphasize greater integration of on-premise and cloud solutions, with expanded product offerings like Oracle Cloud Infrastructure (OCI) and enhanced hybrid deployment models such as Oracle Exadata Cloud@Customer. In fiscal 2024, the company further solidified its strategic focus on hybrid deployments by leveraging OCI to power SaaS applications and improve interoperability across environments, while increasing cloud services revenue to 37% of total revenue (up from 32% in 2023). This reflects a continued emphasis on flexibility, cost-effectiveness, and enabling customers to transition workloads seamlessly between hybrid and cloud environments.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's continued emphasis on hybrid deployments and mentions relevant offerings like Oracle Exadata Cloud@Customer and OCI, which aligns with the original answer. However, it introduces specific quantitative claims not present in the ground truth: stating that cloud services revenue increased from 32% in 2023 to 37% in 2024. This data is not supported by the original answer and cannot be verified from the provided knowledge graph, making it factually inaccurate. (2) There are no calculations in the original answer to verify, but the introduction of unsupported percentages significantly undermines quantitative accuracy. The years (2023–2024) and product names (Exadata Cloud@Customer, OCI) are correctly identified. (3) The reasoning is partially sound—Oracle did evolve its hybrid strategy toward deeper integration, and the LLM captures the strategic emphasis on interoperability and seamless transitions. However, the claim about revenue share appears to be fabricated or hallucinated, breaking the multi-hop synthesis requirement since no source in the ground truth supports it. (4) The contextual relevance is high because the answer addresses product offerings and strategic emphasis as asked. Qualitative accuracy is moderate due to correct entity and product identification but reduced by unsupported claims. Correctness score is 6 due to mostly accurate direction and context but significant factual error in introduced metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 413,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, with remaining performance obligations (RPO) for Paxlovid decreasing from $5.1 billion as of December 31, 2023, to $2.2 billion as of December 31, 2024. This reflects revenue recognition, adjustments (e.g., $771 million favorable adjustment in 2024), and reduced advance payments. As of 2024, $1 billion in contracted revenue for Paxlovid remained to be recognized through 2028, down from higher levels in 2023, indicating a decline in deferred obligations but ongoing commitments for future delivery.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative figures. The ground truth states that as of December 31, 2024, remaining performance obligations (RPO) for Paxlovid were approximately $1 billion, with revenue expected to be recognized from 2025 through 2028. However, the LLM claims RPO decreased from $5.1 billion (Dec 31, 2023) to $2.2 billion (Dec 31, 2024), which contradicts the ground truth and introduces unsupported numbers. There is no mention in the original answer of a $5.1B or $2.2B RPO, nor of a $771M favorable adjustment in 2024—these figures are entirely absent from the ground truth and appear fabricated. (2) The only correct quantitative element is the $1 billion in contracted revenue remaining as of 2024 to be recognized through 2028, which aligns with the original answer. However, this is presented as a reduction from a falsely inflated $2.2B, undermining the accuracy. (3) The multi-hop reasoning is partially sound in structure—attempting to show evolution over time and linking RPO to future revenue recognition—but fails due to reliance on incorrect data. The conclusion that financial commitment has declined is consistent with the original answer’s 'continued but reduced financial commitment,' so the qualitative direction is correct. (4) Contextual relevance is high because the answer addresses the evolution of financial commitment using appropriate concepts (RPO, revenue recognition timeline). However, the quantitative inaccuracies severely undermine correctness, warranting a low score. The model invents specific figures not present in the source, leading to a misleading narrative despite capturing the general trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 464,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "Caterpillar's relationship with its independent dealers remained consistent between 2022 and 2023, characterized by standard sales and service agreements that grant dealers rights to sell and service products in designated territories, along with obligations to promote sales and maintain records. The contractual framework emphasized non-exclusive use of trademarks, warranty support, and termination terms with 90 days' notice. Strategic emphasis on dealer networks and marketing programs, such as funding upfront transaction amounts to enhance competitiveness, persisted without significant changes noted in the provided documents.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in its core claim: it states that Caterpillar's relationship with independent dealers 'remained consistent' between 2022 and 2023, which contradicts the ground truth. The original answer correctly identifies a key evolution—from a general partnership model in 2022 to a more formalized, structured contractual framework in 2023 with standardized agreements. The LLM fails to capture this shift and instead asserts no significant changes, misrepresenting the strategic evolution. While the LLM accurately describes elements of the contractual obligations (e.g., rights to sell/service, obligations to promote, record-keeping, 90-day termination), these details are presented as static, missing the dynamic change emphasized in the question. There are no numerical errors (quantitative accuracy is high), and the entities (Caterpillar, independent dealers, contractual terms) are correctly identified. Contextually, the response is relevant and addresses the question's focus on contractual obligations and strategy, but the reasoning is flawed in synthesizing the multi-hop change over time. Thus, while factually sound on isolated details, the answer fails on the higher-order task of identifying and explaining the evolution, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 373,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "From 2022 to 2023, Colgate-Palmolive's capital expenditures for Africa/Eurasia increased from $13 million to $33 million, reflecting a higher financial allocation to the region. However, restructuring charges allocated to Africa/Eurasia decreased from 11% of total charges in 2022 to 5% in 2023, indicating a reduced focus on restructuring initiatives in the region during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states that capital expenditures increased from $13 million in 2022 to $33 million, when the ground truth shows the opposite: capex was $13 million in 2021, $8 million in 2020, and $33 million in 2022 — meaning the $33M figure is for 2022, not an increase from 2022 to 2023. More critically, the LLM fabricates data about restructuring charges decreasing from 11% in 2022 to 5% in 2023, which is not supported by the original answer. The ground truth states that in 2023, approximately 10% of cumulative pretax charges from the 2022 Global Productivity Initiative relate to Africa/Eurasia — there is no mention of 2023 restructuring charges being lower or any percentage for 2022 specifically. (2) Quantitative accuracy is low: the $33M capex is correctly attributed to 2022 but misused in a false year-over-year comparison; the 11% and 5% figures are entirely incorrect with no basis in the source. (3) The multi-hop reasoning is flawed: instead of identifying a strategic shift from capital investment to restructuring, the LLM incorrectly infers a continued increase in capex and a decline in restructuring, which contradicts the ground truth narrative of a pivot toward cost optimization in 2023. (4) Contextual relevance is moderate because the answer addresses capital expenditures and restructuring in Africa/Eurasia, but the incorrect data and reversed logic undermine the conclusion. The answer misrepresents the evolution and direction of financial allocation, failing the core requirement of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 439,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "Qualcomm's strategic focus on 5G technologies from 2022 to 2024 emphasized sustained investment in R&D for 5G modem and multimedia technologies, ADAS/AD, and XR, alongside expanding into automotive and IoT sectors. Commercialization outcomes included integrating 5G into Snapdragon platforms (e.g., modem-RF products) and maintaining a leading 5G patent portfolio, with continued licensing revenues from 5G-standard essential patents. The 2024 filings highlight ongoing efforts to drive 5G innovation and deployment, supported by partnerships and strategic investments, while addressing risks like customer vertical integration and supply chain challenges.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qualcomm's strategic focus on 5G from 2022 to 2024, including investment in R&D, expansion into automotive and IoT, and commercialization via Snapdragon platforms and patent licensing. It accurately notes the continued licensing revenues from 5G-standard essential patents and mentions relevant risk factors like supply chain and vertical integration. However, it omits key elements from the ground truth: the explicit transition from investment phase (2022) to monetization leadership (2024), and the specific detail that the majority of QTL revenues came from OFDMA-based products (e.g., multimode 3G/4G/5G devices). This shift from development to commercialization is a central point in the original answer and is underemphasized in the LLM response. (2) There are no numeric values, percentages, or dollar amounts in either answer, so quantitative accuracy is not applicable—no errors present, hence a score of 10. (3) The multi-hop reasoning is partially sound: the model connects investment focus with commercial outcomes, but fails to clearly synthesize the evolution over time—particularly the maturation of the 5G portfolio into a dominant revenue driver by 2024. The mention of 'ongoing efforts' in 2024 downplays the achievement of market leadership implied in the ground truth. (4) Contextual relevance is high as the answer addresses both investment emphasis and commercialization outcomes, though with less precision on the phase transition. The qualitative accuracy is reduced due to missing the core narrative of evolution from risk-laden investment to successful monetization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 450,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "Pfizer's Paxlovid revenue declined sharply in 2023 ($1,279M) compared to 2022 ($18,933M) due to a $3.5B non-cash revenue reversal related to U.S. government inventory returns and a transition to commercial markets. However, 2024 saw a rebound to $5,716M, driven by commercialization in the U.S. (post-November 2023) and a $442M revenue recognition for a U.S. Strategic National Stockpile (SNS) supply. Contractual commitments for Paxlovid remained significant, with $1B in remaining performance obligations as of December 31, 2024, alongside $2.2B in deferred revenues, reflecting ongoing obligations tied to government and commercial agreements.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Paxlovid generated $76 million in revenue in 2022, but the LLM claims $18,933 million ($18.9 billion), which is grossly incorrect. The LLM also states 2023 revenue as $1,279M and 2024 as $5,716M, none of which are supported by the original answer—no specific revenue figures for 2023 or 2024 are provided in the ground truth. The only quantitative match is the $1 billion in remaining performance obligations as of 2024, which is correctly cited. However, the LLM introduces $2.2B in deferred revenues and a $3.5B non-cash reversal, which are not mentioned in the original answer and cannot be verified against the provided truth. (2) Calculations and comparisons are therefore invalid due to incorrect base figures. The claimed 'decline' and 'rebound' in revenue are based on fabricated numbers. (3) The multi-hop reasoning is flawed: while the LLM attempts to show evolution in financial and strategic positioning, it invents a narrative around commercialization post-November 2023 and SNS supply revenue that is not present in the ground truth. The original answer emphasizes lack of explicit 2024 revenue but infers strategic positioning from $1B in future obligations—this nuance is lost. (4) Contextual relevance is moderate because the LLM addresses revenue trends and contractual commitments as asked, but the severe factual and quantitative errors undermine correctness. The mention of contractual obligations aligns with the original, but the rest diverges significantly. Thus, the correctness score is low due to pervasive numerical inaccuracies and unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 458,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "The company's exposure to credit market tightness as a supply chain risk remained a noted concern in both 2022 and 2023, as highlighted in the \"Operational Risks\" sections of both filings. In 2022, it was listed as a factor disrupting supply chains due to its impact on suppliers. In 2023, the same risk was reiterated alongside other disruptions like geopolitical events and labor shortages. However, there is no explicit indication of a material change in the company's vulnerability to credit market tightness between the two years, suggesting the risk remained a persistent, though not newly emerging, challenge to its supply chain resilience.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant misinterpretation of the evolution in risk framing between 2022 and 2023. (1) Correctly identifies that credit market tightness was a supply chain risk in both years and that it affects suppliers—this aligns with the original answer. However, the LLM incorrectly concludes there is 'no explicit indication of a material change' in vulnerability, which contradicts the ground truth that the company's framing evolved from suppliers being negatively impacted to the company's own operations being 'impacted by' these conditions—a shift indicating broader, more direct vulnerability. (2) There are no numerical values to verify, so quantitative accuracy is not applicable; however, the absence of numeric errors supports a score of 10. (3) The multi-hop reasoning is flawed: while the model correctly retrieves the presence of the risk in both years, it fails to synthesize the qualitative shift in language that indicates increased integration of financial risk into the company’s own operational exposure. This undermines the qualitative accuracy. (4) Contextually, the response is relevant and addresses the question’s focus on supply chain risk and external financial conditions, but misses the key interpretive point about evolving vulnerability, hence a moderate score on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 380,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "Pfizer's financial commitment and contractual obligations related to Paxlovid evolved significantly from 2022 to 2024. In 2022, Paxlovid generated **$18.9 billion** in revenue, driven by government contracts under emergency use authorizations (EUAs). By 2023, revenue dropped to **$1.3 billion** as the U.S. government transitioned Paxlovid to commercial markets, with a **$3.5 billion non-cash revenue reversal** recorded due to expected returns of EUA-labeled inventory. In 2024, Paxlovid revenue rebounded to **$5.7 billion**, reflecting commercialization efforts. Deferred revenues related to Paxlovid and Comirnaty totaled **$2.2 billion** as of December 31, 2024, down from **$5.1 billion** in 2023, due to revenue recognition and adjustments. Remaining performance obligations for Paxlovid supply contracts were **$1 billion** as of 2024, with obligations expected to be recognized through 2028. These obligations reflect long-term supply agreements, including a **$442 million revenue recognition** for a U.S. Strategic National Stockpile (SNS) agreement in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the revenue figures and adjustments. The ground truth does not mention Paxlovid generating $18.9 billion in 2022, $1.3 billion in 2023, or $5.7 billion in 2024—these numbers are unsupported by the provided truth. Similarly, the $3.5 billion non-cash revenue reversal and $442 million SNS revenue recognition are not present in the original answer. While the $1 billion remaining performance obligations as of 2024 is correctly reported, the context around it is partially misaligned. (2) The only correct numeric value is the $1 billion in remaining performance obligations as of December 31, 2024. All other financial figures (e.g., $18.9B, $1.3B, $5.7B, $3.5B, $442M) are either fabricated or misattributed. The deferred revenue figures ($2.2B and $5.1B) are also not in the original answer and contradict the disclosed $771 million favorable adjustment. (3) The multi-hop reasoning is flawed: the LLM invents a detailed revenue trajectory and deferred revenue trend not present in the ground truth. It incorrectly attributes a $3.5B reversal to inventory returns, while the truth specifies a $771M favorable adjustment from a prior reversal related to U.S. government returns. The model fails to mention the regulatory milestones (EUA, CMA, Japan approval) from 2022, which are key to the evolution of contractual obligations. (4) Despite incorrect numbers, the answer is contextually relevant—focusing on financial commitments, contractual obligations, and evolution over time. It correctly identifies the $1B obligations extending to 2028 and attempts to explain commercial transition dynamics. However, the high number of invented figures severely undermines factual correctness, warranting a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 497,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "From 2023 to 2024, Aearo Technologies' financial liability and risk exposure related to respirator mask/asbestos litigation decreased. In 2023, the Company had an accrual of $574 million for respirator mask/asbestos liabilities (excluding Aearo) and $62 million specifically for Aearo-related claims. By 2024, the accrual for respirator mask/asbestos liabilities dropped to $523 million, and Aearo-related accruals fell to $51 million. This reflects a reduction in the number of claimants (from ~4,042 in 2023 to ~3,500 in 2024) and lower estimated liabilities, though the Company still faces risks due to ongoing litigation, potential claims for serious injuries, and uncertainties in liability allocation among co-defendants. The 2024 accruals were adjusted based on updated claims data and litigation outcomes, but the Company emphasizes inherent uncertainties in estimating future liabilities.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, in 2023, 3M (MMM) had a $574 million accrual for respirator mask/asbestos liabilities *excluding* Aearo, and Aearo was in bankruptcy with no specific accrual mentioned for Aearo-related claims in that year. However, the LLM incorrectly states that in 2023 there was a $62 million accrual specifically for Aearo-related claims, which is not supported by the original answer. The 2024 Aearo-related accrual of $51 million is correct. The LLM also introduces a $523 million total accrual in 2024, which is not mentioned in the ground truth and appears to be a fabricated or miscalculated figure. Additionally, the claimant numbers (~4,042 in 2023, ~3,500 in 2024) are not present in the original answer and are therefore unsupported. (2) The calculation of a drop from $574M to $523M is incorrect and not relevant—the $574M was *excluding* Aearo, so it cannot be directly compared to a total that might include Aearo. The only valid number comparison is the $51M Aearo-specific accrual in 2024, which the LLM gets right. (3) The reasoning is partially sound in that it identifies a reduction in liability, which aligns with the idea of a shift to a more limited liability framework. However, it misses the key multi-hop element: the contractual arrangement between Aearo and Cabot, where Cabot assumes pre-1997 liability in exchange for a $100,000 quarterly fee. This critical risk-mitigation mechanism is entirely omitted, undermining the qualitative accuracy. (4) While the LLM addresses the evolution of financial liability and risk exposure, it does so with incorrect data and incomplete reasoning. The contextual relevance is high because it attempts to answer the right question with appropriate framing (accruals, claimant trends, uncertainty), but the factual foundation is flawed. Correctness is penalized heavily due to invented numbers and missing contractual risk-sharing details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 542,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "Skoal's retail share decreased from 9.3% in 2023 to 7.6% in 2024, a decline of 1.7 percentage points. Between 2020 and 2021, Skoal's shipment volume fell by 5.3% (from 208.5 million to 197.4 million units), while in 2023–2024, shipment volume dropped more sharply by 9.8% (from 163.1 million to 147 million units). Thus, Skoal's retail share decline and shipment volume contraction both occurred, with the latter showing a more pronounced decrease in the 2023–2024 period compared to 2020–2021.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the retail share decline of Skoal from 9.3% in 2023 to 7.6% in 2024, matching the ground truth. However, it introduces shipment volume data for 2023–2024 (163.1 million to 147 million units), which is not present in the original answer and not requested in the question. The original answer only provides shipment volume data for 2020–2021 (208.5M to 197.4M), with no mention of 2023–2024 shipment volumes. (2) The calculation of the 5.3% drop between 2020 and 2021 is approximately correct ((208.5 - 197.4)/208.5 ≈ 5.32%), so that numeric point is accurate. However, the 9.8% drop in 2023–2024 is based on fabricated or extraneous data not found in the ground truth, making it factually unsupported. (3) The multi-hop reasoning is partially sound—correctly linking retail share and shipment trends—but fails by introducing an incorrect comparison across time periods not justified by the original data. The original answer draws a consistent downward trend across both periods, while the LLM incorrectly implies a sharper decline in 2023–2024 shipments, which cannot be validated. (4) The correctness score is 4 due to major factual overreach with unsupported data; quantitative accuracy is 5 because half the numbers are correct but half are not; qualitative accuracy is 5 due to flawed synthesis; contextual relevance is 8 because the response addresses the right question structure and entities, just with incorrect data extension.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 408,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "Qualcomm's approach to multimedia technologies evolved from 2022 to 2024 by expanding engineering focus into AI-driven innovations, ADAS/AD (Advanced Driver Assistance Systems/Advanced Driving), and XR (Extended Reality), alongside broader integration into automotive and IoT applications. In 2022, emphasis was on multimedia components like camera, video, display, and computer vision for mobile devices. By 2024, the focus shifted to generative AI, on-device AI processing, and integrating AI and multimedia capabilities into automotive systems, IoT, and edge networking, reflecting a strategic expansion beyond traditional mobile handsets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Qualcomm's multimedia technology strategy from 2022 to 2024. It correctly identifies the 2022 focus on camera, video, display, and computer vision for mobile devices, aligning with the ground truth. It accurately reflects the 2024 shift toward AI, particularly generative AI and on-device AI processing, and the expanded integration into automotive, IoT, and edge networking. The mention of ADAS/AD and XR, while not explicitly stated in the ground truth, are contextually consistent with Qualcomm’s expansion into automotive and extended reality applications and do not contradict known strategies. The answer omits the specific point about enabling developers across device categories and industries, which is a minor omission but does not undermine the overall correctness. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated). The reasoning is sound, demonstrating multi-hop synthesis across years and strategic domains. The semantic meaning closely matches the original answer, with only slight differences in emphasis. Thus, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 339,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "Between 2023 and 2024, 3M's financial relationship with the Aearo Entities evolved through reconsolidation and settlement adjustments. In the second quarter of 2023, 3M reconsolidated the former deconsolidated Aearo Entities, resulting in a $0.7 billion equity investment asset and a $0.6 billion net liability for intercompany balances. In January 2024, 3M amended the CAE Settlement to pay $1 billion in cash (instead of stock) for the equity portion, reducing its equity investment. The settlement required $6 billion in contributions through 2029, with payments tied to claimant participation thresholds. Intercompany balances were resolved as part of the reconsolidation and settlement terms.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the 2023 reconsolidation of the Aearo Entities and the $0.7 billion equity investment asset and $0.6 billion net liability, it incorrectly states that these balances were 'resulting' from reconsolidation. In fact, the ground truth indicates that reconsolidation led to the *removal* of these balances from 3M's balance sheet as of December 31, 2023. The LLM flips the direction of the accounting impact. (2) The LLM introduces a $1 billion cash payment in January 2024 for an amended CAE Settlement, which is not mentioned in the ground truth. There is no reference to a $6 billion contribution through 2029 or claimant participation thresholds in the original answer, making these details hallucinated or unsupported. These numbers are entirely incorrect and not present in the verified data. (3) The multi-hop reasoning is partially sound in identifying a shift in relationship, but the conclusion that 3M 'reduced its equity investment' due to a 2024 cash payment misrepresents the actual evolution. The ground truth states that by 2024, the Aearo Entities were no longer consolidated and 3M now 'has a stake in' them, indicating a retained equity interest — but without mention of a $1B cash transaction. The LLM invents a mechanism (cash payment replacing stock) not present in the source. (4) The contextual relevance is moderate because the answer addresses the financial relationship and cites relevant concepts (equity investment, intercompany balances), but the core quantitative and qualitative inaccuracies — especially the invented $1B and $6B figures and incorrect characterization of reconsolidation effects — severely undermine correctness. The answer fails to reflect the actual sequence: removal of balances due to reconsolidation in 2023, followed by a new non-consolidated equity stake in 2024. Thus, the correctness score is low despite some accurate keywords and partial structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 540,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "Visa's Risk and Identity Solutions evolved significantly between 2022 and 2024 by expanding their AI-driven fraud prevention capabilities and integrating more deeply into the company's value-added services portfolio. In 2022, the focus was on existing solutions like Visa Advanced Authorization and fraud detection tools, while by 2024, Visa introduced advanced products such as **Visa Deep Authorization** (AI-powered transaction risk scoring) and **Visa Protect for A2A Payments** (fraud prevention for real-time non-card payments). These innovations, part of the broader **Visa Protect suite**, enhanced security across omnichannel transactions and aligned with Visa's strategic emphasis on AI, machine learning, and open banking, solidifying their role in safeguarding the payment ecosystem.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of Visa's Risk and Identity Solutions from fraud prevention to a more advanced, AI-enhanced suite, which aligns with the broader strategic direction mentioned in the ground truth. It correctly references core 2022 products like Visa Advanced Authorization and maintains contextual relevance by discussing omnichannel security and integration into value-added services. However, the answer introduces specific products—'Visa Deep Authorization' and 'Visa Protect for A2A Payments'—that are not mentioned in the original ground truth, nor is the 'Visa Protect suite' referenced as a named category in the provided data. These additions, while plausible, are factually unsupported by the source and represent a significant deviation in entity accuracy. Additionally, the ground truth emphasizes a structural shift in Visa’s portfolio organization—elevating Risk and Identity Solutions as one of five core categories within a 200+ product ecosystem by 2024—but this strategic repositioning is underemphasized in the LLM response. While the focus on AI and machine learning is consistent with modern trends, the original answer does not explicitly cite AI-driven enhancements as a defining evolution. Quantitatively, there are no numbers, dates, or financial figures to verify accuracy, so the score remains neutral on that dimension. The reasoning is partially sound but fails to fully synthesize the multi-hop aspect of how the service category was repositioned within a broader, more diversified portfolio. Thus, while the qualitative direction is reasonable, the introduction of unverified products and omission of structural strategic changes reduce factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 465,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "RTX's disclosure of Acquisition Accounting Adjustments became more granular in 2024, with detailed breakdowns of components like amortization of intangible assets, property/plant/equipment adjustments, and customer contractual obligations. The total impact on operating profit increased slightly from $1,998 million in 2023 to $2,058 million in 2024, reflecting higher amortization of intangible assets ($2,095 million in 2024 vs. $2,021 million in 2023) and reduced amortization of property, plant, and equipment. Despite this, the document notes that adjustments remained \"relatively consistent\" with prior years, indicating stable structural patterns in the adjustments' composition.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM claims RTX disclosed a 2024 impact of $2,058 million on operating profit due to Acquisition Accounting Adjustments, with specific breakdowns such as $2,095 million for amortization of intangible assets. However, the ground truth states that RTX did *not* provide any updated quantitative figures for 2024, meaning all 2024 numbers in the LLM answer are fabricated. The only correct number is the 2023 impact of $1,998 million, which matches the ground truth. (2) The LLM incorrectly asserts that disclosures became 'more granular' in 2024, when in fact the opposite occurred: RTX shifted from quantitative to purely qualitative disclosure, reducing granularity. (3) The reasoning is flawed: the LLM suggests a continuation of year-over-year quantification and even computes implied changes, but the ground truth confirms the discontinuation of such reporting in 2024. (4) The answer fails the multi-hop requirement by not recognizing the shift from numerical to conceptual disclosure, instead inventing data where none was provided. While the topic of acquisition accounting adjustments is relevant, the answer misrepresents the core evolution—transparency decreased, not increased. Thus, the correctness score is very low due to pervasive factual and directional inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 384,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "Microsoft's Office 365 Commercial revenue grew by 18% in fiscal year 2022, driven by 14% seat growth and increased revenue per user, as noted in the 2022 filing. In fiscal year 2023, while the exact percentage growth for Office 365 Commercial isn't explicitly stated, the broader Microsoft Cloud revenue (including Office 365 Commercial) increased to $137.4 billion from $111.6 billion, reflecting continued growth. This trajectory highlights Office 365 Commercial's sustained contribution to Microsoft's cloud ecosystem, underscoring its role in driving overall cloud revenue expansion.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it states that Microsoft Cloud revenue increased to $137.4 billion in FY2023 from $111.6 billion, which is incorrect. The ground truth states Microsoft Cloud revenue was $111.6 billion in FY2023, up from $91.4 billion in FY2022 — the LLM reversed the years and inflated the FY2023 number. This is a major quantitative error. Additionally, while the 18% growth in FY2022 is correctly attributed to the overall company revenue (not specifically Office 365 Commercial), the LLM incorrectly implies that Office 365 Commercial itself grew by 18%, which is not stated in the original answer. (2) The calculation of Microsoft Cloud growth is wrong: the correct increase is $111.6B - $91.4B = $20.2B (about 22% growth), but the LLM reports a fictitious $137.4B for FY2023, which does not appear in any source. (3) The reasoning is partially sound in that it recognizes Office 365 Commercial is now part of a consolidated Microsoft Cloud figure in FY2023 and that explicit growth rates are no longer broken out. However, it fails to accurately represent the consolidation shift from FY2022 to FY2023 and misattributes growth figures. (4) The contextual relevance is high because the answer addresses the evolution of revenue reporting and growth trajectory, and correctly identifies the increasing integration of Office 365 Commercial into the broader cloud ecosystem. However, due to significant numerical errors and misattribution of growth percentages, the correctness score is limited to 5 — partially correct but with major factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 443,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "Merck's alliance revenue related to Lynparza increased by 9% in 2024 compared to 2023, reaching $1,311 million. This growth was primarily driven by higher demand in most international markets. In 2023, alliance revenue for Lynparza grew 7%, also attributed to international demand. The 2024 increase reflects sustained global market expansion, with additional momentum from new approvals, such as China's 2025 approval for adjuvant treatment in early breast cancer, which further bolstered international sales.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies a 9% growth in Lynparza alliance revenue in 2024, which aligns with the ground truth. However, it introduces a specific dollar amount ($1,311 million) not present in the original answer, which cannot be verified and is likely fabricated. Additionally, the LLM claims that in 2023, Lynparza alliance revenue grew by 7%, which is not stated or implied in the ground truth—original information only notes that 2023 revenue was part of broader reporting without specifying a growth rate. The mention of a '2025 approval in China' is factually problematic, as it refers to a future event relative to 2024 and cannot contribute to 2024 revenue growth; this misattributes causality and introduces a forward-looking detail not supported by the source. (2) Quantitative inaccuracies include the unsupported $1.311B figure and the incorrect 7% growth in 2023. The 9% growth for 2024 is correct. The calculation of change between years is not possible due to missing 2023 baseline in ground truth, so introducing precise figures undermines accuracy. (3) The multi-hop reasoning is partially sound—linking international demand to revenue growth is consistent with the original. However, the model overreaches by inferring prior-year growth and attributing 2024 performance to a future regulatory approval, indicating flawed synthesis. (4) Contextual relevance is high as the answer addresses both parts of the question—evolution of revenue and contributing factors—with mostly relevant reasoning. However, the inclusion of unverified numbers and speculative drivers reduces factual reliability. Correctness score is 5 due to partial factual alignment but significant additions not grounded in evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 472,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "The Procter & Gamble 2014 Stock and Incentive Compensation Plan remains disclosed in the 2024 10-K filing under Item 12, as part of the Company's equity compensation plans approved by security holders. However, only the 2019 Stock and Incentive Compensation Plan allows for future grants of securities, as noted in the 2024 disclosure. The 2014 Plan's treatment in equity compensation reporting aligns with SEC requirements, with its details included in the Proxy Statement referenced in the 2024 filing. There is no indication of material changes in its regulatory context or disclosure between 2023 and 2024, though the 2014 Plan no longer permits future issuances compared to the 2019 Plan.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in key aspects: it correctly identifies that the 2014 Plan is still disclosed in the 2024 10-K under Item 12 and that only the 2019 Plan allows future grants, which aligns with SEC reporting requirements. The dates (2014, 2019, 2023, 2024) and entities (Procter & Gamble, equity compensation plans) are correct, and there are no numerical inaccuracies—thus, quantitative accuracy is perfect. Contextual relevance is high, as the response directly addresses the regulatory context and reporting treatment. However, the LLM answer downplays the evolution highlighted in the ground truth: while it notes no 'material changes,' it misses the shift in disclosure emphasis from regulatory documentation in 2023 (alongside other plans) to a broader equity compensation transparency and ownership structure focus in 2024. The original answer emphasizes an integrative evolution in reporting purpose, which the LLM response underrepresents by focusing on continuity and the cessation of future grants. This reflects a partial failure in multi-hop synthesis—connecting changes in disclosure context across years—leading to a lower qualitative accuracy score. The core facts are right, but the interpretive evolution is underdeveloped.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 351,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "The treatment of the 1992 Stock Plan remained consistent between the 2023 and 2024 10-K filings, as it continued to be listed as an active equity compensation plan. However, in the 2024 filing, the 1992 Plan is explicitly noted as **no longer allowing future grants**, with only the 2019 Stock and Incentive Compensation Plan permitting new securities issuances. This shift reflects the 1992 Plan's role evolving from an active compensation tool to a historical plan, while the 2019 Plan now serves as the primary vehicle for future equity awards.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a key evolution in the 1992 Stock Plan's status—specifically, that it no longer allows future grants as of the 2024 filing, with the 2019 Plan now serving as the primary vehicle for new equity awards. This aligns with the broader truth that the 1992 Plan has transitioned from active to historical status. However, the LLM contradicts the ground truth by stating the treatment 'remained consistent' between 2023 and 2024, which is inaccurate. The ground truth emphasizes a structural shift: in 2023, the plan was referenced by incorporation from prior filings (standalone treatment), while in 2024 it appears in a consolidated table with other plans, indicating a change in reporting and role. The LLM misses this presentational and structural evolution entirely, instead focusing only on grant eligibility. While the entity names (1992 Stock Plan, 2019 Plan) and years are correct, and there are no numerical inaccuracies (no numbers involved), the reasoning is partially flawed because it fails to recognize the multi-hop nuance of how the plan’s disclosure format changed, which is central to the question about its evolving role in the equity compensation structure. The answer is contextually relevant and captures part of the truth but omits the key shift in disclosure treatment that defines the evolution. Hence, correctness is partially accurate but misses a core aspect of the transformation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 395,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "The company's emphasis on large-scale transformations remained consistent between 2023 and 2024, with clients continuing to prioritize these initiatives, which generate revenue over extended periods. However, fiscal 2024 noted that economic and geopolitical volatility slowed client spending, particularly on smaller contracts and consulting services, while large-scale transformations retained their longer revenue conversion timelines. This suggests sustained focus on transformative projects despite macroeconomic headwinds.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core information from the ground truth. (1) It correctly identifies that the company's emphasis on large-scale transformations remained consistent between 2023 and 2024, with clients prioritizing these projects despite macroeconomic challenges. It accurately reflects that smaller contracts and consulting services saw reduced spending, aligning with the original answer. (2) There are no numeric values or calculations in the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes client spending patterns and revenue conversion timelines across two years, correctly noting the sustained focus on long-duration transformations. The only minor omission is that the 2023 filing explicitly mentioned clients reducing or deferring spending on shorter-duration contracts, while the 2024 filing 'reiterated' the trend—this nuance of repetition across filings is slightly underemphasized but not misrepresented. (4) The answer is contextually fully relevant, directly addressing the evolution of emphasis, client spending, and revenue timelines. Wording differs slightly but maintains semantic equivalence. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 382,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "Accenture issued 7,970 Class A Ordinary Shares for employee compensation in fiscal 2023 and 8,883 shares in fiscal 2024, as reflected in the \"Issuances of Class A ordinary shares for employee share programs\" line item in the Consolidated Shareholders' Equity Statements. This increase in share issuances expanded the company's equity structure by adding to Class A Ordinary Shares outstanding, while also adjusting additional paid-in capital and reducing treasury shares. The 2024 issuance was slightly higher than 2023, reflecting a continued emphasis on employee compensation through equity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. It incorrectly states that Accenture issued 7,970 shares in fiscal 2023 and 8,883 in 2024, while the ground truth indicates that 7,970 shares were issued in fiscal 2024, with no issuance for employee programs in 2023—instead, shares were acquired via withholding in 2023. The LLM also fabricates a 2024 issuance number (8,883) not present in the original answer. Additionally, the original answer notes a net increase in Class A shares from 15,656,591 to 15,664,561 (an increase of 7,970), which aligns with the 2024 issuance, contradicting the LLM's claim of a 2023 issuance. The treasury share values are completely omitted in the LLM response, and the claim of a decrease in treasury shares is misleading without the correct dollar magnitudes ($(3,408,491) million to $(6,678,037) million). (2) Quantitative accuracy is very low: both years' share issuance numbers are wrong, and the LLM invents a number (8,883) not present in the source. The correct 2024 issuance is 7,970, and 2023 had no such issuance. (3) The reasoning is flawed: the LLM fails to capture the multi-hop shift from share withholding (2023) to active issuance (2024), misrepresenting the nature of the change. It also misses the impact on equity structure involving treasury share reallocation and precise share count changes. (4) Contextual relevance is moderate—the answer addresses employee compensation and equity structure, but due to incorrect data and reasoning, it fails to accurately reflect the transformation in Accenture's approach. The conclusion about 'continued emphasis' is unsupported, as the original indicates a shift to more active use in 2024, not continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 468,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "MDLZ's exposure to Canadian-denominated debt instruments, as reflected in the notional amount of non-U.S. dollar debt designated as net investment hedges, increased slightly from $443 million in 2022 to $453 million in 2023. This aligns with the company's broader trend of managing foreign currency-denominated debt through net investment hedges and derivatives, with adjustments in notional amounts across currencies (e.g., euro and Swiss franc notes fluctuated, while Canadian exposure grew marginally). The overall strategy emphasizes hedging against exchange rate risks, with Canadian debt exposure remaining a smaller component compared to other currencies.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. According to the ground truth, MDLZ's Canadian notes decreased by $3 million in 2022 (from $3M in 2021 to $0M in 2022) and then increased by $8 million in 2023, reversing the prior trend. However, the LLM claims Canadian-denominated debt increased from $443M to $453M between 2022 and 2023, which is factually wrong—these numbers do not align with the actual balances or changes reported. The ground truth shows Canadian exposure was only $3M in 2021 and had been declining since 2019, making the LLM's figures off by orders of magnitude. (2) The calculation of a $10M increase is incorrect; the actual change in 2023 was a +$8M increase after a -$3M change in 2022. The LLM also fails to mention the prior downward trend from $17M (2019) to $3M (2021), which is central to the question. (3) The multi-hop reasoning is flawed: the LLM misidentifies the nature of the change in Canadian debt (portraying it as a steady, small increase rather than a reversal after elimination), and incorrectly frames the overall trend. While it correctly notes fluctuations in euro and Swiss franc notes, it misses that the Canadian reversal is a deviation from a consistent reduction pattern, which is the key insight. (4) The contextual relevance is moderate because the answer discusses foreign currency debt management and mentions relevant currencies, but the factual inaccuracies severely undermine correctness. The core claim—that Canadian exposure increased slightly—contradicts the ground truth that it was nearly eliminated in 2022 and then reappeared in 2023, representing a strategic shift, not a marginal change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 465,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "Accenture's approach to engaging with growth-stage companies, as detailed in the 2024 10-K, emphasizes continued strategic involvement through **Accenture Ventures**, which partners with and invests in growth-stage companies creating innovative enterprise technologies. This aligns with the 2023 disclosure, indicating no significant evolution in the core strategy. However, the 2024 document highlights expanded efforts to apply emerging technology innovations to business architectures, suggesting deeper integration of these partnerships into broader innovation initiatives. No explicit changes in investment activity or strategic focus are noted between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in noting Accenture's continued engagement with growth-stage companies through Accenture Ventures and mentions alignment with innovation initiatives. However, it incorrectly states there is 'no significant evolution' in strategy between 2023 and 2024, which directly contradicts the ground truth. The original answer identifies a clear shift from a partnership model ('partners with') in 2023 to a more direct investment approach ('invests in') in 2024, indicating deeper financial and strategic commitment. This evolution is the core of the question and is missed entirely by the LLM. (2) There are no numeric values in the LLM answer, but it does not contradict the R&D spending figures ($1.3B in 2023, $1.2B in 2024) mentioned in the ground truth—though it also fails to mention them. Thus, quantitative accuracy is not penalized, but the answer lacks supporting data. (3) The multi-hop reasoning is flawed: the model fails to synthesize the change in language and strategic implication across the two years’ filings. The shift from 'partners with' to 'invests in' represents a meaningful evolution in engagement strategy that requires cross-year comparison and interpretation—this is absent in the LLM response. (4) Contextual relevance is moderate because the answer discusses Accenture Ventures and innovation, which are relevant, but it fails to address the key evolution in strategic involvement and investment activity. The conclusion that 'no explicit changes' are noted is factually incorrect based on the provided ground truth, leading to a low correctness and qualitative accuracy score despite accurate terminology and context framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 464,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "Merck's alliance revenue from Lynparza with AstraZeneca grew from $1,116 million in 2022 to $1,311 million in 2024, reflecting increased demand in international markets. The intangible asset related to Lynparza, capitalized at $1.1 billion as of December 31, 2021, continued to be amortized through 2028, with no changes in its useful life or amortization methodology noted between 2022 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.1 billion intangible asset balance related to Lynparza and its amortization through 2028, consistent with the ground truth. However, it introduces specific revenue figures—$1,116 million in 2022 and $1,311 million in 2024—that are not present in the original answer and cannot be verified against the provided ground truth. The original answer mentions a 9% growth in alliance revenue but does not provide absolute revenue values for 2022 or 2024. Thus, the inclusion of precise dollar amounts represents a factual overreach or hallucination, significantly impacting quantitative accuracy. (2) The 9% revenue growth cited in the original answer is qualitative and not contradicted by the LLM’s numbers, but without source data, we cannot confirm if $1,116M to $1,311M equals approximately 9%. A calculation check shows ($1,311 - $1,116) / $1,116 ≈ 17.5%, which contradicts the 9% growth stated in the ground truth, indicating a clear quantitative error. (3) The reasoning around continued amortization and strategic focus is sound and reflects correct synthesis of the asset’s treatment from 2022 to 2024. However, the LLM omits the forward-looking strategic development mentioned in the original—namely, the new 2025 China approval for adjuvant treatment in early breast cancer, which is a key indicator of expanding strategic importance. This omission reduces completeness and qualitative accuracy slightly. (4) Despite the hallucinated numbers and calculation inconsistency, the LLM captures the core evolution: ongoing amortization and increasing international demand driving revenue growth. The context and entities (Merck, AstraZeneca, Lynparza, alliance revenue, intangible asset) are accurate, and the response stays highly relevant to the question. The main failures are in numerical precision and missing a key strategic update.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 512,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "AVGO's strategic emphasis on ValueOps in the Distributed Software portfolio has remained consistent between 2023 and 2024, focusing on value stream management to align business and development teams, reduce inefficiencies, and improve time-to-value. The 2024 filings highlight ValueOps as a critical component of the portfolio, emphasizing its role in optimizing software planning, development, and delivery through end-to-end visibility and integration with DevOps and AIOps. This indicates a sustained commitment to enhancing operational efficiency and aligning cross-functional teams to drive business outcomes.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but contains a significant factual inaccuracy: it claims AVGO's strategic emphasis on ValueOps 'has remained consistent' between 2023 and 2024, which directly contradicts the ground truth. The original answer shows a clear strategic elevation of ValueOps—from being one of several offerings in 2023 to becoming one of three core domains in 2024. This shift indicates a major change in strategic emphasis, not consistency. The LLM fails to capture this evolution, misrepresenting the nature of the change. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—no errors here, hence a score of 10. (3) The multi-hop reasoning is flawed: the question asks how the strategic emphasis changed, requiring comparison across two years and synthesis of positioning within the portfolio. The LLM incorrectly concludes continuity when the evidence shows progression and increased centrality. It does correctly identify ValueOps' role in end-to-end visibility and integration with DevOps/AIOps in 2024, showing partial understanding. (4) Contextual relevance is high—the response addresses the Distributed Software portfolio and discusses ValueOps in relation to business outcomes and integration, which is relevant. However, the core conclusion about 'sustained commitment' and 'remained consistent' undermines factual correctness. The answer reflects qualitative misunderstanding of the strategic shift, warranting a mid-range score of 5 for both correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 436,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "FedEx's Network 2.0 strategy under the DRIVE transformation evolved between 2023 and 2024 by expanding to include the Tricolor initiative, which redesigned the international air network to improve efficiency. While the 2023 filings emphasized expected cost savings from operational efficiencies and network flexibility, the 2024 filings highlighted ongoing integration challenges, including risks of higher-than-anticipated costs, delays, and potential asset impairment charges. Implementation risks such as legal disputes, labor complexities, and operational disruptions were further detailed in 2024, underscoring uncertainties in achieving projected cost savings and benefits.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of FedEx's Network 2.0 strategy between 2023 and 2024. It correctly identifies the shift from emphasizing expected cost savings and operational efficiencies in 2023 to highlighting integration risks and uncertainties in 2024. The mention of asset impairment charges, labor complexities, and legal disputes aligns with the original answer's reference to litigation risks, labor differences, and unforeseen expenses. However, the LLM introduces the 'Tricolor initiative' and claims it was part of the evolution, which is not present in the ground truth and cannot be verified from the provided knowledge graph—this is an extraneous detail that slightly undermines factual accuracy. While the core reasoning and synthesis across years are sound (multi-hop understanding of strategic shift), the addition of unverified initiatives prevents a perfect score. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The answer remains contextually relevant and semantically equivalent in conveying the strategic transition, despite the minor factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 330,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "The financial impact from equity method investment contracts increased from 2022 to 2023, with a pre-tax gain of $7 million in 2023 compared to $2 million in 2021. This indicates MDLZ's ongoing engagement with these investments, as evidenced by the recognition of gains in net earnings related to these contracts. The equity method investment contracts, tied to bifurcated embedded derivatives from a 2021 bond issuance, reflect MDLZ's strategic involvement in hedging and managing exposure through such instruments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states a $2 million gain in 2021, while the question is about 2022–2023 evolution and the ground truth reports a $3 million net liability in 2022 (not a gain in 2021). The $7 million pre-tax gain in 2023 is correctly mentioned, but the comparison is to the wrong year and wrong amount. (2) Quantitative accuracy is severely compromised: the LLM references 2021 instead of 2022, misrepresents a liability as a gain, and fails to capture the reversal from a $3 million liability to a $7 million gain. The correct evolution is a $10 million swing, which is not reflected. (3) The reasoning is flawed: the LLM fails to recognize the shift from a liability to a gain as a reversal in financial impact, instead implying a steady engagement with increasing gains. It introduces irrelevant details about a 2021 bond issuance and bifurcated derivatives not mentioned in the ground truth, suggesting incorrect multi-hop synthesis or hallucination. (4) Contextual relevance is moderate because it discusses equity method investment contracts and MDLZ's engagement, but the incorrect data and reasoning undermine the conclusion. The core message about strategic engagement is partially aligned but unsupported by accurate facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 364,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "Broadcom's estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained **$38 million** from fiscal year 2023 to 2024, as indicated in the IPR&D table. This consistency suggests that the development progress aligned with expectations, as the project was fully released during fiscal year 2024, with no significant changes in estimated costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key fact that Broadcom's estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to 2024, matching the ground truth exactly. All numeric values and fiscal years are accurate. (2) Quantitative accuracy is perfect: the dollar amount ($38 million) and the time frame (FY2023 to FY2024) are correctly reported with no calculation errors. Format is consistent and acceptable. (3) The reasoning is largely sound: the LLM correctly infers that stable cost estimates suggest development progress aligned with expectations. However, it adds the claim that the project was 'fully released during fiscal year 2024,' which is not present in the original answer and cannot be verified from the provided ground truth. This is a minor overreach in inference, slightly weakening the qualitative accuracy. (4) The answer is highly contextually relevant, addressing both parts of the question—evolution of cost and what it indicates about development progress. Despite the small addition of unverified release status, the core multi-hop synthesis (linking unchanged cost to planned progress) is correct and well-reasoned. Thus, correctness is docked slightly to 9 for the unsupported detail, but all other scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 372,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "Between 2023 and 2024, FedEx Office expanded the strategic role of its Ship and Go kiosks by integrating them more deeply into e-commerce logistics and returns management. In 2024, the kiosks were highlighted as part of FedEx Returns Technology, enabling in-store printing of return labels and \"FedEx Consolidated Returns,\" which allow customers to drop off returns without needing a box or label. This evolution reflects FedEx's focus on streamlining end-to-end e-commerce experiences, emphasizing convenience, efficiency, and seamless returns processes to meet growing demand in the online retail sector.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of the Ship and Go kiosk from 2023 to 2024, noting the increased emphasis on integration with FedEx Returns Technology and Consolidated Returns. It accurately reflects that the kiosk's role expanded to support in-store printing of return labels and drop-offs without a box or label, aligning with the ground truth. The only minor omission is that the LLM does not explicitly mention the continuity of the kiosk's presence in approximately 1,300 locations in both years, which is part of the original answer. However, this quantitative detail is not central to the strategic interpretation. (2) There are no numeric values, dates, or calculations in the response that conflict with the ground truth; the years 2023 and 2024 are used appropriately, and no incorrect figures are introduced. (3) The multi-hop reasoning is sound: the model correctly synthesizes information about the kiosk’s functionality shift and links it to broader strategic goals in e-commerce logistics and returns management. It infers the strategic intent—streamlining end-to-end e-commerce experiences—based on the enhanced returns functionality, which is logically supported by the source. (4) The answer is contextually highly relevant, directly addressing both the evolution of the kiosk and what it indicates about FedEx’s strategy. The wording differs slightly but maintains semantic equivalence. The correctness score is 9 because all key facts and reasoning are accurate, with only a minor omission of the consistent footprint (1,300 locations), which does not detract from the core strategic insight.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 450,
        "total_tokens": 1838
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 5.59,
    "average_quantitative_accuracy": 6.63,
    "average_qualitative_accuracy": 5.89,
    "average_contextual_relevance": 8.09,
    "score_distribution": {
      "excellent": 207,
      "good": 187,
      "fair": 333,
      "poor": 273
    }
  },
  "original_experiment_metadata": {
    "model": "qwen3-8b-reasoning",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 6877.05,
    "timestamp": "2026-02-02T17:35:02.798305"
  }
}